
<html lang="en"     class="pb-page"  data-request-id="31465885-5e07-489a-9f63-1a11cc8e8887"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2020.63.issue-23;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.0c00766;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Synthetic Lethality through the Lens of Medicinal Chemistry" /></meta><meta name="dc.Creator" content="Samuel H.  Myers" /></meta><meta name="dc.Creator" content="Jose Antonio  Ortega" /></meta><meta name="dc.Creator" content="Andrea  Cavalli" /></meta><meta name="dc.Description" content="Personalized medicine and therapies represent the goal of modern medicine, as drug discovery strives to move away from one-cure-for-all and makes use of the various targets and biomarkers within di..." /></meta><meta name="Description" content="Personalized medicine and therapies represent the goal of modern medicine, as drug discovery strives to move away from one-cure-for-all and makes use of the various targets and biomarkers within di..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 2, 2020" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00766" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2020 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00766" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00766" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00766" /></link>
        
    
    

<title>Synthetic Lethality through the Lens of Medicinal Chemistry | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00766" /></meta><meta property="og:title" content="Synthetic Lethality through the Lens of Medicinal Chemistry" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0024.jpeg" /></meta><meta property="og:description" content="Personalized medicine and therapies represent the goal of modern medicine, as drug discovery strives to move away from one-cure-for-all and makes use of the various targets and biomarkers within differing disease areas. This approach, especially in oncology, is often undermined when the cells make use of alternative survival pathways. As such, acquired resistance is unfortunately common. In order to combat this phenomenon, synthetic lethality is being investigated, making use of existing genetic fragilities within the cancer cell. This Perspective highlights exciting targets within synthetic lethality, (PARP, ATR, ATM, DNA-PKcs, WEE1, CDK12, RAD51, RAD52, and PD-1) and discusses the medicinal chemistry programs being used to interrogate them, the challenges these programs face, and what the future holds for this promising field." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00766"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00766">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00766&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00766&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00766&amp;href=/doi/10.1021/acs.jmedchem.0c00766" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 23</span><span class="cit-fg-pageRange">, 14151-14183</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/23" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00047" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c00848" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Synthetic Lethality through the Lens of Medicinal Chemistry</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Samuel H. Myers</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Samuel H. Myers</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Computational & Chemical Biology, Istituto Italiano di Tecnologia, 16163 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Samuel+H.++Myers">Samuel H. Myers</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Jose Antonio Ortega</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jose Antonio Ortega</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Computational & Chemical Biology, Istituto Italiano di Tecnologia, 16163 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jose+Antonio++Ortega">Jose Antonio Ortega</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor">Andrea Cavalli</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andrea Cavalli</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Computational & Chemical Biology, Istituto Italiano di Tecnologia, 16163 Genova, Italy</div><div class="loa-info-affiliations-info">Department of Pharmacy and Biotechnology, University of Bologna, 40126 Bologna, Italy</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#4e0f202a3c2b2f600d2f382f2222270e27273a60273a"><span class="__cf_email__" data-cfemail="9ddcf3f9eff8fcb3defcebfcf1f1f4ddf4f4e9b3f4e9">[emailÂ protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andrea++Cavalli">Andrea Cavalli</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6370-1176" title="Orcid link">http://orcid.org/0000-0002-6370-1176</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00766&amp;href=/doi/10.1021%2Facs.jmedchem.0c00766" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 23</span><span class="cit-pageRange">, 14151â14183</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 2, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>6 May 2020</li><li><span class="item_label"><b>Published</b> online</span>2 November 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 December 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00766" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00766</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="https://acsopenscience.org/open-access/licensing-options/"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice" /></img><span>ACS AuthorChoice</span></a><span class="article_header-cc-by"><a href="https://creativecommons.org/licenses/by/4.0/"><img src="/pb-assets/images/licensesLogos/OA_Icons_cc-1612971093887.svg" alt="CC: Creative Commons" /></img><span><strong>CC: </strong>Creative Commons</span></a><a href="https://creativecommons.org/licenses/by/4.0/"><img src="/pb-assets/images/licensesLogos/OA_Icons_by-1612971093257.svg" alt="BY: Credit must be given to the creator" /></img><span><strong>BY: </strong>Credit must be given to the creator</span></a></span></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00766"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3445</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">1</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00766" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Synthetic Lethality through the Lens of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Samuel&quot;,&quot;last_name&quot;:&quot;H. Myers&quot;},{&quot;first_name&quot;:&quot;Jose&quot;,&quot;last_name&quot;:&quot;Antonio Ortega&quot;},{&quot;first_name&quot;:&quot;Andrea&quot;,&quot;last_name&quot;:&quot;Cavalli&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;02&quot;,&quot;issue&quot;:&quot;23&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;14151-14183&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00766&quot;},&quot;abstract&quot;:&quot;Personalized medicine and therapies represent the goal of modern medicine, as drug discovery strives to move away from one-cure-for-all and makes use of the various targets and biomarkers within differing disease areas. This approach, especially in oncology, is often undermined when the cells make use of alternative survival pathways. As such, acquired resistance is unfortunately common. In order to combat this phenomenon, synthetic lethality is being investigated, making use of existing genetic fragilities within the cancer cell. This Perspective highlights exciting targets within synthetic lethality, (PARP, ATR, ATM, DNA-PKcs, WEE1, CDK12, RAD51, RAD52, and PD-1) and discusses the medicinal chemistry programs being used to interrogate them, the challenges these programs face, and what the future holds for this promising field.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00766&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00766" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00766&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00766" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00766&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00766" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00766&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00766&amp;href=/doi/10.1021/acs.jmedchem.0c00766" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00766" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00766" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00766%26sid%3Dliteratum%253Aachs%26pmid%3D33135887%26genre%3Darticle%26aulast%3DMyers%26date%3D2020%26atitle%3DSynthetic%2BLethality%2Bthrough%2Bthe%2BLens%2Bof%2BMedicinal%2BChemistry%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D23%26spage%3D14151%26epage%3D14183%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/23" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/jmcmar.2020.63.issue-23/20201210/jmcmar.2020.63.issue-23.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0024.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Personalized medicine and therapies represent the goal of modern medicine, as drug discovery strives to move away from one-cure-for-all and makes use of the various targets and biomarkers within differing disease areas. This approach, especially in oncology, is often undermined when the cells make use of alternative survival pathways. As such, acquired resistance is unfortunately common. In order to combat this phenomenon, synthetic lethality is being investigated, making use of existing genetic fragilities within the cancer cell. This Perspective highlights exciting targets within synthetic lethality, (PARP, ATR, ATM, DNA-PKcs, WEE1, CDK12, RAD51, RAD52, and PD-1) and discusses the medicinal chemistry programs being used to interrogate them, the challenges these programs face, and what the future holds for this promising field.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17541" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17541" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">It is commonly known that cancer is a disease of the genome, wherein errors in DNA replication and repair cause failures in cell function, while the mechanisms that would normally deal with these faulty cells are also compromised, resulting in cancer cell survival and ultimately proliferation. Before the advent of the human genome project in 2003, cancer treatments were mainly radiotherapy and nonspecific chemotherapy: two treatment methods that are famed for their lack of specificity and severe side effects. The human genome project has aided the route toward personalized medicine, wherein unique biomarkers in individuals can be detected and treated with tailor-made therapeutics for that specific cancer. There have been numerous success stories, primarily where âoncogene addictionâ occurs, in which a particular subtype of cancer is over-reliant for survival on a particular oncogene, and therefore inhibition of this oncogene through small molecules or antibodies causes selected cell death. Examples include imatinib, which targets BCR-ABL that has extended the median survival of patients with chronic myelogenous leukemia to greater than 10 years.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Another success story can be seen in melanoma, where treatment with the BRAF inhibitor vemurafenib has caused melanoma to change from a mostly untreatable disease to one where over 50% of patients show a meaningful clinical response.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> However, this trend toward precision-based personalized medicine has fallen out of fashion in the cancer drug discovery community. First, not all cancers show a simple oncogene addiction, and their survival mechanisms are far more complex; also, certain oncogenes have proved undruggable by small molecules and antibodies.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Furthermore, even with initial success, issues of resistance and poor mechanistic understanding have hampered efforts, resulting in oncology still reliant on radiotherapy and nonspecific chemotherapeutics. Attention has turned toward synthetic lethality, exploiting hampered DNA repair mechanisms in cancer and allowing access to previously undruggable targets by indirect inhibition.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></div><div class="NLM_p">Synthetic lethality (SL) was first discovered in the fruit fly (<i>Drosophila pseudoobscura</i>) in 1946â¯<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> and can be defined as the relationship that can occur between two genes where either one functioning maintains viability of the cell; however upon dysfunction of both genes, the cell becomes unviable.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> In its simplest and most desirable application, this would result in the selective killing of cells that rely on the mechanisms driven by these two genes, i.e., cancer cells, while leaving the healthy cells alive. One synthetically lethal pair, PARP (poly (ADP-ribose) polymerases) and BRCA1/2, are now exploited in standard of care treatments;<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> however this was 6 years ago, and still no other SL-based drugs have gained regulatory approval.</div><div class="NLM_p last">Within the field of synthetic lethality there are numerous examples of synthetically lethal gene pairs; therefore in this Perspective we select prominent and interesting examples to use as case studies for the field. Within these sections the targets typical mode of function is described, followed by the proposed mechanisms of synthetic lethality. Subsequently, medicinal chemistry programs that have produced molecules with potential to cause âsmall molecule-induced synthetic lethalityâ are discussed, including compounds in early stage, preclinical, and clinical studies. The review ultimately concludes with the challenges facing such small molecules and the drugging of their targets.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  PARP and BRCA2</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74536" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74536" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">PARP is a family of enzymes containing 17 members,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> of which 15 have been shown to catalyze the transfer ADP-ribose to target proteins.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9,10)</a> PARP1 and PARP2 play important roles in DNA repair, making them an attractive target for oncology. PARPâs role in DNA repair was first discovered when it was observed that there was a correlation between high amounts of DNA lesions and increased PARP concentration.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> PARP is involved in the repair of single-stranded breaks (SSBs), through base excision repair (BER) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), where it forms a part of the BER complex.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> In addition to this, PARP has been observed to play a role in nucleotide excision repair (NER). This and BER are both mechanisms for DNA repair.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> PARP has been observed in cell-free systems to bind tightly to broken DNA, and after auto-poly-ADP-ribosylation, it allows repair enzymes to access the DNA in order to initiate repair.<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14,15)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Schematic representation of PARPâs role in SSB and DSB repair. Upon formation of a SSB, PARP1 and other acceptor proteins (histone H1, TOP1, and others) are recruited and attached to the lesion site. This recruits other factors involved in DNA repair (PolÎ², LigIII, TDP1, and XRCC1) which, through BER, repair the lesion. If PARP is inhibited, the SSB becomes a DSB which causes Î³H2AX foci formation, which in the presence of BRCA1/2 triggers HR which repairs the DSB. In the absence of BRCA this break becomes synthetically lethal. Adapted from   <cite><i>Clinical Cancer Research</i></cite>, Copyright 2010, Vol. <em>16</em>, Issue 18, Page 4532, <contrib-group>Christophe E. Redon, Asako
J. Nakamura, Yong-Wei Zhang, Jiuping (Jay) Ji, William M. Bonner,
Robert J. Kinders, Ralph E. Parchment, James H. Doroshow, Yves Pommier</contrib-group>, Histone Î³H2AX and Poly(ADP-Ribose) as Clinical
Pharmacodynamic Biomarkers,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> with permission from AACR.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">BRCA2 plays an important role in repairing double-stranded breaks (DSBs), as part of the homologous recombination (HR) pathway, and has been reported to be synthetically lethal when disrupted in combination with PARP,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> which as stated previously is involved in the repairing of SSB. This relationship was first discovered in 2005,<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17,18)</a> and since this date, numerous papers have been published discussing the mechanism behind this.<a onclick="showRef(event, 'ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref19 ref20 ref21">(19â21)</a> In the case of BRCA2 and PARP, in patients with defective BRCA2, PARP inhibitors can be administered to induce synthetic lethality.</div><div class="NLM_p">Numerous cancers have defects in HR: such tumors include ovarian (50%) breast, prostate, and pancreatic cancers (all 10â20%).<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> This is thought to aid cancer initiation and progression, with the hypothesis being that this fault in HR will cause more DNA breaks, resulting in more mutations. Due to cancer cell survival mechanisms, these DNA breaks may not necessarily be fatal to the cell and in fact may allow for more favorable conditions for cell survival.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Due to the high proportion of cancers that express these HR defects, they are prime candidates for treatment with PARPi. Three main mechanisms have been hypothesized to exploit the synthetically lethal relationship between PARP and BRCA2. The first begins with a PARP inhibitor (PARPi) blocking BER, thus causing the conversion of an SSB to a DSB that BRCA2 would normally fix. If the tumor is genetically deficient in BRCA2, it will not be able to perform HR and therefore cause irreparable DNA damage, leading to cell death.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> In the second mechanism, the PARPi binds to the PARP1 enzyme on the chromatin, thus trapping it in mechanism referred to as PARP trapping; this causes a lesion that must be repaired which, due to compromised HR, is not possible and causes cell death. In the third mechanism, DSBs are resected during the S phase; however, since HR is defective, the alternative microhomology-mediated end joining (MMEJ) pathway attempts to repair the break. Since PARP1 is inhibited by the PARPi, it can no longer recruit POLQ, therefore blocking this pathway and triggering cell death;<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> the same effect is thought to be achieved through POLQ dysregulation.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></div><div class="NLM_p">PARP inhibitors demonstrate the first major success in the field of synthetic lethality and became the first evidence of modulating SL in the clinic when, in 2014, olaparib (<b>1</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) became the first PARPi approved by the FDA. This was approved for the treatment of ovarian cancer, following a phase II trial in which 34% of patients exhibiting BRCA1/2 mutations showed compelling response rates. The patients had been given at least three rounds of chemotherapy previously and were then treated with <b>1</b> as a single agent.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> It was seen in this trial and subsequent ones that platinum-sensitive cancers showed a better overall response rate to PARPi compared to platinum-resistant cancers.<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28,29)</a> Despite this, <b>1</b> has shown some success in platinum-resistant cancers in patients with BRCA1/2 mutations.<a onclick="showRef(event, 'ref28 ref30'); return false;" href="javascript:void(0);" class="ref ref28 ref30">(28,30)</a> This diversifies it from the other approved PARPiâs. <b>1</b> was approved in tablet and capsule form for the treatment of advanced ovarian cancer, where the patient had received at least three rounds of prior chemotherapy.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Approved PARP inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The second PARPi to be approved was rucaparib (<b>2</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) in 2016, which demonstrated similar effects to <b>1</b> in phase II trials;<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31,32)</a> however, the side effects between the two drugs are slightly different, affecting treatment choice. <b>2</b> was approved for use in patients with advanced ovarian cancer with deficient BRCA1/2 (either germline or somatic), who had received at least two treatments of chemotherapy in the past. The third FDA approved PARPi for the treatment of advanced ovarian cancer is niraparib (<b>3</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), and in 2017, it was approved for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in platinum-sensitive tumors.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></div><div class="NLM_p">PARPiâs have also been approved for the treatment of breast cancer. This was achieved through two phase III trials, studying <b>1</b><a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> and talazoparib (<b>4</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>)<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> in comparison to the cliniciansâ choice of chemotherapy in patients with human epidermal growth factor receptor 2 (HER-2) negative breast cancer who had received chemotherapy previously and have seen no progression on the platinum-based therapy. PARP inhibition showed an increase in progress-free survival in comparison to the platinum therapies. The final PARPi to gain regulatory approval was <b>4</b> in 2018, which is orally administered to adults with deleterious/suspected deleterious germline BRCA-mutated, (HER2)-negative, locally advanced, or metastatic breast cancer;<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a><b>1</b> was also approved for the same disease area. Furthermore, <b>1</b> was also approved for the treatment of pancreatic cancer as a first line maintenance treatment in cancers with a loss of function of BRCA2, following a double-blind placebo-controlled multicenter trial on 154 patients.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> The median progress-free survival of the participants increased from 3.8 months in the placebo to 7.4 months with <b>1</b>. Although this is a small increase, any progress in this particularly challenging disease area should be applauded.</div><div class="NLM_p">Recently (May 2020), <b>2</b>, followed by <b>1</b>, gained FDA approval for the treatment of germline and/or somatic BRCA-mutated metastatic castration-resistant prostate cancer. <b>2</b> was approved as a result of Triton 2, an ongoing multicenter, single arm clinical trial in 115 patients with BRCA-mutated (germline and/or somatic) mCRPC who had been treated with androgen receptor-directed therapy and taxane-based chemotherapy. <b>2</b> showed an objective response rate of 44% in 62 patients with measurable disease; 56% of these showed a duration of response greater than 6 months.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a><b>1</b> was approved on the basis of a 2019 phase III trial of 387 men, where <b>1</b> increased progression-free survival from 3.6 months to 7.4 months. <b>1</b> also decreased the risk of disease progression or death to a median of 5.8 months vs 3.5 months for standard of care treatment.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></div><div class="NLM_p">The field of PARP inhibition has been covered extensively by the literature; last year, an excellent review summarized the field of PARP inhibitors from a medicinal chemistry perspective, taking advantage of the extensive knowledge of the PARP protein to highlight binding motifs and structural similarities between the various generations of PARP inhibitors.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> The majority of inhibitors discussed in this review could theoretically be applied to inducing the SL phenotype; the field is extensively covered in the review by Jain et al., in which 37 different inhibitors are discussed with the majority of these being discovered after the approval of <b>1</b>.</div><div class="NLM_p last">PARPi resistance can develop in cancer cells showing the BRCA2 mutation, occurring in one of two ways: the cell either finds a way to re-establish HR repair or repairs the break through alternative means, and both are covered in great detail in the review by DâAndrea.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> These mutations are relevant in a clinical setting, as 46% of platinum-resistant serious grade ovarian cancers showed a mutation that resulted in the restoration of the BRCA2 pathway. This is achieved either through genetic events that cancel the loss of function of the BRCA2 mutation or through genetic inversion of the mutation, resulting in restoration of the wild-type (WT) BRCA2 protein. These resistance mechanisms demonstrate the continuous need for evolution of understanding of PARP inhibition, and the BRCA1/2 pathway. Examples of how increased understanding of the PARP1/BRCA2 pathway could bypass resistance are shown later in this text, as these resistance mechanisms rely on the restoration of BRCA2 function. Through an increased understanding of the relationship between BRCA2 and RAD51, it has been proposed that PARP1 inhibitor efficacy could be restored through interruption of the BRCA2/RAD51 interaction. Therefore, given the crossover between many DNA repair mechanism modulating targets, it is possible that other key interactions for BRCA2 could be elucidated as understanding of these pathways increases, providing new potential SL-tools to restore PARPi activity.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">3.  ATR, ATM, and DNA-PKcs Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80785" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80785" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">ATM and DNA-PKcs exhibit complementary functions in DNA damage repair, notably HR and nonhomologous end joining (NHEJ). The co-dependent nature of these two kinases is evident from the inactivation of these two kinases, causing embryonic lethality.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> A loss of function through either genetic malfunction or chemical modulation can cause synthetic lethality within cells. The inhibition of both targets causes an accumulation of DSB, which in turn causes an increase CTBP interacting protein (CtIP) mediated resection, thus forming large single-stranded DNA (ssDNA) tracts, followed by the triggering of apoptosis through the ATR/CHK1 pathway.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> This has been achieved with inhibition of DNA-PKcs as a monotherapy in ATM-defective lymphomas.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> In addition to ATM, inhibition of DNA-PKcs has been shown to be synthetically lethal in cells in a number of other targets that play a key role in the HR process: BRCA1, BRCA2, CHK2, Rad50, PTIP, and PAXIP.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> The inactivation of ATM and DNA-PKcs has been seen to be more effective in BRCA1/2 deficient cells.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> The link between ATM and BRCA1/2 is not well understood: it has been hypothesized that rather than being dependent on BRCA1/2, ATM is dependent on certain genetic changes this genotype causes.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Additionally, it has been seen that deficiency of either ATM or DNA-PKcs causes a sensitization to DNA-damaging agents such as topoisomerase I and II poisons or DNA alkylating agents.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> It has been proposed that the observed SL mechanism is not due to a failing of the DNA repair mechanism; this would differentiate this pathway somewhat from other SL pathways. Lastly, ATM has been shown to be synthetically lethal with the kinases MAPK and MEK1/2,<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> with ATM playing a role in prosurvival pathways, noticeably the AKT/mTOR pathway: when MAPK or MEK1/2 is inhibited, if ATM is also impaired, this pathway is not open and therefore cell death occurs. This is important, as MEK inhibitors have already gained regulatory approval.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></div><div class="NLM_p">As shown by its complementary functions with ATM, DNA-PKcs plays a key role in DNA repair in HR and NHEJ; the role of DNA-PKcs in DNA repair has been reviewed comprehensively by Goodwin et al.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> In addition to these well documented DNA damage repair pathways, DNA-PKcs is also involved with various processes that are thought to be important for tumor progression, such as cell cycle progression, transcription, and telomere maintenance,<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> making DNA-PKcs an attractive target for cancer therapy.</div><div class="NLM_p">DNA-PKcs is dysregulated in numerous cancers such as melanoma, where it encourages angiogenesis and tumor migration, and it has been discovered that the DNA-PKcs is associated with the secretion of prometastatic proteins through modification of the tumor microenvironment.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> DNA-PKcs dysregulation has also been observed in hepatocellular carcinoma<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> and myeloma<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> and is associated with radioresistance in cancers including thyroid,<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> oral cavity,<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> and cervical cancer.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a></div><div class="NLM_p">ATR is not directly associated with the DNA damage response; however it is involved with protecting cells from replication stress.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> It does this through preventing the collapse of the replication fork and inducing G2/M arrest by activating the checkpoint kinase CHK1. Cancer cells rapidly proliferate and therefore tend to undergo much replication stress and thus are particularly dependent on ATR. ATR has been observed to show SL with ATM/CHK2/p53: due to the amount of DSBs that are formed when ATR is inhibited, inhibiting key players in the DSB pathway is likely to result in an SL relationship. Of these SL relationships, ATR-ATM seems to be the most promising, as ATM is involved in both DNA repair in addition to cell cycle checkpoint activation. Furthermore, a deficiency in ATR has been shown to be synthetically lethal with agents that cause DNA stress, such as nonspecific chemotherapeutics. These SL relationships have been seen in various cancer cells including leukemia,<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> pancreatic,<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> and gastric cancer;<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> in some cases, the SL phenotype was only observed in combination with DNA damaging agents.</div><div class="NLM_p">ATR has also been shown to be synthetically lethal with CHK1, where small molecule-induced synthetic lethality has been reported, resulting in the selective killing of cancer cells.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> It has been hypothesized that the mechanism for SL of these two targets is that CHK1 inhibition increases replication stress through the deregulation of origin firing.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> The result of this is the stalling of DNA replication forks, increasing the concentration of ssDNA that must be repaired by the ATR-dependent replication protein A; however, due to ATR inhibition, this cannot occur and therefore a large amount of DSB accumulates, thus causing cell death.</div><div class="NLM_p">ATR, ATM, and DNA-PKcs are promising targets for impeding DNA damage repair, as all are involved in the disruption of the cell cycle and the initiation of the DNA damage repair process (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Currently multiple ATR inhibitors are in clinical trials, the data for which can be seen in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Demonstration of ATM, ATR, and DNA-PKcs involvement in DNA repair networks. Adapted from   <cite><i>Trends
in Cancer</i></cite>, Vol. <em>4</em>, Issue 11, <contrib-group>Omar L. Kantidze, Artem K. Velichko, Artem V. Luzhin,
Nadezhda V. Petrova, Sergey V. Razin</contrib-group>, Synthetically Lethal Interactions of ATM, ATR, and DNAPKcs,<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Page 762, Copyright (2018) with permission from Elsevier.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. List of Current Clinical Trials Involving Inhibition of ATR</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">trial identifier</th><th class="colsep0 rowsep0" align="center">drug</th><th class="colsep0 rowsep0" align="center">phase</th><th class="colsep0 rowsep0" align="center">summary</th><th class="colsep0 rowsep0" align="center">status and accession date</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left">NCT04266912</td><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" rowspan="3" align="left">I/II</td><td class="colsep0 rowsep0" rowspan="3" align="left">AÂ combinationÂ studyÂ of avelumab with <b>6</b>/nediseritib in participants with metastatic or inoperable tumors with deficient DNA damage repair.</td><td class="colsep0 rowsep0" align="left">Recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Avelumab (PD-L1 antibody)</td><td class="colsep0 rowsep0" rowspan="2" align="left">FebruaryÂ 12,Â 2020</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NedisertibÂ (DNA-PKi)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">NCT02589522</td><td class="colsep0 rowsep0" rowspan="2" align="left"><b>6</b></td><td class="colsep0 rowsep0" rowspan="2" align="left">I</td><td class="colsep0 rowsep0" rowspan="2" align="left">Studying the side effects and dose of <b>6</b> in combination with whole brain radiation in participants with non-small-cell lung cancer, small cell lung cancer, or neuroendocrine tumors that have spread to the brain.</td><td class="colsep0 rowsep0" align="left">Recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">October 28, 2015</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">NCT02630199</td><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" rowspan="2" align="left">I</td><td class="colsep0 rowsep0" rowspan="2" align="left">A combination study assessing the safety and tolerability of <b>6</b> and paciltaxel in participating metastatic cancer patients who have failed standard chemotherapy.</td><td class="colsep0 rowsep0" align="left">Recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Paclitaxel (nonspecific chemotherapeutic)</td><td class="colsep0 rowsep0" align="left">December 15, 2015</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">NCT03896503</td><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" rowspan="2" align="left">II</td><td class="colsep0 rowsep0" rowspan="2" align="left">Combination study comparing <b>6</b> and topotecan HCl to topotecan HCl as a single agent in participants with relapsed/extrapulmonary small cell lung cancer.</td><td class="colsep0 rowsep0" align="left">Recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Topotecan HCl (nonspecific chemotherapeutic)</td><td class="colsep0 rowsep0" align="left">April 1, 2019</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">NCT04149145</td><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" rowspan="2" align="left">I</td><td class="colsep0 rowsep0" rowspan="2" align="left">A combination study of <b>3</b> and <b>6</b> in participants with PARP-resistant recurrent ovarian cancer, to assess the safety of the combination, the response rate, and the percentage of participants who proceed to 6 months progression-free survival among patients who have developed PARPi resistance and to assess the indicators of response and progression of this disease following the combination therapy.</td><td class="colsep0 rowsep0" align="left">Not yet recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">November 4, 2019</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="6" align="left">NCT03527147</td><td class="colsep0 rowsep0" align="left">AZD9150</td><td class="colsep0 rowsep0" rowspan="6" align="left">I</td><td class="colsep0 rowsep0" rowspan="6" align="left">A study to investigate various targeted agentsâ safety, tolerability, efficacy, and PK/PD profile in participants with relapsed or refractory aggressive non-Hodgkinâs lymphoma.</td><td class="colsep0 rowsep0" align="left">Recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Acalabrutinib</td><td class="colsep0 rowsep0" rowspan="5" align="left">May 17, 2018</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Hu5F9-G4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Rituximab</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AZD5153</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">NCT03462342</td><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" rowspan="2" align="left">II</td><td class="colsep0 rowsep0" rowspan="2" align="left">A combination study to assess the safety, tolerability, response rate, and progression-free survival of <b>1</b> and <b>11</b> in women with recurrent ovarian cancer (platinum-sensitive or platinum-resistant).</td><td class="colsep0 rowsep0" align="left">Recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">March 12, 2018</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">NCT04065269</td><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" rowspan="2" align="left">II</td><td class="colsep0 rowsep0" rowspan="2" align="left">A combination trial of <b>1</b> and <b>11</b> in participants with gynecological cancers with ARId1A loss or no loss, to assess response rates in groups of participants selected based on their cancer cell subtype and the presence of an abnormality in ARID1A gene.</td><td class="colsep0 rowsep0" align="left">Recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">August 22, 2019</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">NCT02723864</td><td class="colsep0 rowsep0" align="left">Veliparib</td><td class="colsep0 rowsep0" rowspan="2" align="left">I</td><td class="colsep0 rowsep0" rowspan="2" align="left">A combination study to assess the safety, tolerability, and maximum dose of <b>6</b> and veliparib combined with cisplatin in participants with advanced refractory solid tumors.</td><td class="colsep0 rowsep0" align="left">Recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">March 31, 2016</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">NCT04267939</td><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" rowspan="2" align="left">I</td><td class="colsep0 rowsep0" rowspan="2" align="left">A combination study to assess the safety, tolerability, and maximum/recommended phase II dose of <b>8</b> and <b>3</b> in participants with recurrent advanced solid tumors and ovarian cancer.</td><td class="colsep0 rowsep0" align="left">Recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">February 13, 2020</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">NCT03188965</td><td class="colsep0 rowsep0" rowspan="2" align="left"><b>8</b></td><td class="colsep0 rowsep0" rowspan="2" align="left">I</td><td class="colsep0 rowsep0" rowspan="2" align="left">A study to assess the safety, tolerability, maximum dose, and response rate of <b>8</b> in participants with advanced solid tumors and lymphomas.</td><td class="colsep0 rowsep0" align="left">Recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">July 16, 2017</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">NCT04095273</td><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" rowspan="2" align="left">I</td><td class="colsep0 rowsep0" rowspan="2" align="left">A combination study to assess the safety/tolerability, PD/PK profile, and optimum dose for <b>8</b> and pembrolizumab in participants with advanced solid tumors.</td><td class="colsep0 rowsep0" align="left">Recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Pembrolizumab (PD-1 antibody)</td><td class="colsep0 rowsep0" align="left">September 19, 2019</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="4" align="left">NCT03641547</td><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" rowspan="4" align="left">I</td><td class="colsep0 rowsep0" rowspan="4" align="left">A combination study of <b>6</b> with standard of care chemotherapeutics to establish the safety, tolerability, maximum tolerated dose, and efficacy in participants with esophageal and other cancers.</td><td class="colsep0 rowsep0" align="left">Recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cisplatin</td><td class="colsep0 rowsep0" rowspan="3" align="left">August 22, 2018</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Capecitabine</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Radiotherapy (nonspecific chemotherapeutics)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">NCT02223923</td><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" rowspan="2" align="left">I</td><td class="colsep0 rowsep0" rowspan="2" align="left">A study to assess <b>11</b> in combination with radiotherapy. The study will investigate <b>11</b>âs safety, tolerability, dose, and dosing schedule while assessing preliminary drug response rates in participants with solid tumors.</td><td class="colsep0 rowsep0" align="left">Active, not recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Radiotherapy</td><td class="colsep0 rowsep0" align="left">August 22, 2014</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">NCT03682289</td><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" rowspan="2" align="left">II</td><td class="colsep0 rowsep0" rowspan="2" align="left">A study to assess <b>11</b> as a monotherapy and in a separate arm of the trial in combination with <b>1</b>, in participants with metastatic renal cell carcinoma, urothelial carcinoma, all pancreatic cancers, or other solid tumors. This study will assess objective response rate, median duration of response, median progression-free survival, and progression-free survival rate at 6 and 12 months. It will also further assess <b>11</b>âs safety.</td><td class="colsep0 rowsep0" align="left">Recruiting,</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">September 24, 2018</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">NCT03641313</td><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" rowspan="2" align="left">II</td><td class="colsep0 rowsep0" rowspan="2" align="left">A combination study to determine the overall response rate of <b>6</b> and irinotecan in participants with progressive, metastatic, or unresectable TP53 mutant gastric or gastroesophageal junction cancer. Furthermore, it seeks to assess the duration of response, time to progression, progression-free survival, and OS in participants with the combination of drugs in comparison to irinotecan alone and in participants with other DNA damage repair defects such as mutations in RCA1, BRCA2, MRE11, RAD50, RAD51, RAD52, RAD54L, NBN, ATM, H2AX, PALB2, RPA, BRIP1, BARD1, ATR, ATRX, CHK1, CHK2, MDM2, MDM4, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG and FANCL. Lastly, it seeks to compare the combination of <b>6</b> and irinotecan in participants who are Pt-sensitive and resistant.</td><td class="colsep0 rowsep0" align="left">Not yet recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Irinotecan (topoisomerase inhibitor)</td><td class="colsep0 rowsep0" align="left">August 22, 2018</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left">NCT02627443</td><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" rowspan="3" align="left">I/II</td><td class="colsep0 rowsep0" rowspan="3" align="left">A combination study to assess the safety, tolerability, maximum tolerated dose of <b>6</b>, carboplatin, and gemcitabine HCl in patients with recurrent and metastatic ovarian, primary peritoneal, or fallopian tube cancer. Furthermore, this study seeks to assess the maximum tolerated dose effect on overall survival, duration of response, and progression-free survival.</td><td class="colsep0 rowsep0" align="left">Recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Carboplatin (nonspecific chemotherapeutic)</td><td class="colsep0 rowsep0" rowspan="2" align="left">December 11, 2015</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Gemcitabine HCl (Cytotoxic chemotherapeutic)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left">NCT02567409</td><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" rowspan="3" align="left">II</td><td class="colsep0 rowsep0" rowspan="3" align="left">A combination study to assess whether <b>6</b> in combination with standard of care therapeutics improves progression-free survival, in comparison to standard of chemotherapy as a monotherapy in patients with metastatic urothelial cancer. Furthermore, this study seeks to compare overall survival, tumor response rate, and safety between the two study arms. Lastly, to assess the role of p53 in predicting response to <b>6</b>.</td><td class="colsep0 rowsep0" align="left">Active, not recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cisplatin (nonspecific chemotherapeutic)</td><td class="colsep0 rowsep0" rowspan="2" align="left">October 5, 2015</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Gemcitabine HCl (cytotoxic chemotherapeutic)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">NCT02487095</td><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" rowspan="2" align="left">I/II</td><td class="colsep0 rowsep0" rowspan="2" align="left">A study to assess the safety and efficacy of <b>6</b> and topotecan in treating small cell lung cancer.</td><td class="colsep0 rowsep0" align="left">Recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Topotecan (nonspecific chemotherapeutic)</td><td class="colsep0 rowsep0" align="left">July 1, 2015</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">NCT03787680</td><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" rowspan="2" align="left">II</td><td class="colsep0 rowsep0" rowspan="2" align="left">A combination study is to test the effectiveness, safety, and tolerability of <b>1</b> and <b>11</b> for all participants with metastatic castration-resistant prostate cancer.</td><td class="colsep0 rowsep0" align="left">Recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">December 26, 2018</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">NCT02595892</td><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" rowspan="2" align="left">II</td><td class="colsep0 rowsep0" rowspan="2" align="left">A combination study to assess the progression-free survival of <b>6</b> and gemcitabine in comparison to gemcitabine as a monotherapy in participants with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Across both arms will also be tested overall response rate, safety profiles, progression-free survival at 6 months, clinical benefit rate, duration of response, cancer antigen (CA)125 reduction, and overall survival.</td><td class="colsep0 rowsep0" align="left">Active, not recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Gemcitabine (cytotoxic chemotherapeutic)</td><td class="colsep0 rowsep0" align="left">November 4, 2015</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">NCT03669601</td><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" rowspan="2" align="left">I</td><td class="colsep0 rowsep0" rowspan="2" align="left">A dose escalation trial to assess the safety of <b>11</b> in combination with gemcitabine in participants with advanced solid tumors.</td><td class="colsep0 rowsep0" align="left">Recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Gemcitabine (cytotoxic chemotherapeutic)</td><td class="colsep0 rowsep0" align="left">September 13, 2018</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">NCT03328273</td><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" rowspan="2" align="left">I/II</td><td class="colsep0 rowsep0" rowspan="2" align="left">A combination study that evaluates the safety, pharmacokinetics, pharmacodynamics, and efficacy of acalabrutinib and <b>11</b>.</td><td class="colsep0 rowsep0" align="left">Recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Acalabrutinib (BTK inhibitor)</td><td class="colsep0 rowsep0" align="left">November 1, 2017</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">NCT04052555</td><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" rowspan="2" align="left">I</td><td class="colsep0 rowsep0" rowspan="2" align="left">A combination study to test the recommended dose for phase II trials of <b>6</b> in combination with standard of care radiotherapy in participants with triple-negative or estrogen receptor and/or progesterone receptor positive, HER-2 negative breast cancer.</td><td class="colsep0 rowsep0" align="left">Recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Radiotherapy</td><td class="colsep0 rowsep0" align="left">August 12, 2019</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left">NCT02567422</td><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" rowspan="3" align="left">I</td><td class="colsep0 rowsep0" rowspan="3" align="left">A combination study to assess the safety, tolerability, and maximum tolerated dose of <b>6</b> in combination with standard of care cisplatin and radiotherapy in participants with locally advanced head and neck squamous cell carcinoma.</td><td class="colsep0 rowsep0" align="left">Recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cisplatin (nonspecific chemotherapeutic)</td><td class="colsep0 rowsep0" rowspan="2" align="left">October 5, 2015</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Radiotherapy</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">NCT02595931</td><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" rowspan="2" align="left">I</td><td class="colsep0 rowsep0" rowspan="2" align="left">A study to assess the safety, tolerability, and maximum tolerated dose of <b>6</b> and irinotecan hydrochloride in treating participants with metastatic or unresectable DNA damage repair deficient solid tumors.</td><td class="colsep0 rowsep0" align="left">Recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Irinotecan HCl (topoisomerase inhibitor)</td><td class="colsep0 rowsep0" align="left">November 4, 2015</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">NCT04266912</td><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" rowspan="2" align="left">I/II</td><td class="colsep0 rowsep0" rowspan="2" align="left">A study to assess the safety, tolerability, and maximum tolerated dose of <b>6</b> and avelumab in treating participants with metastatic or unresectable DNA damage repair deficient solid tumors.</td><td class="colsep0 rowsep0" align="left">Recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Avelumab (PD-L1 antibody)</td><td class="colsep0 rowsep0" align="left">February 12, 2020</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left">NCT03517969</td><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" rowspan="3" align="left">II</td><td class="colsep0 rowsep0" rowspan="3" align="left">A combination study that studies response rate of <b>20</b> and carboplatin with and without docetaxal in participants with castration-resistant prostate cancer.</td><td class="colsep0 rowsep0" align="left">Recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Carboplatin (nonspecific chemotherapeutic)</td><td class="colsep0 rowsep0" rowspan="2" align="left">May 8, 2018</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Docetaxel (microtubules binder)</td></tr></tbody></table></div></div><div class="NLM_p">VE-821 (<b>5</b>, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A) (ATR IC<sub>50</sub> = 26 nM) is an ATR inhibitor developed by Vertex pharmaceuticals in 2011. This compound is typical of numerous inhibitors from this development program, all of which contain a 2-aminopyrazine binding motif.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> While this compound was a useful tool in understanding the underlying biology associated with ATR inhibition, it did not exhibit good solubility, and its metabolic profile, specifically producing aniline-like metabolites, was undesirable for a clinical candidate; thus Vertex began optimization of <b>5</b>.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> Initial optimization of <b>5</b> involved the replacement of the anilide group with various fused bi-cycles: while these were well-tolerated in terms of ATR inhibition, they also demonstrated a loss in selectivity for ATR against ATM. Through <i>in silico</i> modeling it was theorized that this loss in selectivity was caused by the bulky fused bi-cycles and the gatekeeper residue of the PIKK tyrosine kinase family, causing rotation of the bound inhibitor. This in turn led to a further steric clash between Pro2755 of ATM and the isopropylsulfone group of the inhibitor that caused tighter ATM binding. With this information in hand, Vertex theorized five-membered phenyl substituted heterocycles would avoid these steric clashes and therefore would be able to maintain selectivity, as they more closely resemble the anilide moiety present in <b>5</b>. Additionally, with substitution upon the phenyl ring, a localized highly negatively charged area of the ATP binding pocket could be exploited to further increase potency, selectivity, and solubility. These SAR studies resulted in the eventual synthesis of VX-970 (<b>6</b>, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A), which shows picomolar ATR activity (IC<sub>50</sub> = 0.17 nM) and >250 degree of selectivity over ATM. In cells, it was able to sensitize colorectal cancer cells to cisplatin, using less than 50 nM <b>6</b>. Furthermore, it demonstrated a good pharmacokinetic profile (Cl = 26 mL min<sup>â1</sup> kg<sup>â1</sup>; <i>V</i><sub>ss</sub> = 21 L/kg; <i>T</i><sub>1/2</sub> = 11.6 h), in addition to good bioavailability, making it ideal for further <i>in vivo</i> studies. <b>6</b> is a first-in-class inhibitor and has been tested both as a monotherapy and with nonspecific chemotherapeutics such as topotecan, carboplatin, gemcitabine, and cisplatin.<a onclick="showRef(event, 'ref66 ref67 ref68 ref69'); return false;" href="javascript:void(0);" class="ref ref66 ref67 ref68 ref69">(66â69)</a><b>6</b> presented promising results as a monotherapy, showing a complete response in one patient for greater than 19 months, with no associated toxicity. However, in phase I trials with the nonspecific chemotherapeutics, bone marrow toxicity was observed. The toxicity issues observed are somewhat common for nonspecific chemotherapeutics, and in this instance the combinatorial approach yielded no benefit over the monotherapeutic approach. Several trials are still ongoing for <b>6</b> in numerous cancer subtypes. <b>6</b> has been acquired by Merck KGaA under the new name M6620; additionally Merck has entered a second ATR inhibitor using a different scaffold into clinical trials, M4344 (<b>7</b>, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B) (ATR <i>K</i><sub>i</sub> â¤ 150 pM).<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> The development of <b>7</b> has yet to be published, with preclinical data only being presented at a congress.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) SAR study around ATR inhibitor VE-821 (<b>5</b>) to get VX-970 (<b>6</b>). (B) Structure of ATR inhibitor M4344 (<b>7</b>). (C) Structure of BAY1895344 (<b>8</b>) identified by Bayer AG as a selective ATR inhibitor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">BAY1895344 (<b>8</b>, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C) was developed by Bayer AG as described in a patent (<b>8</b> is example 111 in patent WO 2016/020320),<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> through a high-throughput screen HTS. <b>8</b> is a novel potent (7 nM) and selective ATR inhibitor (hitting 6 of 456 kinases tested in the kinome screen). Furthermore, <b>8</b> was able to selectively inhibit ATR mediated DNA repair and inhibited proliferation in a range of cancer cell lines, being most active in lymphoma cell lines showing an IC<sub>50</sub> of 9 nM.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> It exhibits strong monotherapy efficacy in cancers with impeded DNA damage repair. In addition to this, it synergizes well with nonspecific chemotherapeutics (cisplatin and carboplatin) and other DNA damaging agents (external beam radiotherapy).</div><div class="NLM_p">It is currently under investigation in clinical trials in patients with advanced solid tumors and lymphomas (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Lastly, <b>8</b> showed synergism with <b>1</b> in BRCA1/2 deficient breast cancer cells, suggesting a synthetically lethal interaction; these results were mirrored <i>in vivo</i> in breast cancer models.</div><div class="NLM_p">AstraZeneca (AZ) had previously developed a series of potent and selective ATR inhibitors, of which the best performing was AZ20 (<b>9</b>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) (ATR IC<sub>50</sub> = 5 nM).<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> However, while this compound was able to prevent the growth of ATM-deficient xenograph models in tolerated dosages, its aqueous solubility was poor. Furthermore, it was found to hit cytochrome P450 3A4 (CYP3A4), thereby increasing the chance of drugâdrug interaction: given the unlikeliness of ATR inhibitors being administered as a monotherapy, this would stop it progressing through further studies. Therefore, a drug-discovery program was initiated, looking to keep <b>9</b>âs activity but with improved aqueous solubility and lessened CYP3A4 activity.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> Initial SAR looked at making modifications at the R1 and R2 positions (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>); alterations at the R1 position did not reduce CYP3A4 activity and therefore were quickly abandoned. Modifications at the R2 position began with simple ring substitutions; while this did reduce CYP3A4 activity, it also decreased ATR activity, suggesting that the indole group was the reason for CYP3A4 activity. Ring switch to 6- or 7-azaindole and to 2-aminobenzimidazole showed similar ATR activity in cell-based and biochemical assays to AZ20 while reducing CYP3A4 activity. The best of the series was <b>10</b> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) (ATR IC<sub>50</sub> = 5 nM). Exploration of substitution of the benzimidazole was attempted; however, none of the changes at this position proved fruitful as all modifications in this position resulted in either loss in ATR inhibition or physicochemical properties, such as aqueous solubility.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Chemical modifications introduced in AZ20 (<b>9</b>) to improve solubility and reduce CYP3A4 activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Subsequent modifications began at the sulfone group, looking to expand upon <b>10</b>. While initial replacement of the sulfone with sulfoxide resulted in promising molecules, the metabolic risks associated with sulfoxides were deemed too high, and therefore AZ did not pursue this avenue of research. However, substitution with various sulfoximines resulted in AZD6738 (<b>11</b>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) (ATR IC<sub>50</sub> = 4 nM), which achieved all goals of the lead-development program, with decreased lipophillicity and improved aqueous solubility, in addition to reduced CYP3A4 activity in comparison to <b>9</b>.</div><div class="NLM_p">Compound <b>11</b> was taken through to further screening for its biological, physiochemical, and ADME properties. It was found to be the lead compound from this series due to its excellent solubility, permeability, and selectivity (only hitting â¼60% for PIK3C2G and CLK4 out of the 409 kinases tested in the kinome screen) and demonstrated profound antitumor activity. <b>11</b> has progressed in multiple phase I/II trials, and while some are in combination with nonspecific chemotherapeutics such as carboplatin (NCT02264678), it has also entered trials with the PARP inhibitor <b>1</b>, suggesting synthetic lethality (NCT03462342, NCT03330847), with further preclinical studies underway for other combinations with <b>1</b>.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> Overall, the clinical candidate <b>11</b> has a favorable pharmacokinetic profile for once or twice daily dosing, achieving biological efficacy at moderate dosages. The selectivity of this compound should be noted as it makes it an ideal tool for further exploration of ATRâs synthetically lethal partners such as ATM and CHK1.</div><div class="NLM_p">It has been discovered that homology exists between PI3K and ATR;<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> therefore, it was hoped that it could be harnessed for the discovery of novel ATR inhibitors. Ramachandran et al. had previously been working on dual inhibitors of Brutonâs tyrosine kinase (BTK) and PI3K:<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> this was used as a starting point for the design of ATR inhibitors.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> From the 299 selected compounds in the BTK series, 11 showed inhibition of >50% at 5 Î¼M while only 1 showed inhibition of >50% at 500 nM. Interestingly, despite the homology between the two kinases, there was poor overlap between the inhibition of both, suggesting that the scaffold utilized in this series is differentiated somewhat from other ATR inhibitors (<b>8</b>, <b>9</b>â<b>11</b>), which were also developed from PI3K inhibitors. Of the originally tested compounds, <b>12</b> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A) stood out as the prime target for further optimization not only because of it being the strongest inhibitor of ATR from this series (IC<sub>50</sub> = 0.220 Î¼M) but also because it showed relatively low activity against BRK and PI3K (BRK inh = 24%, PI3Kd inh = 52% at 100 nM). <b>12</b> was tested as a racemic mixture as there was less than a 2-fold difference in ATR activity between the two enantiomers (IC<sub>50</sub> = 0.304 Î¼M vs 0.158 Î¼M). This was tested with three other compounds (<b>13</b>â<b>15</b>, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) that also showed good activity (in the low micromolar range). All four of these compounds share the same common 4-aminopyrazolopyrimidine scaffold functionalized at N1 with a partially aromatic bicyclic system: it was discovered that removal of the hydrogen bond donors/acceptors present in this core scaffold was not well-tolerated, causing either a partial or complete loss of activity against ATR. In addition to this, replacement of the azaindolyl group with an aminopyridine group which displayed the same hydrogen bond acceptors/donors was not tolerated, suggesting the steric bulk present in the aminopyrazolopyrimidine group is necessary for ATR inhibition. Follow-up SAR was conducted, introducing new bulky groups at the C3 position, and yet none of these were able to improve on the activity of <b>12</b>. Therefore the focus of the SAR studies turned to alkylation at the N1 position. While the majority of modifications at this position did not yield a significant improvement on the activity of <b>12</b>, compound <b>16</b> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B), which takes influence from Vertexâs <b>5</b><a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> featuring a phenylsulfonyl group, managed to yield the most potent ATR inhibitor in this series to date with a 3-fold improvement in activity (IC<sub>50</sub> = 66 nM) over <b>12</b>.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Hit compounds from Ramachandran et al. (B) Optimization of <b>12</b> to <b>16</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p"><b>16</b> was compared to the clinical candidate ATR inhibitors <b>6</b> (IC<sub>50</sub> = 15 nM) and <b>11</b> (IC<sub>50</sub> = 86 nM) and in the same testing conditions showed similar levels of ATR inhibition. The lipophilic efficiency of <b>16</b> (5.8) and oxidative stability were in the same region of the two literature compounds. <b>16</b> was also tested for selectivity in a kinome screen of 394 kinases: of these, 10 were inhibited at greater than 70% at 1 Î¼M and 76 were inhibited at greater than 70% at the 10 Î¼M, with only breast tumor kinase (BTK) being inhibited to a greater degree than ATR. Lastly, <b>16</b> was tested <i>in vivo</i> in mice, where it showed good clearance but poor bioavailability, suggesting further optimization is required. Given ATRâs potential for small molecule-induced synthetic lethality, any optimization of this compound should be monitored with interest.</div><div class="NLM_p">In 2004, Hickson et al. developed the first selective ATM inhibitors, as up to this date all molecules that had inhibited ATM were nonspecific PIKK and PI3k inhibitors such as caffeine. Through a combinatorial library approach based around the nonspecific PIKK and PI3k inhibitor LY294002 (<b>17</b>, <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A), the group developed the ATP competitive inhibitor KU-55933 (<b>18</b>, <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A), which demonstrated in biochemical assays an IC<sub>50</sub> of 12.9 Â± 0.1 nM, with at least a 100-fold degree of selectivity over 60 other selected similar kinases.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> In these studies, interesting structural information was gleaned when replacing the oxygen in the morpholine ring (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). This resulted in a significant drop in potency in KU-58050 (<b>19</b>, <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A) (2.96 Â± 0.44 Î¼M), a 200-fold drop in potency in comparison to <b>18</b>, showing the importance of the oxygen at this position. Furthermore, <b>18</b> was able to sensitize cells to ionizing radiation and nonspecific chemotherapeutics, thus increasing the amount of DSB.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) Development of ATM inhibitor LY294002 (<b>17</b>) into KU-60019 (<b>20</b>). (B) Structure of ATM inhibitor CP466722 (<b>21</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Following on from this work, in 2009 Golding et al. developed KU-60019 (<b>20</b>, <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A) by expanding upon the thianthrene group with the aim of improving <b>18</b>âs bioavailability and pharmacokinetics.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a><b>20</b> was more water-soluble, was able to double the potency with respect to <b>18</b> (6.3 nM), and was more selective, showing a 240- and 1600-fold degree of selectivity for DNA-PKcs and ATR, respectively. <b>20</b> is better at sensitizing cells to ionizing radiation, showing an enhancement of 4.4 compared to 1.6 from <b>18</b>, when both compounds were administered to glioma cells at 10 Î¼M. In scratch assays, <b>20</b> was able to reduce invasion <i>in vitro</i> in U87 cells and a greater than 70% drop in invasion was observed in a dose-dependent manner. In the more invasive U1242 glioma cells, a greater than 50% decrease in invasion was observed. It is thought that <b>20</b> showed this anti-invasive phenotype by acting on AKT and MEK/ERK prosurvival pathways. <b>20</b> is currently undergoing a clinical trial (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) in combination studies with CHK2 inhibitors; should this work, it could indicate small molecule-induced synthetic lethality.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Current Clinical Trials Involving ATM Inhibitors</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">trial identifer</th><th class="colsep0 rowsep0" align="center">drug</th><th class="colsep0 rowsep0" align="center">phase</th><th class="colsep0 rowsep0" align="center">summary</th><th class="colsep0 rowsep0" align="center">status and accession date</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">NCT03423628</td><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" rowspan="2" align="left">I</td><td class="colsep0 rowsep0" rowspan="2" align="left">A study to assess the safety, tolerability, and PK of increasing doses of <b>29</b> in combination with distinct regimens of radiation therapy in participants with brain cancer.</td><td class="colsep0 rowsep0" align="left">Recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Radiotherapy</td><td class="colsep0 rowsep0" align="left">FebruaryÂ 6,Â 2018</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="5" align="left">NCT03571438</td><td class="colsep0 rowsep0" align="left">CX4945 (CK2i)</td><td class="colsep0 rowsep0" rowspan="5" align="left">NotÂ applicable</td><td class="colsep0 rowsep0" rowspan="5" align="left">A combination study to compare CX4945 and <b>20</b> to standard of care treatments directly on organotypic cultures of tumors from participants, measuring incidents of cell death.</td><td class="colsep0 rowsep0" align="left">Recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" rowspan="4" align="left">June 27, 2018</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Sunitinib (multiple RTKi)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Pazopanib (multiple RTKi)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TemsirolimusÂ (mTORi)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="5" align="left">NCT02588105</td><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" rowspan="5" align="left">I</td><td class="colsep0 rowsep0" rowspan="5" align="left">AÂ studyÂ toÂ testÂ theÂ safety, tolerance PK/PD, and initial efficacy of <b>28</b> as a monotherapy and in combination with the other listed drugs.</td><td class="colsep0 rowsep0" rowspan="5" align="left">Active, not recruiting October 27, 2015</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Irinotecan (topoisomerase inhibitor)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Fluorouracil (thymidylate synthase inhibitor)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Folinic acid</td></tr></tbody></table></div></div><div class="NLM_p">In 2008 Rainey et al., through use of an <i>in vitro</i> kinase screen of approximately 1500 small molecules, identified CP466722 (<b>21</b>, <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B) (ATM IC<sub>50</sub> = 12.9 nM).<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> This was able to inhibit ATM activity <i>in vitro</i> but did not show activity against the closely related kinases in the PI3k family. <b>21</b> showed a lack of toxicity and the ability to inhibit ATM in human and mouse cells, the latter being important as the group wished to test the compounds <i>in vivo</i> in murine models. Furthermore, <b>21</b> was able to sensitize cancer cells to ionizing radiation. It was also demonstrated that <b>21</b> was a reversible binder, shown to bind quickly and effectively for at least 8 h in tissue culture; however, upon 30 min of wash off, ATM-dependent phosphorylation events were restored. This reversibility is key due to the important role ATM plays in the cell cycle.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> This compound has yet to be used for further studies.</div><div class="NLM_p">AstraZeneca has acquired KuDOS pharmaceuticals and has continued building upon the progress made by <b>20</b>. Through optimization of an initial screening hit, <b>22</b> (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) (ATR cell IC<sub>50</sub> = 82 nM), AZ was able to develop two further compounds: <b>23</b> (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) (ATR cell IC<sub>50</sub> = 46 nM) and <b>24</b> (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) (ATR cell IC<sub>50</sub> = 33 nM). <b>23</b> and <b>24</b> allowed exploration of the ATM inhibitors <i>in vivo</i>.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> At an oral dosage of 100 mg/kg QD, <b>23</b> was able to increase sensitivity to ionizing radiation in a HT29 xenograph mouse model.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> Both <b>23</b> and <b>24</b> were able to enhance the efficacy of irinotecan in a SW620 mouse xenograft models, with <b>24</b> able to contribute to tumor regression.<a onclick="showRef(event, 'ref83 ref84'); return false;" href="javascript:void(0);" class="ref ref83 ref84">(83,84)</a> In line with other ATM inhibitors, <b>23</b> and <b>24</b> were ineffective without a DNA damaging agent to induce DSB. <b>24</b> showed a favorable reduction in activity against hERG relative to <b>23</b> (IC<sub>50</sub> of 22 and 4.5 Î¼M, respectively) and therefore had a lower chance of cardiovascular issues later on in clinical development, suggesting that <b>24</b> would be the better clinical candidate going forward.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> Through pharmacological modeling, it was found that <b>24</b> would have a low half-life (only 4 h) in humans, and therefore the predicted dose would be 700 mg QD, with a maximum unbound concentration <i>C</i><sub>max</sub> of 1.3 Î¼M. In addition, other calculated parameters such as predicted clinically efficacious dose and maximum absorbable dose (<i>D</i><sub>abs</sub>) were unfavorable; therefore AZ concluded that the probable chance of attrition was too high. A further development program was initiated with an aim to produce molecules with a reduced predicted clinical dose and an increased <i>D</i><sub>abs</sub>. AZ set about attempting to increase their compoundsâ volume of distribution (<i>V</i><sub>ss</sub>), as pharmacokinetic half-life is calculated through <i>V</i><sub>ss</sub> and clearance (CL). As <b>24</b> already showed a low metabolic turnover, further reduction of CL would be challenging; therefore, <i>V</i><sub>ss</sub> was chosen as the parameter to optimize. This began with the attempted inclusion of a basic substituent with the molecule, as it has been shown previously that basic compounds increase <i>V</i><sub>ss</sub> with respect to acidic or neutral compounds,<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> with the idea of keeping other parameters the same. While <b>25</b> (ATR cell IC<sub>50</sub> = 8.6 nM) showed an increase in ATM inhibition with respect to <b>24</b>, a drop in permeability to unacceptable levels occurred, meaning that basic substituents would be unlikely to be tolerated going forward. In an effort to increase permeability by reducing the number of hydrogen bond donors, a scaffold hop was attempted. This was done using a pseudo-ring system and a tri-cycle system, imidazo[4,5-<i>c</i>]quinolin-2-one, which was selected from previous AZ in-house data. This scaffold has also seen success in ATM inhibition as an off-target in the dual PI3K/mTOR inhibitor, NVP-BEZ235, which has entered clinical trials.<a onclick="showRef(event, 'ref87 ref88'); return false;" href="javascript:void(0);" class="ref ref87 ref88">(87,88)</a> Of these compounds, <b>26</b> and <b>27</b> (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) were the most potent (ATM IC<sub>50</sub> = 0.95 and 0.36 Î¼M, respectively), with <b>27</b> showing reduced aqueous solubility. Given the promising results with this scaffold, motifs from <b>23</b> and <b>24</b> were modeled upon the imidazo[4,5-<i>c</i>]quinolin-2-one scaffold to create a second series. Through in-depth SAR of the imidazo[4,5-<i>c</i>]quinolin-2-one scaffold, AZ eventually identified AZD0156 (<b>28</b>, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) as the lead compound. <b>28</b> showed an excellent affinity for ATM (IC<sub>50</sub> = 0.04 nM in biochemical assays, 0.57 nM in cells) and an exceptional degree of selectivity, with only 2 of the 397 kinases tested in the kinome screening showing greater than 70% inhibition (mTOR, 93%; LRRK2, 87%). <b>28</b> showed desirable levels of unbound drug in human plus two other mammalian species (rat and dog) and acceptable permeability, and it did not target any of the main five isoforms of P450.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> In addition to this, the predicted pharmacokinetics of <b>28</b> were favorable, with low to moderate clearance in man (â¼8 mL min<sup>â1</sup> kg<sup>â1</sup>), moderate to high <i>V</i><sub>ss</sub> (5.8 L/kg), and high oral bioavailability (66%). In docking studies, <b>28</b> showed good complementarity to ATMâs ATP binding site, displaying two interactions with the kinase hinge region (Cys2770 and Lys2717) and one in the back binding pocket (Tyr2755). In addition to this, the basic amine, present in <b>28</b>, is predicted to be surrounded by three acidic residues (Asp2725, Asp2720, and Asp288). <b>28</b> demonstrated the ability to increase the effectiveness of DSB-inducing agents such as irinotecan. In combination studies, irinotecan (50 mg/kg ip Q7D) and <b>28</b> (dosed orally at 20 mg/kg QD) were tolerated, causing tumor regression in SW620 xenograph models in immunocompromised mice. However, as expected, when <b>28</b> was administered as a monotherapy, it showed no effect. All these results indicate that <b>28</b> is a first-in-class selective ATM inhibitor with promising potential applications for cancer therapy; it is currently involved in a clinical trial highlighted in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Development by AstraZeneca of ATM inhibitor from hit <b>22</b> into candidate AZD1390 (<b>29</b>) through the lead AZD156 (<b>28</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">With the <b>28</b> series showing success, further screens were conducted on related hits to try and find other clinical candidates. Given rates of attrition in drug development, having a second, backup molecule in the pipeline provides a level of security. AZD1390 (<b>29</b>, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) was discovered in an <i>in vitro</i> screen, with a similar structure as <b>28</b>. It was designed to perform well in the following parameters: ATM autophosphorylation activity (IC<sub>50</sub> = 0.09 nM); selectivity against closely related PIKK family kinases (ATR, DNA-PK, mTOR (all IC<sub>50</sub> â¥ 1 Î¼M)); general selectivity across the kinome; lack of activity in novel dual-transfected human MDR1 and BCRP efflux transporters assays.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> In terms of general selectivity, <b>29</b> was tested against a panel of 121 kinases and showed â¥50% inhibition against three targets (CSF1R, NUAK1, and SGK) at 1 Î¼M, with none of the 354 kinases tested showing â¥50% inhibition at 0.1 Î¼M. In a similar fashion to <b>28</b>, <b>29</b> showed minimal hERG activity (>33.3 and 6.55 Î¼M, respectively). <b>29</b> demonstrated good bloodâbrain barrier (BBB) penetration and has favorable physicochemical and PD/PK properties. Furthermore, it was able to interrupt DNA damage repair in glioblastoma and lung cancer cells. In line with previous studies on ATM inhibitors, <b>29</b> was more effective in p53-deficient cells.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> It was also demonstrated that treatment of animal orthotropic brain models of glioblastoma and lung cancer brain metastasis (>3 h) with <b>29</b> at a concentration above the IC<sub>50,</sub> in combination with ionizing radiation, blocked tumor growth. It was also observed that a combination of ionizing radiation and <b>29</b> caused an increase in apoptosis in comparison to <b>29</b> as a monotherapy. In brain cancer models using intracranially implanted xenografts, <b>29</b> was tested in combination with ionizing radiation and a triplet combination of <b>29</b>, ionizing radiation, and the alkylating agent temozolomide.</div><div class="NLM_p">While the triplet combination showed more success than the doublet, it appeared to be an additive effect, while ionizing radiation and <b>29</b>âs combination were synergistic. In neither study, any behavioral abnormalities were observed because of the administration of <b>29</b>, which is key for treatment of the brain. <b>29</b> was tested in human-derived glioblastoma models from patients with either temozolomide resistance or sensitivity and either p53 WT or mutant, with the most sensitive to <b>29</b> and ionizing radiation as expected being in the p53 mutant models, thus agreeing with their previous data. On the basis of these data, <b>29</b> is being considered as a clinical candidate and entered a phase I clinical trial in patients with brain cancer, the information of which are reported in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. These data, in particular the work in glioblastoma, are of great importance to the field. Glioblastoma is the most aggressive cancer of the brain, with poor patient prognosis, a seemingly inevitable rate of recursion, and a median survival rate of 12â14 months with current standard of care therapy.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a><b>29</b> shows the first example of potential SL-related treatment of glioblastoma, one of the most urgent unmet medical needs in oncology.</div><div class="NLM_p">As highlighted earlier in the review, DNA-PKcs is thought to be synthetically lethal with a number of DNA repair modulating targets, specifically ATM. In this section we highlight some of the DNA-PKcs inhibitors currently in clinical and preclinical studies.</div><div class="NLM_p">SU11752 (<b>30</b>, <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>) was the first selective DNA-PK inhibitor to be discovered when it was identified from a library of 3-substituted indolin-2-ones. <b>30</b> showed a similar <i>in vitro</i> DNA-PK activity to the known PI3K inhibitor wortmanin (<b>31</b>, <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>) (<b>30</b> IC<sub>50</sub> = 0.13 Î¼M vs <b>31</b> IC<sub>50</sub> = 0.1 Î¼M). The binding mode of <b>30</b> was then assessed: <b>31</b> has been shown previously to irreversibly bind to DNA-PK, a trait that would be undesirable in a cell cycle modulator;<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> however <b>30</b> was shown to be a reversible ATP competitive inhibitor. Furthermore, <b>30</b> was much more selective than <b>31</b>, as <b>30</b> was 500 times less active against <b>31</b>âs primary target PI3KÎ³. Additionally <b>31</b> inhibits ATM, while in cells <b>31</b> was seen to be a poor inhibitor of ATM. <b>31</b> was able to sensitize glioblastoma cells to ionizing radiation and disrupt DNA repair.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Structure of SU-11752 (<b>30</b>) and wortmannin (<b>31</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p"><b>17</b> is a known PI3K inhibitor (PI3KÎ±, -Î², -Î´ IC<sub>50</sub> = 0.5, 0.97, 0.57 Î¼M) that was used as a starting point in the pursuit of novel selective DNA-PK inhibitors in work conducted by Griffin et al. Initial optimization of <b>17</b> (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>) resulted in the synthesis of a series of DNA-PK inhibitors, which displayed IC<sub>50</sub>âs in the low micromolar or nanomolar range. The most potent of this series were pyrimidoisoquinolinone (<b>32</b>, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>) (DNA-PK IC<sub>50</sub> = 0.28 Î¼M) and NU7026 (33, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>) (DNA-PK IC<sub>50</sub> = 0.23 Î¼M), which were able to sensitize tumor cell lines to ionizing radiation and DNA damaging agents.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a></div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Optimization of PI3K inhibitor <b>17</b> resulting in the discovery of KU-5788 (<b>34</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">This work was continued through the use of a pharmacophore mapping approach, replacing or substituting upon the 2-morpholinyl substituent. This approach resulted in the discovery of KU-57788 (<b>34</b>, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>) (formerly NU7441).<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a><b>34</b> was shown to be a potent DNA-PK inhibitor (IC<sub>50</sub> = 13 nM) with good selectivity against ATM and ATR (no activity at 100 Î¼M); however it also hit mTOR and PI3K (IC<sub>50</sub> = 1.7 and 5 nM, respectively). In a similar manner to other DNA-PK inhibitors <b>34</b> was able to enhance radiosensitization and the cytotoxicity of etoposide, in Hela cells, while showing no cellular toxicity as a single agent.</div><div class="NLM_p">AZ set out to discover a selective DNA-PK inhibitor. AZ had observed that many of the current DNA-PK inhibitors showed poor selectivity over related PI3Ks and PIKK family members such as ATM and mTOR. Through use of an in-house screen searching for DNA-PK activity over PI3K, the initial hit (<b>35</b>, <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>A) (biochemical data not reported) was discovered. <b>35</b> was optimized, improving its potency, physiochemical, and pharmacokinetic properties to give AZD7648 (36, <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>A).<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a><b>36</b> was a potent inhibitor of DNA-PK (IC<sub>50</sub> = 0.6 nM) and showed good selectivity: in a panel of 397 kinases, only 4 showed inhibition of >50% (PK, PI3KÎ±, PI3KÎ´, and PI3KÎ³), and of these 4 kinases 36 showed at least a > 60-fold degree of selectivity for DNA-PKcs. In A549 cells <b>36</b> inhibits DNA-PKcs autophosphorylation at Ser2056 (IC<sub>50</sub> = 90 nM); furthermore its selectively was also repeated in cells, with <b>36</b> showing a >90-fold selectivity for DNA-PKcs over ATM, ATR, mTOR, and three PI3K isoforms (Î±, Î², and Î´), with a 10-fold selectivity increase over PI3KÎ³. The selectivity of <b>36</b> was compared to other notable DNA-PKcs inhibitors (including <b>37</b>) which all had at least one secondary target with <10-fold selectivity. <b>36</b> was able to enhance DNA damaging therapies such as radiotherapy, doxorubicin, and <b>1</b><i>in vitro</i> and <i>in vivo</i>. Due to its mechanism of acting through inhibition of NHEJ, as opposed to HR, <b>36</b> is differentiated from many of the current candidates for SL modulating drugs. This, combined with its potency and selectivity, makes it an interesting compound for further study.</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. (A) Optimization of DNA-PK inhibitor <b>35</b> to AZD7648 (<b>36</b>) by AZ. (B) Structure of DNA-PK inhibitor M3814 (<b>37</b>) developed by Merck.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">M3814 (also known as nedisertib) (<b>37</b>, <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>B) is a potent selective DNA-PK inhibitor (DNA-PK IC<sub>50</sub> â¤ 3 nM).<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> Information on the development of this inhibitor has not been published, and <b>37</b> was first described in a patent filed by Merck.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a><b>37</b> has been shown to enhance the antitumor effect of ionizing radiation in solid tumors and leukemia through inhibition of the NHEJ pathway, a common feature of selective potent DNA-PK inhibitors.<a onclick="showRef(event, 'ref97 ref99 ref100'); return false;" href="javascript:void(0);" class="ref ref97 ref99 ref100">(97,99,100)</a> This effect is much more pronounced in cancer cells that express WT-p53, thought to be due to overactivation of p53/ATM which causes a much higher concentration of p53 in comparison to radiation treatment administered alone, leading to premature cell cycle arrest and senescence. This enhancement of radiotherapy has also been observed in mice, where combination of <b>37</b> and radiotherapy caused complete remission.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> Due to these promising results <i>in vitro</i> and <i>in vivo</i>, four clinical trials are currently underway using <b>37</b>. These are listed in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>. To date, <b>37</b> is the only selective DNA-PK inhibitor involved in clinical development.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. List of Current Clinical Trials Involving Inhibition of DNA-PK</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">trial identifier</th><th class="colsep0 rowsep0" align="center">drug</th><th class="colsep0 rowsep0" align="center">phase</th><th class="colsep0 rowsep0" align="center">summary</th><th class="colsep0 rowsep0" align="center">status and accession date</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">NCT02316197</td><td class="colsep0 rowsep0" rowspan="2" align="left"><b>37</b></td><td class="colsep0 rowsep0" rowspan="2" align="left">I</td><td class="colsep0 rowsep0" rowspan="2" align="left">A first in human trial to assess the safety, efficacy, PK/PD properties, and tolerability of <b>37</b> in patients with advanced solid tumors or chronic lymphocytic leukemia. A secondary aim is to discover the correct dosing regime for <b>37</b> for future studies.</td><td class="colsep0 rowsep0" align="left">Completed (no results posted)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DecemberÂ 12,Â 2014</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">NCT02516813</td><td class="colsep0 rowsep0" align="left"><b>37</b></td><td class="colsep0 rowsep0" rowspan="2" align="left">I</td><td class="colsep0 rowsep0" rowspan="2" align="left">A trial to assess the safety, efficacy, and tolerability of <b>37</b> in combination with radiotherapy and chemotherapy in patients with solid tumors.</td><td class="colsep0 rowsep0" align="left">Recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Radiotherapy cisplatin</td><td class="colsep0 rowsep0" align="left">April 6, 2015</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">NCT03770689</td><td class="colsep0 rowsep0" align="left"><b>37</b></td><td class="colsep0 rowsep0" rowspan="2" align="left">I/II</td><td class="colsep0 rowsep0" rowspan="2" align="left">TheÂ purposeÂ ofÂ thisÂ study in phase Ib is to assess the maximum tolerated dose of <b>37</b> in combination with capecitabine and radiotherapy in participants with locally advanced rectal cancer. In Phase II the study seeks to evaluate the efficacy of <b>37</b> in terms of pathological complete response/clinical complete response in combination with capecitabine and radiotherapy, in comparison with a placebo and capecitabine/radiotherapy administered as monotherapies.</td><td class="colsep0 rowsep0" align="left">Recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CapecitabineÂ radiotherapy</td><td class="colsep0 rowsep0" align="left">December 10, 2018</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">NCT03724890</td><td class="colsep0 rowsep0" align="left"><b>37</b></td><td class="colsep0 rowsep0" rowspan="2" align="left">I</td><td class="colsep0 rowsep0" rowspan="2" align="left">A study to assess the maximum tolerated dose for phase II studies of <b>37</b> in combination with avelumab with or without radiotherapy in participants with advanced solid tumors.</td><td class="colsep0 rowsep0" align="left">Recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Avelumab radiotherapy</td><td class="colsep0 rowsep0" align="left">October 30, 2018</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">NCT01353625</td><td class="colsep0 rowsep0" rowspan="2" align="left"><b>39</b></td><td class="colsep0 rowsep0" rowspan="2" align="left">I</td><td class="colsep0 rowsep0" rowspan="2" align="left">A first in human trial to assess the safety and efficacy of <b>39</b> in participants with advanced solid tumors and hematologic malignancies who are unresponsive to standard of care treatments. The study also seeks to determine optimum dosages for later clinical trials and to assess the bioavailability of tablet and capsule formulations.</td><td class="colsep0 rowsep0" align="left">Active, not recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">May 13, 2011</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">NCT01421524</td><td class="colsep0 rowsep0" rowspan="2" align="left"><b>39</b></td><td class="colsep0 rowsep0" rowspan="2" align="left">I</td><td class="colsep0 rowsep0" rowspan="2" align="left">A trial to assess the safety and efficacy of <b>39</b> in participants with advanced solid tumors, non-Hodgkinâs lymphoma, or multiple myeloma who are unresponsive to standard of care treatments, and to assess optimum dosing regiments for later clinical trials.</td><td class="colsep0 rowsep0" align="left">Active, not recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">August 23, 2011</td></tr></tbody></table></div></div><div class="NLM_p">Mortensen et al. attempted to discover novel selective mTOR inhibitors through SAR studies of a series of 4,6- or 1,7-disubstituted-3,4-dihydropyrazino[2,3-<i>b</i>]pyrazine-2(1<i>H</i>)-ones, and in doing so, they discovered the potent dual mTOR/DNA-PK inhibitor CC-115 (<b>39</b>, <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>).<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> Previous studies had identified CC214-1 (<b>38</b>, <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>) which displayed good on-target potency (mTOR IC<sub>50</sub> = 2 nM); however it showed poor PK properties, showing negligible oral bioavailability. A focused SAR approach featuring 2-methyl-6-(1<i>H</i>-1,2,4-triazol-3-yl)pyridin-3-yl substituted analogues allowed the identification of small substituents in the N1/N4 position, which kept the excellent potency of the early compounds of the series while improving the PK profile. This culminated in the identification of <b>39</b> (mTORIC<sub>50</sub> = 21 nM) as a clinical candidate. The DNA-PK activity of <b>39</b> was identified in separate work conducted by Tsuji et al., where inhibition of autophosphorylation of DNA-PK led to the blocking of DNA-PK facilitated NHEJ.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> In addition to <b>39</b>âs activity against mTOR and DNA-PK it was found to inhibit ATM, which as stated earlier is thought to have an SL relationship with DNA-PK; this interaction appears to have been confirmed as <b>39</b> is more active in ATM deficient cells, suggesting synthetic lethality between DNA-PK inhibition and ATM deficiency. This in combination with antitumor activity seen in solid tumor and hematopoietic cell lines and apoptosis/antiproliferation in various cell lines has lent support to <b>39</b> being explored as a clinical candidate. To date, <b>39</b> is featured in two clinical trials, which are reported in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>.</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Optimization of mTOR inhibitor CC214-1 (<b>38</b>) leading to the discovery of mTOR/DNA-PK dual inhibitor CC-115 (<b>39</b>). Small substituents in the N1/N4 position resulted in the maintenance of high potency but improved PD/PK properties.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">4.  WEE1 Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06300" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06300" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">WEE1 is a kinase involved in cell cycle progression, where it prevents entry into mitosis in response to DNA damage. Furthermore, it has been implicated in the scheduling of cell division and HR repair.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> WEE1 prevents entry into mitosis through regulation of the G/M and S checkpoints through the phosphorylation of CDK1 and CDK2.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> As stated in this review, in the event of DNA damage, ATR or ATM pathways can be activated: ATR activation (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>) results in the phosphorylation of CDK1, which leads to activation of checkpoint regulators of which WEE1 is one, which phosphorylates and inactivates the CDK1-cylin B complex on Tyr15, causing cell cycle arrest in G2.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> This halting of the cell cycle is preferential for cancer cells, as DNA damage is not repaired before replication in the S phase; therefore mutations can occur that favor proliferation, encouraging cancer growth. As the cancer cells are reliant on disruption of the apoptosis process, it is thought that the G2 checkpoint is vital for their survival, thereby presenting WEE1 as a promising target for cancer therapy. It is thought that healthy cells, containing fewer DNA breaks, will not be as affected by the disruption of the G2 checkpoint, and therefore this treatment would be considered somewhat selective for cancer cells.</div><div class="NLM_p">WEE1 is highly expressed in numerous cancer types, including glioblastoma,<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> breast cancer,<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> leukemia,<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> and others. Additionally, high levels of WEE1 expression have been observed in the event of severe DNA stress in various cancer types correlating with a poor prognosis.<a onclick="showRef(event, 'ref109 ref110'); return false;" href="javascript:void(0);" class="ref ref109 ref110">(109,110)</a> The cancer types that highly express WEE1 are thought to be extremely reliant on the G2 halting of the cell cycle, making them an attractive target for WEE1 inhibition.</div><div class="NLM_p">Synthetic lethality has reported between WEE1 and ATR inhibitors. This was achieved through the combination of the WEE1 inhibitor AZD1775 (formally MK-1775) (<b>40</b>, <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>A) and two ATR inhibitors <b>11</b> and ETP-46464 (<b>41</b>, <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>B).<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> In this study synergistic killing of cancer cells from various tissues was observed, but untransformed cell remained unaffected. Through mechanistic studies using reversible inhibition of WEE1/ATR it was revealed that inhibition occurred in the G2/M phase. Additionally, through live cell imaging, it was seen that inhibition of WEE1 and ATR caused cells to enter mitosis, and cells with overly damaged DNA underwent mitotic catastrophe.</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. (A) SAR and optimization of WEE1 inhibitor <b>40</b> to <b>43</b>. (B) Structure of ATR inhibitor ETP-46464 (<b>41</b>). (C) Structure of first WEE1 inhibitor PD0166285 (<b>42</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">SL has been observed between WEE1 and TP53 mutants. TP53 encodes for the tumor suppressor p53 and is the most commonly mutated gene within human cancer and generally is thought to be associated with poor prognosis.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> As the mutations cause a loss of function, TP53 mutations cannot be directly targeted; therefore SL through WEE1 provides an opportunity to drug a previously undruggable target. As cells with TP53 mutations lack an effective G1 checkpoint, they become over-reliant on the G2 checkpoint; therefore inhibition of WEE1, which acts in the G2 checkpoint, is thought to cause SL. This has been demonstrated in TP53 mutant colorectal carcinoma where, after exposure to radiation, inhibition of WEE1 with the preclinical inhibitor PD0166285 (<b>42</b>, <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>C) caused the cells to evade G2 arrest and prematurely enter mitosis.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> Furthermore, <b>40</b> has shown substantial improvement in carboplatin treatment of advanced solid tumors with p53 mutants in phase I and phase II trials.<a onclick="showRef(event, 'ref114 ref115'); return false;" href="javascript:void(0);" class="ref ref114 ref115">(114,115)</a></div><div class="NLM_p">Additionally, in a screen for SL partners for CHK1, WEE1 has been identified as a possible SL partner. Combination studies of <b>40</b> and the CHK1 inhibitor PF-00477736 in brain, ovarian, colon, and prostate cancer cells confirmed synergism between WEE1 and CHK1, independent of p53 status.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a></div><div class="NLM_p">A number of WEE1 inhibitors have been synthesized to date, with some in clinical studies. Here we will touch upon some of the most prominent inhibitors in the field.</div><div class="NLM_p">The first WEE1 inhibitor developed was <b>42</b> and was identified through use of a HTS looking to find WEE1 inhibitors. <b>42</b> is a highly potent ATP competitive WEE1 inhibitor (IC<sub>50</sub> = 24 nM) and was able to inhibit CDC2 at Tyr15 (a direct substrate of WEE1) in cells at 0.5 Î¼M.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> Furthermore, it was able to sensitize cells to radiation therapy, with this effect being more pronounced in p53 deficient cells. However, <b>42</b> is not a selective inhibitor and shows IC<sub>50</sub> < 100 nM for CDK1, MYT1, c-SRC, EGFR, FGFR-1, and PDGFR-Î². <b>42</b> has been used as a tool compound for examining the effect of WEE1 inhibition in numerous cancers such as colon, lung, and melanoma, among others;<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> however, its lack of selectivity has meant its usefulness beyond this is quite limited.</div><div class="NLM_p"><b>40</b> was originally identified by Hirai et al. through use of a HTS; initial hits were optimized through SAR to yield the orally available selective potent small molecule <b>40</b> (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>A) (WEE1 IC<sub>50</sub> = 5.2 nM).<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> A linear relationship between IC<sub>50</sub> and ATP concentration indicated that <b>40</b> acted in an ATP competitive manner. To evaluate selectivity, <b>40</b> was tested in a kinase screen, and only 8 of the 223 kinases were inhibited >80% when treated with 1 Î¼M of <b>41</b>, demonstrating remarkable selectivity for an ATP competitive kinase inhibitor. In cells WEE1 inhibition was observed through <b>40</b> inhibiting phosphorylation of CDC12 at Tyr15.</div><div class="NLM_p">Furthermore, <b>40</b> abrogates the G2 DNA damage checkpoint and in combination with the DNA damaging agents gemcitabine, carboplatin, and cisplatin caused apoptosis in p53 deficient cells. <b>40</b> has also been observed to induce apoptosis and inhibit proliferation as a monotherapy in numerous cell types (acute lymphoblastic leukemia cells, lung cancer cells, and colorectal cancer cells among others).<a onclick="showRef(event, 'ref118 ref119 ref120'); return false;" href="javascript:void(0);" class="ref ref118 ref119 ref120">(118â120)</a> Furthermore, <i>in vivo</i> it was seen to inhibit tumor growth without perceived toxicity. As previous stated in the review, <b>40</b> has entered numerous phase I and II clinical trials and is the most established WEE1 inhibitor in the field.</div><div class="NLM_p">As little SAR data exist for <b>40</b>, Matheson et al. synthesized a series of analogues to evaluate which structural features are necessary for successful WEE1 inhibition.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> The analogues that inhibited WEE1 in the same nM range had lessened cytotoxicity when administered as a single therapy in comparison to <b>40</b>, and synergism was observed in combination with cisplatin in medulloblastoma cells. CJM061 (<b>43</b>, <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>A) was the most active from this analogue series (WEE1 IC<sub>50</sub> = 2.8 nM) and its development can be seen in (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>A).</div><div class="NLM_p last">These promising compounds, especially <b>40</b>, show the potential for WEE1 inhibitors, with at least three confirmed SL relationships. Other than <b>40</b> no other WEE1 inhibitor is in clinical development. Should it prove to be unsuccessful in these clinical trials, more work is needed to fully make use of this attractive target for cancer therapy.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">5.  CDK12 Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86430" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86430" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">CDK12 was first identified when investigating the cell cycle regulator CDC2.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> While it has structural similarities to other members of the CDK subfamily, which play a role in cell cycle regulations, CDK12 is a transcription kinase involved in the transcription of genes involved in DNA repair,<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> regulating specific genes that respond to stress, heat shock, and DNA damage.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> CDK12 presents a great opportunity to test SL due to the high amount of genomic alterations seen in numerous cancers including high-grade ovarian carcinoma,<a onclick="showRef(event, 'ref125 ref126'); return false;" href="javascript:void(0);" class="ref ref125 ref126">(125,126)</a> HER-2 positive breast cancer,<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> and lung adenocarcinoma,<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> resulting in loss of function. To date, SL pairs for CDK12 have been identified as PARP,<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> MYC,<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> and EWS/FLI.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a></div><div class="NLM_p">CDK12 mutations have been shown to sensitize cancers to traditional DNA damaging agents;<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> therefore CDK12 inhibitors have gained traction in recent years as a way of implementing small molecule-induced synthetic lethality. A group within Takeda has developed a series of potent and selective CDK12 inhibtors,<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> which also hit CDK13, another potential modulator of DNA repair. A modest initial CDK12 inhibitor (<b>44</b>, <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>) was identified through a HTS (CDK12 IC<sub>50</sub> = 0.36 Î¼M). While it demonstrated good selectivity over other related kinases within the CDK subfamily, it also showed activity against CDK2, which is involved in healthy regulation of the cell cycle; therefore, for <b>44</b> to be useful, it would need to be optimized further. Through SAR studies, they discovered that, first, the aminopyridyl moiety was binding in the hinge region of CDK12 and could not be modified. This is a fairly typical moiety for kinase inhibitors. Second, it was discovered through the same SAR studies that at the 5-position of the pyridine ring it is likely that an electron-withdrawing group is required. Through later docking simulations of <b>44</b> in both CDK2 and CDK12, it was proposed that the oxygen atom in the sulfonyl moiety interacted with Lys89 in CDK2, which is not conserved in CDK12. This was therefore changed, utilizing experimentally derived conformations from the Cambridge Structural Database, to either a <i>tert</i>-amide or a <i>tert</i>-sulfonamide. Of these, the <i>tert</i>-amide showed better selectivity for CDK12 over CDK2 (compound <b>45</b>, <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>). Some final modifications, such as the introduction of a benzyl group and small modifications to improve physiochemical properties, resulted in the highly selective inhibitor, with it only showing inhibition of over 80% at 1 Î¼M in 3 of the 441 kinases present in the kinome screen. <b>46</b> (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>) (CDK12 IC<sub>50</sub> = 0.052 Î¼M) was shown to inhibit CDK12 phosphorylation of SER2 in SKBR2 cells (pSer2 IC<sub>50</sub> = 0.195 Î¼M). This compound therefore presents a valuable tool in probing SL or could serve as a starting point for further drug discovery programs investigating SL.</div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Optimization of CDK12 inhibitor <b>44</b> to <b>46</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Other CDK12 and CDK13 inhibitors have emerged within the same period, in work completed by Zhang et al.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> Previous work conducted by the group yielded the CDK7 inhibitor THZ1 (<b>47</b>, <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>A).<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a><b>47</b>, while being active against CDK7 (IC<sub>50</sub> = 3.2 nM), also showed activity against CDK12 (IC<sub>50</sub> = 864 nM) and CDK13 (IC<sub>50</sub> = 225 nM) and was therefore a starting point for further drug discovery. It was reasoned initially that alteration of the acrylamide moiety would divert the binding toward Cys1039 of CDK12. Through SAR studies that are yet to be reported, the compound THZ531 (<b>48</b>, <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>A) was synthesized. <b>48</b> has shown IC<sub>50</sub>âs in biochemical assays of 158 nM and 69 nM for CDK12 and CDK13, respectively, and has a more than 50-fold level of selectivity over the other members of CDK family. Interestingly, when the electrophilic acrylamide was replaced by a moiety incapable of covalently binding, propylamide, the activity of the compound dramatically reduced, suggesting that the ability to covalently bind is necessary for preserving CDK12 and CDK13 activity. Its selectivity over the wider kinome is good, with none of the other 211 kinases tested showing an activity of over 55%.</div><div class="NLM_p"><b>48</b> has been cocrystallized with CDK12. This has presented some useful binding information, which could serve others in the field, in the pursuit of novel CDK12 inhibitors (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>). Two CDK12-cycklin K complexes were found, each bound to <b>48</b> in a different rotamer. These crystallization studies revealed that a labile Î±K helix can be displaced from CDK12 allowing binding through the linker of <b>48</b> with Cys1039. The aminopyrimidine of <b>48</b> was found to form two hydrogen bonds to the backbone of M816, with the pendant 3-indolyl and the piperidine groups involved in hydrophobic interactions. The binding of the secondary amide was shown to have two different conformations that caused the solvent exposed groups to pack either against the N-lobe Î² strand or C-lobe Î±D helix. The resolution for the exposed groups was too poor to be defined apart from the position of Cys1039. Interestingly Cys312, the equivalent sulfhydryl to Cys1039 in CDK7, was further away from the binding region, suggesting poorer binding for <b>49</b> against CDK7 in comparison to CDK12. <b>49</b> was able to induce apoptosis in Jurkat cancer cells, in addition to being able to inhibit transcriptional regulation, reducing DNA damage repair and superenhancer gene expression. <b>49</b> has been shown to demonstrate a synergistic effect with PARPiâs in Ewing sarcoma in both cells and mouse models, as it was seen that the Ewing sarcoma cell models were particularly sensitive to CHK12 inhibition. Furthermore, the expression of the tumor specific oncogene EWS/FLI shows SL with CHK12 inhibition. The inhibition of CHK12 was also seen to impair DNA damage repair in Ewing sarcoma cells.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a></div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Cocrystallization of <b>48</b> with CDK12 adapted from Zhang et al.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> (a) <b>48</b> binds to M816 in the kinase hinge region and connects to Cys1039 in two conformations via the compoundâs flexible linker. Solvent-exposed regions of <b>48</b> with poor electron density are represented by thin sticks. (b) Omit map contoured at 2.5Ï for <b>48</b> bound to CDK12 chain C. (c) Omit map contoured at 2.5Ï for <b>48</b> bound to CDK12 chain D. Reproduced with permission from Springer Nature,   <cite><i>Nature Chemical
Biology</i></cite>, Covalent targeting of remote cysteine
residues to develop CDK12 and CDK13 inhibitors, <contrib-group>Tinghu Zhang, Nicholas Kwiatkowski, Calla M. Olson, Sarah E. Dixon-Clarke,
Brian J. Abraham, Ann K. Greifenberg, Scott B. Ficarro, Jonathan M.
Elkins, Yanke Liang, Nancy M. Hannett, Theresa Manz, Mingfeng Hao,
Bartlomiej Bartkowiak, Arno L. Greenleaf, Jarrod A. Marto, Matthias
Geyer, Alex N. Bullock, Richard A. Young, Nathanael S. Gray</contrib-group>,<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> Copyright 2019 Springer Nature.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A known CDK inhibitor, dinaciclib (<b>49</b>, <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>B),<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> whose primary targets are CDK1, CDK2, CDK5, and CDK9, has shown a documented response in breast cancer<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> and in recent years has also been shown to inhibit CDK12. While showing a higher level of promiscuity and also hitting cell cycle kinases within the family, <b>49</b> is the most potent CDK12 inhibitor to date, with an IC<sub>50</sub> of 40â60 nM in biochemical assays.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> In cell-based assays, <b>49</b> showed phenotypic responses typical of CDK12 inhibition, including gene repression of multiple genes involved in HR, whose expression is thought to correlate with CDK12 expression.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> This was achieved with minimal disruption to the cell cycle, indicating CDK12 inhibition as the cause of this observation. Due to the dysregulation of HR influencing genes, it was reasoned that <b>49</b> would be able to sensitize triple-negative breast cancer cells to PARPi. This was observed through the combination of <b>49</b> with the known PARP inhibitor veliparib, which showed a 2.5- to 12.5-fold increase in its activity as a single-agent treatment, demonstrating a synergistic SL effect. This impairment of HR by <b>49</b> was mirrored through knockout of CDK12, showing the same phenotype. Not only was <b>49</b> capable of showing a synergistic effect with PARPiâs, it was also able to resensitize triple-negative breast cancer cells that had become resistant to PARP inhibition to <b>1</b>. These results seem to indicate that the use of <b>49</b> can cause an increase in the effectivity of PARP inhibition even if a partial response is seen with the PARPi being administered as a monotherapy.</div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0027.jpeg" id="GRAPHIC-d7e3073-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. (A) Optimization of CDK inhibitor THZ1 (<b>47</b>). (B) Structure of CDK inhibitor dinaciclib (<b>49</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">CDK12âs progress as a target has meant that the idea of utilization of CDK12âs synthetic lethality has moved on to clinical trials. While there is not a great abundance of trials directly using CDK12 inhibitors, other potential SL partners are being modulated in CDK12 deficient cancers, thus giving an SL effect. If these worked, it opens the door for chemically induced small-molecule lethality. The trials are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>. One CDK12 inhibitor has entered clinical trials, and a number of selective CDK12 inhibitors are currently in preclinical studies. CDK12 inhibitors have the potential to be useful in the application of SL to cancer therapy.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Clinical Trials Involving Loss of CDK12 Function</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">trial identifier</th><th class="colsep0 rowsep0" align="center">drug</th><th class="colsep0 rowsep0" align="center">phase</th><th class="colsep0 rowsep0" align="center">summary</th><th class="colsep0 rowsep0" align="center">status and accession date</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">NCT01434316</td><td class="colsep0 rowsep0" rowspan="2" align="left">VeliparibÂ (PARPi)Â andÂ <b>49</b></td><td class="colsep0 rowsep0" rowspan="2" align="left">I</td><td class="colsep0 rowsep0" rowspan="2" align="left">Studying the safety profile of veliparib and <b>49</b> in participants with advanced solid tumors.</td><td class="colsep0 rowsep0" align="left">Recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SeptemberÂ 14,Â 2011</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">NCT04272645</td><td class="colsep0 rowsep0" rowspan="2" align="left">Abemaciclib and atezolizumab (both PD-L1 immunotheraputics)</td><td class="colsep0 rowsep0" rowspan="2" align="left">II</td><td class="colsep0 rowsep0" rowspan="2" align="left">Studying the effectivity and safety of abemaciclib and atezolizumab in participants with metastatic castration-resistant prostate cancer with and without âCDK12 lossâ mutation.</td><td class="colsep0 rowsep0" align="left">Withdrawn (coordinating site change)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">February 17, 2020</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">NCT03570619</td><td class="colsep0 rowsep0" rowspan="2" align="left">Nivolumab and ipilimumab (both PD-L1 immunotheraptics)</td><td class="colsep0 rowsep0" rowspan="2" align="left">II</td><td class="colsep0 rowsep0" rowspan="2" align="left">StudyingÂ theÂ efficacyÂ of nivolumab/ipilimumab in combination and nivolumab as a monotherapy in participants with castration-resistant metastatic prostate carcinoma or other solid tumor histologies, with CDK12 loss of function.</td><td class="colsep0 rowsep0" align="left">Recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">June 27, 2018</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">NCT04104893</td><td class="colsep0 rowsep0" rowspan="2" align="left">Pembrolizumab (PD-L1 immunotheraptic)</td><td class="colsep0 rowsep0" rowspan="2" align="left">II</td><td class="colsep0 rowsep0" rowspan="2" align="left">A study to assess the activity and efficacy of pembrolizumab in participants with progressive metastatic castration-resistant prostate cancer, characterized by a mismatch repair deficiency or biallelic CDK12 inactivation.</td><td class="colsep0 rowsep0" align="left">Recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">September 26, 2019</td></tr></tbody></table></div></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">6.  PARP and RAD51</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16410" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16410" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">RAD51 is a member of the RAD52 epistasis group, which is made up of RAD50, RAD51, RAD52, RAD54, RAD55, RAD57, RAD59, MRE11, and XRS2.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a><i>In vitro</i> studies have shown that RAD51 promotes homologous pairing and strand transfer reactions. Following treatment by DNA-damaging agents, RAD51 was seen to be upregulated, indicating its role in HR. Early on during HR, DSB or SSB results in the formation of a length of ssDNA. This strand is then paired with recombinases such as RAD51 and afterward is paired with a homologous duplex to form a DNA joint which is termed the D loop.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> RAD51 then goes on to promote an ATP-mediated strand exchange reaction by polymerizing on DNA, resulting in a helical filament. The formation of this is completed in two steps, nucleation and extension, promoting HR. RAD51 has also been shown to cause polymerization of dsDNA; however the reason for this has yet to be elucidated.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a></div><div class="NLM_p">It has been hypothesized that interrupting BRCA2 and RAD51âs interaction would mirror the synthetically lethal effect seen in utilizing PARPi in BRCA2 deficient tumors<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>). This would provide a shortcut to modulating the activity of BRCA2 which, to date, has been thought to be undruggable. While RAD51 inhibitors do exist,<a onclick="showRef(event, 'ref144 ref145 ref146'); return false;" href="javascript:void(0);" class="ref ref144 ref145 ref146">(144â146)</a> they have not been seen to interfere with the BRCA2âRAD51 interaction. For instance, structural data have shown that BRC4 (the fourth BRC repeat of BRCA2) binds to RAD51 in two hydrophobic binding pockets: one of these is critical for RAD51 multimerization (FxxA). Utilizing high-throughput docking, our group began to work developing modulators for this interaction. From the initial hit compounds identified from the HTS, <b>50</b> (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>) was the best performing (EC<sub>50</sub> = 53 Â± 3 Î¼M), and as such, an SAR program was initiated, at first investigating the optimal length of the alkyl chain between the triazole and the phenyl ring. From these studies, <b>51</b> (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>) (EC<sub>50</sub> = 25 Â± 2 Î¼M) which features a propyl phenyl ring was selected for further biological evaluation. <b>51</b> was tested in combination with <b>1</b> in two pancreatic cancer cell lines: Capan-1 which lacks functional BRCA2; BxPC-3 which is BRCA2-positive. Unsurprisingly as a monotherapy, <b>1</b> was more effective in the Capan-1 cells, due to the lack of BRCA2. Upon combination with <b>51</b>, no effect was seen in the Capan-1 cells; however, in the BxPC-3 cells, a synergistic effect was seen between <b>51</b> and <b>1</b>, suggesting small molecule-induced synthetic lethality. <b>51</b> was tested on the same cell lines that had undergone prior treatment by cisplatin: it demonstrated no effect in the BRCA2-negative cells, whereas in the BRCA2-positive cell line, a small increase in a phenotypic indicator for DNA damage was observed, confirmed by silencing of RAD51 which demonstrated a similar effect to <b>51</b>. This work could potentially provide a way of inducing SL in patients who lack the BRCA1/2 mutation, increasing the scope of PARPiâs.</div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0016.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. (A) PARP inhibitors triggering synthetic lethality in BRCA-deficient cells. (B) Proposed triggering of small molecule-induced synthetic lethality using PARP inhibitors in combination with RAD51-BRCA2 disruptors. Adapted from   <cite><i>European Journal
of Medicinal Chemistry</i></cite>, Vol. <em>165</em>, <contrib-group>Marinella Roberti, Fabrizio Schipani, Greta Bagnolini, Domenico Milano,
Elisa Giacomini, Federico Falchi, Andrea Balboni, Marcella Manerba,
Fulvia Farabegoli, Francesca De Franco, Janet Robertson, Saverio Minucci,
Isabella Pallavicini, Giuseppina Di Stefano, S. Girotto, R. Pellicciari,
A. Cavalli</contrib-group>, Rad51/BRCA2 disruptors inhibit
homologous recombination and synergize with olaparib in pancreatic
cancer cells,<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> Page 81, Copyright (2019), with permission from Elsevier.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0017.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Depiction of the SAR strategy for the further development of <b>52</b>. This primarily focused on three areas within the molecule highlighted in green, red, and blue. The proposed moieties in these regions are shown in their accompanying text.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Further SAR optimization of <b>51</b> was undertaken.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> These focused around adjusting the chain length of the N4 nitrogen and introducing substitutes on the phenyl ring. Other modifications included changes at the C3 position of the triazole, introducing a series of heterocycles, saturated and unsaturated rings with differing links. Lastly, changes occurred at the C5 position of the triazole, changing the heterocycle present at the position or removing this substituent entirely, replacing it with either a methyl group or a proton; these alterations are summarized in <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>. Modifications at the C5 and N4 positions were not well-tolerated, with a drop in activity usually observed. A minor tweak, changing the cyclopentyl group for a cyclohexyl group, resulted in the best compound from the series, compound <b>52</b> (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>) (EC<sub>50</sub> = 8 Â± 2 Î¼M).</div><div class="NLM_p"><b>52</b> inhibited the RAD51âBRCA2 interaction, preventing RAD51 function in cells. Furthermore, it significantly improved the function of <b>1</b> in BRCA2-positive cells and increased the amount of DSBs when administered in combination with <b>1</b>. However, due to its low potency or the presence of a mutant from p53 that prevents apoptosis, true synthetic lethality could not be observed, and showing further optimization was needed.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> In order to increase diversity within the field of Rad51âBRCA2 inhibitors, our group ran a second binding screening at the other binding site (LFDE).<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> Mutations in this binding pocket are associated with cellular lethality, in addition to the failure of RAD51 assembly in nuclear foci at the point of DNA breaks <i>in vivo</i>, suggesting a key role in RAD51âs function.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> Of the compounds tested, the dihydroquinolone pyrazoline derivative <b>53</b> (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>) (EC<sub>50</sub> = 16 Â± 4 Î¼M) was the most active, and an SAR program was initiated around this compound (this work will be published in a subsequent paper), eventually yielding compound <b>54</b> (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>) (EC<sub>50</sub> = 19 Â± 1 Î¼M). Like <b>52</b> from the previous work, <b>54</b> was able to bind to RAD51 inhibiting its function, but unlike <b>52</b>, <b>54</b> was able to trigger SL in a dose response manner by impeding HR in pancreatic cancer cells that expressed BRCA2. However, due to <b>54</b>âs poor solubility, it is unlikely to be able to be tested it <i>in vivo</i>, and therefore further optimization is required before these class of compounds can realize their potential. This work is ongoing and demonstrates one of the first programs targeting small molecule-induced synthetic lethality and a way to expand the use of PARPiâs beyond BRCA1/2 deficient cancers, increasing their usefulness.</div><figure id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0018.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Optimization of <b>53</b> to <b>54</b>. All compounds from this series were tested as racemic mixtures after both enantiomers of <b>53</b> showed the same biochemical activity and binding mode.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A number of other RAD51 inhibitors have been reported in the literature,<a onclick="showRef(event, 'ref144 ref145 ref146 ref149 ref150 ref151 ref152 ref153 ref154 ref155 ref156'); return false;" href="javascript:void(0);" class="ref ref144 ref145 ref146 ref149 ref150 ref151 ref152 ref153 ref154 ref155 ref156">(144â146,149â156)</a> the most noteworthy of which are shown in <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>. Only IBR2 (<b>55</b>, <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>) (RAD51 IC<sub>50</sub> not reported) and BO2 (<b>56</b>, <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>) (RAD51 IC<sub>50</sub>= 27.4 Î¼M) have been directly linked to small molecule-induced synthetic lethality.<a onclick="showRef(event, 'ref155 ref157'); return false;" href="javascript:void(0);" class="ref ref155 ref157">(155,157)</a><b>55</b> was observed to synergize with multiple drugs (notably imatinib, regorafenib, EGFR inhibitors (including erlotinib, gefitinib, afatinib, and osimertinib), and vincristine) with differing molecular targets, which were not involved in the RAD51 mediated HR pathway. However, the combination of <b>55</b> with DNA-damaging agents such as cis-platin was not synergistic.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> In the same study <b>55</b> was compared to <b>56</b>, which was able to synergize with imatinib and vincristine, thereby opening the door for these two compounds to be explored for SL. At a recent conference, Maclay et al. reported a novel RAD51 inhibitor: CYT01B.<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> Neither the structure of this compound nor the data associated with it have been published to date; however a patent has been released by the parent company Cytier Therapeutics, which appears to be indicative of the structure.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> CYT01B has been shown to cause DNA stress through DNA replication fork damage. Therefore, it was tested to see if CYT01B could sensitize cells to current therapeutics for the treatment of solid tumors. This was done through combination assays with CYT01B (concentration range of 20 nm to 5 Î¼M) in three cell lines with six targeted agents, the results of which are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>. These studies, in particular the success seen with the platinum-based chemotherapy carboplatin, in addition to PARPiâs, seem to indicate a degree of synthetic lethality. Therefore, this compound should be monitored as it progresses through <i>in vivo</i> models and beyond. As little is known about the compoundâs selectivity panel, it is impossible to say whether the observed SL phenotype is due to RAD51 inhibition; however, should this information come to light, it would no doubt be of interest to the field of not only RAD51 inhibitors but also small molecule-induced synthetically lethality.</div><figure id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0019.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Examples of Rad51 inhibitors reported in the literature.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Summary of Cell-Based Combination Studies Featuring CYT01B</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center">drug combination</th><th class="colsep0 rowsep0" align="center">response observed</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="6" align="left">ARPE19/HPV16 (HPV immortalized normal epithelial cell line)</td><td class="colsep0 rowsep0" align="left">V822Â (ATRi)Â (concentrationÂ rangeÂ ofÂ 39Â nM to 2.5 Î¼M) and CYT01B (20 nM to 5 Î¼M)</td><td class="colsep0 rowsep0" align="left">SynergismÂ observedÂ atÂ allÂ concentrations.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TDRL-505 (RPAi) (concentration range of 39 nM to 5 Î¼M) and CYT01B (20 nM to 5 Î¼M)</td><td class="colsep0 rowsep0" align="left">Antagonism observed at all concentrations.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Bortezomib (proteasome inhibitor) (concentration range of 39 nM to 2.5 Î¼M) and CYT01B (20 nM to 5 Î¼M)</td><td class="colsep0 rowsep0" align="left">Synergism observed at all concentrations.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Carboplatin (nonspecific chemotherapeutic) (concentration range of 156 nM to 10 Î¼M) and CYT01B (20 nM to 5 Î¼M)</td><td class="colsep0 rowsep0" align="left">Synergism observed at all concentrations.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b> (concentration range of 78 nM to 5 Î¼M) and CYT01B (20 nM to 5 Î¼M)</td><td class="colsep0 rowsep0" align="left">Synergism observed at all concentrations but stronger synergy than that of niraparib.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Niraparib (<b>3</b>) (PARPi) (concentration range of 78 nM to 5 Î¼M) and CYT01B (20 nM to 5 Î¼M)</td><td class="colsep0 rowsep0" align="left">Synergism observed at all concentrations.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="6" align="left">KYSE-70Â (headÂ andÂ neckÂ cancerÂ cellÂ line)</td><td class="colsep0 rowsep0" align="left">V822 (ATRi) (concentration range of 39 nM to 2.5 Î¼M) and CYT01B (20 nM to 5 Î¼M)</td><td class="colsep0 rowsep0" align="left">Synergy was observed with CYT01B at 39 nM, but an antagonistic relationship between V822 and CYT01B was seen at low and high concentrations.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TDRL-505 (RPAi) (concentration range of 39 nM to 5 Î¼M) and CYT01B (20 nM to 5 Î¼M)</td><td class="colsep0 rowsep0" align="left">Weak synergy observed at 156 and 312 nM of CYT01B.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Bortezomib (proteasome inhibitor) (concentration range of 39 nM to 2.5 Î¼M) and CYT01B (20 nM to 5 Î¼M)</td><td class="colsep0 rowsep0" align="left">Antagonism observed at all concentrations.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Carboplatin (nonspecific chemotherapeutic) (concentration range of 156 nM to 10 Î¼M) and CYT01B (20 nM to 5 Î¼M)</td><td class="colsep0 rowsep0" align="left">Synergism observed at all concentrations.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b> (concentration range of 78 nM to 5 Î¼M) and CYT01B (20 nM to 5 Î¼M)</td><td class="colsep0 rowsep0" align="left">Synergism observed at all concentrations but stronger synergy than that of niraparib.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Niraparib (<b>3</b>) (PARPi) (concentration range of 78 nM to 5 Î¼M) and CYT01B (20 nM to 5 Î¼M)</td><td class="colsep0 rowsep0" align="left">Synergism observed at all concentrations.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="6" align="left">Daudi (Burkittâs lymphoma cell line)</td><td class="colsep0 rowsep0" align="left">V822 (ATRi) (concentration range of 39 nM to 2.5 Î¼M) and CYT01B (20 nM to 5 Î¼M)</td><td class="colsep0 rowsep0" align="left">Antagonistic effect at high concentrations but additive at low.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TDRL-505 (RPAi) (concentration range of 39 nM to 5 Î¼M) and CYT01B (20 nM to 5 Î¼M)</td><td class="colsep0 rowsep0" align="left">Antagonism observed at all concentrations.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Bortezomib (proteasome inhibitor) (concentration range of 39 nM to 2.5 Î¼M) and CYT01B (20 nM to 5 Î¼M)</td><td class="colsep0 rowsep0" align="left">Antagonism observed at all concentrations.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Carboplatin (nonspecific chemotherapeutic) (concentration range of 156 nM to 10 Î¼M) and CYT01B (20 nM to 5 Î¼M)</td><td class="colsep0 rowsep0" align="left">Synergism observed at all concentrations.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b> (concentration range of 78 nM to 5 Î¼M) and CYT01B (20 nM to 5 Î¼M)</td><td class="colsep0 rowsep0" align="left">Synergism observed at all concentrations but stronger synergy than that of niraparib.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Niraparib (<b>3</b>) (PARPi) (concentration range of 78 nM to 5 Î¼M) and CYT01B (20 nM to 5 Î¼M)</td><td class="colsep0 rowsep0" align="left">Synergism observed at all concentrations.</td></tr></tbody></table></div></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">7.  RAD52 Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21268" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21268" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The RAD52 protein is able to bind to ssDNA and plays a key role in repairing of single-strand and double-strand breaks.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> Within the HR response, it is essential in more simple organisms such as bacteria or yeast, where it acts in aiding RAD51 attachment to ssDNA. However, in more complex organisms such as animals this is largely completed by other proteins such as BRCA1/2. Indeed, knockout of RAD52 in mice does not cause a drop in viability or fertility of the mouse. However, upregulation of RAD52 can have a protecting effect on DNA from ionizing radiation, suggesting it is important to the HR process. Common synthetic lethality partners are BRCA1/2, which play a vital role in annealing RAD51 to ssDNA; however mutations in these proteins are quite common,<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> and when this occurs, the cancer cell can compensate by utilizing RAD52 to perform the task instead. This is represented in <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>. This makes RAD52 an appealing target for cancer therapy, as it will only have key function in HR when BRCA1/2 are inactive: this will therefore have a selective effect on cancer cells, without influencing health cells.</div><figure id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0020.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. RAD52, SL interactions with PARP inhibitors. This figure shows classic SL with PARP inhibition in BRCA2 deficient-cancer cells. These are prone to acquired mutation. The implementation of RAD52 in combination with PARPi has no effect in BRCA2 proficient healthy cells; however, in BRCA2-deficient cancer cells, small-molecule-induced synthetic lethality occurs. Adapted from   <cite><i>Cancers</i></cite>, <span class="NLM_year">2019</span>, Vol. <em>11</em>, Issue 10, <contrib-group>Monika Toma, Katherine Sullivan-Reed, Tomasz
ÅliwiÅski, Tomasz Skorski</contrib-group>, RAD52 as a Potential Target for Synthetic Lethality-Based Anticancer
Therapies,<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> Page 1569, with use of the <a href="https://creativecommons.org/licenses/by/4.0/" class="ext-link">Attribution 4.0 International (CC BY 4.0)</a> open access license.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">One of the mechanisms of synthetic lethality proposed for both RAD52 and BRCA1/2 inhibition is that endonuclease/exonuclease/phosphatase family domains containing protein 1 (EEPD1) mediate DNA cleavage in the absence of BRCA1/2 and RAD52 and cause the production of toxic intermediates that trigger cell death.<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a> This theory is supported by the fact that suppression of EEPD1 in BRCA1/2- and RAD52-compromised cells causes a drop in the level of synthetic lethality.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> With RAD52 appearing to be a promising target for SL-based drugs, a few examples of small molecule inhibitor discovery programs are discussed below.</div><div class="NLM_p">The first attempt to modulate RAD52 activity was not done through use of small molecules but rather use of an aptamer.<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a> This was achieved through use of the F79 aptamer that demonstrated activity in BRCA1/2 deficient cells but had no effect on HR in normal cells. F79 demonstrated SL in leukemia but also breast, pancreatic, and ovarian cells. <i>In vivo</i> tests in mice showed a lengthening of lifespan in mice with BCR-ABL1-positive leukemia. Lastly, RAD52 showed a synergistic effect with nonspecific chemotherapeutics, suggesting that, utilized together, the dose of the chemotherapeutic could be lowered, thereby reducing the risk of side effects. While not being investigated further, aptamers could play a key role in SL targets, specifically those in HR, as elsewhere aptamers have been reported to inhibit the DNA strand exchange of RAD51.<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> Again, this work has not been expanded upon and could provide an untapped resource for the synthetic lethality.</div><div class="NLM_p">6-OH-dopa (<b>57</b>, <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>) is a RAD52 inhibitor that was identified from a HTS of 18â¯304 drug-like compounds combined with 1280 from the Sigma Lopac collection. These compounds were screened through a high-throughput fluorescence polarization assay, and 10 compounds were identified that prevented RAD52 binding to ssDNA at a greater degree than 60%, at IC<sub>50</sub> < 5 Î¼M.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> Of these 10 compounds, only one was able to inhibit single-strand annealing in cells: <b>57</b>. It was later tested to see if it could inhibit HR. Predictably, it did not, due to RAD52âs weak role in healthy cells, therefore indicating some degree of selectivity for RAD52 over other key HR proteins. Furthermore, in biochemical assays, <b>57</b> was shown to have a significant degree of selectivity for RAD52 (1.1 Î¼M) over RAD51 (not determined). <b>57</b> was also observed to halt proliferation in two cell lines deficient in BRCA1/2 (a Chinese hamster cell line and a pancreatic cancer cell line). In addition, separate studies also showed an increased level of apoptosis and DNA damage in BRCA1/2 cells. Despite being a promising compound, <b>57</b> is a dopaminergic derivative, which has been reported to heighten the chance of Parkinsonâs disease by degenerating mitral neurons.<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a> Therefore, within cancer therapy, this is highly unlikely to be explored further. Huang et al. set out to develop small molecule inhibitors of RAD52 through use of a HTS.<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a> The hit compounds from this screen were tested for RAD52 selectivity, especially over RAD51, and in BRCA1/2 positive and deficient pancreas, ovarian, and triple negative breast cancer cells. Two hit compounds, D-G09 (<b>58</b>) and D-103 (<b>59</b>) (<a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>), showed the expected phenotype for RAD52 inhibition in these cell lines, while another three compounds D-105 (<b>60</b>), D-K17 (<b>61</b>), and D-G23 (<b>62</b>) (<a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>) showed activity against two of the cells lines but were of a structurally diverse scaffold, giving more opportunity for chemical space exploration. The best-performing compound of these, <b>59</b> (inhibits RAD52 ssDNA annealing at IC<sub>50</sub> = 5 Î¼M), was also tested in BRCA1/2-positive and -negative chronic myeloid leukemia cells, showing preferential inhibition of growth of the BRCA1/2-negative cells. Through SPR these compounds were confirmed to inhibit DNA, annealing through direct binding with RAD52 as opposed to DNA substrates. It was also demonstrated that <b>59</b> shows an absence of a nonspecific effect on RAD-51 foci production in response to cisplatin, reinforcing the selectivity of the compound.</div><figure id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0021.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Structures of different RAD52 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Hengel et al. embarked on a discovery program for small molecule inhibitors of RAD52, through use of a HTS of the MicroSource SPECTRUM collection.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a> Initial hits were tested for RAD52 binding in FRET-based assays, giving five hits that showed an IC<sub>50</sub> in or near the nanomolar range. Of these hits, two compounds, (â)-epigallocatechin (<b>63</b>, <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>) (RAD52 DNA binding IC<sub>50</sub> = 1.8 Â± 0.1 Î¼M) and epigallocatechin-3-monogallate (<b>64</b>, <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>) (RAD52 DNA binding IC<sub>50</sub> = 277 Â± 22 nM), were shown to physically bind to RAD52 by NMR and were shown to prevent binding and annealing to RPA-coated ssDNA. Virtual screens of <b>63</b> and <b>64</b> within the RAD52 ssDNA binding groove seem to indicate that these compounds show binding in this region. Notable interactions include Arg55, Lys65, Arg153, and Arg156 in the vicinity of <b>63</b> and <b>64</b>, which when docked have previously been shown to impact ssDNA binding. Additionally Lys141 and Lys144 have been shown to be important previously in RAD52 function in yeast and are thought to be somewhat evolutionarily conserved; some of these binding interactions are schematically reported in <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>. <b>63</b> and <b>64</b> were shown to dysregulate DSB repair in BRCA1/2-depleted and MUS81-depleted cells. Furthermore, both compounds showed activity in killing BRCA1/2-depleted cells in addition to MUS81-depleted cells. This phenomenon of lower cell viability in MUS81-deficient cells has been reported previously.<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a> By use of <b>63</b> and <b>64</b>âs predicted docking models, an <i>in silico</i> screen was embarked upon, using the AnalytiCon Discovery MEGx Natural Products Screen Library, which is made up of natural products from plants, fungal, and antimicrobial sources. From this library, NP-004255 (<b>65</b>, <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>) (RAD52 DNA binding IC<sub>50</sub> = 1.5 Â± 0.2 Î¼M) was identified, which had the same binding mode as <b>63</b> and <b>64</b>. <b>65</b> underwent the same binding analysis as <b>63</b> and <b>64</b>, where it was shown to bind to RAD52 and RPA and to inhibit the binding of RAD52 to ssDNA in addition to the ssDNAâRPA complex. However, <b>65</b> did not affect RAD52âs binding to dsDNA or affect DNA binding by RPA.</div><figure id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0022.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Proposed binding regions of the RAD52 inhibitors: (A) <b>63</b> and (B) <b>64</b>. Adapted from   <cite><i>eLIFE</i></cite>, <span class="NLM_year">2016</span>,
Vol. <em>5</em>, e14740, <contrib-group>Sarah R. Hengel, Eva
Malacaria, Laura Folly da Silva Constantino, Fletcher E. Bain, Andrea
Diaz, Brandon G. Koch, Liping Yu, Meng Wu, Pietro Pichierri, M. Ashley
Spies, Maria Spies</contrib-group>, Small-molecule inhibitors
identify the RAD52-ssDNA interaction as critical for recovery from
replication stress and for survival of BRCA2 deficient cells,<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a> with use of the <a href="https://creativecommons.org/licenses/by/4.0/" class="ext-link">Attribution 4.0 International (CC BY 4.0)</a> open access license.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Li et al. investigated new RAD52 inhibitors, beginning with use of a virtual screen, by docking the compounds inside the RAD52 monomer.<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> This HTS consisted of 47â¯737 compounds, with the 30 top-performing compounds being sorted into groups of 5 in relation to their chemotype. These 30 compounds were tested for their ADMET properties, and 4 were selected due to their druglikeness for further testing: F779-0434 (<b>66</b>), F848-0436 (<b>67</b>), G640-1014 (<b>68</b>), and D207-0130 (<b>69</b>) (<a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>), with <b>66</b> appearing to be the most promising RAD52 inhibitor. Similar to the work conducted by Spies et al., all 4 compounds tested were seen to bind in the ssDNA binding pocket. Key binding interactions were observed between the 4 compounds and Arg 55, Lys 152, Arg 165, and Tyr 65. Notably the interaction with Arg 55 is shared between <b>61</b> and <b>66</b>, suggesting this is a key RAD52 interaction. These binding interactions can be seen in more detail in <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>. <b>66</b> was shown to be able to selectivity inhibit growth in a BRCA1/2-dependent pancreas cancer cell to 50% at 10 Î¼M, whereas in the same concentration over 90% of cells from a healthy cell line survived. Furthermore, it was shown to inhibit RAD52 ssDNA annulation beginning at 5 Î¼M, and at 20 Î¼M complete inhibition of the process could be seen. However, the other three compounds selected by the virtual screening did not show as promising an effect in these assays.</div><figure id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0023.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Proposed binding regions of <b>66</b>. Reproduced with permission of The Royal Society of Chemistry, from <contrib-group><span class="NLM_string-name">Li, J.</span>; <span class="NLM_string-name">Yang, Q.</span>; <span class="NLM_string-name">Zhang, Y.</span>; <span class="NLM_string-name">Huang, K.</span>; <span class="NLM_string-name">Sun, R.</span>; <span class="NLM_string-name">Zhao, Q.</span></contrib-group> Compound F779-0434 causes synthetic lethality in BRCA2-deficient cancer cells by disrupting RAD52âssDNA association.   <cite><i>RSC Advances</i></cite>, Vol. <em>8</em>, Issue 34, pp 18859â18869,<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> Copyright 2018, permission conveyed through Copyright Clearance Center, Inc.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">To date, no RAD52 inhibitors have entered clinical trials. However, the numerous successes seen in this section, particularly <i>in vitro</i>, and the greater wealth of information known about the binding pocket and binding modes suggest that the potential for RAD52 inhibitors to work as SL agents is vast.</div></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">8.  PD-1 and Synthetic Lethality</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10632" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10632" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Since the late 19th century, the application of the immune response in cancer therapy has been theorized;<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> while it was quite controversial through much of this time, it is now seen as a promising approach to anticancer therapy. One of the targets that has gained interest is programmed cell death protein 1 (PD-1), which is responsible for fine-tuning T-cell function, the maintenance of homeostasis within the immune response, acting as a natural break, and initiating the checkpoint response usually associated with periphery tolerance.<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> However, in cancer, tumor cells take advantage of this and use the mechanism to suppress and evade the immune response. Therefore, the concept of a checkpoint blockade has been proposed, where inhibition of PD-1 causes reactivation of the immune response toward the cancerous cell, utilizing the bodyâs defenses to fight cancer. Several PD-1 monoclonal antibodies have been successful in clinical trials, leading to FDA approval for several monoclonal antibodies, namely, nivolumab, pembrolizumab, atezolizumab, avelumab, and durvalumab. In various cancers, anti PD-1 agents are standard of care therapies for many malignancies including melanoma, small-cell lung cancer, non-small-cell lung cancer, colorectal cancer, and many more.</div><div class="NLM_p">It is known that blocking DNA repair mechanisms increases genetic instability, which in turn increases epitope expression on the cancer cell surface, which is usually immunodominant.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> It is therefore possible that this increased genetic instability could make the cancer cells more susceptible to the immune response if heightened, making PD-1âs combination with targets involved in the DNA repair appealing as a potential source of synergism, perhaps even to the extent of synthetic lethality. In fact, some DNA-damage regulators such as PARP have been to seen to cause an increase in PD-1 expression, suggesting a likelihood of synthetic lethality. Due to this, PARP and PD-1 joint inhibition has been explored, with synergism seen in preclinical trials in addition to early stage clinical trials, of which there are more than 30 currently in progress in a wide of range of malignancies.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> The potential for PD-1 modulation in combination with other targets is evident throughout this review, with numerous ATR inhibitor clinical trials and trials featuring CDK12 loss of function mutants utilizing PD-1 antibodies. While this approach is still new, with the first work being conducted in 2017,<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a> it could be expanded to other targets mentioned within this review such as RAD51. The theory is that any target which, when modulated, causes a reduction in DNA repair could potentially be more susceptible to T-cells involved in the immune response, once the checkpoint response has been modulated.</div><div class="NLM_p last">In this section, numerous SL targets and strategies have been highlighted. With the rapidly expanding number of known SL partners, it would be impossible to cover them all in one review. The majority of the highlighted discovery programs focus on developing a selective potent modulator of a specific target and work to optimize through a classical medicinal chemistry approach. It is usually at a later stage of the screening cascade where SL is investigated, initially though combination studies in cells; thus, fewer compounds are screened for SL, which renders it difficult to comment on whether or not the SAR approach is in fact increasing SL. This is understandable as, despite being known for many years, SL approaches are still in their infancy; however, the number of promising compounds in late-stage clinical and preclinical studies gives hope that one of these targets will eventually be employed in an SL approach within the clinic.</div></div><div id="sec9" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">9.  Challenges and Opportunity in Developing New SL Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38186" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38186" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">To date, numerous potential synthetic lethal genes have been identified through statistical screening,<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a> genetic screening,<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a> high-throughput phenotypic screening,<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a> and combinational approaches. However, this has yet to correlate with improved medicines in the clinic, with only one SL pair being exploited to date and four drugs acting through the same PARP1 SL mechanism (<b>1</b>, <b>2</b>, <b>3</b>, and <b>4</b>). One of the largest barriers to the development of more drugs acting on SL is the heterogeneity of cancer,<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a> with many SL targets only existing in a small number of cancer subtypes. This therefore means sample sizes are dramatically lowered, be they statistical data points or patient samples for <i>in vitro</i>/<i>in vivo</i> experiments crucial for validating the SL phenotype. Second, more mechanistic detail must be obtained to evaluate how best to drug SL targets. As shown in this review, the mechanistic understanding of many SL relationships is poor, with PARP/BRCA2 being one of the only synthetically lethal gene pairs to have received extensive study. With mechanistic understanding of what drives SL still not fully understood, creative approaches have been employed to investigate this vital piece of the puzzle. Li et al. employed a machine learning approach to discover what âcharacteristic functional featuresâ are required for a protein-coding gene to have the potential for synthetic lethality.<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a> The methodologies involved are outside the scope of this review; however through this study Li et al. discovered 15 key characteristic functional features, 14 of which had previously been reported to play a role in SL to some degree in the literature (these were given a descriptor and can be seen in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). These descriptors are generated using machine learning algorithms, which through an enrichment system derived from gene ontology terms and the Kyoto encyclopedia of genes and genome pathways represent functional features. It is hoped that this study can be utilized in both computational and experimental methods for selecting potential genes to investigate for SL. Other big data approaches<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a> have been employed to try to aid the âhypothesis drivenâ methods that have been used to discover SL pairs previously, with a collated and curated list of SL interactions available for free online via BioGrid.<a onclick="showRef(event, 'ref182'); return false;" href="javascript:void(0);" class="ref ref182">(182)</a></div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Key Characteristics Discovered through a Machine Learning Approach Conducted by Li et al.<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">maximum relevance and minimum redundancy (mRMR) feature name</th><th class="colsep0 rowsep0" align="center">description of function</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GO:Â 0097505</td><td class="colsep0 rowsep0" align="left">ThisÂ termÂ representsÂ theÂ cellularÂ componentÂ namedÂ RAD6â18 complex: a previous study in <i>Saccharomyces cerevisiae</i> confirmed RAD6 and RAD18 exhibit SL. The function in humans is similar to that in yeast, and therefore it is likely that these two are SL in humans.<a onclick="showRef(event, 'ref190'); return false;" href="javascript:void(0);" class="ref ref190">(190)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GO: 0070449</td><td class="colsep0 rowsep0" align="left">This term represents a cellular component named the elongin complex which consists of the elongin transcription factors elongin A, B, and C. These have been seen previously to be SL with the von HippelâLindau protein complex.<a onclick="showRef(event, 'ref191'); return false;" href="javascript:void(0);" class="ref ref191">(191)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GO: 0033503</td><td class="colsep0 rowsep0" align="left">This term represents the histone H2B ubiquitination complex. It generally modulates heterochromatin-independent histone methylation. The individual components of this complex perform similar and redundant tasks involved in the regulation of cell survival.<a onclick="showRef(event, 'ref192'); return false;" href="javascript:void(0);" class="ref ref192">(192)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GO: 1901136</td><td class="colsep0 rowsep0" align="left">A catabolic process associated with carbohydrate derivation, this consists of chemical reactions that contribute to the digestion and breakdown of carbohydrates. The relationship between catabolic processes for carbohydrates and SL has been previously reported, with genes like BCL-2 being involved both in cancer and in carbohydrate digestion.<a onclick="showRef(event, 'ref193'); return false;" href="javascript:void(0);" class="ref ref193">(193)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GO: 0008234</td><td class="colsep0 rowsep0" align="left">A molecular function involving cytosine protease and thiol protease activity that plays a role in oncogene addiction and is involved in the maintenance of cell viability suggesting a potential for SL.<a onclick="showRef(event, 'ref194'); return false;" href="javascript:void(0);" class="ref ref194">(194)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GO: 1903772</td><td class="colsep0 rowsep0" align="left">A complex involved in the regulation of viral budding. Genes involved in the formation of this complex such as SKD1, LIP5, and IST1-LIKE1 are involved in specific SL mechanisms.<a onclick="showRef(event, 'ref195'); return false;" href="javascript:void(0);" class="ref ref195">(195)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GO: 0003383</td><td class="colsep0 rowsep0" align="left">The biological process of the actin-mediated contraction of the apical end of a polarized epithelial cell. Recently it was discovered that Lin-44 and Wnt participate in SL processes in addition to regulating apical constriction; therefore it is theorized that dysfunctional apical constriction could lead to SL.<a onclick="showRef(event, 'ref196'); return false;" href="javascript:void(0);" class="ref ref196">(196)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GO: 1903333</td><td class="colsep0 rowsep0" align="left">This describes the negative regulation of protein folding: it is theorized that this may cause toxic intermediates under the control of chaperones that may cause further cell death.<a onclick="showRef(event, 'ref197'); return false;" href="javascript:void(0);" class="ref ref197">(197)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GO: 0070202</td><td class="colsep0 rowsep0" align="left">This describes the regulation of protein localization in chromosomes. Two groups of genes, which encode for either the structural maintenance of chromosome proteins or chromosome stability proteins including BRCA, show the SL phenotype.<a onclick="showRef(event, 'ref198'); return false;" href="javascript:void(0);" class="ref ref198">(198)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GO: 0070087</td><td class="colsep0 rowsep0" align="left">A biological process of chromoshadow domain binding is predicted to be involved with SL, as the specific heterodomain protein HP1Î³, which is involved in SL, is predicted to bind at the chromoshadow domain, thus connecting this domain to cell viability.<a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(199)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GO: 0004883</td><td class="colsep0 rowsep0" align="left">This feature describes the activity of a glucocorticoid receptor or the participation in transmission and reaction of a glucocorticoid. Recent research shows p53 and GRÎ±/Ã are involved in these biological functions and are SL in non-small-cell lung cancer.<a onclick="showRef(event, 'ref200'); return false;" href="javascript:void(0);" class="ref ref200">(200)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GO: 2001034</td><td class="colsep0 rowsep0" align="left">The biological process of DNA repair through HR or n-HEJ, such as PARP.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GO: 0000209</td><td class="colsep0 rowsep0" align="left">The process of protein polyubiquitination; two examples of genes involved in this process are Slx5 and Slx8, which have also been reported to show synthetic lethality with each other. This suggests a connection between protein polyubiquitination and SL.<a onclick="showRef(event, 'ref201'); return false;" href="javascript:void(0);" class="ref ref201">(201)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Hsa04612</td><td class="colsep0 rowsep0" align="left">This represents antigen processing and presentation in the human immune response. Two genes indicated in this response, BRAF and NRAS, have been seen to be synthetically lethal with each other in melanoma.<a onclick="showRef(event, 'ref202'); return false;" href="javascript:void(0);" class="ref ref202">(202)</a></td></tr></tbody></table></div></div><div class="NLM_p">The ability to generate compounds capable of induced small-molecule synthetic lethality can be hampered by the complexity and size of the binding regions of the targets associated with SL. One such example noted earlier in the text is the attempted induction of SL through the blocking of RAD51âBRCA2 interaction; this is a proteinâprotein interaction that has in the past been difficult to modulate with small molecules, due to the size of the compound in comparison to the large binding region between the proteins. Work performed earlier in the decade by HyvÃ¶nen et al. attempted to modulate the RAD51âBRCA2 interaction through a fragment-based approach. Through protein engineering of RADA, the RAD51 analogue present in <i>archaea</i>, a monomeric form of RAD51 was able to be synthesized.<a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a> A fragment-based approach in 2013 demonstrated, through use of isothermal titration calorimetry (ITC), NMR, and X-ray crystallography, the first small molecule binding at the FxxA site of BRC4, a key binding region for the proteinâprotein interaction between RAD51 and BRCA2. However, a low success rate of only 0.2% was seen in the ITC assay in comparison to previous enzymatic assays. Two fragments were identified from this screen with low mM affinity; while low, it was a good starting point for further evaluation. This work was expanded upon in 2015, resulting in a 500-fold increase in affinity from the initial hits. Although the most promising hits from this series were unable to be crystallized, they performed well in the ITC assay, which seemed to indicate binding at the same site.<a onclick="showRef(event, 'ref184'); return false;" href="javascript:void(0);" class="ref ref184">(184)</a> Taken together, this fragment-based approach, utilizing biophysical assays such as ITC, NMR, SPR, and X-ray crystallography, demonstrates another possible tool in the pursuit of challenging SL targets. The genetic screening approach to evaluate possible SL pairs has gained new tools since the turn of the century. Previously, this was achieved through use of RNA interference (RNAi), where small-interfering RNAs (siRNAs) and/or short hairpin RNAs (shRNA) were employed to knockout genes to investigate whether the simultaneous knockout of two genes caused SL. This has been achieved in a high-throughput manner. An example of such is Novartisâs DRIVE program,<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a> which screened 7837 genes in 398 cell types. Numerous potential SL relationships were discovered in these studies, and these data could serve as a valuable tool for future drug-discovery programs, as all Novartisâs data on the DRIVE project is freely available through an online portal (<a href="https://oncologynibr.shinyapps.io/drive/" class="extLink">https://oncologynibr.shinyapps.io/drive/</a>). However, RNAi-based studies tend to suffer from poor reproducibility and comparison between studies, which can result in false positives and an inability to distinguish between on-target and off-target effects. Recent years have also seen the development of CRISPR-CAS9, which is functionally similar to RNAi but offers a higher-degree of reproducibility. This method involves a strand of single guided RNA (sgRNA) that allows the CAS9 endonuclease to bind with a sequence specific to that strand of sgRNA, thus enabling further modulation or regulation.<a onclick="showRef(event, 'ref185'); return false;" href="javascript:void(0);" class="ref ref185">(185)</a> Its advantages over RNAi are the following: it depletes genes in a more consistent manner; it has a higher degree of sensitivity with genes that have low levels of mRNA or short mRNA half-lives; it reduced RNA interference from heterogeneity among different cell lines.<a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a> This technique has been employed in studies investigating synthetic lethality. As an example, Wang et al.<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a> performed CRISPR analysis in 3 different cell lines that had been treated by the ATR inhibitor, <b>24</b>, in order to discover more SL pairs for ATR. From these studies, it was discovered that RNASEH2 was SL with ATR inhibition <i>in vitro</i> and <i>in vivo</i>. RNASEH2 is rarely upregulated in cancer subtypes; however this was in fact observed in prostate adenocarcinoma, suggesting a potential new biomarker that could be explored in this disease area. The same CRISPR-CAS9 studies reported that ATR inhibitors were SL with numerous other genes involved in the ATR pathway, suggesting that the whole ATR pathway is critical for cell survival; furthermore, members from the BRCA family were observed to be synthetic lethal with ATR, showing potential SL between ATR and HR-mediating targets. Overall, this demonstrates the potential of the CRISPR-CAS9 technique to be employed in the discovery of previously unknown targets for SL and guides further research. Furthermore, CRISPR-CAS9 in theory could be employed for treatment of cancers. This field is quite controversial with many ethical dilemmas that need to be addressed; however to date, a number of CRISPR-CAS9 based therapies have entered clinical trials.<a onclick="showRef(event, 'ref188'); return false;" href="javascript:void(0);" class="ref ref188">(188)</a> Should these be successful, it is possible in the future that CRISPR-CAS9 could be used in a therapeutic way to trigger SL.</div><div class="NLM_p">Testing SL using <i>in vitro</i> models can be difficult. The biological models that are used for the development of such molecules usually include pairs of isogenic cell-based models. These are not an entirely accurate prediction of potential SL phenotypes, as it has been shown that SL pairs can be dependent on context specificity, with cancer presenting a vast array of genotypes. Small differences in the genotype can mean that a pair of small molecules modulating an SL interaction may be effective in one circumstance but not another. Examples of this phenomenon can be seen in colorectal cancer, where the presence of KRAS and NRAS mutations is a predictor for resistance to anti-EGFR antibodies.<a onclick="showRef(event, 'ref189'); return false;" href="javascript:void(0);" class="ref ref189">(189)</a> This is already being used in the clinic and demonstrates the importance of understanding the impact of context specificity on the application of SL-dependent treatments.</div><div class="NLM_p">As it has been shown in the regulatory body approval of the PARP inhibitors, these drugs can be very effective in treating tumors with âBRCAnessâ, i.e., a tumor where the patient shows impeded function of one of the BRCA family genes involved in HR.<a onclick="showRef(event, 'ref203'); return false;" href="javascript:void(0);" class="ref ref203">(203)</a> Unfortunately, while a number of cancers (e.g., ovarian cancer)<a onclick="showRef(event, 'ref204'); return false;" href="javascript:void(0);" class="ref ref204">(204)</a> feature the BRCAness trait, the ability to administer a single inhibitor to induce SL is diminished in cancers that do not express BRCAness. To have these compounds truly be effective and initiate small-molecule-induced synthetic lethality, modulators must be administered in combination with one another in order to see a synergistic effect.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> This has been demonstrated previously with use of the PARP1 inhibitor <b>2</b> and temozolomide, an orally bioavailable monofunctional DNA-alkylating agent.<a onclick="showRef(event, 'ref205'); return false;" href="javascript:void(0);" class="ref ref205">(205)</a> The use of combinational therapy can be challenging, as the number of therapeutics in combination increases the likelihood of unwanted side effects, in addition to the potential for unknown drugâdrug interactions.<a onclick="showRef(event, 'ref206'); return false;" href="javascript:void(0);" class="ref ref206">(206)</a> In order to minimize these issues, it is vitally important that the mechanism of action of the compounds and their safety profiles be well understood. If this is the case, the potential for combinational treatment is vast. Work has been conducted into evaluating more potential drug combinations that currently exist by Heinzel et al.<a onclick="showRef(event, 'ref207'); return false;" href="javascript:void(0);" class="ref ref207">(207)</a> Through a bioinformatics approach, they investigated 358 ovarian cancer trials utilizing the clinicaltrials.gov Web site. The search was refined further by use of keywords, eventually resulting in 68 trials that showed 61 unique drug interactions. These data allowed them to identify numerous combinations that are not currently being investigated in clinical trials but have the potential for SL and merit further investigation. These data illustrate that while combination treatments present challenges, the wealth of data on some of these well-known compounds in several clinical trials can be used as an asset, and there are great opportunities that can still be explored.</div><div class="NLM_p">It is hypothesized by the authors that the use of small molecule-induced synthetic lethality should be approached with caution. In traditional SL approaches, where one of the genes lack function, i.e., through mutation in certain cancers, use of an inhibitor for the other SL gene targets the cancer cell and leaves the healthy cell employing a somewhat selective therapy. However, if this approach is replicated with small molecules, it is possible that the mechanisms these genes perform in DNA repair are utilized throughout healthy cells in addition to cancerous cells. Therefore, while cancer cells are more rapidly dividing and therefore will be reliant on HR, noncancerous cells will also use these mechanisms to some degree, resulting in unwanted side effects. Indeed, cancer cells are less genetically stable than healthy cells and therefore feature more DNA breaks, thus being more reliant on HR. This likely confers to small molecule-induced synthetic lethality a degree of selectivity for cancerous cells over healthy ones. The implications for this approach to be employed safely are that the underlying biology of the targets in healthy and cancer cells should be fully understood so as to apply this innovative approach to suitable target pairs.</div><div class="NLM_p">Synthetic lethality, as shown throughout this review, has been primarily employed in oncology, attempting to disrupt the survival pathways of cancerous cells; however, this is not the only potential application of synthetically lethal therapies. The discovery of new antibiotics is an urgent need, as strains of resistant bacteria such as methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) continue to be a major risk of infection in hospitals throughout the world.<a onclick="showRef(event, 'ref208'); return false;" href="javascript:void(0);" class="ref ref208">(208)</a> Due to bacteria being relatively simple organisms, they are reliant on HR for DNA damage repair;<a onclick="showRef(event, 'ref209'); return false;" href="javascript:void(0);" class="ref ref209">(209)</a> therefore SL has been looked at as a possible way of developing antibacterials. Charusanti et al. utilized a systems biology-guided approach to discover SL pairs for bacteria.<a onclick="showRef(event, 'ref210'); return false;" href="javascript:void(0);" class="ref ref210">(210)</a> The SL pairs identified from the virtual screens employed in these studies were confirmed experimentally with a precision rate of 25â43%. A virtual screen of compounds that were able to dock with 4 pairs of targets was performed subsequently. Two pairs of targets were found through their studies to be synthetically lethal (hemF/hemN, lpdA/sucC), one pair where both genes were found to be singularly essential (glyA/serA), and one pair where only one of the genes was known to be singularly essential (mdh/ppc). These studies did not yield compounds capable of inducing synthetic lethality; however the ability to identify SL pairs in bacteria opens the door to focused drug-discovery programs that may have more success.</div><div class="NLM_p last">Furthermore, additional potential applications can be seen in antiparasitics to treat diseases such as drug-resistant malaria. Due to the high level of conservation of genome integrity and cell cycle genes between species, it has been possible to conduct large screens in yeast and then use the SL pairs discovered to apply to other organisms, using the analogue genes in for example <i>plasmodium</i>.<a onclick="showRef(event, 'ref211'); return false;" href="javascript:void(0);" class="ref ref211">(211)</a> Using this approach, Lee et al. were able to compare yeast SL genes to their analogues present in the malaria parasites <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i> for the potential SL treatment of malaria in humans. Genes were selected that do not have an analogue in mammals, so as to minimize the chance of cross-species promiscuity. Through these studies five SL partners in the <i>plasmodium</i> were discovered. These findings warranted further investigation. To aid this, the group identified a number of commercially available compounds that already act upon these targets, showing a potential application of SL in antiparasitics. Many of the SL relationships discussed in this text have analogues in bacteria and parasites that play key roles in HR due to a high degree of evolutionary conservation. These examples, such as RAD51âs analogue in bacteria RecA or TbRAD51 in <i>T. brucei</i>, perform similar roles in their associated organisms and are heavily involved in HR and DNA repair.<a onclick="showRef(event, 'ref212 ref213'); return false;" href="javascript:void(0);" class="ref ref212 ref213">(212,213)</a> Of course, selectivity between species would be vitally important should any of these targets be explored, which could be challenging due to the large degree of homology between them; however, if this selectivity issue could be resolved, it could expand the usefulness of drugs that function through an SL mechanism greatly and warrants further exploration within the field.</div></div><div id="sec10" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">10.  Future Prospects and Final Thoughts</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71681" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71681" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">It has clearly emerged that the field of SL has much potential for oncology in a need that the personalized medicine from the previous 20 years has struggled to fill. SL offers a way to treat cancer that, in theory, leaves healthy cells unaffected and therefore has reduced side effects compared to nonspecific chemotherapy. However, the application of SL modulators still has a long way to go, as not all cancer subtypes have clearly defined deficiency, such as has been seen with the application of PARP1 and BRCA1/2 inhibitors or the 29 clinical trials currently involving ATR inhibitors. As the fieldsâ understanding of the underlying cancer biology increases, in addition to the growing network of tools to discover more SL pairs and, importantly, the mechanisms involved in SL, the viability of SL related drugs will increase. For this to occur, cross-disciplinary communication is vital, from target selection to compound design and optimization and beyond into <i>in vitro</i>/<i>in vivo</i> and into the clinic, with a willingness to risk and explore previously uninvestigated targets. Furthermore, the way in which SL drugs are implemented will be key to their success. For example, if full small molecule-induced synthetic lethality is to be used, i.e., inhibiting two SL pairs selectively at once, one must consider the greater potential for resistance as the cancer cell survival pathways adapt. Either it must be accepted that these compounds have a short window of effectiveness, or these mechanisms of resistance must be studied and anticipated so that further treatment can be administered to restore sensitivity, as is attempting to be achieved with PARP1 resistance through the restoration of function of BRCA1/2 using RAD51-BRCA2 inhibitors.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> Alternatively, if SL compounds can be implemented to impede HR in cancers that have undergone DNA stress, such as alkylation agents, nonspecific chemotherapeutics, or ionization, it is possible that through this method SL could be employed to lessen the dosage and therefore side effects of these treatments, with a reduced risk of acquired resistance from the SL pathway. Additionally, it has been theorized that SL drugs would be most effective in early stage cancers, as it is hypothesized that premalignant cancers are less heterogenic, and therefore this is where SL is likely to have the greatest impact.<a onclick="showRef(event, 'ref214'); return false;" href="javascript:void(0);" class="ref ref214">(214)</a> Obviously, for this to be viable, early detection of cancers in the clinic has to be achievable, and this chemopreventive approach is very much still in its infancy, existing primarily in animal models.<a onclick="showRef(event, 'ref215'); return false;" href="javascript:void(0);" class="ref ref215">(215)</a> With these considerations in place, it can be seen that the future for SL modulations could be bright, and in years to come the number of projects shining light on this interesting method of combating cancer will surely grow, and hopefully this will be reflected in the clinic. We hope this work inspires the medicinal chemistry community to develop novel compounds that can be exploited to discover innovative SL pathways in a chemical biology framework and, through utilization in drug discovery programs, identify SL-based anticancer compounds.</div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18"><a href="/doi/suppl/10.1021/acs.jmedchem.0c00766" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10315" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10315" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c00766?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00766</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula string (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00766/suppl_file/jm0c00766_si_001.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00766/suppl_file/jm0c00766_si_001.csv">jm0c00766_si_001.csv (4.4 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c00766" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74574" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74574" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrea Cavalli</span> - <span class="hlFld-Affiliation affiliation">Computational
& Chemical Biology, Istituto Italiano
di Tecnologia, 16163 Genova, Italy</span>;Â 
    <span class="hlFld-Affiliation affiliation">Department
of Pharmacy and Biotechnology, University
of Bologna, 40126 Bologna, Italy</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6370-1176" title="Orcid link">http://orcid.org/0000-0002-6370-1176</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#f7b69993859296d9b49681969b9b9eb79e9e83d99e83"><span class="__cf_email__" data-cfemail="febf909a8c9b9fd0bd9f889f929297be97978ad0978a">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Samuel H. Myers</span> - <span class="hlFld-Affiliation affiliation">Computational
& Chemical Biology, Istituto Italiano
di Tecnologia, 16163 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jose Antonio Ortega</span> - <span class="hlFld-Affiliation affiliation">Computational
& Chemical Biology, Istituto Italiano
di Tecnologia, 16163 Genova, Italy</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li><span class="author-information-subsection-header">Funding</span><p>This work was supported in part by the Italian Association for Cancer Research (AIRC) through Grant IG 2018 Id.21386 and the Istituto Italiano di Tecnologia (IIT).</p></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56755" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56755" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Samuel H. Myers</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=BIO-d7e4487-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Samuel H. Myers</b> received his Ph.D. in Medicinal Chemistry from the University of Edinburgh (U.K.) in 2016. After postdoctoral work in medicinal chemistry and chemical biology at University College London (UCL) (U.K.), in 2018 he joined the Italian Institute of Technology, Genova (Italy), where he works as a postdoc in medicinal chemistry.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Jose Antonio Ortega</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=BIO-d7e4492-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jose Antonio Ortega</b> got his Ph.D. degree in Chemistry from the University of Barcelona (UB) in 2006 in the field of nucleic acids research. After working as a chemistry researcher in industrial medicinal chemistry projects at the Scientific Park of Barcelona (PCB), in 2012 he joined the Italian Institute of Technology (IIT) to participate in drug discovery projects mainly focused on the design and synthesis of small molecules for cancer treatment. Within the different strategies applied for the design of new molecular entities, the development of proteinâprotein interaction disruptors to chemically induce synthetic lethality is the center of his most recent research activities in the computational and chemical biology group at IIT.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Andrea Cavalli</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=BIO-d7e4497-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Andrea Cavalli</b> is Professor of Medicinal Chemistry at the University of Bologna and Director of Computational and Chemical Biology at the Italian Institute of Technology, Genova, where he is also Deputy Director for Computational Sciences. Prof. Cavalliâs research has combined computational chemistry with drug discovery, focusing on neurodegenerative diseases, cancer, and neglected tropical diseases. In particular, he has been a pioneer in the use of molecular dynamics approaches to drug discovery. These new methods have led to the identification and characterization of lead candidates within the framework of multitarget drug discovery and polypharmacology. He is an author of more than 230 scientific papers and inventor in several international patents. He has delivered more than 120 invited lectures and seminars.</p></figure></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ATRi</td><td class="NLM_def"><p class="first last">ATR inhibitor</p></td></tr><tr><td class="NLM_term">AZ</td><td class="NLM_def"><p class="first last">AstraZeneca</p></td></tr><tr><td class="NLM_term">BER</td><td class="NLM_def"><p class="first last">base excision repair</p></td></tr><tr><td class="NLM_term">BTK</td><td class="NLM_def"><p class="first last">Brutonâs tyrosine kinase</p></td></tr><tr><td class="NLM_term">CL</td><td class="NLM_def"><p class="first last">clearance</p></td></tr><tr><td class="NLM_term">CtIP</td><td class="NLM_def"><p class="first last">CTBP interacting protein</p></td></tr><tr><td class="NLM_term">CYP3A4</td><td class="NLM_def"><p class="first last">cytochrome P450 3A4</p></td></tr><tr><td class="NLM_term"><i>D</i><sub>abs</sub></td><td class="NLM_def"><p class="first last">maximum absorbable dose</p></td></tr><tr><td class="NLM_term">DNA-PKi</td><td class="NLM_def"><p class="first last">DNA-PK inhibitor</p></td></tr><tr><td class="NLM_term">DSB</td><td class="NLM_def"><p class="first last">double-stranded break</p></td></tr><tr><td class="NLM_term">HER2</td><td class="NLM_def"><p class="first last">human epidermal growth factor 2</p></td></tr><tr><td class="NLM_term">HR</td><td class="NLM_def"><p class="first last">homologous recombination</p></td></tr><tr><td class="NLM_term">HTS</td><td class="NLM_def"><p class="first last">high-throughput screen</p></td></tr><tr><td class="NLM_term">ITC</td><td class="NLM_def"><p class="first last">isothermal titration calorimetry</p></td></tr><tr><td class="NLM_term">MMEJ</td><td class="NLM_def"><p class="first last">microhomology-mediated end joining</p></td></tr><tr><td class="NLM_term">MRSA</td><td class="NLM_def"><p class="first last">methicillin-resistant <i>Staphylococcus aureus</i></p></td></tr><tr><td class="NLM_term">NER</td><td class="NLM_def"><p class="first last">nucleotide excision repair</p></td></tr><tr><td class="NLM_term">NHEJ</td><td class="NLM_def"><p class="first last">nonhomologous end joining</p></td></tr><tr><td class="NLM_term">PARP</td><td class="NLM_def"><p class="first last">poly (ADP-ribose) polymerase</p></td></tr><tr><td class="NLM_term">PARPi</td><td class="NLM_def"><p class="first last">PARP inhibitor</p></td></tr><tr><td class="NLM_term">RAD52i</td><td class="NLM_def"><p class="first last">RAD52 inhibitor</p></td></tr><tr><td class="NLM_term">RNAi</td><td class="NLM_def"><p class="first last">RNA interference</p></td></tr><tr><td class="NLM_term">RPAi</td><td class="NLM_def"><p class="first last">RPA inhibitor</p></td></tr><tr><td class="NLM_term">sgRNA</td><td class="NLM_def"><p class="first last">single-guided RNA</p></td></tr><tr><td class="NLM_term">shRNA</td><td class="NLM_def"><p class="first last">short hairpin RNA</p></td></tr><tr><td class="NLM_term">siRNA</td><td class="NLM_def"><p class="first last">small-interfering RNA</p></td></tr><tr><td class="NLM_term">SL</td><td class="NLM_def"><p class="first last">synthetic lethality</p></td></tr><tr><td class="NLM_term">SSB</td><td class="NLM_def"><p class="first last">single-stranded break</p></td></tr><tr><td class="NLM_term">ssDNA</td><td class="NLM_def"><p class="first last">single-stranded DNA</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>ss</sub></td><td class="NLM_def"><p class="first last">volume of distribution</p></td></tr><tr><td class="NLM_term">WT</td><td class="NLM_def"><p class="first last">wild-type</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74711" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74711" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 215 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hochhaus, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larson, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guilhot, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radich, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Branford, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baccarani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deininger, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervantes, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujihara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortmann, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menssen, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâBrien, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span> <span> </span><span class="NLM_article-title">Long-Term outcomes of Imatinib treatment for chronic myeloid leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>376</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">917</span>â <span class="NLM_lpage">927</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa1609324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1056%2FNEJMoa1609324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=28273028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlyktLfF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2017&pages=917-927&issue=10&author=A.+Hochhausauthor=R.+A.+Larsonauthor=F.+Guilhotauthor=J.+P.+Radichauthor=S.+Branfordauthor=T.+P.+Hughesauthor=M.+Baccaraniauthor=M.+W.+Deiningerauthor=F.+Cervantesauthor=S.+Fujiharaauthor=C.+E.+Ortmannauthor=H.+D.+Menssenauthor=H.+Kantarjianauthor=S.+G.+O%E2%80%99Brienauthor=B.+J.+Druker&title=Long-Term+outcomes+of+Imatinib+treatment+for+chronic+myeloid+leukemia&doi=10.1056%2FNEJMoa1609324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term outcomes of imatinib treatment for chronic myeloid leukemia</span></div><div class="casAuthors">Hochhaus, Andreas; Larson, Richard A.; Guilhot, Francois; Radich, Jerald P.; Branford, Susan; Hughes, Timothy P.; Baccarani, Michele; Deininger, Michael W.; Cervantes, Francisco; Fujihara, Satoko; Ortmann, Christine-Elke; Menssen, Hans D.; Kantarjian, Hagop; O'Brien, Stephen G.; Druker, Brian J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">376</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">917-927</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for patients with chronic myeloid leukemia (CML).  We conducted efficacy and safety analyses on the basis of more than 10 years of follow-up in patients with CML who were treated with imatinib as initial therapy.  METHODS: In this open-label, multicenter trial with crossover design, we randomly assigned patients with newly diagnosed CML in the chronic phase to receive either imatinib or interferon alfa plus cytarabine.  Long-term analyses included overall survival, response to treatment, and serious adverse events.  RESULTS: The median follow-up was 10.9 years.  Given the high rate of crossover among patients who had been randomly assigned to receive interferon alfa plus cytarabine (65.6%) and the short duration of therapy before crossover in these patients (median, 0.8 years), the current analyses focused on patients who had been randomly assigned to receive imatinib.  Among the patients in the imatinib group, the estd. overall survival rate at 10 years was 83.3%.  Approx. half the patients (48.3%) who had been randomly assigned to imatinib completed study treatment with imatinib, and 82.8% had a complete cytogenetic response.  Serious adverse events that were considered by the investigators to be related to imatinib were uncommon and most frequently occurred during the first year of treatment.  CONCLUSIONS: Almost 11 years of follow-up showed that the efficacy of imatinib persisted over time and that long-term administration of imatinib was not assocd. with unacceptable cumulative or late toxic effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ9-B-a7DOrbVg90H21EOLACvtfcHk0ljLV9pEFLe6GQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlyktLfF&md5=2f77f70245de22f00cce881421e8f6a9</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1609324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1609324%26sid%3Dliteratum%253Aachs%26aulast%3DHochhaus%26aufirst%3DA.%26aulast%3DLarson%26aufirst%3DR.%2BA.%26aulast%3DGuilhot%26aufirst%3DF.%26aulast%3DRadich%26aufirst%3DJ.%2BP.%26aulast%3DBranford%26aufirst%3DS.%26aulast%3DHughes%26aufirst%3DT.%2BP.%26aulast%3DBaccarani%26aufirst%3DM.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DCervantes%26aufirst%3DF.%26aulast%3DFujihara%26aufirst%3DS.%26aulast%3DOrtmann%26aufirst%3DC.%2BE.%26aulast%3DMenssen%26aufirst%3DH.%2BD.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%2BG.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DLong-Term%2520outcomes%2520of%2520Imatinib%2520treatment%2520for%2520chronic%2520myeloid%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D376%26issue%3D10%26spage%3D917%26epage%3D927%26doi%3D10.1056%2FNEJMoa1609324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauschild, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haanen, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ascierto, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dummer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Testori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorigan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jouary, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadendorf, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâDay, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkwood, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eggermont, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreno, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolop, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G. A.</span></span> <span> </span><span class="NLM_article-title">Improved survival with vemurafenib in melanoma with BRAF V600E mutation</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>364</i></span> (<span class="NLM_issue">26</span>),  <span class="NLM_fpage">2507</span>â <span class="NLM_lpage">2516</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa1103782</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1056%2FNEJMoa1103782" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=21639808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosVeitbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=2507-2516&issue=26&author=P.+B.+Chapmanauthor=A.+Hauschildauthor=C.+Robertauthor=J.+B.+Haanenauthor=P.+Asciertoauthor=J.+Larkinauthor=R.+Dummerauthor=C.+Garbeauthor=A.+Testoriauthor=M.+Maioauthor=D.+Hoggauthor=P.+Loriganauthor=C.+Lebbeauthor=T.+Jouaryauthor=D.+Schadendorfauthor=A.+Ribasauthor=S.+J.+O%E2%80%99Dayauthor=J.+A.+Sosmanauthor=J.+M.+Kirkwoodauthor=A.+M.+Eggermontauthor=B.+Drenoauthor=K.+Nolopauthor=J.+Liauthor=B.+Nelsonauthor=J.+Houauthor=R.+J.+Leeauthor=K.+T.+Flahertyauthor=G.+A.+McArthur&title=Improved+survival+with+vemurafenib+in+melanoma+with+BRAF+V600E+mutation&doi=10.1056%2FNEJMoa1103782"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Improved survival with vemurafenib in melanoma with BRAF V600E mutation</span></div><div class="casAuthors">Chapman, Paul B.; Hauschild, Axel; Robert, Caroline; Haanen, John B.; Ascierto, Paolo; Larkin, James; Dummer, Reinhard; Garbe, Claus; Testori, Alessandro; Maio, Michele; Hogg, David; Lorigan, Paul; Lebbe, Celeste; Jouary, Thomas; Schadendorf, Dirk; Ribas, Antoni; O'Day, Steven J.; Sosman, Jeffrey A.; Kirkwood, John M.; Eggermont, Alexander M. M.; Dreno, Brigitte; Nolop, Keith; Li, Jiang; Nelson, Betty; Hou, Jeannie; Lee, Richard J.; Flaherty, Keith T.; McArthur, Grant A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2507-2516</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Phase 1 and 2 clin. trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation.  METHODS: We conducted a phase 3 randomized clin. trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation.  Patients were randomly assigned to receive either vemurafenib (960 mg orally twice daily) or dacarbazine (1000 mg per square meter of body-surface area i.v. every 3 wk).  Coprimary end points were rates of overall and progression-free survival.  Secondary end points included the response rate, response duration, and safety.  A final anal. was planned after 196 deaths and an interim anal. after 98 deaths.  RESULTS: At 6 mo, overall survival was 840/ (95% confidence interval [CI], 78 to 89) in the vemurafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group.  In the interim anal. for overall survival and final anal. for progression-free survival, vemurafenib was assocd. with a relative redn. of 63% in the risk of death and of 74% in the risk of either death or disease progression, as compared with dacarbazine (P < 0.001 for both comparisons).  After review of the interim anal. by an independent data and safety monitoring board, crossover from dacarbazine to vemurafenib was recommended.  Response rates were 48% for vemurafenib and 5% for dacarbazine.  Common adverse events assocd. with vemurafenib were arthralgia, rash, fatigue, alopecia, keratoacanthoma or squamous-cell carcinoma, photosensitivity, nausea, and diarrhea; 38% of patients required dose modification because of toxic effects.  CONCLUSIONS: Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4NFxmTaDz97Vg90H21EOLACvtfcHk0lgXENxJHYNqUA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosVeitbs%253D&md5=1a4b4f963221888dc63f620e87408070</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1103782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1103782%26sid%3Dliteratum%253Aachs%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DHaanen%26aufirst%3DJ.%2BB.%26aulast%3DAscierto%26aufirst%3DP.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DTestori%26aufirst%3DA.%26aulast%3DMaio%26aufirst%3DM.%26aulast%3DHogg%26aufirst%3DD.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DLebbe%26aufirst%3DC.%26aulast%3DJouary%26aufirst%3DT.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Day%26aufirst%3DS.%2BJ.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DKirkwood%26aufirst%3DJ.%2BM.%26aulast%3DEggermont%26aufirst%3DA.%2BM.%26aulast%3DDreno%26aufirst%3DB.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DNelson%26aufirst%3DB.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26atitle%3DImproved%2520survival%2520with%2520vemurafenib%2520in%2520melanoma%2520with%2520BRAF%2520V600E%2520mutation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26issue%3D26%26spage%3D2507%26epage%3D2516%26doi%3D10.1056%2FNEJMoa1103782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pagliarini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span> <span> </span><span class="NLM_article-title">Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure</span>. <i>EMBO Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">280</span>â <span class="NLM_lpage">296</span>, <span class="refDoi">Â DOI: 10.15252/embr.201439949</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.15252%2Fembr.201439949" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=25680965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjs1Gnur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=280-296&issue=3&author=R.+Pagliariniauthor=W.+Shaoauthor=W.+R.+Sellers&title=Oncogene+addiction%3A+pathways+of+therapeutic+response%2C+resistance%2C+and+road+maps+toward+a+cure&doi=10.15252%2Fembr.201439949"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure</span></div><div class="casAuthors">Pagliarini, Raymond; Shao, Wenlin; Sellers, William R.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">280-296</span>CODEN:
                <span class="NLM_cas:coden">ERMEAX</span>;
        ISSN:<span class="NLM_cas:issn">1469-221X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  A key goal of cancer therapeutics is to selectively target the genetic lesions that initiate and maintain cancer cell proliferation and survival.  While most cancers harbor multiple oncogenic mutations, a wealth of preclin. and clin. data supports that many cancers are sensitive to inhibition of single oncogenes, a concept referred to as 'oncogene addiction'.  Herein, we describe the clin. evidence supporting oncogene addiction and discuss common mechanistic themes emerging from the response and acquired resistance to oncogene-targeted therapies.  Finally, we suggest several opportunities toward exploiting oncogene addiction to achieve curative cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEtJj2YdGf6LVg90H21EOLACvtfcHk0lilNgKfJoIdpg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjs1Gnur4%253D&md5=30f0b2a45a633e12155d5c7e577753e2</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.15252%2Fembr.201439949&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15252%252Fembr.201439949%26sid%3Dliteratum%253Aachs%26aulast%3DPagliarini%26aufirst%3DR.%26aulast%3DShao%26aufirst%3DW.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26atitle%3DOncogene%2520addiction%253A%2520pathways%2520of%2520therapeutic%2520response%252C%2520resistance%252C%2520and%2520road%2520maps%2520toward%2520a%2520cure%26jtitle%3DEMBO%2520Rep.%26date%3D2015%26volume%3D16%26issue%3D3%26spage%3D280%26epage%3D296%26doi%3D10.15252%2Fembr.201439949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garraway, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashworth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, B.</span></span> <span> </span><span class="NLM_article-title">Synthetic lethality as an engine for cancer drug target discovery</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">23</span>â <span class="NLM_lpage">38</span>, <span class="refDoi">Â DOI: 10.1038/s41573-019-0046-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1038%2Fs41573-019-0046-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=31712683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFegs7jK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2020&pages=23-38&issue=1&author=A.+Huangauthor=L.+A.+Garrawayauthor=A.+Ashworthauthor=B.+Weber&title=Synthetic+lethality+as+an+engine+for+cancer+drug+target+discovery&doi=10.1038%2Fs41573-019-0046-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic lethality as an engine for cancer drug target discovery</span></div><div class="casAuthors">Huang, Alan; Garraway, Levi A.; Ashworth, Alan; Weber, Barbara</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-38</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  The first wave of genetically targeted therapies for cancer focused on drugging gene products that are recurrently mutated in specific cancer types.  However, mutational anal. of tumors has largely been exhausted as a strategy for the identification of new cancer targets that are druggable with conventional approaches.  Furthermore, some known genetic drivers of cancer have not been directly targeted yet owing to their mol. structure (undruggable oncogenes) or because they result in functional loss (tumor suppressor genes).  Functional genomic screening based on the genetic concept of synthetic lethality provides an avenue to discover drug targets in all these areas.  Although synthetic lethality is not a new idea, recent advances, including CRISPR-based gene editing, have made possible systematic screens for synthetic lethal drug targets in human cancers.  Such approaches have broad potential to drive the discovery of the next wave of genetic cancer targets and ultimately the introduction of effective medicines that are still needed for most cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUGZtPqjLRlrVg90H21EOLACvtfcHk0lilNgKfJoIdpg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFegs7jK&md5=227059e12105feecc402ea6ff4f98640</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fs41573-019-0046-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41573-019-0046-z%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DA.%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26aulast%3DAshworth%26aufirst%3DA.%26aulast%3DWeber%26aufirst%3DB.%26atitle%3DSynthetic%2520lethality%2520as%2520an%2520engine%2520for%2520cancer%2520drug%2520target%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2020%26volume%3D19%26issue%3D1%26spage%3D23%26epage%3D38%26doi%3D10.1038%2Fs41573-019-0046-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dobzhansky, T.</span></span> <span> </span><span class="NLM_article-title">Genetics of natural populations. Xiii. Recombination and variability in populations of Drosophila pseudoobscura</span>. <i>Genetics</i> <span class="NLM_year" style="font-weight: bold;">1946</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">269</span>â <span class="NLM_lpage">290</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=20985721" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A280%3ADyaH28%252FgtlyhtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1946&pages=269-290&author=T.+Dobzhansky&title=Genetics+of+natural+populations.+Xiii.+Recombination+and+variability+in+populations+of+Drosophila+pseudoobscura"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Genetics of natural populations; recombination and variability in populations of Drosophila pseudoobscura</span></div><div class="casAuthors">DOBZHANSKY T</div><div class="citationInfo"><span class="NLM_cas:title">Genetics</span>
        (<span class="NLM_cas:date">1946</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">269-90</span>
        ISSN:<span class="NLM_cas:issn">0016-6731</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQXehIoFNdovudfST00W0BcfW6udTcc2eY0trjWzIQPSLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaH28%252FgtlyhtA%253D%253D&md5=51f55835f5a3053a235bdea89458573c</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDobzhansky%26aufirst%3DT.%26atitle%3DGenetics%2520of%2520natural%2520populations.%2520Xiii.%2520Recombination%2520and%2520variability%2520in%2520populations%2520of%2520Drosophila%2520pseudoobscura%26jtitle%3DGenetics%26date%3D1946%26volume%3D31%26spage%3D269%26epage%3D290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parameswaran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kundapur, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vizeacoumar, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freywald, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uppalapati, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vizeacoumar, F. J.</span></span> <span> </span><span class="NLM_article-title">A road map to personalizing targeted cancer therapies using synthetic lethality</span>. <i>Trends Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">11</span>â <span class="NLM_lpage">29</span>, <span class="refDoi">Â DOI: 10.1016/j.trecan.2018.11.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.trecan.2018.11.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=30616753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1MXkvVKluw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2019&pages=11-29&issue=1&author=S.+Parameswaranauthor=D.+Kundapurauthor=F.+S.+Vizeacoumarauthor=A.+Freywaldauthor=M.+Uppalapatiauthor=F.+J.+Vizeacoumar&title=A+road+map+to+personalizing+targeted+cancer+therapies+using+synthetic+lethality&doi=10.1016%2Fj.trecan.2018.11.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">A Road Map to Personalizing Targeted Cancer Therapies Using Synthetic Lethality</span></div><div class="casAuthors">Parameswaran, Sreejit; Kundapur, Deeksha; Vizeacoumar, Frederick S.; Freywald, Andrew; Uppalapati, Maruti; Vizeacoumar, Franco J.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-29</span>CODEN:
                <span class="NLM_cas:coden">TCRAB5</span>;
        ISSN:<span class="NLM_cas:issn">2405-8033</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Targeted therapies rely on the genetic and epigenetic status of the tumor cells and are seen as the most promising approach to treat cancer today.  However, current targeted therapies focus on directly inhibiting those mols. that are altered in tumor cells.  Unfortunately, targeting these mols., even with specific inhibitors, is challenging as tumor cells rewire their genetic circuitry to eliminate genetic dependency on these targets.  Here, we describe how synthetic lethality approaches can be used to identify genetic dependencies and develop personalized targeted therapies.  We also discuss strategies to specifically target these genetic dependencies, using small mol. and biol. drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvte78cztNurVg90H21EOLACvtfcHk0li2jO0OtuWnAg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXkvVKluw%253D%253D&md5=e6e4d907a4d565756650d1762bfd4bb8</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.trecan.2018.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.trecan.2018.11.001%26sid%3Dliteratum%253Aachs%26aulast%3DParameswaran%26aufirst%3DS.%26aulast%3DKundapur%26aufirst%3DD.%26aulast%3DVizeacoumar%26aufirst%3DF.%2BS.%26aulast%3DFreywald%26aufirst%3DA.%26aulast%3DUppalapati%26aufirst%3DM.%26aulast%3DVizeacoumar%26aufirst%3DF.%2BJ.%26atitle%3DA%2520road%2520map%2520to%2520personalizing%2520targeted%2520cancer%2520therapies%2520using%2520synthetic%2520lethality%26jtitle%3DTrends%2520Cancer%26date%3D2019%26volume%3D5%26issue%3D1%26spage%3D11%26epage%3D29%26doi%3D10.1016%2Fj.trecan.2018.11.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deeks, E. D.</span></span> <span> </span><span class="NLM_article-title">Olaparib: first global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">231</span>â <span class="NLM_lpage">240</span>, <span class="refDoi">Â DOI: 10.1007/s40265-015-0345-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1007%2Fs40265-015-0345-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=25616434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVejtbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=231-240&issue=2&author=E.+D.+Deeks&title=Olaparib%3A+first+global+approval&doi=10.1007%2Fs40265-015-0345-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Olaparib: First Global Approval</span></div><div class="casAuthors">Deeks, Emma D.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">231-240</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Olaparib (Lynparza) is an oral, small mol., poly (ADP-ribose) polymerase inhibitor being developed by AstraZeneca for the treatment of solid tumors.  The primary indication that olaparib is being developed for is BRCA mutation-pos. ovarian cancer.  A capsule formulation of the drug has received approval for use in this setting in the EU and USA, and a tablet formulation is in global phase III trials (including in the USA, EU, Australia, Brazil, Canada, China, Israel, Japan, Russia and South Korea).  In addn., phase III trials in breast, gastric and pancreatic cancer are underway/planned, and phase I/II investigation is being conducted in other malignancies, including prostate cancer, non-small cell lung cancer, Ewing's sarcoma and advanced cancer.  This article summarizes the milestones in the development of olaparib leading to this first approval for ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4agVSDkOKqbVg90H21EOLACvtfcHk0li2jO0OtuWnAg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVejtbg%253D&md5=cd68d932b6532a87c0768590afd81058</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0345-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0345-6%26sid%3Dliteratum%253Aachs%26aulast%3DDeeks%26aufirst%3DE.%2BD.%26atitle%3DOlaparib%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26issue%3D2%26spage%3D231%26epage%3D240%26doi%3D10.1007%2Fs40265-015-0345-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ame, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spenlehauer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Murcia, G.</span></span> <span> </span><span class="NLM_article-title">The PARP superfamily</span>. <i>BioEssays</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">882</span>â <span class="NLM_lpage">893</span>, <span class="refDoi">Â DOI: 10.1002/bies.20085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1002%2Fbies.20085" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=15273990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnt1CqtLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2004&pages=882-893&issue=8&author=J.+C.+Ameauthor=C.+Spenlehauerauthor=G.+de+Murcia&title=The+PARP+superfamily&doi=10.1002%2Fbies.20085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The PARP superfamily</span></div><div class="casAuthors">Ame, Jean-Christophe; Spenlehauer, Catherine; de Murcia, Gilbert</div><div class="citationInfo"><span class="NLM_cas:title">BioEssays</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">882-893</span>CODEN:
                <span class="NLM_cas:coden">BIOEEJ</span>;
        ISSN:<span class="NLM_cas:issn">0265-9247</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Poly(ADP-ribosyl)ation is an immediate DNA-damage-dependent post-translational modification of histones and other nuclear proteins that contributes to the survival of injured proliferating cells.  Poly(ADP-ribose) polymerases (PARPs) now constitute a large family of 18 proteins, encoded by different genes and displaying a conserved catalytic domain in which PARP-1 (113 kDa), the founding member, and PARP-2 (62 kDa) are so far the sole enzymes whose catalytic activity has been shown to be immediately stimulated by DNA strand breaks.  A large repertoire of sequences encoding novel PARPs now extends considerably the field of poly(ADP-ribosyl)ation reactions to various aspects of the cell biol. including cell proliferation and cell death.  Some of these new members interact with each other, share common partners and common subcellular localizations suggesting possible fine tuning in the regulation of this post-translational modification of proteins.  This review summarizes the present knowledge of this emerging superfamily, which might ultimately improve pharmacol. strategies to enhance both antitumor efficacy and the treatment of a no. of inflammatory and neurodegenerative disorders.  A provisional nomenclature is proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojkP1P6SYh67Vg90H21EOLACvtfcHk0li2jO0OtuWnAg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnt1CqtLk%253D&md5=892151993f54e3c1a03019001a365fbf</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1002%2Fbies.20085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbies.20085%26sid%3Dliteratum%253Aachs%26aulast%3DAme%26aufirst%3DJ.%2BC.%26aulast%3DSpenlehauer%26aufirst%3DC.%26aulast%3Dde%2BMurcia%26aufirst%3DG.%26atitle%3DThe%2520PARP%2520superfamily%26jtitle%3DBioEssays%26date%3D2004%26volume%3D26%26issue%3D8%26spage%3D882%26epage%3D893%26doi%3D10.1002%2Fbies.20085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DâAmours, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desnoyers, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DâSilva, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poirier, G. G.</span></span> <span> </span><span class="NLM_article-title">Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>342</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">249</span>â <span class="NLM_lpage">268</span>, <span class="refDoi">Â DOI: 10.1042/bj3420249</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1042%2Fbj3420249" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10455009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADyaK1MXmtFChtLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=342&publication_year=1999&pages=249-268&issue=2&author=D.+D%E2%80%99Amoursauthor=S.+Desnoyersauthor=I.+D%E2%80%99Silvaauthor=G.+G.+Poirier&title=Poly%28ADP-ribosyl%29ation+reactions+in+the+regulation+of+nuclear+functions&doi=10.1042%2Fbj3420249"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions</span></div><div class="casAuthors">D'Amours, Damien; Desnoyers, Serge; D'Silva, Icy; Poirier, Guy G.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">342</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">249-268</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review with 351 refs.  Poly(ADP-ribosyl)ation is a post-translational modification of proteins.  During this process, mols. of ADP-ribose are added successively on to acceptor proteins to form branched polymers.  This modification is transient but very extensive in vivo, as polymer chains can reach more than 200 units on protein acceptors.  The existence of the poly(ADP-ribose) polymer was first reported nearly 40 yr ago.  Since then, the importance of poly(ADP-ribose) synthesis has been established in many cellular processes.  However, a clear and unified picture of the physiol. role of poly(ADP-ribosyl)ation still remains to be established.  The total dependence of poly(ADP-ribose) synthesis on DNA strand breaks strongly suggests that this post-translational modification is involved in the metab. of nucleic acids.  This view is also supported by the identification of direct protein-protein interactions involving poly(ADP-ribose) polymerase (113 kDa PARP), an enzyme catalyzing the formation of poly(ADP-ribose), and key effectors of DNA repair, replication and transcription reactions.  The presence of PARP in these multiprotein complexes, in addn. to the actual poly(ADP-ribosyl)ation of some components of these complexes, clearly supports an important role for poly(ADP-ribosyl)ation reactions in DNA transactions.  Accordingly, inhibition of poly(ADP-ribose) synthesis by any of several approaches and the anal. of PARP-deficient cells has revealed that the absence of poly(ADP-ribosyl)ation strongly affects DNA metab., most notably DNA repair.  The recent identification of new poly(ADP-ribosyl)ating enzymes with distinct (non-std.) structures in eukaryotes and archaea has revealed a novel level of complexity in the regulation of poly(ADP-ribose) metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh1dXVUbI2MbVg90H21EOLACvtfcHk0li2jO0OtuWnAg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmtFChtLo%253D&md5=9a9e9c4a9c492cf6841fe146a22f21c5</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1042%2Fbj3420249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj3420249%26sid%3Dliteratum%253Aachs%26aulast%3DD%25E2%2580%2599Amours%26aufirst%3DD.%26aulast%3DDesnoyers%26aufirst%3DS.%26aulast%3DD%25E2%2580%2599Silva%26aufirst%3DI.%26aulast%3DPoirier%26aufirst%3DG.%2BG.%26atitle%3DPoly%2528ADP-ribosyl%2529ation%2520reactions%2520in%2520the%2520regulation%2520of%2520nuclear%2520functions%26jtitle%3DBiochem.%2520J.%26date%3D1999%26volume%3D342%26issue%3D2%26spage%3D249%26epage%3D268%26doi%3D10.1042%2Fbj3420249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupte, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, W. L.</span></span> <span> </span><span class="NLM_article-title">PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes</span>. <i>Genes Dev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">101</span>â <span class="NLM_lpage">126</span>, <span class="refDoi">Â DOI: 10.1101/gad.291518.116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1101%2Fgad.291518.116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=28202539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpvVOitLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=101-126&issue=2&author=R.+Gupteauthor=Z.+Liuauthor=W.+L.+Kraus&title=PARPs+and+ADP-ribosylation%3A+recent+advances+linking+molecular+functions+to+biological+outcomes&doi=10.1101%2Fgad.291518.116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes</span></div><div class="casAuthors">Gupte, Rebecca; Liu, Ziying; Kraus, W. Lee</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">101-126</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">The discovery of poly(ADP-ribose) >50 years ago opened a new field, leading the way for the discovery of the poly(ADP-ribose) polymerase (PARP) family of enzymes and the ADP-ribosylation reactions that they catalyze.  Although the field was initially focused primarily on the biochem. and mol. biol. of PARP-1 in DNA damage detection and repair, the mechanistic and functional understanding of the role of PARPs in different biol. processes has grown considerably of late.  This has been accompanied by a shift of focus from enzymol. to a search for substrates as well as the first attempts to det. the functional consequences of site-specific ADP-ribosylation on those substrates.  Supporting these advances is a host of methodol. approaches from chem. biol., proteomics, genomics, cell biol., and genetics that have propelled new discoveries in the field.  New findings on the diverse roles of PARPs in chromatin regulation, transcription, RNA biol., and DNA repair have been complemented by recent advances that link ADP-ribosylation to stress responses, metab., viral infections, and cancer.  These studies have begun to reveal the promising ways in which PARPs may be targeted therapeutically for the treatment of disease.  In this review, we discuss these topics and relate them to the future directions of the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8MfoT2jFf4LVg90H21EOLACvtfcHk0lgBK1ppxpYGRA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpvVOitLY%253D&md5=d091cc26a4caf725c7619e35badc0eff</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1101%2Fgad.291518.116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.291518.116%26sid%3Dliteratum%253Aachs%26aulast%3DGupte%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DKraus%26aufirst%3DW.%2BL.%26atitle%3DPARPs%2520and%2520ADP-ribosylation%253A%2520recent%2520advances%2520linking%2520molecular%2520functions%2520to%2520biological%2520outcomes%26jtitle%3DGenes%2520Dev.%26date%3D2017%26volume%3D31%26issue%3D2%26spage%3D101%26epage%3D126%26doi%3D10.1101%2Fgad.291518.116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skidmore, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halldorsson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shall, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziaâee, A. A.</span></span> <span> </span><span class="NLM_article-title">The involvement of poly(ADP-ribose) polymerase in the degradation of NAD caused by gamma-radiation and N-methyl-N-nitrosourea</span>. <i>Eur. J. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>101</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">135</span>â <span class="NLM_lpage">142</span>, <span class="refDoi">Â DOI: 10.1111/j.1432-1033.1979.tb04225.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1111%2Fj.1432-1033.1979.tb04225.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=228934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADyaL3cXjsFClug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=1979&pages=135-142&issue=1&author=C.+J.+Skidmoreauthor=M.+I.+Daviesauthor=P.+M.+Goodwinauthor=H.+Halldorssonauthor=P.+J.+Lewisauthor=S.+Shallauthor=A.+A.+Zia%E2%80%99ee&title=The+involvement+of+poly%28ADP-ribose%29+polymerase+in+the+degradation+of+NAD+caused+by+gamma-radiation+and+N-methyl-N-nitrosourea&doi=10.1111%2Fj.1432-1033.1979.tb04225.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The involvement of poly(ADP-ribose) polymerase in the degradation of NAD caused by Î³-radiation and N-methyl-N-nitrosurea</span></div><div class="casAuthors">Skidmore, Christopher J.; Davies, Margaret I.; Goodwin, Patricia M.; Halldorsson, Haraldur; Lewis, Pamela J.; Shall, Sydney; Zia'ee, Abed-Ali</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Biochemistry</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">135-42</span>CODEN:
                <span class="NLM_cas:coden">EJBCAI</span>;
        ISSN:<span class="NLM_cas:issn">0014-2956</span>.
    </div><div class="casAbstract">Both N-methyl-N-nitrosourea  [684-93-5] and Î³-irradn. lowered cellular NAD  [53-84-9] in mouse leukemia cells (L1210) in a dose-dependent way.  The min. NAD level was reached 2 h after a brief exposure to N-methyl-N-nitrosourea, but within 15 min of Î³-irradn.  The cells remained metabolically active; they were able to recover their control NAD levels and were impermeable to trypan blue.  The following inhibitors of poly(ADP-ribose) polymerase  [58319-92-9] inhibited the drop of cellular NAD caused by these 2 agents: 2 mM 5-methylnicotinamide  [70-57-5], 1 mM theophylline  [58-55-9], or 1 mM theobromine  [83-67-0] inhibited the effect of N-methyl-N-nitrosourea on cellular NAD level; 200 Î¼M thymidine  [50-89-5], 500 Î¼M 5-methylnicotinamide, 500 Î¼M theophylline, and 500 Î¼M theobromine prevented the lowering of cellular NAD by Î³-irradn.  The extent to which the drop in cellular NAD was inhibited was dependent on both the concn. of cytotoxic agent and of polymerase inhibitor.  Caffeine  [58-08-2] inhibited the drop in NAD but only at 10 mM, whereas nicotonic acid  [59-67-6] was ineffective even at this dose.  The activity of poly(ADP-ribose) polymerase in permeabilized cells immediately after Î³-irradn. increased with dose up to 12 krads, giving a maximal 3.4-fold stimulation of the enzyme activity, whereas the degrdn. of NAD under conditions optimal for NAD glycohydrolase  [9032-65-9] did not change.  The activity of the polymerase showed a close temporal correlation with the NAD drop following both Î³-irradn. and N-methyl-N-nitrosourea.  The enzyme activity was maximal when the NAD content was decreasing at the highest rate and returned to normal levels when it ceased falling.  In permeabilized cells, poly(ADP-ribose) polymerase and NAD glycohydrolase activity can be distinguished by their differential response to inhibitors.  The polymerase was sensitive to 5-methylnicotinamide, theophylline, theobromine, and thymidine; the NAD glycohydrolase was sensitive to 5-methylnicotinamide and theophylline, but not to theobromine and thymidine.  Evidently, the decrease in cellular NAD level produced by Î³-irradn. and by N-methyl-N-nitrosourea was caused by an increased flux through poly(ADP-ribose) mediated by an increased activity of poly(ADP-ribose) polymerase.  This consequently lowers the cellular NAD level.  This hypothesis implies an involvement of (ADP-ribose)n in the cellular response to cytotoxic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxsOBZrH6V47Vg90H21EOLACvtfcHk0lgBK1ppxpYGRA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXjsFClug%253D%253D&md5=0af7b111b7eecef5152bc4ec9d7c16e4</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1111%2Fj.1432-1033.1979.tb04225.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1432-1033.1979.tb04225.x%26sid%3Dliteratum%253Aachs%26aulast%3DSkidmore%26aufirst%3DC.%2BJ.%26aulast%3DDavies%26aufirst%3DM.%2BI.%26aulast%3DGoodwin%26aufirst%3DP.%2BM.%26aulast%3DHalldorsson%26aufirst%3DH.%26aulast%3DLewis%26aufirst%3DP.%2BJ.%26aulast%3DShall%26aufirst%3DS.%26aulast%3DZia%25E2%2580%2599ee%26aufirst%3DA.%2BA.%26atitle%3DThe%2520involvement%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%2520in%2520the%2520degradation%2520of%2520NAD%2520caused%2520by%2520gamma-radiation%2520and%2520N-methyl-N-nitrosourea%26jtitle%3DEur.%2520J.%2520Biochem.%26date%3D1979%26volume%3D101%26issue%3D1%26spage%3D135%26epage%3D142%26doi%3D10.1111%2Fj.1432-1033.1979.tb04225.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caldecott, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoufouchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shall, S.</span></span> <span> </span><span class="NLM_article-title">XRCC1 polypeptide interacts with DNA polymerase beta and possibly poly (ADP-ribose) polymerase, and DNA ligase III is a novel molecular ânick-sensorâ in vitro</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">4387</span>â <span class="NLM_lpage">4394</span>, <span class="refDoi">Â DOI: 10.1093/nar/24.22.4387</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1093%2Fnar%2F24.22.4387" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=8948628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADyaK28Xnt12ktb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1996&pages=4387-4394&issue=22&author=K.+W.+Caldecottauthor=S.+Aoufouchiauthor=P.+Johnsonauthor=S.+Shall&title=XRCC1+polypeptide+interacts+with+DNA+polymerase+beta+and+possibly+poly+%28ADP-ribose%29+polymerase%2C+and+DNA+ligase+III+is+a+novel+molecular+%E2%80%98nick-sensor%E2%80%99+in+vitro&doi=10.1093%2Fnar%2F24.22.4387"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">XRCC1 polypeptide interacts with DNA polymerase Î² and possibly poly(ADP-ribose) polymerase, and DNA ligase III is a novel molecular 'nick-sensor' in vitro</span></div><div class="casAuthors">Caldecott, Keith W.; Aoufouchi, Said; Johnson, Penny; Shall, Sydney</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">4387-4394</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The DNA repair proteins XRCC1 and DNA ligase III are phys. assocd. in human cells and directly interact in vitro and in vivo.  Here, we demonstrate that XRCC1 is addnly. assocd. with DNA polymerase-Î² in human cells and that these polypeptides also directly interact.  We also present data suggesting that poly(ADP-ribose) polymerase can interact with XRCC1.  Finally, we demonstrate that DNA ligase III shares with poly(ADP-ribose) polymerase the novel function of a mol. DNA nick-sensor, and that the DNA ligase can inhibit activity of the latter polypeptide in vitro.  Taken together, these data suggest that the activity of the four polypeptides described above may be coordinated in human cells within a single multiprotein complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFpzsCdL8M2bVg90H21EOLACvtfcHk0lgBK1ppxpYGRA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xnt12ktb8%253D&md5=9d907b99ab7da9abe32bf022c49e97cd</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1093%2Fnar%2F24.22.4387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252F24.22.4387%26sid%3Dliteratum%253Aachs%26aulast%3DCaldecott%26aufirst%3DK.%2BW.%26aulast%3DAoufouchi%26aufirst%3DS.%26aulast%3DJohnson%26aufirst%3DP.%26aulast%3DShall%26aufirst%3DS.%26atitle%3DXRCC1%2520polypeptide%2520interacts%2520with%2520DNA%2520polymerase%2520beta%2520and%2520possibly%2520poly%2520%2528ADP-ribose%2529%2520polymerase%252C%2520and%2520DNA%2520ligase%2520III%2520is%2520a%2520novel%2520molecular%2520%25E2%2580%2598nick-sensor%25E2%2580%2599%2520in%2520vitro%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D1996%26volume%3D24%26issue%3D22%26spage%3D4387%26epage%3D4394%26doi%3D10.1093%2Fnar%2F24.22.4387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morales, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fattah, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bey, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boothman, D. A.</span></span> <span> </span><span class="NLM_article-title">Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases</span>. <i>Crit. Rev. Eukaryotic Gene Expression</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">15</span>â <span class="NLM_lpage">28</span>, <span class="refDoi">Â DOI: 10.1615/CritRevEukaryotGeneExpr.2013006875</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1615%2FCritRevEukaryotGeneExpr.2013006875" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=24579667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A280%3ADC%252BC2cvpsVSrsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=15-28&issue=1&author=J.+Moralesauthor=L.+Liauthor=F.+J.+Fattahauthor=Y.+Dongauthor=E.+A.+Beyauthor=M.+Patelauthor=J.+Gaoauthor=D.+A.+Boothman&title=Review+of+poly+%28ADP-ribose%29+polymerase+%28PARP%29+mechanisms+of+action+and+rationale+for+targeting+in+cancer+and+other+diseases&doi=10.1615%2FCritRevEukaryotGeneExpr.2013006875"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases</span></div><div class="casAuthors">Morales Julio; Li Longshan; Fattah Farjana J; Dong Ying; Patel Malina; Gao Jinming; Boothman David A; Bey Erik A</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in eukaryotic gene expression</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-28</span>
        ISSN:<span class="NLM_cas:issn">1045-4403</span>.
    </div><div class="casAbstract">Poly (ADP-ribose) polymerases (PARPs) are a family of related enzymes that share the ability to catalyze the transfer of ADP-ribose to target proteins.  PARPs play an important role in various cellular processes, including modulation of chromatin structure, transcription, replication, recombination, and DNA repair.  The role of PARP proteins in DNA repair is of particular interest, in view of the finding that certain tumors defective in homologous recombination mechanisms, may rely on PARP-mediated DNA repair for survival, and are sensitive to its inhibition.  PARP inhibitors may also increase tumor sensitivity to DNA-damaging agents.  Clinical trials of PARP inhibitors are investigating the utility of these approaches in cancer.  The hyperactivation of PARP has also been shown to result in a specific programmed cell death pathway involving NAD+/ATP depletion, mu-calpain activation, loss of mitochondrial membrane potential, and the release of apoptosis inducing factor.  Hyperactivation of the PARP pathway may be exploited to selectively kill cancer cells.  Other PARP forms, including tankyrase 1 (PARP 5a), which plays an important role in enhancing telomere elongation by telomerase, have been found to be potential targets in cancer therapy.  The PARP pathway and its inhibition thus offers a number of opportunities for therapeutic intervention in both cancer and other disease states.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQO6ujQ1G1GLwaK-_ZudimnfW6udTcc2eYb4JPFkf4cELntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cvpsVSrsw%253D%253D&md5=3590812f36c4075309ad19923d2e2852</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1615%2FCritRevEukaryotGeneExpr.2013006875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1615%252FCritRevEukaryotGeneExpr.2013006875%26sid%3Dliteratum%253Aachs%26aulast%3DMorales%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DFattah%26aufirst%3DF.%2BJ.%26aulast%3DDong%26aufirst%3DY.%26aulast%3DBey%26aufirst%3DE.%2BA.%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DGao%26aufirst%3DJ.%26aulast%3DBoothman%26aufirst%3DD.%2BA.%26atitle%3DReview%2520of%2520poly%2520%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520mechanisms%2520of%2520action%2520and%2520rationale%2520for%2520targeting%2520in%2520cancer%2520and%2520other%2520diseases%26jtitle%3DCrit.%2520Rev.%2520Eukaryotic%2520Gene%2520Expression%26date%3D2014%26volume%3D24%26issue%3D1%26spage%3D15%26epage%3D28%26doi%3D10.1615%2FCritRevEukaryotGeneExpr.2013006875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Satoh, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindahl, T.</span></span> <span> </span><span class="NLM_article-title">Role of poly(ADP-ribose) formation in DNA repair</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>356</i></span> (<span class="NLM_issue">6367</span>),  <span class="NLM_fpage">356</span>â <span class="NLM_lpage">358</span>, <span class="refDoi">Â DOI: 10.1038/356356a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1038%2F356356a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1549180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADyaK38XitFSjsLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=1992&pages=356-358&issue=6367&author=M.+S.+Satohauthor=T.+Lindahl&title=Role+of+poly%28ADP-ribose%29+formation+in+DNA+repair&doi=10.1038%2F356356a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Role of poly(ADP-ribose) formation in DNA repair</span></div><div class="casAuthors">Satoh, Masahiko S.; Lindahl, Tomas</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">6367</span>),
    <span class="NLM_cas:pages">356-8</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">The abundant nuclear enzyme poly(ADP-ribose) polymerase catalyzes the synthesis of poly(ADP-ribose) from NAD.  This protein has an N-terminal DNA-binding domain contg. two zinc-fingers, which is linked to the C-terminal NAD+-binding domain by a short region contg. several glutamic acid residues that are sites of auto-poly(ADP-ribosyl)ation.  The intracellular prodn. of poly(ADP-ribose) is induced by agents that generate strand interruptions in DNA.  The branched homopolymer chains may attain a size of 200-300 residues but are rapidly degraded after synthesis.  The function of poly(ADP-ribose) synthesis is not clear, although it seems to be required for DNA repair.  Here, a human cell-free system is described that enables the role of poly(ADP-ribose) synthesis in DNA repair to be characterized.  The results indicate that unmodified polymerase mols. bind tightly to DNA strand breaks; auto-poly(ADP-ribosyl)ation of the protein then effects its release and allows access to lesions for DNA repair enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrosI_oFYfc77Vg90H21EOLACvtfcHk0lhj-9UXM4ZtKw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XitFSjsLg%253D&md5=81580d1996b224b2c4a4bcdd318e72fd</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2F356356a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F356356a0%26sid%3Dliteratum%253Aachs%26aulast%3DSatoh%26aufirst%3DM.%2BS.%26aulast%3DLindahl%26aufirst%3DT.%26atitle%3DRole%2520of%2520poly%2528ADP-ribose%2529%2520formation%2520in%2520DNA%2520repair%26jtitle%3DNature%26date%3D1992%26volume%3D356%26issue%3D6367%26spage%3D356%26epage%3D358%26doi%3D10.1038%2F356356a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Langelier, M.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zandarashvili, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguiar, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascal, J. M.</span></span> <span> </span><span class="NLM_article-title">NAD+ analog reveals PARP-1 substrate-blocking mechanism and allosteric communication from catalytic center to DNA-binding domains</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">844</span>, <span class="refDoi">Â DOI: 10.1038/s41467-018-03234-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1038%2Fs41467-018-03234-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=29487285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A280%3ADC%252BC1MrlvF2gsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=844&issue=1&author=M.-F.+Langelierauthor=L.+Zandarashviliauthor=P.+M.+Aguiarauthor=B.+E.+Blackauthor=J.+M.+Pascal&title=NAD%2B+analog+reveals+PARP-1+substrate-blocking+mechanism+and+allosteric+communication+from+catalytic+center+to+DNA-binding+domains&doi=10.1038%2Fs41467-018-03234-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">NAD(+) analog reveals PARP-1 substrate-blocking mechanism and allosteric communication from catalytic center to DNA-binding domains</span></div><div class="casAuthors">Langelier Marie-France; Pascal John M; Zandarashvili Levani; Black Ben E; Aguiar Pedro M</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">844</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PARP-1 cleaves NAD(+) and transfers the resulting ADP-ribose moiety onto target proteins and onto subsequent polymers of ADP-ribose.  An allosteric network connects PARP-1 multi-domain detection of DNA damage to catalytic domain structural changes that relieve catalytic autoinhibition; however, the mechanism of autoinhibition is undefined.  Here, we show using the non-hydrolyzable NAD(+) analog benzamide adenine dinucleotide (BAD) that PARP-1 autoinhibition results from a selective block on NAD(+) binding.  Following DNA damage detection, BAD binding to the catalytic domain leads to changes in PARP-1 dynamics at distant DNA-binding surfaces, resulting in increased affinity for DNA damage, and providing direct evidence of reverse allostery.  Our findings reveal a two-step mechanism to activate and to then stabilize PARP-1 on a DNA break, indicate that PARP-1 allostery influences persistence on DNA damage, and have important implications for PARP inhibitors that engage the NAD(+) binding site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRcBrbf8zXPoPSAs_PE1QvifW6udTcc2eYb4JPFkf4cELntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrlvF2gsw%253D%253D&md5=783880900aba44e964f270a3ed5f7f01</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-03234-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-03234-8%26sid%3Dliteratum%253Aachs%26aulast%3DLangelier%26aufirst%3DM.-F.%26aulast%3DZandarashvili%26aufirst%3DL.%26aulast%3DAguiar%26aufirst%3DP.%2BM.%26aulast%3DBlack%26aufirst%3DB.%2BE.%26aulast%3DPascal%26aufirst%3DJ.%2BM.%26atitle%3DNAD%252B%2520analog%2520reveals%2520PARP-1%2520substrate-blocking%2520mechanism%2520and%2520allosteric%2520communication%2520from%2520catalytic%2520center%2520to%2520DNA-binding%2520domains%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26issue%3D1%26spage%3D844%26doi%3D10.1038%2Fs41467-018-03234-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lord, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashworth, A.</span></span> <span> </span><span class="NLM_article-title">PARP inhibitors: synthetic lethality in the clinic</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>355</i></span> (<span class="NLM_issue">6330</span>),  <span class="NLM_fpage">1152</span>â <span class="NLM_lpage">1158</span>, <span class="refDoi">Â DOI: 10.1126/science.aam7344</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1126%2Fscience.aam7344" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=28302823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktFOmtrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2017&pages=1152-1158&issue=6330&author=C.+J.+Lordauthor=A.+Ashworth&title=PARP+inhibitors%3A+synthetic+lethality+in+the+clinic&doi=10.1126%2Fscience.aam7344"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">PARP inhibitors: Synthetic lethality in the clinic</span></div><div class="casAuthors">Lord, Christopher J.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">6330</span>),
    <span class="NLM_cas:pages">1152-1158</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  PARP inhibitors (PARPi), a cancer therapy targeting poly(ADP-ribose) polymerase, are the first clin. approved drugs designed to exploit synthetic lethality, a genetic concept proposed nearly a century ago.  Tumors arising in patients who carry germline mutations in either BRCA1 or BRCA2 are sensitive to PARPi because they have a specific type of DNA repair defect.  PARPi also show promising activity in more common cancers that share this repair defect.  However, as with other targeted therapies, resistance to PARPi arises in advanced disease.  In addn., detg. the optimal use of PARPi within drug combination approaches has been challenging.  Nevertheless, the preclin. discovery of PARPi synthetic lethality and the route to clin. approval provide interesting lessons for the development of other therapies.  Here, the authors discuss current knowledge of PARP inhibitors and potential ways to maximize their clin. effectiveness.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAdgOVt6r40rVg90H21EOLACvtfcHk0lgMnldZLXzCYg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktFOmtrg%253D&md5=6f3c5c37b2d5062cb7acbf3a78727f46</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1126%2Fscience.aam7344&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aam7344%26sid%3Dliteratum%253Aachs%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DPARP%2520inhibitors%253A%2520synthetic%2520lethality%2520in%2520the%2520clinic%26jtitle%3DScience%26date%3D2017%26volume%3D355%26issue%3D6330%26spage%3D1152%26epage%3D1158%26doi%3D10.1126%2Fscience.aam7344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flower, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meuth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtin, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helleday, T.</span></span> <span> </span><span class="NLM_article-title">Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>434</i></span> (<span class="NLM_issue">7035</span>),  <span class="NLM_fpage">913</span>â <span class="NLM_lpage">917</span>, <span class="refDoi">Â DOI: 10.1038/nature03443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1038%2Fnature03443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=15829966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=434&publication_year=2005&pages=913-917&issue=7035&author=H.+E.+Bryantauthor=N.+Schultzauthor=H.+D.+Thomasauthor=K.+M.+Parkerauthor=D.+Flowerauthor=E.+Lopezauthor=S.+Kyleauthor=M.+Meuthauthor=N.+J.+Curtinauthor=T.+Helleday&title=Specific+killing+of+BRCA2-deficient+tumours+with+inhibitors+of+poly%28ADP-ribose%29+polymerase&doi=10.1038%2Fnature03443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Specific killing of BRCA2-deficient tumors with inhibitors of poly(ADP-ribose) polymerase</span></div><div class="casAuthors">Bryant, Helen E.; Schultz, Niklas; Thomas, Huw D.; Parker, Kayan M.; Flower, Dan; Lopez, Elena; Kyle, Suzanne; Meuth, Mark; Curtin, Nicola J.; Helleday, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">434</span>
        (<span class="NLM_cas:issue">7035</span>),
    <span class="NLM_cas:pages">913-917</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase (PARP1) facilitates DNA repair by binding to DNA breaks and attracting DNA repair proteins to the site of damage.  Nevertheless, PARP1-/- mice are viable, fertile and do not develop early onset tumors.  Here, the authors show that PARP inhibitors trigger Î³-H2AX and RAD51 foci formation.  The authors propose that, in the absence of PARP1, spontaneous single-strand breaks collapse replication forks and trigger homologous recombination for repair.  Furthermore, the authors show that BRCA2-deficient cells, as a result of their deficiency in homologous recombination, are acutely sensitive to PARP inhibitors, presumably because resultant collapsed replication forks are no longer repaired.  Thus, PARP1 activity is essential in homologous recombination-deficient BRCA2 mutant cells.  The authors exploit this requirement in order to kill BRCA2-deficient tumors by PARP inhibition alone.  Treatment with PARP inhibitors is likely to be highly tumor specific, because only the tumors (which are BRCA2-/-) in BRCA2+/- patients are defective in homologous recombination.  The use of an inhibitor of a DNA repair enzyme alone to selectively kill a tumor, in the absence of an exogenous DNA-damaging agent, represents a new concept in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZJ6B7d7dB77Vg90H21EOLACvtfcHk0lgMnldZLXzCYg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrY%253D&md5=44631eba667cf75ef99c31d011d6db44</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnature03443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature03443%26sid%3Dliteratum%253Aachs%26aulast%3DBryant%26aufirst%3DH.%2BE.%26aulast%3DSchultz%26aufirst%3DN.%26aulast%3DThomas%26aufirst%3DH.%2BD.%26aulast%3DParker%26aufirst%3DK.%2BM.%26aulast%3DFlower%26aufirst%3DD.%26aulast%3DLopez%26aufirst%3DE.%26aulast%3DKyle%26aufirst%3DS.%26aulast%3DMeuth%26aufirst%3DM.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DHelleday%26aufirst%3DT.%26atitle%3DSpecific%2520killing%2520of%2520BRCA2-deficient%2520tumours%2520with%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%26jtitle%3DNature%26date%3D2005%26volume%3D434%26issue%3D7035%26spage%3D913%26epage%3D917%26doi%3D10.1038%2Fnature03443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Farmer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCabe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lord, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tutt, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santarosa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knights, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashworth, A.</span></span> <span> </span><span class="NLM_article-title">Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>434</i></span> (<span class="NLM_issue">7035</span>),  <span class="NLM_fpage">917</span>â <span class="NLM_lpage">921</span>, <span class="refDoi">Â DOI: 10.1038/nature03445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1038%2Fnature03445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=15829967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=434&publication_year=2005&pages=917-921&issue=7035&author=H.+Farmerauthor=N.+McCabeauthor=C.+J.+Lordauthor=A.+N.+Tuttauthor=D.+A.+Johnsonauthor=T.+B.+Richardsonauthor=M.+Santarosaauthor=K.+J.+Dillonauthor=I.+Hicksonauthor=C.+Knightsauthor=N.+M.+Martinauthor=S.+P.+Jacksonauthor=G.+C.+Smithauthor=A.+Ashworth&title=Targeting+the+DNA+repair+defect+in+BRCA+mutant+cells+as+a+therapeutic+strategy&doi=10.1038%2Fnature03445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy</span></div><div class="casAuthors">Farmer, Hannah; McCabe, Nuala; Lord, Christopher J.; Tutt, Andrew N. J.; Johnson, Damian A.; Richardson, Tobias B.; Santarosa, Manuela; Dillon, Krystyna J.; Hickson, Ian; Knights, Charlotte; Martin, Niall M. B.; Jackson, Stephen P.; Smith, Graeme C. M.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">434</span>
        (<span class="NLM_cas:issue">7035</span>),
    <span class="NLM_cas:pages">917-921</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">BRCA1 and BRCA2 are important for DNA double-strand break repair by homologous recombination, and mutations in these genes predispose to breast and other cancers.  Poly(ADP-ribose) polymerase (PARP) is an enzyme involved in base excision repair, a key pathway in the repair of DNA single-strand breaks.  The authors show here that BRCA1 or BRCA2 dysfunction unexpectedly and profoundly sensitizes cells to the inhibition of PARP enzymic activity, resulting in chromosomal instability, cell cycle arrest and subsequent apoptosis.  This seems to be because the inhibition of PARP leads to the persistence of DNA lesions normally repaired by homologous recombination.  These results illustrate how different pathways cooperate to repair damage, and suggest that the targeted inhibition of particular DNA repair pathways may allow the design of specific and less toxic therapies for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomVTKE4mFwfrVg90H21EOLACvtfcHk0lgMnldZLXzCYg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrc%253D&md5=03b5ba0adc21a5627fe17ae535f45078</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnature03445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature03445%26sid%3Dliteratum%253Aachs%26aulast%3DFarmer%26aufirst%3DH.%26aulast%3DMcCabe%26aufirst%3DN.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DTutt%26aufirst%3DA.%2BN.%26aulast%3DJohnson%26aufirst%3DD.%2BA.%26aulast%3DRichardson%26aufirst%3DT.%2BB.%26aulast%3DSantarosa%26aufirst%3DM.%26aulast%3DDillon%26aufirst%3DK.%2BJ.%26aulast%3DHickson%26aufirst%3DI.%26aulast%3DKnights%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DN.%2BM.%26aulast%3DJackson%26aufirst%3DS.%2BP.%26aulast%3DSmith%26aufirst%3DG.%2BC.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DTargeting%2520the%2520DNA%2520repair%2520defect%2520in%2520BRCA%2520mutant%2520cells%2520as%2520a%2520therapeutic%2520strategy%26jtitle%3DNature%26date%3D2005%26volume%3D434%26issue%3D7035%26spage%3D917%26epage%3D921%26doi%3D10.1038%2Fnature03445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Helleday, T.</span></span> <span> </span><span class="NLM_article-title">The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">387</span>â <span class="NLM_lpage">393</span>, <span class="refDoi">Â DOI: 10.1016/j.molonc.2011.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.molonc.2011.07.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=21821475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVyqtL%252FO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2011&pages=387-393&issue=4&author=T.+Helleday&title=The+underlying+mechanism+for+the+PARP+and+BRCA+synthetic+lethality%3A+clearing+up+the+misunderstandings&doi=10.1016%2Fj.molonc.2011.07.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings</span></div><div class="casAuthors">Helleday, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">387-393</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Poly (ADP-ribose) polymerase (PARP) inhibitors effectively kill tumors defective in the BRCA1 or BRCA2 genes through the concept of synthetic lethality.  It is suggested that PARP inhibitors cause an increase in DNA single-strand breaks (SSBs), which are converted during replication to irreparable toxic DNA double-strand breaks (DSBs) in BRCA1/2 defective cells.  There are a no. of recent reports challenging this model.  Here, alternative models that are not mutually exclusive are presented to explain the synthetic lethality between BRCA1/2 and PARP inhibitors.  One such model proposes that PARP inhibition causes PARP-1 to be trapped onto DNA repair intermediates, esp. during base excision repair.  This may in turn cause obstruction to replication forks, which require BRCA-dependent homologous recombination to be resolved.  In another model, PARP is directly involved in catalyzing replication repair in a distinct pathway from homologous recombination.  Exptl. evidence supporting these novel models to explain the PARP-BRCA synthetic lethality are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPUCIzO2NudrVg90H21EOLACvtfcHk0ljztu0Tb7mssQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVyqtL%252FO&md5=1b64dde39e08d863e774de91a0fbe1e9</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2011.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2011.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DHelleday%26aufirst%3DT.%26atitle%3DThe%2520underlying%2520mechanism%2520for%2520the%2520PARP%2520and%2520BRCA%2520synthetic%2520lethality%253A%2520clearing%2520up%2520the%2520misunderstandings%26jtitle%3DMol.%2520Oncol.%26date%3D2011%26volume%3D5%26issue%3D4%26spage%3D387%26epage%3D393%26doi%3D10.1016%2Fj.molonc.2011.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noordermeer, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Attikum, H.</span></span> <span> </span><span class="NLM_article-title">PARP inhibitor resistance: a tug-of-war in BRCA-mutated cells</span>. <i>Trends Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">820</span>â <span class="NLM_lpage">834</span>, <span class="refDoi">Â DOI: 10.1016/j.tcb.2019.07.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.tcb.2019.07.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=31421928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFCmsL3L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=820-834&issue=10&author=S.+M.+Noordermeerauthor=H.+van+Attikum&title=PARP+inhibitor+resistance%3A+a+tug-of-war+in+BRCA-mutated+cells&doi=10.1016%2Fj.tcb.2019.07.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells</span></div><div class="casAuthors">Noordermeer, Sylvie M.; van Attikum, Haico</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cell Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">820-834</span>CODEN:
                <span class="NLM_cas:coden">TCBIEK</span>;
        ISSN:<span class="NLM_cas:issn">0962-8924</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Poly-(ADP)-ribose polymerase (PARP) inhibition is synthetic lethal with deficiency for homologous recombination (HR), a pathway essential for DNA double-strand break repair.  PARP inhibitors (PARPi) therefore hold great promise for the treatment of tumors with disruptive mutations in BRCA1/2 or other HR factors.  Unfortunately, PARPi resistance has proved to be a major problem in the clinic.  Knowledge about PARPi resistance is expanding quickly, revealing four main mechanisms that alter drug availability, affect (de)PARylation enzymes, restore HR, or restore replication fork stability.  We discuss how studies on resistance mechanisms have yielded important insights into the regulation of DNA double-strand break (DSB) repair and replication fork protection, and how these studies could pave the way for novel treatment options to target resistance mechanisms or acquired vulnerabilities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoH34s2W9BmerVg90H21EOLACvtfcHk0ljztu0Tb7mssQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFCmsL3L&md5=921c379ab68a0eeba7a5a2799f9abf1e</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.tcb.2019.07.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tcb.2019.07.008%26sid%3Dliteratum%253Aachs%26aulast%3DNoordermeer%26aufirst%3DS.%2BM.%26aulast%3Dvan%2BAttikum%26aufirst%3DH.%26atitle%3DPARP%2520inhibitor%2520resistance%253A%2520a%2520tug-of-war%2520in%2520BRCA-mutated%2520cells%26jtitle%3DTrends%2520Cell%2520Biol.%26date%3D2019%26volume%3D29%26issue%3D10%26spage%3D820%26epage%3D834%26doi%3D10.1016%2Fj.tcb.2019.07.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giovannini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weller, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Repmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moch, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiricny, J.</span></span> <span> </span><span class="NLM_article-title">Synthetic lethality between BRCA1 deficiency and poly(ADP-ribose) polymerase inhibition is modulated by processing of endogenous oxidative DNA damage</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>47</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">9132</span>â <span class="NLM_lpage">9143</span>, <span class="refDoi">Â DOI: 10.1093/nar/gkz624</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1093%2Fnar%2Fgkz624" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=31329989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVWksrrN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2019&pages=9132-9143&issue=17&author=S.+Giovanniniauthor=M.+C.+Wellerauthor=S.+Repmannauthor=H.+Mochauthor=J.+Jiricny&title=Synthetic+lethality+between+BRCA1+deficiency+and+poly%28ADP-ribose%29+polymerase+inhibition+is+modulated+by+processing+of+endogenous+oxidative+DNA+damage&doi=10.1093%2Fnar%2Fgkz624"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic lethality between BRCA1 deficiency and poly(ADP-ribose) polymerase inhibition is modulated by processing of endogenous oxidative DNA damage</span></div><div class="casAuthors">Giovannini, Sara; Weller, Marie-Christine; Repmann, Simone; Moch, Holger; Jiricny, Josef</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">9132-9143</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">1362-4962</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerases (PARPs) facilitate the repair of DNA single-strand breaks (SSBs).  When PARPs are inhibited, unrepaired SSBs colliding with replication forks give rise to cytotoxic double-strand breaks.  These are normally rescued by homologous recombination (HR), but, in cells with suboptimal HR, PARP inhibition leads to genomic instability and cell death, a phenomenon currently exploited in the therapy of ovarian cancers in BRCA1/2 mutation carriers.  In spite of their promise, resistance to PARP inhibitors (PARPis) has already emerged.  In order to identify the possible underlying causes of the resistance, we set out to identify the endogenous source of DNA damage that activates PARPs.We argued that if the toxicity of PARPis is indeed caused by unrepaired SSBs, these breaks must arise spontaneously, because PARPis are used as single agents.  We now show that a significant contributor to PARPi toxicity is oxygen metab.  While BRCA1-depleted or -mutated cells were hypersensitive to the clin. approved PARPi olaparib, its toxicity was significantly attenuated by depletion of OGG1 or MYH DNA glycosylases, as well as by treatment with reactive oxygen species scavengers, growth under hypoxic conditions or chem. OGG1 inhibition.  Thus, clin. resistance to PARPi therapy may emerge simply through reduced efficiency of oxidative damage repair.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqninqP7DYmTbVg90H21EOLACvtfcHk0ljztu0Tb7mssQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVWksrrN&md5=9c80ddac80505b8b283ff6f87b75ef9d</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkz624&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkz624%26sid%3Dliteratum%253Aachs%26aulast%3DGiovannini%26aufirst%3DS.%26aulast%3DWeller%26aufirst%3DM.%2BC.%26aulast%3DRepmann%26aufirst%3DS.%26aulast%3DMoch%26aufirst%3DH.%26aulast%3DJiricny%26aufirst%3DJ.%26atitle%3DSynthetic%2520lethality%2520between%2520BRCA1%2520deficiency%2520and%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibition%2520is%2520modulated%2520by%2520processing%2520of%2520endogenous%2520oxidative%2520DNA%2520damage%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2019%26volume%3D47%26issue%3D17%26spage%3D9132%26epage%3D9143%26doi%3D10.1093%2Fnar%2Fgkz624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Redon, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonner, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinders, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parchment, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doroshow, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span> <span> </span><span class="NLM_article-title">Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">4532</span>â <span class="NLM_lpage">4542</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-10-0523</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F1078-0432.CCR-10-0523" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=20823146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFGqs7bI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=4532-4542&issue=18&author=C.+E.+Redonauthor=A.+J.+Nakamuraauthor=Y.+W.+Zhangauthor=J.+J.+Jiauthor=W.+M.+Bonnerauthor=R.+J.+Kindersauthor=R.+E.+Parchmentauthor=J.+H.+Doroshowauthor=Y.+Pommier&title=Histone+gammaH2AX+and+poly%28ADP-ribose%29+as+clinical+pharmacodynamic+biomarkers&doi=10.1158%2F1078-0432.CCR-10-0523"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Î³H2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers</span></div><div class="casAuthors">Redon, Christophe E.; Nakamura, Asako J.; Zhang, Yong-Wei; Ji, Jiuping; Bonner, William M.; Kinders, Robert J.; Parchment, Ralph E.; Doroshow, James H.; Pommier, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4532-4542</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Tumor cells are often deficient in DNA damage response (DDR) pathways, and anticancer therapies are commonly based on genotoxic treatments using radiation and/or drugs that damage DNA directly or interfere with DNA metab., leading to the formation of DNA double-strand breaks (DSB), and ultimately to cell death.  Because DSBs induce the phosphorylation of histone H2AX (Î³H2AX) in the chromatin flanking the break site, an antibody directed against Î³H2AX can be employed to measure DNA damage levels before and after patient treatment.  Poly(ADP-ribose) polymerases (PARP1 and PARP2) are also activated by DNA damage, and PARP inhibitors show promising activity in cancers with defective homologous recombination (HR) pathways for DSB repair.  Ongoing clin. trials are testing combinations of PARP inhibitors with DNA damaging agents.  Poly(ADP-ribosylation), abbreviated as PAR, can be measured in clin. samples and used to det. the efficiency of PARP inhibitors.  This review summarizes the roles of Î³H2AX and PAR in the DDR, and their use as biomarkers to monitor drug response and guide clin. trials, esp. phase 0 clin. trials.  We also discuss the choices of relevant samples for Î³H2AX and PAR analyses.  Clin Cancer Res; 16(18); 4532-42.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocLdGwTAJVALVg90H21EOLACvtfcHk0licMplKD0TfxQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFGqs7bI&md5=4a2bc5d90d93f3de000ccb3f8ffd9c74</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-0523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-0523%26sid%3Dliteratum%253Aachs%26aulast%3DRedon%26aufirst%3DC.%2BE.%26aulast%3DNakamura%26aufirst%3DA.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%2BW.%26aulast%3DJi%26aufirst%3DJ.%2BJ.%26aulast%3DBonner%26aufirst%3DW.%2BM.%26aulast%3DKinders%26aufirst%3DR.%2BJ.%26aulast%3DParchment%26aufirst%3DR.%2BE.%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26aulast%3DPommier%26aufirst%3DY.%26atitle%3DHistone%2520gammaH2AX%2520and%2520poly%2528ADP-ribose%2529%2520as%2520clinical%2520pharmacodynamic%2520biomarkers%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26issue%3D18%26spage%3D4532%26epage%3D4542%26doi%3D10.1158%2F1078-0432.CCR-10-0523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DâAndrea, A. D.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of PARP inhibitor sensitivity and resistance</span>. <i>DNA Repair</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">172</span>â <span class="NLM_lpage">176</span>, <span class="refDoi">Â DOI: 10.1016/j.dnarep.2018.08.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.dnarep.2018.08.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=30177437" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Cgs7jI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2018&pages=172-176&author=A.+D.+D%E2%80%99Andrea&title=Mechanisms+of+PARP+inhibitor+sensitivity+and+resistance&doi=10.1016%2Fj.dnarep.2018.08.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of PARP inhibitor sensitivity and resistance</span></div><div class="casAuthors">D'Andrea, Alan D.</div><div class="citationInfo"><span class="NLM_cas:title">DNA Repair</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">172-176</span>CODEN:
                <span class="NLM_cas:coden">DRNEAR</span>;
        ISSN:<span class="NLM_cas:issn">1568-7864</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">BRCA1 and BRCA2 deficient tumor cells are sensitive to inhibitors of Poly ADP Ribose Polymerase (PARP1) through the mechanism of synthetic lethality.  Several PARP inhibitors, which are oral drugs and generally well tolerated, have now received FDA approval for various ovarian cancer and breast cancer indications.  Despite their use in the clinic, PARP inhibitor resistance is common and develops through multiple mechanisms.  Broadly speaking, BRCA1/2-deficient tumor cells can become resistant to PARP inhibitors by restoring homologous recombination (HR) repair and/or by stabilizing their replication forks.  Here, we review the mechanism of PARP inhibitor resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvIBaDAbajp7Vg90H21EOLACvtfcHk0licMplKD0TfxQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Cgs7jI&md5=892ee46fb9b85c7eb00193584b5557b9</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.dnarep.2018.08.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.dnarep.2018.08.021%26sid%3Dliteratum%253Aachs%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DA.%2BD.%26atitle%3DMechanisms%2520of%2520PARP%2520inhibitor%2520sensitivity%2520and%2520resistance%26jtitle%3DDNA%2520Repair%26date%3D2018%26volume%3D71%26spage%3D172%26epage%3D176%26doi%3D10.1016%2Fj.dnarep.2018.08.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cannan, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pederson, D. S.</span></span> <span> </span><span class="NLM_article-title">Mechanisms and consequences of double-strand DNA break formation in Chromatin</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>231</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">3</span>â <span class="NLM_lpage">14</span>, <span class="refDoi">Â DOI: 10.1002/jcp.25048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1002%2Fjcp.25048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=26040249" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFKntbfN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=231&publication_year=2016&pages=3-14&issue=1&author=W.+J.+Cannanauthor=D.+S.+Pederson&title=Mechanisms+and+consequences+of+double-strand+DNA+break+formation+in+Chromatin&doi=10.1002%2Fjcp.25048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms and Consequences of Double-Strand DNA Break Formation in Chromatin</span></div><div class="casAuthors">Cannan, Wendy J.; Pederson, David S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">231</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-14</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  All organisms suffer double-strand breaks (DSBs) in their DNA as a result of exposure to ionizing radiation.  DSBs can also form when replication forks encounter DNA lesions or repair intermediates.  The processing and repair of DSBs can lead to mutations, loss of heterozygosity, and chromosome rearrangements that result in cell death or cancer.  The most common pathway used to repair DSBs in metazoans (non-homologous DNA end joining) is more commonly mutagenic than the alternative pathway (homologous recombination mediated repair).  Thus, factors that influence the choice of pathways used DSB repair can affect an individual's mutation burden and risk of cancer.  This review describes radiol., chem., and biol. mechanisms that generate DSBs, and discusses the impact of such variables as DSB etiol., cell type, cell cycle, and chromatin structure on the yield, distribution, and processing of DSBs.  The final section focuses on nucleosome-specific mechanisms that influence DSB prodn., and the possible relationship between higher order chromosome coiling and chromosome shattering (chromothripsis).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq815Y9VsnxHbVg90H21EOLACvtfcHk0licMplKD0TfxQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFKntbfN&md5=7e6b1765f7b5ae77d0c969f59c806f1d</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1002%2Fjcp.25048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.25048%26sid%3Dliteratum%253Aachs%26aulast%3DCannan%26aufirst%3DW.%2BJ.%26aulast%3DPederson%26aufirst%3DD.%2BS.%26atitle%3DMechanisms%2520and%2520consequences%2520of%2520double-strand%2520DNA%2520break%2520formation%2520in%2520Chromatin%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2016%26volume%3D231%26issue%3D1%26spage%3D3%26epage%3D14%26doi%3D10.1002%2Fjcp.25048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ceccaldi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amunugama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hajdu, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Primack, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petalcorin, M. I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâConnor, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konstantinopoulos, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elledge, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulton, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yusufzai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DâAndrea, A. D.</span></span> <span> </span><span class="NLM_article-title">Homologous-recombination-deficient tumours are dependent on Pol theta-mediated repair</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>518</i></span> (<span class="NLM_issue">7538</span>),  <span class="NLM_fpage">258</span>â <span class="NLM_lpage">U306</span>, <span class="refDoi">Â DOI: 10.1038/nature14184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1038%2Fnature14184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=25642963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGisb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=518&publication_year=2015&pages=258-U306&issue=7538&author=R.+Ceccaldiauthor=J.+C.+Liuauthor=R.+Amunugamaauthor=I.+Hajduauthor=B.+Primackauthor=M.+I.+R.+Petalcorinauthor=K.+W.+O%E2%80%99Connorauthor=P.+A.+Konstantinopoulosauthor=S.+J.+Elledgeauthor=S.+J.+Boultonauthor=T.+Yusufzaiauthor=A.+D.+D%E2%80%99Andrea&title=Homologous-recombination-deficient+tumours+are+dependent+on+Pol+theta-mediated+repair&doi=10.1038%2Fnature14184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Homologous-recombination-deficient tumours are dependent on PolÎ¸-mediated repair</span></div><div class="casAuthors">Ceccaldi, Raphael; Liu, Jessica C.; Amunugama, Ravindra; Hajdu, Ildiko; Primack, Benjamin; Petalcorin, Mark I. R.; O'Connor, Kevin W.; Konstantinopoulos, Panagiotis A.; Elledge, Stephen J.; Boulton, Simon J.; Yusufzai, Timur; D'Andrea, Alan D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">518</span>
        (<span class="NLM_cas:issue">7538</span>),
    <span class="NLM_cas:pages">258-262</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Large-scale genomic studies have shown that half of epithelial ovarian cancers (EOCs) have alterations in genes regulating homologous recombination (HR) repair.  Loss of HR accounts for the genomic instability of EOCs and for their cellular hyper-dependence on alternative poly-ADP ribose polymerase (PARP)-mediated DNA repair mechanisms.  Previous studies have implicated the DNA polymerase Î¸ (PolÎ¸ also known as POLQ, encoded by POLQ) in a pathway required for the repair of DNA double-strand breaks, referred to as the error-prone microhomol.-mediated end-joining (MMEJ) pathway.  Whether PolÎ¸ interacts with canonical DNA repair pathways to prevent genomic instability remains unknown.  Here we report an inverse correlation between HR activity and PolÎ¸ expression in EOCs.  Knockdown of PolÎ¸ in HR-proficient cells upregulates HR activity and RAD51 nucleofilament assembly, while knockdown of PolÎ¸ in HR-deficient EOCs enhances cell death.  Consistent with these results, genetic inactivation of an HR gene (Fancd2) and Polq in mice results in embryonic lethality.  Moreover, PolÎ¸ contains RAD51 binding motifs and it blocks RAD51-mediated recombination.  Our results reveal a synthetic lethal relationship between the HR pathway and PolÎ¸-mediated repair in EOCs, and identify PolÎ¸ as a novel druggable target for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHib0g8CkoT7Vg90H21EOLACvtfcHk0licMplKD0TfxQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGisb4%253D&md5=a0ef28954964cf770115f261c8c14c31</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnature14184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature14184%26sid%3Dliteratum%253Aachs%26aulast%3DCeccaldi%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DJ.%2BC.%26aulast%3DAmunugama%26aufirst%3DR.%26aulast%3DHajdu%26aufirst%3DI.%26aulast%3DPrimack%26aufirst%3DB.%26aulast%3DPetalcorin%26aufirst%3DM.%2BI.%2BR.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DK.%2BW.%26aulast%3DKonstantinopoulos%26aufirst%3DP.%2BA.%26aulast%3DElledge%26aufirst%3DS.%2BJ.%26aulast%3DBoulton%26aufirst%3DS.%2BJ.%26aulast%3DYusufzai%26aufirst%3DT.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DA.%2BD.%26atitle%3DHomologous-recombination-deficient%2520tumours%2520are%2520dependent%2520on%2520Pol%2520theta-mediated%2520repair%26jtitle%3DNature%26date%3D2015%26volume%3D518%26issue%3D7538%26spage%3D258%26epage%3DU306%26doi%3D10.1038%2Fnature14184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiba, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span> <span> </span><span class="NLM_article-title">DNA polymerase theta (POLQ) is important for repair of DNA double-strand breaks caused by fork collapse</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>294</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">3909</span>â <span class="NLM_lpage">3919</span>, <span class="refDoi">Â DOI: 10.1074/jbc.RA118.005188</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1074%2Fjbc.RA118.005188" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=30655289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpvFSmtr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=294&publication_year=2019&pages=3909-3919&issue=11&author=Z.+Wangauthor=Y.+Songauthor=S.+Liauthor=S.+Kurianauthor=R.+Xiangauthor=T.+Chibaauthor=X.+Wu&title=DNA+polymerase+theta+%28POLQ%29+is+important+for+repair+of+DNA+double-strand+breaks+caused+by+fork+collapse&doi=10.1074%2Fjbc.RA118.005188"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">DNA polymerase Î¸ (POLQ) is important for repair of DNA double-strand breaks caused by fork collapse</span></div><div class="casAuthors">Wang, Zi; Song, Yadong; Li, Shibo; Kurian, Sunil; iang, Rong; Chiba, Takuya; Wu, Xiaohua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">294</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3909-3919</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">DNA polymerase Î¸ (POLQ) plays an important role in alternative nonhomologous end joining or micro-homol.-mediated end joining (alt-NHEJ/MMEJ).  Here, we show that POLQ is not only required for MMEJ to repair DNA double strand breaks (DSBs) generated by endonucleases such as I-SceI or Cas9, but is also needed for repair of DSBs derived fromDNA nicks generated by Cas9 nickase.  Consistently, we found that POLQ deficiency leads to sensitivity to topoisomerase inhibitors that cause DNA single-strand break (SSB) accumulation at replication forks and to ATR inhibitors that induce replication fork collapse.  These studies support the function of POLQ in coping with replication stress and repairing DSBs upon fork collapse.  POLQ overexpression is present in many cancer types and is assocd. with poor prognosis, including breast cancer regardless of BRCA1 status.  We provide proof-of-concept evidence to support a novel cancer treatment strategy that combines POLQ inhibition with administration of topoisomerase or ATR inhibitors, which induces replication stress and fork collapse.  Given the prevalence of POLQ overexpression in tumors, such strategy may have a significant impact on developing targeted cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXGrxdkUQBnrVg90H21EOLACvtfcHk0ljg0YYmJF6Eew"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpvFSmtr0%253D&md5=39b8fa600ebd9c95201b0fd3e4c9b99e</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1074%2Fjbc.RA118.005188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.RA118.005188%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DKurian%26aufirst%3DS.%26aulast%3DXiang%26aufirst%3DR.%26aulast%3DChiba%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DX.%26atitle%3DDNA%2520polymerase%2520theta%2520%2528POLQ%2529%2520is%2520important%2520for%2520repair%2520of%2520DNA%2520double-strand%2520breaks%2520caused%2520by%2520fork%2520collapse%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2019%26volume%3D294%26issue%3D11%26spage%3D3909%26epage%3D3919%26doi%3D10.1074%2Fjbc.RA118.005188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Domchek, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aghajanian, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapira-Frommer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmutzler, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audeh, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedlander, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balmana, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fried, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stemmer, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosengarten, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, B.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy</span>. <i>Gynecol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>140</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">199</span>â <span class="NLM_lpage">203</span>, <span class="refDoi">Â DOI: 10.1016/j.ygyno.2015.12.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.ygyno.2015.12.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=26723501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitV2rs7zP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2016&pages=199-203&issue=2&author=S.+M.+Domchekauthor=C.+Aghajanianauthor=R.+Shapira-Frommerauthor=R.+K.+Schmutzlerauthor=M.+W.+Audehauthor=M.+Friedlanderauthor=J.+Balmanaauthor=G.+Mitchellauthor=G.+Friedauthor=S.+M.+Stemmerauthor=A.+Hubertauthor=O.+Rosengartenauthor=N.+Lomanauthor=J.+D.+Robertsonauthor=H.+Mannauthor=B.+Kaufman&title=Efficacy+and+safety+of+olaparib+monotherapy+in+germline+BRCA1%2F2+mutation+carriers+with+advanced+ovarian+cancer+and+three+or+more+lines+of+prior+therapy&doi=10.1016%2Fj.ygyno.2015.12.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy</span></div><div class="casAuthors">Domchek, Susan M.; Aghajanian, Carol; Shapira-Frommer, Ronnie; Schmutzler, Rita K.; Audeh, M. William; Friedlander, Michael; Balmana, Judith; Mitchell, Gillian; Fried, Georgeta; Stemmer, Salomon M.; Hubert, Ayala; Rosengarten, Ora; Loman, Niklas; Robertson, Jane D.; Mann, Helen; Kaufman, Bella</div><div class="citationInfo"><span class="NLM_cas:title">Gynecologic Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">199-203</span>CODEN:
                <span class="NLM_cas:coden">GYNOA3</span>;
        ISSN:<span class="NLM_cas:issn">0090-8258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Objective: The efficacy and safety of olaparib, an oral poly(ADP-ribose) polymerase (PARP) inhibitor, was investigated in a subgroup of patients with germline BRCA1/2 mutated (gBRCA1/2m) advanced ovarian cancer who had received â¥ 3 prior lines of chemotherapy.  Primary data from this Phase II study (Study 42, ClinicalTrials.govNCT01078662) have been reported previously.  Methods: Eligible patients were treated with oral olaparib 400 mg bid capsule monotherapy until disease progression according to RECIST v1.1.  Objective response rate (ORR) and duration of response (DoR) were assessed for patients with measurable disease at baseline.  Safety and tolerability were assessed for all patients by adverse event (AE) incidence and changes in lab. parameters.  Platinum resistance status was obtained retrospectively, and responses to olaparib evaluated.  Results: In patients with gBRCA1/2m ovarian cancer, 154/193 (80%) had received â¥ 3 prior lines of chemotherapy, of whom 137/154 (89%) had measurable disease at baseline.  ORR was 34% (46/137; 95% confidence interval [CI] 26-42) and median DoR was 7.9 (95% CI 5.6-9.6) months.  ORR in platinum-resistant tumors was 30%.  Median DoR for platinum-sensitive and platinum-resistant disease was similar: 8.2 mo (95% CI 5.6-13.5) compared with 8.0 mo (4.8-14.8), resp.  Six of the 193 (3%) patients had an AE with an outcome of death.  None of these AEs at time of occurrence was considered causally related to olaparib.  Conclusion: Following â¥ 3 prior lines of chemotherapy, olaparib 400 mg bid (capsule form) monotherapy demonstrated notable antitumor activity in patients with gBRCA1/2m advanced ovarian cancer.  No new safety signals were identified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNM1gZB7nEubVg90H21EOLACvtfcHk0ljg0YYmJF6Eew"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitV2rs7zP&md5=7cfc0053a94e4951eacc330b8f969e7c</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.ygyno.2015.12.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ygyno.2015.12.020%26sid%3Dliteratum%253Aachs%26aulast%3DDomchek%26aufirst%3DS.%2BM.%26aulast%3DAghajanian%26aufirst%3DC.%26aulast%3DShapira-Frommer%26aufirst%3DR.%26aulast%3DSchmutzler%26aufirst%3DR.%2BK.%26aulast%3DAudeh%26aufirst%3DM.%2BW.%26aulast%3DFriedlander%26aufirst%3DM.%26aulast%3DBalmana%26aufirst%3DJ.%26aulast%3DMitchell%26aufirst%3DG.%26aulast%3DFried%26aufirst%3DG.%26aulast%3DStemmer%26aufirst%3DS.%2BM.%26aulast%3DHubert%26aufirst%3DA.%26aulast%3DRosengarten%26aufirst%3DO.%26aulast%3DLoman%26aufirst%3DN.%26aulast%3DRobertson%26aufirst%3DJ.%2BD.%26aulast%3DMann%26aufirst%3DH.%26aulast%3DKaufman%26aufirst%3DB.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520olaparib%2520monotherapy%2520in%2520germline%2520BRCA1%252F2%2520mutation%2520carriers%2520with%2520advanced%2520ovarian%2520cancer%2520and%2520three%2520or%2520more%2520lines%2520of%2520prior%2520therapy%26jtitle%3DGynecol.%2520Oncol.%26date%3D2016%26volume%3D140%26issue%3D2%26spage%3D199%26epage%3D203%26doi%3D10.1016%2Fj.ygyno.2015.12.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fong, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boss, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carden, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mergui-Roelvink, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gourley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Greve, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubinski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shanley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messiou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">AâHern, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tutt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashworth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmichael, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellens, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bono, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaye, S. B.</span></span> <span> </span><span class="NLM_article-title">Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">2512</span>â <span class="NLM_lpage">2519</span>, <span class="refDoi">Â DOI: 10.1200/JCO.2009.26.9589</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1200%2FJCO.2009.26.9589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=20406929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3cXotVyjtr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=2512-2519&issue=15&author=P.+C.+Fongauthor=T.+A.+Yapauthor=D.+S.+Bossauthor=C.+P.+Cardenauthor=M.+Mergui-Roelvinkauthor=C.+Gourleyauthor=J.+De+Greveauthor=J.+Lubinskiauthor=S.+Shanleyauthor=C.+Messiouauthor=R.+A%E2%80%99Hernauthor=A.+Tuttauthor=A.+Ashworthauthor=J.+Stoneauthor=J.+Carmichaelauthor=J.+H.+Schellensauthor=J.+S.+de+Bonoauthor=S.+B.+Kaye&title=Poly%28ADP%29-ribose+polymerase+inhibition%3A+frequent+durable+responses+in+BRCA+carrier+ovarian+cancer+correlating+with+platinum-free+interval&doi=10.1200%2FJCO.2009.26.9589"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval</span></div><div class="casAuthors">Fong, Peter C.; Yap, Timothy A.; Boss, David S.; Carden, Craig P.; Mergui-Roelvink, Maria; Gourley, Charlie; De Greve, Jacques; Lubinski, Jan; Shanley, Susan; Messiou, Christina; A'Hern, Roger; Tutt, Andrew; Ashworth, Alan; Stone, John; Carmichael, James; Schellens, Jan H. M.; de Bono, Johann S.; Kaye, Stan B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2512-2519</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Selective tumor cell cytotoxicity can be achieved through a synthetic lethal strategy using poly(ADP)-ribose polymerase (PARP) inhibitor therapy in BRCA1/2 mutation carriers in whom tumor cells have defective homologous recombination (HR) DNA repair.  Platinum-based chemotherapy responses correlate with HR DNA repair capacity.  Olaparib is a potent, oral PARP inhibitor that is well tolerated, with antitumor activity in BRCA1/2 mutation carriers.  Patients and Methods: Patients with BRCA1/2-mutated ovarian cancer were treated with olaparib within a dose-escalation and single-stage expansion of a phase I trial.  Antitumor activity was subsequently correlated with platinum sensitivity.  Results: Fifty patients were treated: 48 had germline BRCA1/2 mutations; one had a BRCA2 germline sequence change of unknown significance, and another had a strong family history of BRCA1/2-assocd. cancers who declined mutation testing.  Of the 50 patients, 13 had platinum-sensitive disease, 24 had platinum-resistant disease, and 13 had platinum-refractory disease (according to platinum-free interval).  Twenty (40%; 95% CI, 26% to 55%) achieved Response Evaluation Criteria in Solid Tumors (RECIST) complete or partial responses and/or tumor marker (CA125) responses, and three (6.0%) maintained RECIST disease stabilization for more than 4 mo, giving an overall clin. benefit rate of 46% (95% CI, 32% to 61 %).  Median response duration was 28 wk.  There was a significant assocn. between the clin. benefit rate and platinum-free interval across the platinum-sensitive, resistant, and refractory subgroups (69%, 45%, and 23%, resp.).  Post hoc analyses indicated assocns. between platinum sensitivity and extent of olaparib response (radiol. change, P = .001; CA125 change, P = .002).  Conclusion: Olaparib has antitumor activity in BRCA1/2 mutation ovarian cancer, which is assocd. with platinum sensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyvj9Ym5yY27Vg90H21EOLACvtfcHk0lhsAJuWgan2sg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXotVyjtr4%253D&md5=4198806c2b9d41e7068d26049fd0cd3f</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.26.9589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.26.9589%26sid%3Dliteratum%253Aachs%26aulast%3DFong%26aufirst%3DP.%2BC.%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3DBoss%26aufirst%3DD.%2BS.%26aulast%3DCarden%26aufirst%3DC.%2BP.%26aulast%3DMergui-Roelvink%26aufirst%3DM.%26aulast%3DGourley%26aufirst%3DC.%26aulast%3DDe%2BGreve%26aufirst%3DJ.%26aulast%3DLubinski%26aufirst%3DJ.%26aulast%3DShanley%26aufirst%3DS.%26aulast%3DMessiou%26aufirst%3DC.%26aulast%3DA%25E2%2580%2599Hern%26aufirst%3DR.%26aulast%3DTutt%26aufirst%3DA.%26aulast%3DAshworth%26aufirst%3DA.%26aulast%3DStone%26aufirst%3DJ.%26aulast%3DCarmichael%26aufirst%3DJ.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26aulast%3DKaye%26aufirst%3DS.%2BB.%26atitle%3DPoly%2528ADP%2529-ribose%2520polymerase%2520inhibition%253A%2520frequent%2520durable%2520responses%2520in%2520BRCA%2520carrier%2520ovarian%2520cancer%2520correlating%2520with%2520platinum-free%2520interval%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26issue%3D15%26spage%3D2512%26epage%3D2519%26doi%3D10.1200%2FJCO.2009.26.9589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Audeh, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmichael, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penson, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedlander, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell-McGuinn, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weitzel, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oaknin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmutzler, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matulonis, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickens, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tutt, A.</span></span> <span> </span><span class="NLM_article-title">Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>376</i></span> (<span class="NLM_issue">9737</span>),  <span class="NLM_fpage">245</span>â <span class="NLM_lpage">251</span>, <span class="refDoi">Â DOI: 10.1016/S0140-6736(10)60893-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2FS0140-6736%2810%2960893-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=20609468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1Kktb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2010&pages=245-251&issue=9737&author=M.+W.+Audehauthor=J.+Carmichaelauthor=R.+T.+Pensonauthor=M.+Friedlanderauthor=B.+Powellauthor=K.+M.+Bell-McGuinnauthor=C.+Scottauthor=J.+N.+Weitzelauthor=A.+Oakninauthor=N.+Lomanauthor=K.+Luauthor=R.+K.+Schmutzlerauthor=U.+Matulonisauthor=M.+Wickensauthor=A.+Tutt&title=Oral+poly%28ADP-ribose%29+polymerase+inhibitor+olaparib+in+patients+with+BRCA1+or+BRCA2+mutations+and+recurrent+ovarian+cancer%3A+a+proof-of-concept+trial&doi=10.1016%2FS0140-6736%2810%2960893-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial</span></div><div class="casAuthors">Audeh, M. William; Carmichael, James; Penson, Richard T.; Friedlander, Michael; Powell, Bethan; Bell-McGuinn, Katherine M.; Scott, Clare; Weitzel, Jeffrey N.; Oaknin, Ana; Loman, Niklas; Lu, Karen; Schmutzler, Rita K.; Matulonis, Ursula; Wickens, Mark; Tutt, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">376</span>
        (<span class="NLM_cas:issue">9737</span>),
    <span class="NLM_cas:pages">245-251</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Olaparib is a novel, orally active poly(ADP-ribose) polymerase (PARP) inhibitor that induces synthetic lethality in homozygous BRCA-deficient cells.  We aimed to assess the efficacy and safety of olaparib for treatment of advanced ovarian cancer in patients with BRCA1 or BRCA2 mutations.  In this international, multicentre, phase 2 study, we enrolled two sequential cohorts of women (aged â¥18 years) with confirmed genetic BRCA1 or BRCA2 mutations, and recurrent, measurable disease.  The study was undertaken in 12 centers in Australia, Germany, Spain, Sweden, and the USA.  The first cohort (n=33) was given continuous oral olaparib at the max. tolerated dose of 400 mg twice daily, and the second cohort (n=24) was given continuous oral olaparib at 100 mg twice daily.  The primary efficacy endpoint was objective response rate (ORR).  This study is registered with ClinicalTrials.gov, no. NCT00494442.  Patients had been given a median of three (range 1-16) previous chemotherapy regimens.  ORR was 11 (33%) of 33 patients (95% CI 20-51) in the cohort assigned to olaparib 400 mg twice daily, and three (13%) of 24 (4-31) in the cohort assigned to 100 mg twice daily.  In patients given olaparib 400 mg twice daily, the most frequent causally related adverse events were nausea (grade 1 or 2, 14 [42%]; grade 3 or 4, 2 [6%]), fatigue (grade 1 or 2, 10 [30%]; grade 3 or 4, one [3%]), and anemia (grade 1 or 2, 5 [15%]; grade 3 or 4, 1 [3%]).  The most frequent causally related adverse events in the cohort given 100 mg twice daily were nausea (grade 1 or 2, 7 [29%]; grade 3 or 4, 2 [8%]) and fatigue (grade 1 or 2, 9 [38%]; none grade 3 or 4).  Findings from this phase 2 study provide pos. proof of concept of the efficacy and tolerability of genetically targeted treatment with olaparib in BRCA-mutated advanced ovarian cancer.  Funding: AstraZeneca.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfC3epcFKsLrVg90H21EOLACvtfcHk0lhsAJuWgan2sg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1Kktb4%253D&md5=e74985d2c7ae53462d48277fbc36bb6a</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2810%2960893-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252810%252960893-8%26sid%3Dliteratum%253Aachs%26aulast%3DAudeh%26aufirst%3DM.%2BW.%26aulast%3DCarmichael%26aufirst%3DJ.%26aulast%3DPenson%26aufirst%3DR.%2BT.%26aulast%3DFriedlander%26aufirst%3DM.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DBell-McGuinn%26aufirst%3DK.%2BM.%26aulast%3DScott%26aufirst%3DC.%26aulast%3DWeitzel%26aufirst%3DJ.%2BN.%26aulast%3DOaknin%26aufirst%3DA.%26aulast%3DLoman%26aufirst%3DN.%26aulast%3DLu%26aufirst%3DK.%26aulast%3DSchmutzler%26aufirst%3DR.%2BK.%26aulast%3DMatulonis%26aufirst%3DU.%26aulast%3DWickens%26aufirst%3DM.%26aulast%3DTutt%26aufirst%3DA.%26atitle%3DOral%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitor%2520olaparib%2520in%2520patients%2520with%2520BRCA1%2520or%2520BRCA2%2520mutations%2520and%2520recurrent%2520ovarian%2520cancer%253A%2520a%2520proof-of-concept%2520trial%26jtitle%3DLancet%26date%3D2010%26volume%3D376%26issue%3D9737%26spage%3D245%26epage%3D251%26doi%3D10.1016%2FS0140-6736%2810%2960893-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapira-Frommer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmutzler, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audeh, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedlander, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balmana, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fried, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stemmer, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosengarten, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fielding, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domchek, S. M.</span></span> <span> </span><span class="NLM_article-title">Olaparib monotherapy in patients with advanced cancer and a Germline BRCA1/2 mutation</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">244</span>â <span class="NLM_lpage">250</span>, <span class="refDoi">Â DOI: 10.1200/JCO.2014.56.2728</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1200%2FJCO.2014.56.2728" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=25366685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjsVWrsLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=244-250&issue=3&author=B.+Kaufmanauthor=R.+Shapira-Frommerauthor=R.+K.+Schmutzlerauthor=M.+W.+Audehauthor=M.+Friedlanderauthor=J.+Balmanaauthor=G.+Mitchellauthor=G.+Friedauthor=S.+M.+Stemmerauthor=A.+Hubertauthor=O.+Rosengartenauthor=M.+Steinerauthor=N.+Lomanauthor=K.+Bowenauthor=A.+Fieldingauthor=S.+M.+Domchek&title=Olaparib+monotherapy+in+patients+with+advanced+cancer+and+a+Germline+BRCA1%2F2+mutation&doi=10.1200%2FJCO.2014.56.2728"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation</span></div><div class="casAuthors">Kaufman, Bella; Shapira-Frommer, Ronnie; Schmutzler, Rita K.; Audeh, M. William; Friedlander, Michael; Balmana, Judith; Mitchell, Gillian; Fried, Georgeta; Stemmer, Salomon M.; Hubert, Ayala; Rosengarten, Ora; Steiner, Mariana; Loman, Niklas; Bowen, Karin; Fielding, Anitra; Domchek, Susan M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">244-250</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Olaparib is an oral poly (ADP-ribose) polymerase inhibitor with activity in germline BRCA1 and BRCA2 (BRCA1/2) -assocd. breast and ovarian cancers.  We evaluated the efficacy and safety of olaparib in a spectrum of BRCA1/2-assocd. cancers.  This multicenter phase II study enrolled individuals with a germline BRCA1/2 mutation and recurrent cancer.  Eligibility included ovarian cancer resistant to prior platinum; breast cancer with â¥ three chemotherapy regimens for metastatic disease; pancreatic cancer with prior gemcitabine treatment; or prostate cancer with progression on hormonal and one systemic therapy.  Olaparib was administered at 400 mg twice per day.  The primary efficacy end point was tumor response rate.  A total of 298 patients received treatment and were evaluable.  The tumor response rate was 26.2% (78 of 298; 95% CI, 21.3 to 31.6) overall and 31.1% (60 of 193; 95% CI, 24.6 to 38.1), 12.9% (eight of 62; 95% CI, 5.7 to 23.9), 21.7% (five of 23; 95% CI, 7.5 to 43.7), and 50.0% (four of eight; 95% CI, 15.7 to 84.3) in ovarian, breast, pancreatic, and prostate cancers, resp.  Stable disease â¥ 8 wk was obsd. in 42% of patients (95% CI, 36.0 to 47.4), including 40% (95% CI, 33.4 to 47.7), 47% (95% CI, 34.0 to 59.9), 35% (95% CI, 16.4 to 57.3), and 25% (95% CI, 3.2 to 65.1) of those with ovarian, breast, pancreatic, or prostate cancer, resp.  The most common adverse events (AEs) were fatigue, nausea, and vomiting.  Grade â¥ 3 AEs were reported for 54% of patients; anemia was the most common (17%).  Responses to olaparib were obsd. across different tumor types assocd. with germline BRCA1/2 mutations.  Olaparib warrants further investigation in confirmatory studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooKvduc8Sx3bVg90H21EOLACvtfcHk0lhsAJuWgan2sg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjsVWrsLY%253D&md5=8ba52a3fa98d1137e6c134245ea42b87</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1200%2FJCO.2014.56.2728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2014.56.2728%26sid%3Dliteratum%253Aachs%26aulast%3DKaufman%26aufirst%3DB.%26aulast%3DShapira-Frommer%26aufirst%3DR.%26aulast%3DSchmutzler%26aufirst%3DR.%2BK.%26aulast%3DAudeh%26aufirst%3DM.%2BW.%26aulast%3DFriedlander%26aufirst%3DM.%26aulast%3DBalmana%26aufirst%3DJ.%26aulast%3DMitchell%26aufirst%3DG.%26aulast%3DFried%26aufirst%3DG.%26aulast%3DStemmer%26aufirst%3DS.%2BM.%26aulast%3DHubert%26aufirst%3DA.%26aulast%3DRosengarten%26aufirst%3DO.%26aulast%3DSteiner%26aufirst%3DM.%26aulast%3DLoman%26aufirst%3DN.%26aulast%3DBowen%26aufirst%3DK.%26aulast%3DFielding%26aufirst%3DA.%26aulast%3DDomchek%26aufirst%3DS.%2BM.%26atitle%3DOlaparib%2520monotherapy%2520in%2520patients%2520with%2520advanced%2520cancer%2520and%2520a%2520Germline%2520BRCA1%252F2%2520mutation%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26issue%3D3%26spage%3D244%26epage%3D250%26doi%3D10.1200%2FJCO.2014.56.2728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kristeleit, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oza, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LoRusso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domchek, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balmana, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drew, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safra, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goble, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaacson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borrow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfe, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapira-Frommer, R.</span></span> <span> </span><span class="NLM_article-title">A Phase I-II study of the oral PARP inhibitor Rucaparib in patients with Germline BRCA1/2-mutated ovarian carcinoma or other solid tumors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">4095</span>â <span class="NLM_lpage">4106</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-16-2796</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F1078-0432.CCR-16-2796" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=28264872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Ghu7fK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=4095-4106&issue=15&author=R.+Kristeleitauthor=G.+I.+Shapiroauthor=H.+A.+Burrisauthor=A.+M.+Ozaauthor=P.+LoRussoauthor=M.+R.+Patelauthor=S.+M.+Domchekauthor=J.+Balmanaauthor=Y.+Drewauthor=L.+M.+Chenauthor=T.+Safraauthor=A.+Montesauthor=H.+Giordanoauthor=L.+Maloneyauthor=S.+Gobleauthor=J.+Isaacsonauthor=J.+Xiaoauthor=J.+Borrowauthor=L.+Rolfeauthor=R.+Shapira-Frommer&title=A+Phase+I-II+study+of+the+oral+PARP+inhibitor+Rucaparib+in+patients+with+Germline+BRCA1%2F2-mutated+ovarian+carcinoma+or+other+solid+tumors&doi=10.1158%2F1078-0432.CCR-16-2796"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors</span></div><div class="casAuthors">Kristeleit, Rebecca; Shapiro, Geoffrey I.; Burris, Howard A.; Oza, Amit M.; Lo Russo, Patricia; Patel, Manish R.; Domchek, Susan M.; Balmana, Judith; Drew, Yvette; Chen, Lee-may; Safra, Tamar; Montes, Ana; Giordano, Heidi; Maloney, Lara; Goble, Sandra; Isaacson, Jeff; Xiao, Jim; Borrow, Jen; Rolfe, Lindsey; Shapira-Frommer, Ronnie</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4095-4106</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Rucaparib is a potent, oral, small-mol. PARP inhibitor.  This phase I-II study was the first to evaluate single-agent oral rucaparib at multiple doses.  Exptl. Design: Part 1 (phase I) sought to det. the MTD, recommended phase II dose (RP2D), and pharmacokinetics of oral rucaparib administered in 21-day continuous cycles in patients with advanced solid tumors.  Part 2A (phase II) enrolled patients with platinum-sensitive, high-grade ovarian carcinoma (HGOC) assocd. with a germline BRCA1/2 mutation who received two to four prior regimens and had a progression-free interval of 6 mo or more following their most recent platinum therapy.  The primary endpoint was investigator-assessed objective response rate (ORR) by RECIST version 1.1.  Results: In part 1, 56 patients received oral rucaparib (40 to 500 mg once daily and 240 to 840 mg twice daily).  No MTD was identified per protocol-defined criteria; 600 mg twice daily was selected as the RP2D based on manageable toxicity and clin. activity.  Pharmacokinetics were approx. dose-proportional across all dose levels.  In part 2A, 42 patients with germline BRCA1/2-mutated HGOC received rucaparib 600 mg twice daily.  Investigator-assessed ORR was 59.5%.  The most common treatment-emergent adverse events (all grades) were asthenia/fatigue (85.7%; 36/42), nausea (83.3%; 35/42), anemia (71.4%; 30/42), alanine transaminase and/or aspartate transaminase elevations (57.1%; 24/42), and vomiting (54.8%; 23/42).  Among 98 patients, 5 (5.1%) discontinued because of an adverse event (excluding disease progression).  Conclusions: Rucaparib was tolerable and had activity in patients with platinum-sensitive germline BRCA1/2-mutated HGOC.  Clin Cancer Res; 23(15); 4095-106. Â©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZJ2EmIj6hBLVg90H21EOLACvtfcHk0lhAzs-EFgq23g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Ghu7fK&md5=e9a13775ccd785551e01585bed7f676c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-2796&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-2796%26sid%3Dliteratum%253Aachs%26aulast%3DKristeleit%26aufirst%3DR.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DOza%26aufirst%3DA.%2BM.%26aulast%3DLoRusso%26aufirst%3DP.%26aulast%3DPatel%26aufirst%3DM.%2BR.%26aulast%3DDomchek%26aufirst%3DS.%2BM.%26aulast%3DBalmana%26aufirst%3DJ.%26aulast%3DDrew%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DL.%2BM.%26aulast%3DSafra%26aufirst%3DT.%26aulast%3DMontes%26aufirst%3DA.%26aulast%3DGiordano%26aufirst%3DH.%26aulast%3DMaloney%26aufirst%3DL.%26aulast%3DGoble%26aufirst%3DS.%26aulast%3DIsaacson%26aufirst%3DJ.%26aulast%3DXiao%26aufirst%3DJ.%26aulast%3DBorrow%26aufirst%3DJ.%26aulast%3DRolfe%26aufirst%3DL.%26aulast%3DShapira-Frommer%26aufirst%3DR.%26atitle%3DA%2520Phase%2520I-II%2520study%2520of%2520the%2520oral%2520PARP%2520inhibitor%2520Rucaparib%2520in%2520patients%2520with%2520Germline%2520BRCA1%252F2-mutated%2520ovarian%2520carcinoma%2520or%2520other%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26issue%3D15%26spage%3D4095%26epage%3D4106%26doi%3D10.1158%2F1078-0432.CCR-16-2796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swisher, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oza, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konecny, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tinker, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâMalley, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kristeleit, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell-McGuinn, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenton, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cragun, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oaknin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray-Coquard, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrell, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufmann, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floquet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leary, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goble, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaacson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfe, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yelensky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raponi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeish, I. A.</span></span> <span> </span><span class="NLM_article-title">Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">75</span>â <span class="NLM_lpage">87</span>, <span class="refDoi">Â DOI: 10.1016/S1470-2045(16)30559-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2FS1470-2045%2816%2930559-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=27908594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFKnurbJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=75-87&issue=1&author=E.+M.+Swisherauthor=K.+K.+Linauthor=A.+M.+Ozaauthor=C.+L.+Scottauthor=H.+Giordanoauthor=J.+Sunauthor=G.+E.+Konecnyauthor=R.+L.+Colemanauthor=A.+V.+Tinkerauthor=D.+M.+O%E2%80%99Malleyauthor=R.+S.+Kristeleitauthor=L.+Maauthor=K.+M.+Bell-McGuinnauthor=J.+D.+Brentonauthor=J.+M.+Cragunauthor=A.+Oakninauthor=I.+Ray-Coquardauthor=M.+I.+Harrellauthor=E.+Mannauthor=S.+H.+Kaufmannauthor=A.+Floquetauthor=A.+Learyauthor=T.+C.+Hardingauthor=S.+Gobleauthor=L.+Maloneyauthor=J.+Isaacsonauthor=A.+R.+Allenauthor=L.+Rolfeauthor=R.+Yelenskyauthor=M.+Raponiauthor=I.+A.+McNeish&title=Rucaparib+in+relapsed%2C+platinum-sensitive+high-grade+ovarian+carcinoma+%28ARIEL2+Part+1%29%3A+an+international%2C+multicentre%2C+open-label%2C+phase+2+trial&doi=10.1016%2FS1470-2045%2816%2930559-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial</span></div><div class="casAuthors">Swisher, Elizabeth M.; Lin, Kevin K.; Oza, Amit M.; Scott, Clare L.; Giordano, Heidi; Sun, James; Konecny, Gottfried E.; Coleman, Robert L.; Tinker, Anna V.; O'Malley, David M.; Kristeleit, Rebecca S.; Ma, Ling; Bell-McGuinn, Katherine M.; Brenton, James D.; Cragun, Janiel M.; Oaknin, Ana; Ray-Coquard, Isabelle; Harrell, Maria I.; Mann, Elaina; Kaufmann, Scott H.; Floquet, Anne; Leary, Alexandra; Harding, Thomas C.; Goble, Sandra; Maloney, Lara; Isaacson, Jeff; Allen, Andrew R.; Rolfe, Lindsey; Yelensky, Roman; Raponi, Mitch; McNeish, Iain A.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">75-87</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase (PARP) inhibitors have activity in ovarian carcinomas with homologous recombination deficiency.  Along with BRCA1 and BRCA2 (BRCA) mutations genomic loss of heterozygosity (LOH) might also represent homologous recombination deficiency.  In ARIEL2, we assessed the ability of tumor genomic LOH, quantified with a next-generation sequencing assay, to predict response to rucaparib, an oral PARP inhibitor.  ARIEL2 is an international, multicentre, two-part, phase 2, open-label study done at 49 hospitals and cancer centers in Australia, Canada, France, Spain, the UK, and the USA.  In ARIEL2 Part 1, patients with recurrent, platinum-sensitive, high-grade ovarian carcinoma were classified into one of three predefined homologous recombination deficiency subgroups on the basis of tumor mutational anal.: BRCA mutant (deleterious germline or somatic), BRCA wild-type and LOH high (LOH high group), or BRCA wild-type and LOH low (LOH low group).  We prespecified a cutoff of 14% or more genomic LOH for LOH high.  Patients began treatment with oral rucaparib at 600 mg twice per day for continuous 28 day cycles until disease progression or any other reason for discontinuation.  The primary endpoint was progression-free survival.  All patients treated with at least one dose of rucaparib were included in the safety analyses and all treated patients who were classified were included in the primary endpoint anal.  This trial is registered with ClinicalTrials.gov, no. NCT01891344.  Enrolment into ARIEL2 Part 1 is complete, although an extension (Part 2) is ongoing.256 patients were screened and 206 were enrolled between Oct 30, 2013, and Dec 19, 2014.  At the data cutoff date (Jan 18, 2016), 204 patients had received rucaparib, with 28 patients remaining in the study. 192 patients could be classified into one of the three predefined homologous recombination deficiency subgroups: BRCA mutant (n=40), LOH high (n=82), or LOH low (n=70).  Tumors from 12 patients were established as BRCA wild-type, but could not be classified for LOH, because of insufficient neoplastic nuclei in the sample.  The median duration of treatment for the 204 patients was 5Â·7 mo (IQR 2Â·8-10Â·1). 24 patients in the BRCA mutant subgroup, 56 patients in the LOH high subgroup, and 59 patients in the LOH low subgroup had disease progression or died.  Median progression-free survival after rucaparib treatment was 12Â·8 mo (95% CI 9Â·0-14Â·7) in the BRCA mutant subgroup, 5Â·7 mo (5Â·3-7Â·6) in the LOH high subgroup, and 5Â·2 mo (3Â·6-5Â·5) in the LOH low subgroup.  Progression-free survival was significantly longer in the BRCA mutant (hazard ratio 0Â·27, 95% CI 0Â·16-0Â·44, p<0Â·0001) and LOH high (0Â·62, 0Â·42-0Â·90, p=0Â·011) subgroups compared with the LOH low subgroup.  The most common grade 3 or worse treatment-emergent adverse events were anemia or decreased Hb (45 [22%] patients), and elevations in alanine aminotransferase or aspartate aminotransferase (25 [12%]).  Common serious adverse events included small intestinal obstruction (10 [5%] of 204 patients), malignant neoplasm progression (10 [5%]), and anemia (nine [4%]).  Three patients died during the study (two because of disease progression and one because of sepsis and disease progression).  No treatment-related deaths occurred.  In patients with BRCA mutant or BRCA wild-type and LOH high platinum-sensitive ovarian carcinomas treated with rucaparib, progression-free survival was longer than in patients with BRCA wild-type LOH low carcinomas.  Our results suggest that assessment of tumor LOH can be used to identify patients with BRCA wild-type platinum-sensitive ovarian cancers who might benefit from rucaparib.  These results extend the potential usefulness of PARP inhibitors in the treatment setting beyond BRCA mutant tumors.  Clovis Oncol., US Department of Defense Ovarian Cancer Research Program, Stand Up To Cancer-Ovarian Cancer Research Fund Alliance-National Ovarian Cancer Coalition Dream Team Translational Research Grant, and V Foundation Translational Award.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra4unrxTkAg7Vg90H21EOLACvtfcHk0lhAzs-EFgq23g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFKnurbJ&md5=59f5a328a371683c038d7eec0058c094</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2816%2930559-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252816%252930559-9%26sid%3Dliteratum%253Aachs%26aulast%3DSwisher%26aufirst%3DE.%2BM.%26aulast%3DLin%26aufirst%3DK.%2BK.%26aulast%3DOza%26aufirst%3DA.%2BM.%26aulast%3DScott%26aufirst%3DC.%2BL.%26aulast%3DGiordano%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DKonecny%26aufirst%3DG.%2BE.%26aulast%3DColeman%26aufirst%3DR.%2BL.%26aulast%3DTinker%26aufirst%3DA.%2BV.%26aulast%3DO%25E2%2580%2599Malley%26aufirst%3DD.%2BM.%26aulast%3DKristeleit%26aufirst%3DR.%2BS.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DBell-McGuinn%26aufirst%3DK.%2BM.%26aulast%3DBrenton%26aufirst%3DJ.%2BD.%26aulast%3DCragun%26aufirst%3DJ.%2BM.%26aulast%3DOaknin%26aufirst%3DA.%26aulast%3DRay-Coquard%26aufirst%3DI.%26aulast%3DHarrell%26aufirst%3DM.%2BI.%26aulast%3DMann%26aufirst%3DE.%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26aulast%3DFloquet%26aufirst%3DA.%26aulast%3DLeary%26aufirst%3DA.%26aulast%3DHarding%26aufirst%3DT.%2BC.%26aulast%3DGoble%26aufirst%3DS.%26aulast%3DMaloney%26aufirst%3DL.%26aulast%3DIsaacson%26aufirst%3DJ.%26aulast%3DAllen%26aufirst%3DA.%2BR.%26aulast%3DRolfe%26aufirst%3DL.%26aulast%3DYelensky%26aufirst%3DR.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DMcNeish%26aufirst%3DI.%2BA.%26atitle%3DRucaparib%2520in%2520relapsed%252C%2520platinum-sensitive%2520high-grade%2520ovarian%2520carcinoma%2520%2528ARIEL2%2520Part%25201%2529%253A%2520an%2520international%252C%2520multicentre%252C%2520open-label%252C%2520phase%25202%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2017%26volume%3D18%26issue%3D1%26spage%3D75%26epage%3D87%26doi%3D10.1016%2FS1470-2045%2816%2930559-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mirza, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monk, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrstedt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oza, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redondo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ledermann, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorusso, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergote, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ben-Baruch, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marth, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madry, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berek, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tinker, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">du Bois, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Martin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Follana, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benigno, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimel, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buscema, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balser, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matulonis, U. A.</span></span> <span> </span><span class="NLM_article-title">Niraparib maintenance therapy in Platinum-sensitive, recurrent ovarian cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>375</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">2154</span>â <span class="NLM_lpage">2164</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa1611310</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1056%2FNEJMoa1611310" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=27717299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFaqt77O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2016&pages=2154-2164&issue=22&author=M.+R.+Mirzaauthor=B.+J.+Monkauthor=J.+Herrstedtauthor=A.+M.+Ozaauthor=S.+Mahnerauthor=A.+Redondoauthor=M.+Fabbroauthor=J.+A.+Ledermannauthor=D.+Lorussoauthor=I.+Vergoteauthor=N.+E.+Ben-Baruchauthor=C.+Marthauthor=R.+Madryauthor=R.+D.+Christensenauthor=J.+S.+Berekauthor=A.+Dorumauthor=A.+V.+Tinkerauthor=A.+du+Boisauthor=A.+Gonzalez-Martinauthor=P.+Follanaauthor=B.+Benignoauthor=P.+Rosenbergauthor=L.+Gilbertauthor=B.+J.+Rimelauthor=J.+Buscemaauthor=J.+P.+Balserauthor=S.+Agarwalauthor=U.+A.+Matulonis&title=Niraparib+maintenance+therapy+in+Platinum-sensitive%2C+recurrent+ovarian+cancer&doi=10.1056%2FNEJMoa1611310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer</span></div><div class="casAuthors">Mirza, M. R.; Monk, B. J.; Herrstedt, J.; Oza, A. M.; Mahner, S.; Redondo, A.; Fabbro, M.; Ledermann, J. A.; Lorusso, D.; Vergote, I.; Ben-Baruch, N. E.; Marth, C.; Madry, R.; Christensen, R. D.; Berek, J. S.; Dorum, A.; Tinker, A. V.; du Bois, A.; Gonzalez-Martin, A.; Follana, P.; Benigno, B.; Rosenberg, P.; Gilbert, L.; Rimel, B. J.; Buscema, J.; Balser, J. P.; Agarwal, S.; Matulonis, U. A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">375</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2154-2164</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Niraparib is an oral poly(ADP [ADP]-ribose) polymerase (PARP) 1/2 inhibitor that has shown clin. activity in patients with ovarian cancer.  We sought to evaluate the efficacy of niraparib vs. placebo as maintenance treatment for patients with platinum-sensitive, recurrent ovarian cancer.  METHODS: In this randomized, double-blind, phase 3 trial, patients were categorized according to the presence or absence of a germline BRCA mutation (gBRCA cohort and non-gBRCA cohort) and the type of non-gBRCA mutation and were randomly assigned in a 2:1 ratio to receive niraparib (300 mg) or placebo once daily.  The primary end point was progression-free survival.  RESULTS: Of 553 enrolled patients, 203 were in the gBRCA cohort (with 138 assigned to niraparib and 65 to placebo), and 350 patients were in the non-gBRCA cohort (with 234 assigned to niraparib and 116 to placebo).  Patients in the niraparib group had a significantly longer median duration of progression-free survival than did those in the placebo group, including 21.0 vs. 5.5 mo in the gBRCA cohort (hazard ratio, 0.27; 95% confidence interval [CI], 0.17 to 0.41), as compared with 12.9 mo vs. 3.8 mo in the non-gBRCA cohort for patients who had tumors with homologous recombination deficiency (HRD) (hazard ratio, 0.38; 95% CI, 0.24 to 0.59) and 9.3 mo vs. 3.9 mo in the overall non-gBRCA cohort (hazard ratio, 0.45; 95% CI, 0.34 to 0.61; P<0.001 for all three comparisons).  The most common grade 3 or 4 adverse events that were reported in the niraparib group were thrombocytopenia (in 33.8%), anemia (in 25.3%), and neutropenia (in 19.6%), which were managed with dose modifications.  CONCLUSIONS: Among patients with platinum-sensitive, recurrent ovarian cancer, the median duration of progression-free survival was significantly longer among those receiving niraparib than among those receiving placebo, regardless of the presence or absence of gBRCA mutations or HRD status, with moderate bone marrow toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzlUvEgQyy4rVg90H21EOLACvtfcHk0ljzYaHTlyNXuA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFaqt77O&md5=64b76a6b436ff340df5341339e4606ee</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1611310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1611310%26sid%3Dliteratum%253Aachs%26aulast%3DMirza%26aufirst%3DM.%2BR.%26aulast%3DMonk%26aufirst%3DB.%2BJ.%26aulast%3DHerrstedt%26aufirst%3DJ.%26aulast%3DOza%26aufirst%3DA.%2BM.%26aulast%3DMahner%26aufirst%3DS.%26aulast%3DRedondo%26aufirst%3DA.%26aulast%3DFabbro%26aufirst%3DM.%26aulast%3DLedermann%26aufirst%3DJ.%2BA.%26aulast%3DLorusso%26aufirst%3DD.%26aulast%3DVergote%26aufirst%3DI.%26aulast%3DBen-Baruch%26aufirst%3DN.%2BE.%26aulast%3DMarth%26aufirst%3DC.%26aulast%3DMadry%26aufirst%3DR.%26aulast%3DChristensen%26aufirst%3DR.%2BD.%26aulast%3DBerek%26aufirst%3DJ.%2BS.%26aulast%3DDorum%26aufirst%3DA.%26aulast%3DTinker%26aufirst%3DA.%2BV.%26aulast%3Ddu%2BBois%26aufirst%3DA.%26aulast%3DGonzalez-Martin%26aufirst%3DA.%26aulast%3DFollana%26aufirst%3DP.%26aulast%3DBenigno%26aufirst%3DB.%26aulast%3DRosenberg%26aufirst%3DP.%26aulast%3DGilbert%26aufirst%3DL.%26aulast%3DRimel%26aufirst%3DB.%2BJ.%26aulast%3DBuscema%26aufirst%3DJ.%26aulast%3DBalser%26aufirst%3DJ.%2BP.%26aulast%3DAgarwal%26aufirst%3DS.%26aulast%3DMatulonis%26aufirst%3DU.%2BA.%26atitle%3DNiraparib%2520maintenance%2520therapy%2520in%2520Platinum-sensitive%252C%2520recurrent%2520ovarian%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D375%26issue%3D22%26spage%3D2154%26epage%3D2164%26doi%3D10.1056%2FNEJMoa1611310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, S.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senkus, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domchek, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delaloge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tung, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goessl, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Runswick, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conte, P.</span></span> <span> </span><span class="NLM_article-title">Olaparib for metastatic breast cancer in patients with a germline BRCA mutation</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">523</span>â <span class="NLM_lpage">533</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa1706450</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1056%2FNEJMoa1706450" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=28578601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlyksrbN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2017&pages=523-533&author=M.+Robsonauthor=S.-A.+Imauthor=E.+Senkusauthor=B.+Xuauthor=S.+M.+Domchekauthor=N.+Masudaauthor=S.+Delalogeauthor=W.+Liauthor=N.+Tungauthor=A.+Armstrongauthor=W.+Wuauthor=C.+Goesslauthor=S.+Runswickauthor=P.+Conte&title=Olaparib+for+metastatic+breast+cancer+in+patients+with+a+germline+BRCA+mutation&doi=10.1056%2FNEJMoa1706450"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Olaparib for metastatic breast cancer in patients with a germline BRCA mutation</span></div><div class="casAuthors">Robson, Mark; Im, Seock-Ah; Senkus, Elzbieta; Xu, Binghe; Domchek, Susan M.; Masuda, Norikazu; Delaloge, Suzette; Li, Wei; Tung, Nadine; Armstrong, Anne; Wu, Wenting; Goessl, Carsten; Runswick, Sarah; Conte, Pierfranco</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">523-533</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Olaparib is an oral poly(ADP-ribose) polymerase inhibitor that has promising antitumor activity in patients with metastatic breast cancer and a germline BRCA mutation.  We conducted a randomized, open-label, phase 3 trial in which olaparib monotherapy was compared with std. therapy in patients with a germline BRCA mutation and human epidermal growth factor receptor type 2 (HER2)-neg. metastatic breast cancer who had received no more than two previous chemotherapy regimens for metastatic disease.  Patients were randomly assigned, in a 2:1 ratio, to receive olaparib tablets (300 mg twice daily) or std. therapy with single-agent chemotherapy of the physician's choice (capecitabine, eribulin, or vinorelbine in 21-day cycles).  The primary end point was progression-free survival, which was assessed by blinded independent central review and was analyzed on an intention-to-treat basis. results Of the 302 patients who underwent randomization, 205 were assigned to receive olaparib and 97 were assigned to receive std. therapy.  Median progression-free survival was significantly longer in the olaparib group than in the std.-therapy group (7.0 mo vs. 4.2 mo; hazard ratio for disease progression or death, 0.58; 95% confidence interval, 0.43 to 0.80; P<0.001).  The response rate was 59.9% in the olaparib group and 28.8% in the std.-therapy group.  The rate of grade 3 or higher adverse events was 36.6% in the olaparib group and 50.5% in the std.-therapy group, and the rate of treatment discontinuation due to toxic effects was 4.9% and 7.7%, resp.  Among patients with HER2-neg. metastatic breast cancer and a germline BRCA mutation, olaparib monotherapy provided a significant benefit over std. therapy; median progression-free survival was 2.8 mo longer and the risk of disease progression or death was 42% lower with olaparib monotherapy than with std. therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMXxR-ZN4IGrVg90H21EOLACvtfcHk0ljzYaHTlyNXuA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlyksrbN&md5=7c8c62182a717c16c5762443fb3f6d5d</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1706450&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1706450%26sid%3Dliteratum%253Aachs%26aulast%3DRobson%26aufirst%3DM.%26aulast%3DIm%26aufirst%3DS.-A.%26aulast%3DSenkus%26aufirst%3DE.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DDomchek%26aufirst%3DS.%2BM.%26aulast%3DMasuda%26aufirst%3DN.%26aulast%3DDelaloge%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DTung%26aufirst%3DN.%26aulast%3DArmstrong%26aufirst%3DA.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DGoessl%26aufirst%3DC.%26aulast%3DRunswick%26aufirst%3DS.%26aulast%3DConte%26aufirst%3DP.%26atitle%3DOlaparib%2520for%2520metastatic%2520breast%2520cancer%2520in%2520patients%2520with%2520a%2520germline%2520BRCA%2520mutation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D377%26spage%3D523%26epage%3D533%26doi%3D10.1056%2FNEJMoa1706450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Litton, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rugo, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ettl, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurvitz, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goncalves, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fehrenbacher, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yerushalmi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mina, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roche, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quek, R. G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markova, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tudor, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannah, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eiermann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, J. L.</span></span> <span> </span><span class="NLM_article-title">Talazoparib in patients with advanced breast cancer and a germline BRCA mutation</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>379</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">753</span>â <span class="NLM_lpage">763</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa1802905</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1056%2FNEJMoa1802905" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=30110579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1eqsrnI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2018&pages=753-763&issue=8&author=J.+K.+Littonauthor=H.+S.+Rugoauthor=J.+Ettlauthor=S.+A.+Hurvitzauthor=A.+Goncalvesauthor=K.+H.+Leeauthor=L.+Fehrenbacherauthor=R.+Yerushalmiauthor=L.+A.+Minaauthor=M.+Martinauthor=H.+Rocheauthor=Y.+H.+Imauthor=R.+G.+W.+Quekauthor=D.+Markovaauthor=I.+C.+Tudorauthor=A.+L.+Hannahauthor=W.+Eiermannauthor=J.+L.+Blum&title=Talazoparib+in+patients+with+advanced+breast+cancer+and+a+germline+BRCA+mutation&doi=10.1056%2FNEJMoa1802905"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Talazoparib in patients with advanced breast cancer and a germline BRCA mutation</span></div><div class="casAuthors">Litton, Jennifer K.; Rugo, Hope S.; Ettl, Johannes; Hurvitz, Sara A.; Goncalves, Anthony; Lee, Kyung-Hun; Fehrenbacher, Louis; Yerushalmi, Rinat; Mina, Lida A.; Martin, Miguel; Roche, Henri; Im, Young-Hyuck; Quek, Ruben G. W.; Markova, Denka; Tudor, Iulia C.; Hannah, Alison L.; Eiermann, Wolfgang; Blum, Joanne L.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">379</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">753-763</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: The poly(ADP-ribose) inhibitor talazoparib has shown antitumor activity in patients with advanced breast cancer and germline mutations in BRCA1 and BRCA2 (BRCA1/2).  Methods: We conducted a randomized, open-label, phase 3 trial in which patients with advanced breast cancer and a germline BRCA1/2 mutation were assigned, in a 2:1 ratio, to receive talazoparib (1 mg once daily) or std. single-agent therapy of the physician's choice (capecitabine, eribulin, gemcitabine, or vinorelbine in continuous 21-day cycles).  The primary end point was progression-free survival, which was assessed by blinded independent central review.  Results: Of the 431 patients who underwent randomization, 287 were assigned to receive talazoparib and 144 were assigned to receive std. therapy.  Median progression-free survival was significantly longer in the talazoparib group than in the std.-therapy group (8.6 mo vs. 5.6 mo; hazard ratio for disease progression or death, 0.54; 95% confidence interval [CI], 0.41 to 0.71; P<0.001).  The interim median hazard ratio for death was 0.76 (95% CI, 0.55 to 1.06; P = 0.11 [57% of projected events]).  The objective response rate was higher in the talazoparib group than in the std.-therapy group (62.6% vs. 27.2%; odds ratio, 5.0; 95% CI, 2.9 to 8.8; P<0.001).  Hematol. grade 3-4 adverse events (primarily anemia) occurred in 55% of the patients who received talazoparib and in 38% of the patients who received std. therapy; nonhematol. grade 3 adverse events occurred in 32% and 38% of the patients, resp.  Patient-reported outcomes favored talazoparib; significant overall improvements and significant delays in the time to clin. meaningful deterioration according to both the global health status-quality-of-life and breast symptoms scales were obsd.  Conclusions: Among patients with advanced breast cancer and a germline BRCA1/2 mutation, single-agent talazoparib provided a significant benefit over std. chemotherapy with respect to progression-free survival.  Patient-reported outcomes were superior with talazoparib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouRXoCYNHmv7Vg90H21EOLACvtfcHk0lg9newkRJpKew"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1eqsrnI&md5=82f7478c15bd4790b6fa929227b5ce57</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1802905&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1802905%26sid%3Dliteratum%253Aachs%26aulast%3DLitton%26aufirst%3DJ.%2BK.%26aulast%3DRugo%26aufirst%3DH.%2BS.%26aulast%3DEttl%26aufirst%3DJ.%26aulast%3DHurvitz%26aufirst%3DS.%2BA.%26aulast%3DGoncalves%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DFehrenbacher%26aufirst%3DL.%26aulast%3DYerushalmi%26aufirst%3DR.%26aulast%3DMina%26aufirst%3DL.%2BA.%26aulast%3DMartin%26aufirst%3DM.%26aulast%3DRoche%26aufirst%3DH.%26aulast%3DIm%26aufirst%3DY.%2BH.%26aulast%3DQuek%26aufirst%3DR.%2BG.%2BW.%26aulast%3DMarkova%26aufirst%3DD.%26aulast%3DTudor%26aufirst%3DI.%2BC.%26aulast%3DHannah%26aufirst%3DA.%2BL.%26aulast%3DEiermann%26aufirst%3DW.%26aulast%3DBlum%26aufirst%3DJ.%2BL.%26atitle%3DTalazoparib%2520in%2520patients%2520with%2520advanced%2520breast%2520cancer%2520and%2520a%2520germline%2520BRCA%2520mutation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D379%26issue%3D8%26spage%3D753%26epage%3D763%26doi%3D10.1056%2FNEJMoa1802905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoy, S. M.</span></span> <span> </span><span class="NLM_article-title">Talazoparib: first global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">1939</span>â <span class="NLM_lpage">1946</span>, <span class="refDoi">Â DOI: 10.1007/s40265-018-1026-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1007%2Fs40265-018-1026-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=30506138" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A280%3ADC%252BB3crnslGgsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1939-1946&issue=18&author=S.+M.+Hoy&title=Talazoparib%3A+first+global+approval&doi=10.1007%2Fs40265-018-1026-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Talazoparib: First Global Approval</span></div><div class="casAuthors">Hoy Sheridan M</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1939-1946</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Talazoparib (TALZENNAÂ®) is an oral inhibitor of the polyadenosine 5'-diphosphoribose polymerase (PARP) enzymes, which play a critical role in repairing DNA single-strand breaks.  It has been developed by Pfizer and was recently approved in the USA for the treatment of adults with deleterious or suspected deleterious germline BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer (as detected by a US FDA-approved assay).  A regulatory assessment for talazoparib in this patient population is underway in the EU, with talazoparib also undergoing development for use in metastatic castration-resistant prostate cancer and various solid tumours, and as neoadjuvant therapy in early triple negative breast cancer.  This article summarizes the milestones in the development of talazoparib leading to its first approval for the treatment of adults with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative, locally advanced or metastatic breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSA4VT-ypttQZNiNltV31zlfW6udTcc2ebQ1nP9HDbmf7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3crnslGgsg%253D%253D&md5=e5799d67f592d4e449e18f09fc727a4b</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-1026-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-1026-z%26sid%3Dliteratum%253Aachs%26aulast%3DHoy%26aufirst%3DS.%2BM.%26atitle%3DTalazoparib%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26issue%3D18%26spage%3D1939%26epage%3D1946%26doi%3D10.1007%2Fs40265-018-1026-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Golan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Cutsem, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macarulla, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochhauser, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinacher-Schick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tortora, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Algul, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâReilly, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuinness, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlienger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locker, G. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kindler, H. L.</span></span> <span> </span><span class="NLM_article-title">Maintenance Olaparib for germline BRCA-mutated metastatic pancreatic cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>381</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">317</span>â <span class="NLM_lpage">327</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa1903387</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1056%2FNEJMoa1903387" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=31157963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnsFCqtbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=381&publication_year=2019&pages=317-327&issue=4&author=T.+Golanauthor=P.+Hammelauthor=M.+Reniauthor=E.+Van+Cutsemauthor=T.+Macarullaauthor=M.+J.+Hallauthor=J.+O.+Parkauthor=D.+Hochhauserauthor=D.+Arnoldauthor=D.+Y.+Ohauthor=A.+Reinacher-Schickauthor=G.+Tortoraauthor=H.+Algulauthor=E.+M.+O%E2%80%99Reillyauthor=D.+McGuinnessauthor=K.+Y.+Cuiauthor=K.+Schliengerauthor=G.+Y.+Lockerauthor=H.+L.+Kindler&title=Maintenance+Olaparib+for+germline+BRCA-mutated+metastatic+pancreatic+cancer&doi=10.1056%2FNEJMoa1903387"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer</span></div><div class="casAuthors">Golan, Talia; Hammel, Pascal; Reni, Michele; Van Cutsem, Eric; Macarulla, Teresa; Hall, Michael J.; Park, Joon-Oh; Hochhauser, Daniel; Arnold, Dirk; Oh, Do-Youn; Reinacher-Schick, Anke; Tortora, Giampaolo; Algul, Hana; O'Reilly, Eileen M.; McGuinness, David; Cui, Karen Y.; Schlienger, Katia; Locker, Gershon Y.; Kindler, Hedy L.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">381</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">317-327</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Patients with a germline BRCA1 or BRCA2 mutation make up a small subgroup of those with metastatic pancreatic cancer.  The poly(ADP-ribose) polymerase (PARP) inhibitor olaparib has had antitumor activity in this population. methods We conducted a randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy of olaparib as maintenance therapy in patients who had a germline BRCA1 or BRCA2 mutation and metastatic pancreatic cancer and disease that had not progressed during first-line platinum-based chemotherapy.  Patients were randomly assigned, in a 3:2 ratio, to receive maintenance olaparib tablets (300 mg twice daily) or placebo.  The primary end point was progression-free survival, which was assessed by blinded independent central review. results Of the 3315 patients who underwent screening, 154 underwent randomization and were assigned to a trial intervention (92 to receive olaparib and 62 to receive placebo).  The median progression-free survival was significantly longer in the olaparib group than in the placebo group (7.4 mo vs. 3.8 mo; hazard ratio for disease progression or death, 0.53; 95% confidence interval [CI], 0.35 to 0.82; P = 0.004).  An interim anal. of overall survival, at a data maturity of 46%, showed no difference between the olaparib and placebo groups (median, 18.9 mo vs. 18.1 mo; hazard ratio for death, 0.91; 95% CI, 0.56 to 1.46; P = 0.68).  There was no significant between-group difference in health-related quality of life, as indicated by the overall change from baseline in the global quality-of-life score (on a 100-point scale, with higher scores indicating better quality of life) based on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (between-group difference, -2.47 points; 95% CI, -7.27 to 2.33).  The incidence of grade 3 or higher adverse events was 40% in the olaparib group and 23% in the placebo group (between-group difference, 16 percentage points; 95% CI, -0.02 to 31); 5% and 2% of the patients, resp., discontinued the trial intervention because of an adverse event. conclusions Among patients with a germline BRCA mutation and metastatic pancreatic cancer, progression-free survival was longer with maintenance olaparib than with placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_mABSEPws9rVg90H21EOLACvtfcHk0lg9newkRJpKew"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnsFCqtbo%253D&md5=06afa1aada240931f620ecf6f974b2e2</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1903387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1903387%26sid%3Dliteratum%253Aachs%26aulast%3DGolan%26aufirst%3DT.%26aulast%3DHammel%26aufirst%3DP.%26aulast%3DReni%26aufirst%3DM.%26aulast%3DVan%2BCutsem%26aufirst%3DE.%26aulast%3DMacarulla%26aufirst%3DT.%26aulast%3DHall%26aufirst%3DM.%2BJ.%26aulast%3DPark%26aufirst%3DJ.%2BO.%26aulast%3DHochhauser%26aufirst%3DD.%26aulast%3DArnold%26aufirst%3DD.%26aulast%3DOh%26aufirst%3DD.%2BY.%26aulast%3DReinacher-Schick%26aufirst%3DA.%26aulast%3DTortora%26aufirst%3DG.%26aulast%3DAlgul%26aufirst%3DH.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DE.%2BM.%26aulast%3DMcGuinness%26aufirst%3DD.%26aulast%3DCui%26aufirst%3DK.%2BY.%26aulast%3DSchlienger%26aufirst%3DK.%26aulast%3DLocker%26aufirst%3DG.%2BY.%26aulast%3DKindler%26aufirst%3DH.%2BL.%26atitle%3DMaintenance%2520Olaparib%2520for%2520germline%2520BRCA-mutated%2520metastatic%2520pancreatic%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D381%26issue%3D4%26spage%3D317%26epage%3D327%26doi%3D10.1056%2FNEJMoa1903387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span>U.S.
Food and Drug Administration. <a href="https://www.fda.gov/drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate" class="extLink">https://www.fda.gov/drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate</a> (accessed Jul 7, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=U.S.%0AFood+and+Drug+Administration.+https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Ffda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate+%28accessed+Jul+7%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span>Astra
Zeneca. <a href="https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-more-than-doubled-the-time-without-disease-progression-in-patients-with-brca1-2-atm-mutated-metastatic-castration-resistant-prostate-cancer-30092019.html" class="extLink">https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-more-than-doubled-the-time-without-disease-progression-in-patients-with-brca1-2-atm-mutated-metastatic-castration-resistant-prostate-cancer-30092019.html</a> (accessed Jul 7, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Astra%0AZeneca.+https%3A%2F%2Fwww.astrazeneca.com%2Fmedia-centre%2Fpress-releases%2F2019%2Flynparza-more-than-doubled-the-time-without-disease-progression-in-patients-with-brca1-2-atm-mutated-metastatic-castration-resistant-prostate-cancer-30092019.html+%28accessed+Jul+7%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jain, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, B. D.</span></span> <span> </span><span class="NLM_article-title">Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">198</span>â <span class="NLM_lpage">215</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2019.01.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.ejmech.2019.01.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=30684797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFKks70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2019&pages=198-215&author=P.+G.+Jainauthor=B.+D.+Patel&title=Medicinal+chemistry+approaches+of+poly+ADP-Ribose+polymerase+1+%28PARP1%29+inhibitors+as+anticancer+agents+-+A+recent+update&doi=10.1016%2Fj.ejmech.2019.01.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - a recent update</span></div><div class="casAuthors">Jain, Priyancy G.; Patel, Bhumika D.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">198-215</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Poly (ADP-ribose) Polymerase1 (PARP1) is a member of 17 membered PARP family having diversified biol. functions such as synthetic lethality, DNA repair, apoptosis, necrosis, histone binding etc.  It is primarily a chromatin-bound nuclear enzyme that gets activated by DNA damage.  It binds to DNA signal- and double-strand breaks, does parylation of target proteins (using NAD+ as a substrate) like histones and other DNA repair proteins and modifies them as a part of DNA repair mechanism.  Inhibition of PARP1 prevents the DNA repair and leads to cell death.  Clin., PARP1 Inhibitors have shown their potential in treating BRCAm breast and ovarian cancers and trials are going on for the treatment of other solid tumors like pancreatic, prostate, colorectal etc. as a single agent or in combination.  There are currently three FDA approved PARP1 inhibitors namely Olaparib, Rucaparib and Niraparib in the market while Veliparib and Talazoparib are in the late stage of clin. development.  All these mols. are nonselective PARP1 inhibitors with concurrent inhibition of PARP2 with similar potency.  In addn., resistance to marketed PARP1 inhibitors has been reported.  Overall, looking at the success rate of PARP1 inhibitors into various solid tumors, there is an urge of a novel and selective PARP1 inhibitors.  This review provides an update on various newer heterocyclic PARP1 inhibitors reported in last three years along with their structural design strategies.  We classified them into two main chem. classes; NAD analogs and non-NAD analogs and discussed the medicinal chem. approaches of each class.  To understand the structural features required for in-silico designing of next-generation PARP1 inhibitors, we also reported the crucial amino acid interactions of these inhibitors at the target site.  Thus, present review provides the insight on recent development on new lead structures as PARP1 inhibitors, their SAR, an overview of in-vitro and in-vivo screening methods, current challenges and opinion on future designing of more selective and safe PARP1 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGsZyTB3cxSbVg90H21EOLACvtfcHk0ljaEGXQOwsLXA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFKks70%253D&md5=9dc3e8f13c683d997e62aac79f854f09</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.01.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.01.024%26sid%3Dliteratum%253Aachs%26aulast%3DJain%26aufirst%3DP.%2BG.%26aulast%3DPatel%26aufirst%3DB.%2BD.%26atitle%3DMedicinal%2520chemistry%2520approaches%2520of%2520poly%2520ADP-Ribose%2520polymerase%25201%2520%2528PARP1%2529%2520inhibitors%2520as%2520anticancer%2520agents%2520-%2520A%2520recent%2520update%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D165%26spage%3D198%26epage%3D215%26doi%3D10.1016%2Fj.ejmech.2019.01.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gurley, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemp, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic lethality between mutation in Atm and DNA-PK(cs) during murine embryogenesis</span>. <i>Curr. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">191</span>â <span class="NLM_lpage">194</span>, <span class="refDoi">Â DOI: 10.1016/S0960-9822(01)00048-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2FS0960-9822%2801%2900048-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=11231155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhtlGlu7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=191-194&issue=3&author=K.+E.+Gurleyauthor=C.+J.+Kemp&title=Synthetic+lethality+between+mutation+in+Atm+and+DNA-PK%28cs%29+during+murine+embryogenesis&doi=10.1016%2FS0960-9822%2801%2900048-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic lethality between mutation in Atm and DNA-PKCS during murine embryogenesis</span></div><div class="casAuthors">Gurley, Kay E.; Kemp, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">191-194</span>CODEN:
                <span class="NLM_cas:coden">CUBLE2</span>;
        ISSN:<span class="NLM_cas:issn">0960-9822</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The gene product mutated in ataxia telangiectasia, ATM, is a ubiquitously expressed 370 kDa protein kinase that is a key mediator of the cellular response to DNA damage.  ATM-deficient cells are radiosensitive and show impaired cell cycle arrest and increased chromosome breaks in response to ionizing radiation.  ATM is a member of the phosphatidylinositol-3-kinase (PI3K)-related protein kinase superfamily, which includes the catalytic subunit of DNA-dependent protein kinase (DNA-PKCS) and ATR.  DNA-PK is a 470 kDa protein kinase that is required for proper end-to-end rejoining of DNA double-strand breaks.  Prkdcscid/scid mice have a homozygous mutation in the gene encoding DNA-PKCS and, like Atm-/- mice, are viable and radiosensitive.  To det. if Atm and DNA-PKCS show genetic interaction, we attempted to generate mice deficient in both gene products.  However, no scid/scid Atm-/- pups were recovered from scid/scid Atm+/- intercrosses.  Developmental arrest of scid/scid Atm-/- embryos occurred around E7.5, a developmental stage when embryonic cells are hypersensitive to DNA damage.  This reveals synthetic lethality between mutations in Atm and DNA-PK and suggests that Atm and DNA-PK have complementary functions that are essential for development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHC29RCUtc5LVg90H21EOLACvtfcHk0ljaEGXQOwsLXA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhtlGlu7c%253D&md5=3ae8c1de2e234105e7b127aa3ca96a31</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2FS0960-9822%2801%2900048-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-9822%252801%252900048-3%26sid%3Dliteratum%253Aachs%26aulast%3DGurley%26aufirst%3DK.%2BE.%26aulast%3DKemp%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520lethality%2520between%2520mutation%2520in%2520Atm%2520and%2520DNA-PK%2528cs%2529%2520during%2520murine%2520embryogenesis%26jtitle%3DCurr.%2520Biol.%26date%3D2001%26volume%3D11%26issue%3D3%26spage%3D191%26epage%3D194%26doi%3D10.1016%2FS0960-9822%2801%2900048-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kantidze, O. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velichko, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luzhin, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrova, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Razin, S. V.</span></span> <span> </span><span class="NLM_article-title">Synthetically lethal interactions of ATM, ATR, and DNA-PKcs</span>. <i>Trends Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">755</span>â <span class="NLM_lpage">768</span>, <span class="refDoi">Â DOI: 10.1016/j.trecan.2018.09.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.trecan.2018.09.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=30352678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1MXkvVChtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2018&pages=755-768&issue=11&author=O.+L.+Kantidzeauthor=A.+K.+Velichkoauthor=A.+V.+Luzhinauthor=N.+V.+Petrovaauthor=S.+V.+Razin&title=Synthetically+lethal+interactions+of+ATM%2C+ATR%2C+and+DNA-PKcs&doi=10.1016%2Fj.trecan.2018.09.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetically Lethal Interactions of ATM, ATR, and DNA-PKcs</span></div><div class="casAuthors">Kantidze, Omar L.; Velichko, Artem K.; Luzhin, Artem V.; Petrova, Nadezhda V.; Razin, Sergey V.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">755-768</span>CODEN:
                <span class="NLM_cas:coden">TCRAB5</span>;
        ISSN:<span class="NLM_cas:issn">2405-8033</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Synthetic lethality occurs when simultaneous perturbations of two genes or mol. processes result in a loss of cell viability.  The no. of known synthetically lethal interactions is growing steadily.  We review here synthetically lethal interactions of ataxia-telangiectasia mutated (ATM), ATM- and Rad3-related (ATR), and DNA-dependent protein kinase catalytic subunit (DNA-PKcs).  These kinases are appropriate for synthetic lethal therapies because their genes are frequently mutated in cancer, and specific inhibitors are currently in clin. trials.  Understanding synthetically lethal interactions of a particular gene or gene family can facilitate predicting new synthetically lethal interactions, therapy toxicity, and mechanisms of resistance, as well as defining the spectrum of tumors amenable to these therapeutic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2d1yDujzdrrVg90H21EOLACvtfcHk0ljaEGXQOwsLXA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXkvVChtg%253D%253D&md5=e3cb583663814cbe0a0e5803635cdef9</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.trecan.2018.09.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.trecan.2018.09.007%26sid%3Dliteratum%253Aachs%26aulast%3DKantidze%26aufirst%3DO.%2BL.%26aulast%3DVelichko%26aufirst%3DA.%2BK.%26aulast%3DLuzhin%26aufirst%3DA.%2BV.%26aulast%3DPetrova%26aufirst%3DN.%2BV.%26aulast%3DRazin%26aufirst%3DS.%2BV.%26atitle%3DSynthetically%2520lethal%2520interactions%2520of%2520ATM%252C%2520ATR%252C%2520and%2520DNA-PKcs%26jtitle%3DTrends%2520Cancer%26date%3D2018%26volume%3D4%26issue%3D11%26spage%3D755%26epage%3D768%26doi%3D10.1016%2Fj.trecan.2018.09.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Riabinska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daheim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herter-Sprie, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreuzer, K.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frenzel, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monfared, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins-Boucas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinhardt, H. C.</span></span> <span> </span><span class="NLM_article-title">Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">189</span>),  <span class="NLM_fpage">189ra78</span>â <span class="NLM_lpage">189ra78</span>, <span class="refDoi">Â DOI: 10.1126/scitranslmed.3005814</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1126%2Fscitranslmed.3005814" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=23761041" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=189ra78-189ra78&issue=189&author=A.+Riabinskaauthor=M.+Daheimauthor=G.+S.+Herter-Sprieauthor=J.+Winklerauthor=C.+Fritzauthor=M.+Hallekauthor=R.+K.+Thomasauthor=K.-A.+Kreuzerauthor=L.+P.+Frenzelauthor=P.+Monfaredauthor=J.+Martins-Boucasauthor=S.+Chenauthor=H.+C.+Reinhardt&title=Therapeutic+targeting+of+a+robust+non-oncogene+addiction+to+PRKDC+in+ATM-defective+tumors&doi=10.1126%2Fscitranslmed.3005814"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3005814&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3005814%26sid%3Dliteratum%253Aachs%26aulast%3DRiabinska%26aufirst%3DA.%26aulast%3DDaheim%26aufirst%3DM.%26aulast%3DHerter-Sprie%26aufirst%3DG.%2BS.%26aulast%3DWinkler%26aufirst%3DJ.%26aulast%3DFritz%26aufirst%3DC.%26aulast%3DHallek%26aufirst%3DM.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DKreuzer%26aufirst%3DK.-A.%26aulast%3DFrenzel%26aufirst%3DL.%2BP.%26aulast%3DMonfared%26aufirst%3DP.%26aulast%3DMartins-Boucas%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DReinhardt%26aufirst%3DH.%2BC.%26atitle%3DTherapeutic%2520targeting%2520of%2520a%2520robust%2520non-oncogene%2520addiction%2520to%2520PRKDC%2520in%2520ATM-defective%2520tumors%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2013%26volume%3D5%26issue%3D189%26spage%3D189ra78%26epage%3D189ra78%26doi%3D10.1126%2Fscitranslmed.3005814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dietlein, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thelen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jokic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jachimowicz, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knittel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeser, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Oers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edelmann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heukamp, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinhardt, H. C.</span></span> <span> </span><span class="NLM_article-title">A functional cancer genomics screen identifies a druggable synthetic lethal interaction between MSH3 and PRKDC</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">592</span>â <span class="NLM_lpage">605</span>, <span class="refDoi">Â DOI: 10.1158/2159-8290.CD-13-0907</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F2159-8290.CD-13-0907" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=24556366" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2cXns1CmsLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=592-605&issue=5&author=F.+Dietleinauthor=L.+Thelenauthor=M.+Jokicauthor=R.+D.+Jachimowiczauthor=L.+Ivanauthor=G.+Knittelauthor=U.+Leeserauthor=J.+van+Oersauthor=W.+Edelmannauthor=L.+C.+Heukampauthor=H.+C.+Reinhardt&title=A+functional+cancer+genomics+screen+identifies+a+druggable+synthetic+lethal+interaction+between+MSH3+and+PRKDC&doi=10.1158%2F2159-8290.CD-13-0907"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">A Functional Cancer Genomics Screen Identifies a Druggable Synthetic Lethal Interaction between MSH3 and PRKDC</span></div><div class="casAuthors">Dietlein, Felix; Thelen, Lisa; Jokic, Mladen; Jachimowicz, Ron D.; Ivan, Laura; Knittel, Gero; Leeser, Uschi; van Oers, Johanna; Edelmann, Winfried; Heukamp, Lukas C.; Reinhardt, H. Christian</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">592-605</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Here, we use a large-scale cell line-based approach to identify cancer cell-specific mutations that are assocd. with DNA-dependent protein kinase catalytic subunit (DNA-PKcs) dependence.  For this purpose, we profiled the mutational landscape across 1,319 cancer- assocd. genes of 67 distinct cell lines and identified numerous genes involved in homologous recombination-mediated DNA repair, including BRCA1, BRCA2, ATM, PAXIP, and RAD50, as being assocd. with non-oncogene addiction to DNA-PKcs.  Mutations in the mismatch repair gene MSH3, which have been reported to occur recurrently in numerous human cancer entities, emerged as the most significant predictors of DNA-PKcs addiction.  Concordantly DNA-PKcs inhibition robustly induced apoptosis in MSH3- mutant cell lines in vitro and displayed remarkable single-agent efficacy against MSH3-mutant tumors in vivo.  Thus, we here identify a therapeutically actionable synthetic lethal interaction between MSH3 and the non-homologous end joining kinase DNA-PKcs.  Our observations recommend DNA-PKcs inhibition as a therapeutic concept for the treatment of human cancers displaying homologous recombination defects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG3K376nKgNbVg90H21EOLACvtfcHk0livN5VBKDTX5g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXns1CmsLo%253D&md5=23e812dd0b4cffc2e34eb44f5f9240ee</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0907%26sid%3Dliteratum%253Aachs%26aulast%3DDietlein%26aufirst%3DF.%26aulast%3DThelen%26aufirst%3DL.%26aulast%3DJokic%26aufirst%3DM.%26aulast%3DJachimowicz%26aufirst%3DR.%2BD.%26aulast%3DIvan%26aufirst%3DL.%26aulast%3DKnittel%26aufirst%3DG.%26aulast%3DLeeser%26aufirst%3DU.%26aulast%3Dvan%2BOers%26aufirst%3DJ.%26aulast%3DEdelmann%26aufirst%3DW.%26aulast%3DHeukamp%26aufirst%3DL.%2BC.%26aulast%3DReinhardt%26aufirst%3DH.%2BC.%26atitle%3DA%2520functional%2520cancer%2520genomics%2520screen%2520identifies%2520a%2520druggable%2520synthetic%2520lethal%2520interaction%2520between%2520MSH3%2520and%2520PRKDC%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26issue%3D5%26spage%3D592%26epage%3D605%26doi%3D10.1158%2F2159-8290.CD-13-0907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kass, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, W.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moynahan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhuri, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jasin, M.</span></span> <span> </span><span class="NLM_article-title">ATM loss leads to synthetic lethality in BRCA1 BRCT mutant mice associated with exacerbated defects in homology-directed repair</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>114</i></span> (<span class="NLM_issue">29</span>),  <span class="NLM_fpage">7665</span>â <span class="NLM_lpage">7670</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1706392114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1073%2Fpnas.1706392114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=28659469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVyntr%252FJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=7665-7670&issue=29&author=C.-C.+Chenauthor=E.+M.+Kassauthor=W.-F.+Yenauthor=T.+Ludwigauthor=M.+E.+Moynahanauthor=J.+Chaudhuriauthor=M.+Jasin&title=ATM+loss+leads+to+synthetic+lethality+in+BRCA1+BRCT+mutant+mice+associated+with+exacerbated+defects+in+homology-directed+repair&doi=10.1073%2Fpnas.1706392114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">ATM loss leads to synthetic lethality in BRCA1 BRCT mutant mice associated with exacerbated defects in homology-directed repair</span></div><div class="casAuthors">Chen, Chun-Chin; Kass, Elizabeth M.; Yen, Wei-Feng; Ludwig, Thomas; Moynahan, Mary Ellen; Chaudhuri, Jayanta; Jasin, Maria</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">7665-7670</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">BRCA1 is essential for homol.-directed repair (HDR) of DNA double-strand breaks in part through antagonism of the nonhomologous end-joining factor 53BP1.  The ATM kinase is involved in various aspects of DNA damage signaling and repair, but how ATM participates in HDR and genetically interacts with BRCA1 in this process is unclear.  To investigate this question, we used the Brca1S1598F mouse model carrying a mutation in the BRCA1 C-terminal domain of BRCA1.  Whereas ATM loss leads to a mild HDR defect in adult somatic cells, we find that ATM inhibition leads to severely reduced HDR in Brca1S1598F cells.  Consistent with a crit. role for ATM in HDR in this background, loss of ATM leads to synthetic lethality of Brca1S1598F mice.  Whereas both ATM and BRCA1 promote end resection, which can be regulated by 53BP1, 53bp1 deletion does not rescue the HDR defects of Atm mutant cells, in contrast to Brca1 mutant cells.  These results demonstrate that ATM has a role in HDR independent of the BRCA1-53BP1 antagonism and that its HDR function can become crit. in certain contexts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTtLVgk7hSzbVg90H21EOLACvtfcHk0livN5VBKDTX5g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVyntr%252FJ&md5=b08d8d34e80b5107b080b38e315ace37</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1706392114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1706392114%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.-C.%26aulast%3DKass%26aufirst%3DE.%2BM.%26aulast%3DYen%26aufirst%3DW.-F.%26aulast%3DLudwig%26aufirst%3DT.%26aulast%3DMoynahan%26aufirst%3DM.%2BE.%26aulast%3DChaudhuri%26aufirst%3DJ.%26aulast%3DJasin%26aufirst%3DM.%26atitle%3DATM%2520loss%2520leads%2520to%2520synthetic%2520lethality%2520in%2520BRCA1%2520BRCT%2520mutant%2520mice%2520associated%2520with%2520exacerbated%2520defects%2520in%2520homology-directed%2520repair%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2017%26volume%3D114%26issue%3D29%26spage%3D7665%26epage%3D7670%26doi%3D10.1073%2Fpnas.1706392114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Albarakati, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Fatah, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moseley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arora, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alsubhi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seedhouse, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rakha, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, I. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madhusudan, S.</span></span> <span> </span><span class="NLM_article-title">Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">204</span>â <span class="NLM_lpage">217</span>, <span class="refDoi">Â DOI: 10.1016/j.molonc.2014.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.molonc.2014.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=25205036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsV2ltLvK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=204-217&issue=1&author=N.+Albarakatiauthor=T.+M.+Abdel-Fatahauthor=R.+Dohertyauthor=R.+Russellauthor=D.+Agarwalauthor=P.+Moseleyauthor=C.+Perryauthor=A.+Aroraauthor=N.+Alsubhiauthor=C.+Seedhouseauthor=E.+A.+Rakhaauthor=A.+Greenauthor=G.+Ballauthor=S.+Chanauthor=C.+Caldasauthor=I.+O.+Ellisauthor=S.+Madhusudan&title=Targeting+BRCA1-BER+deficient+breast+cancer+by+ATM+or+DNA-PKcs+blockade+either+alone+or+in+combination+with+cisplatin+for+personalized+therapy&doi=10.1016%2Fj.molonc.2014.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy</span></div><div class="casAuthors">Albarakati, Nada; Abdel-Fatah, Tarek M. A.; Doherty, Rachel; Russell, Roslin; Agarwal, Devika; Moseley, Paul; Perry, Christina; Arora, Arvind; Alsubhi, Nouf; Seedhouse, Claire; Rakha, Emad A.; Green, Andrew; Ball, Graham; Chan, Stephen; Caldas, Carlos; Ellis, Ian O.; Madhusudan, Srinivasan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">204-217</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">BRCA1, a key factor in homologous recombination (HR) repair may also regulate base excision repair (BER).  Targeting BRCA1-BER deficient cells by blockade of ATM and DNA-PKcs could be a promising strategy in breast cancer.  We investigated BRCA1, XRCC1 and pol Î² protein expression in two cohorts (n = 1602 sporadic and n = 50 germ-line BRCA1 mutated) and mRNA expression in two cohorts (n = 1952 and n = 249).  Artificial neural network anal. for BRCA1-DNA repair interacting genes was conducted in 249 tumors.  Pre-clin., BRCA1 proficient and deficient cells were DNA repair expression profiled and evaluated for synthetic lethality using ATM and DNA-PKcs inhibitors either alone or in combination with cisplatin.  In human tumors, BRCA1 negativity was strongly assocd. with low XRCC1, and low pol Î² at mRNA and protein levels (p < 0.0001).  In patients with BRCA1 neg. tumors, low XRCC1 or low pol Î² expression was significantly assocd. with poor survival in univariate and multivariate anal. compared to high XRCC1 or high pol Î² expressing BRCA1 neg. tumors (ps < 0.05).  Pre-clin., BRCA1 neg. cancer cells exhibit low mRNA and low protein expression of XRCC1 and pol Î².  BRCA1-BER deficient cells were sensitive to ATM and DNA-PKcs inhibitor treatment either alone or in combination with cisplatin and synthetic lethality was evidenced by DNA double strand breaks accumulation, cell cycle arrest and apoptosis.  We conclude that XRCC1 and pol Î² expression status in BRCA1 neg. tumors may have prognostic significance.  BRCA1-BER deficient cells could be targeted by ATM or DNA-PKcs inhibitors for personalized therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVHI4vF_PsFbVg90H21EOLACvtfcHk0liplC66UFPlig"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsV2ltLvK&md5=b90b757fa55f5ed5c3d33e37c499d687</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2014.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2014.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DAlbarakati%26aufirst%3DN.%26aulast%3DAbdel-Fatah%26aufirst%3DT.%2BM.%26aulast%3DDoherty%26aufirst%3DR.%26aulast%3DRussell%26aufirst%3DR.%26aulast%3DAgarwal%26aufirst%3DD.%26aulast%3DMoseley%26aufirst%3DP.%26aulast%3DPerry%26aufirst%3DC.%26aulast%3DArora%26aufirst%3DA.%26aulast%3DAlsubhi%26aufirst%3DN.%26aulast%3DSeedhouse%26aufirst%3DC.%26aulast%3DRakha%26aufirst%3DE.%2BA.%26aulast%3DGreen%26aufirst%3DA.%26aulast%3DBall%26aufirst%3DG.%26aulast%3DChan%26aufirst%3DS.%26aulast%3DCaldas%26aufirst%3DC.%26aulast%3DEllis%26aufirst%3DI.%2BO.%26aulast%3DMadhusudan%26aufirst%3DS.%26atitle%3DTargeting%2520BRCA1-BER%2520deficient%2520breast%2520cancer%2520by%2520ATM%2520or%2520DNA-PKcs%2520blockade%2520either%2520alone%2520or%2520in%2520combination%2520with%2520cisplatin%2520for%2520personalized%2520therapy%26jtitle%3DMol.%2520Oncol.%26date%3D2015%26volume%3D9%26issue%3D1%26spage%3D204%26epage%3D217%26doi%3D10.1016%2Fj.molonc.2014.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forment, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradshaw, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Britton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oelschlaegel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xhemalce, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, S. P.</span></span> <span> </span><span class="NLM_article-title">Small-moleculeâinduced DNA damage identifies alternative DNA structures in human genes</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">301</span>â <span class="NLM_lpage">310</span>, <span class="refDoi">Â DOI: 10.1038/nchembio.780</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1038%2Fnchembio.780" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=22306580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslGkur0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=301-310&issue=3&author=R.+Rodriguezauthor=K.+M.+Millerauthor=J.+V.+Formentauthor=C.+R.+Bradshawauthor=M.+Nikanauthor=S.+Brittonauthor=T.+Oelschlaegelauthor=B.+Xhemalceauthor=S.+Balasubramanianauthor=S.+P.+Jackson&title=Small-molecule%E2%80%93induced+DNA+damage+identifies+alternative+DNA+structures+in+human+genes&doi=10.1038%2Fnchembio.780"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule-induced DNA damage identifies alternative DNA structures in human genes</span></div><div class="casAuthors">Rodriguez, Raphael; Miller, Kyle M.; Forment, Josep V.; Bradshaw, Charles R.; Nikan, Mehran; Britton, Sebastien; Oelschlaegel, Tobias; Xhemalce, Blerta; Balasubramanian, Shankar; Jackson, Stephen P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">301-310</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Guanine-rich DNA sequences that can adopt non-Watson-Crick structures in vitro are prevalent in the human genome.  Whether such structures normally exist in mammalian cells has, however, been the subject of active research for decades.  Here we show that the G-quadruplex-interacting drug pyridostatin promotes growth arrest in human cancer cells by inducing replication- and transcription-dependent DNA damage.  A chromatin immunopptn. sequencing anal. of the DNA damage marker Î³H2AX provided the genome-wide distribution of pyridostatin-induced sites of damage and revealed that pyridostatin targets gene bodies contg. clusters of sequences with a propensity for G-quadruplex formation.  As a result, pyridostatin modulated the expression of these genes, including the proto-oncogene SRC.  We obsd. that pyridostatin reduced SRC protein abundance and SRC-dependent cellular motility in human breast cancer cells, validating SRC as a target of this drug.  Our unbiased approach to define genomic sites of action for a drug establishes a framework for discovering functional DNA-drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1Ffpu4Hgf7rVg90H21EOLACvtfcHk0liplC66UFPlig"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslGkur0%253D&md5=60f699970eead8cabd7b3a7a260714e7</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.780%26sid%3Dliteratum%253Aachs%26aulast%3DRodriguez%26aufirst%3DR.%26aulast%3DMiller%26aufirst%3DK.%2BM.%26aulast%3DForment%26aufirst%3DJ.%2BV.%26aulast%3DBradshaw%26aufirst%3DC.%2BR.%26aulast%3DNikan%26aufirst%3DM.%26aulast%3DBritton%26aufirst%3DS.%26aulast%3DOelschlaegel%26aufirst%3DT.%26aulast%3DXhemalce%26aufirst%3DB.%26aulast%3DBalasubramanian%26aufirst%3DS.%26aulast%3DJackson%26aufirst%3DS.%2BP.%26atitle%3DSmall-molecule%25E2%2580%2593induced%2520DNA%2520damage%2520identifies%2520alternative%2520DNA%2520structures%2520in%2520human%2520genes%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2012%26volume%3D8%26issue%3D3%26spage%3D301%26epage%3D310%26doi%3D10.1038%2Fnchembio.780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fece de la Cruz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerzendorfer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uras, I. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mair, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazouzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suchankova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konopka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagy-Bojarszky, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muellner, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bago-Horvath, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haura, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loizou, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nijman, S. M. B.</span></span> <span> </span><span class="NLM_article-title">MEK inhibitors block growth of lung tumours with mutations in ataxiaâtelangiectasia mutated</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">13701</span>, <span class="refDoi">Â DOI: 10.1038/ncomms13701</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1038%2Fncomms13701" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=27922010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A280%3ADC%252BC2sjjvFamtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=13701&issue=1&author=M.+Smidaauthor=F.+Fece+de+la+Cruzauthor=C.+Kerzendorferauthor=I.+Z.+Urasauthor=B.+Mairauthor=A.+Mazouziauthor=T.+Suchankovaauthor=T.+Konopkaauthor=A.+M.+Katzauthor=K.+Pazauthor=K.+Nagy-Bojarszkyauthor=M.+K.+Muellnerauthor=Z.+Bago-Horvathauthor=E.+B.+Hauraauthor=J.+I.+Loizouauthor=S.+M.+B.+Nijman&title=MEK+inhibitors+block+growth+of+lung+tumours+with+mutations+in+ataxia%E2%80%93telangiectasia+mutated&doi=10.1038%2Fncomms13701"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">MEK inhibitors block growth of lung tumours with mutations in ataxia-telangiectasia mutated</span></div><div class="casAuthors">Smida Michal; Fece de la Cruz Ferran; Kerzendorfer Claudia; Uras Iris Z; Mair Barbara; Mazouzi Abdelghani; Konopka Tomasz; Nagy-Bojarszky Katalin; Muellner Markus K; Loizou Joanna I; Nijman Sebastian M B; Smida Michal; Fece de la Cruz Ferran; Mair Barbara; Konopka Tomasz; Nijman Sebastian M B; Fece de la Cruz Ferran; Mair Barbara; Konopka Tomasz; Nijman Sebastian M B; Suchankova Tereza; Katz Amanda M; Paz Keren; Bago-Horvath Zsuzsanna; Bago-Horvath Zsuzsanna; Haura Eric B</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13701</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Lung cancer is the leading cause of cancer deaths, and effective treatments are urgently needed.  Loss-of-function mutations in the DNA damage response kinase ATM are common in lung adenocarcinoma but directly targeting these with drugs remains challenging.  Here we report that ATM loss-of-function is synthetic lethal with drugs inhibiting the central growth factor kinases MEK1/2, including the FDA-approved drug trametinib.  Lung cancer cells resistant to MEK inhibition become highly sensitive upon loss of ATM both in vitro and in vivo.  Mechanistically, ATM mediates crosstalk between the prosurvival MEK/ERK and AKT/mTOR pathways.  ATM loss also enhances the sensitivity of KRAS- or BRAF-mutant lung cancer cells to MEK inhibition.  Thus, ATM mutational status in lung cancer is a mechanistic biomarker for MEK inhibitor response, which may improve patient stratification and extend the applicability of these drugs beyond RAS and BRAF mutant tumours.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQGDRm0tliSqJp6t8nS6Nc3fW6udTcc2ebLcFvgaKBhibntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjjvFamtg%253D%253D&md5=cd33cd5d498c816e0a8661194401c759</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fncomms13701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms13701%26sid%3Dliteratum%253Aachs%26aulast%3DSmida%26aufirst%3DM.%26aulast%3DFece%2Bde%2Bla%2BCruz%26aufirst%3DF.%26aulast%3DKerzendorfer%26aufirst%3DC.%26aulast%3DUras%26aufirst%3DI.%2BZ.%26aulast%3DMair%26aufirst%3DB.%26aulast%3DMazouzi%26aufirst%3DA.%26aulast%3DSuchankova%26aufirst%3DT.%26aulast%3DKonopka%26aufirst%3DT.%26aulast%3DKatz%26aufirst%3DA.%2BM.%26aulast%3DPaz%26aufirst%3DK.%26aulast%3DNagy-Bojarszky%26aufirst%3DK.%26aulast%3DMuellner%26aufirst%3DM.%2BK.%26aulast%3DBago-Horvath%26aufirst%3DZ.%26aulast%3DHaura%26aufirst%3DE.%2BB.%26aulast%3DLoizou%26aufirst%3DJ.%2BI.%26aulast%3DNijman%26aufirst%3DS.%2BM.%2BB.%26atitle%3DMEK%2520inhibitors%2520block%2520growth%2520of%2520lung%2520tumours%2520with%2520mutations%2520in%2520ataxia%25E2%2580%2593telangiectasia%2520mutated%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26issue%3D1%26spage%3D13701%26doi%3D10.1038%2Fncomms13701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, H.</span></span> <span> </span><span class="NLM_article-title">Current development status of MEK inhibitors</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1551</span>, <span class="refDoi">Â DOI: 10.3390/molecules22101551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.3390%2Fmolecules22101551" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Wjsrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=1551&issue=10&author=Y.+Chengauthor=H.+Tian&title=Current+development+status+of+MEK+inhibitors&doi=10.3390%2Fmolecules22101551"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Current development status of MEK inhibitors</span></div><div class="casAuthors">Cheng, Ying; Tian, Hongqi</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1551/1-1551/20</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The current development status of mitogen-activated protein kinase kinase (MEK) inhibitors, including the preclin. data and clin. study progress, has been summarized in this review.  Different MEK inhibitors, possessing specific physicochem. properties and bioactivity characteristics, may provide different options for patients seeking treatment for cancer.  Moreover, the combination of the MEK inhibitors with other therapies-such as chemotherapy, targeted therapy, and immunotherapy-may be a promising approach for clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosd6s1Lx6dYbVg90H21EOLACvtfcHk0ljUJQ9Qvz_7WA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Wjsrk%253D&md5=0210d125f8a46468d67adb4f9aaf6cf3</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.3390%2Fmolecules22101551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules22101551%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DTian%26aufirst%3DH.%26atitle%3DCurrent%2520development%2520status%2520of%2520MEK%2520inhibitors%26jtitle%3DMolecules%26date%3D2017%26volume%3D22%26issue%3D10%26spage%3D1551%26doi%3D10.3390%2Fmolecules22101551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knudsen, K. E.</span></span> <span> </span><span class="NLM_article-title">Beyond DNA repair: DNA-PK function in cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1126</span>â <span class="NLM_lpage">1139</span>, <span class="refDoi">Â DOI: 10.1158/2159-8290.CD-14-0358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F2159-8290.CD-14-0358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=25168287" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs12nsr%252FK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=1126-1139&issue=10&author=J.+F.+Goodwinauthor=K.+E.+Knudsen&title=Beyond+DNA+repair%3A+DNA-PK+function+in+cancer&doi=10.1158%2F2159-8290.CD-14-0358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Beyond DNA repair: DNA-PK function in cancer</span></div><div class="casAuthors">Goodwin, Jonathan F.; Knudsen, Karen E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1126-1139</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The DNA-dependent protein kinase (DNA-PK) is a pivotal component of the DNA repair machinery that governs the response to DNA damage, serving to maintain genome integrity.  However, the DNA-PK kinase component was initially isolated with transcriptional complexes, and recent findings have illuminated the impact of DNA-PK-mediated transcriptional regulation on tumor progression and therapeutic response.  DNA-PK expression has also been correlated with poor outcome in selected tumor types, further underscoring the importance of understanding its role in disease.  Herein, the mol. and cellular consequences of DNA-PK are considered, with an eye toward discerning the rationale for therapeutic targeting of DNA-PK.  Significance: Although DNA-PK is classically considered a component of damage response, recent findings illuminate damage-independent functions of DNA-PK that affect multiple tumor-assocd. pathways and provide a rationale for the development of novel therapeutic strategies.  Cancer Discov; 4(10); 1126-39. Â©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnEmo761qFmbVg90H21EOLACvtfcHk0ljUJQ9Qvz_7WA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs12nsr%252FK&md5=f81d22f39aa77736c1ba8ce08de0d628</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0358%26sid%3Dliteratum%253Aachs%26aulast%3DGoodwin%26aufirst%3DJ.%2BF.%26aulast%3DKnudsen%26aufirst%3DK.%2BE.%26atitle%3DBeyond%2520DNA%2520repair%253A%2520DNA-PK%2520function%2520in%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26issue%3D10%26spage%3D1126%26epage%3D1139%26doi%3D10.1158%2F2159-8290.CD-14-0358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohiuddin, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, M. H.</span></span> <span> </span><span class="NLM_article-title">DNA-PK as an emerging therapeutic target in Cancer</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">635</span>, <span class="refDoi">Â DOI: 10.3389/fonc.2019.00635</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.3389%2Ffonc.2019.00635" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=31380275" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A280%3ADC%252BB3MvkslKmtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=635&author=I.+S.+Mohiuddinauthor=M.+H.+Kang&title=DNA-PK+as+an+emerging+therapeutic+target+in+Cancer&doi=10.3389%2Ffonc.2019.00635"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">DNA-PK as an Emerging Therapeutic Target in Cancer</span></div><div class="casAuthors">Mohiuddin Ismail S; Kang Min H</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">635</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">The DNA-dependent protein kinase (DNA-PK) plays an instrumental role in the overall survival and proliferation of cells.  As a member of the phosphatidylinositol 3-kinase-related kinase (PIKK) family, DNA-PK is best known as a mediator of the cellular response to DNA damage.  In this context, DNA-PK has emerged as an intriguing therapeutic target in the treatment of a variety of cancers, especially when used in conjunction with genotoxic chemotherapy or ionizing radiation.  Beyond the DNA damage response, DNA-PK activity is necessary for multiple cellular functions, including the regulation of transcription, progression of the cell cycle, and in the maintenance of telomeres.  Here, we review what is currently known about DNA-PK regarding its structure and established roles in DNA repair.  We also discuss its lesser-known functions, the pharmacotherapies inhibiting its function in DNA repair, and its potential as a therapeutic target in a broader context.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQGccaQRmYaT-xsqfvU0ziafW6udTcc2eYMbfIBBzJ4mbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MvkslKmtw%253D%253D&md5=19c10c1fa9599f9f2bff50f9a57333ac</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2019.00635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2019.00635%26sid%3Dliteratum%253Aachs%26aulast%3DMohiuddin%26aufirst%3DI.%2BS.%26aulast%3DKang%26aufirst%3DM.%2BH.%26atitle%3DDNA-PK%2520as%2520an%2520emerging%2520therapeutic%2520target%2520in%2520Cancer%26jtitle%3DFront.%2520Oncol.%26date%3D2019%26volume%3D9%26spage%3D635%26doi%3D10.3389%2Ffonc.2019.00635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kotula, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berthault, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agrario, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lienafa, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dingli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loew, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibut, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saule, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutreix, M.</span></span> <span> </span><span class="NLM_article-title">DNA-PKcs plays role in cancer metastasis through regulation of secreted proteins involved in migration and invasion</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1961</span>â <span class="NLM_lpage">1972</span>, <span class="refDoi">Â DOI: 10.1080/15384101.2015.1026522</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1080%2F15384101.2015.1026522" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=26017556" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVKrsLvK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=1961-1972&issue=12&author=E.+Kotulaauthor=N.+Berthaultauthor=C.+Agrarioauthor=M.+C.+Lienafaauthor=A.+Simonauthor=F.+Dingliauthor=D.+Loewauthor=V.+Sibutauthor=S.+Sauleauthor=M.+Dutreix&title=DNA-PKcs+plays+role+in+cancer+metastasis+through+regulation+of+secreted+proteins+involved+in+migration+and+invasion&doi=10.1080%2F15384101.2015.1026522"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">DNA-PKcs plays role in cancer metastasis through regulation of secreted proteins involved in migration and invasion</span></div><div class="casAuthors">Kotula, Ewa; Berthault, Nathalie; Agrario, Celine; Lienafa, Marie-Christine; Simon, Anthony; Dingli, Florent; Loew, Damarys; Sibut, Vonick; Saule, Simon; Dutreix, Marie</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1961-1972</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1551-4005</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The DNA-dependent protein kinase catalytic subunit (DNA-PKcs) plays a major role in DNA damage signaling and repair and is also frequently overexpressed in tumor metastasis.  We used isogenic cell lines expressing different levels of DNA-PKcs to investigate the role of DNA-PKcs in metastatic development.  We found that DNA-PKcs participates in melanoma primary tumor and metastasis development by stimulating angiogenesis, migration and invasion.  Comparison of conditioned medium content from DNA-PKcs-proficient and deficient cells reveals that DNA-PKcs controls secretion of at least 103 proteins (including 44 metastasis-assocd. with FBLN1, SERPINA3, MMP-8, HSPG2 and the inhibitors of matrix metalloproteinases, such as Î±-2M and TIMP-2).  High throughput anal. of secretomes, proteomes and transcriptomes, indicate that DNA-PKcs regulates the secretion of 85 proteins without affecting their gene expression.  Our data demonstrate that DNA-PKcs has a pro-metastatic activity via the modification of the tumor microenvironment.  This study shows for the first time a direct link between DNA damage repair and cancer metastasis and highlights the importance of DNA-PKcs as a potential target for anti-metastatic treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp67ON-80rNR7Vg90H21EOLACvtfcHk0lhO38v7ZhOKSg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVKrsLvK&md5=91a70bb4f33389f7d8313be5841f3d4a</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1080%2F15384101.2015.1026522&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15384101.2015.1026522%26sid%3Dliteratum%253Aachs%26aulast%3DKotula%26aufirst%3DE.%26aulast%3DBerthault%26aufirst%3DN.%26aulast%3DAgrario%26aufirst%3DC.%26aulast%3DLienafa%26aufirst%3DM.%2BC.%26aulast%3DSimon%26aufirst%3DA.%26aulast%3DDingli%26aufirst%3DF.%26aulast%3DLoew%26aufirst%3DD.%26aulast%3DSibut%26aufirst%3DV.%26aulast%3DSaule%26aufirst%3DS.%26aulast%3DDutreix%26aufirst%3DM.%26atitle%3DDNA-PKcs%2520plays%2520role%2520in%2520cancer%2520metastasis%2520through%2520regulation%2520of%2520secreted%2520proteins%2520involved%2520in%2520migration%2520and%2520invasion%26jtitle%3DCell%2520Cycle%26date%3D2015%26volume%3D14%26issue%3D12%26spage%3D1961%26epage%3D1972%26doi%3D10.1080%2F15384101.2015.1026522" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cornell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munck, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alsinet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villanueva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogle, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willoughby, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Televantou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burt, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manas, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtin, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reeves, H. L.</span></span> <span> </span><span class="NLM_article-title">DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">925</span>â <span class="NLM_lpage">933</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-14-0842</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F1078-0432.CCR-14-0842" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=25480831" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2MXislGgtr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=925-933&issue=4&author=L.+Cornellauthor=J.+M.+Munckauthor=C.+Alsinetauthor=A.+Villanuevaauthor=L.+Ogleauthor=C.+E.+Willoughbyauthor=D.+Televantouauthor=H.+D.+Thomasauthor=J.+Jacksonauthor=A.+D.+Burtauthor=D.+Newellauthor=J.+Roseauthor=D.+M.+Manasauthor=G.+I.+Shapiroauthor=N.+J.+Curtinauthor=H.+L.+Reeves&title=DNA-PK-A+candidate+driver+of+hepatocarcinogenesis+and+tissue+biomarker+that+predicts+response+to+treatment+and+survival&doi=10.1158%2F1078-0432.CCR-14-0842"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">DNA-PK-A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival</span></div><div class="casAuthors">Cornell, Liam; Munck, Joanne M.; Alsinet, Clara; Villanueva, Augusto; Ogle, Laura; Willoughby, Catherine E.; Televantou, Despina; Thomas, Huw D.; Jackson, Jennifer; Burt, Alastair D.; Newell, David; Rose, John; Manas, Derek M.; Shapiro, Geoffrey I.; Curtin, Nicola J.; Reeves, Helen L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">925-933</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Therapy resistance and assocd. liver disease make hepatocellular carcinomas (HCC) difficult to treat with traditional cytotoxic therapies, whereas newer targeted approaches offer only modest survival benefit.  We focused on DNA-dependent protein kinase, DNA-PKcs, encoded by PRKDC and central to DNA damage repair by nonhomologous end joining.  Our aim was to explore its roles in hepatocarcinogenesis and as a novel therapeutic candidate.  Exptl. Design: PRKDC was characterized in liver tissues from of 132 patients [normal liver (n = 10), cirrhotic liver (n = 13), dysplastic nodules (n = 18), HCC (n = 91)] using Affymetrix U133 Plus 2.0 and 500 K Human Mapping SNP arrays (cohort 1).  In addn., we studied a case series of 45 patients with HCC undergoing diagnostic biopsy (cohort 2).  Histol. grading, response to treatment, and survival were correlated with DNA-PKcs quantified immunohistochem.  Parallel in vitro studies detd. the impact of DNA-PK on DNA repair and response to cytotoxic therapy.  Results: Increased PRKDC expression in HCC was assocd. with amplification of its genetic locus in cohort 1.  In cohort 2, elevated DNA-PKcs identified patients with treatment-resistant HCC, progressing at a median of 4.5 mo compared with 16.9 mo, whereas elevation of activated pDNA-PK independently predicted poorer survival.  DNA-PKcs was high in HCC cell lines, where its inhibition with NU7441 potentiated irradn. and doxorubicin-induced cytotoxicity, whereas the combination suppressed HCC growth in vitro and in vivo.  Conclusions: These data identify PRKDC/DNA-PKcs as a candidate driver of hepatocarcinogenesis, whose biopsy characterization at diagnosis may impact stratification of current therapies, and whose specific future targeting may overcome resistance.  Clin Cancer Res; 21(4); 925-33. Â©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiEWlFXh8lgrVg90H21EOLACvtfcHk0lhO38v7ZhOKSg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXislGgtr4%253D&md5=0b6ebd7d32c4a95a78f8fb376a66eb0c</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-0842&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-0842%26sid%3Dliteratum%253Aachs%26aulast%3DCornell%26aufirst%3DL.%26aulast%3DMunck%26aufirst%3DJ.%2BM.%26aulast%3DAlsinet%26aufirst%3DC.%26aulast%3DVillanueva%26aufirst%3DA.%26aulast%3DOgle%26aufirst%3DL.%26aulast%3DWilloughby%26aufirst%3DC.%2BE.%26aulast%3DTelevantou%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DH.%2BD.%26aulast%3DJackson%26aufirst%3DJ.%26aulast%3DBurt%26aufirst%3DA.%2BD.%26aulast%3DNewell%26aufirst%3DD.%26aulast%3DRose%26aufirst%3DJ.%26aulast%3DManas%26aufirst%3DD.%2BM.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DReeves%26aufirst%3DH.%2BL.%26atitle%3DDNA-PK-A%2520candidate%2520driver%2520of%2520hepatocarcinogenesis%2520and%2520tissue%2520biomarker%2520that%2520predicts%2520response%2520to%2520treatment%2520and%2520survival%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26issue%3D4%26spage%3D925%26epage%3D933%26doi%3D10.1158%2F1078-0432.CCR-14-0842" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herrero, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Miguel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez, N. C.</span></span> <span> </span><span class="NLM_article-title">Deregulation of DNA double-strand break repair in multiple myeloma: implications for genome stability</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">3</span>), <span class="NLM_elocation-id">e0121581</span> <span class="refDoi">Â DOI: 10.1371/journal.pone.0121581</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1371%2Fjournal.pone.0121581" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=25790254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslWqur7F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&issue=3&author=A.+B.+Herreroauthor=J.+San+Miguelauthor=N.+C.+Gutierrez&title=Deregulation+of+DNA+double-strand+break+repair+in+multiple+myeloma%3A+implications+for+genome+stability&doi=10.1371%2Fjournal.pone.0121581"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Deregulation of DNA double-strand break repair in multiple myeloma: implications for genome stability</span></div><div class="casAuthors">Herrero, Ana B.; San Miguel, Jesus; Gutierrez, Norma C.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e0121581/1-e0121581/21</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Multiple myeloma (MM) is a hematol. malignancy characterized by frequent chromosome abnormalities.  However, the mol. basis for this genome instability remains unknown.  Since both impaired and hyperactive double strand break (DSB) repair pathways can result in DNA rearrangements, we investigated the functionality of DSB repair in MM cells.  Repair kinetics of ionizing-radiation (IR)-induced DSBs was similar in MM and normal control lymphoblastoid cell lines, as revealed by the comet assay.  However, four out of seven MM cell lines analyzed exhibited a subset of persistent DSBs, marked by Î³-H2AX and Rad51 foci that elicited a prolonged G2/M DNA damage checkpoint activation and hypersensitivity to IR, esp. in the presence of checkpoint inhibitors.  An anal. of the proteins involved in DSB repair in MM cells revealed upregulation of DNA-PKcs, Artemis and XRCC4, that participate in non-homologous end joining (NHEJ), and Rad51, involved in homologous recombination (HR).  Accordingly, activity of both NHEJ and HR were elevated in MM cells compared to controls, as detd. by in vivo functional assays.  Interestingly, levels of proteins involved in a highly mutagenic, translocation-promoting, alternative NHEJ subpathway (Alt-NHEJ) were also increased in all MM cell lines, with the Alt-NHEJ protein DNA ligase IIIÎ±, also overexpressed in several plasma cell samples isolated from MM patients.  Overactivation of the Alt-NHEJ pathway was revealed in MM cells by larger deletions and higher sequence microhomol. at repair junctions, which were reduced by chem. inhibition of the pathway.  Taken together, our results uncover a deregulated DSB repair in MM that might underlie the characteristic genome instability of the disease, and could be therapeutically exploited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKGe6l280YnLVg90H21EOLACvtfcHk0liNlNTSuQNJcA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslWqur7F&md5=06fb91b2bcdd57a92d40da6c33855960</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0121581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0121581%26sid%3Dliteratum%253Aachs%26aulast%3DHerrero%26aufirst%3DA.%2BB.%26aulast%3DSan%2BMiguel%26aufirst%3DJ.%26aulast%3DGutierrez%26aufirst%3DN.%2BC.%26atitle%3DDeregulation%2520of%2520DNA%2520double-strand%2520break%2520repair%2520in%2520multiple%2520myeloma%253A%2520implications%2520for%2520genome%2520stability%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26issue%3D3%26doi%3D10.1371%2Fjournal.pone.0121581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ihara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashizawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shichijo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudo, T.</span></span> <span> </span><span class="NLM_article-title">Expression of the DNA-dependent protein kinase catalytic subunit is associated with the radiosensitivity of human thyroid cancer cell lines</span>. <i>J. Radiat. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">171</span>â <span class="NLM_lpage">177</span>, <span class="refDoi">Â DOI: 10.1093/jrr/rry097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1093%2Fjrr%2Frry097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=30476230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjslejtbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2019&pages=171-177&issue=2&author=M.+Iharaauthor=K.+Ashizawaauthor=K.+Shichijoauthor=T.+Kudo&title=Expression+of+the+DNA-dependent+protein+kinase+catalytic+subunit+is+associated+with+the+radiosensitivity+of+human+thyroid+cancer+cell+lines&doi=10.1093%2Fjrr%2Frry097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of the DNA-dependent protein kinase catalytic subunit is associated with the radiosensitivity of human thyroid cancer cell lines</span></div><div class="casAuthors">Ihara, Makoto; Ashizawa, Kiyoto; Shichijo, Kazuko; Kudo, Takashi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Radiation Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">171-177</span>CODEN:
                <span class="NLM_cas:coden">JRARAX</span>;
        ISSN:<span class="NLM_cas:issn">1349-9157</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The prognosis and treatment of thyroid cancer depends on the type and stage of the disease.  Radiosensitivity differs among cancer cells owing to their varying capacity for repair after irradn.  Radioactive iodine can be used to destroy thyroid cancer cells.  However, patient prognosis and improvement after irradn. varies.  Therefore, predictive measures are important for avoiding unnecessary exposure to radiation.  We describe a new method for predicting the effects of radiation in individual cases of thyroid cancer based on the DNA-dependent protein kinase (DNA-PK) activity level in cancer cells.  The radiation sensitivity, DNA-PK activity, and cellular levels of DNA-PK complex subunits in five human thyroid cancer cell lines were analyzed in vitro.  A pos. correlation was obsd. between the D10 value (radiation dose that led to 10% survival) of cells and DNA-PK activity.  This correlation was not obsd. after treatment with NU7441, a DNA-PK-specific inhibitor.  A significant correlation was also obsd. between DNA-PK activity and expression levels of the DNA-PK catalytic subunit (DNA-PKcs).  Cells expressing low DNA-PKcs levels were radiation-sensitive, and cells expressing high DNA-PKcs levels were radiation-resistant.  Our results indicate that radiosensitivity depends on the expression level of DNA-PKcs in thyroid cancer cell lines.  Thus, the DNA-PKcs expression level is a potential predictive marker of the success of radiation therapy for thyroid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuxs3_P27SmLVg90H21EOLACvtfcHk0liNlNTSuQNJcA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjslejtbk%253D&md5=5689f6a281746197a2fa87dcfe682ff6</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1093%2Fjrr%2Frry097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjrr%252Frry097%26sid%3Dliteratum%253Aachs%26aulast%3DIhara%26aufirst%3DM.%26aulast%3DAshizawa%26aufirst%3DK.%26aulast%3DShichijo%26aufirst%3DK.%26aulast%3DKudo%26aufirst%3DT.%26atitle%3DExpression%2520of%2520the%2520DNA-dependent%2520protein%2520kinase%2520catalytic%2520subunit%2520is%2520associated%2520with%2520the%2520radiosensitivity%2520of%2520human%2520thyroid%2520cancer%2520cell%2520lines%26jtitle%3DJ.%2520Radiat.%2520Res.%26date%3D2019%26volume%3D60%26issue%3D2%26spage%3D171%26epage%3D177%26doi%3D10.1093%2Fjrr%2Frry097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shintani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mihara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakahara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hino, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakashiro, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamakawa, H.</span></span> <span> </span><span class="NLM_article-title">Up-regulation of DNA-dependent protein kinase correlates with radiation resistance in oral squamous cell carcinoma</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>94</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">894</span>â <span class="NLM_lpage">900</span>, <span class="refDoi">Â DOI: 10.1111/j.1349-7006.2003.tb01372.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1111%2Fj.1349-7006.2003.tb01372.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=14556663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpsFGhtLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2003&pages=894-900&issue=10&author=S.+Shintaniauthor=M.+Miharaauthor=C.+Liauthor=Y.+Nakaharaauthor=S.+Hinoauthor=K.+Nakashiroauthor=H.+Hamakawa&title=Up-regulation+of+DNA-dependent+protein+kinase+correlates+with+radiation+resistance+in+oral+squamous+cell+carcinoma&doi=10.1111%2Fj.1349-7006.2003.tb01372.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Up-regulation of DNA-dependent protein kinase correlates with radiation resistance in oral squamous cell carcinoma</span></div><div class="casAuthors">Shintani, Satoru; Mihara, Mariko; Li, Chunnan; Nakahara, Yuuji; Hino, Satoshi; Nakashiro, Koh-ichi; Hamakawa, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">894-900</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1347-9032</span>.
    
            (<span class="NLM_cas:orgname">Japanese Cancer Association</span>)
        </div><div class="casAbstract">DNA-PK is a nuclear protein with serine/threonine kinase activity and forms a complex consisting of the DNA-PKcs and a heterodimer of Ku70 and Ku80 proteins.  Recent lab. expts. have demonstrated that the DNA-PK complex formation is one of the major pathways by which mammalian cells respond to DNA double-strand breaks induced by ionizing radiation.  In this study, we evaluated the relationship between expression levels of DNA-PKcs, Ku70 and Ku80 proteins and radiation sensitivity in oral squamous cell carcinoma (OSCC) cell lines and in OSCC patients treated with preoperative radiation therapy.  The OSCC cell lines greatly differed in their response to irradn., as assessed by a std. colony formation assay.  However, the expression levels of the DNA-PK complex proteins were all similar, and there was no assocn. between the magnitude of their expression and the tumor radiation sensitivity.  Expression of DNA-PK complex proteins increased after radiation treatment, and the increased values correlated with the tumor radiation resistance.  Expression of DNA-PKcs and Ku70 after irradn. was increased in the surviving cells of OSCC tissues irradiated preoperatively.  These results suggest that up-regulation of DNA-PK complex protein, esp. DNA-PKcs, after radiation treatment correlates to radiation resistance.  DNA-PKcs might be a mol. target for a novel radiation sensitization therapy of OSCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmDwEDp57_f7Vg90H21EOLACvtfcHk0liNlNTSuQNJcA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpsFGhtLg%253D&md5=cbe71d8e2e925fc375eada7dea5cc73b</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2003.tb01372.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2003.tb01372.x%26sid%3Dliteratum%253Aachs%26aulast%3DShintani%26aufirst%3DS.%26aulast%3DMihara%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DNakahara%26aufirst%3DY.%26aulast%3DHino%26aufirst%3DS.%26aulast%3DNakashiro%26aufirst%3DK.%26aulast%3DHamakawa%26aufirst%3DH.%26atitle%3DUp-regulation%2520of%2520DNA-dependent%2520protein%2520kinase%2520correlates%2520with%2520radiation%2520resistance%2520in%2520oral%2520squamous%2520cell%2520carcinoma%26jtitle%3DCancer%2520Sci.%26date%3D2003%26volume%3D94%26issue%3D10%26spage%3D894%26epage%3D900%26doi%3D10.1111%2Fj.1349-7006.2003.tb01372.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beskow, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skikuniene, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holgersson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewensohn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanter, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viktorsson, K.</span></span> <span> </span><span class="NLM_article-title">Radioresistant cervical cancer shows upregulation of the NHEJ proteins DNA-PKcs, Ku70 and Ku86</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>101</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">816</span>â <span class="NLM_lpage">821</span>, <span class="refDoi">Â DOI: 10.1038/sj.bjc.6605201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1038%2Fsj.bjc.6605201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=19672258" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVGqu7fP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2009&pages=816-821&issue=5&author=C.+Beskowauthor=J.+Skikunieneauthor=A.+Holgerssonauthor=B.+Nilssonauthor=R.+Lewensohnauthor=L.+Kanterauthor=K.+Viktorsson&title=Radioresistant+cervical+cancer+shows+upregulation+of+the+NHEJ+proteins+DNA-PKcs%2C+Ku70+and+Ku86&doi=10.1038%2Fsj.bjc.6605201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Radioresistant cervical cancer shows upregulation of the NHEJ proteins DNA-PKcs, Ku70 and Ku86</span></div><div class="casAuthors">Beskow, C.; Skikuniene, J.; Holgersson, A.; Nilsson, B.; Lewensohn, R.; Kanter, L.; Viktorsson, K.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">816-821</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Radiotherapy is central in the treatment of cervical cancer.  The formation of DNA double-strand breaks is considered to be crit. for the radiotherapeutic effect.  The non-homologous end joining (NHEJ) proteins DNA-PKcs, Ku70 and Ku86 have a major role in repairing DNA lesions.  The objective of this study was to analyze if the expression of DNA-PKcs, Ku70 and Ku86 and their downstream signalling mols. p53, p21 and Mdm-2 are altered in residual cervical tumors after radiotherapy.  Retrospective anal. of 127 patients with cervical cancer stage IB-IIA treated with preoperative radiotherapy and radical surgery, revealed residual tumor in the cervical specimen in 30 patients.  In 22 cases tumor material from residual and corresponding primary tumor were retrieved and the expression of DNA-PKcs, Ku86, Ku70, p53, p21 and Mdm-2 were assessed by immunohistochem.  Residual tumors showed increased frequency of DNA-PKcs (P=0.037), Ku70 (P=0.018), Ku86 (P=0.008) pos. cells.  A correlation in DNA-PKcs expression between primary and residual tumors was found.  The frequency of p21-pos. cells was decreased (P=0.007) in residual tumors whereas no change in p53 or Mdm-2-pos. cells were obsd.  Our results show that cervical carcinoma surviving radiotherapy have an increased DNA-PK expression.  Studies on larger patient cohorts are needed to allow an interpretation that an upregulation of DNA-PK function may be part of a radioresistance mechanism within this tumor type.  British Journal of Cancer (2009) 101, 816-821; doi:10.1038/sj.bjc.6605201 www.bjcancer.com Published online 11 August 2009.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovtmpdncuOILVg90H21EOLACvtfcHk0ljlGx-qAWkIww"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVGqu7fP&md5=6ef1850be5628136461bb9ca1af7bb8f</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6605201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6605201%26sid%3Dliteratum%253Aachs%26aulast%3DBeskow%26aufirst%3DC.%26aulast%3DSkikuniene%26aufirst%3DJ.%26aulast%3DHolgersson%26aufirst%3DA.%26aulast%3DNilsson%26aufirst%3DB.%26aulast%3DLewensohn%26aufirst%3DR.%26aulast%3DKanter%26aufirst%3DL.%26aulast%3DViktorsson%26aufirst%3DK.%26atitle%3DRadioresistant%2520cervical%2520cancer%2520shows%2520upregulation%2520of%2520the%2520NHEJ%2520proteins%2520DNA-PKcs%252C%2520Ku70%2520and%2520Ku86%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2009%26volume%3D101%26issue%3D5%26spage%3D816%26epage%3D821%26doi%3D10.1038%2Fsj.bjc.6605201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saldivar, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cimprich, K. A.</span></span> <span> </span><span class="NLM_article-title">The essential kinase ATR: ensuring faithful duplication of a challenging genome</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">622</span>â <span class="NLM_lpage">636</span>, <span class="refDoi">Â DOI: 10.1038/nrm.2017.67</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1038%2Fnrm.2017.67" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=28811666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlemu7jF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=622-636&issue=10&author=J.+C.+Saldivarauthor=D.+Cortezauthor=K.+A.+Cimprich&title=The+essential+kinase+ATR%3A+ensuring+faithful+duplication+of+a+challenging+genome&doi=10.1038%2Fnrm.2017.67"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">The essential kinase ATR: ensuring faithful duplication of a challenging genome</span></div><div class="casAuthors">Saldivar, Joshua C.; Cortez, David; Cimprich, Karlene A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">622-636</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  One way to preserve a rare book is to lock it away from all potential sources of damage.  Of course, an inaccessible book is also of little use, and the paper and ink will continue to degrade with age in any case.  Like a book, the information stored in our DNA needs to be read, but it is also subject to continuous assault and therefore needs to be protected.  In this Review, we examine how the replication stress response that is controlled by the kinase ataxia telangiectasia and Rad3-related (ATR) senses and resolves threats to DNA integrity so that the DNA remains available to read in all of our cells.  We discuss the multiple data that have revealed an elegant yet increasingly complex mechanism of ATR activation.  This involves a core set of components that recruit ATR to stressed replication forks, stimulate kinase activity and amplify ATR signalling.  We focus on the activities of ATR in the control of cell cycle checkpoints, origin firing and replication fork stability, and on how proper regulation of these processes is crucial to ensure faithful duplication of a challenging genome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqi-97TQtMh0bVg90H21EOLACvtfcHk0ljlGx-qAWkIww"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlemu7jF&md5=b65c70da63f009deae253c8f3f215234</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1038%2Fnrm.2017.67&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm.2017.67%26sid%3Dliteratum%253Aachs%26aulast%3DSaldivar%26aufirst%3DJ.%2BC.%26aulast%3DCortez%26aufirst%3DD.%26aulast%3DCimprich%26aufirst%3DK.%2BA.%26atitle%3DThe%2520essential%2520kinase%2520ATR%253A%2520ensuring%2520faithful%2520duplication%2520of%2520a%2520challenging%2520genome%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2017%26volume%3D18%26issue%3D10%26spage%3D622%26epage%3D636%26doi%3D10.1038%2Fnrm.2017.67" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kwok, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agathanggelou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oldreive, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petermann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parry, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stankovic, T.</span></span> <span> </span><span class="NLM_article-title">ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>127</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">582</span>â <span class="NLM_lpage">595</span>, <span class="refDoi">Â DOI: 10.1182/blood-2015-05-644872</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1182%2Fblood-2015-05-644872" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=26563132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1CqtrnI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2016&pages=582-595&issue=5&author=M.+Kwokauthor=N.+Daviesauthor=A.+Agathanggelouauthor=E.+Smithauthor=C.+Oldreiveauthor=E.+Petermannauthor=G.+Stewartauthor=J.+Brownauthor=A.+Lauauthor=G.+Prattauthor=H.+Parryauthor=M.+Taylorauthor=P.+Mossauthor=P.+Hillmenauthor=T.+Stankovic&title=ATR+inhibition+induces+synthetic+lethality+and+overcomes+chemoresistance+in+TP53-+or+ATM-defective+chronic+lymphocytic+leukemia+cells&doi=10.1182%2Fblood-2015-05-644872"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells</span></div><div class="casAuthors">Kwok, Marwan; Davies, Nicholas; Agathanggelou, Angelo; Smith, Edward; Oldreive, Ceri; Petermann, Eva; Stewart, Grant; Brown, Jeff; Lau, Alan; Pratt, Guy; Parry, Helen; Taylor, Malcolm; Moss, Paul; Hillmen, Peter; Stankovic, Tatjana</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">582-595</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">TP53 and ataxia telangiectasia mutated (ATM) defects are assocd. with genomic instability, clonal evolution, and chemoresistance in chronic lymphocytic leukemia (CLL).  Currently, therapies capable of providing durable remissions in relapsed/refractory TP53- or ATM-defective CLL are lacking.  Ataxia telangiectasia and Rad3- related (ATR) mediates response to replication stress, the absence of which leads to collapse of stalled replication forks into chromatid fragments that require resoln. through the ATM/p53 pathway.  Here, using AZD6738, a novel ATR kinase inhibitor, we investigated ATR inhibition as a synthetically lethal strategy to target CLL cells with TP53 or ATM defects.  Irresp. of TP53 or ATM status, induction of CLL cell proliferation upregulated ATR protein, which then became activated in response to replication stress.  In TP53- or ATM-defective CLL cells, inhibition of ATR signaling by AZD6738 led to an accumulation of unrepaired DNA damage, which was carried through into mitosis because of defective cell cycle checkpoints, resulting in cell death by mitotic catastrophe.  Consequently, AZD6738 was selectively cytotoxic to both TP53- and ATM-defective CLL cell lines and primary cells.  This was confirmed in vivo using primary xenograft models of TP53- or ATM-defective CLL, where treatment with AZD6738 resulted in decreased tumor load and redn. in the proportion of CLL cells with such defects.  Moreover, AZD6738 sensitized TP53- or ATM-defective primary CLL cells to chemotherapy and ibrutinib.  Our findings suggest that ATR is a promising therapeutic target for TP53- or ATM-defective CLL that warrants clin. investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoosV2x8QBkxbVg90H21EOLACvtfcHk0lgG_Q2tDipk3A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1CqtrnI&md5=2d7e9490e26b94b55bf508ca516064a4</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1182%2Fblood-2015-05-644872&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2015-05-644872%26sid%3Dliteratum%253Aachs%26aulast%3DKwok%26aufirst%3DM.%26aulast%3DDavies%26aufirst%3DN.%26aulast%3DAgathanggelou%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DE.%26aulast%3DOldreive%26aufirst%3DC.%26aulast%3DPetermann%26aufirst%3DE.%26aulast%3DStewart%26aufirst%3DG.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DPratt%26aufirst%3DG.%26aulast%3DParry%26aufirst%3DH.%26aulast%3DTaylor%26aufirst%3DM.%26aulast%3DMoss%26aufirst%3DP.%26aulast%3DHillmen%26aufirst%3DP.%26aulast%3DStankovic%26aufirst%3DT.%26atitle%3DATR%2520inhibition%2520induces%2520synthetic%2520lethality%2520and%2520overcomes%2520chemoresistance%2520in%2520TP53-%2520or%2520ATM-defective%2520chronic%2520lymphocytic%2520leukemia%2520cells%26jtitle%3DBlood%26date%3D2016%26volume%3D127%26issue%3D5%26spage%3D582%26epage%3D595%26doi%3D10.1182%2Fblood-2015-05-644872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fokas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prevo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reaper, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelissen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallis, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olcina, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillies McKenna, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muschel, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunner, T. B.</span></span> <span> </span><span class="NLM_article-title">Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">12</span>), <span class="NLM_elocation-id">e441</span> <span class="refDoi">Â DOI: 10.1038/cddis.2012.181</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1038%2Fcddis.2012.181" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=23222511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtVWnsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&issue=12&author=E.+Fokasauthor=R.+Prevoauthor=J.+R.+Pollardauthor=P.+M.+Reaperauthor=P.+A.+Charltonauthor=B.+Cornelissenauthor=K.+A.+Vallisauthor=E.+M.+Hammondauthor=M.+M.+Olcinaauthor=W.+Gillies+McKennaauthor=R.+J.+Muschelauthor=T.+B.+Brunner&title=Targeting+ATR+in+vivo+using+the+novel+inhibitor+VE-822+results+in+selective+sensitization+of+pancreatic+tumors+to+radiation&doi=10.1038%2Fcddis.2012.181"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation</span></div><div class="casAuthors">Fokas, E.; Prevo, R.; Pollard, J. R.; Reaper, P. M.; Charlton, P. A.; Cornelissen, B.; Vallis, K. A.; Hammond, E. M.; Olcina, M. M.; McKenna, W. Gillies; Muschel, R. J.; Brunner, T. B.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Disease</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">Dec.</span>),
    <span class="NLM_cas:pages">e441, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">CDDEA4</span>;
        ISSN:<span class="NLM_cas:issn">2041-4889</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Combined radiochemotherapy is the currently used therapy for locally advanced pancreatic ductal adenocarcinoma (PDAC), but normal tissue toxicity limits its application.  Here we test the hypothesis that inhibition of ATR (ATM-Rad3-related) could increase the sensitivity of the cancer cells to radiation or chemotherapy without affecting normal cells.  We tested VE-822, an ATR inhibitor, for in vitro and in vivo radiosensitization.  Chk1 phosphorylation was used to indicate ATR activity, Î³H2AX and 53BP1 foci as evidence of DNA damage and Rad51 foci for homologous recombination activity.  Sensitivity to radiation (XRT) and gemcitabine was measured with clonogenic assays in vitro and tumor growth delay in vivo.  Murine intestinal damage was evaluated after abdominal XRT.  VE-822 inhibited ATR in vitro and in vivo.  VE-822 decreased maintenance of cell-cycle checkpoints, increased persistent DNA damage and decreased homologous recombination in irradiated cancer cells.  VE-822 decreased survival of pancreatic cancer cells but not normal cells in response to XRT or gemcitabine.  VE-822 markedly prolonged growth delay of pancreatic cancer xenografts after XRT and gemcitabine-based chemoradiation without augmenting normal cell or tissue toxicity.  These findings support ATR inhibition as a promising new approach to improve the therapeutic ration of radiochemotherapy for patients with PDAC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp66nE6ZdMorVg90H21EOLACvtfcHk0lgG_Q2tDipk3A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtVWnsA%253D%253D&md5=7223df6ec5dbca8c50889b5df8e4cce6</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1038%2Fcddis.2012.181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcddis.2012.181%26sid%3Dliteratum%253Aachs%26aulast%3DFokas%26aufirst%3DE.%26aulast%3DPrevo%26aufirst%3DR.%26aulast%3DPollard%26aufirst%3DJ.%2BR.%26aulast%3DReaper%26aufirst%3DP.%2BM.%26aulast%3DCharlton%26aufirst%3DP.%2BA.%26aulast%3DCornelissen%26aufirst%3DB.%26aulast%3DVallis%26aufirst%3DK.%2BA.%26aulast%3DHammond%26aufirst%3DE.%2BM.%26aulast%3DOlcina%26aufirst%3DM.%2BM.%26aulast%3DGillies%2BMcKenna%26aufirst%3DW.%26aulast%3DMuschel%26aufirst%3DR.%2BJ.%26aulast%3DBrunner%26aufirst%3DT.%2BB.%26atitle%3DTargeting%2520ATR%2520in%2520vivo%2520using%2520the%2520novel%2520inhibitor%2520VE-822%2520results%2520in%2520selective%2520sensitization%2520of%2520pancreatic%2520tumors%2520to%2520radiation%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2012%26volume%3D3%26issue%3D12%26doi%3D10.1038%2Fcddis.2012.181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Min, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, S.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, D.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâConnor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bang, Y.-J.</span></span> <span> </span><span class="NLM_article-title">AZD6738, A novel oral inhibitor of ATR, induces synthetic lethality with ATM deficiency in gastric cancer cells</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">566</span>â <span class="NLM_lpage">577</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-16-0378</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F1535-7163.MCT-16-0378" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=28138034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2sXltlOqu7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=566-577&issue=4&author=A.+Minauthor=S.-A.+Imauthor=H.+Jangauthor=S.+Kimauthor=M.+Leeauthor=D.+K.+Kimauthor=Y.+Yangauthor=H.-J.+Kimauthor=K.-H.+Leeauthor=J.+W.+Kimauthor=T.-Y.+Kimauthor=D.-Y.+Ohauthor=J.+Brownauthor=A.+Lauauthor=M.+J.+O%E2%80%99Connorauthor=Y.-J.+Bang&title=AZD6738%2C+A+novel+oral+inhibitor+of+ATR%2C+induces+synthetic+lethality+with+ATM+deficiency+in+gastric+cancer+cells&doi=10.1158%2F1535-7163.MCT-16-0378"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells</span></div><div class="casAuthors">Min, Ahrum; Im, Seock-Ah; Jang, Hyemin; Kim, Seongyeong; Lee, Miso; Kim, Debora Keunyoung; Yang, Yaewon; Kim, Hee-Jun; Lee, Kyung-Hun; Kim, Jin Won; Kim, Tae-Yong; Oh, Do-Youn; Brown, Jeff; Lau, Alan; O'Connor, Mark J.; Bang, Yung-Jue</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">566-577</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Ataxia telangiectasia and Rad3-related (ATR) can be considered an attractive target for cancer treatment due to its deleterious effect on cancer cells harboring a homologous recombination defect.  The aim of this study was to investigate the potential use of the ATR inhibitor, AZD6738, to treat gastric cancer.  In SNU-601 cells with dysfunctional ATM, AZD6738 treatment led to an accumulation of DNA damage due to dysfunctional RAD51 foci formation, S phase arrest, and caspase 3-dependent apoptosis.  In contrast, SNU-484 cells with functional ATM were not sensitive to AZD6738.  Inhibition of ATM in SNU-484 cells enhanced AZD6738 sensitivity to a level comparable with that obsd. in SNU-601 cells, showing that activation of the ATM-Chk2 signaling pathway attenuates AZD6738 sensitivity.  In addn., decreased HDAC1 expression was found to be assocd. with ATM inactivation in SNU-601 cells, demonstrating the interaction between HDAC1 and ATM can affect sensitivity to AZD6738.  Furthermore, in an in vivo tumor xenograft mouse model, AZD6738 significantly suppressed tumor growth and increased apoptosis.  These findings suggest synthetic lethality between ATR inhibition and ATM deficiency in gastric cancer cells.  Further clin. studies on the interaction between AZD 6738 and ATM deficiency are warranted to develop novel treatment strategies for gastric cancer.  Mol Cancer Ther; 16(4); 566-77. Â©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoim-TGgofMcLVg90H21EOLACvtfcHk0lj1XHviDZdTow"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXltlOqu7w%253D&md5=d84b1ad35d29bea19df290b8d6ac36a9</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0378&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0378%26sid%3Dliteratum%253Aachs%26aulast%3DMin%26aufirst%3DA.%26aulast%3DIm%26aufirst%3DS.-A.%26aulast%3DJang%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DD.%2BK.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DH.-J.%26aulast%3DLee%26aufirst%3DK.-H.%26aulast%3DKim%26aufirst%3DJ.%2BW.%26aulast%3DKim%26aufirst%3DT.-Y.%26aulast%3DOh%26aufirst%3DD.-Y.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DBang%26aufirst%3DY.-J.%26atitle%3DAZD6738%252C%2520A%2520novel%2520oral%2520inhibitor%2520of%2520ATR%252C%2520induces%2520synthetic%2520lethality%2520with%2520ATM%2520deficiency%2520in%2520gastric%2520cancer%2520cells%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2017%26volume%3D16%26issue%3D4%26spage%3D566%26epage%3D577%26doi%3D10.1158%2F1535-7163.MCT-16-0378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanjiv, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagenkort, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calderon-Montano, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koolmeister, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reaper, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortusewicz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacques, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuiper, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scobie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berglund, U. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helleday, T.</span></span> <span> </span><span class="NLM_article-title">Cancer-specific synthetic lethality between ATR and CHK1 kinase activities</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">3407</span>â <span class="NLM_lpage">3416</span>, <span class="refDoi">Â DOI: 10.1016/j.celrep.2016.12.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.celrep.2016.12.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=28009306" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFGnsrnL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=3407-3416&issue=12&author=K.+Sanjivauthor=A.+Hagenkortauthor=J.+M.+Calderon-Montanoauthor=T.+Koolmeisterauthor=P.+M.+Reaperauthor=O.+Mortusewiczauthor=S.+A.+Jacquesauthor=R.+V.+Kuiperauthor=N.+Schultzauthor=M.+Scobieauthor=P.+A.+Charltonauthor=J.+R.+Pollardauthor=U.+W.+Berglundauthor=M.+Altunauthor=T.+Helleday&title=Cancer-specific+synthetic+lethality+between+ATR+and+CHK1+kinase+activities&doi=10.1016%2Fj.celrep.2016.12.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities [Erratum to document cited in CA165:589929]</span></div><div class="casAuthors">Sanjiv, Kumar; Hagenkort, Anna; Calderon-Montano, Jose Manuel; Koolmeister, Tobias; Reaper, Philip M.; Mortusewicz, Oliver; Jacques, Sylvain A.; Kuiper, Raoul V.; Schultz, Niklas; Scobie, Martin; Charlton, Peter A.; Pollard, John R.; Berglund, Ulrika Warpman; Altun, Mikael; Helleday, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3407-3416</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-P9L07AcZ7bVg90H21EOLACvtfcHk0lj1XHviDZdTow"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFGnsrnL&md5=1972b2221b3d31fb519def6fb70288e3</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2016.12.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2016.12.031%26sid%3Dliteratum%253Aachs%26aulast%3DSanjiv%26aufirst%3DK.%26aulast%3DHagenkort%26aufirst%3DA.%26aulast%3DCalderon-Montano%26aufirst%3DJ.%2BM.%26aulast%3DKoolmeister%26aufirst%3DT.%26aulast%3DReaper%26aufirst%3DP.%2BM.%26aulast%3DMortusewicz%26aufirst%3DO.%26aulast%3DJacques%26aufirst%3DS.%2BA.%26aulast%3DKuiper%26aufirst%3DR.%2BV.%26aulast%3DSchultz%26aufirst%3DN.%26aulast%3DScobie%26aufirst%3DM.%26aulast%3DCharlton%26aufirst%3DP.%2BA.%26aulast%3DPollard%26aufirst%3DJ.%2BR.%26aulast%3DBerglund%26aufirst%3DU.%2BW.%26aulast%3DAltun%26aufirst%3DM.%26aulast%3DHelleday%26aufirst%3DT.%26atitle%3DCancer-specific%2520synthetic%2520lethality%2520between%2520ATR%2520and%2520CHK1%2520kinase%2520activities%26jtitle%3DCell%2520Rep.%26date%3D2016%26volume%3D17%26issue%3D12%26spage%3D3407%26epage%3D3416%26doi%3D10.1016%2Fj.celrep.2016.12.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toledo, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmeyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rask, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lukas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Povlsen, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bekker-Jensen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mailand, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lukas, J.</span></span> <span> </span><span class="NLM_article-title">ATR prohibits replication catastrophe by preventing global exhaustion of RPA</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>155</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1088</span>â <span class="NLM_lpage">1103</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2013.10.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.cell.2013.10.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=24267891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFWitrnI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2013&pages=1088-1103&issue=5&author=L.+I.+Toledoauthor=M.+Altmeyerauthor=M.+B.+Raskauthor=C.+Lukasauthor=D.+H.+Larsenauthor=L.+K.+Povlsenauthor=S.+Bekker-Jensenauthor=N.+Mailandauthor=J.+Bartekauthor=J.+Lukas&title=ATR+prohibits+replication+catastrophe+by+preventing+global+exhaustion+of+RPA&doi=10.1016%2Fj.cell.2013.10.043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">ATR prohibits replication catastrophe by preventing global exhaustion of RPA</span></div><div class="casAuthors">Toledo, Luis Ignacio; Altmeyer, Matthias; Rask, Maj-Britt; Lukas, Claudia; Larsen, Dorthe Helena; Povlsen, Lou Klitgaard; Bekker-Jensen, Simon; Mailand, Niels; Bartek, Jiri; Lukas, Jiri</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1088-1103</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">ATR, activated by replication stress, protects replication forks locally and suppresses origin firing globally.  Here, we show that these functions of ATR are mechanistically coupled.  Although initially stable, stalled forks in ATR-deficient cells undergo nucleus-wide breakage after unscheduled origin firing generates an excess of single-stranded DNA that exhausts the nuclear pool of RPA.  Partial redn. of RPA accelerated fork breakage, and forced elevation of RPA was sufficient to delay such "replication catastrophe" even in the absence of ATR activity.  Conversely, unscheduled origin firing induced breakage of stalled forks even in cells with active ATR.  Thus, ATR-mediated suppression of dormant origins shields active forks against irreversible breakage via preventing exhaustion of nuclear RPA.  This study elucidates how replicating genomes avoid destabilizing DNA damage.  Because cancer cells commonly feature intrinsically high replication stress, this study also provides a mol. rationale for their hypersensitivity to ATR inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozN6VLaiVbCbVg90H21EOLACvtfcHk0lhIYWD-K0J4Kw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFWitrnI&md5=1e7faf5c8a8af17c3a3797d1dce3aa51</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2013.10.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2013.10.043%26sid%3Dliteratum%253Aachs%26aulast%3DToledo%26aufirst%3DL.%2BI.%26aulast%3DAltmeyer%26aufirst%3DM.%26aulast%3DRask%26aufirst%3DM.%2BB.%26aulast%3DLukas%26aufirst%3DC.%26aulast%3DLarsen%26aufirst%3DD.%2BH.%26aulast%3DPovlsen%26aufirst%3DL.%2BK.%26aulast%3DBekker-Jensen%26aufirst%3DS.%26aulast%3DMailand%26aufirst%3DN.%26aulast%3DBartek%26aufirst%3DJ.%26aulast%3DLukas%26aufirst%3DJ.%26atitle%3DATR%2520prohibits%2520replication%2520catastrophe%2520by%2520preventing%2520global%2520exhaustion%2520of%2520RPA%26jtitle%3DCell%26date%3D2013%26volume%3D155%26issue%3D5%26spage%3D1088%26epage%3D1103%26doi%3D10.1016%2Fj.cell.2013.10.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Charrier, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durrant, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golec, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knegtel, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacCormick, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortimore, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâDonnell, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinder, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reaper, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutherford, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J. R.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2320</span>â <span class="NLM_lpage">2330</span>, <span class="refDoi">Â DOI: 10.1021/jm101488z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101488z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsVCksbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2320-2330&issue=7&author=J.+D.+Charrierauthor=S.+J.+Durrantauthor=J.+M.+Golecauthor=D.+P.+Kayauthor=R.+M.+Knegtelauthor=S.+MacCormickauthor=M.+Mortimoreauthor=M.+E.+O%E2%80%99Donnellauthor=J.+L.+Pinderauthor=P.+M.+Reaperauthor=A.+P.+Rutherfordauthor=P.+S.+Wangauthor=S.+C.+Youngauthor=J.+R.+Pollard&title=Discovery+of+potent+and+selective+inhibitors+of+ataxia+telangiectasia+mutated+and+Rad3+related+%28ATR%29+protein+kinase+as+potential+anticancer+agents&doi=10.1021%2Fjm101488z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase as Potential Anticancer Agents</span></div><div class="casAuthors">Charrier, Jean-Damien; Durrant, Steven J.; Golec, Julian M. C.; Kay, David P.; Knegtel, Ronald M. A.; MacCormick, Somhairle; Mortimore, Michael; O'Donnell, Michael E.; Pinder, Joanne L.; Reaper, Philip M.; Rutherford, Alistair P.; Wang, Paul S. H.; Young, Stephen C.; Pollard, John R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2320-2330</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">DNA-damaging agents are among the most frequently used anticancer drugs.  However, they provide only modest benefit in most cancers.  This may be attributed to a genome maintenance network, the DNA damage response (DDR), that recognizes and repairs damaged DNA.  ATR is a major regulator of the DDR and an attractive anticancer target.  Herein, we describe the discovery of a series of aminopyrazines with potent and selective ATR inhibition.  Compd. (I) inhibits ATR with a Ki of 6 nM, shows >600-fold selectivity over related kinases ATM or DNA-PK, and blocks ATR signaling in cells with an IC50 of 0.42 Î¼M.  Using I, here it is shown that ATR inhibition markedly enhances death induced by DNA-damaging agents in certain cancers but not normal cells.  This differential response between cancer and normal cells highlights the great potential for ATR inhibition as a novel mechanism to dramatically increase the efficacy of many established drugs and ionizing radiation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp56O6NNQ8JNbVg90H21EOLACvtfcHk0lgCVGOQJOg5dQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsVCksbc%253D&md5=4f17e7c44fc6c7bdc32886e3415722c8</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1021%2Fjm101488z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101488z%26sid%3Dliteratum%253Aachs%26aulast%3DCharrier%26aufirst%3DJ.%2BD.%26aulast%3DDurrant%26aufirst%3DS.%2BJ.%26aulast%3DGolec%26aufirst%3DJ.%2BM.%26aulast%3DKay%26aufirst%3DD.%2BP.%26aulast%3DKnegtel%26aufirst%3DR.%2BM.%26aulast%3DMacCormick%26aufirst%3DS.%26aulast%3DMortimore%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DM.%2BE.%26aulast%3DPinder%26aufirst%3DJ.%2BL.%26aulast%3DReaper%26aufirst%3DP.%2BM.%26aulast%3DRutherford%26aufirst%3DA.%2BP.%26aulast%3DWang%26aufirst%3DP.%2BS.%26aulast%3DYoung%26aufirst%3DS.%2BC.%26aulast%3DPollard%26aufirst%3DJ.%2BR.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520selective%2520inhibitors%2520of%2520ataxia%2520telangiectasia%2520mutated%2520and%2520Rad3%2520related%2520%2528ATR%2529%2520protein%2520kinase%2520as%2520potential%2520anticancer%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D7%26spage%3D2320%26epage%3D2330%26doi%3D10.1021%2Fjm101488z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knegtel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charrier, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durrant, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâDonnell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storck, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacCormick, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinder, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Twin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reaper, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Littlewood, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golec, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J.</span></span> <span> </span><span class="NLM_article-title">Rational design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): optimization of intra- and intermolecular polar interactions of a new ataxia telangiectasia mutated and Rad3-related (ATR) kinase inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">5547</span>â <span class="NLM_lpage">5561</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.9b00426</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00426" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1MXptlKrtLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=5547-5561&issue=11&author=R.+Knegtelauthor=J.+D.+Charrierauthor=S.+Durrantauthor=C.+Davisauthor=M.+O%E2%80%99Donnellauthor=P.+Storckauthor=S.+MacCormickauthor=D.+Kayauthor=J.+Pinderauthor=A.+Viraniauthor=H.+Twinauthor=M.+Griffithsauthor=P.+Reaperauthor=P.+Littlewoodauthor=S.+Youngauthor=J.+Golecauthor=J.+Pollard&title=Rational+design+of+5-%284-%28Isopropylsulfonyl%29phenyl%29-3-%283-%284-%28%28methylamino%29methyl%29phenyl%29isoxazol-5-yl%29pyrazin-2-amine+%28VX-970%2C+M6620%29%3A+optimization+of+intra-+and+intermolecular+polar+interactions+of+a+new+ataxia+telangiectasia+mutated+and+Rad3-related+%28ATR%29+kinase+inhibitor&doi=10.1021%2Facs.jmedchem.9b00426"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of Intra- and Intermolecular Polar Interactions of a New Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase Inhibitor</span></div><div class="casAuthors">Knegtel, Ronald; Charrier, Jean-Damien; Durrant, Steven; Davis, Chris; O'Donnell, Michael; Storck, Pierre; MacCormick, Somhairle; Kay, David; Pinder, Joanne; Virani, Anisa; Twin, Heather; Griffiths, Matthew; Reaper, Philip; Littlewood, Peter; Young, Steve; Golec, Julian; Pollard, John</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5547-5561</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The DNA damage response (DDR) is a DNA damage surveillance and repair mechanism that can limit the effectiveness of radiotherapy and DNA-damaging chemotherapy, commonly used treatment modalities in cancer.  Two related kinases, ataxia telangiectasia mutated (ATM) and ATM and Rad3-related kinase (ATR), work together as apical proteins in the DDR to maintain genome stability and cell survival in the face of potentially lethal forms of DNA damage.  However, compromised ATM signaling is a common characteristic of tumor cells, which places greater reliance on ATR to mediate the DDR.  In such circumstances, ATR inhibition has been shown to enhance the toxicity of DNA damaging chemotherapy to many cancer cells in multiple preclin. studies, while healthy tissue with functional ATM can tolerate ATR inhibition.  ATR therefore represents a very attractive anticancer target.  Herein we describe the discovery of VX-970/M6620, the first ATR inhibitor to enter clin. studies, which is based on a 2-aminopyrazine core first reported by Charrier.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn8wwwZ4Hh_rVg90H21EOLACvtfcHk0lgCVGOQJOg5dQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXptlKrtLc%253D&md5=1dfc9458dc23210b4e8fac71c81e966e</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00426%26sid%3Dliteratum%253Aachs%26aulast%3DKnegtel%26aufirst%3DR.%26aulast%3DCharrier%26aufirst%3DJ.%2BD.%26aulast%3DDurrant%26aufirst%3DS.%26aulast%3DDavis%26aufirst%3DC.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DM.%26aulast%3DStorck%26aufirst%3DP.%26aulast%3DMacCormick%26aufirst%3DS.%26aulast%3DKay%26aufirst%3DD.%26aulast%3DPinder%26aufirst%3DJ.%26aulast%3DVirani%26aufirst%3DA.%26aulast%3DTwin%26aufirst%3DH.%26aulast%3DGriffiths%26aufirst%3DM.%26aulast%3DReaper%26aufirst%3DP.%26aulast%3DLittlewood%26aufirst%3DP.%26aulast%3DYoung%26aufirst%3DS.%26aulast%3DGolec%26aufirst%3DJ.%26aulast%3DPollard%26aufirst%3DJ.%26atitle%3DRational%2520design%2520of%25205-%25284-%2528Isopropylsulfonyl%2529phenyl%2529-3-%25283-%25284-%2528%2528methylamino%2529methyl%2529phenyl%2529isoxazol-5-yl%2529pyrazin-2-amine%2520%2528VX-970%252C%2520M6620%2529%253A%2520optimization%2520of%2520intra-%2520and%2520intermolecular%2520polar%2520interactions%2520of%2520a%2520new%2520ataxia%2520telangiectasia%2520mutated%2520and%2520Rad3-related%2520%2528ATR%2529%2520kinase%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D11%26spage%3D5547%26epage%3D5561%26doi%3D10.1021%2Facs.jmedchem.9b00426" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">OâCarrigan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Miguel Luken, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadatos-Pastos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tunariu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez Lopez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganegoda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riisnaes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figueiredo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreira, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hare, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penney, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerji, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Bono, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fields, S. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, T. A.</span></span> <span> </span><span class="NLM_article-title">Phase I trial of a first-in-class ATR inhibitor VX-970 as monotherapy (mono) or in combination (combo) with carboplatin (CP) incorporating pharmacodynamics (PD) studies</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">15_suppl</span>),  <span class="NLM_fpage">2504</span>, <span class="refDoi">Â DOI: 10.1200/JCO.2016.34.15_suppl.2504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1200%2FJCO.2016.34.15_suppl.2504" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=2504&issue=15_suppl&author=B.+O%E2%80%99Carriganauthor=M.+J.+de+Miguel+Lukenauthor=D.+Papadatos-Pastosauthor=J.+Brownauthor=N.+Tunariuauthor=R.+Perez+Lopezauthor=M.+Ganegodaauthor=R.+Riisnaesauthor=I.+Figueiredoauthor=S.+Carreiraauthor=B.+Hareauthor=F.+Yangauthor=K.+McDermottauthor=M.+S.+Penneyauthor=J.+Pollardauthor=J.+S.+Lopezauthor=U.+Banerjiauthor=J.+S.+De+Bonoauthor=S.+Z.+Fieldsauthor=T.+A.+Yap&title=Phase+I+trial+of+a+first-in-class+ATR+inhibitor+VX-970+as+monotherapy+%28mono%29+or+in+combination+%28combo%29+with+carboplatin+%28CP%29+incorporating+pharmacodynamics+%28PD%29+studies&doi=10.1200%2FJCO.2016.34.15_suppl.2504"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1200%2FJCO.2016.34.15_suppl.2504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2016.34.15_suppl.2504%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Carrigan%26aufirst%3DB.%26aulast%3Dde%2BMiguel%2BLuken%26aufirst%3DM.%2BJ.%26aulast%3DPapadatos-Pastos%26aufirst%3DD.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DTunariu%26aufirst%3DN.%26aulast%3DPerez%2BLopez%26aufirst%3DR.%26aulast%3DGanegoda%26aufirst%3DM.%26aulast%3DRiisnaes%26aufirst%3DR.%26aulast%3DFigueiredo%26aufirst%3DI.%26aulast%3DCarreira%26aufirst%3DS.%26aulast%3DHare%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DMcDermott%26aufirst%3DK.%26aulast%3DPenney%26aufirst%3DM.%2BS.%26aulast%3DPollard%26aufirst%3DJ.%26aulast%3DLopez%26aufirst%3DJ.%2BS.%26aulast%3DBanerji%26aufirst%3DU.%26aulast%3DDe%2BBono%26aufirst%3DJ.%2BS.%26aulast%3DFields%26aufirst%3DS.%2BZ.%26aulast%3DYap%26aufirst%3DT.%2BA.%26atitle%3DPhase%2520I%2520trial%2520of%2520a%2520first-in-class%2520ATR%2520inhibitor%2520VX-970%2520as%2520monotherapy%2520%2528mono%2529%2520or%2520in%2520combination%2520%2528combo%2529%2520with%2520carboplatin%2520%2528CP%2529%2520incorporating%2520pharmacodynamics%2520%2528PD%2529%2520studies%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2016%26volume%3D34%26issue%3D15_suppl%26spage%3D2504%26doi%3D10.1200%2FJCO.2016.34.15_suppl.2504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yap, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Miguel Luken, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâCarrigan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roda, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadatos-Pastos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorente, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tunariu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gayle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riisnaes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figueiredo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miranda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreira, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penney, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molife, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerji, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asmal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fields, S. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bono, J. S.</span></span> <span> </span><span class="NLM_article-title">Abstract PR14: Phase I trial of first-in-class ataxia telangiectasia-mutated and Rad3-related (ATR) inhibitor VX-970 as monotherapy (mono) or in combination with carboplatin (CP) in advanced cancer patients (pts) with preliminary evidence of target modulation and antitumor activity</span>. <i>Mol. Cancer. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">12, Suppl. 2</span>), <span class="NLM_elocation-id">PR14</span> <span class="refDoi">Â DOI: 10.1158/1535-7163.TARG-15-PR14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F1535-7163.TARG-15-PR14" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&issue=12%2C+Suppl.+2&author=T.+A.+Yapauthor=M.+J.+de+Miguel+Lukenauthor=B.+O%E2%80%99Carriganauthor=D.+Rodaauthor=D.+Papadatos-Pastosauthor=D.+Lorenteauthor=N.+Tunariuauthor=R.+P.+Lopezauthor=S.+Gayleauthor=R.+Riisnaesauthor=I.+Figueiredoauthor=S.+Mirandaauthor=S.+Carreiraauthor=F.+Yangauthor=S.+Karanauthor=M.+Penneyauthor=J.+Pollardauthor=L.+R.+Molifeauthor=U.+Banerjiauthor=M.+Asmalauthor=S.+Z.+Fieldsauthor=J.+S.+de+Bono&title=Abstract+PR14%3A+Phase+I+trial+of+first-in-class+ataxia+telangiectasia-mutated+and+Rad3-related+%28ATR%29+inhibitor+VX-970+as+monotherapy+%28mono%29+or+in+combination+with+carboplatin+%28CP%29+in+advanced+cancer+patients+%28pts%29+with+preliminary+evidence+of+target+modulation+and+antitumor+activity&doi=10.1158%2F1535-7163.TARG-15-PR14"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.TARG-15-PR14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.TARG-15-PR14%26sid%3Dliteratum%253Aachs%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3Dde%2BMiguel%2BLuken%26aufirst%3DM.%2BJ.%26aulast%3DO%25E2%2580%2599Carrigan%26aufirst%3DB.%26aulast%3DRoda%26aufirst%3DD.%26aulast%3DPapadatos-Pastos%26aufirst%3DD.%26aulast%3DLorente%26aufirst%3DD.%26aulast%3DTunariu%26aufirst%3DN.%26aulast%3DLopez%26aufirst%3DR.%2BP.%26aulast%3DGayle%26aufirst%3DS.%26aulast%3DRiisnaes%26aufirst%3DR.%26aulast%3DFigueiredo%26aufirst%3DI.%26aulast%3DMiranda%26aufirst%3DS.%26aulast%3DCarreira%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DKaran%26aufirst%3DS.%26aulast%3DPenney%26aufirst%3DM.%26aulast%3DPollard%26aufirst%3DJ.%26aulast%3DMolife%26aufirst%3DL.%2BR.%26aulast%3DBanerji%26aufirst%3DU.%26aulast%3DAsmal%26aufirst%3DM.%26aulast%3DFields%26aufirst%3DS.%2BZ.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26atitle%3DAbstract%2520PR14%253A%2520Phase%2520I%2520trial%2520of%2520first-in-class%2520ataxia%2520telangiectasia-mutated%2520and%2520Rad3-related%2520%2528ATR%2529%2520inhibitor%2520VX-970%2520as%2520monotherapy%2520%2528mono%2529%2520or%2520in%2520combination%2520with%2520carboplatin%2520%2528CP%2529%2520in%2520advanced%2520cancer%2520patients%2520%2528pts%2529%2520with%2520preliminary%2520evidence%2520of%2520target%2520modulation%2520and%2520antitumor%2520activity%26jtitle%3DMol.%2520Cancer.%2520Ther.%26date%3D2015%26volume%3D14%26issue%3D12%252C%2520Suppl.%25202%26doi%3D10.1158%2F1535-7163.TARG-15-PR14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wesolowski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devoe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constantinidou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadatos-Pastos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fricano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penney, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asmal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renshaw, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fields, S. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, T. A.</span></span> <span> </span><span class="NLM_article-title">Abstract CT012: phase 1 trial of first-in-class ATR inhibitor VX-970 in combination with cisplatin (Cis) in patients (pts) with advanced solid tumors (NCT02157792)</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span> (<span class="NLM_issue">14, Suppl.</span>), <span class="NLM_elocation-id">CT012</span> <span class="refDoi">Â DOI: 10.1158/1538-7445.AM2016-CT012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F1538-7445.AM2016-CT012" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&issue=14%2C+Suppl.&author=G.+Shapiroauthor=R.+Wesolowskiauthor=M.+Middletonauthor=C.+Devoeauthor=A.+Constantinidouauthor=D.+Papadatos-Pastosauthor=M.+Fricanoauthor=Y.+Zhangauthor=S.+Karanauthor=J.+Pollardauthor=M.+Penneyauthor=M.+Asmalauthor=F.+G.+Renshawauthor=S.+Z.+Fieldsauthor=T.+A.+Yap&title=Abstract+CT012%3A+phase+1+trial+of+first-in-class+ATR+inhibitor+VX-970+in+combination+with+cisplatin+%28Cis%29+in+patients+%28pts%29+with+advanced+solid+tumors+%28NCT02157792%29&doi=10.1158%2F1538-7445.AM2016-CT012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2016-CT012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2016-CT012%26sid%3Dliteratum%253Aachs%26aulast%3DShapiro%26aufirst%3DG.%26aulast%3DWesolowski%26aufirst%3DR.%26aulast%3DMiddleton%26aufirst%3DM.%26aulast%3DDevoe%26aufirst%3DC.%26aulast%3DConstantinidou%26aufirst%3DA.%26aulast%3DPapadatos-Pastos%26aufirst%3DD.%26aulast%3DFricano%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DKaran%26aufirst%3DS.%26aulast%3DPollard%26aufirst%3DJ.%26aulast%3DPenney%26aufirst%3DM.%26aulast%3DAsmal%26aufirst%3DM.%26aulast%3DRenshaw%26aufirst%3DF.%2BG.%26aulast%3DFields%26aufirst%3DS.%2BZ.%26aulast%3DYap%26aufirst%3DT.%2BA.%26atitle%3DAbstract%2520CT012%253A%2520phase%25201%2520trial%2520of%2520first-in-class%2520ATR%2520inhibitor%2520VX-970%2520in%2520combination%2520with%2520cisplatin%2520%2528Cis%2529%2520in%2520patients%2520%2528pts%2529%2520with%2520advanced%2520solid%2520tumors%2520%2528NCT02157792%2529%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26issue%3D14%252C%2520Suppl%26doi%3D10.1158%2F1538-7445.AM2016-CT012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Plummer, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, T. R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greystoke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbschleb, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penney, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asmal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fields, S. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, M. R.</span></span> <span> </span><span class="NLM_article-title">Phase I trial of first-in-class ATR inhibitor VX-970 in combination with gemcitabine (Gem) in advanced solid tumors (NCT02157792)</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">15_suppl</span>),  <span class="NLM_fpage">2513</span>, <span class="refDoi">Â DOI: 10.1200/JCO.2016.34.15_suppl.2513</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1200%2FJCO.2016.34.15_suppl.2513" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=2513&issue=15_suppl&author=E.+R.+Plummerauthor=E.+J.+Deanauthor=T.+R.+J.+Evansauthor=A.+Greystokeauthor=K.+Herbschlebauthor=M.+Ransonauthor=J.+Brownauthor=Y.+Zhangauthor=S.+Karanauthor=J.+Pollardauthor=M.+S.+Penneyauthor=M.+Asmalauthor=S.+Z.+Fieldsauthor=M.+R.+Middleton&title=Phase+I+trial+of+first-in-class+ATR+inhibitor+VX-970+in+combination+with+gemcitabine+%28Gem%29+in+advanced+solid+tumors+%28NCT02157792%29&doi=10.1200%2FJCO.2016.34.15_suppl.2513"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1200%2FJCO.2016.34.15_suppl.2513&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2016.34.15_suppl.2513%26sid%3Dliteratum%253Aachs%26aulast%3DPlummer%26aufirst%3DE.%2BR.%26aulast%3DDean%26aufirst%3DE.%2BJ.%26aulast%3DEvans%26aufirst%3DT.%2BR.%2BJ.%26aulast%3DGreystoke%26aufirst%3DA.%26aulast%3DHerbschleb%26aufirst%3DK.%26aulast%3DRanson%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DKaran%26aufirst%3DS.%26aulast%3DPollard%26aufirst%3DJ.%26aulast%3DPenney%26aufirst%3DM.%2BS.%26aulast%3DAsmal%26aufirst%3DM.%26aulast%3DFields%26aufirst%3DS.%2BZ.%26aulast%3DMiddleton%26aufirst%3DM.%2BR.%26atitle%3DPhase%2520I%2520trial%2520of%2520first-in-class%2520ATR%2520inhibitor%2520VX-970%2520in%2520combination%2520with%2520gemcitabine%2520%2528Gem%2529%2520in%2520advanced%2520solid%2520tumors%2520%2528NCT02157792%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2016%26volume%3D34%26issue%3D15_suppl%26spage%3D2513%26doi%3D10.1200%2FJCO.2016.34.15_suppl.2513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zenke, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahmen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elenbaas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reaper, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagrodia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spilker, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amendt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaukat, A.</span></span> <span> </span><span class="NLM_article-title">Abstract 369: Antitumor activity of M4344, a potent and selective ATR inhibitor, in monotherapy and combination therapy</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span> (<span class="NLM_issue">13, Suppl.</span>),  <span class="NLM_fpage">369</span>, <span class="refDoi">Â DOI: 10.1158/1538-7445.AM2019-369</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F1538-7445.AM2019-369" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=369&issue=13%2C+Suppl.&author=F.+T.+Zenkeauthor=A.+Zimmermannauthor=H.+Dahmenauthor=B.+Elenbaasauthor=J.+Pollardauthor=P.+Reaperauthor=S.+Bagrodiaauthor=M.+E.+Spilkerauthor=C.+Amendtauthor=A.+Blaukat&title=Abstract+369%3A+Antitumor+activity+of+M4344%2C+a+potent+and+selective+ATR+inhibitor%2C+in+monotherapy+and+combination+therapy&doi=10.1158%2F1538-7445.AM2019-369"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2019-369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2019-369%26sid%3Dliteratum%253Aachs%26aulast%3DZenke%26aufirst%3DF.%2BT.%26aulast%3DZimmermann%26aufirst%3DA.%26aulast%3DDahmen%26aufirst%3DH.%26aulast%3DElenbaas%26aufirst%3DB.%26aulast%3DPollard%26aufirst%3DJ.%26aulast%3DReaper%26aufirst%3DP.%26aulast%3DBagrodia%26aufirst%3DS.%26aulast%3DSpilker%26aufirst%3DM.%2BE.%26aulast%3DAmendt%26aufirst%3DC.%26aulast%3DBlaukat%26aufirst%3DA.%26atitle%3DAbstract%2520369%253A%2520Antitumor%2520activity%2520of%2520M4344%252C%2520a%2520potent%2520and%2520selective%2520ATR%2520inhibitor%252C%2520in%2520monotherapy%2520and%2520combination%2520therapy%26jtitle%3DCancer%2520Res.%26date%3D2019%26volume%3D79%26issue%3D13%252C%2520Suppl%26spage%3D369%26doi%3D10.1158%2F1538-7445.AM2019-369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wortmann, L.</span>; <span class="NLM_string-name">Lucking, U.</span>; <span class="NLM_string-name">Lefranc, J.</span>; <span class="NLM_string-name">Briem, H.</span>; <span class="NLM_string-name">Koppitz, M.</span>; <span class="NLM_string-name">Eis, K.</span>; <span class="NLM_string-name">Von Nussbaum, F.</span>; <span class="NLM_string-name">Bader, B.</span>; <span class="NLM_string-name">Wegner, A. M.</span>; <span class="NLM_string-name">Siemeister, G.</span>; <span class="NLM_string-name">Bone, W.</span>; <span class="NLM_string-name">Lienau, P.</span>; <span class="NLM_string-name">Grudzinska-Goebel, J.</span>; <span class="NLM_string-name">Mossmayer, D.</span>; <span class="NLM_string-name">EberspÃ¤cher, U.</span>; <span class="NLM_string-name">Schick, H.</span></span> <span> </span><span class="NLM_article-title">2-Morpholin-yl)-1,7-naphythridines</span>. <span class="NLM_patent">WO/2016/020320</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=L.+Wortmann&author=U.+Lucking&author=J.+Lefranc&author=H.+Briem&author=M.+Koppitz&author=K.+Eis&author=F.+Von+Nussbaum&author=B.+Bader&author=A.+M.+Wegner&author=G.+Siemeister&author=W.+Bone&author=P.+Lienau&author=J.+Grudzinska-Goebel&author=D.+Mossmayer&author=U.+Ebersp%C3%A4cher&author=H.+Schick&title=2-Morpholin-yl%29-1%2C7-naphythridines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWortmann%26aufirst%3DL.%26atitle%3D2-Morpholin-yl%2529-1%252C7-naphythridines%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wengner, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siemeister, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucking, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefranc, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wortmann, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lienau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bomer, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moosmayer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberspacher, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golfier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schatz, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumgart, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haendler, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lejeune, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlicker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Nussbaum, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brands, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegelbauer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mumberg, D.</span></span> <span> </span><span class="NLM_article-title">The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage-inducing or repair-compromising rherapies in preclinical cancer models</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">26</span>â <span class="NLM_lpage">38</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-19-0019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F1535-7163.MCT-19-0019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=31582533" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvVOltbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2020&pages=26-38&issue=1&author=A.+M.+Wengnerauthor=G.+Siemeisterauthor=U.+Luckingauthor=J.+Lefrancauthor=L.+Wortmannauthor=P.+Lienauauthor=B.+Baderauthor=U.+Bomerauthor=D.+Moosmayerauthor=U.+Eberspacherauthor=S.+Golfierauthor=C.+A.+Schatzauthor=S.+J.+Baumgartauthor=B.+Haendlerauthor=P.+Lejeuneauthor=A.+Schlickerauthor=F.+von+Nussbaumauthor=M.+Brandsauthor=K.+Ziegelbauerauthor=D.+Mumberg&title=The+novel+ATR+inhibitor+BAY+1895344+is+efficacious+as+monotherapy+and+combined+with+DNA+damage-inducing+or+repair-compromising+rherapies+in+preclinical+cancer+models&doi=10.1158%2F1535-7163.MCT-19-0019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage-inducing or repair-compromising therapies in preclinical cancer models</span></div><div class="casAuthors">Wengner, Antje M.; Siemeister, Gerhard; Luecking, Ulrich; Lefranc, Julien; Wortmann, Lars; Lienau, Philip; Bader, Benjamin; Boemer, Ulf; Moosmayer, Dieter; Eberspaecher, Uwe; Golfier, Sven; Schatz, Christoph A.; Baumgart, Simon J.; Haendler, Bernard; Lejeune, Pascale; Schlicker, Andreas; von Nussbaum, Franz; Brands, Michael; Ziegelbauer, Karl; Mumberg, Dominik</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">26-38</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The DNA damage response (DDR) secures the integrity of the genome of eukaryotic cells.  Here, we studied the effect of the novel selective ATR kinase inhibitor BAY 1895344 on tumor cell growth and viability.  Potent anti-proliferative activity was demonstrated in a broad spectrum of human tumor cell lines.  BAY 1895344 exhibited strong monotherapy efficacy in cancer xenograft models that carry DNA damage repair deficiencies.  The combination of BAY 1895344 with DNA damage-inducing chemotherapy or external beam radiation therapy (EBRT) showed synergistic anti-tumor activity.  Combination treatment with BAY 1895344 and DDR inhibitors achieved strong synergistic anti-proliferative activity in vitro, and combined inhibition of ATR and poly (ADP-ribose) polymerase (PARP) signaling using olaparib demonstrated synergistic anti-tumor activity in vivo.  Furthermore, the combination of BAY 1895344 with the novel, non-steroidal androgen receptor antagonist darolutamide resulted in significantly improved anti-tumor efficacy compared to resp. single agent treatments in hormone-dependent prostate cancer, and addn. of EBRT resulted in even further enhanced anti-tumor efficacy.  Thus, the ATR inhibitor BAY 1895344 may provide new therapeutic options for the treatment of cancers with certain DDR deficiencies in monotherapy and in combination with DNA damage-inducing or DNA repair-compromising cancer therapies by improving their efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9lU-o29OtpbVg90H21EOLACvtfcHk0ljJMu868JY5FQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvVOltbo%253D&md5=a44cff693597322209acf8e07282fe5d</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-19-0019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-19-0019%26sid%3Dliteratum%253Aachs%26aulast%3DWengner%26aufirst%3DA.%2BM.%26aulast%3DSiemeister%26aufirst%3DG.%26aulast%3DLucking%26aufirst%3DU.%26aulast%3DLefranc%26aufirst%3DJ.%26aulast%3DWortmann%26aufirst%3DL.%26aulast%3DLienau%26aufirst%3DP.%26aulast%3DBader%26aufirst%3DB.%26aulast%3DBomer%26aufirst%3DU.%26aulast%3DMoosmayer%26aufirst%3DD.%26aulast%3DEberspacher%26aufirst%3DU.%26aulast%3DGolfier%26aufirst%3DS.%26aulast%3DSchatz%26aufirst%3DC.%2BA.%26aulast%3DBaumgart%26aufirst%3DS.%2BJ.%26aulast%3DHaendler%26aufirst%3DB.%26aulast%3DLejeune%26aufirst%3DP.%26aulast%3DSchlicker%26aufirst%3DA.%26aulast%3Dvon%2BNussbaum%26aufirst%3DF.%26aulast%3DBrands%26aufirst%3DM.%26aulast%3DZiegelbauer%26aufirst%3DK.%26aulast%3DMumberg%26aufirst%3DD.%26atitle%3DThe%2520novel%2520ATR%2520inhibitor%2520BAY%25201895344%2520is%2520efficacious%2520as%2520monotherapy%2520and%2520combined%2520with%2520DNA%2520damage-inducing%2520or%2520repair-compromising%2520rherapies%2520in%2520preclinical%2520cancer%2520models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2020%26volume%3D19%26issue%3D1%26spage%3D26%26epage%3D38%26doi%3D10.1158%2F1535-7163.MCT-19-0019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foote, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blades, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cronin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fillery, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guichard, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassall, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacq, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewsbury, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissink, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odedra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suleman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thommes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broadhurst, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2125</span>â <span class="NLM_lpage">2138</span>, <span class="refDoi">Â DOI: 10.1021/jm301859s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301859s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3sXit1Ghsr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=2125-2138&issue=5&author=K.+M.+Footeauthor=K.+Bladesauthor=A.+Croninauthor=S.+Filleryauthor=S.+S.+Guichardauthor=L.+Hassallauthor=I.+Hicksonauthor=X.+Jacqauthor=P.+J.+Jewsburyauthor=T.+M.+McGuireauthor=J.+W.+Nissinkauthor=R.+Odedraauthor=K.+Pageauthor=P.+Perkinsauthor=A.+Sulemanauthor=K.+Tamauthor=P.+Thommesauthor=R.+Broadhurstauthor=C.+Wood&title=Discovery+of+4-%7B4-%5B%283R%29-3-Methylmorpholin-4-yl%5D-6-%5B1-%28methylsulfonyl%29cyclopropyl%5Dpyrimidin-2-yl%7D-1H-indole+%28AZ20%29%3A+a+potent+and+selective+inhibitor+of+ATR+protein+kinase+with+monotherapy+in+vivo+antitumor+activity&doi=10.1021%2Fjm301859s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): A Potent and Selective Inhibitor of ATR Protein Kinase with Monotherapy in Vivo Antitumor Activity</span></div><div class="casAuthors">Foote, Kevin M.; Blades, Kevin; Cronin, Anna; Fillery, Shaun; Guichard, Sylvie S.; Hassall, Lorraine; Hickson, Ian; Jacq, Xavier; Jewsbury, Philip J.; McGuire, Thomas M.; Nissink, J. Willem M.; Odedra, Rajesh; Page, Ken; Perkins, Paula; Suleman, Abid; Tam, Kin; Thommes, Pia; Broadhurst, Rebecca; Wood, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2125-2138</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">ATR is an attractive new anticancer drug target whose inhibitors have potential as chemo- or radiation sensitizers or as monotherapy in tumors addicted to particular DNA-repair pathways.  We describe the discovery and synthesis of a series of sulfonylmorpholinopyrimidines that show potent and selective ATR inhibition.  Optimization from a high quality screening hit within tight SAR space led to compd. I (AZ20) which inhibits ATR immunopptd. from HeLa nuclear exts. with an IC50 of 5 nM and ATR mediated phosphorylation of Chk1 in HT29 colorectal adenocarcinoma tumor cells with an IC50 of 50 nM.  Compd. I potently inhibits the growth of LoVo colorectal adenocarcinoma tumor cells in vitro and has high free exposure in mouse following moderate oral doses.  At well tolerated doses I leads to significant growth inhibition of LoVo xenografts grown in nude mice.  Compd. I is a useful compd. to explore ATR pharmacol. in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpY5_RVxXl9LVg90H21EOLACvtfcHk0lgTzYMyiClZUA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXit1Ghsr0%253D&md5=60d2f6fe78e2b82695198b9cba930ae7</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Fjm301859s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301859s%26sid%3Dliteratum%253Aachs%26aulast%3DFoote%26aufirst%3DK.%2BM.%26aulast%3DBlades%26aufirst%3DK.%26aulast%3DCronin%26aufirst%3DA.%26aulast%3DFillery%26aufirst%3DS.%26aulast%3DGuichard%26aufirst%3DS.%2BS.%26aulast%3DHassall%26aufirst%3DL.%26aulast%3DHickson%26aufirst%3DI.%26aulast%3DJacq%26aufirst%3DX.%26aulast%3DJewsbury%26aufirst%3DP.%2BJ.%26aulast%3DMcGuire%26aufirst%3DT.%2BM.%26aulast%3DNissink%26aufirst%3DJ.%2BW.%26aulast%3DOdedra%26aufirst%3DR.%26aulast%3DPage%26aufirst%3DK.%26aulast%3DPerkins%26aufirst%3DP.%26aulast%3DSuleman%26aufirst%3DA.%26aulast%3DTam%26aufirst%3DK.%26aulast%3DThommes%26aufirst%3DP.%26aulast%3DBroadhurst%26aufirst%3DR.%26aulast%3DWood%26aufirst%3DC.%26atitle%3DDiscovery%2520of%25204-%257B4-%255B%25283R%2529-3-Methylmorpholin-4-yl%255D-6-%255B1-%2528methylsulfonyl%2529cyclopropyl%255Dpyrimidin-2-yl%257D-1H-indole%2520%2528AZ20%2529%253A%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520ATR%2520protein%2520kinase%2520with%2520monotherapy%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D5%26spage%3D2125%26epage%3D2138%26doi%3D10.1021%2Fjm301859s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foote, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissink, J. W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guichard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yates, J. W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blades, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heathcote, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odedra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewsbury, P. J.</span></span> <span> </span><span class="NLM_article-title">Discovery and characterization of AZD6738, a potent inhibitor of ataxia telangiectasia mutated and Rad3 related (ATR) kinase with application as an anticancer agent</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">9889</span>â <span class="NLM_lpage">9907</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b01187</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01187" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFOgu77F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9889-9907&issue=22&author=K.+M.+Footeauthor=J.+W.+M.+Nissinkauthor=T.+McGuireauthor=P.+Turnerauthor=S.+Guichardauthor=J.+W.+T.+Yatesauthor=A.+Lauauthor=K.+Bladesauthor=D.+Heathcoteauthor=R.+Odedraauthor=G.+Wilkinsonauthor=Z.+Wilsonauthor=C.+M.+Woodauthor=P.+J.+Jewsbury&title=Discovery+and+characterization+of+AZD6738%2C+a+potent+inhibitor+of+ataxia+telangiectasia+mutated+and+Rad3+related+%28ATR%29+kinase+with+application+as+an+anticancer+agent&doi=10.1021%2Facs.jmedchem.8b01187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent</span></div><div class="casAuthors">Foote, Kevin M.; Nissink, J. Willem M.; McGuire, Thomas; Turner, Paul; Guichard, Sylvie; Yates, James W. T.; Lau, Alan; Blades, Kevin; Heathcote, Dan; Odedra, Rajesh; Wilkinson, Gary; Wilson, Zena; Wood, Christine M.; Jewsbury, Philip J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9889-9907</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and assocd. DNA double-strand breaks.  Inhibition of repair pathways mediated by ATR in a context where alternative pathways are less active is expected to aid clin. response by increasing replication stress.  Here the authors describe the development of the clin. candidate II (AZD6738), a potent and selective sulfoximine morpholinopyrimidine ATR inhibitor with excellent preclin. physicochem. and pharmacokinetic (PK) characteristics.  Compd. II was developed improving aq. soly. and eliminating CYP3A4 time-dependent inhibition starting from the earlier described inhibitor I (AZ20).  The clin. candidate II has favorable human PK suitable for once or twice daily dosing and achieves biol. effective exposure at moderate doses.  Compd. II is currently being tested in multiple phase I/II trials as an anticancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr419z5SGLz_LVg90H21EOLACvtfcHk0lgTzYMyiClZUA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFOgu77F&md5=992b9a9669f1e58926d3e7e4d4e816ba</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01187%26sid%3Dliteratum%253Aachs%26aulast%3DFoote%26aufirst%3DK.%2BM.%26aulast%3DNissink%26aufirst%3DJ.%2BW.%2BM.%26aulast%3DMcGuire%26aufirst%3DT.%26aulast%3DTurner%26aufirst%3DP.%26aulast%3DGuichard%26aufirst%3DS.%26aulast%3DYates%26aufirst%3DJ.%2BW.%2BT.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DBlades%26aufirst%3DK.%26aulast%3DHeathcote%26aufirst%3DD.%26aulast%3DOdedra%26aufirst%3DR.%26aulast%3DWilkinson%26aufirst%3DG.%26aulast%3DWilson%26aufirst%3DZ.%26aulast%3DWood%26aufirst%3DC.%2BM.%26aulast%3DJewsbury%26aufirst%3DP.%2BJ.%26atitle%3DDiscovery%2520and%2520characterization%2520of%2520AZD6738%252C%2520a%2520potent%2520inhibitor%2520of%2520ataxia%2520telangiectasia%2520mutated%2520and%2520Rad3%2520related%2520%2528ATR%2529%2520kinase%2520with%2520application%2520as%2520an%2520anticancer%2520agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D22%26spage%3D9889%26epage%3D9907%26doi%3D10.1021%2Facs.jmedchem.8b01187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lloyd, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falenta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wijnhoven, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chabbert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stott, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yates, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingsworth, S. J.</span></span> <span> </span><span class="NLM_article-title">Abstract 337: The PARP inhibitor olaparib is synergistic with the ATR inhibitor AZD6738 in ATM deficient cancer cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">13, Suppl.</span>),  <span class="NLM_fpage">337</span>, <span class="refDoi">Â DOI: 10.1158/1538-7445.AM2018-337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F1538-7445.AM2018-337" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=337&issue=13%2C+Suppl.&author=R.+Lloydauthor=K.+Falentaauthor=P.+W.+Wijnhovenauthor=C.+Chabbertauthor=J.+Stottauthor=J.+Yatesauthor=A.+Y.+Lauauthor=L.+A.+Youngauthor=S.+J.+Hollingsworth&title=Abstract+337%3A+The+PARP+inhibitor+olaparib+is+synergistic+with+the+ATR+inhibitor+AZD6738+in+ATM+deficient+cancer+cells&doi=10.1158%2F1538-7445.AM2018-337"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2018-337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2018-337%26sid%3Dliteratum%253Aachs%26aulast%3DLloyd%26aufirst%3DR.%26aulast%3DFalenta%26aufirst%3DK.%26aulast%3DWijnhoven%26aufirst%3DP.%2BW.%26aulast%3DChabbert%26aufirst%3DC.%26aulast%3DStott%26aufirst%3DJ.%26aulast%3DYates%26aufirst%3DJ.%26aulast%3DLau%26aufirst%3DA.%2BY.%26aulast%3DYoung%26aufirst%3DL.%2BA.%26aulast%3DHollingsworth%26aufirst%3DS.%2BJ.%26atitle%3DAbstract%2520337%253A%2520The%2520PARP%2520inhibitor%2520olaparib%2520is%2520synergistic%2520with%2520the%2520ATR%2520inhibitor%2520AZD6738%2520in%2520ATM%2520deficient%2520cancer%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2018%26volume%3D78%26issue%3D13%252C%2520Suppl%26spage%3D337%26doi%3D10.1158%2F1538-7445.AM2018-337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barsanti, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aversa, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elling, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudewicz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taricani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, Q.</span></span> <span> </span><span class="NLM_article-title">Structure-Based drug design of novel potent and selective tetrahydropyrazolo[1,5-a]pyrazines as ATR inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">37</span>â <span class="NLM_lpage">41</span>, <span class="refDoi">Â DOI: 10.1021/ml500353p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500353p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFOjsLrM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=37-41&issue=1&author=P.+A.+Barsantiauthor=R.+J.+Aversaauthor=X.+Jinauthor=Y.+Panauthor=Y.+Luauthor=R.+Ellingauthor=R.+Jainauthor=M.+Knappauthor=J.+Lanauthor=X.+Linauthor=P.+Rudewiczauthor=J.+Simauthor=L.+Taricaniauthor=G.+Thomasauthor=L.+Xiaoauthor=Q.+Yue&title=Structure-Based+drug+design+of+novel+potent+and+selective+tetrahydropyrazolo%5B1%2C5-a%5Dpyrazines+as+ATR+inhibitors&doi=10.1021%2Fml500353p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Drug Design of Novel Potent and Selective Tetrahydropyrazolo[1,5-a]pyrazines as ATR Inhibitors</span></div><div class="casAuthors">Barsanti, Paul A.; Aversa, Robert J.; Jin, Xianming; Pan, Yue; Lu, Yipin; Elling, Robert; Jain, Rama; Knapp, Mark; Lan, Jiong; Lin, Xiaodong; Rudewicz, Patrick; Sim, Janet; Taricani, Lorena; Thomas, George; Xiao, Linda; Yue, Qin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">37-41</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A satn. strategy focused on improving the selectivity and physicochem. properties of ATR inhibitor HTS hit I led to a novel series of highly potent and selective tetrahydropyrazolo[1,5-a]pyrazines, e.g. II.  Use of PI3KÎ± mutants as ATR crystal structure surrogates was instrumental in providing cocrystal structures to guide the medicinal chem. designs.  Detailed DMPK studies involving cyanide and GSH as trapping agents during microsomal incubations, in addn. to deuterium-labeled compds. as mechanistic probes uncovered the mol. basis for the obsd. CYP3A4 TDI in the series.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTFngy1BinPLVg90H21EOLACvtfcHk0liyMZwAlI5nLA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFOjsLrM&md5=3f15f48af12efd37411173f9325efda7</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Fml500353p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500353p%26sid%3Dliteratum%253Aachs%26aulast%3DBarsanti%26aufirst%3DP.%2BA.%26aulast%3DAversa%26aufirst%3DR.%2BJ.%26aulast%3DJin%26aufirst%3DX.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DElling%26aufirst%3DR.%26aulast%3DJain%26aufirst%3DR.%26aulast%3DKnapp%26aufirst%3DM.%26aulast%3DLan%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DRudewicz%26aufirst%3DP.%26aulast%3DSim%26aufirst%3DJ.%26aulast%3DTaricani%26aufirst%3DL.%26aulast%3DThomas%26aufirst%3DG.%26aulast%3DXiao%26aufirst%3DL.%26aulast%3DYue%26aufirst%3DQ.%26atitle%3DStructure-Based%2520drug%2520design%2520of%2520novel%2520potent%2520and%2520selective%2520tetrahydropyrazolo%255B1%252C5-a%255Dpyrazines%2520as%2520ATR%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26issue%3D1%26spage%3D37%26epage%3D41%26doi%3D10.1021%2Fml500353p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pujala, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nayak, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khare, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guguloth, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randive, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinde, B. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raja, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfaro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avila, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">PÃ©rez de Arce, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almirez, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanno, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernales, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakravarty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCullagh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, S. M.</span></span> <span> </span><span class="NLM_article-title">Discovery of pyrazolopyrimidine derivatives as novel dual inhibitors of BTK and PI3KÎ´</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1161</span>â <span class="NLM_lpage">1166</span>, <span class="refDoi">Â DOI: 10.1021/acsmedchemlett.6b00356</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00356" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslGhtLfL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=1161-1166&issue=12&author=B.+Pujalaauthor=A.+K.+Agarwalauthor=S.+Middyaauthor=M.+Banerjeeauthor=A.+Suryaauthor=A.+K.+Nayakauthor=A.+Guptaauthor=S.+Khareauthor=R.+Gugulothauthor=N.+A.+Randiveauthor=B.+U.+Shindeauthor=A.+Thakurauthor=D.+I.+Patelauthor=M.+Rajaauthor=M.+J.+Greenauthor=J.+Alfaroauthor=P.+Avilaauthor=F.+P%C3%A9rez+de+Arceauthor=R.+G.+Almirezauthor=S.+Kannoauthor=S.+Bernalesauthor=D.+T.+Hungauthor=S.+Chakravartyauthor=E.+McCullaghauthor=K.+P.+Quinnauthor=R.+Raiauthor=S.+M.+Pham&title=Discovery+of+pyrazolopyrimidine+derivatives+as+novel+dual+inhibitors+of+BTK+and+PI3K%CE%B4&doi=10.1021%2Facsmedchemlett.6b00356"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Pyrazolopyrimidine Derivatives as Novel Dual Inhibitors of BTK and PI3KÎ´</span></div><div class="casAuthors">Pujala, Brahmam; Agarwal, Anil K.; Middya, Sandip; Banerjee, Monali; Surya, Arjun; Nayak, Anjan K.; Gupta, Ashu; Khare, Sweta; Guguloth, Rambabu; Randive, Nitin A.; Shinde, Bharat U.; Thakur, Anamika; Patel, Dhananjay I.; Raja, Mohd.; Green, Michael J.; Alfaro, Jennifer; Avila, Patricio; Perez de Arce, Felipe; Almirez, Ramona G.; Kanno, Stacy; Bernales, Sebastian; Hung, David T.; Chakravarty, Sarvajit; McCullagh, Emma; Quinn, Kevin P.; Rai, Roopa; Pham, Son M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1161-1166</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The aberrant activation of B-cells has been implicated in several types of cancers and hematol. disorders.  BTK and PI3KÎ´ are kinases responsible for B-cell signal transduction, and inhibitors of these enzymes have demonstrated clin. benefit in certain types of lymphoma.  Simultaneous inhibition of these pathways could result in more robust responses or overcome resistance as obsd. in single agent use.  The authors report a series of novel compds. that have low nanomolar potency against both BTK and PI3KÎ´ as well as acceptable PK properties that could be useful in the development of treatments against B-cell related diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4WMataMc2hbVg90H21EOLACvtfcHk0lgurRsfKbSbSA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslGhtLfL&md5=2a977a59c1bd1ccc5682405628990617</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00356%26sid%3Dliteratum%253Aachs%26aulast%3DPujala%26aufirst%3DB.%26aulast%3DAgarwal%26aufirst%3DA.%2BK.%26aulast%3DMiddya%26aufirst%3DS.%26aulast%3DBanerjee%26aufirst%3DM.%26aulast%3DSurya%26aufirst%3DA.%26aulast%3DNayak%26aufirst%3DA.%2BK.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DKhare%26aufirst%3DS.%26aulast%3DGuguloth%26aufirst%3DR.%26aulast%3DRandive%26aufirst%3DN.%2BA.%26aulast%3DShinde%26aufirst%3DB.%2BU.%26aulast%3DThakur%26aufirst%3DA.%26aulast%3DPatel%26aufirst%3DD.%2BI.%26aulast%3DRaja%26aufirst%3DM.%26aulast%3DGreen%26aufirst%3DM.%2BJ.%26aulast%3DAlfaro%26aufirst%3DJ.%26aulast%3DAvila%26aufirst%3DP.%26aulast%3DP%25C3%25A9rez%2Bde%2BArce%26aufirst%3DF.%26aulast%3DAlmirez%26aufirst%3DR.%2BG.%26aulast%3DKanno%26aufirst%3DS.%26aulast%3DBernales%26aufirst%3DS.%26aulast%3DHung%26aufirst%3DD.%2BT.%26aulast%3DChakravarty%26aufirst%3DS.%26aulast%3DMcCullagh%26aufirst%3DE.%26aulast%3DQuinn%26aufirst%3DK.%2BP.%26aulast%3DRai%26aufirst%3DR.%26aulast%3DPham%26aufirst%3DS.%2BM.%26atitle%3DDiscovery%2520of%2520pyrazolopyrimidine%2520derivatives%2520as%2520novel%2520dual%2520inhibitors%2520of%2520BTK%2520and%2520PI3K%25CE%25B4%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26issue%3D12%26spage%3D1161%26epage%3D1166%26doi%3D10.1021%2Facsmedchemlett.6b00356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jadhavar, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagle, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Protter, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindquist, J. N.</span></span> <span> </span><span class="NLM_article-title">Discovery of pyrazolopyrimidine derivatives as novel inhibitors of ataxia telangiectasia and rad3 related protein (ATR)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">750</span>â <span class="NLM_lpage">754</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2017.01.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.bmcl.2017.01.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=28131712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Kgsb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=750-754&issue=4&author=S.+A.+Ramachandranauthor=P.+S.+Jadhavarauthor=M.+P.+Singhauthor=A.+Sharmaauthor=G.+N.+Bagleauthor=K.+P.+Quinnauthor=P.+Y.+Wongauthor=A.+A.+Protterauthor=R.+Raiauthor=S.+M.+Phamauthor=J.+N.+Lindquist&title=Discovery+of+pyrazolopyrimidine+derivatives+as+novel+inhibitors+of+ataxia+telangiectasia+and+rad3+related+protein+%28ATR%29&doi=10.1016%2Fj.bmcl.2017.01.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of pyrazolopyrimidine derivatives as novel inhibitors of ataxia telangiectasia and rad3 related protein (ATR)</span></div><div class="casAuthors">Ramachandran, Sreekanth A.; Jadhavar, Pradeep S.; Singh, Manvendra P.; Sharma, Ankesh; Bagle, Gaurav N.; Quinn, Kevin P.; Wong, Po-yin; Protter, Andrew A.; Rai, Roopa; Pham, Son M.; Lindquist, Jeffrey N.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">750-754</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The ATR pathway is a crit. mediator of the replication stress response in cells.  In aberrantly proliferating cancer cells, this pathway can help maintain sufficient genomic integrity for cancer cell progression.  Herein the authors describe the discovery of 1-(4-(methylsulfonyl)phenyl)-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine, a pyrazolopyrimidine-contg. inhibitor of ATR via a strategic repurposing of compds. targeting PI3K.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOzI0OXLOKdbVg90H21EOLACvtfcHk0lgurRsfKbSbSA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Kgsb4%253D&md5=3317730261d88b63ee6fea216d3c049b</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.01.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.01.045%26sid%3Dliteratum%253Aachs%26aulast%3DRamachandran%26aufirst%3DS.%2BA.%26aulast%3DJadhavar%26aufirst%3DP.%2BS.%26aulast%3DSingh%26aufirst%3DM.%2BP.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DBagle%26aufirst%3DG.%2BN.%26aulast%3DQuinn%26aufirst%3DK.%2BP.%26aulast%3DWong%26aufirst%3DP.%2BY.%26aulast%3DProtter%26aufirst%3DA.%2BA.%26aulast%3DRai%26aufirst%3DR.%26aulast%3DPham%26aufirst%3DS.%2BM.%26aulast%3DLindquist%26aufirst%3DJ.%2BN.%26atitle%3DDiscovery%2520of%2520pyrazolopyrimidine%2520derivatives%2520as%2520novel%2520inhibitors%2520of%2520ataxia%2520telangiectasia%2520and%2520rad3%2520related%2520protein%2520%2528ATR%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26issue%3D4%26spage%3D750%26epage%3D754%26doi%3D10.1016%2Fj.bmcl.2017.01.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hickson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orr, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reaper, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtin, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. C.</span></span> <span> </span><span class="NLM_article-title">Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>64</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">9152</span>â <span class="NLM_lpage">9159</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-04-2727</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F0008-5472.CAN-04-2727" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=15604286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVOmsb7K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=9152-9159&issue=24&author=I.+Hicksonauthor=Y.+Zhaoauthor=C.+J.+Richardsonauthor=S.+J.+Greenauthor=N.+M.+Martinauthor=A.+I.+Orrauthor=P.+M.+Reaperauthor=S.+P.+Jacksonauthor=N.+J.+Curtinauthor=G.+C.+Smith&title=Identification+and+characterization+of+a+novel+and+specific+inhibitor+of+the+ataxia-telangiectasia+mutated+kinase+ATM&doi=10.1158%2F0008-5472.CAN-04-2727"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM</span></div><div class="casAuthors">Hickson, Ian; Zhao, Yan; Richardson, Caroline J.; Green, Sharon J.; Martin, Niall M. B.; Orr, Alisdair I.; Reaper, Philip M.; Jackson, Stephen P.; Curtin, Nicola J.; Smith, Graeme C. M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">9152-9159</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The serine/threonine protein kinase ATM signals to cell cycle and DNA repair components by phosphorylating downstream targets such as p53, CHK2, NBS1, and BRCA1.  Mutation of ATM occurs in the human autosomal recessive disorder ataxia-telangiectasia, which is characterized by hypersensitivity to ionizing radiation and a failure of cells to arrest the cell cycle after the induction of DNA double-strand breaks.  It has thus been proposed that ATM inhibition would cause cellular radio- and chemosensitization.  Through screening a small mol. compd. library developed for the phosphatidylinositol 3'-kinase-like kinase family, we identified an ATP-competitive inhibitor, 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one (KU-55933), that inhibits ATM with an IC50 of 13 nmol/L and a Ki of 2.2 nmol/L.  KU-55933 shows specificity with respect to inhibition of other phosphatidylinositol 3'-kinase-like kinases.  Cellular inhibition of ATM by KU-55933 was demonstrated by the ablation of ionizing radiation-dependent phosphorylation of a range of ATM targets, including p53, Î³H2AX, NBS1, and SMC1.  KU-55933 did not show inhibition of UV light DNA damage induced cellular phosphorylation events.  Exposure of cells to KU-55933 resulted in a significant sensitization to the cytotoxic effects of ionizing radiation and to the DNA double-strand break-inducing chemotherapeutic agents, etoposide, doxorubicin, and camptothecin.  Inhibition of ATM by KU-55933 also caused a loss of ionizing radiation-induced cell cycle arrest.  By contrast, KU-55933 did not potentiate the cytotoxic effects of ionizing radiation on ataxia-telangiectasia cells, nor did it affect their cell cycle profile after DNA damage.  We conclude that KU-55933 is a novel, specific, and potent inhibitor of the ATM kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok44U64rohgrVg90H21EOLACvtfcHk0lichU-wsWInIQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVOmsb7K&md5=fb166cc695613369c9cef7ac451f7dd3</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-2727&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-2727%26sid%3Dliteratum%253Aachs%26aulast%3DHickson%26aufirst%3DI.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DRichardson%26aufirst%3DC.%2BJ.%26aulast%3DGreen%26aufirst%3DS.%2BJ.%26aulast%3DMartin%26aufirst%3DN.%2BM.%26aulast%3DOrr%26aufirst%3DA.%2BI.%26aulast%3DReaper%26aufirst%3DP.%2BM.%26aulast%3DJackson%26aufirst%3DS.%2BP.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DSmith%26aufirst%3DG.%2BC.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520a%2520novel%2520and%2520specific%2520inhibitor%2520of%2520the%2520ataxia-telangiectasia%2520mutated%2520kinase%2520ATM%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26issue%3D24%26spage%3D9152%26epage%3D9159%26doi%3D10.1158%2F0008-5472.CAN-04-2727" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Golding, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valerie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussaini, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frigerio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cockcroft, X. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hummersone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rigoreau, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menear, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâConnor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Povirk, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Meter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valerie, K.</span></span> <span> </span><span class="NLM_article-title">Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2894</span>â <span class="NLM_lpage">2902</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-09-0519</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F1535-7163.MCT-09-0519" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=19808981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Cqur7F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=2894-2902&issue=10&author=S.+E.+Goldingauthor=E.+Rosenbergauthor=N.+Valerieauthor=I.+Hussainiauthor=M.+Frigerioauthor=X.+F.+Cockcroftauthor=W.+Y.+Chongauthor=M.+Hummersoneauthor=L.+Rigoreauauthor=K.+A.+Menearauthor=M.+J.+O%E2%80%99Connorauthor=L.+F.+Povirkauthor=T.+van+Meterauthor=K.+Valerie&title=Improved+ATM+kinase+inhibitor+KU-60019+radiosensitizes+glioma+cells%2C+compromises+insulin%2C+AKT+and+ERK+prosurvival+signaling%2C+and+inhibits+migration+and+invasion&doi=10.1158%2F1535-7163.MCT-09-0519"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion</span></div><div class="casAuthors">Golding, Sarah E.; Rosenberg, Elizabeth; Valerie, Nicholas; Hussaini, Isa; Frigerio, Mark; Cockcroft, Xiaoling F.; Chong, Wei Yee; Hummersone, Marc; Rigoreau, Laurent; Menear, Keith A.; O'Connor, Mark J.; Povirk, Lawrence F.; van Meter, Timothy; Valerie, Kristoffer</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2894-2902</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Ataxia telangiectasia (A-T) mutated (ATM) is crit. for cell cycle checkpoints and DNA repair.  Thus, specific small mol. inhibitors targeting ATM could perhaps be developed into efficient radiosensitizers.  Recently, a specific inhibitor of the ATM kinase, KU-55933, was shown to radiosensitize human cancer cells.  Herein, we report on an improved analog of KU-55933 (KU-60019) with Ki and IC50 values half of those of KU-55933.  KU-60019 is 10-fold more effective than KU-55933 at blocking radiation-induced phosphorylation of key ATM targets in human glioma cells.  As expected, KU-60019 is a highly effective radiosensitizer of human glioma cells.  A-T fibroblasts were not radiosensitized by KU-60019, strongly suggesting that the ATM kinase is specifically targeted.  Furthermore, KU-60019 reduced basal S473 AKT phosphorylation, suggesting that the ATM kinase might regulate a protein phosphatase acting on AKT.  In line with this finding, the effect of KU-60019 on AKT phosphorylation was countered by low levels of okadaic acid, a phosphatase inhibitor, and A-T cells were impaired in S473 AKT phosphorylation in response to radiation and insulin and unresponsive to KU-60019.  We also show that KU-60019 inhibits glioma cell migration and invasion in vitro, suggesting that glioma growth and motility might be controlled by ATM via AKT.  Inhibitors of MEK and AKT did not further radiosensitize cells treated with KU-60019, supporting the idea that KU-60019 interferes with prosurvival signaling sep. from its radiosensitizing properties.  Altogether, KU-60019 inhibits the DNA damage response, reduces AKT phosphorylation and prosurvival signaling, inhibits migration and invasion, and effectively radiosensitizes human glioma cells. [Mol Cancer Ther 2009;8(10):2894-902].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXun9h1lvdbbVg90H21EOLACvtfcHk0lichU-wsWInIQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Cqur7F&md5=32fab13cdf80a5fcb520e358252c8764</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0519%26sid%3Dliteratum%253Aachs%26aulast%3DGolding%26aufirst%3DS.%2BE.%26aulast%3DRosenberg%26aufirst%3DE.%26aulast%3DValerie%26aufirst%3DN.%26aulast%3DHussaini%26aufirst%3DI.%26aulast%3DFrigerio%26aufirst%3DM.%26aulast%3DCockcroft%26aufirst%3DX.%2BF.%26aulast%3DChong%26aufirst%3DW.%2BY.%26aulast%3DHummersone%26aufirst%3DM.%26aulast%3DRigoreau%26aufirst%3DL.%26aulast%3DMenear%26aufirst%3DK.%2BA.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DPovirk%26aufirst%3DL.%2BF.%26aulast%3Dvan%2BMeter%26aufirst%3DT.%26aulast%3DValerie%26aufirst%3DK.%26atitle%3DImproved%2520ATM%2520kinase%2520inhibitor%2520KU-60019%2520radiosensitizes%2520glioma%2520cells%252C%2520compromises%2520insulin%252C%2520AKT%2520and%2520ERK%2520prosurvival%2520signaling%252C%2520and%2520inhibits%2520migration%2520and%2520invasion%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26issue%3D10%26spage%3D2894%26epage%3D2902%26doi%3D10.1158%2F1535-7163.MCT-09-0519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rainey, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanton, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kastan, M. B.</span></span> <span> </span><span class="NLM_article-title">Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>68</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">7466</span>â <span class="NLM_lpage">7474</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-08-0763</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F0008-5472.CAN-08-0763" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=18794134" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFWltb7K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=7466-7474&issue=18&author=M.+D.+Raineyauthor=M.+E.+Charltonauthor=R.+V.+Stantonauthor=M.+B.+Kastan&title=Transient+inhibition+of+ATM+kinase+is+sufficient+to+enhance+cellular+sensitivity+to+ionizing+radiation&doi=10.1158%2F0008-5472.CAN-08-0763"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Transient Inhibition of ATM Kinase Is Sufficient to Enhance Cellular Sensitivity to Ionizing Radiation</span></div><div class="casAuthors">Rainey, Michael D.; Charlton, Maura E.; Stanton, Robert V.; Kastan, Michael B.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7466-7474</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">In response to DNA damage, the ATM protein kinase activates signal transduction pathways essential for coordinating cell cycle progression with DNA repair.  In the human disease ataxia-telangiectasia, mutation of the ATM gene results in multiple cellular defects, including enhanced sensitivity to ionizing radiation (IR).  This phenotype highlights ATM as a potential target for novel inhibitors that could be used to enhance tumor cell sensitivity to radiotherapy.  A targeted compd. library was screened for potential inhibitors of the ATM kinase, and CP466722 was identified.  The compd. is nontoxic and does not inhibit phosphatidylinositol 3-kinase (PI3K) or PI3K-like protein kinase family members in cells.  CP466722 inhibited cellular ATM-dependent phosphorylation events and disruption of ATM function resulted in characteristic cell cycle checkpoint defects.  Inhibition of cellular ATM kinase activity was rapidly and completely reversed by removing CP466722.  Interestingly, clonogenic survival assays showed that transient inhibition of ATM is sufficient to sensitize cells to IR and suggests that therapeutic radiosensitization may only require ATM inhibition for short periods of time.  The ability of CP466722 to rapidly and reversibly regulate ATM activity provides a new tool to ask questions about ATM function that could not easily be addressed using genetic models or RNA interference technologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOLYFcaRvfPrVg90H21EOLACvtfcHk0li2az6_r88-eQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFWltb7K&md5=f228e55406cd0f91e0543aa0f93f70f8</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-0763&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-0763%26sid%3Dliteratum%253Aachs%26aulast%3DRainey%26aufirst%3DM.%2BD.%26aulast%3DCharlton%26aufirst%3DM.%2BE.%26aulast%3DStanton%26aufirst%3DR.%2BV.%26aulast%3DKastan%26aufirst%3DM.%2BB.%26atitle%3DTransient%2520inhibition%2520of%2520ATM%2520kinase%2520is%2520sufficient%2520to%2520enhance%2520cellular%2520sensitivity%2520to%2520ionizing%2520radiation%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26issue%3D18%26spage%3D7466%26epage%3D7474%26doi%3D10.1158%2F0008-5472.CAN-08-0763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Awasthi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foiani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span> <span> </span><span class="NLM_article-title">ATM and ATR signaling at a glance</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>128</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">4255</span>â <span class="NLM_lpage">4262</span>, <span class="refDoi">Â DOI: 10.1242/jcs.169730</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1242%2Fjcs.169730" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=26567218" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC28XosFCltbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2015&pages=4255-4262&issue=23&author=P.+Awasthiauthor=M.+Foianiauthor=A.+Kumar&title=ATM+and+ATR+signaling+at+a+glance&doi=10.1242%2Fjcs.169730"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">ATM and ATR signaling at a glance</span></div><div class="casAuthors">Awasthi, Poorwa; Foiani, Marco; Kumar, Amit</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4255-4262</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">ATM and ATR signaling pathways are well conserved throughout evolution and are central to the maintenance of genome integrity.  Although the role of both ATM and ATR in DNA repair, cell cycle regulation and apoptosis have been well studied, both still remain in the focus of current research activities owing to their role in cancer.  Recent advances in the field suggest that these proteins have an addnl. function in maintaining cellular homeostasis under both stressed and non-stressed conditions.  In this Cell Science at a Glance article and the accompanying poster, we present an overview of recent advances in ATR and ATM research with emphasis on that into the modes of ATM and ATR activation, the different signaling pathways they participate in - including those that do not involve DNA damage - and highlight their relevance in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2wacg1aItObVg90H21EOLACvtfcHk0li2az6_r88-eQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosFCltbk%253D&md5=e10656180a9b2b226e67b8bd99643a3b</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1242%2Fjcs.169730&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.169730%26sid%3Dliteratum%253Aachs%26aulast%3DAwasthi%26aufirst%3DP.%26aulast%3DFoiani%26aufirst%3DM.%26aulast%3DKumar%26aufirst%3DA.%26atitle%3DATM%2520and%2520ATR%2520signaling%2520at%2520a%2520glance%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2015%26volume%3D128%26issue%3D23%26spage%3D4255%26epage%3D4262%26doi%3D10.1242%2Fjcs.169730" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Degorce, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlaam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cadogan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dishington, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ducray, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glossop, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassall, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lach, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouvry, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomason, A. G.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel 3-quinoline carboxamides as potent, selective, and orally bioavailable inhibitors of ataxia telangiectasia mutated (ATM) kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">6281</span>â <span class="NLM_lpage">6292</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b00519</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00519" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC28XptFentrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=6281-6292&issue=13&author=S.+L.+Degorceauthor=B.+Barlaamauthor=E.+Cadoganauthor=A.+Dishingtonauthor=R.+Ducrayauthor=S.+C.+Glossopauthor=L.+A.+Hassallauthor=F.+Lachauthor=A.+Lauauthor=T.+M.+McGuireauthor=T.+Nowakauthor=G.+Ouvryauthor=K.+G.+Pikeauthor=A.+G.+Thomason&title=Discovery+of+novel+3-quinoline+carboxamides+as+potent%2C+selective%2C+and+orally+bioavailable+inhibitors+of+ataxia+telangiectasia+mutated+%28ATM%29+kinase&doi=10.1021%2Facs.jmedchem.6b00519"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase</span></div><div class="casAuthors">Degorce, Sebastien L.; Barlaam, Bernard; Cadogan, Elaine; Dishington, Allan; Ducray, Richard; Glossop, Steven C.; Hassall, Lorraine A.; Lach, Franck; Lau, Alan; McGuire, Thomas M.; Nowak, Thorsten; Ouvry, Gilles; Pike, Kurt G.; Thomason, Andrew G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6281-6292</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of 3-quinoline carboxamides has been discovered and optimized as selective inhibitors of the ataxia telangiectasia mutated (ATM) kinase.  From a modestly potent HTS hit (4), we identified mols. such as 6-[6-(methoxymethyl)-3-pyridinyl]-4-{[(1R)-1-(tetrahydro-2H-pyran-4-yl)ethyl]amino}-3-quinolinecarboxamide (72) and 7-fluoro-6-[6-(methoxymethyl)pyridin-3-yl]-4-{[(1S)-1-(1-methyl-1H-pyrazol-3-yl)ethyl]amino}quinoline-3-carboxamide (74) as potent and highly selective ATM inhibitors with overall ADME properties suitable for oral administration. 72 and 74 constitute excellent oral tools to probe ATM inhibition in vivo.  Efficacy in combination with the DSB-inducing agent irinotecan was obsd. in a disease relevant model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3a9n-YFghx7Vg90H21EOLACvtfcHk0li2az6_r88-eQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptFentrg%253D&md5=99e98b54eb61ec56bb6883378bad9324</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00519%26sid%3Dliteratum%253Aachs%26aulast%3DDegorce%26aufirst%3DS.%2BL.%26aulast%3DBarlaam%26aufirst%3DB.%26aulast%3DCadogan%26aufirst%3DE.%26aulast%3DDishington%26aufirst%3DA.%26aulast%3DDucray%26aufirst%3DR.%26aulast%3DGlossop%26aufirst%3DS.%2BC.%26aulast%3DHassall%26aufirst%3DL.%2BA.%26aulast%3DLach%26aufirst%3DF.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DMcGuire%26aufirst%3DT.%2BM.%26aulast%3DNowak%26aufirst%3DT.%26aulast%3DOuvry%26aufirst%3DG.%26aulast%3DPike%26aufirst%3DK.%2BG.%26aulast%3DThomason%26aufirst%3DA.%2BG.%26atitle%3DDiscovery%2520of%2520novel%25203-quinoline%2520carboxamides%2520as%2520potent%252C%2520selective%252C%2520and%2520orally%2520bioavailable%2520inhibitors%2520of%2520ataxia%2520telangiectasia%2520mutated%2520%2528ATM%2529%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D13%26spage%3D6281%26epage%3D6292%26doi%3D10.1021%2Facs.jmedchem.6b00519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karlin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheridan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odedra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrington, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cadogan, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riches, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Trinidad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomason, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sule, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valerie, N. C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biddlestone-Thorpe, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckta, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukhopadhyay, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlaam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degorce, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kettle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colclough, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, I. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pass, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durant, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valerie, K.</span></span> <span> </span><span class="NLM_article-title">Orally bioavailable and blood-brain barrier-penetrating ATM inhibitor (AZ32) radiosensitizes intracranial gliomas in mice</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1637</span>â <span class="NLM_lpage">1647</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-17-0975</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F1535-7163.MCT-17-0975" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=29769307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVWrtrbP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=1637-1647&issue=8&author=J.+Karlinauthor=J.+Allenauthor=S.+F.+Ahmadauthor=G.+Hughesauthor=V.+Sheridanauthor=R.+Odedraauthor=P.+Farringtonauthor=E.+B.+Cadoganauthor=L.+C.+Richesauthor=A.+Garcia-Trinidadauthor=A.+G.+Thomasonauthor=B.+Patelauthor=J.+Vincentauthor=A.+Lauauthor=K.+G.+Pikeauthor=T.+A.+Huntauthor=A.+Suleauthor=N.+C.+K.+Valerieauthor=L.+Biddlestone-Thorpeauthor=J.+Kahnauthor=J.+M.+Becktaauthor=N.+Mukhopadhyayauthor=B.+Barlaamauthor=S.+L.+Degorceauthor=J.+Kettleauthor=N.+Colcloughauthor=J.+Wilsonauthor=A.+Smithauthor=I.+P.+Barrettauthor=L.+Zhengauthor=T.+Zhangauthor=Y.+Wangauthor=K.+Chenauthor=M.+Passauthor=S.+T.+Durantauthor=K.+Valerie&title=Orally+bioavailable+and+blood-brain+barrier-penetrating+ATM+inhibitor+%28AZ32%29+radiosensitizes+intracranial+gliomas+in+mice&doi=10.1158%2F1535-7163.MCT-17-0975"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Orally Bioavailable and Blood-Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice</span></div><div class="casAuthors">Karlin, Jeremy; Allen, Jasmine; Ahmad, Syed F.; Hughes, Gareth; Sheridan, Victoria; Odedra, Rajesh; Farrington, Paul; Cadogan, Elaine B.; Riches, Lucy C.; Garcia-Trinidad, Antonio; Thomason, Andrew G.; Patel, Bhavika; Vincent, Jennifer; Lau, Alan; Pike, Kurt G.; Hunt, Thomas A.; Sule, Amrita; Valerie, Nicholas C. K.; Biddlestone-Thorpe, Laura; Kahn, Jenna; Beckta, Jason M.; Mukhopadhyay, Nitai; Barlaam, Bernard; Degorce, Sebastien L.; Kettle, Jason; Colclough, Nicola; Wilson, Joanne; Smith, Aaron; Barrett, Ian P.; Zheng, Li; Zhang, Tianwei; Wang, Yingchun; Chen, Kan; Pass, Martin; Durant, Stephen T.; Valerie, Kristoffer</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1637-1647</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Inhibition of ataxia-telangiectasia mutated (ATM) during radiotherapy of glioblastoma multiforme (GBM) may improve tumor control by short-circuiting the response to radiation-induced DNA damage.  A major impediment for clin. implementation is that current inhibitors have limited central nervous system (CNS) bioavailability; thus, the goal was to identify ATM inhibitors (ATMi) with improved CNS penetration.  Drug screens and refinement of lead compds. identified AZ31 and AZ32.  The compds. were then tested in vivo for efficacy and impact on tumor and healthy brain.  Both AZ31 and AZ32 blocked the DNA damage response and radiosensitized GBM cells in vitro.  AZ32, with enhanced blood-brain barrier (BBB) penetration, was highly efficient in vivo as radiosensitizer in syngeneic and human, orthotopic mouse glioma model compared with AZ31.  Furthermore, human glioma cell lines expressing mutant p53 or having checkpoint-defective mutations were particularly sensitive to ATMi radiosensitization.  The mechanism for this p53 effect involves a propensity to undergo mitotic catastrophe relative to cells with wild-type p53.  In vivo, apoptosis was >6-fold higher in tumor relative to healthy brain after exposure to AZ32 and low-dose radiation.  AZ32 is the first ATMi with oral bioavailability shown to radiosensitize glioma and improve survival in orthotopic mouse models.  These findings support the development of a clin.-grade, BBB-penetrating ATMi for the treatment of GBM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBsLUOcyCbjbVg90H21EOLACvtfcHk0liOpV956Fj0cw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVWrtrbP&md5=41e779561c69dbc6e52c14052c5622d9</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-17-0975&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-17-0975%26sid%3Dliteratum%253Aachs%26aulast%3DKarlin%26aufirst%3DJ.%26aulast%3DAllen%26aufirst%3DJ.%26aulast%3DAhmad%26aufirst%3DS.%2BF.%26aulast%3DHughes%26aufirst%3DG.%26aulast%3DSheridan%26aufirst%3DV.%26aulast%3DOdedra%26aufirst%3DR.%26aulast%3DFarrington%26aufirst%3DP.%26aulast%3DCadogan%26aufirst%3DE.%2BB.%26aulast%3DRiches%26aufirst%3DL.%2BC.%26aulast%3DGarcia-Trinidad%26aufirst%3DA.%26aulast%3DThomason%26aufirst%3DA.%2BG.%26aulast%3DPatel%26aufirst%3DB.%26aulast%3DVincent%26aufirst%3DJ.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DPike%26aufirst%3DK.%2BG.%26aulast%3DHunt%26aufirst%3DT.%2BA.%26aulast%3DSule%26aufirst%3DA.%26aulast%3DValerie%26aufirst%3DN.%2BC.%2BK.%26aulast%3DBiddlestone-Thorpe%26aufirst%3DL.%26aulast%3DKahn%26aufirst%3DJ.%26aulast%3DBeckta%26aufirst%3DJ.%2BM.%26aulast%3DMukhopadhyay%26aufirst%3DN.%26aulast%3DBarlaam%26aufirst%3DB.%26aulast%3DDegorce%26aufirst%3DS.%2BL.%26aulast%3DKettle%26aufirst%3DJ.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DWilson%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DBarrett%26aufirst%3DI.%2BP.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DPass%26aufirst%3DM.%26aulast%3DDurant%26aufirst%3DS.%2BT.%26aulast%3DValerie%26aufirst%3DK.%26atitle%3DOrally%2520bioavailable%2520and%2520blood-brain%2520barrier-penetrating%2520ATM%2520inhibitor%2520%2528AZ32%2529%2520radiosensitizes%2520intracranial%2520gliomas%2520in%2520mice%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2018%26volume%3D17%26issue%3D8%26spage%3D1637%26epage%3D1647%26doi%3D10.1158%2F1535-7163.MCT-17-0975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pike, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlaam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cadogan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colclough, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de-Almeida, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degorce, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Didelot, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dishington, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ducray, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durant, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassall, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacFaul, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulholland, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouvry, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pass, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robb, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stratton, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Huniti, N.</span></span> <span> </span><span class="NLM_article-title">The identification of potent, selective, and orally available inhibitors of ataxia telangiectasia mutated (ATM) kinase: the discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H-pyran-4-yl)-1,3-dihydro-2 H-imidazo[4,5- c]quinolin-2-one)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">3823</span>â <span class="NLM_lpage">3841</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b01896</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01896" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotFaru7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=3823-3841&issue=9&author=K.+G.+Pikeauthor=B.+Barlaamauthor=E.+Cadoganauthor=A.+Campbellauthor=Y.+Chenauthor=N.+Colcloughauthor=N.+L.+Daviesauthor=C.+de-Almeidaauthor=S.+L.+Degorceauthor=M.+Didelotauthor=A.+Dishingtonauthor=R.+Ducrayauthor=S.+T.+Durantauthor=L.+A.+Hassallauthor=J.+Holmesauthor=G.+D.+Hughesauthor=P.+A.+MacFaulauthor=K.+R.+Mulhollandauthor=T.+M.+McGuireauthor=G.+Ouvryauthor=M.+Passauthor=G.+Robbauthor=N.+Strattonauthor=Z.+Wangauthor=J.+Wilsonauthor=B.+Zhaiauthor=K.+Zhaoauthor=N.+Al-Huniti&title=The+identification+of+potent%2C+selective%2C+and+orally+available+inhibitors+of+ataxia+telangiectasia+mutated+%28ATM%29+kinase%3A+the+discovery+of+AZD0156+%288-%7B6-%5B3-%28Dimethylamino%29propoxy%5Dpyridin-3-yl%7D-3-methyl-1-%28tetrahydro-2+H-pyran-4-yl%29-1%2C3-dihydro-2+H-imidazo%5B4%2C5-+c%5Dquinolin-2-one%29&doi=10.1021%2Facs.jmedchem.7b01896"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one)</span></div><div class="casAuthors">Pike, Kurt G.; Barlaam, Bernard; Cadogan, Elaine; Campbell, Andrew; Chen, Yingxue; Colclough, Nicola; Davies, Nichola L.; de-Almeida, Camila; Degorce, Sebastien L.; Didelot, Myriam; Dishington, Allan; Ducray, Richard; Durant, Stephen T.; Hassall, Lorraine A.; Holmes, Jane; Hughes, Gareth D.; MacFaul, Philip A.; Mulholland, Keith R.; McGuire, Thomas M.; Ouvry, Gilles; Pass, Martin; Robb, Graeme; Stratton, Natalie; Wang, Zhenhua; Wilson, Joanne; Zhai, Baochang; Zhao, Kang; Al-Huniti, Nidal</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3823-3841</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">ATM inhibitors, such as I, have demonstrated the antitumor potential of ATM inhibition when combined with DNA double-strand break-inducing agents in mouse xenograft models.  However, the properties of I result in a relatively high predicted clin. efficacious dose.  In an attempt to minimize attrition during clin. development, we sought to identify ATM inhibitors with a low predicted clin. dose (<50 mg) and focused on strategies to increase both ATM potency and predicted human pharmacokinetic half-life (predominantly through the increase of vol. of distribution).  These efforts resulted in the discovery of II (AZD0156), an exceptionally potent and selective inhibitor of ATM based on an imidazo[4,5-c]quinolin-2-one core.  Compd. II has good preclin. pharmacokinetics, a low predicted clin. dose, and a high max. absorbable dose. 64 has been shown to potentiate the efficacy of the approved drugs irinotecan and olaparib in disease relevant mouse models and is currently undergoing clin. evaluation with these agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZZLVXgx3Y2LVg90H21EOLACvtfcHk0ljPvHuvK9PEuQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotFaru7w%253D&md5=ae6d4ef920cf3205a9f69c55d18f0f4b</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01896%26sid%3Dliteratum%253Aachs%26aulast%3DPike%26aufirst%3DK.%2BG.%26aulast%3DBarlaam%26aufirst%3DB.%26aulast%3DCadogan%26aufirst%3DE.%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DDavies%26aufirst%3DN.%2BL.%26aulast%3Dde-Almeida%26aufirst%3DC.%26aulast%3DDegorce%26aufirst%3DS.%2BL.%26aulast%3DDidelot%26aufirst%3DM.%26aulast%3DDishington%26aufirst%3DA.%26aulast%3DDucray%26aufirst%3DR.%26aulast%3DDurant%26aufirst%3DS.%2BT.%26aulast%3DHassall%26aufirst%3DL.%2BA.%26aulast%3DHolmes%26aufirst%3DJ.%26aulast%3DHughes%26aufirst%3DG.%2BD.%26aulast%3DMacFaul%26aufirst%3DP.%2BA.%26aulast%3DMulholland%26aufirst%3DK.%2BR.%26aulast%3DMcGuire%26aufirst%3DT.%2BM.%26aulast%3DOuvry%26aufirst%3DG.%26aulast%3DPass%26aufirst%3DM.%26aulast%3DRobb%26aufirst%3DG.%26aulast%3DStratton%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DWilson%26aufirst%3DJ.%26aulast%3DZhai%26aufirst%3DB.%26aulast%3DZhao%26aufirst%3DK.%26aulast%3DAl-Huniti%26aufirst%3DN.%26atitle%3DThe%2520identification%2520of%2520potent%252C%2520selective%252C%2520and%2520orally%2520available%2520inhibitors%2520of%2520ataxia%2520telangiectasia%2520mutated%2520%2528ATM%2529%2520kinase%253A%2520the%2520discovery%2520of%2520AZD0156%2520%25288-%257B6-%255B3-%2528Dimethylamino%2529propoxy%255Dpyridin-3-yl%257D-3-methyl-1-%2528tetrahydro-2%2520H-pyran-4-yl%2529-1%252C3-dihydro-2%2520H-imidazo%255B4%252C5-%2520c%255Dquinolin-2-one%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D9%26spage%3D3823%26epage%3D3841%26doi%3D10.1021%2Facs.jmedchem.7b01896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span> <span> </span><span class="NLM_article-title">Volume of distribution in drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">5691</span>â <span class="NLM_lpage">5698</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b00201</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00201" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltFSlsb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=5691-5698&issue=15&author=D.+A.+Smithauthor=K.+Beaumontauthor=T.+S.+Maurerauthor=L.+Di&title=Volume+of+distribution+in+drug+design&doi=10.1021%2Facs.jmedchem.5b00201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Volume of Distribution in Drug Design</span></div><div class="casAuthors">Smith, Dennis A.; Beaumont, Kevin; Maurer, Tristan S.; Di, Li</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5691-5698</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Vol. of distribution is one of the most important pharmacokinetic properties of a drug candidate.  It is a major determinant of half-life and dosing frequency of a drug.  For a similar log P, a basic mol. will tend to exhibit higher vol. of distribution than a neutral mol.  Acids often exhibit low vols. of distribution.  Although a design strategy against vol. of distribution can be advantageous in achieving desirable dosing regimen, it must be well-directed in order to avoid detrimental effects to other important properties.  Strategies to increase vol. of distribution include adding lipophilicity and introducing basic functional groups in a way that does not increase metabolic clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP7QwgPahf4bVg90H21EOLACvtfcHk0ljPvHuvK9PEuQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltFSlsb0%253D&md5=2c7289b3602a8edef2d9ef0e6a82e483</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00201%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DBeaumont%26aufirst%3DK.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DDi%26aufirst%3DL.%26atitle%3DVolume%2520of%2520distribution%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D15%26spage%3D5691%26epage%3D5698%26doi%3D10.1021%2Facs.jmedchem.5b00201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maira, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauffer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brueggen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brachmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chene, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Pover, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoemaker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabriel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Echeverria, C.</span></span> <span> </span><span class="NLM_article-title">Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1851</span>â <span class="NLM_lpage">1863</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-08-0017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F1535-7163.MCT-08-0017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=18606717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslCgtb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=1851-1863&issue=7&author=S.+M.+Mairaauthor=F.+Staufferauthor=J.+Brueggenauthor=P.+Furetauthor=C.+Schnellauthor=C.+Fritschauthor=S.+Brachmannauthor=P.+Cheneauthor=A.+De+Poverauthor=K.+Schoemakerauthor=D.+Fabbroauthor=D.+Gabrielauthor=M.+Simonenauthor=L.+Murphyauthor=P.+Finanauthor=W.+Sellersauthor=C.+Garcia-Echeverria&title=Identification+and+characterization+of+NVP-BEZ235%2C+a+new+orally+available+dual+phosphatidylinositol+3-kinase%2Fmammalian+target+of+rapamycin+inhibitor+with+potent+in+vivo+antitumor+activity&doi=10.1158%2F1535-7163.MCT-08-0017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity</span></div><div class="casAuthors">Maira, Sauveur-Michel; Stauffer, Frederic; Brueggen, Josef; Furet, Pascal; Schnell, Christian; Fritsch, Christine; Brachmann, Saskia; Chene, Patrick; De Pover, Alain; Schoemaker, Kevin; Fabbro, Doriano; Gabriel, Daniela; Simonen, Marjo; Murphy, Leon; Finan, Peter; Sellers, William; Garcia-Echeverria, Carlos</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1851-1863</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin inhibitor (mTOR) pathway is often constitutively activated in human tumor cells, providing unique opportunities for anticancer therapeutic intervention.  NVP-BEZ235 is an imidazo[4,5-c]quinoline deriv. that inhibits PI3K and mTOR kinase activity by binding to the ATP-binding cleft of these enzymes.  In cellular settings using human tumor cell lines, this mol. is able to effectively and specifically block the dysfunctional activation of the PI3K pathway, inducing G1 arrest.  The cellular activity of NVP-BEZ235 translates well in in vivo models of human cancer.  Thus, the compd. was well tolerated, displayed disease stasis when administered orally, and enhanced the efficacy of other anticancer agents when used in in vivo combination studies.  Ex vivo pharmacokinetic/pharmacodynamic analyses of tumor tissues showed a time-dependent correlation between compd. concn. and PI3K/Akt pathway inhibition.  Collectively, the preclin. data show that NVP-BEZ235 is a potent dual PI3K/mTOR modulator with favorable pharmaceutical properties.  NVP-BEZ235 is currently in phase I clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyO784qv52vrVg90H21EOLACvtfcHk0lgw-YN8L1ykxw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslCgtb4%253D&md5=5b1979e134dd12065198d86dbc11ce15</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-08-0017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-08-0017%26sid%3Dliteratum%253Aachs%26aulast%3DMaira%26aufirst%3DS.%2BM.%26aulast%3DStauffer%26aufirst%3DF.%26aulast%3DBrueggen%26aufirst%3DJ.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DSchnell%26aufirst%3DC.%26aulast%3DFritsch%26aufirst%3DC.%26aulast%3DBrachmann%26aufirst%3DS.%26aulast%3DChene%26aufirst%3DP.%26aulast%3DDe%2BPover%26aufirst%3DA.%26aulast%3DSchoemaker%26aufirst%3DK.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DGabriel%26aufirst%3DD.%26aulast%3DSimonen%26aufirst%3DM.%26aulast%3DMurphy%26aufirst%3DL.%26aulast%3DFinan%26aufirst%3DP.%26aulast%3DSellers%26aufirst%3DW.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520NVP-BEZ235%252C%2520a%2520new%2520orally%2520available%2520dual%2520phosphatidylinositol%25203-kinase%252Fmammalian%2520target%2520of%2520rapamycin%2520inhibitor%2520with%2520potent%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26issue%3D7%26spage%3D1851%26epage%3D1863%26doi%3D10.1158%2F1535-7163.MCT-08-0017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mukherjee, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomimatsu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amancherla, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camacho, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pichamoorthy, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burma, S.</span></span> <span> </span><span class="NLM_article-title">The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses</span>. <i>Neoplasia</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">34</span>â <span class="NLM_lpage">43</span>, <span class="refDoi">Â DOI: 10.1593/neo.111512</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1593%2Fneo.111512" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=22355272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjtlamt7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2012&pages=34-43&issue=1&author=B.+Mukherjeeauthor=N.+Tomimatsuauthor=K.+Amancherlaauthor=C.+V.+Camachoauthor=N.+Pichamoorthyauthor=S.+Burma&title=The+dual+PI3K%2FmTOR+inhibitor+NVP-BEZ235+is+a+potent+inhibitor+of+ATM-+and+DNA-PKCs-mediated+DNA+damage+responses&doi=10.1593%2Fneo.111512"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKcs-mediated DNA damage responses</span></div><div class="casAuthors">Mukherjee, Bipasha; Tomimatsu, Nozomi; Amancherla, Kaushik; Camacho, Cristel V.; Pichamoorthy, Nandini; Burma, Sandeep</div><div class="citationInfo"><span class="NLM_cas:title">Neoplasia (Ann Arbor, MI, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">34-43</span>CODEN:
                <span class="NLM_cas:coden">NEOPFL</span>;
        ISSN:<span class="NLM_cas:issn">1522-8002</span>.
    
            (<span class="NLM_cas:orgname">Neoplasia Press Inc.</span>)
        </div><div class="casAbstract">Inhibitors of PI3K/Akt signaling are being actively developed for tumor therapy owing to the frequent mutational activation of the PI3K-Akt-mTORC1 pathway in many cancers, including glioblastomas (GBMs).  NVP-BEZ235 is a novel and potent dual PI3K/mTOR inhibitor that is currently in phase 1/2 clin. trials for advanced solid tumors.  Here, we show that NVP-BEZ235 also potently inhibits ATM and DNA-PKcs, the two major kinases responding to ionizing radiation (IR)-induced DNA double-strand breaks (DSBs).  Consequently, NVP-BEZ235 blocks both nonhomologous end joining and homologous recombination DNA repair pathways resulting in significant attenuation of DSB repair.  In addn., phosphorylation of ATM targets and implementation of the G2/Mcell cycle checkpoint are also attenuated by this drug.  As a result, NVP-BEZ235 confers an extreme degree of radiosensitization and impairs DSB repair in a panel of GBMcell lines irresp. of their Akt activation status.  NVP-BEZ235 also significantly impairs DSB repair in a mouse tumor model thereby validating the efficacy of this drug as a DNA repair inhibitor in vivo.  Our results, showing that NVP-BEZ235 is a potent and novel inhibitor of ATM and DNA-PKcs, have important implications for the informed and rational design of clin. trials involving this drug and also reveal the potential utility of NVP-BEZ235 as an effective radiosensitizer for GBMs in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9NAac1mePaLVg90H21EOLACvtfcHk0lgw-YN8L1ykxw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjtlamt7s%253D&md5=a6cfa1eee6d959c84bec642e0c175fb7</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1593%2Fneo.111512&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1593%252Fneo.111512%26sid%3Dliteratum%253Aachs%26aulast%3DMukherjee%26aufirst%3DB.%26aulast%3DTomimatsu%26aufirst%3DN.%26aulast%3DAmancherla%26aufirst%3DK.%26aulast%3DCamacho%26aufirst%3DC.%2BV.%26aulast%3DPichamoorthy%26aufirst%3DN.%26aulast%3DBurma%26aufirst%3DS.%26atitle%3DThe%2520dual%2520PI3K%252FmTOR%2520inhibitor%2520NVP-BEZ235%2520is%2520a%2520potent%2520inhibitor%2520of%2520ATM-%2520and%2520DNA-PKCs-mediated%2520DNA%2520damage%2520responses%26jtitle%3DNeoplasia%26date%3D2012%26volume%3D14%26issue%3D1%26spage%3D34%26epage%3D43%26doi%3D10.1593%2Fneo.111512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Riches, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trinidad, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomason, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavine, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stott, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlaam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pass, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâConnor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cadogan, E. B.</span></span> <span> </span><span class="NLM_article-title">Pharmacology of the ATM Inhibitor AZD0156: Potentiation of irradiation and olaparib responses preclinically</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">13</span>â <span class="NLM_lpage">25</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-18-1394</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F1535-7163.MCT-18-1394" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=31534013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvVOltbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2020&pages=13-25&issue=1&author=L.+C.+Richesauthor=A.+G.+Trinidadauthor=G.+Hughesauthor=G.+N.+Jonesauthor=A.+M.+Hughesauthor=A.+G.+Thomasonauthor=P.+Gavineauthor=A.+Cuiauthor=S.+Lingauthor=J.+Stottauthor=R.+Clarkauthor=S.+Peelauthor=P.+Gillauthor=L.+M.+Goodwinauthor=A.+Smithauthor=K.+G.+Pikeauthor=B.+Barlaamauthor=M.+Passauthor=M.+J.+O%E2%80%99Connorauthor=G.+Smithauthor=E.+B.+Cadogan&title=Pharmacology+of+the+ATM+Inhibitor+AZD0156%3A+Potentiation+of+irradiation+and+olaparib+responses+preclinically&doi=10.1158%2F1535-7163.MCT-18-1394"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacology of the ATM inhibitor AZD0156: potentiation of irradiation and olaparib responses pre-clinically</span></div><div class="casAuthors">Riches, Lucy C.; Trinidad, Antonio G.; Hughes, Gareth; Jones, Gemma N.; Hughes, Adina M.; Thomason, Andrew G.; Gavine, Paul; Cui, Andy; Ling, Stephanie; Stott, Jonathan; Clark, Roger; Peel, Samantha; Gill, Pendeep; Goodwin, Louise M.; Smith, Aaron; Pike, Kurt G.; Barlaam, Bernard; Pass, Martin; O'Connor, Mark J.; Smith, Graeme; Cadogan, Elaine B.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-25</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">AZD0156 is a potent and selective, bio-available inhibitor of Ataxia Telangiectasia Mutated (ATM) protein, a signaling kinase involved in the DNA damage response (DDR).  We present preclin. data demonstrating abrogation of irradn.-induced ATM signaling by low doses of AZD0156, as measured by phosphorylation of ATM substrates.  AZD0156 is a strong radio-sensitizer in vitro, and using a lung xenograft model, we show that systemic delivery of AZD0156 enhances the tumor growth inhibitory effects of radiation treatment in vivo.  Since ATM deficiency contributes to PARP inhibitor sensitivity, preclinically, we evaluated the effect of combining AZD0156 with the PARP inhibitor olaparib.  Using ATM isogenic FaDu cells, we demonstrate that AZD0156 impedes the repair of olaparib induced DNA damage, resulting in elevated DNA double strand break (DSB) signaling, cell cycle arrest and apoptosis.  Preclinically, AZD0156 potentiated the effects of olaparib across a panel of lung, gastric and breast cancer cell lines in vitro, and improved the efficacy of olaparib in two patient-derived triple -neg. breast cancer (TNBC) xenograft models.  AZD0156 is currently being evaluated in phase I studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyxSyhBLkkR7Vg90H21EOLACvtfcHk0linoO_jdlp_fQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvVOltbw%253D&md5=8a47212e061f386c37be2315095ba9ff</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-18-1394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-18-1394%26sid%3Dliteratum%253Aachs%26aulast%3DRiches%26aufirst%3DL.%2BC.%26aulast%3DTrinidad%26aufirst%3DA.%2BG.%26aulast%3DHughes%26aufirst%3DG.%26aulast%3DJones%26aufirst%3DG.%2BN.%26aulast%3DHughes%26aufirst%3DA.%2BM.%26aulast%3DThomason%26aufirst%3DA.%2BG.%26aulast%3DGavine%26aufirst%3DP.%26aulast%3DCui%26aufirst%3DA.%26aulast%3DLing%26aufirst%3DS.%26aulast%3DStott%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DR.%26aulast%3DPeel%26aufirst%3DS.%26aulast%3DGill%26aufirst%3DP.%26aulast%3DGoodwin%26aufirst%3DL.%2BM.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DPike%26aufirst%3DK.%2BG.%26aulast%3DBarlaam%26aufirst%3DB.%26aulast%3DPass%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DSmith%26aufirst%3DG.%26aulast%3DCadogan%26aufirst%3DE.%2BB.%26atitle%3DPharmacology%2520of%2520the%2520ATM%2520Inhibitor%2520AZD0156%253A%2520Potentiation%2520of%2520irradiation%2520and%2520olaparib%2520responses%2520preclinically%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2020%26volume%3D19%26issue%3D1%26spage%3D13%26epage%3D25%26doi%3D10.1158%2F1535-7163.MCT-18-1394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Durant, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riches, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trinidad, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fok, J. H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colclough, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sykes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janefeldt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstrom, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varnas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stott, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roudier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sule, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cronin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valerie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illingworth, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pass, M.</span></span> <span> </span><span class="NLM_article-title">The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models</span>. <i>Sci. Adv.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">6</span>), <span class="NLM_elocation-id">eaat1719</span> <span class="refDoi">Â DOI: 10.1126/sciadv.aat1719</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1126%2Fsciadv.aat1719" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=29938225" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2018&issue=6&author=S.+T.+Durantauthor=L.+Zhengauthor=Y.+Wangauthor=K.+Chenauthor=L.+Zhangauthor=T.+Zhangauthor=Z.+Yangauthor=L.+Richesauthor=A.+G.+Trinidadauthor=J.+H.+L.+Fokauthor=T.+Huntauthor=K.+G.+Pikeauthor=J.+Wilsonauthor=A.+Smithauthor=N.+Colcloughauthor=V.+P.+Reddyauthor=A.+Sykesauthor=A.+Janefeldtauthor=P.+Johnstromauthor=K.+Varnasauthor=A.+Takanoauthor=S.+Lingauthor=J.+Ormeauthor=J.+Stottauthor=C.+Robertsauthor=I.+Barrettauthor=G.+Jonesauthor=M.+Roudierauthor=A.+Pierceauthor=J.+Allenauthor=J.+Kahnauthor=A.+Suleauthor=J.+Karlinauthor=A.+Croninauthor=M.+Chapmanauthor=K.+Valerieauthor=R.+Illingworthauthor=M.+Pass&title=The+brain-penetrant+clinical+ATM+inhibitor+AZD1390+radiosensitizes+and+improves+survival+of+preclinical+brain+tumor+models&doi=10.1126%2Fsciadv.aat1719"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1126%2Fsciadv.aat1719&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fsciadv.aat1719%26sid%3Dliteratum%253Aachs%26aulast%3DDurant%26aufirst%3DS.%2BT.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DRiches%26aufirst%3DL.%26aulast%3DTrinidad%26aufirst%3DA.%2BG.%26aulast%3DFok%26aufirst%3DJ.%2BH.%2BL.%26aulast%3DHunt%26aufirst%3DT.%26aulast%3DPike%26aufirst%3DK.%2BG.%26aulast%3DWilson%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DReddy%26aufirst%3DV.%2BP.%26aulast%3DSykes%26aufirst%3DA.%26aulast%3DJanefeldt%26aufirst%3DA.%26aulast%3DJohnstrom%26aufirst%3DP.%26aulast%3DVarnas%26aufirst%3DK.%26aulast%3DTakano%26aufirst%3DA.%26aulast%3DLing%26aufirst%3DS.%26aulast%3DOrme%26aufirst%3DJ.%26aulast%3DStott%26aufirst%3DJ.%26aulast%3DRoberts%26aufirst%3DC.%26aulast%3DBarrett%26aufirst%3DI.%26aulast%3DJones%26aufirst%3DG.%26aulast%3DRoudier%26aufirst%3DM.%26aulast%3DPierce%26aufirst%3DA.%26aulast%3DAllen%26aufirst%3DJ.%26aulast%3DKahn%26aufirst%3DJ.%26aulast%3DSule%26aufirst%3DA.%26aulast%3DKarlin%26aufirst%3DJ.%26aulast%3DCronin%26aufirst%3DA.%26aulast%3DChapman%26aufirst%3DM.%26aulast%3DValerie%26aufirst%3DK.%26aulast%3DIllingworth%26aufirst%3DR.%26aulast%3DPass%26aufirst%3DM.%26atitle%3DThe%2520brain-penetrant%2520clinical%2520ATM%2520inhibitor%2520AZD1390%2520radiosensitizes%2520and%2520improves%2520survival%2520of%2520preclinical%2520brain%2520tumor%2520models%26jtitle%3DSci.%2520Adv.%26date%3D2018%26volume%3D4%26issue%3D6%26doi%3D10.1126%2Fsciadv.aat1719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Biddlestone-Thorpe, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sajjad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckta, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valerie, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokarz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khalil, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilfor, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golding, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deb, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Temesi, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâConnor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choe, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parada, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukhopadhyay, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valerie, K.</span></span> <span> </span><span class="NLM_article-title">ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">3189</span>â <span class="NLM_lpage">3200</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-12-3408</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F1078-0432.CCR-12-3408" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=23620409" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpsVynsL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=3189-3200&issue=12&author=L.+Biddlestone-Thorpeauthor=M.+Sajjadauthor=E.+Rosenbergauthor=J.+M.+Becktaauthor=N.+C.+Valerieauthor=M.+Tokarzauthor=B.+R.+Adamsauthor=A.+F.+Wagnerauthor=A.+Khalilauthor=D.+Gilforauthor=S.+E.+Goldingauthor=S.+Debauthor=D.+G.+Temesiauthor=A.+Lauauthor=M.+J.+O%E2%80%99Connorauthor=K.+S.+Choeauthor=L.+F.+Paradaauthor=S.+K.+Limauthor=N.+D.+Mukhopadhyayauthor=K.+Valerie&title=ATM+kinase+inhibition+preferentially+sensitizes+p53-mutant+glioma+to+ionizing+radiation&doi=10.1158%2F1078-0432.CCR-12-3408"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">ATM Kinase Inhibition Preferentially Sensitizes p53-Mutant Glioma to Ionizing Radiation</span></div><div class="casAuthors">Biddlestone-Thorpe, Laura; Sajjad, Muhammad; Rosenberg, Elizabeth; Beckta, Jason M.; Valerie, Nicholas C. K.; Tokarz, Mary; Adams, Bret R.; Wagner, Alison F.; Khalil, Ashraf; Gilfor, Donna; Golding, Sarah E.; Deb, Sumitra; Temesi, David G.; Lau, Alan; O'Connor, Mark J.; Choe, Kevin S.; Parada, Luis F.; Lim, Sang Kyun; Mukhopadhyay, Nitai D.; Valerie, Kristoffer</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3189-3200</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Glioblastoma multiforme (GBM) is the most lethal form of brain cancer with a median survival of only 12 to 15 mo.  Current std. treatment consists of surgery followed by chemoradiation.  The poor survival of patients with GBM is due to aggressive tumor invasiveness, an inability to remove all tumor tissue, and an innate tumor chemo- and radioresistance.  Ataxia-telangiectasia mutated (ATM) is an excellent target for radiosensitizing GBM because of its crit. role in regulating the DNA damage response and p53, among other cellular processes.  As a first step toward this goal, we recently showed that the novel ATM kinase inhibitor KU-60019 reduced migration, invasion, and growth, and potently radiosensitized human glioma cells in vitro.  Exptl. Design: Using orthotopic xenograft models of GBM, we now show that KU-60019 is also an effective radiosensitizer in vivo.  Human glioma cells expressing reporter genes for monitoring tumor growth and dispersal were grown intracranially, and KU-60019 was administered intratumorally by convection-enhanced delivery or osmotic pump.  Results: Our results show that the combined effect of KU-60019 and radiation significantly increased survival of mice 2- to 3-fold over controls.  Importantly, we show that glioma with mutant p53 is much more sensitive to KU-60019 radiosensitization than genetically matched wild-type glioma.  Conclusions: Taken together, our results suggest that an ATM kinase inhibitor may be an effective radiosensitizer and adjuvant therapy for patients with mutant p53 brain cancers.  Clin Cancer Res; 19(12); 3189-200. Â©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIW6Z_3LrXLbVg90H21EOLACvtfcHk0lh0bQxJ4VcIFg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpsVynsL4%253D&md5=b77a60ce3d07e969f3cacb897676e6f8</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-3408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-3408%26sid%3Dliteratum%253Aachs%26aulast%3DBiddlestone-Thorpe%26aufirst%3DL.%26aulast%3DSajjad%26aufirst%3DM.%26aulast%3DRosenberg%26aufirst%3DE.%26aulast%3DBeckta%26aufirst%3DJ.%2BM.%26aulast%3DValerie%26aufirst%3DN.%2BC.%26aulast%3DTokarz%26aufirst%3DM.%26aulast%3DAdams%26aufirst%3DB.%2BR.%26aulast%3DWagner%26aufirst%3DA.%2BF.%26aulast%3DKhalil%26aufirst%3DA.%26aulast%3DGilfor%26aufirst%3DD.%26aulast%3DGolding%26aufirst%3DS.%2BE.%26aulast%3DDeb%26aufirst%3DS.%26aulast%3DTemesi%26aufirst%3DD.%2BG.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DChoe%26aufirst%3DK.%2BS.%26aulast%3DParada%26aufirst%3DL.%2BF.%26aulast%3DLim%26aufirst%3DS.%2BK.%26aulast%3DMukhopadhyay%26aufirst%3DN.%2BD.%26aulast%3DValerie%26aufirst%3DK.%26atitle%3DATM%2520kinase%2520inhibition%2520preferentially%2520sensitizes%2520p53-mutant%2520glioma%2520to%2520ionizing%2520radiation%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26issue%3D12%26spage%3D3189%26epage%3D3200%26doi%3D10.1158%2F1078-0432.CCR-12-3408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, O. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brzozowski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skelding, K. A.</span></span> <span> </span><span class="NLM_article-title">Glioblastoma multiforme: an overview of emerging therapeutic targets</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">963</span>, <span class="refDoi">Â DOI: 10.3389/fonc.2019.00963</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.3389%2Ffonc.2019.00963" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=31616641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A280%3ADC%252BB3Mnot1Ogtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=963&author=O.+G.+Taylorauthor=J.+S.+Brzozowskiauthor=K.+A.+Skelding&title=Glioblastoma+multiforme%3A+an+overview+of+emerging+therapeutic+targets&doi=10.3389%2Ffonc.2019.00963"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Glioblastoma Multiforme: An Overview of Emerging Therapeutic Targets</span></div><div class="casAuthors">Taylor Olivia G; Brzozowski Joshua S; Skelding Kathryn A; Taylor Olivia G; Brzozowski Joshua S; Skelding Kathryn A</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">963</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary brain tumour in humans and has a very poor prognosis.  The existing treatments have had limited success in increasing overall survival.  Thus, identifying and understanding the key molecule(s) responsible for the malignant phenotype of GBM will yield new potential therapeutic targets.  The treatment of brain tumours faces unique challenges, including the presence of the blood brain barrier (BBB), which limits the concentration of drugs that can reach the site of the tumour.  Nevertheless, several promising treatments have been shown to cross the BBB and have shown promising pre-clinical results.  This review will outline the status of several of these promising targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS_de8wcSgngMuCWE5mhx1RfW6udTcc2eZJsRjxKRQFn7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mnot1Ogtw%253D%253D&md5=edf2d943f5e3a14021a27a885858f472</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2019.00963&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2019.00963%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DO.%2BG.%26aulast%3DBrzozowski%26aufirst%3DJ.%2BS.%26aulast%3DSkelding%26aufirst%3DK.%2BA.%26atitle%3DGlioblastoma%2520multiforme%253A%2520an%2520overview%2520of%2520emerging%2520therapeutic%2520targets%26jtitle%3DFront.%2520Oncol.%26date%3D2019%26volume%3D9%26spage%3D963%26doi%3D10.3389%2Ffonc.2019.00963" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stoyanova, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bulgarelli-Leva, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanck, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetzker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span> <span> </span><span class="NLM_article-title">Lipid kinase and protein kinase activities of G-protein-coupled phosphoinositide 3-kinase gamma: structure-activity analysis and interactions with wortmannin</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>324</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">489</span>â <span class="NLM_lpage">495</span>, <span class="refDoi">Â DOI: 10.1042/bj3240489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1042%2Fbj3240489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=9182708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADyaK2sXjvFClur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=324&publication_year=1997&pages=489-495&issue=2&author=S.+Stoyanovaauthor=G.+Bulgarelli-Levaauthor=C.+Kirschauthor=T.+Hanckauthor=R.+Klingerauthor=R.+Wetzkerauthor=M.+P.+Wymann&title=Lipid+kinase+and+protein+kinase+activities+of+G-protein-coupled+phosphoinositide+3-kinase+gamma%3A+structure-activity+analysis+and+interactions+with+wortmannin&doi=10.1042%2Fbj3240489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Lipid kinase and protein kinase activities of G-protein-coupled phosphoinositide 3-kinase Î³: structure-activity analysis and interactions with wortmannin</span></div><div class="casAuthors">Stoyanova, Stefka; Bulgarelli-Leva, Ginette; Kirsch, Cornelia; Hanck, Theodor; Klinger, Reinhard; Wetzker, Reinhard; Wymann, Matthias P.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">324</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">489-495</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press</span>)
        </div><div class="casAbstract">Signaling via 7-transmembrane helix receptors can lead to a massive increase in cellular phosphoinositide 3,4,5-trisphosphate [PtdIns(3,4,5)P3], which is crit. for the induction of various cell responses and is likely to be produced by a trimeric G-protein-sensitive phosphoinositide 3-kinase (PI3KÎ³).  P13KÎ³ is shown to be a bifunctional lipid kinase and protein kinase, and both activities are inhibited by wortmannin at concns. equal to those affecting the p85p110Î± heterodimeric PI3K (IC50 â¼2 nM).  The binding of wortmannin to PI3KÎ³, as detected by anti-wortmannin antisera, closely followed the inhibition of the kinase activities.  Truncation of >98 N-terminal amino acid residues from PI3KÎ³ produced proteins that were inactive in wortmannin binding and kinase assays.  This suggests that regions apart from the core catalytic domain are important in catalysis and inhibitor interaction.  The covalent reaction of wortmannin with PI3KÎ³ was prevented by preincubation with phosphoinositides, ATP and its analogs adenine and 5'-(4-fluorosulfonylbenzoyl)-adenine.  Proteolytic anal. of wortmannin-prelabeled PI3KÎ³ revealed candidate wortmannin-binding peptides around Lys-799.  Replacement of Lys-799 by Arg through site-directed mutagenesis aborted the covalent reaction with wortmannin and the lipid kinase and protein kinase activities completely.  The above illustrates that Lys-799 is crucial to the phosphate transfer reaction and wortmannin reactivity.  Parallel inhibition of the PI3KÎ³-assocd. protein kinase and lipid kinase by wortmannin and by the Lys-799 â Arg mutation reveals that both activities are inherent in the PI3KÎ³ polypeptide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsQd9i80PXLrVg90H21EOLACvtfcHk0ljBtrpAIHR74A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjvFClur8%253D&md5=ede792404df92ce1d5753bd99c583a40</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1042%2Fbj3240489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj3240489%26sid%3Dliteratum%253Aachs%26aulast%3DStoyanova%26aufirst%3DS.%26aulast%3DBulgarelli-Leva%26aufirst%3DG.%26aulast%3DKirsch%26aufirst%3DC.%26aulast%3DHanck%26aufirst%3DT.%26aulast%3DKlinger%26aufirst%3DR.%26aulast%3DWetzker%26aufirst%3DR.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3DLipid%2520kinase%2520and%2520protein%2520kinase%2520activities%2520of%2520G-protein-coupled%2520phosphoinositide%25203-kinase%2520gamma%253A%2520structure-activity%2520analysis%2520and%2520interactions%2520with%2520wortmannin%26jtitle%3DBiochem.%2520J.%26date%3D1997%26volume%3D324%26issue%3D2%26spage%3D489%26epage%3D495%26doi%3D10.1042%2Fbj3240489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golding, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guiard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardcastle, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leahy, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rigoreau, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stockley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. C.</span></span> <span> </span><span class="NLM_article-title">Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and radiosensitization of a human tumor cell line in vitro</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">569</span>â <span class="NLM_lpage">585</span>, <span class="refDoi">Â DOI: 10.1021/jm049526a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049526a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtFCrur%252FN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=569-585&issue=2&author=R.+J.+Griffinauthor=G.+Fontanaauthor=B.+T.+Goldingauthor=S.+Guiardauthor=I.+R.+Hardcastleauthor=J.+J.+Leahyauthor=N.+Martinauthor=C.+Richardsonauthor=L.+Rigoreauauthor=M.+Stockleyauthor=G.+C.+Smith&title=Selective+benzopyranone+and+pyrimido%5B2%2C1-a%5Disoquinolin-4-one+inhibitors+of+DNA-dependent+protein+kinase%3A+synthesis%2C+structure-activity+studies%2C+and+radiosensitization+of+a+human+tumor+cell+line+in+vitro&doi=10.1021%2Fjm049526a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: Synthesis, structure-activity studies, and radiosensitization of a human tumor cell line in vitro</span></div><div class="casAuthors">Griffin, Roger J.; Fontana, Gabriele; Golding, Bernard T.; Guiard, Sophie; Hardcastle, Ian R.; Leahy, Justin J. J.; Martin, Niall; Richardson, Caroline; Rigoreau, Laurent; Stockley, Martin; Smith, Graeme C. M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">569-585</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A diverse range of chromen-2-ones, chromen-4-ones, e.g., I, and pyrimidoisoquinolin-4-ones was synthesized and evaluated for inhibitory activity against the DNA repair enzyme DNA-dependent protein kinase (DNA-PK), with a view to elucidating structure-activity relationships for potency and kinase selectivity.  DNA-PK inhibitory activity varied widely over the series of compds. evaluated (IC50 values ranged from 0.19 to >10 Î¼M), with excellent activity being obsd. for the 7,8-benzochromen-4-one and pyrimido[2,1-a]isoquinolin-4-one templates.  By contrast, inhibitors based on the benzochromen-2-one (coumarin) or 2-aryl-7,8-benzochromen-4-one (flavone) scaffolds were less potent.  Crucially, these studies revealed a very constrained structure-activity relationship at the 2-position of the benzopyranone and pyrimido[2,1-a]isoquinolin-4-one pharmacophore, with only a 2-morpholino or 2-(2'-methylmorpholino) group being tolerated at this position.  More detailed biol. studies conducted with the most potent inhibitor NU7163 (I; IC50 = 0.19 Î¼M) demonstrated ATP-competitive DNA-PK inhibition, with a Ki value of 24 nM, and I exhibited selectivity for DNA-PK compared with the related enzymes ATM, ATR, mTOR, and PI 3-K (p110alpha).  I sensitized the HeLa human tumor cell line to the cytotoxic effects of ionizing radiation in vitro, a dose modification factor of 2.3 at 10% survival being obsd. with an inhibitor concn. of 5 Î¼M.  This study identified these structural classes as novel DNA-PK inhibitors and delineated initial structure-activity relationships against DNA-PK.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4N9L9Av3ZHbVg90H21EOLACvtfcHk0ljBtrpAIHR74A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtFCrur%252FN&md5=fc86e38ca5b8648a17a9b7911fa6b2ae</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1021%2Fjm049526a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049526a%26sid%3Dliteratum%253Aachs%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DFontana%26aufirst%3DG.%26aulast%3DGolding%26aufirst%3DB.%2BT.%26aulast%3DGuiard%26aufirst%3DS.%26aulast%3DHardcastle%26aufirst%3DI.%2BR.%26aulast%3DLeahy%26aufirst%3DJ.%2BJ.%26aulast%3DMartin%26aufirst%3DN.%26aulast%3DRichardson%26aufirst%3DC.%26aulast%3DRigoreau%26aufirst%3DL.%26aulast%3DStockley%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DG.%2BC.%26atitle%3DSelective%2520benzopyranone%2520and%2520pyrimido%255B2%252C1-a%255Disoquinolin-4-one%2520inhibitors%2520of%2520DNA-dependent%2520protein%2520kinase%253A%2520synthesis%252C%2520structure-activity%2520studies%252C%2520and%2520radiosensitization%2520of%2520a%2520human%2520tumor%2520cell%2520line%2520in%2520vitro%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26issue%3D2%26spage%3D569%26epage%3D585%26doi%3D10.1021%2Fjm049526a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hardcastle, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cockcroft, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtin, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Murr, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leahy, J. J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stockley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golding, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rigoreau, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, R. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">7829</span>â <span class="NLM_lpage">7846</span>, <span class="refDoi">Â DOI: 10.1021/jm050444b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050444b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFKgsLbP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=7829-7846&issue=24&author=I.+R.+Hardcastleauthor=X.+Cockcroftauthor=N.+J.+Curtinauthor=M.+D.+El-Murrauthor=J.+J.+J.+Leahyauthor=M.+Stockleyauthor=B.+T.+Goldingauthor=L.+Rigoreauauthor=C.+Richardsonauthor=G.+C.+M.+Smithauthor=R.+J.+Griffin&title=Discovery+of+potent+chromen-4-one+inhibitors+of+the+DNA-dependent+protein+kinase+%28DNA-PK%29+using+a+small-molecule+library+approach&doi=10.1021%2Fjm050444b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent Chromen-4-one Inhibitors of the DNA-Dependent Protein Kinase (DNA-PK) Using a Small-Molecule Library Approach</span></div><div class="casAuthors">Hardcastle, Ian R.; Cockcroft, Xiaoling; Curtin, Nicola J.; El-Murr, Marine Desage; Leahy, Justin J. J.; Stockley, Martin; Golding, Bernard T.; Rigoreau, Laurent; Richardson, Caroline; Smith, Graeme C. M.; Griffin, Roger J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7829-7846</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-activity relationships for inhibition of DNA-dependent protein kinase (DNA-PK) have been defined for substituted chromen-4-ones.  For the 2-amino-substituted benzo[h]chromen-4-ones, a morpholine substituent at this position was essential for activity.  Small libraries of 6- and 7-alkoxy-substituted chromen-4-ones showed that a no. of 7-alkoxy-substituted chromenones displayed improved activity.  Focused libraries incorporating 6-, 7-, and 8-aryl and heteroaryl substituents were prepd.  In these cases, 6- and 7-substitution was disfavored, whereas 8-substitution was largely tolerated.  Surprisingly, two compds., 2-N-morpholino-8-dibenzofuranyl-chromen-4-one (NU7427, 32{38}) and the 2-N-morpholino-8-dibenzothiophenyl-chromen-4-one (NU7441, 32{26}) were excellent inhibitors (IC50 vs DNA-PK = 40 and 13 nM, resp.).  The ring-satd. analog 2-N-morpholino-8-(6',7',8',9'-tetrahydrodibenzothiophene)chromen-4-one, 36, retained potent activity (IC50 vs DNA-PK = 23 nM).  The dibenzothiophene 32{38} sensitized HeLa cells to ionizing radiation in vitro, with dose modification factors of 2.5 at 10% survival being obsd. at 0.5 Î¼M.  The cytotoxicity of the topoisomerase II inhibitor etoposide was also potentiated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0FBCga-GuubVg90H21EOLACvtfcHk0lgu3e_dG2KzAg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFKgsLbP&md5=35f849c46fb62110f13b3d02367e75cc</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1021%2Fjm050444b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050444b%26sid%3Dliteratum%253Aachs%26aulast%3DHardcastle%26aufirst%3DI.%2BR.%26aulast%3DCockcroft%26aufirst%3DX.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DEl-Murr%26aufirst%3DM.%2BD.%26aulast%3DLeahy%26aufirst%3DJ.%2BJ.%2BJ.%26aulast%3DStockley%26aufirst%3DM.%26aulast%3DGolding%26aufirst%3DB.%2BT.%26aulast%3DRigoreau%26aufirst%3DL.%26aulast%3DRichardson%26aufirst%3DC.%26aulast%3DSmith%26aufirst%3DG.%2BC.%2BM.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26atitle%3DDiscovery%2520of%2520potent%2520chromen-4-one%2520inhibitors%2520of%2520the%2520DNA-dependent%2520protein%2520kinase%2520%2528DNA-PK%2529%2520using%2520a%2520small-molecule%2520library%2520approach%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26issue%3D24%26spage%3D7829%26epage%3D7846%26doi%3D10.1021%2Fjm050444b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fok, J. H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos-Montoya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez-Chantada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wijnhoven, P. W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Follia, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrington, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karmokar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willis, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cairns, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">NikkilÃ¤, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beattie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâConnor, L. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fawell, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâConnor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingsworth, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cadogan, E. B.</span></span> <span> </span><span class="NLM_article-title">AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">5065</span>, <span class="refDoi">Â DOI: 10.1038/s41467-019-12836-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1038%2Fs41467-019-12836-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=31699977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A280%3ADC%252BB3MjmsVOltA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=5065&issue=1&author=J.+H.+L.+Fokauthor=A.+Ramos-Montoyaauthor=M.+Vazquez-Chantadaauthor=P.+W.+G.+Wijnhovenauthor=V.+Folliaauthor=N.+Jamesauthor=P.+M.+Farringtonauthor=A.+Karmokarauthor=S.+E.+Willisauthor=J.+Cairnsauthor=J.+Nikkil%C3%A4author=D.+Beattieauthor=G.+M.+Lamontauthor=M.+R.+V.+Finlayauthor=J.+Wilsonauthor=A.+Smithauthor=L.+O.+O%E2%80%99Connorauthor=S.+Lingauthor=S.+E.+Fawellauthor=M.+J.+O%E2%80%99Connorauthor=S.+J.+Hollingsworthauthor=E.+Deanauthor=F.+W.+Goldbergauthor=B.+R.+Daviesauthor=E.+B.+Cadogan&title=AZD7648+is+a+potent+and+selective+DNA-PK+inhibitor+that+enhances+radiation%2C+chemotherapy+and+olaparib+activity&doi=10.1038%2Fs41467-019-12836-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity</span></div><div class="casAuthors">Fok Jacqueline H L; Ramos-Montoya Antonio; Wijnhoven Paul W G; Follia Valeria; James Neil; Farrington Paul M; Karmokar Ankur; Nikkila Jenni; Fawell Stephen E; O'Connor Mark J; Davies Barry R; Cadogan Elaine B; Vazquez-Chantada Mercedes; Ling Stephanie; Willis Sophie E; O'Connor Lenka Oplustil; Cairns Jonathan; Beattie David; Lamont Gillian M; Finlay M Raymond V; Goldberg Frederick W; Wilson Joanne; Smith Aaron; Hollingsworth Simon J; Dean Emma</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5065</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">DNA-dependent protein kinase (DNA-PK) is a critical player in the DNA damage response (DDR) and instrumental in the non-homologous end-joining pathway (NHEJ) used to detect and repair DNA double-strand breaks (DSBs).  We demonstrate that the potent and highly selective DNA-PK inhibitor, AZD7648, is an efficient sensitizer of radiation- and doxorubicin-induced DNA damage, with combinations in xenograft and patient-derived xenograft (PDX) models inducing sustained regressions.  Using ATM-deficient cells, we demonstrate that AZD7648, in combination with the PARP inhibitor olaparib, increases genomic instability, resulting in cell growth inhibition and apoptosis.  AZD7648 enhanced olaparib efficacy across a range of doses and schedules in xenograft and PDX models, enabling sustained tumour regression and providing a clear rationale for its clinical investigation.  Through its differentiated mechanism of action as an NHEJ inhibitor, AZD7648 complements the current armamentarium of DDR-targeted agents and has potential in combination with these agents to achieve deeper responses to current therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQf_5P1MX4JaXtlzo9xastyfW6udTcc2eYT2WQmMqAxbbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MjmsVOltA%253D%253D&md5=b41d0e83963ad440f12b93fbdeed861e</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1038%2Fs41467-019-12836-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-019-12836-9%26sid%3Dliteratum%253Aachs%26aulast%3DFok%26aufirst%3DJ.%2BH.%2BL.%26aulast%3DRamos-Montoya%26aufirst%3DA.%26aulast%3DVazquez-Chantada%26aufirst%3DM.%26aulast%3DWijnhoven%26aufirst%3DP.%2BW.%2BG.%26aulast%3DFollia%26aufirst%3DV.%26aulast%3DJames%26aufirst%3DN.%26aulast%3DFarrington%26aufirst%3DP.%2BM.%26aulast%3DKarmokar%26aufirst%3DA.%26aulast%3DWillis%26aufirst%3DS.%2BE.%26aulast%3DCairns%26aufirst%3DJ.%26aulast%3DNikkil%25C3%25A4%26aufirst%3DJ.%26aulast%3DBeattie%26aufirst%3DD.%26aulast%3DLamont%26aufirst%3DG.%2BM.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DWilson%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DL.%2BO.%26aulast%3DLing%26aufirst%3DS.%26aulast%3DFawell%26aufirst%3DS.%2BE.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DHollingsworth%26aufirst%3DS.%2BJ.%26aulast%3DDean%26aufirst%3DE.%26aulast%3DGoldberg%26aufirst%3DF.%2BW.%26aulast%3DDavies%26aufirst%3DB.%2BR.%26aulast%3DCadogan%26aufirst%3DE.%2BB.%26atitle%3DAZD7648%2520is%2520a%2520potent%2520and%2520selective%2520DNA-PK%2520inhibitor%2520that%2520enhances%2520radiation%252C%2520chemotherapy%2520and%2520olaparib%2520activity%26jtitle%3DNat.%2520Commun.%26date%3D2019%26volume%3D10%26issue%3D1%26spage%3D5065%26doi%3D10.1038%2Fs41467-019-12836-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zenke, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirrenberg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahmen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vassilev, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pehl, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchss, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaukat, A.</span></span> <span> </span><span class="NLM_article-title">Abstract 1658: M3814, a novel investigational DNA-PK inhibitor: enhancing the effect of fractionated radiotherapy leading to complete regression of tumors in mice</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span> (<span class="NLM_issue">14, Suppl.</span>),  <span class="NLM_fpage">1658</span>, <span class="refDoi">Â DOI: 10.1158/1538-7445.AM2016-1658</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F1538-7445.AM2016-1658" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=1658&issue=14%2C+Suppl.&author=F.+T.+Zenkeauthor=A.+Zimmermannauthor=C.+Sirrenbergauthor=H.+Dahmenauthor=L.+Vassilevauthor=U.+Pehlauthor=T.+Fuchssauthor=A.+Blaukat&title=Abstract+1658%3A+M3814%2C+a+novel+investigational+DNA-PK+inhibitor%3A+enhancing+the+effect+of+fractionated+radiotherapy+leading+to+complete+regression+of+tumors+in+mice&doi=10.1158%2F1538-7445.AM2016-1658"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2016-1658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2016-1658%26sid%3Dliteratum%253Aachs%26aulast%3DZenke%26aufirst%3DF.%2BT.%26aulast%3DZimmermann%26aufirst%3DA.%26aulast%3DSirrenberg%26aufirst%3DC.%26aulast%3DDahmen%26aufirst%3DH.%26aulast%3DVassilev%26aufirst%3DL.%26aulast%3DPehl%26aufirst%3DU.%26aulast%3DFuchss%26aufirst%3DT.%26aulast%3DBlaukat%26aufirst%3DA.%26atitle%3DAbstract%25201658%253A%2520M3814%252C%2520a%2520novel%2520investigational%2520DNA-PK%2520inhibitor%253A%2520enhancing%2520the%2520effect%2520of%2520fractionated%2520radiotherapy%2520leading%2520to%2520complete%2520regression%2520of%2520tumors%2520in%2520mice%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26issue%3D14%252C%2520Suppl%26spage%3D1658%26doi%3D10.1158%2F1538-7445.AM2016-1658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fuchss, T.</span>; <span class="NLM_string-name">Emde, U.</span>; <span class="NLM_string-name">Buchstaller, H.-P.</span>; <span class="NLM_string-name">Merski, W.</span></span> <span> </span><span class="NLM_article-title">Arylquinazolines</span>. <span class="NLM_patent">WO2014183850</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=T.+Fuchss&author=U.+Emde&author=H.-P.+Buchstaller&author=W.+Merski&title=Arylquinazolines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFuchss%26aufirst%3DT.%26atitle%3DArylquinazolines%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czauderna, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zenke, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaukat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vassilev, L. T.</span></span> <span> </span><span class="NLM_article-title">Therapeutic implications of p53 status on cancer cell fate following exposure to ionizing radiation and the DNA-PK inhibitor M3814</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2457</span>â <span class="NLM_lpage">2468</span>, <span class="refDoi">Â DOI: 10.1158/1541-7786.MCR-19-0362</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F1541-7786.MCR-19-0362" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=31551253" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjsleqsro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2019&pages=2457-2468&issue=12&author=Q.+Sunauthor=Y.+Guoauthor=X.+Liuauthor=F.+Czaudernaauthor=M.+I.+Carrauthor=F.+T.+Zenkeauthor=A.+Blaukatauthor=L.+T.+Vassilev&title=Therapeutic+implications+of+p53+status+on+cancer+cell+fate+following+exposure+to+ionizing+radiation+and+the+DNA-PK+inhibitor+M3814&doi=10.1158%2F1541-7786.MCR-19-0362"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic implications of p53 status on cancer cell fate following exposure to ionizing radiation and the DNA-PK Inhibitor M3814</span></div><div class="casAuthors">Sun, Qing; Guo, Yige; Liu, Xiaohong; Czauderna, Frank; Carr, Michael I.; Zenke, Frank T.; Blaukat, Andree; Vassilev, Lyubomir T.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2457-2468</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Inhibition of DNA double-strand break (DSB) repair in cancer cells has been proposed as a new therapeutic strategy for potentiating the anticancer effects of radiotherapy.  M3814 is a novel, selective pharmacol. inhibitor of the serine/threonine kinase DNA-dependent protein kinase (DNA-PK), a key driver of nonhomologous end-joining, one of the main DSB-repair pathways, currently under clin. investigation.  Here, we show that M3814 effectively blocks the repair of radiation-induced DSBs and potently enhances p53 phosphorylation and activation.  In p53 wild-type cells, ataxia telangiectasia-mutated (ATM) and its targets, p53 and checkpoint kinase 2 (CHK2), were more strongly activated by combination treatment with M3814 and radiation than by radiation alone, leading to a complete p53-dependent cell-cycle block and premature cell senescence.  Cancer cells with dysfunctional p53 were unable to fully arrest their cell cycle and entered S and M phases with unrepaired DNA, leading to mitotic catastrophe and apoptotic cell death.  Isogenic p53-null/wild-type A549 and HT-1080 cell lines were generated and used to demonstrate that p53 plays a crit. role in detg. the response to ionizing radiation and M3814.  Time-lapse imaging of cell death and measuring apoptosis in panels of p53 wild-type and p53-null/mutant cancer lines confirmed the clear differences in cell fate, dependent on p53 status.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGZeMEmQ9_MrVg90H21EOLACvtfcHk0lgac04HWZxT2A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjsleqsro%253D&md5=502bf7a52d1da6188e73406602c5402d</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-19-0362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-19-0362%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DCzauderna%26aufirst%3DF.%26aulast%3DCarr%26aufirst%3DM.%2BI.%26aulast%3DZenke%26aufirst%3DF.%2BT.%26aulast%3DBlaukat%26aufirst%3DA.%26aulast%3DVassilev%26aufirst%3DL.%2BT.%26atitle%3DTherapeutic%2520implications%2520of%2520p53%2520status%2520on%2520cancer%2520cell%2520fate%2520following%2520exposure%2520to%2520ionizing%2520radiation%2520and%2520the%2520DNA-PK%2520inhibitor%2520M3814%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2019%26volume%3D17%26issue%3D12%26spage%3D2457%26epage%3D2468%26doi%3D10.1158%2F1541-7786.MCR-19-0362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carr, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, L.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zenke, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaukat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vassilev, L. T.</span></span> <span> </span><span class="NLM_article-title">DNA-PK inhibitor, M3814, as a new combination partner of Mylotarg in the treatment of acute myeloid leukemia</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">127</span>, <span class="refDoi">Â DOI: 10.3389/fonc.2020.00127</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.3389%2Ffonc.2020.00127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=32117773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A280%3ADC%252BB387otVCruw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=127&author=M.+I.+Carrauthor=A.+Zimmermannauthor=L.-Y.+Chiuauthor=F.+T.+Zenkeauthor=A.+Blaukatauthor=L.+T.+Vassilev&title=DNA-PK+inhibitor%2C+M3814%2C+as+a+new+combination+partner+of+Mylotarg+in+the+treatment+of+acute+myeloid+leukemia&doi=10.3389%2Ffonc.2020.00127"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">DNA-PK Inhibitor, M3814, as a New Combination Partner of Mylotarg in the Treatment of Acute Myeloid Leukemia</span></div><div class="casAuthors">Carr Michael I; Chiu Li-Ya; Vassilev Lyubomir T; Zimmermann Astrid; Zenke Frank T; Blaukat Andree</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">127</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Despite significant advances in the treatment of acute myeloid leukemia (AML) the long-term prognosis remains relatively poor and there is an urgent need for improved therapies with increased potency and tumor selectivity.  Mylotarg is the first AML-targeting drug from a new generation of antibody drug conjugate (ADC) therapies aiming at the acute leukemia cell compartment with increased specificity.  This agent targets leukemia cells for apoptosis with a cytotoxic payload, calicheamicin, carried by a CD33-specific antibody.  Calicheamicin induces DNA double strand breaks (DSB) which, if left unrepaired, lead to cell cycle arrest and apoptosis in cancer cells.  However, repair of DSB by the non-homologous end joining pathway driven by DNA-dependent protein kinase (DNA-PK) can reduce the efficacy of calicheamicin.  M3814 is a novel, potent and selective inhibitor of DNA-PK.  This compound effectively blocks DSB repair, strongly potentiates the antitumor activity of ionizing radiation and DSB-inducing chemotherapeutics and is currently under clinical investigation.  Suppressing DSB repair with M3814 synergistically enhanced the apoptotic activity of calicheamicin in cultured AML cells.  Combination of M3814 with Mylotarg in two AML xenograft models, MV4-11 and HL-60, demonstrated increased efficacy and significantly improved survival benefit without elevated body weight loss.  Our results support a new application for pharmacological DNA-PK inhibitors as enhancers of Mylotarg and a potential new combination treatment option for AML patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQppVGC0sO745agfuraLLzSfW6udTcc2eZby3UUjSoq7bntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB387otVCruw%253D%253D&md5=ca2888c2088e0baa327d885479e4b7ec</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2020.00127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2020.00127%26sid%3Dliteratum%253Aachs%26aulast%3DCarr%26aufirst%3DM.%2BI.%26aulast%3DZimmermann%26aufirst%3DA.%26aulast%3DChiu%26aufirst%3DL.-Y.%26aulast%3DZenke%26aufirst%3DF.%2BT.%26aulast%3DBlaukat%26aufirst%3DA.%26aulast%3DVassilev%26aufirst%3DL.%2BT.%26atitle%3DDNA-PK%2520inhibitor%252C%2520M3814%252C%2520as%2520a%2520new%2520combination%2520partner%2520of%2520Mylotarg%2520in%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DFront.%2520Oncol.%26date%3D2020%26volume%3D10%26spage%3D127%26doi%3D10.3389%2Ffonc.2020.00127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mortensen, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrin-Ninkovic, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shevlin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elsner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitefield, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tehrani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sapienza, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riggs, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parnes, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Packard, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B. G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahmanyar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leisten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khambatta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamez, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisonette, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apuy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cathers, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canan, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moghaddam, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raymon, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Worland, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narla, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fultz, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sankar, S.</span></span> <span> </span><span class="NLM_article-title">Optimization of a series of triazole containing mammalian target of rapamycin (mTOR) kinase Inhibitors and the discovery of CC-115</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">5599</span>â <span class="NLM_lpage">5608</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b00627</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00627" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVKit7jF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=5599-5608&issue=14&author=D.+S.+Mortensenauthor=S.+M.+Perrin-Ninkovicauthor=G.+Shevlinauthor=J.+Elsnerauthor=J.+Zhaoauthor=B.+Whitefieldauthor=L.+Tehraniauthor=J.+Sapienzaauthor=J.+R.+Riggsauthor=J.+S.+Parnesauthor=P.+Papaauthor=G.+Packardauthor=B.+G.+S.+Leeauthor=R.+Harrisauthor=M.+Correaauthor=S.+Bahmanyarauthor=S.+J.+Richardsonauthor=S.+X.+Pengauthor=J.+Leistenauthor=G.+Khambattaauthor=M.+Hickmanauthor=J.+C.+Gamezauthor=R.+R.+Bisonetteauthor=J.+Apuyauthor=B.+E.+Cathersauthor=S.+S.+Cananauthor=M.+F.+Moghaddamauthor=H.+K.+Raymonauthor=P.+Worlandauthor=R.+K.+Narlaauthor=K.+E.+Fultzauthor=S.+Sankar&title=Optimization+of+a+series+of+triazole+containing+mammalian+target+of+rapamycin+%28mTOR%29+kinase+Inhibitors+and+the+discovery+of+CC-115&doi=10.1021%2Facs.jmedchem.5b00627"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115</span></div><div class="casAuthors">Mortensen, Deborah S.; Perrin-Ninkovic, Sophie M.; Shevlin, Graziella; Elsner, Jan; Zhao, Jingjing; Whitefield, Brandon; Tehrani, Lida; Sapienza, John; Riggs, Jennifer R.; Parnes, Jason S.; Papa, Patrick; Packard, Garrick; Lee, Branden G. S.; Harris, Roy; Correa, Matthew; Bahmanyar, Sogole; Richardson, Samantha J.; Peng, Sophie X.; Leisten, Jim; Khambatta, Godrej; Hickman, Matt; Gamez, James C.; Bisonette, Rene R.; Apuy, Julius; Cathers, Brian E.; Canan, Stacie S.; Moghaddam, Mehran F.; Raymon, Heather K.; Worland, Peter; Narla, Rama Krishna; Fultz, Kimberly E.; Sankar, Sabita</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5599-5608</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis and structure-activity relationship (SAR) of a novel series of triazoles contg. mammalian target of rapamycin (mTOR) kinase inhibitors is reported.  SAR studies examg. the potency, selectivity, and PK parameters for a series of triazole contg. 4,6- or 1,7-disubstituted-3,4-dihydropyrazino[2,3-b]pyrazine-2(1H)-ones resulted in the identification of triazole contg. mTOR kinase inhibitors with improved PK properties.  Potent compds. from this series were found to block both mTORC1(pS6) and mTORC2(pAktS473) signaling in PC-3 cancer cells, in vitro and in vivo.  When assessed in efficacy models, analogs exhibited dose-dependent efficacy in tumor xenograft models.  This work resulted in the selection of CC-115 (I) for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5ItrhIWvAFLVg90H21EOLACvtfcHk0ljYhRweDRa_ig"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVKit7jF&md5=b7e5351dd7b16119cafe97fb961dd3d9</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00627&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00627%26sid%3Dliteratum%253Aachs%26aulast%3DMortensen%26aufirst%3DD.%2BS.%26aulast%3DPerrin-Ninkovic%26aufirst%3DS.%2BM.%26aulast%3DShevlin%26aufirst%3DG.%26aulast%3DElsner%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DWhitefield%26aufirst%3DB.%26aulast%3DTehrani%26aufirst%3DL.%26aulast%3DSapienza%26aufirst%3DJ.%26aulast%3DRiggs%26aufirst%3DJ.%2BR.%26aulast%3DParnes%26aufirst%3DJ.%2BS.%26aulast%3DPapa%26aufirst%3DP.%26aulast%3DPackard%26aufirst%3DG.%26aulast%3DLee%26aufirst%3DB.%2BG.%2BS.%26aulast%3DHarris%26aufirst%3DR.%26aulast%3DCorrea%26aufirst%3DM.%26aulast%3DBahmanyar%26aufirst%3DS.%26aulast%3DRichardson%26aufirst%3DS.%2BJ.%26aulast%3DPeng%26aufirst%3DS.%2BX.%26aulast%3DLeisten%26aufirst%3DJ.%26aulast%3DKhambatta%26aufirst%3DG.%26aulast%3DHickman%26aufirst%3DM.%26aulast%3DGamez%26aufirst%3DJ.%2BC.%26aulast%3DBisonette%26aufirst%3DR.%2BR.%26aulast%3DApuy%26aufirst%3DJ.%26aulast%3DCathers%26aufirst%3DB.%2BE.%26aulast%3DCanan%26aufirst%3DS.%2BS.%26aulast%3DMoghaddam%26aufirst%3DM.%2BF.%26aulast%3DRaymon%26aufirst%3DH.%2BK.%26aulast%3DWorland%26aufirst%3DP.%26aulast%3DNarla%26aufirst%3DR.%2BK.%26aulast%3DFultz%26aufirst%3DK.%2BE.%26aulast%3DSankar%26aufirst%3DS.%26atitle%3DOptimization%2520of%2520a%2520series%2520of%2520triazole%2520containing%2520mammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%2520kinase%2520Inhibitors%2520and%2520the%2520discovery%2520of%2520CC-115%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D14%26spage%3D5599%26epage%3D5608%26doi%3D10.1021%2Facs.jmedchem.5b00627" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsuji, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sapinoso, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaffney, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sankar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raymon, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortensen, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span> <span> </span><span class="NLM_article-title">CC-115, a dual inhibitor of mTOR kinase and DNA-PK, blocks DNA damage repair pathways and selectively inhibits ATM-deficient cell growth in vitro</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">43</span>),  <span class="NLM_fpage">74688</span>â <span class="NLM_lpage">74702</span>, <span class="refDoi">Â DOI: 10.18632/oncotarget.20342</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.18632%2Foncotarget.20342" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=29088817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A280%3ADC%252BC1M7mtlegsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=74688-74702&issue=43&author=T.+Tsujiauthor=L.+M.+Sapinosoauthor=T.+Tranauthor=B.+Gaffneyauthor=L.+Wongauthor=S.+Sankarauthor=H.+K.+Raymonauthor=D.+S.+Mortensenauthor=S.+Xu&title=CC-115%2C+a+dual+inhibitor+of+mTOR+kinase+and+DNA-PK%2C+blocks+DNA+damage+repair+pathways+and+selectively+inhibits+ATM-deficient+cell+growth+in+vitro&doi=10.18632%2Foncotarget.20342"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">CC-115, a dual inhibitor of mTOR kinase and DNA-PK, blocks DNA damage repair pathways and selectively inhibits ATM-deficient cell growth in vitro</span></div><div class="casAuthors">Tsuji Toshiya; Sapinoso Lisa M; Tran Tam; Gaffney Bonny; Wong Lilly; Sankar Sabita; Xu Shuichan; Raymon Heather K; Mortensen Deborah S</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">74688-74702</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">CC-115, a selective dual inhibitor of the mammalian target of rapamycin (mTOR) kinase and DNA-dependent protein kinase (DNA-PK), is undergoing Phase 1 clinical studies.  Here we report the characterization of DNA-PK inhibitory activity of CC-115 in cancer cell lines.  CC-115 inhibits auto-phosphorylation of the catalytic subunit of DNA-PK (DNA-PKcs) at the S2056 site (pDNA-PK S2056), leading to blockade of DNA-PK-mediated non-homologous end joining (NHEJ).  CC-115 also indirectly reduces the phosphorylation of ataxia-telangiectasia mutated kinase (ATM) at S1981 and its substrates as well as homologous recombination (HR).  The mTOR kinase and DNA-PK inhibitory activity of CC-115 leads to not only potent anti-tumor activity against a large panel of hematopoietic and solid cancer cell lines but also strong induction of apoptosis in a subset of cancer lines.  Mechanistically, CC-115 prevents NHEJ by inhibiting the dissociation of DNA-PKcs, X-ray repair cross-complementing protein 4 (XRCC4), and DNA ligase IV from DNA ends.  CC-115 inhibits colony formation of ATM-deficient cells more potently than ATM-proficient cells, indicating that inhibition of DNA-PK is synthetically lethal with the loss of functional ATM.  In conclusion, CC-115 inhibits both mTOR signaling and NHEJ and HR by direct inhibition of DNA-PK.  The mechanistic data not only provide selection of potential pharmacodynamic (PD) markers but also support CC-115 clinical development in patients with ATM-deficient tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQRKdIxzbJTPHy-c-E1v-fmfW6udTcc2eZRTekHz8ZKq7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7mtlegsA%253D%253D&md5=c3f7816332465ea83b64ca56671754b1</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.20342&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.20342%26sid%3Dliteratum%253Aachs%26aulast%3DTsuji%26aufirst%3DT.%26aulast%3DSapinoso%26aufirst%3DL.%2BM.%26aulast%3DTran%26aufirst%3DT.%26aulast%3DGaffney%26aufirst%3DB.%26aulast%3DWong%26aufirst%3DL.%26aulast%3DSankar%26aufirst%3DS.%26aulast%3DRaymon%26aufirst%3DH.%2BK.%26aulast%3DMortensen%26aufirst%3DD.%2BS.%26aulast%3DXu%26aufirst%3DS.%26atitle%3DCC-115%252C%2520a%2520dual%2520inhibitor%2520of%2520mTOR%2520kinase%2520and%2520DNA-PK%252C%2520blocks%2520DNA%2520damage%2520repair%2520pathways%2520and%2520selectively%2520inhibits%2520ATM-deficient%2520cell%2520growth%2520in%2520vitro%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26issue%3D43%26spage%3D74688%26epage%3D74702%26doi%3D10.18632%2Foncotarget.20342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DomÃ­nguez-Kelly, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MartÃ­n, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koundrioukoff, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanenbaum, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smits, V. A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medema, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debatisse, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freire, R.</span></span> <span> </span><span class="NLM_article-title">Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonuclease</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>194</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">567</span>â <span class="NLM_lpage">579</span>, <span class="refDoi">Â DOI: 10.1083/jcb.201101047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1083%2Fjcb.201101047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=21859861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtV2gt7jK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=194&publication_year=2011&pages=567-579&issue=4&author=R.+Dom%C3%ADnguez-Kellyauthor=Y.+Mart%C3%ADnauthor=S.+Koundrioukoffauthor=M.+E.+Tanenbaumauthor=V.+A.+J.+Smitsauthor=R.+H.+Medemaauthor=M.+Debatisseauthor=R.+Freire&title=Wee1+controls+genomic+stability+during+replication+by+regulating+the+Mus81-Eme1+endonuclease&doi=10.1083%2Fjcb.201101047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonuclease</span></div><div class="casAuthors">Dominguez-Kelly, Raquel; Martin, Yuse; Koundrioukoff, Stephane; Tanenboum, Marvin E.; Smits, Veronique A. J.; Medema, Rene H.; Debatisse, Michelle; Freire, Raimundo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">194</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">567-579</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Correct replication of the genome and protection of its integrity are essential for cell survival.  In a high-throughput screen studying H2AX phosphorylation, we identified Wee1 as a regulator of genomic stability.  Wee1 down-regulation not only induced H2AX phosphorylation but also triggered a general DNA (DNA) damage response (DDR) and caused a block in DNA replication, resulting in accumulation of cells in S phase.  Wee1-deficient cells showed a decrease in replication fork speed, demonstrating the involvement of Wee1 in DNA replication.  Inhibiting Wee1 in cells treated with short treatment of hydroxyurea enhanced the DDR, which suggests that Wee1 specifically protects the stability of stalled replication forks.  Notably, the DDR induced by depletion of Wee1 critically depends on the Mus81-Eme1 endonuclease, and we found that codepletion of Mus81 and Wee1 abrogated the S phase delay.  Importantly, Wee1 and Mus81 interact in vivo, suggesting direct regulation.  Altogether, these results demonstrate a novel role of Wee1 in controlling Mus81 and DNA replication in human cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFrPVJtI5YbLVg90H21EOLACvtfcHk0ljReNzcSf0ZyA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtV2gt7jK&md5=06f366f4e9dae5264bf2cd28f192c829</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1083%2Fjcb.201101047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.201101047%26sid%3Dliteratum%253Aachs%26aulast%3DDom%25C3%25ADnguez-Kelly%26aufirst%3DR.%26aulast%3DMart%25C3%25ADn%26aufirst%3DY.%26aulast%3DKoundrioukoff%26aufirst%3DS.%26aulast%3DTanenbaum%26aufirst%3DM.%2BE.%26aulast%3DSmits%26aufirst%3DV.%2BA.%2BJ.%26aulast%3DMedema%26aufirst%3DR.%2BH.%26aulast%3DDebatisse%26aufirst%3DM.%26aulast%3DFreire%26aufirst%3DR.%26atitle%3DWee1%2520controls%2520genomic%2520stability%2520during%2520replication%2520by%2520regulating%2520the%2520Mus81-Eme1%2520endonuclease%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2011%26volume%3D194%26issue%3D4%26spage%3D567%26epage%3D579%26doi%3D10.1083%2Fjcb.201101047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Do, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doroshow, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kummar, S.</span></span> <span> </span><span class="NLM_article-title">Wee1 kinase as a target for cancer therapy</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">3159</span>â <span class="NLM_lpage">3164</span>, <span class="refDoi">Â DOI: 10.4161/cc.26062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.4161%2Fcc.26062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=24013427" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvV2jsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=3159-3164&issue=19&author=K.+Doauthor=J.+H.+Doroshowauthor=S.+Kummar&title=Wee1+kinase+as+a+target+for+cancer+therapy&doi=10.4161%2Fcc.26062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Wee1 kinase as a target for cancer therapy</span></div><div class="casAuthors">Do, Khanh; Doroshow, James H.; Kummar, Shivaani</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3159-3164</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1538-4101</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">A review.  Wee1, a protein kinase, regulates the G2 checkpoint in response to DNA damage.  Preclin. studies have elucidated the role of wee1 in DNA damage repair and the stabilization of replication forks, supporting the validity of wee1 inhibition as a viable therapeutic target in cancer.  MK-1775, a selective and potent small-mol. inhibitor of wee1, is under clin. development as a potentiator of DNA damage caused by cytotoxic chemotherapies.  We present a review of the role of wee1 in the cell cycle and DNA replication and summarize the clin. development to date of this novel class of anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlvNzPGTmRbrVg90H21EOLACvtfcHk0ljReNzcSf0ZyA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvV2jsrg%253D&md5=19dbe1e7386a614dda65e85e856cdefb</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.4161%2Fcc.26062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.26062%26sid%3Dliteratum%253Aachs%26aulast%3DDo%26aufirst%3DK.%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26aulast%3DKummar%26aufirst%3DS.%26atitle%3DWee1%2520kinase%2520as%2520a%2520target%2520for%2520cancer%2520therapy%26jtitle%3DCell%2520Cycle%26date%3D2013%26volume%3D12%26issue%3D19%26spage%3D3159%26epage%3D3164%26doi%3D10.4161%2Fcc.26062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matheson, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Backos, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reigan, P.</span></span> <span> </span><span class="NLM_article-title">Targeting WEE1 kinase in cancer</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">872</span>â <span class="NLM_lpage">881</span>, <span class="refDoi">Â DOI: 10.1016/j.tips.2016.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.tips.2016.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=27427153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVKnsbfK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=872-881&issue=10&author=C.+J.+Mathesonauthor=D.+S.+Backosauthor=P.+Reigan&title=Targeting+WEE1+kinase+in+cancer&doi=10.1016%2Fj.tips.2016.06.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting WEE1 Kinase in Cancer</span></div><div class="casAuthors">Matheson, Christopher J.; Backos, Donald S.; Reigan, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">872-881</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">WEE1 kinase plays a crucial role in the G2-M cell-cycle checkpoint arrest for DNA repair before mitotic entry.  Normal cells repair damaged DNA during G1 arrest; however, cancer cells often have a deficient G1-S checkpoint and depend on a functional G2-M checkpoint for DNA repair.  WEE1 is expressed at high levels in various cancer types including breast cancers, leukemia, melanoma, and adult and pediatric brain tumors.  Many of these cancers are treated with DNA-damaging agents; therefore, targeting WEE1 for inhibition and compromising the G2-M checkpoint presents an opportunity to potentiate therapy.  In this review we summarize the current WEE1 inhibitors, the potential for further inhibitor development, and the challenges in the clinic for the WEE1 inhibitor strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_mgdRwiwqLbVg90H21EOLACvtfcHk0ljReNzcSf0ZyA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVKnsbfK&md5=f56e9e7a3c30a041cb8e65a097c78fa9</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2016.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2016.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DMatheson%26aufirst%3DC.%2BJ.%26aulast%3DBackos%26aufirst%3DD.%2BS.%26aulast%3DReigan%26aufirst%3DP.%26atitle%3DTargeting%2520WEE1%2520kinase%2520in%2520cancer%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2016%26volume%3D37%26issue%3D10%26spage%3D872%26epage%3D881%26doi%3D10.1016%2Fj.tips.2016.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Music, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlrot, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermansen, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hjelmborg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Stricker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kristensen, B. W.</span></span> <span> </span><span class="NLM_article-title">Expression and prognostic value of the WEE1 kinase in gliomas</span>. <i>J. Neuro-Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>127</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">381</span>â <span class="NLM_lpage">389</span>, <span class="refDoi">Â DOI: 10.1007/s11060-015-2050-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1007%2Fs11060-015-2050-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=26738845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC28XksF2msA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2016&pages=381-389&issue=2&author=D.+Musicauthor=R.+H.+Dahlrotauthor=S.+K.+Hermansenauthor=J.+Hjelmborgauthor=K.+de+Strickerauthor=S.+Hansenauthor=B.+W.+Kristensen&title=Expression+and+prognostic+value+of+the+WEE1+kinase+in+gliomas&doi=10.1007%2Fs11060-015-2050-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Expression and prognostic value of the WEE1 kinase in gliomas</span></div><div class="casAuthors">Music, Darija; Dahlrot, Rikke Hedegaard; Hermansen, Simon Kjaer; Hjelmborg, Jacob; de Stricker, Karin; Hansen, Steinbjoern; Kristensen, Bjarne Winther</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuro-Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">381-389</span>CODEN:
                <span class="NLM_cas:coden">JNODD2</span>;
        ISSN:<span class="NLM_cas:issn">0167-594X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">High-grade gliomas have an aggressive clin. course and new clin. biomarkers and therapeutic targets are highly needed.  WEE1 is a regulator of the G2 checkpoint in glioblastoma (GBM) cells.  Inhibition of this kinase has, in exptl. glioma studies, been suggested to enhance sensitivity to irradn. and temozolomide.  However, expression level and prognostic potential of WEE1 protein in gliomas remain uninvestigated.  In this study, glioma samples from 235 patients across all four WHO grades were analyzed by immunohistochem.  Using image anal., we calcd. the area fraction of WEE1 pos. nuclei.  We found that WEE1 protein was localized in tumor cell nuclei and expressed in all glioma types and grades.  Although WEE1 protein levels are higher in GBMs (mean 24.5 %) relative to grade III (mean 14,0 %, p < 0.05) and grade II (mean 6.8 %, p < 0.001) gliomas, high WEE1 protein was assocd. with better survival in GBMs (p = 0.002).  This was confirmed in multivariate anal. (HR 0.60, p = 0.003) even when adjusted for MGMT status (HR 0.60, p = 0.005).  In conclusion, we report a nuclear expression of WEE1 protein in all glioma grades and types.  The WEE1 pos. nuclear area was correlated with malignancy grade but it was inversely assocd. with prognosis in GBM.  Although WEE1 is a frequently occurring protein and has been proposed as a novel target in GBM, the role of WEE1 in glioma patient survival appears to be connected to the MGMT status and is more complex than previously anticipated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKinaeuX9iRbVg90H21EOLACvtfcHk0lhpIHtVeQkejA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XksF2msA%253D%253D&md5=b3c8a429feb3fcdc7d9f2ff194bfdeea</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1007%2Fs11060-015-2050-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11060-015-2050-4%26sid%3Dliteratum%253Aachs%26aulast%3DMusic%26aufirst%3DD.%26aulast%3DDahlrot%26aufirst%3DR.%2BH.%26aulast%3DHermansen%26aufirst%3DS.%2BK.%26aulast%3DHjelmborg%26aufirst%3DJ.%26aulast%3Dde%2BStricker%26aufirst%3DK.%26aulast%3DHansen%26aufirst%3DS.%26aulast%3DKristensen%26aufirst%3DB.%2BW.%26atitle%3DExpression%2520and%2520prognostic%2520value%2520of%2520the%2520WEE1%2520kinase%2520in%2520gliomas%26jtitle%3DJ.%2520Neuro-Oncol.%26date%3D2016%26volume%3D127%26issue%3D2%26spage%3D381%26epage%3D389%26doi%3D10.1007%2Fs11060-015-2050-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iorns, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lord, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grigoriadis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenwick, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mein, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natrajan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savage, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamber, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis-Filho, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashworth, A.</span></span> <span> </span><span class="NLM_article-title">Integrated functional, gene expression and genomic analysis for the identification of cancer targets</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">4</span>), <span class="NLM_elocation-id">e5120</span> <span class="refDoi">Â DOI: 10.1371/journal.pone.0005120</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1371%2Fjournal.pone.0005120" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=19357772" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&issue=4&author=E.+Iornsauthor=C.+J.+Lordauthor=A.+Grigoriadisauthor=S.+McDonaldauthor=K.+Fenwickauthor=A.+Mackayauthor=C.+A.+Meinauthor=R.+Natrajanauthor=K.+Savageauthor=N.+Tamberauthor=J.+S.+Reis-Filhoauthor=N.+C.+Turnerauthor=A.+Ashworth&title=Integrated+functional%2C+gene+expression+and+genomic+analysis+for+the+identification+of+cancer+targets&doi=10.1371%2Fjournal.pone.0005120"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0005120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0005120%26sid%3Dliteratum%253Aachs%26aulast%3DIorns%26aufirst%3DE.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DGrigoriadis%26aufirst%3DA.%26aulast%3DMcDonald%26aufirst%3DS.%26aulast%3DFenwick%26aufirst%3DK.%26aulast%3DMackay%26aufirst%3DA.%26aulast%3DMein%26aufirst%3DC.%2BA.%26aulast%3DNatrajan%26aufirst%3DR.%26aulast%3DSavage%26aufirst%3DK.%26aulast%3DTamber%26aufirst%3DN.%26aulast%3DReis-Filho%26aufirst%3DJ.%2BS.%26aulast%3DTurner%26aufirst%3DN.%2BC.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DIntegrated%2520functional%252C%2520gene%2520expression%2520and%2520genomic%2520analysis%2520for%2520the%2520identification%2520of%2520cancer%2520targets%26jtitle%3DPLoS%2520One%26date%3D2009%26volume%3D4%26issue%3D4%26doi%3D10.1371%2Fjournal.pone.0005120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porter, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fosmire, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gearheart, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Linden, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baturin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaberezhnyy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeGregori, J.</span></span> <span> </span><span class="NLM_article-title">Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1266</span>â <span class="NLM_lpage">1276</span>, <span class="refDoi">Â DOI: 10.1038/leu.2011.392</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1038%2Fleu.2011.392" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=22289989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC38Xot1entbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=1266-1276&issue=6&author=C.+C.+Porterauthor=J.+Kimauthor=S.+Fosmireauthor=C.+M.+Gearheartauthor=A.+van+Lindenauthor=D.+Baturinauthor=V.+Zaberezhnyyauthor=P.+R.+Patelauthor=D.+Gaoauthor=A.+C.+Tanauthor=J.+DeGregori&title=Integrated+genomic+analyses+identify+WEE1+as+a+critical+mediator+of+cell+fate+and+a+novel+therapeutic+target+in+acute+myeloid+leukemia&doi=10.1038%2Fleu.2011.392"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia</span></div><div class="casAuthors">Porter, C. C.; Kim, J.; Fosmire, S.; Gearheart, C. M.; van Linden, A.; Baturin, D.; Zaberezhnyy, V.; Patel, P. R.; Gao, D.; Tan, A. C.; DeGregori, J.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1266-1276</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) remains a therapeutic challenge despite increasing knowledge about the mol. origins of the disease, as the mechanisms of AML cell escape from chemotherapy remain poorly defined.  We hypothesized that AML cells are addicted to mol. pathways in the context of chemotherapy and used complementary approaches to identify these addictions.  Using novel mol. and computational approaches, we performed genome-wide short-hairpin RNA screens to identify proteins that mediate AML cell fate after cytarabine exposure; gene expression profiling of AML cells exposed to cytarabine to identify genes with induced expression in this context; and examn. of existing gene expression data from primary patient samples.  Integration of these independent analyses strongly implicates cell-cycle checkpoint proteins, particularly WEE1, as crit. mediators of AML cell survival after cytarabine exposure.  Knockdown of WEE1 in a secondary screen confirmed its role in AML cell survival.  Pharmacol. inhibition of WEE1 in AML cell lines and primary cells is synergistic with cytarabine.  Further expts. demonstrate that inhibition of WEE1 prevents S-phase arrest induced by cytarabine, broadening the functions of WEE1 that may be exploited therapeutically.  These data highlight the power of integrating functional and descriptive genomics, and identify WEE1 as a potential therapeutic target in AML.  Leukemia (2012) 26, 1266-1276; doi:10.1038/leu.2011.392; published online 13 Jan. 2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8GuoDeHF677Vg90H21EOLACvtfcHk0lj34CWokYyNXA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xot1entbg%253D&md5=171ea333a0f7d287aac2ac5293356767</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1038%2Fleu.2011.392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2011.392%26sid%3Dliteratum%253Aachs%26aulast%3DPorter%26aufirst%3DC.%2BC.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DFosmire%26aufirst%3DS.%26aulast%3DGearheart%26aufirst%3DC.%2BM.%26aulast%3Dvan%2BLinden%26aufirst%3DA.%26aulast%3DBaturin%26aufirst%3DD.%26aulast%3DZaberezhnyy%26aufirst%3DV.%26aulast%3DPatel%26aufirst%3DP.%2BR.%26aulast%3DGao%26aufirst%3DD.%26aulast%3DTan%26aufirst%3DA.%2BC.%26aulast%3DDeGregori%26aufirst%3DJ.%26atitle%3DIntegrated%2520genomic%2520analyses%2520identify%2520WEE1%2520as%2520a%2520critical%2520mediator%2520of%2520cell%2520fate%2520and%2520a%2520novel%2520therapeutic%2520target%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeukemia%26date%3D2012%26volume%3D26%26issue%3D6%26spage%3D1266%26epage%3D1276%26doi%3D10.1038%2Fleu.2011.392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Magnussen, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holm, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emilsen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosnes, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slipicevic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florenes, V. A.</span></span> <span> </span><span class="NLM_article-title">High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">6</span>), <span class="NLM_elocation-id">e38254</span> <span class="refDoi">Â DOI: 10.1371/journal.pone.0038254</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1371%2Fjournal.pone.0038254" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=22719872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC38XovFyqt74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&issue=6&author=G.+I.+Magnussenauthor=R.+Holmauthor=E.+Emilsenauthor=A.+K.+Rosnesauthor=A.+Slipicevicauthor=V.+A.+Florenes&title=High+expression+of+Wee1+is+associated+with+poor+disease-free+survival+in+malignant+melanoma%3A+potential+for+targeted+therapy&doi=10.1371%2Fjournal.pone.0038254"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy</span></div><div class="casAuthors">Magnussen, Gry Irene; Holm, Ruth; Emilsen, Elisabeth; Rosnes, Anne Katrine Ree; Slipicevic, Ana; Floerenes, Vivi Ann</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e38254</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Notoriously resistant malignant melanoma is one of the most increasing forms of cancer worldwide; there is thus a precarious need for new treatment options.  The Wee1 kinase is a major regulator of the G2/M checkpoint, and halts the cell cycle by adding a neg. phosphorylation on CDK1 (Tyr15).  Addnl., Wee1 has a function in safeguarding the genome integrity during DNA synthesis.  To assess the role of Wee1 in development and progression of malignant melanoma we examd. its expression in a panel of paraffin-embedded patient derived tissue of benign nevi and primary- and metastatic melanomas, as well as in agarose-embedded cultured melanocytes.  We found that Wee1 expression increased in the direction of malignancy, and showed a strong, pos. correlation with known biomarkers involved in cell cycle regulation: Cyclin A (p < 0.0001), Ki67 (p < 0.0001), Cyclin D3 (p = 0.001), p21Cip1/WAF1 (p = 0.003), p53 (p = 0.025).  Furthermore, high Wee1 expression was assocd. with thicker primary tumors (p = 0.001), ulceration (p = 0.005) and poor disease-free survival (p = 0.008).  Transfections using siWee1 in metastatic melanoma cell lines; WM239WTp53, WM45.1MUTp53 and LOXWTp53, further support our hypothesis of a tumor promoting role of Wee1 in melanomas.  Whereas no effect was obsd. in LOX cells, transfection with siWee1 led to accumulation of cells in G1/S and S phase of the cell cycle in WM239 and WM45.1 cells, resp.  Both latter cell lines displayed DNA damage and induction of apoptosis, in the absence of Wee1, indicating that the effect of silencing Wee1 may not be solely dependent of the p53 status of the cells.  Together these results reveal the importance of Wee1 as a prognostic biomarker in melanomas, and indicate a potential role for targeted therapy, alone or in combination with other agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTZWeckNBhlbVg90H21EOLACvtfcHk0lj34CWokYyNXA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovFyqt74%253D&md5=fcf3590d96cccfdfef8abb332d68d523</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0038254&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0038254%26sid%3Dliteratum%253Aachs%26aulast%3DMagnussen%26aufirst%3DG.%2BI.%26aulast%3DHolm%26aufirst%3DR.%26aulast%3DEmilsen%26aufirst%3DE.%26aulast%3DRosnes%26aufirst%3DA.%2BK.%26aulast%3DSlipicevic%26aufirst%3DA.%26aulast%3DFlorenes%26aufirst%3DV.%2BA.%26atitle%3DHigh%2520expression%2520of%2520Wee1%2520is%2520associated%2520with%2520poor%2520disease-free%2520survival%2520in%2520malignant%2520melanoma%253A%2520potential%2520for%2520targeted%2520therapy%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26issue%3D6%26doi%3D10.1371%2Fjournal.pone.0038254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Slipicevic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellesylt, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trope, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florenes, V. A.</span></span> <span> </span><span class="NLM_article-title">Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions</span>. <i>Gynecol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>135</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">118</span>â <span class="NLM_lpage">124</span>, <span class="refDoi">Â DOI: 10.1016/j.ygyno.2014.07.102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.ygyno.2014.07.102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=25093290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlSqtrjM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2014&pages=118-124&issue=1&author=A.+Slipicevicauthor=A.+Holthauthor=E.+Hellesyltauthor=C.+G.+Tropeauthor=B.+Davidsonauthor=V.+A.+Florenes&title=Wee1+is+a+novel+independent+prognostic+marker+of+poor+survival+in+post-chemotherapy+ovarian+carcinoma+effusions&doi=10.1016%2Fj.ygyno.2014.07.102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions</span></div><div class="casAuthors">Slipicevic, Ana; Holth, Arild; Hellesylt, Ellen; Trope, Claes G.; Davidson, Ben; Floerenes, Vivi Ann</div><div class="citationInfo"><span class="NLM_cas:title">Gynecologic Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">118-124</span>CODEN:
                <span class="NLM_cas:coden">GYNOA3</span>;
        ISSN:<span class="NLM_cas:issn">0090-8258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Wee1-like kinase (Wee1) is a tyrosine kinase which neg. regulates entry into mitosis at the G2 to M-phase transition and has a role in inhibition of unscheduled DNA replication in S-phase.  The present study investigated the clin. role of Wee1 in advanced-stage (FIGO III-IV) ovarian serous carcinoma.Wee1 protein expression was analyzed in 287 effusions using immunohistochem.  Expression was analyzed for assocn. with clinicopathol. parameters, including survival.  Forty-five effusions were addnl. studied using Western blotting.  Wee1 was further silenced in SKOV3 and OVCAR8 cells by siRNA knockdown and proliferation was assessed.Nuclear expression of Wee1 in tumor cells was obsd. in 265/287 (92%) and 45/45 (100%) effusions by immunohistochem. and Western blotting, resp.  Wee1 expression by immunohistochem. was significantly higher in post-chemotherapy disease recurrence compared to pre-chemotherapy effusions obtained at diagnosis (p = 0.002).  Wee1 silencing in SKOV3 and OVCAR8 cells reduced proliferation.  In univariate survival anal. of the entire cohort, a trend was obsd. between high (> 25% of cells) Wee1 expression and poor overall survival (p = 0.083).  Survival anal. for 109 patients with post-chemotherapy effusions showed significant assocn. between Wee1 expression and poor overall survival (p = 0.004), a finding which retained its independent prognostic role in Cox multivariate anal. (p = 0.003).Wee1 is frequently expressed in ovarian serous carcinoma effusions, and its expression is significantly higher following exposure to chemotherapy.  The present study is the first to report that Wee1 is an independent prognostic marker in serous ovarian carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUb8EUEghrP7Vg90H21EOLACvtfcHk0lj34CWokYyNXA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlSqtrjM&md5=41d4a5ae2962a842ca879793e2372fee</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2Fj.ygyno.2014.07.102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ygyno.2014.07.102%26sid%3Dliteratum%253Aachs%26aulast%3DSlipicevic%26aufirst%3DA.%26aulast%3DHolth%26aufirst%3DA.%26aulast%3DHellesylt%26aufirst%3DE.%26aulast%3DTrope%26aufirst%3DC.%2BG.%26aulast%3DDavidson%26aufirst%3DB.%26aulast%3DFlorenes%26aufirst%3DV.%2BA.%26atitle%3DWee1%2520is%2520a%2520novel%2520independent%2520prognostic%2520marker%2520of%2520poor%2520survival%2520in%2520post-chemotherapy%2520ovarian%2520carcinoma%2520effusions%26jtitle%3DGynecol.%2520Oncol.%26date%3D2014%26volume%3D135%26issue%3D1%26spage%3D118%26epage%3D124%26doi%3D10.1016%2Fj.ygyno.2014.07.102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bukhari, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearce, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamper, A. M.</span></span> <span> </span><span class="NLM_article-title">Inhibiting Wee1 and ATR kinases produces tumor-selective synthetic lethality and suppresses metastasis</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>129</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1329</span>â <span class="NLM_lpage">1344</span>, <span class="refDoi">Â DOI: 10.1172/JCI122622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1172%2FJCI122622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=30645202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A280%3ADC%252BB3cjhs1Wmtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2019&pages=1329-1344&issue=3&author=A.+B.+Bukhariauthor=C.+W.+Lewisauthor=J.+J.+Pearceauthor=D.+Luongauthor=G.+K.+Chanauthor=A.+M.+Gamper&title=Inhibiting+Wee1+and+ATR+kinases+produces+tumor-selective+synthetic+lethality+and+suppresses+metastasis&doi=10.1172%2FJCI122622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting Wee1 and ATR kinases produces tumor-selective synthetic lethality and suppresses metastasis</span></div><div class="casAuthors">Bukhari Amirali B; Lewis Cody W; Pearce Joanna J; Luong Deandra; Chan Gordon K; Gamper Armin M</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1329-1344</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">We used the cancer-intrinsic property of oncogene-induced DNA damage as the base for a conditional synthetic lethality approach.  To target mechanisms important for cancer cell adaptation to genotoxic stress and thereby to achieve cancer cell-specific killing, we combined inhibition of the kinases ATR and Wee1.  Wee1 regulates cell cycle progression, whereas ATR is an apical kinase in the DNA-damage response.  In an orthotopic breast cancer model, tumor-selective synthetic lethality of the combination of bioavailable ATR and Wee1 inhibitors led to tumor remission and inhibited metastasis with minimal side effects.  ATR and Wee1 inhibition had a higher synergistic effect in cancer stem cells than in bulk cancer cells, compensating for the lower sensitivity of cancer stem cells to the individual drugs.  Mechanistically, the combination treatment caused cells with unrepaired or under-replicated DNA to enter mitosis leading to mitotic catastrophe.  As these inhibitors of ATR and Wee1 are already in phase I/II clinical trials, this knowledge could soon be translated into the clinic, especially as we showed that the combination treatment targets a wide range of tumor cells.  Particularly, the antimetastatic effect of combined Wee1/ATR inhibition and the low toxicity of ATR inhibitors compared with Chk1 inhibitors have great clinical potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSkSJzGKNxKWLZpSb_XWfMrfW6udTcc2ebqsfD6E0ErVLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjhs1Wmtg%253D%253D&md5=da702f6fe769547cd7d6746e9a9748b3</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1172%2FJCI122622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI122622%26sid%3Dliteratum%253Aachs%26aulast%3DBukhari%26aufirst%3DA.%2BB.%26aulast%3DLewis%26aufirst%3DC.%2BW.%26aulast%3DPearce%26aufirst%3DJ.%2BJ.%26aulast%3DLuong%26aufirst%3DD.%26aulast%3DChan%26aufirst%3DG.%2BK.%26aulast%3DGamper%26aufirst%3DA.%2BM.%26atitle%3DInhibiting%2520Wee1%2520and%2520ATR%2520kinases%2520produces%2520tumor-selective%2520synthetic%2520lethality%2520and%2520suppresses%2520metastasis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2019%26volume%3D129%26issue%3D3%26spage%3D1329%26epage%3D1344%26doi%3D10.1172%2FJCI122622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bauman, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C. H.</span></span> <span> </span><span class="NLM_article-title">CHK it out! Blocking WEE kinase routs TP53 mutant cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">4173</span>â <span class="NLM_lpage">4175</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-14-0720</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F1078-0432.CCR-14-0720" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=25125257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlCltr%252FJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=4173-4175&issue=16&author=J.+E.+Baumanauthor=C.+H.+Chung&title=CHK+it+out%21+Blocking+WEE+kinase+routs+TP53+mutant+cancer&doi=10.1158%2F1078-0432.CCR-14-0720"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">CHK It Out! Blocking WEE Kinase Routs TP53 Mutant Cancer</span></div><div class="casAuthors">Bauman, Julie E.; Chung, Christine H.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4173-4175</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Mutations in TP53, encoding the master tumor suppressor p53, have posed a developmental therapeutic dilemma due to inability to target loss of function.  Inhibition of WEE1 or CHK1 kinase, neg. regulators of the G2-M checkpoint, selectively sensitizes p53-deficient cells to exogenous DNA damage, abrogating G2 arrest and pptg. mitotic catastrophe.  Clin Cancer Res; 20(16); 4173-5. Â©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvIGJ2c1Fo27Vg90H21EOLACvtfcHk0lh78pqoOyIj0Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlCltr%252FJ&md5=be755141636e31e8c163be48e70a1f46</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-0720&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-0720%26sid%3Dliteratum%253Aachs%26aulast%3DBauman%26aufirst%3DJ.%2BE.%26aulast%3DChung%26aufirst%3DC.%2BH.%26atitle%3DCHK%2520it%2520out%2521%2520Blocking%2520WEE%2520kinase%2520routs%2520TP53%2520mutant%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26issue%3D16%26spage%3D4173%26epage%3D4175%26doi%3D10.1158%2F1078-0432.CCR-14-0720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booher, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leopold, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span> <span> </span><span class="NLM_article-title">Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">8211</span>â <span class="NLM_lpage">8217</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=11719452" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD3MXovVShsLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=8211-8217&issue=22&author=Y.+Wangauthor=J.+Liauthor=R.+N.+Booherauthor=A.+Krakerauthor=T.+Lawrenceauthor=W.+R.+Leopoldauthor=Y.+Sun&title=Radiosensitization+of+p53+mutant+cells+by+PD0166285%2C+a+novel+G%282%29+checkpoint+abrogator"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Radiosensitization of p53 mutant cells by PD0166285, a novel G2 checkpoint abrogator</span></div><div class="casAuthors">Wang, Yuli; Li, Jun; Booher, Robert N.; Kraker, Alan; Lawrence, Theodore; Leopold, Wilbur R.; Sun, Yi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8211-8217</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The lack of functional p53 in many cancer cells offers a therapeutic target for treatment.  Cells lacking p53 would not be anticipated to demonstrate a G1 checkpoint and would depend on the G2 checkpoint to permit DNA repair prior to undergoing mitosis.  We hypothesized that the G2 checkpoint abrogator could preferentially kill p53-inactive cancer cells by removing the only checkpoint that protects these cells from premature mitosis in response to DNA damage.  Because Wee1 kinase is crucial in maintaining G2 arrest through its inhibitory phosphorylation of Cdc2, we developed a high-throughput mass screening assay and used it to screen chem. library for Wee1 inhibitors.  A pyridopyrimidine class of mol., PD0166285 was identified that inhibited Wee1 at a nanomolar concn.  At the cellular level, 0.5 Î¼M PD0166285 dramatically inhibits irradn.-induced Cdc2 phosphorylation at the Tyr-15 and Thr-14 in seven of seven cancer cell lines tested.  PD0166285 abrogates irradn.-induced G2 arrest as shown by both biochem. markers and fluorescence-activated cell sorter anal. and significantly increases mitotic cell populations.  Biol., PD0166285 acts as a radiosensitizer to sensitize cells to radiation-induced cell death with a sensitivity enhancement ratio of 1.23 as shown by std. clonogenic assay.  This radiosensitizing activity is p53 dependent with a higher efficacy in p53-inactive cells.  Thus, G2 checkpoint abrogators represent a novel class of anticancer drugs that enhance cell killing of conventional cancer therapy through the induction of premature mitosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0KkLReKZ6X7Vg90H21EOLACvtfcHk0liRKpzMz3u50A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXovVShsLs%253D&md5=c6eee9020eac54270d29e94180549a80</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DBooher%26aufirst%3DR.%2BN.%26aulast%3DKraker%26aufirst%3DA.%26aulast%3DLawrence%26aufirst%3DT.%26aulast%3DLeopold%26aufirst%3DW.%2BR.%26aulast%3DSun%26aufirst%3DY.%26atitle%3DRadiosensitization%2520of%2520p53%2520mutant%2520cells%2520by%2520PD0166285%252C%2520a%2520novel%2520G%25282%2529%2520checkpoint%2520abrogator%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26issue%3D22%26spage%3D8211%26epage%3D8217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leijen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Geel, R. M. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavlick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tibes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Razak, A. R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demuth, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freshwater, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shumway, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oza, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellens, J. H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span> <span> </span><span class="NLM_article-title">Phase I study evaluating WEE1 inhibitor AZD1775 as monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">36</span>),  <span class="NLM_fpage">4371</span>â <span class="NLM_lpage">4380</span>, <span class="refDoi">Â DOI: 10.1200/JCO.2016.67.5991</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1200%2FJCO.2016.67.5991" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=27601554" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlegtbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=4371-4380&issue=36&author=S.+Leijenauthor=R.+M.+J.+M.+van+Geelauthor=A.+C.+Pavlickauthor=R.+Tibesauthor=L.+Rosenauthor=A.+R.+A.+Razakauthor=R.+Lamauthor=T.+Demuthauthor=S.+Roseauthor=M.+A.+Leeauthor=T.+Freshwaterauthor=S.+Shumwayauthor=L.+W.+Liangauthor=A.+M.+Ozaauthor=J.+H.+M.+Schellensauthor=G.+I.+Shapiro&title=Phase+I+study+evaluating+WEE1+inhibitor+AZD1775+as+monotherapy+and+in+combination+with+gemcitabine%2C+cisplatin%2C+or+carboplatin+in+patients+with+advanced+solid+tumors&doi=10.1200%2FJCO.2016.67.5991"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study evaluating WEE1 inhibitor AZD1775 as monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors</span></div><div class="casAuthors">Leijen, Suzanne; van Geel, Robin M. J. M.; Pavlick, Anna C.; Tibes, Raoul; Rosen, Lee; Abdul Razak, Albiruni R.; Lam, Raymond; Demuth, Tim; Rose, Shelonitda; Lee, Mark A.; Freshwater, Tomoko; Shumway, Stuart; Liang, Li Wen; Oza, Amit M.; Schellens, Jan H. M.; Shapiro, Geoffrey I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">4371-4389</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: AZD1775 is a WEE1 kinase inhibitor targeting G2 checkpoint control, preferentially sensitizing TP53-deficient tumor cells to DNA damage.  This phase I study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of oral AZD1775 as monotherapy or in combination with chemotherapy in patients with refractory solid tumors.  Patients and Methods In part 1, patients received a single dose of AZD1775 followed by 14 days of observation.  In part 2, patients received AZD1775 as a single dose (part 2A) or as five twice per day doses or two once per day doses (part 2B) in combination with one of the following chemotherapy agents: gemcitabine (1,000 mg/m2), cisplatin (75 mg/m2), or carboplatin (area under the curve, 5 mg/mLâ¥min).  Skin biopsies were collected for pharmacodynamic assessments.  TP53 status was detd. retrospectively in archival tumor tissue.  Results: Two hundred two patients were enrolled onto the study, including nine patients in part 1, 43 in part 2A (including eight rollover patients from part 1), and 158 in part 2B.  AZD1775 monotherapy given as single dose was well tolerated, and the max.-tolerated dose was not reached.  In the combination regimens, the most common adverse events consisted of fatigue, nausea and vomiting, diarrhea, and hematol. toxicity.  The max.-tolerated doses and biol. EDs were established for each combination.  Target engagement, as a predefined 50% pCDK1 redn. in surrogate tissue, was obsd. in combination with cisplatin and carboplatin.  Of 176 patients evaluable for efficacy, 94 (53%) had stable disease as best response, and 17 (10%) achieved a partial response.  The response rate in TP53-mutated patients (n = 19) was 21% compared with 12% in TP53 wild-type patients (n = 33).  Conclusion: AZD1775 was safe and tolerable as a single agent and in combination with chemotherapy at doses assocd. with target engagement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqU_jqg7_dUtLVg90H21EOLACvtfcHk0liRKpzMz3u50A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlegtbw%253D&md5=183b1f187776fa77da6bcff2a4e430e1</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1200%2FJCO.2016.67.5991&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2016.67.5991%26sid%3Dliteratum%253Aachs%26aulast%3DLeijen%26aufirst%3DS.%26aulast%3Dvan%2BGeel%26aufirst%3DR.%2BM.%2BJ.%2BM.%26aulast%3DPavlick%26aufirst%3DA.%2BC.%26aulast%3DTibes%26aufirst%3DR.%26aulast%3DRosen%26aufirst%3DL.%26aulast%3DRazak%26aufirst%3DA.%2BR.%2BA.%26aulast%3DLam%26aufirst%3DR.%26aulast%3DDemuth%26aufirst%3DT.%26aulast%3DRose%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DM.%2BA.%26aulast%3DFreshwater%26aufirst%3DT.%26aulast%3DShumway%26aufirst%3DS.%26aulast%3DLiang%26aufirst%3DL.%2BW.%26aulast%3DOza%26aufirst%3DA.%2BM.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%2BM.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26atitle%3DPhase%2520I%2520study%2520evaluating%2520WEE1%2520inhibitor%2520AZD1775%2520as%2520monotherapy%2520and%2520in%2520combination%2520with%2520gemcitabine%252C%2520cisplatin%252C%2520or%2520carboplatin%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2016%26volume%3D34%26issue%3D36%26spage%3D4371%26epage%3D4380%26doi%3D10.1200%2FJCO.2016.67.5991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leijen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Geel, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonke, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchetti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pluim, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Werkhoven, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freshwater, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beijnen, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellens, J. H.</span></span> <span> </span><span class="NLM_article-title">Phase II study of WEE1 inhibitor AZD1775 plus carboplatin in patients with TP53-mutated ovarian cancer refractory or resistant to first-line therapy within 3 months</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">36</span>),  <span class="NLM_fpage">4354</span>â <span class="NLM_lpage">4361</span>, <span class="refDoi">Â DOI: 10.1200/JCO.2016.67.5942</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1200%2FJCO.2016.67.5942" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=27998224" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlegtb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=4354-4361&issue=36&author=S.+Leijenauthor=R.+M.+van+Geelauthor=G.+S.+Sonkeauthor=D.+de+Jongauthor=E.+H.+Rosenbergauthor=S.+Marchettiauthor=D.+Pluimauthor=E.+van+Werkhovenauthor=S.+Roseauthor=M.+A.+Leeauthor=T.+Freshwaterauthor=J.+H.+Beijnenauthor=J.+H.+Schellens&title=Phase+II+study+of+WEE1+inhibitor+AZD1775+plus+carboplatin+in+patients+with+TP53-mutated+ovarian+cancer+refractory+or+resistant+to+first-line+therapy+within+3+months&doi=10.1200%2FJCO.2016.67.5942"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II study of WEE1 inhibitor AZD1775 plus carboplatin in patients with TP53-mutated ovarian cancer refractory or resistant to first-line therapy within 3 months</span></div><div class="casAuthors">Leijen, Suzanne; van Geel, Robin M. J. M.; Sonke, Gabe S.; de Jong, Daphne; Rosenberg, Efraim H.; Marchetti, Serena; Pluim, Dick; van Werkhoven, Erik; Rose, Shelonitda; Lee, Mark A.; Freshwater, Tomoko; Beijnen, Jos H.; Schellens, Jan H. M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">4354-4363</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: AZD1775 is a first-in-class, potent, and selective inhibitor of WEE1 with proof of chemopotentiation in p53-deficient tumors in preclin. models.  In a phase I study, the max. tolerated dose of AZD1775 in combination with carboplatin demonstrated target engagement.  We conducted a proofof- principle phase II study in patients with p53 tumor suppressor gene (TP53)-mutated ovarian cancer refractory or resistant (< 3 mo) to first-line platinum-based therapy to det. overall response rate, progression-free and overall survival, pharmacokinetics, and modulation of phosphorylated cyclin-dependent kinase (CDK1) in skin biopsies.  Patients and Methods: Patients were treated with carboplatin (area under the curve, 5 mg/mL$min) combined with AZD1775 225 mg orally twice daily over 2.5 days every 21-day cycle until disease progression.  Results: AZD1775 plus carboplatin demonstrated manageable toxicity; fatigue (87%), nausea (78%), thrombocytopenia (70%), diarrhea (70%), and vomiting (48%) were the most common adverse events.  The most frequent grade 3 or 4 adverse events were thrombocytopenia (48%) and neutropenia (37%).  Of 24 patients enrolled, 21 patients were evaluable for efficacy end points.  The overall response rate was 43% (95% CI, 22% to 66%), including one patient (5%) with a prolonged complete response.  Median progression-free and overall survival times were 5.3 mo (95% CI, 2.3 to 9.0 mo) and 12.6 mo (95% CI, 4.9 to 19.7), resp., with two patients with ongoing response for more than 31 and 42 mo at data cutoff.  Conclusion: To our knowledge, this is the first report providing clin. proof that AZD1775 enhances carboplatin efficacy in TP53-mutated tumors.  The encouraging antitumor activity obsd. in patients with TP53-mutated ovarian cancer who were refractory or resistant (< 3 mo) to first-line therapy warrants further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3Qq3dxv0cmLVg90H21EOLACvtfcHk0li7n7IZV13LUw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlegtb4%253D&md5=507ba8f42bc2e5c712fbccbc5db685a2</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1200%2FJCO.2016.67.5942&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2016.67.5942%26sid%3Dliteratum%253Aachs%26aulast%3DLeijen%26aufirst%3DS.%26aulast%3Dvan%2BGeel%26aufirst%3DR.%2BM.%26aulast%3DSonke%26aufirst%3DG.%2BS.%26aulast%3Dde%2BJong%26aufirst%3DD.%26aulast%3DRosenberg%26aufirst%3DE.%2BH.%26aulast%3DMarchetti%26aufirst%3DS.%26aulast%3DPluim%26aufirst%3DD.%26aulast%3Dvan%2BWerkhoven%26aufirst%3DE.%26aulast%3DRose%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DM.%2BA.%26aulast%3DFreshwater%26aufirst%3DT.%26aulast%3DBeijnen%26aufirst%3DJ.%2BH.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%26atitle%3DPhase%2520II%2520study%2520of%2520WEE1%2520inhibitor%2520AZD1775%2520plus%2520carboplatin%2520in%2520patients%2520with%2520TP53-mutated%2520ovarian%2520cancer%2520refractory%2520or%2520resistant%2520to%2520first-line%2520therapy%2520within%25203%2520months%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2016%26volume%3D34%26issue%3D36%26spage%3D4354%26epage%3D4361%26doi%3D10.1200%2FJCO.2016.67.5942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carrassa, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ChilÃ , R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricci, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celenza, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzoletti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broggini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damia, G.</span></span> <span> </span><span class="NLM_article-title">Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">2507</span>â <span class="NLM_lpage">2517</span>, <span class="refDoi">Â DOI: 10.4161/cc.20899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.4161%2Fcc.20899" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=22713237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFegsLrP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=2507-2517&issue=13&author=L.+Carrassaauthor=R.+Chil%C3%A0author=M.+Lupiauthor=F.+Ricciauthor=C.+Celenzaauthor=M.+Mazzolettiauthor=M.+Brogginiauthor=G.+Damia&title=Combined+inhibition+of+Chk1+and+Wee1%3A+in+vitro+synergistic+effect+translates+to+tumor+growth+inhibition+in+vivo&doi=10.4161%2Fcc.20899"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo</span></div><div class="casAuthors">Carrassa, Laura; Chila, Rosaria; Lupi, Monica; Ricci, Francesca; Celenza, Cinzia; Mazzoletti, Marco; Broggini, Massimo; Damia, Giovanna</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2507-2517</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1538-4101</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">Targeting Chk1 protein kinase can enhance the antitumor effects of radio- and chemotherapy.  Recent evidence disclosed a role of Chk1 in unperturbed cell proliferation and survival, implying that Chk1 inhibitors could also be effective as single agents in tumors with a specific genetic background.  To identify genes in synthetic lethality with Chk1, we did a high-throughput screening using a siRNA library directed against 719 human protein kinases in the human ovarian cancer cell line OVCAR-5, resistant to Chk1 inhibitors.  Wee1 tyrosine kinase was the most significant gene in synthetic lethality with Chk1.  Treatment with non-toxic concns. of a Chk1 inhibitor (PF-00477736) and a Wee1 inhibitor (MK-1775) confirmed the marked synergistic effect in various human cancer cell lines (breast, ovarian, colon, prostate), independently of the p53 status.  Detailed mol. anal. showed that the combination caused cancer cells to undergo premature mitosis before the end of DNA replication, with damaged DNA leading to cell death partly by apoptosis.  In vivo treatment of mice bearing OVCAR-5 xenografts with the combination of Chk1 and Wee1 inhibitors led to greater tumor growth inhibition than with the inhibitors used as single agents with no toxicity.  These data provide a strong rationale for the clin. investigation of the combination of a Chk1 and a Wee1 inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoG4SOnNomb9LVg90H21EOLACvtfcHk0li7n7IZV13LUw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFegsLrP&md5=69672526de832f7c93bf336c58961db2</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.4161%2Fcc.20899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.20899%26sid%3Dliteratum%253Aachs%26aulast%3DCarrassa%26aufirst%3DL.%26aulast%3DChil%25C3%25A0%26aufirst%3DR.%26aulast%3DLupi%26aufirst%3DM.%26aulast%3DRicci%26aufirst%3DF.%26aulast%3DCelenza%26aufirst%3DC.%26aulast%3DMazzoletti%26aufirst%3DM.%26aulast%3DBroggini%26aufirst%3DM.%26aulast%3DDamia%26aufirst%3DG.%26atitle%3DCombined%2520inhibition%2520of%2520Chk1%2520and%2520Wee1%253A%2520in%2520vitro%2520synergistic%2520effect%2520translates%2520to%2520tumor%2520growth%2520inhibition%2520in%2520vivo%26jtitle%3DCell%2520Cycle%26date%3D2012%26volume%3D11%26issue%3D13%26spage%3D2507%26epage%3D2517%26doi%3D10.4161%2Fcc.20899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwasawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishibata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohtani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamanaka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itadani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi-Suzuki, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukasawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nambu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arakawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sagara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshizumi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizuarai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotani, H.</span></span> <span> </span><span class="NLM_article-title">Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2992</span>â <span class="NLM_lpage">3000</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-09-0463</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F1535-7163.MCT-09-0463" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=19887545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlyrt77J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=2992-3000&issue=11&author=H.+Hiraiauthor=Y.+Iwasawaauthor=M.+Okadaauthor=T.+Araiauthor=T.+Nishibataauthor=M.+Kobayashiauthor=T.+Kimuraauthor=N.+Kanekoauthor=J.+Ohtaniauthor=K.+Yamanakaauthor=H.+Itadaniauthor=I.+Takahashi-Suzukiauthor=K.+Fukasawaauthor=H.+Okiauthor=T.+Nambuauthor=J.+Jiangauthor=T.+Sakaiauthor=H.+Arakawaauthor=T.+Sakamotoauthor=T.+Sagaraauthor=T.+Yoshizumiauthor=S.+Mizuaraiauthor=H.+Kotani&title=Small-molecule+inhibition+of+Wee1+kinase+by+MK-1775+selectively+sensitizes+p53-deficient+tumor+cells+to+DNA-damaging+agents&doi=10.1158%2F1535-7163.MCT-09-0463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents</span></div><div class="casAuthors">Hirai, Hiroshi; Iwasawa, Yoshikazu; Okada, Megumu; Arai, Tsuyoshi; Nishibata, Toshihide; Kobayashi, Makiko; Kimura, Toshifumi; Kaneko, Naoki; Ohtani, Junko; Yamanaka, Kazunori; Itadani, Hiraku; Takahashi-Suzuki, Ikuko; Fukasawa, Kazuhiro; Oki, Hiroko; Nambu, Tadahiro; Jiang, Jian; Sakai, Takumi; Arakawa, Hiroharu; Sakamoto, Toshihiro; Sagara, Takeshi; Yoshizumi, Takashi; Mizuarai, Shinji; Kotani, Hidehito</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2992-3000</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Wee1 is a tyrosine kinase that phosphorylates and inactivates CDC2 and is involved in G2 checkpoint signaling.  Because p53 is a key regulator in the G1 checkpoint, p53-deficient tumors rely only on the G2 checkpoint after DNA damage.  Hence, such tumors are selectively sensitized to DNA-damaging agents by Wee1 inhibition.  Here, we report the discovery of a potent and selective small-mol. inhibitor of Wee1 kinase, MK-1775.  This compd. inhibits phosphorylation of CDC2 at Tyr15 (CDC2Y15), a direct substrate of Wee1 kinase in cells.  MK-1775 abrogates G2 DNA damage checkpoint, leading to apoptosis in combination with DNA-damaging chemotherapeutic agents such as gemcitabine, carboplatin, and cisplatin selectively in p53-deficient cells.  In vivo, MK-1775 potentiates tumor growth inhibition by these agents, and cotreatment does not significantly increase toxicity.  The enhancement of antitumor effect by MK-1775 was well correlated with inhibition of CDC2Y15 phosphorylation in tumor tissue and skin hair follicles.  Our data indicate that Wee1 inhibition provides a new approach for treatment of multiple human malignancies. [Mol Cancer Ther 2009;8(11):2992-3000].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCLXV8e5coBbVg90H21EOLACvtfcHk0lini_y_hfpZMg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlyrt77J&md5=30d5a094709960f25929dfafc2d4a115</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0463%26sid%3Dliteratum%253Aachs%26aulast%3DHirai%26aufirst%3DH.%26aulast%3DIwasawa%26aufirst%3DY.%26aulast%3DOkada%26aufirst%3DM.%26aulast%3DArai%26aufirst%3DT.%26aulast%3DNishibata%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DM.%26aulast%3DKimura%26aufirst%3DT.%26aulast%3DKaneko%26aufirst%3DN.%26aulast%3DOhtani%26aufirst%3DJ.%26aulast%3DYamanaka%26aufirst%3DK.%26aulast%3DItadani%26aufirst%3DH.%26aulast%3DTakahashi-Suzuki%26aufirst%3DI.%26aulast%3DFukasawa%26aufirst%3DK.%26aulast%3DOki%26aufirst%3DH.%26aulast%3DNambu%26aufirst%3DT.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DSakai%26aufirst%3DT.%26aulast%3DArakawa%26aufirst%3DH.%26aulast%3DSakamoto%26aufirst%3DT.%26aulast%3DSagara%26aufirst%3DT.%26aulast%3DYoshizumi%26aufirst%3DT.%26aulast%3DMizuarai%26aufirst%3DS.%26aulast%3DKotani%26aufirst%3DH.%26atitle%3DSmall-molecule%2520inhibition%2520of%2520Wee1%2520kinase%2520by%2520MK-1775%2520selectively%2520sensitizes%2520p53-deficient%2520tumor%2520cells%2520to%2520DNA-damaging%2520agents%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26issue%3D11%26spage%3D2992%26epage%3D3000%26doi%3D10.1158%2F1535-7163.MCT-09-0463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, C.</span></span> <span> </span><span class="NLM_article-title">Wee1 kinase inhibitor MK-1775 induces apoptosis of acute lymphoblastic leukemia cells and enhances the efficacy of doxorubicin involving downregulation of Notch pathway</span>. <i>Oncol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">5473</span>â <span class="NLM_lpage">5481</span>, <span class="refDoi">Â DOI: 10.3892/ol.2018.9291</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.3892%2Fol.2018.9291" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=30250620" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A280%3ADC%252BB3czitlegtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2018&pages=5473-5481&issue=4&author=Y.+Duanauthor=X.+Dongauthor=J.+Nieauthor=P.+Liauthor=F.+Luauthor=D.+Maauthor=C.+Ji&title=Wee1+kinase+inhibitor+MK-1775+induces+apoptosis+of+acute+lymphoblastic+leukemia+cells+and+enhances+the+efficacy+of+doxorubicin+involving+downregulation+of+Notch+pathway&doi=10.3892%2Fol.2018.9291"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Wee1 kinase inhibitor MK-1775 induces apoptosis of acute lymphoblastic leukemia cells and enhances the efficacy of doxorubicin involving downregulation of Notch pathway</span></div><div class="casAuthors">Duan Yanchao; Dong Xin; Li Peng; Lu Fei; Ma Daoxin; Ji Chunyan; Duan Yanchao; Nie Jing</div><div class="citationInfo"><span class="NLM_cas:title">Oncology letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">5473-5481</span>
        ISSN:<span class="NLM_cas:issn">1792-1074</span>.
    </div><div class="casAbstract">Acute lymphoblastic leukemia (ALL) is an aggressive hematologic malignancy affecting pediatric and adult populations.  Although the outcomes of ALL in children have improved markedly in previous years, limited treatment strategies are available at present for adult patients with ALL.  Wee1 is a crucial cell cycle checkpoint kinase of G2/M that regulates cell cycle progression and maintains chromatin integrity.  MK-1775, a selective inhibitor of Wee1 has recently been identified to be able to induce apoptosis of tumor cells by abrogating G2/M checkpoint.  The present study investigated the anti-leukemic activity of MK-1775 alone and in combination with doxorubicin (Adriamycin(Â®); ADM) in various human ALL cell lines.  MK-1775 treatment induced apoptosis of ALL cells, accompanied by unscheduled mitotic entry and downregulation of Notch pathway.  The anti-leukemic activity of MK-1775 was in a concentration- and time-dependent manner.  The data also indicated that it decreased the half-maximal inhibitory concentration (IC50) of ADM compared with the control group.  The combination of MK-1775 and ADM induced an increased apoptotic rate compared with each agent alone.  In addition, the human bone marrow stromal cell HS-5 cell line was detected to exhibit an increased IC50 value of MK-1775 treatment in contrast to ALL cell lines.  It indicates that the hematopoietic supportive capability may remain intact during the treatment of MK-1775.  Taken together, the Wee1 inhibitor MK-1775 may be an attractive agent in the treatment of patients with ALL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTOQT7xZP5J1JWtyewyzkyLfW6udTcc2eacRnOiLX2VLrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3czitlegtg%253D%253D&md5=958ab9c3bc862d4d52833cd324141844</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.3892%2Fol.2018.9291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fol.2018.9291%26sid%3Dliteratum%253Aachs%26aulast%3DDuan%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DX.%26aulast%3DNie%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DLu%26aufirst%3DF.%26aulast%3DMa%26aufirst%3DD.%26aulast%3DJi%26aufirst%3DC.%26atitle%3DWee1%2520kinase%2520inhibitor%2520MK-1775%2520induces%2520apoptosis%2520of%2520acute%2520lymphoblastic%2520leukemia%2520cells%2520and%2520enhances%2520the%2520efficacy%2520of%2520doxorubicin%2520involving%2520downregulation%2520of%2520Notch%2520pathway%26jtitle%3DOncol.%2520Lett.%26date%3D2018%26volume%3D16%26issue%3D4%26spage%3D5473%26epage%3D5481%26doi%3D10.3892%2Fol.2018.9291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richer, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cala, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâBrien, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carson, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inge, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitsett, T. G.</span></span> <span> </span><span class="NLM_article-title">WEE1 kinase inhibitor AZD1775 has preclinical efficacy in LKB1-deficient non-small cell lung cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">4663</span>â <span class="NLM_lpage">4672</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-16-3565</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F0008-5472.CAN-16-3565" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=28652249" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsV2mu73I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=4663-4672&issue=17&author=A.+L.+Richerauthor=J.+M.+Calaauthor=K.+O%E2%80%99Brienauthor=V.+M.+Carsonauthor=L.+J.+Ingeauthor=T.+G.+Whitsett&title=WEE1+kinase+inhibitor+AZD1775+has+preclinical+efficacy+in+LKB1-deficient+non-small+cell+lung+cancer&doi=10.1158%2F0008-5472.CAN-16-3565"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Richer, Amanda L.; Cala, Jacqueline M.; O'Brien, Kelley; Carson, Vashti M.; Inge, Landon J.; Whitsett, Timothy G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4663-4672</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">G1-S checkpoint loss contributes to carcinogenesis and increases reliance upon the G2-M checkpoint for adaptation to stress and DNA repair, making G2-M checkpoint inhibition a target for novel therapeutic development.  AZD1775, an inhibitor against the crit. G2-M checkpoint protein WEE1, is currently in clin. trials across a no. of tumor types.  AZD1775 and DNA-damaging agents have displayed favorable activity in several preclin. tumor models, often in the mol. context of TP53 loss.  Whether AZD1775 efficacy is modulated by other mol. contexts remains poorly understood.  The tumor suppressor serine/threonine kinase 11 (LKB1/STK11) is one of the most frequently mutated genes in non-small cell lung cancer (NSCLC) and is commonly comutated with oncogenic KRAS mutations.  We investigated the preclin. effects of AZD1775 in the context of KRAS/LKB1 in NSCLC.  Using NSCLC cell lines, we found that AZD1775 alone and in combination with DNA-damaging agents (e.g., cisplatin and radiation) decreased tumor cell viability in LKB1-deficient NSCLC cells.  In vitro, LKB1 deficiency enhanced DNA damage and apoptosis in response to AZD1775 exposure compared with wild-type LKB1 cells.  In a genetically engineered mouse model of mutant Kras with concomitant loss of Lkb1, combined AZD1775 and cisplatin extended overall survival compared with cisplatin alone.  Our data suggest that lack of phosphorylation of LKB1 by ATM was involved in AZD1775-mediated cytotoxicity.  Collectively, these findings provide a clin. application for AZD1775 with DNA-damaging agents in KRAS/LKB1 NSCLC.  Cancer Res; 77(17); 4663-72. Â©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdS7k15I3MCLVg90H21EOLACvtfcHk0lgFHC7Xa60RqQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsV2mu73I&md5=2676307db49d4e96e03985a1ee96607c</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-16-3565&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-16-3565%26sid%3Dliteratum%253Aachs%26aulast%3DRicher%26aufirst%3DA.%2BL.%26aulast%3DCala%26aufirst%3DJ.%2BM.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DK.%26aulast%3DCarson%26aufirst%3DV.%2BM.%26aulast%3DInge%26aufirst%3DL.%2BJ.%26aulast%3DWhitsett%26aufirst%3DT.%2BG.%26atitle%3DWEE1%2520kinase%2520inhibitor%2520AZD1775%2520has%2520preclinical%2520efficacy%2520in%2520LKB1-deficient%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26issue%3D17%26spage%3D4663%26epage%3D4672%26doi%3D10.1158%2F0008-5472.CAN-16-3565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Webster, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Littlejohns, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaunt, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beech, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, D. A.</span></span> <span> </span><span class="NLM_article-title">AZD1775 induces toxicity through double-stranded DNA breaks independently of chemotherapeutic agents in p53-mutated colorectal cancer cells</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">2176</span>â <span class="NLM_lpage">2182</span>, <span class="refDoi">Â DOI: 10.1080/15384101.2017.1301329</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1080%2F15384101.2017.1301329" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=28296564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsl2ju7%252FE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=2176-2182&issue=22&author=P.+J.+Websterauthor=A.+T.+Littlejohnsauthor=H.+J.+Gauntauthor=K.+R.+Prasadauthor=D.+J.+Beechauthor=D.+A.+Burke&title=AZD1775+induces+toxicity+through+double-stranded+DNA+breaks+independently+of+chemotherapeutic+agents+in+p53-mutated+colorectal+cancer+cells&doi=10.1080%2F15384101.2017.1301329"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">AZD1775 induces toxicity through double-stranded DNA breaks independently of chemotherapeutic agents in p53-mutated colorectal cancer cells</span></div><div class="casAuthors">Webster, Peter John; Littlejohns, Anna Tiffany; Gaunt, Hannah Jane; Prasad, K. Raj; Beech, David John; Burke, Dermot Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2176-2182</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1551-4005</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">AZD1775 is a small mol. WEE1 inhibitor used in combination with DNA-damaging agents to cause premature mitosis and cell death in p53-mutated cancer cells.  Here we sought to det. the mechanism of action of AZD1775 in combination with chemotherapeutic agents in light of recent findings that AZD1775 can cause double-stranded DNA (DS-DNA) breaks.  AZD1775 significantly improved the cytotoxicity of 5-FU in a p53-mutated colorectal cancer cell line (HT29 cells), decreasing the IC50 from 9.3Î¼M to 3.5Î¼M.  Flow cytometry showed a significant increase in the mitotic marker pHH3 (3.4% vs. 56.2%) and DS-DNA break marker Î³H2AX (5.1% vs. 50.7%) for combination therapy compared with 5-FU alone.  Combination therapy also increased the amt. of caspase-3 dependent apoptosis compared with 5-FU alone (4% vs. 13%).  The addn. of exogenous nucleosides to combination therapy significantly rescued the increased DS-DNA breaks and caspase-3 dependent apoptosis almost to the levels of 5-FU monotherapy.  In conclusion, AZD1775 enhances 5-FU cytotoxicity through increased DS-DNA breaks, not premature mitosis, in p53-mutated colorectal cancer cells.  This finding is important for designers of future clin. trials when considering the optimal timing and duration of AZD1775 treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN2xmi0S1pwLVg90H21EOLACvtfcHk0lgFHC7Xa60RqQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsl2ju7%252FE&md5=b1548a7e7d6eac24438e27ccdbf7b535</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1080%2F15384101.2017.1301329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15384101.2017.1301329%26sid%3Dliteratum%253Aachs%26aulast%3DWebster%26aufirst%3DP.%2BJ.%26aulast%3DLittlejohns%26aufirst%3DA.%2BT.%26aulast%3DGaunt%26aufirst%3DH.%2BJ.%26aulast%3DPrasad%26aufirst%3DK.%2BR.%26aulast%3DBeech%26aufirst%3DD.%2BJ.%26aulast%3DBurke%26aufirst%3DD.%2BA.%26atitle%3DAZD1775%2520induces%2520toxicity%2520through%2520double-stranded%2520DNA%2520breaks%2520independently%2520of%2520chemotherapeutic%2520agents%2520in%2520p53-mutated%2520colorectal%2520cancer%2520cells%26jtitle%3DCell%2520Cycle%26date%3D2017%26volume%3D16%26issue%3D22%26spage%3D2176%26epage%3D2182%26doi%3D10.1080%2F15384101.2017.1301329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matheson, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkataraman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amani, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Backos, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donson, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wempe, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foreman, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vibhakar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reigan, P.</span></span> <span> </span><span class="NLM_article-title">A WEE1 inhibitor analog of AZD1775 maintains synergy with cisplatin and demonstrates reduced single-agent cytotoxicity in medulloblastoma cells</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2066</span>â <span class="NLM_lpage">2067</span>, <span class="refDoi">Â DOI: 10.1021/acschembio.6b00466</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.6b00466" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC28XpslaqsLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=2066-2067&issue=7&author=C.+J.+Mathesonauthor=S.+Venkataramanauthor=V.+Amaniauthor=P.+S.+Harrisauthor=D.+S.+Backosauthor=A.+M.+Donsonauthor=M.+F.+Wempeauthor=N.+K.+Foremanauthor=R.+Vibhakarauthor=P.+Reigan&title=A+WEE1+inhibitor+analog+of+AZD1775+maintains+synergy+with+cisplatin+and+demonstrates+reduced+single-agent+cytotoxicity+in+medulloblastoma+cells&doi=10.1021%2Facschembio.6b00466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">A WEE1 Inhibitor Analog of AZD1775 Maintains Synergy with Cisplatin and Demonstrates Reduced Single-Agent Cytotoxicity in Medulloblastoma Cells [Erratum to document cited in CA164:432708]</span></div><div class="casAuthors">Matheson, Christopher J.; Venkataraman, Sujatha; Amani, Vladimir; Harris, Peter S.; Backos, Donald S.; Donson, Andrew M.; Wempe, Michael F.; Foreman, Nicholas K.; Vibhakar, Rajeev; Reigan, Philip</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2066-2067</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The purpose of this correction is to report a calcn. error in the IC50 values derived from the TR-FRET assay.  An incorrect concn. range was used in Graphpad Prism, and as a result all IC50 values were off by a factor of 10.  Thecorrect values are shown in the table within Figure 2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqCJCK4Mu0c7Vg90H21EOLACvtfcHk0liL1NNklHDhhg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpslaqsLw%253D&md5=8959cc16ff340840618b12b15cd519b5</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1021%2Facschembio.6b00466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.6b00466%26sid%3Dliteratum%253Aachs%26aulast%3DMatheson%26aufirst%3DC.%2BJ.%26aulast%3DVenkataraman%26aufirst%3DS.%26aulast%3DAmani%26aufirst%3DV.%26aulast%3DHarris%26aufirst%3DP.%2BS.%26aulast%3DBackos%26aufirst%3DD.%2BS.%26aulast%3DDonson%26aufirst%3DA.%2BM.%26aulast%3DWempe%26aufirst%3DM.%2BF.%26aulast%3DForeman%26aufirst%3DN.%2BK.%26aulast%3DVibhakar%26aufirst%3DR.%26aulast%3DReigan%26aufirst%3DP.%26atitle%3DA%2520WEE1%2520inhibitor%2520analog%2520of%2520AZD1775%2520maintains%2520synergy%2520with%2520cisplatin%2520and%2520demonstrates%2520reduced%2520single-agent%2520cytotoxicity%2520in%2520medulloblastoma%2520cells%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2016%26volume%3D11%26issue%3D7%26spage%3D2066%26epage%3D2067%26doi%3D10.1021%2Facschembio.6b00466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marques, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peaucellier, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozano, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schatt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picard, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callebaut, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perret, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geneviere, A. M.</span></span> <span> </span><span class="NLM_article-title">A new subfamily of high molecular mass CDC2-related kinases with PITAI/VRE motifs</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>279</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">832</span>â <span class="NLM_lpage">837</span>, <span class="refDoi">Â DOI: 10.1006/bbrc.2000.4042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1006%2Fbbrc.2000.4042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=11162436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivVakug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2000&pages=832-837&issue=3&author=F.+Marquesauthor=J.+L.+Moreauauthor=G.+Peaucellierauthor=J.+C.+Lozanoauthor=P.+Schattauthor=A.+Picardauthor=I.+Callebautauthor=E.+Perretauthor=A.+M.+Geneviere&title=A+new+subfamily+of+high+molecular+mass+CDC2-related+kinases+with+PITAI%2FVRE+motifs&doi=10.1006%2Fbbrc.2000.4042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">A New Subfamily of High Molecular Mass CDC2-Related Kinases with PITAI/VRE Motifs</span></div><div class="casAuthors">Marques, Francois; Moreau, Jean-Luc; Peaucellier, Gerard; Lozano, Jean-Claude; Schatt, Philippe; Picard, Andre; Callebaut, Isabelle; Perret, Eric; Geneviere, Anne-Marie</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">832-837</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Kinases of the CDC2 family play a key role in cell cycle regulation and gene expression.  In the present work, we identified sea urchin and human cDNAs encoding homologs of a high mol. mass CDC2-like kinase (designated CDC2L5) sharing resp. a PITAVRE and PITAIRE motif.  The human cDNA encodes the full-length amino acid sequence of the Cholinesterase-related cell division controller (CHED) kinase, a previously published partial coding sequence.  CDC2L5 overexpressed in mammalian cells is a â170-kDa nuclear protein.  The mRNA is present during the sea urchin early embryogenesis and is ubiquitously expressed in human tissues.  (c) 2000 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRDQCi585Z7rVg90H21EOLACvtfcHk0liL1NNklHDhhg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivVakug%253D%253D&md5=3b8d397220badcda9cd43e79449ea31e</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1006%2Fbbrc.2000.4042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fbbrc.2000.4042%26sid%3Dliteratum%253Aachs%26aulast%3DMarques%26aufirst%3DF.%26aulast%3DMoreau%26aufirst%3DJ.%2BL.%26aulast%3DPeaucellier%26aufirst%3DG.%26aulast%3DLozano%26aufirst%3DJ.%2BC.%26aulast%3DSchatt%26aufirst%3DP.%26aulast%3DPicard%26aufirst%3DA.%26aulast%3DCallebaut%26aufirst%3DI.%26aulast%3DPerret%26aufirst%3DE.%26aulast%3DGeneviere%26aufirst%3DA.%2BM.%26atitle%3DA%2520new%2520subfamily%2520of%2520high%2520molecular%2520mass%2520CDC2-related%2520kinases%2520with%2520PITAI%252FVRE%2520motifs%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2000%26volume%3D279%26issue%3D3%26spage%3D832%26epage%3D837%26doi%3D10.1006%2Fbbrc.2000.4042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spirohn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boutros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohmann, D.</span></span> <span> </span><span class="NLM_article-title">Cdk12 is a gene-selective RNA polymerase II kinase that regulates a subset of the transcriptome, including Nrf2 target genes</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">21455</span>, <span class="refDoi">Â DOI: 10.1038/srep21455</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1038%2Fsrep21455" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=26911346" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjt1ekurc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=21455&issue=1&author=X.+Liauthor=N.+Chatterjeeauthor=K.+Spirohnauthor=M.+Boutrosauthor=D.+Bohmann&title=Cdk12+is+a+gene-selective+RNA+polymerase+II+kinase+that+regulates+a+subset+of+the+transcriptome%2C+including+Nrf2+target+genes&doi=10.1038%2Fsrep21455"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Cdk12 Is A Gene-Selective RNA Polymerase II Kinase That Regulates a Subset of the Transcriptome, Including Nrf2 Target Genes</span></div><div class="casAuthors">Li, Xuan; Chatterjee, Nirmalya; Spirohn, Kerstin; Boutros, Michael; Bohmann, Dirk</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">21455</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The Nrf2 transcription factor is well conserved throughout metazoan evolution and serves as a central regulator of adaptive cellular responses to oxidative stress.  We carried out an RNAi screen in Drosophila S2 cells to better understand the regulatory mechanisms governing Nrf2 target gene expression.  This paper describes the identification and characterization of the RNA polymerase II (Pol II) kinase Cdk12 as a factor that is required for Nrf2 target gene expression in cell culture and in vivo.  Cdk12 is, however, not essential for bulk mRNA transcription and cells lacking CDK12 function are viable and able to proliferate.  Consistent with previous findings on the DNA damage and heat shock responses, it emerges that Cdk12 may be specifically required for stress activated gene expression.  Transcriptome anal. revealed that antioxidant gene expression is compromised in flies with reduced Cdk12 function, which makes them oxidative stress sensitive.  In addn. to supporting Reactive Oxygen Species (ROS) induced gene activation, Cdk12 suppresses genes that support metabolic functions in stressed conditions.  We suggest that Cdk12 acts as a gene-selective Pol II kinase that engages a global shift in gene expression to switch cells from a metabolically active state to "stress-defense mode" when challenged by external stress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYog5K9zQd7rVg90H21EOLACvtfcHk0lhvDNRNxvmsMA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjt1ekurc%253D&md5=af5217255a3758257f675c78c51eae8b</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1038%2Fsrep21455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep21455%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DChatterjee%26aufirst%3DN.%26aulast%3DSpirohn%26aufirst%3DK.%26aulast%3DBoutros%26aufirst%3DM.%26aulast%3DBohmann%26aufirst%3DD.%26atitle%3DCdk12%2520is%2520a%2520gene-selective%2520RNA%2520polymerase%2520II%2520kinase%2520that%2520regulates%2520a%2520subset%2520of%2520the%2520transcriptome%252C%2520including%2520Nrf2%2520target%2520genes%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26issue%3D1%26spage%3D21455%26doi%3D10.1038%2Fsrep21455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lui, G. Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandori, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemp, C. J.</span></span> <span> </span><span class="NLM_article-title">CDK12: an emerging therapeutic target for cancer</span>. <i>J. Clin. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>71</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">957</span>â <span class="NLM_lpage">962</span>, <span class="refDoi">Â DOI: 10.1136/jclinpath-2018-205356</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1136%2Fjclinpath-2018-205356" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=30104286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFaisLvO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2018&pages=957-962&issue=11&author=G.+Y.+L.+Luiauthor=C.+Grandoriauthor=C.+J.+Kemp&title=CDK12%3A+an+emerging+therapeutic+target+for+cancer&doi=10.1136%2Fjclinpath-2018-205356"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">CDK12: an emerging therapeutic target for cancer</span></div><div class="casAuthors">Lui, Goldie Y. L.; Grandori, Carla; Kemp, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pathology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">957-962</span>CODEN:
                <span class="NLM_cas:coden">JCPAAK</span>;
        ISSN:<span class="NLM_cas:issn">0021-9746</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cyclin-dependent kinase 12 (CDK12) belongs to the cyclin-dependent kinase (CDK) family of serine/threonine protein kinases that regulate transcriptional and posttranscriptional processes, thereby modulating multiple cellular functions.  Early studies characterised CDK12 as a transcriptional CDK that complexes with cyclin K to mediate gene transcription by phosphorylating RNA polymerase II.  CDK12 has been demonstrated to specifically upregulate the expression of genes involved in response to DNA damage, stress and heat shock.  More recent studies have implicated CDK12 in regulating mRNA splicing, 3' end processing, prereplication complex assembly and genomic stability during embryonic development.  Genomic alterations in CDK12 have been detected in oesophageal, stomach, breast, endometrial, uterine, ovarian, bladder, colorectal and pancreatic cancers, ranging from 5% to 15% of sequenced cases.  An increasing no. of studies point to CDK12 inhibition as an effective strategy to inhibit tumor growth, and synthetic lethal interactions have been described with MYC, EWS/FLI and PARP/CHK1 inhibition.  Herein, we discuss the present literature on CDK12 in cell function and human cancer, highlighting important roles for CDK12 as a clin. biomarker for treatment response and potential as an effective therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzHmC04t6Ds7Vg90H21EOLACvtfcHk0lhvDNRNxvmsMA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFaisLvO&md5=cbc3224b1ec312eafb2a136bd8c25fcb</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1136%2Fjclinpath-2018-205356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fjclinpath-2018-205356%26sid%3Dliteratum%253Aachs%26aulast%3DLui%26aufirst%3DG.%2BY.%2BL.%26aulast%3DGrandori%26aufirst%3DC.%26aulast%3DKemp%26aufirst%3DC.%2BJ.%26atitle%3DCDK12%253A%2520an%2520emerging%2520therapeutic%2520target%2520for%2520cancer%26jtitle%3DJ.%2520Clin.%2520Pathol.%26date%3D2018%26volume%3D71%26issue%3D11%26spage%3D957%26epage%3D962%26doi%3D10.1136%2Fjclinpath-2018-205356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutor, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huntoon, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karnitz, L. M.</span></span> <span> </span><span class="NLM_article-title">Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>289</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">9247</span>â <span class="NLM_lpage">9253</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M114.551143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1074%2Fjbc.M114.551143" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=24554720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltVSksrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2014&pages=9247-9253&issue=13&author=P.+M.+Joshiauthor=S.+L.+Sutorauthor=C.+J.+Huntoonauthor=L.+M.+Karnitz&title=Ovarian+cancer-associated+mutations+disable+catalytic+activity+of+CDK12%2C+a+kinase+that+promotes+homologous+recombination+repair+and+resistance+to+cisplatin+and+poly%28ADP-ribose%29+polymerase+inhibitors&doi=10.1074%2Fjbc.M114.551143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Ovarian Cancer-associated Mutations Disable Catalytic Activity of CDK12, a Kinase That Promotes Homologous Recombination Repair and Resistance to Cisplatin and Poly(ADP-ribose) Polymerase Inhibitors</span></div><div class="casAuthors">Joshi, Poorval M.; Sutor, Shari L.; Huntoon, Catherine J.; Karnitz, Larry M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">9247-9253</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Mutations in the tumor suppressors BRCA1 and BRCA2, which encode proteins that are key participants in homologous recombination (HR) repair, occur in â¼20% of high grade serous ovarian cancers.  Although only 20% of these tumors have mutations in BRCA1 and BRCA2, nearly 50% of these tumors have defects in HR.  Notably, however, the underlying genetic defects that give rise to HR defects in the absence of BRCA1 and BRCA2 mutations have not been fully elucidated.  Here we show that the recurrent somatic CDK12 mutations identified in ovarian cancers impair the catalytic activity of this kinase, which is involved in the transcription of a subset of genes, including BRCA1 and other DNA repair genes.  Furthermore, we show that disabling CDK12 function in ovarian cancer cells reduces BRCA1 levels, disrupts HR repair, and sensitizes these cells to the crosslinking agents melphalan and cisplatin and to the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888).  Taken together, these findings suggest that many CDK12 mutations are an unrecognized cause of HR defects in ovarian cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTj3CX_FsX_rVg90H21EOLACvtfcHk0lhvDNRNxvmsMA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltVSksrg%253D&md5=1ac9807318b6002c6134ef49751f3145</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.551143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.551143%26sid%3Dliteratum%253Aachs%26aulast%3DJoshi%26aufirst%3DP.%2BM.%26aulast%3DSutor%26aufirst%3DS.%2BL.%26aulast%3DHuntoon%26aufirst%3DC.%2BJ.%26aulast%3DKarnitz%26aufirst%3DL.%2BM.%26atitle%3DOvarian%2520cancer-associated%2520mutations%2520disable%2520catalytic%2520activity%2520of%2520CDK12%252C%2520a%2520kinase%2520that%2520promotes%2520homologous%2520recombination%2520repair%2520and%2520resistance%2520to%2520cisplatin%2520and%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2014%26volume%3D289%26issue%3D13%26spage%3D9247%26epage%3D9253%26doi%3D10.1074%2Fjbc.M114.551143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekumi, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paculova, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenasi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pospichalova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosken, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rybarikova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryja, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blazek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barboric, M.</span></span> <span> </span><span class="NLM_article-title">Ovarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the Cdk12/CycK complex</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>43</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2575</span>â <span class="NLM_lpage">2589</span>, <span class="refDoi">Â DOI: 10.1093/nar/gkv101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1093%2Fnar%2Fgkv101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=25712099" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFaiurzF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=2575-2589&issue=5&author=K.+M.+Ekumiauthor=H.+Paculovaauthor=T.+Lenasiauthor=V.+Pospichalovaauthor=C.+A.+Boskenauthor=J.+Rybarikovaauthor=V.+Bryjaauthor=M.+Geyerauthor=D.+Blazekauthor=M.+Barboric&title=Ovarian+carcinoma+CDK12+mutations+misregulate+expression+of+DNA+repair+genes+via+deficient+formation+and+function+of+the+Cdk12%2FCycK+complex&doi=10.1093%2Fnar%2Fgkv101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Ovarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the Cdk12/CycK complex</span></div><div class="casAuthors">Ekumi, Kingsley M.; Paculova, Hana; Lenasi, Tina; Pospichalova, Vendula; Bosken, Christian A.; Rybarikova, Jana; Bryja, Vitezslav; Geyer, Matthias; Blazek, Dalibor; Barboric, Matjaz</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2575-2589</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The Cdk12/CycK complex promotes expression of a subset of RNA polymerase II genes, including those of the DNA damage response.  CDK12 is among only nine genes with recurrent somatic mutations in high-grade serous ovarian carcinoma.  However, the influence of these mutations on the Cdk12/CycK complex and their link to carcinogenesis remain ill-defined.  Here, we show that most mutations prevent formation of the Cdk12/CycK complex, rendering the kinase inactive.  By examg. the mutations within the Cdk12/CycK structure, we find that they likely provoke structural rearrangements detrimental to Cdk12 activation.  Our mRNA expression anal. of the patient samples contg. the CDK12 mutations reveals coordinated downregulation of genes crit. to the homologous recombination DNA repair pathway.  Moreover, we establish that the Cdk12/CycK complex occupies these genes and promotes phosphorylation of RNA polymerase II at Ser2.  Accordingly, we demonstrate that the mutant Cdk12 proteins fail to stimulate the faithful DNA double strand break repair via homologous recombination.  Together, we provide the mol. basis of how mutated CDK12 ceases to function in ovarian carcinoma.  We propose that CDK12 is a tumor suppressor of which the loss-of-function mutations may elicit defects in multiple DNA repair pathways, leading to genomic instability underlying the genesis of the cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqK-JxTmiCnhLVg90H21EOLACvtfcHk0lioeXAY-k3MwQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFaiurzF&md5=dc10eb689b1ef25ba3b5bedfd96053d8</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkv101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkv101%26sid%3Dliteratum%253Aachs%26aulast%3DEkumi%26aufirst%3DK.%2BM.%26aulast%3DPaculova%26aufirst%3DH.%26aulast%3DLenasi%26aufirst%3DT.%26aulast%3DPospichalova%26aufirst%3DV.%26aulast%3DBosken%26aufirst%3DC.%2BA.%26aulast%3DRybarikova%26aufirst%3DJ.%26aulast%3DBryja%26aufirst%3DV.%26aulast%3DGeyer%26aufirst%3DM.%26aulast%3DBlazek%26aufirst%3DD.%26aulast%3DBarboric%26aufirst%3DM.%26atitle%3DOvarian%2520carcinoma%2520CDK12%2520mutations%2520misregulate%2520expression%2520of%2520DNA%2520repair%2520genes%2520via%2520deficient%2520formation%2520and%2520function%2520of%2520the%2520Cdk12%252FCycK%2520complex%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2015%26volume%3D43%26issue%3D5%26spage%3D2575%26epage%3D2589%26doi%3D10.1093%2Fnar%2Fgkv101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naidoo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wai, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maguire, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daley, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haider, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kriplani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirza, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grigoriadis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tutt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moseley, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Fatah, T. M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S. Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madhusudan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhaka, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, I. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lord, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natrajan, R.</span></span> <span> </span><span class="NLM_article-title">Evaluation of CDK12 protein expression as a potential novel biomarker for DNA damage response-targeted therapies in breast cancer</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">306</span>â <span class="NLM_lpage">315</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-17-0760</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F1535-7163.MCT-17-0760" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=29133620" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Gitw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=306-315&issue=1&author=K.+Naidooauthor=P.+T.+Waiauthor=S.+L.+Maguireauthor=F.+Daleyauthor=S.+Haiderauthor=D.+Kriplaniauthor=J.+Campbellauthor=H.+Mirzaauthor=A.+Grigoriadisauthor=A.+Tuttauthor=P.+M.+Moseleyauthor=T.+M.+A.+Abdel-Fatahauthor=S.+Y.+T.+Chanauthor=S.+Madhusudanauthor=E.+A.+Rhakaauthor=I.+O.+Ellisauthor=C.+J.+Lordauthor=Y.+Yuanauthor=A.+R.+Greenauthor=R.+Natrajan&title=Evaluation+of+CDK12+protein+expression+as+a+potential+novel+biomarker+for+DNA+damage+response-targeted+therapies+in+breast+cancer&doi=10.1158%2F1535-7163.MCT-17-0760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response-Targeted Therapies in Breast Cancer</span></div><div class="casAuthors">Naidoo, Kalnisha; Wai, Patty T.; Maguire, Sarah L.; Daley, Frances; Haider, Syed; Kriplani, Divya; Campbell, James; Mirza, Hasan; Grigoriadis, Anita; Tutt, Andrew; Moseley, Paul M.; Abdel-Fatah, Tarek M. A.; Chan, Stephen Y. T.; Madhusudan, Srinivasan; Rhaka, Emad A.; Ellis, Ian O.; Lord, Christopher J.; Yuan, Yinyin; Green, Andrew R.; Natrajan, Rachael</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">306-315</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Disruption of Cyclin-Dependent Kinase 12 (CDK12) is known to lead to defects in DNA repair and sensitivity to platinum salts and PARP1/2 inhibitors.  However, CDK12 has also been proposed as an oncogene in breast cancer.  We therefore aimed to assess the frequency and distribution of CDK12 protein expression by IHC in independent cohorts of breast cancer and correlate this with outcome and genomic status.  We found that 21% of primary unselected breast cancers were CDK12 high, and 10.5% were absent, by IHC.  CDK12 positivity correlated with HER2 positivity but was not an independent predictor of breast cancer-specific survival taking HER2 status into account; however, absent CDK12 protein expression significantly correlated with a triple-neg. phenotype.  Interestingly, CDK12 protein absence was assocd. with reduced expression of a no. of DDR proteins including ATR, Ku70/Ku80, PARP1, DNA-PK, and Î³H2AX, suggesting a novel mechanism of CDK12-assocd. DDR dysregulation in breast cancer.  Our data suggest that diagnostic IHC quantification of CDK12 in breast cancer is feasible, with CDK12 absence possibly signifying defective DDR function.  This may have important therapeutic implications, particularly for triple-neg. breast cancers.  Mol Cancer Ther; 17(1); 306-15. Â©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK7g_s8kIxRrVg90H21EOLACvtfcHk0lioeXAY-k3MwQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Gitw%253D%253D&md5=66790735980e31d1736272e2c20be108</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-17-0760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-17-0760%26sid%3Dliteratum%253Aachs%26aulast%3DNaidoo%26aufirst%3DK.%26aulast%3DWai%26aufirst%3DP.%2BT.%26aulast%3DMaguire%26aufirst%3DS.%2BL.%26aulast%3DDaley%26aufirst%3DF.%26aulast%3DHaider%26aufirst%3DS.%26aulast%3DKriplani%26aufirst%3DD.%26aulast%3DCampbell%26aufirst%3DJ.%26aulast%3DMirza%26aufirst%3DH.%26aulast%3DGrigoriadis%26aufirst%3DA.%26aulast%3DTutt%26aufirst%3DA.%26aulast%3DMoseley%26aufirst%3DP.%2BM.%26aulast%3DAbdel-Fatah%26aufirst%3DT.%2BM.%2BA.%26aulast%3DChan%26aufirst%3DS.%2BY.%2BT.%26aulast%3DMadhusudan%26aufirst%3DS.%26aulast%3DRhaka%26aufirst%3DE.%2BA.%26aulast%3DEllis%26aufirst%3DI.%2BO.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DYuan%26aufirst%3DY.%26aulast%3DGreen%26aufirst%3DA.%2BR.%26aulast%3DNatrajan%26aufirst%3DR.%26atitle%3DEvaluation%2520of%2520CDK12%2520protein%2520expression%2520as%2520a%2520potential%2520novel%2520biomarker%2520for%2520DNA%2520damage%2520response-targeted%2520therapies%2520in%2520breast%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2018%26volume%3D17%26issue%3D1%26spage%3D306%26epage%3D315%26doi%3D10.1158%2F1535-7163.MCT-17-0760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Biswas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cultraro, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maity, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venugopalan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdullaev, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaytan, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitts, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bass, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanada, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meltzer, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panchenko, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pack, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giaccone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrump, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guha, U.</span></span> <span> </span><span class="NLM_article-title">Genomic profiling of multiple sequentially acquired tumor metastatic sites from an âexceptional responderâ lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response</span>. <i>Cold Spring Harb. Mol. Case Stud.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">6</span>), <span class="NLM_elocation-id">a001263</span> <span class="refDoi">Â DOI: 10.1101/mcs.a001263</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1101%2Fmcs.a001263" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=27900369" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotlSksbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2016&issue=6&author=R.+Biswasauthor=S.+Gaoauthor=C.+M.+Cultraroauthor=T.+K.+Maityauthor=A.+Venugopalanauthor=Z.+Abdullaevauthor=A.+K.+Shaytanauthor=C.+A.+Carterauthor=A.+Thomasauthor=A.+Rajanauthor=Y.+Songauthor=S.+Pittsauthor=K.+Chenauthor=S.+Bassauthor=J.+Bolandauthor=K.+I.+Hanadaauthor=J.+Chenauthor=P.+S.+Meltzerauthor=A.+R.+Panchenkoauthor=J.+C.+Yangauthor=S.+Packauthor=G.+Giacconeauthor=D.+S.+Schrumpauthor=J.+Khanauthor=U.+Guha&title=Genomic+profiling+of+multiple+sequentially+acquired+tumor+metastatic+sites+from+an+%E2%80%9Cexceptional+responder%E2%80%9D+lung+adenocarcinoma+patient+reveals+extensive+genomic+heterogeneity+and+novel+somatic+variants+driving+treatment+response&doi=10.1101%2Fmcs.a001263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Genomic profiling of multiple sequentially acquired tumor metastatic sites from an "exceptional responder" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response</span></div><div class="casAuthors">Biswas, Romi; Gao, Shaojian; Cultraro, Constance M.; Maity, Tapan K.; Venugopalan, Abhilash; Abdullaev, Zied; Shaytan, Alexey K.; Carter, Corey A.; Thomas, Anish; Rajan, Arun; Song, Young; Pitts, Stephanie; Chen, Kevin; Bass, Sara; Boland, Joseph; Hanada, Ken-Ichi; Chen, Jinqiu; Meltzer, Paul S.; Panchenko, Anna R.; Yang, James C.; Pack, Svetlana; Giaccone, Giuseppe; Schrump, David S.; Khan, Javed; Guha, Udayan</div><div class="citationInfo"><span class="NLM_cas:title">Cold Spring Harbor Molecular Case Studies</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">a001263/1-a001263/27</span>CODEN:
                <span class="NLM_cas:coden">CSHMCJ</span>;
        ISSN:<span class="NLM_cas:issn">2373-2873</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">We used next-generation sequencing to identify somatic alterations in multiple metastatic sites from an "exceptional responder" lung adenocarcinoma patient during his 7-yr course of ERBB2-directed therapies.  The degree of heterogeneity was unprecedented, with â¼1% similarity between somatic alterations of the lung and lymph nodes.  One novel translocation, PLAG1-ACTA2, present in both sites, up-regulated ACTA2 expression.  ERBB2, the predominant driver oncogene, was amplified in both sites, more pronounced in the lung, and harbored an L869R mutation in the lymph node.  Functional studies showed increased proliferation, migration, metastasis, and resistance to ERBB2- directed therapy because of L869R mutation and increased migration because of ACTA2 overexpression.  Within the lung, a nonfunctional CDK12, due to a novel G879V mutation, correlated with down-regulation of DNA damage response genes, causing genomic instability, and sensitivity to chemotherapy.  We propose a model whereby a subclone metastasized early fromthe primary site and evolved independently in lymph nodes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWKbpk3UH287Vg90H21EOLACvtfcHk0lgA_kNCTTIqiw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotlSksbc%253D&md5=6d6898c62f0f2d8879859b32cded3201</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1101%2Fmcs.a001263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fmcs.a001263%26sid%3Dliteratum%253Aachs%26aulast%3DBiswas%26aufirst%3DR.%26aulast%3DGao%26aufirst%3DS.%26aulast%3DCultraro%26aufirst%3DC.%2BM.%26aulast%3DMaity%26aufirst%3DT.%2BK.%26aulast%3DVenugopalan%26aufirst%3DA.%26aulast%3DAbdullaev%26aufirst%3DZ.%26aulast%3DShaytan%26aufirst%3DA.%2BK.%26aulast%3DCarter%26aufirst%3DC.%2BA.%26aulast%3DThomas%26aufirst%3DA.%26aulast%3DRajan%26aufirst%3DA.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DPitts%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DBass%26aufirst%3DS.%26aulast%3DBoland%26aufirst%3DJ.%26aulast%3DHanada%26aufirst%3DK.%2BI.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DMeltzer%26aufirst%3DP.%2BS.%26aulast%3DPanchenko%26aufirst%3DA.%2BR.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DPack%26aufirst%3DS.%26aulast%3DGiaccone%26aufirst%3DG.%26aulast%3DSchrump%26aufirst%3DD.%2BS.%26aulast%3DKhan%26aufirst%3DJ.%26aulast%3DGuha%26aufirst%3DU.%26atitle%3DGenomic%2520profiling%2520of%2520multiple%2520sequentially%2520acquired%2520tumor%2520metastatic%2520sites%2520from%2520an%2520%25E2%2580%259Cexceptional%2520responder%25E2%2580%259D%2520lung%2520adenocarcinoma%2520patient%2520reveals%2520extensive%2520genomic%2520heterogeneity%2520and%2520novel%2520somatic%2520variants%2520driving%2520treatment%2520response%26jtitle%3DCold%2520Spring%2520Harb.%2520Mol.%2520Case%2520Stud.%26date%3D2016%26volume%3D2%26issue%3D6%26doi%3D10.1101%2Fmcs.a001263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bajrami, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frankum, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rehman, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brough, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sims, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rafiq, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooper, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozarewa, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assiotis, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenwick, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natrajan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lord, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashworth, A.</span></span> <span> </span><span class="NLM_article-title">Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">287</span>â <span class="NLM_lpage">297</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-13-2541</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F0008-5472.CAN-13-2541" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=24240700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2cXislKjuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=287-297&issue=1&author=I.+Bajramiauthor=J.+R.+Frankumauthor=A.+Kondeauthor=R.+E.+Millerauthor=F.+L.+Rehmanauthor=R.+Broughauthor=J.+Campbellauthor=D.+Simsauthor=R.+Rafiqauthor=S.+Hooperauthor=L.+Chenauthor=I.+Kozarewaauthor=I.+Assiotisauthor=K.+Fenwickauthor=R.+Natrajanauthor=C.+J.+Lordauthor=A.+Ashworth&title=Genome-wide+profiling+of+genetic+synthetic+lethality+identifies+CDK12+as+a+novel+determinant+of+PARP1%2F2+inhibitor+sensitivity&doi=10.1158%2F0008-5472.CAN-13-2541"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity</span></div><div class="casAuthors">Bajrami, Ilirjana; Frankum, Jessica R.; Konde, Asha; Miller, Rowan E.; Rehman, Farah L.; Brough, Rachel; Campbell, James; Sims, David; Rafiq, Rumana; Hooper, Sean; Chen, Lina; Kozarewa, Iwanka; Assiotis, Ioannis; Fenwick, Kerry; Natrajan, Rachael; Lord, Christopher J.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">287-297</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Small-mol. inhibitors of PARP1/2, such as olaparib, have been proposed to serve as a synthetic lethal therapy for cancers that harbor BRCA1 or BRCA2 mutations.  Indeed, in clin. trials, PARP1/2 inhibitors elicit sustained antitumor responses in patients with germline BRCA gene mutations.  In hypothesizing that addnl. genetic determinants might direct use of these drugs, we conducted a genome-wide synthetic lethal screen for candidate olaparib sensitivity genes.  In support of this hypothesis, the set of identified genes included known determinants of olaparib sensitivity, such as BRCA1, RAD51, and Fanconi's anemia susceptibility genes.  In addn., the set included genes implicated in established networks of DNA repair, DNA cohesion, and chromatin remodeling, none of which were known previously to confer sensitivity to PARP1/2 inhibition.  Notably, integration of the list of candidate sensitivity genes with data from tumor DNA sequencing studies identified CDK12 deficiency as a clin. relevant biomarker of PARP1/2 inhibitor sensitivity.  In models of high-grade serous ovarian cancer (HGS-OVCa), CDK12 attenuation was sufficient to confer sensitivity to PARP1/2 inhibition, suppression of DNA repair via homologous recombination, and reduced expression of BRCA1.  As one of only nine genes known to be significantly mutated in HGS-OVCa, CDK12 has properties that should confirm interest in its use as a biomarker, particularly in ongoing clin. trials of PARP1/2 inhibitors and other agents that trigger replication fork arrest.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNCJR_Nh_WjbVg90H21EOLACvtfcHk0lhXUvdghyP1Tg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXislKjuw%253D%253D&md5=9e07aa538aed0fb3a5ac6be21659d051</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-13-2541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-13-2541%26sid%3Dliteratum%253Aachs%26aulast%3DBajrami%26aufirst%3DI.%26aulast%3DFrankum%26aufirst%3DJ.%2BR.%26aulast%3DKonde%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DR.%2BE.%26aulast%3DRehman%26aufirst%3DF.%2BL.%26aulast%3DBrough%26aufirst%3DR.%26aulast%3DCampbell%26aufirst%3DJ.%26aulast%3DSims%26aufirst%3DD.%26aulast%3DRafiq%26aufirst%3DR.%26aulast%3DHooper%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DKozarewa%26aufirst%3DI.%26aulast%3DAssiotis%26aufirst%3DI.%26aulast%3DFenwick%26aufirst%3DK.%26aulast%3DNatrajan%26aufirst%3DR.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DGenome-wide%2520profiling%2520of%2520genetic%2520synthetic%2520lethality%2520identifies%2520CDK12%2520as%2520a%2520novel%2520determinant%2520of%2520PARP1%252F2%2520inhibitor%2520sensitivity%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26issue%3D1%26spage%3D287%26epage%3D297%26doi%3D10.1158%2F0008-5472.CAN-13-2541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muniz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, S.</span></span> <span> </span><span class="NLM_article-title">3â² end formation of pre-mRNA and phosphorylation of Ser2 on the RNA polymerase II CTD are reciprocally coupled in human cells</span>. <i>Genes Dev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">342</span>â <span class="NLM_lpage">356</span>, <span class="refDoi">Â DOI: 10.1101/gad.231274.113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1101%2Fgad.231274.113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=24478330" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktFektLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=342-356&issue=4&author=L.+Davidsonauthor=L.+Munizauthor=S.+West&title=3%E2%80%B2+end+formation+of+pre-mRNA+and+phosphorylation+of+Ser2+on+the+RNA+polymerase+II+CTD+are+reciprocally+coupled+in+human+cells&doi=10.1101%2Fgad.231274.113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">3' end formation of pre-mRNA and phosphorylation of Ser2 on the RNA polymerase II CTD are reciprocally coupled in human cells</span></div><div class="casAuthors">Davidson, Lee; Muniz, Lisa; West, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">342-356</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">3' End formation of pre-mRNAs is coupled to their transcription via the C-terminal domain (CTD) of RNA polymerase II (Pol II).  Nearly all protein-coding transcripts are matured by cleavage and polyadenylation (CPA), which is frequently misregulated in disease.  Understanding how transcription is coordinated with CPA in human cells is therefore very important.  We found that the CTD is heavily phosphorylated on Ser2 (Ser2p) at poly(A) (pA) signals coincident with recruitment of the CstF77 CPA factor.  Depletion of the Ser2 kinase Cdk12 impairs Ser2p, CstF77 recruitment, and CPA, strongly suggesting that the processes are linked, as they are in budding yeast.  Importantly, we addnl. show that the high Ser2p signals at the 3' end depend on pA signal function.  Down-regulation of CPA results in the loss of a 3' Ser2p peak, whereas a new peak is formed when CPA is induced de novo.  Finally, high Ser2p signals are generated by Pol II pausing, which is a well-known feature of pA site recognition.  Thus, a reciprocal relationship between early steps in pA site processing and Ser2p ensures efficient 3' end formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqV79r2OLuIbVg90H21EOLACvtfcHk0lhXUvdghyP1Tg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktFektLo%253D&md5=b69cb0685b08cd5b9653f8a0285bf283</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1101%2Fgad.231274.113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.231274.113%26sid%3Dliteratum%253Aachs%26aulast%3DDavidson%26aufirst%3DL.%26aulast%3DMuniz%26aufirst%3DL.%26aulast%3DWest%26aufirst%3DS.%26atitle%3D3%25E2%2580%25B2%2520end%2520formation%2520of%2520pre-mRNA%2520and%2520phosphorylation%2520of%2520Ser2%2520on%2520the%2520RNA%2520polymerase%2520II%2520CTD%2520are%2520reciprocally%2520coupled%2520in%2520human%2520cells%26jtitle%3DGenes%2520Dev.%26date%3D2014%26volume%3D28%26issue%3D4%26spage%3D342%26epage%3D356%26doi%3D10.1101%2Fgad.231274.113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iniguez, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolte, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conway, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dharia, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mora, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalev, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leggett, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chowdhury, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benes, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stegmaier, K.</span></span> <span> </span><span class="NLM_article-title">EWS/FLI confers tumor cell synthetic lethality to CDK12 inhibition in Ewing sarcoma</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">202</span>â <span class="NLM_lpage">216</span>, <span class="refDoi">Â DOI: 10.1016/j.ccell.2017.12.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.ccell.2017.12.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=29358035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlOgu7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2018&pages=202-216&issue=2&author=A.+B.+Iniguezauthor=B.+Stolteauthor=E.+J.+Wangauthor=A.+S.+Conwayauthor=G.+Alexeauthor=N.+V.+Dhariaauthor=N.+Kwiatkowskiauthor=T.+Zhangauthor=B.+J.+Abrahamauthor=J.+Moraauthor=P.+Kalevauthor=A.+Leggettauthor=D.+Chowdhuryauthor=C.+H.+Benesauthor=R.+A.+Youngauthor=N.+S.+Grayauthor=K.+Stegmaier&title=EWS%2FFLI+confers+tumor+cell+synthetic+lethality+to+CDK12+inhibition+in+Ewing+sarcoma&doi=10.1016%2Fj.ccell.2017.12.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma</span></div><div class="casAuthors">Iniguez, Amanda Balboni; Stolte, Bjorn; Wang, Emily Jue; Conway, Amy Saur; Alexe, Gabriela; Dharia, Neekesh V.; Kwiatkowski, Nicholas; Zhang, Tinghu; Abraham, Brian J.; Mora, Jaume; Kalev, Peter; Leggett, Alan; Chowdhury, Dipanjan; Benes, Cyril H.; Young, Richard A.; Gray, Nathanael S.; Stegmaier, Kimberly</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">202-216.e6</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Many cancer types are driven by oncogenic transcription factors that have been difficult to drug.  Transcriptional inhibitors, however, may offer inroads into targeting these cancers.  Through chem. genomics screening, we identified that Ewing sarcoma is a disease with preferential sensitivity to THZ1, a covalent small-mol. CDK7/12/13 inhibitor.  The selective CDK12/13 inhibitor, THZ531, impairs DNA damage repair in an EWS/FLI-dependent manner, supporting a synthetic lethal relationship between response to THZ1/THZ531 and EWS/FLI expression.  The combination of these mols. with PARP inhibitors showed striking synergy in cell viability and DNA damage assays in vitro and in multiple models of Ewing sarcoma, including a PDX, in vivo without hematopoietic toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8OOYhMwzME7Vg90H21EOLACvtfcHk0ljPrhYjInbHmA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlOgu7c%253D&md5=c844fbd1a91828c87dda66646e4acd03</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2017.12.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2017.12.009%26sid%3Dliteratum%253Aachs%26aulast%3DIniguez%26aufirst%3DA.%2BB.%26aulast%3DStolte%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DE.%2BJ.%26aulast%3DConway%26aufirst%3DA.%2BS.%26aulast%3DAlexe%26aufirst%3DG.%26aulast%3DDharia%26aufirst%3DN.%2BV.%26aulast%3DKwiatkowski%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DAbraham%26aufirst%3DB.%2BJ.%26aulast%3DMora%26aufirst%3DJ.%26aulast%3DKalev%26aufirst%3DP.%26aulast%3DLeggett%26aufirst%3DA.%26aulast%3DChowdhury%26aufirst%3DD.%26aulast%3DBenes%26aufirst%3DC.%2BH.%26aulast%3DYoung%26aufirst%3DR.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DStegmaier%26aufirst%3DK.%26atitle%3DEWS%252FFLI%2520confers%2520tumor%2520cell%2520synthetic%2520lethality%2520to%2520CDK12%2520inhibition%2520in%2520Ewing%2520sarcoma%26jtitle%3DCancer%2520Cell%26date%3D2018%26volume%3D33%26issue%3D2%26spage%3D202%26epage%3D216%26doi%3D10.1016%2Fj.ccell.2017.12.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marineau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malojcic, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlando, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, C.</span></span> <span> </span><span class="NLM_article-title">Targeting the transcriptional kinases CDK12 and CDK13 in breast and ovarian cancer</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">1_supplement</span>),  <span class="NLM_fpage">938.9</span>, <span class="refDoi">Â DOI: 10.1096/fasebj.31.1_supplement.938.9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1096%2Ffasebj.31.1_supplement.938.9" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=938.9&issue=1_supplement&author=K.+Hammanauthor=M.+Bradleyauthor=J.+Marineauauthor=Y.+Choiauthor=G.+Malojcicauthor=D.+Orlandoauthor=Y.+Renauthor=N.+Keauthor=S.+Huauthor=E.+Olsonauthor=C.+Fritzauthor=C.+Roberts&title=Targeting+the+transcriptional+kinases+CDK12+and+CDK13+in+breast+and+ovarian+cancer&doi=10.1096%2Ffasebj.31.1_supplement.938.9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1096%2Ffasebj.31.1_supplement.938.9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffasebj.31.1_supplement.938.9%26sid%3Dliteratum%253Aachs%26aulast%3DHamman%26aufirst%3DK.%26aulast%3DBradley%26aufirst%3DM.%26aulast%3DMarineau%26aufirst%3DJ.%26aulast%3DChoi%26aufirst%3DY.%26aulast%3DMalojcic%26aufirst%3DG.%26aulast%3DOrlando%26aufirst%3DD.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DKe%26aufirst%3DN.%26aulast%3DHu%26aufirst%3DS.%26aulast%3DOlson%26aufirst%3DE.%26aulast%3DFritz%26aufirst%3DC.%26aulast%3DRoberts%26aufirst%3DC.%26atitle%3DTargeting%2520the%2520transcriptional%2520kinases%2520CDK12%2520and%2520CDK13%2520in%2520breast%2520and%2520ovarian%2520cancer%26jtitle%3DFASEB%2520J.%26date%3D2017%26volume%3D31%26issue%3D1_supplement%26spage%3D938.9%26doi%3D10.1096%2Ffasebj.31.1_supplement.938.9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchiyama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokubo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morishita, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sameshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Araki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morin, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakanishi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maezaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imaeda, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of 3-benzyl-1-(trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea derivatives as novel and selective cyclin-dependent kinase 12 (CDK12) Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">7710</span>â <span class="NLM_lpage">7728</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b00683</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00683" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVWrsbjI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7710-7728&issue=17&author=M.+Itoauthor=T.+Tanakaauthor=A.+Toitaauthor=N.+Uchiyamaauthor=H.+Kokuboauthor=N.+Morishitaauthor=M.+G.+Kleinauthor=H.+Zouauthor=M.+Murakamiauthor=M.+Kondoauthor=T.+Sameshimaauthor=S.+Arakiauthor=S.+Endoauthor=T.+Kawamotoauthor=G.+B.+Morinauthor=S.+A.+Aparicioauthor=A.+Nakanishiauthor=H.+Maezakiauthor=Y.+Imaeda&title=Discovery+of+3-benzyl-1-%28trans-4-%28%285-cyanopyridin-2-yl%29amino%29cyclohexyl%29-1-arylurea+derivatives+as+novel+and+selective+cyclin-dependent+kinase+12+%28CDK12%29+Inhibitors&doi=10.1021%2Facs.jmedchem.8b00683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 3-Benzyl-1-(trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea Derivatives as Novel and Selective Cyclin-Dependent Kinase 12 (CDK12) Inhibitors</span></div><div class="casAuthors">Ito, Masahiro; Tanaka, Toshio; Toita, Akinori; Uchiyama, Noriko; Kokubo, Hironori; Morishita, Nao; Klein, Michael G.; Zou, Hua; Murakami, Morio; Kondo, Mitsuyo; Sameshima, Tomoya; Araki, Shinsuke; Endo, Satoshi; Kawamoto, Tomohiro; Morin, Gregg B.; Aparicio, Samuel A.; Nakanishi, Atsushi; Maezaki, Hironobu; Imaeda, Yasuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7710-7728</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase 12 (CDK12) plays a key role in the coordination of transcription with elongation and mRNA processing.  CDK12 mutations found in tumors and CDK12 inhibition sensitize cancer cells to DNA-damaging reagents and DNA-repair inhibitors.  This suggests that CDK12 inhibitors are potential therapeutics for cancer that may cause synthetic lethality.  Here, we report the discovery of 3-benzyl-1-(trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea derivs. as novel and selective CDK12 inhibitors.  Structure-activity relationship studies of a HTS hit, structure-based drug design, and conformation-oriented design using the Cambridge Structural Database afforded the optimized compd. 2, which exhibited not only potent CDK12 (and CDK13) inhibitory activity and excellent selectivity but also good physicochem. properties.  Furthermore, 2 inhibited the phosphorylation of Ser2 in the C-terminal domain of RNA polymerase II and induced growth inhibition in SK-BR-3 cells.  Therefore, 2 represents an excellent chem. probe for functional studies of CDK12 and could be a promising lead compd. for drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXLhQTcUpBfLVg90H21EOLACvtfcHk0ljPrhYjInbHmA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVWrsbjI&md5=6d22fd36823d459fb60113c1212aa84e</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00683%26sid%3Dliteratum%253Aachs%26aulast%3DIto%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DToita%26aufirst%3DA.%26aulast%3DUchiyama%26aufirst%3DN.%26aulast%3DKokubo%26aufirst%3DH.%26aulast%3DMorishita%26aufirst%3DN.%26aulast%3DKlein%26aufirst%3DM.%2BG.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DMurakami%26aufirst%3DM.%26aulast%3DKondo%26aufirst%3DM.%26aulast%3DSameshima%26aufirst%3DT.%26aulast%3DAraki%26aufirst%3DS.%26aulast%3DEndo%26aufirst%3DS.%26aulast%3DKawamoto%26aufirst%3DT.%26aulast%3DMorin%26aufirst%3DG.%2BB.%26aulast%3DAparicio%26aufirst%3DS.%2BA.%26aulast%3DNakanishi%26aufirst%3DA.%26aulast%3DMaezaki%26aufirst%3DH.%26aulast%3DImaeda%26aufirst%3DY.%26atitle%3DDiscovery%2520of%25203-benzyl-1-%2528trans-4-%2528%25285-cyanopyridin-2-yl%2529amino%2529cyclohexyl%2529-1-arylurea%2520derivatives%2520as%2520novel%2520and%2520selective%2520cyclin-dependent%2520kinase%252012%2520%2528CDK12%2529%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D17%26spage%3D7710%26epage%3D7728%26doi%3D10.1021%2Facs.jmedchem.8b00683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixon-Clarke, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greifenberg, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ficarro, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannett, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartkowiak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenleaf, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marto, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">876</span>â <span class="NLM_lpage">884</span>, <span class="refDoi">Â DOI: 10.1038/nchembio.2166</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1038%2Fnchembio.2166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=27571479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlyqsbbJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=876-884&issue=10&author=T.+Zhangauthor=N.+Kwiatkowskiauthor=C.+M.+Olsonauthor=S.+E.+Dixon-Clarkeauthor=B.+J.+Abrahamauthor=A.+K.+Greifenbergauthor=S.+B.+Ficarroauthor=J.+M.+Elkinsauthor=Y.+Liangauthor=N.+M.+Hannettauthor=T.+Manzauthor=M.+Haoauthor=B.+Bartkowiakauthor=A.+L.+Greenleafauthor=J.+A.+Martoauthor=M.+Geyerauthor=A.+N.+Bullockauthor=R.+A.+Youngauthor=N.+S.+Gray&title=Covalent+targeting+of+remote+cysteine+residues+to+develop+CDK12+and+CDK13+inhibitors&doi=10.1038%2Fnchembio.2166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors</span></div><div class="casAuthors">Zhang, Tinghu; Kwiatkowski, Nicholas; Olson, Calla M.; Dixon-Clarke, Sarah E.; Abraham, Brian J.; Greifenberg, Ann K.; Ficarro, Scott B.; Elkins, Jonathan M.; Liang, Yanke; Hannett, Nancy M.; Manz, Theresa; Hao, Mingfeng; Bartkowiak, Bartlomiej; Greenleaf, Arno L.; Marto, Jarrod A.; Geyer, Matthias; Bullock, Alex N.; Young, Richard A.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">876-884</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cyclin-dependent kinases 12 and 13 (CDK12 and CDK13) play crit. roles in the regulation of gene transcription.  However, the absence of CDK12 and CDK13 inhibitors has hindered the ability to investigate the consequences of their inhibition in healthy cells and cancer cells.  Here we describe the rational design of a first-in-class CDK12 and CDK13 covalent inhibitor, THZ531.  Co-crystn. of THZ531 with CDK12-cyclin K indicates that THZ531 irreversibly targets a cysteine located outside the kinase domain.  THZ531 causes a loss of gene expression with concurrent loss of elongating and hyperphosphorylated RNA polymerase II.  In particular, THZ531 substantially decreases the expression of DNA damage response genes and key super-enhancer-assocd. transcription factor genes.  Coincident with transcriptional perturbation, THZ531 dramatically induced apoptotic cell death.  Small mols. capable of specifically targeting CDK12 and CDK13 may thus help identify cancer subtypes that are particularly dependent on their kinase activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXIyvy8vbjvrVg90H21EOLACvtfcHk0lhOxRekNfVrjg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlyqsbbJ&md5=5ac265105d1654e129c3c1325572f389</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2166%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DKwiatkowski%26aufirst%3DN.%26aulast%3DOlson%26aufirst%3DC.%2BM.%26aulast%3DDixon-Clarke%26aufirst%3DS.%2BE.%26aulast%3DAbraham%26aufirst%3DB.%2BJ.%26aulast%3DGreifenberg%26aufirst%3DA.%2BK.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DElkins%26aufirst%3DJ.%2BM.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DHannett%26aufirst%3DN.%2BM.%26aulast%3DManz%26aufirst%3DT.%26aulast%3DHao%26aufirst%3DM.%26aulast%3DBartkowiak%26aufirst%3DB.%26aulast%3DGreenleaf%26aufirst%3DA.%2BL.%26aulast%3DMarto%26aufirst%3DJ.%2BA.%26aulast%3DGeyer%26aufirst%3DM.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DYoung%26aufirst%3DR.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DCovalent%2520targeting%2520of%2520remote%2520cysteine%2520residues%2520to%2520develop%2520CDK12%2520and%2520CDK13%2520inhibitors%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2016%26volume%3D12%26issue%3D10%26spage%3D876%26epage%3D884%26doi%3D10.1038%2Fnchembio.2166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahl, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ficarro, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dastur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amzallag, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramaswamy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannett, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMillin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Look, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsiades, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benes, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marto, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Targeting transcription regulation in cancer with a covalent CDK7 inhibitor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>511</i></span> (<span class="NLM_issue">7511</span>),  <span class="NLM_fpage">616</span>â <span class="NLM_lpage">620</span>, <span class="refDoi">Â DOI: 10.1038/nature13393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1038%2Fnature13393" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=25043025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1ChurnF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=511&publication_year=2014&pages=616-620&issue=7511&author=N.+Kwiatkowskiauthor=T.+Zhangauthor=P.+B.+Rahlauthor=B.+J.+Abrahamauthor=J.+Reddyauthor=S.+B.+Ficarroauthor=A.+Dasturauthor=A.+Amzallagauthor=S.+Ramaswamyauthor=B.+Tesarauthor=C.+E.+Jenkinsauthor=N.+M.+Hannettauthor=D.+McMillinauthor=T.+Sandaauthor=T.+Simauthor=N.+D.+Kimauthor=T.+Lookauthor=C.+S.+Mitsiadesauthor=A.+P.+Wengauthor=J.+R.+Brownauthor=C.+H.+Benesauthor=J.+A.+Martoauthor=R.+A.+Youngauthor=N.+S.+Gray&title=Targeting+transcription+regulation+in+cancer+with+a+covalent+CDK7+inhibitor&doi=10.1038%2Fnature13393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting transcription regulation in cancer with a covalent CDK7 inhibitor</span></div><div class="casAuthors">Kwiatkowski, Nicholas; Zhang, Tinghu; Rahl, Peter B.; Abraham, Brian J.; Reddy, Jessica; Ficarro, Scott B.; Dastur, Anahita; Amzallag, Arnaud; Ramaswamy, Sridhar; Tesar, Bethany; Jenkins, Catherine E.; Hannett, Nancy M.; McMillin, Douglas; Sanda, Takaomi; Sim, Taebo; Kim, Nam Doo; Look, Thomas; Mitsiades, Constantine S.; Weng, Andrew P.; Brown, Jennifer R.; Benes, Cyril H.; Marto, Jarrod A.; Young, Richard A.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">511</span>
        (<span class="NLM_cas:issue">7511</span>),
    <span class="NLM_cas:pages">616-620</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Tumor oncogenes include transcription factors that co-opt the general transcriptional machinery to sustain the oncogenic state, but direct pharmacol. inhibition of transcription factors has so far proven difficult.  However, the transcriptional machinery contains various enzymic cofactors that can be targeted for the development of new therapeutic candidates, including cyclin-dependent kinases (CDKs).  Here the authors present the discovery and characterization of a covalent CDK7 inhibitor, THZ1, which has the unprecedented ability to target a remote cysteine residue located outside of the canonical kinase domain, providing an unanticipated means of achieving selectivity for CDK7.  Cancer cell-line profiling indicates that a subset of cancer cell lines, including human T-cell acute lymphoblastic leukemia (T-ALL), have exceptional sensitivity to THZ1.  Genome-wide anal. in Jurkat T-ALL cells shows that THZ1 disproportionally affects transcription of RUNX1 and suggests that sensitivity to THZ1 may be due to vulnerability conferred by the RUNX1 super-enhancer and the key role of RUNX1 in the core transcriptional regulatory circuitry of these tumor cells.  Pharmacol. modulation of CDK7 kinase activity may thus provide an approach to identify and treat tumor types that are dependent on transcription for maintenance of the oncogenic state.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVD-DeTAQCqrVg90H21EOLACvtfcHk0lhVAYvcJUH5jg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1ChurnF&md5=895a28fb536663a31e7558fe79ce628b</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1038%2Fnature13393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13393%26sid%3Dliteratum%253Aachs%26aulast%3DKwiatkowski%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DRahl%26aufirst%3DP.%2BB.%26aulast%3DAbraham%26aufirst%3DB.%2BJ.%26aulast%3DReddy%26aufirst%3DJ.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DDastur%26aufirst%3DA.%26aulast%3DAmzallag%26aufirst%3DA.%26aulast%3DRamaswamy%26aufirst%3DS.%26aulast%3DTesar%26aufirst%3DB.%26aulast%3DJenkins%26aufirst%3DC.%2BE.%26aulast%3DHannett%26aufirst%3DN.%2BM.%26aulast%3DMcMillin%26aufirst%3DD.%26aulast%3DSanda%26aufirst%3DT.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DN.%2BD.%26aulast%3DLook%26aufirst%3DT.%26aulast%3DMitsiades%26aufirst%3DC.%2BS.%26aulast%3DWeng%26aufirst%3DA.%2BP.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3DBenes%26aufirst%3DC.%2BH.%26aulast%3DMarto%26aufirst%3DJ.%2BA.%26aulast%3DYoung%26aufirst%3DR.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DTargeting%2520transcription%2520regulation%2520in%2520cancer%2520with%2520a%2520covalent%2520CDK7%2520inhibitor%26jtitle%3DNature%26date%3D2014%26volume%3D511%26issue%3D7511%26spage%3D616%26epage%3D620%26doi%3D10.1038%2Fnature13393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parry, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shanahan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabhavalkar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiswell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seghezzi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paruch, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwyer, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doll, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomeir, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Windsor, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oft, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirschmeier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lees, E. M.</span></span> <span> </span><span class="NLM_article-title">Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2344</span>â <span class="NLM_lpage">2353</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-10-0324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F1535-7163.MCT-10-0324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=20663931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvVOjtrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=2344-2353&issue=8&author=D.+Parryauthor=T.+Guziauthor=F.+Shanahanauthor=N.+Davisauthor=D.+Prabhavalkarauthor=D.+Wiswellauthor=W.+Seghezziauthor=K.+Paruchauthor=M.+P.+Dwyerauthor=R.+Dollauthor=A.+Nomeirauthor=W.+Windsorauthor=T.+Fischmannauthor=Y.+Wangauthor=M.+Oftauthor=T.+Chenauthor=P.+Kirschmeierauthor=E.+M.+Lees&title=Dinaciclib+%28SCH+727965%29%2C+a+novel+and+potent+cyclin-dependent+kinase+inhibitor&doi=10.1158%2F1535-7163.MCT-10-0324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor</span></div><div class="casAuthors">Parry, David; Guzi, Timothy; Shanahan, Frances; Davis, Nicole; Prabhavalkar, Deepa; Wiswell, Derek; Seghezzi, Wolfgang; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald; Nomeir, Amin; Windsor, William; Fischmann, Thierry; Wang, Yaolin; Oft, Martin; Chen, Taiying; Kirschmeier, Paul; Lees, Emma M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2344-2353</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cyclin-dependent kinases (CDK) are key pos. regulators of cell cycle progression and attractive targets in oncol.  SCH 727965 inhibits CDK2, CDK5, CDK1, and CDK9 activity in vitro with IC50 values of 1, 1, 3, and 4 nmol/L, resp.  SCH 727965 was selected as a clin. candidate using a functional screen in vivo that integrated both efficacy and safety parameters.  Compared with flavopiridol, SCH 727965 exhibits superior activity with an improved therapeutic index.  In cell-based assays, SCH 727965 completely suppressed retinoblastoma phosphorylation, which correlated with apoptosis onset and total inhibition of bromodeoxyuridine incorporation in >100 tumor cell lines of diverse origin and background.  Moreover, short exposures to SCH 727965 were sufficient for long-lasting cellular effects.  SCH 727965 induced regression of established solid tumors in a range of mouse models following intermittent scheduling of doses below the maximally tolerated level.  This was assocd. with modulation of pharmacodynamic biomarkers in skin punch biopsies and rapidly reversible, mechanism-based effects on hematol. parameters.  These results suggest that SCH 727965 is a potent and selective CDK inhibitor and a novel cytotoxic agent.  Mol Cancer Ther; 9(8); 2344-53.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxn1NtmEAh7LVg90H21EOLACvtfcHk0li9svJy0sag3Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvVOjtrw%253D&md5=bd2d30fdfdca0f2bceb3f5c0b44b8630</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-0324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-0324%26sid%3Dliteratum%253Aachs%26aulast%3DParry%26aufirst%3DD.%26aulast%3DGuzi%26aufirst%3DT.%26aulast%3DShanahan%26aufirst%3DF.%26aulast%3DDavis%26aufirst%3DN.%26aulast%3DPrabhavalkar%26aufirst%3DD.%26aulast%3DWiswell%26aufirst%3DD.%26aulast%3DSeghezzi%26aufirst%3DW.%26aulast%3DParuch%26aufirst%3DK.%26aulast%3DDwyer%26aufirst%3DM.%2BP.%26aulast%3DDoll%26aufirst%3DR.%26aulast%3DNomeir%26aufirst%3DA.%26aulast%3DWindsor%26aufirst%3DW.%26aulast%3DFischmann%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DOft%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DKirschmeier%26aufirst%3DP.%26aulast%3DLees%26aufirst%3DE.%2BM.%26atitle%3DDinaciclib%2520%2528SCH%2520727965%2529%252C%2520a%2520novel%2520and%2520potent%2520cyclin-dependent%2520kinase%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26issue%3D8%26spage%3D2344%26epage%3D2353%26doi%3D10.1158%2F1535-7163.MCT-10-0324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mita, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joy, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sankhala, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jou, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Statkevich, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bannerji, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, C. L.</span></span> <span> </span><span class="NLM_article-title">Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer</span>. <i>Clin. Breast Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">169</span>â <span class="NLM_lpage">176</span>, <span class="refDoi">Â DOI: 10.1016/j.clbc.2013.10.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.clbc.2013.10.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=24393852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivVWrtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=169-176&issue=3&author=M.+M.+Mitaauthor=A.+A.+Joyauthor=A.+Mitaauthor=K.+Sankhalaauthor=Y.+M.+Jouauthor=D.+Zhangauthor=P.+Statkevichauthor=Y.+Zhuauthor=S.+L.+Yaoauthor=K.+Smallauthor=R.+Bannerjiauthor=C.+L.+Shapiro&title=Randomized+phase+II+trial+of+the+cyclin-dependent+kinase+inhibitor+dinaciclib+%28MK-7965%29+versus+capecitabine+in+patients+with+advanced+breast+cancer&doi=10.1016%2Fj.clbc.2013.10.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer</span></div><div class="casAuthors">Mita, Monica M.; Joy, Anil A.; Mita, Alain; Sankhala, Kamalesh; Jou, Ying-Ming; Zhang, Da; Statkevich, Paul; Zhu, Yali; Yao, Siu-Long; Small, Karen; Bannerji, Rajat; Shapiro, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Breast Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">169-176</span>CODEN:
                <span class="NLM_cas:coden">CBCLB7</span>;
        ISSN:<span class="NLM_cas:issn">1526-8209</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Introduction: Effective therapies after failure of treatment with anthracyclines and taxanes are needed for patients with metastatic breast cancer.  Dinaciclib (MK-7965, formerly SCH727965), a small-mol. cyclin-dependent kinase inhibitor, has demonstrated antitumor activity in phase I studies with solid-tumor patients.  This phase II trial was designed to assess the efficacy and safety of dinaciclib compared with that of capecitabine in women with previously treated advanced breast cancer.  Patients and Methods: Patients were randomized to receive either dinaciclib at 50 mg/m2, administered as a 2-h infusion every 21 days, or 1250 mg/m2 capecitabine, administered orally twice daily in 21-day cycles.  Results: An unplanned interim anal. showed that the time to disease progression was inferior with dinaciclib treatment compared with capecitabine treatment; therefore, the trial was stopped after 30 patients were randomized.  Dinaciclib treatment demonstrated antitumor activity in 2 of 7 patients with estrogen receptor-pos. and human epidermal growth factor receptor 2-neg. metastatic breast cancer (1 confirmed and 1 unconfirmed partial response), as well as acceptable safety and tolerability.  Grade 3 or 4 treatment-related adverse events were common and included neutropenia, leukopenia, increase in aspartate aminotransferase, and febrile neutropenia.  Population pharmacokinetic model-predicted mean dinaciclib exposure (area under the concn.-time curve extrapolated to infinity [AUC[I]]) at 50 mg/m2 was similar to that obsd. in a previous phase I trial, and no drug accumulation was obsd. after multiple-dose administration.  Conclusion: Although dinaciclib monotherapy demonstrated some antitumor activity and was generally tolerated, efficacy was not superior to capecitabine.  Future studies may be considered to evaluate dinaciclib in select patient populations with metastatic breast cancer and in combination with other agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpetvZlPAou-LVg90H21EOLACvtfcHk0li9svJy0sag3Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivVWrtQ%253D%253D&md5=5f91dd3e13e17bac5c9bbb227ed1a107</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2Fj.clbc.2013.10.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clbc.2013.10.016%26sid%3Dliteratum%253Aachs%26aulast%3DMita%26aufirst%3DM.%2BM.%26aulast%3DJoy%26aufirst%3DA.%2BA.%26aulast%3DMita%26aufirst%3DA.%26aulast%3DSankhala%26aufirst%3DK.%26aulast%3DJou%26aufirst%3DY.%2BM.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DStatkevich%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DYao%26aufirst%3DS.%2BL.%26aulast%3DSmall%26aufirst%3DK.%26aulast%3DBannerji%26aufirst%3DR.%26aulast%3DShapiro%26aufirst%3DC.%2BL.%26atitle%3DRandomized%2520phase%2520II%2520trial%2520of%2520the%2520cyclin-dependent%2520kinase%2520inhibitor%2520dinaciclib%2520%2528MK-7965%2529%2520versus%2520capecitabine%2520in%2520patients%2520with%2520advanced%2520breast%2520cancer%26jtitle%3DClin.%2520Breast%2520Cancer%26date%3D2014%26volume%3D14%26issue%3D3%26spage%3D169%26epage%3D176%26doi%3D10.1016%2Fj.clbc.2013.10.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greifenberg, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dust, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stover, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Primack, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernhardy, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazaro, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kochupurakkal, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unitt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarosiek, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scaltriti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juric, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodig, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DâAndrea, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balmana, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serra, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span> <span> </span><span class="NLM_article-title">CDK12 inhibition reverses de novo and acquired PARPinhibitor resistance in BRCA wild-type and mutated models of triple-negative breast cancer</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2367</span>â <span class="NLM_lpage">2381</span>, <span class="refDoi">Â DOI: 10.1016/j.celrep.2016.10.077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.celrep.2016.10.077" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=27880910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFGqt7%252FL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=2367-2381&issue=9&author=S.+F.+Johnsonauthor=C.+Cruzauthor=A.+K.+Greifenbergauthor=S.+Dustauthor=D.+G.+Stoverauthor=D.+Chiauthor=B.+Primackauthor=S.+Caoauthor=A.+J.+Bernhardyauthor=R.+Coulsonauthor=J.+B.+Lazaroauthor=B.+Kochupurakkalauthor=H.+Sunauthor=C.+Unittauthor=L.+A.+Moreauauthor=K.+A.+Sarosiekauthor=M.+Scaltritiauthor=D.+Juricauthor=J.+Baselgaauthor=A.+L.+Richardsonauthor=S.+J.+Rodigauthor=A.+D.+D%E2%80%99Andreaauthor=J.+Balmanaauthor=N.+Johnsonauthor=M.+Geyerauthor=V.+Serraauthor=E.+Limauthor=G.+I.+Shapiro&title=CDK12+inhibition+reverses+de+novo+and+acquired+PARPinhibitor+resistance+in+BRCA+wild-type+and+mutated+models+of+triple-negative+breast+cancer&doi=10.1016%2Fj.celrep.2016.10.077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer</span></div><div class="casAuthors">Johnson, Shawn F.; Cruz, Cristina; Greifenberg, Ann Katrin; Dust, Sofia; Stover, Daniel G.; Chi, David; Primack, Benjamin; Cao, Shiliang; Bernhardy, Andrea J.; Coulson, Rhiannon; Lazaro, Jean-Bernard; Kochupurakkal, Bose; Sun, Heather; Unitt, Christine; Moreau, Lisa A.; Sarosiek, Kristopher A.; Scaltriti, Maurizio; Juric, Dejan; Baselga, Jose; Richardson, Andrea L.; Rodig, Scott J.; D'Andrea, Alan D.; Balmana, Judith; Johnson, Neil; Geyer, Matthias; Serra, Violeta; Lim, Elgene; Shapiro, Geoffrey I.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2367-2381</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Although poly(ADP-ribose) polymerase (PARP) inhibitors are active in homologous recombination (HR)-deficient cancers, their utility is limited by acquired resistance after restoration of HR.  Here, we report that dinaciclib, an inhibitor of cyclin-dependent kinases (CDKs) 1, 2, 5, and 9, addnl. has potent activity against CDK12, a transcriptional regulator of HR.  In BRCA-mutated triple-neg. breast cancer (TNBC) cells and patient-derived xenografts (PDXs), dinaciclib ablates restored HR and reverses PARP inhibitor resistance.  Addnl., we show that de novo resistance to PARP inhibition in BRCA1-mutated cell lines and a PDX derived from a PARP-inhibitor-naive BRCA1 carrier is mediated by residual HR and is reversed by CDK12 inhibition.  Finally, dinaciclib augments the degree of response in a PARP-inhibitor-sensitive model, converting tumor growth inhibition to durable regression.  These results highlight the significance of HR disruption as a therapeutic strategy and support the broad use of combined CDK12 and PARP inhibition in TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyVKyKNc3G1bVg90H21EOLACvtfcHk0lhZiJudxWRPJA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFGqt7%252FL&md5=ae666e75b7a49d0c348789e2d59643fa</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2016.10.077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2016.10.077%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DS.%2BF.%26aulast%3DCruz%26aufirst%3DC.%26aulast%3DGreifenberg%26aufirst%3DA.%2BK.%26aulast%3DDust%26aufirst%3DS.%26aulast%3DStover%26aufirst%3DD.%2BG.%26aulast%3DChi%26aufirst%3DD.%26aulast%3DPrimack%26aufirst%3DB.%26aulast%3DCao%26aufirst%3DS.%26aulast%3DBernhardy%26aufirst%3DA.%2BJ.%26aulast%3DCoulson%26aufirst%3DR.%26aulast%3DLazaro%26aufirst%3DJ.%2BB.%26aulast%3DKochupurakkal%26aufirst%3DB.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DUnitt%26aufirst%3DC.%26aulast%3DMoreau%26aufirst%3DL.%2BA.%26aulast%3DSarosiek%26aufirst%3DK.%2BA.%26aulast%3DScaltriti%26aufirst%3DM.%26aulast%3DJuric%26aufirst%3DD.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DRichardson%26aufirst%3DA.%2BL.%26aulast%3DRodig%26aufirst%3DS.%2BJ.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DA.%2BD.%26aulast%3DBalmana%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DN.%26aulast%3DGeyer%26aufirst%3DM.%26aulast%3DSerra%26aufirst%3DV.%26aulast%3DLim%26aufirst%3DE.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26atitle%3DCDK12%2520inhibition%2520reverses%2520de%2520novo%2520and%2520acquired%2520PARPinhibitor%2520resistance%2520in%2520BRCA%2520wild-type%2520and%2520mutated%2520models%2520of%2520triple-negative%2520breast%2520cancer%26jtitle%3DCell%2520Rep.%26date%3D2016%26volume%3D17%26issue%3D9%26spage%3D2367%26epage%3D2381%26doi%3D10.1016%2Fj.celrep.2016.10.077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blazek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohoutek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartholomeeusen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulinkova, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cimermancic, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ule, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterlin, B. M.</span></span> <span> </span><span class="NLM_article-title">The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes</span>. <i>Genes Dev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">2158</span>â <span class="NLM_lpage">2172</span>, <span class="refDoi">Â DOI: 10.1101/gad.16962311</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1101%2Fgad.16962311" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=22012619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVant73E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=2158-2172&issue=20&author=D.+Blazekauthor=J.+Kohoutekauthor=K.+Bartholomeeusenauthor=E.+Johansenauthor=P.+Hulinkovaauthor=Z.+Luoauthor=P.+Cimermancicauthor=J.+Uleauthor=B.+M.+Peterlin&title=The+Cyclin+K%2FCdk12+complex+maintains+genomic+stability+via+regulation+of+expression+of+DNA+damage+response+genes&doi=10.1101%2Fgad.16962311"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">The cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes</span></div><div class="casAuthors">Blazek, Dalibor; Kohoutek, Jiri; Bartholomeeusen, Koen; Johansen, Eric; Hulinkova, Petra; Luo, Zeping; Cimermancic, Peter; Ule, Jernej; Peterlin, B. Matija</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2158-2172</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">Various cyclin-dependent kinase (Cdk) complexes have been implicated in the regulation of transcription.  In this study, we identified a 70-kDa Cyclin K (CycK) that binds Cdk12 and Cdk13 to form two different complexes (CycK/Cdk12 or CycK/Cdk13) in human cells.  The CycK/Cdk12 complex regulates phosphorylation of Ser2 in the C-terminal domain of RNA polymerase II and expression of a small subset of human genes, as revealed in expression microarrays.  Depletion of CycK/Cdk12 results in decreased expression of predominantly long genes with high nos. of exons.  The most prominent group of down-regulated genes are the DNA damage response genes, including the crit. regulators of genomic stability: BRCA1 (breast and ovarian cancer type 1 susceptibility protein 1), ATR (ataxia telangiectasia and Rad3-related), FANCI, and FANCD2.  We show that CycK/Cdk12, rather than CycK/Cdk13, is necessary for their expression.  Nuclear run-on assays and chromatin immunopptns. with RNA polymerase II on the BRCA1 and FANCI genes suggest a transcriptional defect in the absence of CycK/Cdk12.  Consistent with these findings, cells without CycK/Cdk12 induce spontaneous DNA damage and are sensitive to a variety of DNA damage agents.  We conclude that through regulation of expression of DNA damage response genes, CycK/Cdk12 protects cells from genomic instability.  The essential role of CycK for organisms in vivo is further supported by the result that genetic inactivation of CycK in mice causes early embryonic lethality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPlifbvX1LXrVg90H21EOLACvtfcHk0lhZiJudxWRPJA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVant73E&md5=4e472d0f324bbfae1a9d0a8a7302fa1d</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1101%2Fgad.16962311&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.16962311%26sid%3Dliteratum%253Aachs%26aulast%3DBlazek%26aufirst%3DD.%26aulast%3DKohoutek%26aufirst%3DJ.%26aulast%3DBartholomeeusen%26aufirst%3DK.%26aulast%3DJohansen%26aufirst%3DE.%26aulast%3DHulinkova%26aufirst%3DP.%26aulast%3DLuo%26aufirst%3DZ.%26aulast%3DCimermancic%26aufirst%3DP.%26aulast%3DUle%26aufirst%3DJ.%26aulast%3DPeterlin%26aufirst%3DB.%2BM.%26atitle%3DThe%2520Cyclin%2520K%252FCdk12%2520complex%2520maintains%2520genomic%2520stability%2520via%2520regulation%2520of%2520expression%2520of%2520DNA%2520damage%2520response%2520genes%26jtitle%3DGenes%2520Dev.%26date%3D2011%26volume%3D25%26issue%3D20%26spage%3D2158%26epage%3D2172%26doi%3D10.1101%2Fgad.16962311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, S. C.</span></span> <span> </span><span class="NLM_article-title">The human Rad51 protein: polarity of strand transfer and stimulation by hRP-A</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">5198</span>â <span class="NLM_lpage">5206</span>, <span class="refDoi">Â DOI: 10.1093/emboj/16.17.5198</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1093%2Femboj%2F16.17.5198" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=9311980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADyaK2sXmsVGlsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1997&pages=5198-5206&issue=17&author=P.+Baumannauthor=S.+C.+West&title=The+human+Rad51+protein%3A+polarity+of+strand+transfer+and+stimulation+by+hRP-A&doi=10.1093%2Femboj%2F16.17.5198"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">The human Rad51 protein: polarity of strand transfer and stimulation by hRP-A</span></div><div class="casAuthors">Baumann, Peter; West, Stephen C.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5198-5206</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The human Rad51 protein is homologous to the Escherichia coli RecA protein and catalyzes homologous pairing and strand transfer reactions in vitro.  Using single-stranded circular and homologous linear duplex DNA, we show that hRad51 forms stable joint mols. by transfer of the 5' end of the complementary strand of the linear duplex to the ssDNA.  The polarity of strand transfer is therefore 3' to 5', defined relative to the ssDNA on which hRad51 initiates filament formation.  This polarity is opposite to that obsd. with RecA.  Homologous pairing and strand transfer require stoichiometric amts. of hRad51, corresponding to one hRad51 monomer per three nucleotides of ssDNA.  Joint mols. are not obsd. when the protein is present in limiting or excessive amts.  The human ssDNA binding-protein, hRP-A, stimulates hRad51-mediated reactions.  Its effect is consistent with a role in the removal of secondary structures from ssDNA, thereby facilitating the formation of continuous Rad51 filaments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBIelzJ9gRULVg90H21EOLACvtfcHk0lgzycRgUTC_dw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmsVGlsrg%253D&md5=77f065b85373422dcaeb9353b23a5139</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1093%2Femboj%2F16.17.5198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252F16.17.5198%26sid%3Dliteratum%253Aachs%26aulast%3DBaumann%26aufirst%3DP.%26aulast%3DWest%26aufirst%3DS.%2BC.%26atitle%3DThe%2520human%2520Rad51%2520protein%253A%2520polarity%2520of%2520strand%2520transfer%2520and%2520stimulation%2520by%2520hRP-A%26jtitle%3DEMBO%2520J.%26date%3D1997%26volume%3D16%26issue%3D17%26spage%3D5198%26epage%3D5206%26doi%3D10.1093%2Femboj%2F16.17.5198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sung, P.</span></span> <span> </span><span class="NLM_article-title">Catalysis of ATP-dependent homologous DNA pairing and strand exchange by yeast RAD51 protein</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>265</i></span> (<span class="NLM_issue">5176</span>),  <span class="NLM_fpage">1241</span>â <span class="NLM_lpage">1243</span>, <span class="refDoi">Â DOI: 10.1126/science.8066464</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1126%2Fscience.8066464" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=8066464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADyaK2cXmt1emsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=265&publication_year=1994&pages=1241-1243&issue=5176&author=P.+Sung&title=Catalysis+of+ATP-dependent+homologous+DNA+pairing+and+strand+exchange+by+yeast+RAD51+protein&doi=10.1126%2Fscience.8066464"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Catalysis of ATP-dependent homologous DNA pairing and strand exchange by yeast RAD51 protein</span></div><div class="casAuthors">Sung, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">265</span>
        (<span class="NLM_cas:issue">5176</span>),
    <span class="NLM_cas:pages">1241-3</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">The RAD51 gene of Saccharomyces cerevisiae is required for genetic recombination and DNA double-strand break repair.  Here it is demonstrated that RAD51 protein pairs circular viral single-stranded DNA from Î¸X 174 or M13 with its resp. homologous linear double-stranded form.  The product of synapsis between these DNA partners is further processed by RAD51 to yield nicked circular duplex DNA, which indicates that RAD51 can catalyze strand exchange.  The pairing and strand exchange reaction requires ATP, a result consistent with the presence of a DNA-dependent ATPase activity in RAD51 protein.  Thus, RAD51 is a eukaryotic recombination protein that can catalyze the strand exchange reaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpizYt10YhEpLVg90H21EOLACvtfcHk0lgzycRgUTC_dw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmt1emsr8%253D&md5=8163a27cb6b73c1e14e534e4fcc0221a</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1126%2Fscience.8066464&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.8066464%26sid%3Dliteratum%253Aachs%26aulast%3DSung%26aufirst%3DP.%26atitle%3DCatalysis%2520of%2520ATP-dependent%2520homologous%2520DNA%2520pairing%2520and%2520strand%2520exchange%2520by%2520yeast%2520RAD51%2520protein%26jtitle%3DScience%26date%3D1994%26volume%3D265%26issue%3D5176%26spage%3D1241%26epage%3D1243%26doi%3D10.1126%2Fscience.8066464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zaitseva, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaitsev, E. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowalczykowski, S. C.</span></span> <span> </span><span class="NLM_article-title">The DNA binding properties of saccharomyces cerevisiae Rad51 protein</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>274</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2907</span>â <span class="NLM_lpage">2915</span>, <span class="refDoi">Â DOI: 10.1074/jbc.274.5.2907</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1074%2Fjbc.274.5.2907" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=9915828" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADyaK1MXpsVektA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=1999&pages=2907-2915&issue=5&author=E.+M.+Zaitsevaauthor=E.+N.+Zaitsevauthor=S.+C.+Kowalczykowski&title=The+DNA+binding+properties+of+saccharomyces+cerevisiae+Rad51+protein&doi=10.1074%2Fjbc.274.5.2907"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">The DNA binding properties of Saccharomyces cerevisiae Rad51 protein</span></div><div class="casAuthors">Zaitseva, Elena M.; Zaitsev, Eugene N.; Kowalczykowski, Stephen C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">274</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2907-2915</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Saccharomyces cerevisiae Rad51 protein is the paradigm for eukaryotic ATP-dependent DNA strand exchange proteins.  To explain some of the unique characteristics of DNA strand exchange promoted by Rad51 protein, when compared with its prokaryotic homolog the Escherichia coli RecA protein, we analyzed the DNA binding properties of the Rad51 protein.  Rad51 protein binds both single-stranded DNA (ssDNA) and double-stranded DNA (dsDNA) in an ATP- and Mg2+-dependent manner, over a wide range of pH, with an apparent binding stoichiometry of approx. 1 protein monomer per 4 (Â±1) nucleotides or base pairs, resp.  Only dATP and adenosine 5'-Î³-(Thiotriphosphate) (ATPÎ³S) can substitute for ATP, but binding in the presence of ATPÎ³S requires more than a 5-fold stoichiometric excess of protein.  Without nucleotide cofactor, Rad51 protein binds both ssDNA and dsDNA but only at pH values lower than 6.8; in this case, the apparent binding stoichiometry covers the range of 1 protein monomer per 6-9 nucleotides or base pairs.  Therefore, Rad51 protein displays two distinct modes of DNA binding.  These binding modes are not inter-convertible; however, their initial selection is governed by ATP binding.  On the basis of these DNA binding properties, we conclude that the main reason for the low efficiency of the DNA strand exchange promoted by Rad51 protein in vitro is its enhanced dsDNA-binding ability, which inhibits both the presynaptic and synaptic phases of the DNA strand exchange reaction as follows: during presynapsis, Rad51 protein interacts with and stabilizes secondary structures in ssDNA thereby inhibiting formation of a contiguous nucleoprotein filament; during synapsis, Rad51 protein inactivates the homologous dsDNA partner by directly binding to it.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrObmOEA3L-jLVg90H21EOLACvtfcHk0lha2VT671-8mg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXpsVektA%253D%253D&md5=6e4bdce9ed811231f32b142c8efb6d9f</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1074%2Fjbc.274.5.2907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.274.5.2907%26sid%3Dliteratum%253Aachs%26aulast%3DZaitseva%26aufirst%3DE.%2BM.%26aulast%3DZaitsev%26aufirst%3DE.%2BN.%26aulast%3DKowalczykowski%26aufirst%3DS.%2BC.%26atitle%3DThe%2520DNA%2520binding%2520properties%2520of%2520saccharomyces%2520cerevisiae%2520Rad51%2520protein%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1999%26volume%3D274%26issue%3D5%26spage%3D2907%26epage%3D2915%26doi%3D10.1074%2Fjbc.274.5.2907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roberti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schipani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagnolini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milano, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giacomini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falchi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balboni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manerba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farabegoli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Franco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minucci, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallavicini, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Stefano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girotto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellicciari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span> <span> </span><span class="NLM_article-title">Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">80</span>â <span class="NLM_lpage">92</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2019.01.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.ejmech.2019.01.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=30660828" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVOku7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2019&pages=80-92&author=M.+Robertiauthor=F.+Schipaniauthor=G.+Bagnoliniauthor=D.+Milanoauthor=E.+Giacominiauthor=F.+Falchiauthor=A.+Balboniauthor=M.+Manerbaauthor=F.+Farabegoliauthor=F.+De+Francoauthor=J.+Robertsonauthor=S.+Minucciauthor=I.+Pallaviciniauthor=G.+Di+Stefanoauthor=S.+Girottoauthor=R.+Pellicciariauthor=A.+Cavalli&title=Rad51%2FBRCA2+disruptors+inhibit+homologous+recombination+and+synergize+with+olaparib+in+pancreatic+cancer+cells&doi=10.1016%2Fj.ejmech.2019.01.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells</span></div><div class="casAuthors">Roberti, Marinella; Schipani, Fabrizio; Bagnolini, Greta; Milano, Domenico; Giacomini, Elisa; Falchi, Federico; Balboni, Andrea; Manerba, Marcella; Farabegoli, Fulvia; De Franco, Francesca; Robertson, Janet; Minucci, Saverio; Pallavicini, Isabella; Di Stefano, Giuseppina; Girotto, Stefania; Pellicciari, Roberto; Cavalli, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">80-92</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Olaparib is a PARP inhibitor (PARPi).  For patients bearing BRCA1 or BRCA2 mutations, olaparib is approved to treat ovarian cancer and in clin. trials to treat breast and pancreatic cancers.  In BRCA2-defective patients, PARPi inhibits DNA single-strand break repair, while BRCA2 mutations hamper double-strand break repair.  Recently, the authors identified a series of triazole derivs. that mimic BRCA2 mutations by disrupting the Rad51-BRCA2 interaction and thus double-strand break repair.  Here, the authors have computationally designed, synthesized, and tested over 40 novel derivs.  Addnl., they designed and conducted novel biol. assays to characterize how they disrupt the Rad51-BRCA2 interaction and inhibit double-strand break repair.  These compds., synergized with olaparib to target pancreatic cancer cells with functional BRCA2.  Compd. I significantly increased olaparib's effect on the viability of BxPC-3 cells.  This supports the idea that small org. mols. can mimic genetic mutations to improve the profile of anticancer drugs for precision medicine.  Moreover, this paradigm could be exploited in other genetic pathways to discover innovative anticancer targets and drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrO64ucZDf8MLVg90H21EOLACvtfcHk0lha2VT671-8mg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVOku7k%253D&md5=3090401197babb650036d569a0195a7a</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.01.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.01.008%26sid%3Dliteratum%253Aachs%26aulast%3DRoberti%26aufirst%3DM.%26aulast%3DSchipani%26aufirst%3DF.%26aulast%3DBagnolini%26aufirst%3DG.%26aulast%3DMilano%26aufirst%3DD.%26aulast%3DGiacomini%26aufirst%3DE.%26aulast%3DFalchi%26aufirst%3DF.%26aulast%3DBalboni%26aufirst%3DA.%26aulast%3DManerba%26aufirst%3DM.%26aulast%3DFarabegoli%26aufirst%3DF.%26aulast%3DDe%2BFranco%26aufirst%3DF.%26aulast%3DRobertson%26aufirst%3DJ.%26aulast%3DMinucci%26aufirst%3DS.%26aulast%3DPallavicini%26aufirst%3DI.%26aulast%3DDi%2BStefano%26aufirst%3DG.%26aulast%3DGirotto%26aufirst%3DS.%26aulast%3DPellicciari%26aufirst%3DR.%26aulast%3DCavalli%26aufirst%3DA.%26atitle%3DRad51%252FBRCA2%2520disruptors%2520inhibit%2520homologous%2520recombination%2520and%2520synergize%2520with%2520olaparib%2520in%2520pancreatic%2520cancer%2520cells%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D165%26spage%3D80%26epage%3D92%26doi%3D10.1016%2Fj.ejmech.2019.01.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Budke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tueckmantel, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miles, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connell, P. P.</span></span> <span> </span><span class="NLM_article-title">Optimization of drug candidates that inhibit the D-loop activity of RAD51</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1031</span>â <span class="NLM_lpage">1040</span>, <span class="refDoi">Â DOI: 10.1002/cmdc.201900075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1002%2Fcmdc.201900075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=30957434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnsFSrurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=1031-1040&issue=10&author=B.+Budkeauthor=W.+Tueckmantelauthor=K.+Milesauthor=A.+P.+Kozikowskiauthor=P.+P.+Connell&title=Optimization+of+drug+candidates+that+inhibit+the+D-loop+activity+of+RAD51&doi=10.1002%2Fcmdc.201900075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of drug candidates that inhibit the D-loop activity of RAD51</span></div><div class="casAuthors">Budke, Brian; Tueckmantel, Werner; Miles, Kelsey; Kozikowski, Alan P.; Connell, Philip P.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1031-1040</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">RAD51 is the central protein in homologous recombination (HR) repair, where it first binds ssDNA and then catalyzes strand invasion via a D-loop intermediate.  Addnl., RAD51 plays a role in faithful DNA replication by protecting stalled replication forks; this requires RAD51 to bind DNA but may not require the strand invasion activity of RAD51.  We previously described a small-mol. inhibitor of RAD51 named RI(dl)-2 (RAD51 inhibitor of D-loop formation #2, hereafter called 2h(I)), which inhibits D-loop activity while sparing ssDNA binding.  However, I is limited in its ability to inhibit HR in vivo, preventing only about 50 % of total HR events in cells.  We sought to improve upon this by performing a structure-activity relationship (SAR) campaign for more potent analogs of I.  Most compds. were prepd. from 1-(2-aminophenyl)pyrroles by forming the quinoxaline moiety either by condensation with aldehydes, then dehydrogenation of the resulting 4,5-dihydro intermediates, or by condensation with N,N'-carbonyldiimidazole, chlorination, and installation of the 4-substituent through Suzuki-Miyaura coupling.  Many analogs exhibited enhanced activity against human RAD51, but in several of these compds. the increased inhibition was due to the introduction of dsDNA intercalation activity.  We developed a sensitive assay to measure dsDNA intercalation, and identified two analogs of I that promote complete HR inhibition in cells while exerting minimal intercalation activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZp0WNPT_GobVg90H21EOLACvtfcHk0ljKsJPKfgeFBQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnsFSrurw%253D&md5=e7bd3885759308c4f5980891580239db</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201900075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201900075%26sid%3Dliteratum%253Aachs%26aulast%3DBudke%26aufirst%3DB.%26aulast%3DTueckmantel%26aufirst%3DW.%26aulast%3DMiles%26aufirst%3DK.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DConnell%26aufirst%3DP.%2BP.%26atitle%3DOptimization%2520of%2520drug%2520candidates%2520that%2520inhibit%2520the%2520D-loop%2520activity%2520of%2520RAD51%26jtitle%3DChemMedChem%26date%3D2019%26volume%3D14%26issue%3D10%26spage%3D1031%26epage%3D1040%26doi%3D10.1002%2Fcmdc.201900075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Normand, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riviere, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renodon-Corniere, A.</span></span> <span> </span><span class="NLM_article-title">Identification and characterization of human Rad51 inhibitors by screening of an existing drug library</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>91</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">293</span>â <span class="NLM_lpage">300</span>, <span class="refDoi">Â DOI: 10.1016/j.bcp.2014.07.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.bcp.2014.07.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=25124703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlKmtLbM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2014&pages=293-300&issue=3&author=A.+Normandauthor=E.+Riviereauthor=A.+Renodon-Corniere&title=Identification+and+characterization+of+human+Rad51+inhibitors+by+screening+of+an+existing+drug+library&doi=10.1016%2Fj.bcp.2014.07.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and characterization of human Rad51 inhibitors by screening of an existing drug library</span></div><div class="casAuthors">Normand, Anais; Riviere, Emmanuelle; Renodon-Corniere, Axelle</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">293-300</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Homologous Recombination (HR) plays an essential role in cellular proliferation and in maintaining genomic stability by repairing DNA double-stranded breaks that appear during replication.  Rad51, a key protein of HR in eukaryotes, can have an elevated expression level in tumor cells, which correlates with their resistance to anticancer therapies.  Therefore, targeted inhibition of Rad51 through inhibitor may improve the tumor response to these therapies.  In order to identify small mols. that inhibit Rad51 activity, we screened the Prestwick Library (1120 mols.) for their effect on the strand exchange reaction catalyzed by Rad51.  We found that Chicago Sky Blue (CSB) is a potent inhibitor of Rad51, showing IC50 values in the low nanomolar range (400 nM).  Biochem. anal. demonstrated that the inhibitory mechanism probably occurs by disrupting the Rad51 assocn. with the single-stranded DNA, which prevents the nucleoprotein filament formation, the first step of the protein activity.  Structure Activity Relationship anal. with a no. of compds. that shared structure homol. with CSB was also performed.  The sensitivity of Rad51 inhibition to CSB modifications suggests specific interactions between the mol. and Rad51 nucleofilament.  CSB and some of its analogs open up new perspectives in the search for agents capable of potentiating chemo- and radio-therapy treatments for cancer.  Moreover, these compds. may be excellent tools to analyze Rad51 cellular functions.  Our study also highlights how CSB and its analogs, which are frequently used in colorants, stains and markers, could be responsible of unwanted side effects by perturbing the DNA repair process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkjkOCGdXzDbVg90H21EOLACvtfcHk0ljKsJPKfgeFBQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlKmtLbM&md5=e7daa87d941c0a81393205f0a6b72bab</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2014.07.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2014.07.033%26sid%3Dliteratum%253Aachs%26aulast%3DNormand%26aufirst%3DA.%26aulast%3DRiviere%26aufirst%3DE.%26aulast%3DRenodon-Corniere%26aufirst%3DA.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520human%2520Rad51%2520inhibitors%2520by%2520screening%2520of%2520an%2520existing%2520drug%2520library%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2014%26volume%3D91%26issue%3D3%26spage%3D293%26epage%3D300%26doi%3D10.1016%2Fj.bcp.2014.07.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlin, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. H.</span></span> <span> </span><span class="NLM_article-title">Synthesis, molecular modeling, and biological evaluation of novel RAD51 inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">196</span>â <span class="NLM_lpage">208</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2015.04.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.ejmech.2015.04.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=25874343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtlOjurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2015&pages=196-208&author=J.+Zhuauthor=H.+Chenauthor=X.+E.+Guoauthor=X.+L.+Qiuauthor=C.+M.+Huauthor=A.+R.+Chamberlinauthor=W.+H.+Lee&title=Synthesis%2C+molecular+modeling%2C+and+biological+evaluation+of+novel+RAD51+inhibitors&doi=10.1016%2Fj.ejmech.2015.04.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, molecular modeling, and biological evaluation of novel RAD51 inhibitors</span></div><div class="casAuthors">Zhu, Jiewen; Chen, Hongyuan; Guo, Xuning Emily; Qiu, Xiao-Long; Hu, Chun-Mei; Chamberlin, A. Richard; Lee, Wen-Hwa</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">196-208</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">RAD51 recombinase plays a crit. role for cancer cell proliferation and survival.  Targeting RAD51 is therefore an attractive strategy for treating difficult-to-treat cancers, e.g. triple neg. breast cancers which are often resistant to existing therapeutics.  To this end, we have designed, synthesized and evaluated a panel of new RAD51 inhibitors, denoted IBR compds.  Among these compds., we have identified a novel small mol. RAD51 inhibitor, IBR120 (I), which exhibited a 4.8-fold improved growth inhibition activity in triple neg. human breast cancer cell line MBA-MD-468.  I also inhibited the proliferation of a broad spectrum of other cancer cell types.  Approx. 10-fold difference between the IC50 values in normal and cancer cells were obsd.  Moreover, I was capable of disrupting RAD51 multimerization, impairing homologous recombination repair, and inducing apoptotic cell death.  Therefore, these novel RAD51 inhibitors may serve as potential candidates for the development of pharmaceutical strategies against difficult-to-treat cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryxK_VB6pue7Vg90H21EOLACvtfcHk0lg5lZf3dKTJrg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtlOjurw%253D&md5=39ff6eca8df36a8c8af9cbff3fcc7b46</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.04.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.04.021%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DGuo%26aufirst%3DX.%2BE.%26aulast%3DQiu%26aufirst%3DX.%2BL.%26aulast%3DHu%26aufirst%3DC.%2BM.%26aulast%3DChamberlin%26aufirst%3DA.%2BR.%26aulast%3DLee%26aufirst%3DW.%2BH.%26atitle%3DSynthesis%252C%2520molecular%2520modeling%252C%2520and%2520biological%2520evaluation%2520of%2520novel%2520RAD51%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D96%26spage%3D196%26epage%3D208%26doi%3D10.1016%2Fj.ejmech.2015.04.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bagnolini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milano, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manerba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schipani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortega, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gioia, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falchi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balboni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farabegoli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Franco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellicciari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallavicini, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minucci, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girotto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Stefano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span> <span> </span><span class="NLM_article-title">Synthetic lethality in pancreatic cancer: discovery of a new RAD51-BRCA2 small molecule disruptor that inhibits homologous recombination and synergizes with Olaparib</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2588</span>â <span class="NLM_lpage">2619</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.9b01526</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01526" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFKrurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=2588-2619&issue=5&author=G.+Bagnoliniauthor=D.+Milanoauthor=M.+Manerbaauthor=F.+Schipaniauthor=J.+A.+Ortegaauthor=D.+Gioiaauthor=F.+Falchiauthor=A.+Balboniauthor=F.+Farabegoliauthor=F.+De+Francoauthor=J.+Robertsonauthor=R.+Pellicciariauthor=I.+Pallaviciniauthor=S.+Periauthor=S.+Minucciauthor=S.+Girottoauthor=G.+Di+Stefanoauthor=M.+Robertiauthor=A.+Cavalli&title=Synthetic+lethality+in+pancreatic+cancer%3A+discovery+of+a+new+RAD51-BRCA2+small+molecule+disruptor+that+inhibits+homologous+recombination+and+synergizes+with+Olaparib&doi=10.1021%2Facs.jmedchem.9b01526"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib</span></div><div class="casAuthors">Bagnolini, Greta; Milano, Domenico; Manerba, Marcella; Schipani, Fabrizio; Ortega, Jose Antonio; Gioia, Dario; Falchi, Federico; Balboni, Andrea; Farabegoli, Fulvia; De Franco, Francesca; Robertson, Janet; Pellicciari, Roberto; Pallavicini, Isabella; Peri, Sebastiano; Minucci, Saverio; Girotto, Stefania; Di Stefano, Giuseppina; Roberti, Marinella; Cavalli, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2588-2619</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Synthetic lethality is an innovative framework for discovering novel anticancer drug candidates.  One example is the use of PARP inhibitors (PARPi) in oncol. patients with BRCA mutations.  Here, we exploit a new paradigm based on the possibility of triggering synthetic lethality using only small org. mols. (dubbed "fully small-mol.-induced synthetic lethality").  We exploited this paradigm to target pancreatic cancer, one of the major unmet needs in oncol.  We discovered a dihydroquinolone pyrazoline-based mol. (35d) that disrupts the RAD51-BRCA2 protein-protein interaction, thus mimicking the effect of BRCA2 mutation. 35d inhibits the homologous recombination in a human pancreatic adenocarcinoma cell line.  In addn., it synergizes with olaparib (a PARPi) to trigger synthetic lethality.  This strategy aims to widen the use of PARPi in BRCA-competent and olaparib-resistant cancers, making fully small-mol.-induced synthetic lethality an innovative approach toward unmet oncol. needs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiTSEdA8VygbVg90H21EOLACvtfcHk0lg5lZf3dKTJrg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFKrurg%253D&md5=1cae61064fc0e637f9b5f00c47e0bdeb</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01526&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01526%26sid%3Dliteratum%253Aachs%26aulast%3DBagnolini%26aufirst%3DG.%26aulast%3DMilano%26aufirst%3DD.%26aulast%3DManerba%26aufirst%3DM.%26aulast%3DSchipani%26aufirst%3DF.%26aulast%3DOrtega%26aufirst%3DJ.%2BA.%26aulast%3DGioia%26aufirst%3DD.%26aulast%3DFalchi%26aufirst%3DF.%26aulast%3DBalboni%26aufirst%3DA.%26aulast%3DFarabegoli%26aufirst%3DF.%26aulast%3DDe%2BFranco%26aufirst%3DF.%26aulast%3DRobertson%26aufirst%3DJ.%26aulast%3DPellicciari%26aufirst%3DR.%26aulast%3DPallavicini%26aufirst%3DI.%26aulast%3DPeri%26aufirst%3DS.%26aulast%3DMinucci%26aufirst%3DS.%26aulast%3DGirotto%26aufirst%3DS.%26aulast%3DDi%2BStefano%26aufirst%3DG.%26aulast%3DRoberti%26aufirst%3DM.%26aulast%3DCavalli%26aufirst%3DA.%26atitle%3DSynthetic%2520lethality%2520in%2520pancreatic%2520cancer%253A%2520discovery%2520of%2520a%2520new%2520RAD51-BRCA2%2520small%2520molecule%2520disruptor%2520that%2520inhibits%2520homologous%2520recombination%2520and%2520synergizes%2520with%2520Olaparib%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26issue%3D5%26spage%3D2588%26epage%3D2619%26doi%3D10.1021%2Facs.jmedchem.9b01526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rajendra, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkitaraman, A. R.</span></span> <span> </span><span class="NLM_article-title">Two modules in the BRC repeats of BRCA2 mediate structural and functional interactions with the RAD51 recombinase</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">82</span>â <span class="NLM_lpage">96</span>, <span class="refDoi">Â DOI: 10.1093/nar/gkp873</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1093%2Fnar%2Fgkp873" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=19875419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtF2nuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=82-96&issue=1&author=E.+Rajendraauthor=A.+R.+Venkitaraman&title=Two+modules+in+the+BRC+repeats+of+BRCA2+mediate+structural+and+functional+interactions+with+the+RAD51+recombinase&doi=10.1093%2Fnar%2Fgkp873"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Two modules in the BRC repeats of BRCA2 mediate structural and functional interactions with the RAD51 recombinase</span></div><div class="casAuthors">Rajendra, Eeson; Venkitaraman, Ashok R.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">82-96</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The breast and ovarian cancer suppressor protein BRCA2 controls the RAD51 recombinase in reactions that lead to homologous DNA recombination (HDR).  BRCA2 binds RAD51 via eight conserved BRC repeat motifs of approx. 35 amino acids, each with a varying capacity to bind RAD51.  BRC repeats both promote and inhibit RAD51 assembly on different DNA substrates to regulate HDR, but the structural basis for these functions is unclear.  Here, we demarcate two tetrameric clusters of hydrophobic residues in the BRC repeats, interacting with distinct pockets in RAD51, and show that the co-location of both modules within a single BRC repeat is necessary for BRC-RAD51 binding and function.  The two modules comprise the sequence FxxA, known to inhibit RAD51 assembly by blocking the oligomerization interface, and a previously unrecognized tetramer with the consensus sequence LFDE, which binds to a RAD51 pocket distinct from this interface.  The LFDE motif is essential in BRC repeats for modes of RAD51 binding both permissive and inhibitory to RAD51 oligomerization.  Targeted insertion of point mutations in RAD51 that disrupt the LFDE-binding pocket impair its assembly at DNA damage sites in living cells.  Our findings suggest a model for the modular architecture of BRC repeats that provides fresh insight into the mechanisms regulating homologous DNA recombination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrl7J1JIDpuErVg90H21EOLACvtfcHk0lgM5-J9MIeYnA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtF2nuw%253D%253D&md5=8fec23291c3037866be93b27f8a6f685</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkp873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkp873%26sid%3Dliteratum%253Aachs%26aulast%3DRajendra%26aufirst%3DE.%26aulast%3DVenkitaraman%26aufirst%3DA.%2BR.%26atitle%3DTwo%2520modules%2520in%2520the%2520BRC%2520repeats%2520of%2520BRCA2%2520mediate%2520structural%2520and%2520functional%2520interactions%2520with%2520the%2520RAD51%2520recombinase%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2010%26volume%3D38%26issue%3D1%26spage%3D82%26epage%3D96%26doi%3D10.1093%2Fnar%2Fgkp873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lv, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawlowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connell, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Development of small molecules that specifically inhibit the D-loop activity of RAD51</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4511</span>â <span class="NLM_lpage">4525</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b01762</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01762" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsFKqu78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4511-4525&issue=10&author=W.+Lvauthor=B.+Budkeauthor=M.+Pawlowskiauthor=P.+P.+Connellauthor=A.+P.+Kozikowski&title=Development+of+small+molecules+that+specifically+inhibit+the+D-loop+activity+of+RAD51&doi=10.1021%2Facs.jmedchem.5b01762"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Small Molecules that Specifically Inhibit the D-loop Activity of RAD51</span></div><div class="casAuthors">Lv, Wei; Budke, Brian; Pawlowski, Michal; Connell, Philip P.; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4511-4525</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">RAD51 is the central protein in homologous recombination (HR) DNA repair and represents a therapeutic target in oncol.  Herein we report a novel class of RAD51 inhibitors that were identified by high throughput screening.  In contrast to many previously reported RAD51 inhibitors, our lead compd. 1 is capable of blocking RAD51-mediated D-loop formation (IC50 21.3 Â± 7.8 Î¼M) at concns. that do not influence RAD51 binding to ssDNA.  In human cells, 1 inhibits HR (IC50 13.1 Â± 1.6 Î¼M) without blocking RAD51's ability to assemble into subnuclear foci at sites of DNA damage.  We detd. that the active constituent of 1 is actually an oxidized deriv. (termed RI(dl)-1 or 8) of the original screening compd.  Our SAR campaign also yielded RI(dl)-2 (hereafter termed 9h), which effectively blocks RAD51's D-loop activity in biochem. systems (IC50 11.1 Â± 1.3 Î¼M) and inhibits HR activity in human cells (IC50 3.0 Â± 1.8 Î¼M).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVW4_0QRMRGbVg90H21EOLACvtfcHk0lgM5-J9MIeYnA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsFKqu78%253D&md5=443c5b08e2e85236d68a31e7ea4ac33e</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01762%26sid%3Dliteratum%253Aachs%26aulast%3DLv%26aufirst%3DW.%26aulast%3DBudke%26aufirst%3DB.%26aulast%3DPawlowski%26aufirst%3DM.%26aulast%3DConnell%26aufirst%3DP.%2BP.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DDevelopment%2520of%2520small%2520molecules%2520that%2520specifically%2520inhibit%2520the%2520D-loop%2520activity%2520of%2520RAD51%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D10%26spage%3D4511%26epage%3D4525%26doi%3D10.1021%2Facs.jmedchem.5b01762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Budke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logan, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalin, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zelivianskaia, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron McGuire, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishop, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connell, P. P.</span></span> <span> </span><span class="NLM_article-title">RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">7347</span>â <span class="NLM_lpage">7357</span>, <span class="refDoi">Â DOI: 10.1093/nar/gks353</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1093%2Fnar%2Fgks353" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=22573178" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Kjs7nP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=7347-7357&issue=15&author=B.+Budkeauthor=H.+L.+Loganauthor=J.+H.+Kalinauthor=A.+S.+Zelivianskaiaauthor=W.+Cameron+McGuireauthor=L.+L.+Millerauthor=J.+M.+Starkauthor=A.+P.+Kozikowskiauthor=D.+K.+Bishopauthor=P.+P.+Connell&title=RI-1%3A+a+chemical+inhibitor+of+RAD51+that+disrupts+homologous+recombination+in+human+cells&doi=10.1093%2Fnar%2Fgks353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells</span></div><div class="casAuthors">Budke, Brian; Logan, Hillary L.; Kalin, Jay H.; Zelivianskaia, Anna S.; Cameron McGuire, William; Miller, Luke L.; Stark, Jeremy M.; Kozikowski, Alan P.; Bishop, Douglas K.; Connell, Philip P.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7347-7357</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Homologous recombination serves multiple roles in DNA repair that are essential for maintaining genomic stability.  We here describe RI-1, a small mol. that inhibits the central recombination protein RAD51.  RI-1 specifically reduces gene conversion in human cells while stimulating single strand annealing.  RI-1 binds covalently to the surface of RAD51 protein at cysteine 319 that likely destabilizes an interface used by RAD51 monomers to oligomerize into filaments on DNA.  Correspondingly, the mol. inhibits the formation of subnuclear RAD51 foci in cells following DNA damage, while leaving replication protein A focus formation unaffected.  Finally, it potentiates the lethal effects of a DNA crosslinking drug in human cells.  Given that this inhibitory activity is seen in multiple human tumor cell lines, RI-1 holds promise as an oncol. drug.  Furthermore, RI-1 represents a unique tool to dissect the network of reaction pathways that contribute to DNA repair in cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpko01Pxf0QsLVg90H21EOLACvtfcHk0livDb7z4Is1aQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Kjs7nP&md5=5249409b6df355e2c585472a160fb078</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgks353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgks353%26sid%3Dliteratum%253Aachs%26aulast%3DBudke%26aufirst%3DB.%26aulast%3DLogan%26aufirst%3DH.%2BL.%26aulast%3DKalin%26aufirst%3DJ.%2BH.%26aulast%3DZelivianskaia%26aufirst%3DA.%2BS.%26aulast%3DCameron%2BMcGuire%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DL.%2BL.%26aulast%3DStark%26aufirst%3DJ.%2BM.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DBishop%26aufirst%3DD.%2BK.%26aulast%3DConnell%26aufirst%3DP.%2BP.%26atitle%3DRI-1%253A%2520a%2520chemical%2520inhibitor%2520of%2520RAD51%2520that%2520disrupts%2520homologous%2520recombination%2520in%2520human%2520cells%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2012%26volume%3D40%26issue%3D15%26spage%3D7347%26epage%3D7357%26doi%3D10.1093%2Fnar%2Fgks353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Budke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalin, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawlowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zelivianskaia, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connell, P. P.</span></span> <span> </span><span class="NLM_article-title">An optimized RAD51 inhibitor that disrupts homologous recombination without requiring Michael acceptor reactivity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">254</span>â <span class="NLM_lpage">263</span>, <span class="refDoi">Â DOI: 10.1021/jm301565b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301565b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVWqtL%252FP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=254-263&issue=1&author=B.+Budkeauthor=J.+H.+Kalinauthor=M.+Pawlowskiauthor=A.+S.+Zelivianskaiaauthor=M.+Wuauthor=A.+P.+Kozikowskiauthor=P.+P.+Connell&title=An+optimized+RAD51+inhibitor+that+disrupts+homologous+recombination+without+requiring+Michael+acceptor+reactivity&doi=10.1021%2Fjm301565b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">An Optimized RAD51 Inhibitor That Disrupts Homologous Recombination without Requiring Michael Acceptor Reactivity</span></div><div class="casAuthors">Budke, Brian; Kalin, Jay H.; Pawlowski, Michal; Zelivianskaia, Anna S.; Wu, Megan; Kozikowski, Alan P.; Connell, Philip P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">254-263</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Homologous recombination (HR) is an essential process in cells that provides repair of DNA double-strand breaks and lesions that block DNA replication.  RAD51 is an evolutionarily conserved protein that is central to HR.  Overexpression of RAD51 protein is common in cancer cells and represents a potential therapeutic target in oncol.  We previously described a chem. inhibitor of RAD51, called RI-1 (referred to as compd. 1 in this report).  The chloromaleimide group of this compd. is thought to act as a Michael acceptor and react with the thiol group on C319 of RAD51, using a conjugate addn.-elimination mechanism.  In order to reduce the likelihood of off-target effects and to improve compd. stability in biol. systems, we developed an analog of compd. 1 that lacks maleimide-based reactivity but retains RAD51 inhibitory activity.  This compd., 1-(3,4-dichlorophenyl)-3-(4-methoxyphenyl)-4-morpholino-1H-pyrrole-2,5-dione, named RI-2 (referred to as compd. 7a in this report), appears to bind reversibly to the same site on the RAD51 protein as does compd. 1.  Like compd. 1, compd. 7a specifically inhibits HR repair in human cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5NFygiYR-q7Vg90H21EOLACvtfcHk0livDb7z4Is1aQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVWqtL%252FP&md5=141a877dedfd9397c8846289e317f560</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1021%2Fjm301565b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301565b%26sid%3Dliteratum%253Aachs%26aulast%3DBudke%26aufirst%3DB.%26aulast%3DKalin%26aufirst%3DJ.%2BH.%26aulast%3DPawlowski%26aufirst%3DM.%26aulast%3DZelivianskaia%26aufirst%3DA.%2BS.%26aulast%3DWu%26aufirst%3DM.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DConnell%26aufirst%3DP.%2BP.%26atitle%3DAn%2520optimized%2520RAD51%2520inhibitor%2520that%2520disrupts%2520homologous%2520recombination%2520without%2520requiring%2520Michael%2520acceptor%2520reactivity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D1%26spage%3D254%26epage%3D263%26doi%3D10.1021%2Fjm301565b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kanvatirth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeeves, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bacon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besra, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alderwick, L. J.</span></span> <span> </span><span class="NLM_article-title">Utilisation of the Prestwick chemical library to identify drugs that inhibit the growth of mycobacteria</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">3</span>), <span class="NLM_elocation-id">e0213713</span> <span class="refDoi">Â DOI: 10.1371/journal.pone.0213713</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1371%2Fjournal.pone.0213713" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=30861059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFaku78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&issue=3&author=P.+Kanvatirthauthor=R.+E.+Jeevesauthor=J.+Baconauthor=G.+S.+Besraauthor=L.+J.+Alderwick&title=Utilisation+of+the+Prestwick+chemical+library+to+identify+drugs+that+inhibit+the+growth+of+mycobacteria&doi=10.1371%2Fjournal.pone.0213713"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Utilisation of the Prestwick Chemical Library to identify drugs that inhibit the growth of mycobacteria</span></div><div class="casAuthors">Kanvatirth, Panchali; Jeeves, Rose E.; Bacon, Joanna; Besra, Gurdyal S.; Alderwick, Luke J.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e0213713</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Tuberculosis (TB) is an infectious bacterial disease that kills approx. 1.3 million people every year.  Despite global efforts to reduce both the incidence and mortality assocd. with TB, the emergence of drug resistant strains has slowed any progress made towards combating the spread of this deadly disease.  The current TB drug regimen is inadequate, takes months to complete and poses significant challenges when administering to patients suffering from drug resistant TB.  New treatments that are faster, simpler and more affordable are urgently required.  Arguably, a good strategy to discover new drugs is to start with an old drug.  Here, we have screened a library of 1200 FDA approved drugs from the Prestwick Chem. library using a GFP microplate assay.  Drugs were screened against GFP expressing strains of Mycobacterium smegmatis and Mycobacterium bovis BCG as surrogates for Mycobacterium tuberculosis, the causative agent of TB in humans.  We identified several classes of drugs that displayed antimycobacterial activity against both M. smegmatis and BCG, however each organism also displayed some selectivity towards certain drug classes.  Variant anal. of whole genomes sequenced for resistant mutants raised to florfenicol, vanoxerine and pentamidine highlight new pathways that could be exploited in drug repurposing programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1hjyD_Vs8jbVg90H21EOLACvtfcHk0li_6bTVmLdXzQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFaku78%253D&md5=08cdc1e84c3abd7d9d2f97766ebc4367</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0213713&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0213713%26sid%3Dliteratum%253Aachs%26aulast%3DKanvatirth%26aufirst%3DP.%26aulast%3DJeeves%26aufirst%3DR.%2BE.%26aulast%3DBacon%26aufirst%3DJ.%26aulast%3DBesra%26aufirst%3DG.%2BS.%26aulast%3DAlderwick%26aufirst%3DL.%2BJ.%26atitle%3DUtilisation%2520of%2520the%2520Prestwick%2520chemical%2520library%2520to%2520identify%2520drugs%2520that%2520inhibit%2520the%2520growth%2520of%2520mycobacteria%26jtitle%3DPLoS%2520One%26date%3D2019%26volume%3D14%26issue%3D3%26doi%3D10.1371%2Fjournal.pone.0213713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takaku, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kainuma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishida-Takaku, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishigami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tashiro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Soest, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurumizaka, H.</span></span> <span> </span><span class="NLM_article-title">Halenaquinone, a chemical compound that specifically inhibits the secondary DNA binding of RAD51</span>. <i>Genes Cells</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">427</span>â <span class="NLM_lpage">436</span>, <span class="refDoi">Â DOI: 10.1111/j.1365-2443.2011.01494.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1111%2Fj.1365-2443.2011.01494.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=21375680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkvVOltr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=427-436&issue=4&author=M.+Takakuauthor=T.+Kainumaauthor=T.+Ishida-Takakuauthor=S.+Ishigamiauthor=H.+Suzukiauthor=S.+Tashiroauthor=R.+W.+van+Soestauthor=Y.+Nakaoauthor=H.+Kurumizaka&title=Halenaquinone%2C+a+chemical+compound+that+specifically+inhibits+the+secondary+DNA+binding+of+RAD51&doi=10.1111%2Fj.1365-2443.2011.01494.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Halenaquinone, a chemical compound that specifically inhibits the secondary DNA binding of RAD51</span></div><div class="casAuthors">Takaku, Motoki; Kainuma, Takashi; Ishida-Takaku, Takako; Ishigami, Shintaro; Suzuki, Hidekazu; Tashiro, Satoshi; van Soest, Rob W. M.; Nakao, Yoichi; Kurumizaka, Hitoshi</div><div class="citationInfo"><span class="NLM_cas:title">Genes to Cells</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">427-436</span>CODEN:
                <span class="NLM_cas:coden">GECEFL</span>;
        ISSN:<span class="NLM_cas:issn">1356-9597</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Mutations and single-nucleotide polymorphisms affecting RAD51 gene function have been identified in several tumors, suggesting that the inappropriate expression of RAD51 activity may cause tumorigenesis.  RAD51 is an essential enzyme for the homologous recombinational repair (HRR) of DNA double-strand breaks.  In the HRR pathway, RAD51 catalyzes the homologous pairing between single-stranded DNA (ssDNA) and double-stranded DNA (dsDNA), which is the central step of the HRR pathway.  To identify a chem. compd. that regulates the homologous-pairing activity of RAD51, in the present study, we screened crude ext. fractions from marine sponges by the RAD51-mediated homologous-pairing assay.  Halenaquinone was identified as an inhibitor of the RAD51 homologous-pairing activity.  A surface plasmon resonance anal. indicated that halenaquinone directly bound to RAD51.  Intriguingly, halenaquinone specifically inhibited dsDNA binding by RAD51 alone or the RAD51-ssDNA complex, but only weakly affected the RAD51-ssDNA binding.  In vivo, halenaquinone significantly inhibited the retention of RAD51 at double-strand break sites.  Therefore, halenaquinone is a novel type of RAD51 inhibitor that specifically inhibits the RAD51-dsDNA binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxMwn_1wFlCbVg90H21EOLACvtfcHk0li_6bTVmLdXzQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkvVOltr0%253D&md5=ed3855965594722e133f322eff2aa8e1</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2443.2011.01494.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2443.2011.01494.x%26sid%3Dliteratum%253Aachs%26aulast%3DTakaku%26aufirst%3DM.%26aulast%3DKainuma%26aufirst%3DT.%26aulast%3DIshida-Takaku%26aufirst%3DT.%26aulast%3DIshigami%26aufirst%3DS.%26aulast%3DSuzuki%26aufirst%3DH.%26aulast%3DTashiro%26aufirst%3DS.%26aulast%3Dvan%2BSoest%26aufirst%3DR.%2BW.%26aulast%3DNakao%26aufirst%3DY.%26aulast%3DKurumizaka%26aufirst%3DH.%26atitle%3DHalenaquinone%252C%2520a%2520chemical%2520compound%2520that%2520specifically%2520inhibits%2520the%2520secondary%2520DNA%2520binding%2520of%2520RAD51%26jtitle%3DGenes%2520Cells%26date%3D2011%26volume%3D16%26issue%3D4%26spage%3D427%26epage%3D436%26doi%3D10.1111%2Fj.1365-2443.2011.01494.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konig, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldblatt, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlin, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. H.</span></span> <span> </span><span class="NLM_article-title">A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia</span>. <i>EMBO Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">353</span>â <span class="NLM_lpage">365</span>, <span class="refDoi">Â DOI: 10.1002/emmm.201201760</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1002%2Femmm.201201760" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=23341130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsFKhtr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=353-365&issue=3&author=J.+Zhuauthor=L.+Zhouauthor=G.+Wuauthor=H.+Konigauthor=X.+Linauthor=G.+Liauthor=X.+L.+Qiuauthor=C.+F.+Chenauthor=C.+M.+Huauthor=E.+Goldblattauthor=R.+Bhatiaauthor=A.+R.+Chamberlinauthor=P.+L.+Chenauthor=W.+H.+Lee&title=A+novel+small+molecule+RAD51+inactivator+overcomes+imatinib-resistance+in+chronic+myeloid+leukaemia&doi=10.1002%2Femmm.201201760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia</span></div><div class="casAuthors">Zhu, Jiewen; Zhou, Longen; Wu, Guikai; Konig, Heiko; Lin, Xiaoqin; Li, Guideng; Qiu, Xiao-Long; Chen, Chi-Fen; Hu, Chun-Mei; Goldblatt, Erin; Bhatia, Ravi; Chamberlin, A. Richard; Chen, Phang-Lang; Lee, Wen-Hwa</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Molecular Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">353-365</span>CODEN:
                <span class="NLM_cas:coden">EMMMAM</span>;
        ISSN:<span class="NLM_cas:issn">1757-4684</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">RAD51 recombinase activity plays a crit. role for cancer cell proliferation and survival, and often contributes to drug-resistance.  Abnormally elevated RAD51 function and hyperactive homologous recombination (HR) rates have been found in a panel of cancers, including breast cancer and chronic myeloid leukemia (CML).  Directly targeting RAD51 and attenuating the deregulated RAD51 activity has therefore been proposed as an alternative and supplementary strategy for cancer treatment.  Here we show that a newly identified small mol., IBR2, disrupts RAD51 multimerization, accelerates proteasome-mediated RAD51 protein degrdn., reduces ionizing radiation-induced RAD51 foci formation, impairs HR, inhibits cancer cell growth and induces apoptosis.  In a murine imatinib-resistant CML model bearing the T315I Bcr-abl mutation, IBR2, but not imatinib, significantly prolonged animal survival.  Moreover, IBR2 effectively inhibits the proliferation of CD34+ progenitor cells from CML patients resistant to known BCR-ABL inhibitors.  Therefore, small mol. inhibitors of RAD51 may suggest a novel class of broad-spectrum therapeutics for difficult-to-treat cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwQGeSwZ19nrVg90H21EOLACvtfcHk0lg415-iw3zesA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsFKhtr8%253D&md5=e956911425043bd5e2f18ddc0c10eec7</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1002%2Femmm.201201760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Femmm.201201760%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DKonig%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DQiu%26aufirst%3DX.%2BL.%26aulast%3DChen%26aufirst%3DC.%2BF.%26aulast%3DHu%26aufirst%3DC.%2BM.%26aulast%3DGoldblatt%26aufirst%3DE.%26aulast%3DBhatia%26aufirst%3DR.%26aulast%3DChamberlin%26aufirst%3DA.%2BR.%26aulast%3DChen%26aufirst%3DP.%2BL.%26aulast%3DLee%26aufirst%3DW.%2BH.%26atitle%3DA%2520novel%2520small%2520molecule%2520RAD51%2520inactivator%2520overcomes%2520imatinib-resistance%2520in%2520chronic%2520myeloid%2520leukaemia%26jtitle%3DEMBO%2520Mol.%2520Med.%26date%3D2013%26volume%3D5%26issue%3D3%26spage%3D353%26epage%3D365%26doi%3D10.1002%2Femmm.201201760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koropatnick, J.</span></span> <span> </span><span class="NLM_article-title">Synergistic antiproliferative activity of the RAD51 inhibitor IBR2 with inhibitors of receptor tyrosine kinases and microtubule protein</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>364</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">46</span>â <span class="NLM_lpage">54</span>, <span class="refDoi">Â DOI: 10.1124/jpet.117.241661</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1124%2Fjpet.117.241661" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=29061656" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsF2rtLnL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2018&pages=46-54&issue=1&author=P.+J.+Fergusonauthor=M.+D.+Vincentauthor=J.+Koropatnick&title=Synergistic+antiproliferative+activity+of+the+RAD51+inhibitor+IBR2+with+inhibitors+of+receptor+tyrosine+kinases+and+microtubule+protein&doi=10.1124%2Fjpet.117.241661"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic antiproliferative activity of the RAD51 inhibitor IBR2 with inhibitors of receptor tyrosine kinases and microtubule protein</span></div><div class="casAuthors">Ferguson, Peter J.; Vincent, Mark D.; Koropatnick, James</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">46-54</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Although cancer cell genetic instability contributes to characteristics that mediate tumorigenicity, it also contributes to the tumor-selective toxicity of some chemotherapy drugs.  This synthetic lethality can be enhanced by inhibitors of DNA repair.  To exploit this potential Achilles heel, we tested the ability of a RAD51 inhibitor to potentiate the cytotoxicity of chemotherapy drugs. 2-(Benzylsulfonyl)-1-(1H-indol-3-yl)-1,2-dihydroisoquinoline (IBR2) inhibits RAD51-mediated DNA double-strand break repair but also enhances cytotoxicity of the Bcr-Abl inhibitor imatinib.  The potential for synergy between IBR2 and more drugs was examd. in vitro across a spectrum of cancer cell lines from various tissues.  Cells were exposed to IBR2 simultaneously with inhibitors of receptor tyrosine kinases, DNA-damaging agents, or microtubule disruptors.  IBR2, at concns. that inhibited proliferation between 0% and 75%, enhanced toxicity by up to 80% of imatinib and regorafenib (targets RAF and kit); epidermal growth factor receptor inhibitors erlotinib, gefitinib, afatinib, and osimertinib; and vincristine, an inhibitor of microtubule function.  However, IBR2 antagonized the action of olaparib, cisplatin, melphalan, and irinotecan.  A vincristine-resistant squamous cell line was not cross resistant to imatinib, but IBR2 and another RAD51 inhibitor (B02) enhanced imatinib toxicity in this cell line, its HN-5a parent, and the colon cancer line HT-29 by up to 60% and much better than verapamil, a P-glycoprotein inhibitor (P < 0.05).  Given the disparate agents the functions of which are enhanced by IBR2, the mechanisms of enhancement may be multimodal.  Whether RAD51 is common to these mechanisms remains to be elucidated, but it provides the potential for selectivity to tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS83IVpSgnZrVg90H21EOLACvtfcHk0lg415-iw3zesA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsF2rtLnL&md5=0e7e8831f137a0ca09d18e057c9f8b9c</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1124%2Fjpet.117.241661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.117.241661%26sid%3Dliteratum%253Aachs%26aulast%3DFerguson%26aufirst%3DP.%2BJ.%26aulast%3DVincent%26aufirst%3DM.%2BD.%26aulast%3DKoropatnick%26aufirst%3DJ.%26atitle%3DSynergistic%2520antiproliferative%2520activity%2520of%2520the%2520RAD51%2520inhibitor%2520IBR2%2520with%2520inhibitors%2520of%2520receptor%2520tyrosine%2520kinases%2520and%2520microtubule%2520protein%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2018%26volume%3D364%26issue%3D1%26spage%3D46%26epage%3D54%26doi%3D10.1124%2Fjpet.117.241661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motlekar, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgwin, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Napper, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamond, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazin, A. V.</span></span> <span> </span><span class="NLM_article-title">Identification of specific inhibitors of human RAD51 recombinase using high-throughput screening</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">628</span>â <span class="NLM_lpage">635</span>, <span class="refDoi">Â DOI: 10.1021/cb100428c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb100428c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjs1Chtbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=628-635&issue=6&author=F.+Huangauthor=N.+A.+Motlekarauthor=C.+M.+Burgwinauthor=A.+D.+Napperauthor=S.+L.+Diamondauthor=A.+V.+Mazin&title=Identification+of+specific+inhibitors+of+human+RAD51+recombinase+using+high-throughput+screening&doi=10.1021%2Fcb100428c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Specific Inhibitors of Human RAD51 Recombinase Using High-Throughput Screening</span></div><div class="casAuthors">Huang, Fei; Motlekar, Nuzhat A.; Burgwin, Chelsea M.; Napper, Andrew D.; Diamond, Scott L.; Mazin, Alexander V.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">628-635</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">RAD51 is a key protein of homologous recombination that plays a crit. role in the repair of DNA double-strand breaks (DSB) and interstrand cross-links (ICL).  To better understand the cellular function(s) of human RAD51, we propose to develop specific RAD51 inhibitors.  RAD51 inhibitors may also help to increase the potency of anticancer drugs that act by inducing DSBs or ICLs, e.g., cisplatin or ionizing radiation.  In vitro, RAD51 promotes DNA strand exchange between homologous ss- and dsDNA.  Here, we developed a DNA strand exchange assay based on fluorescence resonance energy transfer and used this assay to identify RAD51 inhibitors by high-throughput screening of the NIH Small Mol. Repository (>200,000 compds.).  Seventeen RAD51 inhibitors were identified and analyzed for selectivity using addnl. nonfluorescent DNA-based assays.  As a result, we identified a compd. (B02) that specifically inhibited human RAD51 (IC50 = 27.4 Î¼M) but not its E. coli homolog RecA (IC50 > 250 Î¼M).  Two other compds. (A03 and A10) were identified that inhibited both RAD51 and RecA but not the structurally unrelated RAD54 protein.  The structure-activity relationship (SAR) anal. allowed us to identify the structural components of B02 that are crit. for RAD51 inhibition.  The described approach can be used for identification of specific inhibitors of other human proteins that play an important role in DNA repair, e.g., RAD54 or Bloom's syndrome helicase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSBfvKiy1Mn7Vg90H21EOLACvtfcHk0lg415-iw3zesA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjs1Chtbw%253D&md5=80f6887b67cd82b8a15d3f0a9612fce2</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1021%2Fcb100428c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb100428c%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DF.%26aulast%3DMotlekar%26aufirst%3DN.%2BA.%26aulast%3DBurgwin%26aufirst%3DC.%2BM.%26aulast%3DNapper%26aufirst%3DA.%2BD.%26aulast%3DDiamond%26aufirst%3DS.%2BL.%26aulast%3DMazin%26aufirst%3DA.%2BV.%26atitle%3DIdentification%2520of%2520specific%2520inhibitors%2520of%2520human%2520RAD51%2520recombinase%2520using%2520high-throughput%2520screening%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2011%26volume%3D6%26issue%3D6%26spage%3D628%26epage%3D635%26doi%3D10.1021%2Fcb100428c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">WÃ©ra, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lobbens, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoyanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michiels, C.</span></span> <span> </span><span class="NLM_article-title">Radiation-induced synthetic lethality: combination of poly(ADP-ribose) polymerase and RAD51 inhibitors to sensitize cells to proton irradiation</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">1770</span>â <span class="NLM_lpage">1783</span>, <span class="refDoi">Â DOI: 10.1080/15384101.2019.1632640</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1080%2F15384101.2019.1632640" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=31238782" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1Gis7rJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=1770-1783&issue=15&author=A.+C.+W%C3%A9raauthor=A.+Lobbensauthor=M.+Stoyanovauthor=S.+Lucasauthor=C.+Michiels&title=Radiation-induced+synthetic+lethality%3A+combination+of+poly%28ADP-ribose%29+polymerase+and+RAD51+inhibitors+to+sensitize+cells+to+proton+irradiation&doi=10.1080%2F15384101.2019.1632640"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Radiation-induced synthetic lethality: combination of poly(ADP-ribose) polymerase and RAD51 inhibitors to sensitize cells to proton irradiation</span></div><div class="casAuthors">Wera, Anne-Catherine; Lobbens, Alison; Stoyanov, Miroslav; Lucas, Stephane; Michiels, Carine</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1770-1783</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1551-4005</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Although improvements in radiation therapy were made over the years, radioresistance is still a major challenge.  Cancer cells are often deficient for DNA repair response, a feature that is currently exploited as a new anti-cancer strategy.  In this context, combination of inhibitors targeting complementary pathways is of interest to sensitize cells to radiation.  In this work, we used PARP (Olaparib) and RAD51 (B02) inhibitors to radiosensitize cancer cells to proton and X-ray radiation.  More particularly, Olaparib and B02 were used at concn. leading to limited cytotoxic (alone or in combination) but increasing cell death when the cells were irradiated.  We showed that, although at limited concn., Olaparib and B02 were able to radiosensitize different cancer cell lines, i.e. lung and pancreatic cancer cells.  Antagonistic, additive or synergistic effects were obsd. and correlated to cell proliferation rate.  The inhibitors enhanced persistent DNA damage, delayed apoptosis, prolonged cell cycle arrest and senescence upon irradn.  These results demonstrated that radiation-induced synthetic lethality might widen the therapeutic window, hence extending the use of PARP inhibitors to patients without BRCAness.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdkyCV1HkelLVg90H21EOLACvtfcHk0livz4xP9gwf3Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1Gis7rJ&md5=2bfda9cbf0101f44880ab669d3f8c243</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1080%2F15384101.2019.1632640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15384101.2019.1632640%26sid%3Dliteratum%253Aachs%26aulast%3DW%25C3%25A9ra%26aufirst%3DA.%2BC.%26aulast%3DLobbens%26aufirst%3DA.%26aulast%3DStoyanov%26aufirst%3DM.%26aulast%3DLucas%26aufirst%3DS.%26aulast%3DMichiels%26aufirst%3DC.%26atitle%3DRadiation-induced%2520synthetic%2520lethality%253A%2520combination%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%2520and%2520RAD51%2520inhibitors%2520to%2520sensitize%2520cells%2520to%2520proton%2520irradiation%26jtitle%3DCell%2520Cycle%26date%3D2019%26volume%3D18%26issue%3D15%26spage%3D1770%26epage%3D1783%26doi%3D10.1080%2F15384101.2019.1632640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maclay, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McComas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, K.</span></span> <span> </span><span class="NLM_article-title">CYT01B, a novel RAD51 inhibitor, act synergistically with both targeted and chemotherapeutic anti-cancer agents</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>132</i></span> (<span class="NLM_issue">Suppl. 1</span>),  <span class="NLM_fpage">3963</span>, <span class="refDoi">Â DOI: 10.1182/blood-2018-99-119373</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1182%2Fblood-2018-99-119373" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2018&pages=3963&issue=Suppl.+1&author=T.+Maclayauthor=J.+Vaccaauthor=C.+McComasauthor=A.+Castroauthor=M.+Dayauthor=K.+Mills&title=CYT01B%2C+a+novel+RAD51+inhibitor%2C+act+synergistically+with+both+targeted+and+chemotherapeutic+anti-cancer+agents&doi=10.1182%2Fblood-2018-99-119373"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1182%2Fblood-2018-99-119373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2018-99-119373%26sid%3Dliteratum%253Aachs%26aulast%3DMaclay%26aufirst%3DT.%26aulast%3DVacca%26aufirst%3DJ.%26aulast%3DMcComas%26aufirst%3DC.%26aulast%3DCastro%26aufirst%3DA.%26aulast%3DDay%26aufirst%3DM.%26aulast%3DMills%26aufirst%3DK.%26atitle%3DCYT01B%252C%2520a%2520novel%2520RAD51%2520inhibitor%252C%2520act%2520synergistically%2520with%2520both%2520targeted%2520and%2520chemotherapeutic%2520anti-cancer%2520agents%26jtitle%3DBlood%26date%3D2018%26volume%3D132%26issue%3DSuppl.%25201%26spage%3D3963%26doi%3D10.1182%2Fblood-2018-99-119373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Castro, A.</span>; <span class="NLM_string-name">McComas, C.</span>; <span class="NLM_string-name">Vacca, J.</span>; <span class="NLM_string-name">Maclay, T.</span></span> <span> </span><span class="NLM_article-title">RAD51 Inhibitors</span>. <span class="NLM_patent">US20190077799 A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=A.+Castro&author=C.+McComas&author=J.+Vacca&author=T.+Maclay&title=RAD51+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCastro%26aufirst%3DA.%26atitle%3DRAD51%2520Inhibitors%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xue, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, E. C.</span></span> <span> </span><span class="NLM_article-title">New roles for RAD52 in DNA repair</span>. <i>Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1127</span>â <span class="NLM_lpage">1128</span>, <span class="refDoi">Â DOI: 10.1038/s41422-018-0105-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1038%2Fs41422-018-0105-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=30367126" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A280%3ADC%252BB3cvjvFWhsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=1127-1128&issue=12&author=C.+Xueauthor=E.+C.+Greene&title=New+roles+for+RAD52+in+DNA+repair&doi=10.1038%2Fs41422-018-0105-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">New roles for RAD52 in DNA repair</span></div><div class="casAuthors">Xue Chaoyou; Greene Eric C</div><div class="citationInfo"><span class="NLM_cas:title">Cell research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1127-1128</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT5hx99QqDO5jDnmmyUf5qOfW6udTcc2eY8q7eFZBLXkrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvjvFWhsQ%253D%253D&md5=6a2e833af486b4babd3745232839e972</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1038%2Fs41422-018-0105-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41422-018-0105-8%26sid%3Dliteratum%253Aachs%26aulast%3DXue%26aufirst%3DC.%26aulast%3DGreene%26aufirst%3DE.%2BC.%26atitle%3DNew%2520roles%2520for%2520RAD52%2520in%2520DNA%2520repair%26jtitle%3DCell%2520Res.%26date%3D2018%26volume%3D28%26issue%3D12%26spage%3D1127%26epage%3D1128%26doi%3D10.1038%2Fs41422-018-0105-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Norquist, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurz, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennil, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakai, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlan, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swisher, E. M.</span></span> <span> </span><span class="NLM_article-title">Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">3008</span>â <span class="NLM_lpage">3015</span>, <span class="refDoi">Â DOI: 10.1200/JCO.2010.34.2980</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1200%2FJCO.2010.34.2980" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=21709188" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFCqtLbL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=3008-3015&issue=22&author=B.+Norquistauthor=K.+A.+Wurzauthor=C.+C.+Pennilauthor=R.+Garciaauthor=J.+Grossauthor=W.+Sakaiauthor=B.+Y.+Karlanauthor=T.+Taniguchiauthor=E.+M.+Swisher&title=Secondary+somatic+mutations+restoring+BRCA1%2F2+predict+chemotherapy+resistance+in+hereditary+ovarian+carcinomas&doi=10.1200%2FJCO.2010.34.2980"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas</span></div><div class="casAuthors">Norquist, Barbara; Wurz, Kaitlyn A.; Pennil, Christopher C.; Garcia, Rochelle; Gross, Jenny; Sakai, Wataru; Karlan, Beth Y.; Taniguchi, Toshiyasu; Swisher, Elizabeth M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3008-3015</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Secondary somatic BRCA1/2 mutations may restore BRCA1/2 protein in hereditary ovarian carcinomas.  In cell lines, BRCA2 restoration mediates resistance to platinum chemotherapy and poly (ADP-ribose) polymerase (PARP) inhibitors.  We assessed primary and recurrent BRCA1/2-mutated ovarian carcinomas to define the frequency of secondary mutations and correlate these changes with clin. outcomes.  Methods Neoplastic cells were isolated with laser capture microdissection, and DNA was sequenced at the site of the known germline BRCA1/2 mutation.  When secondary mutations were found that restored wild-type sequence, haplotyping was performed using single nucleotide polymorphisms in tumor and paired lymphocyte DNA to rule out retention of the wild-type allele.  Results There were 64 primary and 46 recurrent ovarian carcinomas assessed.  Thirteen (28.3%) of 46 (95% CI, 17.3% to 42.6%) recurrent carcinomas had a secondary mutation compared with two (3.1%) of 64(95% CI, 1.0% to 10.7%) primary carcinomas (P= .0003, Fisher's exact test).  Twelve (46.2%) of 26 (95% CI, 28.7% to 64.7%) platinum-resistant recurrences had secondary mutations restoring BRCA1/2, compared with one (5.3%) of 19 (95% CI, 1.2% to 24.8%) platinum-sensitive recurrences (P = .003, Fisher's exact test).  Six (66.7%) of nine (95% CI, 34.8% to 87.8%) women with prior breast carcinoma had a recurrent carcinoma with a secondary mutation, compared with six (17.1%) of 35(95% CI, 8.2% to 32.8%) with no history of breast carcinoma (P = .007, Fisher's exact test).  Conclusion Secondary somatic mutations that restore BRCA1/2 in carcinomas from women with germline BRCA1/2 mutations predict resistance to platinum chemotherapy and may also predict resistance to PARP inhibitors.  These mutations were detectable only in ovarian carcinomas of women whom have had previous chemotherapy, either for ovarian or breast carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4mKtBwo-3h7Vg90H21EOLACvtfcHk0ljznYTy8EVz2g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFCqtLbL&md5=998befc1b2df55cb5fdf40353c5d613d</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1200%2FJCO.2010.34.2980&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2010.34.2980%26sid%3Dliteratum%253Aachs%26aulast%3DNorquist%26aufirst%3DB.%26aulast%3DWurz%26aufirst%3DK.%2BA.%26aulast%3DPennil%26aufirst%3DC.%2BC.%26aulast%3DGarcia%26aufirst%3DR.%26aulast%3DGross%26aufirst%3DJ.%26aulast%3DSakai%26aufirst%3DW.%26aulast%3DKarlan%26aufirst%3DB.%2BY.%26aulast%3DTaniguchi%26aufirst%3DT.%26aulast%3DSwisher%26aufirst%3DE.%2BM.%26atitle%3DSecondary%2520somatic%2520mutations%2520restoring%2520BRCA1%252F2%2520predict%2520chemotherapy%2520resistance%2520in%2520hereditary%2520ovarian%2520carcinomas%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26issue%3D22%26spage%3D3008%26epage%3D3015%26doi%3D10.1200%2FJCO.2010.34.2980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan-Reed, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sliwinski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skorski, T.</span></span> <span> </span><span class="NLM_article-title">RAD52 as a potential target for synthetic lethality-based anticancer therapies</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1561</span>, <span class="refDoi">Â DOI: 10.3390/cancers11101561</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.3390%2Fcancers11101561" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnsVKht70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=1561&issue=10&author=M.+Tomaauthor=K.+Sullivan-Reedauthor=T.+Sliwinskiauthor=T.+Skorski&title=RAD52+as+a+potential+target+for+synthetic+lethality-based+anticancer+therapies&doi=10.3390%2Fcancers11101561"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">RAD52 as a potential target for synthetic lethality-based anticancer therapies</span></div><div class="casAuthors">Toma, Monika; Sullivan-Reed, Katherine; Sliwinski, Tomasz; Skorski, Tomasz</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1561</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Alterations in DNA repair systems play a key role in the induction and progression of cancer.  Tumor-specific defects in DNA repair mechanisms and activation of alternative repair routes create the opportunity to employ a phenomenon called "synthetic lethality" to eliminate cancer cells.  Targeting the backup pathways may amplify endogenous and drug-induced DNA damage and lead to specific eradication of cancer cells.  So far, the synthetic lethal interaction between BRCA1/2 and PARP1 has been successfully applied as an anticancer treatment.  Although PARP1 constitutes a promising target in the treatment of tumors harboring deficiencies in BRCA1/2-mediated homologous recombination (HR), some tumor cells survive, resulting in disease relapse.  It has been suggested that alternative RAD52-mediated HR can protect BRCA1/2-deficient cells from the accumulation of DNA damage and the synthetic lethal effect of PARPi.  Thus, simultaneous inhibition of RAD52 and PARP1 might result in a robust dual synthetic lethality, effectively eradicating BRCA1/2-deficient tumor cells.  In this review, we will discuss the role of RAD52 and its potential application in synthetic lethality-based anticancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2He7i98xWULVg90H21EOLACvtfcHk0ljznYTy8EVz2g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnsVKht70%253D&md5=5c86f533c7696fab5deab28b8d179d38</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.3390%2Fcancers11101561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers11101561%26sid%3Dliteratum%253Aachs%26aulast%3DToma%26aufirst%3DM.%26aulast%3DSullivan-Reed%26aufirst%3DK.%26aulast%3DSliwinski%26aufirst%3DT.%26aulast%3DSkorski%26aufirst%3DT.%26atitle%3DRAD52%2520as%2520a%2520potential%2520target%2520for%2520synthetic%2520lethality-based%2520anticancer%2520therapies%26jtitle%3DCancers%26date%3D2019%26volume%3D11%26issue%3D10%26spage%3D1561%26doi%3D10.3390%2Fcancers11101561" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hromas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidhu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaiswal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Totterdale, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nole, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickoloff, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, K. Y.</span></span> <span> </span><span class="NLM_article-title">The endonuclease EEPD1 mediates synthetic lethality in RAD52-depleted BRCA1 mutant breast cancer cells</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">122</span>, <span class="refDoi">Â DOI: 10.1186/s13058-017-0912-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1186%2Fs13058-017-0912-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=29145865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFWnu7zN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=122&author=R.+Hromasauthor=H.+S.+Kimauthor=G.+Sidhuauthor=E.+Williamsonauthor=A.+Jaiswalauthor=T.+A.+Totterdaleauthor=J.+Noleauthor=S.+H.+Leeauthor=J.+A.+Nickoloffauthor=K.+Y.+Kong&title=The+endonuclease+EEPD1+mediates+synthetic+lethality+in+RAD52-depleted+BRCA1+mutant+breast+cancer+cells&doi=10.1186%2Fs13058-017-0912-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">The endonuclease EEPD1 mediates synthetic lethality in RAD52-depleted BRCA1 mutant breast cancer cells</span></div><div class="casAuthors">Hromas, Robert; Kim, Hyun-Suk; Sidhu, Gurjit; Williamson, Elizabeth; Jaiswal, Aruna; Totterdale, Taylor A.; Nole, Jocelyn; Lee, Suk-Hee; Nickoloff, Jac A.; Kong, Kimi Y.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">122/1-122/14</span>CODEN:
                <span class="NLM_cas:coden">BRCRFS</span>;
        ISSN:<span class="NLM_cas:issn">1465-542X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Proper repair and restart of stressed replication forks requires intact homologous recombination (HR).  HR at stressed replication forks can be initiated by the 5' endonuclease EEPD1, which cleaves the stalled replication fork.  Inherited or acquired defects in HR, such as mutations in breast cancer susceptibility protein-1 (BRCA1) or BRCA2, predispose to cancer, including breast and ovarian cancers.  In order for these HR-deficient tumor cells to proliferate, they become addicted to a bypass replication fork repair pathway mediated by radiation repair protein 52 (RAD52).  Depleting RAD52 can cause synthetic lethality in BRCA1/2 mutant cancers by an unknown mol. mechanism.  Methods: We hypothesized that cleavage of stressed replication forks by EEPD1 generates a fork repair intermediate that is toxic when HR-deficient cells cannot complete repair with the RAD52 bypass pathway.  To test this hypothesis, we applied cell survival assays, immunofluorescence staining, DNA fiber and western blot analyses to look at the correlation between cell survival and genome integrity in control, EEPD1, RAD52 and EEPD1/RAD52 co-depletion BRCA1-deficient breast cancer cells.  Results: Our data show that depletion of EEPD1 suppresses synthetic lethality, genome instability, mitotic catastrophe, and hypersensitivity to stress of replication of RAD52-depleted, BRCA1 mutant breast cancer cells.  Without HR and the RAD52-dependent backup pathway, the BRCA1 mutant cancer cells depleted of EEPD1 skew to the alternative non-homologous end-joining DNA repair pathway for survival.  Conclusion: This study indicates that the mechanism of synthetic lethality in RAD52-depleted BRCA1 mutant cancer cells depends on the endonuclease EEPD1.  The data imply that EEPD1 cleavage of stressed replication forks may result in a toxic intermediate when replication fork repair cannot be completed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKOoJ61fL57LVg90H21EOLACvtfcHk0lgFJMZK4gSU8g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFWnu7zN&md5=7dd4dfb4a777b828e752bcb32fcfb1fd</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1186%2Fs13058-017-0912-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13058-017-0912-8%26sid%3Dliteratum%253Aachs%26aulast%3DHromas%26aufirst%3DR.%26aulast%3DKim%26aufirst%3DH.%2BS.%26aulast%3DSidhu%26aufirst%3DG.%26aulast%3DWilliamson%26aufirst%3DE.%26aulast%3DJaiswal%26aufirst%3DA.%26aulast%3DTotterdale%26aufirst%3DT.%2BA.%26aulast%3DNole%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DNickoloff%26aufirst%3DJ.%2BA.%26aulast%3DKong%26aufirst%3DK.%2BY.%26atitle%3DThe%2520endonuclease%2520EEPD1%2520mediates%2520synthetic%2520lethality%2520in%2520RAD52-depleted%2520BRCA1%2520mutant%2520breast%2520cancer%2520cells%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2017%26volume%3D19%26spage%3D122%26doi%3D10.1186%2Fs13058-017-0912-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cramer-Morales, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieborowska-Skorska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheibner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padget, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irvine, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sliwinski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slupianek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rassool, F. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasik, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Childers, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copland, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muschen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Civin, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skorski, T.</span></span> <span> </span><span class="NLM_article-title">Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>122</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1293</span>â <span class="NLM_lpage">1304</span>, <span class="refDoi">Â DOI: 10.1182/blood-2013-05-501072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1182%2Fblood-2013-05-501072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=23836560" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlOjsb7K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2013&pages=1293-1304&issue=7&author=K.+Cramer-Moralesauthor=M.+Nieborowska-Skorskaauthor=K.+Scheibnerauthor=M.+Padgetauthor=D.+A.+Irvineauthor=T.+Sliwinskiauthor=K.+Haasauthor=J.+Leeauthor=H.+Gengauthor=D.+Royauthor=A.+Slupianekauthor=F.+V.+Rassoolauthor=M.+A.+Wasikauthor=W.+Childersauthor=M.+Coplandauthor=M.+Muschenauthor=C.+I.+Civinauthor=T.+Skorski&title=Personalized+synthetic+lethality+induced+by+targeting+RAD52+in+leukemias+identified+by+gene+mutation+and+expression+profile&doi=10.1182%2Fblood-2013-05-501072"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile</span></div><div class="casAuthors">Cramer-Morales, Kimberly; Nieborowska-Skorska, Margaret; Scheibner, Kara; Padget, Michelle; Irvine, David A.; Sliwinski, Tomasz; Haas, Kimberly; Lee, Jaewoong; Geng, Huimin; Roy, Darshan; Slupianek, Artur; Rassool, Feyruz V.; Wasik, Mariusz A.; Childers, Wayne; Copland, Mhairi; Muschen, Markus; Civin, Curt I.; Skorski, Tomasz</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1293-1304</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Homologous recombination repair (HRR) protects cells from the lethal effect of spontaneous and therapy-induced DNA double-stand breaks.  HRR usually depends on BRCA1/2-RAD51, and RAD52-RAD51 serves as back-up.  To target HRR in tumor cells, a phenomenon called "synthetic lethality" was applied, which relies on the addiction of cancer cells to a single DNA repair pathway, whereas normal cells operate 2 or more mechanisms.  Using mutagenesis and a peptide aptamer approach, we pinpointed phenylalanine 79 in RAD52 DNA binding domain I (RAD52-phenylalanine 79 [F79]) as a valid target to induce synthetic lethality in BRCA1- and/or BRCA2-deficient leukemias and carcinomas without affecting normal cells and tissues.  Targeting RAD52-F79 disrupts the RAD52-DNA interaction, resulting in the accumulation of toxic DNA double-stand breaks in malignant cells, but not in normal counterparts.  In addn., abrogation of RAD52-DNA interaction enhanced the antileukemia effect of already-approved drugs.  BRCA-deficient status predisposing to RAD52-dependent synthetic lethality could be predicted by genetic abnormalities such as oncogenes BCR-ABL1 and PML-RAR, mutations in BRCA1 and/or BRCA2 genes, and gene expression profiles identifying leukemias displaying low levels of BRCA1 and/or BRCA2.  We believe this work may initiate a personalized therapeutic approach in numerous patients with tumors displaying encoded and functional BRCA deficiency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiS-g84hhhgbVg90H21EOLACvtfcHk0lgFJMZK4gSU8g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlOjsb7K&md5=e3ff26e6fef134ac1272758932cd42cf</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1182%2Fblood-2013-05-501072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2013-05-501072%26sid%3Dliteratum%253Aachs%26aulast%3DCramer-Morales%26aufirst%3DK.%26aulast%3DNieborowska-Skorska%26aufirst%3DM.%26aulast%3DScheibner%26aufirst%3DK.%26aulast%3DPadget%26aufirst%3DM.%26aulast%3DIrvine%26aufirst%3DD.%2BA.%26aulast%3DSliwinski%26aufirst%3DT.%26aulast%3DHaas%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DGeng%26aufirst%3DH.%26aulast%3DRoy%26aufirst%3DD.%26aulast%3DSlupianek%26aufirst%3DA.%26aulast%3DRassool%26aufirst%3DF.%2BV.%26aulast%3DWasik%26aufirst%3DM.%2BA.%26aulast%3DChilders%26aufirst%3DW.%26aulast%3DCopland%26aufirst%3DM.%26aulast%3DMuschen%26aufirst%3DM.%26aulast%3DCivin%26aufirst%3DC.%2BI.%26aulast%3DSkorski%26aufirst%3DT.%26atitle%3DPersonalized%2520synthetic%2520lethality%2520induced%2520by%2520targeting%2520RAD52%2520in%2520leukemias%2520identified%2520by%2520gene%2520mutation%2520and%2520expression%2520profile%26jtitle%3DBlood%26date%3D2013%26volume%3D122%26issue%3D7%26spage%3D1293%26epage%3D1304%26doi%3D10.1182%2Fblood-2013-05-501072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renodon-Corniere, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomme, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eveillard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleury, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigel, P.</span></span> <span> </span><span class="NLM_article-title">Targeting human Rad51 by specific DNA aptamers induces inhibition of homologous recombination</span>. <i>Biochimie</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>92</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1832</span>â <span class="NLM_lpage">1838</span>, <span class="refDoi">Â DOI: 10.1016/j.biochi.2010.08.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.biochi.2010.08.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=20713120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFantbjM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2010&pages=1832-1838&issue=12&author=S.+F.+Martinezauthor=A.+Renodon-Corniereauthor=J.+Nommeauthor=D.+Eveillardauthor=F.+Fleuryauthor=M.+Takahashiauthor=P.+Weigel&title=Targeting+human+Rad51+by+specific+DNA+aptamers+induces+inhibition+of+homologous+recombination&doi=10.1016%2Fj.biochi.2010.08.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting human Rad51 by specific DNA aptamers induces inhibition of homologous recombination</span></div><div class="casAuthors">Martinez, Susan F.; Renodon-Corniere, Axelle; Nomme, Julian; Eveillard, Damien; Fleury, Fabrice; Takahashi, Masayuki; Weigel, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Biochimie</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1832-1838</span>CODEN:
                <span class="NLM_cas:coden">BICMBE</span>;
        ISSN:<span class="NLM_cas:issn">0300-9084</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Human Rad51 (HsRad51), a key element of the homologous recombination repair pathway, is related to the resistance of cancer cells to chemo- and radio-therapies.  This protein is thus a good target for the development of anti-cancer treatments.  We have searched for new inhibitors directed against HsRad51 using the Systematic Evolution of Ligands by EXponential enrichment (SELEX) approach.  We have selected three aptamers displaying strong effects on strand exchange activity.  Anal. by CD shows that they are highly structured DNA mols.  Our results also show that they affect the first step of the strand exchange reaction by promoting the dissocn. of DNA from the ATP/HsRad51/DNA complex.  Moreover, these inhibitors bind only weakly to RecA, a prokaryotic ortholog of HsRad51.  Both the specificity and the efficiency of their inhibition of recombinase activity offer an anal. tool based on mol. recognition and the prospect of developing new therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTE5PR_ksvXrVg90H21EOLACvtfcHk0liB3zsJhelenQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFantbjM&md5=60dbf853e0eee951929046683e95c190</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1016%2Fj.biochi.2010.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biochi.2010.08.006%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez%26aufirst%3DS.%2BF.%26aulast%3DRenodon-Corniere%26aufirst%3DA.%26aulast%3DNomme%26aufirst%3DJ.%26aulast%3DEveillard%26aufirst%3DD.%26aulast%3DFleury%26aufirst%3DF.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DWeigel%26aufirst%3DP.%26atitle%3DTargeting%2520human%2520Rad51%2520by%2520specific%2520DNA%2520aptamers%2520induces%2520inhibition%2520of%2520homologous%2520recombination%26jtitle%3DBiochimie%26date%3D2010%26volume%3D92%26issue%3D12%26spage%3D1832%26epage%3D1838%26doi%3D10.1016%2Fj.biochi.2010.08.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chandramouly, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDevitt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kent, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glickman, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrake, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skorski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pomerantz, R. T.</span></span> <span> </span><span class="NLM_article-title">Small-molecule disruption of RAD52 rings as a mechanism for precision medicine in BRCA-deficient cancers</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1491</span>â <span class="NLM_lpage">1504</span>, <span class="refDoi">Â DOI: 10.1016/j.chembiol.2015.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.chembiol.2015.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=26548611" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsl2gsr7K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=1491-1504&issue=11&author=G.+Chandramoulyauthor=S.+McDevittauthor=K.+Sullivanauthor=T.+Kentauthor=A.+Luzauthor=J.+F.+Glickmanauthor=M.+Andrakeauthor=T.+Skorskiauthor=R.+T.+Pomerantz&title=Small-molecule+disruption+of+RAD52+rings+as+a+mechanism+for+precision+medicine+in+BRCA-deficient+cancers&doi=10.1016%2Fj.chembiol.2015.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Disruption of RAD52 Rings as a Mechanism for Precision Medicine in BRCA-Deficient Cancers</span></div><div class="casAuthors">Chandramouly, Gurushankar; McDevitt, Shane; Sullivan, Katherine; Kent, Tatiana; Luz, Antonio; Glickman, J. Fraser; Andrake, Mark; Skorski, Tomasz; Pomerantz, Richard T.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1491-1504</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Suppression of RAD52 causes synthetic lethality in BRCA-deficient cells.  Yet pharmacol. inhibition of RAD52, which binds single-strand DNA (ssDNA) and lacks enzymic activity, has not been demonstrated.  Here, we identify the small mol. 6-hydroxy-DL-dopa (6-OH-dopa) as a major allosteric inhibitor of the RAD52 ssDNA binding domain.  For example, we find that multiple small mols. bind to and completely transform RAD52 undecamer rings into dimers, which abolishes the ssDNA binding channel obsd. in crystal structures.  6-OH-Dopa also disrupts RAD52 heptamer and undecamer ring superstructures, and suppresses RAD52 recruitment and recombination activity in cells with negligible effects on other double-strand break repair pathways.  Importantly, we show that 6-OH-dopa selectively inhibits the proliferation of BRCA-deficient cancer cells, including those obtained from leukemia patients.  Taken together, these data demonstrate small-mol. disruption of RAD52 rings as a promising mechanism for precision medicine in BRCA-deficient cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocg0mbVDvBErVg90H21EOLACvtfcHk0liB3zsJhelenQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsl2gsr7K&md5=a1ce2852f876ce70b7b8c5275d6050ab</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2015.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2015.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DChandramouly%26aufirst%3DG.%26aulast%3DMcDevitt%26aufirst%3DS.%26aulast%3DSullivan%26aufirst%3DK.%26aulast%3DKent%26aufirst%3DT.%26aulast%3DLuz%26aufirst%3DA.%26aulast%3DGlickman%26aufirst%3DJ.%2BF.%26aulast%3DAndrake%26aufirst%3DM.%26aulast%3DSkorski%26aufirst%3DT.%26aulast%3DPomerantz%26aufirst%3DR.%2BT.%26atitle%3DSmall-molecule%2520disruption%2520of%2520RAD52%2520rings%2520as%2520a%2520mechanism%2520for%2520precision%2520medicine%2520in%2520BRCA-deficient%2520cancers%26jtitle%3DChem.%2520Biol.%26date%3D2015%26volume%3D22%26issue%3D11%26spage%3D1491%26epage%3D1504%26doi%3D10.1016%2Fj.chembiol.2015.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olney, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zorumski, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labruyere, J.</span></span> <span> </span><span class="NLM_article-title">Excitotoxicity of L-dopa and 6-OH-dopa: implications for Parkinsonâs and Huntingtonâs diseases</span>. <i>Exp. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>108</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">269</span>â <span class="NLM_lpage">272</span>, <span class="refDoi">Â DOI: 10.1016/0014-4886(90)90134-E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2F0014-4886%2890%2990134-E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1972067" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADyaK3cXltlSjurs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=1990&pages=269-272&issue=3&author=J.+W.+Olneyauthor=C.+F.+Zorumskiauthor=G.+R.+Stewartauthor=M.+T.+Priceauthor=G.+J.+Wangauthor=J.+Labruyere&title=Excitotoxicity+of+L-dopa+and+6-OH-dopa%3A+implications+for+Parkinson%E2%80%99s+and+Huntington%E2%80%99s+diseases&doi=10.1016%2F0014-4886%2890%2990134-E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Excitotoxicity of L-DOPA and 6-OH-DOPA:  implications for Parkinson's and Huntington's diseases</span></div><div class="casAuthors">Olney, John W.; Zorumski, Charles F.; Stewart, Gregory R.; Price, Madelon T.; Wang, Guangjian; Labruyere, Joann</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Neurology</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">269-72</span>CODEN:
                <span class="NLM_cas:coden">EXNEAC</span>;
        ISSN:<span class="NLM_cas:issn">0014-4886</span>.
    </div><div class="casAbstract">Despite several decades of research aimed at elucidating the mechanisms underlying neuronal degeneration in Parkinson's and Huntington's diseases, these mysteries remain unfathomed.  The brain contains high concns. of the putative transmitters, glutamate and aspartate, which have neurotoxic (excitotoxic) potential and are thought to cause neuronal degeneration in certain acute neurol. disorders.  However, no mechanism has been identified by which these diffusely distributed agents might cause the regionally selective patterns of neuronal degeneration characterizing Parkinson's and Huntington's diseases.  This study reports that L-DOPA, the natural precursor to dopamine, is a weak excitotoxin and its o-hydroxylated deriv., 6-OH-DOPA, is a powerful excitotoxin.  The authors propose that an excitotoxic process mediated by L-DOPA or an acidic deriv. such as 6-OH-DOPA might be responsible for degeneration of nigral neurons in Parkinson's disease or striatal neurons in Huntington's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpihHszOClV9bVg90H21EOLACvtfcHk0ljEQCKawMUR7A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXltlSjurs%253D&md5=8c651f238b831643af5eb088207c786d</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1016%2F0014-4886%2890%2990134-E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-4886%252890%252990134-E%26sid%3Dliteratum%253Aachs%26aulast%3DOlney%26aufirst%3DJ.%2BW.%26aulast%3DZorumski%26aufirst%3DC.%2BF.%26aulast%3DStewart%26aufirst%3DG.%2BR.%26aulast%3DPrice%26aufirst%3DM.%2BT.%26aulast%3DWang%26aufirst%3DG.%2BJ.%26aulast%3DLabruyere%26aufirst%3DJ.%26atitle%3DExcitotoxicity%2520of%2520L-dopa%2520and%25206-OH-dopa%253A%2520implications%2520for%2520Parkinson%25E2%2580%2599s%2520and%2520Huntington%25E2%2580%2599s%2520diseases%26jtitle%3DExp.%2520Neurol.%26date%3D1990%26volume%3D108%26issue%3D3%26spage%3D269%26epage%3D272%26doi%3D10.1016%2F0014-4886%2890%2990134-E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goyal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanamshet, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazina, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spoonamore, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmitte, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cocklin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skorski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazin, A. V.</span></span> <span> </span><span class="NLM_article-title">Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>44</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">4189</span>â <span class="NLM_lpage">4199</span>, <span class="refDoi">Â DOI: 10.1093/nar/gkw087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1093%2Fnar%2Fgkw087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=26873923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFSisLvN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2016&pages=4189-4199&issue=9&author=F.+Huangauthor=N.+Goyalauthor=K.+Sullivanauthor=K.+Hanamshetauthor=M.+Patelauthor=O.+M.+Mazinaauthor=C.+X.+Wangauthor=W.+F.+Anauthor=J.+Spoonamoreauthor=S.+Metkarauthor=K.+A.+Emmitteauthor=S.+Cocklinauthor=T.+Skorskiauthor=A.+V.+Mazin&title=Targeting+BRCA1-+and+BRCA2-deficient+cells+with+RAD52+small+molecule+inhibitors&doi=10.1093%2Fnar%2Fgkw087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors</span></div><div class="casAuthors">Huang, Fei; Goyal, Nadish; Sullivan, Katherine; Hanamshet, Kritika; Patel, Mikir; Mazina, Olga M.; Wang, Charles X.; An, W. Frank; Spoonamore, James; Metkar, Shailesh; Emmitte, Kyle A.; Cocklin, Simon; Skorski, Tomasz; Mazin, Alexander V.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4189-4199</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">RAD52 is a member of the homologous recombination (HR) pathway that is important for maintenance of genome integrity.  While single RAD52 mutations show no significant phenotype in mammals, their combination with mutations in genes that cause hereditary breast cancer and ovarian cancer like BRCA1, BRCA2, PALB2 and RAD51C are lethal.  Consequently, RAD52 may represent an important target for cancer therapy.  In vitro, RAD52 has ss-DNA annealing and DNA strand exchange activities.  Here, to identify small mol. inhibitors of RAD52 we screened a 372,903-compd. library using a fluorescence-quenching assay for ssDNA annealing activity of RAD52.  The obtained 70 putative inhibitors were further characterized using biochem. and cell-based assays.  As a result, we identified compds. that specifically inhibit the biochem. activities of RAD52, suppress growth of BRCA1- and BRCA2-deficient cells and inhibit RAD52-dependent single-strand annealing (SSA) in human cells.  We will use these compds. for development of novel cancer therapy and as a probe to study mechanisms of DNA repair.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkx222q1LMmLVg90H21EOLACvtfcHk0ljEQCKawMUR7A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFSisLvN&md5=be5d7e3c4195a3de90e2f45218af8d7d</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkw087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkw087%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DF.%26aulast%3DGoyal%26aufirst%3DN.%26aulast%3DSullivan%26aufirst%3DK.%26aulast%3DHanamshet%26aufirst%3DK.%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DMazina%26aufirst%3DO.%2BM.%26aulast%3DWang%26aufirst%3DC.%2BX.%26aulast%3DAn%26aufirst%3DW.%2BF.%26aulast%3DSpoonamore%26aufirst%3DJ.%26aulast%3DMetkar%26aufirst%3DS.%26aulast%3DEmmitte%26aufirst%3DK.%2BA.%26aulast%3DCocklin%26aufirst%3DS.%26aulast%3DSkorski%26aufirst%3DT.%26aulast%3DMazin%26aufirst%3DA.%2BV.%26atitle%3DTargeting%2520BRCA1-%2520and%2520BRCA2-deficient%2520cells%2520with%2520RAD52%2520small%2520molecule%2520inhibitors%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2016%26volume%3D44%26issue%3D9%26spage%3D4189%26epage%3D4199%26doi%3D10.1093%2Fnar%2Fgkw087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hengel, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malacaria, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Folly da Silva Constantino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bain, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pichierri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spies, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spies, M.</span></span> <span> </span><span class="NLM_article-title">Small-molecule inhibitors identify the RAD52-ssDNA interaction as critical for recovery from replication stress and for survival of BRCA2 deficient cells</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">e14740</span> <span class="refDoi">Â DOI: 10.7554/eLife.14740</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.7554%2FeLife.14740" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=27434671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmslahtLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&author=S.+R.+Hengelauthor=E.+Malacariaauthor=L.+Folly+da+Silva+Constantinoauthor=F.+E.+Bainauthor=A.+Diazauthor=B.+G.+Kochauthor=L.+Yuauthor=M.+Wuauthor=P.+Pichierriauthor=M.+A.+Spiesauthor=M.+Spies&title=Small-molecule+inhibitors+identify+the+RAD52-ssDNA+interaction+as+critical+for+recovery+from+replication+stress+and+for+survival+of+BRCA2+deficient+cells&doi=10.7554%2FeLife.14740"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule inhibitors identify the RAD52-ssDNA interaction as critical for recovery from replication stress and for survival of BRCA2 deficient cells</span></div><div class="casAuthors">Hengel, Sarah R.; Malacaria, Eva; Constantino, Laura Folly da Silva; Bain, Fletcher E.; Diaz, Andrea; Koch, Brandon G.; Yu, Liping; Wu, Meng; Pichierri, Pietro; Spies, M. Ashley; Spies, Maria</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e14740/1-e14740/30</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">The DNA repair protein RAD52 is an emerging therapeutic target of high importance for BRCA-deficient tumors.  Depletion of RAD52 is synthetically lethal with defects in tumor suppressors BRCA1, BRCA2 and PALB2.  RAD52 also participates in recovery of the stalled replication forks.  Anticipating that ssDNA binding activity underlies the RAD52 cellular functions, we carried out a high throughput screening campaign to identify compds. that disrupt the RAD52-ssDNA interaction.  Lead compds. were confirmed as RAD52 inhibitors in biochem. assays.  Computational anal. predicted that these inhibitors bind within the ssDNA-binding groove of the RAD52 oligomeric ring.  The nature of the inhibtor-RAD52 complex was validated through an in silico screening campaign, culminating in the discovery of an addnl. RAD52 inhibitor.  Cellular studies with our inhibitors showed that the RAD52-ssDNA interaction enables its function at stalled replication forks, and that the inhibition of RAD52-ssDNA binding acts additively with BRCA2 or MUS81 depletion in cell killing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb53M_Y1A5NrVg90H21EOLACvtfcHk0lgpU71nIyiq-w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmslahtLc%253D&md5=1b2e48184b06ceab1655578b8e5bc7cd</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.7554%2FeLife.14740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.14740%26sid%3Dliteratum%253Aachs%26aulast%3DHengel%26aufirst%3DS.%2BR.%26aulast%3DMalacaria%26aufirst%3DE.%26aulast%3DFolly%2Bda%2BSilva%2BConstantino%26aufirst%3DL.%26aulast%3DBain%26aufirst%3DF.%2BE.%26aulast%3DDiaz%26aufirst%3DA.%26aulast%3DKoch%26aufirst%3DB.%2BG.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DM.%26aulast%3DPichierri%26aufirst%3DP.%26aulast%3DSpies%26aufirst%3DM.%2BA.%26aulast%3DSpies%26aufirst%3DM.%26atitle%3DSmall-molecule%2520inhibitors%2520identify%2520the%2520RAD52-ssDNA%2520interaction%2520as%2520critical%2520for%2520recovery%2520from%2520replication%2520stress%2520and%2520for%2520survival%2520of%2520BRCA2%2520deficient%2520cells%26jtitle%3DeLife%26date%3D2016%26volume%3D5%26doi%3D10.7554%2FeLife.14740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murfuni, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basile, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanyam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malacaria, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bignami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spies, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franchitto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pichierri, P.</span></span> <span> </span><span class="NLM_article-title">Survival of the replication checkpoint deficient cells requires MUS81-RAD52 function</span>. <i>PLoS Genet.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">10</span>), <span class="NLM_elocation-id">e1003910</span> <span class="refDoi">Â DOI: 10.1371/journal.pgen.1003910</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1371%2Fjournal.pgen.1003910" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=24204313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFKqs7jN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&issue=10&author=I.+Murfuniauthor=G.+Basileauthor=S.+Subramanyamauthor=E.+Malacariaauthor=M.+Bignamiauthor=M.+Spiesauthor=A.+Franchittoauthor=P.+Pichierri&title=Survival+of+the+replication+checkpoint+deficient+cells+requires+MUS81-RAD52+function&doi=10.1371%2Fjournal.pgen.1003910"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Survival of the replication checkpoint deficient cells requires MUS81-RAD52 function</span></div><div class="casAuthors">Murfuni, Ivana; Basile, Giorgia; Subramanyam, Shyamal; Malacaria, Eva; Bignami, Margherita; Spies, Maria; Franchitto, Annapaola; Pichierri, Pietro</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Genetics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e1003910/1-e1003910/21, 21 pp.</span>CODEN:
                <span class="NLM_cas:coden">PGLEB5</span>;
        ISSN:<span class="NLM_cas:issn">1553-7404</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">In checkpoint-deficient cells, DNA double-strand breaks (DSBs) are produced during replication by the structure-specific endonuclease MUS81.  The mechanism underlying MUS81-dependent cleavage, and the effect on chromosome integrity and viability of checkpoint deficient cells is only partly understood, esp. in human cells.  Here, we show that MUS81-induced DSBs are specifically triggered by CHK1 inhibition in a manner that is unrelated to the loss of RAD51, and does not involve formation of a RAD51 substrate.  Indeed, CHK1 deficiency results in the formation of a RAD52-dependent structure that is cleaved by MUS81.  Moreover, in CHK1-deficient cells depletion of RAD52, but not of MUS81, rescues chromosome instability obsd. after replication fork stalling.  However, when RAD52 is down-regulated, recovery from replication stress requires MUS81, and loss of both these proteins results in massive cell death that can be suppressed by RAD51 depletion.  Our findings reveal a novel RAD52/MUS81-dependent mechanism that promotes cell viability and genome integrity in checkpoint-deficient cells, and disclose the involvement of MUS81 to multiple processes after replication stress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwrq-97V9t37Vg90H21EOLACvtfcHk0lgpU71nIyiq-w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFKqs7jN&md5=83f809637973fa264443aea7de37433c</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pgen.1003910&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pgen.1003910%26sid%3Dliteratum%253Aachs%26aulast%3DMurfuni%26aufirst%3DI.%26aulast%3DBasile%26aufirst%3DG.%26aulast%3DSubramanyam%26aufirst%3DS.%26aulast%3DMalacaria%26aufirst%3DE.%26aulast%3DBignami%26aufirst%3DM.%26aulast%3DSpies%26aufirst%3DM.%26aulast%3DFranchitto%26aufirst%3DA.%26aulast%3DPichierri%26aufirst%3DP.%26atitle%3DSurvival%2520of%2520the%2520replication%2520checkpoint%2520deficient%2520cells%2520requires%2520MUS81-RAD52%2520function%26jtitle%3DPLoS%2520Genet.%26date%3D2013%26volume%3D9%26issue%3D10%26doi%3D10.1371%2Fjournal.pgen.1003910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span> <span> </span><span class="NLM_article-title">Compound F779-0434 causes synthetic lethality in BRCA2-deficient cancer cells by disrupting RAD52âssDNA association</span>. <i>RSC Adv.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">34</span>),  <span class="NLM_fpage">18859</span>â <span class="NLM_lpage">18869</span>, <span class="refDoi">Â DOI: 10.1039/C8RA01919C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1039%2FC8RA01919C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpvFWku74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=18859-18869&issue=34&author=J.+Liauthor=Q.+Yangauthor=Y.+Zhangauthor=K.+Huangauthor=R.+Sunauthor=Q.+Zhao&title=Compound+F779-0434+causes+synthetic+lethality+in+BRCA2-deficient+cancer+cells+by+disrupting+RAD52%E2%80%93ssDNA+association&doi=10.1039%2FC8RA01919C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Compound F779-0434 causes synthetic lethality in BRCA2-deficient cancer cells by disrupting RAD52-ssDNA association</span></div><div class="casAuthors">Li, Jian; Yang, Qianye; Zhang, Yang; Huang, Kejia; Sun, Rong; Zhao, Qi</div><div class="citationInfo"><span class="NLM_cas:title">RSC Advances</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">18859-18869</span>CODEN:
                <span class="NLM_cas:coden">RSCACL</span>;
        ISSN:<span class="NLM_cas:issn">2046-2069</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Maintenance of genomic integrity is essential for the survival of all organisms.  Homologous recombination (HR) is the major pathway for high-fidelity repair of DNA double-stranded breaks (DSBs).  In addn. to the classic BRCA-RAD51 pathway, another secondary HR sub-pathway dependent on RAD52 has been suggested to be functioning in mammalian cells.  Importantly, RAD52 has been shown to be synthetically lethal to BRCA1/2-deficient cells, rendering RAD52 to be a desirable target in cancer therapy.  In the current study, we performed a structure-based virtual screening of 47 737 drug-like compds. to identify RAD52-specific inhibitors.  The top ranked virtual screening hits were further characterized using mol. dynamics simulation and biochem. and cell-based assays.  We found that one compd., namely, F779-0434 specifically suppressed the growth of BRCA2-deficient cells and disrupted RAD52-ssDNA interaction in vitro.  This RAD52-specific inhibitor identified in the current study is a promising compd. for targeted cancer therapy, and it can also be used as a probe to study the mechanisms of DNA repair in human cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIn2jOn1KT-bVg90H21EOLACvtfcHk0liDfFFoB0-QSw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpvFWku74%253D&md5=fb396904e27644dc8ee99613ed49c216</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1039%2FC8RA01919C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8RA01919C%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DK.%26aulast%3DSun%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DQ.%26atitle%3DCompound%2520F779-0434%2520causes%2520synthetic%2520lethality%2520in%2520BRCA2-deficient%2520cancer%2520cells%2520by%2520disrupting%2520RAD52%25E2%2580%2593ssDNA%2520association%26jtitle%3DRSC%2520Adv.%26date%3D2018%26volume%3D8%26issue%3D34%26spage%3D18859%26epage%3D18869%26doi%3D10.1039%2FC8RA01919C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coley, W. B.,  II.</span></span> <span> </span><span class="NLM_article-title">Contribution to the knowledge of sarcoma</span>. <i>Ann. Surg.</i> <span class="NLM_year" style="font-weight: bold;">1891</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">199</span>â <span class="NLM_lpage">220</span>, <span class="refDoi">Â DOI: 10.1097/00000658-189112000-00015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1097%2F00000658-189112000-00015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=17859590" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A280%3ADC%252BD2srksVKlsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1891&pages=199-220&issue=3&author=W.+B.+Coley&title=Contribution+to+the+knowledge+of+sarcoma&doi=10.1097%2F00000658-189112000-00015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">II. Contribution to the Knowledge of Sarcoma</span></div><div class="casAuthors">Coley W B</div><div class="citationInfo"><span class="NLM_cas:title">Annals of surgery</span>
        (<span class="NLM_cas:date">1891</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">199-220</span>
        ISSN:<span class="NLM_cas:issn">0003-4932</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRo-f4FsyvzhTQLBVDQn4bCfW6udTcc2eZAcBLUphK2tbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2srksVKlsg%253D%253D&md5=41f295141a7469993cfd74031506e71d</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1097%2F00000658-189112000-00015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00000658-189112000-00015%26sid%3Dliteratum%253Aachs%26aulast%3DColey%26aufirst%3DW.%2BB.%26atitle%3DContribution%2520to%2520the%2520knowledge%2520of%2520sarcoma%26jtitle%3DAnn.%2520Surg.%26date%3D1891%26volume%3D14%26issue%3D3%26spage%3D199%26epage%3D220%26doi%3D10.1097%2F00000658-189112000-00015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">Application of PD-1 blockade in cancer immunotherapy</span>. <i>Comput. Struct. Biotechnol. J.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">661</span>â <span class="NLM_lpage">674</span>, <span class="refDoi">Â DOI: 10.1016/j.csbj.2019.03.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.csbj.2019.03.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=31205619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFGqtrzL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2019&pages=661-674&author=X.+Wuauthor=Z.+Guauthor=Y.+Chenauthor=B.+Chenauthor=W.+Chenauthor=L.+Wengauthor=X.+Liu&title=Application+of+PD-1+blockade+in+cancer+immunotherapy&doi=10.1016%2Fj.csbj.2019.03.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Application of PD-1 Blockade in Cancer Immunotherapy</span></div><div class="casAuthors">Wu, Xiaomo; Gu, Zhongkai; Chen, Yang; Chen, Borui; Chen, Wei; Weng, Liqiang; Liu, Xiaolong</div><div class="citationInfo"><span class="NLM_cas:title">Computational and Structural Biotechnology Journal</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">661-674</span>CODEN:
                <span class="NLM_cas:coden">CSBJAC</span>;
        ISSN:<span class="NLM_cas:issn">2001-0370</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The programmed cell death protein 1 (PD-1) pathway has received considerable attention due to its role in eliciting the immune checkpoint response of T cells, resulting in tumor cells capable of evading immune surveillance and being highly refractory to conventional chemotherapy.  Application of anti-PD-1/PD-L1 antibodies as checkpoint inhibitors is rapidly becoming a promising therapeutic approach in treating tumors, and some of them have successfully been commercialized in the past few years.  However, not all patients show complete responses and adverse events have been noted, suggesting a better understanding of PD-1 pathway mediated immunosuppression is needed to predict patient response and improve treatment efficacy.  Here, we review the progresses on the studies of the mechanistic role of PD-1 pathway in the tumor immune evasion, recent clin. development and commercialization of PD-1 pathway inhibitors, the toxicities assocd. with PD-1 blockade obsd. in clin. trials as well as how to improve therapeutic efficacy and safety of cancer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdmCsowbiei7Vg90H21EOLACvtfcHk0lijEKzfavBb9Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFGqtrzL&md5=a9ebe11e2901ed40ce38edfa607ec5e6</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1016%2Fj.csbj.2019.03.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.csbj.2019.03.006%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DX.%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DWeng%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DApplication%2520of%2520PD-1%2520blockade%2520in%2520cancer%2520immunotherapy%26jtitle%3DComput.%2520Struct.%2520Biotechnol.%2520J.%26date%3D2019%26volume%3D17%26spage%3D661%26epage%3D674%26doi%3D10.1016%2Fj.csbj.2019.03.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K.</span></span> <span> </span><span class="NLM_article-title">Prospects for combining immune checkpoint blockade with PARP inhibition</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">98</span>, <span class="refDoi">Â DOI: 10.1186/s13045-019-0784-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1186%2Fs13045-019-0784-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=31521196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A280%3ADC%252BB3MroslyrsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&pages=98&issue=1&author=A.+Liauthor=M.+Yiauthor=S.+Qinauthor=Q.+Chuauthor=S.+Luoauthor=K.+Wu&title=Prospects+for+combining+immune+checkpoint+blockade+with+PARP+inhibition&doi=10.1186%2Fs13045-019-0784-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Prospects for combining immune checkpoint blockade with PARP inhibition</span></div><div class="casAuthors">Li Anping; Luo Suxia; Wu Kongming; Yi Ming; Qin Shuang; Chu Qian; Wu Kongming</div><div class="citationInfo"><span class="NLM_cas:title">Journal of hematology & oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">98</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The immunogenicity of a cancer cell is derived from accumulated somatic mutations.  However, on the contrary to increased immunogenicity, anti-cancer immune response tends to be feeble.  This impaired anti-cancer immunity could be attributed to multiple factors including loss of immunodominant epitopes, downregulation of major histocompatibility complex, and immunosuppressive microenvironment, as well as aberrant negative co-stimulatory signals.  Immune checkpoint inhibitors block negative co-stimulatory signals such as programmed cell death-1 and cytotoxic T-lymphocyte-associated protein 4, ultimately reactivating anti-cancer immunity.  Immune checkpoint inhibitors elicit potent anti-cancer effect and have been approved for multiple cancers.  Nevertheless, there still are significant potential improvements for the applications of checkpoint inhibitor, especially considering frequent resistance.  Recent studies demonstrated that additional PARP inhibition could alleviate resistance and enhance efficacy of immune checkpoint blockade therapy via promoting cross-presentation and modifying immune microenvironment.  We proposed that PARP inhibitors could enhance the priming and tumor-killing activities of T cell, boost the whole cancer-immunity cycle, and thereby improve the response to immune checkpoint blockade.  In this review, we focused the latest understanding of the effect of PARP inhibitors on anti-cancer immunity and PARP inhibitors combining immune checkpoint blockade therapy.  Moreover, we summarized the preclinical and clinical evidence and discussed the feasibility of this combination therapy in future clinical practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT02g9Y5ozDhpSWdIdmEou5fW6udTcc2eY7YEShug_-LLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MroslyrsQ%253D%253D&md5=a1a2183aca7ccdf41862a284ae9af48e</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1186%2Fs13045-019-0784-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-019-0784-8%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DA.%26aulast%3DYi%26aufirst%3DM.%26aulast%3DQin%26aufirst%3DS.%26aulast%3DChu%26aufirst%3DQ.%26aulast%3DLuo%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DK.%26atitle%3DProspects%2520for%2520combining%2520immune%2520checkpoint%2520blockade%2520with%2520PARP%2520inhibition%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2019%26volume%3D12%26issue%3D1%26spage%3D98%26doi%3D10.1186%2Fs13045-019-0784-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arun, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hortobagyi, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, M. C.</span></span> <span> </span><span class="NLM_article-title">PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">3711</span>â <span class="NLM_lpage">3720</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-16-3215</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F1078-0432.CCR-16-3215" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=28167507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFKiurfL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=3711-3720&issue=14&author=S.+Jiaoauthor=W.+Xiaauthor=H.+Yamaguchiauthor=Y.+Weiauthor=M.+K.+Chenauthor=J.+M.+Hsuauthor=J.+L.+Hsuauthor=W.+H.+Yuauthor=Y.+Duauthor=H.+H.+Leeauthor=C.+W.+Liauthor=C.+K.+Chouauthor=S.+O.+Limauthor=S.+S.+Changauthor=J.+Littonauthor=B.+Arunauthor=G.+N.+Hortobagyiauthor=M.+C.+Hung&title=PARP+inhibitor+upregulates+PD-L1+expression+and+enhances+cancer-associated+immunosuppression&doi=10.1158%2F1078-0432.CCR-16-3215"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression</span></div><div class="casAuthors">Jiao, Shiping; Xia, Weiya; Yamaguchi, Hirohito; Wei, Yongkun; Chen, Mei-Kuang; Hsu, Jung-Mao; Hsu, Jennifer L.; Yu, Wen-Hsuan; Du, Yi; Lee, Heng-Huan; Li, Chia-Wei; Chou, Chao-Kai; Lim, Seung-Oe; Chang, Shih-Shin; Litton, Jennifer; Arun, Banu; Hortobagyi, Gabriel N.; Hung, Mien-Chie</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3711-3720</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">To explore whether a cross-talk exists between PARP inhibition and PD-L1/PD-1 immune checkpoint axis, and det. whether blockade of PD-L1/PD-1 potentiates PARP inhibitor (PARPi) in tumor suppression.  Breast cancer cell lines, xenograft tumors, and syngeneic tumors treated with PARPi were assessed for PD-L1 expression by immunoblotting, IHC, and FACS analyses.  The phospho-kinase antibody array screen was used to explore the underlying mechanism of PARPi-induced PD-L1 upregulation.  The therapeutic efficacy of PARPi alone, PD-L1 blockade alone, or their combination was tested in a syngeneic tumor model.  The tumor-infiltrating lymphocytes and tumor cells isolated from syngeneic tumors were analyzed by CyTOF and FACS to evaluate the activity of antitumor immunity in the tumor microenvironment.  PARPi upregulated PD-L1 expression in breast cancer cell lines and animal models.  Mechanistically, PARPi inactivated GSK3Î², which in turn enhanced PARPi-mediated PD-L1 upregulation.  PARPi attenuated anticancer immunity via upregulation of PD-L1, and blockade of PD-L1 resensitized PARPi-treated cancer cells to T-cell killing.  The combination of PARPi and anti-PD-L1 therapy compared with each agent alone significantly increased the therapeutic efficacy in vivo.  Our study demonstrates a cross-talk between PARPi and tumor-assocd. immunosuppression and provides evidence to support the combination of PARPi and PD-L1 or PD-1 immune checkpoint blockade as a potential therapeutic approach to treat breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7F64RimeUWrVg90H21EOLACvtfcHk0lijEKzfavBb9Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFKiurfL&md5=21c11c52b9b5a6a7bad9c2e743a7a22c</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-3215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-3215%26sid%3Dliteratum%253Aachs%26aulast%3DJiao%26aufirst%3DS.%26aulast%3DXia%26aufirst%3DW.%26aulast%3DYamaguchi%26aufirst%3DH.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DM.%2BK.%26aulast%3DHsu%26aufirst%3DJ.%2BM.%26aulast%3DHsu%26aufirst%3DJ.%2BL.%26aulast%3DYu%26aufirst%3DW.%2BH.%26aulast%3DDu%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DH.%2BH.%26aulast%3DLi%26aufirst%3DC.%2BW.%26aulast%3DChou%26aufirst%3DC.%2BK.%26aulast%3DLim%26aufirst%3DS.%2BO.%26aulast%3DChang%26aufirst%3DS.%2BS.%26aulast%3DLitton%26aufirst%3DJ.%26aulast%3DArun%26aufirst%3DB.%26aulast%3DHortobagyi%26aufirst%3DG.%2BN.%26aulast%3DHung%26aufirst%3DM.%2BC.%26atitle%3DPARP%2520inhibitor%2520upregulates%2520PD-L1%2520expression%2520and%2520enhances%2520cancer-associated%2520immunosuppression%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26issue%3D14%26spage%3D3711%26epage%3D3720%26doi%3D10.1158%2F1078-0432.CCR-16-3215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Le Meur, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gentleman, R.</span></span> <span> </span><span class="NLM_article-title">Modeling synthetic lethality</span>. <i>Genome Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">9</span>), <span class="NLM_elocation-id">R135</span> <span class="refDoi">Â DOI: 10.1186/gb-2008-9-9-r135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1186%2Fgb-2008-9-9-r135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=18789146" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&issue=9&author=N.+Le+Meurauthor=R.+Gentleman&title=Modeling+synthetic+lethality&doi=10.1186%2Fgb-2008-9-9-r135"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1186%2Fgb-2008-9-9-r135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fgb-2008-9-9-r135%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BMeur%26aufirst%3DN.%26aulast%3DGentleman%26aufirst%3DR.%26atitle%3DModeling%2520synthetic%2520lethality%26jtitle%3DGenome%2520Biol.%26date%3D2008%26volume%3D9%26issue%3D9%26doi%3D10.1186%2Fgb-2008-9-9-r135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, E. R.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Weck, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlabach, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mavrakis, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belur, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castelletti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frias, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gampa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golji, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kao, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Megel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramadan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruddy, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silver, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sovath, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stump, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widmer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramowski, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ackley, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernard, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brachmann, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buxton, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caothien, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caushi, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes-Cros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">deBeaumont, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delaunay, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desplat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwoske, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eldridge, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farsidjani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flemming, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forrester, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galli, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauter, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibaja, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattenberger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hood, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurov, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jagani, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapoor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loo, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macchi, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAllister, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagliarini, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phadke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Repko, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schouwey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shanahan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamm, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stucke, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiedt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varadarajan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatesan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitari, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallroth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mickanin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myer, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bitter, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lees, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kauffmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stegmeier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmelzle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span> <span> </span><span class="NLM_article-title">Project DRIVE: A compendium of cancer dependencies and synthetic lethal relationships uncovered by large-scale, deep RNAi screening</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>170</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">577</span>â <span class="NLM_lpage">592</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2017.07.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.cell.2017.07.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=28753431" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1GisLvI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2017&pages=577-592&issue=3&author=E.+R.+McDonaldauthor=A.+de+Weckauthor=M.+R.+Schlabachauthor=E.+Billyauthor=K.+J.+Mavrakisauthor=G.+R.+Hoffmanauthor=D.+Belurauthor=D.+Castellettiauthor=E.+Friasauthor=K.+Gampaauthor=J.+Goljiauthor=I.+Kaoauthor=L.+Liauthor=P.+Megelauthor=T.+A.+Perkinsauthor=N.+Ramadanauthor=D.+A.+Ruddyauthor=S.+J.+Silverauthor=S.+Sovathauthor=M.+Stumpauthor=O.+Weberauthor=R.+Widmerauthor=J.+Yuauthor=K.+Yuauthor=Y.+Yueauthor=D.+Abramowskiauthor=E.+Ackleyauthor=R.+Barrettauthor=J.+Bergerauthor=J.+L.+Bernardauthor=R.+Billigauthor=S.+M.+Brachmannauthor=F.+Buxtonauthor=R.+Caothienauthor=J.+X.+Caushiauthor=F.+S.+Chungauthor=M.+Cortes-Crosauthor=R.+S.+deBeaumontauthor=C.+Delaunayauthor=A.+Desplatauthor=W.+Duongauthor=D.+A.+Dwoskeauthor=R.+S.+Eldridgeauthor=A.+Farsidjaniauthor=F.+Fengauthor=J.+Fengauthor=D.+Flemmingauthor=W.+Forresterauthor=G.+G.+Galliauthor=Z.+Gaoauthor=F.+Gauterauthor=V.+Gibajaauthor=K.+Haasauthor=M.+Hattenbergerauthor=T.+Hoodauthor=K.+E.+Hurovauthor=Z.+Jaganiauthor=M.+Jenalauthor=J.+A.+Johnsonauthor=M.+D.+Jonesauthor=A.+Kapoorauthor=J.+Kornauthor=J.+Liuauthor=Q.+Liuauthor=S.+Liuauthor=Y.+Liuauthor=A.+T.+Looauthor=K.+J.+Macchiauthor=T.+Martinauthor=G.+McAllisterauthor=A.+Meyerauthor=S.+Molleauthor=R.+A.+Pagliariniauthor=T.+Phadkeauthor=B.+Repkoauthor=T.+Schouweyauthor=F.+Shanahanauthor=Q.+Shenauthor=C.+Stammauthor=C.+Stephanauthor=V.+M.+Stuckeauthor=R.+Tiedtauthor=M.+Varadarajanauthor=K.+Venkatesanauthor=A.+C.+Vitariauthor=M.+Wallrothauthor=J.+Weilerauthor=J.+Zhangauthor=C.+Mickaninauthor=V.+E.+Myerauthor=J.+A.+Porterauthor=A.+Laiauthor=H.+Bitterauthor=E.+Leesauthor=N.+Keenauthor=A.+Kauffmannauthor=F.+Stegmeierauthor=F.+Hofmannauthor=T.+Schmelzleauthor=W.+R.+Sellers&title=Project+DRIVE%3A+A+compendium+of+cancer+dependencies+and+synthetic+lethal+relationships+uncovered+by+large-scale%2C+deep+RNAi+screening&doi=10.1016%2Fj.cell.2017.07.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Project DRIVE: A compendium of cancer dependencies and synthetic lethal relationships uncovered by large-scale, deep RNAi screening</span></div><div class="casAuthors">McDonald, E. Robert, III; de Weck, Antoine; Schlabach, Michael R.; Billy, Eric; Mavrakis, Konstantinos J.; Hoffman, Gregory R.; Belur, Dhiren; Castelletti, Deborah; Frias, Elizabeth; Gampa, Kalyani; Golji, Javad; Kao, Iris; Li, Li; Megel, Philippe; Perkins, Thomas A.; Ramadan, Nadire; Ruddy, David A.; Silver, Serena J.; Sovath, Sosathya; Stump, Mark; Weber, Odile; Widmer, Roland; Yu, Jianjun; Yu, Kristine; Yue, Yingzi; Abramowski, Dorothee; Ackley, Elizabeth; Barrett, Rosemary; Berger, Joel; Bernard, Julie L.; Billig, Rebecca; Brachmann, Saskia M.; Buxton, Frank; Caothien, Roger; Caushi, Justina X.; Chung, Franklin S.; Cortes-Cros, Marta; de Beaumont, Rosalie S.; Delaunay, Clara; Desplat, Aurore; Duong, William; Dwoske, Donald A.; Eldridge, Richard S.; Farsidjani, Ali; Feng, Fei; Feng, Jia Jia; Flemming, Daisy; Forrester, William; Galli, Giorgio G.; Gao, Zhenhai; Gauter, Francois; Gibaja, Veronica; Haas, Kristy; Hattenberger, Marc; Hood, Tami; Hurov, Kristen E.; Jagani, Zainab; Jenal, Mathias; Johnson, Jennifer A.; Jones, Michael D.; Kapoor, Avnish; Korn, Joshua; Liu, Jilin; Liu, Qiumei; Liu, Shumei; Liu, Yue; Loo, Alice T.; Macchi, Kaitlin J.; Martin, Typhaine; McAllister, Gregory; Meyer, Amandine; Molle, Sandra; Pagliarini, Raymond A.; Phadke, Tanushree; Repko, Brian; Schouwey, Tanja; Shanahan, Frances; Shen, Qiong; Stamm, Christelle; Stephan, Christine; Stucke, Volker M.; Tiedt, Ralph; Varadarajan, Malini; Venkatesan, Kavitha; Vitari, Alberto C.; Wallroth, Marco; Weiler, Jan; Zhang, Jing; Mickanin, Craig; Myer, Vic E.; Porter, Jeffery A.; Lai, Albert; Bitter, Hans; Lees, Emma; Keen, Nicholas; Kauffmann, Audrey; Stegmeier, Frank; Hofmann, Francesco; Schmelzle, Tobias; Sellers, William R.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">577-592.e10</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Elucidation of the mutational landscape of human cancer has progressed rapidly and been accompanied by the development of therapeutics targeting mutant oncogenes.  However, a comprehensive mapping of cancer dependencies has lagged behind and the discovery of therapeutic targets for counteracting tumor suppressor gene loss is needed.  To identify vulnerabilities relevant to specific cancer subtypes, we conducted a large-scale RNAi screen in which viability effects of mRNA knockdown were assessed for 7837 genes using an av. of 20 shRNAs per gene in 398 cancer cell lines.  We describe findings of this screen, outlining the classes of cancer dependency genes and their relationships to genetic, expression, and lineage features.  In addn., we describe robust gene-interaction networks recapitulating both protein complexes and functional cooperation among complexes and pathways.  This dataset along with a web portal is provided to the community to assist in the discovery and translation of new therapeutic approaches for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokUs33_s2nC7Vg90H21EOLACvtfcHk0lhUlvHTNnEErQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1GisLvI&md5=41592e684cc8f2cd28117cb3303f6120</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.07.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.07.005%26sid%3Dliteratum%253Aachs%26aulast%3DMcDonald%26aufirst%3DE.%2BR.%26aulast%3Dde%2BWeck%26aufirst%3DA.%26aulast%3DSchlabach%26aufirst%3DM.%2BR.%26aulast%3DBilly%26aufirst%3DE.%26aulast%3DMavrakis%26aufirst%3DK.%2BJ.%26aulast%3DHoffman%26aufirst%3DG.%2BR.%26aulast%3DBelur%26aufirst%3DD.%26aulast%3DCastelletti%26aufirst%3DD.%26aulast%3DFrias%26aufirst%3DE.%26aulast%3DGampa%26aufirst%3DK.%26aulast%3DGolji%26aufirst%3DJ.%26aulast%3DKao%26aufirst%3DI.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DMegel%26aufirst%3DP.%26aulast%3DPerkins%26aufirst%3DT.%2BA.%26aulast%3DRamadan%26aufirst%3DN.%26aulast%3DRuddy%26aufirst%3DD.%2BA.%26aulast%3DSilver%26aufirst%3DS.%2BJ.%26aulast%3DSovath%26aufirst%3DS.%26aulast%3DStump%26aufirst%3DM.%26aulast%3DWeber%26aufirst%3DO.%26aulast%3DWidmer%26aufirst%3DR.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DYue%26aufirst%3DY.%26aulast%3DAbramowski%26aufirst%3DD.%26aulast%3DAckley%26aufirst%3DE.%26aulast%3DBarrett%26aufirst%3DR.%26aulast%3DBerger%26aufirst%3DJ.%26aulast%3DBernard%26aufirst%3DJ.%2BL.%26aulast%3DBillig%26aufirst%3DR.%26aulast%3DBrachmann%26aufirst%3DS.%2BM.%26aulast%3DBuxton%26aufirst%3DF.%26aulast%3DCaothien%26aufirst%3DR.%26aulast%3DCaushi%26aufirst%3DJ.%2BX.%26aulast%3DChung%26aufirst%3DF.%2BS.%26aulast%3DCortes-Cros%26aufirst%3DM.%26aulast%3DdeBeaumont%26aufirst%3DR.%2BS.%26aulast%3DDelaunay%26aufirst%3DC.%26aulast%3DDesplat%26aufirst%3DA.%26aulast%3DDuong%26aufirst%3DW.%26aulast%3DDwoske%26aufirst%3DD.%2BA.%26aulast%3DEldridge%26aufirst%3DR.%2BS.%26aulast%3DFarsidjani%26aufirst%3DA.%26aulast%3DFeng%26aufirst%3DF.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DFlemming%26aufirst%3DD.%26aulast%3DForrester%26aufirst%3DW.%26aulast%3DGalli%26aufirst%3DG.%2BG.%26aulast%3DGao%26aufirst%3DZ.%26aulast%3DGauter%26aufirst%3DF.%26aulast%3DGibaja%26aufirst%3DV.%26aulast%3DHaas%26aufirst%3DK.%26aulast%3DHattenberger%26aufirst%3DM.%26aulast%3DHood%26aufirst%3DT.%26aulast%3DHurov%26aufirst%3DK.%2BE.%26aulast%3DJagani%26aufirst%3DZ.%26aulast%3DJenal%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DJ.%2BA.%26aulast%3DJones%26aufirst%3DM.%2BD.%26aulast%3DKapoor%26aufirst%3DA.%26aulast%3DKorn%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLoo%26aufirst%3DA.%2BT.%26aulast%3DMacchi%26aufirst%3DK.%2BJ.%26aulast%3DMartin%26aufirst%3DT.%26aulast%3DMcAllister%26aufirst%3DG.%26aulast%3DMeyer%26aufirst%3DA.%26aulast%3DMolle%26aufirst%3DS.%26aulast%3DPagliarini%26aufirst%3DR.%2BA.%26aulast%3DPhadke%26aufirst%3DT.%26aulast%3DRepko%26aufirst%3DB.%26aulast%3DSchouwey%26aufirst%3DT.%26aulast%3DShanahan%26aufirst%3DF.%26aulast%3DShen%26aufirst%3DQ.%26aulast%3DStamm%26aufirst%3DC.%26aulast%3DStephan%26aufirst%3DC.%26aulast%3DStucke%26aufirst%3DV.%2BM.%26aulast%3DTiedt%26aufirst%3DR.%26aulast%3DVaradarajan%26aufirst%3DM.%26aulast%3DVenkatesan%26aufirst%3DK.%26aulast%3DVitari%26aufirst%3DA.%2BC.%26aulast%3DWallroth%26aufirst%3DM.%26aulast%3DWeiler%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DMickanin%26aufirst%3DC.%26aulast%3DMyer%26aufirst%3DV.%2BE.%26aulast%3DPorter%26aufirst%3DJ.%2BA.%26aulast%3DLai%26aufirst%3DA.%26aulast%3DBitter%26aufirst%3DH.%26aulast%3DLees%26aufirst%3DE.%26aulast%3DKeen%26aufirst%3DN.%26aulast%3DKauffmann%26aufirst%3DA.%26aulast%3DStegmeier%26aufirst%3DF.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DSchmelzle%26aufirst%3DT.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26atitle%3DProject%2520DRIVE%253A%2520A%2520compendium%2520of%2520cancer%2520dependencies%2520and%2520synthetic%2520lethal%2520relationships%2520uncovered%2520by%2520large-scale%252C%2520deep%2520RNAi%2520screening%26jtitle%3DCell%26date%3D2017%26volume%3D170%26issue%3D3%26spage%3D577%26epage%3D592%26doi%3D10.1016%2Fj.cell.2017.07.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beetham, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telford, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Single, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarman, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackovic, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luxenburger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guilford, P.</span></span> <span> </span><span class="NLM_article-title">A high-throughput screen to identify novel synthetic lethal compounds for the treatment of E-cadherin-deficient cells</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">12511</span>, <span class="refDoi">Â DOI: 10.1038/s41598-019-48929-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1038%2Fs41598-019-48929-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=31467357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A280%3ADC%252BB3MrjsVWmtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=12511&issue=1&author=H.+Beethamauthor=A.+Chenauthor=B.+J.+Telfordauthor=A.+Singleauthor=K.+E.+Jarmanauthor=K.+Lackovicauthor=A.+Luxenburgerauthor=P.+Guilford&title=A+high-throughput+screen+to+identify+novel+synthetic+lethal+compounds+for+the+treatment+of+E-cadherin-deficient+cells&doi=10.1038%2Fs41598-019-48929-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">A high-throughput screen to identify novel synthetic lethal compounds for the treatment of E-cadherin-deficient cells</span></div><div class="casAuthors">Beetham Henry; Chen Augustine; Telford Bryony J; Single Andrew; Guilford Parry; Jarman Kate E; Lackovic Kurt; Jarman Kate E; Lackovic Kurt; Luxenburger Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12511</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The cell-cell adhesion protein E-cadherin (CDH1) is a tumor suppressor that is required to maintain cell adhesion, cell polarity and cell survival signalling.  Somatic mutations in CDH1 are common in diffuse gastric cancer (DGC) and lobular breast cancer (LBC).  In addition, germline mutations in CDH1 predispose to the autosomal dominant cancer syndrome Hereditary Diffuse Gastric Cancer (HDGC).  One approach to target cells with mutations in specific tumor suppressor genes is synthetic lethality.  To identify novel synthetic lethal compounds for the treatment of cancers associated with E-cadherin loss, we have undertaken a high-throughput screening campaign of ~114,000 lead-like compounds on an isogenic pair of human mammary epithelial cell lines - with and without CDH1 expression.  This unbiased approach identified 12 novel compounds that preferentially harmed E-cadherin-deficient cells.  Validation of these compounds using both real-time and end-point viability assays identified two novel compounds with significant synthetic lethal activity, thereby demonstrating that E-cadherin loss creates druggable vulnerabilities within tumor cells.  In summary, we have identified novel synthetic lethal compounds that may provide a new strategy for the prevention and treatment of both sporadic and hereditary LBC and DGC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRhgHigE2q0VMjl5L8hwNX0fW6udTcc2eZuwmCRPWP9zLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MrjsVWmtA%253D%253D&md5=c29bb1bc6eb8c9124b310f2ab4d67930</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-48929-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-48929-0%26sid%3Dliteratum%253Aachs%26aulast%3DBeetham%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DTelford%26aufirst%3DB.%2BJ.%26aulast%3DSingle%26aufirst%3DA.%26aulast%3DJarman%26aufirst%3DK.%2BE.%26aulast%3DLackovic%26aufirst%3DK.%26aulast%3DLuxenburger%26aufirst%3DA.%26aulast%3DGuilford%26aufirst%3DP.%26atitle%3DA%2520high-throughput%2520screen%2520to%2520identify%2520novel%2520synthetic%2520lethal%2520compounds%2520for%2520the%2520treatment%2520of%2520E-cadherin-deficient%2520cells%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26issue%3D1%26spage%3D12511%26doi%3D10.1038%2Fs41598-019-48929-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hofree, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ideker, T.</span></span> <span> </span><span class="NLM_article-title">Network-based stratification of tumor mutations</span>. <i>Nat. Methods</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1108</span>â <span class="NLM_lpage">1115</span>, <span class="refDoi">Â DOI: 10.1038/nmeth.2651</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1038%2Fnmeth.2651" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=24037242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVeqsrvM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=1108-1115&issue=11&author=M.+Hofreeauthor=J.+P.+Shenauthor=H.+Carterauthor=A.+Grossauthor=T.+Ideker&title=Network-based+stratification+of+tumor+mutations&doi=10.1038%2Fnmeth.2651"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Network-based stratification of tumor mutations</span></div><div class="casAuthors">Hofree, Matan; Shen, John P.; Carter, Hannah; Gross, Andrew; Ideker, Trey</div><div class="citationInfo"><span class="NLM_cas:title">Nature Methods</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1108-1115</span>CODEN:
                <span class="NLM_cas:coden">NMAEA3</span>;
        ISSN:<span class="NLM_cas:issn">1548-7091</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Many forms of cancer have multiple subtypes with different causes and clin. outcomes.  Somatic tumor genome sequences provide a rich new source of data for uncovering these subtypes but have proven difficult to compare, as two tumors rarely share the same mutations.  Here we introduce network-based stratification (NBS), a method to integrate somatic tumor genomes with gene networks.  This approach allows for stratification of cancer into informative subtypes by clustering together patients with mutations in similar network regions.  We demonstrate NBS in ovarian, uterine and lung cancer cohorts from The Cancer Genome Atlas.  For each tissue, NBS identifies subtypes that are predictive of clin. outcomes such as patient survival, response to therapy or tumor histol.  We identify network regions characteristic of each subtype and show how mutation-derived subtypes can be used to train an mRNA expression signature, which provides similar information in the absence of DNA sequence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpD4Es1VR8In7Vg90H21EOLACvtfcHk0lhznoXnarPCDw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVeqsrvM&md5=4a305ef2d3b1521e344d8895e77efa49</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1038%2Fnmeth.2651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnmeth.2651%26sid%3Dliteratum%253Aachs%26aulast%3DHofree%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DJ.%2BP.%26aulast%3DCarter%26aufirst%3DH.%26aulast%3DGross%26aufirst%3DA.%26aulast%3DIdeker%26aufirst%3DT.%26atitle%3DNetwork-based%2520stratification%2520of%2520tumor%2520mutations%26jtitle%3DNat.%2520Methods%26date%3D2013%26volume%3D10%26issue%3D11%26spage%3D1108%26epage%3D1115%26doi%3D10.1038%2Fnmeth.2651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Y. D.</span></span> <span> </span><span class="NLM_article-title">Identification of synthetic lethality based on a functional network by using machine learning algorithms</span>. <i>J. Cell. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>120</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">405</span>â <span class="NLM_lpage">416</span>, <span class="refDoi">Â DOI: 10.1002/jcb.27395</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1002%2Fjcb.27395" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=30125975" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFequ73E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2019&pages=405-416&issue=1&author=J.+Liauthor=L.+Luauthor=Y.+H.+Zhangauthor=M.+Liuauthor=L.+Chenauthor=T.+Huangauthor=Y.+D.+Cai&title=Identification+of+synthetic+lethality+based+on+a+functional+network+by+using+machine+learning+algorithms&doi=10.1002%2Fjcb.27395"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of synthetic lethality based on a functional network by using machine learning algorithms</span></div><div class="casAuthors">Li, JiaRui; Lu, Lin; Zhang, Yu-Hang; Liu, Min; Chen, Lei; Huang, Tao; Cai, Yu-Dong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Biochemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">405-416</span>CODEN:
                <span class="NLM_cas:coden">JCEBD5</span>;
        ISSN:<span class="NLM_cas:issn">0730-2312</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Synthetic lethality is the synthesis of mutations leading to cell death.  Tumor-specific synthetic lethality has been targeted in research to improve cancer therapy.  With the advances of techniques in mol. biol., such as RNAi and CRISPR/Cas9 gene editing, efforts have been made to systematically identify synthetic lethal interactions, esp. for frequently mutated genes in cancers.  However, elucidating the mechanism of synthetic lethality remains a challenge because of the complexity of its influencing conditions.  In this study, we proposed a new computational method to identify crit. functional features that can accurately predict synthetic lethal interactions.  This method incorporates several machine learning algorithms and encodes protein-coding genes by an enrichment system derived from gene ontol. terms and Kyoto Encyclopedia of Genes and Genomes pathways to represent their functional features.  We built a random forest-based prediction engine by using 2120 selected features and obtained a Matthews correlation coeff. of 0.532.  We examd. the top 15 features and found that most of them have potential roles in synthetic lethality according to previous studies.  These results demonstrate the ability of our proposed method to predict synthetic lethal interactions and provide a basis for further characterization of these particular genetic combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIqf6Yn5s8yrVg90H21EOLACvtfcHk0lhznoXnarPCDw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFequ73E&md5=264fc3080910418aa96659b623b300d4</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1002%2Fjcb.27395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcb.27395%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%2BH.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DCai%26aufirst%3DY.%2BD.%26atitle%3DIdentification%2520of%2520synthetic%2520lethality%2520based%2520on%2520a%2520functional%2520network%2520by%2520using%2520machine%2520learning%2520algorithms%26jtitle%3DJ.%2520Cell.%2520Biochem.%26date%3D2019%26volume%3D120%26issue%3D1%26spage%3D405%26epage%3D416%26doi%3D10.1002%2Fjcb.27395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benstead-Hume, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wooller, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearl, F. M. G.</span></span> <span> </span><span class="NLM_article-title">âBig dataâ approaches for novel anti-cancer drug discovery</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">599</span>â <span class="NLM_lpage">609</span>, <span class="refDoi">Â DOI: 10.1080/17460441.2017.1319356</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1080%2F17460441.2017.1319356" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=28462602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntVaksbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=599-609&issue=6&author=G.+Benstead-Humeauthor=S.+K.+Woollerauthor=F.+M.+G.+Pearl&title=%E2%80%98Big+data%E2%80%99+approaches+for+novel+anti-cancer+drug+discovery&doi=10.1080%2F17460441.2017.1319356"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">'Big data' approaches for novel anti-cancer drug discovery</span></div><div class="casAuthors">Benstead-Hume, Graeme; Wooller, Sarah K.; Pearl, Frances M. G.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">599-609</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  The development of improved cancer therapies is frequently cited as an urgent unmet medical need.  Recent advances in platform technologies and the increasing availability of biol. 'big data' are providing an unparalleled opportunity to systematically identify the key genes and pathways involved in tumorigenesis.  The discoveries made using these new technologies may lead to novel therapeutic interventions.: The authors discuss the current approaches that use 'big data' to identify cancer drivers.  These approaches include the anal. of genomic sequencing data, pathway data, multi-platform data, identifying genetic interactions such as synthetic lethality and using cell line data.  They review how big data is being used to identify novel drug targets.  The authors then provide an overview of the available data repositories and tools being used at the forefront of cancer drug discovery.: Targeted therapies based on the genomic events driving the tumor will eventually inform treatment protocols.  However, using a tailored approach to treat all tumor patients may require developing a large repertoire of targeted drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9PmQgXTfJvrVg90H21EOLACvtfcHk0lhfMSF518xRZQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntVaksbc%253D&md5=cf1b0f7e3b9eb520a51efd2d81803b12</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1080%2F17460441.2017.1319356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17460441.2017.1319356%26sid%3Dliteratum%253Aachs%26aulast%3DBenstead-Hume%26aufirst%3DG.%26aulast%3DWooller%26aufirst%3DS.%2BK.%26aulast%3DPearl%26aufirst%3DF.%2BM.%2BG.%26atitle%3D%25E2%2580%2598Big%2520data%25E2%2580%2599%2520approaches%2520for%2520novel%2520anti-cancer%2520drug%2520discovery%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2017%26volume%3D12%26issue%3D6%26spage%3D599%26epage%3D609%26doi%3D10.1080%2F17460441.2017.1319356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oughtred, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breitkreutz, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rust, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucher, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolas, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâDonnell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAdam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willems, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulombe-Huntington, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatr-Aryamontri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolinski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyers, M.</span></span> <span> </span><span class="NLM_article-title">The BioGRID interaction database: 2019 update</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>47</i></span> (<span class="NLM_issue">D1</span>),  <span class="NLM_fpage">D529</span>â <span class="NLM_lpage">D541</span>, <span class="refDoi">Â DOI: 10.1093/nar/gky1079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1093%2Fnar%2Fgky1079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=30476227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1GqsbfP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2019&pages=D529-D541&issue=D1&author=R.+Oughtredauthor=C.+Starkauthor=B.+J.+Breitkreutzauthor=J.+Rustauthor=L.+Boucherauthor=C.+Changauthor=N.+Kolasauthor=L.+O%E2%80%99Donnellauthor=G.+Leungauthor=R.+McAdamauthor=F.+Zhangauthor=S.+Dolmaauthor=A.+Willemsauthor=J.+Coulombe-Huntingtonauthor=A.+Chatr-Aryamontriauthor=K.+Dolinskiauthor=M.+Tyers&title=The+BioGRID+interaction+database%3A+2019+update&doi=10.1093%2Fnar%2Fgky1079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">The BioGRID interaction database: 2019 update</span></div><div class="casAuthors">Oughtred, Rose; Stark, Chris; Breitkreutz, Bobby-Joe; Rust, Jennifer; Boucher, Lorrie; Chang, Christie; Kolas, Nadine; O'Donnell, Lara; Leung, Genie; McAdam, Rochelle; Zhang, Frederick; Dolma, Sonam; Willems, Andrew; Coulombe-Huntington, Jasmin; Chatr-aryamontri, Andrew; Dolinski, Kara; Tyers, Mike</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">D1</span>),
    <span class="NLM_cas:pages">D529-D541</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">1362-4962</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The Biol. General Repository for Interaction Datasets is an open access database dedicated to the curation and archival storage of protein, genetic and chem. interactions for all major model organism species and humans.  As of Sept. 2018 (build 3.4.164), BioGRID contains records for 1,598 688 biol. interactions manually annotated from 55,809 publications for 71 species, as classified by an updated set of controlled vocabularies for exptl. detection methods.  BioGRID also houses records for >700, 000 post-translational modification sites.  BioGRID now captures chem. interaction data, including chem.-protein interactions for human drug targets drawn from the DrugBank database and manually curated bioactive compds. reported in the literature.  A new dedicated aspect of BioGRID annotates genome-wide CRISPR/Cas9-based screens that report gene-phenotype and gene-gene relationships.  An extension of the BioGRID resource called the Open Repository for CRISPR Screens (ORCS) database currently contains over 500 genome-wide screens carried out in human or mouse cell lines.  All data in BioGRID is made freely available without restriction, is directly downloadable in std. formats and can be readily incorporated into existing applications via our web service platforms.  BioGRID data are also freely distributed through partner model organism databases and meta-databases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeOLWfYFTAqrVg90H21EOLACvtfcHk0lhfMSF518xRZQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1GqsbfP&md5=c113318699cae700308688e95853c56c</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgky1079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgky1079%26sid%3Dliteratum%253Aachs%26aulast%3DOughtred%26aufirst%3DR.%26aulast%3DStark%26aufirst%3DC.%26aulast%3DBreitkreutz%26aufirst%3DB.%2BJ.%26aulast%3DRust%26aufirst%3DJ.%26aulast%3DBoucher%26aufirst%3DL.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DKolas%26aufirst%3DN.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DL.%26aulast%3DLeung%26aufirst%3DG.%26aulast%3DMcAdam%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DDolma%26aufirst%3DS.%26aulast%3DWillems%26aufirst%3DA.%26aulast%3DCoulombe-Huntington%26aufirst%3DJ.%26aulast%3DChatr-Aryamontri%26aufirst%3DA.%26aulast%3DDolinski%26aufirst%3DK.%26aulast%3DTyers%26aufirst%3DM.%26atitle%3DThe%2520BioGRID%2520interaction%2520database%253A%25202019%2520update%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2019%26volume%3D47%26issue%3DD1%26spage%3DD529%26epage%3DD541%26doi%3D10.1093%2Fnar%2Fgky1079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehebauer, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pukala, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blundell, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkitaraman, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyvonen, M.</span></span> <span> </span><span class="NLM_article-title">Using a fragment-based approach to target protein-protein interactions</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">332</span>â <span class="NLM_lpage">342</span>, <span class="refDoi">Â DOI: 10.1002/cbic.201200521</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1002%2Fcbic.201200521" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=23344974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Gks7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=332-342&issue=3&author=D.+E.+Scottauthor=M.+T.+Ehebauerauthor=T.+Pukalaauthor=M.+Marshauthor=T.+L.+Blundellauthor=A.+R.+Venkitaramanauthor=C.+Abellauthor=M.+Hyvonen&title=Using+a+fragment-based+approach+to+target+protein-protein+interactions&doi=10.1002%2Fcbic.201200521"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Using a Fragment-Based Approach To Target Protein-Protein Interactions</span></div><div class="casAuthors">Scott, Duncan E.; Ehebauer, Matthias T.; Pukala, Tara; Marsh, May; Blundell, Tom L.; Venkitaraman, Ashok R.; Abell, Chris; Hyvoenen, Marko</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">332-342</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The ability to identify inhibitors of protein-protein interactions represents a major challenge in modern drug discovery and in the development of tools for chem. biol.  In recent years, fragment-based approaches have emerged as a new methodol. in drug discovery; however, few examples of small mols. that are active against chemotherapeutic targets have been published.  Herein, we describe the fragment-based approach of targeting the interaction between the tumor suppressor BRCA2 and the recombination enzyme RAD51; it makes use of a screening pipeline of biophys. techniques that we expect to be more generally applicable to similar targets.  Disruption of this interaction in vivo is hypothesised to give rise to cellular hypersensitivity to radiation and genotoxic drugs.  We have used protein engineering to create a monomeric form of RAD51 by humanising a thermostable archaeal orthologue, RadA, and used this protein for fragment screening.  The initial fragment hits were thoroughly validated biophys. by isothermal titrn. calorimetry (ITC) and NMR techniques and obsd. by X-ray crystallog. to bind in a shallow surface pocket that is occupied in the native complex by the side chain of a phenylalanine from the conserved FxxA interaction motif found in BRCA2.  This represents the first report of fragments or any small mol. binding at this protein-protein interaction site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1wXYv8oa-xLVg90H21EOLACvtfcHk0lhMge0L_dwrIw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Gks7Y%253D&md5=deca5d3416f3f07e4614007cc76880c9</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201200521&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201200521%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DD.%2BE.%26aulast%3DEhebauer%26aufirst%3DM.%2BT.%26aulast%3DPukala%26aufirst%3DT.%26aulast%3DMarsh%26aufirst%3DM.%26aulast%3DBlundell%26aufirst%3DT.%2BL.%26aulast%3DVenkitaraman%26aufirst%3DA.%2BR.%26aulast%3DAbell%26aufirst%3DC.%26aulast%3DHyvonen%26aufirst%3DM.%26atitle%3DUsing%2520a%2520fragment-based%2520approach%2520to%2520target%2520protein-protein%2520interactions%26jtitle%3DChemBioChem%26date%3D2013%26volume%3D14%26issue%3D3%26spage%3D332%26epage%3D342%26doi%3D10.1002%2Fcbic.201200521" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coyne, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkitaraman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blundell, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyvonen, M.</span></span> <span> </span><span class="NLM_article-title">Small-molecule inhibitors that target protein-protein interactions in the RAD51 family of recombinases</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">296</span>â <span class="NLM_lpage">303</span>, <span class="refDoi">Â DOI: 10.1002/cmdc.201402428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1002%2Fcmdc.201402428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=25470112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVShtr%252FE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=296-303&issue=2&author=D.+E.+Scottauthor=A.+G.+Coyneauthor=A.+Venkitaramanauthor=T.+L.+Blundellauthor=C.+Abellauthor=M.+Hyvonen&title=Small-molecule+inhibitors+that+target+protein-protein+interactions+in+the+RAD51+family+of+recombinases&doi=10.1002%2Fcmdc.201402428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Inhibitors That Target Protein-Protein Interactions in the RAD51 Family of Recombinases</span></div><div class="casAuthors">Scott, Duncan E.; Coyne, Anthony G.; Venkitaraman, Ashok; Blundell, Tom L.; Abell, Chris; Hyvoenen, Marko</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">296-303</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The development of small mols. that inhibit protein-protein interactions continues to be a challenge in chem. biol. and drug discovery.  Herein we report the development of indole-based fragments that bind in a shallow surface pocket of a humanized surrogate of RAD51.  RAD51 is an ATP-dependent recombinase that plays a key role in the repair of double-strand DNA breaks.  It both self-assocs., forming filament structures with DNA, and interacts with the BRCA2 protein through a common "FxxA" tetrapeptide motif.  We elaborated previously identified fragment hits that target the FxxA motif site and developed small-mol. inhibitors that are approx. 500-fold more potent than the initial fragments.  The lead compds. were shown to compete with the BRCA2-derived Ac-FHTA-NH2 peptide and the self-assocn. peptide of RAD51, but they had no effect on ATP binding.  This study is the first reported elaboration of small-mol.-wt. fragments against this challenging target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppzNQlrMDCabVg90H21EOLACvtfcHk0lhMge0L_dwrIw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVShtr%252FE&md5=6e08d0758ee37533018de5e1c28ce596</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201402428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201402428%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DD.%2BE.%26aulast%3DCoyne%26aufirst%3DA.%2BG.%26aulast%3DVenkitaraman%26aufirst%3DA.%26aulast%3DBlundell%26aufirst%3DT.%2BL.%26aulast%3DAbell%26aufirst%3DC.%26aulast%3DHyvonen%26aufirst%3DM.%26atitle%3DSmall-molecule%2520inhibitors%2520that%2520target%2520protein-protein%2520interactions%2520in%2520the%2520RAD51%2520family%2520of%2520recombinases%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26issue%3D2%26spage%3D296%26epage%3D303%26doi%3D10.1002%2Fcmdc.201402428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, L.</span></span> <span> </span><span class="NLM_article-title">Synthetic lethality in drug development: the dawn is coming</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">2129</span>â <span class="NLM_lpage">2132</span>, <span class="refDoi">Â DOI: 10.4155/fmc-2018-0227</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.4155%2Ffmc-2018-0227" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=30043635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1entr%252FI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=2129-2132&issue=18&author=S.+Gaoauthor=L.+Lai&title=Synthetic+lethality+in+drug+development%3A+the+dawn+is+coming&doi=10.4155%2Ffmc-2018-0227"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic lethality in drug development: the dawn is coming</span></div><div class="casAuthors">Gao, Shuaishi; Lai, Luhua</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2129-2132</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  This article discuss about the role of synthetic lethality screening for clin. development and discovery of therapeutic drugs and therapeutic solns. for treatment of complex diseases including prostate cancer in human and Drosophila melanogaster model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwWpGIiqNzAbVg90H21EOLACvtfcHk0lhMge0L_dwrIw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1entr%252FI&md5=c6ae84ac8f197590f7aec362da2bca98</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.4155%2Ffmc-2018-0227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc-2018-0227%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DS.%26aulast%3DLai%26aufirst%3DL.%26atitle%3DSynthetic%2520lethality%2520in%2520drug%2520development%253A%2520the%2520dawn%2520is%2520coming%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2018%26volume%3D10%26issue%3D18%26spage%3D2129%26epage%3D2132%26doi%3D10.4155%2Ffmc-2018-0227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, W.</span></span> <span> </span><span class="NLM_article-title">Genome-wide CRISPR/Cas9 screening for high-throughput functional genomics in human cells</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>1656</i></span>,  <span class="NLM_fpage">175</span>â <span class="NLM_lpage">181</span>, <span class="refDoi">Â DOI: 10.1007/978-1-4939-7237-1_11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1007%2F978-1-4939-7237-1_11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=28808970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVygtLbL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1656&publication_year=2017&pages=175-181&author=S.+Zhuauthor=Y.+Zhouauthor=W.+Wei&title=Genome-wide+CRISPR%2FCas9+screening+for+high-throughput+functional+genomics+in+human+cells&doi=10.1007%2F978-1-4939-7237-1_11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Genome-wide CRISPR/Cas9 screening for high-throughput functional genomics in human cells</span></div><div class="casAuthors">Zhu, Shiyou; Zhou, Yuexin; Wei, Wensheng</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">1656</span>
        (<span class="NLM_cas:issue">Innate Antiviral Immunity</span>),
    <span class="NLM_cas:pages">175-181</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1940-6029</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">It is highly desirable to identify gene's function in a high-throughput fashion, and the CRISPR/Cas9 system has been harnessed to meet such a need.  Here, we describe a general method to generate genome-scale lentiviral single-guide RNA (sgRNA) library and conduct a pooled function-based screening in human cells.  This protocol would be of interest to researchers to rapidly identify genes in a variety of biol. processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrE_GA6Br0tRrVg90H21EOLACvtfcHk0lh0oOIGIbQrBg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVygtLbL&md5=789bbde3f991fc30c9ed5f48e9240de1</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-7237-1_11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4939-7237-1_11%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DWei%26aufirst%3DW.%26atitle%3DGenome-wide%2520CRISPR%252FCas9%2520screening%2520for%2520high-throughput%2520functional%2520genomics%2520in%2520human%2520cells%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2017%26volume%3D1656%26spage%3D175%26epage%3D181%26doi%3D10.1007%2F978-1-4939-7237-1_11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref187"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref187'); return false;" data-citation="" class="refNumLink">187</a></strong><div class="NLM_citation" id="cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navone, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">2451</span>â <span class="NLM_lpage">2463</span>, <span class="refDoi">Â DOI: 10.1038/s41388-018-0606-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1038%2Fs41388-018-0606-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=30532030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVKqtbzK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2019&pages=2451-2463&issue=14&author=C.+Wangauthor=G.+Wangauthor=X.+Fengauthor=P.+Shepherdauthor=J.+Zhangauthor=M.+Tangauthor=Z.+Chenauthor=M.+Srivastavaauthor=M.+E.+McLaughlinauthor=N.+M.+Navoneauthor=G.+T.+Hartauthor=J.+Chen&title=Genome-wide+CRISPR+screens+reveal+synthetic+lethality+of+RNASEH2+deficiency+and+ATR+inhibition&doi=10.1038%2Fs41388-018-0606-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition</span></div><div class="casAuthors">Wang, Chao; Wang, Gang; Feng, Xu; Shepherd, Peter; Zhang, Jie; Tang, Mengfan; Chen, Zhen; Srivastava, Mrinal; McLaughlin, Megan E.; Navone, Nora M.; Hart, Glen Traver; Chen, Junjie</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2451-2463</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Ataxia telangiectasia mutated and RAD3 related (ATR) protein kinase plays crit. roles in ensuring DNA replication, DNA repair, and cell cycle control in response to replication stress, making ATR inhibition a promising therapeutic strategy for cancer treatment.  To identify genes whose loss makes tumor cells hypersensitive to ATR inhibition, we performed CRISPR/Cas9-based whole-genome screens in 3 independent cell lines treated with a highly selective ATR inhibitor, AZD6738.  These screens uncovered a comprehensive genome-wide profile of ATR inhibitor sensitivity.  From the candidate genes, we demonstrated that RNASEH2 deficiency is synthetic lethal with ATR inhibition both in vitro and in vivo.  RNASEH2-deficient cells exhibited elevated levels of DNA damage and, when treated with AZD6738, underwent apoptosis (short-time treated) or senescence (long-time treated).  Notably, RNASEH2 deficiency is frequently found in prostate adenocarcinoma; we found decreased RNASEH2B protein levels in prostate adenocarcinoma patient-derived xenograft (PDX) samples.  Our findings suggest that ATR inhibition may be beneficial for cancer patients with reduced levels of RNASEH2 and that RNASEH2 merits further exploration as a potential biomarker for ATR inhibitor-based therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7pP6ZnD1nMrVg90H21EOLACvtfcHk0lh0oOIGIbQrBg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVKqtbzK&md5=3007fcb24e0eef9c0155d4ec8f68558a</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1038%2Fs41388-018-0606-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41388-018-0606-4%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DFeng%26aufirst%3DX.%26aulast%3DShepherd%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DSrivastava%26aufirst%3DM.%26aulast%3DMcLaughlin%26aufirst%3DM.%2BE.%26aulast%3DNavone%26aufirst%3DN.%2BM.%26aulast%3DHart%26aufirst%3DG.%2BT.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DGenome-wide%2520CRISPR%2520screens%2520reveal%2520synthetic%2520lethality%2520of%2520RNASEH2%2520deficiency%2520and%2520ATR%2520inhibition%26jtitle%3DOncogene%26date%3D2019%26volume%3D38%26issue%3D14%26spage%3D2451%26epage%3D2463%26doi%3D10.1038%2Fs41388-018-0606-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref188"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref188'); return false;" data-citation="" class="refNumLink">188</a></strong><div class="NLM_citation" id="cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stadtmauer, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraietta, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lancaster, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangan, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulikovskaya, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, I.-y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melenhorst, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plesa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shea, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matlawski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaymon, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desjardins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamontagne, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salas-Mckee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fesnak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jadlowsky, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chew, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, W.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hexner, E. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreno, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nobles, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bushman, F. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satpathy, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacey, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">June, C. H.</span></span> <span> </span><span class="NLM_article-title">CRISPR-engineered T cells in patients with refractory cancer</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>367</i></span> (<span class="NLM_issue">6481</span>), <span class="NLM_elocation-id">eaba7365</span> <span class="refDoi">Â DOI: 10.1126/science.aba7365</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1126%2Fscience.aba7365" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=32029687" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2020&issue=6481&author=E.+A.+Stadtmauerauthor=J.+A.+Fraiettaauthor=M.+M.+Davisauthor=A.+D.+Cohenauthor=K.+L.+Weberauthor=E.+Lancasterauthor=P.+A.+Manganauthor=I.+Kulikovskayaauthor=M.+Guptaauthor=F.+Chenauthor=L.+Tianauthor=V.+E.+Gonzalezauthor=J.+Xuauthor=I.-y.+Jungauthor=J.+J.+Melenhorstauthor=G.+Plesaauthor=J.+Sheaauthor=T.+Matlawskiauthor=A.+Cerviniauthor=A.+L.+Gaymonauthor=S.+Desjardinsauthor=A.+Lamontagneauthor=J.+Salas-Mckeeauthor=A.+Fesnakauthor=D.+L.+Siegelauthor=B.+L.+Levineauthor=J.+K.+Jadlowskyauthor=R.+M.+Youngauthor=A.+Chewauthor=W.-T.+Hwangauthor=E.+O.+Hexnerauthor=B.+M.+Carrenoauthor=C.+L.+Noblesauthor=F.+D.+Bushmanauthor=K.+R.+Parkerauthor=Y.+Qiauthor=A.+T.+Satpathyauthor=H.+Y.+Changauthor=Y.+Zhaoauthor=S.+F.+Laceyauthor=C.+H.+June&title=CRISPR-engineered+T+cells+in+patients+with+refractory+cancer&doi=10.1126%2Fscience.aba7365"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1126%2Fscience.aba7365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aba7365%26sid%3Dliteratum%253Aachs%26aulast%3DStadtmauer%26aufirst%3DE.%2BA.%26aulast%3DFraietta%26aufirst%3DJ.%2BA.%26aulast%3DDavis%26aufirst%3DM.%2BM.%26aulast%3DCohen%26aufirst%3DA.%2BD.%26aulast%3DWeber%26aufirst%3DK.%2BL.%26aulast%3DLancaster%26aufirst%3DE.%26aulast%3DMangan%26aufirst%3DP.%2BA.%26aulast%3DKulikovskaya%26aufirst%3DI.%26aulast%3DGupta%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DTian%26aufirst%3DL.%26aulast%3DGonzalez%26aufirst%3DV.%2BE.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DJung%26aufirst%3DI.-y.%26aulast%3DMelenhorst%26aufirst%3DJ.%2BJ.%26aulast%3DPlesa%26aufirst%3DG.%26aulast%3DShea%26aufirst%3DJ.%26aulast%3DMatlawski%26aufirst%3DT.%26aulast%3DCervini%26aufirst%3DA.%26aulast%3DGaymon%26aufirst%3DA.%2BL.%26aulast%3DDesjardins%26aufirst%3DS.%26aulast%3DLamontagne%26aufirst%3DA.%26aulast%3DSalas-Mckee%26aufirst%3DJ.%26aulast%3DFesnak%26aufirst%3DA.%26aulast%3DSiegel%26aufirst%3DD.%2BL.%26aulast%3DLevine%26aufirst%3DB.%2BL.%26aulast%3DJadlowsky%26aufirst%3DJ.%2BK.%26aulast%3DYoung%26aufirst%3DR.%2BM.%26aulast%3DChew%26aufirst%3DA.%26aulast%3DHwang%26aufirst%3DW.-T.%26aulast%3DHexner%26aufirst%3DE.%2BO.%26aulast%3DCarreno%26aufirst%3DB.%2BM.%26aulast%3DNobles%26aufirst%3DC.%2BL.%26aulast%3DBushman%26aufirst%3DF.%2BD.%26aulast%3DParker%26aufirst%3DK.%2BR.%26aulast%3DQi%26aufirst%3DY.%26aulast%3DSatpathy%26aufirst%3DA.%2BT.%26aulast%3DChang%26aufirst%3DH.%2BY.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DLacey%26aufirst%3DS.%2BF.%26aulast%3DJune%26aufirst%3DC.%2BH.%26atitle%3DCRISPR-engineered%2520T%2520cells%2520in%2520patients%2520with%2520refractory%2520cancer%26jtitle%3DScience%26date%3D2020%26volume%3D367%26issue%3D6481%26doi%3D10.1126%2Fscience.aba7365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref189"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref189'); return false;" data-citation="" class="refNumLink">189</a></strong><div class="NLM_citation" id="cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LiÃ¨vre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachet, J.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Corre, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boige, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emile, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">CÃ´tÃ©, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomasic, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penna, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ducreux, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rougier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penault-Llorca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurent-Puig, P.</span></span> <span> </span><span class="NLM_article-title">KRAS mutation status is predictive of response to Cetuximab therapy in colorectal cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">3992</span>â <span class="NLM_lpage">3995</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-06-0191</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F0008-5472.CAN-06-0191" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=16618717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD28XjsFSlsb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=3992-3995&issue=8&author=A.+Li%C3%A8vreauthor=J.-B.+Bachetauthor=D.+Le+Correauthor=V.+Boigeauthor=B.+Landiauthor=J.-F.+Emileauthor=J.-F.+C%C3%B4t%C3%A9author=G.+Tomasicauthor=C.+Pennaauthor=M.+Ducreuxauthor=P.+Rougierauthor=F.+Penault-Llorcaauthor=P.+Laurent-Puig&title=KRAS+mutation+status+is+predictive+of+response+to+Cetuximab+therapy+in+colorectal+cancer&doi=10.1158%2F0008-5472.CAN-06-0191"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer</span></div><div class="casAuthors">Lievre, Astrid; Bachet, Jean-Baptiste; Le Corre, Delphine; Boige, Valerie; Landi, Bruno; Emile, Jean-Francois; Cote, Jean-Francois; Tomasic, Gorana; Penna, Christophe; Ducreux, Michel; Rougier, Philippe; Penault-Llorca, Frederique; Laurent-Puig, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3992-3995</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The anti-epidermal growth factor receptor (anti-EGFR) cetuximab has been proven to be efficient in metastatic colorectal cancer.  The mol. mechanisms underlying the clin. response to this drug remain unknown.  Genetic alterations of the intracellular effectors involved in EGFR-related signaling pathways may have an effect on response to this targeted therapy.  In this study, tumors from 30 metastatic colorectal cancer patients treated by cetuximab were screened for KRAS, BRAF, and PIK3CA mutation by direct sequencing and for EGFR copy no. by chromogenic in situ hybridization.  Eleven of the 30 patients (37%) responded to cetuximab.  A KRAS mutation was found in 13 tumors (43%) and was significantly assocd. with the absence of response to cetuximab (KRAS mutation in 0% of the 11 responder patients vs. 68.4% of the 19 nonresponder patients; P = 0.0003).  The overall survival of patients without KRAS mutation in their tumor was significantly higher compared with those patients with a mutated tumor (P = 0.016; median, 16.3 vs. 6.9 mo).  An increased EGFR copy no. was found in 3 patients (10%) and was significantly assocd. with an objective tumor response to cetuximab (P = 0.04).  In conclusion, in this study, KRAS mutations are a predictor of resistance to cetuximab therapy and are assocd. with a worse prognosis.  The EGFR amplification, which is not as frequent as initially reported, is also assocd. with response to this treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpS9KZkED-vf7Vg90H21EOLACvtfcHk0lh4rp-RweF0Vw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjsFSlsb0%253D&md5=f34ea7f50a0be481474624bc494aa9dd</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-0191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-0191%26sid%3Dliteratum%253Aachs%26aulast%3DLi%25C3%25A8vre%26aufirst%3DA.%26aulast%3DBachet%26aufirst%3DJ.-B.%26aulast%3DLe%2BCorre%26aufirst%3DD.%26aulast%3DBoige%26aufirst%3DV.%26aulast%3DLandi%26aufirst%3DB.%26aulast%3DEmile%26aufirst%3DJ.-F.%26aulast%3DC%25C3%25B4t%25C3%25A9%26aufirst%3DJ.-F.%26aulast%3DTomasic%26aufirst%3DG.%26aulast%3DPenna%26aufirst%3DC.%26aulast%3DDucreux%26aufirst%3DM.%26aulast%3DRougier%26aufirst%3DP.%26aulast%3DPenault-Llorca%26aufirst%3DF.%26aulast%3DLaurent-Puig%26aufirst%3DP.%26atitle%3DKRAS%2520mutation%2520status%2520is%2520predictive%2520of%2520response%2520to%2520Cetuximab%2520therapy%2520in%2520colorectal%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26issue%3D8%26spage%3D3992%26epage%3D3995%26doi%3D10.1158%2F0008-5472.CAN-06-0191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref190"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref190'); return false;" data-citation="" class="refNumLink">190</a></strong><div class="NLM_citation" id="cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shiomi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuji, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tateishi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaizumi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiomi, T.</span></span> <span> </span><span class="NLM_article-title">Human RAD18 is involved in S phase-specific single-strand break repair without PCNA monoubiquitination</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">2</span>), <span class="NLM_elocation-id">e9</span> <span class="refDoi">Â DOI: 10.1093/nar/gkl979</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1093%2Fnar%2Fgkl979" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=17158148" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2006&issue=2&author=N.+Shiomiauthor=M.+Moriauthor=H.+Tsujiauthor=T.+Imaiauthor=H.+Inoueauthor=S.+Tateishiauthor=M.+Yamaizumiauthor=T.+Shiomi&title=Human+RAD18+is+involved+in+S+phase-specific+single-strand+break+repair+without+PCNA+monoubiquitination&doi=10.1093%2Fnar%2Fgkl979"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkl979&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkl979%26sid%3Dliteratum%253Aachs%26aulast%3DShiomi%26aufirst%3DN.%26aulast%3DMori%26aufirst%3DM.%26aulast%3DTsuji%26aufirst%3DH.%26aulast%3DImai%26aufirst%3DT.%26aulast%3DInoue%26aufirst%3DH.%26aulast%3DTateishi%26aufirst%3DS.%26aulast%3DYamaizumi%26aufirst%3DM.%26aulast%3DShiomi%26aufirst%3DT.%26atitle%3DHuman%2520RAD18%2520is%2520involved%2520in%2520S%2520phase-specific%2520single-strand%2520break%2520repair%2520without%2520PCNA%2520monoubiquitination%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2006%26volume%3D35%26issue%3D2%26doi%3D10.1093%2Fnar%2Fgkl979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref191"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref191'); return false;" data-citation="" class="refNumLink">191</a></strong><div class="NLM_citation" id="cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawauchi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchida, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasukawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conaway, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conaway, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aso, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitajima, S.</span></span> <span> </span><span class="NLM_article-title">Transcriptional properties of mammalian elongin A and its role in stress response</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>288</i></span> (<span class="NLM_issue">34</span>),  <span class="NLM_fpage">24302</span>â <span class="NLM_lpage">24315</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M113.496703</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1074%2Fjbc.M113.496703" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=23828199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlarsr%252FM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=24302-24315&issue=34&author=J.+Kawauchiauthor=M.+Inoueauthor=M.+Fukudaauthor=Y.+Uchidaauthor=T.+Yasukawaauthor=R.+C.+Conawayauthor=J.+W.+Conawayauthor=T.+Asoauthor=S.+Kitajima&title=Transcriptional+properties+of+mammalian+elongin+A+and+its+role+in+stress+response&doi=10.1074%2Fjbc.M113.496703"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Transcriptional Properties of Mammalian Elongin A and Its Role in Stress Response</span></div><div class="casAuthors">Kawauchi, Junya; Inoue, Makoto; Fukuda, Mizue; Uchida, Yohei; Yasukawa, Takashi; Conaway, Ronald C.; Conaway, Joan W.; Aso, Teijiro; Kitajima, Shigetaka</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">24302-24315</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Elongin A was shown previously to be capable of potently activating the rate of RNA polymerase II (RNAPII) transcription elongation in vitro by suppressing transient pausing by the enzyme at many sites along DNA templates.  The role of Elongin A in RNAPII transcription in mammalian cells, however, has not been clearly established.  In this report, we investigate the function of Elongin A in RNAPII transcription.  We present evidence that Elongin A assocs. with the IIO form of RNAPII at sites of newly transcribed RNA and is relocated to dotlike domains distinct from those contg. RNAPII when cells are treated with the kinase inhibitor 5,6-dichloro-1-Î²-Î´-ribofuranosylbenzimidazole.  Significantly, Elongin A is required for maximal induction of transcription of the stress response genes ATF3 and p21 in response to several stimuli.  Evidence from structure-function studies argues that Elongin A transcription elongation activity, but not its ubiquitination activity, is most important for its function in induction of transcription of ATF3 and p21.  Taken together, our data provide new insights into the function of Elongin A in RNAPII transcription and bring to light a previously unrecognized role for Elongin A in the regulation of stress response genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolU6NWPn2xb7Vg90H21EOLACvtfcHk0lif-S9vZaSINQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlarsr%252FM&md5=847e65efaf35307e86dd7cb0eca12358</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M113.496703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M113.496703%26sid%3Dliteratum%253Aachs%26aulast%3DKawauchi%26aufirst%3DJ.%26aulast%3DInoue%26aufirst%3DM.%26aulast%3DFukuda%26aufirst%3DM.%26aulast%3DUchida%26aufirst%3DY.%26aulast%3DYasukawa%26aufirst%3DT.%26aulast%3DConaway%26aufirst%3DR.%2BC.%26aulast%3DConaway%26aufirst%3DJ.%2BW.%26aulast%3DAso%26aufirst%3DT.%26aulast%3DKitajima%26aufirst%3DS.%26atitle%3DTranscriptional%2520properties%2520of%2520mammalian%2520elongin%2520A%2520and%2520its%2520role%2520in%2520stress%2520response%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26issue%3D34%26spage%3D24302%26epage%3D24315%26doi%3D10.1074%2Fjbc.M113.496703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref192"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref192'); return false;" data-citation="" class="refNumLink">192</a></strong><div class="NLM_citation" id="cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zofall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grewal, S. I.</span></span> <span> </span><span class="NLM_article-title">HULC, a histone H2B ubiquitinating complex, modulates heterochromatin independent of histone methylation in fission yeast</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>282</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">14065</span>â <span class="NLM_lpage">14072</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M700292200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1074%2Fjbc.M700292200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=17363370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkvVygu7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=14065-14072&issue=19&author=M.+Zofallauthor=S.+I.+Grewal&title=HULC%2C+a+histone+H2B+ubiquitinating+complex%2C+modulates+heterochromatin+independent+of+histone+methylation+in+fission+yeast&doi=10.1074%2Fjbc.M700292200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">HULC, a Histone H2B Ubiquitinating Complex, Modulates Heterochromatin Independent of Histone Methylation in Fission Yeast</span></div><div class="casAuthors">Zofall, Martin; Grewal, Shiv I. S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">282</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">14065-14072</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Heterochromatin in fission yeast is targeted dynamically by opposing chromatin-modifying activities capable of alleviating or promoting transcriptional gene silencing.  In this study, we report the biochem. and genetic characterization of a ubiquitin-conjugating enzyme Rhp6 (a homolog of budding yeast Rad6), which has been shown to neg. affect stability of heterochromatic structures.  We show that Rhp6 is a component of the multisubunit protein complex (termed HULC) that also contains two RING finger proteins Rfp1 and Rfp2, sharing homol. with budding yeast Bre1 protein and a unique serine-rich protein Shf1.  HULC is required for ubiquitination of histone H2B at lysine 119 (H2B-K119), and it localizes to heterochromatic sequences.  Moreover, our analyses suggest that Rhp6-induced changes in heterochromatic silencing are mediated predominantly through H2B ubiquitination (ubH2B), and they correlate with increased RNA polymerase II levels at repeat elements embedded within heterochromatin domains.  Interestingly, heterochromatic derepression caused by Rhp6 occurs independently of the involvement of HULC subunits and ubH2B in methylation of histone H3 at lysine 4 (H3K4me).  These analyses implicate ubH2B in modulation of heterochromatin, which has important implications for dynamics and many functions assocd. with heterochromatic structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqraOlKCKZKjLVg90H21EOLACvtfcHk0lif-S9vZaSINQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkvVygu7c%253D&md5=64a81c877ab14b353dfab64d26f318a3</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M700292200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M700292200%26sid%3Dliteratum%253Aachs%26aulast%3DZofall%26aufirst%3DM.%26aulast%3DGrewal%26aufirst%3DS.%2BI.%26atitle%3DHULC%252C%2520a%2520histone%2520H2B%2520ubiquitinating%2520complex%252C%2520modulates%2520heterochromatin%2520independent%2520of%2520histone%2520methylation%2520in%2520fission%2520yeast%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26issue%3D19%26spage%3D14065%26epage%3D14072%26doi%3D10.1074%2Fjbc.M700292200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref193"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref193'); return false;" data-citation="" class="refNumLink">193</a></strong><div class="NLM_citation" id="cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cencic, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ertel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roulston, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvius, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shore, G. C.</span></span> <span> </span><span class="NLM_article-title">Obatoclax is a direct and potent antagonist of membrane-restricted Mcl-1 and is synthetic lethal with treatment that induces Bim</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">568</span>, <span class="refDoi">Â DOI: 10.1186/s12885-015-1582-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1186%2Fs12885-015-1582-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=26231047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FpsFKhsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=568&author=M.+Nguyenauthor=R.+Cencicauthor=F.+Ertelauthor=C.+Bernierauthor=J.+Pelletierauthor=A.+Roulstonauthor=J.+R.+Silviusauthor=G.+C.+Shore&title=Obatoclax+is+a+direct+and+potent+antagonist+of+membrane-restricted+Mcl-1+and+is+synthetic+lethal+with+treatment+that+induces+Bim&doi=10.1186%2Fs12885-015-1582-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Obatoclax is a direct and potent antagonist of membrane-restricted Mcl-1 and is synthetic lethal with treatment that induces Bim</span></div><div class="casAuthors">Nguyen Mai; Cencic Regina; Ertel Franziska; Pelletier Jerry; Silvius John R; Shore Gordon C; Bernier Cynthia; Pelletier Jerry; Roulston Anne; Shore Gordon C</div><div class="citationInfo"><span class="NLM_cas:title">BMC cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">568</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Obatoclax is a clinical stage drug candidate that has been proposed to target and inhibit prosurvival members of the Bcl-2 family, and thereby contribute to cancer cell lethality.  The insolubility of this compound, however, has precluded the use of many classical drug-target interaction assays for its study.  Thus, a direct demonstration of the proposed mechanism of action, and preferences for individual Bcl-2 family members, remain to be established.  METHODS:  Employing modified proteins and lipids, we recapitulated the constitutive association and topology of mitochondrial outer membrane Mcl-1 and Bak in synthetic large unilamellar liposomes, and measured bakdependent bilayer permeability.  Additionally, cellular and tumor models, dependent on Mcl-1 for survival, were employed.  RESULTS:  We show that regulation of bilayer permeabilization by the tBid - Mcl-1 - Bak axis closely resemblesthe tBid - Bcl-XL - Bax model.  Obatoclax rapidly and completely partitioned into liposomal lipid but also rapidly exchanged between liposome particles.  In this system, obatoclax was found to be a direct and potent antagonist of liposome-bound Mcl-1 but not of liposome-bound Bcl-XL, and did not directly influence Bak.  A 2.5 molar excess of obatoclax relative to Mcl-1 overcame Mcl-1-mediated inhibition of tBid-Bak activation.  Similar results were found for induction of Bak oligomers by Bim.  Obatoclax exhibited potent lethality in a cellmodel dependent on Mcl-1 for viability but not in cells dependent on Bcl-XL.  Molecular modeling predicts that the 3-methoxy moiety of obatoclax penetrates into the P2 pocket of the BH3 binding site of Mcl-1.  A desmethoxy derivative of obatoclax failed to inhibit Mcl-1 in proteoliposomes and did not kill cells whose survival depends on Mcl-1.  Systemic treatment of mice bearing Tsc2(+) (/) (-) Em-myc lymphomas (whose cells depend on Mcl-1 for survival) with obatoclax conferred a survival advantage compared to vehicle alone (median 31 days vs 22 days, respectively; p=0.003).  In an Akt-lymphoma mouse model, the anti-tumor effects of obatoclax synergized with doxorubicin.  Finally, treatment of the multiple myeloma KMS11 cell model (dependent on Mcl-1 for survival) with dexamethasone induced Bim and Bim-dependent lethality.  As predicted for an Mcl-1 antagonist, obatoclax and dexamethasone were synergistic in this model.  CONCLUSIONS:  Taken together, these findings indicate that obatoclax is a potent antagonist of membranerestricted Mcl-1.  Obatoclax represents an attractive chemical series to generate second generation Mcl-1 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRDceLtzp7_yGlSCSgBhwJFfW6udTcc2eZW1U1hqkB9h7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FpsFKhsg%253D%253D&md5=9e8ac00d7bcf310fed6489fcf841e245</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1186%2Fs12885-015-1582-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12885-015-1582-5%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DM.%26aulast%3DCencic%26aufirst%3DR.%26aulast%3DErtel%26aufirst%3DF.%26aulast%3DBernier%26aufirst%3DC.%26aulast%3DPelletier%26aufirst%3DJ.%26aulast%3DRoulston%26aufirst%3DA.%26aulast%3DSilvius%26aufirst%3DJ.%2BR.%26aulast%3DShore%26aufirst%3DG.%2BC.%26atitle%3DObatoclax%2520is%2520a%2520direct%2520and%2520potent%2520antagonist%2520of%2520membrane-restricted%2520Mcl-1%2520and%2520is%2520synthetic%2520lethal%2520with%2520treatment%2520that%2520induces%2520Bim%26jtitle%3DBMC%2520Cancer%26date%3D2015%26volume%3D15%26spage%3D568%26doi%3D10.1186%2Fs12885-015-1582-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref194"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref194'); return false;" data-citation="" class="refNumLink">194</a></strong><div class="NLM_citation" id="cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Freije, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraile, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Otin, C.</span></span> <span> </span><span class="NLM_article-title">Protease addiction and synthetic lethality in cancer</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">25</span>, <span class="refDoi">Â DOI: 10.3389/fonc.2011.00025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.3389%2Ffonc.2011.00025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=22655236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A280%3ADC%252BC38notFWgsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2011&pages=25&author=J.+M.+Freijeauthor=J.+M.+Fraileauthor=C.+Lopez-Otin&title=Protease+addiction+and+synthetic+lethality+in+cancer&doi=10.3389%2Ffonc.2011.00025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Protease addiction and synthetic lethality in cancer</span></div><div class="casAuthors">Freije Jose M P; Fraile Julia M; Lopez-Otin Carlos</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">25</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The "oncogene addiction" concept refers to the dependence of cancer cells on the function of the oncogenes responsible for their transformed phenotype, while the term "non-oncogene addiction" has been introduced to define the exacerbated necessity of the normal function of non-mutated genes.  In this Perspective, we focus on the importance of proteolytic enzymes to maintain the viability of cancer cells and hypothesize that most, if not all, tumors present "addiction" to a number of proteolytic activities, which in turn may represent valuable targets of anti-cancer therapies, even without being mutated or over-expressed by the malignant cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQGOjJJch7csyCEBeYuoi7AfW6udTcc2eZW1U1hqkB9h7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38notFWgsQ%253D%253D&md5=c7638722f1588919cde3972f6ae4b48f</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2011.00025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2011.00025%26sid%3Dliteratum%253Aachs%26aulast%3DFreije%26aufirst%3DJ.%2BM.%26aulast%3DFraile%26aufirst%3DJ.%2BM.%26aulast%3DLopez-Otin%26aufirst%3DC.%26atitle%3DProtease%2520addiction%2520and%2520synthetic%2520lethality%2520in%2520cancer%26jtitle%3DFront.%2520Oncol.%26date%3D2011%26volume%3D1%26spage%3D25%26doi%3D10.3389%2Ffonc.2011.00025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref195"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref195'); return false;" data-citation="" class="refNumLink">195</a></strong><div class="NLM_citation" id="cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buono, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paez-Valencia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spalding, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otegui, M. S.</span></span> <span> </span><span class="NLM_article-title">Role of SKD1 regulators LIP5 and IST1-LIKE1 in endosomal sorting and plant development</span>. <i>Plant Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>171</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">251</span>â <span class="NLM_lpage">264</span>, <span class="refDoi">Â DOI: 10.1104/pp.16.00240</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1104%2Fpp.16.00240" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=26983994" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslChsrjI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2016&pages=251-264&issue=1&author=R.+A.+Buonoauthor=J.+Paez-Valenciaauthor=N.+D.+Millerauthor=K.+Goodmanauthor=C.+Spitzerauthor=E.+P.+Spaldingauthor=M.+S.+Otegui&title=Role+of+SKD1+regulators+LIP5+and+IST1-LIKE1+in+endosomal+sorting+and+plant+development&doi=10.1104%2Fpp.16.00240"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Role of SKD1 regulators LIP5 and IST1-LIKE1 in endosomal sorting and plant development1[OPEN]</span></div><div class="casAuthors">Buono, Rafael Andrade; Paez-Valencia, Julio; Miller, Nathan D.; Goodman, Kaija; Spitzer, Christoph; Spalding, Edgar P.; Otegui, Marisa S.</div><div class="citationInfo"><span class="NLM_cas:title">Plant Physiology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">251-264</span>CODEN:
                <span class="NLM_cas:coden">PLPHAY</span>;
        ISSN:<span class="NLM_cas:issn">1532-2548</span>.
    
            (<span class="NLM_cas:orgname">American Society of Plant Biologists</span>)
        </div><div class="casAbstract">SKD1 is a core component of the mechanism that degrades plasma membrane proteins via the Endosomal Sorting Complex Required for Transport (ESCRT) pathway.  Its ATPase activity and endosomal recruitment are regulated by the ESCRT components LIP5 and IST1.  How LIP5 and IST1 affect ESCRT-mediated endosomal trafficking and development in plants is not known.  Here we use Arabidopsis mutants to demonstrate that LIP5 controls the constitutive degrdn. of plasma membrane proteins and the formation of endosomal intraluminal vesicles.  Although lip5 mutants were able to polarize the auxin efflux facilitators PIN2 and PIN3, both proteins were mis-sorted to the tonoplast in lip5 root cells.  In addn., lip5 root cells over-accumulated PIN2 at the plasma membrane.  Consistently with the trafficking defects of PIN proteins, the lip5 roots showed abnormal gravitropism with an enhanced response within the first 4 h after gravistimulation.  LIP5 phys. interacts with IST1-LIKE1 (ISTL1), a protein predicted to be the Arabidopsis homolog of yeast IST1.  However, we found that Arabidopsis contains 12 genes coding for predicted IST1-domain contg. proteins (ISTL1-12).  Within the ISTL1-6 group, ISTL1 showed the strongest interaction with LIP5, SKD1, and the ESCRT-III-related proteins CHMP1A in yeast two hybrid assays.  Through the anal. of single and double mutants, we found that the synthetic interaction of LIP5 with ISTL1, but not with ISTL2, 3, or 6, is essential for normal plant growth, repression of spontaneous cell death, and post-embryonic lethality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJn7O_VlyAO7Vg90H21EOLACvtfcHk0lh3kHwAD5NLJw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslChsrjI&md5=3dcd874baf8c0a9cf054cd8e9f214158</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1104%2Fpp.16.00240&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1104%252Fpp.16.00240%26sid%3Dliteratum%253Aachs%26aulast%3DBuono%26aufirst%3DR.%2BA.%26aulast%3DPaez-Valencia%26aufirst%3DJ.%26aulast%3DMiller%26aufirst%3DN.%2BD.%26aulast%3DGoodman%26aufirst%3DK.%26aulast%3DSpitzer%26aufirst%3DC.%26aulast%3DSpalding%26aufirst%3DE.%2BP.%26aulast%3DOtegui%26aufirst%3DM.%2BS.%26atitle%3DRole%2520of%2520SKD1%2520regulators%2520LIP5%2520and%2520IST1-LIKE1%2520in%2520endosomal%2520sorting%2520and%2520plant%2520development%26jtitle%3DPlant%2520Physiol.%26date%3D2016%26volume%3D171%26issue%3D1%26spage%3D251%26epage%3D264%26doi%3D10.1104%2Fpp.16.00240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref196"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref196'); return false;" data-citation="" class="refNumLink">196</a></strong><div class="NLM_citation" id="cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hardin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, R. S.</span></span> <span> </span><span class="NLM_article-title">The long and the short of Wnt signaling in C. elegans</span>. <i>Curr. Opin. Genet. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">362</span>â <span class="NLM_lpage">367</span>, <span class="refDoi">Â DOI: 10.1016/j.gde.2008.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.gde.2008.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=18625312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1KmtbfF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=362-367&issue=4&author=J.+Hardinauthor=R.+S.+King&title=The+long+and+the+short+of+Wnt+signaling+in+C.+elegans&doi=10.1016%2Fj.gde.2008.06.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">The long and the short of Wnt signaling in C. elegans</span></div><div class="casAuthors">Hardin, Jeff; King, Ryan S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Genetics & Development</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">362-367</span>CODEN:
                <span class="NLM_cas:coden">COGDET</span>;
        ISSN:<span class="NLM_cas:issn">0959-437X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The simplicity of Caenorhabditis elegans makes it an outstanding system to study the role of Wnt signaling in development.  Many asym. cell divisions in C. elegans require the Wnt/Î²-catenin asymmetry pathway.  Recent studies confirm that SYS-1 is a structurally and functionally divergent Î²-catenin, and implicate lipids and retrograde trafficking in maintenance of WRM-1/Î²-catenin asymmetry.  Wnts also regulate short-range events such as spindle rotation and gastrulation, and a PCP-like pathway regulates asym. divisions.  Long-range, cell non-autonomous Wnt signals regulate vulval induction.  Both short-range and long-range Wnt signals are regulated by recycling of MIG-14/Wntless via the retromer complex.  These studies indicate that C. elegans continues to be useful for identifying new, conserved mechanisms underlying Wnt signaling in metazoans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB2CTQvx3SI7Vg90H21EOLACvtfcHk0lh3kHwAD5NLJw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1KmtbfF&md5=886af4022ffd5aeee035959e8fb2f25a</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1016%2Fj.gde.2008.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gde.2008.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DHardin%26aufirst%3DJ.%26aulast%3DKing%26aufirst%3DR.%2BS.%26atitle%3DThe%2520long%2520and%2520the%2520short%2520of%2520Wnt%2520signaling%2520in%2520C.%2520elegans%26jtitle%3DCurr.%2520Opin.%2520Genet.%2520Dev.%26date%3D2008%26volume%3D18%26issue%3D4%26spage%3D362%26epage%3D367%26doi%3D10.1016%2Fj.gde.2008.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref197"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref197'); return false;" data-citation="" class="refNumLink">197</a></strong><div class="NLM_citation" id="cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zinovyev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuperstein, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barillot, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyer, W. D.</span></span> <span> </span><span class="NLM_article-title">Synthetic lethality between gene defects affecting a single non-essential molecular pathway with reversible steps</span>. <i>PLoS Comput. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">4</span>), <span class="NLM_elocation-id">e1003016</span> <span class="refDoi">Â DOI: 10.1371/journal.pcbi.1003016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1371%2Fjournal.pcbi.1003016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=23592964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnt1ejtLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&issue=4&author=A.+Zinovyevauthor=I.+Kupersteinauthor=E.+Barillotauthor=W.+D.+Heyer&title=Synthetic+lethality+between+gene+defects+affecting+a+single+non-essential+molecular+pathway+with+reversible+steps&doi=10.1371%2Fjournal.pcbi.1003016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic lethality between gene defects affecting a single non-essential molecular pathway with reversible steps</span></div><div class="casAuthors">Zinovyev, Andrei; Kuperstein, Inna; Barillot, Emmanuel; Heyer, Wolf-Dietrich</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Computational Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e1003016</span>CODEN:
                <span class="NLM_cas:coden">PCBLBG</span>;
        ISSN:<span class="NLM_cas:issn">1553-7358</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Systematic anal. of synthetic lethality (SL) constitutes a crit. tool for systems biol. to decipher mol. pathways.  The most accepted mechanistic explanation of SL is that the two genes function in parallel, mutually compensatory pathways, known as between-pathway SL.  However, recent genome-wide analyses in yeast identified a significant no. of within-pathway neg. genetic interactions.  The mol. mechanisms leading to within-pathway SL are not fully understood.  Here, we propose a novel mechanism leading to within-pathway SL involving two genes functioning in a single non-essential pathway.  This type of SL termed within-reversible-pathway SL involves reversible pathway steps, catalyzed by different enzymes in the forward and backward directions, and kinetic trapping of a potentially toxic intermediate.  Exptl. data with recombinational DNA repair genes validate the concept.  Math. modeling recapitulates the possibility of kinetic trapping and revealed the potential contributions of synthetic, dosage-lethal interactions in such a genetic system as well as the possibility of within-pathway pos. masking interactions.  Anal. of yeast gene interaction and pathway data suggests broad applicability of this novel concept.  These observations extend the canonical interpretation of synthetic-lethal or synthetic-sick interactions with direct implications to reconstruct mol. pathways and improve therapeutic approaches to diseases such as cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-mNvqfaiz5rVg90H21EOLACvtfcHk0lgL71vI0NBBPQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnt1ejtLc%253D&md5=f405707774525d3c1d635df77940b1cc</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pcbi.1003016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pcbi.1003016%26sid%3Dliteratum%253Aachs%26aulast%3DZinovyev%26aufirst%3DA.%26aulast%3DKuperstein%26aufirst%3DI.%26aulast%3DBarillot%26aufirst%3DE.%26aulast%3DHeyer%26aufirst%3DW.%2BD.%26atitle%3DSynthetic%2520lethality%2520between%2520gene%2520defects%2520affecting%2520a%2520single%2520non-essential%2520molecular%2520pathway%2520with%2520reversible%2520steps%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2013%26volume%3D9%26issue%3D4%26doi%3D10.1371%2Fjournal.pcbi.1003016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref198"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref198'); return false;" data-citation="" class="refNumLink">198</a></strong><div class="NLM_citation" id="cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dasgupta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malhotra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meeker, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amedei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashraf, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aquilano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azmi, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhakta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilsland, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boosani, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciriolo, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guha, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halicka, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helferich, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keith, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammed, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niccolai, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honoki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parslow, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prakash, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rezazadeh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shackelford, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidransky, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maxwell, C. A.</span></span> <span> </span><span class="NLM_article-title">Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition</span>. <i>Semin. Cancer Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">Suppl</span>),  <span class="NLM_fpage">S5</span>â <span class="NLM_lpage">S24</span>, <span class="refDoi">Â DOI: 10.1016/j.semcancer.2015.03.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.semcancer.2015.03.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=25869442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmt1Skt7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2015&pages=S5-S24&issue=Suppl&author=L.+R.+Fergusonauthor=H.+Chenauthor=A.+R.+Collinsauthor=M.+Connellauthor=G.+Damiaauthor=S.+Dasguptaauthor=M.+Malhotraauthor=A.+K.+Meekerauthor=A.+Amedeiauthor=A.+Aminauthor=S.+S.+Ashrafauthor=K.+Aquilanoauthor=A.+S.+Azmiauthor=D.+Bhaktaauthor=A.+Bilslandauthor=C.+S.+Boosaniauthor=S.+Chenauthor=M.+R.+Cirioloauthor=H.+Fujiiauthor=G.+Guhaauthor=D.+Halickaauthor=W.+G.+Helferichauthor=W.+N.+Keithauthor=S.+I.+Mohammedauthor=E.+Niccolaiauthor=X.+Yangauthor=K.+Honokiauthor=V.+R.+Parslowauthor=S.+Prakashauthor=S.+Rezazadehauthor=R.+E.+Shackelfordauthor=D.+Sidranskyauthor=P.+T.+Tranauthor=E.+S.+Yangauthor=C.+A.+Maxwell&title=Genomic+instability+in+human+cancer%3A+Molecular+insights+and+opportunities+for+therapeutic+attack+and+prevention+through+diet+and+nutrition&doi=10.1016%2Fj.semcancer.2015.03.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition</span></div><div class="casAuthors">Ferguson, Lynnette R.; Chen, Helen; Collins, Andrew R.; Connell, Marisa; Damia, Giovanna; Dasgupta, Santanu; Malhotra, Meenakshi; Meeker, Alan K.; Amedei, Amedeo; Amin, Amr; Ashraf, S. Salman; Aquilano, Katia; Azmi, Asfar S.; Bhakta, Dipita; Bilsland, Alan; Boosani, Chandra S.; Chen, Sophie; Ciriolo, Maria Rosa; Fujii, Hiromasa; Guha, Gunjan; Halicka, Dorota; Helferich, William G.; Keith, W. Nicol; Mohammed, Sulma I.; Niccolai, Elena; Yang, Xujuan; Honoki, Kanya; Parslow, Virginia R.; Prakash, Satya; Rezazadeh, Sarallah; Shackelford, Rodney E.; Sidransky, David; Tran, Phuoc T.; Yang, Eddy S.; Maxwell, Christopher A.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Cancer Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">35_Suppl.</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">S5-S24</span>CODEN:
                <span class="NLM_cas:coden">SECBE7</span>;
        ISSN:<span class="NLM_cas:issn">1044-579X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Genomic instability can initiate cancer, augment progression, and influence the overall prognosis of the affected patient.  Genomic instability arises from many different pathways, such as telomere damage, centrosome amplification, epigenetic modifications, and DNA damage from endogenous and exogenous sources, and can be perpetuating, or limiting, through the induction of mutations or aneuploidy, both enabling and catastrophic.  Many cancer treatments induce DNA damage to impair cell division on a global scale but it is accepted that personalized treatments, those that are tailored to the particular patient and type of cancer, must also be developed.  In this review, we detail the mechanisms from which genomic instability arises and can lead to cancer, as well as treatments and measures that prevent genomic instability or take advantage of the cellular defects caused by genomic instability.  In particular, we identify and discuss five priority targets against genomic instability: (1) prevention of DNA damage; (2) enhancement of DNA repair; (3) targeting deficient DNA repair; (4) impairing centrosome clustering; and, (5) inhibition of telomerase activity.  Moreover, we highlight vitamin D and B, selenium, carotenoids, PARP inhibitors, resveratrol, and isothiocyanates as priority approaches against genomic instability.  The prioritized target sites and approaches were cross validated to identify potential synergistic effects on a no. of important areas of cancer biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqluPZhUX3PLrVg90H21EOLACvtfcHk0lgL71vI0NBBPQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmt1Skt7w%253D&md5=e030d940320e97bb5498badc7fd7fb28</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1016%2Fj.semcancer.2015.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semcancer.2015.03.005%26sid%3Dliteratum%253Aachs%26aulast%3DFerguson%26aufirst%3DL.%2BR.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DCollins%26aufirst%3DA.%2BR.%26aulast%3DConnell%26aufirst%3DM.%26aulast%3DDamia%26aufirst%3DG.%26aulast%3DDasgupta%26aufirst%3DS.%26aulast%3DMalhotra%26aufirst%3DM.%26aulast%3DMeeker%26aufirst%3DA.%2BK.%26aulast%3DAmedei%26aufirst%3DA.%26aulast%3DAmin%26aufirst%3DA.%26aulast%3DAshraf%26aufirst%3DS.%2BS.%26aulast%3DAquilano%26aufirst%3DK.%26aulast%3DAzmi%26aufirst%3DA.%2BS.%26aulast%3DBhakta%26aufirst%3DD.%26aulast%3DBilsland%26aufirst%3DA.%26aulast%3DBoosani%26aufirst%3DC.%2BS.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DCiriolo%26aufirst%3DM.%2BR.%26aulast%3DFujii%26aufirst%3DH.%26aulast%3DGuha%26aufirst%3DG.%26aulast%3DHalicka%26aufirst%3DD.%26aulast%3DHelferich%26aufirst%3DW.%2BG.%26aulast%3DKeith%26aufirst%3DW.%2BN.%26aulast%3DMohammed%26aufirst%3DS.%2BI.%26aulast%3DNiccolai%26aufirst%3DE.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DHonoki%26aufirst%3DK.%26aulast%3DParslow%26aufirst%3DV.%2BR.%26aulast%3DPrakash%26aufirst%3DS.%26aulast%3DRezazadeh%26aufirst%3DS.%26aulast%3DShackelford%26aufirst%3DR.%2BE.%26aulast%3DSidransky%26aufirst%3DD.%26aulast%3DTran%26aufirst%3DP.%2BT.%26aulast%3DYang%26aufirst%3DE.%2BS.%26aulast%3DMaxwell%26aufirst%3DC.%2BA.%26atitle%3DGenomic%2520instability%2520in%2520human%2520cancer%253A%2520Molecular%2520insights%2520and%2520opportunities%2520for%2520therapeutic%2520attack%2520and%2520prevention%2520through%2520diet%2520and%2520nutrition%26jtitle%3DSemin.%2520Cancer%2520Biol.%26date%3D2015%26volume%3D35%26issue%3DSuppl%26spage%3DS5%26epage%3DS24%26doi%3D10.1016%2Fj.semcancer.2015.03.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref199"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref199'); return false;" data-citation="" class="refNumLink">199</a></strong><div class="NLM_citation" id="cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schott, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coustham, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palladino, F.</span></span> <span> </span><span class="NLM_article-title">Unique and redundant functions of C. elegans HP1 proteins in post-embryonic development</span>. <i>Dev. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>298</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">176</span>â <span class="NLM_lpage">187</span>, <span class="refDoi">Â DOI: 10.1016/j.ydbio.2006.06.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.ydbio.2006.06.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=16905130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD28XpvFeksLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=298&publication_year=2006&pages=176-187&issue=1&author=S.+Schottauthor=V.+Cousthamauthor=T.+Simonetauthor=C.+Bedetauthor=F.+Palladino&title=Unique+and+redundant+functions+of+C.+elegans+HP1+proteins+in+post-embryonic+development&doi=10.1016%2Fj.ydbio.2006.06.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">Unique and redundant functions of C. elegans HP1 proteins in post-embryonic development</span></div><div class="casAuthors">Schott, Sonia; Coustham, Vincent; Simonet, Thomas; Bedet, Cecile; Palladino, Francesca</div><div class="citationInfo"><span class="NLM_cas:title">Developmental Biology (San Diego, CA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">298</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">176-187</span>CODEN:
                <span class="NLM_cas:coden">DEBIAO</span>;
        ISSN:<span class="NLM_cas:issn">0012-1606</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">HP1 proteins are essential components of heterochromatin and contribute to the transcriptional repression of euchromatic genes.  Although most species contain more than one HP1 family member which differ in their chromosomal distribution, it is not known to what extent the activity of these different family members is redundant or specific in a developmental context.  C. elegans has two HP1 homologs, HPL-1 and HPL-2.  While HPL-2 functions in vulval and germline development, no function has so far been attributed to HPL-1.  Here the authors report the characterization of an hpl-1 null allele.  The authors show that while the absence of hpl-1 alone results in no obvious phenotype, hpl-1;hpl-2 double mutants show synthetic, temp. sensitive phenotypes including larval lethality and severe defects in the development of the somatic gonad.  Furthermore, the authors find that hpl-1 has an unexpected role in vulval development by acting redundantly with hpl-2, but not other genes previously implicated in vulval development.  Localization studies show that like HPL-2, HPL-1 is a ubiquitously expressed nuclear protein.  However, HPL-1 and HPL-2 localization does not completely overlap.  The authors' results show that HPL-1 and HPL-2 play both unique and redundant functions in post-embryonic development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoBFG-QUbyZ7Vg90H21EOLACvtfcHk0lh1N7bUjMLThA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpvFeksLo%253D&md5=c43b54e246d793cbcfba1989ee91cb24</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1016%2Fj.ydbio.2006.06.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ydbio.2006.06.039%26sid%3Dliteratum%253Aachs%26aulast%3DSchott%26aufirst%3DS.%26aulast%3DCoustham%26aufirst%3DV.%26aulast%3DSimonet%26aufirst%3DT.%26aulast%3DBedet%26aufirst%3DC.%26aulast%3DPalladino%26aufirst%3DF.%26atitle%3DUnique%2520and%2520redundant%2520functions%2520of%2520C.%2520elegans%2520HP1%2520proteins%2520in%2520post-embryonic%2520development%26jtitle%3DDev.%2520Biol.%26date%3D2006%26volume%3D298%26issue%3D1%26spage%3D176%26epage%3D187%26doi%3D10.1016%2Fj.ydbio.2006.06.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref200"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref200'); return false;" data-citation="" class="refNumLink">200</a></strong><div class="NLM_citation" id="cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadgeel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFall, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shields, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matherly, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bepler, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratnam, M.</span></span> <span> </span><span class="NLM_article-title">Glucocorticoid receptor status is a principal determinant of variability in the sensitivity of non-small-cell lung cancer cells to pemetrexed</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">519</span>â <span class="NLM_lpage">526</span>, <span class="refDoi">Â DOI: 10.1097/JTO.0000000000000111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1097%2FJTO.0000000000000111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=24736075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnsFeksr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=519-526&issue=4&author=M.+Patkiauthor=S.+Gadgeelauthor=Y.+Huangauthor=T.+McFallauthor=A.+F.+Shieldsauthor=L.+H.+Matherlyauthor=G.+Beplerauthor=M.+Ratnam&title=Glucocorticoid+receptor+status+is+a+principal+determinant+of+variability+in+the+sensitivity+of+non-small-cell+lung+cancer+cells+to+pemetrexed&doi=10.1097%2FJTO.0000000000000111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Glucocorticoid Receptor Status Is a Principal Determinant of Variability in the Sensitivity of Non-Small-Cell Lung Cancer Cells to Pemetrexed</span></div><div class="casAuthors">Patki, Mugdha; Gadgeel, Shirish; Huang, Yanfang; McFall, Thomas; Shields, Anthony F.; Matherly, Larry H.; Bepler, Gerold; Ratnam, Manohar</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">519-526</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-0864</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Introduction: Pemetrexed is an S-phase targeted drug in front-line or maintenance therapy of advanced nonsquamous non-small-cell lung cancer (NSCLC) but methods are needed for predicting the drug response.  Dexamethasone is typically administered the day before, the day of, and the day after pemetrexed.  As dexamethasone strongly regulates many genes including p53 through the glucocorticoid receptor (GR), we hypothesized that dexamethasone influences tumor response to pemetrexed.  Methods: Eight nonsquamous NSCLC cell line models with varied p53 and GRÎ±/GRÎ² status were used for gene expression and cell-cycle analyses and for loss- or gain-of-function expts.  Results: In three cell lines dexamethasone profoundly, but reversibly, suppressed the fraction of S-phase cells.  Dexamethasone also reversibly repressed expression of thymidylate synthase and dihydrofolate reductase, which are primary targets of pemetrexed but are also quintessential S-phase enzymes as well as the S-phase-dependent expression of thymidine kinase 1.  Dexamethasone also decreased expression of the major pemetrexed transporters, the reduced folate carrier and the proton coupled folate transporter.  Only cells expressing relatively high GRÎ± showed these dexamethasone effects, regardless of p53 status.  In cells expressing low GRÎ±, the dexamethasone response was rescued by ectopic GRÎ±.  Further, depletion of p53 did not attenuate the dexamethasone effects.  The presence of dexamethasone during pemetrexed treatment protected against pemetrexed cytotoxicity in only the dexamethasone responsive cells.  Conclusions: The results predict that in nonsquamous NSCLC tumors, reversible S-phase suppression by dexamethasone, possibly combined with a redn. in the drug transporters, attenuates responsiveness to pemetrexed and that GR status is a principal determinant of tumor variability of this response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonlr2Xw1TFtbVg90H21EOLACvtfcHk0lh1N7bUjMLThA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnsFeksr4%253D&md5=58902ee75fed6685f594546685c195f3</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1097%2FJTO.0000000000000111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0000000000000111%26sid%3Dliteratum%253Aachs%26aulast%3DPatki%26aufirst%3DM.%26aulast%3DGadgeel%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DMcFall%26aufirst%3DT.%26aulast%3DShields%26aufirst%3DA.%2BF.%26aulast%3DMatherly%26aufirst%3DL.%2BH.%26aulast%3DBepler%26aufirst%3DG.%26aulast%3DRatnam%26aufirst%3DM.%26atitle%3DGlucocorticoid%2520receptor%2520status%2520is%2520a%2520principal%2520determinant%2520of%2520variability%2520in%2520the%2520sensitivity%2520of%2520non-small-cell%2520lung%2520cancer%2520cells%2520to%2520pemetrexed%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2014%26volume%3D9%26issue%3D4%26spage%3D519%26epage%3D526%26doi%3D10.1097%2FJTO.0000000000000111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref201"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref201'); return false;" data-citation="" class="refNumLink">201</a></strong><div class="NLM_citation" id="cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mullen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brill, S. J.</span></span> <span> </span><span class="NLM_article-title">Activation of the Slx5-Slx8 ubiquitin ligase by poly-small ubiquitin-like modifier conjugates</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>283</i></span> (<span class="NLM_issue">29</span>),  <span class="NLM_fpage">19912</span>â <span class="NLM_lpage">19921</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M802690200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1074%2Fjbc.M802690200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=18499666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotlOit7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=19912-19921&issue=29&author=J.+R.+Mullenauthor=S.+J.+Brill&title=Activation+of+the+Slx5-Slx8+ubiquitin+ligase+by+poly-small+ubiquitin-like+modifier+conjugates&doi=10.1074%2Fjbc.M802690200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of the Slx5-Slx8 Ubiquitin Ligase by Poly-small Ubiquitin-like Modifier Conjugates</span></div><div class="casAuthors">Mullen, Janet R.; Brill, Steven J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">19912-19921</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Protein sumoylation is a regulated process that is important for the health of human and yeast cells.  In budding yeast, a subset of sumoylated proteins is targeted for ubiquitination by a conserved heterodimeric ubiquitin (Ub) ligase, Slx5-Slx8, which is needed to suppress the accumulation of high mol. wt. small ubiquitin-like modifier (SUMO) conjugates.  Structure-function anal. indicates that the Slx5-Slx8 complex contains multiple SUMO-binding domains that are collectively required for in vivo function.  To det. the specificity of Slx5-Slx8, we assayed its Ub ligase activity using sumoylated Siz2 as an in vitro substrate.  In contrast to unsumoylated or multisumoylated Siz2, substrates contg. poly-SUMO conjugates were efficiently ubiquitinated by Slx5-Slx8.  Although Siz2 itself was ubiquitinated, the bulk of the Ub was conjugated to SUMO residues.  Slx5-Slx8 primarily mono-ubiquitinated the N-terminal SUMO moiety of the chain.  These data indicate that the Slx5-Slx8 Ub ligase is stimulated by poly-SUMO conjugates and that it can ubiquitinate a poly-SUMO chain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNXx0geOY3ZbVg90H21EOLACvtfcHk0ljCPJ3eirR5Tg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotlOit7w%253D&md5=bfa4e56b59c26cdce11cb56959bddd4f</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M802690200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M802690200%26sid%3Dliteratum%253Aachs%26aulast%3DMullen%26aufirst%3DJ.%2BR.%26aulast%3DBrill%26aufirst%3DS.%2BJ.%26atitle%3DActivation%2520of%2520the%2520Slx5-Slx8%2520ubiquitin%2520ligase%2520by%2520poly-small%2520ubiquitin-like%2520modifier%2520conjugates%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26issue%3D29%26spage%3D19912%26epage%3D19921%26doi%3D10.1074%2Fjbc.M802690200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref202"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref202'); return false;" data-citation="" class="refNumLink">202</a></strong><div class="NLM_citation" id="cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vegetti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrone, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anichini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensi, M.</span></span> <span> </span><span class="NLM_article-title">Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">6503</span>â <span class="NLM_lpage">6511</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-05-4671</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F0008-5472.CAN-05-4671" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=16818621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD28XmsVamtr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=6503-6511&issue=13&author=C.+Pettiauthor=A.+Mollaauthor=C.+Vegettiauthor=S.+Ferroneauthor=A.+Anichiniauthor=M.+Sensi&title=Coexpression+of+NRASQ61R+and+BRAFV600E+in+human+melanoma+cells+activates+senescence+and+increases+susceptibility+to+cell-mediated+cytotoxicity&doi=10.1158%2F0008-5472.CAN-05-4671"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">Coexpression of NRASQ61R and BRAFV600E in Human Melanoma Cells Activates Senescence and Increases Susceptibility to Cell-Mediated Cytotoxicity</span></div><div class="casAuthors">Petti, Carlotta; Molla, Alessandra; Vegetti, Claudia; Ferrone, Soldano; Anichini, Andrea; Sensi, Marialuisa</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6503-6511</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Activating mutations in BRAF and NRAS oncogenes in human melanomas are mutually exclusive.  This finding has suggested an epistatic relationship but is consistent even with synthetic lethality.  To evaluate the latter possibility, a mutated NRASQ61R oncogene was expressed, under a constitutive or a doxycycline-regulated promoter, in a metastatic melanoma clone (clone 21) harboring an activated BRAFV600E oncogene.  After the first 10 to 12 in vitro passages, the constitutive NRASQ61R transfectant displayed progressive accumulation in G0-G1 phase of the cell cycle and stained for the senescence-assocd. Î²-galactosidase activity (SA-Î²-Gal).  Inducible expression of NRASQ61R, by the Tet-Off system, in clone 21 cells (21NRAS61ON) led to overactivation of the RAS/RAF/mitogen-activated protein kinase signaling pathway and, after the 10th in vitro passage, led to promotion of senescence.  This was documented by reduced proliferation, flattened cell morphol., reduced growth in Matrigel, pos. staining for SA-Î²-Gal, and expression of AMP-activated protein kinase and of the cell cycle inhibitor p21waf1/Cip1.  These effects were detected neither in 21 cells with silenced NRASQ61R (21NRAS61OFF) nor in cells transfected with an inducible wild-type NRAS gene (21NRASWTON).  In addn., when compared with parental 21 cells, or with 21NRAS61OFF, 21NRAS61ON and constitutive NRASQ61R transfectants cells showed increased susceptibility to cytotoxicity by both HLA class I antigen-restricted and nonspecific T cells and up-regulation of several MHC class I antigen processing machinery components.  These results suggest a relationship of synthetic lethality between NRAS and BRAF oncogenes, leading to selection against "double-mutant" cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpe5ZV46jNLpbVg90H21EOLACvtfcHk0ljCPJ3eirR5Tg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmsVamtr0%253D&md5=cb9b674e12d8b306a320fe51c8c0016c</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-4671&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-4671%26sid%3Dliteratum%253Aachs%26aulast%3DPetti%26aufirst%3DC.%26aulast%3DMolla%26aufirst%3DA.%26aulast%3DVegetti%26aufirst%3DC.%26aulast%3DFerrone%26aufirst%3DS.%26aulast%3DAnichini%26aufirst%3DA.%26aulast%3DSensi%26aufirst%3DM.%26atitle%3DCoexpression%2520of%2520NRASQ61R%2520and%2520BRAFV600E%2520in%2520human%2520melanoma%2520cells%2520activates%2520senescence%2520and%2520increases%2520susceptibility%2520to%2520cell-mediated%2520cytotoxicity%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26issue%3D13%26spage%3D6503%26epage%3D6511%26doi%3D10.1158%2F0008-5472.CAN-05-4671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref203"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref203'); return false;" data-citation="" class="refNumLink">203</a></strong><div class="NLM_citation" id="cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Byrum, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vindigni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosammaparast, N.</span></span> <span> </span><span class="NLM_article-title">Defining and modulating âBRCAnessâ</span>. <i>Trends Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">740</span>â <span class="NLM_lpage">751</span>, <span class="refDoi">Â DOI: 10.1016/j.tcb.2019.06.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.tcb.2019.06.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=31362850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlOgsbbO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=740-751&issue=9&author=A.+K.+Byrumauthor=A.+Vindigniauthor=N.+Mosammaparast&title=Defining+and+modulating+%E2%80%98BRCAness%E2%80%99&doi=10.1016%2Fj.tcb.2019.06.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Defining and Modulating 'BRCAness'</span></div><div class="casAuthors">Byrum, Andrea K.; Vindigni, Alessandro; Mosammaparast, Nima</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cell Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">740-751</span>CODEN:
                <span class="NLM_cas:coden">TCBIEK</span>;
        ISSN:<span class="NLM_cas:issn">0962-8924</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The concept of 'BRCAness' defines the pathogenesis and vulnerability of multiple cancers.  The canonical definition of BRCAness is a defect in homologous recombination repair, mimicking BRCA1 or BRCA2 loss.  In turn, BRCA-deficient cells utilize error-prone DNA-repair pathways, causing increased genomic instability, which may be responsible for their sensitivity to DNA damaging agents and poly-(ADP)-ribose polymerase inhibitors (PARPis).  However, recent work has expanded the mechanistic basis of BRCAness, to include defects in replication fork protection (RFP).  Here, we broaden the definition of BRCAness to include RFP and regulatory mechanisms that cause synthetic lethality with PARPis.  We highlight these recent discoveries, which include mechanisms of RFP regulation, DNA damage checkpoint proteins, as well as kinases that regulate BRCA1/2 function.  Importantly, many of these emerging mechanisms may be targeted for inhibition with small mol. inhibitors, thus inducing BRCAness in a much larger subset of BRCA-proficient tumors, with significant translational potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrX_47gRy6gbVg90H21EOLACvtfcHk0ljCPJ3eirR5Tg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlOgsbbO&md5=6c96ca15e1ff882a13c00540c1dfccac</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1016%2Fj.tcb.2019.06.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tcb.2019.06.005%26sid%3Dliteratum%253Aachs%26aulast%3DByrum%26aufirst%3DA.%2BK.%26aulast%3DVindigni%26aufirst%3DA.%26aulast%3DMosammaparast%26aufirst%3DN.%26atitle%3DDefining%2520and%2520modulating%2520%25E2%2580%2598BRCAness%25E2%2580%2599%26jtitle%3DTrends%2520Cell%2520Biol.%26date%3D2019%26volume%3D29%26issue%3D9%26spage%3D740%26epage%3D751%26doi%3D10.1016%2Fj.tcb.2019.06.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref204"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref204'); return false;" data-citation="" class="refNumLink">204</a></strong><div class="NLM_citation" id="cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muggia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safra, T.</span></span> <span> </span><span class="NLM_article-title">âBRCAnessâ and its implications for platinum action in gynecologic cancer</span>. <i>Anticancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">551</span>â <span class="NLM_lpage">556</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=24510983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvVCqu70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=551-556&issue=2&author=F.+Muggiaauthor=T.+Safra&title=%E2%80%98BRCAness%E2%80%99+and+its+implications+for+platinum+action+in+gynecologic+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">'BRCAness' and its implications for platinum action in gynecologic cancer</span></div><div class="casAuthors">Muggia, Franco; Safra, Tamar</div><div class="citationInfo"><span class="NLM_cas:title">Anticancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">551-556</span>CODEN:
                <span class="NLM_cas:coden">ANTRD4</span>;
        ISSN:<span class="NLM_cas:issn">0250-7005</span>.
    
            (<span class="NLM_cas:orgname">International Institute of Anticancer Research</span>)
        </div><div class="casAbstract">A review.  Gynecol. carcinomas are major therapeutic targets of platinum-contg. regimens.  They may be particularly susceptible to these agents if their origins are related to hereditary breast cancer (BRCA) mutations; this implicates defective DNA repair secondary to inherited alterations in BRCA function.  The concept of 'BRCAness' was introduced by Ashworth and colleagues in order to identify phenotypic changes in sporadic cancer that would lead to analogous treatment susceptibility.  In fact, recent analyses of genetic alterations in ovarian cancer have led to further extending this concept to all women with high-grade serous cancer, the predominant form of ovarian cancer arising in assocn. with hereditary mutations in BRCA genes.  Presumably, most serous types of cancer of gynecol. origin share BRCA dysfunction to some extent.  This renders these types of cancer susceptible to platinum and to other DNA-damaging agents, justifying the general inclusion of this histol. in trials of new drugs and therapeutic strategies that have shown activity against hereditary cancer.  More recently, however, differences in outcome between BRCA mutation carriers vis-a-vis those with no mutations or those with epigenetic or acquired forms of BRCA genes (somatic mutations) in their resp. tumors have been identified.  These findings raise addnl. questions on modifiers of 'BRCAness' and other pathways that appear to contribute to the effects of platinum and other DNA-damaging agents in ovarian cancer.  The Cancer Genome Atlas analyses delineate the complexity of genomic alterations in ovarian cancer and other malignancies of Mullerian epithelial origin promising further refinements of the 'BRCAness' concept.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3xJ2W88bG67Vg90H21EOLACvtfcHk0lh046T7SwD9vA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvVCqu70%253D&md5=509058ca9c85e653d19561025eacfd37</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMuggia%26aufirst%3DF.%26aulast%3DSafra%26aufirst%3DT.%26atitle%3D%25E2%2580%2598BRCAness%25E2%2580%2599%2520and%2520its%2520implications%2520for%2520platinum%2520action%2520in%2520gynecologic%2520cancer%26jtitle%3DAnticancer%2520Res.%26date%3D2014%26volume%3D34%26issue%3D2%26spage%3D551%26epage%3D556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref205"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref205'); return false;" data-citation="" class="refNumLink">205</a></strong><div class="NLM_citation" id="cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Plummer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boddy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHugh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinfeldt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewji, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvert, H.</span></span> <span> </span><span class="NLM_article-title">Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">7917</span>â <span class="NLM_lpage">7923</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-08-1223</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F1078-0432.CCR-08-1223" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=19047122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVegt7%252FM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=7917-7923&issue=23&author=R.+Plummerauthor=C.+Jonesauthor=M.+Middletonauthor=R.+Wilsonauthor=J.+Evansauthor=A.+Olsenauthor=N.+Curtinauthor=A.+Boddyauthor=P.+McHughauthor=D.+Newellauthor=A.+Harrisauthor=P.+Johnsonauthor=H.+Steinfeldtauthor=R.+Dewjiauthor=D.+Wangauthor=L.+Robsonauthor=H.+Calvert&title=Phase+I+study+of+the+poly%28ADP-ribose%29+polymerase+inhibitor%2C+AG014699%2C+in+combination+with+temozolomide+in+patients+with+advanced+solid+tumors&doi=10.1158%2F1078-0432.CCR-08-1223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Plummer, Ruth; Jones, Christopher; Middleton, Mark; Wilson, Richard; Evans, Jeffrey; Olsen, Anna; Curtin, Nicola; Boddy, Alan; McHugh, Peter; Newell, David; Harris, Adrian; Johnson, Patrick; Steinfeldt, Heidi; Dewji, Raz; Wang, Diane; Robson, Lesley; Calvert, Hilary</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7917-7923</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: One mechanism of tumor resistance to cytotoxic therapy is repair of damaged DNA.  Poly(ADP-ribose) polymerase (PARP)-1 is a nuclear enzyme involved in base excision repair, one of the five major repair pathways.  PARP inhibitors are emerging as a new class of agents that can potentiate chemotherapy and radiotherapy.  The article reports safety, efficacy, pharmacokinetic, and pharmacodynamic results of the first-in-class trial of a PARP inhibitor, AG014699, combined with temozolomide in adults with advanced malignancy.  Exptl. Design: Initially, patients with solid tumors received escalating doses of AG014699 with 100 mg/m2/d temozolomide x 5 every 28 days to establish the PARP ID (PID).  Subsequently, AG014699 dose was fixed at PID and temozolomide escalated to max. tolerated dose or 200 mg/m2 in metastatic melanoma patients whose tumors were biopsied.  AG014699 and temozolomide pharmacokinetics, PARP activity, DNA strand single-strand breaks, response, and toxicity were evaluated.  RESULTS: Thirty-three patients were enrolled.  PARP inhibition was seen at all doses; PID was 12 mg/m2 based on 74% to 97% inhibition of peripheral blood lymphocyte PARP activity.  Recommended doses were 12 mg/m2 AG014699 and 200 mg/m2 temozolomide.  Mean tumor PARP inhibition at 5 h was 92% (range, 46-97%).  No toxicity attributable to AG014699 alone was obsd.  AG014699 showed linear pharmacokinetics with no interaction with temozolomide.  All patients treated at PID showed increases in DNA single-strand breaks and encouraging evidence of activity was seen.  CONCLUSIONS: The combination of AG014699 and temozolomide is well tolerated, pharmacodynamic assessments showing proof of principle of the mode of action of this new class of agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoh3DGcSbf45bVg90H21EOLACvtfcHk0lh046T7SwD9vA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVegt7%252FM&md5=76b77d0a31dcb652c31e049a7f6163c2</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-1223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-1223%26sid%3Dliteratum%253Aachs%26aulast%3DPlummer%26aufirst%3DR.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DMiddleton%26aufirst%3DM.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DEvans%26aufirst%3DJ.%26aulast%3DOlsen%26aufirst%3DA.%26aulast%3DCurtin%26aufirst%3DN.%26aulast%3DBoddy%26aufirst%3DA.%26aulast%3DMcHugh%26aufirst%3DP.%26aulast%3DNewell%26aufirst%3DD.%26aulast%3DHarris%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DP.%26aulast%3DSteinfeldt%26aufirst%3DH.%26aulast%3DDewji%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DRobson%26aufirst%3DL.%26aulast%3DCalvert%26aufirst%3DH.%26atitle%3DPhase%2520I%2520study%2520of%2520the%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitor%252C%2520AG014699%252C%2520in%2520combination%2520with%2520temozolomide%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26issue%3D23%26spage%3D7917%26epage%3D7923%26doi%3D10.1158%2F1078-0432.CCR-08-1223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref206"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref206'); return false;" data-citation="" class="refNumLink">206</a></strong><div class="NLM_citation" id="cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poleksic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span> <span> </span><span class="NLM_article-title">Database of adverse events associated with drugs and drug combinations</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">20025</span>, <span class="refDoi">Â DOI: 10.1038/s41598-019-56525-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1038%2Fs41598-019-56525-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=31882773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmtFWqtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=20025&issue=1&author=A.+Poleksicauthor=L.+Xie&title=Database+of+adverse+events+associated+with+drugs+and+drug+combinations&doi=10.1038%2Fs41598-019-56525-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">Database of adverse events associated with drugs and drug combinations</span></div><div class="casAuthors">Poleksic, Aleksandar; Xie, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20025</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Due to the aging world population and increasing trend in clin. practice to treat patients with multiple drugs, adverse events (AEs) are becoming a major challenge in drug discovery and public health.  In particular, identifying AEs caused by drug combinations remains a challenging task.  Clin. trials typically focus on individual drugs rather than drug combinations and animal models are unreliable.  An added difficulty is the combinatorial explosion in the no. of possible combinations that can be made using the increasingly large set of FDA approved chems.  We present a statistical and computational technique for identifying AEs caused by two-drug combinations.  Taking advantage of the large and increasing data deposited in FDA's postmarketing reports, we demonstrate that the task of predicting AEs for 2-drug combinations is amenable to the Likelihood Ratio Test (LRT).  Our pAERS database constructed with LRT contains almost 77 thousand assocns. between pairs of drugs and corresponding AEs caused solely by drug-drug interactions (DDIs).  The DDIs stored in pAERS complement the existing data sets.  Due to our stringent statistical test, we expect many of the assocns. in pAERS to be unrecorded or poorly documented in the literature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmCw2kId84NbVg90H21EOLACvtfcHk0lj6zmExx5-Wrg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmtFWqtw%253D%253D&md5=540dbe70825cb60aab98e58c3abfc496</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-56525-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-56525-5%26sid%3Dliteratum%253Aachs%26aulast%3DPoleksic%26aufirst%3DA.%26aulast%3DXie%26aufirst%3DL.%26atitle%3DDatabase%2520of%2520adverse%2520events%2520associated%2520with%2520drugs%2520and%2520drug%2520combinations%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26issue%3D1%26spage%3D20025%26doi%3D10.1038%2Fs41598-019-56525-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref207"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref207'); return false;" data-citation="" class="refNumLink">207</a></strong><div class="NLM_citation" id="cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heinzel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marhold, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomasich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lukas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krainer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perco, P.</span></span> <span> </span><span class="NLM_article-title">Synthetic lethality guiding selection of drug combinations in ovarian cancer</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">1</span>), <span class="NLM_elocation-id">e0210859</span> <span class="refDoi">Â DOI: 10.1371/journal.pone.0210859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1371%2Fjournal.pone.0210859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=30682083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtFCmsbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&issue=1&author=A.+Heinzelauthor=M.+Marholdauthor=P.+Mayerauthor=M.+Schwarzauthor=E.+Tomasichauthor=A.+Lukasauthor=M.+Krainerauthor=P.+Perco&title=Synthetic+lethality+guiding+selection+of+drug+combinations+in+ovarian+cancer&doi=10.1371%2Fjournal.pone.0210859"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic lethality guiding selection of drug combinations in ovarian cancer</span></div><div class="casAuthors">Heinzel, Andreas; Marhold, Maximilian; Mayer, Paul; Schwarz, Michael; Tomasich, Erwin; Lukas, Arno; Krainer, Michael; Perco, Paul</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e0210859</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background: Synthetic lethality describes a relationship between two genes where single loss of either gene does not trigger significant impact on cell viability, but simultaneous loss of both gene functions results in lethality.  Targeting synthetic lethal interactions with drug combinations promises increased efficacy in tumor therapy.  Materials and methods: We established a set of synthetic lethal interactions using publicly available data from yeast screens which were mapped to their resp. human orthologs using information from orthol. databases.  This set of exptl. synthetic lethal interactions was complemented by a set of predicted synthetic lethal interactions based on a set of protein meta-data like e.g. mol. pathway assignment.  Based on the combined set, we evaluated drug combinations used in late stage clin. development (clin. phase III and IV trials) or already in clin. use for ovarian cancer with respect to their effect on synthetic lethal interactions.  We furthermore identified a set of drug combinations currently not being tested in late stage ovarian cancer clin. trials that however have impact on synthetic lethal interactions thus being worth of further investigations regarding their therapeutic potential in ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraSOZUkEy3M7Vg90H21EOLACvtfcHk0lj6zmExx5-Wrg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtFCmsbw%253D&md5=1f7a4b658923fc7c46128bb51e4913b3</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0210859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0210859%26sid%3Dliteratum%253Aachs%26aulast%3DHeinzel%26aufirst%3DA.%26aulast%3DMarhold%26aufirst%3DM.%26aulast%3DMayer%26aufirst%3DP.%26aulast%3DSchwarz%26aufirst%3DM.%26aulast%3DTomasich%26aufirst%3DE.%26aulast%3DLukas%26aufirst%3DA.%26aulast%3DKrainer%26aufirst%3DM.%26aulast%3DPerco%26aufirst%3DP.%26atitle%3DSynthetic%2520lethality%2520guiding%2520selection%2520of%2520drug%2520combinations%2520in%2520ovarian%2520cancer%26jtitle%3DPLoS%2520One%26date%3D2019%26volume%3D14%26issue%3D1%26doi%3D10.1371%2Fjournal.pone.0210859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref208"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref208'); return false;" data-citation="" class="refNumLink">208</a></strong><div class="NLM_citation" id="cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sassmannshausen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deurenberg, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kock, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrix, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossen, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedrich, A. W.</span></span> <span> </span><span class="NLM_article-title">MRSA prevalence and associated risk factors among health-care workers in non-outbreak situations in the dutch-german EUREGIO</span>. <i>Front. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1273</span>, <span class="refDoi">Â DOI: 10.3389/fmicb.2016.01273</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.3389%2Ffmicb.2016.01273" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=27597843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A280%3ADC%252BC2sznvFKnuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=1273&author=R.+Sassmannshausenauthor=R.+H.+Deurenbergauthor=R.+Kockauthor=R.+Hendrixauthor=A.+Jurkeauthor=J.+W.+Rossenauthor=A.+W.+Friedrich&title=MRSA+prevalence+and+associated+risk+factors+among+health-care+workers+in+non-outbreak+situations+in+the+dutch-german+EUREGIO&doi=10.3389%2Ffmicb.2016.01273"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">MRSA Prevalence and Associated Risk Factors among Health-Care Workers in Non-outbreak Situations in the Dutch-German EUREGIO</span></div><div class="casAuthors">Sassmannshausen Ricarda; Deurenberg Ruud H; Rossen John W A; Friedrich Alexander W; Kock Robin; Hendrix Ron; Jurke Annette</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in microbiology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1273</span>
        ISSN:<span class="NLM_cas:issn">1664-302X</span>.
    </div><div class="casAbstract">Preventing the spread of methicillin-resistant Staphylococcus aureus (MRSA) in healthcare facilities is a major infection control target.  However, only a few studies have assessed the potential role of healthcare workers (HCWs) for MRSA dissemination.  To investigate the MRSA prevalence and the risk factors for MRSA colonization among HCWs, nasopharyngeal swabs were taken between June 2010 and January 2011 from 726 employees from nine acute care hospitals with different care levels within the German part of a Dutch-German border region (EUREGIO).  The isolated MRSA strains were investigated using spa typing.  The overall MRSA prevalence among HCWs in a non-outbreak situation was 4.6% (33 of 726), and was higher in nurses (5.6%, 29 of 514) than in physicians (1.2%, 1 of 83).  Possible risk factors associated with MRSA colonization were a known history of MRSA carriage and the presence of acne.  Intensive contact with patients may facilitate MRSA transmission between patients and HCWs.  Furthermore, an accumulation of risk factors was accompanied by an increased MRSA prevalence in HCW.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQjOr1PdgGetLmQt-ICR3qNfW6udTcc2eZ_soGuBtZMNbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sznvFKnuw%253D%253D&md5=dae7426d591e50c4963fd080465a5d62</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.3389%2Ffmicb.2016.01273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffmicb.2016.01273%26sid%3Dliteratum%253Aachs%26aulast%3DSassmannshausen%26aufirst%3DR.%26aulast%3DDeurenberg%26aufirst%3DR.%2BH.%26aulast%3DKock%26aufirst%3DR.%26aulast%3DHendrix%26aufirst%3DR.%26aulast%3DJurke%26aufirst%3DA.%26aulast%3DRossen%26aufirst%3DJ.%2BW.%26aulast%3DFriedrich%26aufirst%3DA.%2BW.%26atitle%3DMRSA%2520prevalence%2520and%2520associated%2520risk%2520factors%2520among%2520health-care%2520workers%2520in%2520non-outbreak%2520situations%2520in%2520the%2520dutch-german%2520EUREGIO%26jtitle%3DFront.%2520Microbiol.%26date%3D2016%26volume%3D7%26spage%3D1273%26doi%3D10.3389%2Ffmicb.2016.01273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref209"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref209'); return false;" data-citation="" class="refNumLink">209</a></strong><div class="NLM_citation" id="cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vos, M.</span></span> <span> </span><span class="NLM_article-title">Why do bacteria engage in homologous recombination?</span>. <i>Trends Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">226</span>â <span class="NLM_lpage">232</span>, <span class="refDoi">Â DOI: 10.1016/j.tim.2009.03.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.tim.2009.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=19464181" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntVGmu7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=226-232&issue=6&author=M.+Vos&title=Why+do+bacteria+engage+in+homologous+recombination%3F&doi=10.1016%2Fj.tim.2009.03.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Why do bacteria engage in homologous recombination?</span></div><div class="casAuthors">Vos, Michiel</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Microbiology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">226-232</span>CODEN:
                <span class="NLM_cas:coden">TRMIEA</span>;
        ISSN:<span class="NLM_cas:issn">0966-842X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Microbiologists have long recognized that the uptake and incorporation of homologous DNA from outside the cell is a common feature of bacteria, with important implications for their evolution.  However, the exact reasons why bacteria engage in homologous recombination remain elusive.  This Opinion article aims to reinvigorate the debate by examg. the costs and benefits that homologous recombination could engender in natural populations of bacteria.  It specifically focuses on the hypothesis that homologous recombination is selectively maintained because the genetic variation it generates improves the response of bacterial populations to natural selection, analogous to sex in eukaryotes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9KpYfEk7CerVg90H21EOLACvtfcHk0lgQNNb81wTZrg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntVGmu7c%253D&md5=76ef5f4b44ec31d7b216ffe292c7983b</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1016%2Fj.tim.2009.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tim.2009.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DVos%26aufirst%3DM.%26atitle%3DWhy%2520do%2520bacteria%2520engage%2520in%2520homologous%2520recombination%253F%26jtitle%3DTrends%2520Microbiol.%26date%3D2009%26volume%3D17%26issue%3D6%26spage%3D226%26epage%3D232%26doi%3D10.1016%2Fj.tim.2009.03.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref210"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref210'); return false;" data-citation="" class="refNumLink">210</a></strong><div class="NLM_citation" id="cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aziz, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monk, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">In Loh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abhay Nagle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satyanarayana, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhakshinamoorthy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luche, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitchen, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palsson, B. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charusanti, P.</span></span> <span> </span><span class="NLM_article-title">Systems biology-guided identification of synthetic lethal gene pairs and its potential use to discover antibiotic combinations</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">16025</span>, <span class="refDoi">Â DOI: 10.1038/srep16025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1038%2Fsrep16025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=26531810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslOnsbjO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=16025&author=R.+K.+Azizauthor=J.+M.+Monkauthor=R.+M.+Lewisauthor=S.+In+Lohauthor=A.+Mishraauthor=A.+Abhay+Nagleauthor=C.+Satyanarayanaauthor=S.+Dhakshinamoorthyauthor=M.+Lucheauthor=D.+B.+Kitchenauthor=K.+A.+Andrewsauthor=N.+L.+Fongauthor=H.+J.+Liauthor=B.+O.+Palssonauthor=P.+Charusanti&title=Systems+biology-guided+identification+of+synthetic+lethal+gene+pairs+and+its+potential+use+to+discover+antibiotic+combinations&doi=10.1038%2Fsrep16025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">Systems biology-guided identification of synthetic lethal gene pairs and its potential use to discover antibiotic combinations</span></div><div class="casAuthors">Aziz, Ramy K.; Monk, Jonathan M.; Lewis, Robert M.; In Loh, Suh; Mishra, Arti; Abhay Nagle, Amrita; Satyanarayana, Chitkala; Dhakshinamoorthy, Saravanakumar; Luche, Michele; Kitchen, Douglas B.; Andrews, Kathleen A.; Fong, Nicole L.; Li, Howard J.; Palsson, Bernhard O.; Charusanti, Pep</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">16025</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Math. models of metab. from bacterial systems biol. have proven their utility across multiple fields, for example metabolic engineering, growth phenotype simulation, and biol. discovery.  The usefulness of the models stems from their ability to compute a link between genotype and phenotype, but their ability to accurately simulate gene-gene interactions has not been investigated extensively.  Here we assess how accurately a metabolic model for Escherichia coli computes one particular type of gene-gene interaction, synthetic lethality, and find that the accuracy rate is between 25% and 43%.  The most common failure modes were incorrect computation of single gene essentiality and biol. information that was missing from the model.  Moreover, we performed virtual and biol. screening against several synthetic lethal pairs to explore whether two-compd. formulations could be found that inhibit the growth of Gram-neg. bacteria.  One set of mols. was identified that, depending on the concns., inhibits E. coli and S. enterica serovar Typhimurium in an additive or antagonistic manner.  These findings pinpoint specific ways in which to improve the predictive ability of metabolic models, and highlight one potential application of systems biol. to drug discovery and translational medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIY7RkarwZ07Vg90H21EOLACvtfcHk0lgQNNb81wTZrg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslOnsbjO&md5=cf0a1e402e1c5985e6edf46dcca5943d</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1038%2Fsrep16025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep16025%26sid%3Dliteratum%253Aachs%26aulast%3DAziz%26aufirst%3DR.%2BK.%26aulast%3DMonk%26aufirst%3DJ.%2BM.%26aulast%3DLewis%26aufirst%3DR.%2BM.%26aulast%3DIn%2BLoh%26aufirst%3DS.%26aulast%3DMishra%26aufirst%3DA.%26aulast%3DAbhay%2BNagle%26aufirst%3DA.%26aulast%3DSatyanarayana%26aufirst%3DC.%26aulast%3DDhakshinamoorthy%26aufirst%3DS.%26aulast%3DLuche%26aufirst%3DM.%26aulast%3DKitchen%26aufirst%3DD.%2BB.%26aulast%3DAndrews%26aufirst%3DK.%2BA.%26aulast%3DFong%26aufirst%3DN.%2BL.%26aulast%3DLi%26aufirst%3DH.%2BJ.%26aulast%3DPalsson%26aufirst%3DB.%2BO.%26aulast%3DCharusanti%26aufirst%3DP.%26atitle%3DSystems%2520biology-guided%2520identification%2520of%2520synthetic%2520lethal%2520gene%2520pairs%2520and%2520its%2520potential%2520use%2520to%2520discover%2520antibiotic%2520combinations%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D5%26spage%3D16025%26doi%3D10.1038%2Fsrep16025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref211"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref211'); return false;" data-citation="" class="refNumLink">211</a></strong><div class="NLM_citation" id="cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, Y.</span></span> <span> </span><span class="NLM_article-title">Proposal for a new therapy for drug-resistant malaria using plasmodium synthetic lethality inference</span>. <i>Int. J. Parasitol.: Drugs Drug Resist.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">119</span>â <span class="NLM_lpage">128</span>, <span class="refDoi">Â DOI: 10.1016/j.ijpddr.2013.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.ijpddr.2013.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=24533301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A280%3ADC%252BC2cvls1ensQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=119-128&author=S.+J.+Leeauthor=E.+Seoauthor=Y.+Cho&title=Proposal+for+a+new+therapy+for+drug-resistant+malaria+using+plasmodium+synthetic+lethality+inference&doi=10.1016%2Fj.ijpddr.2013.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">Proposal for a new therapy for drug-resistant malaria using Plasmodium synthetic lethality inference</span></div><div class="casAuthors">Lee Sang Joon; Seo Eunseok; Cho Yonghyun</div><div class="citationInfo"><span class="NLM_cas:title">International journal for parasitology. Drugs and drug resistance</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">119-28</span>
        ISSN:<span class="NLM_cas:issn">2211-3207</span>.
    </div><div class="casAbstract">Many antimalarial drugs kill malaria parasites, but antimalarial drug resistance (ADR) and toxicity to normal cells limit their usefulness.  To solve this problem, we suggest a new therapy for drug-resistant malaria.  The approach consists of data integration and inference through homology analysis of yeast-human-Plasmodium.  If one gene of a Plasmodium synthetic lethal (SL) gene pair has a mutation that causes ADR, a drug targeting the other gene of the SL pair might be used as an effective treatment for drug-resistant strains of malaria.  A simple computational tool to analyze the inferred SL genes of Plasmodium species (malaria parasites Plasmodium falciparum and Plasmodium vivax for human malarial therapy, and rodent parasite Plasmodium berghei for in vivo studies of human malarias) was established to identify SL genes that can be used as drug targets.  Information on SL gene pairs with ADR genes and their first neighbors was inferred from yeast SL genes to search for pertinent antimalarial drug targets.  We not only suggest drug target gene candidates for further experimental validation, but also provide information on new usage for already-described drugs.  The proposed specific antimalarial drug candidates can be inferred by searching drugs that cause a fitness defect in yeast SL genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ0kT6fDiRpcZPlX7E30qdzfW6udTcc2eaQo9v7ZO_Pbrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cvls1ensQ%253D%253D&md5=99215a9d36aaf4d1d2e5ef71a506f7de</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpddr.2013.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpddr.2013.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DSeo%26aufirst%3DE.%26aulast%3DCho%26aufirst%3DY.%26atitle%3DProposal%2520for%2520a%2520new%2520therapy%2520for%2520drug-resistant%2520malaria%2520using%2520plasmodium%2520synthetic%2520lethality%2520inference%26jtitle%3DInt.%2520J.%2520Parasitol.%253A%2520Drugs%2520Drug%2520Resist.%26date%3D2013%26volume%3D3%26spage%3D119%26epage%3D128%26doi%3D10.1016%2Fj.ijpddr.2013.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref212"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref212'); return false;" data-citation="" class="refNumLink">212</a></strong><div class="NLM_citation" id="cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Symington, L. S.</span></span> <span> </span><span class="NLM_article-title">Role of RAD52 epistasis group genes in homologous recombination and double-strand break repair</span>. <i>Microbiol. Mol. Biol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>66</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">630</span>â <span class="NLM_lpage">670</span>, <span class="refDoi">Â DOI: 10.1128/MMBR.66.4.630-670.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1128%2FMMBR.66.4.630-670.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=12456786" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD38XpslemtL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2002&pages=630-670&issue=4&author=L.+S.+Symington&title=Role+of+RAD52+epistasis+group+genes+in+homologous+recombination+and+double-strand+break+repair&doi=10.1128%2FMMBR.66.4.630-670.2002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit212R"><div class="casContent"><span class="casTitleNuber">212</span><div class="casTitle"><span class="NLM_cas:atitle">Role of RAD52 epistasis group genes in homologous recombination and double-strand break repair</span></div><div class="casAuthors">Symington, Lorraine S.</div><div class="citationInfo"><span class="NLM_cas:title">Microbiology and Molecular Biology Reviews</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">630-670</span>CODEN:
                <span class="NLM_cas:coden">MMBRF7</span>;
        ISSN:<span class="NLM_cas:issn">1092-2172</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A review.  The goal of this review is to provide an update of the role of the RAD52 group genes in spontaneous and DSB-induced homologous recombination.  Most of the genes in the RAD52 epistasis group (RAD50, RAD51, RAD52, RAD54, RAD55, RAD57, RAD59, RDH54 [TID1], MRE11 [RAD58], and XRS2) were identified by their requirement in the repair of ionizing-radiation-induced DNA damage.  Mutations in these genes lead to defects in meiotic and/or mitotic recombination, providing evidence for a link between DSB repair (DSBR) and homologous recombination.  Homologues of the RAD52 group of genes have been identified in many other eukaryotes, and in some cases in prokaryotes and archaea, indicating high conservation of the recombinational repair pathway.  The recent discovery that several human cancer-prone syndromes, for example, Nijmegen breakage syndrome (NBS) and ataxia-telangiectasia-like disorder (A-TLD), are caused by defects in DSBR has highlighted the importance of this repair pathway in maintaining genome integrity and cancer avoidance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNsMWVxVWj8LVg90H21EOLACvtfcHk0lhneDYsygadvA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpslemtL0%253D&md5=6f3c085982682e6cb06ee70a4c8dff9c</span></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.1128%2FMMBR.66.4.630-670.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMMBR.66.4.630-670.2002%26sid%3Dliteratum%253Aachs%26aulast%3DSymington%26aufirst%3DL.%2BS.%26atitle%3DRole%2520of%2520RAD52%2520epistasis%2520group%2520genes%2520in%2520homologous%2520recombination%2520and%2520double-strand%2520break%2520repair%26jtitle%3DMicrobiol.%2520Mol.%2520Biol.%2520Rev.%26date%3D2002%26volume%3D66%26issue%3D4%26spage%3D630%26epage%3D670%26doi%3D10.1128%2FMMBR.66.4.630-670.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref213"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref213'); return false;" data-citation="" class="refNumLink">213</a></strong><div class="NLM_citation" id="cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kelso, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldvogel, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luthman, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sehorn, M. G.</span></span> <span> </span><span class="NLM_article-title">Homologous recombination in protozoan parasites and recombinase inhibitors</span>. <i>Front. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1716</span>, <span class="refDoi">Â DOI: 10.3389/fmicb.2017.01716</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.3389%2Ffmicb.2017.01716" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=28936205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A280%3ADC%252BC1M%252FhtFemug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1716&author=A.+A.+Kelsoauthor=S.+M.+Waldvogelauthor=A.+J.+Luthmanauthor=M.+G.+Sehorn&title=Homologous+recombination+in+protozoan+parasites+and+recombinase+inhibitors&doi=10.3389%2Ffmicb.2017.01716"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">Homologous Recombination in Protozoan Parasites and Recombinase Inhibitors</span></div><div class="casAuthors">Kelso Andrew A; Waldvogel Sarah M; Luthman Adam J; Sehorn Michael G; Kelso Andrew A; Sehorn Michael G; Sehorn Michael G; Sehorn Michael G</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in microbiology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1716</span>
        ISSN:<span class="NLM_cas:issn">1664-302X</span>.
    </div><div class="casAbstract">Homologous recombination (HR) is a DNA double-strand break (DSB) repair pathway that utilizes a homologous template to fully repair the damaged DNA.  HR is critical to maintain genome stability and to ensure genetic diversity during meiosis.  A specialized class of enzymes known as recombinases facilitate the exchange of genetic information between sister chromatids or homologous chromosomes with the help of numerous protein accessory factors.  The majority of the HR machinery is highly conserved among eukaryotes.  In many protozoan parasites, HR is an essential DSB repair pathway that allows these organisms to adapt to environmental conditions and evade host immune systems through genetic recombination.  Therefore, small molecule inhibitors, capable of disrupting HR in protozoan parasites, represent potential therapeutic options.  A number of small molecule inhibitors were identified that disrupt the activities of the human recombinase RAD51.  Recent studies have examined the effect of two of these molecules on the Entamoeba recombinases.  Here, we discuss the current understandings of HR in the protozoan parasites Trypanosoma, Leishmania, Plasmodium, and Entamoeba, and we review the small molecule inhibitors known to disrupt human RAD51 activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR2cvYA9hPVZ1vAgqb2vdc5fW6udTcc2eZwCDvrd6zFVLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M%252FhtFemug%253D%253D&md5=1552e6bc7a85d8d6d5bda8ebc1b5bb69</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.3389%2Ffmicb.2017.01716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffmicb.2017.01716%26sid%3Dliteratum%253Aachs%26aulast%3DKelso%26aufirst%3DA.%2BA.%26aulast%3DWaldvogel%26aufirst%3DS.%2BM.%26aulast%3DLuthman%26aufirst%3DA.%2BJ.%26aulast%3DSehorn%26aufirst%3DM.%2BG.%26atitle%3DHomologous%2520recombination%2520in%2520protozoan%2520parasites%2520and%2520recombinase%2520inhibitors%26jtitle%3DFront.%2520Microbiol.%26date%3D2017%26volume%3D8%26spage%3D1716%26doi%3D10.3389%2Ffmicb.2017.01716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref214"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref214'); return false;" data-citation="" class="refNumLink">214</a></strong><div class="NLM_citation" id="cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">OâNeil, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hieter, P.</span></span> <span> </span><span class="NLM_article-title">Synthetic lethality and cancer</span>. <i>Nat. Rev. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">613</span>â <span class="NLM_lpage">623</span>, <span class="refDoi">Â DOI: 10.1038/nrg.2017.47</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1038%2Fnrg.2017.47" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=28649135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVOjsLvL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=613-623&issue=10&author=N.+J.+O%E2%80%99Neilauthor=M.+L.+Baileyauthor=P.+Hieter&title=Synthetic+lethality+and+cancer&doi=10.1038%2Fnrg.2017.47"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit214R"><div class="casContent"><span class="casTitleNuber">214</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic lethality and cancer</span></div><div class="casAuthors">O'Neil, Nigel J.; Bailey, Melanie L.; Hieter, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Genetics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">613-623</span>CODEN:
                <span class="NLM_cas:coden">NRGAAM</span>;
        ISSN:<span class="NLM_cas:issn">1471-0056</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A synthetic lethal interaction occurs between two genes when the perturbation of either gene alone is viable but the perturbation of both genes simultaneously results in the loss of viability.  Key to exploiting synthetic lethality in cancer treatment are the identification and the mechanistic characterization of robust synthetic lethal genetic interactions.  Advances in next-generation sequencing technologies are enabling the identification of hundreds of tumor-specific mutations and alterations in gene expression that could be targeted by a synthetic lethality approach.  The translation of synthetic lethality to therapy will be assisted by the synthesis of genetic interaction data from model organisms, tumor genomes and human cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopIYVNGqWJ77Vg90H21EOLACvtfcHk0liIEeyY_GLrNw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVOjsLvL&md5=cdcf1455ecb19ab834c01001d1ee9200</span></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.1038%2Fnrg.2017.47&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrg.2017.47%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Neil%26aufirst%3DN.%2BJ.%26aulast%3DBailey%26aufirst%3DM.%2BL.%26aulast%3DHieter%26aufirst%3DP.%26atitle%3DSynthetic%2520lethality%2520and%2520cancer%26jtitle%3DNat.%2520Rev.%2520Genet.%26date%3D2017%26volume%3D18%26issue%3D10%26spage%3D613%26epage%3D623%26doi%3D10.1038%2Fnrg.2017.47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref215"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref215'); return false;" data-citation="" class="refNumLink">215</a></strong><div class="NLM_citation" id="cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walcott, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubet, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calzone, K. A.</span></span> <span> </span><span class="NLM_article-title">Hereditary cancer syndromes as model systems for chemopreventive agent development</span>. <i>Semin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>43</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">134</span>â <span class="NLM_lpage">145</span>, <span class="refDoi">Â DOI: 10.1053/j.seminoncol.2015.09.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1053%2Fj.seminoncol.2015.09.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=26970132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFKgsb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2016&pages=134-145&issue=1&author=F.+L.+Walcottauthor=J.+Patelauthor=R.+Lubetauthor=L.+Rodriguezauthor=K.+A.+Calzone&title=Hereditary+cancer+syndromes+as+model+systems+for+chemopreventive+agent+development&doi=10.1053%2Fj.seminoncol.2015.09.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit215R"><div class="casContent"><span class="casTitleNuber">215</span><div class="casTitle"><span class="NLM_cas:atitle">Hereditary cancer syndromes as model systems for chemopreventive agent development</span></div><div class="casAuthors">Walcott, Farzana L.; Patel, Jigar; Lubet, Ronald; Rodriguez, Luz; Calzone, Kathleen A.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">134-145</span>CODEN:
                <span class="NLM_cas:coden">SOLGAV</span>;
        ISSN:<span class="NLM_cas:issn">0093-7754</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Research in chemoprevention has undergone a shift in emphasis for pragmatic reasons from large, phase III randomized studies to earlier phase studies focused on safety, mechanisms, and utilization of surrogate endpoints such as biomarkers instead of cancer incidence.  This transition permits trials to be conducted in smaller populations and at substantially reduced costs while still yielding valuable information.  This article will summarize some of the current chemoprevention challenges and the justification for the use of animal models to facilitate identification and testing of chemopreventive agents as illustrated though four inherited cancer syndromes.  Preclin. models of inherited cancer syndromes serve as prototypical systems in which chemopreventive agents can be developed for ultimate application to both the sporadic and inherited cancer settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRCj_VaL3uXbVg90H21EOLACvtfcHk0liIEeyY_GLrNw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFKgsb4%253D&md5=26e21d29bc336ac5e15821b059ff84b1</span></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.1053%2Fj.seminoncol.2015.09.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.seminoncol.2015.09.015%26sid%3Dliteratum%253Aachs%26aulast%3DWalcott%26aufirst%3DF.%2BL.%26aulast%3DPatel%26aufirst%3DJ.%26aulast%3DLubet%26aufirst%3DR.%26aulast%3DRodriguez%26aufirst%3DL.%26aulast%3DCalzone%26aufirst%3DK.%2BA.%26atitle%3DHereditary%2520cancer%2520syndromes%2520as%2520model%2520systems%2520for%2520chemopreventive%2520agent%2520development%26jtitle%3DSemin.%2520Oncol.%26date%3D2016%26volume%3D43%26issue%3D1%26spage%3D134%26epage%3D145%26doi%3D10.1053%2Fj.seminoncol.2015.09.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185'],'ref186':['cit186'],'ref187':['cit187'],'ref188':['cit188'],'ref189':['cit189'],'ref190':['cit190'],'ref191':['cit191'],'ref192':['cit192'],'ref193':['cit193'],'ref194':['cit194'],'ref195':['cit195'],'ref196':['cit196'],'ref197':['cit197'],'ref198':['cit198'],'ref199':['cit199'],'ref200':['cit200'],'ref201':['cit201'],'ref202':['cit202'],'ref203':['cit203'],'ref204':['cit204'],'ref205':['cit205'],'ref206':['cit206'],'ref207':['cit207'],'ref208':['cit208'],'ref209':['cit209'],'ref210':['cit210'],'ref211':['cit211'],'ref212':['cit212'],'ref213':['cit213'],'ref214':['cit214'],'ref215':['cit215']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 1 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hugh C.  Osborne</span>, <span class="hlFld-ContribAuthor ">Elsa  Irving</span>, <span class="hlFld-ContribAuthor ">Josep V.  Forment</span>, <span class="hlFld-ContribAuthor ">Christine K.  Schmidt</span>. </span><span class="cited-content_cbyCitation_article-title">E2 enzymes in genome stability: pulling the strings behind the scenes. </span><span class="cited-content_cbyCitation_journal-name">Trends in Cell Biology</span><span> <strong>2021,</strong> <em>31 </em>
                                    (8)
                                     , 628-643. <a href="https://doi.org/10.1016/j.tcb.2021.01.009" title="DOI URL">https://doi.org/10.1016/j.tcb.2021.01.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tcb.2021.01.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tcb.2021.01.009%26sid%3Dliteratum%253Aachs%26jtitle%3DTrends%2520in%2520Cell%2520Biology%26atitle%3DE2%252Benzymes%252Bin%252Bgenome%252Bstability%25253A%252Bpulling%252Bthe%252Bstrings%252Bbehind%252Bthe%252Bscenes%26aulast%3DOsborne%26aufirst%3DHugh%2BC.%26date%3D2021%26volume%3D31%26issue%3D8%26spage%3D628%26epage%3D643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0024.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Schematic representation of PARPâs role in SSB and DSB repair. Upon formation of a SSB, PARP1 and other acceptor proteins (histone H1, TOP1, and others) are recruited and attached to the lesion site. This recruits other factors involved in DNA repair (PolÎ², LigIII, TDP1, and XRCC1) which, through BER, repair the lesion. If PARP is inhibited, the SSB becomes a DSB which causes Î³H2AX foci formation, which in the presence of BRCA1/2 triggers HR which repairs the DSB. In the absence of BRCA this break becomes synthetically lethal. Adapted from   <cite><i>Clinical Cancer Research</i></cite>, Copyright 2010, Vol. <em>16</em>, Issue 18, Page 4532, <contrib-group>Christophe E. Redon, Asako
J. Nakamura, Yong-Wei Zhang, Jiuping (Jay) Ji, William M. Bonner,
Robert J. Kinders, Ralph E. Parchment, James H. Doroshow, Yves Pommier</contrib-group>, Histone Î³H2AX and Poly(ADP-Ribose) as Clinical
Pharmacodynamic Biomarkers,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> with permission from AACR.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Approved PARP inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Demonstration of ATM, ATR, and DNA-PKcs involvement in DNA repair networks. Adapted from   <cite><i>Trends
in Cancer</i></cite>, Vol. <em>4</em>, Issue 11, <contrib-group>Omar L. Kantidze, Artem K. Velichko, Artem V. Luzhin,
Nadezhda V. Petrova, Sergey V. Razin</contrib-group>, Synthetically Lethal Interactions of ATM, ATR, and DNAPKcs,<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Page 762, Copyright (2018) with permission from Elsevier.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) SAR study around ATR inhibitor VE-821 (<b>5</b>) to get VX-970 (<b>6</b>). (B) Structure of ATR inhibitor M4344 (<b>7</b>). (C) Structure of BAY1895344 (<b>8</b>) identified by Bayer AG as a selective ATR inhibitor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Chemical modifications introduced in AZ20 (<b>9</b>) to improve solubility and reduce CYP3A4 activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Hit compounds from Ramachandran et al. (B) Optimization of <b>12</b> to <b>16</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) Development of ATM inhibitor LY294002 (<b>17</b>) into KU-60019 (<b>20</b>). (B) Structure of ATM inhibitor CP466722 (<b>21</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Development by AstraZeneca of ATM inhibitor from hit <b>22</b> into candidate AZD1390 (<b>29</b>) through the lead AZD156 (<b>28</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Structure of SU-11752 (<b>30</b>) and wortmannin (<b>31</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Optimization of PI3K inhibitor <b>17</b> resulting in the discovery of KU-5788 (<b>34</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. (A) Optimization of DNA-PK inhibitor <b>35</b> to AZD7648 (<b>36</b>) by AZ. (B) Structure of DNA-PK inhibitor M3814 (<b>37</b>) developed by Merck.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Optimization of mTOR inhibitor CC214-1 (<b>38</b>) leading to the discovery of mTOR/DNA-PK dual inhibitor CC-115 (<b>39</b>). Small substituents in the N1/N4 position resulted in the maintenance of high potency but improved PD/PK properties.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. (A) SAR and optimization of WEE1 inhibitor <b>40</b> to <b>43</b>. (B) Structure of ATR inhibitor ETP-46464 (<b>41</b>). (C) Structure of first WEE1 inhibitor PD0166285 (<b>42</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Optimization of CDK12 inhibitor <b>44</b> to <b>46</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Cocrystallization of <b>48</b> with CDK12 adapted from Zhang et al.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> (a) <b>48</b> binds to M816 in the kinase hinge region and connects to Cys1039 in two conformations via the compoundâs flexible linker. Solvent-exposed regions of <b>48</b> with poor electron density are represented by thin sticks. (b) Omit map contoured at 2.5Ï for <b>48</b> bound to CDK12 chain C. (c) Omit map contoured at 2.5Ï for <b>48</b> bound to CDK12 chain D. Reproduced with permission from Springer Nature,   <cite><i>Nature Chemical
Biology</i></cite>, Covalent targeting of remote cysteine
residues to develop CDK12 and CDK13 inhibitors, <contrib-group>Tinghu Zhang, Nicholas Kwiatkowski, Calla M. Olson, Sarah E. Dixon-Clarke,
Brian J. Abraham, Ann K. Greifenberg, Scott B. Ficarro, Jonathan M.
Elkins, Yanke Liang, Nancy M. Hannett, Theresa Manz, Mingfeng Hao,
Bartlomiej Bartkowiak, Arno L. Greenleaf, Jarrod A. Marto, Matthias
Geyer, Alex N. Bullock, Richard A. Young, Nathanael S. Gray</contrib-group>,<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> Copyright 2019 Springer Nature.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0027.jpeg" id="rightTab-GRAPHIC-d7e3073-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. (A) Optimization of CDK inhibitor THZ1 (<b>47</b>). (B) Structure of CDK inhibitor dinaciclib (<b>49</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0016.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. (A) PARP inhibitors triggering synthetic lethality in BRCA-deficient cells. (B) Proposed triggering of small molecule-induced synthetic lethality using PARP inhibitors in combination with RAD51-BRCA2 disruptors. Adapted from   <cite><i>European Journal
of Medicinal Chemistry</i></cite>, Vol. <em>165</em>, <contrib-group>Marinella Roberti, Fabrizio Schipani, Greta Bagnolini, Domenico Milano,
Elisa Giacomini, Federico Falchi, Andrea Balboni, Marcella Manerba,
Fulvia Farabegoli, Francesca De Franco, Janet Robertson, Saverio Minucci,
Isabella Pallavicini, Giuseppina Di Stefano, S. Girotto, R. Pellicciari,
A. Cavalli</contrib-group>, Rad51/BRCA2 disruptors inhibit
homologous recombination and synergize with olaparib in pancreatic
cancer cells,<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> Page 81, Copyright (2019), with permission from Elsevier.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0017.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Depiction of the SAR strategy for the further development of <b>52</b>. This primarily focused on three areas within the molecule highlighted in green, red, and blue. The proposed moieties in these regions are shown in their accompanying text.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0018.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Optimization of <b>53</b> to <b>54</b>. All compounds from this series were tested as racemic mixtures after both enantiomers of <b>53</b> showed the same biochemical activity and binding mode.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0019.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Examples of Rad51 inhibitors reported in the literature.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0020.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. RAD52, SL interactions with PARP inhibitors. This figure shows classic SL with PARP inhibition in BRCA2 deficient-cancer cells. These are prone to acquired mutation. The implementation of RAD52 in combination with PARPi has no effect in BRCA2 proficient healthy cells; however, in BRCA2-deficient cancer cells, small-molecule-induced synthetic lethality occurs. Adapted from   <cite><i>Cancers</i></cite>, <span class="NLM_year">2019</span>, Vol. <em>11</em>, Issue 10, <contrib-group>Monika Toma, Katherine Sullivan-Reed, Tomasz
ÅliwiÅski, Tomasz Skorski</contrib-group>, RAD52 as a Potential Target for Synthetic Lethality-Based Anticancer
Therapies,<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> Page 1569, with use of the <a href="https://creativecommons.org/licenses/by/4.0/" class="ext-link">Attribution 4.0 International (CC BY 4.0)</a> open access license.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0021.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Structures of different RAD52 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0022.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Proposed binding regions of the RAD52 inhibitors: (A) <b>63</b> and (B) <b>64</b>. Adapted from   <cite><i>eLIFE</i></cite>, <span class="NLM_year">2016</span>,
Vol. <em>5</em>, e14740, <contrib-group>Sarah R. Hengel, Eva
Malacaria, Laura Folly da Silva Constantino, Fletcher E. Bain, Andrea
Diaz, Brandon G. Koch, Liping Yu, Meng Wu, Pietro Pichierri, M. Ashley
Spies, Maria Spies</contrib-group>, Small-molecule inhibitors
identify the RAD52-ssDNA interaction as critical for recovery from
replication stress and for survival of BRCA2 deficient cells,<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a> with use of the <a href="https://creativecommons.org/licenses/by/4.0/" class="ext-link">Attribution 4.0 International (CC BY 4.0)</a> open access license.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/medium/jm0c00766_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0023.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Proposed binding regions of <b>66</b>. Reproduced with permission of The Royal Society of Chemistry, from <contrib-group><span class="NLM_string-name">Li, J.</span>; <span class="NLM_string-name">Yang, Q.</span>; <span class="NLM_string-name">Zhang, Y.</span>; <span class="NLM_string-name">Huang, K.</span>; <span class="NLM_string-name">Sun, R.</span>; <span class="NLM_string-name">Zhao, Q.</span></contrib-group> Compound F779-0434 causes synthetic lethality in BRCA2-deficient cancer cells by disrupting RAD52âssDNA association.   <cite><i>RSC Advances</i></cite>, Vol. <em>8</em>, Issue 34, pp 18859â18869,<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> Copyright 2018, permission conveyed through Copyright Clearance Center, Inc.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00766/20210217/images/large/jm0c00766_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00766&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i24">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63865" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63865" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 215 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hochhaus, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larson, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guilhot, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radich, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Branford, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baccarani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deininger, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervantes, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujihara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortmann, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menssen, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâBrien, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span> <span> </span><span class="NLM_article-title">Long-Term outcomes of Imatinib treatment for chronic myeloid leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>376</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">917</span>â <span class="NLM_lpage">927</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa1609324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1056%2FNEJMoa1609324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=28273028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlyktLfF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2017&pages=917-927&issue=10&author=A.+Hochhausauthor=R.+A.+Larsonauthor=F.+Guilhotauthor=J.+P.+Radichauthor=S.+Branfordauthor=T.+P.+Hughesauthor=M.+Baccaraniauthor=M.+W.+Deiningerauthor=F.+Cervantesauthor=S.+Fujiharaauthor=C.+E.+Ortmannauthor=H.+D.+Menssenauthor=H.+Kantarjianauthor=S.+G.+O%E2%80%99Brienauthor=B.+J.+Druker&title=Long-Term+outcomes+of+Imatinib+treatment+for+chronic+myeloid+leukemia&doi=10.1056%2FNEJMoa1609324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term outcomes of imatinib treatment for chronic myeloid leukemia</span></div><div class="casAuthors">Hochhaus, Andreas; Larson, Richard A.; Guilhot, Francois; Radich, Jerald P.; Branford, Susan; Hughes, Timothy P.; Baccarani, Michele; Deininger, Michael W.; Cervantes, Francisco; Fujihara, Satoko; Ortmann, Christine-Elke; Menssen, Hans D.; Kantarjian, Hagop; O'Brien, Stephen G.; Druker, Brian J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">376</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">917-927</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for patients with chronic myeloid leukemia (CML).  We conducted efficacy and safety analyses on the basis of more than 10 years of follow-up in patients with CML who were treated with imatinib as initial therapy.  METHODS: In this open-label, multicenter trial with crossover design, we randomly assigned patients with newly diagnosed CML in the chronic phase to receive either imatinib or interferon alfa plus cytarabine.  Long-term analyses included overall survival, response to treatment, and serious adverse events.  RESULTS: The median follow-up was 10.9 years.  Given the high rate of crossover among patients who had been randomly assigned to receive interferon alfa plus cytarabine (65.6%) and the short duration of therapy before crossover in these patients (median, 0.8 years), the current analyses focused on patients who had been randomly assigned to receive imatinib.  Among the patients in the imatinib group, the estd. overall survival rate at 10 years was 83.3%.  Approx. half the patients (48.3%) who had been randomly assigned to imatinib completed study treatment with imatinib, and 82.8% had a complete cytogenetic response.  Serious adverse events that were considered by the investigators to be related to imatinib were uncommon and most frequently occurred during the first year of treatment.  CONCLUSIONS: Almost 11 years of follow-up showed that the efficacy of imatinib persisted over time and that long-term administration of imatinib was not assocd. with unacceptable cumulative or late toxic effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ9-B-a7DOrbVg90H21EOLACvtfcHk0liS1dX6voQgUg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlyktLfF&md5=2f77f70245de22f00cce881421e8f6a9</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1609324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1609324%26sid%3Dliteratum%253Aachs%26aulast%3DHochhaus%26aufirst%3DA.%26aulast%3DLarson%26aufirst%3DR.%2BA.%26aulast%3DGuilhot%26aufirst%3DF.%26aulast%3DRadich%26aufirst%3DJ.%2BP.%26aulast%3DBranford%26aufirst%3DS.%26aulast%3DHughes%26aufirst%3DT.%2BP.%26aulast%3DBaccarani%26aufirst%3DM.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DCervantes%26aufirst%3DF.%26aulast%3DFujihara%26aufirst%3DS.%26aulast%3DOrtmann%26aufirst%3DC.%2BE.%26aulast%3DMenssen%26aufirst%3DH.%2BD.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%2BG.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DLong-Term%2520outcomes%2520of%2520Imatinib%2520treatment%2520for%2520chronic%2520myeloid%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D376%26issue%3D10%26spage%3D917%26epage%3D927%26doi%3D10.1056%2FNEJMoa1609324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauschild, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haanen, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ascierto, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dummer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Testori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorigan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jouary, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadendorf, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâDay, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkwood, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eggermont, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreno, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolop, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G. A.</span></span> <span> </span><span class="NLM_article-title">Improved survival with vemurafenib in melanoma with BRAF V600E mutation</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>364</i></span> (<span class="NLM_issue">26</span>),  <span class="NLM_fpage">2507</span>â <span class="NLM_lpage">2516</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa1103782</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1056%2FNEJMoa1103782" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=21639808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosVeitbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=2507-2516&issue=26&author=P.+B.+Chapmanauthor=A.+Hauschildauthor=C.+Robertauthor=J.+B.+Haanenauthor=P.+Asciertoauthor=J.+Larkinauthor=R.+Dummerauthor=C.+Garbeauthor=A.+Testoriauthor=M.+Maioauthor=D.+Hoggauthor=P.+Loriganauthor=C.+Lebbeauthor=T.+Jouaryauthor=D.+Schadendorfauthor=A.+Ribasauthor=S.+J.+O%E2%80%99Dayauthor=J.+A.+Sosmanauthor=J.+M.+Kirkwoodauthor=A.+M.+Eggermontauthor=B.+Drenoauthor=K.+Nolopauthor=J.+Liauthor=B.+Nelsonauthor=J.+Houauthor=R.+J.+Leeauthor=K.+T.+Flahertyauthor=G.+A.+McArthur&title=Improved+survival+with+vemurafenib+in+melanoma+with+BRAF+V600E+mutation&doi=10.1056%2FNEJMoa1103782"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Improved survival with vemurafenib in melanoma with BRAF V600E mutation</span></div><div class="casAuthors">Chapman, Paul B.; Hauschild, Axel; Robert, Caroline; Haanen, John B.; Ascierto, Paolo; Larkin, James; Dummer, Reinhard; Garbe, Claus; Testori, Alessandro; Maio, Michele; Hogg, David; Lorigan, Paul; Lebbe, Celeste; Jouary, Thomas; Schadendorf, Dirk; Ribas, Antoni; O'Day, Steven J.; Sosman, Jeffrey A.; Kirkwood, John M.; Eggermont, Alexander M. M.; Dreno, Brigitte; Nolop, Keith; Li, Jiang; Nelson, Betty; Hou, Jeannie; Lee, Richard J.; Flaherty, Keith T.; McArthur, Grant A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2507-2516</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Phase 1 and 2 clin. trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation.  METHODS: We conducted a phase 3 randomized clin. trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation.  Patients were randomly assigned to receive either vemurafenib (960 mg orally twice daily) or dacarbazine (1000 mg per square meter of body-surface area i.v. every 3 wk).  Coprimary end points were rates of overall and progression-free survival.  Secondary end points included the response rate, response duration, and safety.  A final anal. was planned after 196 deaths and an interim anal. after 98 deaths.  RESULTS: At 6 mo, overall survival was 840/ (95% confidence interval [CI], 78 to 89) in the vemurafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group.  In the interim anal. for overall survival and final anal. for progression-free survival, vemurafenib was assocd. with a relative redn. of 63% in the risk of death and of 74% in the risk of either death or disease progression, as compared with dacarbazine (P < 0.001 for both comparisons).  After review of the interim anal. by an independent data and safety monitoring board, crossover from dacarbazine to vemurafenib was recommended.  Response rates were 48% for vemurafenib and 5% for dacarbazine.  Common adverse events assocd. with vemurafenib were arthralgia, rash, fatigue, alopecia, keratoacanthoma or squamous-cell carcinoma, photosensitivity, nausea, and diarrhea; 38% of patients required dose modification because of toxic effects.  CONCLUSIONS: Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4NFxmTaDz97Vg90H21EOLACvtfcHk0lhUyihLIKUYhQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosVeitbs%253D&md5=1a4b4f963221888dc63f620e87408070</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1103782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1103782%26sid%3Dliteratum%253Aachs%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DHaanen%26aufirst%3DJ.%2BB.%26aulast%3DAscierto%26aufirst%3DP.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DTestori%26aufirst%3DA.%26aulast%3DMaio%26aufirst%3DM.%26aulast%3DHogg%26aufirst%3DD.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DLebbe%26aufirst%3DC.%26aulast%3DJouary%26aufirst%3DT.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Day%26aufirst%3DS.%2BJ.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DKirkwood%26aufirst%3DJ.%2BM.%26aulast%3DEggermont%26aufirst%3DA.%2BM.%26aulast%3DDreno%26aufirst%3DB.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DNelson%26aufirst%3DB.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26atitle%3DImproved%2520survival%2520with%2520vemurafenib%2520in%2520melanoma%2520with%2520BRAF%2520V600E%2520mutation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26issue%3D26%26spage%3D2507%26epage%3D2516%26doi%3D10.1056%2FNEJMoa1103782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pagliarini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span> <span> </span><span class="NLM_article-title">Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure</span>. <i>EMBO Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">280</span>â <span class="NLM_lpage">296</span>, <span class="refDoi">Â DOI: 10.15252/embr.201439949</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.15252%2Fembr.201439949" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=25680965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjs1Gnur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=280-296&issue=3&author=R.+Pagliariniauthor=W.+Shaoauthor=W.+R.+Sellers&title=Oncogene+addiction%3A+pathways+of+therapeutic+response%2C+resistance%2C+and+road+maps+toward+a+cure&doi=10.15252%2Fembr.201439949"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure</span></div><div class="casAuthors">Pagliarini, Raymond; Shao, Wenlin; Sellers, William R.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">280-296</span>CODEN:
                <span class="NLM_cas:coden">ERMEAX</span>;
        ISSN:<span class="NLM_cas:issn">1469-221X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  A key goal of cancer therapeutics is to selectively target the genetic lesions that initiate and maintain cancer cell proliferation and survival.  While most cancers harbor multiple oncogenic mutations, a wealth of preclin. and clin. data supports that many cancers are sensitive to inhibition of single oncogenes, a concept referred to as 'oncogene addiction'.  Herein, we describe the clin. evidence supporting oncogene addiction and discuss common mechanistic themes emerging from the response and acquired resistance to oncogene-targeted therapies.  Finally, we suggest several opportunities toward exploiting oncogene addiction to achieve curative cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEtJj2YdGf6LVg90H21EOLACvtfcHk0lgX2bh7822lIw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjs1Gnur4%253D&md5=30f0b2a45a633e12155d5c7e577753e2</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.15252%2Fembr.201439949&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15252%252Fembr.201439949%26sid%3Dliteratum%253Aachs%26aulast%3DPagliarini%26aufirst%3DR.%26aulast%3DShao%26aufirst%3DW.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26atitle%3DOncogene%2520addiction%253A%2520pathways%2520of%2520therapeutic%2520response%252C%2520resistance%252C%2520and%2520road%2520maps%2520toward%2520a%2520cure%26jtitle%3DEMBO%2520Rep.%26date%3D2015%26volume%3D16%26issue%3D3%26spage%3D280%26epage%3D296%26doi%3D10.15252%2Fembr.201439949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garraway, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashworth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, B.</span></span> <span> </span><span class="NLM_article-title">Synthetic lethality as an engine for cancer drug target discovery</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">23</span>â <span class="NLM_lpage">38</span>, <span class="refDoi">Â DOI: 10.1038/s41573-019-0046-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1038%2Fs41573-019-0046-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=31712683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFegs7jK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2020&pages=23-38&issue=1&author=A.+Huangauthor=L.+A.+Garrawayauthor=A.+Ashworthauthor=B.+Weber&title=Synthetic+lethality+as+an+engine+for+cancer+drug+target+discovery&doi=10.1038%2Fs41573-019-0046-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic lethality as an engine for cancer drug target discovery</span></div><div class="casAuthors">Huang, Alan; Garraway, Levi A.; Ashworth, Alan; Weber, Barbara</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-38</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  The first wave of genetically targeted therapies for cancer focused on drugging gene products that are recurrently mutated in specific cancer types.  However, mutational anal. of tumors has largely been exhausted as a strategy for the identification of new cancer targets that are druggable with conventional approaches.  Furthermore, some known genetic drivers of cancer have not been directly targeted yet owing to their mol. structure (undruggable oncogenes) or because they result in functional loss (tumor suppressor genes).  Functional genomic screening based on the genetic concept of synthetic lethality provides an avenue to discover drug targets in all these areas.  Although synthetic lethality is not a new idea, recent advances, including CRISPR-based gene editing, have made possible systematic screens for synthetic lethal drug targets in human cancers.  Such approaches have broad potential to drive the discovery of the next wave of genetic cancer targets and ultimately the introduction of effective medicines that are still needed for most cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUGZtPqjLRlrVg90H21EOLACvtfcHk0lgX2bh7822lIw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFegs7jK&md5=227059e12105feecc402ea6ff4f98640</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fs41573-019-0046-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41573-019-0046-z%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DA.%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26aulast%3DAshworth%26aufirst%3DA.%26aulast%3DWeber%26aufirst%3DB.%26atitle%3DSynthetic%2520lethality%2520as%2520an%2520engine%2520for%2520cancer%2520drug%2520target%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2020%26volume%3D19%26issue%3D1%26spage%3D23%26epage%3D38%26doi%3D10.1038%2Fs41573-019-0046-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dobzhansky, T.</span></span> <span> </span><span class="NLM_article-title">Genetics of natural populations. Xiii. Recombination and variability in populations of Drosophila pseudoobscura</span>. <i>Genetics</i> <span class="NLM_year" style="font-weight: bold;">1946</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">269</span>â <span class="NLM_lpage">290</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=20985721" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A280%3ADyaH28%252FgtlyhtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1946&pages=269-290&author=T.+Dobzhansky&title=Genetics+of+natural+populations.+Xiii.+Recombination+and+variability+in+populations+of+Drosophila+pseudoobscura"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Genetics of natural populations; recombination and variability in populations of Drosophila pseudoobscura</span></div><div class="casAuthors">DOBZHANSKY T</div><div class="citationInfo"><span class="NLM_cas:title">Genetics</span>
        (<span class="NLM_cas:date">1946</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">269-90</span>
        ISSN:<span class="NLM_cas:issn">0016-6731</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQXehIoFNdovudfST00W0BcfW6udTcc2eZUnkXnqnkAprntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaH28%252FgtlyhtA%253D%253D&md5=51f55835f5a3053a235bdea89458573c</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDobzhansky%26aufirst%3DT.%26atitle%3DGenetics%2520of%2520natural%2520populations.%2520Xiii.%2520Recombination%2520and%2520variability%2520in%2520populations%2520of%2520Drosophila%2520pseudoobscura%26jtitle%3DGenetics%26date%3D1946%26volume%3D31%26spage%3D269%26epage%3D290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parameswaran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kundapur, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vizeacoumar, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freywald, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uppalapati, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vizeacoumar, F. J.</span></span> <span> </span><span class="NLM_article-title">A road map to personalizing targeted cancer therapies using synthetic lethality</span>. <i>Trends Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">11</span>â <span class="NLM_lpage">29</span>, <span class="refDoi">Â DOI: 10.1016/j.trecan.2018.11.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.trecan.2018.11.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=30616753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1MXkvVKluw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2019&pages=11-29&issue=1&author=S.+Parameswaranauthor=D.+Kundapurauthor=F.+S.+Vizeacoumarauthor=A.+Freywaldauthor=M.+Uppalapatiauthor=F.+J.+Vizeacoumar&title=A+road+map+to+personalizing+targeted+cancer+therapies+using+synthetic+lethality&doi=10.1016%2Fj.trecan.2018.11.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">A Road Map to Personalizing Targeted Cancer Therapies Using Synthetic Lethality</span></div><div class="casAuthors">Parameswaran, Sreejit; Kundapur, Deeksha; Vizeacoumar, Frederick S.; Freywald, Andrew; Uppalapati, Maruti; Vizeacoumar, Franco J.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-29</span>CODEN:
                <span class="NLM_cas:coden">TCRAB5</span>;
        ISSN:<span class="NLM_cas:issn">2405-8033</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Targeted therapies rely on the genetic and epigenetic status of the tumor cells and are seen as the most promising approach to treat cancer today.  However, current targeted therapies focus on directly inhibiting those mols. that are altered in tumor cells.  Unfortunately, targeting these mols., even with specific inhibitors, is challenging as tumor cells rewire their genetic circuitry to eliminate genetic dependency on these targets.  Here, we describe how synthetic lethality approaches can be used to identify genetic dependencies and develop personalized targeted therapies.  We also discuss strategies to specifically target these genetic dependencies, using small mol. and biol. drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvte78cztNurVg90H21EOLACvtfcHk0li1HaUnpeMjvQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXkvVKluw%253D%253D&md5=e6e4d907a4d565756650d1762bfd4bb8</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.trecan.2018.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.trecan.2018.11.001%26sid%3Dliteratum%253Aachs%26aulast%3DParameswaran%26aufirst%3DS.%26aulast%3DKundapur%26aufirst%3DD.%26aulast%3DVizeacoumar%26aufirst%3DF.%2BS.%26aulast%3DFreywald%26aufirst%3DA.%26aulast%3DUppalapati%26aufirst%3DM.%26aulast%3DVizeacoumar%26aufirst%3DF.%2BJ.%26atitle%3DA%2520road%2520map%2520to%2520personalizing%2520targeted%2520cancer%2520therapies%2520using%2520synthetic%2520lethality%26jtitle%3DTrends%2520Cancer%26date%3D2019%26volume%3D5%26issue%3D1%26spage%3D11%26epage%3D29%26doi%3D10.1016%2Fj.trecan.2018.11.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deeks, E. D.</span></span> <span> </span><span class="NLM_article-title">Olaparib: first global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">231</span>â <span class="NLM_lpage">240</span>, <span class="refDoi">Â DOI: 10.1007/s40265-015-0345-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1007%2Fs40265-015-0345-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=25616434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVejtbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=231-240&issue=2&author=E.+D.+Deeks&title=Olaparib%3A+first+global+approval&doi=10.1007%2Fs40265-015-0345-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Olaparib: First Global Approval</span></div><div class="casAuthors">Deeks, Emma D.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">231-240</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Olaparib (Lynparza) is an oral, small mol., poly (ADP-ribose) polymerase inhibitor being developed by AstraZeneca for the treatment of solid tumors.  The primary indication that olaparib is being developed for is BRCA mutation-pos. ovarian cancer.  A capsule formulation of the drug has received approval for use in this setting in the EU and USA, and a tablet formulation is in global phase III trials (including in the USA, EU, Australia, Brazil, Canada, China, Israel, Japan, Russia and South Korea).  In addn., phase III trials in breast, gastric and pancreatic cancer are underway/planned, and phase I/II investigation is being conducted in other malignancies, including prostate cancer, non-small cell lung cancer, Ewing's sarcoma and advanced cancer.  This article summarizes the milestones in the development of olaparib leading to this first approval for ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4agVSDkOKqbVg90H21EOLACvtfcHk0li1HaUnpeMjvQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVejtbg%253D&md5=cd68d932b6532a87c0768590afd81058</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0345-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0345-6%26sid%3Dliteratum%253Aachs%26aulast%3DDeeks%26aufirst%3DE.%2BD.%26atitle%3DOlaparib%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26issue%3D2%26spage%3D231%26epage%3D240%26doi%3D10.1007%2Fs40265-015-0345-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ame, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spenlehauer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Murcia, G.</span></span> <span> </span><span class="NLM_article-title">The PARP superfamily</span>. <i>BioEssays</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">882</span>â <span class="NLM_lpage">893</span>, <span class="refDoi">Â DOI: 10.1002/bies.20085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1002%2Fbies.20085" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=15273990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnt1CqtLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2004&pages=882-893&issue=8&author=J.+C.+Ameauthor=C.+Spenlehauerauthor=G.+de+Murcia&title=The+PARP+superfamily&doi=10.1002%2Fbies.20085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The PARP superfamily</span></div><div class="casAuthors">Ame, Jean-Christophe; Spenlehauer, Catherine; de Murcia, Gilbert</div><div class="citationInfo"><span class="NLM_cas:title">BioEssays</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">882-893</span>CODEN:
                <span class="NLM_cas:coden">BIOEEJ</span>;
        ISSN:<span class="NLM_cas:issn">0265-9247</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Poly(ADP-ribosyl)ation is an immediate DNA-damage-dependent post-translational modification of histones and other nuclear proteins that contributes to the survival of injured proliferating cells.  Poly(ADP-ribose) polymerases (PARPs) now constitute a large family of 18 proteins, encoded by different genes and displaying a conserved catalytic domain in which PARP-1 (113 kDa), the founding member, and PARP-2 (62 kDa) are so far the sole enzymes whose catalytic activity has been shown to be immediately stimulated by DNA strand breaks.  A large repertoire of sequences encoding novel PARPs now extends considerably the field of poly(ADP-ribosyl)ation reactions to various aspects of the cell biol. including cell proliferation and cell death.  Some of these new members interact with each other, share common partners and common subcellular localizations suggesting possible fine tuning in the regulation of this post-translational modification of proteins.  This review summarizes the present knowledge of this emerging superfamily, which might ultimately improve pharmacol. strategies to enhance both antitumor efficacy and the treatment of a no. of inflammatory and neurodegenerative disorders.  A provisional nomenclature is proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojkP1P6SYh67Vg90H21EOLACvtfcHk0lgfMGYown_xpg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnt1CqtLk%253D&md5=892151993f54e3c1a03019001a365fbf</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1002%2Fbies.20085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbies.20085%26sid%3Dliteratum%253Aachs%26aulast%3DAme%26aufirst%3DJ.%2BC.%26aulast%3DSpenlehauer%26aufirst%3DC.%26aulast%3Dde%2BMurcia%26aufirst%3DG.%26atitle%3DThe%2520PARP%2520superfamily%26jtitle%3DBioEssays%26date%3D2004%26volume%3D26%26issue%3D8%26spage%3D882%26epage%3D893%26doi%3D10.1002%2Fbies.20085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DâAmours, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desnoyers, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DâSilva, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poirier, G. G.</span></span> <span> </span><span class="NLM_article-title">Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>342</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">249</span>â <span class="NLM_lpage">268</span>, <span class="refDoi">Â DOI: 10.1042/bj3420249</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1042%2Fbj3420249" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10455009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADyaK1MXmtFChtLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=342&publication_year=1999&pages=249-268&issue=2&author=D.+D%E2%80%99Amoursauthor=S.+Desnoyersauthor=I.+D%E2%80%99Silvaauthor=G.+G.+Poirier&title=Poly%28ADP-ribosyl%29ation+reactions+in+the+regulation+of+nuclear+functions&doi=10.1042%2Fbj3420249"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions</span></div><div class="casAuthors">D'Amours, Damien; Desnoyers, Serge; D'Silva, Icy; Poirier, Guy G.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">342</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">249-268</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review with 351 refs.  Poly(ADP-ribosyl)ation is a post-translational modification of proteins.  During this process, mols. of ADP-ribose are added successively on to acceptor proteins to form branched polymers.  This modification is transient but very extensive in vivo, as polymer chains can reach more than 200 units on protein acceptors.  The existence of the poly(ADP-ribose) polymer was first reported nearly 40 yr ago.  Since then, the importance of poly(ADP-ribose) synthesis has been established in many cellular processes.  However, a clear and unified picture of the physiol. role of poly(ADP-ribosyl)ation still remains to be established.  The total dependence of poly(ADP-ribose) synthesis on DNA strand breaks strongly suggests that this post-translational modification is involved in the metab. of nucleic acids.  This view is also supported by the identification of direct protein-protein interactions involving poly(ADP-ribose) polymerase (113 kDa PARP), an enzyme catalyzing the formation of poly(ADP-ribose), and key effectors of DNA repair, replication and transcription reactions.  The presence of PARP in these multiprotein complexes, in addn. to the actual poly(ADP-ribosyl)ation of some components of these complexes, clearly supports an important role for poly(ADP-ribosyl)ation reactions in DNA transactions.  Accordingly, inhibition of poly(ADP-ribose) synthesis by any of several approaches and the anal. of PARP-deficient cells has revealed that the absence of poly(ADP-ribosyl)ation strongly affects DNA metab., most notably DNA repair.  The recent identification of new poly(ADP-ribosyl)ating enzymes with distinct (non-std.) structures in eukaryotes and archaea has revealed a novel level of complexity in the regulation of poly(ADP-ribose) metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh1dXVUbI2MbVg90H21EOLACvtfcHk0lgfMGYown_xpg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmtFChtLo%253D&md5=9a9e9c4a9c492cf6841fe146a22f21c5</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1042%2Fbj3420249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj3420249%26sid%3Dliteratum%253Aachs%26aulast%3DD%25E2%2580%2599Amours%26aufirst%3DD.%26aulast%3DDesnoyers%26aufirst%3DS.%26aulast%3DD%25E2%2580%2599Silva%26aufirst%3DI.%26aulast%3DPoirier%26aufirst%3DG.%2BG.%26atitle%3DPoly%2528ADP-ribosyl%2529ation%2520reactions%2520in%2520the%2520regulation%2520of%2520nuclear%2520functions%26jtitle%3DBiochem.%2520J.%26date%3D1999%26volume%3D342%26issue%3D2%26spage%3D249%26epage%3D268%26doi%3D10.1042%2Fbj3420249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupte, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, W. L.</span></span> <span> </span><span class="NLM_article-title">PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes</span>. <i>Genes Dev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">101</span>â <span class="NLM_lpage">126</span>, <span class="refDoi">Â DOI: 10.1101/gad.291518.116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1101%2Fgad.291518.116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=28202539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpvVOitLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=101-126&issue=2&author=R.+Gupteauthor=Z.+Liuauthor=W.+L.+Kraus&title=PARPs+and+ADP-ribosylation%3A+recent+advances+linking+molecular+functions+to+biological+outcomes&doi=10.1101%2Fgad.291518.116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes</span></div><div class="casAuthors">Gupte, Rebecca; Liu, Ziying; Kraus, W. Lee</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">101-126</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">The discovery of poly(ADP-ribose) >50 years ago opened a new field, leading the way for the discovery of the poly(ADP-ribose) polymerase (PARP) family of enzymes and the ADP-ribosylation reactions that they catalyze.  Although the field was initially focused primarily on the biochem. and mol. biol. of PARP-1 in DNA damage detection and repair, the mechanistic and functional understanding of the role of PARPs in different biol. processes has grown considerably of late.  This has been accompanied by a shift of focus from enzymol. to a search for substrates as well as the first attempts to det. the functional consequences of site-specific ADP-ribosylation on those substrates.  Supporting these advances is a host of methodol. approaches from chem. biol., proteomics, genomics, cell biol., and genetics that have propelled new discoveries in the field.  New findings on the diverse roles of PARPs in chromatin regulation, transcription, RNA biol., and DNA repair have been complemented by recent advances that link ADP-ribosylation to stress responses, metab., viral infections, and cancer.  These studies have begun to reveal the promising ways in which PARPs may be targeted therapeutically for the treatment of disease.  In this review, we discuss these topics and relate them to the future directions of the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8MfoT2jFf4LVg90H21EOLACvtfcHk0lgfMGYown_xpg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpvVOitLY%253D&md5=d091cc26a4caf725c7619e35badc0eff</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1101%2Fgad.291518.116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.291518.116%26sid%3Dliteratum%253Aachs%26aulast%3DGupte%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DKraus%26aufirst%3DW.%2BL.%26atitle%3DPARPs%2520and%2520ADP-ribosylation%253A%2520recent%2520advances%2520linking%2520molecular%2520functions%2520to%2520biological%2520outcomes%26jtitle%3DGenes%2520Dev.%26date%3D2017%26volume%3D31%26issue%3D2%26spage%3D101%26epage%3D126%26doi%3D10.1101%2Fgad.291518.116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skidmore, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halldorsson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shall, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziaâee, A. A.</span></span> <span> </span><span class="NLM_article-title">The involvement of poly(ADP-ribose) polymerase in the degradation of NAD caused by gamma-radiation and N-methyl-N-nitrosourea</span>. <i>Eur. J. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>101</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">135</span>â <span class="NLM_lpage">142</span>, <span class="refDoi">Â DOI: 10.1111/j.1432-1033.1979.tb04225.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1111%2Fj.1432-1033.1979.tb04225.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=228934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADyaL3cXjsFClug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=1979&pages=135-142&issue=1&author=C.+J.+Skidmoreauthor=M.+I.+Daviesauthor=P.+M.+Goodwinauthor=H.+Halldorssonauthor=P.+J.+Lewisauthor=S.+Shallauthor=A.+A.+Zia%E2%80%99ee&title=The+involvement+of+poly%28ADP-ribose%29+polymerase+in+the+degradation+of+NAD+caused+by+gamma-radiation+and+N-methyl-N-nitrosourea&doi=10.1111%2Fj.1432-1033.1979.tb04225.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The involvement of poly(ADP-ribose) polymerase in the degradation of NAD caused by Î³-radiation and N-methyl-N-nitrosurea</span></div><div class="casAuthors">Skidmore, Christopher J.; Davies, Margaret I.; Goodwin, Patricia M.; Halldorsson, Haraldur; Lewis, Pamela J.; Shall, Sydney; Zia'ee, Abed-Ali</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Biochemistry</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">135-42</span>CODEN:
                <span class="NLM_cas:coden">EJBCAI</span>;
        ISSN:<span class="NLM_cas:issn">0014-2956</span>.
    </div><div class="casAbstract">Both N-methyl-N-nitrosourea  [684-93-5] and Î³-irradn. lowered cellular NAD  [53-84-9] in mouse leukemia cells (L1210) in a dose-dependent way.  The min. NAD level was reached 2 h after a brief exposure to N-methyl-N-nitrosourea, but within 15 min of Î³-irradn.  The cells remained metabolically active; they were able to recover their control NAD levels and were impermeable to trypan blue.  The following inhibitors of poly(ADP-ribose) polymerase  [58319-92-9] inhibited the drop of cellular NAD caused by these 2 agents: 2 mM 5-methylnicotinamide  [70-57-5], 1 mM theophylline  [58-55-9], or 1 mM theobromine  [83-67-0] inhibited the effect of N-methyl-N-nitrosourea on cellular NAD level; 200 Î¼M thymidine  [50-89-5], 500 Î¼M 5-methylnicotinamide, 500 Î¼M theophylline, and 500 Î¼M theobromine prevented the lowering of cellular NAD by Î³-irradn.  The extent to which the drop in cellular NAD was inhibited was dependent on both the concn. of cytotoxic agent and of polymerase inhibitor.  Caffeine  [58-08-2] inhibited the drop in NAD but only at 10 mM, whereas nicotonic acid  [59-67-6] was ineffective even at this dose.  The activity of poly(ADP-ribose) polymerase in permeabilized cells immediately after Î³-irradn. increased with dose up to 12 krads, giving a maximal 3.4-fold stimulation of the enzyme activity, whereas the degrdn. of NAD under conditions optimal for NAD glycohydrolase  [9032-65-9] did not change.  The activity of the polymerase showed a close temporal correlation with the NAD drop following both Î³-irradn. and N-methyl-N-nitrosourea.  The enzyme activity was maximal when the NAD content was decreasing at the highest rate and returned to normal levels when it ceased falling.  In permeabilized cells, poly(ADP-ribose) polymerase and NAD glycohydrolase activity can be distinguished by their differential response to inhibitors.  The polymerase was sensitive to 5-methylnicotinamide, theophylline, theobromine, and thymidine; the NAD glycohydrolase was sensitive to 5-methylnicotinamide and theophylline, but not to theobromine and thymidine.  Evidently, the decrease in cellular NAD level produced by Î³-irradn. and by N-methyl-N-nitrosourea was caused by an increased flux through poly(ADP-ribose) mediated by an increased activity of poly(ADP-ribose) polymerase.  This consequently lowers the cellular NAD level.  This hypothesis implies an involvement of (ADP-ribose)n in the cellular response to cytotoxic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxsOBZrH6V47Vg90H21EOLACvtfcHk0ljoMkGfHiA1oQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXjsFClug%253D%253D&md5=0af7b111b7eecef5152bc4ec9d7c16e4</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1111%2Fj.1432-1033.1979.tb04225.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1432-1033.1979.tb04225.x%26sid%3Dliteratum%253Aachs%26aulast%3DSkidmore%26aufirst%3DC.%2BJ.%26aulast%3DDavies%26aufirst%3DM.%2BI.%26aulast%3DGoodwin%26aufirst%3DP.%2BM.%26aulast%3DHalldorsson%26aufirst%3DH.%26aulast%3DLewis%26aufirst%3DP.%2BJ.%26aulast%3DShall%26aufirst%3DS.%26aulast%3DZia%25E2%2580%2599ee%26aufirst%3DA.%2BA.%26atitle%3DThe%2520involvement%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%2520in%2520the%2520degradation%2520of%2520NAD%2520caused%2520by%2520gamma-radiation%2520and%2520N-methyl-N-nitrosourea%26jtitle%3DEur.%2520J.%2520Biochem.%26date%3D1979%26volume%3D101%26issue%3D1%26spage%3D135%26epage%3D142%26doi%3D10.1111%2Fj.1432-1033.1979.tb04225.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caldecott, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoufouchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shall, S.</span></span> <span> </span><span class="NLM_article-title">XRCC1 polypeptide interacts with DNA polymerase beta and possibly poly (ADP-ribose) polymerase, and DNA ligase III is a novel molecular ânick-sensorâ in vitro</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">4387</span>â <span class="NLM_lpage">4394</span>, <span class="refDoi">Â DOI: 10.1093/nar/24.22.4387</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1093%2Fnar%2F24.22.4387" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=8948628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADyaK28Xnt12ktb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1996&pages=4387-4394&issue=22&author=K.+W.+Caldecottauthor=S.+Aoufouchiauthor=P.+Johnsonauthor=S.+Shall&title=XRCC1+polypeptide+interacts+with+DNA+polymerase+beta+and+possibly+poly+%28ADP-ribose%29+polymerase%2C+and+DNA+ligase+III+is+a+novel+molecular+%E2%80%98nick-sensor%E2%80%99+in+vitro&doi=10.1093%2Fnar%2F24.22.4387"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">XRCC1 polypeptide interacts with DNA polymerase Î² and possibly poly(ADP-ribose) polymerase, and DNA ligase III is a novel molecular 'nick-sensor' in vitro</span></div><div class="casAuthors">Caldecott, Keith W.; Aoufouchi, Said; Johnson, Penny; Shall, Sydney</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">4387-4394</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The DNA repair proteins XRCC1 and DNA ligase III are phys. assocd. in human cells and directly interact in vitro and in vivo.  Here, we demonstrate that XRCC1 is addnly. assocd. with DNA polymerase-Î² in human cells and that these polypeptides also directly interact.  We also present data suggesting that poly(ADP-ribose) polymerase can interact with XRCC1.  Finally, we demonstrate that DNA ligase III shares with poly(ADP-ribose) polymerase the novel function of a mol. DNA nick-sensor, and that the DNA ligase can inhibit activity of the latter polypeptide in vitro.  Taken together, these data suggest that the activity of the four polypeptides described above may be coordinated in human cells within a single multiprotein complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFpzsCdL8M2bVg90H21EOLACvtfcHk0ljoMkGfHiA1oQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xnt12ktb8%253D&md5=9d907b99ab7da9abe32bf022c49e97cd</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1093%2Fnar%2F24.22.4387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252F24.22.4387%26sid%3Dliteratum%253Aachs%26aulast%3DCaldecott%26aufirst%3DK.%2BW.%26aulast%3DAoufouchi%26aufirst%3DS.%26aulast%3DJohnson%26aufirst%3DP.%26aulast%3DShall%26aufirst%3DS.%26atitle%3DXRCC1%2520polypeptide%2520interacts%2520with%2520DNA%2520polymerase%2520beta%2520and%2520possibly%2520poly%2520%2528ADP-ribose%2529%2520polymerase%252C%2520and%2520DNA%2520ligase%2520III%2520is%2520a%2520novel%2520molecular%2520%25E2%2580%2598nick-sensor%25E2%2580%2599%2520in%2520vitro%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D1996%26volume%3D24%26issue%3D22%26spage%3D4387%26epage%3D4394%26doi%3D10.1093%2Fnar%2F24.22.4387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morales, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fattah, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bey, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boothman, D. A.</span></span> <span> </span><span class="NLM_article-title">Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases</span>. <i>Crit. Rev. Eukaryotic Gene Expression</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">15</span>â <span class="NLM_lpage">28</span>, <span class="refDoi">Â DOI: 10.1615/CritRevEukaryotGeneExpr.2013006875</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1615%2FCritRevEukaryotGeneExpr.2013006875" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=24579667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A280%3ADC%252BC2cvpsVSrsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=15-28&issue=1&author=J.+Moralesauthor=L.+Liauthor=F.+J.+Fattahauthor=Y.+Dongauthor=E.+A.+Beyauthor=M.+Patelauthor=J.+Gaoauthor=D.+A.+Boothman&title=Review+of+poly+%28ADP-ribose%29+polymerase+%28PARP%29+mechanisms+of+action+and+rationale+for+targeting+in+cancer+and+other+diseases&doi=10.1615%2FCritRevEukaryotGeneExpr.2013006875"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases</span></div><div class="casAuthors">Morales Julio; Li Longshan; Fattah Farjana J; Dong Ying; Patel Malina; Gao Jinming; Boothman David A; Bey Erik A</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in eukaryotic gene expression</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-28</span>
        ISSN:<span class="NLM_cas:issn">1045-4403</span>.
    </div><div class="casAbstract">Poly (ADP-ribose) polymerases (PARPs) are a family of related enzymes that share the ability to catalyze the transfer of ADP-ribose to target proteins.  PARPs play an important role in various cellular processes, including modulation of chromatin structure, transcription, replication, recombination, and DNA repair.  The role of PARP proteins in DNA repair is of particular interest, in view of the finding that certain tumors defective in homologous recombination mechanisms, may rely on PARP-mediated DNA repair for survival, and are sensitive to its inhibition.  PARP inhibitors may also increase tumor sensitivity to DNA-damaging agents.  Clinical trials of PARP inhibitors are investigating the utility of these approaches in cancer.  The hyperactivation of PARP has also been shown to result in a specific programmed cell death pathway involving NAD+/ATP depletion, mu-calpain activation, loss of mitochondrial membrane potential, and the release of apoptosis inducing factor.  Hyperactivation of the PARP pathway may be exploited to selectively kill cancer cells.  Other PARP forms, including tankyrase 1 (PARP 5a), which plays an important role in enhancing telomere elongation by telomerase, have been found to be potential targets in cancer therapy.  The PARP pathway and its inhibition thus offers a number of opportunities for therapeutic intervention in both cancer and other disease states.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQO6ujQ1G1GLwaK-_ZudimnfW6udTcc2eZ3Qs0g43jUzrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cvpsVSrsw%253D%253D&md5=3590812f36c4075309ad19923d2e2852</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1615%2FCritRevEukaryotGeneExpr.2013006875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1615%252FCritRevEukaryotGeneExpr.2013006875%26sid%3Dliteratum%253Aachs%26aulast%3DMorales%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DFattah%26aufirst%3DF.%2BJ.%26aulast%3DDong%26aufirst%3DY.%26aulast%3DBey%26aufirst%3DE.%2BA.%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DGao%26aufirst%3DJ.%26aulast%3DBoothman%26aufirst%3DD.%2BA.%26atitle%3DReview%2520of%2520poly%2520%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520mechanisms%2520of%2520action%2520and%2520rationale%2520for%2520targeting%2520in%2520cancer%2520and%2520other%2520diseases%26jtitle%3DCrit.%2520Rev.%2520Eukaryotic%2520Gene%2520Expression%26date%3D2014%26volume%3D24%26issue%3D1%26spage%3D15%26epage%3D28%26doi%3D10.1615%2FCritRevEukaryotGeneExpr.2013006875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Satoh, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindahl, T.</span></span> <span> </span><span class="NLM_article-title">Role of poly(ADP-ribose) formation in DNA repair</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>356</i></span> (<span class="NLM_issue">6367</span>),  <span class="NLM_fpage">356</span>â <span class="NLM_lpage">358</span>, <span class="refDoi">Â DOI: 10.1038/356356a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1038%2F356356a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1549180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADyaK38XitFSjsLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=1992&pages=356-358&issue=6367&author=M.+S.+Satohauthor=T.+Lindahl&title=Role+of+poly%28ADP-ribose%29+formation+in+DNA+repair&doi=10.1038%2F356356a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Role of poly(ADP-ribose) formation in DNA repair</span></div><div class="casAuthors">Satoh, Masahiko S.; Lindahl, Tomas</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">6367</span>),
    <span class="NLM_cas:pages">356-8</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">The abundant nuclear enzyme poly(ADP-ribose) polymerase catalyzes the synthesis of poly(ADP-ribose) from NAD.  This protein has an N-terminal DNA-binding domain contg. two zinc-fingers, which is linked to the C-terminal NAD+-binding domain by a short region contg. several glutamic acid residues that are sites of auto-poly(ADP-ribosyl)ation.  The intracellular prodn. of poly(ADP-ribose) is induced by agents that generate strand interruptions in DNA.  The branched homopolymer chains may attain a size of 200-300 residues but are rapidly degraded after synthesis.  The function of poly(ADP-ribose) synthesis is not clear, although it seems to be required for DNA repair.  Here, a human cell-free system is described that enables the role of poly(ADP-ribose) synthesis in DNA repair to be characterized.  The results indicate that unmodified polymerase mols. bind tightly to DNA strand breaks; auto-poly(ADP-ribosyl)ation of the protein then effects its release and allows access to lesions for DNA repair enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrosI_oFYfc77Vg90H21EOLACvtfcHk0liF_TAoplA3DA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XitFSjsLg%253D&md5=81580d1996b224b2c4a4bcdd318e72fd</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2F356356a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F356356a0%26sid%3Dliteratum%253Aachs%26aulast%3DSatoh%26aufirst%3DM.%2BS.%26aulast%3DLindahl%26aufirst%3DT.%26atitle%3DRole%2520of%2520poly%2528ADP-ribose%2529%2520formation%2520in%2520DNA%2520repair%26jtitle%3DNature%26date%3D1992%26volume%3D356%26issue%3D6367%26spage%3D356%26epage%3D358%26doi%3D10.1038%2F356356a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Langelier, M.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zandarashvili, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguiar, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascal, J. M.</span></span> <span> </span><span class="NLM_article-title">NAD+ analog reveals PARP-1 substrate-blocking mechanism and allosteric communication from catalytic center to DNA-binding domains</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">844</span>, <span class="refDoi">Â DOI: 10.1038/s41467-018-03234-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1038%2Fs41467-018-03234-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=29487285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A280%3ADC%252BC1MrlvF2gsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=844&issue=1&author=M.-F.+Langelierauthor=L.+Zandarashviliauthor=P.+M.+Aguiarauthor=B.+E.+Blackauthor=J.+M.+Pascal&title=NAD%2B+analog+reveals+PARP-1+substrate-blocking+mechanism+and+allosteric+communication+from+catalytic+center+to+DNA-binding+domains&doi=10.1038%2Fs41467-018-03234-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">NAD(+) analog reveals PARP-1 substrate-blocking mechanism and allosteric communication from catalytic center to DNA-binding domains</span></div><div class="casAuthors">Langelier Marie-France; Pascal John M; Zandarashvili Levani; Black Ben E; Aguiar Pedro M</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">844</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PARP-1 cleaves NAD(+) and transfers the resulting ADP-ribose moiety onto target proteins and onto subsequent polymers of ADP-ribose.  An allosteric network connects PARP-1 multi-domain detection of DNA damage to catalytic domain structural changes that relieve catalytic autoinhibition; however, the mechanism of autoinhibition is undefined.  Here, we show using the non-hydrolyzable NAD(+) analog benzamide adenine dinucleotide (BAD) that PARP-1 autoinhibition results from a selective block on NAD(+) binding.  Following DNA damage detection, BAD binding to the catalytic domain leads to changes in PARP-1 dynamics at distant DNA-binding surfaces, resulting in increased affinity for DNA damage, and providing direct evidence of reverse allostery.  Our findings reveal a two-step mechanism to activate and to then stabilize PARP-1 on a DNA break, indicate that PARP-1 allostery influences persistence on DNA damage, and have important implications for PARP inhibitors that engage the NAD(+) binding site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRcBrbf8zXPoPSAs_PE1QvifW6udTcc2eYtSaNtTTzxjLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrlvF2gsw%253D%253D&md5=783880900aba44e964f270a3ed5f7f01</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-03234-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-03234-8%26sid%3Dliteratum%253Aachs%26aulast%3DLangelier%26aufirst%3DM.-F.%26aulast%3DZandarashvili%26aufirst%3DL.%26aulast%3DAguiar%26aufirst%3DP.%2BM.%26aulast%3DBlack%26aufirst%3DB.%2BE.%26aulast%3DPascal%26aufirst%3DJ.%2BM.%26atitle%3DNAD%252B%2520analog%2520reveals%2520PARP-1%2520substrate-blocking%2520mechanism%2520and%2520allosteric%2520communication%2520from%2520catalytic%2520center%2520to%2520DNA-binding%2520domains%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26issue%3D1%26spage%3D844%26doi%3D10.1038%2Fs41467-018-03234-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lord, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashworth, A.</span></span> <span> </span><span class="NLM_article-title">PARP inhibitors: synthetic lethality in the clinic</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>355</i></span> (<span class="NLM_issue">6330</span>),  <span class="NLM_fpage">1152</span>â <span class="NLM_lpage">1158</span>, <span class="refDoi">Â DOI: 10.1126/science.aam7344</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1126%2Fscience.aam7344" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=28302823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktFOmtrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2017&pages=1152-1158&issue=6330&author=C.+J.+Lordauthor=A.+Ashworth&title=PARP+inhibitors%3A+synthetic+lethality+in+the+clinic&doi=10.1126%2Fscience.aam7344"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">PARP inhibitors: Synthetic lethality in the clinic</span></div><div class="casAuthors">Lord, Christopher J.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">6330</span>),
    <span class="NLM_cas:pages">1152-1158</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  PARP inhibitors (PARPi), a cancer therapy targeting poly(ADP-ribose) polymerase, are the first clin. approved drugs designed to exploit synthetic lethality, a genetic concept proposed nearly a century ago.  Tumors arising in patients who carry germline mutations in either BRCA1 or BRCA2 are sensitive to PARPi because they have a specific type of DNA repair defect.  PARPi also show promising activity in more common cancers that share this repair defect.  However, as with other targeted therapies, resistance to PARPi arises in advanced disease.  In addn., detg. the optimal use of PARPi within drug combination approaches has been challenging.  Nevertheless, the preclin. discovery of PARPi synthetic lethality and the route to clin. approval provide interesting lessons for the development of other therapies.  Here, the authors discuss current knowledge of PARP inhibitors and potential ways to maximize their clin. effectiveness.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAdgOVt6r40rVg90H21EOLACvtfcHk0ljP_V3etJMUAw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktFOmtrg%253D&md5=6f3c5c37b2d5062cb7acbf3a78727f46</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1126%2Fscience.aam7344&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aam7344%26sid%3Dliteratum%253Aachs%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DPARP%2520inhibitors%253A%2520synthetic%2520lethality%2520in%2520the%2520clinic%26jtitle%3DScience%26date%3D2017%26volume%3D355%26issue%3D6330%26spage%3D1152%26epage%3D1158%26doi%3D10.1126%2Fscience.aam7344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flower, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meuth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtin, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helleday, T.</span></span> <span> </span><span class="NLM_article-title">Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>434</i></span> (<span class="NLM_issue">7035</span>),  <span class="NLM_fpage">913</span>â <span class="NLM_lpage">917</span>, <span class="refDoi">Â DOI: 10.1038/nature03443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1038%2Fnature03443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=15829966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=434&publication_year=2005&pages=913-917&issue=7035&author=H.+E.+Bryantauthor=N.+Schultzauthor=H.+D.+Thomasauthor=K.+M.+Parkerauthor=D.+Flowerauthor=E.+Lopezauthor=S.+Kyleauthor=M.+Meuthauthor=N.+J.+Curtinauthor=T.+Helleday&title=Specific+killing+of+BRCA2-deficient+tumours+with+inhibitors+of+poly%28ADP-ribose%29+polymerase&doi=10.1038%2Fnature03443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Specific killing of BRCA2-deficient tumors with inhibitors of poly(ADP-ribose) polymerase</span></div><div class="casAuthors">Bryant, Helen E.; Schultz, Niklas; Thomas, Huw D.; Parker, Kayan M.; Flower, Dan; Lopez, Elena; Kyle, Suzanne; Meuth, Mark; Curtin, Nicola J.; Helleday, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">434</span>
        (<span class="NLM_cas:issue">7035</span>),
    <span class="NLM_cas:pages">913-917</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase (PARP1) facilitates DNA repair by binding to DNA breaks and attracting DNA repair proteins to the site of damage.  Nevertheless, PARP1-/- mice are viable, fertile and do not develop early onset tumors.  Here, the authors show that PARP inhibitors trigger Î³-H2AX and RAD51 foci formation.  The authors propose that, in the absence of PARP1, spontaneous single-strand breaks collapse replication forks and trigger homologous recombination for repair.  Furthermore, the authors show that BRCA2-deficient cells, as a result of their deficiency in homologous recombination, are acutely sensitive to PARP inhibitors, presumably because resultant collapsed replication forks are no longer repaired.  Thus, PARP1 activity is essential in homologous recombination-deficient BRCA2 mutant cells.  The authors exploit this requirement in order to kill BRCA2-deficient tumors by PARP inhibition alone.  Treatment with PARP inhibitors is likely to be highly tumor specific, because only the tumors (which are BRCA2-/-) in BRCA2+/- patients are defective in homologous recombination.  The use of an inhibitor of a DNA repair enzyme alone to selectively kill a tumor, in the absence of an exogenous DNA-damaging agent, represents a new concept in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZJ6B7d7dB77Vg90H21EOLACvtfcHk0lgD2rDpdoNhSg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrY%253D&md5=44631eba667cf75ef99c31d011d6db44</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnature03443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature03443%26sid%3Dliteratum%253Aachs%26aulast%3DBryant%26aufirst%3DH.%2BE.%26aulast%3DSchultz%26aufirst%3DN.%26aulast%3DThomas%26aufirst%3DH.%2BD.%26aulast%3DParker%26aufirst%3DK.%2BM.%26aulast%3DFlower%26aufirst%3DD.%26aulast%3DLopez%26aufirst%3DE.%26aulast%3DKyle%26aufirst%3DS.%26aulast%3DMeuth%26aufirst%3DM.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DHelleday%26aufirst%3DT.%26atitle%3DSpecific%2520killing%2520of%2520BRCA2-deficient%2520tumours%2520with%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%26jtitle%3DNature%26date%3D2005%26volume%3D434%26issue%3D7035%26spage%3D913%26epage%3D917%26doi%3D10.1038%2Fnature03443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Farmer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCabe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lord, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tutt, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santarosa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knights, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashworth, A.</span></span> <span> </span><span class="NLM_article-title">Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>434</i></span> (<span class="NLM_issue">7035</span>),  <span class="NLM_fpage">917</span>â <span class="NLM_lpage">921</span>, <span class="refDoi">Â DOI: 10.1038/nature03445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1038%2Fnature03445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=15829967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=434&publication_year=2005&pages=917-921&issue=7035&author=H.+Farmerauthor=N.+McCabeauthor=C.+J.+Lordauthor=A.+N.+Tuttauthor=D.+A.+Johnsonauthor=T.+B.+Richardsonauthor=M.+Santarosaauthor=K.+J.+Dillonauthor=I.+Hicksonauthor=C.+Knightsauthor=N.+M.+Martinauthor=S.+P.+Jacksonauthor=G.+C.+Smithauthor=A.+Ashworth&title=Targeting+the+DNA+repair+defect+in+BRCA+mutant+cells+as+a+therapeutic+strategy&doi=10.1038%2Fnature03445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy</span></div><div class="casAuthors">Farmer, Hannah; McCabe, Nuala; Lord, Christopher J.; Tutt, Andrew N. J.; Johnson, Damian A.; Richardson, Tobias B.; Santarosa, Manuela; Dillon, Krystyna J.; Hickson, Ian; Knights, Charlotte; Martin, Niall M. B.; Jackson, Stephen P.; Smith, Graeme C. M.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">434</span>
        (<span class="NLM_cas:issue">7035</span>),
    <span class="NLM_cas:pages">917-921</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">BRCA1 and BRCA2 are important for DNA double-strand break repair by homologous recombination, and mutations in these genes predispose to breast and other cancers.  Poly(ADP-ribose) polymerase (PARP) is an enzyme involved in base excision repair, a key pathway in the repair of DNA single-strand breaks.  The authors show here that BRCA1 or BRCA2 dysfunction unexpectedly and profoundly sensitizes cells to the inhibition of PARP enzymic activity, resulting in chromosomal instability, cell cycle arrest and subsequent apoptosis.  This seems to be because the inhibition of PARP leads to the persistence of DNA lesions normally repaired by homologous recombination.  These results illustrate how different pathways cooperate to repair damage, and suggest that the targeted inhibition of particular DNA repair pathways may allow the design of specific and less toxic therapies for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomVTKE4mFwfrVg90H21EOLACvtfcHk0lgD2rDpdoNhSg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrc%253D&md5=03b5ba0adc21a5627fe17ae535f45078</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnature03445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature03445%26sid%3Dliteratum%253Aachs%26aulast%3DFarmer%26aufirst%3DH.%26aulast%3DMcCabe%26aufirst%3DN.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DTutt%26aufirst%3DA.%2BN.%26aulast%3DJohnson%26aufirst%3DD.%2BA.%26aulast%3DRichardson%26aufirst%3DT.%2BB.%26aulast%3DSantarosa%26aufirst%3DM.%26aulast%3DDillon%26aufirst%3DK.%2BJ.%26aulast%3DHickson%26aufirst%3DI.%26aulast%3DKnights%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DN.%2BM.%26aulast%3DJackson%26aufirst%3DS.%2BP.%26aulast%3DSmith%26aufirst%3DG.%2BC.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DTargeting%2520the%2520DNA%2520repair%2520defect%2520in%2520BRCA%2520mutant%2520cells%2520as%2520a%2520therapeutic%2520strategy%26jtitle%3DNature%26date%3D2005%26volume%3D434%26issue%3D7035%26spage%3D917%26epage%3D921%26doi%3D10.1038%2Fnature03445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Helleday, T.</span></span> <span> </span><span class="NLM_article-title">The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">387</span>â <span class="NLM_lpage">393</span>, <span class="refDoi">Â DOI: 10.1016/j.molonc.2011.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.molonc.2011.07.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=21821475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVyqtL%252FO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2011&pages=387-393&issue=4&author=T.+Helleday&title=The+underlying+mechanism+for+the+PARP+and+BRCA+synthetic+lethality%3A+clearing+up+the+misunderstandings&doi=10.1016%2Fj.molonc.2011.07.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings</span></div><div class="casAuthors">Helleday, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">387-393</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Poly (ADP-ribose) polymerase (PARP) inhibitors effectively kill tumors defective in the BRCA1 or BRCA2 genes through the concept of synthetic lethality.  It is suggested that PARP inhibitors cause an increase in DNA single-strand breaks (SSBs), which are converted during replication to irreparable toxic DNA double-strand breaks (DSBs) in BRCA1/2 defective cells.  There are a no. of recent reports challenging this model.  Here, alternative models that are not mutually exclusive are presented to explain the synthetic lethality between BRCA1/2 and PARP inhibitors.  One such model proposes that PARP inhibition causes PARP-1 to be trapped onto DNA repair intermediates, esp. during base excision repair.  This may in turn cause obstruction to replication forks, which require BRCA-dependent homologous recombination to be resolved.  In another model, PARP is directly involved in catalyzing replication repair in a distinct pathway from homologous recombination.  Exptl. evidence supporting these novel models to explain the PARP-BRCA synthetic lethality are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPUCIzO2NudrVg90H21EOLACvtfcHk0lgD2rDpdoNhSg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVyqtL%252FO&md5=1b64dde39e08d863e774de91a0fbe1e9</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2011.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2011.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DHelleday%26aufirst%3DT.%26atitle%3DThe%2520underlying%2520mechanism%2520for%2520the%2520PARP%2520and%2520BRCA%2520synthetic%2520lethality%253A%2520clearing%2520up%2520the%2520misunderstandings%26jtitle%3DMol.%2520Oncol.%26date%3D2011%26volume%3D5%26issue%3D4%26spage%3D387%26epage%3D393%26doi%3D10.1016%2Fj.molonc.2011.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noordermeer, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Attikum, H.</span></span> <span> </span><span class="NLM_article-title">PARP inhibitor resistance: a tug-of-war in BRCA-mutated cells</span>. <i>Trends Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">820</span>â <span class="NLM_lpage">834</span>, <span class="refDoi">Â DOI: 10.1016/j.tcb.2019.07.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.tcb.2019.07.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=31421928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFCmsL3L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=820-834&issue=10&author=S.+M.+Noordermeerauthor=H.+van+Attikum&title=PARP+inhibitor+resistance%3A+a+tug-of-war+in+BRCA-mutated+cells&doi=10.1016%2Fj.tcb.2019.07.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells</span></div><div class="casAuthors">Noordermeer, Sylvie M.; van Attikum, Haico</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cell Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">820-834</span>CODEN:
                <span class="NLM_cas:coden">TCBIEK</span>;
        ISSN:<span class="NLM_cas:issn">0962-8924</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Poly-(ADP)-ribose polymerase (PARP) inhibition is synthetic lethal with deficiency for homologous recombination (HR), a pathway essential for DNA double-strand break repair.  PARP inhibitors (PARPi) therefore hold great promise for the treatment of tumors with disruptive mutations in BRCA1/2 or other HR factors.  Unfortunately, PARPi resistance has proved to be a major problem in the clinic.  Knowledge about PARPi resistance is expanding quickly, revealing four main mechanisms that alter drug availability, affect (de)PARylation enzymes, restore HR, or restore replication fork stability.  We discuss how studies on resistance mechanisms have yielded important insights into the regulation of DNA double-strand break (DSB) repair and replication fork protection, and how these studies could pave the way for novel treatment options to target resistance mechanisms or acquired vulnerabilities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoH34s2W9BmerVg90H21EOLACvtfcHk0lgbJJ9d2_v96Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFCmsL3L&md5=921c379ab68a0eeba7a5a2799f9abf1e</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.tcb.2019.07.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tcb.2019.07.008%26sid%3Dliteratum%253Aachs%26aulast%3DNoordermeer%26aufirst%3DS.%2BM.%26aulast%3Dvan%2BAttikum%26aufirst%3DH.%26atitle%3DPARP%2520inhibitor%2520resistance%253A%2520a%2520tug-of-war%2520in%2520BRCA-mutated%2520cells%26jtitle%3DTrends%2520Cell%2520Biol.%26date%3D2019%26volume%3D29%26issue%3D10%26spage%3D820%26epage%3D834%26doi%3D10.1016%2Fj.tcb.2019.07.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giovannini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weller, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Repmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moch, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiricny, J.</span></span> <span> </span><span class="NLM_article-title">Synthetic lethality between BRCA1 deficiency and poly(ADP-ribose) polymerase inhibition is modulated by processing of endogenous oxidative DNA damage</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>47</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">9132</span>â <span class="NLM_lpage">9143</span>, <span class="refDoi">Â DOI: 10.1093/nar/gkz624</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1093%2Fnar%2Fgkz624" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=31329989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVWksrrN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2019&pages=9132-9143&issue=17&author=S.+Giovanniniauthor=M.+C.+Wellerauthor=S.+Repmannauthor=H.+Mochauthor=J.+Jiricny&title=Synthetic+lethality+between+BRCA1+deficiency+and+poly%28ADP-ribose%29+polymerase+inhibition+is+modulated+by+processing+of+endogenous+oxidative+DNA+damage&doi=10.1093%2Fnar%2Fgkz624"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic lethality between BRCA1 deficiency and poly(ADP-ribose) polymerase inhibition is modulated by processing of endogenous oxidative DNA damage</span></div><div class="casAuthors">Giovannini, Sara; Weller, Marie-Christine; Repmann, Simone; Moch, Holger; Jiricny, Josef</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">9132-9143</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">1362-4962</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerases (PARPs) facilitate the repair of DNA single-strand breaks (SSBs).  When PARPs are inhibited, unrepaired SSBs colliding with replication forks give rise to cytotoxic double-strand breaks.  These are normally rescued by homologous recombination (HR), but, in cells with suboptimal HR, PARP inhibition leads to genomic instability and cell death, a phenomenon currently exploited in the therapy of ovarian cancers in BRCA1/2 mutation carriers.  In spite of their promise, resistance to PARP inhibitors (PARPis) has already emerged.  In order to identify the possible underlying causes of the resistance, we set out to identify the endogenous source of DNA damage that activates PARPs.We argued that if the toxicity of PARPis is indeed caused by unrepaired SSBs, these breaks must arise spontaneously, because PARPis are used as single agents.  We now show that a significant contributor to PARPi toxicity is oxygen metab.  While BRCA1-depleted or -mutated cells were hypersensitive to the clin. approved PARPi olaparib, its toxicity was significantly attenuated by depletion of OGG1 or MYH DNA glycosylases, as well as by treatment with reactive oxygen species scavengers, growth under hypoxic conditions or chem. OGG1 inhibition.  Thus, clin. resistance to PARPi therapy may emerge simply through reduced efficiency of oxidative damage repair.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqninqP7DYmTbVg90H21EOLACvtfcHk0lgbJJ9d2_v96Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVWksrrN&md5=9c80ddac80505b8b283ff6f87b75ef9d</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkz624&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkz624%26sid%3Dliteratum%253Aachs%26aulast%3DGiovannini%26aufirst%3DS.%26aulast%3DWeller%26aufirst%3DM.%2BC.%26aulast%3DRepmann%26aufirst%3DS.%26aulast%3DMoch%26aufirst%3DH.%26aulast%3DJiricny%26aufirst%3DJ.%26atitle%3DSynthetic%2520lethality%2520between%2520BRCA1%2520deficiency%2520and%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibition%2520is%2520modulated%2520by%2520processing%2520of%2520endogenous%2520oxidative%2520DNA%2520damage%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2019%26volume%3D47%26issue%3D17%26spage%3D9132%26epage%3D9143%26doi%3D10.1093%2Fnar%2Fgkz624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Redon, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonner, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinders, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parchment, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doroshow, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span> <span> </span><span class="NLM_article-title">Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">4532</span>â <span class="NLM_lpage">4542</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-10-0523</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F1078-0432.CCR-10-0523" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=20823146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFGqs7bI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=4532-4542&issue=18&author=C.+E.+Redonauthor=A.+J.+Nakamuraauthor=Y.+W.+Zhangauthor=J.+J.+Jiauthor=W.+M.+Bonnerauthor=R.+J.+Kindersauthor=R.+E.+Parchmentauthor=J.+H.+Doroshowauthor=Y.+Pommier&title=Histone+gammaH2AX+and+poly%28ADP-ribose%29+as+clinical+pharmacodynamic+biomarkers&doi=10.1158%2F1078-0432.CCR-10-0523"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Î³H2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers</span></div><div class="casAuthors">Redon, Christophe E.; Nakamura, Asako J.; Zhang, Yong-Wei; Ji, Jiuping; Bonner, William M.; Kinders, Robert J.; Parchment, Ralph E.; Doroshow, James H.; Pommier, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4532-4542</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Tumor cells are often deficient in DNA damage response (DDR) pathways, and anticancer therapies are commonly based on genotoxic treatments using radiation and/or drugs that damage DNA directly or interfere with DNA metab., leading to the formation of DNA double-strand breaks (DSB), and ultimately to cell death.  Because DSBs induce the phosphorylation of histone H2AX (Î³H2AX) in the chromatin flanking the break site, an antibody directed against Î³H2AX can be employed to measure DNA damage levels before and after patient treatment.  Poly(ADP-ribose) polymerases (PARP1 and PARP2) are also activated by DNA damage, and PARP inhibitors show promising activity in cancers with defective homologous recombination (HR) pathways for DSB repair.  Ongoing clin. trials are testing combinations of PARP inhibitors with DNA damaging agents.  Poly(ADP-ribosylation), abbreviated as PAR, can be measured in clin. samples and used to det. the efficiency of PARP inhibitors.  This review summarizes the roles of Î³H2AX and PAR in the DDR, and their use as biomarkers to monitor drug response and guide clin. trials, esp. phase 0 clin. trials.  We also discuss the choices of relevant samples for Î³H2AX and PAR analyses.  Clin Cancer Res; 16(18); 4532-42.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocLdGwTAJVALVg90H21EOLACvtfcHk0lgbJJ9d2_v96Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFGqs7bI&md5=4a2bc5d90d93f3de000ccb3f8ffd9c74</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-0523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-0523%26sid%3Dliteratum%253Aachs%26aulast%3DRedon%26aufirst%3DC.%2BE.%26aulast%3DNakamura%26aufirst%3DA.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%2BW.%26aulast%3DJi%26aufirst%3DJ.%2BJ.%26aulast%3DBonner%26aufirst%3DW.%2BM.%26aulast%3DKinders%26aufirst%3DR.%2BJ.%26aulast%3DParchment%26aufirst%3DR.%2BE.%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26aulast%3DPommier%26aufirst%3DY.%26atitle%3DHistone%2520gammaH2AX%2520and%2520poly%2528ADP-ribose%2529%2520as%2520clinical%2520pharmacodynamic%2520biomarkers%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26issue%3D18%26spage%3D4532%26epage%3D4542%26doi%3D10.1158%2F1078-0432.CCR-10-0523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DâAndrea, A. D.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of PARP inhibitor sensitivity and resistance</span>. <i>DNA Repair</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">172</span>â <span class="NLM_lpage">176</span>, <span class="refDoi">Â DOI: 10.1016/j.dnarep.2018.08.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.dnarep.2018.08.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=30177437" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Cgs7jI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2018&pages=172-176&author=A.+D.+D%E2%80%99Andrea&title=Mechanisms+of+PARP+inhibitor+sensitivity+and+resistance&doi=10.1016%2Fj.dnarep.2018.08.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of PARP inhibitor sensitivity and resistance</span></div><div class="casAuthors">D'Andrea, Alan D.</div><div class="citationInfo"><span class="NLM_cas:title">DNA Repair</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">172-176</span>CODEN:
                <span class="NLM_cas:coden">DRNEAR</span>;
        ISSN:<span class="NLM_cas:issn">1568-7864</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">BRCA1 and BRCA2 deficient tumor cells are sensitive to inhibitors of Poly ADP Ribose Polymerase (PARP1) through the mechanism of synthetic lethality.  Several PARP inhibitors, which are oral drugs and generally well tolerated, have now received FDA approval for various ovarian cancer and breast cancer indications.  Despite their use in the clinic, PARP inhibitor resistance is common and develops through multiple mechanisms.  Broadly speaking, BRCA1/2-deficient tumor cells can become resistant to PARP inhibitors by restoring homologous recombination (HR) repair and/or by stabilizing their replication forks.  Here, we review the mechanism of PARP inhibitor resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvIBaDAbajp7Vg90H21EOLACvtfcHk0ljWzKvikMs2eA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Cgs7jI&md5=892ee46fb9b85c7eb00193584b5557b9</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.dnarep.2018.08.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.dnarep.2018.08.021%26sid%3Dliteratum%253Aachs%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DA.%2BD.%26atitle%3DMechanisms%2520of%2520PARP%2520inhibitor%2520sensitivity%2520and%2520resistance%26jtitle%3DDNA%2520Repair%26date%3D2018%26volume%3D71%26spage%3D172%26epage%3D176%26doi%3D10.1016%2Fj.dnarep.2018.08.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cannan, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pederson, D. S.</span></span> <span> </span><span class="NLM_article-title">Mechanisms and consequences of double-strand DNA break formation in Chromatin</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>231</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">3</span>â <span class="NLM_lpage">14</span>, <span class="refDoi">Â DOI: 10.1002/jcp.25048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1002%2Fjcp.25048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=26040249" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFKntbfN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=231&publication_year=2016&pages=3-14&issue=1&author=W.+J.+Cannanauthor=D.+S.+Pederson&title=Mechanisms+and+consequences+of+double-strand+DNA+break+formation+in+Chromatin&doi=10.1002%2Fjcp.25048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms and Consequences of Double-Strand DNA Break Formation in Chromatin</span></div><div class="casAuthors">Cannan, Wendy J.; Pederson, David S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">231</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-14</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  All organisms suffer double-strand breaks (DSBs) in their DNA as a result of exposure to ionizing radiation.  DSBs can also form when replication forks encounter DNA lesions or repair intermediates.  The processing and repair of DSBs can lead to mutations, loss of heterozygosity, and chromosome rearrangements that result in cell death or cancer.  The most common pathway used to repair DSBs in metazoans (non-homologous DNA end joining) is more commonly mutagenic than the alternative pathway (homologous recombination mediated repair).  Thus, factors that influence the choice of pathways used DSB repair can affect an individual's mutation burden and risk of cancer.  This review describes radiol., chem., and biol. mechanisms that generate DSBs, and discusses the impact of such variables as DSB etiol., cell type, cell cycle, and chromatin structure on the yield, distribution, and processing of DSBs.  The final section focuses on nucleosome-specific mechanisms that influence DSB prodn., and the possible relationship between higher order chromosome coiling and chromosome shattering (chromothripsis).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq815Y9VsnxHbVg90H21EOLACvtfcHk0ljWzKvikMs2eA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFKntbfN&md5=7e6b1765f7b5ae77d0c969f59c806f1d</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1002%2Fjcp.25048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.25048%26sid%3Dliteratum%253Aachs%26aulast%3DCannan%26aufirst%3DW.%2BJ.%26aulast%3DPederson%26aufirst%3DD.%2BS.%26atitle%3DMechanisms%2520and%2520consequences%2520of%2520double-strand%2520DNA%2520break%2520formation%2520in%2520Chromatin%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2016%26volume%3D231%26issue%3D1%26spage%3D3%26epage%3D14%26doi%3D10.1002%2Fjcp.25048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ceccaldi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amunugama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hajdu, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Primack, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petalcorin, M. I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâConnor, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konstantinopoulos, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elledge, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulton, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yusufzai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DâAndrea, A. D.</span></span> <span> </span><span class="NLM_article-title">Homologous-recombination-deficient tumours are dependent on Pol theta-mediated repair</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>518</i></span> (<span class="NLM_issue">7538</span>),  <span class="NLM_fpage">258</span>â <span class="NLM_lpage">U306</span>, <span class="refDoi">Â DOI: 10.1038/nature14184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1038%2Fnature14184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=25642963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGisb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=518&publication_year=2015&pages=258-U306&issue=7538&author=R.+Ceccaldiauthor=J.+C.+Liuauthor=R.+Amunugamaauthor=I.+Hajduauthor=B.+Primackauthor=M.+I.+R.+Petalcorinauthor=K.+W.+O%E2%80%99Connorauthor=P.+A.+Konstantinopoulosauthor=S.+J.+Elledgeauthor=S.+J.+Boultonauthor=T.+Yusufzaiauthor=A.+D.+D%E2%80%99Andrea&title=Homologous-recombination-deficient+tumours+are+dependent+on+Pol+theta-mediated+repair&doi=10.1038%2Fnature14184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Homologous-recombination-deficient tumours are dependent on PolÎ¸-mediated repair</span></div><div class="casAuthors">Ceccaldi, Raphael; Liu, Jessica C.; Amunugama, Ravindra; Hajdu, Ildiko; Primack, Benjamin; Petalcorin, Mark I. R.; O'Connor, Kevin W.; Konstantinopoulos, Panagiotis A.; Elledge, Stephen J.; Boulton, Simon J.; Yusufzai, Timur; D'Andrea, Alan D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">518</span>
        (<span class="NLM_cas:issue">7538</span>),
    <span class="NLM_cas:pages">258-262</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Large-scale genomic studies have shown that half of epithelial ovarian cancers (EOCs) have alterations in genes regulating homologous recombination (HR) repair.  Loss of HR accounts for the genomic instability of EOCs and for their cellular hyper-dependence on alternative poly-ADP ribose polymerase (PARP)-mediated DNA repair mechanisms.  Previous studies have implicated the DNA polymerase Î¸ (PolÎ¸ also known as POLQ, encoded by POLQ) in a pathway required for the repair of DNA double-strand breaks, referred to as the error-prone microhomol.-mediated end-joining (MMEJ) pathway.  Whether PolÎ¸ interacts with canonical DNA repair pathways to prevent genomic instability remains unknown.  Here we report an inverse correlation between HR activity and PolÎ¸ expression in EOCs.  Knockdown of PolÎ¸ in HR-proficient cells upregulates HR activity and RAD51 nucleofilament assembly, while knockdown of PolÎ¸ in HR-deficient EOCs enhances cell death.  Consistent with these results, genetic inactivation of an HR gene (Fancd2) and Polq in mice results in embryonic lethality.  Moreover, PolÎ¸ contains RAD51 binding motifs and it blocks RAD51-mediated recombination.  Our results reveal a synthetic lethal relationship between the HR pathway and PolÎ¸-mediated repair in EOCs, and identify PolÎ¸ as a novel druggable target for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHib0g8CkoT7Vg90H21EOLACvtfcHk0ljWzKvikMs2eA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGisb4%253D&md5=a0ef28954964cf770115f261c8c14c31</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnature14184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature14184%26sid%3Dliteratum%253Aachs%26aulast%3DCeccaldi%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DJ.%2BC.%26aulast%3DAmunugama%26aufirst%3DR.%26aulast%3DHajdu%26aufirst%3DI.%26aulast%3DPrimack%26aufirst%3DB.%26aulast%3DPetalcorin%26aufirst%3DM.%2BI.%2BR.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DK.%2BW.%26aulast%3DKonstantinopoulos%26aufirst%3DP.%2BA.%26aulast%3DElledge%26aufirst%3DS.%2BJ.%26aulast%3DBoulton%26aufirst%3DS.%2BJ.%26aulast%3DYusufzai%26aufirst%3DT.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DA.%2BD.%26atitle%3DHomologous-recombination-deficient%2520tumours%2520are%2520dependent%2520on%2520Pol%2520theta-mediated%2520repair%26jtitle%3DNature%26date%3D2015%26volume%3D518%26issue%3D7538%26spage%3D258%26epage%3DU306%26doi%3D10.1038%2Fnature14184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiba, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span> <span> </span><span class="NLM_article-title">DNA polymerase theta (POLQ) is important for repair of DNA double-strand breaks caused by fork collapse</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>294</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">3909</span>â <span class="NLM_lpage">3919</span>, <span class="refDoi">Â DOI: 10.1074/jbc.RA118.005188</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1074%2Fjbc.RA118.005188" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=30655289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpvFSmtr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=294&publication_year=2019&pages=3909-3919&issue=11&author=Z.+Wangauthor=Y.+Songauthor=S.+Liauthor=S.+Kurianauthor=R.+Xiangauthor=T.+Chibaauthor=X.+Wu&title=DNA+polymerase+theta+%28POLQ%29+is+important+for+repair+of+DNA+double-strand+breaks+caused+by+fork+collapse&doi=10.1074%2Fjbc.RA118.005188"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">DNA polymerase Î¸ (POLQ) is important for repair of DNA double-strand breaks caused by fork collapse</span></div><div class="casAuthors">Wang, Zi; Song, Yadong; Li, Shibo; Kurian, Sunil; iang, Rong; Chiba, Takuya; Wu, Xiaohua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">294</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3909-3919</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">DNA polymerase Î¸ (POLQ) plays an important role in alternative nonhomologous end joining or micro-homol.-mediated end joining (alt-NHEJ/MMEJ).  Here, we show that POLQ is not only required for MMEJ to repair DNA double strand breaks (DSBs) generated by endonucleases such as I-SceI or Cas9, but is also needed for repair of DSBs derived fromDNA nicks generated by Cas9 nickase.  Consistently, we found that POLQ deficiency leads to sensitivity to topoisomerase inhibitors that cause DNA single-strand break (SSB) accumulation at replication forks and to ATR inhibitors that induce replication fork collapse.  These studies support the function of POLQ in coping with replication stress and repairing DSBs upon fork collapse.  POLQ overexpression is present in many cancer types and is assocd. with poor prognosis, including breast cancer regardless of BRCA1 status.  We provide proof-of-concept evidence to support a novel cancer treatment strategy that combines POLQ inhibition with administration of topoisomerase or ATR inhibitors, which induces replication stress and fork collapse.  Given the prevalence of POLQ overexpression in tumors, such strategy may have a significant impact on developing targeted cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXGrxdkUQBnrVg90H21EOLACvtfcHk0ljx8pL_dknmCQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpvFSmtr0%253D&md5=39b8fa600ebd9c95201b0fd3e4c9b99e</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1074%2Fjbc.RA118.005188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.RA118.005188%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DKurian%26aufirst%3DS.%26aulast%3DXiang%26aufirst%3DR.%26aulast%3DChiba%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DX.%26atitle%3DDNA%2520polymerase%2520theta%2520%2528POLQ%2529%2520is%2520important%2520for%2520repair%2520of%2520DNA%2520double-strand%2520breaks%2520caused%2520by%2520fork%2520collapse%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2019%26volume%3D294%26issue%3D11%26spage%3D3909%26epage%3D3919%26doi%3D10.1074%2Fjbc.RA118.005188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Domchek, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aghajanian, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapira-Frommer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmutzler, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audeh, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedlander, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balmana, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fried, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stemmer, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosengarten, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, B.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy</span>. <i>Gynecol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>140</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">199</span>â <span class="NLM_lpage">203</span>, <span class="refDoi">Â DOI: 10.1016/j.ygyno.2015.12.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.ygyno.2015.12.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=26723501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitV2rs7zP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2016&pages=199-203&issue=2&author=S.+M.+Domchekauthor=C.+Aghajanianauthor=R.+Shapira-Frommerauthor=R.+K.+Schmutzlerauthor=M.+W.+Audehauthor=M.+Friedlanderauthor=J.+Balmanaauthor=G.+Mitchellauthor=G.+Friedauthor=S.+M.+Stemmerauthor=A.+Hubertauthor=O.+Rosengartenauthor=N.+Lomanauthor=J.+D.+Robertsonauthor=H.+Mannauthor=B.+Kaufman&title=Efficacy+and+safety+of+olaparib+monotherapy+in+germline+BRCA1%2F2+mutation+carriers+with+advanced+ovarian+cancer+and+three+or+more+lines+of+prior+therapy&doi=10.1016%2Fj.ygyno.2015.12.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy</span></div><div class="casAuthors">Domchek, Susan M.; Aghajanian, Carol; Shapira-Frommer, Ronnie; Schmutzler, Rita K.; Audeh, M. William; Friedlander, Michael; Balmana, Judith; Mitchell, Gillian; Fried, Georgeta; Stemmer, Salomon M.; Hubert, Ayala; Rosengarten, Ora; Loman, Niklas; Robertson, Jane D.; Mann, Helen; Kaufman, Bella</div><div class="citationInfo"><span class="NLM_cas:title">Gynecologic Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">199-203</span>CODEN:
                <span class="NLM_cas:coden">GYNOA3</span>;
        ISSN:<span class="NLM_cas:issn">0090-8258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Objective: The efficacy and safety of olaparib, an oral poly(ADP-ribose) polymerase (PARP) inhibitor, was investigated in a subgroup of patients with germline BRCA1/2 mutated (gBRCA1/2m) advanced ovarian cancer who had received â¥ 3 prior lines of chemotherapy.  Primary data from this Phase II study (Study 42, ClinicalTrials.govNCT01078662) have been reported previously.  Methods: Eligible patients were treated with oral olaparib 400 mg bid capsule monotherapy until disease progression according to RECIST v1.1.  Objective response rate (ORR) and duration of response (DoR) were assessed for patients with measurable disease at baseline.  Safety and tolerability were assessed for all patients by adverse event (AE) incidence and changes in lab. parameters.  Platinum resistance status was obtained retrospectively, and responses to olaparib evaluated.  Results: In patients with gBRCA1/2m ovarian cancer, 154/193 (80%) had received â¥ 3 prior lines of chemotherapy, of whom 137/154 (89%) had measurable disease at baseline.  ORR was 34% (46/137; 95% confidence interval [CI] 26-42) and median DoR was 7.9 (95% CI 5.6-9.6) months.  ORR in platinum-resistant tumors was 30%.  Median DoR for platinum-sensitive and platinum-resistant disease was similar: 8.2 mo (95% CI 5.6-13.5) compared with 8.0 mo (4.8-14.8), resp.  Six of the 193 (3%) patients had an AE with an outcome of death.  None of these AEs at time of occurrence was considered causally related to olaparib.  Conclusion: Following â¥ 3 prior lines of chemotherapy, olaparib 400 mg bid (capsule form) monotherapy demonstrated notable antitumor activity in patients with gBRCA1/2m advanced ovarian cancer.  No new safety signals were identified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNM1gZB7nEubVg90H21EOLACvtfcHk0ljx8pL_dknmCQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitV2rs7zP&md5=7cfc0053a94e4951eacc330b8f969e7c</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.ygyno.2015.12.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ygyno.2015.12.020%26sid%3Dliteratum%253Aachs%26aulast%3DDomchek%26aufirst%3DS.%2BM.%26aulast%3DAghajanian%26aufirst%3DC.%26aulast%3DShapira-Frommer%26aufirst%3DR.%26aulast%3DSchmutzler%26aufirst%3DR.%2BK.%26aulast%3DAudeh%26aufirst%3DM.%2BW.%26aulast%3DFriedlander%26aufirst%3DM.%26aulast%3DBalmana%26aufirst%3DJ.%26aulast%3DMitchell%26aufirst%3DG.%26aulast%3DFried%26aufirst%3DG.%26aulast%3DStemmer%26aufirst%3DS.%2BM.%26aulast%3DHubert%26aufirst%3DA.%26aulast%3DRosengarten%26aufirst%3DO.%26aulast%3DLoman%26aufirst%3DN.%26aulast%3DRobertson%26aufirst%3DJ.%2BD.%26aulast%3DMann%26aufirst%3DH.%26aulast%3DKaufman%26aufirst%3DB.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520olaparib%2520monotherapy%2520in%2520germline%2520BRCA1%252F2%2520mutation%2520carriers%2520with%2520advanced%2520ovarian%2520cancer%2520and%2520three%2520or%2520more%2520lines%2520of%2520prior%2520therapy%26jtitle%3DGynecol.%2520Oncol.%26date%3D2016%26volume%3D140%26issue%3D2%26spage%3D199%26epage%3D203%26doi%3D10.1016%2Fj.ygyno.2015.12.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fong, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boss, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carden, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mergui-Roelvink, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gourley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Greve, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubinski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shanley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messiou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">AâHern, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tutt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashworth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmichael, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellens, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bono, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaye, S. B.</span></span> <span> </span><span class="NLM_article-title">Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">2512</span>â <span class="NLM_lpage">2519</span>, <span class="refDoi">Â DOI: 10.1200/JCO.2009.26.9589</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1200%2FJCO.2009.26.9589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=20406929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3cXotVyjtr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=2512-2519&issue=15&author=P.+C.+Fongauthor=T.+A.+Yapauthor=D.+S.+Bossauthor=C.+P.+Cardenauthor=M.+Mergui-Roelvinkauthor=C.+Gourleyauthor=J.+De+Greveauthor=J.+Lubinskiauthor=S.+Shanleyauthor=C.+Messiouauthor=R.+A%E2%80%99Hernauthor=A.+Tuttauthor=A.+Ashworthauthor=J.+Stoneauthor=J.+Carmichaelauthor=J.+H.+Schellensauthor=J.+S.+de+Bonoauthor=S.+B.+Kaye&title=Poly%28ADP%29-ribose+polymerase+inhibition%3A+frequent+durable+responses+in+BRCA+carrier+ovarian+cancer+correlating+with+platinum-free+interval&doi=10.1200%2FJCO.2009.26.9589"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval</span></div><div class="casAuthors">Fong, Peter C.; Yap, Timothy A.; Boss, David S.; Carden, Craig P.; Mergui-Roelvink, Maria; Gourley, Charlie; De Greve, Jacques; Lubinski, Jan; Shanley, Susan; Messiou, Christina; A'Hern, Roger; Tutt, Andrew; Ashworth, Alan; Stone, John; Carmichael, James; Schellens, Jan H. M.; de Bono, Johann S.; Kaye, Stan B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2512-2519</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Selective tumor cell cytotoxicity can be achieved through a synthetic lethal strategy using poly(ADP)-ribose polymerase (PARP) inhibitor therapy in BRCA1/2 mutation carriers in whom tumor cells have defective homologous recombination (HR) DNA repair.  Platinum-based chemotherapy responses correlate with HR DNA repair capacity.  Olaparib is a potent, oral PARP inhibitor that is well tolerated, with antitumor activity in BRCA1/2 mutation carriers.  Patients and Methods: Patients with BRCA1/2-mutated ovarian cancer were treated with olaparib within a dose-escalation and single-stage expansion of a phase I trial.  Antitumor activity was subsequently correlated with platinum sensitivity.  Results: Fifty patients were treated: 48 had germline BRCA1/2 mutations; one had a BRCA2 germline sequence change of unknown significance, and another had a strong family history of BRCA1/2-assocd. cancers who declined mutation testing.  Of the 50 patients, 13 had platinum-sensitive disease, 24 had platinum-resistant disease, and 13 had platinum-refractory disease (according to platinum-free interval).  Twenty (40%; 95% CI, 26% to 55%) achieved Response Evaluation Criteria in Solid Tumors (RECIST) complete or partial responses and/or tumor marker (CA125) responses, and three (6.0%) maintained RECIST disease stabilization for more than 4 mo, giving an overall clin. benefit rate of 46% (95% CI, 32% to 61 %).  Median response duration was 28 wk.  There was a significant assocn. between the clin. benefit rate and platinum-free interval across the platinum-sensitive, resistant, and refractory subgroups (69%, 45%, and 23%, resp.).  Post hoc analyses indicated assocns. between platinum sensitivity and extent of olaparib response (radiol. change, P = .001; CA125 change, P = .002).  Conclusion: Olaparib has antitumor activity in BRCA1/2 mutation ovarian cancer, which is assocd. with platinum sensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyvj9Ym5yY27Vg90H21EOLACvtfcHk0ljkEcuKWWgEeQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXotVyjtr4%253D&md5=4198806c2b9d41e7068d26049fd0cd3f</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.26.9589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.26.9589%26sid%3Dliteratum%253Aachs%26aulast%3DFong%26aufirst%3DP.%2BC.%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3DBoss%26aufirst%3DD.%2BS.%26aulast%3DCarden%26aufirst%3DC.%2BP.%26aulast%3DMergui-Roelvink%26aufirst%3DM.%26aulast%3DGourley%26aufirst%3DC.%26aulast%3DDe%2BGreve%26aufirst%3DJ.%26aulast%3DLubinski%26aufirst%3DJ.%26aulast%3DShanley%26aufirst%3DS.%26aulast%3DMessiou%26aufirst%3DC.%26aulast%3DA%25E2%2580%2599Hern%26aufirst%3DR.%26aulast%3DTutt%26aufirst%3DA.%26aulast%3DAshworth%26aufirst%3DA.%26aulast%3DStone%26aufirst%3DJ.%26aulast%3DCarmichael%26aufirst%3DJ.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26aulast%3DKaye%26aufirst%3DS.%2BB.%26atitle%3DPoly%2528ADP%2529-ribose%2520polymerase%2520inhibition%253A%2520frequent%2520durable%2520responses%2520in%2520BRCA%2520carrier%2520ovarian%2520cancer%2520correlating%2520with%2520platinum-free%2520interval%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26issue%3D15%26spage%3D2512%26epage%3D2519%26doi%3D10.1200%2FJCO.2009.26.9589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Audeh, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmichael, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penson, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedlander, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell-McGuinn, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weitzel, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oaknin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmutzler, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matulonis, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickens, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tutt, A.</span></span> <span> </span><span class="NLM_article-title">Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>376</i></span> (<span class="NLM_issue">9737</span>),  <span class="NLM_fpage">245</span>â <span class="NLM_lpage">251</span>, <span class="refDoi">Â DOI: 10.1016/S0140-6736(10)60893-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2FS0140-6736%2810%2960893-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=20609468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1Kktb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2010&pages=245-251&issue=9737&author=M.+W.+Audehauthor=J.+Carmichaelauthor=R.+T.+Pensonauthor=M.+Friedlanderauthor=B.+Powellauthor=K.+M.+Bell-McGuinnauthor=C.+Scottauthor=J.+N.+Weitzelauthor=A.+Oakninauthor=N.+Lomanauthor=K.+Luauthor=R.+K.+Schmutzlerauthor=U.+Matulonisauthor=M.+Wickensauthor=A.+Tutt&title=Oral+poly%28ADP-ribose%29+polymerase+inhibitor+olaparib+in+patients+with+BRCA1+or+BRCA2+mutations+and+recurrent+ovarian+cancer%3A+a+proof-of-concept+trial&doi=10.1016%2FS0140-6736%2810%2960893-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial</span></div><div class="casAuthors">Audeh, M. William; Carmichael, James; Penson, Richard T.; Friedlander, Michael; Powell, Bethan; Bell-McGuinn, Katherine M.; Scott, Clare; Weitzel, Jeffrey N.; Oaknin, Ana; Loman, Niklas; Lu, Karen; Schmutzler, Rita K.; Matulonis, Ursula; Wickens, Mark; Tutt, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">376</span>
        (<span class="NLM_cas:issue">9737</span>),
    <span class="NLM_cas:pages">245-251</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Olaparib is a novel, orally active poly(ADP-ribose) polymerase (PARP) inhibitor that induces synthetic lethality in homozygous BRCA-deficient cells.  We aimed to assess the efficacy and safety of olaparib for treatment of advanced ovarian cancer in patients with BRCA1 or BRCA2 mutations.  In this international, multicentre, phase 2 study, we enrolled two sequential cohorts of women (aged â¥18 years) with confirmed genetic BRCA1 or BRCA2 mutations, and recurrent, measurable disease.  The study was undertaken in 12 centers in Australia, Germany, Spain, Sweden, and the USA.  The first cohort (n=33) was given continuous oral olaparib at the max. tolerated dose of 400 mg twice daily, and the second cohort (n=24) was given continuous oral olaparib at 100 mg twice daily.  The primary efficacy endpoint was objective response rate (ORR).  This study is registered with ClinicalTrials.gov, no. NCT00494442.  Patients had been given a median of three (range 1-16) previous chemotherapy regimens.  ORR was 11 (33%) of 33 patients (95% CI 20-51) in the cohort assigned to olaparib 400 mg twice daily, and three (13%) of 24 (4-31) in the cohort assigned to 100 mg twice daily.  In patients given olaparib 400 mg twice daily, the most frequent causally related adverse events were nausea (grade 1 or 2, 14 [42%]; grade 3 or 4, 2 [6%]), fatigue (grade 1 or 2, 10 [30%]; grade 3 or 4, one [3%]), and anemia (grade 1 or 2, 5 [15%]; grade 3 or 4, 1 [3%]).  The most frequent causally related adverse events in the cohort given 100 mg twice daily were nausea (grade 1 or 2, 7 [29%]; grade 3 or 4, 2 [8%]) and fatigue (grade 1 or 2, 9 [38%]; none grade 3 or 4).  Findings from this phase 2 study provide pos. proof of concept of the efficacy and tolerability of genetically targeted treatment with olaparib in BRCA-mutated advanced ovarian cancer.  Funding: AstraZeneca.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfC3epcFKsLrVg90H21EOLACvtfcHk0ljkEcuKWWgEeQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1Kktb4%253D&md5=e74985d2c7ae53462d48277fbc36bb6a</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2810%2960893-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252810%252960893-8%26sid%3Dliteratum%253Aachs%26aulast%3DAudeh%26aufirst%3DM.%2BW.%26aulast%3DCarmichael%26aufirst%3DJ.%26aulast%3DPenson%26aufirst%3DR.%2BT.%26aulast%3DFriedlander%26aufirst%3DM.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DBell-McGuinn%26aufirst%3DK.%2BM.%26aulast%3DScott%26aufirst%3DC.%26aulast%3DWeitzel%26aufirst%3DJ.%2BN.%26aulast%3DOaknin%26aufirst%3DA.%26aulast%3DLoman%26aufirst%3DN.%26aulast%3DLu%26aufirst%3DK.%26aulast%3DSchmutzler%26aufirst%3DR.%2BK.%26aulast%3DMatulonis%26aufirst%3DU.%26aulast%3DWickens%26aufirst%3DM.%26aulast%3DTutt%26aufirst%3DA.%26atitle%3DOral%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitor%2520olaparib%2520in%2520patients%2520with%2520BRCA1%2520or%2520BRCA2%2520mutations%2520and%2520recurrent%2520ovarian%2520cancer%253A%2520a%2520proof-of-concept%2520trial%26jtitle%3DLancet%26date%3D2010%26volume%3D376%26issue%3D9737%26spage%3D245%26epage%3D251%26doi%3D10.1016%2FS0140-6736%2810%2960893-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapira-Frommer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmutzler, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audeh, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedlander, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balmana, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fried, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stemmer, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosengarten, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fielding, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domchek, S. M.</span></span> <span> </span><span class="NLM_article-title">Olaparib monotherapy in patients with advanced cancer and a Germline BRCA1/2 mutation</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">244</span>â <span class="NLM_lpage">250</span>, <span class="refDoi">Â DOI: 10.1200/JCO.2014.56.2728</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1200%2FJCO.2014.56.2728" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=25366685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjsVWrsLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=244-250&issue=3&author=B.+Kaufmanauthor=R.+Shapira-Frommerauthor=R.+K.+Schmutzlerauthor=M.+W.+Audehauthor=M.+Friedlanderauthor=J.+Balmanaauthor=G.+Mitchellauthor=G.+Friedauthor=S.+M.+Stemmerauthor=A.+Hubertauthor=O.+Rosengartenauthor=M.+Steinerauthor=N.+Lomanauthor=K.+Bowenauthor=A.+Fieldingauthor=S.+M.+Domchek&title=Olaparib+monotherapy+in+patients+with+advanced+cancer+and+a+Germline+BRCA1%2F2+mutation&doi=10.1200%2FJCO.2014.56.2728"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation</span></div><div class="casAuthors">Kaufman, Bella; Shapira-Frommer, Ronnie; Schmutzler, Rita K.; Audeh, M. William; Friedlander, Michael; Balmana, Judith; Mitchell, Gillian; Fried, Georgeta; Stemmer, Salomon M.; Hubert, Ayala; Rosengarten, Ora; Steiner, Mariana; Loman, Niklas; Bowen, Karin; Fielding, Anitra; Domchek, Susan M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">244-250</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Olaparib is an oral poly (ADP-ribose) polymerase inhibitor with activity in germline BRCA1 and BRCA2 (BRCA1/2) -assocd. breast and ovarian cancers.  We evaluated the efficacy and safety of olaparib in a spectrum of BRCA1/2-assocd. cancers.  This multicenter phase II study enrolled individuals with a germline BRCA1/2 mutation and recurrent cancer.  Eligibility included ovarian cancer resistant to prior platinum; breast cancer with â¥ three chemotherapy regimens for metastatic disease; pancreatic cancer with prior gemcitabine treatment; or prostate cancer with progression on hormonal and one systemic therapy.  Olaparib was administered at 400 mg twice per day.  The primary efficacy end point was tumor response rate.  A total of 298 patients received treatment and were evaluable.  The tumor response rate was 26.2% (78 of 298; 95% CI, 21.3 to 31.6) overall and 31.1% (60 of 193; 95% CI, 24.6 to 38.1), 12.9% (eight of 62; 95% CI, 5.7 to 23.9), 21.7% (five of 23; 95% CI, 7.5 to 43.7), and 50.0% (four of eight; 95% CI, 15.7 to 84.3) in ovarian, breast, pancreatic, and prostate cancers, resp.  Stable disease â¥ 8 wk was obsd. in 42% of patients (95% CI, 36.0 to 47.4), including 40% (95% CI, 33.4 to 47.7), 47% (95% CI, 34.0 to 59.9), 35% (95% CI, 16.4 to 57.3), and 25% (95% CI, 3.2 to 65.1) of those with ovarian, breast, pancreatic, or prostate cancer, resp.  The most common adverse events (AEs) were fatigue, nausea, and vomiting.  Grade â¥ 3 AEs were reported for 54% of patients; anemia was the most common (17%).  Responses to olaparib were obsd. across different tumor types assocd. with germline BRCA1/2 mutations.  Olaparib warrants further investigation in confirmatory studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooKvduc8Sx3bVg90H21EOLACvtfcHk0ljkEcuKWWgEeQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjsVWrsLY%253D&md5=8ba52a3fa98d1137e6c134245ea42b87</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1200%2FJCO.2014.56.2728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2014.56.2728%26sid%3Dliteratum%253Aachs%26aulast%3DKaufman%26aufirst%3DB.%26aulast%3DShapira-Frommer%26aufirst%3DR.%26aulast%3DSchmutzler%26aufirst%3DR.%2BK.%26aulast%3DAudeh%26aufirst%3DM.%2BW.%26aulast%3DFriedlander%26aufirst%3DM.%26aulast%3DBalmana%26aufirst%3DJ.%26aulast%3DMitchell%26aufirst%3DG.%26aulast%3DFried%26aufirst%3DG.%26aulast%3DStemmer%26aufirst%3DS.%2BM.%26aulast%3DHubert%26aufirst%3DA.%26aulast%3DRosengarten%26aufirst%3DO.%26aulast%3DSteiner%26aufirst%3DM.%26aulast%3DLoman%26aufirst%3DN.%26aulast%3DBowen%26aufirst%3DK.%26aulast%3DFielding%26aufirst%3DA.%26aulast%3DDomchek%26aufirst%3DS.%2BM.%26atitle%3DOlaparib%2520monotherapy%2520in%2520patients%2520with%2520advanced%2520cancer%2520and%2520a%2520Germline%2520BRCA1%252F2%2520mutation%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26issue%3D3%26spage%3D244%26epage%3D250%26doi%3D10.1200%2FJCO.2014.56.2728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kristeleit, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oza, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LoRusso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domchek, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balmana, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drew, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safra, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goble, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaacson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borrow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfe, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapira-Frommer, R.</span></span> <span> </span><span class="NLM_article-title">A Phase I-II study of the oral PARP inhibitor Rucaparib in patients with Germline BRCA1/2-mutated ovarian carcinoma or other solid tumors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">4095</span>â <span class="NLM_lpage">4106</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-16-2796</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F1078-0432.CCR-16-2796" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=28264872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Ghu7fK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=4095-4106&issue=15&author=R.+Kristeleitauthor=G.+I.+Shapiroauthor=H.+A.+Burrisauthor=A.+M.+Ozaauthor=P.+LoRussoauthor=M.+R.+Patelauthor=S.+M.+Domchekauthor=J.+Balmanaauthor=Y.+Drewauthor=L.+M.+Chenauthor=T.+Safraauthor=A.+Montesauthor=H.+Giordanoauthor=L.+Maloneyauthor=S.+Gobleauthor=J.+Isaacsonauthor=J.+Xiaoauthor=J.+Borrowauthor=L.+Rolfeauthor=R.+Shapira-Frommer&title=A+Phase+I-II+study+of+the+oral+PARP+inhibitor+Rucaparib+in+patients+with+Germline+BRCA1%2F2-mutated+ovarian+carcinoma+or+other+solid+tumors&doi=10.1158%2F1078-0432.CCR-16-2796"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors</span></div><div class="casAuthors">Kristeleit, Rebecca; Shapiro, Geoffrey I.; Burris, Howard A.; Oza, Amit M.; Lo Russo, Patricia; Patel, Manish R.; Domchek, Susan M.; Balmana, Judith; Drew, Yvette; Chen, Lee-may; Safra, Tamar; Montes, Ana; Giordano, Heidi; Maloney, Lara; Goble, Sandra; Isaacson, Jeff; Xiao, Jim; Borrow, Jen; Rolfe, Lindsey; Shapira-Frommer, Ronnie</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4095-4106</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Rucaparib is a potent, oral, small-mol. PARP inhibitor.  This phase I-II study was the first to evaluate single-agent oral rucaparib at multiple doses.  Exptl. Design: Part 1 (phase I) sought to det. the MTD, recommended phase II dose (RP2D), and pharmacokinetics of oral rucaparib administered in 21-day continuous cycles in patients with advanced solid tumors.  Part 2A (phase II) enrolled patients with platinum-sensitive, high-grade ovarian carcinoma (HGOC) assocd. with a germline BRCA1/2 mutation who received two to four prior regimens and had a progression-free interval of 6 mo or more following their most recent platinum therapy.  The primary endpoint was investigator-assessed objective response rate (ORR) by RECIST version 1.1.  Results: In part 1, 56 patients received oral rucaparib (40 to 500 mg once daily and 240 to 840 mg twice daily).  No MTD was identified per protocol-defined criteria; 600 mg twice daily was selected as the RP2D based on manageable toxicity and clin. activity.  Pharmacokinetics were approx. dose-proportional across all dose levels.  In part 2A, 42 patients with germline BRCA1/2-mutated HGOC received rucaparib 600 mg twice daily.  Investigator-assessed ORR was 59.5%.  The most common treatment-emergent adverse events (all grades) were asthenia/fatigue (85.7%; 36/42), nausea (83.3%; 35/42), anemia (71.4%; 30/42), alanine transaminase and/or aspartate transaminase elevations (57.1%; 24/42), and vomiting (54.8%; 23/42).  Among 98 patients, 5 (5.1%) discontinued because of an adverse event (excluding disease progression).  Conclusions: Rucaparib was tolerable and had activity in patients with platinum-sensitive germline BRCA1/2-mutated HGOC.  Clin Cancer Res; 23(15); 4095-106. Â©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZJ2EmIj6hBLVg90H21EOLACvtfcHk0lgX5Evekvi5HQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Ghu7fK&md5=e9a13775ccd785551e01585bed7f676c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-2796&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-2796%26sid%3Dliteratum%253Aachs%26aulast%3DKristeleit%26aufirst%3DR.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DOza%26aufirst%3DA.%2BM.%26aulast%3DLoRusso%26aufirst%3DP.%26aulast%3DPatel%26aufirst%3DM.%2BR.%26aulast%3DDomchek%26aufirst%3DS.%2BM.%26aulast%3DBalmana%26aufirst%3DJ.%26aulast%3DDrew%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DL.%2BM.%26aulast%3DSafra%26aufirst%3DT.%26aulast%3DMontes%26aufirst%3DA.%26aulast%3DGiordano%26aufirst%3DH.%26aulast%3DMaloney%26aufirst%3DL.%26aulast%3DGoble%26aufirst%3DS.%26aulast%3DIsaacson%26aufirst%3DJ.%26aulast%3DXiao%26aufirst%3DJ.%26aulast%3DBorrow%26aufirst%3DJ.%26aulast%3DRolfe%26aufirst%3DL.%26aulast%3DShapira-Frommer%26aufirst%3DR.%26atitle%3DA%2520Phase%2520I-II%2520study%2520of%2520the%2520oral%2520PARP%2520inhibitor%2520Rucaparib%2520in%2520patients%2520with%2520Germline%2520BRCA1%252F2-mutated%2520ovarian%2520carcinoma%2520or%2520other%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26issue%3D15%26spage%3D4095%26epage%3D4106%26doi%3D10.1158%2F1078-0432.CCR-16-2796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swisher, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oza, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konecny, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tinker, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâMalley, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kristeleit, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell-McGuinn, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenton, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cragun, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oaknin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray-Coquard, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrell, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufmann, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floquet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leary, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goble, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaacson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfe, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yelensky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raponi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeish, I. A.</span></span> <span> </span><span class="NLM_article-title">Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">75</span>â <span class="NLM_lpage">87</span>, <span class="refDoi">Â DOI: 10.1016/S1470-2045(16)30559-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2FS1470-2045%2816%2930559-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=27908594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFKnurbJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=75-87&issue=1&author=E.+M.+Swisherauthor=K.+K.+Linauthor=A.+M.+Ozaauthor=C.+L.+Scottauthor=H.+Giordanoauthor=J.+Sunauthor=G.+E.+Konecnyauthor=R.+L.+Colemanauthor=A.+V.+Tinkerauthor=D.+M.+O%E2%80%99Malleyauthor=R.+S.+Kristeleitauthor=L.+Maauthor=K.+M.+Bell-McGuinnauthor=J.+D.+Brentonauthor=J.+M.+Cragunauthor=A.+Oakninauthor=I.+Ray-Coquardauthor=M.+I.+Harrellauthor=E.+Mannauthor=S.+H.+Kaufmannauthor=A.+Floquetauthor=A.+Learyauthor=T.+C.+Hardingauthor=S.+Gobleauthor=L.+Maloneyauthor=J.+Isaacsonauthor=A.+R.+Allenauthor=L.+Rolfeauthor=R.+Yelenskyauthor=M.+Raponiauthor=I.+A.+McNeish&title=Rucaparib+in+relapsed%2C+platinum-sensitive+high-grade+ovarian+carcinoma+%28ARIEL2+Part+1%29%3A+an+international%2C+multicentre%2C+open-label%2C+phase+2+trial&doi=10.1016%2FS1470-2045%2816%2930559-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial</span></div><div class="casAuthors">Swisher, Elizabeth M.; Lin, Kevin K.; Oza, Amit M.; Scott, Clare L.; Giordano, Heidi; Sun, James; Konecny, Gottfried E.; Coleman, Robert L.; Tinker, Anna V.; O'Malley, David M.; Kristeleit, Rebecca S.; Ma, Ling; Bell-McGuinn, Katherine M.; Brenton, James D.; Cragun, Janiel M.; Oaknin, Ana; Ray-Coquard, Isabelle; Harrell, Maria I.; Mann, Elaina; Kaufmann, Scott H.; Floquet, Anne; Leary, Alexandra; Harding, Thomas C.; Goble, Sandra; Maloney, Lara; Isaacson, Jeff; Allen, Andrew R.; Rolfe, Lindsey; Yelensky, Roman; Raponi, Mitch; McNeish, Iain A.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">75-87</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase (PARP) inhibitors have activity in ovarian carcinomas with homologous recombination deficiency.  Along with BRCA1 and BRCA2 (BRCA) mutations genomic loss of heterozygosity (LOH) might also represent homologous recombination deficiency.  In ARIEL2, we assessed the ability of tumor genomic LOH, quantified with a next-generation sequencing assay, to predict response to rucaparib, an oral PARP inhibitor.  ARIEL2 is an international, multicentre, two-part, phase 2, open-label study done at 49 hospitals and cancer centers in Australia, Canada, France, Spain, the UK, and the USA.  In ARIEL2 Part 1, patients with recurrent, platinum-sensitive, high-grade ovarian carcinoma were classified into one of three predefined homologous recombination deficiency subgroups on the basis of tumor mutational anal.: BRCA mutant (deleterious germline or somatic), BRCA wild-type and LOH high (LOH high group), or BRCA wild-type and LOH low (LOH low group).  We prespecified a cutoff of 14% or more genomic LOH for LOH high.  Patients began treatment with oral rucaparib at 600 mg twice per day for continuous 28 day cycles until disease progression or any other reason for discontinuation.  The primary endpoint was progression-free survival.  All patients treated with at least one dose of rucaparib were included in the safety analyses and all treated patients who were classified were included in the primary endpoint anal.  This trial is registered with ClinicalTrials.gov, no. NCT01891344.  Enrolment into ARIEL2 Part 1 is complete, although an extension (Part 2) is ongoing.256 patients were screened and 206 were enrolled between Oct 30, 2013, and Dec 19, 2014.  At the data cutoff date (Jan 18, 2016), 204 patients had received rucaparib, with 28 patients remaining in the study. 192 patients could be classified into one of the three predefined homologous recombination deficiency subgroups: BRCA mutant (n=40), LOH high (n=82), or LOH low (n=70).  Tumors from 12 patients were established as BRCA wild-type, but could not be classified for LOH, because of insufficient neoplastic nuclei in the sample.  The median duration of treatment for the 204 patients was 5Â·7 mo (IQR 2Â·8-10Â·1). 24 patients in the BRCA mutant subgroup, 56 patients in the LOH high subgroup, and 59 patients in the LOH low subgroup had disease progression or died.  Median progression-free survival after rucaparib treatment was 12Â·8 mo (95% CI 9Â·0-14Â·7) in the BRCA mutant subgroup, 5Â·7 mo (5Â·3-7Â·6) in the LOH high subgroup, and 5Â·2 mo (3Â·6-5Â·5) in the LOH low subgroup.  Progression-free survival was significantly longer in the BRCA mutant (hazard ratio 0Â·27, 95% CI 0Â·16-0Â·44, p<0Â·0001) and LOH high (0Â·62, 0Â·42-0Â·90, p=0Â·011) subgroups compared with the LOH low subgroup.  The most common grade 3 or worse treatment-emergent adverse events were anemia or decreased Hb (45 [22%] patients), and elevations in alanine aminotransferase or aspartate aminotransferase (25 [12%]).  Common serious adverse events included small intestinal obstruction (10 [5%] of 204 patients), malignant neoplasm progression (10 [5%]), and anemia (nine [4%]).  Three patients died during the study (two because of disease progression and one because of sepsis and disease progression).  No treatment-related deaths occurred.  In patients with BRCA mutant or BRCA wild-type and LOH high platinum-sensitive ovarian carcinomas treated with rucaparib, progression-free survival was longer than in patients with BRCA wild-type LOH low carcinomas.  Our results suggest that assessment of tumor LOH can be used to identify patients with BRCA wild-type platinum-sensitive ovarian cancers who might benefit from rucaparib.  These results extend the potential usefulness of PARP inhibitors in the treatment setting beyond BRCA mutant tumors.  Clovis Oncol., US Department of Defense Ovarian Cancer Research Program, Stand Up To Cancer-Ovarian Cancer Research Fund Alliance-National Ovarian Cancer Coalition Dream Team Translational Research Grant, and V Foundation Translational Award.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra4unrxTkAg7Vg90H21EOLACvtfcHk0lgX5Evekvi5HQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFKnurbJ&md5=59f5a328a371683c038d7eec0058c094</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2816%2930559-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252816%252930559-9%26sid%3Dliteratum%253Aachs%26aulast%3DSwisher%26aufirst%3DE.%2BM.%26aulast%3DLin%26aufirst%3DK.%2BK.%26aulast%3DOza%26aufirst%3DA.%2BM.%26aulast%3DScott%26aufirst%3DC.%2BL.%26aulast%3DGiordano%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DKonecny%26aufirst%3DG.%2BE.%26aulast%3DColeman%26aufirst%3DR.%2BL.%26aulast%3DTinker%26aufirst%3DA.%2BV.%26aulast%3DO%25E2%2580%2599Malley%26aufirst%3DD.%2BM.%26aulast%3DKristeleit%26aufirst%3DR.%2BS.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DBell-McGuinn%26aufirst%3DK.%2BM.%26aulast%3DBrenton%26aufirst%3DJ.%2BD.%26aulast%3DCragun%26aufirst%3DJ.%2BM.%26aulast%3DOaknin%26aufirst%3DA.%26aulast%3DRay-Coquard%26aufirst%3DI.%26aulast%3DHarrell%26aufirst%3DM.%2BI.%26aulast%3DMann%26aufirst%3DE.%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26aulast%3DFloquet%26aufirst%3DA.%26aulast%3DLeary%26aufirst%3DA.%26aulast%3DHarding%26aufirst%3DT.%2BC.%26aulast%3DGoble%26aufirst%3DS.%26aulast%3DMaloney%26aufirst%3DL.%26aulast%3DIsaacson%26aufirst%3DJ.%26aulast%3DAllen%26aufirst%3DA.%2BR.%26aulast%3DRolfe%26aufirst%3DL.%26aulast%3DYelensky%26aufirst%3DR.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DMcNeish%26aufirst%3DI.%2BA.%26atitle%3DRucaparib%2520in%2520relapsed%252C%2520platinum-sensitive%2520high-grade%2520ovarian%2520carcinoma%2520%2528ARIEL2%2520Part%25201%2529%253A%2520an%2520international%252C%2520multicentre%252C%2520open-label%252C%2520phase%25202%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2017%26volume%3D18%26issue%3D1%26spage%3D75%26epage%3D87%26doi%3D10.1016%2FS1470-2045%2816%2930559-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mirza, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monk, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrstedt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oza, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redondo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ledermann, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorusso, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergote, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ben-Baruch, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marth, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madry, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berek, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tinker, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">du Bois, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Martin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Follana, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benigno, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimel, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buscema, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balser, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matulonis, U. A.</span></span> <span> </span><span class="NLM_article-title">Niraparib maintenance therapy in Platinum-sensitive, recurrent ovarian cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>375</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">2154</span>â <span class="NLM_lpage">2164</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa1611310</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1056%2FNEJMoa1611310" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=27717299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFaqt77O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2016&pages=2154-2164&issue=22&author=M.+R.+Mirzaauthor=B.+J.+Monkauthor=J.+Herrstedtauthor=A.+M.+Ozaauthor=S.+Mahnerauthor=A.+Redondoauthor=M.+Fabbroauthor=J.+A.+Ledermannauthor=D.+Lorussoauthor=I.+Vergoteauthor=N.+E.+Ben-Baruchauthor=C.+Marthauthor=R.+Madryauthor=R.+D.+Christensenauthor=J.+S.+Berekauthor=A.+Dorumauthor=A.+V.+Tinkerauthor=A.+du+Boisauthor=A.+Gonzalez-Martinauthor=P.+Follanaauthor=B.+Benignoauthor=P.+Rosenbergauthor=L.+Gilbertauthor=B.+J.+Rimelauthor=J.+Buscemaauthor=J.+P.+Balserauthor=S.+Agarwalauthor=U.+A.+Matulonis&title=Niraparib+maintenance+therapy+in+Platinum-sensitive%2C+recurrent+ovarian+cancer&doi=10.1056%2FNEJMoa1611310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer</span></div><div class="casAuthors">Mirza, M. R.; Monk, B. J.; Herrstedt, J.; Oza, A. M.; Mahner, S.; Redondo, A.; Fabbro, M.; Ledermann, J. A.; Lorusso, D.; Vergote, I.; Ben-Baruch, N. E.; Marth, C.; Madry, R.; Christensen, R. D.; Berek, J. S.; Dorum, A.; Tinker, A. V.; du Bois, A.; Gonzalez-Martin, A.; Follana, P.; Benigno, B.; Rosenberg, P.; Gilbert, L.; Rimel, B. J.; Buscema, J.; Balser, J. P.; Agarwal, S.; Matulonis, U. A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">375</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2154-2164</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Niraparib is an oral poly(ADP [ADP]-ribose) polymerase (PARP) 1/2 inhibitor that has shown clin. activity in patients with ovarian cancer.  We sought to evaluate the efficacy of niraparib vs. placebo as maintenance treatment for patients with platinum-sensitive, recurrent ovarian cancer.  METHODS: In this randomized, double-blind, phase 3 trial, patients were categorized according to the presence or absence of a germline BRCA mutation (gBRCA cohort and non-gBRCA cohort) and the type of non-gBRCA mutation and were randomly assigned in a 2:1 ratio to receive niraparib (300 mg) or placebo once daily.  The primary end point was progression-free survival.  RESULTS: Of 553 enrolled patients, 203 were in the gBRCA cohort (with 138 assigned to niraparib and 65 to placebo), and 350 patients were in the non-gBRCA cohort (with 234 assigned to niraparib and 116 to placebo).  Patients in the niraparib group had a significantly longer median duration of progression-free survival than did those in the placebo group, including 21.0 vs. 5.5 mo in the gBRCA cohort (hazard ratio, 0.27; 95% confidence interval [CI], 0.17 to 0.41), as compared with 12.9 mo vs. 3.8 mo in the non-gBRCA cohort for patients who had tumors with homologous recombination deficiency (HRD) (hazard ratio, 0.38; 95% CI, 0.24 to 0.59) and 9.3 mo vs. 3.9 mo in the overall non-gBRCA cohort (hazard ratio, 0.45; 95% CI, 0.34 to 0.61; P<0.001 for all three comparisons).  The most common grade 3 or 4 adverse events that were reported in the niraparib group were thrombocytopenia (in 33.8%), anemia (in 25.3%), and neutropenia (in 19.6%), which were managed with dose modifications.  CONCLUSIONS: Among patients with platinum-sensitive, recurrent ovarian cancer, the median duration of progression-free survival was significantly longer among those receiving niraparib than among those receiving placebo, regardless of the presence or absence of gBRCA mutations or HRD status, with moderate bone marrow toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzlUvEgQyy4rVg90H21EOLACvtfcHk0ljyd88l91913w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFaqt77O&md5=64b76a6b436ff340df5341339e4606ee</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1611310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1611310%26sid%3Dliteratum%253Aachs%26aulast%3DMirza%26aufirst%3DM.%2BR.%26aulast%3DMonk%26aufirst%3DB.%2BJ.%26aulast%3DHerrstedt%26aufirst%3DJ.%26aulast%3DOza%26aufirst%3DA.%2BM.%26aulast%3DMahner%26aufirst%3DS.%26aulast%3DRedondo%26aufirst%3DA.%26aulast%3DFabbro%26aufirst%3DM.%26aulast%3DLedermann%26aufirst%3DJ.%2BA.%26aulast%3DLorusso%26aufirst%3DD.%26aulast%3DVergote%26aufirst%3DI.%26aulast%3DBen-Baruch%26aufirst%3DN.%2BE.%26aulast%3DMarth%26aufirst%3DC.%26aulast%3DMadry%26aufirst%3DR.%26aulast%3DChristensen%26aufirst%3DR.%2BD.%26aulast%3DBerek%26aufirst%3DJ.%2BS.%26aulast%3DDorum%26aufirst%3DA.%26aulast%3DTinker%26aufirst%3DA.%2BV.%26aulast%3Ddu%2BBois%26aufirst%3DA.%26aulast%3DGonzalez-Martin%26aufirst%3DA.%26aulast%3DFollana%26aufirst%3DP.%26aulast%3DBenigno%26aufirst%3DB.%26aulast%3DRosenberg%26aufirst%3DP.%26aulast%3DGilbert%26aufirst%3DL.%26aulast%3DRimel%26aufirst%3DB.%2BJ.%26aulast%3DBuscema%26aufirst%3DJ.%26aulast%3DBalser%26aufirst%3DJ.%2BP.%26aulast%3DAgarwal%26aufirst%3DS.%26aulast%3DMatulonis%26aufirst%3DU.%2BA.%26atitle%3DNiraparib%2520maintenance%2520therapy%2520in%2520Platinum-sensitive%252C%2520recurrent%2520ovarian%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D375%26issue%3D22%26spage%3D2154%26epage%3D2164%26doi%3D10.1056%2FNEJMoa1611310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, S.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senkus, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domchek, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delaloge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tung, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goessl, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Runswick, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conte, P.</span></span> <span> </span><span class="NLM_article-title">Olaparib for metastatic breast cancer in patients with a germline BRCA mutation</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">523</span>â <span class="NLM_lpage">533</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa1706450</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1056%2FNEJMoa1706450" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=28578601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlyksrbN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2017&pages=523-533&author=M.+Robsonauthor=S.-A.+Imauthor=E.+Senkusauthor=B.+Xuauthor=S.+M.+Domchekauthor=N.+Masudaauthor=S.+Delalogeauthor=W.+Liauthor=N.+Tungauthor=A.+Armstrongauthor=W.+Wuauthor=C.+Goesslauthor=S.+Runswickauthor=P.+Conte&title=Olaparib+for+metastatic+breast+cancer+in+patients+with+a+germline+BRCA+mutation&doi=10.1056%2FNEJMoa1706450"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Olaparib for metastatic breast cancer in patients with a germline BRCA mutation</span></div><div class="casAuthors">Robson, Mark; Im, Seock-Ah; Senkus, Elzbieta; Xu, Binghe; Domchek, Susan M.; Masuda, Norikazu; Delaloge, Suzette; Li, Wei; Tung, Nadine; Armstrong, Anne; Wu, Wenting; Goessl, Carsten; Runswick, Sarah; Conte, Pierfranco</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">523-533</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Olaparib is an oral poly(ADP-ribose) polymerase inhibitor that has promising antitumor activity in patients with metastatic breast cancer and a germline BRCA mutation.  We conducted a randomized, open-label, phase 3 trial in which olaparib monotherapy was compared with std. therapy in patients with a germline BRCA mutation and human epidermal growth factor receptor type 2 (HER2)-neg. metastatic breast cancer who had received no more than two previous chemotherapy regimens for metastatic disease.  Patients were randomly assigned, in a 2:1 ratio, to receive olaparib tablets (300 mg twice daily) or std. therapy with single-agent chemotherapy of the physician's choice (capecitabine, eribulin, or vinorelbine in 21-day cycles).  The primary end point was progression-free survival, which was assessed by blinded independent central review and was analyzed on an intention-to-treat basis. results Of the 302 patients who underwent randomization, 205 were assigned to receive olaparib and 97 were assigned to receive std. therapy.  Median progression-free survival was significantly longer in the olaparib group than in the std.-therapy group (7.0 mo vs. 4.2 mo; hazard ratio for disease progression or death, 0.58; 95% confidence interval, 0.43 to 0.80; P<0.001).  The response rate was 59.9% in the olaparib group and 28.8% in the std.-therapy group.  The rate of grade 3 or higher adverse events was 36.6% in the olaparib group and 50.5% in the std.-therapy group, and the rate of treatment discontinuation due to toxic effects was 4.9% and 7.7%, resp.  Among patients with HER2-neg. metastatic breast cancer and a germline BRCA mutation, olaparib monotherapy provided a significant benefit over std. therapy; median progression-free survival was 2.8 mo longer and the risk of disease progression or death was 42% lower with olaparib monotherapy than with std. therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMXxR-ZN4IGrVg90H21EOLACvtfcHk0ljyd88l91913w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlyksrbN&md5=7c8c62182a717c16c5762443fb3f6d5d</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1706450&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1706450%26sid%3Dliteratum%253Aachs%26aulast%3DRobson%26aufirst%3DM.%26aulast%3DIm%26aufirst%3DS.-A.%26aulast%3DSenkus%26aufirst%3DE.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DDomchek%26aufirst%3DS.%2BM.%26aulast%3DMasuda%26aufirst%3DN.%26aulast%3DDelaloge%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DTung%26aufirst%3DN.%26aulast%3DArmstrong%26aufirst%3DA.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DGoessl%26aufirst%3DC.%26aulast%3DRunswick%26aufirst%3DS.%26aulast%3DConte%26aufirst%3DP.%26atitle%3DOlaparib%2520for%2520metastatic%2520breast%2520cancer%2520in%2520patients%2520with%2520a%2520germline%2520BRCA%2520mutation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D377%26spage%3D523%26epage%3D533%26doi%3D10.1056%2FNEJMoa1706450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Litton, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rugo, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ettl, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurvitz, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goncalves, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fehrenbacher, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yerushalmi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mina, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roche, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quek, R. G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markova, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tudor, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannah, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eiermann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, J. L.</span></span> <span> </span><span class="NLM_article-title">Talazoparib in patients with advanced breast cancer and a germline BRCA mutation</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>379</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">753</span>â <span class="NLM_lpage">763</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa1802905</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1056%2FNEJMoa1802905" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=30110579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1eqsrnI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2018&pages=753-763&issue=8&author=J.+K.+Littonauthor=H.+S.+Rugoauthor=J.+Ettlauthor=S.+A.+Hurvitzauthor=A.+Goncalvesauthor=K.+H.+Leeauthor=L.+Fehrenbacherauthor=R.+Yerushalmiauthor=L.+A.+Minaauthor=M.+Martinauthor=H.+Rocheauthor=Y.+H.+Imauthor=R.+G.+W.+Quekauthor=D.+Markovaauthor=I.+C.+Tudorauthor=A.+L.+Hannahauthor=W.+Eiermannauthor=J.+L.+Blum&title=Talazoparib+in+patients+with+advanced+breast+cancer+and+a+germline+BRCA+mutation&doi=10.1056%2FNEJMoa1802905"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Talazoparib in patients with advanced breast cancer and a germline BRCA mutation</span></div><div class="casAuthors">Litton, Jennifer K.; Rugo, Hope S.; Ettl, Johannes; Hurvitz, Sara A.; Goncalves, Anthony; Lee, Kyung-Hun; Fehrenbacher, Louis; Yerushalmi, Rinat; Mina, Lida A.; Martin, Miguel; Roche, Henri; Im, Young-Hyuck; Quek, Ruben G. W.; Markova, Denka; Tudor, Iulia C.; Hannah, Alison L.; Eiermann, Wolfgang; Blum, Joanne L.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">379</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">753-763</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: The poly(ADP-ribose) inhibitor talazoparib has shown antitumor activity in patients with advanced breast cancer and germline mutations in BRCA1 and BRCA2 (BRCA1/2).  Methods: We conducted a randomized, open-label, phase 3 trial in which patients with advanced breast cancer and a germline BRCA1/2 mutation were assigned, in a 2:1 ratio, to receive talazoparib (1 mg once daily) or std. single-agent therapy of the physician's choice (capecitabine, eribulin, gemcitabine, or vinorelbine in continuous 21-day cycles).  The primary end point was progression-free survival, which was assessed by blinded independent central review.  Results: Of the 431 patients who underwent randomization, 287 were assigned to receive talazoparib and 144 were assigned to receive std. therapy.  Median progression-free survival was significantly longer in the talazoparib group than in the std.-therapy group (8.6 mo vs. 5.6 mo; hazard ratio for disease progression or death, 0.54; 95% confidence interval [CI], 0.41 to 0.71; P<0.001).  The interim median hazard ratio for death was 0.76 (95% CI, 0.55 to 1.06; P = 0.11 [57% of projected events]).  The objective response rate was higher in the talazoparib group than in the std.-therapy group (62.6% vs. 27.2%; odds ratio, 5.0; 95% CI, 2.9 to 8.8; P<0.001).  Hematol. grade 3-4 adverse events (primarily anemia) occurred in 55% of the patients who received talazoparib and in 38% of the patients who received std. therapy; nonhematol. grade 3 adverse events occurred in 32% and 38% of the patients, resp.  Patient-reported outcomes favored talazoparib; significant overall improvements and significant delays in the time to clin. meaningful deterioration according to both the global health status-quality-of-life and breast symptoms scales were obsd.  Conclusions: Among patients with advanced breast cancer and a germline BRCA1/2 mutation, single-agent talazoparib provided a significant benefit over std. chemotherapy with respect to progression-free survival.  Patient-reported outcomes were superior with talazoparib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouRXoCYNHmv7Vg90H21EOLACvtfcHk0likX1l143pgKw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1eqsrnI&md5=82f7478c15bd4790b6fa929227b5ce57</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1802905&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1802905%26sid%3Dliteratum%253Aachs%26aulast%3DLitton%26aufirst%3DJ.%2BK.%26aulast%3DRugo%26aufirst%3DH.%2BS.%26aulast%3DEttl%26aufirst%3DJ.%26aulast%3DHurvitz%26aufirst%3DS.%2BA.%26aulast%3DGoncalves%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DFehrenbacher%26aufirst%3DL.%26aulast%3DYerushalmi%26aufirst%3DR.%26aulast%3DMina%26aufirst%3DL.%2BA.%26aulast%3DMartin%26aufirst%3DM.%26aulast%3DRoche%26aufirst%3DH.%26aulast%3DIm%26aufirst%3DY.%2BH.%26aulast%3DQuek%26aufirst%3DR.%2BG.%2BW.%26aulast%3DMarkova%26aufirst%3DD.%26aulast%3DTudor%26aufirst%3DI.%2BC.%26aulast%3DHannah%26aufirst%3DA.%2BL.%26aulast%3DEiermann%26aufirst%3DW.%26aulast%3DBlum%26aufirst%3DJ.%2BL.%26atitle%3DTalazoparib%2520in%2520patients%2520with%2520advanced%2520breast%2520cancer%2520and%2520a%2520germline%2520BRCA%2520mutation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D379%26issue%3D8%26spage%3D753%26epage%3D763%26doi%3D10.1056%2FNEJMoa1802905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoy, S. M.</span></span> <span> </span><span class="NLM_article-title">Talazoparib: first global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">1939</span>â <span class="NLM_lpage">1946</span>, <span class="refDoi">Â DOI: 10.1007/s40265-018-1026-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1007%2Fs40265-018-1026-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=30506138" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A280%3ADC%252BB3crnslGgsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1939-1946&issue=18&author=S.+M.+Hoy&title=Talazoparib%3A+first+global+approval&doi=10.1007%2Fs40265-018-1026-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Talazoparib: First Global Approval</span></div><div class="casAuthors">Hoy Sheridan M</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1939-1946</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Talazoparib (TALZENNAÂ®) is an oral inhibitor of the polyadenosine 5'-diphosphoribose polymerase (PARP) enzymes, which play a critical role in repairing DNA single-strand breaks.  It has been developed by Pfizer and was recently approved in the USA for the treatment of adults with deleterious or suspected deleterious germline BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer (as detected by a US FDA-approved assay).  A regulatory assessment for talazoparib in this patient population is underway in the EU, with talazoparib also undergoing development for use in metastatic castration-resistant prostate cancer and various solid tumours, and as neoadjuvant therapy in early triple negative breast cancer.  This article summarizes the milestones in the development of talazoparib leading to its first approval for the treatment of adults with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative, locally advanced or metastatic breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSA4VT-ypttQZNiNltV31zlfW6udTcc2eZ6BuNDGS9Axbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3crnslGgsg%253D%253D&md5=e5799d67f592d4e449e18f09fc727a4b</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-1026-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-1026-z%26sid%3Dliteratum%253Aachs%26aulast%3DHoy%26aufirst%3DS.%2BM.%26atitle%3DTalazoparib%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26issue%3D18%26spage%3D1939%26epage%3D1946%26doi%3D10.1007%2Fs40265-018-1026-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Golan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Cutsem, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macarulla, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochhauser, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinacher-Schick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tortora, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Algul, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâReilly, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuinness, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlienger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locker, G. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kindler, H. L.</span></span> <span> </span><span class="NLM_article-title">Maintenance Olaparib for germline BRCA-mutated metastatic pancreatic cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>381</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">317</span>â <span class="NLM_lpage">327</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa1903387</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1056%2FNEJMoa1903387" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=31157963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnsFCqtbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=381&publication_year=2019&pages=317-327&issue=4&author=T.+Golanauthor=P.+Hammelauthor=M.+Reniauthor=E.+Van+Cutsemauthor=T.+Macarullaauthor=M.+J.+Hallauthor=J.+O.+Parkauthor=D.+Hochhauserauthor=D.+Arnoldauthor=D.+Y.+Ohauthor=A.+Reinacher-Schickauthor=G.+Tortoraauthor=H.+Algulauthor=E.+M.+O%E2%80%99Reillyauthor=D.+McGuinnessauthor=K.+Y.+Cuiauthor=K.+Schliengerauthor=G.+Y.+Lockerauthor=H.+L.+Kindler&title=Maintenance+Olaparib+for+germline+BRCA-mutated+metastatic+pancreatic+cancer&doi=10.1056%2FNEJMoa1903387"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer</span></div><div class="casAuthors">Golan, Talia; Hammel, Pascal; Reni, Michele; Van Cutsem, Eric; Macarulla, Teresa; Hall, Michael J.; Park, Joon-Oh; Hochhauser, Daniel; Arnold, Dirk; Oh, Do-Youn; Reinacher-Schick, Anke; Tortora, Giampaolo; Algul, Hana; O'Reilly, Eileen M.; McGuinness, David; Cui, Karen Y.; Schlienger, Katia; Locker, Gershon Y.; Kindler, Hedy L.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">381</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">317-327</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Patients with a germline BRCA1 or BRCA2 mutation make up a small subgroup of those with metastatic pancreatic cancer.  The poly(ADP-ribose) polymerase (PARP) inhibitor olaparib has had antitumor activity in this population. methods We conducted a randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy of olaparib as maintenance therapy in patients who had a germline BRCA1 or BRCA2 mutation and metastatic pancreatic cancer and disease that had not progressed during first-line platinum-based chemotherapy.  Patients were randomly assigned, in a 3:2 ratio, to receive maintenance olaparib tablets (300 mg twice daily) or placebo.  The primary end point was progression-free survival, which was assessed by blinded independent central review. results Of the 3315 patients who underwent screening, 154 underwent randomization and were assigned to a trial intervention (92 to receive olaparib and 62 to receive placebo).  The median progression-free survival was significantly longer in the olaparib group than in the placebo group (7.4 mo vs. 3.8 mo; hazard ratio for disease progression or death, 0.53; 95% confidence interval [CI], 0.35 to 0.82; P = 0.004).  An interim anal. of overall survival, at a data maturity of 46%, showed no difference between the olaparib and placebo groups (median, 18.9 mo vs. 18.1 mo; hazard ratio for death, 0.91; 95% CI, 0.56 to 1.46; P = 0.68).  There was no significant between-group difference in health-related quality of life, as indicated by the overall change from baseline in the global quality-of-life score (on a 100-point scale, with higher scores indicating better quality of life) based on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (between-group difference, -2.47 points; 95% CI, -7.27 to 2.33).  The incidence of grade 3 or higher adverse events was 40% in the olaparib group and 23% in the placebo group (between-group difference, 16 percentage points; 95% CI, -0.02 to 31); 5% and 2% of the patients, resp., discontinued the trial intervention because of an adverse event. conclusions Among patients with a germline BRCA mutation and metastatic pancreatic cancer, progression-free survival was longer with maintenance olaparib than with placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_mABSEPws9rVg90H21EOLACvtfcHk0likX1l143pgKw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnsFCqtbo%253D&md5=06afa1aada240931f620ecf6f974b2e2</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1903387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1903387%26sid%3Dliteratum%253Aachs%26aulast%3DGolan%26aufirst%3DT.%26aulast%3DHammel%26aufirst%3DP.%26aulast%3DReni%26aufirst%3DM.%26aulast%3DVan%2BCutsem%26aufirst%3DE.%26aulast%3DMacarulla%26aufirst%3DT.%26aulast%3DHall%26aufirst%3DM.%2BJ.%26aulast%3DPark%26aufirst%3DJ.%2BO.%26aulast%3DHochhauser%26aufirst%3DD.%26aulast%3DArnold%26aufirst%3DD.%26aulast%3DOh%26aufirst%3DD.%2BY.%26aulast%3DReinacher-Schick%26aufirst%3DA.%26aulast%3DTortora%26aufirst%3DG.%26aulast%3DAlgul%26aufirst%3DH.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DE.%2BM.%26aulast%3DMcGuinness%26aufirst%3DD.%26aulast%3DCui%26aufirst%3DK.%2BY.%26aulast%3DSchlienger%26aufirst%3DK.%26aulast%3DLocker%26aufirst%3DG.%2BY.%26aulast%3DKindler%26aufirst%3DH.%2BL.%26atitle%3DMaintenance%2520Olaparib%2520for%2520germline%2520BRCA-mutated%2520metastatic%2520pancreatic%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D381%26issue%3D4%26spage%3D317%26epage%3D327%26doi%3D10.1056%2FNEJMoa1903387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span>U.S.
Food and Drug Administration. <a href="https://www.fda.gov/drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate" class="extLink">https://www.fda.gov/drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate</a> (accessed Jul 7, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=U.S.%0AFood+and+Drug+Administration.+https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Ffda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate+%28accessed+Jul+7%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span>Astra
Zeneca. <a href="https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-more-than-doubled-the-time-without-disease-progression-in-patients-with-brca1-2-atm-mutated-metastatic-castration-resistant-prostate-cancer-30092019.html" class="extLink">https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-more-than-doubled-the-time-without-disease-progression-in-patients-with-brca1-2-atm-mutated-metastatic-castration-resistant-prostate-cancer-30092019.html</a> (accessed Jul 7, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Astra%0AZeneca.+https%3A%2F%2Fwww.astrazeneca.com%2Fmedia-centre%2Fpress-releases%2F2019%2Flynparza-more-than-doubled-the-time-without-disease-progression-in-patients-with-brca1-2-atm-mutated-metastatic-castration-resistant-prostate-cancer-30092019.html+%28accessed+Jul+7%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jain, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, B. D.</span></span> <span> </span><span class="NLM_article-title">Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">198</span>â <span class="NLM_lpage">215</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2019.01.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.ejmech.2019.01.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=30684797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFKks70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2019&pages=198-215&author=P.+G.+Jainauthor=B.+D.+Patel&title=Medicinal+chemistry+approaches+of+poly+ADP-Ribose+polymerase+1+%28PARP1%29+inhibitors+as+anticancer+agents+-+A+recent+update&doi=10.1016%2Fj.ejmech.2019.01.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - a recent update</span></div><div class="casAuthors">Jain, Priyancy G.; Patel, Bhumika D.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">198-215</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Poly (ADP-ribose) Polymerase1 (PARP1) is a member of 17 membered PARP family having diversified biol. functions such as synthetic lethality, DNA repair, apoptosis, necrosis, histone binding etc.  It is primarily a chromatin-bound nuclear enzyme that gets activated by DNA damage.  It binds to DNA signal- and double-strand breaks, does parylation of target proteins (using NAD+ as a substrate) like histones and other DNA repair proteins and modifies them as a part of DNA repair mechanism.  Inhibition of PARP1 prevents the DNA repair and leads to cell death.  Clin., PARP1 Inhibitors have shown their potential in treating BRCAm breast and ovarian cancers and trials are going on for the treatment of other solid tumors like pancreatic, prostate, colorectal etc. as a single agent or in combination.  There are currently three FDA approved PARP1 inhibitors namely Olaparib, Rucaparib and Niraparib in the market while Veliparib and Talazoparib are in the late stage of clin. development.  All these mols. are nonselective PARP1 inhibitors with concurrent inhibition of PARP2 with similar potency.  In addn., resistance to marketed PARP1 inhibitors has been reported.  Overall, looking at the success rate of PARP1 inhibitors into various solid tumors, there is an urge of a novel and selective PARP1 inhibitors.  This review provides an update on various newer heterocyclic PARP1 inhibitors reported in last three years along with their structural design strategies.  We classified them into two main chem. classes; NAD analogs and non-NAD analogs and discussed the medicinal chem. approaches of each class.  To understand the structural features required for in-silico designing of next-generation PARP1 inhibitors, we also reported the crucial amino acid interactions of these inhibitors at the target site.  Thus, present review provides the insight on recent development on new lead structures as PARP1 inhibitors, their SAR, an overview of in-vitro and in-vivo screening methods, current challenges and opinion on future designing of more selective and safe PARP1 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGsZyTB3cxSbVg90H21EOLACvtfcHk0liAyIf0donlnw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFKks70%253D&md5=9dc3e8f13c683d997e62aac79f854f09</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.01.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.01.024%26sid%3Dliteratum%253Aachs%26aulast%3DJain%26aufirst%3DP.%2BG.%26aulast%3DPatel%26aufirst%3DB.%2BD.%26atitle%3DMedicinal%2520chemistry%2520approaches%2520of%2520poly%2520ADP-Ribose%2520polymerase%25201%2520%2528PARP1%2529%2520inhibitors%2520as%2520anticancer%2520agents%2520-%2520A%2520recent%2520update%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D165%26spage%3D198%26epage%3D215%26doi%3D10.1016%2Fj.ejmech.2019.01.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gurley, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemp, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic lethality between mutation in Atm and DNA-PK(cs) during murine embryogenesis</span>. <i>Curr. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">191</span>â <span class="NLM_lpage">194</span>, <span class="refDoi">Â DOI: 10.1016/S0960-9822(01)00048-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2FS0960-9822%2801%2900048-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=11231155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhtlGlu7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=191-194&issue=3&author=K.+E.+Gurleyauthor=C.+J.+Kemp&title=Synthetic+lethality+between+mutation+in+Atm+and+DNA-PK%28cs%29+during+murine+embryogenesis&doi=10.1016%2FS0960-9822%2801%2900048-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic lethality between mutation in Atm and DNA-PKCS during murine embryogenesis</span></div><div class="casAuthors">Gurley, Kay E.; Kemp, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">191-194</span>CODEN:
                <span class="NLM_cas:coden">CUBLE2</span>;
        ISSN:<span class="NLM_cas:issn">0960-9822</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The gene product mutated in ataxia telangiectasia, ATM, is a ubiquitously expressed 370 kDa protein kinase that is a key mediator of the cellular response to DNA damage.  ATM-deficient cells are radiosensitive and show impaired cell cycle arrest and increased chromosome breaks in response to ionizing radiation.  ATM is a member of the phosphatidylinositol-3-kinase (PI3K)-related protein kinase superfamily, which includes the catalytic subunit of DNA-dependent protein kinase (DNA-PKCS) and ATR.  DNA-PK is a 470 kDa protein kinase that is required for proper end-to-end rejoining of DNA double-strand breaks.  Prkdcscid/scid mice have a homozygous mutation in the gene encoding DNA-PKCS and, like Atm-/- mice, are viable and radiosensitive.  To det. if Atm and DNA-PKCS show genetic interaction, we attempted to generate mice deficient in both gene products.  However, no scid/scid Atm-/- pups were recovered from scid/scid Atm+/- intercrosses.  Developmental arrest of scid/scid Atm-/- embryos occurred around E7.5, a developmental stage when embryonic cells are hypersensitive to DNA damage.  This reveals synthetic lethality between mutations in Atm and DNA-PK and suggests that Atm and DNA-PK have complementary functions that are essential for development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHC29RCUtc5LVg90H21EOLACvtfcHk0liAyIf0donlnw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhtlGlu7c%253D&md5=3ae8c1de2e234105e7b127aa3ca96a31</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2FS0960-9822%2801%2900048-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-9822%252801%252900048-3%26sid%3Dliteratum%253Aachs%26aulast%3DGurley%26aufirst%3DK.%2BE.%26aulast%3DKemp%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520lethality%2520between%2520mutation%2520in%2520Atm%2520and%2520DNA-PK%2528cs%2529%2520during%2520murine%2520embryogenesis%26jtitle%3DCurr.%2520Biol.%26date%3D2001%26volume%3D11%26issue%3D3%26spage%3D191%26epage%3D194%26doi%3D10.1016%2FS0960-9822%2801%2900048-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kantidze, O. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velichko, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luzhin, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrova, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Razin, S. V.</span></span> <span> </span><span class="NLM_article-title">Synthetically lethal interactions of ATM, ATR, and DNA-PKcs</span>. <i>Trends Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">755</span>â <span class="NLM_lpage">768</span>, <span class="refDoi">Â DOI: 10.1016/j.trecan.2018.09.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.trecan.2018.09.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=30352678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1MXkvVChtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2018&pages=755-768&issue=11&author=O.+L.+Kantidzeauthor=A.+K.+Velichkoauthor=A.+V.+Luzhinauthor=N.+V.+Petrovaauthor=S.+V.+Razin&title=Synthetically+lethal+interactions+of+ATM%2C+ATR%2C+and+DNA-PKcs&doi=10.1016%2Fj.trecan.2018.09.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetically Lethal Interactions of ATM, ATR, and DNA-PKcs</span></div><div class="casAuthors">Kantidze, Omar L.; Velichko, Artem K.; Luzhin, Artem V.; Petrova, Nadezhda V.; Razin, Sergey V.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">755-768</span>CODEN:
                <span class="NLM_cas:coden">TCRAB5</span>;
        ISSN:<span class="NLM_cas:issn">2405-8033</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Synthetic lethality occurs when simultaneous perturbations of two genes or mol. processes result in a loss of cell viability.  The no. of known synthetically lethal interactions is growing steadily.  We review here synthetically lethal interactions of ataxia-telangiectasia mutated (ATM), ATM- and Rad3-related (ATR), and DNA-dependent protein kinase catalytic subunit (DNA-PKcs).  These kinases are appropriate for synthetic lethal therapies because their genes are frequently mutated in cancer, and specific inhibitors are currently in clin. trials.  Understanding synthetically lethal interactions of a particular gene or gene family can facilitate predicting new synthetically lethal interactions, therapy toxicity, and mechanisms of resistance, as well as defining the spectrum of tumors amenable to these therapeutic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2d1yDujzdrrVg90H21EOLACvtfcHk0liAyIf0donlnw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXkvVChtg%253D%253D&md5=e3cb583663814cbe0a0e5803635cdef9</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.trecan.2018.09.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.trecan.2018.09.007%26sid%3Dliteratum%253Aachs%26aulast%3DKantidze%26aufirst%3DO.%2BL.%26aulast%3DVelichko%26aufirst%3DA.%2BK.%26aulast%3DLuzhin%26aufirst%3DA.%2BV.%26aulast%3DPetrova%26aufirst%3DN.%2BV.%26aulast%3DRazin%26aufirst%3DS.%2BV.%26atitle%3DSynthetically%2520lethal%2520interactions%2520of%2520ATM%252C%2520ATR%252C%2520and%2520DNA-PKcs%26jtitle%3DTrends%2520Cancer%26date%3D2018%26volume%3D4%26issue%3D11%26spage%3D755%26epage%3D768%26doi%3D10.1016%2Fj.trecan.2018.09.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Riabinska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daheim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herter-Sprie, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreuzer, K.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frenzel, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monfared, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins-Boucas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinhardt, H. C.</span></span> <span> </span><span class="NLM_article-title">Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">189</span>),  <span class="NLM_fpage">189ra78</span>â <span class="NLM_lpage">189ra78</span>, <span class="refDoi">Â DOI: 10.1126/scitranslmed.3005814</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1126%2Fscitranslmed.3005814" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=23761041" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=189ra78-189ra78&issue=189&author=A.+Riabinskaauthor=M.+Daheimauthor=G.+S.+Herter-Sprieauthor=J.+Winklerauthor=C.+Fritzauthor=M.+Hallekauthor=R.+K.+Thomasauthor=K.-A.+Kreuzerauthor=L.+P.+Frenzelauthor=P.+Monfaredauthor=J.+Martins-Boucasauthor=S.+Chenauthor=H.+C.+Reinhardt&title=Therapeutic+targeting+of+a+robust+non-oncogene+addiction+to+PRKDC+in+ATM-defective+tumors&doi=10.1126%2Fscitranslmed.3005814"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3005814&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3005814%26sid%3Dliteratum%253Aachs%26aulast%3DRiabinska%26aufirst%3DA.%26aulast%3DDaheim%26aufirst%3DM.%26aulast%3DHerter-Sprie%26aufirst%3DG.%2BS.%26aulast%3DWinkler%26aufirst%3DJ.%26aulast%3DFritz%26aufirst%3DC.%26aulast%3DHallek%26aufirst%3DM.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DKreuzer%26aufirst%3DK.-A.%26aulast%3DFrenzel%26aufirst%3DL.%2BP.%26aulast%3DMonfared%26aufirst%3DP.%26aulast%3DMartins-Boucas%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DReinhardt%26aufirst%3DH.%2BC.%26atitle%3DTherapeutic%2520targeting%2520of%2520a%2520robust%2520non-oncogene%2520addiction%2520to%2520PRKDC%2520in%2520ATM-defective%2520tumors%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2013%26volume%3D5%26issue%3D189%26spage%3D189ra78%26epage%3D189ra78%26doi%3D10.1126%2Fscitranslmed.3005814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dietlein, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thelen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jokic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jachimowicz, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knittel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeser, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Oers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edelmann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heukamp, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinhardt, H. C.</span></span> <span> </span><span class="NLM_article-title">A functional cancer genomics screen identifies a druggable synthetic lethal interaction between MSH3 and PRKDC</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">592</span>â <span class="NLM_lpage">605</span>, <span class="refDoi">Â DOI: 10.1158/2159-8290.CD-13-0907</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F2159-8290.CD-13-0907" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=24556366" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2cXns1CmsLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=592-605&issue=5&author=F.+Dietleinauthor=L.+Thelenauthor=M.+Jokicauthor=R.+D.+Jachimowiczauthor=L.+Ivanauthor=G.+Knittelauthor=U.+Leeserauthor=J.+van+Oersauthor=W.+Edelmannauthor=L.+C.+Heukampauthor=H.+C.+Reinhardt&title=A+functional+cancer+genomics+screen+identifies+a+druggable+synthetic+lethal+interaction+between+MSH3+and+PRKDC&doi=10.1158%2F2159-8290.CD-13-0907"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">A Functional Cancer Genomics Screen Identifies a Druggable Synthetic Lethal Interaction between MSH3 and PRKDC</span></div><div class="casAuthors">Dietlein, Felix; Thelen, Lisa; Jokic, Mladen; Jachimowicz, Ron D.; Ivan, Laura; Knittel, Gero; Leeser, Uschi; van Oers, Johanna; Edelmann, Winfried; Heukamp, Lukas C.; Reinhardt, H. Christian</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">592-605</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Here, we use a large-scale cell line-based approach to identify cancer cell-specific mutations that are assocd. with DNA-dependent protein kinase catalytic subunit (DNA-PKcs) dependence.  For this purpose, we profiled the mutational landscape across 1,319 cancer- assocd. genes of 67 distinct cell lines and identified numerous genes involved in homologous recombination-mediated DNA repair, including BRCA1, BRCA2, ATM, PAXIP, and RAD50, as being assocd. with non-oncogene addiction to DNA-PKcs.  Mutations in the mismatch repair gene MSH3, which have been reported to occur recurrently in numerous human cancer entities, emerged as the most significant predictors of DNA-PKcs addiction.  Concordantly DNA-PKcs inhibition robustly induced apoptosis in MSH3- mutant cell lines in vitro and displayed remarkable single-agent efficacy against MSH3-mutant tumors in vivo.  Thus, we here identify a therapeutically actionable synthetic lethal interaction between MSH3 and the non-homologous end joining kinase DNA-PKcs.  Our observations recommend DNA-PKcs inhibition as a therapeutic concept for the treatment of human cancers displaying homologous recombination defects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG3K376nKgNbVg90H21EOLACvtfcHk0liuHW_5dTAurg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXns1CmsLo%253D&md5=23e812dd0b4cffc2e34eb44f5f9240ee</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0907%26sid%3Dliteratum%253Aachs%26aulast%3DDietlein%26aufirst%3DF.%26aulast%3DThelen%26aufirst%3DL.%26aulast%3DJokic%26aufirst%3DM.%26aulast%3DJachimowicz%26aufirst%3DR.%2BD.%26aulast%3DIvan%26aufirst%3DL.%26aulast%3DKnittel%26aufirst%3DG.%26aulast%3DLeeser%26aufirst%3DU.%26aulast%3Dvan%2BOers%26aufirst%3DJ.%26aulast%3DEdelmann%26aufirst%3DW.%26aulast%3DHeukamp%26aufirst%3DL.%2BC.%26aulast%3DReinhardt%26aufirst%3DH.%2BC.%26atitle%3DA%2520functional%2520cancer%2520genomics%2520screen%2520identifies%2520a%2520druggable%2520synthetic%2520lethal%2520interaction%2520between%2520MSH3%2520and%2520PRKDC%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26issue%3D5%26spage%3D592%26epage%3D605%26doi%3D10.1158%2F2159-8290.CD-13-0907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kass, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, W.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moynahan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhuri, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jasin, M.</span></span> <span> </span><span class="NLM_article-title">ATM loss leads to synthetic lethality in BRCA1 BRCT mutant mice associated with exacerbated defects in homology-directed repair</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>114</i></span> (<span class="NLM_issue">29</span>),  <span class="NLM_fpage">7665</span>â <span class="NLM_lpage">7670</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1706392114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1073%2Fpnas.1706392114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=28659469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVyntr%252FJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=7665-7670&issue=29&author=C.-C.+Chenauthor=E.+M.+Kassauthor=W.-F.+Yenauthor=T.+Ludwigauthor=M.+E.+Moynahanauthor=J.+Chaudhuriauthor=M.+Jasin&title=ATM+loss+leads+to+synthetic+lethality+in+BRCA1+BRCT+mutant+mice+associated+with+exacerbated+defects+in+homology-directed+repair&doi=10.1073%2Fpnas.1706392114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">ATM loss leads to synthetic lethality in BRCA1 BRCT mutant mice associated with exacerbated defects in homology-directed repair</span></div><div class="casAuthors">Chen, Chun-Chin; Kass, Elizabeth M.; Yen, Wei-Feng; Ludwig, Thomas; Moynahan, Mary Ellen; Chaudhuri, Jayanta; Jasin, Maria</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">7665-7670</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">BRCA1 is essential for homol.-directed repair (HDR) of DNA double-strand breaks in part through antagonism of the nonhomologous end-joining factor 53BP1.  The ATM kinase is involved in various aspects of DNA damage signaling and repair, but how ATM participates in HDR and genetically interacts with BRCA1 in this process is unclear.  To investigate this question, we used the Brca1S1598F mouse model carrying a mutation in the BRCA1 C-terminal domain of BRCA1.  Whereas ATM loss leads to a mild HDR defect in adult somatic cells, we find that ATM inhibition leads to severely reduced HDR in Brca1S1598F cells.  Consistent with a crit. role for ATM in HDR in this background, loss of ATM leads to synthetic lethality of Brca1S1598F mice.  Whereas both ATM and BRCA1 promote end resection, which can be regulated by 53BP1, 53bp1 deletion does not rescue the HDR defects of Atm mutant cells, in contrast to Brca1 mutant cells.  These results demonstrate that ATM has a role in HDR independent of the BRCA1-53BP1 antagonism and that its HDR function can become crit. in certain contexts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTtLVgk7hSzbVg90H21EOLACvtfcHk0liuHW_5dTAurg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVyntr%252FJ&md5=b08d8d34e80b5107b080b38e315ace37</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1706392114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1706392114%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.-C.%26aulast%3DKass%26aufirst%3DE.%2BM.%26aulast%3DYen%26aufirst%3DW.-F.%26aulast%3DLudwig%26aufirst%3DT.%26aulast%3DMoynahan%26aufirst%3DM.%2BE.%26aulast%3DChaudhuri%26aufirst%3DJ.%26aulast%3DJasin%26aufirst%3DM.%26atitle%3DATM%2520loss%2520leads%2520to%2520synthetic%2520lethality%2520in%2520BRCA1%2520BRCT%2520mutant%2520mice%2520associated%2520with%2520exacerbated%2520defects%2520in%2520homology-directed%2520repair%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2017%26volume%3D114%26issue%3D29%26spage%3D7665%26epage%3D7670%26doi%3D10.1073%2Fpnas.1706392114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Albarakati, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Fatah, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moseley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arora, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alsubhi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seedhouse, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rakha, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, I. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madhusudan, S.</span></span> <span> </span><span class="NLM_article-title">Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">204</span>â <span class="NLM_lpage">217</span>, <span class="refDoi">Â DOI: 10.1016/j.molonc.2014.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.molonc.2014.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=25205036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsV2ltLvK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=204-217&issue=1&author=N.+Albarakatiauthor=T.+M.+Abdel-Fatahauthor=R.+Dohertyauthor=R.+Russellauthor=D.+Agarwalauthor=P.+Moseleyauthor=C.+Perryauthor=A.+Aroraauthor=N.+Alsubhiauthor=C.+Seedhouseauthor=E.+A.+Rakhaauthor=A.+Greenauthor=G.+Ballauthor=S.+Chanauthor=C.+Caldasauthor=I.+O.+Ellisauthor=S.+Madhusudan&title=Targeting+BRCA1-BER+deficient+breast+cancer+by+ATM+or+DNA-PKcs+blockade+either+alone+or+in+combination+with+cisplatin+for+personalized+therapy&doi=10.1016%2Fj.molonc.2014.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy</span></div><div class="casAuthors">Albarakati, Nada; Abdel-Fatah, Tarek M. A.; Doherty, Rachel; Russell, Roslin; Agarwal, Devika; Moseley, Paul; Perry, Christina; Arora, Arvind; Alsubhi, Nouf; Seedhouse, Claire; Rakha, Emad A.; Green, Andrew; Ball, Graham; Chan, Stephen; Caldas, Carlos; Ellis, Ian O.; Madhusudan, Srinivasan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">204-217</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">BRCA1, a key factor in homologous recombination (HR) repair may also regulate base excision repair (BER).  Targeting BRCA1-BER deficient cells by blockade of ATM and DNA-PKcs could be a promising strategy in breast cancer.  We investigated BRCA1, XRCC1 and pol Î² protein expression in two cohorts (n = 1602 sporadic and n = 50 germ-line BRCA1 mutated) and mRNA expression in two cohorts (n = 1952 and n = 249).  Artificial neural network anal. for BRCA1-DNA repair interacting genes was conducted in 249 tumors.  Pre-clin., BRCA1 proficient and deficient cells were DNA repair expression profiled and evaluated for synthetic lethality using ATM and DNA-PKcs inhibitors either alone or in combination with cisplatin.  In human tumors, BRCA1 negativity was strongly assocd. with low XRCC1, and low pol Î² at mRNA and protein levels (p < 0.0001).  In patients with BRCA1 neg. tumors, low XRCC1 or low pol Î² expression was significantly assocd. with poor survival in univariate and multivariate anal. compared to high XRCC1 or high pol Î² expressing BRCA1 neg. tumors (ps < 0.05).  Pre-clin., BRCA1 neg. cancer cells exhibit low mRNA and low protein expression of XRCC1 and pol Î².  BRCA1-BER deficient cells were sensitive to ATM and DNA-PKcs inhibitor treatment either alone or in combination with cisplatin and synthetic lethality was evidenced by DNA double strand breaks accumulation, cell cycle arrest and apoptosis.  We conclude that XRCC1 and pol Î² expression status in BRCA1 neg. tumors may have prognostic significance.  BRCA1-BER deficient cells could be targeted by ATM or DNA-PKcs inhibitors for personalized therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVHI4vF_PsFbVg90H21EOLACvtfcHk0lifYVuYF8XEqQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsV2ltLvK&md5=b90b757fa55f5ed5c3d33e37c499d687</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2014.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2014.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DAlbarakati%26aufirst%3DN.%26aulast%3DAbdel-Fatah%26aufirst%3DT.%2BM.%26aulast%3DDoherty%26aufirst%3DR.%26aulast%3DRussell%26aufirst%3DR.%26aulast%3DAgarwal%26aufirst%3DD.%26aulast%3DMoseley%26aufirst%3DP.%26aulast%3DPerry%26aufirst%3DC.%26aulast%3DArora%26aufirst%3DA.%26aulast%3DAlsubhi%26aufirst%3DN.%26aulast%3DSeedhouse%26aufirst%3DC.%26aulast%3DRakha%26aufirst%3DE.%2BA.%26aulast%3DGreen%26aufirst%3DA.%26aulast%3DBall%26aufirst%3DG.%26aulast%3DChan%26aufirst%3DS.%26aulast%3DCaldas%26aufirst%3DC.%26aulast%3DEllis%26aufirst%3DI.%2BO.%26aulast%3DMadhusudan%26aufirst%3DS.%26atitle%3DTargeting%2520BRCA1-BER%2520deficient%2520breast%2520cancer%2520by%2520ATM%2520or%2520DNA-PKcs%2520blockade%2520either%2520alone%2520or%2520in%2520combination%2520with%2520cisplatin%2520for%2520personalized%2520therapy%26jtitle%3DMol.%2520Oncol.%26date%3D2015%26volume%3D9%26issue%3D1%26spage%3D204%26epage%3D217%26doi%3D10.1016%2Fj.molonc.2014.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forment, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradshaw, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Britton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oelschlaegel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xhemalce, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, S. P.</span></span> <span> </span><span class="NLM_article-title">Small-moleculeâinduced DNA damage identifies alternative DNA structures in human genes</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">301</span>â <span class="NLM_lpage">310</span>, <span class="refDoi">Â DOI: 10.1038/nchembio.780</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1038%2Fnchembio.780" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=22306580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslGkur0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=301-310&issue=3&author=R.+Rodriguezauthor=K.+M.+Millerauthor=J.+V.+Formentauthor=C.+R.+Bradshawauthor=M.+Nikanauthor=S.+Brittonauthor=T.+Oelschlaegelauthor=B.+Xhemalceauthor=S.+Balasubramanianauthor=S.+P.+Jackson&title=Small-molecule%E2%80%93induced+DNA+damage+identifies+alternative+DNA+structures+in+human+genes&doi=10.1038%2Fnchembio.780"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule-induced DNA damage identifies alternative DNA structures in human genes</span></div><div class="casAuthors">Rodriguez, Raphael; Miller, Kyle M.; Forment, Josep V.; Bradshaw, Charles R.; Nikan, Mehran; Britton, Sebastien; Oelschlaegel, Tobias; Xhemalce, Blerta; Balasubramanian, Shankar; Jackson, Stephen P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">301-310</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Guanine-rich DNA sequences that can adopt non-Watson-Crick structures in vitro are prevalent in the human genome.  Whether such structures normally exist in mammalian cells has, however, been the subject of active research for decades.  Here we show that the G-quadruplex-interacting drug pyridostatin promotes growth arrest in human cancer cells by inducing replication- and transcription-dependent DNA damage.  A chromatin immunopptn. sequencing anal. of the DNA damage marker Î³H2AX provided the genome-wide distribution of pyridostatin-induced sites of damage and revealed that pyridostatin targets gene bodies contg. clusters of sequences with a propensity for G-quadruplex formation.  As a result, pyridostatin modulated the expression of these genes, including the proto-oncogene SRC.  We obsd. that pyridostatin reduced SRC protein abundance and SRC-dependent cellular motility in human breast cancer cells, validating SRC as a target of this drug.  Our unbiased approach to define genomic sites of action for a drug establishes a framework for discovering functional DNA-drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1Ffpu4Hgf7rVg90H21EOLACvtfcHk0lifYVuYF8XEqQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslGkur0%253D&md5=60f699970eead8cabd7b3a7a260714e7</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.780%26sid%3Dliteratum%253Aachs%26aulast%3DRodriguez%26aufirst%3DR.%26aulast%3DMiller%26aufirst%3DK.%2BM.%26aulast%3DForment%26aufirst%3DJ.%2BV.%26aulast%3DBradshaw%26aufirst%3DC.%2BR.%26aulast%3DNikan%26aufirst%3DM.%26aulast%3DBritton%26aufirst%3DS.%26aulast%3DOelschlaegel%26aufirst%3DT.%26aulast%3DXhemalce%26aufirst%3DB.%26aulast%3DBalasubramanian%26aufirst%3DS.%26aulast%3DJackson%26aufirst%3DS.%2BP.%26atitle%3DSmall-molecule%25E2%2580%2593induced%2520DNA%2520damage%2520identifies%2520alternative%2520DNA%2520structures%2520in%2520human%2520genes%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2012%26volume%3D8%26issue%3D3%26spage%3D301%26epage%3D310%26doi%3D10.1038%2Fnchembio.780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fece de la Cruz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerzendorfer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uras, I. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mair, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazouzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suchankova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konopka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagy-Bojarszky, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muellner, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bago-Horvath, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haura, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loizou, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nijman, S. M. B.</span></span> <span> </span><span class="NLM_article-title">MEK inhibitors block growth of lung tumours with mutations in ataxiaâtelangiectasia mutated</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">13701</span>, <span class="refDoi">Â DOI: 10.1038/ncomms13701</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1038%2Fncomms13701" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=27922010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A280%3ADC%252BC2sjjvFamtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=13701&issue=1&author=M.+Smidaauthor=F.+Fece+de+la+Cruzauthor=C.+Kerzendorferauthor=I.+Z.+Urasauthor=B.+Mairauthor=A.+Mazouziauthor=T.+Suchankovaauthor=T.+Konopkaauthor=A.+M.+Katzauthor=K.+Pazauthor=K.+Nagy-Bojarszkyauthor=M.+K.+Muellnerauthor=Z.+Bago-Horvathauthor=E.+B.+Hauraauthor=J.+I.+Loizouauthor=S.+M.+B.+Nijman&title=MEK+inhibitors+block+growth+of+lung+tumours+with+mutations+in+ataxia%E2%80%93telangiectasia+mutated&doi=10.1038%2Fncomms13701"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">MEK inhibitors block growth of lung tumours with mutations in ataxia-telangiectasia mutated</span></div><div class="casAuthors">Smida Michal; Fece de la Cruz Ferran; Kerzendorfer Claudia; Uras Iris Z; Mair Barbara; Mazouzi Abdelghani; Konopka Tomasz; Nagy-Bojarszky Katalin; Muellner Markus K; Loizou Joanna I; Nijman Sebastian M B; Smida Michal; Fece de la Cruz Ferran; Mair Barbara; Konopka Tomasz; Nijman Sebastian M B; Fece de la Cruz Ferran; Mair Barbara; Konopka Tomasz; Nijman Sebastian M B; Suchankova Tereza; Katz Amanda M; Paz Keren; Bago-Horvath Zsuzsanna; Bago-Horvath Zsuzsanna; Haura Eric B</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13701</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Lung cancer is the leading cause of cancer deaths, and effective treatments are urgently needed.  Loss-of-function mutations in the DNA damage response kinase ATM are common in lung adenocarcinoma but directly targeting these with drugs remains challenging.  Here we report that ATM loss-of-function is synthetic lethal with drugs inhibiting the central growth factor kinases MEK1/2, including the FDA-approved drug trametinib.  Lung cancer cells resistant to MEK inhibition become highly sensitive upon loss of ATM both in vitro and in vivo.  Mechanistically, ATM mediates crosstalk between the prosurvival MEK/ERK and AKT/mTOR pathways.  ATM loss also enhances the sensitivity of KRAS- or BRAF-mutant lung cancer cells to MEK inhibition.  Thus, ATM mutational status in lung cancer is a mechanistic biomarker for MEK inhibitor response, which may improve patient stratification and extend the applicability of these drugs beyond RAS and BRAF mutant tumours.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQGDRm0tliSqJp6t8nS6Nc3fW6udTcc2ean8DwvLcRIZLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjjvFamtg%253D%253D&md5=cd33cd5d498c816e0a8661194401c759</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fncomms13701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms13701%26sid%3Dliteratum%253Aachs%26aulast%3DSmida%26aufirst%3DM.%26aulast%3DFece%2Bde%2Bla%2BCruz%26aufirst%3DF.%26aulast%3DKerzendorfer%26aufirst%3DC.%26aulast%3DUras%26aufirst%3DI.%2BZ.%26aulast%3DMair%26aufirst%3DB.%26aulast%3DMazouzi%26aufirst%3DA.%26aulast%3DSuchankova%26aufirst%3DT.%26aulast%3DKonopka%26aufirst%3DT.%26aulast%3DKatz%26aufirst%3DA.%2BM.%26aulast%3DPaz%26aufirst%3DK.%26aulast%3DNagy-Bojarszky%26aufirst%3DK.%26aulast%3DMuellner%26aufirst%3DM.%2BK.%26aulast%3DBago-Horvath%26aufirst%3DZ.%26aulast%3DHaura%26aufirst%3DE.%2BB.%26aulast%3DLoizou%26aufirst%3DJ.%2BI.%26aulast%3DNijman%26aufirst%3DS.%2BM.%2BB.%26atitle%3DMEK%2520inhibitors%2520block%2520growth%2520of%2520lung%2520tumours%2520with%2520mutations%2520in%2520ataxia%25E2%2580%2593telangiectasia%2520mutated%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26issue%3D1%26spage%3D13701%26doi%3D10.1038%2Fncomms13701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, H.</span></span> <span> </span><span class="NLM_article-title">Current development status of MEK inhibitors</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1551</span>, <span class="refDoi">Â DOI: 10.3390/molecules22101551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.3390%2Fmolecules22101551" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Wjsrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=1551&issue=10&author=Y.+Chengauthor=H.+Tian&title=Current+development+status+of+MEK+inhibitors&doi=10.3390%2Fmolecules22101551"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Current development status of MEK inhibitors</span></div><div class="casAuthors">Cheng, Ying; Tian, Hongqi</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1551/1-1551/20</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The current development status of mitogen-activated protein kinase kinase (MEK) inhibitors, including the preclin. data and clin. study progress, has been summarized in this review.  Different MEK inhibitors, possessing specific physicochem. properties and bioactivity characteristics, may provide different options for patients seeking treatment for cancer.  Moreover, the combination of the MEK inhibitors with other therapies-such as chemotherapy, targeted therapy, and immunotherapy-may be a promising approach for clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosd6s1Lx6dYbVg90H21EOLACvtfcHk0lgjCcqI4EtDuQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Wjsrk%253D&md5=0210d125f8a46468d67adb4f9aaf6cf3</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.3390%2Fmolecules22101551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules22101551%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DTian%26aufirst%3DH.%26atitle%3DCurrent%2520development%2520status%2520of%2520MEK%2520inhibitors%26jtitle%3DMolecules%26date%3D2017%26volume%3D22%26issue%3D10%26spage%3D1551%26doi%3D10.3390%2Fmolecules22101551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knudsen, K. E.</span></span> <span> </span><span class="NLM_article-title">Beyond DNA repair: DNA-PK function in cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1126</span>â <span class="NLM_lpage">1139</span>, <span class="refDoi">Â DOI: 10.1158/2159-8290.CD-14-0358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F2159-8290.CD-14-0358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=25168287" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs12nsr%252FK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=1126-1139&issue=10&author=J.+F.+Goodwinauthor=K.+E.+Knudsen&title=Beyond+DNA+repair%3A+DNA-PK+function+in+cancer&doi=10.1158%2F2159-8290.CD-14-0358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Beyond DNA repair: DNA-PK function in cancer</span></div><div class="casAuthors">Goodwin, Jonathan F.; Knudsen, Karen E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1126-1139</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The DNA-dependent protein kinase (DNA-PK) is a pivotal component of the DNA repair machinery that governs the response to DNA damage, serving to maintain genome integrity.  However, the DNA-PK kinase component was initially isolated with transcriptional complexes, and recent findings have illuminated the impact of DNA-PK-mediated transcriptional regulation on tumor progression and therapeutic response.  DNA-PK expression has also been correlated with poor outcome in selected tumor types, further underscoring the importance of understanding its role in disease.  Herein, the mol. and cellular consequences of DNA-PK are considered, with an eye toward discerning the rationale for therapeutic targeting of DNA-PK.  Significance: Although DNA-PK is classically considered a component of damage response, recent findings illuminate damage-independent functions of DNA-PK that affect multiple tumor-assocd. pathways and provide a rationale for the development of novel therapeutic strategies.  Cancer Discov; 4(10); 1126-39. Â©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnEmo761qFmbVg90H21EOLACvtfcHk0lgjCcqI4EtDuQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs12nsr%252FK&md5=f81d22f39aa77736c1ba8ce08de0d628</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0358%26sid%3Dliteratum%253Aachs%26aulast%3DGoodwin%26aufirst%3DJ.%2BF.%26aulast%3DKnudsen%26aufirst%3DK.%2BE.%26atitle%3DBeyond%2520DNA%2520repair%253A%2520DNA-PK%2520function%2520in%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26issue%3D10%26spage%3D1126%26epage%3D1139%26doi%3D10.1158%2F2159-8290.CD-14-0358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohiuddin, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, M. H.</span></span> <span> </span><span class="NLM_article-title">DNA-PK as an emerging therapeutic target in Cancer</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">635</span>, <span class="refDoi">Â DOI: 10.3389/fonc.2019.00635</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.3389%2Ffonc.2019.00635" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=31380275" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A280%3ADC%252BB3MvkslKmtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=635&author=I.+S.+Mohiuddinauthor=M.+H.+Kang&title=DNA-PK+as+an+emerging+therapeutic+target+in+Cancer&doi=10.3389%2Ffonc.2019.00635"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">DNA-PK as an Emerging Therapeutic Target in Cancer</span></div><div class="casAuthors">Mohiuddin Ismail S; Kang Min H</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">635</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">The DNA-dependent protein kinase (DNA-PK) plays an instrumental role in the overall survival and proliferation of cells.  As a member of the phosphatidylinositol 3-kinase-related kinase (PIKK) family, DNA-PK is best known as a mediator of the cellular response to DNA damage.  In this context, DNA-PK has emerged as an intriguing therapeutic target in the treatment of a variety of cancers, especially when used in conjunction with genotoxic chemotherapy or ionizing radiation.  Beyond the DNA damage response, DNA-PK activity is necessary for multiple cellular functions, including the regulation of transcription, progression of the cell cycle, and in the maintenance of telomeres.  Here, we review what is currently known about DNA-PK regarding its structure and established roles in DNA repair.  We also discuss its lesser-known functions, the pharmacotherapies inhibiting its function in DNA repair, and its potential as a therapeutic target in a broader context.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQGccaQRmYaT-xsqfvU0ziafW6udTcc2ebo5Qq3SXU-XLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MvkslKmtw%253D%253D&md5=19c10c1fa9599f9f2bff50f9a57333ac</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2019.00635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2019.00635%26sid%3Dliteratum%253Aachs%26aulast%3DMohiuddin%26aufirst%3DI.%2BS.%26aulast%3DKang%26aufirst%3DM.%2BH.%26atitle%3DDNA-PK%2520as%2520an%2520emerging%2520therapeutic%2520target%2520in%2520Cancer%26jtitle%3DFront.%2520Oncol.%26date%3D2019%26volume%3D9%26spage%3D635%26doi%3D10.3389%2Ffonc.2019.00635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kotula, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berthault, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agrario, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lienafa, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dingli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loew, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibut, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saule, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutreix, M.</span></span> <span> </span><span class="NLM_article-title">DNA-PKcs plays role in cancer metastasis through regulation of secreted proteins involved in migration and invasion</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1961</span>â <span class="NLM_lpage">1972</span>, <span class="refDoi">Â DOI: 10.1080/15384101.2015.1026522</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1080%2F15384101.2015.1026522" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=26017556" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVKrsLvK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=1961-1972&issue=12&author=E.+Kotulaauthor=N.+Berthaultauthor=C.+Agrarioauthor=M.+C.+Lienafaauthor=A.+Simonauthor=F.+Dingliauthor=D.+Loewauthor=V.+Sibutauthor=S.+Sauleauthor=M.+Dutreix&title=DNA-PKcs+plays+role+in+cancer+metastasis+through+regulation+of+secreted+proteins+involved+in+migration+and+invasion&doi=10.1080%2F15384101.2015.1026522"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">DNA-PKcs plays role in cancer metastasis through regulation of secreted proteins involved in migration and invasion</span></div><div class="casAuthors">Kotula, Ewa; Berthault, Nathalie; Agrario, Celine; Lienafa, Marie-Christine; Simon, Anthony; Dingli, Florent; Loew, Damarys; Sibut, Vonick; Saule, Simon; Dutreix, Marie</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1961-1972</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1551-4005</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The DNA-dependent protein kinase catalytic subunit (DNA-PKcs) plays a major role in DNA damage signaling and repair and is also frequently overexpressed in tumor metastasis.  We used isogenic cell lines expressing different levels of DNA-PKcs to investigate the role of DNA-PKcs in metastatic development.  We found that DNA-PKcs participates in melanoma primary tumor and metastasis development by stimulating angiogenesis, migration and invasion.  Comparison of conditioned medium content from DNA-PKcs-proficient and deficient cells reveals that DNA-PKcs controls secretion of at least 103 proteins (including 44 metastasis-assocd. with FBLN1, SERPINA3, MMP-8, HSPG2 and the inhibitors of matrix metalloproteinases, such as Î±-2M and TIMP-2).  High throughput anal. of secretomes, proteomes and transcriptomes, indicate that DNA-PKcs regulates the secretion of 85 proteins without affecting their gene expression.  Our data demonstrate that DNA-PKcs has a pro-metastatic activity via the modification of the tumor microenvironment.  This study shows for the first time a direct link between DNA damage repair and cancer metastasis and highlights the importance of DNA-PKcs as a potential target for anti-metastatic treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp67ON-80rNR7Vg90H21EOLACvtfcHk0lhwSr9inlO9ag"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVKrsLvK&md5=91a70bb4f33389f7d8313be5841f3d4a</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1080%2F15384101.2015.1026522&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15384101.2015.1026522%26sid%3Dliteratum%253Aachs%26aulast%3DKotula%26aufirst%3DE.%26aulast%3DBerthault%26aufirst%3DN.%26aulast%3DAgrario%26aufirst%3DC.%26aulast%3DLienafa%26aufirst%3DM.%2BC.%26aulast%3DSimon%26aufirst%3DA.%26aulast%3DDingli%26aufirst%3DF.%26aulast%3DLoew%26aufirst%3DD.%26aulast%3DSibut%26aufirst%3DV.%26aulast%3DSaule%26aufirst%3DS.%26aulast%3DDutreix%26aufirst%3DM.%26atitle%3DDNA-PKcs%2520plays%2520role%2520in%2520cancer%2520metastasis%2520through%2520regulation%2520of%2520secreted%2520proteins%2520involved%2520in%2520migration%2520and%2520invasion%26jtitle%3DCell%2520Cycle%26date%3D2015%26volume%3D14%26issue%3D12%26spage%3D1961%26epage%3D1972%26doi%3D10.1080%2F15384101.2015.1026522" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cornell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munck, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alsinet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villanueva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogle, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willoughby, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Televantou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burt, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manas, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtin, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reeves, H. L.</span></span> <span> </span><span class="NLM_article-title">DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">925</span>â <span class="NLM_lpage">933</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-14-0842</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F1078-0432.CCR-14-0842" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=25480831" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2MXislGgtr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=925-933&issue=4&author=L.+Cornellauthor=J.+M.+Munckauthor=C.+Alsinetauthor=A.+Villanuevaauthor=L.+Ogleauthor=C.+E.+Willoughbyauthor=D.+Televantouauthor=H.+D.+Thomasauthor=J.+Jacksonauthor=A.+D.+Burtauthor=D.+Newellauthor=J.+Roseauthor=D.+M.+Manasauthor=G.+I.+Shapiroauthor=N.+J.+Curtinauthor=H.+L.+Reeves&title=DNA-PK-A+candidate+driver+of+hepatocarcinogenesis+and+tissue+biomarker+that+predicts+response+to+treatment+and+survival&doi=10.1158%2F1078-0432.CCR-14-0842"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">DNA-PK-A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival</span></div><div class="casAuthors">Cornell, Liam; Munck, Joanne M.; Alsinet, Clara; Villanueva, Augusto; Ogle, Laura; Willoughby, Catherine E.; Televantou, Despina; Thomas, Huw D.; Jackson, Jennifer; Burt, Alastair D.; Newell, David; Rose, John; Manas, Derek M.; Shapiro, Geoffrey I.; Curtin, Nicola J.; Reeves, Helen L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">925-933</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Therapy resistance and assocd. liver disease make hepatocellular carcinomas (HCC) difficult to treat with traditional cytotoxic therapies, whereas newer targeted approaches offer only modest survival benefit.  We focused on DNA-dependent protein kinase, DNA-PKcs, encoded by PRKDC and central to DNA damage repair by nonhomologous end joining.  Our aim was to explore its roles in hepatocarcinogenesis and as a novel therapeutic candidate.  Exptl. Design: PRKDC was characterized in liver tissues from of 132 patients [normal liver (n = 10), cirrhotic liver (n = 13), dysplastic nodules (n = 18), HCC (n = 91)] using Affymetrix U133 Plus 2.0 and 500 K Human Mapping SNP arrays (cohort 1).  In addn., we studied a case series of 45 patients with HCC undergoing diagnostic biopsy (cohort 2).  Histol. grading, response to treatment, and survival were correlated with DNA-PKcs quantified immunohistochem.  Parallel in vitro studies detd. the impact of DNA-PK on DNA repair and response to cytotoxic therapy.  Results: Increased PRKDC expression in HCC was assocd. with amplification of its genetic locus in cohort 1.  In cohort 2, elevated DNA-PKcs identified patients with treatment-resistant HCC, progressing at a median of 4.5 mo compared with 16.9 mo, whereas elevation of activated pDNA-PK independently predicted poorer survival.  DNA-PKcs was high in HCC cell lines, where its inhibition with NU7441 potentiated irradn. and doxorubicin-induced cytotoxicity, whereas the combination suppressed HCC growth in vitro and in vivo.  Conclusions: These data identify PRKDC/DNA-PKcs as a candidate driver of hepatocarcinogenesis, whose biopsy characterization at diagnosis may impact stratification of current therapies, and whose specific future targeting may overcome resistance.  Clin Cancer Res; 21(4); 925-33. Â©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiEWlFXh8lgrVg90H21EOLACvtfcHk0lhwSr9inlO9ag"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXislGgtr4%253D&md5=0b6ebd7d32c4a95a78f8fb376a66eb0c</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-0842&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-0842%26sid%3Dliteratum%253Aachs%26aulast%3DCornell%26aufirst%3DL.%26aulast%3DMunck%26aufirst%3DJ.%2BM.%26aulast%3DAlsinet%26aufirst%3DC.%26aulast%3DVillanueva%26aufirst%3DA.%26aulast%3DOgle%26aufirst%3DL.%26aulast%3DWilloughby%26aufirst%3DC.%2BE.%26aulast%3DTelevantou%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DH.%2BD.%26aulast%3DJackson%26aufirst%3DJ.%26aulast%3DBurt%26aufirst%3DA.%2BD.%26aulast%3DNewell%26aufirst%3DD.%26aulast%3DRose%26aufirst%3DJ.%26aulast%3DManas%26aufirst%3DD.%2BM.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DReeves%26aufirst%3DH.%2BL.%26atitle%3DDNA-PK-A%2520candidate%2520driver%2520of%2520hepatocarcinogenesis%2520and%2520tissue%2520biomarker%2520that%2520predicts%2520response%2520to%2520treatment%2520and%2520survival%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26issue%3D4%26spage%3D925%26epage%3D933%26doi%3D10.1158%2F1078-0432.CCR-14-0842" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herrero, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Miguel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez, N. C.</span></span> <span> </span><span class="NLM_article-title">Deregulation of DNA double-strand break repair in multiple myeloma: implications for genome stability</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">3</span>), <span class="NLM_elocation-id">e0121581</span> <span class="refDoi">Â DOI: 10.1371/journal.pone.0121581</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1371%2Fjournal.pone.0121581" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=25790254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslWqur7F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&issue=3&author=A.+B.+Herreroauthor=J.+San+Miguelauthor=N.+C.+Gutierrez&title=Deregulation+of+DNA+double-strand+break+repair+in+multiple+myeloma%3A+implications+for+genome+stability&doi=10.1371%2Fjournal.pone.0121581"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Deregulation of DNA double-strand break repair in multiple myeloma: implications for genome stability</span></div><div class="casAuthors">Herrero, Ana B.; San Miguel, Jesus; Gutierrez, Norma C.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e0121581/1-e0121581/21</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Multiple myeloma (MM) is a hematol. malignancy characterized by frequent chromosome abnormalities.  However, the mol. basis for this genome instability remains unknown.  Since both impaired and hyperactive double strand break (DSB) repair pathways can result in DNA rearrangements, we investigated the functionality of DSB repair in MM cells.  Repair kinetics of ionizing-radiation (IR)-induced DSBs was similar in MM and normal control lymphoblastoid cell lines, as revealed by the comet assay.  However, four out of seven MM cell lines analyzed exhibited a subset of persistent DSBs, marked by Î³-H2AX and Rad51 foci that elicited a prolonged G2/M DNA damage checkpoint activation and hypersensitivity to IR, esp. in the presence of checkpoint inhibitors.  An anal. of the proteins involved in DSB repair in MM cells revealed upregulation of DNA-PKcs, Artemis and XRCC4, that participate in non-homologous end joining (NHEJ), and Rad51, involved in homologous recombination (HR).  Accordingly, activity of both NHEJ and HR were elevated in MM cells compared to controls, as detd. by in vivo functional assays.  Interestingly, levels of proteins involved in a highly mutagenic, translocation-promoting, alternative NHEJ subpathway (Alt-NHEJ) were also increased in all MM cell lines, with the Alt-NHEJ protein DNA ligase IIIÎ±, also overexpressed in several plasma cell samples isolated from MM patients.  Overactivation of the Alt-NHEJ pathway was revealed in MM cells by larger deletions and higher sequence microhomol. at repair junctions, which were reduced by chem. inhibition of the pathway.  Taken together, our results uncover a deregulated DSB repair in MM that might underlie the characteristic genome instability of the disease, and could be therapeutically exploited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKGe6l280YnLVg90H21EOLACvtfcHk0lhwSr9inlO9ag"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslWqur7F&md5=06fb91b2bcdd57a92d40da6c33855960</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0121581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0121581%26sid%3Dliteratum%253Aachs%26aulast%3DHerrero%26aufirst%3DA.%2BB.%26aulast%3DSan%2BMiguel%26aufirst%3DJ.%26aulast%3DGutierrez%26aufirst%3DN.%2BC.%26atitle%3DDeregulation%2520of%2520DNA%2520double-strand%2520break%2520repair%2520in%2520multiple%2520myeloma%253A%2520implications%2520for%2520genome%2520stability%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26issue%3D3%26doi%3D10.1371%2Fjournal.pone.0121581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ihara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashizawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shichijo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudo, T.</span></span> <span> </span><span class="NLM_article-title">Expression of the DNA-dependent protein kinase catalytic subunit is associated with the radiosensitivity of human thyroid cancer cell lines</span>. <i>J. Radiat. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">171</span>â <span class="NLM_lpage">177</span>, <span class="refDoi">Â DOI: 10.1093/jrr/rry097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1093%2Fjrr%2Frry097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=30476230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjslejtbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2019&pages=171-177&issue=2&author=M.+Iharaauthor=K.+Ashizawaauthor=K.+Shichijoauthor=T.+Kudo&title=Expression+of+the+DNA-dependent+protein+kinase+catalytic+subunit+is+associated+with+the+radiosensitivity+of+human+thyroid+cancer+cell+lines&doi=10.1093%2Fjrr%2Frry097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of the DNA-dependent protein kinase catalytic subunit is associated with the radiosensitivity of human thyroid cancer cell lines</span></div><div class="casAuthors">Ihara, Makoto; Ashizawa, Kiyoto; Shichijo, Kazuko; Kudo, Takashi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Radiation Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">171-177</span>CODEN:
                <span class="NLM_cas:coden">JRARAX</span>;
        ISSN:<span class="NLM_cas:issn">1349-9157</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The prognosis and treatment of thyroid cancer depends on the type and stage of the disease.  Radiosensitivity differs among cancer cells owing to their varying capacity for repair after irradn.  Radioactive iodine can be used to destroy thyroid cancer cells.  However, patient prognosis and improvement after irradn. varies.  Therefore, predictive measures are important for avoiding unnecessary exposure to radiation.  We describe a new method for predicting the effects of radiation in individual cases of thyroid cancer based on the DNA-dependent protein kinase (DNA-PK) activity level in cancer cells.  The radiation sensitivity, DNA-PK activity, and cellular levels of DNA-PK complex subunits in five human thyroid cancer cell lines were analyzed in vitro.  A pos. correlation was obsd. between the D10 value (radiation dose that led to 10% survival) of cells and DNA-PK activity.  This correlation was not obsd. after treatment with NU7441, a DNA-PK-specific inhibitor.  A significant correlation was also obsd. between DNA-PK activity and expression levels of the DNA-PK catalytic subunit (DNA-PKcs).  Cells expressing low DNA-PKcs levels were radiation-sensitive, and cells expressing high DNA-PKcs levels were radiation-resistant.  Our results indicate that radiosensitivity depends on the expression level of DNA-PKcs in thyroid cancer cell lines.  Thus, the DNA-PKcs expression level is a potential predictive marker of the success of radiation therapy for thyroid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuxs3_P27SmLVg90H21EOLACvtfcHk0li5Re_9PBBEJw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjslejtbk%253D&md5=5689f6a281746197a2fa87dcfe682ff6</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1093%2Fjrr%2Frry097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjrr%252Frry097%26sid%3Dliteratum%253Aachs%26aulast%3DIhara%26aufirst%3DM.%26aulast%3DAshizawa%26aufirst%3DK.%26aulast%3DShichijo%26aufirst%3DK.%26aulast%3DKudo%26aufirst%3DT.%26atitle%3DExpression%2520of%2520the%2520DNA-dependent%2520protein%2520kinase%2520catalytic%2520subunit%2520is%2520associated%2520with%2520the%2520radiosensitivity%2520of%2520human%2520thyroid%2520cancer%2520cell%2520lines%26jtitle%3DJ.%2520Radiat.%2520Res.%26date%3D2019%26volume%3D60%26issue%3D2%26spage%3D171%26epage%3D177%26doi%3D10.1093%2Fjrr%2Frry097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shintani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mihara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakahara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hino, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakashiro, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamakawa, H.</span></span> <span> </span><span class="NLM_article-title">Up-regulation of DNA-dependent protein kinase correlates with radiation resistance in oral squamous cell carcinoma</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>94</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">894</span>â <span class="NLM_lpage">900</span>, <span class="refDoi">Â DOI: 10.1111/j.1349-7006.2003.tb01372.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1111%2Fj.1349-7006.2003.tb01372.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=14556663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpsFGhtLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2003&pages=894-900&issue=10&author=S.+Shintaniauthor=M.+Miharaauthor=C.+Liauthor=Y.+Nakaharaauthor=S.+Hinoauthor=K.+Nakashiroauthor=H.+Hamakawa&title=Up-regulation+of+DNA-dependent+protein+kinase+correlates+with+radiation+resistance+in+oral+squamous+cell+carcinoma&doi=10.1111%2Fj.1349-7006.2003.tb01372.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Up-regulation of DNA-dependent protein kinase correlates with radiation resistance in oral squamous cell carcinoma</span></div><div class="casAuthors">Shintani, Satoru; Mihara, Mariko; Li, Chunnan; Nakahara, Yuuji; Hino, Satoshi; Nakashiro, Koh-ichi; Hamakawa, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">894-900</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1347-9032</span>.
    
            (<span class="NLM_cas:orgname">Japanese Cancer Association</span>)
        </div><div class="casAbstract">DNA-PK is a nuclear protein with serine/threonine kinase activity and forms a complex consisting of the DNA-PKcs and a heterodimer of Ku70 and Ku80 proteins.  Recent lab. expts. have demonstrated that the DNA-PK complex formation is one of the major pathways by which mammalian cells respond to DNA double-strand breaks induced by ionizing radiation.  In this study, we evaluated the relationship between expression levels of DNA-PKcs, Ku70 and Ku80 proteins and radiation sensitivity in oral squamous cell carcinoma (OSCC) cell lines and in OSCC patients treated with preoperative radiation therapy.  The OSCC cell lines greatly differed in their response to irradn., as assessed by a std. colony formation assay.  However, the expression levels of the DNA-PK complex proteins were all similar, and there was no assocn. between the magnitude of their expression and the tumor radiation sensitivity.  Expression of DNA-PK complex proteins increased after radiation treatment, and the increased values correlated with the tumor radiation resistance.  Expression of DNA-PKcs and Ku70 after irradn. was increased in the surviving cells of OSCC tissues irradiated preoperatively.  These results suggest that up-regulation of DNA-PK complex protein, esp. DNA-PKcs, after radiation treatment correlates to radiation resistance.  DNA-PKcs might be a mol. target for a novel radiation sensitization therapy of OSCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmDwEDp57_f7Vg90H21EOLACvtfcHk0li5Re_9PBBEJw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpsFGhtLg%253D&md5=cbe71d8e2e925fc375eada7dea5cc73b</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2003.tb01372.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2003.tb01372.x%26sid%3Dliteratum%253Aachs%26aulast%3DShintani%26aufirst%3DS.%26aulast%3DMihara%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DNakahara%26aufirst%3DY.%26aulast%3DHino%26aufirst%3DS.%26aulast%3DNakashiro%26aufirst%3DK.%26aulast%3DHamakawa%26aufirst%3DH.%26atitle%3DUp-regulation%2520of%2520DNA-dependent%2520protein%2520kinase%2520correlates%2520with%2520radiation%2520resistance%2520in%2520oral%2520squamous%2520cell%2520carcinoma%26jtitle%3DCancer%2520Sci.%26date%3D2003%26volume%3D94%26issue%3D10%26spage%3D894%26epage%3D900%26doi%3D10.1111%2Fj.1349-7006.2003.tb01372.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beskow, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skikuniene, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holgersson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewensohn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanter, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viktorsson, K.</span></span> <span> </span><span class="NLM_article-title">Radioresistant cervical cancer shows upregulation of the NHEJ proteins DNA-PKcs, Ku70 and Ku86</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>101</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">816</span>â <span class="NLM_lpage">821</span>, <span class="refDoi">Â DOI: 10.1038/sj.bjc.6605201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1038%2Fsj.bjc.6605201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=19672258" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVGqu7fP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2009&pages=816-821&issue=5&author=C.+Beskowauthor=J.+Skikunieneauthor=A.+Holgerssonauthor=B.+Nilssonauthor=R.+Lewensohnauthor=L.+Kanterauthor=K.+Viktorsson&title=Radioresistant+cervical+cancer+shows+upregulation+of+the+NHEJ+proteins+DNA-PKcs%2C+Ku70+and+Ku86&doi=10.1038%2Fsj.bjc.6605201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Radioresistant cervical cancer shows upregulation of the NHEJ proteins DNA-PKcs, Ku70 and Ku86</span></div><div class="casAuthors">Beskow, C.; Skikuniene, J.; Holgersson, A.; Nilsson, B.; Lewensohn, R.; Kanter, L.; Viktorsson, K.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">816-821</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Radiotherapy is central in the treatment of cervical cancer.  The formation of DNA double-strand breaks is considered to be crit. for the radiotherapeutic effect.  The non-homologous end joining (NHEJ) proteins DNA-PKcs, Ku70 and Ku86 have a major role in repairing DNA lesions.  The objective of this study was to analyze if the expression of DNA-PKcs, Ku70 and Ku86 and their downstream signalling mols. p53, p21 and Mdm-2 are altered in residual cervical tumors after radiotherapy.  Retrospective anal. of 127 patients with cervical cancer stage IB-IIA treated with preoperative radiotherapy and radical surgery, revealed residual tumor in the cervical specimen in 30 patients.  In 22 cases tumor material from residual and corresponding primary tumor were retrieved and the expression of DNA-PKcs, Ku86, Ku70, p53, p21 and Mdm-2 were assessed by immunohistochem.  Residual tumors showed increased frequency of DNA-PKcs (P=0.037), Ku70 (P=0.018), Ku86 (P=0.008) pos. cells.  A correlation in DNA-PKcs expression between primary and residual tumors was found.  The frequency of p21-pos. cells was decreased (P=0.007) in residual tumors whereas no change in p53 or Mdm-2-pos. cells were obsd.  Our results show that cervical carcinoma surviving radiotherapy have an increased DNA-PK expression.  Studies on larger patient cohorts are needed to allow an interpretation that an upregulation of DNA-PK function may be part of a radioresistance mechanism within this tumor type.  British Journal of Cancer (2009) 101, 816-821; doi:10.1038/sj.bjc.6605201 www.bjcancer.com Published online 11 August 2009.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovtmpdncuOILVg90H21EOLACvtfcHk0li5Re_9PBBEJw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVGqu7fP&md5=6ef1850be5628136461bb9ca1af7bb8f</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6605201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6605201%26sid%3Dliteratum%253Aachs%26aulast%3DBeskow%26aufirst%3DC.%26aulast%3DSkikuniene%26aufirst%3DJ.%26aulast%3DHolgersson%26aufirst%3DA.%26aulast%3DNilsson%26aufirst%3DB.%26aulast%3DLewensohn%26aufirst%3DR.%26aulast%3DKanter%26aufirst%3DL.%26aulast%3DViktorsson%26aufirst%3DK.%26atitle%3DRadioresistant%2520cervical%2520cancer%2520shows%2520upregulation%2520of%2520the%2520NHEJ%2520proteins%2520DNA-PKcs%252C%2520Ku70%2520and%2520Ku86%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2009%26volume%3D101%26issue%3D5%26spage%3D816%26epage%3D821%26doi%3D10.1038%2Fsj.bjc.6605201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saldivar, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cimprich, K. A.</span></span> <span> </span><span class="NLM_article-title">The essential kinase ATR: ensuring faithful duplication of a challenging genome</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">622</span>â <span class="NLM_lpage">636</span>, <span class="refDoi">Â DOI: 10.1038/nrm.2017.67</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1038%2Fnrm.2017.67" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=28811666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlemu7jF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=622-636&issue=10&author=J.+C.+Saldivarauthor=D.+Cortezauthor=K.+A.+Cimprich&title=The+essential+kinase+ATR%3A+ensuring+faithful+duplication+of+a+challenging+genome&doi=10.1038%2Fnrm.2017.67"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">The essential kinase ATR: ensuring faithful duplication of a challenging genome</span></div><div class="casAuthors">Saldivar, Joshua C.; Cortez, David; Cimprich, Karlene A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">622-636</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  One way to preserve a rare book is to lock it away from all potential sources of damage.  Of course, an inaccessible book is also of little use, and the paper and ink will continue to degrade with age in any case.  Like a book, the information stored in our DNA needs to be read, but it is also subject to continuous assault and therefore needs to be protected.  In this Review, we examine how the replication stress response that is controlled by the kinase ataxia telangiectasia and Rad3-related (ATR) senses and resolves threats to DNA integrity so that the DNA remains available to read in all of our cells.  We discuss the multiple data that have revealed an elegant yet increasingly complex mechanism of ATR activation.  This involves a core set of components that recruit ATR to stressed replication forks, stimulate kinase activity and amplify ATR signalling.  We focus on the activities of ATR in the control of cell cycle checkpoints, origin firing and replication fork stability, and on how proper regulation of these processes is crucial to ensure faithful duplication of a challenging genome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqi-97TQtMh0bVg90H21EOLACvtfcHk0liJUMUaDt_6JA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlemu7jF&md5=b65c70da63f009deae253c8f3f215234</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1038%2Fnrm.2017.67&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm.2017.67%26sid%3Dliteratum%253Aachs%26aulast%3DSaldivar%26aufirst%3DJ.%2BC.%26aulast%3DCortez%26aufirst%3DD.%26aulast%3DCimprich%26aufirst%3DK.%2BA.%26atitle%3DThe%2520essential%2520kinase%2520ATR%253A%2520ensuring%2520faithful%2520duplication%2520of%2520a%2520challenging%2520genome%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2017%26volume%3D18%26issue%3D10%26spage%3D622%26epage%3D636%26doi%3D10.1038%2Fnrm.2017.67" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kwok, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agathanggelou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oldreive, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petermann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parry, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stankovic, T.</span></span> <span> </span><span class="NLM_article-title">ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>127</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">582</span>â <span class="NLM_lpage">595</span>, <span class="refDoi">Â DOI: 10.1182/blood-2015-05-644872</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1182%2Fblood-2015-05-644872" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=26563132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1CqtrnI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2016&pages=582-595&issue=5&author=M.+Kwokauthor=N.+Daviesauthor=A.+Agathanggelouauthor=E.+Smithauthor=C.+Oldreiveauthor=E.+Petermannauthor=G.+Stewartauthor=J.+Brownauthor=A.+Lauauthor=G.+Prattauthor=H.+Parryauthor=M.+Taylorauthor=P.+Mossauthor=P.+Hillmenauthor=T.+Stankovic&title=ATR+inhibition+induces+synthetic+lethality+and+overcomes+chemoresistance+in+TP53-+or+ATM-defective+chronic+lymphocytic+leukemia+cells&doi=10.1182%2Fblood-2015-05-644872"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells</span></div><div class="casAuthors">Kwok, Marwan; Davies, Nicholas; Agathanggelou, Angelo; Smith, Edward; Oldreive, Ceri; Petermann, Eva; Stewart, Grant; Brown, Jeff; Lau, Alan; Pratt, Guy; Parry, Helen; Taylor, Malcolm; Moss, Paul; Hillmen, Peter; Stankovic, Tatjana</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">582-595</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">TP53 and ataxia telangiectasia mutated (ATM) defects are assocd. with genomic instability, clonal evolution, and chemoresistance in chronic lymphocytic leukemia (CLL).  Currently, therapies capable of providing durable remissions in relapsed/refractory TP53- or ATM-defective CLL are lacking.  Ataxia telangiectasia and Rad3- related (ATR) mediates response to replication stress, the absence of which leads to collapse of stalled replication forks into chromatid fragments that require resoln. through the ATM/p53 pathway.  Here, using AZD6738, a novel ATR kinase inhibitor, we investigated ATR inhibition as a synthetically lethal strategy to target CLL cells with TP53 or ATM defects.  Irresp. of TP53 or ATM status, induction of CLL cell proliferation upregulated ATR protein, which then became activated in response to replication stress.  In TP53- or ATM-defective CLL cells, inhibition of ATR signaling by AZD6738 led to an accumulation of unrepaired DNA damage, which was carried through into mitosis because of defective cell cycle checkpoints, resulting in cell death by mitotic catastrophe.  Consequently, AZD6738 was selectively cytotoxic to both TP53- and ATM-defective CLL cell lines and primary cells.  This was confirmed in vivo using primary xenograft models of TP53- or ATM-defective CLL, where treatment with AZD6738 resulted in decreased tumor load and redn. in the proportion of CLL cells with such defects.  Moreover, AZD6738 sensitized TP53- or ATM-defective primary CLL cells to chemotherapy and ibrutinib.  Our findings suggest that ATR is a promising therapeutic target for TP53- or ATM-defective CLL that warrants clin. investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoosV2x8QBkxbVg90H21EOLACvtfcHk0liJUMUaDt_6JA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1CqtrnI&md5=2d7e9490e26b94b55bf508ca516064a4</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1182%2Fblood-2015-05-644872&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2015-05-644872%26sid%3Dliteratum%253Aachs%26aulast%3DKwok%26aufirst%3DM.%26aulast%3DDavies%26aufirst%3DN.%26aulast%3DAgathanggelou%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DE.%26aulast%3DOldreive%26aufirst%3DC.%26aulast%3DPetermann%26aufirst%3DE.%26aulast%3DStewart%26aufirst%3DG.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DPratt%26aufirst%3DG.%26aulast%3DParry%26aufirst%3DH.%26aulast%3DTaylor%26aufirst%3DM.%26aulast%3DMoss%26aufirst%3DP.%26aulast%3DHillmen%26aufirst%3DP.%26aulast%3DStankovic%26aufirst%3DT.%26atitle%3DATR%2520inhibition%2520induces%2520synthetic%2520lethality%2520and%2520overcomes%2520chemoresistance%2520in%2520TP53-%2520or%2520ATM-defective%2520chronic%2520lymphocytic%2520leukemia%2520cells%26jtitle%3DBlood%26date%3D2016%26volume%3D127%26issue%3D5%26spage%3D582%26epage%3D595%26doi%3D10.1182%2Fblood-2015-05-644872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fokas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prevo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reaper, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelissen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallis, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olcina, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillies McKenna, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muschel, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunner, T. B.</span></span> <span> </span><span class="NLM_article-title">Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">12</span>), <span class="NLM_elocation-id">e441</span> <span class="refDoi">Â DOI: 10.1038/cddis.2012.181</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1038%2Fcddis.2012.181" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=23222511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtVWnsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&issue=12&author=E.+Fokasauthor=R.+Prevoauthor=J.+R.+Pollardauthor=P.+M.+Reaperauthor=P.+A.+Charltonauthor=B.+Cornelissenauthor=K.+A.+Vallisauthor=E.+M.+Hammondauthor=M.+M.+Olcinaauthor=W.+Gillies+McKennaauthor=R.+J.+Muschelauthor=T.+B.+Brunner&title=Targeting+ATR+in+vivo+using+the+novel+inhibitor+VE-822+results+in+selective+sensitization+of+pancreatic+tumors+to+radiation&doi=10.1038%2Fcddis.2012.181"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation</span></div><div class="casAuthors">Fokas, E.; Prevo, R.; Pollard, J. R.; Reaper, P. M.; Charlton, P. A.; Cornelissen, B.; Vallis, K. A.; Hammond, E. M.; Olcina, M. M.; McKenna, W. Gillies; Muschel, R. J.; Brunner, T. B.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Disease</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">Dec.</span>),
    <span class="NLM_cas:pages">e441, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">CDDEA4</span>;
        ISSN:<span class="NLM_cas:issn">2041-4889</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Combined radiochemotherapy is the currently used therapy for locally advanced pancreatic ductal adenocarcinoma (PDAC), but normal tissue toxicity limits its application.  Here we test the hypothesis that inhibition of ATR (ATM-Rad3-related) could increase the sensitivity of the cancer cells to radiation or chemotherapy without affecting normal cells.  We tested VE-822, an ATR inhibitor, for in vitro and in vivo radiosensitization.  Chk1 phosphorylation was used to indicate ATR activity, Î³H2AX and 53BP1 foci as evidence of DNA damage and Rad51 foci for homologous recombination activity.  Sensitivity to radiation (XRT) and gemcitabine was measured with clonogenic assays in vitro and tumor growth delay in vivo.  Murine intestinal damage was evaluated after abdominal XRT.  VE-822 inhibited ATR in vitro and in vivo.  VE-822 decreased maintenance of cell-cycle checkpoints, increased persistent DNA damage and decreased homologous recombination in irradiated cancer cells.  VE-822 decreased survival of pancreatic cancer cells but not normal cells in response to XRT or gemcitabine.  VE-822 markedly prolonged growth delay of pancreatic cancer xenografts after XRT and gemcitabine-based chemoradiation without augmenting normal cell or tissue toxicity.  These findings support ATR inhibition as a promising new approach to improve the therapeutic ration of radiochemotherapy for patients with PDAC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp66nE6ZdMorVg90H21EOLACvtfcHk0liJUMUaDt_6JA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtVWnsA%253D%253D&md5=7223df6ec5dbca8c50889b5df8e4cce6</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1038%2Fcddis.2012.181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcddis.2012.181%26sid%3Dliteratum%253Aachs%26aulast%3DFokas%26aufirst%3DE.%26aulast%3DPrevo%26aufirst%3DR.%26aulast%3DPollard%26aufirst%3DJ.%2BR.%26aulast%3DReaper%26aufirst%3DP.%2BM.%26aulast%3DCharlton%26aufirst%3DP.%2BA.%26aulast%3DCornelissen%26aufirst%3DB.%26aulast%3DVallis%26aufirst%3DK.%2BA.%26aulast%3DHammond%26aufirst%3DE.%2BM.%26aulast%3DOlcina%26aufirst%3DM.%2BM.%26aulast%3DGillies%2BMcKenna%26aufirst%3DW.%26aulast%3DMuschel%26aufirst%3DR.%2BJ.%26aulast%3DBrunner%26aufirst%3DT.%2BB.%26atitle%3DTargeting%2520ATR%2520in%2520vivo%2520using%2520the%2520novel%2520inhibitor%2520VE-822%2520results%2520in%2520selective%2520sensitization%2520of%2520pancreatic%2520tumors%2520to%2520radiation%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2012%26volume%3D3%26issue%3D12%26doi%3D10.1038%2Fcddis.2012.181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Min, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, S.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, D.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâConnor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bang, Y.-J.</span></span> <span> </span><span class="NLM_article-title">AZD6738, A novel oral inhibitor of ATR, induces synthetic lethality with ATM deficiency in gastric cancer cells</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">566</span>â <span class="NLM_lpage">577</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-16-0378</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F1535-7163.MCT-16-0378" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=28138034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2sXltlOqu7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=566-577&issue=4&author=A.+Minauthor=S.-A.+Imauthor=H.+Jangauthor=S.+Kimauthor=M.+Leeauthor=D.+K.+Kimauthor=Y.+Yangauthor=H.-J.+Kimauthor=K.-H.+Leeauthor=J.+W.+Kimauthor=T.-Y.+Kimauthor=D.-Y.+Ohauthor=J.+Brownauthor=A.+Lauauthor=M.+J.+O%E2%80%99Connorauthor=Y.-J.+Bang&title=AZD6738%2C+A+novel+oral+inhibitor+of+ATR%2C+induces+synthetic+lethality+with+ATM+deficiency+in+gastric+cancer+cells&doi=10.1158%2F1535-7163.MCT-16-0378"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells</span></div><div class="casAuthors">Min, Ahrum; Im, Seock-Ah; Jang, Hyemin; Kim, Seongyeong; Lee, Miso; Kim, Debora Keunyoung; Yang, Yaewon; Kim, Hee-Jun; Lee, Kyung-Hun; Kim, Jin Won; Kim, Tae-Yong; Oh, Do-Youn; Brown, Jeff; Lau, Alan; O'Connor, Mark J.; Bang, Yung-Jue</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">566-577</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Ataxia telangiectasia and Rad3-related (ATR) can be considered an attractive target for cancer treatment due to its deleterious effect on cancer cells harboring a homologous recombination defect.  The aim of this study was to investigate the potential use of the ATR inhibitor, AZD6738, to treat gastric cancer.  In SNU-601 cells with dysfunctional ATM, AZD6738 treatment led to an accumulation of DNA damage due to dysfunctional RAD51 foci formation, S phase arrest, and caspase 3-dependent apoptosis.  In contrast, SNU-484 cells with functional ATM were not sensitive to AZD6738.  Inhibition of ATM in SNU-484 cells enhanced AZD6738 sensitivity to a level comparable with that obsd. in SNU-601 cells, showing that activation of the ATM-Chk2 signaling pathway attenuates AZD6738 sensitivity.  In addn., decreased HDAC1 expression was found to be assocd. with ATM inactivation in SNU-601 cells, demonstrating the interaction between HDAC1 and ATM can affect sensitivity to AZD6738.  Furthermore, in an in vivo tumor xenograft mouse model, AZD6738 significantly suppressed tumor growth and increased apoptosis.  These findings suggest synthetic lethality between ATR inhibition and ATM deficiency in gastric cancer cells.  Further clin. studies on the interaction between AZD 6738 and ATM deficiency are warranted to develop novel treatment strategies for gastric cancer.  Mol Cancer Ther; 16(4); 566-77. Â©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoim-TGgofMcLVg90H21EOLACvtfcHk0liIL3Lzl0wkXA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXltlOqu7w%253D&md5=d84b1ad35d29bea19df290b8d6ac36a9</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0378&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0378%26sid%3Dliteratum%253Aachs%26aulast%3DMin%26aufirst%3DA.%26aulast%3DIm%26aufirst%3DS.-A.%26aulast%3DJang%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DD.%2BK.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DH.-J.%26aulast%3DLee%26aufirst%3DK.-H.%26aulast%3DKim%26aufirst%3DJ.%2BW.%26aulast%3DKim%26aufirst%3DT.-Y.%26aulast%3DOh%26aufirst%3DD.-Y.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DBang%26aufirst%3DY.-J.%26atitle%3DAZD6738%252C%2520A%2520novel%2520oral%2520inhibitor%2520of%2520ATR%252C%2520induces%2520synthetic%2520lethality%2520with%2520ATM%2520deficiency%2520in%2520gastric%2520cancer%2520cells%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2017%26volume%3D16%26issue%3D4%26spage%3D566%26epage%3D577%26doi%3D10.1158%2F1535-7163.MCT-16-0378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanjiv, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagenkort, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calderon-Montano, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koolmeister, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reaper, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortusewicz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacques, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuiper, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scobie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berglund, U. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helleday, T.</span></span> <span> </span><span class="NLM_article-title">Cancer-specific synthetic lethality between ATR and CHK1 kinase activities</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">3407</span>â <span class="NLM_lpage">3416</span>, <span class="refDoi">Â DOI: 10.1016/j.celrep.2016.12.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.celrep.2016.12.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=28009306" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFGnsrnL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=3407-3416&issue=12&author=K.+Sanjivauthor=A.+Hagenkortauthor=J.+M.+Calderon-Montanoauthor=T.+Koolmeisterauthor=P.+M.+Reaperauthor=O.+Mortusewiczauthor=S.+A.+Jacquesauthor=R.+V.+Kuiperauthor=N.+Schultzauthor=M.+Scobieauthor=P.+A.+Charltonauthor=J.+R.+Pollardauthor=U.+W.+Berglundauthor=M.+Altunauthor=T.+Helleday&title=Cancer-specific+synthetic+lethality+between+ATR+and+CHK1+kinase+activities&doi=10.1016%2Fj.celrep.2016.12.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities [Erratum to document cited in CA165:589929]</span></div><div class="casAuthors">Sanjiv, Kumar; Hagenkort, Anna; Calderon-Montano, Jose Manuel; Koolmeister, Tobias; Reaper, Philip M.; Mortusewicz, Oliver; Jacques, Sylvain A.; Kuiper, Raoul V.; Schultz, Niklas; Scobie, Martin; Charlton, Peter A.; Pollard, John R.; Berglund, Ulrika Warpman; Altun, Mikael; Helleday, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3407-3416</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-P9L07AcZ7bVg90H21EOLACvtfcHk0liIL3Lzl0wkXA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFGnsrnL&md5=1972b2221b3d31fb519def6fb70288e3</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2016.12.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2016.12.031%26sid%3Dliteratum%253Aachs%26aulast%3DSanjiv%26aufirst%3DK.%26aulast%3DHagenkort%26aufirst%3DA.%26aulast%3DCalderon-Montano%26aufirst%3DJ.%2BM.%26aulast%3DKoolmeister%26aufirst%3DT.%26aulast%3DReaper%26aufirst%3DP.%2BM.%26aulast%3DMortusewicz%26aufirst%3DO.%26aulast%3DJacques%26aufirst%3DS.%2BA.%26aulast%3DKuiper%26aufirst%3DR.%2BV.%26aulast%3DSchultz%26aufirst%3DN.%26aulast%3DScobie%26aufirst%3DM.%26aulast%3DCharlton%26aufirst%3DP.%2BA.%26aulast%3DPollard%26aufirst%3DJ.%2BR.%26aulast%3DBerglund%26aufirst%3DU.%2BW.%26aulast%3DAltun%26aufirst%3DM.%26aulast%3DHelleday%26aufirst%3DT.%26atitle%3DCancer-specific%2520synthetic%2520lethality%2520between%2520ATR%2520and%2520CHK1%2520kinase%2520activities%26jtitle%3DCell%2520Rep.%26date%3D2016%26volume%3D17%26issue%3D12%26spage%3D3407%26epage%3D3416%26doi%3D10.1016%2Fj.celrep.2016.12.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toledo, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmeyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rask, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lukas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Povlsen, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bekker-Jensen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mailand, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lukas, J.</span></span> <span> </span><span class="NLM_article-title">ATR prohibits replication catastrophe by preventing global exhaustion of RPA</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>155</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1088</span>â <span class="NLM_lpage">1103</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2013.10.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.cell.2013.10.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=24267891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFWitrnI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2013&pages=1088-1103&issue=5&author=L.+I.+Toledoauthor=M.+Altmeyerauthor=M.+B.+Raskauthor=C.+Lukasauthor=D.+H.+Larsenauthor=L.+K.+Povlsenauthor=S.+Bekker-Jensenauthor=N.+Mailandauthor=J.+Bartekauthor=J.+Lukas&title=ATR+prohibits+replication+catastrophe+by+preventing+global+exhaustion+of+RPA&doi=10.1016%2Fj.cell.2013.10.043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">ATR prohibits replication catastrophe by preventing global exhaustion of RPA</span></div><div class="casAuthors">Toledo, Luis Ignacio; Altmeyer, Matthias; Rask, Maj-Britt; Lukas, Claudia; Larsen, Dorthe Helena; Povlsen, Lou Klitgaard; Bekker-Jensen, Simon; Mailand, Niels; Bartek, Jiri; Lukas, Jiri</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1088-1103</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">ATR, activated by replication stress, protects replication forks locally and suppresses origin firing globally.  Here, we show that these functions of ATR are mechanistically coupled.  Although initially stable, stalled forks in ATR-deficient cells undergo nucleus-wide breakage after unscheduled origin firing generates an excess of single-stranded DNA that exhausts the nuclear pool of RPA.  Partial redn. of RPA accelerated fork breakage, and forced elevation of RPA was sufficient to delay such "replication catastrophe" even in the absence of ATR activity.  Conversely, unscheduled origin firing induced breakage of stalled forks even in cells with active ATR.  Thus, ATR-mediated suppression of dormant origins shields active forks against irreversible breakage via preventing exhaustion of nuclear RPA.  This study elucidates how replicating genomes avoid destabilizing DNA damage.  Because cancer cells commonly feature intrinsically high replication stress, this study also provides a mol. rationale for their hypersensitivity to ATR inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozN6VLaiVbCbVg90H21EOLACvtfcHk0ljQLY7nAVsLTA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFWitrnI&md5=1e7faf5c8a8af17c3a3797d1dce3aa51</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2013.10.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2013.10.043%26sid%3Dliteratum%253Aachs%26aulast%3DToledo%26aufirst%3DL.%2BI.%26aulast%3DAltmeyer%26aufirst%3DM.%26aulast%3DRask%26aufirst%3DM.%2BB.%26aulast%3DLukas%26aufirst%3DC.%26aulast%3DLarsen%26aufirst%3DD.%2BH.%26aulast%3DPovlsen%26aufirst%3DL.%2BK.%26aulast%3DBekker-Jensen%26aufirst%3DS.%26aulast%3DMailand%26aufirst%3DN.%26aulast%3DBartek%26aufirst%3DJ.%26aulast%3DLukas%26aufirst%3DJ.%26atitle%3DATR%2520prohibits%2520replication%2520catastrophe%2520by%2520preventing%2520global%2520exhaustion%2520of%2520RPA%26jtitle%3DCell%26date%3D2013%26volume%3D155%26issue%3D5%26spage%3D1088%26epage%3D1103%26doi%3D10.1016%2Fj.cell.2013.10.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Charrier, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durrant, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golec, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knegtel, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacCormick, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortimore, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâDonnell, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinder, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reaper, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutherford, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J. R.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2320</span>â <span class="NLM_lpage">2330</span>, <span class="refDoi">Â DOI: 10.1021/jm101488z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101488z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsVCksbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2320-2330&issue=7&author=J.+D.+Charrierauthor=S.+J.+Durrantauthor=J.+M.+Golecauthor=D.+P.+Kayauthor=R.+M.+Knegtelauthor=S.+MacCormickauthor=M.+Mortimoreauthor=M.+E.+O%E2%80%99Donnellauthor=J.+L.+Pinderauthor=P.+M.+Reaperauthor=A.+P.+Rutherfordauthor=P.+S.+Wangauthor=S.+C.+Youngauthor=J.+R.+Pollard&title=Discovery+of+potent+and+selective+inhibitors+of+ataxia+telangiectasia+mutated+and+Rad3+related+%28ATR%29+protein+kinase+as+potential+anticancer+agents&doi=10.1021%2Fjm101488z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase as Potential Anticancer Agents</span></div><div class="casAuthors">Charrier, Jean-Damien; Durrant, Steven J.; Golec, Julian M. C.; Kay, David P.; Knegtel, Ronald M. A.; MacCormick, Somhairle; Mortimore, Michael; O'Donnell, Michael E.; Pinder, Joanne L.; Reaper, Philip M.; Rutherford, Alistair P.; Wang, Paul S. H.; Young, Stephen C.; Pollard, John R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2320-2330</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">DNA-damaging agents are among the most frequently used anticancer drugs.  However, they provide only modest benefit in most cancers.  This may be attributed to a genome maintenance network, the DNA damage response (DDR), that recognizes and repairs damaged DNA.  ATR is a major regulator of the DDR and an attractive anticancer target.  Herein, we describe the discovery of a series of aminopyrazines with potent and selective ATR inhibition.  Compd. (I) inhibits ATR with a Ki of 6 nM, shows >600-fold selectivity over related kinases ATM or DNA-PK, and blocks ATR signaling in cells with an IC50 of 0.42 Î¼M.  Using I, here it is shown that ATR inhibition markedly enhances death induced by DNA-damaging agents in certain cancers but not normal cells.  This differential response between cancer and normal cells highlights the great potential for ATR inhibition as a novel mechanism to dramatically increase the efficacy of many established drugs and ionizing radiation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp56O6NNQ8JNbVg90H21EOLACvtfcHk0ljQLY7nAVsLTA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsVCksbc%253D&md5=4f17e7c44fc6c7bdc32886e3415722c8</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1021%2Fjm101488z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101488z%26sid%3Dliteratum%253Aachs%26aulast%3DCharrier%26aufirst%3DJ.%2BD.%26aulast%3DDurrant%26aufirst%3DS.%2BJ.%26aulast%3DGolec%26aufirst%3DJ.%2BM.%26aulast%3DKay%26aufirst%3DD.%2BP.%26aulast%3DKnegtel%26aufirst%3DR.%2BM.%26aulast%3DMacCormick%26aufirst%3DS.%26aulast%3DMortimore%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DM.%2BE.%26aulast%3DPinder%26aufirst%3DJ.%2BL.%26aulast%3DReaper%26aufirst%3DP.%2BM.%26aulast%3DRutherford%26aufirst%3DA.%2BP.%26aulast%3DWang%26aufirst%3DP.%2BS.%26aulast%3DYoung%26aufirst%3DS.%2BC.%26aulast%3DPollard%26aufirst%3DJ.%2BR.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520selective%2520inhibitors%2520of%2520ataxia%2520telangiectasia%2520mutated%2520and%2520Rad3%2520related%2520%2528ATR%2529%2520protein%2520kinase%2520as%2520potential%2520anticancer%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D7%26spage%3D2320%26epage%3D2330%26doi%3D10.1021%2Fjm101488z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knegtel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charrier, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durrant, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâDonnell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storck, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacCormick, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinder, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Twin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reaper, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Littlewood, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golec, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J.</span></span> <span> </span><span class="NLM_article-title">Rational design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): optimization of intra- and intermolecular polar interactions of a new ataxia telangiectasia mutated and Rad3-related (ATR) kinase inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">5547</span>â <span class="NLM_lpage">5561</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.9b00426</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00426" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1MXptlKrtLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=5547-5561&issue=11&author=R.+Knegtelauthor=J.+D.+Charrierauthor=S.+Durrantauthor=C.+Davisauthor=M.+O%E2%80%99Donnellauthor=P.+Storckauthor=S.+MacCormickauthor=D.+Kayauthor=J.+Pinderauthor=A.+Viraniauthor=H.+Twinauthor=M.+Griffithsauthor=P.+Reaperauthor=P.+Littlewoodauthor=S.+Youngauthor=J.+Golecauthor=J.+Pollard&title=Rational+design+of+5-%284-%28Isopropylsulfonyl%29phenyl%29-3-%283-%284-%28%28methylamino%29methyl%29phenyl%29isoxazol-5-yl%29pyrazin-2-amine+%28VX-970%2C+M6620%29%3A+optimization+of+intra-+and+intermolecular+polar+interactions+of+a+new+ataxia+telangiectasia+mutated+and+Rad3-related+%28ATR%29+kinase+inhibitor&doi=10.1021%2Facs.jmedchem.9b00426"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of Intra- and Intermolecular Polar Interactions of a New Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase Inhibitor</span></div><div class="casAuthors">Knegtel, Ronald; Charrier, Jean-Damien; Durrant, Steven; Davis, Chris; O'Donnell, Michael; Storck, Pierre; MacCormick, Somhairle; Kay, David; Pinder, Joanne; Virani, Anisa; Twin, Heather; Griffiths, Matthew; Reaper, Philip; Littlewood, Peter; Young, Steve; Golec, Julian; Pollard, John</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5547-5561</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The DNA damage response (DDR) is a DNA damage surveillance and repair mechanism that can limit the effectiveness of radiotherapy and DNA-damaging chemotherapy, commonly used treatment modalities in cancer.  Two related kinases, ataxia telangiectasia mutated (ATM) and ATM and Rad3-related kinase (ATR), work together as apical proteins in the DDR to maintain genome stability and cell survival in the face of potentially lethal forms of DNA damage.  However, compromised ATM signaling is a common characteristic of tumor cells, which places greater reliance on ATR to mediate the DDR.  In such circumstances, ATR inhibition has been shown to enhance the toxicity of DNA damaging chemotherapy to many cancer cells in multiple preclin. studies, while healthy tissue with functional ATM can tolerate ATR inhibition.  ATR therefore represents a very attractive anticancer target.  Herein we describe the discovery of VX-970/M6620, the first ATR inhibitor to enter clin. studies, which is based on a 2-aminopyrazine core first reported by Charrier.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn8wwwZ4Hh_rVg90H21EOLACvtfcHk0ljQLY7nAVsLTA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXptlKrtLc%253D&md5=1dfc9458dc23210b4e8fac71c81e966e</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00426&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00426%26sid%3Dliteratum%253Aachs%26aulast%3DKnegtel%26aufirst%3DR.%26aulast%3DCharrier%26aufirst%3DJ.%2BD.%26aulast%3DDurrant%26aufirst%3DS.%26aulast%3DDavis%26aufirst%3DC.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DM.%26aulast%3DStorck%26aufirst%3DP.%26aulast%3DMacCormick%26aufirst%3DS.%26aulast%3DKay%26aufirst%3DD.%26aulast%3DPinder%26aufirst%3DJ.%26aulast%3DVirani%26aufirst%3DA.%26aulast%3DTwin%26aufirst%3DH.%26aulast%3DGriffiths%26aufirst%3DM.%26aulast%3DReaper%26aufirst%3DP.%26aulast%3DLittlewood%26aufirst%3DP.%26aulast%3DYoung%26aufirst%3DS.%26aulast%3DGolec%26aufirst%3DJ.%26aulast%3DPollard%26aufirst%3DJ.%26atitle%3DRational%2520design%2520of%25205-%25284-%2528Isopropylsulfonyl%2529phenyl%2529-3-%25283-%25284-%2528%2528methylamino%2529methyl%2529phenyl%2529isoxazol-5-yl%2529pyrazin-2-amine%2520%2528VX-970%252C%2520M6620%2529%253A%2520optimization%2520of%2520intra-%2520and%2520intermolecular%2520polar%2520interactions%2520of%2520a%2520new%2520ataxia%2520telangiectasia%2520mutated%2520and%2520Rad3-related%2520%2528ATR%2529%2520kinase%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D11%26spage%3D5547%26epage%3D5561%26doi%3D10.1021%2Facs.jmedchem.9b00426" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">OâCarrigan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Miguel Luken, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadatos-Pastos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tunariu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez Lopez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganegoda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riisnaes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figueiredo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreira, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hare, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penney, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerji, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Bono, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fields, S. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, T. A.</span></span> <span> </span><span class="NLM_article-title">Phase I trial of a first-in-class ATR inhibitor VX-970 as monotherapy (mono) or in combination (combo) with carboplatin (CP) incorporating pharmacodynamics (PD) studies</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">15_suppl</span>),  <span class="NLM_fpage">2504</span>, <span class="refDoi">Â DOI: 10.1200/JCO.2016.34.15_suppl.2504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1200%2FJCO.2016.34.15_suppl.2504" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=2504&issue=15_suppl&author=B.+O%E2%80%99Carriganauthor=M.+J.+de+Miguel+Lukenauthor=D.+Papadatos-Pastosauthor=J.+Brownauthor=N.+Tunariuauthor=R.+Perez+Lopezauthor=M.+Ganegodaauthor=R.+Riisnaesauthor=I.+Figueiredoauthor=S.+Carreiraauthor=B.+Hareauthor=F.+Yangauthor=K.+McDermottauthor=M.+S.+Penneyauthor=J.+Pollardauthor=J.+S.+Lopezauthor=U.+Banerjiauthor=J.+S.+De+Bonoauthor=S.+Z.+Fieldsauthor=T.+A.+Yap&title=Phase+I+trial+of+a+first-in-class+ATR+inhibitor+VX-970+as+monotherapy+%28mono%29+or+in+combination+%28combo%29+with+carboplatin+%28CP%29+incorporating+pharmacodynamics+%28PD%29+studies&doi=10.1200%2FJCO.2016.34.15_suppl.2504"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1200%2FJCO.2016.34.15_suppl.2504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2016.34.15_suppl.2504%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Carrigan%26aufirst%3DB.%26aulast%3Dde%2BMiguel%2BLuken%26aufirst%3DM.%2BJ.%26aulast%3DPapadatos-Pastos%26aufirst%3DD.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DTunariu%26aufirst%3DN.%26aulast%3DPerez%2BLopez%26aufirst%3DR.%26aulast%3DGanegoda%26aufirst%3DM.%26aulast%3DRiisnaes%26aufirst%3DR.%26aulast%3DFigueiredo%26aufirst%3DI.%26aulast%3DCarreira%26aufirst%3DS.%26aulast%3DHare%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DMcDermott%26aufirst%3DK.%26aulast%3DPenney%26aufirst%3DM.%2BS.%26aulast%3DPollard%26aufirst%3DJ.%26aulast%3DLopez%26aufirst%3DJ.%2BS.%26aulast%3DBanerji%26aufirst%3DU.%26aulast%3DDe%2BBono%26aufirst%3DJ.%2BS.%26aulast%3DFields%26aufirst%3DS.%2BZ.%26aulast%3DYap%26aufirst%3DT.%2BA.%26atitle%3DPhase%2520I%2520trial%2520of%2520a%2520first-in-class%2520ATR%2520inhibitor%2520VX-970%2520as%2520monotherapy%2520%2528mono%2529%2520or%2520in%2520combination%2520%2528combo%2529%2520with%2520carboplatin%2520%2528CP%2529%2520incorporating%2520pharmacodynamics%2520%2528PD%2529%2520studies%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2016%26volume%3D34%26issue%3D15_suppl%26spage%3D2504%26doi%3D10.1200%2FJCO.2016.34.15_suppl.2504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yap, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Miguel Luken, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâCarrigan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roda, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadatos-Pastos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorente, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tunariu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gayle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riisnaes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figueiredo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miranda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreira, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penney, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molife, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerji, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asmal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fields, S. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bono, J. S.</span></span> <span> </span><span class="NLM_article-title">Abstract PR14: Phase I trial of first-in-class ataxia telangiectasia-mutated and Rad3-related (ATR) inhibitor VX-970 as monotherapy (mono) or in combination with carboplatin (CP) in advanced cancer patients (pts) with preliminary evidence of target modulation and antitumor activity</span>. <i>Mol. Cancer. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">12, Suppl. 2</span>), <span class="NLM_elocation-id">PR14</span> <span class="refDoi">Â DOI: 10.1158/1535-7163.TARG-15-PR14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F1535-7163.TARG-15-PR14" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&issue=12%2C+Suppl.+2&author=T.+A.+Yapauthor=M.+J.+de+Miguel+Lukenauthor=B.+O%E2%80%99Carriganauthor=D.+Rodaauthor=D.+Papadatos-Pastosauthor=D.+Lorenteauthor=N.+Tunariuauthor=R.+P.+Lopezauthor=S.+Gayleauthor=R.+Riisnaesauthor=I.+Figueiredoauthor=S.+Mirandaauthor=S.+Carreiraauthor=F.+Yangauthor=S.+Karanauthor=M.+Penneyauthor=J.+Pollardauthor=L.+R.+Molifeauthor=U.+Banerjiauthor=M.+Asmalauthor=S.+Z.+Fieldsauthor=J.+S.+de+Bono&title=Abstract+PR14%3A+Phase+I+trial+of+first-in-class+ataxia+telangiectasia-mutated+and+Rad3-related+%28ATR%29+inhibitor+VX-970+as+monotherapy+%28mono%29+or+in+combination+with+carboplatin+%28CP%29+in+advanced+cancer+patients+%28pts%29+with+preliminary+evidence+of+target+modulation+and+antitumor+activity&doi=10.1158%2F1535-7163.TARG-15-PR14"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.TARG-15-PR14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.TARG-15-PR14%26sid%3Dliteratum%253Aachs%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3Dde%2BMiguel%2BLuken%26aufirst%3DM.%2BJ.%26aulast%3DO%25E2%2580%2599Carrigan%26aufirst%3DB.%26aulast%3DRoda%26aufirst%3DD.%26aulast%3DPapadatos-Pastos%26aufirst%3DD.%26aulast%3DLorente%26aufirst%3DD.%26aulast%3DTunariu%26aufirst%3DN.%26aulast%3DLopez%26aufirst%3DR.%2BP.%26aulast%3DGayle%26aufirst%3DS.%26aulast%3DRiisnaes%26aufirst%3DR.%26aulast%3DFigueiredo%26aufirst%3DI.%26aulast%3DMiranda%26aufirst%3DS.%26aulast%3DCarreira%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DKaran%26aufirst%3DS.%26aulast%3DPenney%26aufirst%3DM.%26aulast%3DPollard%26aufirst%3DJ.%26aulast%3DMolife%26aufirst%3DL.%2BR.%26aulast%3DBanerji%26aufirst%3DU.%26aulast%3DAsmal%26aufirst%3DM.%26aulast%3DFields%26aufirst%3DS.%2BZ.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26atitle%3DAbstract%2520PR14%253A%2520Phase%2520I%2520trial%2520of%2520first-in-class%2520ataxia%2520telangiectasia-mutated%2520and%2520Rad3-related%2520%2528ATR%2529%2520inhibitor%2520VX-970%2520as%2520monotherapy%2520%2528mono%2529%2520or%2520in%2520combination%2520with%2520carboplatin%2520%2528CP%2529%2520in%2520advanced%2520cancer%2520patients%2520%2528pts%2529%2520with%2520preliminary%2520evidence%2520of%2520target%2520modulation%2520and%2520antitumor%2520activity%26jtitle%3DMol.%2520Cancer.%2520Ther.%26date%3D2015%26volume%3D14%26issue%3D12%252C%2520Suppl.%25202%26doi%3D10.1158%2F1535-7163.TARG-15-PR14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wesolowski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devoe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constantinidou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadatos-Pastos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fricano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penney, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asmal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renshaw, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fields, S. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, T. A.</span></span> <span> </span><span class="NLM_article-title">Abstract CT012: phase 1 trial of first-in-class ATR inhibitor VX-970 in combination with cisplatin (Cis) in patients (pts) with advanced solid tumors (NCT02157792)</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span> (<span class="NLM_issue">14, Suppl.</span>), <span class="NLM_elocation-id">CT012</span> <span class="refDoi">Â DOI: 10.1158/1538-7445.AM2016-CT012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F1538-7445.AM2016-CT012" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&issue=14%2C+Suppl.&author=G.+Shapiroauthor=R.+Wesolowskiauthor=M.+Middletonauthor=C.+Devoeauthor=A.+Constantinidouauthor=D.+Papadatos-Pastosauthor=M.+Fricanoauthor=Y.+Zhangauthor=S.+Karanauthor=J.+Pollardauthor=M.+Penneyauthor=M.+Asmalauthor=F.+G.+Renshawauthor=S.+Z.+Fieldsauthor=T.+A.+Yap&title=Abstract+CT012%3A+phase+1+trial+of+first-in-class+ATR+inhibitor+VX-970+in+combination+with+cisplatin+%28Cis%29+in+patients+%28pts%29+with+advanced+solid+tumors+%28NCT02157792%29&doi=10.1158%2F1538-7445.AM2016-CT012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2016-CT012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2016-CT012%26sid%3Dliteratum%253Aachs%26aulast%3DShapiro%26aufirst%3DG.%26aulast%3DWesolowski%26aufirst%3DR.%26aulast%3DMiddleton%26aufirst%3DM.%26aulast%3DDevoe%26aufirst%3DC.%26aulast%3DConstantinidou%26aufirst%3DA.%26aulast%3DPapadatos-Pastos%26aufirst%3DD.%26aulast%3DFricano%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DKaran%26aufirst%3DS.%26aulast%3DPollard%26aufirst%3DJ.%26aulast%3DPenney%26aufirst%3DM.%26aulast%3DAsmal%26aufirst%3DM.%26aulast%3DRenshaw%26aufirst%3DF.%2BG.%26aulast%3DFields%26aufirst%3DS.%2BZ.%26aulast%3DYap%26aufirst%3DT.%2BA.%26atitle%3DAbstract%2520CT012%253A%2520phase%25201%2520trial%2520of%2520first-in-class%2520ATR%2520inhibitor%2520VX-970%2520in%2520combination%2520with%2520cisplatin%2520%2528Cis%2529%2520in%2520patients%2520%2528pts%2529%2520with%2520advanced%2520solid%2520tumors%2520%2528NCT02157792%2529%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26issue%3D14%252C%2520Suppl%26doi%3D10.1158%2F1538-7445.AM2016-CT012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Plummer, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, T. R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greystoke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbschleb, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penney, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asmal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fields, S. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, M. R.</span></span> <span> </span><span class="NLM_article-title">Phase I trial of first-in-class ATR inhibitor VX-970 in combination with gemcitabine (Gem) in advanced solid tumors (NCT02157792)</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">15_suppl</span>),  <span class="NLM_fpage">2513</span>, <span class="refDoi">Â DOI: 10.1200/JCO.2016.34.15_suppl.2513</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1200%2FJCO.2016.34.15_suppl.2513" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=2513&issue=15_suppl&author=E.+R.+Plummerauthor=E.+J.+Deanauthor=T.+R.+J.+Evansauthor=A.+Greystokeauthor=K.+Herbschlebauthor=M.+Ransonauthor=J.+Brownauthor=Y.+Zhangauthor=S.+Karanauthor=J.+Pollardauthor=M.+S.+Penneyauthor=M.+Asmalauthor=S.+Z.+Fieldsauthor=M.+R.+Middleton&title=Phase+I+trial+of+first-in-class+ATR+inhibitor+VX-970+in+combination+with+gemcitabine+%28Gem%29+in+advanced+solid+tumors+%28NCT02157792%29&doi=10.1200%2FJCO.2016.34.15_suppl.2513"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1200%2FJCO.2016.34.15_suppl.2513&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2016.34.15_suppl.2513%26sid%3Dliteratum%253Aachs%26aulast%3DPlummer%26aufirst%3DE.%2BR.%26aulast%3DDean%26aufirst%3DE.%2BJ.%26aulast%3DEvans%26aufirst%3DT.%2BR.%2BJ.%26aulast%3DGreystoke%26aufirst%3DA.%26aulast%3DHerbschleb%26aufirst%3DK.%26aulast%3DRanson%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DKaran%26aufirst%3DS.%26aulast%3DPollard%26aufirst%3DJ.%26aulast%3DPenney%26aufirst%3DM.%2BS.%26aulast%3DAsmal%26aufirst%3DM.%26aulast%3DFields%26aufirst%3DS.%2BZ.%26aulast%3DMiddleton%26aufirst%3DM.%2BR.%26atitle%3DPhase%2520I%2520trial%2520of%2520first-in-class%2520ATR%2520inhibitor%2520VX-970%2520in%2520combination%2520with%2520gemcitabine%2520%2528Gem%2529%2520in%2520advanced%2520solid%2520tumors%2520%2528NCT02157792%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2016%26volume%3D34%26issue%3D15_suppl%26spage%3D2513%26doi%3D10.1200%2FJCO.2016.34.15_suppl.2513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zenke, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahmen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elenbaas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reaper, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagrodia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spilker, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amendt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaukat, A.</span></span> <span> </span><span class="NLM_article-title">Abstract 369: Antitumor activity of M4344, a potent and selective ATR inhibitor, in monotherapy and combination therapy</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span> (<span class="NLM_issue">13, Suppl.</span>),  <span class="NLM_fpage">369</span>, <span class="refDoi">Â DOI: 10.1158/1538-7445.AM2019-369</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F1538-7445.AM2019-369" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=369&issue=13%2C+Suppl.&author=F.+T.+Zenkeauthor=A.+Zimmermannauthor=H.+Dahmenauthor=B.+Elenbaasauthor=J.+Pollardauthor=P.+Reaperauthor=S.+Bagrodiaauthor=M.+E.+Spilkerauthor=C.+Amendtauthor=A.+Blaukat&title=Abstract+369%3A+Antitumor+activity+of+M4344%2C+a+potent+and+selective+ATR+inhibitor%2C+in+monotherapy+and+combination+therapy&doi=10.1158%2F1538-7445.AM2019-369"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2019-369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2019-369%26sid%3Dliteratum%253Aachs%26aulast%3DZenke%26aufirst%3DF.%2BT.%26aulast%3DZimmermann%26aufirst%3DA.%26aulast%3DDahmen%26aufirst%3DH.%26aulast%3DElenbaas%26aufirst%3DB.%26aulast%3DPollard%26aufirst%3DJ.%26aulast%3DReaper%26aufirst%3DP.%26aulast%3DBagrodia%26aufirst%3DS.%26aulast%3DSpilker%26aufirst%3DM.%2BE.%26aulast%3DAmendt%26aufirst%3DC.%26aulast%3DBlaukat%26aufirst%3DA.%26atitle%3DAbstract%2520369%253A%2520Antitumor%2520activity%2520of%2520M4344%252C%2520a%2520potent%2520and%2520selective%2520ATR%2520inhibitor%252C%2520in%2520monotherapy%2520and%2520combination%2520therapy%26jtitle%3DCancer%2520Res.%26date%3D2019%26volume%3D79%26issue%3D13%252C%2520Suppl%26spage%3D369%26doi%3D10.1158%2F1538-7445.AM2019-369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wortmann, L.</span>; <span class="NLM_string-name">Lucking, U.</span>; <span class="NLM_string-name">Lefranc, J.</span>; <span class="NLM_string-name">Briem, H.</span>; <span class="NLM_string-name">Koppitz, M.</span>; <span class="NLM_string-name">Eis, K.</span>; <span class="NLM_string-name">Von Nussbaum, F.</span>; <span class="NLM_string-name">Bader, B.</span>; <span class="NLM_string-name">Wegner, A. M.</span>; <span class="NLM_string-name">Siemeister, G.</span>; <span class="NLM_string-name">Bone, W.</span>; <span class="NLM_string-name">Lienau, P.</span>; <span class="NLM_string-name">Grudzinska-Goebel, J.</span>; <span class="NLM_string-name">Mossmayer, D.</span>; <span class="NLM_string-name">EberspÃ¤cher, U.</span>; <span class="NLM_string-name">Schick, H.</span></span> <span> </span><span class="NLM_article-title">2-Morpholin-yl)-1,7-naphythridines</span>. <span class="NLM_patent">WO/2016/020320</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=L.+Wortmann&author=U.+Lucking&author=J.+Lefranc&author=H.+Briem&author=M.+Koppitz&author=K.+Eis&author=F.+Von+Nussbaum&author=B.+Bader&author=A.+M.+Wegner&author=G.+Siemeister&author=W.+Bone&author=P.+Lienau&author=J.+Grudzinska-Goebel&author=D.+Mossmayer&author=U.+Ebersp%C3%A4cher&author=H.+Schick&title=2-Morpholin-yl%29-1%2C7-naphythridines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWortmann%26aufirst%3DL.%26atitle%3D2-Morpholin-yl%2529-1%252C7-naphythridines%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wengner, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siemeister, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucking, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefranc, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wortmann, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lienau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bomer, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moosmayer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberspacher, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golfier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schatz, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumgart, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haendler, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lejeune, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlicker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Nussbaum, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brands, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegelbauer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mumberg, D.</span></span> <span> </span><span class="NLM_article-title">The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage-inducing or repair-compromising rherapies in preclinical cancer models</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">26</span>â <span class="NLM_lpage">38</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-19-0019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F1535-7163.MCT-19-0019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=31582533" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvVOltbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2020&pages=26-38&issue=1&author=A.+M.+Wengnerauthor=G.+Siemeisterauthor=U.+Luckingauthor=J.+Lefrancauthor=L.+Wortmannauthor=P.+Lienauauthor=B.+Baderauthor=U.+Bomerauthor=D.+Moosmayerauthor=U.+Eberspacherauthor=S.+Golfierauthor=C.+A.+Schatzauthor=S.+J.+Baumgartauthor=B.+Haendlerauthor=P.+Lejeuneauthor=A.+Schlickerauthor=F.+von+Nussbaumauthor=M.+Brandsauthor=K.+Ziegelbauerauthor=D.+Mumberg&title=The+novel+ATR+inhibitor+BAY+1895344+is+efficacious+as+monotherapy+and+combined+with+DNA+damage-inducing+or+repair-compromising+rherapies+in+preclinical+cancer+models&doi=10.1158%2F1535-7163.MCT-19-0019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage-inducing or repair-compromising therapies in preclinical cancer models</span></div><div class="casAuthors">Wengner, Antje M.; Siemeister, Gerhard; Luecking, Ulrich; Lefranc, Julien; Wortmann, Lars; Lienau, Philip; Bader, Benjamin; Boemer, Ulf; Moosmayer, Dieter; Eberspaecher, Uwe; Golfier, Sven; Schatz, Christoph A.; Baumgart, Simon J.; Haendler, Bernard; Lejeune, Pascale; Schlicker, Andreas; von Nussbaum, Franz; Brands, Michael; Ziegelbauer, Karl; Mumberg, Dominik</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">26-38</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The DNA damage response (DDR) secures the integrity of the genome of eukaryotic cells.  Here, we studied the effect of the novel selective ATR kinase inhibitor BAY 1895344 on tumor cell growth and viability.  Potent anti-proliferative activity was demonstrated in a broad spectrum of human tumor cell lines.  BAY 1895344 exhibited strong monotherapy efficacy in cancer xenograft models that carry DNA damage repair deficiencies.  The combination of BAY 1895344 with DNA damage-inducing chemotherapy or external beam radiation therapy (EBRT) showed synergistic anti-tumor activity.  Combination treatment with BAY 1895344 and DDR inhibitors achieved strong synergistic anti-proliferative activity in vitro, and combined inhibition of ATR and poly (ADP-ribose) polymerase (PARP) signaling using olaparib demonstrated synergistic anti-tumor activity in vivo.  Furthermore, the combination of BAY 1895344 with the novel, non-steroidal androgen receptor antagonist darolutamide resulted in significantly improved anti-tumor efficacy compared to resp. single agent treatments in hormone-dependent prostate cancer, and addn. of EBRT resulted in even further enhanced anti-tumor efficacy.  Thus, the ATR inhibitor BAY 1895344 may provide new therapeutic options for the treatment of cancers with certain DDR deficiencies in monotherapy and in combination with DNA damage-inducing or DNA repair-compromising cancer therapies by improving their efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9lU-o29OtpbVg90H21EOLACvtfcHk0lh8ftWQVZzCqA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvVOltbo%253D&md5=a44cff693597322209acf8e07282fe5d</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-19-0019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-19-0019%26sid%3Dliteratum%253Aachs%26aulast%3DWengner%26aufirst%3DA.%2BM.%26aulast%3DSiemeister%26aufirst%3DG.%26aulast%3DLucking%26aufirst%3DU.%26aulast%3DLefranc%26aufirst%3DJ.%26aulast%3DWortmann%26aufirst%3DL.%26aulast%3DLienau%26aufirst%3DP.%26aulast%3DBader%26aufirst%3DB.%26aulast%3DBomer%26aufirst%3DU.%26aulast%3DMoosmayer%26aufirst%3DD.%26aulast%3DEberspacher%26aufirst%3DU.%26aulast%3DGolfier%26aufirst%3DS.%26aulast%3DSchatz%26aufirst%3DC.%2BA.%26aulast%3DBaumgart%26aufirst%3DS.%2BJ.%26aulast%3DHaendler%26aufirst%3DB.%26aulast%3DLejeune%26aufirst%3DP.%26aulast%3DSchlicker%26aufirst%3DA.%26aulast%3Dvon%2BNussbaum%26aufirst%3DF.%26aulast%3DBrands%26aufirst%3DM.%26aulast%3DZiegelbauer%26aufirst%3DK.%26aulast%3DMumberg%26aufirst%3DD.%26atitle%3DThe%2520novel%2520ATR%2520inhibitor%2520BAY%25201895344%2520is%2520efficacious%2520as%2520monotherapy%2520and%2520combined%2520with%2520DNA%2520damage-inducing%2520or%2520repair-compromising%2520rherapies%2520in%2520preclinical%2520cancer%2520models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2020%26volume%3D19%26issue%3D1%26spage%3D26%26epage%3D38%26doi%3D10.1158%2F1535-7163.MCT-19-0019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foote, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blades, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cronin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fillery, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guichard, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassall, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacq, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewsbury, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissink, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odedra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suleman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thommes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broadhurst, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2125</span>â <span class="NLM_lpage">2138</span>, <span class="refDoi">Â DOI: 10.1021/jm301859s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301859s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3sXit1Ghsr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=2125-2138&issue=5&author=K.+M.+Footeauthor=K.+Bladesauthor=A.+Croninauthor=S.+Filleryauthor=S.+S.+Guichardauthor=L.+Hassallauthor=I.+Hicksonauthor=X.+Jacqauthor=P.+J.+Jewsburyauthor=T.+M.+McGuireauthor=J.+W.+Nissinkauthor=R.+Odedraauthor=K.+Pageauthor=P.+Perkinsauthor=A.+Sulemanauthor=K.+Tamauthor=P.+Thommesauthor=R.+Broadhurstauthor=C.+Wood&title=Discovery+of+4-%7B4-%5B%283R%29-3-Methylmorpholin-4-yl%5D-6-%5B1-%28methylsulfonyl%29cyclopropyl%5Dpyrimidin-2-yl%7D-1H-indole+%28AZ20%29%3A+a+potent+and+selective+inhibitor+of+ATR+protein+kinase+with+monotherapy+in+vivo+antitumor+activity&doi=10.1021%2Fjm301859s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): A Potent and Selective Inhibitor of ATR Protein Kinase with Monotherapy in Vivo Antitumor Activity</span></div><div class="casAuthors">Foote, Kevin M.; Blades, Kevin; Cronin, Anna; Fillery, Shaun; Guichard, Sylvie S.; Hassall, Lorraine; Hickson, Ian; Jacq, Xavier; Jewsbury, Philip J.; McGuire, Thomas M.; Nissink, J. Willem M.; Odedra, Rajesh; Page, Ken; Perkins, Paula; Suleman, Abid; Tam, Kin; Thommes, Pia; Broadhurst, Rebecca; Wood, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2125-2138</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">ATR is an attractive new anticancer drug target whose inhibitors have potential as chemo- or radiation sensitizers or as monotherapy in tumors addicted to particular DNA-repair pathways.  We describe the discovery and synthesis of a series of sulfonylmorpholinopyrimidines that show potent and selective ATR inhibition.  Optimization from a high quality screening hit within tight SAR space led to compd. I (AZ20) which inhibits ATR immunopptd. from HeLa nuclear exts. with an IC50 of 5 nM and ATR mediated phosphorylation of Chk1 in HT29 colorectal adenocarcinoma tumor cells with an IC50 of 50 nM.  Compd. I potently inhibits the growth of LoVo colorectal adenocarcinoma tumor cells in vitro and has high free exposure in mouse following moderate oral doses.  At well tolerated doses I leads to significant growth inhibition of LoVo xenografts grown in nude mice.  Compd. I is a useful compd. to explore ATR pharmacol. in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpY5_RVxXl9LVg90H21EOLACvtfcHk0ljcGxiLgJSrcg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXit1Ghsr0%253D&md5=60d2f6fe78e2b82695198b9cba930ae7</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Fjm301859s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301859s%26sid%3Dliteratum%253Aachs%26aulast%3DFoote%26aufirst%3DK.%2BM.%26aulast%3DBlades%26aufirst%3DK.%26aulast%3DCronin%26aufirst%3DA.%26aulast%3DFillery%26aufirst%3DS.%26aulast%3DGuichard%26aufirst%3DS.%2BS.%26aulast%3DHassall%26aufirst%3DL.%26aulast%3DHickson%26aufirst%3DI.%26aulast%3DJacq%26aufirst%3DX.%26aulast%3DJewsbury%26aufirst%3DP.%2BJ.%26aulast%3DMcGuire%26aufirst%3DT.%2BM.%26aulast%3DNissink%26aufirst%3DJ.%2BW.%26aulast%3DOdedra%26aufirst%3DR.%26aulast%3DPage%26aufirst%3DK.%26aulast%3DPerkins%26aufirst%3DP.%26aulast%3DSuleman%26aufirst%3DA.%26aulast%3DTam%26aufirst%3DK.%26aulast%3DThommes%26aufirst%3DP.%26aulast%3DBroadhurst%26aufirst%3DR.%26aulast%3DWood%26aufirst%3DC.%26atitle%3DDiscovery%2520of%25204-%257B4-%255B%25283R%2529-3-Methylmorpholin-4-yl%255D-6-%255B1-%2528methylsulfonyl%2529cyclopropyl%255Dpyrimidin-2-yl%257D-1H-indole%2520%2528AZ20%2529%253A%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520ATR%2520protein%2520kinase%2520with%2520monotherapy%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D5%26spage%3D2125%26epage%3D2138%26doi%3D10.1021%2Fjm301859s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foote, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissink, J. W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guichard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yates, J. W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blades, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heathcote, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odedra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewsbury, P. J.</span></span> <span> </span><span class="NLM_article-title">Discovery and characterization of AZD6738, a potent inhibitor of ataxia telangiectasia mutated and Rad3 related (ATR) kinase with application as an anticancer agent</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">9889</span>â <span class="NLM_lpage">9907</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b01187</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01187" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFOgu77F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9889-9907&issue=22&author=K.+M.+Footeauthor=J.+W.+M.+Nissinkauthor=T.+McGuireauthor=P.+Turnerauthor=S.+Guichardauthor=J.+W.+T.+Yatesauthor=A.+Lauauthor=K.+Bladesauthor=D.+Heathcoteauthor=R.+Odedraauthor=G.+Wilkinsonauthor=Z.+Wilsonauthor=C.+M.+Woodauthor=P.+J.+Jewsbury&title=Discovery+and+characterization+of+AZD6738%2C+a+potent+inhibitor+of+ataxia+telangiectasia+mutated+and+Rad3+related+%28ATR%29+kinase+with+application+as+an+anticancer+agent&doi=10.1021%2Facs.jmedchem.8b01187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent</span></div><div class="casAuthors">Foote, Kevin M.; Nissink, J. Willem M.; McGuire, Thomas; Turner, Paul; Guichard, Sylvie; Yates, James W. T.; Lau, Alan; Blades, Kevin; Heathcote, Dan; Odedra, Rajesh; Wilkinson, Gary; Wilson, Zena; Wood, Christine M.; Jewsbury, Philip J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9889-9907</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and assocd. DNA double-strand breaks.  Inhibition of repair pathways mediated by ATR in a context where alternative pathways are less active is expected to aid clin. response by increasing replication stress.  Here the authors describe the development of the clin. candidate II (AZD6738), a potent and selective sulfoximine morpholinopyrimidine ATR inhibitor with excellent preclin. physicochem. and pharmacokinetic (PK) characteristics.  Compd. II was developed improving aq. soly. and eliminating CYP3A4 time-dependent inhibition starting from the earlier described inhibitor I (AZ20).  The clin. candidate II has favorable human PK suitable for once or twice daily dosing and achieves biol. effective exposure at moderate doses.  Compd. II is currently being tested in multiple phase I/II trials as an anticancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr419z5SGLz_LVg90H21EOLACvtfcHk0ljcGxiLgJSrcg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFOgu77F&md5=992b9a9669f1e58926d3e7e4d4e816ba</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01187%26sid%3Dliteratum%253Aachs%26aulast%3DFoote%26aufirst%3DK.%2BM.%26aulast%3DNissink%26aufirst%3DJ.%2BW.%2BM.%26aulast%3DMcGuire%26aufirst%3DT.%26aulast%3DTurner%26aufirst%3DP.%26aulast%3DGuichard%26aufirst%3DS.%26aulast%3DYates%26aufirst%3DJ.%2BW.%2BT.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DBlades%26aufirst%3DK.%26aulast%3DHeathcote%26aufirst%3DD.%26aulast%3DOdedra%26aufirst%3DR.%26aulast%3DWilkinson%26aufirst%3DG.%26aulast%3DWilson%26aufirst%3DZ.%26aulast%3DWood%26aufirst%3DC.%2BM.%26aulast%3DJewsbury%26aufirst%3DP.%2BJ.%26atitle%3DDiscovery%2520and%2520characterization%2520of%2520AZD6738%252C%2520a%2520potent%2520inhibitor%2520of%2520ataxia%2520telangiectasia%2520mutated%2520and%2520Rad3%2520related%2520%2528ATR%2529%2520kinase%2520with%2520application%2520as%2520an%2520anticancer%2520agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D22%26spage%3D9889%26epage%3D9907%26doi%3D10.1021%2Facs.jmedchem.8b01187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lloyd, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falenta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wijnhoven, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chabbert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stott, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yates, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingsworth, S. J.</span></span> <span> </span><span class="NLM_article-title">Abstract 337: The PARP inhibitor olaparib is synergistic with the ATR inhibitor AZD6738 in ATM deficient cancer cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">13, Suppl.</span>),  <span class="NLM_fpage">337</span>, <span class="refDoi">Â DOI: 10.1158/1538-7445.AM2018-337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F1538-7445.AM2018-337" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=337&issue=13%2C+Suppl.&author=R.+Lloydauthor=K.+Falentaauthor=P.+W.+Wijnhovenauthor=C.+Chabbertauthor=J.+Stottauthor=J.+Yatesauthor=A.+Y.+Lauauthor=L.+A.+Youngauthor=S.+J.+Hollingsworth&title=Abstract+337%3A+The+PARP+inhibitor+olaparib+is+synergistic+with+the+ATR+inhibitor+AZD6738+in+ATM+deficient+cancer+cells&doi=10.1158%2F1538-7445.AM2018-337"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2018-337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2018-337%26sid%3Dliteratum%253Aachs%26aulast%3DLloyd%26aufirst%3DR.%26aulast%3DFalenta%26aufirst%3DK.%26aulast%3DWijnhoven%26aufirst%3DP.%2BW.%26aulast%3DChabbert%26aufirst%3DC.%26aulast%3DStott%26aufirst%3DJ.%26aulast%3DYates%26aufirst%3DJ.%26aulast%3DLau%26aufirst%3DA.%2BY.%26aulast%3DYoung%26aufirst%3DL.%2BA.%26aulast%3DHollingsworth%26aufirst%3DS.%2BJ.%26atitle%3DAbstract%2520337%253A%2520The%2520PARP%2520inhibitor%2520olaparib%2520is%2520synergistic%2520with%2520the%2520ATR%2520inhibitor%2520AZD6738%2520in%2520ATM%2520deficient%2520cancer%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2018%26volume%3D78%26issue%3D13%252C%2520Suppl%26spage%3D337%26doi%3D10.1158%2F1538-7445.AM2018-337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barsanti, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aversa, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elling, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudewicz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taricani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, Q.</span></span> <span> </span><span class="NLM_article-title">Structure-Based drug design of novel potent and selective tetrahydropyrazolo[1,5-a]pyrazines as ATR inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">37</span>â <span class="NLM_lpage">41</span>, <span class="refDoi">Â DOI: 10.1021/ml500353p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500353p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFOjsLrM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=37-41&issue=1&author=P.+A.+Barsantiauthor=R.+J.+Aversaauthor=X.+Jinauthor=Y.+Panauthor=Y.+Luauthor=R.+Ellingauthor=R.+Jainauthor=M.+Knappauthor=J.+Lanauthor=X.+Linauthor=P.+Rudewiczauthor=J.+Simauthor=L.+Taricaniauthor=G.+Thomasauthor=L.+Xiaoauthor=Q.+Yue&title=Structure-Based+drug+design+of+novel+potent+and+selective+tetrahydropyrazolo%5B1%2C5-a%5Dpyrazines+as+ATR+inhibitors&doi=10.1021%2Fml500353p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Drug Design of Novel Potent and Selective Tetrahydropyrazolo[1,5-a]pyrazines as ATR Inhibitors</span></div><div class="casAuthors">Barsanti, Paul A.; Aversa, Robert J.; Jin, Xianming; Pan, Yue; Lu, Yipin; Elling, Robert; Jain, Rama; Knapp, Mark; Lan, Jiong; Lin, Xiaodong; Rudewicz, Patrick; Sim, Janet; Taricani, Lorena; Thomas, George; Xiao, Linda; Yue, Qin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">37-41</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A satn. strategy focused on improving the selectivity and physicochem. properties of ATR inhibitor HTS hit I led to a novel series of highly potent and selective tetrahydropyrazolo[1,5-a]pyrazines, e.g. II.  Use of PI3KÎ± mutants as ATR crystal structure surrogates was instrumental in providing cocrystal structures to guide the medicinal chem. designs.  Detailed DMPK studies involving cyanide and GSH as trapping agents during microsomal incubations, in addn. to deuterium-labeled compds. as mechanistic probes uncovered the mol. basis for the obsd. CYP3A4 TDI in the series.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTFngy1BinPLVg90H21EOLACvtfcHk0lg2g3vU3Klmaw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFOjsLrM&md5=3f15f48af12efd37411173f9325efda7</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Fml500353p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500353p%26sid%3Dliteratum%253Aachs%26aulast%3DBarsanti%26aufirst%3DP.%2BA.%26aulast%3DAversa%26aufirst%3DR.%2BJ.%26aulast%3DJin%26aufirst%3DX.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DElling%26aufirst%3DR.%26aulast%3DJain%26aufirst%3DR.%26aulast%3DKnapp%26aufirst%3DM.%26aulast%3DLan%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DRudewicz%26aufirst%3DP.%26aulast%3DSim%26aufirst%3DJ.%26aulast%3DTaricani%26aufirst%3DL.%26aulast%3DThomas%26aufirst%3DG.%26aulast%3DXiao%26aufirst%3DL.%26aulast%3DYue%26aufirst%3DQ.%26atitle%3DStructure-Based%2520drug%2520design%2520of%2520novel%2520potent%2520and%2520selective%2520tetrahydropyrazolo%255B1%252C5-a%255Dpyrazines%2520as%2520ATR%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26issue%3D1%26spage%3D37%26epage%3D41%26doi%3D10.1021%2Fml500353p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pujala, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nayak, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khare, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guguloth, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randive, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinde, B. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raja, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfaro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avila, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">PÃ©rez de Arce, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almirez, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanno, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernales, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakravarty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCullagh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, S. M.</span></span> <span> </span><span class="NLM_article-title">Discovery of pyrazolopyrimidine derivatives as novel dual inhibitors of BTK and PI3KÎ´</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1161</span>â <span class="NLM_lpage">1166</span>, <span class="refDoi">Â DOI: 10.1021/acsmedchemlett.6b00356</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00356" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslGhtLfL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=1161-1166&issue=12&author=B.+Pujalaauthor=A.+K.+Agarwalauthor=S.+Middyaauthor=M.+Banerjeeauthor=A.+Suryaauthor=A.+K.+Nayakauthor=A.+Guptaauthor=S.+Khareauthor=R.+Gugulothauthor=N.+A.+Randiveauthor=B.+U.+Shindeauthor=A.+Thakurauthor=D.+I.+Patelauthor=M.+Rajaauthor=M.+J.+Greenauthor=J.+Alfaroauthor=P.+Avilaauthor=F.+P%C3%A9rez+de+Arceauthor=R.+G.+Almirezauthor=S.+Kannoauthor=S.+Bernalesauthor=D.+T.+Hungauthor=S.+Chakravartyauthor=E.+McCullaghauthor=K.+P.+Quinnauthor=R.+Raiauthor=S.+M.+Pham&title=Discovery+of+pyrazolopyrimidine+derivatives+as+novel+dual+inhibitors+of+BTK+and+PI3K%CE%B4&doi=10.1021%2Facsmedchemlett.6b00356"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Pyrazolopyrimidine Derivatives as Novel Dual Inhibitors of BTK and PI3KÎ´</span></div><div class="casAuthors">Pujala, Brahmam; Agarwal, Anil K.; Middya, Sandip; Banerjee, Monali; Surya, Arjun; Nayak, Anjan K.; Gupta, Ashu; Khare, Sweta; Guguloth, Rambabu; Randive, Nitin A.; Shinde, Bharat U.; Thakur, Anamika; Patel, Dhananjay I.; Raja, Mohd.; Green, Michael J.; Alfaro, Jennifer; Avila, Patricio; Perez de Arce, Felipe; Almirez, Ramona G.; Kanno, Stacy; Bernales, Sebastian; Hung, David T.; Chakravarty, Sarvajit; McCullagh, Emma; Quinn, Kevin P.; Rai, Roopa; Pham, Son M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1161-1166</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The aberrant activation of B-cells has been implicated in several types of cancers and hematol. disorders.  BTK and PI3KÎ´ are kinases responsible for B-cell signal transduction, and inhibitors of these enzymes have demonstrated clin. benefit in certain types of lymphoma.  Simultaneous inhibition of these pathways could result in more robust responses or overcome resistance as obsd. in single agent use.  The authors report a series of novel compds. that have low nanomolar potency against both BTK and PI3KÎ´ as well as acceptable PK properties that could be useful in the development of treatments against B-cell related diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4WMataMc2hbVg90H21EOLACvtfcHk0lg2g3vU3Klmaw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslGhtLfL&md5=2a977a59c1bd1ccc5682405628990617</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00356%26sid%3Dliteratum%253Aachs%26aulast%3DPujala%26aufirst%3DB.%26aulast%3DAgarwal%26aufirst%3DA.%2BK.%26aulast%3DMiddya%26aufirst%3DS.%26aulast%3DBanerjee%26aufirst%3DM.%26aulast%3DSurya%26aufirst%3DA.%26aulast%3DNayak%26aufirst%3DA.%2BK.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DKhare%26aufirst%3DS.%26aulast%3DGuguloth%26aufirst%3DR.%26aulast%3DRandive%26aufirst%3DN.%2BA.%26aulast%3DShinde%26aufirst%3DB.%2BU.%26aulast%3DThakur%26aufirst%3DA.%26aulast%3DPatel%26aufirst%3DD.%2BI.%26aulast%3DRaja%26aufirst%3DM.%26aulast%3DGreen%26aufirst%3DM.%2BJ.%26aulast%3DAlfaro%26aufirst%3DJ.%26aulast%3DAvila%26aufirst%3DP.%26aulast%3DP%25C3%25A9rez%2Bde%2BArce%26aufirst%3DF.%26aulast%3DAlmirez%26aufirst%3DR.%2BG.%26aulast%3DKanno%26aufirst%3DS.%26aulast%3DBernales%26aufirst%3DS.%26aulast%3DHung%26aufirst%3DD.%2BT.%26aulast%3DChakravarty%26aufirst%3DS.%26aulast%3DMcCullagh%26aufirst%3DE.%26aulast%3DQuinn%26aufirst%3DK.%2BP.%26aulast%3DRai%26aufirst%3DR.%26aulast%3DPham%26aufirst%3DS.%2BM.%26atitle%3DDiscovery%2520of%2520pyrazolopyrimidine%2520derivatives%2520as%2520novel%2520dual%2520inhibitors%2520of%2520BTK%2520and%2520PI3K%25CE%25B4%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26issue%3D12%26spage%3D1161%26epage%3D1166%26doi%3D10.1021%2Facsmedchemlett.6b00356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jadhavar, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagle, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Protter, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindquist, J. N.</span></span> <span> </span><span class="NLM_article-title">Discovery of pyrazolopyrimidine derivatives as novel inhibitors of ataxia telangiectasia and rad3 related protein (ATR)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">750</span>â <span class="NLM_lpage">754</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2017.01.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.bmcl.2017.01.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=28131712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Kgsb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=750-754&issue=4&author=S.+A.+Ramachandranauthor=P.+S.+Jadhavarauthor=M.+P.+Singhauthor=A.+Sharmaauthor=G.+N.+Bagleauthor=K.+P.+Quinnauthor=P.+Y.+Wongauthor=A.+A.+Protterauthor=R.+Raiauthor=S.+M.+Phamauthor=J.+N.+Lindquist&title=Discovery+of+pyrazolopyrimidine+derivatives+as+novel+inhibitors+of+ataxia+telangiectasia+and+rad3+related+protein+%28ATR%29&doi=10.1016%2Fj.bmcl.2017.01.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of pyrazolopyrimidine derivatives as novel inhibitors of ataxia telangiectasia and rad3 related protein (ATR)</span></div><div class="casAuthors">Ramachandran, Sreekanth A.; Jadhavar, Pradeep S.; Singh, Manvendra P.; Sharma, Ankesh; Bagle, Gaurav N.; Quinn, Kevin P.; Wong, Po-yin; Protter, Andrew A.; Rai, Roopa; Pham, Son M.; Lindquist, Jeffrey N.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">750-754</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The ATR pathway is a crit. mediator of the replication stress response in cells.  In aberrantly proliferating cancer cells, this pathway can help maintain sufficient genomic integrity for cancer cell progression.  Herein the authors describe the discovery of 1-(4-(methylsulfonyl)phenyl)-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine, a pyrazolopyrimidine-contg. inhibitor of ATR via a strategic repurposing of compds. targeting PI3K.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOzI0OXLOKdbVg90H21EOLACvtfcHk0lhe2_10Je4yfw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Kgsb4%253D&md5=3317730261d88b63ee6fea216d3c049b</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.01.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.01.045%26sid%3Dliteratum%253Aachs%26aulast%3DRamachandran%26aufirst%3DS.%2BA.%26aulast%3DJadhavar%26aufirst%3DP.%2BS.%26aulast%3DSingh%26aufirst%3DM.%2BP.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DBagle%26aufirst%3DG.%2BN.%26aulast%3DQuinn%26aufirst%3DK.%2BP.%26aulast%3DWong%26aufirst%3DP.%2BY.%26aulast%3DProtter%26aufirst%3DA.%2BA.%26aulast%3DRai%26aufirst%3DR.%26aulast%3DPham%26aufirst%3DS.%2BM.%26aulast%3DLindquist%26aufirst%3DJ.%2BN.%26atitle%3DDiscovery%2520of%2520pyrazolopyrimidine%2520derivatives%2520as%2520novel%2520inhibitors%2520of%2520ataxia%2520telangiectasia%2520and%2520rad3%2520related%2520protein%2520%2528ATR%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26issue%3D4%26spage%3D750%26epage%3D754%26doi%3D10.1016%2Fj.bmcl.2017.01.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hickson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orr, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reaper, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtin, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. C.</span></span> <span> </span><span class="NLM_article-title">Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>64</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">9152</span>â <span class="NLM_lpage">9159</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-04-2727</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F0008-5472.CAN-04-2727" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=15604286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVOmsb7K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=9152-9159&issue=24&author=I.+Hicksonauthor=Y.+Zhaoauthor=C.+J.+Richardsonauthor=S.+J.+Greenauthor=N.+M.+Martinauthor=A.+I.+Orrauthor=P.+M.+Reaperauthor=S.+P.+Jacksonauthor=N.+J.+Curtinauthor=G.+C.+Smith&title=Identification+and+characterization+of+a+novel+and+specific+inhibitor+of+the+ataxia-telangiectasia+mutated+kinase+ATM&doi=10.1158%2F0008-5472.CAN-04-2727"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM</span></div><div class="casAuthors">Hickson, Ian; Zhao, Yan; Richardson, Caroline J.; Green, Sharon J.; Martin, Niall M. B.; Orr, Alisdair I.; Reaper, Philip M.; Jackson, Stephen P.; Curtin, Nicola J.; Smith, Graeme C. M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">9152-9159</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The serine/threonine protein kinase ATM signals to cell cycle and DNA repair components by phosphorylating downstream targets such as p53, CHK2, NBS1, and BRCA1.  Mutation of ATM occurs in the human autosomal recessive disorder ataxia-telangiectasia, which is characterized by hypersensitivity to ionizing radiation and a failure of cells to arrest the cell cycle after the induction of DNA double-strand breaks.  It has thus been proposed that ATM inhibition would cause cellular radio- and chemosensitization.  Through screening a small mol. compd. library developed for the phosphatidylinositol 3'-kinase-like kinase family, we identified an ATP-competitive inhibitor, 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one (KU-55933), that inhibits ATM with an IC50 of 13 nmol/L and a Ki of 2.2 nmol/L.  KU-55933 shows specificity with respect to inhibition of other phosphatidylinositol 3'-kinase-like kinases.  Cellular inhibition of ATM by KU-55933 was demonstrated by the ablation of ionizing radiation-dependent phosphorylation of a range of ATM targets, including p53, Î³H2AX, NBS1, and SMC1.  KU-55933 did not show inhibition of UV light DNA damage induced cellular phosphorylation events.  Exposure of cells to KU-55933 resulted in a significant sensitization to the cytotoxic effects of ionizing radiation and to the DNA double-strand break-inducing chemotherapeutic agents, etoposide, doxorubicin, and camptothecin.  Inhibition of ATM by KU-55933 also caused a loss of ionizing radiation-induced cell cycle arrest.  By contrast, KU-55933 did not potentiate the cytotoxic effects of ionizing radiation on ataxia-telangiectasia cells, nor did it affect their cell cycle profile after DNA damage.  We conclude that KU-55933 is a novel, specific, and potent inhibitor of the ATM kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok44U64rohgrVg90H21EOLACvtfcHk0lhtTAXOVvdAsw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVOmsb7K&md5=fb166cc695613369c9cef7ac451f7dd3</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-2727&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-2727%26sid%3Dliteratum%253Aachs%26aulast%3DHickson%26aufirst%3DI.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DRichardson%26aufirst%3DC.%2BJ.%26aulast%3DGreen%26aufirst%3DS.%2BJ.%26aulast%3DMartin%26aufirst%3DN.%2BM.%26aulast%3DOrr%26aufirst%3DA.%2BI.%26aulast%3DReaper%26aufirst%3DP.%2BM.%26aulast%3DJackson%26aufirst%3DS.%2BP.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DSmith%26aufirst%3DG.%2BC.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520a%2520novel%2520and%2520specific%2520inhibitor%2520of%2520the%2520ataxia-telangiectasia%2520mutated%2520kinase%2520ATM%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26issue%3D24%26spage%3D9152%26epage%3D9159%26doi%3D10.1158%2F0008-5472.CAN-04-2727" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Golding, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valerie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussaini, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frigerio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cockcroft, X. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hummersone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rigoreau, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menear, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâConnor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Povirk, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Meter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valerie, K.</span></span> <span> </span><span class="NLM_article-title">Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2894</span>â <span class="NLM_lpage">2902</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-09-0519</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F1535-7163.MCT-09-0519" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=19808981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Cqur7F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=2894-2902&issue=10&author=S.+E.+Goldingauthor=E.+Rosenbergauthor=N.+Valerieauthor=I.+Hussainiauthor=M.+Frigerioauthor=X.+F.+Cockcroftauthor=W.+Y.+Chongauthor=M.+Hummersoneauthor=L.+Rigoreauauthor=K.+A.+Menearauthor=M.+J.+O%E2%80%99Connorauthor=L.+F.+Povirkauthor=T.+van+Meterauthor=K.+Valerie&title=Improved+ATM+kinase+inhibitor+KU-60019+radiosensitizes+glioma+cells%2C+compromises+insulin%2C+AKT+and+ERK+prosurvival+signaling%2C+and+inhibits+migration+and+invasion&doi=10.1158%2F1535-7163.MCT-09-0519"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion</span></div><div class="casAuthors">Golding, Sarah E.; Rosenberg, Elizabeth; Valerie, Nicholas; Hussaini, Isa; Frigerio, Mark; Cockcroft, Xiaoling F.; Chong, Wei Yee; Hummersone, Marc; Rigoreau, Laurent; Menear, Keith A.; O'Connor, Mark J.; Povirk, Lawrence F.; van Meter, Timothy; Valerie, Kristoffer</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2894-2902</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Ataxia telangiectasia (A-T) mutated (ATM) is crit. for cell cycle checkpoints and DNA repair.  Thus, specific small mol. inhibitors targeting ATM could perhaps be developed into efficient radiosensitizers.  Recently, a specific inhibitor of the ATM kinase, KU-55933, was shown to radiosensitize human cancer cells.  Herein, we report on an improved analog of KU-55933 (KU-60019) with Ki and IC50 values half of those of KU-55933.  KU-60019 is 10-fold more effective than KU-55933 at blocking radiation-induced phosphorylation of key ATM targets in human glioma cells.  As expected, KU-60019 is a highly effective radiosensitizer of human glioma cells.  A-T fibroblasts were not radiosensitized by KU-60019, strongly suggesting that the ATM kinase is specifically targeted.  Furthermore, KU-60019 reduced basal S473 AKT phosphorylation, suggesting that the ATM kinase might regulate a protein phosphatase acting on AKT.  In line with this finding, the effect of KU-60019 on AKT phosphorylation was countered by low levels of okadaic acid, a phosphatase inhibitor, and A-T cells were impaired in S473 AKT phosphorylation in response to radiation and insulin and unresponsive to KU-60019.  We also show that KU-60019 inhibits glioma cell migration and invasion in vitro, suggesting that glioma growth and motility might be controlled by ATM via AKT.  Inhibitors of MEK and AKT did not further radiosensitize cells treated with KU-60019, supporting the idea that KU-60019 interferes with prosurvival signaling sep. from its radiosensitizing properties.  Altogether, KU-60019 inhibits the DNA damage response, reduces AKT phosphorylation and prosurvival signaling, inhibits migration and invasion, and effectively radiosensitizes human glioma cells. [Mol Cancer Ther 2009;8(10):2894-902].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXun9h1lvdbbVg90H21EOLACvtfcHk0lhtTAXOVvdAsw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Cqur7F&md5=32fab13cdf80a5fcb520e358252c8764</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0519%26sid%3Dliteratum%253Aachs%26aulast%3DGolding%26aufirst%3DS.%2BE.%26aulast%3DRosenberg%26aufirst%3DE.%26aulast%3DValerie%26aufirst%3DN.%26aulast%3DHussaini%26aufirst%3DI.%26aulast%3DFrigerio%26aufirst%3DM.%26aulast%3DCockcroft%26aufirst%3DX.%2BF.%26aulast%3DChong%26aufirst%3DW.%2BY.%26aulast%3DHummersone%26aufirst%3DM.%26aulast%3DRigoreau%26aufirst%3DL.%26aulast%3DMenear%26aufirst%3DK.%2BA.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DPovirk%26aufirst%3DL.%2BF.%26aulast%3Dvan%2BMeter%26aufirst%3DT.%26aulast%3DValerie%26aufirst%3DK.%26atitle%3DImproved%2520ATM%2520kinase%2520inhibitor%2520KU-60019%2520radiosensitizes%2520glioma%2520cells%252C%2520compromises%2520insulin%252C%2520AKT%2520and%2520ERK%2520prosurvival%2520signaling%252C%2520and%2520inhibits%2520migration%2520and%2520invasion%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26issue%3D10%26spage%3D2894%26epage%3D2902%26doi%3D10.1158%2F1535-7163.MCT-09-0519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rainey, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanton, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kastan, M. B.</span></span> <span> </span><span class="NLM_article-title">Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>68</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">7466</span>â <span class="NLM_lpage">7474</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-08-0763</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F0008-5472.CAN-08-0763" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=18794134" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFWltb7K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=7466-7474&issue=18&author=M.+D.+Raineyauthor=M.+E.+Charltonauthor=R.+V.+Stantonauthor=M.+B.+Kastan&title=Transient+inhibition+of+ATM+kinase+is+sufficient+to+enhance+cellular+sensitivity+to+ionizing+radiation&doi=10.1158%2F0008-5472.CAN-08-0763"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Transient Inhibition of ATM Kinase Is Sufficient to Enhance Cellular Sensitivity to Ionizing Radiation</span></div><div class="casAuthors">Rainey, Michael D.; Charlton, Maura E.; Stanton, Robert V.; Kastan, Michael B.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7466-7474</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">In response to DNA damage, the ATM protein kinase activates signal transduction pathways essential for coordinating cell cycle progression with DNA repair.  In the human disease ataxia-telangiectasia, mutation of the ATM gene results in multiple cellular defects, including enhanced sensitivity to ionizing radiation (IR).  This phenotype highlights ATM as a potential target for novel inhibitors that could be used to enhance tumor cell sensitivity to radiotherapy.  A targeted compd. library was screened for potential inhibitors of the ATM kinase, and CP466722 was identified.  The compd. is nontoxic and does not inhibit phosphatidylinositol 3-kinase (PI3K) or PI3K-like protein kinase family members in cells.  CP466722 inhibited cellular ATM-dependent phosphorylation events and disruption of ATM function resulted in characteristic cell cycle checkpoint defects.  Inhibition of cellular ATM kinase activity was rapidly and completely reversed by removing CP466722.  Interestingly, clonogenic survival assays showed that transient inhibition of ATM is sufficient to sensitize cells to IR and suggests that therapeutic radiosensitization may only require ATM inhibition for short periods of time.  The ability of CP466722 to rapidly and reversibly regulate ATM activity provides a new tool to ask questions about ATM function that could not easily be addressed using genetic models or RNA interference technologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOLYFcaRvfPrVg90H21EOLACvtfcHk0lhtTAXOVvdAsw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFWltb7K&md5=f228e55406cd0f91e0543aa0f93f70f8</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-0763&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-0763%26sid%3Dliteratum%253Aachs%26aulast%3DRainey%26aufirst%3DM.%2BD.%26aulast%3DCharlton%26aufirst%3DM.%2BE.%26aulast%3DStanton%26aufirst%3DR.%2BV.%26aulast%3DKastan%26aufirst%3DM.%2BB.%26atitle%3DTransient%2520inhibition%2520of%2520ATM%2520kinase%2520is%2520sufficient%2520to%2520enhance%2520cellular%2520sensitivity%2520to%2520ionizing%2520radiation%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26issue%3D18%26spage%3D7466%26epage%3D7474%26doi%3D10.1158%2F0008-5472.CAN-08-0763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Awasthi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foiani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span> <span> </span><span class="NLM_article-title">ATM and ATR signaling at a glance</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>128</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">4255</span>â <span class="NLM_lpage">4262</span>, <span class="refDoi">Â DOI: 10.1242/jcs.169730</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1242%2Fjcs.169730" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=26567218" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC28XosFCltbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2015&pages=4255-4262&issue=23&author=P.+Awasthiauthor=M.+Foianiauthor=A.+Kumar&title=ATM+and+ATR+signaling+at+a+glance&doi=10.1242%2Fjcs.169730"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">ATM and ATR signaling at a glance</span></div><div class="casAuthors">Awasthi, Poorwa; Foiani, Marco; Kumar, Amit</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4255-4262</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">ATM and ATR signaling pathways are well conserved throughout evolution and are central to the maintenance of genome integrity.  Although the role of both ATM and ATR in DNA repair, cell cycle regulation and apoptosis have been well studied, both still remain in the focus of current research activities owing to their role in cancer.  Recent advances in the field suggest that these proteins have an addnl. function in maintaining cellular homeostasis under both stressed and non-stressed conditions.  In this Cell Science at a Glance article and the accompanying poster, we present an overview of recent advances in ATR and ATM research with emphasis on that into the modes of ATM and ATR activation, the different signaling pathways they participate in - including those that do not involve DNA damage - and highlight their relevance in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2wacg1aItObVg90H21EOLACvtfcHk0lg_9MIgpiKtXA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosFCltbk%253D&md5=e10656180a9b2b226e67b8bd99643a3b</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1242%2Fjcs.169730&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.169730%26sid%3Dliteratum%253Aachs%26aulast%3DAwasthi%26aufirst%3DP.%26aulast%3DFoiani%26aufirst%3DM.%26aulast%3DKumar%26aufirst%3DA.%26atitle%3DATM%2520and%2520ATR%2520signaling%2520at%2520a%2520glance%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2015%26volume%3D128%26issue%3D23%26spage%3D4255%26epage%3D4262%26doi%3D10.1242%2Fjcs.169730" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Degorce, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlaam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cadogan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dishington, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ducray, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glossop, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassall, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lach, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouvry, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomason, A. G.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel 3-quinoline carboxamides as potent, selective, and orally bioavailable inhibitors of ataxia telangiectasia mutated (ATM) kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">6281</span>â <span class="NLM_lpage">6292</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b00519</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00519" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC28XptFentrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=6281-6292&issue=13&author=S.+L.+Degorceauthor=B.+Barlaamauthor=E.+Cadoganauthor=A.+Dishingtonauthor=R.+Ducrayauthor=S.+C.+Glossopauthor=L.+A.+Hassallauthor=F.+Lachauthor=A.+Lauauthor=T.+M.+McGuireauthor=T.+Nowakauthor=G.+Ouvryauthor=K.+G.+Pikeauthor=A.+G.+Thomason&title=Discovery+of+novel+3-quinoline+carboxamides+as+potent%2C+selective%2C+and+orally+bioavailable+inhibitors+of+ataxia+telangiectasia+mutated+%28ATM%29+kinase&doi=10.1021%2Facs.jmedchem.6b00519"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase</span></div><div class="casAuthors">Degorce, Sebastien L.; Barlaam, Bernard; Cadogan, Elaine; Dishington, Allan; Ducray, Richard; Glossop, Steven C.; Hassall, Lorraine A.; Lach, Franck; Lau, Alan; McGuire, Thomas M.; Nowak, Thorsten; Ouvry, Gilles; Pike, Kurt G.; Thomason, Andrew G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6281-6292</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of 3-quinoline carboxamides has been discovered and optimized as selective inhibitors of the ataxia telangiectasia mutated (ATM) kinase.  From a modestly potent HTS hit (4), we identified mols. such as 6-[6-(methoxymethyl)-3-pyridinyl]-4-{[(1R)-1-(tetrahydro-2H-pyran-4-yl)ethyl]amino}-3-quinolinecarboxamide (72) and 7-fluoro-6-[6-(methoxymethyl)pyridin-3-yl]-4-{[(1S)-1-(1-methyl-1H-pyrazol-3-yl)ethyl]amino}quinoline-3-carboxamide (74) as potent and highly selective ATM inhibitors with overall ADME properties suitable for oral administration. 72 and 74 constitute excellent oral tools to probe ATM inhibition in vivo.  Efficacy in combination with the DSB-inducing agent irinotecan was obsd. in a disease relevant model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3a9n-YFghx7Vg90H21EOLACvtfcHk0lg_9MIgpiKtXA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptFentrg%253D&md5=99e98b54eb61ec56bb6883378bad9324</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00519%26sid%3Dliteratum%253Aachs%26aulast%3DDegorce%26aufirst%3DS.%2BL.%26aulast%3DBarlaam%26aufirst%3DB.%26aulast%3DCadogan%26aufirst%3DE.%26aulast%3DDishington%26aufirst%3DA.%26aulast%3DDucray%26aufirst%3DR.%26aulast%3DGlossop%26aufirst%3DS.%2BC.%26aulast%3DHassall%26aufirst%3DL.%2BA.%26aulast%3DLach%26aufirst%3DF.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DMcGuire%26aufirst%3DT.%2BM.%26aulast%3DNowak%26aufirst%3DT.%26aulast%3DOuvry%26aufirst%3DG.%26aulast%3DPike%26aufirst%3DK.%2BG.%26aulast%3DThomason%26aufirst%3DA.%2BG.%26atitle%3DDiscovery%2520of%2520novel%25203-quinoline%2520carboxamides%2520as%2520potent%252C%2520selective%252C%2520and%2520orally%2520bioavailable%2520inhibitors%2520of%2520ataxia%2520telangiectasia%2520mutated%2520%2528ATM%2529%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D13%26spage%3D6281%26epage%3D6292%26doi%3D10.1021%2Facs.jmedchem.6b00519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karlin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheridan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odedra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrington, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cadogan, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riches, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Trinidad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomason, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sule, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valerie, N. C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biddlestone-Thorpe, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckta, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukhopadhyay, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlaam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degorce, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kettle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colclough, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, I. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pass, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durant, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valerie, K.</span></span> <span> </span><span class="NLM_article-title">Orally bioavailable and blood-brain barrier-penetrating ATM inhibitor (AZ32) radiosensitizes intracranial gliomas in mice</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1637</span>â <span class="NLM_lpage">1647</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-17-0975</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F1535-7163.MCT-17-0975" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=29769307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVWrtrbP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=1637-1647&issue=8&author=J.+Karlinauthor=J.+Allenauthor=S.+F.+Ahmadauthor=G.+Hughesauthor=V.+Sheridanauthor=R.+Odedraauthor=P.+Farringtonauthor=E.+B.+Cadoganauthor=L.+C.+Richesauthor=A.+Garcia-Trinidadauthor=A.+G.+Thomasonauthor=B.+Patelauthor=J.+Vincentauthor=A.+Lauauthor=K.+G.+Pikeauthor=T.+A.+Huntauthor=A.+Suleauthor=N.+C.+K.+Valerieauthor=L.+Biddlestone-Thorpeauthor=J.+Kahnauthor=J.+M.+Becktaauthor=N.+Mukhopadhyayauthor=B.+Barlaamauthor=S.+L.+Degorceauthor=J.+Kettleauthor=N.+Colcloughauthor=J.+Wilsonauthor=A.+Smithauthor=I.+P.+Barrettauthor=L.+Zhengauthor=T.+Zhangauthor=Y.+Wangauthor=K.+Chenauthor=M.+Passauthor=S.+T.+Durantauthor=K.+Valerie&title=Orally+bioavailable+and+blood-brain+barrier-penetrating+ATM+inhibitor+%28AZ32%29+radiosensitizes+intracranial+gliomas+in+mice&doi=10.1158%2F1535-7163.MCT-17-0975"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Orally Bioavailable and Blood-Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice</span></div><div class="casAuthors">Karlin, Jeremy; Allen, Jasmine; Ahmad, Syed F.; Hughes, Gareth; Sheridan, Victoria; Odedra, Rajesh; Farrington, Paul; Cadogan, Elaine B.; Riches, Lucy C.; Garcia-Trinidad, Antonio; Thomason, Andrew G.; Patel, Bhavika; Vincent, Jennifer; Lau, Alan; Pike, Kurt G.; Hunt, Thomas A.; Sule, Amrita; Valerie, Nicholas C. K.; Biddlestone-Thorpe, Laura; Kahn, Jenna; Beckta, Jason M.; Mukhopadhyay, Nitai; Barlaam, Bernard; Degorce, Sebastien L.; Kettle, Jason; Colclough, Nicola; Wilson, Joanne; Smith, Aaron; Barrett, Ian P.; Zheng, Li; Zhang, Tianwei; Wang, Yingchun; Chen, Kan; Pass, Martin; Durant, Stephen T.; Valerie, Kristoffer</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1637-1647</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Inhibition of ataxia-telangiectasia mutated (ATM) during radiotherapy of glioblastoma multiforme (GBM) may improve tumor control by short-circuiting the response to radiation-induced DNA damage.  A major impediment for clin. implementation is that current inhibitors have limited central nervous system (CNS) bioavailability; thus, the goal was to identify ATM inhibitors (ATMi) with improved CNS penetration.  Drug screens and refinement of lead compds. identified AZ31 and AZ32.  The compds. were then tested in vivo for efficacy and impact on tumor and healthy brain.  Both AZ31 and AZ32 blocked the DNA damage response and radiosensitized GBM cells in vitro.  AZ32, with enhanced blood-brain barrier (BBB) penetration, was highly efficient in vivo as radiosensitizer in syngeneic and human, orthotopic mouse glioma model compared with AZ31.  Furthermore, human glioma cell lines expressing mutant p53 or having checkpoint-defective mutations were particularly sensitive to ATMi radiosensitization.  The mechanism for this p53 effect involves a propensity to undergo mitotic catastrophe relative to cells with wild-type p53.  In vivo, apoptosis was >6-fold higher in tumor relative to healthy brain after exposure to AZ32 and low-dose radiation.  AZ32 is the first ATMi with oral bioavailability shown to radiosensitize glioma and improve survival in orthotopic mouse models.  These findings support the development of a clin.-grade, BBB-penetrating ATMi for the treatment of GBM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBsLUOcyCbjbVg90H21EOLACvtfcHk0ljEVOtxDTOgIA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVWrtrbP&md5=41e779561c69dbc6e52c14052c5622d9</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-17-0975&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-17-0975%26sid%3Dliteratum%253Aachs%26aulast%3DKarlin%26aufirst%3DJ.%26aulast%3DAllen%26aufirst%3DJ.%26aulast%3DAhmad%26aufirst%3DS.%2BF.%26aulast%3DHughes%26aufirst%3DG.%26aulast%3DSheridan%26aufirst%3DV.%26aulast%3DOdedra%26aufirst%3DR.%26aulast%3DFarrington%26aufirst%3DP.%26aulast%3DCadogan%26aufirst%3DE.%2BB.%26aulast%3DRiches%26aufirst%3DL.%2BC.%26aulast%3DGarcia-Trinidad%26aufirst%3DA.%26aulast%3DThomason%26aufirst%3DA.%2BG.%26aulast%3DPatel%26aufirst%3DB.%26aulast%3DVincent%26aufirst%3DJ.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DPike%26aufirst%3DK.%2BG.%26aulast%3DHunt%26aufirst%3DT.%2BA.%26aulast%3DSule%26aufirst%3DA.%26aulast%3DValerie%26aufirst%3DN.%2BC.%2BK.%26aulast%3DBiddlestone-Thorpe%26aufirst%3DL.%26aulast%3DKahn%26aufirst%3DJ.%26aulast%3DBeckta%26aufirst%3DJ.%2BM.%26aulast%3DMukhopadhyay%26aufirst%3DN.%26aulast%3DBarlaam%26aufirst%3DB.%26aulast%3DDegorce%26aufirst%3DS.%2BL.%26aulast%3DKettle%26aufirst%3DJ.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DWilson%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DBarrett%26aufirst%3DI.%2BP.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DPass%26aufirst%3DM.%26aulast%3DDurant%26aufirst%3DS.%2BT.%26aulast%3DValerie%26aufirst%3DK.%26atitle%3DOrally%2520bioavailable%2520and%2520blood-brain%2520barrier-penetrating%2520ATM%2520inhibitor%2520%2528AZ32%2529%2520radiosensitizes%2520intracranial%2520gliomas%2520in%2520mice%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2018%26volume%3D17%26issue%3D8%26spage%3D1637%26epage%3D1647%26doi%3D10.1158%2F1535-7163.MCT-17-0975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pike, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlaam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cadogan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colclough, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de-Almeida, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degorce, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Didelot, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dishington, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ducray, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durant, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassall, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacFaul, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulholland, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouvry, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pass, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robb, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stratton, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Huniti, N.</span></span> <span> </span><span class="NLM_article-title">The identification of potent, selective, and orally available inhibitors of ataxia telangiectasia mutated (ATM) kinase: the discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H-pyran-4-yl)-1,3-dihydro-2 H-imidazo[4,5- c]quinolin-2-one)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">3823</span>â <span class="NLM_lpage">3841</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b01896</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01896" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotFaru7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=3823-3841&issue=9&author=K.+G.+Pikeauthor=B.+Barlaamauthor=E.+Cadoganauthor=A.+Campbellauthor=Y.+Chenauthor=N.+Colcloughauthor=N.+L.+Daviesauthor=C.+de-Almeidaauthor=S.+L.+Degorceauthor=M.+Didelotauthor=A.+Dishingtonauthor=R.+Ducrayauthor=S.+T.+Durantauthor=L.+A.+Hassallauthor=J.+Holmesauthor=G.+D.+Hughesauthor=P.+A.+MacFaulauthor=K.+R.+Mulhollandauthor=T.+M.+McGuireauthor=G.+Ouvryauthor=M.+Passauthor=G.+Robbauthor=N.+Strattonauthor=Z.+Wangauthor=J.+Wilsonauthor=B.+Zhaiauthor=K.+Zhaoauthor=N.+Al-Huniti&title=The+identification+of+potent%2C+selective%2C+and+orally+available+inhibitors+of+ataxia+telangiectasia+mutated+%28ATM%29+kinase%3A+the+discovery+of+AZD0156+%288-%7B6-%5B3-%28Dimethylamino%29propoxy%5Dpyridin-3-yl%7D-3-methyl-1-%28tetrahydro-2+H-pyran-4-yl%29-1%2C3-dihydro-2+H-imidazo%5B4%2C5-+c%5Dquinolin-2-one%29&doi=10.1021%2Facs.jmedchem.7b01896"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one)</span></div><div class="casAuthors">Pike, Kurt G.; Barlaam, Bernard; Cadogan, Elaine; Campbell, Andrew; Chen, Yingxue; Colclough, Nicola; Davies, Nichola L.; de-Almeida, Camila; Degorce, Sebastien L.; Didelot, Myriam; Dishington, Allan; Ducray, Richard; Durant, Stephen T.; Hassall, Lorraine A.; Holmes, Jane; Hughes, Gareth D.; MacFaul, Philip A.; Mulholland, Keith R.; McGuire, Thomas M.; Ouvry, Gilles; Pass, Martin; Robb, Graeme; Stratton, Natalie; Wang, Zhenhua; Wilson, Joanne; Zhai, Baochang; Zhao, Kang; Al-Huniti, Nidal</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3823-3841</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">ATM inhibitors, such as I, have demonstrated the antitumor potential of ATM inhibition when combined with DNA double-strand break-inducing agents in mouse xenograft models.  However, the properties of I result in a relatively high predicted clin. efficacious dose.  In an attempt to minimize attrition during clin. development, we sought to identify ATM inhibitors with a low predicted clin. dose (<50 mg) and focused on strategies to increase both ATM potency and predicted human pharmacokinetic half-life (predominantly through the increase of vol. of distribution).  These efforts resulted in the discovery of II (AZD0156), an exceptionally potent and selective inhibitor of ATM based on an imidazo[4,5-c]quinolin-2-one core.  Compd. II has good preclin. pharmacokinetics, a low predicted clin. dose, and a high max. absorbable dose. 64 has been shown to potentiate the efficacy of the approved drugs irinotecan and olaparib in disease relevant mouse models and is currently undergoing clin. evaluation with these agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZZLVXgx3Y2LVg90H21EOLACvtfcHk0ljEVOtxDTOgIA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotFaru7w%253D&md5=ae6d4ef920cf3205a9f69c55d18f0f4b</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01896%26sid%3Dliteratum%253Aachs%26aulast%3DPike%26aufirst%3DK.%2BG.%26aulast%3DBarlaam%26aufirst%3DB.%26aulast%3DCadogan%26aufirst%3DE.%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DDavies%26aufirst%3DN.%2BL.%26aulast%3Dde-Almeida%26aufirst%3DC.%26aulast%3DDegorce%26aufirst%3DS.%2BL.%26aulast%3DDidelot%26aufirst%3DM.%26aulast%3DDishington%26aufirst%3DA.%26aulast%3DDucray%26aufirst%3DR.%26aulast%3DDurant%26aufirst%3DS.%2BT.%26aulast%3DHassall%26aufirst%3DL.%2BA.%26aulast%3DHolmes%26aufirst%3DJ.%26aulast%3DHughes%26aufirst%3DG.%2BD.%26aulast%3DMacFaul%26aufirst%3DP.%2BA.%26aulast%3DMulholland%26aufirst%3DK.%2BR.%26aulast%3DMcGuire%26aufirst%3DT.%2BM.%26aulast%3DOuvry%26aufirst%3DG.%26aulast%3DPass%26aufirst%3DM.%26aulast%3DRobb%26aufirst%3DG.%26aulast%3DStratton%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DWilson%26aufirst%3DJ.%26aulast%3DZhai%26aufirst%3DB.%26aulast%3DZhao%26aufirst%3DK.%26aulast%3DAl-Huniti%26aufirst%3DN.%26atitle%3DThe%2520identification%2520of%2520potent%252C%2520selective%252C%2520and%2520orally%2520available%2520inhibitors%2520of%2520ataxia%2520telangiectasia%2520mutated%2520%2528ATM%2529%2520kinase%253A%2520the%2520discovery%2520of%2520AZD0156%2520%25288-%257B6-%255B3-%2528Dimethylamino%2529propoxy%255Dpyridin-3-yl%257D-3-methyl-1-%2528tetrahydro-2%2520H-pyran-4-yl%2529-1%252C3-dihydro-2%2520H-imidazo%255B4%252C5-%2520c%255Dquinolin-2-one%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D9%26spage%3D3823%26epage%3D3841%26doi%3D10.1021%2Facs.jmedchem.7b01896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span> <span> </span><span class="NLM_article-title">Volume of distribution in drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">5691</span>â <span class="NLM_lpage">5698</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b00201</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00201" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltFSlsb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=5691-5698&issue=15&author=D.+A.+Smithauthor=K.+Beaumontauthor=T.+S.+Maurerauthor=L.+Di&title=Volume+of+distribution+in+drug+design&doi=10.1021%2Facs.jmedchem.5b00201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Volume of Distribution in Drug Design</span></div><div class="casAuthors">Smith, Dennis A.; Beaumont, Kevin; Maurer, Tristan S.; Di, Li</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5691-5698</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Vol. of distribution is one of the most important pharmacokinetic properties of a drug candidate.  It is a major determinant of half-life and dosing frequency of a drug.  For a similar log P, a basic mol. will tend to exhibit higher vol. of distribution than a neutral mol.  Acids often exhibit low vols. of distribution.  Although a design strategy against vol. of distribution can be advantageous in achieving desirable dosing regimen, it must be well-directed in order to avoid detrimental effects to other important properties.  Strategies to increase vol. of distribution include adding lipophilicity and introducing basic functional groups in a way that does not increase metabolic clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP7QwgPahf4bVg90H21EOLACvtfcHk0ljEVOtxDTOgIA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltFSlsb0%253D&md5=2c7289b3602a8edef2d9ef0e6a82e483</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00201%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DBeaumont%26aufirst%3DK.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DDi%26aufirst%3DL.%26atitle%3DVolume%2520of%2520distribution%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D15%26spage%3D5691%26epage%3D5698%26doi%3D10.1021%2Facs.jmedchem.5b00201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maira, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauffer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brueggen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brachmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chene, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Pover, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoemaker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabriel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Echeverria, C.</span></span> <span> </span><span class="NLM_article-title">Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1851</span>â <span class="NLM_lpage">1863</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-08-0017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F1535-7163.MCT-08-0017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=18606717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslCgtb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=1851-1863&issue=7&author=S.+M.+Mairaauthor=F.+Staufferauthor=J.+Brueggenauthor=P.+Furetauthor=C.+Schnellauthor=C.+Fritschauthor=S.+Brachmannauthor=P.+Cheneauthor=A.+De+Poverauthor=K.+Schoemakerauthor=D.+Fabbroauthor=D.+Gabrielauthor=M.+Simonenauthor=L.+Murphyauthor=P.+Finanauthor=W.+Sellersauthor=C.+Garcia-Echeverria&title=Identification+and+characterization+of+NVP-BEZ235%2C+a+new+orally+available+dual+phosphatidylinositol+3-kinase%2Fmammalian+target+of+rapamycin+inhibitor+with+potent+in+vivo+antitumor+activity&doi=10.1158%2F1535-7163.MCT-08-0017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity</span></div><div class="casAuthors">Maira, Sauveur-Michel; Stauffer, Frederic; Brueggen, Josef; Furet, Pascal; Schnell, Christian; Fritsch, Christine; Brachmann, Saskia; Chene, Patrick; De Pover, Alain; Schoemaker, Kevin; Fabbro, Doriano; Gabriel, Daniela; Simonen, Marjo; Murphy, Leon; Finan, Peter; Sellers, William; Garcia-Echeverria, Carlos</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1851-1863</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin inhibitor (mTOR) pathway is often constitutively activated in human tumor cells, providing unique opportunities for anticancer therapeutic intervention.  NVP-BEZ235 is an imidazo[4,5-c]quinoline deriv. that inhibits PI3K and mTOR kinase activity by binding to the ATP-binding cleft of these enzymes.  In cellular settings using human tumor cell lines, this mol. is able to effectively and specifically block the dysfunctional activation of the PI3K pathway, inducing G1 arrest.  The cellular activity of NVP-BEZ235 translates well in in vivo models of human cancer.  Thus, the compd. was well tolerated, displayed disease stasis when administered orally, and enhanced the efficacy of other anticancer agents when used in in vivo combination studies.  Ex vivo pharmacokinetic/pharmacodynamic analyses of tumor tissues showed a time-dependent correlation between compd. concn. and PI3K/Akt pathway inhibition.  Collectively, the preclin. data show that NVP-BEZ235 is a potent dual PI3K/mTOR modulator with favorable pharmaceutical properties.  NVP-BEZ235 is currently in phase I clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyO784qv52vrVg90H21EOLACvtfcHk0liLO9aptwNOKA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslCgtb4%253D&md5=5b1979e134dd12065198d86dbc11ce15</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-08-0017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-08-0017%26sid%3Dliteratum%253Aachs%26aulast%3DMaira%26aufirst%3DS.%2BM.%26aulast%3DStauffer%26aufirst%3DF.%26aulast%3DBrueggen%26aufirst%3DJ.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DSchnell%26aufirst%3DC.%26aulast%3DFritsch%26aufirst%3DC.%26aulast%3DBrachmann%26aufirst%3DS.%26aulast%3DChene%26aufirst%3DP.%26aulast%3DDe%2BPover%26aufirst%3DA.%26aulast%3DSchoemaker%26aufirst%3DK.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DGabriel%26aufirst%3DD.%26aulast%3DSimonen%26aufirst%3DM.%26aulast%3DMurphy%26aufirst%3DL.%26aulast%3DFinan%26aufirst%3DP.%26aulast%3DSellers%26aufirst%3DW.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520NVP-BEZ235%252C%2520a%2520new%2520orally%2520available%2520dual%2520phosphatidylinositol%25203-kinase%252Fmammalian%2520target%2520of%2520rapamycin%2520inhibitor%2520with%2520potent%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26issue%3D7%26spage%3D1851%26epage%3D1863%26doi%3D10.1158%2F1535-7163.MCT-08-0017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mukherjee, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomimatsu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amancherla, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camacho, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pichamoorthy, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burma, S.</span></span> <span> </span><span class="NLM_article-title">The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses</span>. <i>Neoplasia</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">34</span>â <span class="NLM_lpage">43</span>, <span class="refDoi">Â DOI: 10.1593/neo.111512</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1593%2Fneo.111512" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=22355272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjtlamt7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2012&pages=34-43&issue=1&author=B.+Mukherjeeauthor=N.+Tomimatsuauthor=K.+Amancherlaauthor=C.+V.+Camachoauthor=N.+Pichamoorthyauthor=S.+Burma&title=The+dual+PI3K%2FmTOR+inhibitor+NVP-BEZ235+is+a+potent+inhibitor+of+ATM-+and+DNA-PKCs-mediated+DNA+damage+responses&doi=10.1593%2Fneo.111512"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKcs-mediated DNA damage responses</span></div><div class="casAuthors">Mukherjee, Bipasha; Tomimatsu, Nozomi; Amancherla, Kaushik; Camacho, Cristel V.; Pichamoorthy, Nandini; Burma, Sandeep</div><div class="citationInfo"><span class="NLM_cas:title">Neoplasia (Ann Arbor, MI, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">34-43</span>CODEN:
                <span class="NLM_cas:coden">NEOPFL</span>;
        ISSN:<span class="NLM_cas:issn">1522-8002</span>.
    
            (<span class="NLM_cas:orgname">Neoplasia Press Inc.</span>)
        </div><div class="casAbstract">Inhibitors of PI3K/Akt signaling are being actively developed for tumor therapy owing to the frequent mutational activation of the PI3K-Akt-mTORC1 pathway in many cancers, including glioblastomas (GBMs).  NVP-BEZ235 is a novel and potent dual PI3K/mTOR inhibitor that is currently in phase 1/2 clin. trials for advanced solid tumors.  Here, we show that NVP-BEZ235 also potently inhibits ATM and DNA-PKcs, the two major kinases responding to ionizing radiation (IR)-induced DNA double-strand breaks (DSBs).  Consequently, NVP-BEZ235 blocks both nonhomologous end joining and homologous recombination DNA repair pathways resulting in significant attenuation of DSB repair.  In addn., phosphorylation of ATM targets and implementation of the G2/Mcell cycle checkpoint are also attenuated by this drug.  As a result, NVP-BEZ235 confers an extreme degree of radiosensitization and impairs DSB repair in a panel of GBMcell lines irresp. of their Akt activation status.  NVP-BEZ235 also significantly impairs DSB repair in a mouse tumor model thereby validating the efficacy of this drug as a DNA repair inhibitor in vivo.  Our results, showing that NVP-BEZ235 is a potent and novel inhibitor of ATM and DNA-PKcs, have important implications for the informed and rational design of clin. trials involving this drug and also reveal the potential utility of NVP-BEZ235 as an effective radiosensitizer for GBMs in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9NAac1mePaLVg90H21EOLACvtfcHk0liLO9aptwNOKA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjtlamt7s%253D&md5=a6cfa1eee6d959c84bec642e0c175fb7</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1593%2Fneo.111512&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1593%252Fneo.111512%26sid%3Dliteratum%253Aachs%26aulast%3DMukherjee%26aufirst%3DB.%26aulast%3DTomimatsu%26aufirst%3DN.%26aulast%3DAmancherla%26aufirst%3DK.%26aulast%3DCamacho%26aufirst%3DC.%2BV.%26aulast%3DPichamoorthy%26aufirst%3DN.%26aulast%3DBurma%26aufirst%3DS.%26atitle%3DThe%2520dual%2520PI3K%252FmTOR%2520inhibitor%2520NVP-BEZ235%2520is%2520a%2520potent%2520inhibitor%2520of%2520ATM-%2520and%2520DNA-PKCs-mediated%2520DNA%2520damage%2520responses%26jtitle%3DNeoplasia%26date%3D2012%26volume%3D14%26issue%3D1%26spage%3D34%26epage%3D43%26doi%3D10.1593%2Fneo.111512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Riches, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trinidad, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomason, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavine, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stott, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlaam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pass, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâConnor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cadogan, E. B.</span></span> <span> </span><span class="NLM_article-title">Pharmacology of the ATM Inhibitor AZD0156: Potentiation of irradiation and olaparib responses preclinically</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">13</span>â <span class="NLM_lpage">25</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-18-1394</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F1535-7163.MCT-18-1394" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=31534013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvVOltbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2020&pages=13-25&issue=1&author=L.+C.+Richesauthor=A.+G.+Trinidadauthor=G.+Hughesauthor=G.+N.+Jonesauthor=A.+M.+Hughesauthor=A.+G.+Thomasonauthor=P.+Gavineauthor=A.+Cuiauthor=S.+Lingauthor=J.+Stottauthor=R.+Clarkauthor=S.+Peelauthor=P.+Gillauthor=L.+M.+Goodwinauthor=A.+Smithauthor=K.+G.+Pikeauthor=B.+Barlaamauthor=M.+Passauthor=M.+J.+O%E2%80%99Connorauthor=G.+Smithauthor=E.+B.+Cadogan&title=Pharmacology+of+the+ATM+Inhibitor+AZD0156%3A+Potentiation+of+irradiation+and+olaparib+responses+preclinically&doi=10.1158%2F1535-7163.MCT-18-1394"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacology of the ATM inhibitor AZD0156: potentiation of irradiation and olaparib responses pre-clinically</span></div><div class="casAuthors">Riches, Lucy C.; Trinidad, Antonio G.; Hughes, Gareth; Jones, Gemma N.; Hughes, Adina M.; Thomason, Andrew G.; Gavine, Paul; Cui, Andy; Ling, Stephanie; Stott, Jonathan; Clark, Roger; Peel, Samantha; Gill, Pendeep; Goodwin, Louise M.; Smith, Aaron; Pike, Kurt G.; Barlaam, Bernard; Pass, Martin; O'Connor, Mark J.; Smith, Graeme; Cadogan, Elaine B.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-25</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">AZD0156 is a potent and selective, bio-available inhibitor of Ataxia Telangiectasia Mutated (ATM) protein, a signaling kinase involved in the DNA damage response (DDR).  We present preclin. data demonstrating abrogation of irradn.-induced ATM signaling by low doses of AZD0156, as measured by phosphorylation of ATM substrates.  AZD0156 is a strong radio-sensitizer in vitro, and using a lung xenograft model, we show that systemic delivery of AZD0156 enhances the tumor growth inhibitory effects of radiation treatment in vivo.  Since ATM deficiency contributes to PARP inhibitor sensitivity, preclinically, we evaluated the effect of combining AZD0156 with the PARP inhibitor olaparib.  Using ATM isogenic FaDu cells, we demonstrate that AZD0156 impedes the repair of olaparib induced DNA damage, resulting in elevated DNA double strand break (DSB) signaling, cell cycle arrest and apoptosis.  Preclinically, AZD0156 potentiated the effects of olaparib across a panel of lung, gastric and breast cancer cell lines in vitro, and improved the efficacy of olaparib in two patient-derived triple -neg. breast cancer (TNBC) xenograft models.  AZD0156 is currently being evaluated in phase I studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyxSyhBLkkR7Vg90H21EOLACvtfcHk0liMJIzPwAR8yQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvVOltbw%253D&md5=8a47212e061f386c37be2315095ba9ff</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-18-1394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-18-1394%26sid%3Dliteratum%253Aachs%26aulast%3DRiches%26aufirst%3DL.%2BC.%26aulast%3DTrinidad%26aufirst%3DA.%2BG.%26aulast%3DHughes%26aufirst%3DG.%26aulast%3DJones%26aufirst%3DG.%2BN.%26aulast%3DHughes%26aufirst%3DA.%2BM.%26aulast%3DThomason%26aufirst%3DA.%2BG.%26aulast%3DGavine%26aufirst%3DP.%26aulast%3DCui%26aufirst%3DA.%26aulast%3DLing%26aufirst%3DS.%26aulast%3DStott%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DR.%26aulast%3DPeel%26aufirst%3DS.%26aulast%3DGill%26aufirst%3DP.%26aulast%3DGoodwin%26aufirst%3DL.%2BM.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DPike%26aufirst%3DK.%2BG.%26aulast%3DBarlaam%26aufirst%3DB.%26aulast%3DPass%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DSmith%26aufirst%3DG.%26aulast%3DCadogan%26aufirst%3DE.%2BB.%26atitle%3DPharmacology%2520of%2520the%2520ATM%2520Inhibitor%2520AZD0156%253A%2520Potentiation%2520of%2520irradiation%2520and%2520olaparib%2520responses%2520preclinically%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2020%26volume%3D19%26issue%3D1%26spage%3D13%26epage%3D25%26doi%3D10.1158%2F1535-7163.MCT-18-1394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Durant, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riches, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trinidad, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fok, J. H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colclough, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sykes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janefeldt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstrom, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varnas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stott, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roudier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sule, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cronin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valerie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illingworth, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pass, M.</span></span> <span> </span><span class="NLM_article-title">The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models</span>. <i>Sci. Adv.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">6</span>), <span class="NLM_elocation-id">eaat1719</span> <span class="refDoi">Â DOI: 10.1126/sciadv.aat1719</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1126%2Fsciadv.aat1719" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=29938225" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2018&issue=6&author=S.+T.+Durantauthor=L.+Zhengauthor=Y.+Wangauthor=K.+Chenauthor=L.+Zhangauthor=T.+Zhangauthor=Z.+Yangauthor=L.+Richesauthor=A.+G.+Trinidadauthor=J.+H.+L.+Fokauthor=T.+Huntauthor=K.+G.+Pikeauthor=J.+Wilsonauthor=A.+Smithauthor=N.+Colcloughauthor=V.+P.+Reddyauthor=A.+Sykesauthor=A.+Janefeldtauthor=P.+Johnstromauthor=K.+Varnasauthor=A.+Takanoauthor=S.+Lingauthor=J.+Ormeauthor=J.+Stottauthor=C.+Robertsauthor=I.+Barrettauthor=G.+Jonesauthor=M.+Roudierauthor=A.+Pierceauthor=J.+Allenauthor=J.+Kahnauthor=A.+Suleauthor=J.+Karlinauthor=A.+Croninauthor=M.+Chapmanauthor=K.+Valerieauthor=R.+Illingworthauthor=M.+Pass&title=The+brain-penetrant+clinical+ATM+inhibitor+AZD1390+radiosensitizes+and+improves+survival+of+preclinical+brain+tumor+models&doi=10.1126%2Fsciadv.aat1719"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1126%2Fsciadv.aat1719&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fsciadv.aat1719%26sid%3Dliteratum%253Aachs%26aulast%3DDurant%26aufirst%3DS.%2BT.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DRiches%26aufirst%3DL.%26aulast%3DTrinidad%26aufirst%3DA.%2BG.%26aulast%3DFok%26aufirst%3DJ.%2BH.%2BL.%26aulast%3DHunt%26aufirst%3DT.%26aulast%3DPike%26aufirst%3DK.%2BG.%26aulast%3DWilson%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DReddy%26aufirst%3DV.%2BP.%26aulast%3DSykes%26aufirst%3DA.%26aulast%3DJanefeldt%26aufirst%3DA.%26aulast%3DJohnstrom%26aufirst%3DP.%26aulast%3DVarnas%26aufirst%3DK.%26aulast%3DTakano%26aufirst%3DA.%26aulast%3DLing%26aufirst%3DS.%26aulast%3DOrme%26aufirst%3DJ.%26aulast%3DStott%26aufirst%3DJ.%26aulast%3DRoberts%26aufirst%3DC.%26aulast%3DBarrett%26aufirst%3DI.%26aulast%3DJones%26aufirst%3DG.%26aulast%3DRoudier%26aufirst%3DM.%26aulast%3DPierce%26aufirst%3DA.%26aulast%3DAllen%26aufirst%3DJ.%26aulast%3DKahn%26aufirst%3DJ.%26aulast%3DSule%26aufirst%3DA.%26aulast%3DKarlin%26aufirst%3DJ.%26aulast%3DCronin%26aufirst%3DA.%26aulast%3DChapman%26aufirst%3DM.%26aulast%3DValerie%26aufirst%3DK.%26aulast%3DIllingworth%26aufirst%3DR.%26aulast%3DPass%26aufirst%3DM.%26atitle%3DThe%2520brain-penetrant%2520clinical%2520ATM%2520inhibitor%2520AZD1390%2520radiosensitizes%2520and%2520improves%2520survival%2520of%2520preclinical%2520brain%2520tumor%2520models%26jtitle%3DSci.%2520Adv.%26date%3D2018%26volume%3D4%26issue%3D6%26doi%3D10.1126%2Fsciadv.aat1719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Biddlestone-Thorpe, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sajjad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckta, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valerie, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokarz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khalil, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilfor, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golding, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deb, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Temesi, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâConnor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choe, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parada, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukhopadhyay, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valerie, K.</span></span> <span> </span><span class="NLM_article-title">ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">3189</span>â <span class="NLM_lpage">3200</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-12-3408</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F1078-0432.CCR-12-3408" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=23620409" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpsVynsL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=3189-3200&issue=12&author=L.+Biddlestone-Thorpeauthor=M.+Sajjadauthor=E.+Rosenbergauthor=J.+M.+Becktaauthor=N.+C.+Valerieauthor=M.+Tokarzauthor=B.+R.+Adamsauthor=A.+F.+Wagnerauthor=A.+Khalilauthor=D.+Gilforauthor=S.+E.+Goldingauthor=S.+Debauthor=D.+G.+Temesiauthor=A.+Lauauthor=M.+J.+O%E2%80%99Connorauthor=K.+S.+Choeauthor=L.+F.+Paradaauthor=S.+K.+Limauthor=N.+D.+Mukhopadhyayauthor=K.+Valerie&title=ATM+kinase+inhibition+preferentially+sensitizes+p53-mutant+glioma+to+ionizing+radiation&doi=10.1158%2F1078-0432.CCR-12-3408"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">ATM Kinase Inhibition Preferentially Sensitizes p53-Mutant Glioma to Ionizing Radiation</span></div><div class="casAuthors">Biddlestone-Thorpe, Laura; Sajjad, Muhammad; Rosenberg, Elizabeth; Beckta, Jason M.; Valerie, Nicholas C. K.; Tokarz, Mary; Adams, Bret R.; Wagner, Alison F.; Khalil, Ashraf; Gilfor, Donna; Golding, Sarah E.; Deb, Sumitra; Temesi, David G.; Lau, Alan; O'Connor, Mark J.; Choe, Kevin S.; Parada, Luis F.; Lim, Sang Kyun; Mukhopadhyay, Nitai D.; Valerie, Kristoffer</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3189-3200</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Glioblastoma multiforme (GBM) is the most lethal form of brain cancer with a median survival of only 12 to 15 mo.  Current std. treatment consists of surgery followed by chemoradiation.  The poor survival of patients with GBM is due to aggressive tumor invasiveness, an inability to remove all tumor tissue, and an innate tumor chemo- and radioresistance.  Ataxia-telangiectasia mutated (ATM) is an excellent target for radiosensitizing GBM because of its crit. role in regulating the DNA damage response and p53, among other cellular processes.  As a first step toward this goal, we recently showed that the novel ATM kinase inhibitor KU-60019 reduced migration, invasion, and growth, and potently radiosensitized human glioma cells in vitro.  Exptl. Design: Using orthotopic xenograft models of GBM, we now show that KU-60019 is also an effective radiosensitizer in vivo.  Human glioma cells expressing reporter genes for monitoring tumor growth and dispersal were grown intracranially, and KU-60019 was administered intratumorally by convection-enhanced delivery or osmotic pump.  Results: Our results show that the combined effect of KU-60019 and radiation significantly increased survival of mice 2- to 3-fold over controls.  Importantly, we show that glioma with mutant p53 is much more sensitive to KU-60019 radiosensitization than genetically matched wild-type glioma.  Conclusions: Taken together, our results suggest that an ATM kinase inhibitor may be an effective radiosensitizer and adjuvant therapy for patients with mutant p53 brain cancers.  Clin Cancer Res; 19(12); 3189-200. Â©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIW6Z_3LrXLbVg90H21EOLACvtfcHk0ljnptMzyMmDmA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpsVynsL4%253D&md5=b77a60ce3d07e969f3cacb897676e6f8</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-3408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-3408%26sid%3Dliteratum%253Aachs%26aulast%3DBiddlestone-Thorpe%26aufirst%3DL.%26aulast%3DSajjad%26aufirst%3DM.%26aulast%3DRosenberg%26aufirst%3DE.%26aulast%3DBeckta%26aufirst%3DJ.%2BM.%26aulast%3DValerie%26aufirst%3DN.%2BC.%26aulast%3DTokarz%26aufirst%3DM.%26aulast%3DAdams%26aufirst%3DB.%2BR.%26aulast%3DWagner%26aufirst%3DA.%2BF.%26aulast%3DKhalil%26aufirst%3DA.%26aulast%3DGilfor%26aufirst%3DD.%26aulast%3DGolding%26aufirst%3DS.%2BE.%26aulast%3DDeb%26aufirst%3DS.%26aulast%3DTemesi%26aufirst%3DD.%2BG.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DChoe%26aufirst%3DK.%2BS.%26aulast%3DParada%26aufirst%3DL.%2BF.%26aulast%3DLim%26aufirst%3DS.%2BK.%26aulast%3DMukhopadhyay%26aufirst%3DN.%2BD.%26aulast%3DValerie%26aufirst%3DK.%26atitle%3DATM%2520kinase%2520inhibition%2520preferentially%2520sensitizes%2520p53-mutant%2520glioma%2520to%2520ionizing%2520radiation%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26issue%3D12%26spage%3D3189%26epage%3D3200%26doi%3D10.1158%2F1078-0432.CCR-12-3408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, O. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brzozowski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skelding, K. A.</span></span> <span> </span><span class="NLM_article-title">Glioblastoma multiforme: an overview of emerging therapeutic targets</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">963</span>, <span class="refDoi">Â DOI: 10.3389/fonc.2019.00963</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.3389%2Ffonc.2019.00963" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=31616641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A280%3ADC%252BB3Mnot1Ogtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=963&author=O.+G.+Taylorauthor=J.+S.+Brzozowskiauthor=K.+A.+Skelding&title=Glioblastoma+multiforme%3A+an+overview+of+emerging+therapeutic+targets&doi=10.3389%2Ffonc.2019.00963"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Glioblastoma Multiforme: An Overview of Emerging Therapeutic Targets</span></div><div class="casAuthors">Taylor Olivia G; Brzozowski Joshua S; Skelding Kathryn A; Taylor Olivia G; Brzozowski Joshua S; Skelding Kathryn A</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">963</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary brain tumour in humans and has a very poor prognosis.  The existing treatments have had limited success in increasing overall survival.  Thus, identifying and understanding the key molecule(s) responsible for the malignant phenotype of GBM will yield new potential therapeutic targets.  The treatment of brain tumours faces unique challenges, including the presence of the blood brain barrier (BBB), which limits the concentration of drugs that can reach the site of the tumour.  Nevertheless, several promising treatments have been shown to cross the BBB and have shown promising pre-clinical results.  This review will outline the status of several of these promising targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS_de8wcSgngMuCWE5mhx1RfW6udTcc2ebIAJjR_rXkebntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mnot1Ogtw%253D%253D&md5=edf2d943f5e3a14021a27a885858f472</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2019.00963&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2019.00963%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DO.%2BG.%26aulast%3DBrzozowski%26aufirst%3DJ.%2BS.%26aulast%3DSkelding%26aufirst%3DK.%2BA.%26atitle%3DGlioblastoma%2520multiforme%253A%2520an%2520overview%2520of%2520emerging%2520therapeutic%2520targets%26jtitle%3DFront.%2520Oncol.%26date%3D2019%26volume%3D9%26spage%3D963%26doi%3D10.3389%2Ffonc.2019.00963" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stoyanova, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bulgarelli-Leva, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanck, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetzker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span> <span> </span><span class="NLM_article-title">Lipid kinase and protein kinase activities of G-protein-coupled phosphoinositide 3-kinase gamma: structure-activity analysis and interactions with wortmannin</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>324</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">489</span>â <span class="NLM_lpage">495</span>, <span class="refDoi">Â DOI: 10.1042/bj3240489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1042%2Fbj3240489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=9182708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADyaK2sXjvFClur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=324&publication_year=1997&pages=489-495&issue=2&author=S.+Stoyanovaauthor=G.+Bulgarelli-Levaauthor=C.+Kirschauthor=T.+Hanckauthor=R.+Klingerauthor=R.+Wetzkerauthor=M.+P.+Wymann&title=Lipid+kinase+and+protein+kinase+activities+of+G-protein-coupled+phosphoinositide+3-kinase+gamma%3A+structure-activity+analysis+and+interactions+with+wortmannin&doi=10.1042%2Fbj3240489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Lipid kinase and protein kinase activities of G-protein-coupled phosphoinositide 3-kinase Î³: structure-activity analysis and interactions with wortmannin</span></div><div class="casAuthors">Stoyanova, Stefka; Bulgarelli-Leva, Ginette; Kirsch, Cornelia; Hanck, Theodor; Klinger, Reinhard; Wetzker, Reinhard; Wymann, Matthias P.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">324</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">489-495</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press</span>)
        </div><div class="casAbstract">Signaling via 7-transmembrane helix receptors can lead to a massive increase in cellular phosphoinositide 3,4,5-trisphosphate [PtdIns(3,4,5)P3], which is crit. for the induction of various cell responses and is likely to be produced by a trimeric G-protein-sensitive phosphoinositide 3-kinase (PI3KÎ³).  P13KÎ³ is shown to be a bifunctional lipid kinase and protein kinase, and both activities are inhibited by wortmannin at concns. equal to those affecting the p85p110Î± heterodimeric PI3K (IC50 â¼2 nM).  The binding of wortmannin to PI3KÎ³, as detected by anti-wortmannin antisera, closely followed the inhibition of the kinase activities.  Truncation of >98 N-terminal amino acid residues from PI3KÎ³ produced proteins that were inactive in wortmannin binding and kinase assays.  This suggests that regions apart from the core catalytic domain are important in catalysis and inhibitor interaction.  The covalent reaction of wortmannin with PI3KÎ³ was prevented by preincubation with phosphoinositides, ATP and its analogs adenine and 5'-(4-fluorosulfonylbenzoyl)-adenine.  Proteolytic anal. of wortmannin-prelabeled PI3KÎ³ revealed candidate wortmannin-binding peptides around Lys-799.  Replacement of Lys-799 by Arg through site-directed mutagenesis aborted the covalent reaction with wortmannin and the lipid kinase and protein kinase activities completely.  The above illustrates that Lys-799 is crucial to the phosphate transfer reaction and wortmannin reactivity.  Parallel inhibition of the PI3KÎ³-assocd. protein kinase and lipid kinase by wortmannin and by the Lys-799 â Arg mutation reveals that both activities are inherent in the PI3KÎ³ polypeptide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsQd9i80PXLrVg90H21EOLACvtfcHk0ljnptMzyMmDmA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjvFClur8%253D&md5=ede792404df92ce1d5753bd99c583a40</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1042%2Fbj3240489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj3240489%26sid%3Dliteratum%253Aachs%26aulast%3DStoyanova%26aufirst%3DS.%26aulast%3DBulgarelli-Leva%26aufirst%3DG.%26aulast%3DKirsch%26aufirst%3DC.%26aulast%3DHanck%26aufirst%3DT.%26aulast%3DKlinger%26aufirst%3DR.%26aulast%3DWetzker%26aufirst%3DR.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3DLipid%2520kinase%2520and%2520protein%2520kinase%2520activities%2520of%2520G-protein-coupled%2520phosphoinositide%25203-kinase%2520gamma%253A%2520structure-activity%2520analysis%2520and%2520interactions%2520with%2520wortmannin%26jtitle%3DBiochem.%2520J.%26date%3D1997%26volume%3D324%26issue%3D2%26spage%3D489%26epage%3D495%26doi%3D10.1042%2Fbj3240489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golding, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guiard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardcastle, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leahy, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rigoreau, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stockley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. C.</span></span> <span> </span><span class="NLM_article-title">Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and radiosensitization of a human tumor cell line in vitro</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">569</span>â <span class="NLM_lpage">585</span>, <span class="refDoi">Â DOI: 10.1021/jm049526a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049526a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtFCrur%252FN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=569-585&issue=2&author=R.+J.+Griffinauthor=G.+Fontanaauthor=B.+T.+Goldingauthor=S.+Guiardauthor=I.+R.+Hardcastleauthor=J.+J.+Leahyauthor=N.+Martinauthor=C.+Richardsonauthor=L.+Rigoreauauthor=M.+Stockleyauthor=G.+C.+Smith&title=Selective+benzopyranone+and+pyrimido%5B2%2C1-a%5Disoquinolin-4-one+inhibitors+of+DNA-dependent+protein+kinase%3A+synthesis%2C+structure-activity+studies%2C+and+radiosensitization+of+a+human+tumor+cell+line+in+vitro&doi=10.1021%2Fjm049526a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: Synthesis, structure-activity studies, and radiosensitization of a human tumor cell line in vitro</span></div><div class="casAuthors">Griffin, Roger J.; Fontana, Gabriele; Golding, Bernard T.; Guiard, Sophie; Hardcastle, Ian R.; Leahy, Justin J. J.; Martin, Niall; Richardson, Caroline; Rigoreau, Laurent; Stockley, Martin; Smith, Graeme C. M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">569-585</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A diverse range of chromen-2-ones, chromen-4-ones, e.g., I, and pyrimidoisoquinolin-4-ones was synthesized and evaluated for inhibitory activity against the DNA repair enzyme DNA-dependent protein kinase (DNA-PK), with a view to elucidating structure-activity relationships for potency and kinase selectivity.  DNA-PK inhibitory activity varied widely over the series of compds. evaluated (IC50 values ranged from 0.19 to >10 Î¼M), with excellent activity being obsd. for the 7,8-benzochromen-4-one and pyrimido[2,1-a]isoquinolin-4-one templates.  By contrast, inhibitors based on the benzochromen-2-one (coumarin) or 2-aryl-7,8-benzochromen-4-one (flavone) scaffolds were less potent.  Crucially, these studies revealed a very constrained structure-activity relationship at the 2-position of the benzopyranone and pyrimido[2,1-a]isoquinolin-4-one pharmacophore, with only a 2-morpholino or 2-(2'-methylmorpholino) group being tolerated at this position.  More detailed biol. studies conducted with the most potent inhibitor NU7163 (I; IC50 = 0.19 Î¼M) demonstrated ATP-competitive DNA-PK inhibition, with a Ki value of 24 nM, and I exhibited selectivity for DNA-PK compared with the related enzymes ATM, ATR, mTOR, and PI 3-K (p110alpha).  I sensitized the HeLa human tumor cell line to the cytotoxic effects of ionizing radiation in vitro, a dose modification factor of 2.3 at 10% survival being obsd. with an inhibitor concn. of 5 Î¼M.  This study identified these structural classes as novel DNA-PK inhibitors and delineated initial structure-activity relationships against DNA-PK.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4N9L9Av3ZHbVg90H21EOLACvtfcHk0lh4zcMoNjDrug"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtFCrur%252FN&md5=fc86e38ca5b8648a17a9b7911fa6b2ae</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1021%2Fjm049526a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049526a%26sid%3Dliteratum%253Aachs%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DFontana%26aufirst%3DG.%26aulast%3DGolding%26aufirst%3DB.%2BT.%26aulast%3DGuiard%26aufirst%3DS.%26aulast%3DHardcastle%26aufirst%3DI.%2BR.%26aulast%3DLeahy%26aufirst%3DJ.%2BJ.%26aulast%3DMartin%26aufirst%3DN.%26aulast%3DRichardson%26aufirst%3DC.%26aulast%3DRigoreau%26aufirst%3DL.%26aulast%3DStockley%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DG.%2BC.%26atitle%3DSelective%2520benzopyranone%2520and%2520pyrimido%255B2%252C1-a%255Disoquinolin-4-one%2520inhibitors%2520of%2520DNA-dependent%2520protein%2520kinase%253A%2520synthesis%252C%2520structure-activity%2520studies%252C%2520and%2520radiosensitization%2520of%2520a%2520human%2520tumor%2520cell%2520line%2520in%2520vitro%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26issue%3D2%26spage%3D569%26epage%3D585%26doi%3D10.1021%2Fjm049526a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hardcastle, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cockcroft, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtin, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Murr, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leahy, J. J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stockley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golding, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rigoreau, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, R. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">7829</span>â <span class="NLM_lpage">7846</span>, <span class="refDoi">Â DOI: 10.1021/jm050444b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050444b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFKgsLbP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=7829-7846&issue=24&author=I.+R.+Hardcastleauthor=X.+Cockcroftauthor=N.+J.+Curtinauthor=M.+D.+El-Murrauthor=J.+J.+J.+Leahyauthor=M.+Stockleyauthor=B.+T.+Goldingauthor=L.+Rigoreauauthor=C.+Richardsonauthor=G.+C.+M.+Smithauthor=R.+J.+Griffin&title=Discovery+of+potent+chromen-4-one+inhibitors+of+the+DNA-dependent+protein+kinase+%28DNA-PK%29+using+a+small-molecule+library+approach&doi=10.1021%2Fjm050444b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent Chromen-4-one Inhibitors of the DNA-Dependent Protein Kinase (DNA-PK) Using a Small-Molecule Library Approach</span></div><div class="casAuthors">Hardcastle, Ian R.; Cockcroft, Xiaoling; Curtin, Nicola J.; El-Murr, Marine Desage; Leahy, Justin J. J.; Stockley, Martin; Golding, Bernard T.; Rigoreau, Laurent; Richardson, Caroline; Smith, Graeme C. M.; Griffin, Roger J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7829-7846</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-activity relationships for inhibition of DNA-dependent protein kinase (DNA-PK) have been defined for substituted chromen-4-ones.  For the 2-amino-substituted benzo[h]chromen-4-ones, a morpholine substituent at this position was essential for activity.  Small libraries of 6- and 7-alkoxy-substituted chromen-4-ones showed that a no. of 7-alkoxy-substituted chromenones displayed improved activity.  Focused libraries incorporating 6-, 7-, and 8-aryl and heteroaryl substituents were prepd.  In these cases, 6- and 7-substitution was disfavored, whereas 8-substitution was largely tolerated.  Surprisingly, two compds., 2-N-morpholino-8-dibenzofuranyl-chromen-4-one (NU7427, 32{38}) and the 2-N-morpholino-8-dibenzothiophenyl-chromen-4-one (NU7441, 32{26}) were excellent inhibitors (IC50 vs DNA-PK = 40 and 13 nM, resp.).  The ring-satd. analog 2-N-morpholino-8-(6',7',8',9'-tetrahydrodibenzothiophene)chromen-4-one, 36, retained potent activity (IC50 vs DNA-PK = 23 nM).  The dibenzothiophene 32{38} sensitized HeLa cells to ionizing radiation in vitro, with dose modification factors of 2.5 at 10% survival being obsd. at 0.5 Î¼M.  The cytotoxicity of the topoisomerase II inhibitor etoposide was also potentiated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0FBCga-GuubVg90H21EOLACvtfcHk0lh4zcMoNjDrug"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFKgsLbP&md5=35f849c46fb62110f13b3d02367e75cc</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1021%2Fjm050444b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050444b%26sid%3Dliteratum%253Aachs%26aulast%3DHardcastle%26aufirst%3DI.%2BR.%26aulast%3DCockcroft%26aufirst%3DX.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DEl-Murr%26aufirst%3DM.%2BD.%26aulast%3DLeahy%26aufirst%3DJ.%2BJ.%2BJ.%26aulast%3DStockley%26aufirst%3DM.%26aulast%3DGolding%26aufirst%3DB.%2BT.%26aulast%3DRigoreau%26aufirst%3DL.%26aulast%3DRichardson%26aufirst%3DC.%26aulast%3DSmith%26aufirst%3DG.%2BC.%2BM.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26atitle%3DDiscovery%2520of%2520potent%2520chromen-4-one%2520inhibitors%2520of%2520the%2520DNA-dependent%2520protein%2520kinase%2520%2528DNA-PK%2529%2520using%2520a%2520small-molecule%2520library%2520approach%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26issue%3D24%26spage%3D7829%26epage%3D7846%26doi%3D10.1021%2Fjm050444b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fok, J. H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos-Montoya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez-Chantada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wijnhoven, P. W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Follia, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrington, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karmokar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willis, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cairns, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">NikkilÃ¤, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beattie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâConnor, L. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fawell, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâConnor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingsworth, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cadogan, E. B.</span></span> <span> </span><span class="NLM_article-title">AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">5065</span>, <span class="refDoi">Â DOI: 10.1038/s41467-019-12836-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1038%2Fs41467-019-12836-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=31699977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A280%3ADC%252BB3MjmsVOltA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=5065&issue=1&author=J.+H.+L.+Fokauthor=A.+Ramos-Montoyaauthor=M.+Vazquez-Chantadaauthor=P.+W.+G.+Wijnhovenauthor=V.+Folliaauthor=N.+Jamesauthor=P.+M.+Farringtonauthor=A.+Karmokarauthor=S.+E.+Willisauthor=J.+Cairnsauthor=J.+Nikkil%C3%A4author=D.+Beattieauthor=G.+M.+Lamontauthor=M.+R.+V.+Finlayauthor=J.+Wilsonauthor=A.+Smithauthor=L.+O.+O%E2%80%99Connorauthor=S.+Lingauthor=S.+E.+Fawellauthor=M.+J.+O%E2%80%99Connorauthor=S.+J.+Hollingsworthauthor=E.+Deanauthor=F.+W.+Goldbergauthor=B.+R.+Daviesauthor=E.+B.+Cadogan&title=AZD7648+is+a+potent+and+selective+DNA-PK+inhibitor+that+enhances+radiation%2C+chemotherapy+and+olaparib+activity&doi=10.1038%2Fs41467-019-12836-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity</span></div><div class="casAuthors">Fok Jacqueline H L; Ramos-Montoya Antonio; Wijnhoven Paul W G; Follia Valeria; James Neil; Farrington Paul M; Karmokar Ankur; Nikkila Jenni; Fawell Stephen E; O'Connor Mark J; Davies Barry R; Cadogan Elaine B; Vazquez-Chantada Mercedes; Ling Stephanie; Willis Sophie E; O'Connor Lenka Oplustil; Cairns Jonathan; Beattie David; Lamont Gillian M; Finlay M Raymond V; Goldberg Frederick W; Wilson Joanne; Smith Aaron; Hollingsworth Simon J; Dean Emma</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5065</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">DNA-dependent protein kinase (DNA-PK) is a critical player in the DNA damage response (DDR) and instrumental in the non-homologous end-joining pathway (NHEJ) used to detect and repair DNA double-strand breaks (DSBs).  We demonstrate that the potent and highly selective DNA-PK inhibitor, AZD7648, is an efficient sensitizer of radiation- and doxorubicin-induced DNA damage, with combinations in xenograft and patient-derived xenograft (PDX) models inducing sustained regressions.  Using ATM-deficient cells, we demonstrate that AZD7648, in combination with the PARP inhibitor olaparib, increases genomic instability, resulting in cell growth inhibition and apoptosis.  AZD7648 enhanced olaparib efficacy across a range of doses and schedules in xenograft and PDX models, enabling sustained tumour regression and providing a clear rationale for its clinical investigation.  Through its differentiated mechanism of action as an NHEJ inhibitor, AZD7648 complements the current armamentarium of DDR-targeted agents and has potential in combination with these agents to achieve deeper responses to current therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQf_5P1MX4JaXtlzo9xastyfW6udTcc2ebabpHd-0XGz7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MjmsVOltA%253D%253D&md5=b41d0e83963ad440f12b93fbdeed861e</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1038%2Fs41467-019-12836-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-019-12836-9%26sid%3Dliteratum%253Aachs%26aulast%3DFok%26aufirst%3DJ.%2BH.%2BL.%26aulast%3DRamos-Montoya%26aufirst%3DA.%26aulast%3DVazquez-Chantada%26aufirst%3DM.%26aulast%3DWijnhoven%26aufirst%3DP.%2BW.%2BG.%26aulast%3DFollia%26aufirst%3DV.%26aulast%3DJames%26aufirst%3DN.%26aulast%3DFarrington%26aufirst%3DP.%2BM.%26aulast%3DKarmokar%26aufirst%3DA.%26aulast%3DWillis%26aufirst%3DS.%2BE.%26aulast%3DCairns%26aufirst%3DJ.%26aulast%3DNikkil%25C3%25A4%26aufirst%3DJ.%26aulast%3DBeattie%26aufirst%3DD.%26aulast%3DLamont%26aufirst%3DG.%2BM.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DWilson%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DL.%2BO.%26aulast%3DLing%26aufirst%3DS.%26aulast%3DFawell%26aufirst%3DS.%2BE.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DHollingsworth%26aufirst%3DS.%2BJ.%26aulast%3DDean%26aufirst%3DE.%26aulast%3DGoldberg%26aufirst%3DF.%2BW.%26aulast%3DDavies%26aufirst%3DB.%2BR.%26aulast%3DCadogan%26aufirst%3DE.%2BB.%26atitle%3DAZD7648%2520is%2520a%2520potent%2520and%2520selective%2520DNA-PK%2520inhibitor%2520that%2520enhances%2520radiation%252C%2520chemotherapy%2520and%2520olaparib%2520activity%26jtitle%3DNat.%2520Commun.%26date%3D2019%26volume%3D10%26issue%3D1%26spage%3D5065%26doi%3D10.1038%2Fs41467-019-12836-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zenke, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirrenberg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahmen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vassilev, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pehl, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchss, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaukat, A.</span></span> <span> </span><span class="NLM_article-title">Abstract 1658: M3814, a novel investigational DNA-PK inhibitor: enhancing the effect of fractionated radiotherapy leading to complete regression of tumors in mice</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span> (<span class="NLM_issue">14, Suppl.</span>),  <span class="NLM_fpage">1658</span>, <span class="refDoi">Â DOI: 10.1158/1538-7445.AM2016-1658</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F1538-7445.AM2016-1658" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=1658&issue=14%2C+Suppl.&author=F.+T.+Zenkeauthor=A.+Zimmermannauthor=C.+Sirrenbergauthor=H.+Dahmenauthor=L.+Vassilevauthor=U.+Pehlauthor=T.+Fuchssauthor=A.+Blaukat&title=Abstract+1658%3A+M3814%2C+a+novel+investigational+DNA-PK+inhibitor%3A+enhancing+the+effect+of+fractionated+radiotherapy+leading+to+complete+regression+of+tumors+in+mice&doi=10.1158%2F1538-7445.AM2016-1658"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2016-1658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2016-1658%26sid%3Dliteratum%253Aachs%26aulast%3DZenke%26aufirst%3DF.%2BT.%26aulast%3DZimmermann%26aufirst%3DA.%26aulast%3DSirrenberg%26aufirst%3DC.%26aulast%3DDahmen%26aufirst%3DH.%26aulast%3DVassilev%26aufirst%3DL.%26aulast%3DPehl%26aufirst%3DU.%26aulast%3DFuchss%26aufirst%3DT.%26aulast%3DBlaukat%26aufirst%3DA.%26atitle%3DAbstract%25201658%253A%2520M3814%252C%2520a%2520novel%2520investigational%2520DNA-PK%2520inhibitor%253A%2520enhancing%2520the%2520effect%2520of%2520fractionated%2520radiotherapy%2520leading%2520to%2520complete%2520regression%2520of%2520tumors%2520in%2520mice%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26issue%3D14%252C%2520Suppl%26spage%3D1658%26doi%3D10.1158%2F1538-7445.AM2016-1658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fuchss, T.</span>; <span class="NLM_string-name">Emde, U.</span>; <span class="NLM_string-name">Buchstaller, H.-P.</span>; <span class="NLM_string-name">Merski, W.</span></span> <span> </span><span class="NLM_article-title">Arylquinazolines</span>. <span class="NLM_patent">WO2014183850</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=T.+Fuchss&author=U.+Emde&author=H.-P.+Buchstaller&author=W.+Merski&title=Arylquinazolines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFuchss%26aufirst%3DT.%26atitle%3DArylquinazolines%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czauderna, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zenke, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaukat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vassilev, L. T.</span></span> <span> </span><span class="NLM_article-title">Therapeutic implications of p53 status on cancer cell fate following exposure to ionizing radiation and the DNA-PK inhibitor M3814</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2457</span>â <span class="NLM_lpage">2468</span>, <span class="refDoi">Â DOI: 10.1158/1541-7786.MCR-19-0362</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F1541-7786.MCR-19-0362" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=31551253" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjsleqsro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2019&pages=2457-2468&issue=12&author=Q.+Sunauthor=Y.+Guoauthor=X.+Liuauthor=F.+Czaudernaauthor=M.+I.+Carrauthor=F.+T.+Zenkeauthor=A.+Blaukatauthor=L.+T.+Vassilev&title=Therapeutic+implications+of+p53+status+on+cancer+cell+fate+following+exposure+to+ionizing+radiation+and+the+DNA-PK+inhibitor+M3814&doi=10.1158%2F1541-7786.MCR-19-0362"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic implications of p53 status on cancer cell fate following exposure to ionizing radiation and the DNA-PK Inhibitor M3814</span></div><div class="casAuthors">Sun, Qing; Guo, Yige; Liu, Xiaohong; Czauderna, Frank; Carr, Michael I.; Zenke, Frank T.; Blaukat, Andree; Vassilev, Lyubomir T.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2457-2468</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Inhibition of DNA double-strand break (DSB) repair in cancer cells has been proposed as a new therapeutic strategy for potentiating the anticancer effects of radiotherapy.  M3814 is a novel, selective pharmacol. inhibitor of the serine/threonine kinase DNA-dependent protein kinase (DNA-PK), a key driver of nonhomologous end-joining, one of the main DSB-repair pathways, currently under clin. investigation.  Here, we show that M3814 effectively blocks the repair of radiation-induced DSBs and potently enhances p53 phosphorylation and activation.  In p53 wild-type cells, ataxia telangiectasia-mutated (ATM) and its targets, p53 and checkpoint kinase 2 (CHK2), were more strongly activated by combination treatment with M3814 and radiation than by radiation alone, leading to a complete p53-dependent cell-cycle block and premature cell senescence.  Cancer cells with dysfunctional p53 were unable to fully arrest their cell cycle and entered S and M phases with unrepaired DNA, leading to mitotic catastrophe and apoptotic cell death.  Isogenic p53-null/wild-type A549 and HT-1080 cell lines were generated and used to demonstrate that p53 plays a crit. role in detg. the response to ionizing radiation and M3814.  Time-lapse imaging of cell death and measuring apoptosis in panels of p53 wild-type and p53-null/mutant cancer lines confirmed the clear differences in cell fate, dependent on p53 status.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGZeMEmQ9_MrVg90H21EOLACvtfcHk0lhStCZMMZFjWQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjsleqsro%253D&md5=502bf7a52d1da6188e73406602c5402d</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-19-0362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-19-0362%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DCzauderna%26aufirst%3DF.%26aulast%3DCarr%26aufirst%3DM.%2BI.%26aulast%3DZenke%26aufirst%3DF.%2BT.%26aulast%3DBlaukat%26aufirst%3DA.%26aulast%3DVassilev%26aufirst%3DL.%2BT.%26atitle%3DTherapeutic%2520implications%2520of%2520p53%2520status%2520on%2520cancer%2520cell%2520fate%2520following%2520exposure%2520to%2520ionizing%2520radiation%2520and%2520the%2520DNA-PK%2520inhibitor%2520M3814%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2019%26volume%3D17%26issue%3D12%26spage%3D2457%26epage%3D2468%26doi%3D10.1158%2F1541-7786.MCR-19-0362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carr, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, L.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zenke, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaukat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vassilev, L. T.</span></span> <span> </span><span class="NLM_article-title">DNA-PK inhibitor, M3814, as a new combination partner of Mylotarg in the treatment of acute myeloid leukemia</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">127</span>, <span class="refDoi">Â DOI: 10.3389/fonc.2020.00127</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.3389%2Ffonc.2020.00127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=32117773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A280%3ADC%252BB387otVCruw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=127&author=M.+I.+Carrauthor=A.+Zimmermannauthor=L.-Y.+Chiuauthor=F.+T.+Zenkeauthor=A.+Blaukatauthor=L.+T.+Vassilev&title=DNA-PK+inhibitor%2C+M3814%2C+as+a+new+combination+partner+of+Mylotarg+in+the+treatment+of+acute+myeloid+leukemia&doi=10.3389%2Ffonc.2020.00127"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">DNA-PK Inhibitor, M3814, as a New Combination Partner of Mylotarg in the Treatment of Acute Myeloid Leukemia</span></div><div class="casAuthors">Carr Michael I; Chiu Li-Ya; Vassilev Lyubomir T; Zimmermann Astrid; Zenke Frank T; Blaukat Andree</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">127</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Despite significant advances in the treatment of acute myeloid leukemia (AML) the long-term prognosis remains relatively poor and there is an urgent need for improved therapies with increased potency and tumor selectivity.  Mylotarg is the first AML-targeting drug from a new generation of antibody drug conjugate (ADC) therapies aiming at the acute leukemia cell compartment with increased specificity.  This agent targets leukemia cells for apoptosis with a cytotoxic payload, calicheamicin, carried by a CD33-specific antibody.  Calicheamicin induces DNA double strand breaks (DSB) which, if left unrepaired, lead to cell cycle arrest and apoptosis in cancer cells.  However, repair of DSB by the non-homologous end joining pathway driven by DNA-dependent protein kinase (DNA-PK) can reduce the efficacy of calicheamicin.  M3814 is a novel, potent and selective inhibitor of DNA-PK.  This compound effectively blocks DSB repair, strongly potentiates the antitumor activity of ionizing radiation and DSB-inducing chemotherapeutics and is currently under clinical investigation.  Suppressing DSB repair with M3814 synergistically enhanced the apoptotic activity of calicheamicin in cultured AML cells.  Combination of M3814 with Mylotarg in two AML xenograft models, MV4-11 and HL-60, demonstrated increased efficacy and significantly improved survival benefit without elevated body weight loss.  Our results support a new application for pharmacological DNA-PK inhibitors as enhancers of Mylotarg and a potential new combination treatment option for AML patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQppVGC0sO745agfuraLLzSfW6udTcc2eaHYFAowm0KJ7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB387otVCruw%253D%253D&md5=ca2888c2088e0baa327d885479e4b7ec</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2020.00127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2020.00127%26sid%3Dliteratum%253Aachs%26aulast%3DCarr%26aufirst%3DM.%2BI.%26aulast%3DZimmermann%26aufirst%3DA.%26aulast%3DChiu%26aufirst%3DL.-Y.%26aulast%3DZenke%26aufirst%3DF.%2BT.%26aulast%3DBlaukat%26aufirst%3DA.%26aulast%3DVassilev%26aufirst%3DL.%2BT.%26atitle%3DDNA-PK%2520inhibitor%252C%2520M3814%252C%2520as%2520a%2520new%2520combination%2520partner%2520of%2520Mylotarg%2520in%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DFront.%2520Oncol.%26date%3D2020%26volume%3D10%26spage%3D127%26doi%3D10.3389%2Ffonc.2020.00127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mortensen, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrin-Ninkovic, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shevlin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elsner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitefield, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tehrani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sapienza, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riggs, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parnes, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Packard, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B. G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahmanyar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leisten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khambatta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamez, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisonette, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apuy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cathers, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canan, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moghaddam, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raymon, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Worland, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narla, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fultz, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sankar, S.</span></span> <span> </span><span class="NLM_article-title">Optimization of a series of triazole containing mammalian target of rapamycin (mTOR) kinase Inhibitors and the discovery of CC-115</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">5599</span>â <span class="NLM_lpage">5608</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b00627</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00627" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVKit7jF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=5599-5608&issue=14&author=D.+S.+Mortensenauthor=S.+M.+Perrin-Ninkovicauthor=G.+Shevlinauthor=J.+Elsnerauthor=J.+Zhaoauthor=B.+Whitefieldauthor=L.+Tehraniauthor=J.+Sapienzaauthor=J.+R.+Riggsauthor=J.+S.+Parnesauthor=P.+Papaauthor=G.+Packardauthor=B.+G.+S.+Leeauthor=R.+Harrisauthor=M.+Correaauthor=S.+Bahmanyarauthor=S.+J.+Richardsonauthor=S.+X.+Pengauthor=J.+Leistenauthor=G.+Khambattaauthor=M.+Hickmanauthor=J.+C.+Gamezauthor=R.+R.+Bisonetteauthor=J.+Apuyauthor=B.+E.+Cathersauthor=S.+S.+Cananauthor=M.+F.+Moghaddamauthor=H.+K.+Raymonauthor=P.+Worlandauthor=R.+K.+Narlaauthor=K.+E.+Fultzauthor=S.+Sankar&title=Optimization+of+a+series+of+triazole+containing+mammalian+target+of+rapamycin+%28mTOR%29+kinase+Inhibitors+and+the+discovery+of+CC-115&doi=10.1021%2Facs.jmedchem.5b00627"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115</span></div><div class="casAuthors">Mortensen, Deborah S.; Perrin-Ninkovic, Sophie M.; Shevlin, Graziella; Elsner, Jan; Zhao, Jingjing; Whitefield, Brandon; Tehrani, Lida; Sapienza, John; Riggs, Jennifer R.; Parnes, Jason S.; Papa, Patrick; Packard, Garrick; Lee, Branden G. S.; Harris, Roy; Correa, Matthew; Bahmanyar, Sogole; Richardson, Samantha J.; Peng, Sophie X.; Leisten, Jim; Khambatta, Godrej; Hickman, Matt; Gamez, James C.; Bisonette, Rene R.; Apuy, Julius; Cathers, Brian E.; Canan, Stacie S.; Moghaddam, Mehran F.; Raymon, Heather K.; Worland, Peter; Narla, Rama Krishna; Fultz, Kimberly E.; Sankar, Sabita</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5599-5608</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis and structure-activity relationship (SAR) of a novel series of triazoles contg. mammalian target of rapamycin (mTOR) kinase inhibitors is reported.  SAR studies examg. the potency, selectivity, and PK parameters for a series of triazole contg. 4,6- or 1,7-disubstituted-3,4-dihydropyrazino[2,3-b]pyrazine-2(1H)-ones resulted in the identification of triazole contg. mTOR kinase inhibitors with improved PK properties.  Potent compds. from this series were found to block both mTORC1(pS6) and mTORC2(pAktS473) signaling in PC-3 cancer cells, in vitro and in vivo.  When assessed in efficacy models, analogs exhibited dose-dependent efficacy in tumor xenograft models.  This work resulted in the selection of CC-115 (I) for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5ItrhIWvAFLVg90H21EOLACvtfcHk0ljz9J4F8K_pMg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVKit7jF&md5=b7e5351dd7b16119cafe97fb961dd3d9</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00627&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00627%26sid%3Dliteratum%253Aachs%26aulast%3DMortensen%26aufirst%3DD.%2BS.%26aulast%3DPerrin-Ninkovic%26aufirst%3DS.%2BM.%26aulast%3DShevlin%26aufirst%3DG.%26aulast%3DElsner%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DWhitefield%26aufirst%3DB.%26aulast%3DTehrani%26aufirst%3DL.%26aulast%3DSapienza%26aufirst%3DJ.%26aulast%3DRiggs%26aufirst%3DJ.%2BR.%26aulast%3DParnes%26aufirst%3DJ.%2BS.%26aulast%3DPapa%26aufirst%3DP.%26aulast%3DPackard%26aufirst%3DG.%26aulast%3DLee%26aufirst%3DB.%2BG.%2BS.%26aulast%3DHarris%26aufirst%3DR.%26aulast%3DCorrea%26aufirst%3DM.%26aulast%3DBahmanyar%26aufirst%3DS.%26aulast%3DRichardson%26aufirst%3DS.%2BJ.%26aulast%3DPeng%26aufirst%3DS.%2BX.%26aulast%3DLeisten%26aufirst%3DJ.%26aulast%3DKhambatta%26aufirst%3DG.%26aulast%3DHickman%26aufirst%3DM.%26aulast%3DGamez%26aufirst%3DJ.%2BC.%26aulast%3DBisonette%26aufirst%3DR.%2BR.%26aulast%3DApuy%26aufirst%3DJ.%26aulast%3DCathers%26aufirst%3DB.%2BE.%26aulast%3DCanan%26aufirst%3DS.%2BS.%26aulast%3DMoghaddam%26aufirst%3DM.%2BF.%26aulast%3DRaymon%26aufirst%3DH.%2BK.%26aulast%3DWorland%26aufirst%3DP.%26aulast%3DNarla%26aufirst%3DR.%2BK.%26aulast%3DFultz%26aufirst%3DK.%2BE.%26aulast%3DSankar%26aufirst%3DS.%26atitle%3DOptimization%2520of%2520a%2520series%2520of%2520triazole%2520containing%2520mammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%2520kinase%2520Inhibitors%2520and%2520the%2520discovery%2520of%2520CC-115%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D14%26spage%3D5599%26epage%3D5608%26doi%3D10.1021%2Facs.jmedchem.5b00627" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsuji, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sapinoso, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaffney, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sankar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raymon, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortensen, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span> <span> </span><span class="NLM_article-title">CC-115, a dual inhibitor of mTOR kinase and DNA-PK, blocks DNA damage repair pathways and selectively inhibits ATM-deficient cell growth in vitro</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">43</span>),  <span class="NLM_fpage">74688</span>â <span class="NLM_lpage">74702</span>, <span class="refDoi">Â DOI: 10.18632/oncotarget.20342</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.18632%2Foncotarget.20342" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=29088817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A280%3ADC%252BC1M7mtlegsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=74688-74702&issue=43&author=T.+Tsujiauthor=L.+M.+Sapinosoauthor=T.+Tranauthor=B.+Gaffneyauthor=L.+Wongauthor=S.+Sankarauthor=H.+K.+Raymonauthor=D.+S.+Mortensenauthor=S.+Xu&title=CC-115%2C+a+dual+inhibitor+of+mTOR+kinase+and+DNA-PK%2C+blocks+DNA+damage+repair+pathways+and+selectively+inhibits+ATM-deficient+cell+growth+in+vitro&doi=10.18632%2Foncotarget.20342"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">CC-115, a dual inhibitor of mTOR kinase and DNA-PK, blocks DNA damage repair pathways and selectively inhibits ATM-deficient cell growth in vitro</span></div><div class="casAuthors">Tsuji Toshiya; Sapinoso Lisa M; Tran Tam; Gaffney Bonny; Wong Lilly; Sankar Sabita; Xu Shuichan; Raymon Heather K; Mortensen Deborah S</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">74688-74702</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">CC-115, a selective dual inhibitor of the mammalian target of rapamycin (mTOR) kinase and DNA-dependent protein kinase (DNA-PK), is undergoing Phase 1 clinical studies.  Here we report the characterization of DNA-PK inhibitory activity of CC-115 in cancer cell lines.  CC-115 inhibits auto-phosphorylation of the catalytic subunit of DNA-PK (DNA-PKcs) at the S2056 site (pDNA-PK S2056), leading to blockade of DNA-PK-mediated non-homologous end joining (NHEJ).  CC-115 also indirectly reduces the phosphorylation of ataxia-telangiectasia mutated kinase (ATM) at S1981 and its substrates as well as homologous recombination (HR).  The mTOR kinase and DNA-PK inhibitory activity of CC-115 leads to not only potent anti-tumor activity against a large panel of hematopoietic and solid cancer cell lines but also strong induction of apoptosis in a subset of cancer lines.  Mechanistically, CC-115 prevents NHEJ by inhibiting the dissociation of DNA-PKcs, X-ray repair cross-complementing protein 4 (XRCC4), and DNA ligase IV from DNA ends.  CC-115 inhibits colony formation of ATM-deficient cells more potently than ATM-proficient cells, indicating that inhibition of DNA-PK is synthetically lethal with the loss of functional ATM.  In conclusion, CC-115 inhibits both mTOR signaling and NHEJ and HR by direct inhibition of DNA-PK.  The mechanistic data not only provide selection of potential pharmacodynamic (PD) markers but also support CC-115 clinical development in patients with ATM-deficient tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQRKdIxzbJTPHy-c-E1v-fmfW6udTcc2eaHYFAowm0KJ7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7mtlegsA%253D%253D&md5=c3f7816332465ea83b64ca56671754b1</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.20342&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.20342%26sid%3Dliteratum%253Aachs%26aulast%3DTsuji%26aufirst%3DT.%26aulast%3DSapinoso%26aufirst%3DL.%2BM.%26aulast%3DTran%26aufirst%3DT.%26aulast%3DGaffney%26aufirst%3DB.%26aulast%3DWong%26aufirst%3DL.%26aulast%3DSankar%26aufirst%3DS.%26aulast%3DRaymon%26aufirst%3DH.%2BK.%26aulast%3DMortensen%26aufirst%3DD.%2BS.%26aulast%3DXu%26aufirst%3DS.%26atitle%3DCC-115%252C%2520a%2520dual%2520inhibitor%2520of%2520mTOR%2520kinase%2520and%2520DNA-PK%252C%2520blocks%2520DNA%2520damage%2520repair%2520pathways%2520and%2520selectively%2520inhibits%2520ATM-deficient%2520cell%2520growth%2520in%2520vitro%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26issue%3D43%26spage%3D74688%26epage%3D74702%26doi%3D10.18632%2Foncotarget.20342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DomÃ­nguez-Kelly, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MartÃ­n, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koundrioukoff, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanenbaum, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smits, V. A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medema, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debatisse, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freire, R.</span></span> <span> </span><span class="NLM_article-title">Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonuclease</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>194</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">567</span>â <span class="NLM_lpage">579</span>, <span class="refDoi">Â DOI: 10.1083/jcb.201101047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1083%2Fjcb.201101047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=21859861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtV2gt7jK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=194&publication_year=2011&pages=567-579&issue=4&author=R.+Dom%C3%ADnguez-Kellyauthor=Y.+Mart%C3%ADnauthor=S.+Koundrioukoffauthor=M.+E.+Tanenbaumauthor=V.+A.+J.+Smitsauthor=R.+H.+Medemaauthor=M.+Debatisseauthor=R.+Freire&title=Wee1+controls+genomic+stability+during+replication+by+regulating+the+Mus81-Eme1+endonuclease&doi=10.1083%2Fjcb.201101047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonuclease</span></div><div class="casAuthors">Dominguez-Kelly, Raquel; Martin, Yuse; Koundrioukoff, Stephane; Tanenboum, Marvin E.; Smits, Veronique A. J.; Medema, Rene H.; Debatisse, Michelle; Freire, Raimundo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">194</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">567-579</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Correct replication of the genome and protection of its integrity are essential for cell survival.  In a high-throughput screen studying H2AX phosphorylation, we identified Wee1 as a regulator of genomic stability.  Wee1 down-regulation not only induced H2AX phosphorylation but also triggered a general DNA (DNA) damage response (DDR) and caused a block in DNA replication, resulting in accumulation of cells in S phase.  Wee1-deficient cells showed a decrease in replication fork speed, demonstrating the involvement of Wee1 in DNA replication.  Inhibiting Wee1 in cells treated with short treatment of hydroxyurea enhanced the DDR, which suggests that Wee1 specifically protects the stability of stalled replication forks.  Notably, the DDR induced by depletion of Wee1 critically depends on the Mus81-Eme1 endonuclease, and we found that codepletion of Mus81 and Wee1 abrogated the S phase delay.  Importantly, Wee1 and Mus81 interact in vivo, suggesting direct regulation.  Altogether, these results demonstrate a novel role of Wee1 in controlling Mus81 and DNA replication in human cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFrPVJtI5YbLVg90H21EOLACvtfcHk0ljZno1ZnBbbSw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtV2gt7jK&md5=06f366f4e9dae5264bf2cd28f192c829</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1083%2Fjcb.201101047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.201101047%26sid%3Dliteratum%253Aachs%26aulast%3DDom%25C3%25ADnguez-Kelly%26aufirst%3DR.%26aulast%3DMart%25C3%25ADn%26aufirst%3DY.%26aulast%3DKoundrioukoff%26aufirst%3DS.%26aulast%3DTanenbaum%26aufirst%3DM.%2BE.%26aulast%3DSmits%26aufirst%3DV.%2BA.%2BJ.%26aulast%3DMedema%26aufirst%3DR.%2BH.%26aulast%3DDebatisse%26aufirst%3DM.%26aulast%3DFreire%26aufirst%3DR.%26atitle%3DWee1%2520controls%2520genomic%2520stability%2520during%2520replication%2520by%2520regulating%2520the%2520Mus81-Eme1%2520endonuclease%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2011%26volume%3D194%26issue%3D4%26spage%3D567%26epage%3D579%26doi%3D10.1083%2Fjcb.201101047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Do, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doroshow, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kummar, S.</span></span> <span> </span><span class="NLM_article-title">Wee1 kinase as a target for cancer therapy</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">3159</span>â <span class="NLM_lpage">3164</span>, <span class="refDoi">Â DOI: 10.4161/cc.26062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.4161%2Fcc.26062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=24013427" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvV2jsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=3159-3164&issue=19&author=K.+Doauthor=J.+H.+Doroshowauthor=S.+Kummar&title=Wee1+kinase+as+a+target+for+cancer+therapy&doi=10.4161%2Fcc.26062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Wee1 kinase as a target for cancer therapy</span></div><div class="casAuthors">Do, Khanh; Doroshow, James H.; Kummar, Shivaani</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3159-3164</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1538-4101</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">A review.  Wee1, a protein kinase, regulates the G2 checkpoint in response to DNA damage.  Preclin. studies have elucidated the role of wee1 in DNA damage repair and the stabilization of replication forks, supporting the validity of wee1 inhibition as a viable therapeutic target in cancer.  MK-1775, a selective and potent small-mol. inhibitor of wee1, is under clin. development as a potentiator of DNA damage caused by cytotoxic chemotherapies.  We present a review of the role of wee1 in the cell cycle and DNA replication and summarize the clin. development to date of this novel class of anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlvNzPGTmRbrVg90H21EOLACvtfcHk0ljZno1ZnBbbSw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvV2jsrg%253D&md5=19dbe1e7386a614dda65e85e856cdefb</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.4161%2Fcc.26062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.26062%26sid%3Dliteratum%253Aachs%26aulast%3DDo%26aufirst%3DK.%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26aulast%3DKummar%26aufirst%3DS.%26atitle%3DWee1%2520kinase%2520as%2520a%2520target%2520for%2520cancer%2520therapy%26jtitle%3DCell%2520Cycle%26date%3D2013%26volume%3D12%26issue%3D19%26spage%3D3159%26epage%3D3164%26doi%3D10.4161%2Fcc.26062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matheson, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Backos, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reigan, P.</span></span> <span> </span><span class="NLM_article-title">Targeting WEE1 kinase in cancer</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">872</span>â <span class="NLM_lpage">881</span>, <span class="refDoi">Â DOI: 10.1016/j.tips.2016.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.tips.2016.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=27427153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVKnsbfK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=872-881&issue=10&author=C.+J.+Mathesonauthor=D.+S.+Backosauthor=P.+Reigan&title=Targeting+WEE1+kinase+in+cancer&doi=10.1016%2Fj.tips.2016.06.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting WEE1 Kinase in Cancer</span></div><div class="casAuthors">Matheson, Christopher J.; Backos, Donald S.; Reigan, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">872-881</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">WEE1 kinase plays a crucial role in the G2-M cell-cycle checkpoint arrest for DNA repair before mitotic entry.  Normal cells repair damaged DNA during G1 arrest; however, cancer cells often have a deficient G1-S checkpoint and depend on a functional G2-M checkpoint for DNA repair.  WEE1 is expressed at high levels in various cancer types including breast cancers, leukemia, melanoma, and adult and pediatric brain tumors.  Many of these cancers are treated with DNA-damaging agents; therefore, targeting WEE1 for inhibition and compromising the G2-M checkpoint presents an opportunity to potentiate therapy.  In this review we summarize the current WEE1 inhibitors, the potential for further inhibitor development, and the challenges in the clinic for the WEE1 inhibitor strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_mgdRwiwqLbVg90H21EOLACvtfcHk0ljZno1ZnBbbSw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVKnsbfK&md5=f56e9e7a3c30a041cb8e65a097c78fa9</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2016.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2016.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DMatheson%26aufirst%3DC.%2BJ.%26aulast%3DBackos%26aufirst%3DD.%2BS.%26aulast%3DReigan%26aufirst%3DP.%26atitle%3DTargeting%2520WEE1%2520kinase%2520in%2520cancer%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2016%26volume%3D37%26issue%3D10%26spage%3D872%26epage%3D881%26doi%3D10.1016%2Fj.tips.2016.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Music, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlrot, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermansen, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hjelmborg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Stricker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kristensen, B. W.</span></span> <span> </span><span class="NLM_article-title">Expression and prognostic value of the WEE1 kinase in gliomas</span>. <i>J. Neuro-Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>127</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">381</span>â <span class="NLM_lpage">389</span>, <span class="refDoi">Â DOI: 10.1007/s11060-015-2050-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1007%2Fs11060-015-2050-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=26738845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC28XksF2msA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2016&pages=381-389&issue=2&author=D.+Musicauthor=R.+H.+Dahlrotauthor=S.+K.+Hermansenauthor=J.+Hjelmborgauthor=K.+de+Strickerauthor=S.+Hansenauthor=B.+W.+Kristensen&title=Expression+and+prognostic+value+of+the+WEE1+kinase+in+gliomas&doi=10.1007%2Fs11060-015-2050-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Expression and prognostic value of the WEE1 kinase in gliomas</span></div><div class="casAuthors">Music, Darija; Dahlrot, Rikke Hedegaard; Hermansen, Simon Kjaer; Hjelmborg, Jacob; de Stricker, Karin; Hansen, Steinbjoern; Kristensen, Bjarne Winther</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuro-Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">381-389</span>CODEN:
                <span class="NLM_cas:coden">JNODD2</span>;
        ISSN:<span class="NLM_cas:issn">0167-594X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">High-grade gliomas have an aggressive clin. course and new clin. biomarkers and therapeutic targets are highly needed.  WEE1 is a regulator of the G2 checkpoint in glioblastoma (GBM) cells.  Inhibition of this kinase has, in exptl. glioma studies, been suggested to enhance sensitivity to irradn. and temozolomide.  However, expression level and prognostic potential of WEE1 protein in gliomas remain uninvestigated.  In this study, glioma samples from 235 patients across all four WHO grades were analyzed by immunohistochem.  Using image anal., we calcd. the area fraction of WEE1 pos. nuclei.  We found that WEE1 protein was localized in tumor cell nuclei and expressed in all glioma types and grades.  Although WEE1 protein levels are higher in GBMs (mean 24.5 %) relative to grade III (mean 14,0 %, p < 0.05) and grade II (mean 6.8 %, p < 0.001) gliomas, high WEE1 protein was assocd. with better survival in GBMs (p = 0.002).  This was confirmed in multivariate anal. (HR 0.60, p = 0.003) even when adjusted for MGMT status (HR 0.60, p = 0.005).  In conclusion, we report a nuclear expression of WEE1 protein in all glioma grades and types.  The WEE1 pos. nuclear area was correlated with malignancy grade but it was inversely assocd. with prognosis in GBM.  Although WEE1 is a frequently occurring protein and has been proposed as a novel target in GBM, the role of WEE1 in glioma patient survival appears to be connected to the MGMT status and is more complex than previously anticipated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKinaeuX9iRbVg90H21EOLACvtfcHk0litwHEuB1HmhA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XksF2msA%253D%253D&md5=b3c8a429feb3fcdc7d9f2ff194bfdeea</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1007%2Fs11060-015-2050-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11060-015-2050-4%26sid%3Dliteratum%253Aachs%26aulast%3DMusic%26aufirst%3DD.%26aulast%3DDahlrot%26aufirst%3DR.%2BH.%26aulast%3DHermansen%26aufirst%3DS.%2BK.%26aulast%3DHjelmborg%26aufirst%3DJ.%26aulast%3Dde%2BStricker%26aufirst%3DK.%26aulast%3DHansen%26aufirst%3DS.%26aulast%3DKristensen%26aufirst%3DB.%2BW.%26atitle%3DExpression%2520and%2520prognostic%2520value%2520of%2520the%2520WEE1%2520kinase%2520in%2520gliomas%26jtitle%3DJ.%2520Neuro-Oncol.%26date%3D2016%26volume%3D127%26issue%3D2%26spage%3D381%26epage%3D389%26doi%3D10.1007%2Fs11060-015-2050-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iorns, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lord, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grigoriadis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenwick, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mein, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natrajan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savage, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamber, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis-Filho, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashworth, A.</span></span> <span> </span><span class="NLM_article-title">Integrated functional, gene expression and genomic analysis for the identification of cancer targets</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">4</span>), <span class="NLM_elocation-id">e5120</span> <span class="refDoi">Â DOI: 10.1371/journal.pone.0005120</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1371%2Fjournal.pone.0005120" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=19357772" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&issue=4&author=E.+Iornsauthor=C.+J.+Lordauthor=A.+Grigoriadisauthor=S.+McDonaldauthor=K.+Fenwickauthor=A.+Mackayauthor=C.+A.+Meinauthor=R.+Natrajanauthor=K.+Savageauthor=N.+Tamberauthor=J.+S.+Reis-Filhoauthor=N.+C.+Turnerauthor=A.+Ashworth&title=Integrated+functional%2C+gene+expression+and+genomic+analysis+for+the+identification+of+cancer+targets&doi=10.1371%2Fjournal.pone.0005120"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0005120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0005120%26sid%3Dliteratum%253Aachs%26aulast%3DIorns%26aufirst%3DE.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DGrigoriadis%26aufirst%3DA.%26aulast%3DMcDonald%26aufirst%3DS.%26aulast%3DFenwick%26aufirst%3DK.%26aulast%3DMackay%26aufirst%3DA.%26aulast%3DMein%26aufirst%3DC.%2BA.%26aulast%3DNatrajan%26aufirst%3DR.%26aulast%3DSavage%26aufirst%3DK.%26aulast%3DTamber%26aufirst%3DN.%26aulast%3DReis-Filho%26aufirst%3DJ.%2BS.%26aulast%3DTurner%26aufirst%3DN.%2BC.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DIntegrated%2520functional%252C%2520gene%2520expression%2520and%2520genomic%2520analysis%2520for%2520the%2520identification%2520of%2520cancer%2520targets%26jtitle%3DPLoS%2520One%26date%3D2009%26volume%3D4%26issue%3D4%26doi%3D10.1371%2Fjournal.pone.0005120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porter, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fosmire, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gearheart, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Linden, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baturin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaberezhnyy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeGregori, J.</span></span> <span> </span><span class="NLM_article-title">Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1266</span>â <span class="NLM_lpage">1276</span>, <span class="refDoi">Â DOI: 10.1038/leu.2011.392</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1038%2Fleu.2011.392" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=22289989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC38Xot1entbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=1266-1276&issue=6&author=C.+C.+Porterauthor=J.+Kimauthor=S.+Fosmireauthor=C.+M.+Gearheartauthor=A.+van+Lindenauthor=D.+Baturinauthor=V.+Zaberezhnyyauthor=P.+R.+Patelauthor=D.+Gaoauthor=A.+C.+Tanauthor=J.+DeGregori&title=Integrated+genomic+analyses+identify+WEE1+as+a+critical+mediator+of+cell+fate+and+a+novel+therapeutic+target+in+acute+myeloid+leukemia&doi=10.1038%2Fleu.2011.392"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia</span></div><div class="casAuthors">Porter, C. C.; Kim, J.; Fosmire, S.; Gearheart, C. M.; van Linden, A.; Baturin, D.; Zaberezhnyy, V.; Patel, P. R.; Gao, D.; Tan, A. C.; DeGregori, J.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1266-1276</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) remains a therapeutic challenge despite increasing knowledge about the mol. origins of the disease, as the mechanisms of AML cell escape from chemotherapy remain poorly defined.  We hypothesized that AML cells are addicted to mol. pathways in the context of chemotherapy and used complementary approaches to identify these addictions.  Using novel mol. and computational approaches, we performed genome-wide short-hairpin RNA screens to identify proteins that mediate AML cell fate after cytarabine exposure; gene expression profiling of AML cells exposed to cytarabine to identify genes with induced expression in this context; and examn. of existing gene expression data from primary patient samples.  Integration of these independent analyses strongly implicates cell-cycle checkpoint proteins, particularly WEE1, as crit. mediators of AML cell survival after cytarabine exposure.  Knockdown of WEE1 in a secondary screen confirmed its role in AML cell survival.  Pharmacol. inhibition of WEE1 in AML cell lines and primary cells is synergistic with cytarabine.  Further expts. demonstrate that inhibition of WEE1 prevents S-phase arrest induced by cytarabine, broadening the functions of WEE1 that may be exploited therapeutically.  These data highlight the power of integrating functional and descriptive genomics, and identify WEE1 as a potential therapeutic target in AML.  Leukemia (2012) 26, 1266-1276; doi:10.1038/leu.2011.392; published online 13 Jan. 2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8GuoDeHF677Vg90H21EOLACvtfcHk0litwHEuB1HmhA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xot1entbg%253D&md5=171ea333a0f7d287aac2ac5293356767</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1038%2Fleu.2011.392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2011.392%26sid%3Dliteratum%253Aachs%26aulast%3DPorter%26aufirst%3DC.%2BC.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DFosmire%26aufirst%3DS.%26aulast%3DGearheart%26aufirst%3DC.%2BM.%26aulast%3Dvan%2BLinden%26aufirst%3DA.%26aulast%3DBaturin%26aufirst%3DD.%26aulast%3DZaberezhnyy%26aufirst%3DV.%26aulast%3DPatel%26aufirst%3DP.%2BR.%26aulast%3DGao%26aufirst%3DD.%26aulast%3DTan%26aufirst%3DA.%2BC.%26aulast%3DDeGregori%26aufirst%3DJ.%26atitle%3DIntegrated%2520genomic%2520analyses%2520identify%2520WEE1%2520as%2520a%2520critical%2520mediator%2520of%2520cell%2520fate%2520and%2520a%2520novel%2520therapeutic%2520target%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeukemia%26date%3D2012%26volume%3D26%26issue%3D6%26spage%3D1266%26epage%3D1276%26doi%3D10.1038%2Fleu.2011.392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Magnussen, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holm, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emilsen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosnes, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slipicevic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florenes, V. A.</span></span> <span> </span><span class="NLM_article-title">High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">6</span>), <span class="NLM_elocation-id">e38254</span> <span class="refDoi">Â DOI: 10.1371/journal.pone.0038254</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1371%2Fjournal.pone.0038254" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=22719872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC38XovFyqt74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&issue=6&author=G.+I.+Magnussenauthor=R.+Holmauthor=E.+Emilsenauthor=A.+K.+Rosnesauthor=A.+Slipicevicauthor=V.+A.+Florenes&title=High+expression+of+Wee1+is+associated+with+poor+disease-free+survival+in+malignant+melanoma%3A+potential+for+targeted+therapy&doi=10.1371%2Fjournal.pone.0038254"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy</span></div><div class="casAuthors">Magnussen, Gry Irene; Holm, Ruth; Emilsen, Elisabeth; Rosnes, Anne Katrine Ree; Slipicevic, Ana; Floerenes, Vivi Ann</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e38254</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Notoriously resistant malignant melanoma is one of the most increasing forms of cancer worldwide; there is thus a precarious need for new treatment options.  The Wee1 kinase is a major regulator of the G2/M checkpoint, and halts the cell cycle by adding a neg. phosphorylation on CDK1 (Tyr15).  Addnl., Wee1 has a function in safeguarding the genome integrity during DNA synthesis.  To assess the role of Wee1 in development and progression of malignant melanoma we examd. its expression in a panel of paraffin-embedded patient derived tissue of benign nevi and primary- and metastatic melanomas, as well as in agarose-embedded cultured melanocytes.  We found that Wee1 expression increased in the direction of malignancy, and showed a strong, pos. correlation with known biomarkers involved in cell cycle regulation: Cyclin A (p < 0.0001), Ki67 (p < 0.0001), Cyclin D3 (p = 0.001), p21Cip1/WAF1 (p = 0.003), p53 (p = 0.025).  Furthermore, high Wee1 expression was assocd. with thicker primary tumors (p = 0.001), ulceration (p = 0.005) and poor disease-free survival (p = 0.008).  Transfections using siWee1 in metastatic melanoma cell lines; WM239WTp53, WM45.1MUTp53 and LOXWTp53, further support our hypothesis of a tumor promoting role of Wee1 in melanomas.  Whereas no effect was obsd. in LOX cells, transfection with siWee1 led to accumulation of cells in G1/S and S phase of the cell cycle in WM239 and WM45.1 cells, resp.  Both latter cell lines displayed DNA damage and induction of apoptosis, in the absence of Wee1, indicating that the effect of silencing Wee1 may not be solely dependent of the p53 status of the cells.  Together these results reveal the importance of Wee1 as a prognostic biomarker in melanomas, and indicate a potential role for targeted therapy, alone or in combination with other agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTZWeckNBhlbVg90H21EOLACvtfcHk0lhWpW_NxVMsGQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovFyqt74%253D&md5=fcf3590d96cccfdfef8abb332d68d523</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0038254&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0038254%26sid%3Dliteratum%253Aachs%26aulast%3DMagnussen%26aufirst%3DG.%2BI.%26aulast%3DHolm%26aufirst%3DR.%26aulast%3DEmilsen%26aufirst%3DE.%26aulast%3DRosnes%26aufirst%3DA.%2BK.%26aulast%3DSlipicevic%26aufirst%3DA.%26aulast%3DFlorenes%26aufirst%3DV.%2BA.%26atitle%3DHigh%2520expression%2520of%2520Wee1%2520is%2520associated%2520with%2520poor%2520disease-free%2520survival%2520in%2520malignant%2520melanoma%253A%2520potential%2520for%2520targeted%2520therapy%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26issue%3D6%26doi%3D10.1371%2Fjournal.pone.0038254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Slipicevic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellesylt, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trope, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florenes, V. A.</span></span> <span> </span><span class="NLM_article-title">Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions</span>. <i>Gynecol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>135</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">118</span>â <span class="NLM_lpage">124</span>, <span class="refDoi">Â DOI: 10.1016/j.ygyno.2014.07.102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.ygyno.2014.07.102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=25093290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlSqtrjM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2014&pages=118-124&issue=1&author=A.+Slipicevicauthor=A.+Holthauthor=E.+Hellesyltauthor=C.+G.+Tropeauthor=B.+Davidsonauthor=V.+A.+Florenes&title=Wee1+is+a+novel+independent+prognostic+marker+of+poor+survival+in+post-chemotherapy+ovarian+carcinoma+effusions&doi=10.1016%2Fj.ygyno.2014.07.102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions</span></div><div class="casAuthors">Slipicevic, Ana; Holth, Arild; Hellesylt, Ellen; Trope, Claes G.; Davidson, Ben; Floerenes, Vivi Ann</div><div class="citationInfo"><span class="NLM_cas:title">Gynecologic Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">118-124</span>CODEN:
                <span class="NLM_cas:coden">GYNOA3</span>;
        ISSN:<span class="NLM_cas:issn">0090-8258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Wee1-like kinase (Wee1) is a tyrosine kinase which neg. regulates entry into mitosis at the G2 to M-phase transition and has a role in inhibition of unscheduled DNA replication in S-phase.  The present study investigated the clin. role of Wee1 in advanced-stage (FIGO III-IV) ovarian serous carcinoma.Wee1 protein expression was analyzed in 287 effusions using immunohistochem.  Expression was analyzed for assocn. with clinicopathol. parameters, including survival.  Forty-five effusions were addnl. studied using Western blotting.  Wee1 was further silenced in SKOV3 and OVCAR8 cells by siRNA knockdown and proliferation was assessed.Nuclear expression of Wee1 in tumor cells was obsd. in 265/287 (92%) and 45/45 (100%) effusions by immunohistochem. and Western blotting, resp.  Wee1 expression by immunohistochem. was significantly higher in post-chemotherapy disease recurrence compared to pre-chemotherapy effusions obtained at diagnosis (p = 0.002).  Wee1 silencing in SKOV3 and OVCAR8 cells reduced proliferation.  In univariate survival anal. of the entire cohort, a trend was obsd. between high (> 25% of cells) Wee1 expression and poor overall survival (p = 0.083).  Survival anal. for 109 patients with post-chemotherapy effusions showed significant assocn. between Wee1 expression and poor overall survival (p = 0.004), a finding which retained its independent prognostic role in Cox multivariate anal. (p = 0.003).Wee1 is frequently expressed in ovarian serous carcinoma effusions, and its expression is significantly higher following exposure to chemotherapy.  The present study is the first to report that Wee1 is an independent prognostic marker in serous ovarian carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUb8EUEghrP7Vg90H21EOLACvtfcHk0lhWpW_NxVMsGQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlSqtrjM&md5=41d4a5ae2962a842ca879793e2372fee</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2Fj.ygyno.2014.07.102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ygyno.2014.07.102%26sid%3Dliteratum%253Aachs%26aulast%3DSlipicevic%26aufirst%3DA.%26aulast%3DHolth%26aufirst%3DA.%26aulast%3DHellesylt%26aufirst%3DE.%26aulast%3DTrope%26aufirst%3DC.%2BG.%26aulast%3DDavidson%26aufirst%3DB.%26aulast%3DFlorenes%26aufirst%3DV.%2BA.%26atitle%3DWee1%2520is%2520a%2520novel%2520independent%2520prognostic%2520marker%2520of%2520poor%2520survival%2520in%2520post-chemotherapy%2520ovarian%2520carcinoma%2520effusions%26jtitle%3DGynecol.%2520Oncol.%26date%3D2014%26volume%3D135%26issue%3D1%26spage%3D118%26epage%3D124%26doi%3D10.1016%2Fj.ygyno.2014.07.102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bukhari, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearce, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamper, A. M.</span></span> <span> </span><span class="NLM_article-title">Inhibiting Wee1 and ATR kinases produces tumor-selective synthetic lethality and suppresses metastasis</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>129</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1329</span>â <span class="NLM_lpage">1344</span>, <span class="refDoi">Â DOI: 10.1172/JCI122622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1172%2FJCI122622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=30645202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A280%3ADC%252BB3cjhs1Wmtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2019&pages=1329-1344&issue=3&author=A.+B.+Bukhariauthor=C.+W.+Lewisauthor=J.+J.+Pearceauthor=D.+Luongauthor=G.+K.+Chanauthor=A.+M.+Gamper&title=Inhibiting+Wee1+and+ATR+kinases+produces+tumor-selective+synthetic+lethality+and+suppresses+metastasis&doi=10.1172%2FJCI122622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting Wee1 and ATR kinases produces tumor-selective synthetic lethality and suppresses metastasis</span></div><div class="casAuthors">Bukhari Amirali B; Lewis Cody W; Pearce Joanna J; Luong Deandra; Chan Gordon K; Gamper Armin M</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1329-1344</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">We used the cancer-intrinsic property of oncogene-induced DNA damage as the base for a conditional synthetic lethality approach.  To target mechanisms important for cancer cell adaptation to genotoxic stress and thereby to achieve cancer cell-specific killing, we combined inhibition of the kinases ATR and Wee1.  Wee1 regulates cell cycle progression, whereas ATR is an apical kinase in the DNA-damage response.  In an orthotopic breast cancer model, tumor-selective synthetic lethality of the combination of bioavailable ATR and Wee1 inhibitors led to tumor remission and inhibited metastasis with minimal side effects.  ATR and Wee1 inhibition had a higher synergistic effect in cancer stem cells than in bulk cancer cells, compensating for the lower sensitivity of cancer stem cells to the individual drugs.  Mechanistically, the combination treatment caused cells with unrepaired or under-replicated DNA to enter mitosis leading to mitotic catastrophe.  As these inhibitors of ATR and Wee1 are already in phase I/II clinical trials, this knowledge could soon be translated into the clinic, especially as we showed that the combination treatment targets a wide range of tumor cells.  Particularly, the antimetastatic effect of combined Wee1/ATR inhibition and the low toxicity of ATR inhibitors compared with Chk1 inhibitors have great clinical potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSkSJzGKNxKWLZpSb_XWfMrfW6udTcc2eZnqGwCXZU5Prntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjhs1Wmtg%253D%253D&md5=da702f6fe769547cd7d6746e9a9748b3</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1172%2FJCI122622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI122622%26sid%3Dliteratum%253Aachs%26aulast%3DBukhari%26aufirst%3DA.%2BB.%26aulast%3DLewis%26aufirst%3DC.%2BW.%26aulast%3DPearce%26aufirst%3DJ.%2BJ.%26aulast%3DLuong%26aufirst%3DD.%26aulast%3DChan%26aufirst%3DG.%2BK.%26aulast%3DGamper%26aufirst%3DA.%2BM.%26atitle%3DInhibiting%2520Wee1%2520and%2520ATR%2520kinases%2520produces%2520tumor-selective%2520synthetic%2520lethality%2520and%2520suppresses%2520metastasis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2019%26volume%3D129%26issue%3D3%26spage%3D1329%26epage%3D1344%26doi%3D10.1172%2FJCI122622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bauman, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C. H.</span></span> <span> </span><span class="NLM_article-title">CHK it out! Blocking WEE kinase routs TP53 mutant cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">4173</span>â <span class="NLM_lpage">4175</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-14-0720</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F1078-0432.CCR-14-0720" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=25125257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlCltr%252FJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=4173-4175&issue=16&author=J.+E.+Baumanauthor=C.+H.+Chung&title=CHK+it+out%21+Blocking+WEE+kinase+routs+TP53+mutant+cancer&doi=10.1158%2F1078-0432.CCR-14-0720"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">CHK It Out! Blocking WEE Kinase Routs TP53 Mutant Cancer</span></div><div class="casAuthors">Bauman, Julie E.; Chung, Christine H.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4173-4175</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Mutations in TP53, encoding the master tumor suppressor p53, have posed a developmental therapeutic dilemma due to inability to target loss of function.  Inhibition of WEE1 or CHK1 kinase, neg. regulators of the G2-M checkpoint, selectively sensitizes p53-deficient cells to exogenous DNA damage, abrogating G2 arrest and pptg. mitotic catastrophe.  Clin Cancer Res; 20(16); 4173-5. Â©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvIGJ2c1Fo27Vg90H21EOLACvtfcHk0lhxmnjvCIY3Yw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlCltr%252FJ&md5=be755141636e31e8c163be48e70a1f46</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-0720&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-0720%26sid%3Dliteratum%253Aachs%26aulast%3DBauman%26aufirst%3DJ.%2BE.%26aulast%3DChung%26aufirst%3DC.%2BH.%26atitle%3DCHK%2520it%2520out%2521%2520Blocking%2520WEE%2520kinase%2520routs%2520TP53%2520mutant%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26issue%3D16%26spage%3D4173%26epage%3D4175%26doi%3D10.1158%2F1078-0432.CCR-14-0720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booher, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leopold, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span> <span> </span><span class="NLM_article-title">Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">8211</span>â <span class="NLM_lpage">8217</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=11719452" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD3MXovVShsLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=8211-8217&issue=22&author=Y.+Wangauthor=J.+Liauthor=R.+N.+Booherauthor=A.+Krakerauthor=T.+Lawrenceauthor=W.+R.+Leopoldauthor=Y.+Sun&title=Radiosensitization+of+p53+mutant+cells+by+PD0166285%2C+a+novel+G%282%29+checkpoint+abrogator"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Radiosensitization of p53 mutant cells by PD0166285, a novel G2 checkpoint abrogator</span></div><div class="casAuthors">Wang, Yuli; Li, Jun; Booher, Robert N.; Kraker, Alan; Lawrence, Theodore; Leopold, Wilbur R.; Sun, Yi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8211-8217</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The lack of functional p53 in many cancer cells offers a therapeutic target for treatment.  Cells lacking p53 would not be anticipated to demonstrate a G1 checkpoint and would depend on the G2 checkpoint to permit DNA repair prior to undergoing mitosis.  We hypothesized that the G2 checkpoint abrogator could preferentially kill p53-inactive cancer cells by removing the only checkpoint that protects these cells from premature mitosis in response to DNA damage.  Because Wee1 kinase is crucial in maintaining G2 arrest through its inhibitory phosphorylation of Cdc2, we developed a high-throughput mass screening assay and used it to screen chem. library for Wee1 inhibitors.  A pyridopyrimidine class of mol., PD0166285 was identified that inhibited Wee1 at a nanomolar concn.  At the cellular level, 0.5 Î¼M PD0166285 dramatically inhibits irradn.-induced Cdc2 phosphorylation at the Tyr-15 and Thr-14 in seven of seven cancer cell lines tested.  PD0166285 abrogates irradn.-induced G2 arrest as shown by both biochem. markers and fluorescence-activated cell sorter anal. and significantly increases mitotic cell populations.  Biol., PD0166285 acts as a radiosensitizer to sensitize cells to radiation-induced cell death with a sensitivity enhancement ratio of 1.23 as shown by std. clonogenic assay.  This radiosensitizing activity is p53 dependent with a higher efficacy in p53-inactive cells.  Thus, G2 checkpoint abrogators represent a novel class of anticancer drugs that enhance cell killing of conventional cancer therapy through the induction of premature mitosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0KkLReKZ6X7Vg90H21EOLACvtfcHk0lhxmnjvCIY3Yw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXovVShsLs%253D&md5=c6eee9020eac54270d29e94180549a80</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DBooher%26aufirst%3DR.%2BN.%26aulast%3DKraker%26aufirst%3DA.%26aulast%3DLawrence%26aufirst%3DT.%26aulast%3DLeopold%26aufirst%3DW.%2BR.%26aulast%3DSun%26aufirst%3DY.%26atitle%3DRadiosensitization%2520of%2520p53%2520mutant%2520cells%2520by%2520PD0166285%252C%2520a%2520novel%2520G%25282%2529%2520checkpoint%2520abrogator%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26issue%3D22%26spage%3D8211%26epage%3D8217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leijen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Geel, R. M. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavlick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tibes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Razak, A. R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demuth, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freshwater, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shumway, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oza, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellens, J. H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span> <span> </span><span class="NLM_article-title">Phase I study evaluating WEE1 inhibitor AZD1775 as monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">36</span>),  <span class="NLM_fpage">4371</span>â <span class="NLM_lpage">4380</span>, <span class="refDoi">Â DOI: 10.1200/JCO.2016.67.5991</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1200%2FJCO.2016.67.5991" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=27601554" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlegtbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=4371-4380&issue=36&author=S.+Leijenauthor=R.+M.+J.+M.+van+Geelauthor=A.+C.+Pavlickauthor=R.+Tibesauthor=L.+Rosenauthor=A.+R.+A.+Razakauthor=R.+Lamauthor=T.+Demuthauthor=S.+Roseauthor=M.+A.+Leeauthor=T.+Freshwaterauthor=S.+Shumwayauthor=L.+W.+Liangauthor=A.+M.+Ozaauthor=J.+H.+M.+Schellensauthor=G.+I.+Shapiro&title=Phase+I+study+evaluating+WEE1+inhibitor+AZD1775+as+monotherapy+and+in+combination+with+gemcitabine%2C+cisplatin%2C+or+carboplatin+in+patients+with+advanced+solid+tumors&doi=10.1200%2FJCO.2016.67.5991"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study evaluating WEE1 inhibitor AZD1775 as monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors</span></div><div class="casAuthors">Leijen, Suzanne; van Geel, Robin M. J. M.; Pavlick, Anna C.; Tibes, Raoul; Rosen, Lee; Abdul Razak, Albiruni R.; Lam, Raymond; Demuth, Tim; Rose, Shelonitda; Lee, Mark A.; Freshwater, Tomoko; Shumway, Stuart; Liang, Li Wen; Oza, Amit M.; Schellens, Jan H. M.; Shapiro, Geoffrey I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">4371-4389</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: AZD1775 is a WEE1 kinase inhibitor targeting G2 checkpoint control, preferentially sensitizing TP53-deficient tumor cells to DNA damage.  This phase I study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of oral AZD1775 as monotherapy or in combination with chemotherapy in patients with refractory solid tumors.  Patients and Methods In part 1, patients received a single dose of AZD1775 followed by 14 days of observation.  In part 2, patients received AZD1775 as a single dose (part 2A) or as five twice per day doses or two once per day doses (part 2B) in combination with one of the following chemotherapy agents: gemcitabine (1,000 mg/m2), cisplatin (75 mg/m2), or carboplatin (area under the curve, 5 mg/mLâ¥min).  Skin biopsies were collected for pharmacodynamic assessments.  TP53 status was detd. retrospectively in archival tumor tissue.  Results: Two hundred two patients were enrolled onto the study, including nine patients in part 1, 43 in part 2A (including eight rollover patients from part 1), and 158 in part 2B.  AZD1775 monotherapy given as single dose was well tolerated, and the max.-tolerated dose was not reached.  In the combination regimens, the most common adverse events consisted of fatigue, nausea and vomiting, diarrhea, and hematol. toxicity.  The max.-tolerated doses and biol. EDs were established for each combination.  Target engagement, as a predefined 50% pCDK1 redn. in surrogate tissue, was obsd. in combination with cisplatin and carboplatin.  Of 176 patients evaluable for efficacy, 94 (53%) had stable disease as best response, and 17 (10%) achieved a partial response.  The response rate in TP53-mutated patients (n = 19) was 21% compared with 12% in TP53 wild-type patients (n = 33).  Conclusion: AZD1775 was safe and tolerable as a single agent and in combination with chemotherapy at doses assocd. with target engagement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqU_jqg7_dUtLVg90H21EOLACvtfcHk0lhxmnjvCIY3Yw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlegtbw%253D&md5=183b1f187776fa77da6bcff2a4e430e1</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1200%2FJCO.2016.67.5991&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2016.67.5991%26sid%3Dliteratum%253Aachs%26aulast%3DLeijen%26aufirst%3DS.%26aulast%3Dvan%2BGeel%26aufirst%3DR.%2BM.%2BJ.%2BM.%26aulast%3DPavlick%26aufirst%3DA.%2BC.%26aulast%3DTibes%26aufirst%3DR.%26aulast%3DRosen%26aufirst%3DL.%26aulast%3DRazak%26aufirst%3DA.%2BR.%2BA.%26aulast%3DLam%26aufirst%3DR.%26aulast%3DDemuth%26aufirst%3DT.%26aulast%3DRose%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DM.%2BA.%26aulast%3DFreshwater%26aufirst%3DT.%26aulast%3DShumway%26aufirst%3DS.%26aulast%3DLiang%26aufirst%3DL.%2BW.%26aulast%3DOza%26aufirst%3DA.%2BM.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%2BM.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26atitle%3DPhase%2520I%2520study%2520evaluating%2520WEE1%2520inhibitor%2520AZD1775%2520as%2520monotherapy%2520and%2520in%2520combination%2520with%2520gemcitabine%252C%2520cisplatin%252C%2520or%2520carboplatin%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2016%26volume%3D34%26issue%3D36%26spage%3D4371%26epage%3D4380%26doi%3D10.1200%2FJCO.2016.67.5991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leijen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Geel, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonke, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchetti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pluim, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Werkhoven, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freshwater, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beijnen, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellens, J. H.</span></span> <span> </span><span class="NLM_article-title">Phase II study of WEE1 inhibitor AZD1775 plus carboplatin in patients with TP53-mutated ovarian cancer refractory or resistant to first-line therapy within 3 months</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">36</span>),  <span class="NLM_fpage">4354</span>â <span class="NLM_lpage">4361</span>, <span class="refDoi">Â DOI: 10.1200/JCO.2016.67.5942</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1200%2FJCO.2016.67.5942" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=27998224" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlegtb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=4354-4361&issue=36&author=S.+Leijenauthor=R.+M.+van+Geelauthor=G.+S.+Sonkeauthor=D.+de+Jongauthor=E.+H.+Rosenbergauthor=S.+Marchettiauthor=D.+Pluimauthor=E.+van+Werkhovenauthor=S.+Roseauthor=M.+A.+Leeauthor=T.+Freshwaterauthor=J.+H.+Beijnenauthor=J.+H.+Schellens&title=Phase+II+study+of+WEE1+inhibitor+AZD1775+plus+carboplatin+in+patients+with+TP53-mutated+ovarian+cancer+refractory+or+resistant+to+first-line+therapy+within+3+months&doi=10.1200%2FJCO.2016.67.5942"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II study of WEE1 inhibitor AZD1775 plus carboplatin in patients with TP53-mutated ovarian cancer refractory or resistant to first-line therapy within 3 months</span></div><div class="casAuthors">Leijen, Suzanne; van Geel, Robin M. J. M.; Sonke, Gabe S.; de Jong, Daphne; Rosenberg, Efraim H.; Marchetti, Serena; Pluim, Dick; van Werkhoven, Erik; Rose, Shelonitda; Lee, Mark A.; Freshwater, Tomoko; Beijnen, Jos H.; Schellens, Jan H. M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">4354-4363</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: AZD1775 is a first-in-class, potent, and selective inhibitor of WEE1 with proof of chemopotentiation in p53-deficient tumors in preclin. models.  In a phase I study, the max. tolerated dose of AZD1775 in combination with carboplatin demonstrated target engagement.  We conducted a proofof- principle phase II study in patients with p53 tumor suppressor gene (TP53)-mutated ovarian cancer refractory or resistant (< 3 mo) to first-line platinum-based therapy to det. overall response rate, progression-free and overall survival, pharmacokinetics, and modulation of phosphorylated cyclin-dependent kinase (CDK1) in skin biopsies.  Patients and Methods: Patients were treated with carboplatin (area under the curve, 5 mg/mL$min) combined with AZD1775 225 mg orally twice daily over 2.5 days every 21-day cycle until disease progression.  Results: AZD1775 plus carboplatin demonstrated manageable toxicity; fatigue (87%), nausea (78%), thrombocytopenia (70%), diarrhea (70%), and vomiting (48%) were the most common adverse events.  The most frequent grade 3 or 4 adverse events were thrombocytopenia (48%) and neutropenia (37%).  Of 24 patients enrolled, 21 patients were evaluable for efficacy end points.  The overall response rate was 43% (95% CI, 22% to 66%), including one patient (5%) with a prolonged complete response.  Median progression-free and overall survival times were 5.3 mo (95% CI, 2.3 to 9.0 mo) and 12.6 mo (95% CI, 4.9 to 19.7), resp., with two patients with ongoing response for more than 31 and 42 mo at data cutoff.  Conclusion: To our knowledge, this is the first report providing clin. proof that AZD1775 enhances carboplatin efficacy in TP53-mutated tumors.  The encouraging antitumor activity obsd. in patients with TP53-mutated ovarian cancer who were refractory or resistant (< 3 mo) to first-line therapy warrants further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3Qq3dxv0cmLVg90H21EOLACvtfcHk0lhuKE9BjHedPQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlegtb4%253D&md5=507ba8f42bc2e5c712fbccbc5db685a2</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1200%2FJCO.2016.67.5942&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2016.67.5942%26sid%3Dliteratum%253Aachs%26aulast%3DLeijen%26aufirst%3DS.%26aulast%3Dvan%2BGeel%26aufirst%3DR.%2BM.%26aulast%3DSonke%26aufirst%3DG.%2BS.%26aulast%3Dde%2BJong%26aufirst%3DD.%26aulast%3DRosenberg%26aufirst%3DE.%2BH.%26aulast%3DMarchetti%26aufirst%3DS.%26aulast%3DPluim%26aufirst%3DD.%26aulast%3Dvan%2BWerkhoven%26aufirst%3DE.%26aulast%3DRose%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DM.%2BA.%26aulast%3DFreshwater%26aufirst%3DT.%26aulast%3DBeijnen%26aufirst%3DJ.%2BH.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%26atitle%3DPhase%2520II%2520study%2520of%2520WEE1%2520inhibitor%2520AZD1775%2520plus%2520carboplatin%2520in%2520patients%2520with%2520TP53-mutated%2520ovarian%2520cancer%2520refractory%2520or%2520resistant%2520to%2520first-line%2520therapy%2520within%25203%2520months%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2016%26volume%3D34%26issue%3D36%26spage%3D4354%26epage%3D4361%26doi%3D10.1200%2FJCO.2016.67.5942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carrassa, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ChilÃ , R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricci, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celenza, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzoletti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broggini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damia, G.</span></span> <span> </span><span class="NLM_article-title">Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">2507</span>â <span class="NLM_lpage">2517</span>, <span class="refDoi">Â DOI: 10.4161/cc.20899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.4161%2Fcc.20899" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=22713237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFegsLrP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=2507-2517&issue=13&author=L.+Carrassaauthor=R.+Chil%C3%A0author=M.+Lupiauthor=F.+Ricciauthor=C.+Celenzaauthor=M.+Mazzolettiauthor=M.+Brogginiauthor=G.+Damia&title=Combined+inhibition+of+Chk1+and+Wee1%3A+in+vitro+synergistic+effect+translates+to+tumor+growth+inhibition+in+vivo&doi=10.4161%2Fcc.20899"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo</span></div><div class="casAuthors">Carrassa, Laura; Chila, Rosaria; Lupi, Monica; Ricci, Francesca; Celenza, Cinzia; Mazzoletti, Marco; Broggini, Massimo; Damia, Giovanna</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2507-2517</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1538-4101</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">Targeting Chk1 protein kinase can enhance the antitumor effects of radio- and chemotherapy.  Recent evidence disclosed a role of Chk1 in unperturbed cell proliferation and survival, implying that Chk1 inhibitors could also be effective as single agents in tumors with a specific genetic background.  To identify genes in synthetic lethality with Chk1, we did a high-throughput screening using a siRNA library directed against 719 human protein kinases in the human ovarian cancer cell line OVCAR-5, resistant to Chk1 inhibitors.  Wee1 tyrosine kinase was the most significant gene in synthetic lethality with Chk1.  Treatment with non-toxic concns. of a Chk1 inhibitor (PF-00477736) and a Wee1 inhibitor (MK-1775) confirmed the marked synergistic effect in various human cancer cell lines (breast, ovarian, colon, prostate), independently of the p53 status.  Detailed mol. anal. showed that the combination caused cancer cells to undergo premature mitosis before the end of DNA replication, with damaged DNA leading to cell death partly by apoptosis.  In vivo treatment of mice bearing OVCAR-5 xenografts with the combination of Chk1 and Wee1 inhibitors led to greater tumor growth inhibition than with the inhibitors used as single agents with no toxicity.  These data provide a strong rationale for the clin. investigation of the combination of a Chk1 and a Wee1 inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoG4SOnNomb9LVg90H21EOLACvtfcHk0lhuKE9BjHedPQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFegsLrP&md5=69672526de832f7c93bf336c58961db2</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.4161%2Fcc.20899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.20899%26sid%3Dliteratum%253Aachs%26aulast%3DCarrassa%26aufirst%3DL.%26aulast%3DChil%25C3%25A0%26aufirst%3DR.%26aulast%3DLupi%26aufirst%3DM.%26aulast%3DRicci%26aufirst%3DF.%26aulast%3DCelenza%26aufirst%3DC.%26aulast%3DMazzoletti%26aufirst%3DM.%26aulast%3DBroggini%26aufirst%3DM.%26aulast%3DDamia%26aufirst%3DG.%26atitle%3DCombined%2520inhibition%2520of%2520Chk1%2520and%2520Wee1%253A%2520in%2520vitro%2520synergistic%2520effect%2520translates%2520to%2520tumor%2520growth%2520inhibition%2520in%2520vivo%26jtitle%3DCell%2520Cycle%26date%3D2012%26volume%3D11%26issue%3D13%26spage%3D2507%26epage%3D2517%26doi%3D10.4161%2Fcc.20899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwasawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishibata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohtani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamanaka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itadani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi-Suzuki, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukasawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nambu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arakawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sagara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshizumi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizuarai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotani, H.</span></span> <span> </span><span class="NLM_article-title">Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2992</span>â <span class="NLM_lpage">3000</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-09-0463</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F1535-7163.MCT-09-0463" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=19887545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlyrt77J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=2992-3000&issue=11&author=H.+Hiraiauthor=Y.+Iwasawaauthor=M.+Okadaauthor=T.+Araiauthor=T.+Nishibataauthor=M.+Kobayashiauthor=T.+Kimuraauthor=N.+Kanekoauthor=J.+Ohtaniauthor=K.+Yamanakaauthor=H.+Itadaniauthor=I.+Takahashi-Suzukiauthor=K.+Fukasawaauthor=H.+Okiauthor=T.+Nambuauthor=J.+Jiangauthor=T.+Sakaiauthor=H.+Arakawaauthor=T.+Sakamotoauthor=T.+Sagaraauthor=T.+Yoshizumiauthor=S.+Mizuaraiauthor=H.+Kotani&title=Small-molecule+inhibition+of+Wee1+kinase+by+MK-1775+selectively+sensitizes+p53-deficient+tumor+cells+to+DNA-damaging+agents&doi=10.1158%2F1535-7163.MCT-09-0463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents</span></div><div class="casAuthors">Hirai, Hiroshi; Iwasawa, Yoshikazu; Okada, Megumu; Arai, Tsuyoshi; Nishibata, Toshihide; Kobayashi, Makiko; Kimura, Toshifumi; Kaneko, Naoki; Ohtani, Junko; Yamanaka, Kazunori; Itadani, Hiraku; Takahashi-Suzuki, Ikuko; Fukasawa, Kazuhiro; Oki, Hiroko; Nambu, Tadahiro; Jiang, Jian; Sakai, Takumi; Arakawa, Hiroharu; Sakamoto, Toshihiro; Sagara, Takeshi; Yoshizumi, Takashi; Mizuarai, Shinji; Kotani, Hidehito</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2992-3000</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Wee1 is a tyrosine kinase that phosphorylates and inactivates CDC2 and is involved in G2 checkpoint signaling.  Because p53 is a key regulator in the G1 checkpoint, p53-deficient tumors rely only on the G2 checkpoint after DNA damage.  Hence, such tumors are selectively sensitized to DNA-damaging agents by Wee1 inhibition.  Here, we report the discovery of a potent and selective small-mol. inhibitor of Wee1 kinase, MK-1775.  This compd. inhibits phosphorylation of CDC2 at Tyr15 (CDC2Y15), a direct substrate of Wee1 kinase in cells.  MK-1775 abrogates G2 DNA damage checkpoint, leading to apoptosis in combination with DNA-damaging chemotherapeutic agents such as gemcitabine, carboplatin, and cisplatin selectively in p53-deficient cells.  In vivo, MK-1775 potentiates tumor growth inhibition by these agents, and cotreatment does not significantly increase toxicity.  The enhancement of antitumor effect by MK-1775 was well correlated with inhibition of CDC2Y15 phosphorylation in tumor tissue and skin hair follicles.  Our data indicate that Wee1 inhibition provides a new approach for treatment of multiple human malignancies. [Mol Cancer Ther 2009;8(11):2992-3000].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCLXV8e5coBbVg90H21EOLACvtfcHk0lhuKE9BjHedPQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlyrt77J&md5=30d5a094709960f25929dfafc2d4a115</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0463%26sid%3Dliteratum%253Aachs%26aulast%3DHirai%26aufirst%3DH.%26aulast%3DIwasawa%26aufirst%3DY.%26aulast%3DOkada%26aufirst%3DM.%26aulast%3DArai%26aufirst%3DT.%26aulast%3DNishibata%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DM.%26aulast%3DKimura%26aufirst%3DT.%26aulast%3DKaneko%26aufirst%3DN.%26aulast%3DOhtani%26aufirst%3DJ.%26aulast%3DYamanaka%26aufirst%3DK.%26aulast%3DItadani%26aufirst%3DH.%26aulast%3DTakahashi-Suzuki%26aufirst%3DI.%26aulast%3DFukasawa%26aufirst%3DK.%26aulast%3DOki%26aufirst%3DH.%26aulast%3DNambu%26aufirst%3DT.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DSakai%26aufirst%3DT.%26aulast%3DArakawa%26aufirst%3DH.%26aulast%3DSakamoto%26aufirst%3DT.%26aulast%3DSagara%26aufirst%3DT.%26aulast%3DYoshizumi%26aufirst%3DT.%26aulast%3DMizuarai%26aufirst%3DS.%26aulast%3DKotani%26aufirst%3DH.%26atitle%3DSmall-molecule%2520inhibition%2520of%2520Wee1%2520kinase%2520by%2520MK-1775%2520selectively%2520sensitizes%2520p53-deficient%2520tumor%2520cells%2520to%2520DNA-damaging%2520agents%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26issue%3D11%26spage%3D2992%26epage%3D3000%26doi%3D10.1158%2F1535-7163.MCT-09-0463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, C.</span></span> <span> </span><span class="NLM_article-title">Wee1 kinase inhibitor MK-1775 induces apoptosis of acute lymphoblastic leukemia cells and enhances the efficacy of doxorubicin involving downregulation of Notch pathway</span>. <i>Oncol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">5473</span>â <span class="NLM_lpage">5481</span>, <span class="refDoi">Â DOI: 10.3892/ol.2018.9291</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.3892%2Fol.2018.9291" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=30250620" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A280%3ADC%252BB3czitlegtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2018&pages=5473-5481&issue=4&author=Y.+Duanauthor=X.+Dongauthor=J.+Nieauthor=P.+Liauthor=F.+Luauthor=D.+Maauthor=C.+Ji&title=Wee1+kinase+inhibitor+MK-1775+induces+apoptosis+of+acute+lymphoblastic+leukemia+cells+and+enhances+the+efficacy+of+doxorubicin+involving+downregulation+of+Notch+pathway&doi=10.3892%2Fol.2018.9291"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Wee1 kinase inhibitor MK-1775 induces apoptosis of acute lymphoblastic leukemia cells and enhances the efficacy of doxorubicin involving downregulation of Notch pathway</span></div><div class="casAuthors">Duan Yanchao; Dong Xin; Li Peng; Lu Fei; Ma Daoxin; Ji Chunyan; Duan Yanchao; Nie Jing</div><div class="citationInfo"><span class="NLM_cas:title">Oncology letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">5473-5481</span>
        ISSN:<span class="NLM_cas:issn">1792-1074</span>.
    </div><div class="casAbstract">Acute lymphoblastic leukemia (ALL) is an aggressive hematologic malignancy affecting pediatric and adult populations.  Although the outcomes of ALL in children have improved markedly in previous years, limited treatment strategies are available at present for adult patients with ALL.  Wee1 is a crucial cell cycle checkpoint kinase of G2/M that regulates cell cycle progression and maintains chromatin integrity.  MK-1775, a selective inhibitor of Wee1 has recently been identified to be able to induce apoptosis of tumor cells by abrogating G2/M checkpoint.  The present study investigated the anti-leukemic activity of MK-1775 alone and in combination with doxorubicin (Adriamycin(Â®); ADM) in various human ALL cell lines.  MK-1775 treatment induced apoptosis of ALL cells, accompanied by unscheduled mitotic entry and downregulation of Notch pathway.  The anti-leukemic activity of MK-1775 was in a concentration- and time-dependent manner.  The data also indicated that it decreased the half-maximal inhibitory concentration (IC50) of ADM compared with the control group.  The combination of MK-1775 and ADM induced an increased apoptotic rate compared with each agent alone.  In addition, the human bone marrow stromal cell HS-5 cell line was detected to exhibit an increased IC50 value of MK-1775 treatment in contrast to ALL cell lines.  It indicates that the hematopoietic supportive capability may remain intact during the treatment of MK-1775.  Taken together, the Wee1 inhibitor MK-1775 may be an attractive agent in the treatment of patients with ALL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTOQT7xZP5J1JWtyewyzkyLfW6udTcc2easDya6cbtHm7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3czitlegtg%253D%253D&md5=958ab9c3bc862d4d52833cd324141844</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.3892%2Fol.2018.9291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fol.2018.9291%26sid%3Dliteratum%253Aachs%26aulast%3DDuan%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DX.%26aulast%3DNie%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DLu%26aufirst%3DF.%26aulast%3DMa%26aufirst%3DD.%26aulast%3DJi%26aufirst%3DC.%26atitle%3DWee1%2520kinase%2520inhibitor%2520MK-1775%2520induces%2520apoptosis%2520of%2520acute%2520lymphoblastic%2520leukemia%2520cells%2520and%2520enhances%2520the%2520efficacy%2520of%2520doxorubicin%2520involving%2520downregulation%2520of%2520Notch%2520pathway%26jtitle%3DOncol.%2520Lett.%26date%3D2018%26volume%3D16%26issue%3D4%26spage%3D5473%26epage%3D5481%26doi%3D10.3892%2Fol.2018.9291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richer, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cala, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâBrien, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carson, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inge, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitsett, T. G.</span></span> <span> </span><span class="NLM_article-title">WEE1 kinase inhibitor AZD1775 has preclinical efficacy in LKB1-deficient non-small cell lung cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">4663</span>â <span class="NLM_lpage">4672</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-16-3565</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F0008-5472.CAN-16-3565" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=28652249" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsV2mu73I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=4663-4672&issue=17&author=A.+L.+Richerauthor=J.+M.+Calaauthor=K.+O%E2%80%99Brienauthor=V.+M.+Carsonauthor=L.+J.+Ingeauthor=T.+G.+Whitsett&title=WEE1+kinase+inhibitor+AZD1775+has+preclinical+efficacy+in+LKB1-deficient+non-small+cell+lung+cancer&doi=10.1158%2F0008-5472.CAN-16-3565"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Richer, Amanda L.; Cala, Jacqueline M.; O'Brien, Kelley; Carson, Vashti M.; Inge, Landon J.; Whitsett, Timothy G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4663-4672</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">G1-S checkpoint loss contributes to carcinogenesis and increases reliance upon the G2-M checkpoint for adaptation to stress and DNA repair, making G2-M checkpoint inhibition a target for novel therapeutic development.  AZD1775, an inhibitor against the crit. G2-M checkpoint protein WEE1, is currently in clin. trials across a no. of tumor types.  AZD1775 and DNA-damaging agents have displayed favorable activity in several preclin. tumor models, often in the mol. context of TP53 loss.  Whether AZD1775 efficacy is modulated by other mol. contexts remains poorly understood.  The tumor suppressor serine/threonine kinase 11 (LKB1/STK11) is one of the most frequently mutated genes in non-small cell lung cancer (NSCLC) and is commonly comutated with oncogenic KRAS mutations.  We investigated the preclin. effects of AZD1775 in the context of KRAS/LKB1 in NSCLC.  Using NSCLC cell lines, we found that AZD1775 alone and in combination with DNA-damaging agents (e.g., cisplatin and radiation) decreased tumor cell viability in LKB1-deficient NSCLC cells.  In vitro, LKB1 deficiency enhanced DNA damage and apoptosis in response to AZD1775 exposure compared with wild-type LKB1 cells.  In a genetically engineered mouse model of mutant Kras with concomitant loss of Lkb1, combined AZD1775 and cisplatin extended overall survival compared with cisplatin alone.  Our data suggest that lack of phosphorylation of LKB1 by ATM was involved in AZD1775-mediated cytotoxicity.  Collectively, these findings provide a clin. application for AZD1775 with DNA-damaging agents in KRAS/LKB1 NSCLC.  Cancer Res; 77(17); 4663-72. Â©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdS7k15I3MCLVg90H21EOLACvtfcHk0lhaWhFED5RscA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsV2mu73I&md5=2676307db49d4e96e03985a1ee96607c</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-16-3565&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-16-3565%26sid%3Dliteratum%253Aachs%26aulast%3DRicher%26aufirst%3DA.%2BL.%26aulast%3DCala%26aufirst%3DJ.%2BM.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DK.%26aulast%3DCarson%26aufirst%3DV.%2BM.%26aulast%3DInge%26aufirst%3DL.%2BJ.%26aulast%3DWhitsett%26aufirst%3DT.%2BG.%26atitle%3DWEE1%2520kinase%2520inhibitor%2520AZD1775%2520has%2520preclinical%2520efficacy%2520in%2520LKB1-deficient%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26issue%3D17%26spage%3D4663%26epage%3D4672%26doi%3D10.1158%2F0008-5472.CAN-16-3565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Webster, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Littlejohns, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaunt, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beech, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, D. A.</span></span> <span> </span><span class="NLM_article-title">AZD1775 induces toxicity through double-stranded DNA breaks independently of chemotherapeutic agents in p53-mutated colorectal cancer cells</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">2176</span>â <span class="NLM_lpage">2182</span>, <span class="refDoi">Â DOI: 10.1080/15384101.2017.1301329</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1080%2F15384101.2017.1301329" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=28296564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsl2ju7%252FE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=2176-2182&issue=22&author=P.+J.+Websterauthor=A.+T.+Littlejohnsauthor=H.+J.+Gauntauthor=K.+R.+Prasadauthor=D.+J.+Beechauthor=D.+A.+Burke&title=AZD1775+induces+toxicity+through+double-stranded+DNA+breaks+independently+of+chemotherapeutic+agents+in+p53-mutated+colorectal+cancer+cells&doi=10.1080%2F15384101.2017.1301329"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">AZD1775 induces toxicity through double-stranded DNA breaks independently of chemotherapeutic agents in p53-mutated colorectal cancer cells</span></div><div class="casAuthors">Webster, Peter John; Littlejohns, Anna Tiffany; Gaunt, Hannah Jane; Prasad, K. Raj; Beech, David John; Burke, Dermot Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2176-2182</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1551-4005</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">AZD1775 is a small mol. WEE1 inhibitor used in combination with DNA-damaging agents to cause premature mitosis and cell death in p53-mutated cancer cells.  Here we sought to det. the mechanism of action of AZD1775 in combination with chemotherapeutic agents in light of recent findings that AZD1775 can cause double-stranded DNA (DS-DNA) breaks.  AZD1775 significantly improved the cytotoxicity of 5-FU in a p53-mutated colorectal cancer cell line (HT29 cells), decreasing the IC50 from 9.3Î¼M to 3.5Î¼M.  Flow cytometry showed a significant increase in the mitotic marker pHH3 (3.4% vs. 56.2%) and DS-DNA break marker Î³H2AX (5.1% vs. 50.7%) for combination therapy compared with 5-FU alone.  Combination therapy also increased the amt. of caspase-3 dependent apoptosis compared with 5-FU alone (4% vs. 13%).  The addn. of exogenous nucleosides to combination therapy significantly rescued the increased DS-DNA breaks and caspase-3 dependent apoptosis almost to the levels of 5-FU monotherapy.  In conclusion, AZD1775 enhances 5-FU cytotoxicity through increased DS-DNA breaks, not premature mitosis, in p53-mutated colorectal cancer cells.  This finding is important for designers of future clin. trials when considering the optimal timing and duration of AZD1775 treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN2xmi0S1pwLVg90H21EOLACvtfcHk0lhaWhFED5RscA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsl2ju7%252FE&md5=b1548a7e7d6eac24438e27ccdbf7b535</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1080%2F15384101.2017.1301329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15384101.2017.1301329%26sid%3Dliteratum%253Aachs%26aulast%3DWebster%26aufirst%3DP.%2BJ.%26aulast%3DLittlejohns%26aufirst%3DA.%2BT.%26aulast%3DGaunt%26aufirst%3DH.%2BJ.%26aulast%3DPrasad%26aufirst%3DK.%2BR.%26aulast%3DBeech%26aufirst%3DD.%2BJ.%26aulast%3DBurke%26aufirst%3DD.%2BA.%26atitle%3DAZD1775%2520induces%2520toxicity%2520through%2520double-stranded%2520DNA%2520breaks%2520independently%2520of%2520chemotherapeutic%2520agents%2520in%2520p53-mutated%2520colorectal%2520cancer%2520cells%26jtitle%3DCell%2520Cycle%26date%3D2017%26volume%3D16%26issue%3D22%26spage%3D2176%26epage%3D2182%26doi%3D10.1080%2F15384101.2017.1301329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matheson, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkataraman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amani, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Backos, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donson, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wempe, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foreman, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vibhakar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reigan, P.</span></span> <span> </span><span class="NLM_article-title">A WEE1 inhibitor analog of AZD1775 maintains synergy with cisplatin and demonstrates reduced single-agent cytotoxicity in medulloblastoma cells</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2066</span>â <span class="NLM_lpage">2067</span>, <span class="refDoi">Â DOI: 10.1021/acschembio.6b00466</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.6b00466" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC28XpslaqsLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=2066-2067&issue=7&author=C.+J.+Mathesonauthor=S.+Venkataramanauthor=V.+Amaniauthor=P.+S.+Harrisauthor=D.+S.+Backosauthor=A.+M.+Donsonauthor=M.+F.+Wempeauthor=N.+K.+Foremanauthor=R.+Vibhakarauthor=P.+Reigan&title=A+WEE1+inhibitor+analog+of+AZD1775+maintains+synergy+with+cisplatin+and+demonstrates+reduced+single-agent+cytotoxicity+in+medulloblastoma+cells&doi=10.1021%2Facschembio.6b00466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">A WEE1 Inhibitor Analog of AZD1775 Maintains Synergy with Cisplatin and Demonstrates Reduced Single-Agent Cytotoxicity in Medulloblastoma Cells [Erratum to document cited in CA164:432708]</span></div><div class="casAuthors">Matheson, Christopher J.; Venkataraman, Sujatha; Amani, Vladimir; Harris, Peter S.; Backos, Donald S.; Donson, Andrew M.; Wempe, Michael F.; Foreman, Nicholas K.; Vibhakar, Rajeev; Reigan, Philip</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2066-2067</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The purpose of this correction is to report a calcn. error in the IC50 values derived from the TR-FRET assay.  An incorrect concn. range was used in Graphpad Prism, and as a result all IC50 values were off by a factor of 10.  Thecorrect values are shown in the table within Figure 2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqCJCK4Mu0c7Vg90H21EOLACvtfcHk0lg9HGHxKivgZg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpslaqsLw%253D&md5=8959cc16ff340840618b12b15cd519b5</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1021%2Facschembio.6b00466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.6b00466%26sid%3Dliteratum%253Aachs%26aulast%3DMatheson%26aufirst%3DC.%2BJ.%26aulast%3DVenkataraman%26aufirst%3DS.%26aulast%3DAmani%26aufirst%3DV.%26aulast%3DHarris%26aufirst%3DP.%2BS.%26aulast%3DBackos%26aufirst%3DD.%2BS.%26aulast%3DDonson%26aufirst%3DA.%2BM.%26aulast%3DWempe%26aufirst%3DM.%2BF.%26aulast%3DForeman%26aufirst%3DN.%2BK.%26aulast%3DVibhakar%26aufirst%3DR.%26aulast%3DReigan%26aufirst%3DP.%26atitle%3DA%2520WEE1%2520inhibitor%2520analog%2520of%2520AZD1775%2520maintains%2520synergy%2520with%2520cisplatin%2520and%2520demonstrates%2520reduced%2520single-agent%2520cytotoxicity%2520in%2520medulloblastoma%2520cells%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2016%26volume%3D11%26issue%3D7%26spage%3D2066%26epage%3D2067%26doi%3D10.1021%2Facschembio.6b00466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marques, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peaucellier, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozano, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schatt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picard, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callebaut, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perret, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geneviere, A. M.</span></span> <span> </span><span class="NLM_article-title">A new subfamily of high molecular mass CDC2-related kinases with PITAI/VRE motifs</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>279</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">832</span>â <span class="NLM_lpage">837</span>, <span class="refDoi">Â DOI: 10.1006/bbrc.2000.4042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1006%2Fbbrc.2000.4042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=11162436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivVakug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2000&pages=832-837&issue=3&author=F.+Marquesauthor=J.+L.+Moreauauthor=G.+Peaucellierauthor=J.+C.+Lozanoauthor=P.+Schattauthor=A.+Picardauthor=I.+Callebautauthor=E.+Perretauthor=A.+M.+Geneviere&title=A+new+subfamily+of+high+molecular+mass+CDC2-related+kinases+with+PITAI%2FVRE+motifs&doi=10.1006%2Fbbrc.2000.4042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">A New Subfamily of High Molecular Mass CDC2-Related Kinases with PITAI/VRE Motifs</span></div><div class="casAuthors">Marques, Francois; Moreau, Jean-Luc; Peaucellier, Gerard; Lozano, Jean-Claude; Schatt, Philippe; Picard, Andre; Callebaut, Isabelle; Perret, Eric; Geneviere, Anne-Marie</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">832-837</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Kinases of the CDC2 family play a key role in cell cycle regulation and gene expression.  In the present work, we identified sea urchin and human cDNAs encoding homologs of a high mol. mass CDC2-like kinase (designated CDC2L5) sharing resp. a PITAVRE and PITAIRE motif.  The human cDNA encodes the full-length amino acid sequence of the Cholinesterase-related cell division controller (CHED) kinase, a previously published partial coding sequence.  CDC2L5 overexpressed in mammalian cells is a â170-kDa nuclear protein.  The mRNA is present during the sea urchin early embryogenesis and is ubiquitously expressed in human tissues.  (c) 2000 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRDQCi585Z7rVg90H21EOLACvtfcHk0lg9HGHxKivgZg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivVakug%253D%253D&md5=3b8d397220badcda9cd43e79449ea31e</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1006%2Fbbrc.2000.4042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fbbrc.2000.4042%26sid%3Dliteratum%253Aachs%26aulast%3DMarques%26aufirst%3DF.%26aulast%3DMoreau%26aufirst%3DJ.%2BL.%26aulast%3DPeaucellier%26aufirst%3DG.%26aulast%3DLozano%26aufirst%3DJ.%2BC.%26aulast%3DSchatt%26aufirst%3DP.%26aulast%3DPicard%26aufirst%3DA.%26aulast%3DCallebaut%26aufirst%3DI.%26aulast%3DPerret%26aufirst%3DE.%26aulast%3DGeneviere%26aufirst%3DA.%2BM.%26atitle%3DA%2520new%2520subfamily%2520of%2520high%2520molecular%2520mass%2520CDC2-related%2520kinases%2520with%2520PITAI%252FVRE%2520motifs%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2000%26volume%3D279%26issue%3D3%26spage%3D832%26epage%3D837%26doi%3D10.1006%2Fbbrc.2000.4042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spirohn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boutros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohmann, D.</span></span> <span> </span><span class="NLM_article-title">Cdk12 is a gene-selective RNA polymerase II kinase that regulates a subset of the transcriptome, including Nrf2 target genes</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">21455</span>, <span class="refDoi">Â DOI: 10.1038/srep21455</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1038%2Fsrep21455" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=26911346" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjt1ekurc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=21455&issue=1&author=X.+Liauthor=N.+Chatterjeeauthor=K.+Spirohnauthor=M.+Boutrosauthor=D.+Bohmann&title=Cdk12+is+a+gene-selective+RNA+polymerase+II+kinase+that+regulates+a+subset+of+the+transcriptome%2C+including+Nrf2+target+genes&doi=10.1038%2Fsrep21455"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Cdk12 Is A Gene-Selective RNA Polymerase II Kinase That Regulates a Subset of the Transcriptome, Including Nrf2 Target Genes</span></div><div class="casAuthors">Li, Xuan; Chatterjee, Nirmalya; Spirohn, Kerstin; Boutros, Michael; Bohmann, Dirk</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">21455</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The Nrf2 transcription factor is well conserved throughout metazoan evolution and serves as a central regulator of adaptive cellular responses to oxidative stress.  We carried out an RNAi screen in Drosophila S2 cells to better understand the regulatory mechanisms governing Nrf2 target gene expression.  This paper describes the identification and characterization of the RNA polymerase II (Pol II) kinase Cdk12 as a factor that is required for Nrf2 target gene expression in cell culture and in vivo.  Cdk12 is, however, not essential for bulk mRNA transcription and cells lacking CDK12 function are viable and able to proliferate.  Consistent with previous findings on the DNA damage and heat shock responses, it emerges that Cdk12 may be specifically required for stress activated gene expression.  Transcriptome anal. revealed that antioxidant gene expression is compromised in flies with reduced Cdk12 function, which makes them oxidative stress sensitive.  In addn. to supporting Reactive Oxygen Species (ROS) induced gene activation, Cdk12 suppresses genes that support metabolic functions in stressed conditions.  We suggest that Cdk12 acts as a gene-selective Pol II kinase that engages a global shift in gene expression to switch cells from a metabolically active state to "stress-defense mode" when challenged by external stress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYog5K9zQd7rVg90H21EOLACvtfcHk0ljkaFGAD3Dvbg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjt1ekurc%253D&md5=af5217255a3758257f675c78c51eae8b</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1038%2Fsrep21455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep21455%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DChatterjee%26aufirst%3DN.%26aulast%3DSpirohn%26aufirst%3DK.%26aulast%3DBoutros%26aufirst%3DM.%26aulast%3DBohmann%26aufirst%3DD.%26atitle%3DCdk12%2520is%2520a%2520gene-selective%2520RNA%2520polymerase%2520II%2520kinase%2520that%2520regulates%2520a%2520subset%2520of%2520the%2520transcriptome%252C%2520including%2520Nrf2%2520target%2520genes%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26issue%3D1%26spage%3D21455%26doi%3D10.1038%2Fsrep21455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lui, G. Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandori, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemp, C. J.</span></span> <span> </span><span class="NLM_article-title">CDK12: an emerging therapeutic target for cancer</span>. <i>J. Clin. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>71</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">957</span>â <span class="NLM_lpage">962</span>, <span class="refDoi">Â DOI: 10.1136/jclinpath-2018-205356</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1136%2Fjclinpath-2018-205356" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=30104286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFaisLvO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2018&pages=957-962&issue=11&author=G.+Y.+L.+Luiauthor=C.+Grandoriauthor=C.+J.+Kemp&title=CDK12%3A+an+emerging+therapeutic+target+for+cancer&doi=10.1136%2Fjclinpath-2018-205356"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">CDK12: an emerging therapeutic target for cancer</span></div><div class="casAuthors">Lui, Goldie Y. L.; Grandori, Carla; Kemp, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pathology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">957-962</span>CODEN:
                <span class="NLM_cas:coden">JCPAAK</span>;
        ISSN:<span class="NLM_cas:issn">0021-9746</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cyclin-dependent kinase 12 (CDK12) belongs to the cyclin-dependent kinase (CDK) family of serine/threonine protein kinases that regulate transcriptional and posttranscriptional processes, thereby modulating multiple cellular functions.  Early studies characterised CDK12 as a transcriptional CDK that complexes with cyclin K to mediate gene transcription by phosphorylating RNA polymerase II.  CDK12 has been demonstrated to specifically upregulate the expression of genes involved in response to DNA damage, stress and heat shock.  More recent studies have implicated CDK12 in regulating mRNA splicing, 3' end processing, prereplication complex assembly and genomic stability during embryonic development.  Genomic alterations in CDK12 have been detected in oesophageal, stomach, breast, endometrial, uterine, ovarian, bladder, colorectal and pancreatic cancers, ranging from 5% to 15% of sequenced cases.  An increasing no. of studies point to CDK12 inhibition as an effective strategy to inhibit tumor growth, and synthetic lethal interactions have been described with MYC, EWS/FLI and PARP/CHK1 inhibition.  Herein, we discuss the present literature on CDK12 in cell function and human cancer, highlighting important roles for CDK12 as a clin. biomarker for treatment response and potential as an effective therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzHmC04t6Ds7Vg90H21EOLACvtfcHk0ljkaFGAD3Dvbg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFaisLvO&md5=cbc3224b1ec312eafb2a136bd8c25fcb</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1136%2Fjclinpath-2018-205356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fjclinpath-2018-205356%26sid%3Dliteratum%253Aachs%26aulast%3DLui%26aufirst%3DG.%2BY.%2BL.%26aulast%3DGrandori%26aufirst%3DC.%26aulast%3DKemp%26aufirst%3DC.%2BJ.%26atitle%3DCDK12%253A%2520an%2520emerging%2520therapeutic%2520target%2520for%2520cancer%26jtitle%3DJ.%2520Clin.%2520Pathol.%26date%3D2018%26volume%3D71%26issue%3D11%26spage%3D957%26epage%3D962%26doi%3D10.1136%2Fjclinpath-2018-205356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutor, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huntoon, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karnitz, L. M.</span></span> <span> </span><span class="NLM_article-title">Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>289</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">9247</span>â <span class="NLM_lpage">9253</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M114.551143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1074%2Fjbc.M114.551143" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=24554720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltVSksrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2014&pages=9247-9253&issue=13&author=P.+M.+Joshiauthor=S.+L.+Sutorauthor=C.+J.+Huntoonauthor=L.+M.+Karnitz&title=Ovarian+cancer-associated+mutations+disable+catalytic+activity+of+CDK12%2C+a+kinase+that+promotes+homologous+recombination+repair+and+resistance+to+cisplatin+and+poly%28ADP-ribose%29+polymerase+inhibitors&doi=10.1074%2Fjbc.M114.551143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Ovarian Cancer-associated Mutations Disable Catalytic Activity of CDK12, a Kinase That Promotes Homologous Recombination Repair and Resistance to Cisplatin and Poly(ADP-ribose) Polymerase Inhibitors</span></div><div class="casAuthors">Joshi, Poorval M.; Sutor, Shari L.; Huntoon, Catherine J.; Karnitz, Larry M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">9247-9253</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Mutations in the tumor suppressors BRCA1 and BRCA2, which encode proteins that are key participants in homologous recombination (HR) repair, occur in â¼20% of high grade serous ovarian cancers.  Although only 20% of these tumors have mutations in BRCA1 and BRCA2, nearly 50% of these tumors have defects in HR.  Notably, however, the underlying genetic defects that give rise to HR defects in the absence of BRCA1 and BRCA2 mutations have not been fully elucidated.  Here we show that the recurrent somatic CDK12 mutations identified in ovarian cancers impair the catalytic activity of this kinase, which is involved in the transcription of a subset of genes, including BRCA1 and other DNA repair genes.  Furthermore, we show that disabling CDK12 function in ovarian cancer cells reduces BRCA1 levels, disrupts HR repair, and sensitizes these cells to the crosslinking agents melphalan and cisplatin and to the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888).  Taken together, these findings suggest that many CDK12 mutations are an unrecognized cause of HR defects in ovarian cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTj3CX_FsX_rVg90H21EOLACvtfcHk0ljkaFGAD3Dvbg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltVSksrg%253D&md5=1ac9807318b6002c6134ef49751f3145</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.551143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.551143%26sid%3Dliteratum%253Aachs%26aulast%3DJoshi%26aufirst%3DP.%2BM.%26aulast%3DSutor%26aufirst%3DS.%2BL.%26aulast%3DHuntoon%26aufirst%3DC.%2BJ.%26aulast%3DKarnitz%26aufirst%3DL.%2BM.%26atitle%3DOvarian%2520cancer-associated%2520mutations%2520disable%2520catalytic%2520activity%2520of%2520CDK12%252C%2520a%2520kinase%2520that%2520promotes%2520homologous%2520recombination%2520repair%2520and%2520resistance%2520to%2520cisplatin%2520and%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2014%26volume%3D289%26issue%3D13%26spage%3D9247%26epage%3D9253%26doi%3D10.1074%2Fjbc.M114.551143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekumi, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paculova, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenasi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pospichalova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosken, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rybarikova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryja, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blazek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barboric, M.</span></span> <span> </span><span class="NLM_article-title">Ovarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the Cdk12/CycK complex</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>43</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2575</span>â <span class="NLM_lpage">2589</span>, <span class="refDoi">Â DOI: 10.1093/nar/gkv101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1093%2Fnar%2Fgkv101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=25712099" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFaiurzF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=2575-2589&issue=5&author=K.+M.+Ekumiauthor=H.+Paculovaauthor=T.+Lenasiauthor=V.+Pospichalovaauthor=C.+A.+Boskenauthor=J.+Rybarikovaauthor=V.+Bryjaauthor=M.+Geyerauthor=D.+Blazekauthor=M.+Barboric&title=Ovarian+carcinoma+CDK12+mutations+misregulate+expression+of+DNA+repair+genes+via+deficient+formation+and+function+of+the+Cdk12%2FCycK+complex&doi=10.1093%2Fnar%2Fgkv101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Ovarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the Cdk12/CycK complex</span></div><div class="casAuthors">Ekumi, Kingsley M.; Paculova, Hana; Lenasi, Tina; Pospichalova, Vendula; Bosken, Christian A.; Rybarikova, Jana; Bryja, Vitezslav; Geyer, Matthias; Blazek, Dalibor; Barboric, Matjaz</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2575-2589</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The Cdk12/CycK complex promotes expression of a subset of RNA polymerase II genes, including those of the DNA damage response.  CDK12 is among only nine genes with recurrent somatic mutations in high-grade serous ovarian carcinoma.  However, the influence of these mutations on the Cdk12/CycK complex and their link to carcinogenesis remain ill-defined.  Here, we show that most mutations prevent formation of the Cdk12/CycK complex, rendering the kinase inactive.  By examg. the mutations within the Cdk12/CycK structure, we find that they likely provoke structural rearrangements detrimental to Cdk12 activation.  Our mRNA expression anal. of the patient samples contg. the CDK12 mutations reveals coordinated downregulation of genes crit. to the homologous recombination DNA repair pathway.  Moreover, we establish that the Cdk12/CycK complex occupies these genes and promotes phosphorylation of RNA polymerase II at Ser2.  Accordingly, we demonstrate that the mutant Cdk12 proteins fail to stimulate the faithful DNA double strand break repair via homologous recombination.  Together, we provide the mol. basis of how mutated CDK12 ceases to function in ovarian carcinoma.  We propose that CDK12 is a tumor suppressor of which the loss-of-function mutations may elicit defects in multiple DNA repair pathways, leading to genomic instability underlying the genesis of the cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqK-JxTmiCnhLVg90H21EOLACvtfcHk0ljXpe-y_6ZJxg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFaiurzF&md5=dc10eb689b1ef25ba3b5bedfd96053d8</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkv101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkv101%26sid%3Dliteratum%253Aachs%26aulast%3DEkumi%26aufirst%3DK.%2BM.%26aulast%3DPaculova%26aufirst%3DH.%26aulast%3DLenasi%26aufirst%3DT.%26aulast%3DPospichalova%26aufirst%3DV.%26aulast%3DBosken%26aufirst%3DC.%2BA.%26aulast%3DRybarikova%26aufirst%3DJ.%26aulast%3DBryja%26aufirst%3DV.%26aulast%3DGeyer%26aufirst%3DM.%26aulast%3DBlazek%26aufirst%3DD.%26aulast%3DBarboric%26aufirst%3DM.%26atitle%3DOvarian%2520carcinoma%2520CDK12%2520mutations%2520misregulate%2520expression%2520of%2520DNA%2520repair%2520genes%2520via%2520deficient%2520formation%2520and%2520function%2520of%2520the%2520Cdk12%252FCycK%2520complex%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2015%26volume%3D43%26issue%3D5%26spage%3D2575%26epage%3D2589%26doi%3D10.1093%2Fnar%2Fgkv101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naidoo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wai, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maguire, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daley, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haider, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kriplani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirza, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grigoriadis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tutt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moseley, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Fatah, T. M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S. Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madhusudan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhaka, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, I. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lord, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natrajan, R.</span></span> <span> </span><span class="NLM_article-title">Evaluation of CDK12 protein expression as a potential novel biomarker for DNA damage response-targeted therapies in breast cancer</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">306</span>â <span class="NLM_lpage">315</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-17-0760</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F1535-7163.MCT-17-0760" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=29133620" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Gitw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=306-315&issue=1&author=K.+Naidooauthor=P.+T.+Waiauthor=S.+L.+Maguireauthor=F.+Daleyauthor=S.+Haiderauthor=D.+Kriplaniauthor=J.+Campbellauthor=H.+Mirzaauthor=A.+Grigoriadisauthor=A.+Tuttauthor=P.+M.+Moseleyauthor=T.+M.+A.+Abdel-Fatahauthor=S.+Y.+T.+Chanauthor=S.+Madhusudanauthor=E.+A.+Rhakaauthor=I.+O.+Ellisauthor=C.+J.+Lordauthor=Y.+Yuanauthor=A.+R.+Greenauthor=R.+Natrajan&title=Evaluation+of+CDK12+protein+expression+as+a+potential+novel+biomarker+for+DNA+damage+response-targeted+therapies+in+breast+cancer&doi=10.1158%2F1535-7163.MCT-17-0760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response-Targeted Therapies in Breast Cancer</span></div><div class="casAuthors">Naidoo, Kalnisha; Wai, Patty T.; Maguire, Sarah L.; Daley, Frances; Haider, Syed; Kriplani, Divya; Campbell, James; Mirza, Hasan; Grigoriadis, Anita; Tutt, Andrew; Moseley, Paul M.; Abdel-Fatah, Tarek M. A.; Chan, Stephen Y. T.; Madhusudan, Srinivasan; Rhaka, Emad A.; Ellis, Ian O.; Lord, Christopher J.; Yuan, Yinyin; Green, Andrew R.; Natrajan, Rachael</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">306-315</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Disruption of Cyclin-Dependent Kinase 12 (CDK12) is known to lead to defects in DNA repair and sensitivity to platinum salts and PARP1/2 inhibitors.  However, CDK12 has also been proposed as an oncogene in breast cancer.  We therefore aimed to assess the frequency and distribution of CDK12 protein expression by IHC in independent cohorts of breast cancer and correlate this with outcome and genomic status.  We found that 21% of primary unselected breast cancers were CDK12 high, and 10.5% were absent, by IHC.  CDK12 positivity correlated with HER2 positivity but was not an independent predictor of breast cancer-specific survival taking HER2 status into account; however, absent CDK12 protein expression significantly correlated with a triple-neg. phenotype.  Interestingly, CDK12 protein absence was assocd. with reduced expression of a no. of DDR proteins including ATR, Ku70/Ku80, PARP1, DNA-PK, and Î³H2AX, suggesting a novel mechanism of CDK12-assocd. DDR dysregulation in breast cancer.  Our data suggest that diagnostic IHC quantification of CDK12 in breast cancer is feasible, with CDK12 absence possibly signifying defective DDR function.  This may have important therapeutic implications, particularly for triple-neg. breast cancers.  Mol Cancer Ther; 17(1); 306-15. Â©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK7g_s8kIxRrVg90H21EOLACvtfcHk0ljXpe-y_6ZJxg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Gitw%253D%253D&md5=66790735980e31d1736272e2c20be108</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-17-0760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-17-0760%26sid%3Dliteratum%253Aachs%26aulast%3DNaidoo%26aufirst%3DK.%26aulast%3DWai%26aufirst%3DP.%2BT.%26aulast%3DMaguire%26aufirst%3DS.%2BL.%26aulast%3DDaley%26aufirst%3DF.%26aulast%3DHaider%26aufirst%3DS.%26aulast%3DKriplani%26aufirst%3DD.%26aulast%3DCampbell%26aufirst%3DJ.%26aulast%3DMirza%26aufirst%3DH.%26aulast%3DGrigoriadis%26aufirst%3DA.%26aulast%3DTutt%26aufirst%3DA.%26aulast%3DMoseley%26aufirst%3DP.%2BM.%26aulast%3DAbdel-Fatah%26aufirst%3DT.%2BM.%2BA.%26aulast%3DChan%26aufirst%3DS.%2BY.%2BT.%26aulast%3DMadhusudan%26aufirst%3DS.%26aulast%3DRhaka%26aufirst%3DE.%2BA.%26aulast%3DEllis%26aufirst%3DI.%2BO.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DYuan%26aufirst%3DY.%26aulast%3DGreen%26aufirst%3DA.%2BR.%26aulast%3DNatrajan%26aufirst%3DR.%26atitle%3DEvaluation%2520of%2520CDK12%2520protein%2520expression%2520as%2520a%2520potential%2520novel%2520biomarker%2520for%2520DNA%2520damage%2520response-targeted%2520therapies%2520in%2520breast%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2018%26volume%3D17%26issue%3D1%26spage%3D306%26epage%3D315%26doi%3D10.1158%2F1535-7163.MCT-17-0760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Biswas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cultraro, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maity, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venugopalan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdullaev, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaytan, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitts, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bass, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanada, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meltzer, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panchenko, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pack, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giaccone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrump, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guha, U.</span></span> <span> </span><span class="NLM_article-title">Genomic profiling of multiple sequentially acquired tumor metastatic sites from an âexceptional responderâ lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response</span>. <i>Cold Spring Harb. Mol. Case Stud.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">6</span>), <span class="NLM_elocation-id">a001263</span> <span class="refDoi">Â DOI: 10.1101/mcs.a001263</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1101%2Fmcs.a001263" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=27900369" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotlSksbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2016&issue=6&author=R.+Biswasauthor=S.+Gaoauthor=C.+M.+Cultraroauthor=T.+K.+Maityauthor=A.+Venugopalanauthor=Z.+Abdullaevauthor=A.+K.+Shaytanauthor=C.+A.+Carterauthor=A.+Thomasauthor=A.+Rajanauthor=Y.+Songauthor=S.+Pittsauthor=K.+Chenauthor=S.+Bassauthor=J.+Bolandauthor=K.+I.+Hanadaauthor=J.+Chenauthor=P.+S.+Meltzerauthor=A.+R.+Panchenkoauthor=J.+C.+Yangauthor=S.+Packauthor=G.+Giacconeauthor=D.+S.+Schrumpauthor=J.+Khanauthor=U.+Guha&title=Genomic+profiling+of+multiple+sequentially+acquired+tumor+metastatic+sites+from+an+%E2%80%9Cexceptional+responder%E2%80%9D+lung+adenocarcinoma+patient+reveals+extensive+genomic+heterogeneity+and+novel+somatic+variants+driving+treatment+response&doi=10.1101%2Fmcs.a001263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Genomic profiling of multiple sequentially acquired tumor metastatic sites from an "exceptional responder" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response</span></div><div class="casAuthors">Biswas, Romi; Gao, Shaojian; Cultraro, Constance M.; Maity, Tapan K.; Venugopalan, Abhilash; Abdullaev, Zied; Shaytan, Alexey K.; Carter, Corey A.; Thomas, Anish; Rajan, Arun; Song, Young; Pitts, Stephanie; Chen, Kevin; Bass, Sara; Boland, Joseph; Hanada, Ken-Ichi; Chen, Jinqiu; Meltzer, Paul S.; Panchenko, Anna R.; Yang, James C.; Pack, Svetlana; Giaccone, Giuseppe; Schrump, David S.; Khan, Javed; Guha, Udayan</div><div class="citationInfo"><span class="NLM_cas:title">Cold Spring Harbor Molecular Case Studies</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">a001263/1-a001263/27</span>CODEN:
                <span class="NLM_cas:coden">CSHMCJ</span>;
        ISSN:<span class="NLM_cas:issn">2373-2873</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">We used next-generation sequencing to identify somatic alterations in multiple metastatic sites from an "exceptional responder" lung adenocarcinoma patient during his 7-yr course of ERBB2-directed therapies.  The degree of heterogeneity was unprecedented, with â¼1% similarity between somatic alterations of the lung and lymph nodes.  One novel translocation, PLAG1-ACTA2, present in both sites, up-regulated ACTA2 expression.  ERBB2, the predominant driver oncogene, was amplified in both sites, more pronounced in the lung, and harbored an L869R mutation in the lymph node.  Functional studies showed increased proliferation, migration, metastasis, and resistance to ERBB2- directed therapy because of L869R mutation and increased migration because of ACTA2 overexpression.  Within the lung, a nonfunctional CDK12, due to a novel G879V mutation, correlated with down-regulation of DNA damage response genes, causing genomic instability, and sensitivity to chemotherapy.  We propose a model whereby a subclone metastasized early fromthe primary site and evolved independently in lymph nodes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWKbpk3UH287Vg90H21EOLACvtfcHk0liUEjD2sHZO9g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotlSksbc%253D&md5=6d6898c62f0f2d8879859b32cded3201</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1101%2Fmcs.a001263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fmcs.a001263%26sid%3Dliteratum%253Aachs%26aulast%3DBiswas%26aufirst%3DR.%26aulast%3DGao%26aufirst%3DS.%26aulast%3DCultraro%26aufirst%3DC.%2BM.%26aulast%3DMaity%26aufirst%3DT.%2BK.%26aulast%3DVenugopalan%26aufirst%3DA.%26aulast%3DAbdullaev%26aufirst%3DZ.%26aulast%3DShaytan%26aufirst%3DA.%2BK.%26aulast%3DCarter%26aufirst%3DC.%2BA.%26aulast%3DThomas%26aufirst%3DA.%26aulast%3DRajan%26aufirst%3DA.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DPitts%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DBass%26aufirst%3DS.%26aulast%3DBoland%26aufirst%3DJ.%26aulast%3DHanada%26aufirst%3DK.%2BI.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DMeltzer%26aufirst%3DP.%2BS.%26aulast%3DPanchenko%26aufirst%3DA.%2BR.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DPack%26aufirst%3DS.%26aulast%3DGiaccone%26aufirst%3DG.%26aulast%3DSchrump%26aufirst%3DD.%2BS.%26aulast%3DKhan%26aufirst%3DJ.%26aulast%3DGuha%26aufirst%3DU.%26atitle%3DGenomic%2520profiling%2520of%2520multiple%2520sequentially%2520acquired%2520tumor%2520metastatic%2520sites%2520from%2520an%2520%25E2%2580%259Cexceptional%2520responder%25E2%2580%259D%2520lung%2520adenocarcinoma%2520patient%2520reveals%2520extensive%2520genomic%2520heterogeneity%2520and%2520novel%2520somatic%2520variants%2520driving%2520treatment%2520response%26jtitle%3DCold%2520Spring%2520Harb.%2520Mol.%2520Case%2520Stud.%26date%3D2016%26volume%3D2%26issue%3D6%26doi%3D10.1101%2Fmcs.a001263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bajrami, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frankum, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rehman, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brough, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sims, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rafiq, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooper, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozarewa, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assiotis, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenwick, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natrajan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lord, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashworth, A.</span></span> <span> </span><span class="NLM_article-title">Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">287</span>â <span class="NLM_lpage">297</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-13-2541</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F0008-5472.CAN-13-2541" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=24240700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2cXislKjuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=287-297&issue=1&author=I.+Bajramiauthor=J.+R.+Frankumauthor=A.+Kondeauthor=R.+E.+Millerauthor=F.+L.+Rehmanauthor=R.+Broughauthor=J.+Campbellauthor=D.+Simsauthor=R.+Rafiqauthor=S.+Hooperauthor=L.+Chenauthor=I.+Kozarewaauthor=I.+Assiotisauthor=K.+Fenwickauthor=R.+Natrajanauthor=C.+J.+Lordauthor=A.+Ashworth&title=Genome-wide+profiling+of+genetic+synthetic+lethality+identifies+CDK12+as+a+novel+determinant+of+PARP1%2F2+inhibitor+sensitivity&doi=10.1158%2F0008-5472.CAN-13-2541"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity</span></div><div class="casAuthors">Bajrami, Ilirjana; Frankum, Jessica R.; Konde, Asha; Miller, Rowan E.; Rehman, Farah L.; Brough, Rachel; Campbell, James; Sims, David; Rafiq, Rumana; Hooper, Sean; Chen, Lina; Kozarewa, Iwanka; Assiotis, Ioannis; Fenwick, Kerry; Natrajan, Rachael; Lord, Christopher J.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">287-297</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Small-mol. inhibitors of PARP1/2, such as olaparib, have been proposed to serve as a synthetic lethal therapy for cancers that harbor BRCA1 or BRCA2 mutations.  Indeed, in clin. trials, PARP1/2 inhibitors elicit sustained antitumor responses in patients with germline BRCA gene mutations.  In hypothesizing that addnl. genetic determinants might direct use of these drugs, we conducted a genome-wide synthetic lethal screen for candidate olaparib sensitivity genes.  In support of this hypothesis, the set of identified genes included known determinants of olaparib sensitivity, such as BRCA1, RAD51, and Fanconi's anemia susceptibility genes.  In addn., the set included genes implicated in established networks of DNA repair, DNA cohesion, and chromatin remodeling, none of which were known previously to confer sensitivity to PARP1/2 inhibition.  Notably, integration of the list of candidate sensitivity genes with data from tumor DNA sequencing studies identified CDK12 deficiency as a clin. relevant biomarker of PARP1/2 inhibitor sensitivity.  In models of high-grade serous ovarian cancer (HGS-OVCa), CDK12 attenuation was sufficient to confer sensitivity to PARP1/2 inhibition, suppression of DNA repair via homologous recombination, and reduced expression of BRCA1.  As one of only nine genes known to be significantly mutated in HGS-OVCa, CDK12 has properties that should confirm interest in its use as a biomarker, particularly in ongoing clin. trials of PARP1/2 inhibitors and other agents that trigger replication fork arrest.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNCJR_Nh_WjbVg90H21EOLACvtfcHk0liUEjD2sHZO9g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXislKjuw%253D%253D&md5=9e07aa538aed0fb3a5ac6be21659d051</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-13-2541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-13-2541%26sid%3Dliteratum%253Aachs%26aulast%3DBajrami%26aufirst%3DI.%26aulast%3DFrankum%26aufirst%3DJ.%2BR.%26aulast%3DKonde%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DR.%2BE.%26aulast%3DRehman%26aufirst%3DF.%2BL.%26aulast%3DBrough%26aufirst%3DR.%26aulast%3DCampbell%26aufirst%3DJ.%26aulast%3DSims%26aufirst%3DD.%26aulast%3DRafiq%26aufirst%3DR.%26aulast%3DHooper%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DKozarewa%26aufirst%3DI.%26aulast%3DAssiotis%26aufirst%3DI.%26aulast%3DFenwick%26aufirst%3DK.%26aulast%3DNatrajan%26aufirst%3DR.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DGenome-wide%2520profiling%2520of%2520genetic%2520synthetic%2520lethality%2520identifies%2520CDK12%2520as%2520a%2520novel%2520determinant%2520of%2520PARP1%252F2%2520inhibitor%2520sensitivity%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26issue%3D1%26spage%3D287%26epage%3D297%26doi%3D10.1158%2F0008-5472.CAN-13-2541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muniz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, S.</span></span> <span> </span><span class="NLM_article-title">3â² end formation of pre-mRNA and phosphorylation of Ser2 on the RNA polymerase II CTD are reciprocally coupled in human cells</span>. <i>Genes Dev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">342</span>â <span class="NLM_lpage">356</span>, <span class="refDoi">Â DOI: 10.1101/gad.231274.113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1101%2Fgad.231274.113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=24478330" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktFektLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=342-356&issue=4&author=L.+Davidsonauthor=L.+Munizauthor=S.+West&title=3%E2%80%B2+end+formation+of+pre-mRNA+and+phosphorylation+of+Ser2+on+the+RNA+polymerase+II+CTD+are+reciprocally+coupled+in+human+cells&doi=10.1101%2Fgad.231274.113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">3' end formation of pre-mRNA and phosphorylation of Ser2 on the RNA polymerase II CTD are reciprocally coupled in human cells</span></div><div class="casAuthors">Davidson, Lee; Muniz, Lisa; West, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">342-356</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">3' End formation of pre-mRNAs is coupled to their transcription via the C-terminal domain (CTD) of RNA polymerase II (Pol II).  Nearly all protein-coding transcripts are matured by cleavage and polyadenylation (CPA), which is frequently misregulated in disease.  Understanding how transcription is coordinated with CPA in human cells is therefore very important.  We found that the CTD is heavily phosphorylated on Ser2 (Ser2p) at poly(A) (pA) signals coincident with recruitment of the CstF77 CPA factor.  Depletion of the Ser2 kinase Cdk12 impairs Ser2p, CstF77 recruitment, and CPA, strongly suggesting that the processes are linked, as they are in budding yeast.  Importantly, we addnl. show that the high Ser2p signals at the 3' end depend on pA signal function.  Down-regulation of CPA results in the loss of a 3' Ser2p peak, whereas a new peak is formed when CPA is induced de novo.  Finally, high Ser2p signals are generated by Pol II pausing, which is a well-known feature of pA site recognition.  Thus, a reciprocal relationship between early steps in pA site processing and Ser2p ensures efficient 3' end formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqV79r2OLuIbVg90H21EOLACvtfcHk0liUEjD2sHZO9g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktFektLo%253D&md5=b69cb0685b08cd5b9653f8a0285bf283</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1101%2Fgad.231274.113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.231274.113%26sid%3Dliteratum%253Aachs%26aulast%3DDavidson%26aufirst%3DL.%26aulast%3DMuniz%26aufirst%3DL.%26aulast%3DWest%26aufirst%3DS.%26atitle%3D3%25E2%2580%25B2%2520end%2520formation%2520of%2520pre-mRNA%2520and%2520phosphorylation%2520of%2520Ser2%2520on%2520the%2520RNA%2520polymerase%2520II%2520CTD%2520are%2520reciprocally%2520coupled%2520in%2520human%2520cells%26jtitle%3DGenes%2520Dev.%26date%3D2014%26volume%3D28%26issue%3D4%26spage%3D342%26epage%3D356%26doi%3D10.1101%2Fgad.231274.113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iniguez, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolte, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conway, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dharia, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mora, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalev, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leggett, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chowdhury, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benes, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stegmaier, K.</span></span> <span> </span><span class="NLM_article-title">EWS/FLI confers tumor cell synthetic lethality to CDK12 inhibition in Ewing sarcoma</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">202</span>â <span class="NLM_lpage">216</span>, <span class="refDoi">Â DOI: 10.1016/j.ccell.2017.12.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.ccell.2017.12.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=29358035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlOgu7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2018&pages=202-216&issue=2&author=A.+B.+Iniguezauthor=B.+Stolteauthor=E.+J.+Wangauthor=A.+S.+Conwayauthor=G.+Alexeauthor=N.+V.+Dhariaauthor=N.+Kwiatkowskiauthor=T.+Zhangauthor=B.+J.+Abrahamauthor=J.+Moraauthor=P.+Kalevauthor=A.+Leggettauthor=D.+Chowdhuryauthor=C.+H.+Benesauthor=R.+A.+Youngauthor=N.+S.+Grayauthor=K.+Stegmaier&title=EWS%2FFLI+confers+tumor+cell+synthetic+lethality+to+CDK12+inhibition+in+Ewing+sarcoma&doi=10.1016%2Fj.ccell.2017.12.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma</span></div><div class="casAuthors">Iniguez, Amanda Balboni; Stolte, Bjorn; Wang, Emily Jue; Conway, Amy Saur; Alexe, Gabriela; Dharia, Neekesh V.; Kwiatkowski, Nicholas; Zhang, Tinghu; Abraham, Brian J.; Mora, Jaume; Kalev, Peter; Leggett, Alan; Chowdhury, Dipanjan; Benes, Cyril H.; Young, Richard A.; Gray, Nathanael S.; Stegmaier, Kimberly</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">202-216.e6</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Many cancer types are driven by oncogenic transcription factors that have been difficult to drug.  Transcriptional inhibitors, however, may offer inroads into targeting these cancers.  Through chem. genomics screening, we identified that Ewing sarcoma is a disease with preferential sensitivity to THZ1, a covalent small-mol. CDK7/12/13 inhibitor.  The selective CDK12/13 inhibitor, THZ531, impairs DNA damage repair in an EWS/FLI-dependent manner, supporting a synthetic lethal relationship between response to THZ1/THZ531 and EWS/FLI expression.  The combination of these mols. with PARP inhibitors showed striking synergy in cell viability and DNA damage assays in vitro and in multiple models of Ewing sarcoma, including a PDX, in vivo without hematopoietic toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8OOYhMwzME7Vg90H21EOLACvtfcHk0lhyekf4cgzCFw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlOgu7c%253D&md5=c844fbd1a91828c87dda66646e4acd03</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2017.12.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2017.12.009%26sid%3Dliteratum%253Aachs%26aulast%3DIniguez%26aufirst%3DA.%2BB.%26aulast%3DStolte%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DE.%2BJ.%26aulast%3DConway%26aufirst%3DA.%2BS.%26aulast%3DAlexe%26aufirst%3DG.%26aulast%3DDharia%26aufirst%3DN.%2BV.%26aulast%3DKwiatkowski%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DAbraham%26aufirst%3DB.%2BJ.%26aulast%3DMora%26aufirst%3DJ.%26aulast%3DKalev%26aufirst%3DP.%26aulast%3DLeggett%26aufirst%3DA.%26aulast%3DChowdhury%26aufirst%3DD.%26aulast%3DBenes%26aufirst%3DC.%2BH.%26aulast%3DYoung%26aufirst%3DR.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DStegmaier%26aufirst%3DK.%26atitle%3DEWS%252FFLI%2520confers%2520tumor%2520cell%2520synthetic%2520lethality%2520to%2520CDK12%2520inhibition%2520in%2520Ewing%2520sarcoma%26jtitle%3DCancer%2520Cell%26date%3D2018%26volume%3D33%26issue%3D2%26spage%3D202%26epage%3D216%26doi%3D10.1016%2Fj.ccell.2017.12.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marineau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malojcic, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlando, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, C.</span></span> <span> </span><span class="NLM_article-title">Targeting the transcriptional kinases CDK12 and CDK13 in breast and ovarian cancer</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">1_supplement</span>),  <span class="NLM_fpage">938.9</span>, <span class="refDoi">Â DOI: 10.1096/fasebj.31.1_supplement.938.9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1096%2Ffasebj.31.1_supplement.938.9" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=938.9&issue=1_supplement&author=K.+Hammanauthor=M.+Bradleyauthor=J.+Marineauauthor=Y.+Choiauthor=G.+Malojcicauthor=D.+Orlandoauthor=Y.+Renauthor=N.+Keauthor=S.+Huauthor=E.+Olsonauthor=C.+Fritzauthor=C.+Roberts&title=Targeting+the+transcriptional+kinases+CDK12+and+CDK13+in+breast+and+ovarian+cancer&doi=10.1096%2Ffasebj.31.1_supplement.938.9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1096%2Ffasebj.31.1_supplement.938.9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffasebj.31.1_supplement.938.9%26sid%3Dliteratum%253Aachs%26aulast%3DHamman%26aufirst%3DK.%26aulast%3DBradley%26aufirst%3DM.%26aulast%3DMarineau%26aufirst%3DJ.%26aulast%3DChoi%26aufirst%3DY.%26aulast%3DMalojcic%26aufirst%3DG.%26aulast%3DOrlando%26aufirst%3DD.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DKe%26aufirst%3DN.%26aulast%3DHu%26aufirst%3DS.%26aulast%3DOlson%26aufirst%3DE.%26aulast%3DFritz%26aufirst%3DC.%26aulast%3DRoberts%26aufirst%3DC.%26atitle%3DTargeting%2520the%2520transcriptional%2520kinases%2520CDK12%2520and%2520CDK13%2520in%2520breast%2520and%2520ovarian%2520cancer%26jtitle%3DFASEB%2520J.%26date%3D2017%26volume%3D31%26issue%3D1_supplement%26spage%3D938.9%26doi%3D10.1096%2Ffasebj.31.1_supplement.938.9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchiyama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokubo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morishita, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sameshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Araki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morin, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakanishi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maezaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imaeda, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of 3-benzyl-1-(trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea derivatives as novel and selective cyclin-dependent kinase 12 (CDK12) Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">7710</span>â <span class="NLM_lpage">7728</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b00683</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00683" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVWrsbjI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7710-7728&issue=17&author=M.+Itoauthor=T.+Tanakaauthor=A.+Toitaauthor=N.+Uchiyamaauthor=H.+Kokuboauthor=N.+Morishitaauthor=M.+G.+Kleinauthor=H.+Zouauthor=M.+Murakamiauthor=M.+Kondoauthor=T.+Sameshimaauthor=S.+Arakiauthor=S.+Endoauthor=T.+Kawamotoauthor=G.+B.+Morinauthor=S.+A.+Aparicioauthor=A.+Nakanishiauthor=H.+Maezakiauthor=Y.+Imaeda&title=Discovery+of+3-benzyl-1-%28trans-4-%28%285-cyanopyridin-2-yl%29amino%29cyclohexyl%29-1-arylurea+derivatives+as+novel+and+selective+cyclin-dependent+kinase+12+%28CDK12%29+Inhibitors&doi=10.1021%2Facs.jmedchem.8b00683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 3-Benzyl-1-(trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea Derivatives as Novel and Selective Cyclin-Dependent Kinase 12 (CDK12) Inhibitors</span></div><div class="casAuthors">Ito, Masahiro; Tanaka, Toshio; Toita, Akinori; Uchiyama, Noriko; Kokubo, Hironori; Morishita, Nao; Klein, Michael G.; Zou, Hua; Murakami, Morio; Kondo, Mitsuyo; Sameshima, Tomoya; Araki, Shinsuke; Endo, Satoshi; Kawamoto, Tomohiro; Morin, Gregg B.; Aparicio, Samuel A.; Nakanishi, Atsushi; Maezaki, Hironobu; Imaeda, Yasuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7710-7728</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase 12 (CDK12) plays a key role in the coordination of transcription with elongation and mRNA processing.  CDK12 mutations found in tumors and CDK12 inhibition sensitize cancer cells to DNA-damaging reagents and DNA-repair inhibitors.  This suggests that CDK12 inhibitors are potential therapeutics for cancer that may cause synthetic lethality.  Here, we report the discovery of 3-benzyl-1-(trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea derivs. as novel and selective CDK12 inhibitors.  Structure-activity relationship studies of a HTS hit, structure-based drug design, and conformation-oriented design using the Cambridge Structural Database afforded the optimized compd. 2, which exhibited not only potent CDK12 (and CDK13) inhibitory activity and excellent selectivity but also good physicochem. properties.  Furthermore, 2 inhibited the phosphorylation of Ser2 in the C-terminal domain of RNA polymerase II and induced growth inhibition in SK-BR-3 cells.  Therefore, 2 represents an excellent chem. probe for functional studies of CDK12 and could be a promising lead compd. for drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXLhQTcUpBfLVg90H21EOLACvtfcHk0lhyekf4cgzCFw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVWrsbjI&md5=6d22fd36823d459fb60113c1212aa84e</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00683%26sid%3Dliteratum%253Aachs%26aulast%3DIto%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DToita%26aufirst%3DA.%26aulast%3DUchiyama%26aufirst%3DN.%26aulast%3DKokubo%26aufirst%3DH.%26aulast%3DMorishita%26aufirst%3DN.%26aulast%3DKlein%26aufirst%3DM.%2BG.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DMurakami%26aufirst%3DM.%26aulast%3DKondo%26aufirst%3DM.%26aulast%3DSameshima%26aufirst%3DT.%26aulast%3DAraki%26aufirst%3DS.%26aulast%3DEndo%26aufirst%3DS.%26aulast%3DKawamoto%26aufirst%3DT.%26aulast%3DMorin%26aufirst%3DG.%2BB.%26aulast%3DAparicio%26aufirst%3DS.%2BA.%26aulast%3DNakanishi%26aufirst%3DA.%26aulast%3DMaezaki%26aufirst%3DH.%26aulast%3DImaeda%26aufirst%3DY.%26atitle%3DDiscovery%2520of%25203-benzyl-1-%2528trans-4-%2528%25285-cyanopyridin-2-yl%2529amino%2529cyclohexyl%2529-1-arylurea%2520derivatives%2520as%2520novel%2520and%2520selective%2520cyclin-dependent%2520kinase%252012%2520%2528CDK12%2529%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D17%26spage%3D7710%26epage%3D7728%26doi%3D10.1021%2Facs.jmedchem.8b00683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixon-Clarke, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greifenberg, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ficarro, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannett, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartkowiak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenleaf, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marto, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">876</span>â <span class="NLM_lpage">884</span>, <span class="refDoi">Â DOI: 10.1038/nchembio.2166</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1038%2Fnchembio.2166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=27571479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlyqsbbJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=876-884&issue=10&author=T.+Zhangauthor=N.+Kwiatkowskiauthor=C.+M.+Olsonauthor=S.+E.+Dixon-Clarkeauthor=B.+J.+Abrahamauthor=A.+K.+Greifenbergauthor=S.+B.+Ficarroauthor=J.+M.+Elkinsauthor=Y.+Liangauthor=N.+M.+Hannettauthor=T.+Manzauthor=M.+Haoauthor=B.+Bartkowiakauthor=A.+L.+Greenleafauthor=J.+A.+Martoauthor=M.+Geyerauthor=A.+N.+Bullockauthor=R.+A.+Youngauthor=N.+S.+Gray&title=Covalent+targeting+of+remote+cysteine+residues+to+develop+CDK12+and+CDK13+inhibitors&doi=10.1038%2Fnchembio.2166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors</span></div><div class="casAuthors">Zhang, Tinghu; Kwiatkowski, Nicholas; Olson, Calla M.; Dixon-Clarke, Sarah E.; Abraham, Brian J.; Greifenberg, Ann K.; Ficarro, Scott B.; Elkins, Jonathan M.; Liang, Yanke; Hannett, Nancy M.; Manz, Theresa; Hao, Mingfeng; Bartkowiak, Bartlomiej; Greenleaf, Arno L.; Marto, Jarrod A.; Geyer, Matthias; Bullock, Alex N.; Young, Richard A.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">876-884</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cyclin-dependent kinases 12 and 13 (CDK12 and CDK13) play crit. roles in the regulation of gene transcription.  However, the absence of CDK12 and CDK13 inhibitors has hindered the ability to investigate the consequences of their inhibition in healthy cells and cancer cells.  Here we describe the rational design of a first-in-class CDK12 and CDK13 covalent inhibitor, THZ531.  Co-crystn. of THZ531 with CDK12-cyclin K indicates that THZ531 irreversibly targets a cysteine located outside the kinase domain.  THZ531 causes a loss of gene expression with concurrent loss of elongating and hyperphosphorylated RNA polymerase II.  In particular, THZ531 substantially decreases the expression of DNA damage response genes and key super-enhancer-assocd. transcription factor genes.  Coincident with transcriptional perturbation, THZ531 dramatically induced apoptotic cell death.  Small mols. capable of specifically targeting CDK12 and CDK13 may thus help identify cancer subtypes that are particularly dependent on their kinase activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXIyvy8vbjvrVg90H21EOLACvtfcHk0lgt4opk2Wbfag"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlyqsbbJ&md5=5ac265105d1654e129c3c1325572f389</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2166%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DKwiatkowski%26aufirst%3DN.%26aulast%3DOlson%26aufirst%3DC.%2BM.%26aulast%3DDixon-Clarke%26aufirst%3DS.%2BE.%26aulast%3DAbraham%26aufirst%3DB.%2BJ.%26aulast%3DGreifenberg%26aufirst%3DA.%2BK.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DElkins%26aufirst%3DJ.%2BM.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DHannett%26aufirst%3DN.%2BM.%26aulast%3DManz%26aufirst%3DT.%26aulast%3DHao%26aufirst%3DM.%26aulast%3DBartkowiak%26aufirst%3DB.%26aulast%3DGreenleaf%26aufirst%3DA.%2BL.%26aulast%3DMarto%26aufirst%3DJ.%2BA.%26aulast%3DGeyer%26aufirst%3DM.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DYoung%26aufirst%3DR.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DCovalent%2520targeting%2520of%2520remote%2520cysteine%2520residues%2520to%2520develop%2520CDK12%2520and%2520CDK13%2520inhibitors%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2016%26volume%3D12%26issue%3D10%26spage%3D876%26epage%3D884%26doi%3D10.1038%2Fnchembio.2166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahl, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ficarro, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dastur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amzallag, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramaswamy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannett, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMillin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Look, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsiades, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benes, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marto, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Targeting transcription regulation in cancer with a covalent CDK7 inhibitor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>511</i></span> (<span class="NLM_issue">7511</span>),  <span class="NLM_fpage">616</span>â <span class="NLM_lpage">620</span>, <span class="refDoi">Â DOI: 10.1038/nature13393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1038%2Fnature13393" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=25043025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1ChurnF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=511&publication_year=2014&pages=616-620&issue=7511&author=N.+Kwiatkowskiauthor=T.+Zhangauthor=P.+B.+Rahlauthor=B.+J.+Abrahamauthor=J.+Reddyauthor=S.+B.+Ficarroauthor=A.+Dasturauthor=A.+Amzallagauthor=S.+Ramaswamyauthor=B.+Tesarauthor=C.+E.+Jenkinsauthor=N.+M.+Hannettauthor=D.+McMillinauthor=T.+Sandaauthor=T.+Simauthor=N.+D.+Kimauthor=T.+Lookauthor=C.+S.+Mitsiadesauthor=A.+P.+Wengauthor=J.+R.+Brownauthor=C.+H.+Benesauthor=J.+A.+Martoauthor=R.+A.+Youngauthor=N.+S.+Gray&title=Targeting+transcription+regulation+in+cancer+with+a+covalent+CDK7+inhibitor&doi=10.1038%2Fnature13393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting transcription regulation in cancer with a covalent CDK7 inhibitor</span></div><div class="casAuthors">Kwiatkowski, Nicholas; Zhang, Tinghu; Rahl, Peter B.; Abraham, Brian J.; Reddy, Jessica; Ficarro, Scott B.; Dastur, Anahita; Amzallag, Arnaud; Ramaswamy, Sridhar; Tesar, Bethany; Jenkins, Catherine E.; Hannett, Nancy M.; McMillin, Douglas; Sanda, Takaomi; Sim, Taebo; Kim, Nam Doo; Look, Thomas; Mitsiades, Constantine S.; Weng, Andrew P.; Brown, Jennifer R.; Benes, Cyril H.; Marto, Jarrod A.; Young, Richard A.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">511</span>
        (<span class="NLM_cas:issue">7511</span>),
    <span class="NLM_cas:pages">616-620</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Tumor oncogenes include transcription factors that co-opt the general transcriptional machinery to sustain the oncogenic state, but direct pharmacol. inhibition of transcription factors has so far proven difficult.  However, the transcriptional machinery contains various enzymic cofactors that can be targeted for the development of new therapeutic candidates, including cyclin-dependent kinases (CDKs).  Here the authors present the discovery and characterization of a covalent CDK7 inhibitor, THZ1, which has the unprecedented ability to target a remote cysteine residue located outside of the canonical kinase domain, providing an unanticipated means of achieving selectivity for CDK7.  Cancer cell-line profiling indicates that a subset of cancer cell lines, including human T-cell acute lymphoblastic leukemia (T-ALL), have exceptional sensitivity to THZ1.  Genome-wide anal. in Jurkat T-ALL cells shows that THZ1 disproportionally affects transcription of RUNX1 and suggests that sensitivity to THZ1 may be due to vulnerability conferred by the RUNX1 super-enhancer and the key role of RUNX1 in the core transcriptional regulatory circuitry of these tumor cells.  Pharmacol. modulation of CDK7 kinase activity may thus provide an approach to identify and treat tumor types that are dependent on transcription for maintenance of the oncogenic state.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVD-DeTAQCqrVg90H21EOLACvtfcHk0lgt4opk2Wbfag"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1ChurnF&md5=895a28fb536663a31e7558fe79ce628b</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1038%2Fnature13393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13393%26sid%3Dliteratum%253Aachs%26aulast%3DKwiatkowski%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DRahl%26aufirst%3DP.%2BB.%26aulast%3DAbraham%26aufirst%3DB.%2BJ.%26aulast%3DReddy%26aufirst%3DJ.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DDastur%26aufirst%3DA.%26aulast%3DAmzallag%26aufirst%3DA.%26aulast%3DRamaswamy%26aufirst%3DS.%26aulast%3DTesar%26aufirst%3DB.%26aulast%3DJenkins%26aufirst%3DC.%2BE.%26aulast%3DHannett%26aufirst%3DN.%2BM.%26aulast%3DMcMillin%26aufirst%3DD.%26aulast%3DSanda%26aufirst%3DT.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DN.%2BD.%26aulast%3DLook%26aufirst%3DT.%26aulast%3DMitsiades%26aufirst%3DC.%2BS.%26aulast%3DWeng%26aufirst%3DA.%2BP.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3DBenes%26aufirst%3DC.%2BH.%26aulast%3DMarto%26aufirst%3DJ.%2BA.%26aulast%3DYoung%26aufirst%3DR.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DTargeting%2520transcription%2520regulation%2520in%2520cancer%2520with%2520a%2520covalent%2520CDK7%2520inhibitor%26jtitle%3DNature%26date%3D2014%26volume%3D511%26issue%3D7511%26spage%3D616%26epage%3D620%26doi%3D10.1038%2Fnature13393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parry, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shanahan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabhavalkar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiswell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seghezzi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paruch, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwyer, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doll, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomeir, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Windsor, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oft, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirschmeier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lees, E. M.</span></span> <span> </span><span class="NLM_article-title">Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2344</span>â <span class="NLM_lpage">2353</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-10-0324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F1535-7163.MCT-10-0324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=20663931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvVOjtrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=2344-2353&issue=8&author=D.+Parryauthor=T.+Guziauthor=F.+Shanahanauthor=N.+Davisauthor=D.+Prabhavalkarauthor=D.+Wiswellauthor=W.+Seghezziauthor=K.+Paruchauthor=M.+P.+Dwyerauthor=R.+Dollauthor=A.+Nomeirauthor=W.+Windsorauthor=T.+Fischmannauthor=Y.+Wangauthor=M.+Oftauthor=T.+Chenauthor=P.+Kirschmeierauthor=E.+M.+Lees&title=Dinaciclib+%28SCH+727965%29%2C+a+novel+and+potent+cyclin-dependent+kinase+inhibitor&doi=10.1158%2F1535-7163.MCT-10-0324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor</span></div><div class="casAuthors">Parry, David; Guzi, Timothy; Shanahan, Frances; Davis, Nicole; Prabhavalkar, Deepa; Wiswell, Derek; Seghezzi, Wolfgang; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald; Nomeir, Amin; Windsor, William; Fischmann, Thierry; Wang, Yaolin; Oft, Martin; Chen, Taiying; Kirschmeier, Paul; Lees, Emma M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2344-2353</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cyclin-dependent kinases (CDK) are key pos. regulators of cell cycle progression and attractive targets in oncol.  SCH 727965 inhibits CDK2, CDK5, CDK1, and CDK9 activity in vitro with IC50 values of 1, 1, 3, and 4 nmol/L, resp.  SCH 727965 was selected as a clin. candidate using a functional screen in vivo that integrated both efficacy and safety parameters.  Compared with flavopiridol, SCH 727965 exhibits superior activity with an improved therapeutic index.  In cell-based assays, SCH 727965 completely suppressed retinoblastoma phosphorylation, which correlated with apoptosis onset and total inhibition of bromodeoxyuridine incorporation in >100 tumor cell lines of diverse origin and background.  Moreover, short exposures to SCH 727965 were sufficient for long-lasting cellular effects.  SCH 727965 induced regression of established solid tumors in a range of mouse models following intermittent scheduling of doses below the maximally tolerated level.  This was assocd. with modulation of pharmacodynamic biomarkers in skin punch biopsies and rapidly reversible, mechanism-based effects on hematol. parameters.  These results suggest that SCH 727965 is a potent and selective CDK inhibitor and a novel cytotoxic agent.  Mol Cancer Ther; 9(8); 2344-53.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxn1NtmEAh7LVg90H21EOLACvtfcHk0lhsjj0kwi-5mQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvVOjtrw%253D&md5=bd2d30fdfdca0f2bceb3f5c0b44b8630</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-0324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-0324%26sid%3Dliteratum%253Aachs%26aulast%3DParry%26aufirst%3DD.%26aulast%3DGuzi%26aufirst%3DT.%26aulast%3DShanahan%26aufirst%3DF.%26aulast%3DDavis%26aufirst%3DN.%26aulast%3DPrabhavalkar%26aufirst%3DD.%26aulast%3DWiswell%26aufirst%3DD.%26aulast%3DSeghezzi%26aufirst%3DW.%26aulast%3DParuch%26aufirst%3DK.%26aulast%3DDwyer%26aufirst%3DM.%2BP.%26aulast%3DDoll%26aufirst%3DR.%26aulast%3DNomeir%26aufirst%3DA.%26aulast%3DWindsor%26aufirst%3DW.%26aulast%3DFischmann%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DOft%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DKirschmeier%26aufirst%3DP.%26aulast%3DLees%26aufirst%3DE.%2BM.%26atitle%3DDinaciclib%2520%2528SCH%2520727965%2529%252C%2520a%2520novel%2520and%2520potent%2520cyclin-dependent%2520kinase%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26issue%3D8%26spage%3D2344%26epage%3D2353%26doi%3D10.1158%2F1535-7163.MCT-10-0324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mita, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joy, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sankhala, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jou, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Statkevich, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bannerji, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, C. L.</span></span> <span> </span><span class="NLM_article-title">Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer</span>. <i>Clin. Breast Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">169</span>â <span class="NLM_lpage">176</span>, <span class="refDoi">Â DOI: 10.1016/j.clbc.2013.10.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.clbc.2013.10.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=24393852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivVWrtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=169-176&issue=3&author=M.+M.+Mitaauthor=A.+A.+Joyauthor=A.+Mitaauthor=K.+Sankhalaauthor=Y.+M.+Jouauthor=D.+Zhangauthor=P.+Statkevichauthor=Y.+Zhuauthor=S.+L.+Yaoauthor=K.+Smallauthor=R.+Bannerjiauthor=C.+L.+Shapiro&title=Randomized+phase+II+trial+of+the+cyclin-dependent+kinase+inhibitor+dinaciclib+%28MK-7965%29+versus+capecitabine+in+patients+with+advanced+breast+cancer&doi=10.1016%2Fj.clbc.2013.10.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer</span></div><div class="casAuthors">Mita, Monica M.; Joy, Anil A.; Mita, Alain; Sankhala, Kamalesh; Jou, Ying-Ming; Zhang, Da; Statkevich, Paul; Zhu, Yali; Yao, Siu-Long; Small, Karen; Bannerji, Rajat; Shapiro, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Breast Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">169-176</span>CODEN:
                <span class="NLM_cas:coden">CBCLB7</span>;
        ISSN:<span class="NLM_cas:issn">1526-8209</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Introduction: Effective therapies after failure of treatment with anthracyclines and taxanes are needed for patients with metastatic breast cancer.  Dinaciclib (MK-7965, formerly SCH727965), a small-mol. cyclin-dependent kinase inhibitor, has demonstrated antitumor activity in phase I studies with solid-tumor patients.  This phase II trial was designed to assess the efficacy and safety of dinaciclib compared with that of capecitabine in women with previously treated advanced breast cancer.  Patients and Methods: Patients were randomized to receive either dinaciclib at 50 mg/m2, administered as a 2-h infusion every 21 days, or 1250 mg/m2 capecitabine, administered orally twice daily in 21-day cycles.  Results: An unplanned interim anal. showed that the time to disease progression was inferior with dinaciclib treatment compared with capecitabine treatment; therefore, the trial was stopped after 30 patients were randomized.  Dinaciclib treatment demonstrated antitumor activity in 2 of 7 patients with estrogen receptor-pos. and human epidermal growth factor receptor 2-neg. metastatic breast cancer (1 confirmed and 1 unconfirmed partial response), as well as acceptable safety and tolerability.  Grade 3 or 4 treatment-related adverse events were common and included neutropenia, leukopenia, increase in aspartate aminotransferase, and febrile neutropenia.  Population pharmacokinetic model-predicted mean dinaciclib exposure (area under the concn.-time curve extrapolated to infinity [AUC[I]]) at 50 mg/m2 was similar to that obsd. in a previous phase I trial, and no drug accumulation was obsd. after multiple-dose administration.  Conclusion: Although dinaciclib monotherapy demonstrated some antitumor activity and was generally tolerated, efficacy was not superior to capecitabine.  Future studies may be considered to evaluate dinaciclib in select patient populations with metastatic breast cancer and in combination with other agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpetvZlPAou-LVg90H21EOLACvtfcHk0lhsjj0kwi-5mQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivVWrtQ%253D%253D&md5=5f91dd3e13e17bac5c9bbb227ed1a107</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2Fj.clbc.2013.10.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clbc.2013.10.016%26sid%3Dliteratum%253Aachs%26aulast%3DMita%26aufirst%3DM.%2BM.%26aulast%3DJoy%26aufirst%3DA.%2BA.%26aulast%3DMita%26aufirst%3DA.%26aulast%3DSankhala%26aufirst%3DK.%26aulast%3DJou%26aufirst%3DY.%2BM.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DStatkevich%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DYao%26aufirst%3DS.%2BL.%26aulast%3DSmall%26aufirst%3DK.%26aulast%3DBannerji%26aufirst%3DR.%26aulast%3DShapiro%26aufirst%3DC.%2BL.%26atitle%3DRandomized%2520phase%2520II%2520trial%2520of%2520the%2520cyclin-dependent%2520kinase%2520inhibitor%2520dinaciclib%2520%2528MK-7965%2529%2520versus%2520capecitabine%2520in%2520patients%2520with%2520advanced%2520breast%2520cancer%26jtitle%3DClin.%2520Breast%2520Cancer%26date%3D2014%26volume%3D14%26issue%3D3%26spage%3D169%26epage%3D176%26doi%3D10.1016%2Fj.clbc.2013.10.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greifenberg, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dust, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stover, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Primack, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernhardy, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazaro, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kochupurakkal, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unitt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarosiek, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scaltriti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juric, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodig, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DâAndrea, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balmana, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serra, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span> <span> </span><span class="NLM_article-title">CDK12 inhibition reverses de novo and acquired PARPinhibitor resistance in BRCA wild-type and mutated models of triple-negative breast cancer</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2367</span>â <span class="NLM_lpage">2381</span>, <span class="refDoi">Â DOI: 10.1016/j.celrep.2016.10.077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.celrep.2016.10.077" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=27880910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFGqt7%252FL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=2367-2381&issue=9&author=S.+F.+Johnsonauthor=C.+Cruzauthor=A.+K.+Greifenbergauthor=S.+Dustauthor=D.+G.+Stoverauthor=D.+Chiauthor=B.+Primackauthor=S.+Caoauthor=A.+J.+Bernhardyauthor=R.+Coulsonauthor=J.+B.+Lazaroauthor=B.+Kochupurakkalauthor=H.+Sunauthor=C.+Unittauthor=L.+A.+Moreauauthor=K.+A.+Sarosiekauthor=M.+Scaltritiauthor=D.+Juricauthor=J.+Baselgaauthor=A.+L.+Richardsonauthor=S.+J.+Rodigauthor=A.+D.+D%E2%80%99Andreaauthor=J.+Balmanaauthor=N.+Johnsonauthor=M.+Geyerauthor=V.+Serraauthor=E.+Limauthor=G.+I.+Shapiro&title=CDK12+inhibition+reverses+de+novo+and+acquired+PARPinhibitor+resistance+in+BRCA+wild-type+and+mutated+models+of+triple-negative+breast+cancer&doi=10.1016%2Fj.celrep.2016.10.077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer</span></div><div class="casAuthors">Johnson, Shawn F.; Cruz, Cristina; Greifenberg, Ann Katrin; Dust, Sofia; Stover, Daniel G.; Chi, David; Primack, Benjamin; Cao, Shiliang; Bernhardy, Andrea J.; Coulson, Rhiannon; Lazaro, Jean-Bernard; Kochupurakkal, Bose; Sun, Heather; Unitt, Christine; Moreau, Lisa A.; Sarosiek, Kristopher A.; Scaltriti, Maurizio; Juric, Dejan; Baselga, Jose; Richardson, Andrea L.; Rodig, Scott J.; D'Andrea, Alan D.; Balmana, Judith; Johnson, Neil; Geyer, Matthias; Serra, Violeta; Lim, Elgene; Shapiro, Geoffrey I.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2367-2381</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Although poly(ADP-ribose) polymerase (PARP) inhibitors are active in homologous recombination (HR)-deficient cancers, their utility is limited by acquired resistance after restoration of HR.  Here, we report that dinaciclib, an inhibitor of cyclin-dependent kinases (CDKs) 1, 2, 5, and 9, addnl. has potent activity against CDK12, a transcriptional regulator of HR.  In BRCA-mutated triple-neg. breast cancer (TNBC) cells and patient-derived xenografts (PDXs), dinaciclib ablates restored HR and reverses PARP inhibitor resistance.  Addnl., we show that de novo resistance to PARP inhibition in BRCA1-mutated cell lines and a PDX derived from a PARP-inhibitor-naive BRCA1 carrier is mediated by residual HR and is reversed by CDK12 inhibition.  Finally, dinaciclib augments the degree of response in a PARP-inhibitor-sensitive model, converting tumor growth inhibition to durable regression.  These results highlight the significance of HR disruption as a therapeutic strategy and support the broad use of combined CDK12 and PARP inhibition in TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyVKyKNc3G1bVg90H21EOLACvtfcHk0lii7JkFD8c9ZQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFGqt7%252FL&md5=ae666e75b7a49d0c348789e2d59643fa</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2016.10.077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2016.10.077%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DS.%2BF.%26aulast%3DCruz%26aufirst%3DC.%26aulast%3DGreifenberg%26aufirst%3DA.%2BK.%26aulast%3DDust%26aufirst%3DS.%26aulast%3DStover%26aufirst%3DD.%2BG.%26aulast%3DChi%26aufirst%3DD.%26aulast%3DPrimack%26aufirst%3DB.%26aulast%3DCao%26aufirst%3DS.%26aulast%3DBernhardy%26aufirst%3DA.%2BJ.%26aulast%3DCoulson%26aufirst%3DR.%26aulast%3DLazaro%26aufirst%3DJ.%2BB.%26aulast%3DKochupurakkal%26aufirst%3DB.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DUnitt%26aufirst%3DC.%26aulast%3DMoreau%26aufirst%3DL.%2BA.%26aulast%3DSarosiek%26aufirst%3DK.%2BA.%26aulast%3DScaltriti%26aufirst%3DM.%26aulast%3DJuric%26aufirst%3DD.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DRichardson%26aufirst%3DA.%2BL.%26aulast%3DRodig%26aufirst%3DS.%2BJ.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DA.%2BD.%26aulast%3DBalmana%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DN.%26aulast%3DGeyer%26aufirst%3DM.%26aulast%3DSerra%26aufirst%3DV.%26aulast%3DLim%26aufirst%3DE.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26atitle%3DCDK12%2520inhibition%2520reverses%2520de%2520novo%2520and%2520acquired%2520PARPinhibitor%2520resistance%2520in%2520BRCA%2520wild-type%2520and%2520mutated%2520models%2520of%2520triple-negative%2520breast%2520cancer%26jtitle%3DCell%2520Rep.%26date%3D2016%26volume%3D17%26issue%3D9%26spage%3D2367%26epage%3D2381%26doi%3D10.1016%2Fj.celrep.2016.10.077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blazek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohoutek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartholomeeusen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulinkova, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cimermancic, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ule, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterlin, B. M.</span></span> <span> </span><span class="NLM_article-title">The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes</span>. <i>Genes Dev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">2158</span>â <span class="NLM_lpage">2172</span>, <span class="refDoi">Â DOI: 10.1101/gad.16962311</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1101%2Fgad.16962311" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=22012619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVant73E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=2158-2172&issue=20&author=D.+Blazekauthor=J.+Kohoutekauthor=K.+Bartholomeeusenauthor=E.+Johansenauthor=P.+Hulinkovaauthor=Z.+Luoauthor=P.+Cimermancicauthor=J.+Uleauthor=B.+M.+Peterlin&title=The+Cyclin+K%2FCdk12+complex+maintains+genomic+stability+via+regulation+of+expression+of+DNA+damage+response+genes&doi=10.1101%2Fgad.16962311"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">The cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes</span></div><div class="casAuthors">Blazek, Dalibor; Kohoutek, Jiri; Bartholomeeusen, Koen; Johansen, Eric; Hulinkova, Petra; Luo, Zeping; Cimermancic, Peter; Ule, Jernej; Peterlin, B. Matija</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2158-2172</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">Various cyclin-dependent kinase (Cdk) complexes have been implicated in the regulation of transcription.  In this study, we identified a 70-kDa Cyclin K (CycK) that binds Cdk12 and Cdk13 to form two different complexes (CycK/Cdk12 or CycK/Cdk13) in human cells.  The CycK/Cdk12 complex regulates phosphorylation of Ser2 in the C-terminal domain of RNA polymerase II and expression of a small subset of human genes, as revealed in expression microarrays.  Depletion of CycK/Cdk12 results in decreased expression of predominantly long genes with high nos. of exons.  The most prominent group of down-regulated genes are the DNA damage response genes, including the crit. regulators of genomic stability: BRCA1 (breast and ovarian cancer type 1 susceptibility protein 1), ATR (ataxia telangiectasia and Rad3-related), FANCI, and FANCD2.  We show that CycK/Cdk12, rather than CycK/Cdk13, is necessary for their expression.  Nuclear run-on assays and chromatin immunopptns. with RNA polymerase II on the BRCA1 and FANCI genes suggest a transcriptional defect in the absence of CycK/Cdk12.  Consistent with these findings, cells without CycK/Cdk12 induce spontaneous DNA damage and are sensitive to a variety of DNA damage agents.  We conclude that through regulation of expression of DNA damage response genes, CycK/Cdk12 protects cells from genomic instability.  The essential role of CycK for organisms in vivo is further supported by the result that genetic inactivation of CycK in mice causes early embryonic lethality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPlifbvX1LXrVg90H21EOLACvtfcHk0lii7JkFD8c9ZQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVant73E&md5=4e472d0f324bbfae1a9d0a8a7302fa1d</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1101%2Fgad.16962311&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.16962311%26sid%3Dliteratum%253Aachs%26aulast%3DBlazek%26aufirst%3DD.%26aulast%3DKohoutek%26aufirst%3DJ.%26aulast%3DBartholomeeusen%26aufirst%3DK.%26aulast%3DJohansen%26aufirst%3DE.%26aulast%3DHulinkova%26aufirst%3DP.%26aulast%3DLuo%26aufirst%3DZ.%26aulast%3DCimermancic%26aufirst%3DP.%26aulast%3DUle%26aufirst%3DJ.%26aulast%3DPeterlin%26aufirst%3DB.%2BM.%26atitle%3DThe%2520Cyclin%2520K%252FCdk12%2520complex%2520maintains%2520genomic%2520stability%2520via%2520regulation%2520of%2520expression%2520of%2520DNA%2520damage%2520response%2520genes%26jtitle%3DGenes%2520Dev.%26date%3D2011%26volume%3D25%26issue%3D20%26spage%3D2158%26epage%3D2172%26doi%3D10.1101%2Fgad.16962311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, S. C.</span></span> <span> </span><span class="NLM_article-title">The human Rad51 protein: polarity of strand transfer and stimulation by hRP-A</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">5198</span>â <span class="NLM_lpage">5206</span>, <span class="refDoi">Â DOI: 10.1093/emboj/16.17.5198</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1093%2Femboj%2F16.17.5198" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=9311980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADyaK2sXmsVGlsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1997&pages=5198-5206&issue=17&author=P.+Baumannauthor=S.+C.+West&title=The+human+Rad51+protein%3A+polarity+of+strand+transfer+and+stimulation+by+hRP-A&doi=10.1093%2Femboj%2F16.17.5198"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">The human Rad51 protein: polarity of strand transfer and stimulation by hRP-A</span></div><div class="casAuthors">Baumann, Peter; West, Stephen C.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5198-5206</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The human Rad51 protein is homologous to the Escherichia coli RecA protein and catalyzes homologous pairing and strand transfer reactions in vitro.  Using single-stranded circular and homologous linear duplex DNA, we show that hRad51 forms stable joint mols. by transfer of the 5' end of the complementary strand of the linear duplex to the ssDNA.  The polarity of strand transfer is therefore 3' to 5', defined relative to the ssDNA on which hRad51 initiates filament formation.  This polarity is opposite to that obsd. with RecA.  Homologous pairing and strand transfer require stoichiometric amts. of hRad51, corresponding to one hRad51 monomer per three nucleotides of ssDNA.  Joint mols. are not obsd. when the protein is present in limiting or excessive amts.  The human ssDNA binding-protein, hRP-A, stimulates hRad51-mediated reactions.  Its effect is consistent with a role in the removal of secondary structures from ssDNA, thereby facilitating the formation of continuous Rad51 filaments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBIelzJ9gRULVg90H21EOLACvtfcHk0lii7JkFD8c9ZQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmsVGlsrg%253D&md5=77f065b85373422dcaeb9353b23a5139</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1093%2Femboj%2F16.17.5198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252F16.17.5198%26sid%3Dliteratum%253Aachs%26aulast%3DBaumann%26aufirst%3DP.%26aulast%3DWest%26aufirst%3DS.%2BC.%26atitle%3DThe%2520human%2520Rad51%2520protein%253A%2520polarity%2520of%2520strand%2520transfer%2520and%2520stimulation%2520by%2520hRP-A%26jtitle%3DEMBO%2520J.%26date%3D1997%26volume%3D16%26issue%3D17%26spage%3D5198%26epage%3D5206%26doi%3D10.1093%2Femboj%2F16.17.5198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sung, P.</span></span> <span> </span><span class="NLM_article-title">Catalysis of ATP-dependent homologous DNA pairing and strand exchange by yeast RAD51 protein</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>265</i></span> (<span class="NLM_issue">5176</span>),  <span class="NLM_fpage">1241</span>â <span class="NLM_lpage">1243</span>, <span class="refDoi">Â DOI: 10.1126/science.8066464</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1126%2Fscience.8066464" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=8066464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADyaK2cXmt1emsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=265&publication_year=1994&pages=1241-1243&issue=5176&author=P.+Sung&title=Catalysis+of+ATP-dependent+homologous+DNA+pairing+and+strand+exchange+by+yeast+RAD51+protein&doi=10.1126%2Fscience.8066464"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Catalysis of ATP-dependent homologous DNA pairing and strand exchange by yeast RAD51 protein</span></div><div class="casAuthors">Sung, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">265</span>
        (<span class="NLM_cas:issue">5176</span>),
    <span class="NLM_cas:pages">1241-3</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">The RAD51 gene of Saccharomyces cerevisiae is required for genetic recombination and DNA double-strand break repair.  Here it is demonstrated that RAD51 protein pairs circular viral single-stranded DNA from Î¸X 174 or M13 with its resp. homologous linear double-stranded form.  The product of synapsis between these DNA partners is further processed by RAD51 to yield nicked circular duplex DNA, which indicates that RAD51 can catalyze strand exchange.  The pairing and strand exchange reaction requires ATP, a result consistent with the presence of a DNA-dependent ATPase activity in RAD51 protein.  Thus, RAD51 is a eukaryotic recombination protein that can catalyze the strand exchange reaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpizYt10YhEpLVg90H21EOLACvtfcHk0lgakCetEy2HJA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmt1emsr8%253D&md5=8163a27cb6b73c1e14e534e4fcc0221a</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1126%2Fscience.8066464&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.8066464%26sid%3Dliteratum%253Aachs%26aulast%3DSung%26aufirst%3DP.%26atitle%3DCatalysis%2520of%2520ATP-dependent%2520homologous%2520DNA%2520pairing%2520and%2520strand%2520exchange%2520by%2520yeast%2520RAD51%2520protein%26jtitle%3DScience%26date%3D1994%26volume%3D265%26issue%3D5176%26spage%3D1241%26epage%3D1243%26doi%3D10.1126%2Fscience.8066464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zaitseva, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaitsev, E. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowalczykowski, S. C.</span></span> <span> </span><span class="NLM_article-title">The DNA binding properties of saccharomyces cerevisiae Rad51 protein</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>274</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2907</span>â <span class="NLM_lpage">2915</span>, <span class="refDoi">Â DOI: 10.1074/jbc.274.5.2907</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1074%2Fjbc.274.5.2907" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=9915828" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADyaK1MXpsVektA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=1999&pages=2907-2915&issue=5&author=E.+M.+Zaitsevaauthor=E.+N.+Zaitsevauthor=S.+C.+Kowalczykowski&title=The+DNA+binding+properties+of+saccharomyces+cerevisiae+Rad51+protein&doi=10.1074%2Fjbc.274.5.2907"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">The DNA binding properties of Saccharomyces cerevisiae Rad51 protein</span></div><div class="casAuthors">Zaitseva, Elena M.; Zaitsev, Eugene N.; Kowalczykowski, Stephen C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">274</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2907-2915</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Saccharomyces cerevisiae Rad51 protein is the paradigm for eukaryotic ATP-dependent DNA strand exchange proteins.  To explain some of the unique characteristics of DNA strand exchange promoted by Rad51 protein, when compared with its prokaryotic homolog the Escherichia coli RecA protein, we analyzed the DNA binding properties of the Rad51 protein.  Rad51 protein binds both single-stranded DNA (ssDNA) and double-stranded DNA (dsDNA) in an ATP- and Mg2+-dependent manner, over a wide range of pH, with an apparent binding stoichiometry of approx. 1 protein monomer per 4 (Â±1) nucleotides or base pairs, resp.  Only dATP and adenosine 5'-Î³-(Thiotriphosphate) (ATPÎ³S) can substitute for ATP, but binding in the presence of ATPÎ³S requires more than a 5-fold stoichiometric excess of protein.  Without nucleotide cofactor, Rad51 protein binds both ssDNA and dsDNA but only at pH values lower than 6.8; in this case, the apparent binding stoichiometry covers the range of 1 protein monomer per 6-9 nucleotides or base pairs.  Therefore, Rad51 protein displays two distinct modes of DNA binding.  These binding modes are not inter-convertible; however, their initial selection is governed by ATP binding.  On the basis of these DNA binding properties, we conclude that the main reason for the low efficiency of the DNA strand exchange promoted by Rad51 protein in vitro is its enhanced dsDNA-binding ability, which inhibits both the presynaptic and synaptic phases of the DNA strand exchange reaction as follows: during presynapsis, Rad51 protein interacts with and stabilizes secondary structures in ssDNA thereby inhibiting formation of a contiguous nucleoprotein filament; during synapsis, Rad51 protein inactivates the homologous dsDNA partner by directly binding to it.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrObmOEA3L-jLVg90H21EOLACvtfcHk0lgakCetEy2HJA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXpsVektA%253D%253D&md5=6e4bdce9ed811231f32b142c8efb6d9f</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1074%2Fjbc.274.5.2907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.274.5.2907%26sid%3Dliteratum%253Aachs%26aulast%3DZaitseva%26aufirst%3DE.%2BM.%26aulast%3DZaitsev%26aufirst%3DE.%2BN.%26aulast%3DKowalczykowski%26aufirst%3DS.%2BC.%26atitle%3DThe%2520DNA%2520binding%2520properties%2520of%2520saccharomyces%2520cerevisiae%2520Rad51%2520protein%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1999%26volume%3D274%26issue%3D5%26spage%3D2907%26epage%3D2915%26doi%3D10.1074%2Fjbc.274.5.2907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roberti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schipani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagnolini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milano, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giacomini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falchi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balboni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manerba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farabegoli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Franco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minucci, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallavicini, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Stefano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girotto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellicciari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span> <span> </span><span class="NLM_article-title">Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">80</span>â <span class="NLM_lpage">92</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2019.01.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.ejmech.2019.01.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=30660828" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVOku7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2019&pages=80-92&author=M.+Robertiauthor=F.+Schipaniauthor=G.+Bagnoliniauthor=D.+Milanoauthor=E.+Giacominiauthor=F.+Falchiauthor=A.+Balboniauthor=M.+Manerbaauthor=F.+Farabegoliauthor=F.+De+Francoauthor=J.+Robertsonauthor=S.+Minucciauthor=I.+Pallaviciniauthor=G.+Di+Stefanoauthor=S.+Girottoauthor=R.+Pellicciariauthor=A.+Cavalli&title=Rad51%2FBRCA2+disruptors+inhibit+homologous+recombination+and+synergize+with+olaparib+in+pancreatic+cancer+cells&doi=10.1016%2Fj.ejmech.2019.01.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells</span></div><div class="casAuthors">Roberti, Marinella; Schipani, Fabrizio; Bagnolini, Greta; Milano, Domenico; Giacomini, Elisa; Falchi, Federico; Balboni, Andrea; Manerba, Marcella; Farabegoli, Fulvia; De Franco, Francesca; Robertson, Janet; Minucci, Saverio; Pallavicini, Isabella; Di Stefano, Giuseppina; Girotto, Stefania; Pellicciari, Roberto; Cavalli, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">80-92</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Olaparib is a PARP inhibitor (PARPi).  For patients bearing BRCA1 or BRCA2 mutations, olaparib is approved to treat ovarian cancer and in clin. trials to treat breast and pancreatic cancers.  In BRCA2-defective patients, PARPi inhibits DNA single-strand break repair, while BRCA2 mutations hamper double-strand break repair.  Recently, the authors identified a series of triazole derivs. that mimic BRCA2 mutations by disrupting the Rad51-BRCA2 interaction and thus double-strand break repair.  Here, the authors have computationally designed, synthesized, and tested over 40 novel derivs.  Addnl., they designed and conducted novel biol. assays to characterize how they disrupt the Rad51-BRCA2 interaction and inhibit double-strand break repair.  These compds., synergized with olaparib to target pancreatic cancer cells with functional BRCA2.  Compd. I significantly increased olaparib's effect on the viability of BxPC-3 cells.  This supports the idea that small org. mols. can mimic genetic mutations to improve the profile of anticancer drugs for precision medicine.  Moreover, this paradigm could be exploited in other genetic pathways to discover innovative anticancer targets and drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrO64ucZDf8MLVg90H21EOLACvtfcHk0lgakCetEy2HJA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVOku7k%253D&md5=3090401197babb650036d569a0195a7a</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.01.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.01.008%26sid%3Dliteratum%253Aachs%26aulast%3DRoberti%26aufirst%3DM.%26aulast%3DSchipani%26aufirst%3DF.%26aulast%3DBagnolini%26aufirst%3DG.%26aulast%3DMilano%26aufirst%3DD.%26aulast%3DGiacomini%26aufirst%3DE.%26aulast%3DFalchi%26aufirst%3DF.%26aulast%3DBalboni%26aufirst%3DA.%26aulast%3DManerba%26aufirst%3DM.%26aulast%3DFarabegoli%26aufirst%3DF.%26aulast%3DDe%2BFranco%26aufirst%3DF.%26aulast%3DRobertson%26aufirst%3DJ.%26aulast%3DMinucci%26aufirst%3DS.%26aulast%3DPallavicini%26aufirst%3DI.%26aulast%3DDi%2BStefano%26aufirst%3DG.%26aulast%3DGirotto%26aufirst%3DS.%26aulast%3DPellicciari%26aufirst%3DR.%26aulast%3DCavalli%26aufirst%3DA.%26atitle%3DRad51%252FBRCA2%2520disruptors%2520inhibit%2520homologous%2520recombination%2520and%2520synergize%2520with%2520olaparib%2520in%2520pancreatic%2520cancer%2520cells%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D165%26spage%3D80%26epage%3D92%26doi%3D10.1016%2Fj.ejmech.2019.01.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Budke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tueckmantel, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miles, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connell, P. P.</span></span> <span> </span><span class="NLM_article-title">Optimization of drug candidates that inhibit the D-loop activity of RAD51</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1031</span>â <span class="NLM_lpage">1040</span>, <span class="refDoi">Â DOI: 10.1002/cmdc.201900075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1002%2Fcmdc.201900075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=30957434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnsFSrurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=1031-1040&issue=10&author=B.+Budkeauthor=W.+Tueckmantelauthor=K.+Milesauthor=A.+P.+Kozikowskiauthor=P.+P.+Connell&title=Optimization+of+drug+candidates+that+inhibit+the+D-loop+activity+of+RAD51&doi=10.1002%2Fcmdc.201900075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of drug candidates that inhibit the D-loop activity of RAD51</span></div><div class="casAuthors">Budke, Brian; Tueckmantel, Werner; Miles, Kelsey; Kozikowski, Alan P.; Connell, Philip P.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1031-1040</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">RAD51 is the central protein in homologous recombination (HR) repair, where it first binds ssDNA and then catalyzes strand invasion via a D-loop intermediate.  Addnl., RAD51 plays a role in faithful DNA replication by protecting stalled replication forks; this requires RAD51 to bind DNA but may not require the strand invasion activity of RAD51.  We previously described a small-mol. inhibitor of RAD51 named RI(dl)-2 (RAD51 inhibitor of D-loop formation #2, hereafter called 2h(I)), which inhibits D-loop activity while sparing ssDNA binding.  However, I is limited in its ability to inhibit HR in vivo, preventing only about 50 % of total HR events in cells.  We sought to improve upon this by performing a structure-activity relationship (SAR) campaign for more potent analogs of I.  Most compds. were prepd. from 1-(2-aminophenyl)pyrroles by forming the quinoxaline moiety either by condensation with aldehydes, then dehydrogenation of the resulting 4,5-dihydro intermediates, or by condensation with N,N'-carbonyldiimidazole, chlorination, and installation of the 4-substituent through Suzuki-Miyaura coupling.  Many analogs exhibited enhanced activity against human RAD51, but in several of these compds. the increased inhibition was due to the introduction of dsDNA intercalation activity.  We developed a sensitive assay to measure dsDNA intercalation, and identified two analogs of I that promote complete HR inhibition in cells while exerting minimal intercalation activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZp0WNPT_GobVg90H21EOLACvtfcHk0lgmU8WrpjccCw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnsFSrurw%253D&md5=e7bd3885759308c4f5980891580239db</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201900075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201900075%26sid%3Dliteratum%253Aachs%26aulast%3DBudke%26aufirst%3DB.%26aulast%3DTueckmantel%26aufirst%3DW.%26aulast%3DMiles%26aufirst%3DK.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DConnell%26aufirst%3DP.%2BP.%26atitle%3DOptimization%2520of%2520drug%2520candidates%2520that%2520inhibit%2520the%2520D-loop%2520activity%2520of%2520RAD51%26jtitle%3DChemMedChem%26date%3D2019%26volume%3D14%26issue%3D10%26spage%3D1031%26epage%3D1040%26doi%3D10.1002%2Fcmdc.201900075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Normand, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riviere, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renodon-Corniere, A.</span></span> <span> </span><span class="NLM_article-title">Identification and characterization of human Rad51 inhibitors by screening of an existing drug library</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>91</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">293</span>â <span class="NLM_lpage">300</span>, <span class="refDoi">Â DOI: 10.1016/j.bcp.2014.07.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.bcp.2014.07.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=25124703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlKmtLbM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2014&pages=293-300&issue=3&author=A.+Normandauthor=E.+Riviereauthor=A.+Renodon-Corniere&title=Identification+and+characterization+of+human+Rad51+inhibitors+by+screening+of+an+existing+drug+library&doi=10.1016%2Fj.bcp.2014.07.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and characterization of human Rad51 inhibitors by screening of an existing drug library</span></div><div class="casAuthors">Normand, Anais; Riviere, Emmanuelle; Renodon-Corniere, Axelle</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">293-300</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Homologous Recombination (HR) plays an essential role in cellular proliferation and in maintaining genomic stability by repairing DNA double-stranded breaks that appear during replication.  Rad51, a key protein of HR in eukaryotes, can have an elevated expression level in tumor cells, which correlates with their resistance to anticancer therapies.  Therefore, targeted inhibition of Rad51 through inhibitor may improve the tumor response to these therapies.  In order to identify small mols. that inhibit Rad51 activity, we screened the Prestwick Library (1120 mols.) for their effect on the strand exchange reaction catalyzed by Rad51.  We found that Chicago Sky Blue (CSB) is a potent inhibitor of Rad51, showing IC50 values in the low nanomolar range (400 nM).  Biochem. anal. demonstrated that the inhibitory mechanism probably occurs by disrupting the Rad51 assocn. with the single-stranded DNA, which prevents the nucleoprotein filament formation, the first step of the protein activity.  Structure Activity Relationship anal. with a no. of compds. that shared structure homol. with CSB was also performed.  The sensitivity of Rad51 inhibition to CSB modifications suggests specific interactions between the mol. and Rad51 nucleofilament.  CSB and some of its analogs open up new perspectives in the search for agents capable of potentiating chemo- and radio-therapy treatments for cancer.  Moreover, these compds. may be excellent tools to analyze Rad51 cellular functions.  Our study also highlights how CSB and its analogs, which are frequently used in colorants, stains and markers, could be responsible of unwanted side effects by perturbing the DNA repair process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkjkOCGdXzDbVg90H21EOLACvtfcHk0lgmU8WrpjccCw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlKmtLbM&md5=e7daa87d941c0a81393205f0a6b72bab</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2014.07.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2014.07.033%26sid%3Dliteratum%253Aachs%26aulast%3DNormand%26aufirst%3DA.%26aulast%3DRiviere%26aufirst%3DE.%26aulast%3DRenodon-Corniere%26aufirst%3DA.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520human%2520Rad51%2520inhibitors%2520by%2520screening%2520of%2520an%2520existing%2520drug%2520library%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2014%26volume%3D91%26issue%3D3%26spage%3D293%26epage%3D300%26doi%3D10.1016%2Fj.bcp.2014.07.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlin, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. H.</span></span> <span> </span><span class="NLM_article-title">Synthesis, molecular modeling, and biological evaluation of novel RAD51 inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">196</span>â <span class="NLM_lpage">208</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2015.04.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.ejmech.2015.04.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=25874343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtlOjurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2015&pages=196-208&author=J.+Zhuauthor=H.+Chenauthor=X.+E.+Guoauthor=X.+L.+Qiuauthor=C.+M.+Huauthor=A.+R.+Chamberlinauthor=W.+H.+Lee&title=Synthesis%2C+molecular+modeling%2C+and+biological+evaluation+of+novel+RAD51+inhibitors&doi=10.1016%2Fj.ejmech.2015.04.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, molecular modeling, and biological evaluation of novel RAD51 inhibitors</span></div><div class="casAuthors">Zhu, Jiewen; Chen, Hongyuan; Guo, Xuning Emily; Qiu, Xiao-Long; Hu, Chun-Mei; Chamberlin, A. Richard; Lee, Wen-Hwa</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">196-208</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">RAD51 recombinase plays a crit. role for cancer cell proliferation and survival.  Targeting RAD51 is therefore an attractive strategy for treating difficult-to-treat cancers, e.g. triple neg. breast cancers which are often resistant to existing therapeutics.  To this end, we have designed, synthesized and evaluated a panel of new RAD51 inhibitors, denoted IBR compds.  Among these compds., we have identified a novel small mol. RAD51 inhibitor, IBR120 (I), which exhibited a 4.8-fold improved growth inhibition activity in triple neg. human breast cancer cell line MBA-MD-468.  I also inhibited the proliferation of a broad spectrum of other cancer cell types.  Approx. 10-fold difference between the IC50 values in normal and cancer cells were obsd.  Moreover, I was capable of disrupting RAD51 multimerization, impairing homologous recombination repair, and inducing apoptotic cell death.  Therefore, these novel RAD51 inhibitors may serve as potential candidates for the development of pharmaceutical strategies against difficult-to-treat cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryxK_VB6pue7Vg90H21EOLACvtfcHk0lgmU8WrpjccCw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtlOjurw%253D&md5=39ff6eca8df36a8c8af9cbff3fcc7b46</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.04.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.04.021%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DGuo%26aufirst%3DX.%2BE.%26aulast%3DQiu%26aufirst%3DX.%2BL.%26aulast%3DHu%26aufirst%3DC.%2BM.%26aulast%3DChamberlin%26aufirst%3DA.%2BR.%26aulast%3DLee%26aufirst%3DW.%2BH.%26atitle%3DSynthesis%252C%2520molecular%2520modeling%252C%2520and%2520biological%2520evaluation%2520of%2520novel%2520RAD51%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D96%26spage%3D196%26epage%3D208%26doi%3D10.1016%2Fj.ejmech.2015.04.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bagnolini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milano, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manerba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schipani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortega, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gioia, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falchi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balboni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farabegoli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Franco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellicciari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallavicini, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minucci, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girotto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Stefano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span> <span> </span><span class="NLM_article-title">Synthetic lethality in pancreatic cancer: discovery of a new RAD51-BRCA2 small molecule disruptor that inhibits homologous recombination and synergizes with Olaparib</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2588</span>â <span class="NLM_lpage">2619</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.9b01526</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01526" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFKrurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=2588-2619&issue=5&author=G.+Bagnoliniauthor=D.+Milanoauthor=M.+Manerbaauthor=F.+Schipaniauthor=J.+A.+Ortegaauthor=D.+Gioiaauthor=F.+Falchiauthor=A.+Balboniauthor=F.+Farabegoliauthor=F.+De+Francoauthor=J.+Robertsonauthor=R.+Pellicciariauthor=I.+Pallaviciniauthor=S.+Periauthor=S.+Minucciauthor=S.+Girottoauthor=G.+Di+Stefanoauthor=M.+Robertiauthor=A.+Cavalli&title=Synthetic+lethality+in+pancreatic+cancer%3A+discovery+of+a+new+RAD51-BRCA2+small+molecule+disruptor+that+inhibits+homologous+recombination+and+synergizes+with+Olaparib&doi=10.1021%2Facs.jmedchem.9b01526"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib</span></div><div class="casAuthors">Bagnolini, Greta; Milano, Domenico; Manerba, Marcella; Schipani, Fabrizio; Ortega, Jose Antonio; Gioia, Dario; Falchi, Federico; Balboni, Andrea; Farabegoli, Fulvia; De Franco, Francesca; Robertson, Janet; Pellicciari, Roberto; Pallavicini, Isabella; Peri, Sebastiano; Minucci, Saverio; Girotto, Stefania; Di Stefano, Giuseppina; Roberti, Marinella; Cavalli, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2588-2619</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Synthetic lethality is an innovative framework for discovering novel anticancer drug candidates.  One example is the use of PARP inhibitors (PARPi) in oncol. patients with BRCA mutations.  Here, we exploit a new paradigm based on the possibility of triggering synthetic lethality using only small org. mols. (dubbed "fully small-mol.-induced synthetic lethality").  We exploited this paradigm to target pancreatic cancer, one of the major unmet needs in oncol.  We discovered a dihydroquinolone pyrazoline-based mol. (35d) that disrupts the RAD51-BRCA2 protein-protein interaction, thus mimicking the effect of BRCA2 mutation. 35d inhibits the homologous recombination in a human pancreatic adenocarcinoma cell line.  In addn., it synergizes with olaparib (a PARPi) to trigger synthetic lethality.  This strategy aims to widen the use of PARPi in BRCA-competent and olaparib-resistant cancers, making fully small-mol.-induced synthetic lethality an innovative approach toward unmet oncol. needs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiTSEdA8VygbVg90H21EOLACvtfcHk0lik9LvXdt_nMw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFKrurg%253D&md5=1cae61064fc0e637f9b5f00c47e0bdeb</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01526&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01526%26sid%3Dliteratum%253Aachs%26aulast%3DBagnolini%26aufirst%3DG.%26aulast%3DMilano%26aufirst%3DD.%26aulast%3DManerba%26aufirst%3DM.%26aulast%3DSchipani%26aufirst%3DF.%26aulast%3DOrtega%26aufirst%3DJ.%2BA.%26aulast%3DGioia%26aufirst%3DD.%26aulast%3DFalchi%26aufirst%3DF.%26aulast%3DBalboni%26aufirst%3DA.%26aulast%3DFarabegoli%26aufirst%3DF.%26aulast%3DDe%2BFranco%26aufirst%3DF.%26aulast%3DRobertson%26aufirst%3DJ.%26aulast%3DPellicciari%26aufirst%3DR.%26aulast%3DPallavicini%26aufirst%3DI.%26aulast%3DPeri%26aufirst%3DS.%26aulast%3DMinucci%26aufirst%3DS.%26aulast%3DGirotto%26aufirst%3DS.%26aulast%3DDi%2BStefano%26aufirst%3DG.%26aulast%3DRoberti%26aufirst%3DM.%26aulast%3DCavalli%26aufirst%3DA.%26atitle%3DSynthetic%2520lethality%2520in%2520pancreatic%2520cancer%253A%2520discovery%2520of%2520a%2520new%2520RAD51-BRCA2%2520small%2520molecule%2520disruptor%2520that%2520inhibits%2520homologous%2520recombination%2520and%2520synergizes%2520with%2520Olaparib%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26issue%3D5%26spage%3D2588%26epage%3D2619%26doi%3D10.1021%2Facs.jmedchem.9b01526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rajendra, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkitaraman, A. R.</span></span> <span> </span><span class="NLM_article-title">Two modules in the BRC repeats of BRCA2 mediate structural and functional interactions with the RAD51 recombinase</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">82</span>â <span class="NLM_lpage">96</span>, <span class="refDoi">Â DOI: 10.1093/nar/gkp873</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1093%2Fnar%2Fgkp873" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=19875419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtF2nuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=82-96&issue=1&author=E.+Rajendraauthor=A.+R.+Venkitaraman&title=Two+modules+in+the+BRC+repeats+of+BRCA2+mediate+structural+and+functional+interactions+with+the+RAD51+recombinase&doi=10.1093%2Fnar%2Fgkp873"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Two modules in the BRC repeats of BRCA2 mediate structural and functional interactions with the RAD51 recombinase</span></div><div class="casAuthors">Rajendra, Eeson; Venkitaraman, Ashok R.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">82-96</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The breast and ovarian cancer suppressor protein BRCA2 controls the RAD51 recombinase in reactions that lead to homologous DNA recombination (HDR).  BRCA2 binds RAD51 via eight conserved BRC repeat motifs of approx. 35 amino acids, each with a varying capacity to bind RAD51.  BRC repeats both promote and inhibit RAD51 assembly on different DNA substrates to regulate HDR, but the structural basis for these functions is unclear.  Here, we demarcate two tetrameric clusters of hydrophobic residues in the BRC repeats, interacting with distinct pockets in RAD51, and show that the co-location of both modules within a single BRC repeat is necessary for BRC-RAD51 binding and function.  The two modules comprise the sequence FxxA, known to inhibit RAD51 assembly by blocking the oligomerization interface, and a previously unrecognized tetramer with the consensus sequence LFDE, which binds to a RAD51 pocket distinct from this interface.  The LFDE motif is essential in BRC repeats for modes of RAD51 binding both permissive and inhibitory to RAD51 oligomerization.  Targeted insertion of point mutations in RAD51 that disrupt the LFDE-binding pocket impair its assembly at DNA damage sites in living cells.  Our findings suggest a model for the modular architecture of BRC repeats that provides fresh insight into the mechanisms regulating homologous DNA recombination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrl7J1JIDpuErVg90H21EOLACvtfcHk0lik9LvXdt_nMw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtF2nuw%253D%253D&md5=8fec23291c3037866be93b27f8a6f685</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkp873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkp873%26sid%3Dliteratum%253Aachs%26aulast%3DRajendra%26aufirst%3DE.%26aulast%3DVenkitaraman%26aufirst%3DA.%2BR.%26atitle%3DTwo%2520modules%2520in%2520the%2520BRC%2520repeats%2520of%2520BRCA2%2520mediate%2520structural%2520and%2520functional%2520interactions%2520with%2520the%2520RAD51%2520recombinase%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2010%26volume%3D38%26issue%3D1%26spage%3D82%26epage%3D96%26doi%3D10.1093%2Fnar%2Fgkp873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lv, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawlowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connell, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Development of small molecules that specifically inhibit the D-loop activity of RAD51</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4511</span>â <span class="NLM_lpage">4525</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b01762</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01762" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsFKqu78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4511-4525&issue=10&author=W.+Lvauthor=B.+Budkeauthor=M.+Pawlowskiauthor=P.+P.+Connellauthor=A.+P.+Kozikowski&title=Development+of+small+molecules+that+specifically+inhibit+the+D-loop+activity+of+RAD51&doi=10.1021%2Facs.jmedchem.5b01762"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Small Molecules that Specifically Inhibit the D-loop Activity of RAD51</span></div><div class="casAuthors">Lv, Wei; Budke, Brian; Pawlowski, Michal; Connell, Philip P.; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4511-4525</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">RAD51 is the central protein in homologous recombination (HR) DNA repair and represents a therapeutic target in oncol.  Herein we report a novel class of RAD51 inhibitors that were identified by high throughput screening.  In contrast to many previously reported RAD51 inhibitors, our lead compd. 1 is capable of blocking RAD51-mediated D-loop formation (IC50 21.3 Â± 7.8 Î¼M) at concns. that do not influence RAD51 binding to ssDNA.  In human cells, 1 inhibits HR (IC50 13.1 Â± 1.6 Î¼M) without blocking RAD51's ability to assemble into subnuclear foci at sites of DNA damage.  We detd. that the active constituent of 1 is actually an oxidized deriv. (termed RI(dl)-1 or 8) of the original screening compd.  Our SAR campaign also yielded RI(dl)-2 (hereafter termed 9h), which effectively blocks RAD51's D-loop activity in biochem. systems (IC50 11.1 Â± 1.3 Î¼M) and inhibits HR activity in human cells (IC50 3.0 Â± 1.8 Î¼M).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVW4_0QRMRGbVg90H21EOLACvtfcHk0lik9LvXdt_nMw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsFKqu78%253D&md5=443c5b08e2e85236d68a31e7ea4ac33e</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01762%26sid%3Dliteratum%253Aachs%26aulast%3DLv%26aufirst%3DW.%26aulast%3DBudke%26aufirst%3DB.%26aulast%3DPawlowski%26aufirst%3DM.%26aulast%3DConnell%26aufirst%3DP.%2BP.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DDevelopment%2520of%2520small%2520molecules%2520that%2520specifically%2520inhibit%2520the%2520D-loop%2520activity%2520of%2520RAD51%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D10%26spage%3D4511%26epage%3D4525%26doi%3D10.1021%2Facs.jmedchem.5b01762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Budke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logan, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalin, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zelivianskaia, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron McGuire, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishop, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connell, P. P.</span></span> <span> </span><span class="NLM_article-title">RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">7347</span>â <span class="NLM_lpage">7357</span>, <span class="refDoi">Â DOI: 10.1093/nar/gks353</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1093%2Fnar%2Fgks353" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=22573178" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Kjs7nP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=7347-7357&issue=15&author=B.+Budkeauthor=H.+L.+Loganauthor=J.+H.+Kalinauthor=A.+S.+Zelivianskaiaauthor=W.+Cameron+McGuireauthor=L.+L.+Millerauthor=J.+M.+Starkauthor=A.+P.+Kozikowskiauthor=D.+K.+Bishopauthor=P.+P.+Connell&title=RI-1%3A+a+chemical+inhibitor+of+RAD51+that+disrupts+homologous+recombination+in+human+cells&doi=10.1093%2Fnar%2Fgks353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells</span></div><div class="casAuthors">Budke, Brian; Logan, Hillary L.; Kalin, Jay H.; Zelivianskaia, Anna S.; Cameron McGuire, William; Miller, Luke L.; Stark, Jeremy M.; Kozikowski, Alan P.; Bishop, Douglas K.; Connell, Philip P.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7347-7357</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Homologous recombination serves multiple roles in DNA repair that are essential for maintaining genomic stability.  We here describe RI-1, a small mol. that inhibits the central recombination protein RAD51.  RI-1 specifically reduces gene conversion in human cells while stimulating single strand annealing.  RI-1 binds covalently to the surface of RAD51 protein at cysteine 319 that likely destabilizes an interface used by RAD51 monomers to oligomerize into filaments on DNA.  Correspondingly, the mol. inhibits the formation of subnuclear RAD51 foci in cells following DNA damage, while leaving replication protein A focus formation unaffected.  Finally, it potentiates the lethal effects of a DNA crosslinking drug in human cells.  Given that this inhibitory activity is seen in multiple human tumor cell lines, RI-1 holds promise as an oncol. drug.  Furthermore, RI-1 represents a unique tool to dissect the network of reaction pathways that contribute to DNA repair in cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpko01Pxf0QsLVg90H21EOLACvtfcHk0lhjYgTEl5J4fw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Kjs7nP&md5=5249409b6df355e2c585472a160fb078</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgks353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgks353%26sid%3Dliteratum%253Aachs%26aulast%3DBudke%26aufirst%3DB.%26aulast%3DLogan%26aufirst%3DH.%2BL.%26aulast%3DKalin%26aufirst%3DJ.%2BH.%26aulast%3DZelivianskaia%26aufirst%3DA.%2BS.%26aulast%3DCameron%2BMcGuire%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DL.%2BL.%26aulast%3DStark%26aufirst%3DJ.%2BM.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DBishop%26aufirst%3DD.%2BK.%26aulast%3DConnell%26aufirst%3DP.%2BP.%26atitle%3DRI-1%253A%2520a%2520chemical%2520inhibitor%2520of%2520RAD51%2520that%2520disrupts%2520homologous%2520recombination%2520in%2520human%2520cells%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2012%26volume%3D40%26issue%3D15%26spage%3D7347%26epage%3D7357%26doi%3D10.1093%2Fnar%2Fgks353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Budke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalin, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawlowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zelivianskaia, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connell, P. P.</span></span> <span> </span><span class="NLM_article-title">An optimized RAD51 inhibitor that disrupts homologous recombination without requiring Michael acceptor reactivity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">254</span>â <span class="NLM_lpage">263</span>, <span class="refDoi">Â DOI: 10.1021/jm301565b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301565b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVWqtL%252FP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=254-263&issue=1&author=B.+Budkeauthor=J.+H.+Kalinauthor=M.+Pawlowskiauthor=A.+S.+Zelivianskaiaauthor=M.+Wuauthor=A.+P.+Kozikowskiauthor=P.+P.+Connell&title=An+optimized+RAD51+inhibitor+that+disrupts+homologous+recombination+without+requiring+Michael+acceptor+reactivity&doi=10.1021%2Fjm301565b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">An Optimized RAD51 Inhibitor That Disrupts Homologous Recombination without Requiring Michael Acceptor Reactivity</span></div><div class="casAuthors">Budke, Brian; Kalin, Jay H.; Pawlowski, Michal; Zelivianskaia, Anna S.; Wu, Megan; Kozikowski, Alan P.; Connell, Philip P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">254-263</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Homologous recombination (HR) is an essential process in cells that provides repair of DNA double-strand breaks and lesions that block DNA replication.  RAD51 is an evolutionarily conserved protein that is central to HR.  Overexpression of RAD51 protein is common in cancer cells and represents a potential therapeutic target in oncol.  We previously described a chem. inhibitor of RAD51, called RI-1 (referred to as compd. 1 in this report).  The chloromaleimide group of this compd. is thought to act as a Michael acceptor and react with the thiol group on C319 of RAD51, using a conjugate addn.-elimination mechanism.  In order to reduce the likelihood of off-target effects and to improve compd. stability in biol. systems, we developed an analog of compd. 1 that lacks maleimide-based reactivity but retains RAD51 inhibitory activity.  This compd., 1-(3,4-dichlorophenyl)-3-(4-methoxyphenyl)-4-morpholino-1H-pyrrole-2,5-dione, named RI-2 (referred to as compd. 7a in this report), appears to bind reversibly to the same site on the RAD51 protein as does compd. 1.  Like compd. 1, compd. 7a specifically inhibits HR repair in human cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5NFygiYR-q7Vg90H21EOLACvtfcHk0lhjYgTEl5J4fw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVWqtL%252FP&md5=141a877dedfd9397c8846289e317f560</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1021%2Fjm301565b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301565b%26sid%3Dliteratum%253Aachs%26aulast%3DBudke%26aufirst%3DB.%26aulast%3DKalin%26aufirst%3DJ.%2BH.%26aulast%3DPawlowski%26aufirst%3DM.%26aulast%3DZelivianskaia%26aufirst%3DA.%2BS.%26aulast%3DWu%26aufirst%3DM.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DConnell%26aufirst%3DP.%2BP.%26atitle%3DAn%2520optimized%2520RAD51%2520inhibitor%2520that%2520disrupts%2520homologous%2520recombination%2520without%2520requiring%2520Michael%2520acceptor%2520reactivity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D1%26spage%3D254%26epage%3D263%26doi%3D10.1021%2Fjm301565b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kanvatirth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeeves, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bacon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besra, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alderwick, L. J.</span></span> <span> </span><span class="NLM_article-title">Utilisation of the Prestwick chemical library to identify drugs that inhibit the growth of mycobacteria</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">3</span>), <span class="NLM_elocation-id">e0213713</span> <span class="refDoi">Â DOI: 10.1371/journal.pone.0213713</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1371%2Fjournal.pone.0213713" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=30861059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFaku78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&issue=3&author=P.+Kanvatirthauthor=R.+E.+Jeevesauthor=J.+Baconauthor=G.+S.+Besraauthor=L.+J.+Alderwick&title=Utilisation+of+the+Prestwick+chemical+library+to+identify+drugs+that+inhibit+the+growth+of+mycobacteria&doi=10.1371%2Fjournal.pone.0213713"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Utilisation of the Prestwick Chemical Library to identify drugs that inhibit the growth of mycobacteria</span></div><div class="casAuthors">Kanvatirth, Panchali; Jeeves, Rose E.; Bacon, Joanna; Besra, Gurdyal S.; Alderwick, Luke J.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e0213713</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Tuberculosis (TB) is an infectious bacterial disease that kills approx. 1.3 million people every year.  Despite global efforts to reduce both the incidence and mortality assocd. with TB, the emergence of drug resistant strains has slowed any progress made towards combating the spread of this deadly disease.  The current TB drug regimen is inadequate, takes months to complete and poses significant challenges when administering to patients suffering from drug resistant TB.  New treatments that are faster, simpler and more affordable are urgently required.  Arguably, a good strategy to discover new drugs is to start with an old drug.  Here, we have screened a library of 1200 FDA approved drugs from the Prestwick Chem. library using a GFP microplate assay.  Drugs were screened against GFP expressing strains of Mycobacterium smegmatis and Mycobacterium bovis BCG as surrogates for Mycobacterium tuberculosis, the causative agent of TB in humans.  We identified several classes of drugs that displayed antimycobacterial activity against both M. smegmatis and BCG, however each organism also displayed some selectivity towards certain drug classes.  Variant anal. of whole genomes sequenced for resistant mutants raised to florfenicol, vanoxerine and pentamidine highlight new pathways that could be exploited in drug repurposing programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1hjyD_Vs8jbVg90H21EOLACvtfcHk0lhjYgTEl5J4fw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFaku78%253D&md5=08cdc1e84c3abd7d9d2f97766ebc4367</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0213713&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0213713%26sid%3Dliteratum%253Aachs%26aulast%3DKanvatirth%26aufirst%3DP.%26aulast%3DJeeves%26aufirst%3DR.%2BE.%26aulast%3DBacon%26aufirst%3DJ.%26aulast%3DBesra%26aufirst%3DG.%2BS.%26aulast%3DAlderwick%26aufirst%3DL.%2BJ.%26atitle%3DUtilisation%2520of%2520the%2520Prestwick%2520chemical%2520library%2520to%2520identify%2520drugs%2520that%2520inhibit%2520the%2520growth%2520of%2520mycobacteria%26jtitle%3DPLoS%2520One%26date%3D2019%26volume%3D14%26issue%3D3%26doi%3D10.1371%2Fjournal.pone.0213713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takaku, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kainuma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishida-Takaku, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishigami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tashiro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Soest, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurumizaka, H.</span></span> <span> </span><span class="NLM_article-title">Halenaquinone, a chemical compound that specifically inhibits the secondary DNA binding of RAD51</span>. <i>Genes Cells</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">427</span>â <span class="NLM_lpage">436</span>, <span class="refDoi">Â DOI: 10.1111/j.1365-2443.2011.01494.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1111%2Fj.1365-2443.2011.01494.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=21375680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkvVOltr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=427-436&issue=4&author=M.+Takakuauthor=T.+Kainumaauthor=T.+Ishida-Takakuauthor=S.+Ishigamiauthor=H.+Suzukiauthor=S.+Tashiroauthor=R.+W.+van+Soestauthor=Y.+Nakaoauthor=H.+Kurumizaka&title=Halenaquinone%2C+a+chemical+compound+that+specifically+inhibits+the+secondary+DNA+binding+of+RAD51&doi=10.1111%2Fj.1365-2443.2011.01494.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Halenaquinone, a chemical compound that specifically inhibits the secondary DNA binding of RAD51</span></div><div class="casAuthors">Takaku, Motoki; Kainuma, Takashi; Ishida-Takaku, Takako; Ishigami, Shintaro; Suzuki, Hidekazu; Tashiro, Satoshi; van Soest, Rob W. M.; Nakao, Yoichi; Kurumizaka, Hitoshi</div><div class="citationInfo"><span class="NLM_cas:title">Genes to Cells</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">427-436</span>CODEN:
                <span class="NLM_cas:coden">GECEFL</span>;
        ISSN:<span class="NLM_cas:issn">1356-9597</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Mutations and single-nucleotide polymorphisms affecting RAD51 gene function have been identified in several tumors, suggesting that the inappropriate expression of RAD51 activity may cause tumorigenesis.  RAD51 is an essential enzyme for the homologous recombinational repair (HRR) of DNA double-strand breaks.  In the HRR pathway, RAD51 catalyzes the homologous pairing between single-stranded DNA (ssDNA) and double-stranded DNA (dsDNA), which is the central step of the HRR pathway.  To identify a chem. compd. that regulates the homologous-pairing activity of RAD51, in the present study, we screened crude ext. fractions from marine sponges by the RAD51-mediated homologous-pairing assay.  Halenaquinone was identified as an inhibitor of the RAD51 homologous-pairing activity.  A surface plasmon resonance anal. indicated that halenaquinone directly bound to RAD51.  Intriguingly, halenaquinone specifically inhibited dsDNA binding by RAD51 alone or the RAD51-ssDNA complex, but only weakly affected the RAD51-ssDNA binding.  In vivo, halenaquinone significantly inhibited the retention of RAD51 at double-strand break sites.  Therefore, halenaquinone is a novel type of RAD51 inhibitor that specifically inhibits the RAD51-dsDNA binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxMwn_1wFlCbVg90H21EOLACvtfcHk0ljQUJGkOjHrKQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkvVOltr0%253D&md5=ed3855965594722e133f322eff2aa8e1</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2443.2011.01494.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2443.2011.01494.x%26sid%3Dliteratum%253Aachs%26aulast%3DTakaku%26aufirst%3DM.%26aulast%3DKainuma%26aufirst%3DT.%26aulast%3DIshida-Takaku%26aufirst%3DT.%26aulast%3DIshigami%26aufirst%3DS.%26aulast%3DSuzuki%26aufirst%3DH.%26aulast%3DTashiro%26aufirst%3DS.%26aulast%3Dvan%2BSoest%26aufirst%3DR.%2BW.%26aulast%3DNakao%26aufirst%3DY.%26aulast%3DKurumizaka%26aufirst%3DH.%26atitle%3DHalenaquinone%252C%2520a%2520chemical%2520compound%2520that%2520specifically%2520inhibits%2520the%2520secondary%2520DNA%2520binding%2520of%2520RAD51%26jtitle%3DGenes%2520Cells%26date%3D2011%26volume%3D16%26issue%3D4%26spage%3D427%26epage%3D436%26doi%3D10.1111%2Fj.1365-2443.2011.01494.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konig, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldblatt, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlin, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. H.</span></span> <span> </span><span class="NLM_article-title">A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia</span>. <i>EMBO Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">353</span>â <span class="NLM_lpage">365</span>, <span class="refDoi">Â DOI: 10.1002/emmm.201201760</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1002%2Femmm.201201760" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=23341130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsFKhtr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=353-365&issue=3&author=J.+Zhuauthor=L.+Zhouauthor=G.+Wuauthor=H.+Konigauthor=X.+Linauthor=G.+Liauthor=X.+L.+Qiuauthor=C.+F.+Chenauthor=C.+M.+Huauthor=E.+Goldblattauthor=R.+Bhatiaauthor=A.+R.+Chamberlinauthor=P.+L.+Chenauthor=W.+H.+Lee&title=A+novel+small+molecule+RAD51+inactivator+overcomes+imatinib-resistance+in+chronic+myeloid+leukaemia&doi=10.1002%2Femmm.201201760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia</span></div><div class="casAuthors">Zhu, Jiewen; Zhou, Longen; Wu, Guikai; Konig, Heiko; Lin, Xiaoqin; Li, Guideng; Qiu, Xiao-Long; Chen, Chi-Fen; Hu, Chun-Mei; Goldblatt, Erin; Bhatia, Ravi; Chamberlin, A. Richard; Chen, Phang-Lang; Lee, Wen-Hwa</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Molecular Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">353-365</span>CODEN:
                <span class="NLM_cas:coden">EMMMAM</span>;
        ISSN:<span class="NLM_cas:issn">1757-4684</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">RAD51 recombinase activity plays a crit. role for cancer cell proliferation and survival, and often contributes to drug-resistance.  Abnormally elevated RAD51 function and hyperactive homologous recombination (HR) rates have been found in a panel of cancers, including breast cancer and chronic myeloid leukemia (CML).  Directly targeting RAD51 and attenuating the deregulated RAD51 activity has therefore been proposed as an alternative and supplementary strategy for cancer treatment.  Here we show that a newly identified small mol., IBR2, disrupts RAD51 multimerization, accelerates proteasome-mediated RAD51 protein degrdn., reduces ionizing radiation-induced RAD51 foci formation, impairs HR, inhibits cancer cell growth and induces apoptosis.  In a murine imatinib-resistant CML model bearing the T315I Bcr-abl mutation, IBR2, but not imatinib, significantly prolonged animal survival.  Moreover, IBR2 effectively inhibits the proliferation of CD34+ progenitor cells from CML patients resistant to known BCR-ABL inhibitors.  Therefore, small mol. inhibitors of RAD51 may suggest a novel class of broad-spectrum therapeutics for difficult-to-treat cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwQGeSwZ19nrVg90H21EOLACvtfcHk0ljQUJGkOjHrKQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsFKhtr8%253D&md5=e956911425043bd5e2f18ddc0c10eec7</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1002%2Femmm.201201760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Femmm.201201760%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DKonig%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DQiu%26aufirst%3DX.%2BL.%26aulast%3DChen%26aufirst%3DC.%2BF.%26aulast%3DHu%26aufirst%3DC.%2BM.%26aulast%3DGoldblatt%26aufirst%3DE.%26aulast%3DBhatia%26aufirst%3DR.%26aulast%3DChamberlin%26aufirst%3DA.%2BR.%26aulast%3DChen%26aufirst%3DP.%2BL.%26aulast%3DLee%26aufirst%3DW.%2BH.%26atitle%3DA%2520novel%2520small%2520molecule%2520RAD51%2520inactivator%2520overcomes%2520imatinib-resistance%2520in%2520chronic%2520myeloid%2520leukaemia%26jtitle%3DEMBO%2520Mol.%2520Med.%26date%3D2013%26volume%3D5%26issue%3D3%26spage%3D353%26epage%3D365%26doi%3D10.1002%2Femmm.201201760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koropatnick, J.</span></span> <span> </span><span class="NLM_article-title">Synergistic antiproliferative activity of the RAD51 inhibitor IBR2 with inhibitors of receptor tyrosine kinases and microtubule protein</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>364</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">46</span>â <span class="NLM_lpage">54</span>, <span class="refDoi">Â DOI: 10.1124/jpet.117.241661</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1124%2Fjpet.117.241661" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=29061656" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsF2rtLnL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2018&pages=46-54&issue=1&author=P.+J.+Fergusonauthor=M.+D.+Vincentauthor=J.+Koropatnick&title=Synergistic+antiproliferative+activity+of+the+RAD51+inhibitor+IBR2+with+inhibitors+of+receptor+tyrosine+kinases+and+microtubule+protein&doi=10.1124%2Fjpet.117.241661"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic antiproliferative activity of the RAD51 inhibitor IBR2 with inhibitors of receptor tyrosine kinases and microtubule protein</span></div><div class="casAuthors">Ferguson, Peter J.; Vincent, Mark D.; Koropatnick, James</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">46-54</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Although cancer cell genetic instability contributes to characteristics that mediate tumorigenicity, it also contributes to the tumor-selective toxicity of some chemotherapy drugs.  This synthetic lethality can be enhanced by inhibitors of DNA repair.  To exploit this potential Achilles heel, we tested the ability of a RAD51 inhibitor to potentiate the cytotoxicity of chemotherapy drugs. 2-(Benzylsulfonyl)-1-(1H-indol-3-yl)-1,2-dihydroisoquinoline (IBR2) inhibits RAD51-mediated DNA double-strand break repair but also enhances cytotoxicity of the Bcr-Abl inhibitor imatinib.  The potential for synergy between IBR2 and more drugs was examd. in vitro across a spectrum of cancer cell lines from various tissues.  Cells were exposed to IBR2 simultaneously with inhibitors of receptor tyrosine kinases, DNA-damaging agents, or microtubule disruptors.  IBR2, at concns. that inhibited proliferation between 0% and 75%, enhanced toxicity by up to 80% of imatinib and regorafenib (targets RAF and kit); epidermal growth factor receptor inhibitors erlotinib, gefitinib, afatinib, and osimertinib; and vincristine, an inhibitor of microtubule function.  However, IBR2 antagonized the action of olaparib, cisplatin, melphalan, and irinotecan.  A vincristine-resistant squamous cell line was not cross resistant to imatinib, but IBR2 and another RAD51 inhibitor (B02) enhanced imatinib toxicity in this cell line, its HN-5a parent, and the colon cancer line HT-29 by up to 60% and much better than verapamil, a P-glycoprotein inhibitor (P < 0.05).  Given the disparate agents the functions of which are enhanced by IBR2, the mechanisms of enhancement may be multimodal.  Whether RAD51 is common to these mechanisms remains to be elucidated, but it provides the potential for selectivity to tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS83IVpSgnZrVg90H21EOLACvtfcHk0ljQUJGkOjHrKQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsF2rtLnL&md5=0e7e8831f137a0ca09d18e057c9f8b9c</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1124%2Fjpet.117.241661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.117.241661%26sid%3Dliteratum%253Aachs%26aulast%3DFerguson%26aufirst%3DP.%2BJ.%26aulast%3DVincent%26aufirst%3DM.%2BD.%26aulast%3DKoropatnick%26aufirst%3DJ.%26atitle%3DSynergistic%2520antiproliferative%2520activity%2520of%2520the%2520RAD51%2520inhibitor%2520IBR2%2520with%2520inhibitors%2520of%2520receptor%2520tyrosine%2520kinases%2520and%2520microtubule%2520protein%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2018%26volume%3D364%26issue%3D1%26spage%3D46%26epage%3D54%26doi%3D10.1124%2Fjpet.117.241661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motlekar, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgwin, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Napper, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamond, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazin, A. V.</span></span> <span> </span><span class="NLM_article-title">Identification of specific inhibitors of human RAD51 recombinase using high-throughput screening</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">628</span>â <span class="NLM_lpage">635</span>, <span class="refDoi">Â DOI: 10.1021/cb100428c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb100428c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjs1Chtbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=628-635&issue=6&author=F.+Huangauthor=N.+A.+Motlekarauthor=C.+M.+Burgwinauthor=A.+D.+Napperauthor=S.+L.+Diamondauthor=A.+V.+Mazin&title=Identification+of+specific+inhibitors+of+human+RAD51+recombinase+using+high-throughput+screening&doi=10.1021%2Fcb100428c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Specific Inhibitors of Human RAD51 Recombinase Using High-Throughput Screening</span></div><div class="casAuthors">Huang, Fei; Motlekar, Nuzhat A.; Burgwin, Chelsea M.; Napper, Andrew D.; Diamond, Scott L.; Mazin, Alexander V.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">628-635</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">RAD51 is a key protein of homologous recombination that plays a crit. role in the repair of DNA double-strand breaks (DSB) and interstrand cross-links (ICL).  To better understand the cellular function(s) of human RAD51, we propose to develop specific RAD51 inhibitors.  RAD51 inhibitors may also help to increase the potency of anticancer drugs that act by inducing DSBs or ICLs, e.g., cisplatin or ionizing radiation.  In vitro, RAD51 promotes DNA strand exchange between homologous ss- and dsDNA.  Here, we developed a DNA strand exchange assay based on fluorescence resonance energy transfer and used this assay to identify RAD51 inhibitors by high-throughput screening of the NIH Small Mol. Repository (>200,000 compds.).  Seventeen RAD51 inhibitors were identified and analyzed for selectivity using addnl. nonfluorescent DNA-based assays.  As a result, we identified a compd. (B02) that specifically inhibited human RAD51 (IC50 = 27.4 Î¼M) but not its E. coli homolog RecA (IC50 > 250 Î¼M).  Two other compds. (A03 and A10) were identified that inhibited both RAD51 and RecA but not the structurally unrelated RAD54 protein.  The structure-activity relationship (SAR) anal. allowed us to identify the structural components of B02 that are crit. for RAD51 inhibition.  The described approach can be used for identification of specific inhibitors of other human proteins that play an important role in DNA repair, e.g., RAD54 or Bloom's syndrome helicase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSBfvKiy1Mn7Vg90H21EOLACvtfcHk0liphk-Is6Ns1A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjs1Chtbw%253D&md5=80f6887b67cd82b8a15d3f0a9612fce2</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1021%2Fcb100428c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb100428c%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DF.%26aulast%3DMotlekar%26aufirst%3DN.%2BA.%26aulast%3DBurgwin%26aufirst%3DC.%2BM.%26aulast%3DNapper%26aufirst%3DA.%2BD.%26aulast%3DDiamond%26aufirst%3DS.%2BL.%26aulast%3DMazin%26aufirst%3DA.%2BV.%26atitle%3DIdentification%2520of%2520specific%2520inhibitors%2520of%2520human%2520RAD51%2520recombinase%2520using%2520high-throughput%2520screening%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2011%26volume%3D6%26issue%3D6%26spage%3D628%26epage%3D635%26doi%3D10.1021%2Fcb100428c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">WÃ©ra, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lobbens, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoyanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michiels, C.</span></span> <span> </span><span class="NLM_article-title">Radiation-induced synthetic lethality: combination of poly(ADP-ribose) polymerase and RAD51 inhibitors to sensitize cells to proton irradiation</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">1770</span>â <span class="NLM_lpage">1783</span>, <span class="refDoi">Â DOI: 10.1080/15384101.2019.1632640</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1080%2F15384101.2019.1632640" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=31238782" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1Gis7rJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=1770-1783&issue=15&author=A.+C.+W%C3%A9raauthor=A.+Lobbensauthor=M.+Stoyanovauthor=S.+Lucasauthor=C.+Michiels&title=Radiation-induced+synthetic+lethality%3A+combination+of+poly%28ADP-ribose%29+polymerase+and+RAD51+inhibitors+to+sensitize+cells+to+proton+irradiation&doi=10.1080%2F15384101.2019.1632640"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Radiation-induced synthetic lethality: combination of poly(ADP-ribose) polymerase and RAD51 inhibitors to sensitize cells to proton irradiation</span></div><div class="casAuthors">Wera, Anne-Catherine; Lobbens, Alison; Stoyanov, Miroslav; Lucas, Stephane; Michiels, Carine</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1770-1783</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1551-4005</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Although improvements in radiation therapy were made over the years, radioresistance is still a major challenge.  Cancer cells are often deficient for DNA repair response, a feature that is currently exploited as a new anti-cancer strategy.  In this context, combination of inhibitors targeting complementary pathways is of interest to sensitize cells to radiation.  In this work, we used PARP (Olaparib) and RAD51 (B02) inhibitors to radiosensitize cancer cells to proton and X-ray radiation.  More particularly, Olaparib and B02 were used at concn. leading to limited cytotoxic (alone or in combination) but increasing cell death when the cells were irradiated.  We showed that, although at limited concn., Olaparib and B02 were able to radiosensitize different cancer cell lines, i.e. lung and pancreatic cancer cells.  Antagonistic, additive or synergistic effects were obsd. and correlated to cell proliferation rate.  The inhibitors enhanced persistent DNA damage, delayed apoptosis, prolonged cell cycle arrest and senescence upon irradn.  These results demonstrated that radiation-induced synthetic lethality might widen the therapeutic window, hence extending the use of PARP inhibitors to patients without BRCAness.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdkyCV1HkelLVg90H21EOLACvtfcHk0liphk-Is6Ns1A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1Gis7rJ&md5=2bfda9cbf0101f44880ab669d3f8c243</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1080%2F15384101.2019.1632640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15384101.2019.1632640%26sid%3Dliteratum%253Aachs%26aulast%3DW%25C3%25A9ra%26aufirst%3DA.%2BC.%26aulast%3DLobbens%26aufirst%3DA.%26aulast%3DStoyanov%26aufirst%3DM.%26aulast%3DLucas%26aufirst%3DS.%26aulast%3DMichiels%26aufirst%3DC.%26atitle%3DRadiation-induced%2520synthetic%2520lethality%253A%2520combination%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%2520and%2520RAD51%2520inhibitors%2520to%2520sensitize%2520cells%2520to%2520proton%2520irradiation%26jtitle%3DCell%2520Cycle%26date%3D2019%26volume%3D18%26issue%3D15%26spage%3D1770%26epage%3D1783%26doi%3D10.1080%2F15384101.2019.1632640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maclay, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McComas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, K.</span></span> <span> </span><span class="NLM_article-title">CYT01B, a novel RAD51 inhibitor, act synergistically with both targeted and chemotherapeutic anti-cancer agents</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>132</i></span> (<span class="NLM_issue">Suppl. 1</span>),  <span class="NLM_fpage">3963</span>, <span class="refDoi">Â DOI: 10.1182/blood-2018-99-119373</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1182%2Fblood-2018-99-119373" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2018&pages=3963&issue=Suppl.+1&author=T.+Maclayauthor=J.+Vaccaauthor=C.+McComasauthor=A.+Castroauthor=M.+Dayauthor=K.+Mills&title=CYT01B%2C+a+novel+RAD51+inhibitor%2C+act+synergistically+with+both+targeted+and+chemotherapeutic+anti-cancer+agents&doi=10.1182%2Fblood-2018-99-119373"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1182%2Fblood-2018-99-119373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2018-99-119373%26sid%3Dliteratum%253Aachs%26aulast%3DMaclay%26aufirst%3DT.%26aulast%3DVacca%26aufirst%3DJ.%26aulast%3DMcComas%26aufirst%3DC.%26aulast%3DCastro%26aufirst%3DA.%26aulast%3DDay%26aufirst%3DM.%26aulast%3DMills%26aufirst%3DK.%26atitle%3DCYT01B%252C%2520a%2520novel%2520RAD51%2520inhibitor%252C%2520act%2520synergistically%2520with%2520both%2520targeted%2520and%2520chemotherapeutic%2520anti-cancer%2520agents%26jtitle%3DBlood%26date%3D2018%26volume%3D132%26issue%3DSuppl.%25201%26spage%3D3963%26doi%3D10.1182%2Fblood-2018-99-119373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Castro, A.</span>; <span class="NLM_string-name">McComas, C.</span>; <span class="NLM_string-name">Vacca, J.</span>; <span class="NLM_string-name">Maclay, T.</span></span> <span> </span><span class="NLM_article-title">RAD51 Inhibitors</span>. <span class="NLM_patent">US20190077799 A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=A.+Castro&author=C.+McComas&author=J.+Vacca&author=T.+Maclay&title=RAD51+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCastro%26aufirst%3DA.%26atitle%3DRAD51%2520Inhibitors%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xue, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, E. C.</span></span> <span> </span><span class="NLM_article-title">New roles for RAD52 in DNA repair</span>. <i>Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1127</span>â <span class="NLM_lpage">1128</span>, <span class="refDoi">Â DOI: 10.1038/s41422-018-0105-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1038%2Fs41422-018-0105-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=30367126" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A280%3ADC%252BB3cvjvFWhsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=1127-1128&issue=12&author=C.+Xueauthor=E.+C.+Greene&title=New+roles+for+RAD52+in+DNA+repair&doi=10.1038%2Fs41422-018-0105-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">New roles for RAD52 in DNA repair</span></div><div class="casAuthors">Xue Chaoyou; Greene Eric C</div><div class="citationInfo"><span class="NLM_cas:title">Cell research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1127-1128</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT5hx99QqDO5jDnmmyUf5qOfW6udTcc2ebT70xTwJPKq7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvjvFWhsQ%253D%253D&md5=6a2e833af486b4babd3745232839e972</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1038%2Fs41422-018-0105-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41422-018-0105-8%26sid%3Dliteratum%253Aachs%26aulast%3DXue%26aufirst%3DC.%26aulast%3DGreene%26aufirst%3DE.%2BC.%26atitle%3DNew%2520roles%2520for%2520RAD52%2520in%2520DNA%2520repair%26jtitle%3DCell%2520Res.%26date%3D2018%26volume%3D28%26issue%3D12%26spage%3D1127%26epage%3D1128%26doi%3D10.1038%2Fs41422-018-0105-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Norquist, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurz, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennil, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakai, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlan, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swisher, E. M.</span></span> <span> </span><span class="NLM_article-title">Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">3008</span>â <span class="NLM_lpage">3015</span>, <span class="refDoi">Â DOI: 10.1200/JCO.2010.34.2980</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1200%2FJCO.2010.34.2980" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=21709188" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFCqtLbL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=3008-3015&issue=22&author=B.+Norquistauthor=K.+A.+Wurzauthor=C.+C.+Pennilauthor=R.+Garciaauthor=J.+Grossauthor=W.+Sakaiauthor=B.+Y.+Karlanauthor=T.+Taniguchiauthor=E.+M.+Swisher&title=Secondary+somatic+mutations+restoring+BRCA1%2F2+predict+chemotherapy+resistance+in+hereditary+ovarian+carcinomas&doi=10.1200%2FJCO.2010.34.2980"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas</span></div><div class="casAuthors">Norquist, Barbara; Wurz, Kaitlyn A.; Pennil, Christopher C.; Garcia, Rochelle; Gross, Jenny; Sakai, Wataru; Karlan, Beth Y.; Taniguchi, Toshiyasu; Swisher, Elizabeth M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3008-3015</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Secondary somatic BRCA1/2 mutations may restore BRCA1/2 protein in hereditary ovarian carcinomas.  In cell lines, BRCA2 restoration mediates resistance to platinum chemotherapy and poly (ADP-ribose) polymerase (PARP) inhibitors.  We assessed primary and recurrent BRCA1/2-mutated ovarian carcinomas to define the frequency of secondary mutations and correlate these changes with clin. outcomes.  Methods Neoplastic cells were isolated with laser capture microdissection, and DNA was sequenced at the site of the known germline BRCA1/2 mutation.  When secondary mutations were found that restored wild-type sequence, haplotyping was performed using single nucleotide polymorphisms in tumor and paired lymphocyte DNA to rule out retention of the wild-type allele.  Results There were 64 primary and 46 recurrent ovarian carcinomas assessed.  Thirteen (28.3%) of 46 (95% CI, 17.3% to 42.6%) recurrent carcinomas had a secondary mutation compared with two (3.1%) of 64(95% CI, 1.0% to 10.7%) primary carcinomas (P= .0003, Fisher's exact test).  Twelve (46.2%) of 26 (95% CI, 28.7% to 64.7%) platinum-resistant recurrences had secondary mutations restoring BRCA1/2, compared with one (5.3%) of 19 (95% CI, 1.2% to 24.8%) platinum-sensitive recurrences (P = .003, Fisher's exact test).  Six (66.7%) of nine (95% CI, 34.8% to 87.8%) women with prior breast carcinoma had a recurrent carcinoma with a secondary mutation, compared with six (17.1%) of 35(95% CI, 8.2% to 32.8%) with no history of breast carcinoma (P = .007, Fisher's exact test).  Conclusion Secondary somatic mutations that restore BRCA1/2 in carcinomas from women with germline BRCA1/2 mutations predict resistance to platinum chemotherapy and may also predict resistance to PARP inhibitors.  These mutations were detectable only in ovarian carcinomas of women whom have had previous chemotherapy, either for ovarian or breast carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4mKtBwo-3h7Vg90H21EOLACvtfcHk0liMd2KTok91Kg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFCqtLbL&md5=998befc1b2df55cb5fdf40353c5d613d</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1200%2FJCO.2010.34.2980&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2010.34.2980%26sid%3Dliteratum%253Aachs%26aulast%3DNorquist%26aufirst%3DB.%26aulast%3DWurz%26aufirst%3DK.%2BA.%26aulast%3DPennil%26aufirst%3DC.%2BC.%26aulast%3DGarcia%26aufirst%3DR.%26aulast%3DGross%26aufirst%3DJ.%26aulast%3DSakai%26aufirst%3DW.%26aulast%3DKarlan%26aufirst%3DB.%2BY.%26aulast%3DTaniguchi%26aufirst%3DT.%26aulast%3DSwisher%26aufirst%3DE.%2BM.%26atitle%3DSecondary%2520somatic%2520mutations%2520restoring%2520BRCA1%252F2%2520predict%2520chemotherapy%2520resistance%2520in%2520hereditary%2520ovarian%2520carcinomas%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26issue%3D22%26spage%3D3008%26epage%3D3015%26doi%3D10.1200%2FJCO.2010.34.2980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan-Reed, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sliwinski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skorski, T.</span></span> <span> </span><span class="NLM_article-title">RAD52 as a potential target for synthetic lethality-based anticancer therapies</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1561</span>, <span class="refDoi">Â DOI: 10.3390/cancers11101561</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.3390%2Fcancers11101561" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnsVKht70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=1561&issue=10&author=M.+Tomaauthor=K.+Sullivan-Reedauthor=T.+Sliwinskiauthor=T.+Skorski&title=RAD52+as+a+potential+target+for+synthetic+lethality-based+anticancer+therapies&doi=10.3390%2Fcancers11101561"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">RAD52 as a potential target for synthetic lethality-based anticancer therapies</span></div><div class="casAuthors">Toma, Monika; Sullivan-Reed, Katherine; Sliwinski, Tomasz; Skorski, Tomasz</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1561</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Alterations in DNA repair systems play a key role in the induction and progression of cancer.  Tumor-specific defects in DNA repair mechanisms and activation of alternative repair routes create the opportunity to employ a phenomenon called "synthetic lethality" to eliminate cancer cells.  Targeting the backup pathways may amplify endogenous and drug-induced DNA damage and lead to specific eradication of cancer cells.  So far, the synthetic lethal interaction between BRCA1/2 and PARP1 has been successfully applied as an anticancer treatment.  Although PARP1 constitutes a promising target in the treatment of tumors harboring deficiencies in BRCA1/2-mediated homologous recombination (HR), some tumor cells survive, resulting in disease relapse.  It has been suggested that alternative RAD52-mediated HR can protect BRCA1/2-deficient cells from the accumulation of DNA damage and the synthetic lethal effect of PARPi.  Thus, simultaneous inhibition of RAD52 and PARP1 might result in a robust dual synthetic lethality, effectively eradicating BRCA1/2-deficient tumor cells.  In this review, we will discuss the role of RAD52 and its potential application in synthetic lethality-based anticancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2He7i98xWULVg90H21EOLACvtfcHk0liMd2KTok91Kg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnsVKht70%253D&md5=5c86f533c7696fab5deab28b8d179d38</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.3390%2Fcancers11101561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers11101561%26sid%3Dliteratum%253Aachs%26aulast%3DToma%26aufirst%3DM.%26aulast%3DSullivan-Reed%26aufirst%3DK.%26aulast%3DSliwinski%26aufirst%3DT.%26aulast%3DSkorski%26aufirst%3DT.%26atitle%3DRAD52%2520as%2520a%2520potential%2520target%2520for%2520synthetic%2520lethality-based%2520anticancer%2520therapies%26jtitle%3DCancers%26date%3D2019%26volume%3D11%26issue%3D10%26spage%3D1561%26doi%3D10.3390%2Fcancers11101561" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hromas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidhu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaiswal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Totterdale, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nole, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickoloff, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, K. Y.</span></span> <span> </span><span class="NLM_article-title">The endonuclease EEPD1 mediates synthetic lethality in RAD52-depleted BRCA1 mutant breast cancer cells</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">122</span>, <span class="refDoi">Â DOI: 10.1186/s13058-017-0912-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1186%2Fs13058-017-0912-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=29145865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFWnu7zN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=122&author=R.+Hromasauthor=H.+S.+Kimauthor=G.+Sidhuauthor=E.+Williamsonauthor=A.+Jaiswalauthor=T.+A.+Totterdaleauthor=J.+Noleauthor=S.+H.+Leeauthor=J.+A.+Nickoloffauthor=K.+Y.+Kong&title=The+endonuclease+EEPD1+mediates+synthetic+lethality+in+RAD52-depleted+BRCA1+mutant+breast+cancer+cells&doi=10.1186%2Fs13058-017-0912-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">The endonuclease EEPD1 mediates synthetic lethality in RAD52-depleted BRCA1 mutant breast cancer cells</span></div><div class="casAuthors">Hromas, Robert; Kim, Hyun-Suk; Sidhu, Gurjit; Williamson, Elizabeth; Jaiswal, Aruna; Totterdale, Taylor A.; Nole, Jocelyn; Lee, Suk-Hee; Nickoloff, Jac A.; Kong, Kimi Y.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">122/1-122/14</span>CODEN:
                <span class="NLM_cas:coden">BRCRFS</span>;
        ISSN:<span class="NLM_cas:issn">1465-542X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Proper repair and restart of stressed replication forks requires intact homologous recombination (HR).  HR at stressed replication forks can be initiated by the 5' endonuclease EEPD1, which cleaves the stalled replication fork.  Inherited or acquired defects in HR, such as mutations in breast cancer susceptibility protein-1 (BRCA1) or BRCA2, predispose to cancer, including breast and ovarian cancers.  In order for these HR-deficient tumor cells to proliferate, they become addicted to a bypass replication fork repair pathway mediated by radiation repair protein 52 (RAD52).  Depleting RAD52 can cause synthetic lethality in BRCA1/2 mutant cancers by an unknown mol. mechanism.  Methods: We hypothesized that cleavage of stressed replication forks by EEPD1 generates a fork repair intermediate that is toxic when HR-deficient cells cannot complete repair with the RAD52 bypass pathway.  To test this hypothesis, we applied cell survival assays, immunofluorescence staining, DNA fiber and western blot analyses to look at the correlation between cell survival and genome integrity in control, EEPD1, RAD52 and EEPD1/RAD52 co-depletion BRCA1-deficient breast cancer cells.  Results: Our data show that depletion of EEPD1 suppresses synthetic lethality, genome instability, mitotic catastrophe, and hypersensitivity to stress of replication of RAD52-depleted, BRCA1 mutant breast cancer cells.  Without HR and the RAD52-dependent backup pathway, the BRCA1 mutant cancer cells depleted of EEPD1 skew to the alternative non-homologous end-joining DNA repair pathway for survival.  Conclusion: This study indicates that the mechanism of synthetic lethality in RAD52-depleted BRCA1 mutant cancer cells depends on the endonuclease EEPD1.  The data imply that EEPD1 cleavage of stressed replication forks may result in a toxic intermediate when replication fork repair cannot be completed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKOoJ61fL57LVg90H21EOLACvtfcHk0liMd2KTok91Kg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFWnu7zN&md5=7dd4dfb4a777b828e752bcb32fcfb1fd</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1186%2Fs13058-017-0912-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13058-017-0912-8%26sid%3Dliteratum%253Aachs%26aulast%3DHromas%26aufirst%3DR.%26aulast%3DKim%26aufirst%3DH.%2BS.%26aulast%3DSidhu%26aufirst%3DG.%26aulast%3DWilliamson%26aufirst%3DE.%26aulast%3DJaiswal%26aufirst%3DA.%26aulast%3DTotterdale%26aufirst%3DT.%2BA.%26aulast%3DNole%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DNickoloff%26aufirst%3DJ.%2BA.%26aulast%3DKong%26aufirst%3DK.%2BY.%26atitle%3DThe%2520endonuclease%2520EEPD1%2520mediates%2520synthetic%2520lethality%2520in%2520RAD52-depleted%2520BRCA1%2520mutant%2520breast%2520cancer%2520cells%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2017%26volume%3D19%26spage%3D122%26doi%3D10.1186%2Fs13058-017-0912-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cramer-Morales, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieborowska-Skorska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheibner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padget, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irvine, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sliwinski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slupianek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rassool, F. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasik, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Childers, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copland, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muschen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Civin, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skorski, T.</span></span> <span> </span><span class="NLM_article-title">Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>122</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1293</span>â <span class="NLM_lpage">1304</span>, <span class="refDoi">Â DOI: 10.1182/blood-2013-05-501072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1182%2Fblood-2013-05-501072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=23836560" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlOjsb7K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2013&pages=1293-1304&issue=7&author=K.+Cramer-Moralesauthor=M.+Nieborowska-Skorskaauthor=K.+Scheibnerauthor=M.+Padgetauthor=D.+A.+Irvineauthor=T.+Sliwinskiauthor=K.+Haasauthor=J.+Leeauthor=H.+Gengauthor=D.+Royauthor=A.+Slupianekauthor=F.+V.+Rassoolauthor=M.+A.+Wasikauthor=W.+Childersauthor=M.+Coplandauthor=M.+Muschenauthor=C.+I.+Civinauthor=T.+Skorski&title=Personalized+synthetic+lethality+induced+by+targeting+RAD52+in+leukemias+identified+by+gene+mutation+and+expression+profile&doi=10.1182%2Fblood-2013-05-501072"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile</span></div><div class="casAuthors">Cramer-Morales, Kimberly; Nieborowska-Skorska, Margaret; Scheibner, Kara; Padget, Michelle; Irvine, David A.; Sliwinski, Tomasz; Haas, Kimberly; Lee, Jaewoong; Geng, Huimin; Roy, Darshan; Slupianek, Artur; Rassool, Feyruz V.; Wasik, Mariusz A.; Childers, Wayne; Copland, Mhairi; Muschen, Markus; Civin, Curt I.; Skorski, Tomasz</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1293-1304</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Homologous recombination repair (HRR) protects cells from the lethal effect of spontaneous and therapy-induced DNA double-stand breaks.  HRR usually depends on BRCA1/2-RAD51, and RAD52-RAD51 serves as back-up.  To target HRR in tumor cells, a phenomenon called "synthetic lethality" was applied, which relies on the addiction of cancer cells to a single DNA repair pathway, whereas normal cells operate 2 or more mechanisms.  Using mutagenesis and a peptide aptamer approach, we pinpointed phenylalanine 79 in RAD52 DNA binding domain I (RAD52-phenylalanine 79 [F79]) as a valid target to induce synthetic lethality in BRCA1- and/or BRCA2-deficient leukemias and carcinomas without affecting normal cells and tissues.  Targeting RAD52-F79 disrupts the RAD52-DNA interaction, resulting in the accumulation of toxic DNA double-stand breaks in malignant cells, but not in normal counterparts.  In addn., abrogation of RAD52-DNA interaction enhanced the antileukemia effect of already-approved drugs.  BRCA-deficient status predisposing to RAD52-dependent synthetic lethality could be predicted by genetic abnormalities such as oncogenes BCR-ABL1 and PML-RAR, mutations in BRCA1 and/or BRCA2 genes, and gene expression profiles identifying leukemias displaying low levels of BRCA1 and/or BRCA2.  We believe this work may initiate a personalized therapeutic approach in numerous patients with tumors displaying encoded and functional BRCA deficiency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiS-g84hhhgbVg90H21EOLACvtfcHk0ljxfj8vkGo8PQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlOjsb7K&md5=e3ff26e6fef134ac1272758932cd42cf</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1182%2Fblood-2013-05-501072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2013-05-501072%26sid%3Dliteratum%253Aachs%26aulast%3DCramer-Morales%26aufirst%3DK.%26aulast%3DNieborowska-Skorska%26aufirst%3DM.%26aulast%3DScheibner%26aufirst%3DK.%26aulast%3DPadget%26aufirst%3DM.%26aulast%3DIrvine%26aufirst%3DD.%2BA.%26aulast%3DSliwinski%26aufirst%3DT.%26aulast%3DHaas%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DGeng%26aufirst%3DH.%26aulast%3DRoy%26aufirst%3DD.%26aulast%3DSlupianek%26aufirst%3DA.%26aulast%3DRassool%26aufirst%3DF.%2BV.%26aulast%3DWasik%26aufirst%3DM.%2BA.%26aulast%3DChilders%26aufirst%3DW.%26aulast%3DCopland%26aufirst%3DM.%26aulast%3DMuschen%26aufirst%3DM.%26aulast%3DCivin%26aufirst%3DC.%2BI.%26aulast%3DSkorski%26aufirst%3DT.%26atitle%3DPersonalized%2520synthetic%2520lethality%2520induced%2520by%2520targeting%2520RAD52%2520in%2520leukemias%2520identified%2520by%2520gene%2520mutation%2520and%2520expression%2520profile%26jtitle%3DBlood%26date%3D2013%26volume%3D122%26issue%3D7%26spage%3D1293%26epage%3D1304%26doi%3D10.1182%2Fblood-2013-05-501072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renodon-Corniere, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomme, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eveillard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleury, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigel, P.</span></span> <span> </span><span class="NLM_article-title">Targeting human Rad51 by specific DNA aptamers induces inhibition of homologous recombination</span>. <i>Biochimie</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>92</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1832</span>â <span class="NLM_lpage">1838</span>, <span class="refDoi">Â DOI: 10.1016/j.biochi.2010.08.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.biochi.2010.08.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=20713120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFantbjM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2010&pages=1832-1838&issue=12&author=S.+F.+Martinezauthor=A.+Renodon-Corniereauthor=J.+Nommeauthor=D.+Eveillardauthor=F.+Fleuryauthor=M.+Takahashiauthor=P.+Weigel&title=Targeting+human+Rad51+by+specific+DNA+aptamers+induces+inhibition+of+homologous+recombination&doi=10.1016%2Fj.biochi.2010.08.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting human Rad51 by specific DNA aptamers induces inhibition of homologous recombination</span></div><div class="casAuthors">Martinez, Susan F.; Renodon-Corniere, Axelle; Nomme, Julian; Eveillard, Damien; Fleury, Fabrice; Takahashi, Masayuki; Weigel, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Biochimie</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1832-1838</span>CODEN:
                <span class="NLM_cas:coden">BICMBE</span>;
        ISSN:<span class="NLM_cas:issn">0300-9084</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Human Rad51 (HsRad51), a key element of the homologous recombination repair pathway, is related to the resistance of cancer cells to chemo- and radio-therapies.  This protein is thus a good target for the development of anti-cancer treatments.  We have searched for new inhibitors directed against HsRad51 using the Systematic Evolution of Ligands by EXponential enrichment (SELEX) approach.  We have selected three aptamers displaying strong effects on strand exchange activity.  Anal. by CD shows that they are highly structured DNA mols.  Our results also show that they affect the first step of the strand exchange reaction by promoting the dissocn. of DNA from the ATP/HsRad51/DNA complex.  Moreover, these inhibitors bind only weakly to RecA, a prokaryotic ortholog of HsRad51.  Both the specificity and the efficiency of their inhibition of recombinase activity offer an anal. tool based on mol. recognition and the prospect of developing new therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTE5PR_ksvXrVg90H21EOLACvtfcHk0ljxfj8vkGo8PQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFantbjM&md5=60dbf853e0eee951929046683e95c190</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1016%2Fj.biochi.2010.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biochi.2010.08.006%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez%26aufirst%3DS.%2BF.%26aulast%3DRenodon-Corniere%26aufirst%3DA.%26aulast%3DNomme%26aufirst%3DJ.%26aulast%3DEveillard%26aufirst%3DD.%26aulast%3DFleury%26aufirst%3DF.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DWeigel%26aufirst%3DP.%26atitle%3DTargeting%2520human%2520Rad51%2520by%2520specific%2520DNA%2520aptamers%2520induces%2520inhibition%2520of%2520homologous%2520recombination%26jtitle%3DBiochimie%26date%3D2010%26volume%3D92%26issue%3D12%26spage%3D1832%26epage%3D1838%26doi%3D10.1016%2Fj.biochi.2010.08.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chandramouly, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDevitt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kent, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glickman, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrake, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skorski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pomerantz, R. T.</span></span> <span> </span><span class="NLM_article-title">Small-molecule disruption of RAD52 rings as a mechanism for precision medicine in BRCA-deficient cancers</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1491</span>â <span class="NLM_lpage">1504</span>, <span class="refDoi">Â DOI: 10.1016/j.chembiol.2015.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.chembiol.2015.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=26548611" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsl2gsr7K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=1491-1504&issue=11&author=G.+Chandramoulyauthor=S.+McDevittauthor=K.+Sullivanauthor=T.+Kentauthor=A.+Luzauthor=J.+F.+Glickmanauthor=M.+Andrakeauthor=T.+Skorskiauthor=R.+T.+Pomerantz&title=Small-molecule+disruption+of+RAD52+rings+as+a+mechanism+for+precision+medicine+in+BRCA-deficient+cancers&doi=10.1016%2Fj.chembiol.2015.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Disruption of RAD52 Rings as a Mechanism for Precision Medicine in BRCA-Deficient Cancers</span></div><div class="casAuthors">Chandramouly, Gurushankar; McDevitt, Shane; Sullivan, Katherine; Kent, Tatiana; Luz, Antonio; Glickman, J. Fraser; Andrake, Mark; Skorski, Tomasz; Pomerantz, Richard T.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1491-1504</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Suppression of RAD52 causes synthetic lethality in BRCA-deficient cells.  Yet pharmacol. inhibition of RAD52, which binds single-strand DNA (ssDNA) and lacks enzymic activity, has not been demonstrated.  Here, we identify the small mol. 6-hydroxy-DL-dopa (6-OH-dopa) as a major allosteric inhibitor of the RAD52 ssDNA binding domain.  For example, we find that multiple small mols. bind to and completely transform RAD52 undecamer rings into dimers, which abolishes the ssDNA binding channel obsd. in crystal structures.  6-OH-Dopa also disrupts RAD52 heptamer and undecamer ring superstructures, and suppresses RAD52 recruitment and recombination activity in cells with negligible effects on other double-strand break repair pathways.  Importantly, we show that 6-OH-dopa selectively inhibits the proliferation of BRCA-deficient cancer cells, including those obtained from leukemia patients.  Taken together, these data demonstrate small-mol. disruption of RAD52 rings as a promising mechanism for precision medicine in BRCA-deficient cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocg0mbVDvBErVg90H21EOLACvtfcHk0ljxfj8vkGo8PQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsl2gsr7K&md5=a1ce2852f876ce70b7b8c5275d6050ab</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2015.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2015.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DChandramouly%26aufirst%3DG.%26aulast%3DMcDevitt%26aufirst%3DS.%26aulast%3DSullivan%26aufirst%3DK.%26aulast%3DKent%26aufirst%3DT.%26aulast%3DLuz%26aufirst%3DA.%26aulast%3DGlickman%26aufirst%3DJ.%2BF.%26aulast%3DAndrake%26aufirst%3DM.%26aulast%3DSkorski%26aufirst%3DT.%26aulast%3DPomerantz%26aufirst%3DR.%2BT.%26atitle%3DSmall-molecule%2520disruption%2520of%2520RAD52%2520rings%2520as%2520a%2520mechanism%2520for%2520precision%2520medicine%2520in%2520BRCA-deficient%2520cancers%26jtitle%3DChem.%2520Biol.%26date%3D2015%26volume%3D22%26issue%3D11%26spage%3D1491%26epage%3D1504%26doi%3D10.1016%2Fj.chembiol.2015.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olney, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zorumski, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labruyere, J.</span></span> <span> </span><span class="NLM_article-title">Excitotoxicity of L-dopa and 6-OH-dopa: implications for Parkinsonâs and Huntingtonâs diseases</span>. <i>Exp. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>108</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">269</span>â <span class="NLM_lpage">272</span>, <span class="refDoi">Â DOI: 10.1016/0014-4886(90)90134-E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2F0014-4886%2890%2990134-E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1972067" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADyaK3cXltlSjurs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=1990&pages=269-272&issue=3&author=J.+W.+Olneyauthor=C.+F.+Zorumskiauthor=G.+R.+Stewartauthor=M.+T.+Priceauthor=G.+J.+Wangauthor=J.+Labruyere&title=Excitotoxicity+of+L-dopa+and+6-OH-dopa%3A+implications+for+Parkinson%E2%80%99s+and+Huntington%E2%80%99s+diseases&doi=10.1016%2F0014-4886%2890%2990134-E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Excitotoxicity of L-DOPA and 6-OH-DOPA:  implications for Parkinson's and Huntington's diseases</span></div><div class="casAuthors">Olney, John W.; Zorumski, Charles F.; Stewart, Gregory R.; Price, Madelon T.; Wang, Guangjian; Labruyere, Joann</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Neurology</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">269-72</span>CODEN:
                <span class="NLM_cas:coden">EXNEAC</span>;
        ISSN:<span class="NLM_cas:issn">0014-4886</span>.
    </div><div class="casAbstract">Despite several decades of research aimed at elucidating the mechanisms underlying neuronal degeneration in Parkinson's and Huntington's diseases, these mysteries remain unfathomed.  The brain contains high concns. of the putative transmitters, glutamate and aspartate, which have neurotoxic (excitotoxic) potential and are thought to cause neuronal degeneration in certain acute neurol. disorders.  However, no mechanism has been identified by which these diffusely distributed agents might cause the regionally selective patterns of neuronal degeneration characterizing Parkinson's and Huntington's diseases.  This study reports that L-DOPA, the natural precursor to dopamine, is a weak excitotoxin and its o-hydroxylated deriv., 6-OH-DOPA, is a powerful excitotoxin.  The authors propose that an excitotoxic process mediated by L-DOPA or an acidic deriv. such as 6-OH-DOPA might be responsible for degeneration of nigral neurons in Parkinson's disease or striatal neurons in Huntington's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpihHszOClV9bVg90H21EOLACvtfcHk0lg0Ugprah9U_Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXltlSjurs%253D&md5=8c651f238b831643af5eb088207c786d</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1016%2F0014-4886%2890%2990134-E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-4886%252890%252990134-E%26sid%3Dliteratum%253Aachs%26aulast%3DOlney%26aufirst%3DJ.%2BW.%26aulast%3DZorumski%26aufirst%3DC.%2BF.%26aulast%3DStewart%26aufirst%3DG.%2BR.%26aulast%3DPrice%26aufirst%3DM.%2BT.%26aulast%3DWang%26aufirst%3DG.%2BJ.%26aulast%3DLabruyere%26aufirst%3DJ.%26atitle%3DExcitotoxicity%2520of%2520L-dopa%2520and%25206-OH-dopa%253A%2520implications%2520for%2520Parkinson%25E2%2580%2599s%2520and%2520Huntington%25E2%2580%2599s%2520diseases%26jtitle%3DExp.%2520Neurol.%26date%3D1990%26volume%3D108%26issue%3D3%26spage%3D269%26epage%3D272%26doi%3D10.1016%2F0014-4886%2890%2990134-E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goyal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanamshet, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazina, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spoonamore, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmitte, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cocklin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skorski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazin, A. V.</span></span> <span> </span><span class="NLM_article-title">Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>44</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">4189</span>â <span class="NLM_lpage">4199</span>, <span class="refDoi">Â DOI: 10.1093/nar/gkw087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1093%2Fnar%2Fgkw087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=26873923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFSisLvN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2016&pages=4189-4199&issue=9&author=F.+Huangauthor=N.+Goyalauthor=K.+Sullivanauthor=K.+Hanamshetauthor=M.+Patelauthor=O.+M.+Mazinaauthor=C.+X.+Wangauthor=W.+F.+Anauthor=J.+Spoonamoreauthor=S.+Metkarauthor=K.+A.+Emmitteauthor=S.+Cocklinauthor=T.+Skorskiauthor=A.+V.+Mazin&title=Targeting+BRCA1-+and+BRCA2-deficient+cells+with+RAD52+small+molecule+inhibitors&doi=10.1093%2Fnar%2Fgkw087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors</span></div><div class="casAuthors">Huang, Fei; Goyal, Nadish; Sullivan, Katherine; Hanamshet, Kritika; Patel, Mikir; Mazina, Olga M.; Wang, Charles X.; An, W. Frank; Spoonamore, James; Metkar, Shailesh; Emmitte, Kyle A.; Cocklin, Simon; Skorski, Tomasz; Mazin, Alexander V.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4189-4199</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">RAD52 is a member of the homologous recombination (HR) pathway that is important for maintenance of genome integrity.  While single RAD52 mutations show no significant phenotype in mammals, their combination with mutations in genes that cause hereditary breast cancer and ovarian cancer like BRCA1, BRCA2, PALB2 and RAD51C are lethal.  Consequently, RAD52 may represent an important target for cancer therapy.  In vitro, RAD52 has ss-DNA annealing and DNA strand exchange activities.  Here, to identify small mol. inhibitors of RAD52 we screened a 372,903-compd. library using a fluorescence-quenching assay for ssDNA annealing activity of RAD52.  The obtained 70 putative inhibitors were further characterized using biochem. and cell-based assays.  As a result, we identified compds. that specifically inhibit the biochem. activities of RAD52, suppress growth of BRCA1- and BRCA2-deficient cells and inhibit RAD52-dependent single-strand annealing (SSA) in human cells.  We will use these compds. for development of novel cancer therapy and as a probe to study mechanisms of DNA repair.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkx222q1LMmLVg90H21EOLACvtfcHk0lg0Ugprah9U_Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFSisLvN&md5=be5d7e3c4195a3de90e2f45218af8d7d</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkw087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkw087%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DF.%26aulast%3DGoyal%26aufirst%3DN.%26aulast%3DSullivan%26aufirst%3DK.%26aulast%3DHanamshet%26aufirst%3DK.%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DMazina%26aufirst%3DO.%2BM.%26aulast%3DWang%26aufirst%3DC.%2BX.%26aulast%3DAn%26aufirst%3DW.%2BF.%26aulast%3DSpoonamore%26aufirst%3DJ.%26aulast%3DMetkar%26aufirst%3DS.%26aulast%3DEmmitte%26aufirst%3DK.%2BA.%26aulast%3DCocklin%26aufirst%3DS.%26aulast%3DSkorski%26aufirst%3DT.%26aulast%3DMazin%26aufirst%3DA.%2BV.%26atitle%3DTargeting%2520BRCA1-%2520and%2520BRCA2-deficient%2520cells%2520with%2520RAD52%2520small%2520molecule%2520inhibitors%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2016%26volume%3D44%26issue%3D9%26spage%3D4189%26epage%3D4199%26doi%3D10.1093%2Fnar%2Fgkw087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hengel, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malacaria, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Folly da Silva Constantino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bain, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pichierri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spies, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spies, M.</span></span> <span> </span><span class="NLM_article-title">Small-molecule inhibitors identify the RAD52-ssDNA interaction as critical for recovery from replication stress and for survival of BRCA2 deficient cells</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">e14740</span> <span class="refDoi">Â DOI: 10.7554/eLife.14740</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.7554%2FeLife.14740" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=27434671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmslahtLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&author=S.+R.+Hengelauthor=E.+Malacariaauthor=L.+Folly+da+Silva+Constantinoauthor=F.+E.+Bainauthor=A.+Diazauthor=B.+G.+Kochauthor=L.+Yuauthor=M.+Wuauthor=P.+Pichierriauthor=M.+A.+Spiesauthor=M.+Spies&title=Small-molecule+inhibitors+identify+the+RAD52-ssDNA+interaction+as+critical+for+recovery+from+replication+stress+and+for+survival+of+BRCA2+deficient+cells&doi=10.7554%2FeLife.14740"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule inhibitors identify the RAD52-ssDNA interaction as critical for recovery from replication stress and for survival of BRCA2 deficient cells</span></div><div class="casAuthors">Hengel, Sarah R.; Malacaria, Eva; Constantino, Laura Folly da Silva; Bain, Fletcher E.; Diaz, Andrea; Koch, Brandon G.; Yu, Liping; Wu, Meng; Pichierri, Pietro; Spies, M. Ashley; Spies, Maria</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e14740/1-e14740/30</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">The DNA repair protein RAD52 is an emerging therapeutic target of high importance for BRCA-deficient tumors.  Depletion of RAD52 is synthetically lethal with defects in tumor suppressors BRCA1, BRCA2 and PALB2.  RAD52 also participates in recovery of the stalled replication forks.  Anticipating that ssDNA binding activity underlies the RAD52 cellular functions, we carried out a high throughput screening campaign to identify compds. that disrupt the RAD52-ssDNA interaction.  Lead compds. were confirmed as RAD52 inhibitors in biochem. assays.  Computational anal. predicted that these inhibitors bind within the ssDNA-binding groove of the RAD52 oligomeric ring.  The nature of the inhibtor-RAD52 complex was validated through an in silico screening campaign, culminating in the discovery of an addnl. RAD52 inhibitor.  Cellular studies with our inhibitors showed that the RAD52-ssDNA interaction enables its function at stalled replication forks, and that the inhibition of RAD52-ssDNA binding acts additively with BRCA2 or MUS81 depletion in cell killing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb53M_Y1A5NrVg90H21EOLACvtfcHk0lirJnRE3MKS2w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmslahtLc%253D&md5=1b2e48184b06ceab1655578b8e5bc7cd</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.7554%2FeLife.14740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.14740%26sid%3Dliteratum%253Aachs%26aulast%3DHengel%26aufirst%3DS.%2BR.%26aulast%3DMalacaria%26aufirst%3DE.%26aulast%3DFolly%2Bda%2BSilva%2BConstantino%26aufirst%3DL.%26aulast%3DBain%26aufirst%3DF.%2BE.%26aulast%3DDiaz%26aufirst%3DA.%26aulast%3DKoch%26aufirst%3DB.%2BG.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DM.%26aulast%3DPichierri%26aufirst%3DP.%26aulast%3DSpies%26aufirst%3DM.%2BA.%26aulast%3DSpies%26aufirst%3DM.%26atitle%3DSmall-molecule%2520inhibitors%2520identify%2520the%2520RAD52-ssDNA%2520interaction%2520as%2520critical%2520for%2520recovery%2520from%2520replication%2520stress%2520and%2520for%2520survival%2520of%2520BRCA2%2520deficient%2520cells%26jtitle%3DeLife%26date%3D2016%26volume%3D5%26doi%3D10.7554%2FeLife.14740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murfuni, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basile, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanyam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malacaria, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bignami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spies, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franchitto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pichierri, P.</span></span> <span> </span><span class="NLM_article-title">Survival of the replication checkpoint deficient cells requires MUS81-RAD52 function</span>. <i>PLoS Genet.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">10</span>), <span class="NLM_elocation-id">e1003910</span> <span class="refDoi">Â DOI: 10.1371/journal.pgen.1003910</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1371%2Fjournal.pgen.1003910" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=24204313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFKqs7jN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&issue=10&author=I.+Murfuniauthor=G.+Basileauthor=S.+Subramanyamauthor=E.+Malacariaauthor=M.+Bignamiauthor=M.+Spiesauthor=A.+Franchittoauthor=P.+Pichierri&title=Survival+of+the+replication+checkpoint+deficient+cells+requires+MUS81-RAD52+function&doi=10.1371%2Fjournal.pgen.1003910"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Survival of the replication checkpoint deficient cells requires MUS81-RAD52 function</span></div><div class="casAuthors">Murfuni, Ivana; Basile, Giorgia; Subramanyam, Shyamal; Malacaria, Eva; Bignami, Margherita; Spies, Maria; Franchitto, Annapaola; Pichierri, Pietro</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Genetics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e1003910/1-e1003910/21, 21 pp.</span>CODEN:
                <span class="NLM_cas:coden">PGLEB5</span>;
        ISSN:<span class="NLM_cas:issn">1553-7404</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">In checkpoint-deficient cells, DNA double-strand breaks (DSBs) are produced during replication by the structure-specific endonuclease MUS81.  The mechanism underlying MUS81-dependent cleavage, and the effect on chromosome integrity and viability of checkpoint deficient cells is only partly understood, esp. in human cells.  Here, we show that MUS81-induced DSBs are specifically triggered by CHK1 inhibition in a manner that is unrelated to the loss of RAD51, and does not involve formation of a RAD51 substrate.  Indeed, CHK1 deficiency results in the formation of a RAD52-dependent structure that is cleaved by MUS81.  Moreover, in CHK1-deficient cells depletion of RAD52, but not of MUS81, rescues chromosome instability obsd. after replication fork stalling.  However, when RAD52 is down-regulated, recovery from replication stress requires MUS81, and loss of both these proteins results in massive cell death that can be suppressed by RAD51 depletion.  Our findings reveal a novel RAD52/MUS81-dependent mechanism that promotes cell viability and genome integrity in checkpoint-deficient cells, and disclose the involvement of MUS81 to multiple processes after replication stress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwrq-97V9t37Vg90H21EOLACvtfcHk0lirJnRE3MKS2w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFKqs7jN&md5=83f809637973fa264443aea7de37433c</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pgen.1003910&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pgen.1003910%26sid%3Dliteratum%253Aachs%26aulast%3DMurfuni%26aufirst%3DI.%26aulast%3DBasile%26aufirst%3DG.%26aulast%3DSubramanyam%26aufirst%3DS.%26aulast%3DMalacaria%26aufirst%3DE.%26aulast%3DBignami%26aufirst%3DM.%26aulast%3DSpies%26aufirst%3DM.%26aulast%3DFranchitto%26aufirst%3DA.%26aulast%3DPichierri%26aufirst%3DP.%26atitle%3DSurvival%2520of%2520the%2520replication%2520checkpoint%2520deficient%2520cells%2520requires%2520MUS81-RAD52%2520function%26jtitle%3DPLoS%2520Genet.%26date%3D2013%26volume%3D9%26issue%3D10%26doi%3D10.1371%2Fjournal.pgen.1003910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span> <span> </span><span class="NLM_article-title">Compound F779-0434 causes synthetic lethality in BRCA2-deficient cancer cells by disrupting RAD52âssDNA association</span>. <i>RSC Adv.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">34</span>),  <span class="NLM_fpage">18859</span>â <span class="NLM_lpage">18869</span>, <span class="refDoi">Â DOI: 10.1039/C8RA01919C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1039%2FC8RA01919C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpvFWku74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=18859-18869&issue=34&author=J.+Liauthor=Q.+Yangauthor=Y.+Zhangauthor=K.+Huangauthor=R.+Sunauthor=Q.+Zhao&title=Compound+F779-0434+causes+synthetic+lethality+in+BRCA2-deficient+cancer+cells+by+disrupting+RAD52%E2%80%93ssDNA+association&doi=10.1039%2FC8RA01919C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Compound F779-0434 causes synthetic lethality in BRCA2-deficient cancer cells by disrupting RAD52-ssDNA association</span></div><div class="casAuthors">Li, Jian; Yang, Qianye; Zhang, Yang; Huang, Kejia; Sun, Rong; Zhao, Qi</div><div class="citationInfo"><span class="NLM_cas:title">RSC Advances</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">18859-18869</span>CODEN:
                <span class="NLM_cas:coden">RSCACL</span>;
        ISSN:<span class="NLM_cas:issn">2046-2069</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Maintenance of genomic integrity is essential for the survival of all organisms.  Homologous recombination (HR) is the major pathway for high-fidelity repair of DNA double-stranded breaks (DSBs).  In addn. to the classic BRCA-RAD51 pathway, another secondary HR sub-pathway dependent on RAD52 has been suggested to be functioning in mammalian cells.  Importantly, RAD52 has been shown to be synthetically lethal to BRCA1/2-deficient cells, rendering RAD52 to be a desirable target in cancer therapy.  In the current study, we performed a structure-based virtual screening of 47 737 drug-like compds. to identify RAD52-specific inhibitors.  The top ranked virtual screening hits were further characterized using mol. dynamics simulation and biochem. and cell-based assays.  We found that one compd., namely, F779-0434 specifically suppressed the growth of BRCA2-deficient cells and disrupted RAD52-ssDNA interaction in vitro.  This RAD52-specific inhibitor identified in the current study is a promising compd. for targeted cancer therapy, and it can also be used as a probe to study the mechanisms of DNA repair in human cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIn2jOn1KT-bVg90H21EOLACvtfcHk0lirJnRE3MKS2w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpvFWku74%253D&md5=fb396904e27644dc8ee99613ed49c216</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1039%2FC8RA01919C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8RA01919C%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DK.%26aulast%3DSun%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DQ.%26atitle%3DCompound%2520F779-0434%2520causes%2520synthetic%2520lethality%2520in%2520BRCA2-deficient%2520cancer%2520cells%2520by%2520disrupting%2520RAD52%25E2%2580%2593ssDNA%2520association%26jtitle%3DRSC%2520Adv.%26date%3D2018%26volume%3D8%26issue%3D34%26spage%3D18859%26epage%3D18869%26doi%3D10.1039%2FC8RA01919C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coley, W. B.,  II.</span></span> <span> </span><span class="NLM_article-title">Contribution to the knowledge of sarcoma</span>. <i>Ann. Surg.</i> <span class="NLM_year" style="font-weight: bold;">1891</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">199</span>â <span class="NLM_lpage">220</span>, <span class="refDoi">Â DOI: 10.1097/00000658-189112000-00015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1097%2F00000658-189112000-00015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=17859590" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A280%3ADC%252BD2srksVKlsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1891&pages=199-220&issue=3&author=W.+B.+Coley&title=Contribution+to+the+knowledge+of+sarcoma&doi=10.1097%2F00000658-189112000-00015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">II. Contribution to the Knowledge of Sarcoma</span></div><div class="casAuthors">Coley W B</div><div class="citationInfo"><span class="NLM_cas:title">Annals of surgery</span>
        (<span class="NLM_cas:date">1891</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">199-220</span>
        ISSN:<span class="NLM_cas:issn">0003-4932</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRo-f4FsyvzhTQLBVDQn4bCfW6udTcc2eYZwkT-nCbirLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2srksVKlsg%253D%253D&md5=41f295141a7469993cfd74031506e71d</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1097%2F00000658-189112000-00015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00000658-189112000-00015%26sid%3Dliteratum%253Aachs%26aulast%3DColey%26aufirst%3DW.%2BB.%26atitle%3DContribution%2520to%2520the%2520knowledge%2520of%2520sarcoma%26jtitle%3DAnn.%2520Surg.%26date%3D1891%26volume%3D14%26issue%3D3%26spage%3D199%26epage%3D220%26doi%3D10.1097%2F00000658-189112000-00015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">Application of PD-1 blockade in cancer immunotherapy</span>. <i>Comput. Struct. Biotechnol. J.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">661</span>â <span class="NLM_lpage">674</span>, <span class="refDoi">Â DOI: 10.1016/j.csbj.2019.03.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.csbj.2019.03.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=31205619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFGqtrzL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2019&pages=661-674&author=X.+Wuauthor=Z.+Guauthor=Y.+Chenauthor=B.+Chenauthor=W.+Chenauthor=L.+Wengauthor=X.+Liu&title=Application+of+PD-1+blockade+in+cancer+immunotherapy&doi=10.1016%2Fj.csbj.2019.03.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Application of PD-1 Blockade in Cancer Immunotherapy</span></div><div class="casAuthors">Wu, Xiaomo; Gu, Zhongkai; Chen, Yang; Chen, Borui; Chen, Wei; Weng, Liqiang; Liu, Xiaolong</div><div class="citationInfo"><span class="NLM_cas:title">Computational and Structural Biotechnology Journal</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">661-674</span>CODEN:
                <span class="NLM_cas:coden">CSBJAC</span>;
        ISSN:<span class="NLM_cas:issn">2001-0370</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The programmed cell death protein 1 (PD-1) pathway has received considerable attention due to its role in eliciting the immune checkpoint response of T cells, resulting in tumor cells capable of evading immune surveillance and being highly refractory to conventional chemotherapy.  Application of anti-PD-1/PD-L1 antibodies as checkpoint inhibitors is rapidly becoming a promising therapeutic approach in treating tumors, and some of them have successfully been commercialized in the past few years.  However, not all patients show complete responses and adverse events have been noted, suggesting a better understanding of PD-1 pathway mediated immunosuppression is needed to predict patient response and improve treatment efficacy.  Here, we review the progresses on the studies of the mechanistic role of PD-1 pathway in the tumor immune evasion, recent clin. development and commercialization of PD-1 pathway inhibitors, the toxicities assocd. with PD-1 blockade obsd. in clin. trials as well as how to improve therapeutic efficacy and safety of cancer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdmCsowbiei7Vg90H21EOLACvtfcHk0lieaeFLZHVpCQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFGqtrzL&md5=a9ebe11e2901ed40ce38edfa607ec5e6</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1016%2Fj.csbj.2019.03.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.csbj.2019.03.006%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DX.%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DWeng%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DApplication%2520of%2520PD-1%2520blockade%2520in%2520cancer%2520immunotherapy%26jtitle%3DComput.%2520Struct.%2520Biotechnol.%2520J.%26date%3D2019%26volume%3D17%26spage%3D661%26epage%3D674%26doi%3D10.1016%2Fj.csbj.2019.03.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K.</span></span> <span> </span><span class="NLM_article-title">Prospects for combining immune checkpoint blockade with PARP inhibition</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">98</span>, <span class="refDoi">Â DOI: 10.1186/s13045-019-0784-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1186%2Fs13045-019-0784-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=31521196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A280%3ADC%252BB3MroslyrsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&pages=98&issue=1&author=A.+Liauthor=M.+Yiauthor=S.+Qinauthor=Q.+Chuauthor=S.+Luoauthor=K.+Wu&title=Prospects+for+combining+immune+checkpoint+blockade+with+PARP+inhibition&doi=10.1186%2Fs13045-019-0784-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Prospects for combining immune checkpoint blockade with PARP inhibition</span></div><div class="casAuthors">Li Anping; Luo Suxia; Wu Kongming; Yi Ming; Qin Shuang; Chu Qian; Wu Kongming</div><div class="citationInfo"><span class="NLM_cas:title">Journal of hematology & oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">98</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The immunogenicity of a cancer cell is derived from accumulated somatic mutations.  However, on the contrary to increased immunogenicity, anti-cancer immune response tends to be feeble.  This impaired anti-cancer immunity could be attributed to multiple factors including loss of immunodominant epitopes, downregulation of major histocompatibility complex, and immunosuppressive microenvironment, as well as aberrant negative co-stimulatory signals.  Immune checkpoint inhibitors block negative co-stimulatory signals such as programmed cell death-1 and cytotoxic T-lymphocyte-associated protein 4, ultimately reactivating anti-cancer immunity.  Immune checkpoint inhibitors elicit potent anti-cancer effect and have been approved for multiple cancers.  Nevertheless, there still are significant potential improvements for the applications of checkpoint inhibitor, especially considering frequent resistance.  Recent studies demonstrated that additional PARP inhibition could alleviate resistance and enhance efficacy of immune checkpoint blockade therapy via promoting cross-presentation and modifying immune microenvironment.  We proposed that PARP inhibitors could enhance the priming and tumor-killing activities of T cell, boost the whole cancer-immunity cycle, and thereby improve the response to immune checkpoint blockade.  In this review, we focused the latest understanding of the effect of PARP inhibitors on anti-cancer immunity and PARP inhibitors combining immune checkpoint blockade therapy.  Moreover, we summarized the preclinical and clinical evidence and discussed the feasibility of this combination therapy in future clinical practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT02g9Y5ozDhpSWdIdmEou5fW6udTcc2eYZwkT-nCbirLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MroslyrsQ%253D%253D&md5=a1a2183aca7ccdf41862a284ae9af48e</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1186%2Fs13045-019-0784-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-019-0784-8%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DA.%26aulast%3DYi%26aufirst%3DM.%26aulast%3DQin%26aufirst%3DS.%26aulast%3DChu%26aufirst%3DQ.%26aulast%3DLuo%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DK.%26atitle%3DProspects%2520for%2520combining%2520immune%2520checkpoint%2520blockade%2520with%2520PARP%2520inhibition%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2019%26volume%3D12%26issue%3D1%26spage%3D98%26doi%3D10.1186%2Fs13045-019-0784-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arun, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hortobagyi, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, M. C.</span></span> <span> </span><span class="NLM_article-title">PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">3711</span>â <span class="NLM_lpage">3720</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-16-3215</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F1078-0432.CCR-16-3215" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=28167507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFKiurfL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=3711-3720&issue=14&author=S.+Jiaoauthor=W.+Xiaauthor=H.+Yamaguchiauthor=Y.+Weiauthor=M.+K.+Chenauthor=J.+M.+Hsuauthor=J.+L.+Hsuauthor=W.+H.+Yuauthor=Y.+Duauthor=H.+H.+Leeauthor=C.+W.+Liauthor=C.+K.+Chouauthor=S.+O.+Limauthor=S.+S.+Changauthor=J.+Littonauthor=B.+Arunauthor=G.+N.+Hortobagyiauthor=M.+C.+Hung&title=PARP+inhibitor+upregulates+PD-L1+expression+and+enhances+cancer-associated+immunosuppression&doi=10.1158%2F1078-0432.CCR-16-3215"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression</span></div><div class="casAuthors">Jiao, Shiping; Xia, Weiya; Yamaguchi, Hirohito; Wei, Yongkun; Chen, Mei-Kuang; Hsu, Jung-Mao; Hsu, Jennifer L.; Yu, Wen-Hsuan; Du, Yi; Lee, Heng-Huan; Li, Chia-Wei; Chou, Chao-Kai; Lim, Seung-Oe; Chang, Shih-Shin; Litton, Jennifer; Arun, Banu; Hortobagyi, Gabriel N.; Hung, Mien-Chie</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3711-3720</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">To explore whether a cross-talk exists between PARP inhibition and PD-L1/PD-1 immune checkpoint axis, and det. whether blockade of PD-L1/PD-1 potentiates PARP inhibitor (PARPi) in tumor suppression.  Breast cancer cell lines, xenograft tumors, and syngeneic tumors treated with PARPi were assessed for PD-L1 expression by immunoblotting, IHC, and FACS analyses.  The phospho-kinase antibody array screen was used to explore the underlying mechanism of PARPi-induced PD-L1 upregulation.  The therapeutic efficacy of PARPi alone, PD-L1 blockade alone, or their combination was tested in a syngeneic tumor model.  The tumor-infiltrating lymphocytes and tumor cells isolated from syngeneic tumors were analyzed by CyTOF and FACS to evaluate the activity of antitumor immunity in the tumor microenvironment.  PARPi upregulated PD-L1 expression in breast cancer cell lines and animal models.  Mechanistically, PARPi inactivated GSK3Î², which in turn enhanced PARPi-mediated PD-L1 upregulation.  PARPi attenuated anticancer immunity via upregulation of PD-L1, and blockade of PD-L1 resensitized PARPi-treated cancer cells to T-cell killing.  The combination of PARPi and anti-PD-L1 therapy compared with each agent alone significantly increased the therapeutic efficacy in vivo.  Our study demonstrates a cross-talk between PARPi and tumor-assocd. immunosuppression and provides evidence to support the combination of PARPi and PD-L1 or PD-1 immune checkpoint blockade as a potential therapeutic approach to treat breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7F64RimeUWrVg90H21EOLACvtfcHk0liFhW1mfhRAng"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFKiurfL&md5=21c11c52b9b5a6a7bad9c2e743a7a22c</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-3215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-3215%26sid%3Dliteratum%253Aachs%26aulast%3DJiao%26aufirst%3DS.%26aulast%3DXia%26aufirst%3DW.%26aulast%3DYamaguchi%26aufirst%3DH.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DM.%2BK.%26aulast%3DHsu%26aufirst%3DJ.%2BM.%26aulast%3DHsu%26aufirst%3DJ.%2BL.%26aulast%3DYu%26aufirst%3DW.%2BH.%26aulast%3DDu%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DH.%2BH.%26aulast%3DLi%26aufirst%3DC.%2BW.%26aulast%3DChou%26aufirst%3DC.%2BK.%26aulast%3DLim%26aufirst%3DS.%2BO.%26aulast%3DChang%26aufirst%3DS.%2BS.%26aulast%3DLitton%26aufirst%3DJ.%26aulast%3DArun%26aufirst%3DB.%26aulast%3DHortobagyi%26aufirst%3DG.%2BN.%26aulast%3DHung%26aufirst%3DM.%2BC.%26atitle%3DPARP%2520inhibitor%2520upregulates%2520PD-L1%2520expression%2520and%2520enhances%2520cancer-associated%2520immunosuppression%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26issue%3D14%26spage%3D3711%26epage%3D3720%26doi%3D10.1158%2F1078-0432.CCR-16-3215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Le Meur, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gentleman, R.</span></span> <span> </span><span class="NLM_article-title">Modeling synthetic lethality</span>. <i>Genome Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">9</span>), <span class="NLM_elocation-id">R135</span> <span class="refDoi">Â DOI: 10.1186/gb-2008-9-9-r135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1186%2Fgb-2008-9-9-r135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=18789146" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&issue=9&author=N.+Le+Meurauthor=R.+Gentleman&title=Modeling+synthetic+lethality&doi=10.1186%2Fgb-2008-9-9-r135"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1186%2Fgb-2008-9-9-r135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fgb-2008-9-9-r135%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BMeur%26aufirst%3DN.%26aulast%3DGentleman%26aufirst%3DR.%26atitle%3DModeling%2520synthetic%2520lethality%26jtitle%3DGenome%2520Biol.%26date%3D2008%26volume%3D9%26issue%3D9%26doi%3D10.1186%2Fgb-2008-9-9-r135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, E. R.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Weck, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlabach, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mavrakis, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belur, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castelletti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frias, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gampa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golji, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kao, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Megel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramadan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruddy, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silver, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sovath, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stump, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widmer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramowski, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ackley, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernard, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brachmann, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buxton, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caothien, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caushi, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes-Cros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">deBeaumont, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delaunay, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desplat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwoske, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eldridge, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farsidjani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flemming, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forrester, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galli, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauter, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibaja, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattenberger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hood, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurov, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jagani, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapoor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loo, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macchi, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAllister, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagliarini, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phadke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Repko, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schouwey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shanahan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamm, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stucke, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiedt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varadarajan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatesan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitari, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallroth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mickanin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myer, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bitter, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lees, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kauffmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stegmeier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmelzle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span> <span> </span><span class="NLM_article-title">Project DRIVE: A compendium of cancer dependencies and synthetic lethal relationships uncovered by large-scale, deep RNAi screening</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>170</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">577</span>â <span class="NLM_lpage">592</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2017.07.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.cell.2017.07.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=28753431" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1GisLvI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2017&pages=577-592&issue=3&author=E.+R.+McDonaldauthor=A.+de+Weckauthor=M.+R.+Schlabachauthor=E.+Billyauthor=K.+J.+Mavrakisauthor=G.+R.+Hoffmanauthor=D.+Belurauthor=D.+Castellettiauthor=E.+Friasauthor=K.+Gampaauthor=J.+Goljiauthor=I.+Kaoauthor=L.+Liauthor=P.+Megelauthor=T.+A.+Perkinsauthor=N.+Ramadanauthor=D.+A.+Ruddyauthor=S.+J.+Silverauthor=S.+Sovathauthor=M.+Stumpauthor=O.+Weberauthor=R.+Widmerauthor=J.+Yuauthor=K.+Yuauthor=Y.+Yueauthor=D.+Abramowskiauthor=E.+Ackleyauthor=R.+Barrettauthor=J.+Bergerauthor=J.+L.+Bernardauthor=R.+Billigauthor=S.+M.+Brachmannauthor=F.+Buxtonauthor=R.+Caothienauthor=J.+X.+Caushiauthor=F.+S.+Chungauthor=M.+Cortes-Crosauthor=R.+S.+deBeaumontauthor=C.+Delaunayauthor=A.+Desplatauthor=W.+Duongauthor=D.+A.+Dwoskeauthor=R.+S.+Eldridgeauthor=A.+Farsidjaniauthor=F.+Fengauthor=J.+Fengauthor=D.+Flemmingauthor=W.+Forresterauthor=G.+G.+Galliauthor=Z.+Gaoauthor=F.+Gauterauthor=V.+Gibajaauthor=K.+Haasauthor=M.+Hattenbergerauthor=T.+Hoodauthor=K.+E.+Hurovauthor=Z.+Jaganiauthor=M.+Jenalauthor=J.+A.+Johnsonauthor=M.+D.+Jonesauthor=A.+Kapoorauthor=J.+Kornauthor=J.+Liuauthor=Q.+Liuauthor=S.+Liuauthor=Y.+Liuauthor=A.+T.+Looauthor=K.+J.+Macchiauthor=T.+Martinauthor=G.+McAllisterauthor=A.+Meyerauthor=S.+Molleauthor=R.+A.+Pagliariniauthor=T.+Phadkeauthor=B.+Repkoauthor=T.+Schouweyauthor=F.+Shanahanauthor=Q.+Shenauthor=C.+Stammauthor=C.+Stephanauthor=V.+M.+Stuckeauthor=R.+Tiedtauthor=M.+Varadarajanauthor=K.+Venkatesanauthor=A.+C.+Vitariauthor=M.+Wallrothauthor=J.+Weilerauthor=J.+Zhangauthor=C.+Mickaninauthor=V.+E.+Myerauthor=J.+A.+Porterauthor=A.+Laiauthor=H.+Bitterauthor=E.+Leesauthor=N.+Keenauthor=A.+Kauffmannauthor=F.+Stegmeierauthor=F.+Hofmannauthor=T.+Schmelzleauthor=W.+R.+Sellers&title=Project+DRIVE%3A+A+compendium+of+cancer+dependencies+and+synthetic+lethal+relationships+uncovered+by+large-scale%2C+deep+RNAi+screening&doi=10.1016%2Fj.cell.2017.07.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Project DRIVE: A compendium of cancer dependencies and synthetic lethal relationships uncovered by large-scale, deep RNAi screening</span></div><div class="casAuthors">McDonald, E. Robert, III; de Weck, Antoine; Schlabach, Michael R.; Billy, Eric; Mavrakis, Konstantinos J.; Hoffman, Gregory R.; Belur, Dhiren; Castelletti, Deborah; Frias, Elizabeth; Gampa, Kalyani; Golji, Javad; Kao, Iris; Li, Li; Megel, Philippe; Perkins, Thomas A.; Ramadan, Nadire; Ruddy, David A.; Silver, Serena J.; Sovath, Sosathya; Stump, Mark; Weber, Odile; Widmer, Roland; Yu, Jianjun; Yu, Kristine; Yue, Yingzi; Abramowski, Dorothee; Ackley, Elizabeth; Barrett, Rosemary; Berger, Joel; Bernard, Julie L.; Billig, Rebecca; Brachmann, Saskia M.; Buxton, Frank; Caothien, Roger; Caushi, Justina X.; Chung, Franklin S.; Cortes-Cros, Marta; de Beaumont, Rosalie S.; Delaunay, Clara; Desplat, Aurore; Duong, William; Dwoske, Donald A.; Eldridge, Richard S.; Farsidjani, Ali; Feng, Fei; Feng, Jia Jia; Flemming, Daisy; Forrester, William; Galli, Giorgio G.; Gao, Zhenhai; Gauter, Francois; Gibaja, Veronica; Haas, Kristy; Hattenberger, Marc; Hood, Tami; Hurov, Kristen E.; Jagani, Zainab; Jenal, Mathias; Johnson, Jennifer A.; Jones, Michael D.; Kapoor, Avnish; Korn, Joshua; Liu, Jilin; Liu, Qiumei; Liu, Shumei; Liu, Yue; Loo, Alice T.; Macchi, Kaitlin J.; Martin, Typhaine; McAllister, Gregory; Meyer, Amandine; Molle, Sandra; Pagliarini, Raymond A.; Phadke, Tanushree; Repko, Brian; Schouwey, Tanja; Shanahan, Frances; Shen, Qiong; Stamm, Christelle; Stephan, Christine; Stucke, Volker M.; Tiedt, Ralph; Varadarajan, Malini; Venkatesan, Kavitha; Vitari, Alberto C.; Wallroth, Marco; Weiler, Jan; Zhang, Jing; Mickanin, Craig; Myer, Vic E.; Porter, Jeffery A.; Lai, Albert; Bitter, Hans; Lees, Emma; Keen, Nicholas; Kauffmann, Audrey; Stegmeier, Frank; Hofmann, Francesco; Schmelzle, Tobias; Sellers, William R.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">577-592.e10</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Elucidation of the mutational landscape of human cancer has progressed rapidly and been accompanied by the development of therapeutics targeting mutant oncogenes.  However, a comprehensive mapping of cancer dependencies has lagged behind and the discovery of therapeutic targets for counteracting tumor suppressor gene loss is needed.  To identify vulnerabilities relevant to specific cancer subtypes, we conducted a large-scale RNAi screen in which viability effects of mRNA knockdown were assessed for 7837 genes using an av. of 20 shRNAs per gene in 398 cancer cell lines.  We describe findings of this screen, outlining the classes of cancer dependency genes and their relationships to genetic, expression, and lineage features.  In addn., we describe robust gene-interaction networks recapitulating both protein complexes and functional cooperation among complexes and pathways.  This dataset along with a web portal is provided to the community to assist in the discovery and translation of new therapeutic approaches for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokUs33_s2nC7Vg90H21EOLACvtfcHk0lhy-GOGnDl07Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1GisLvI&md5=41592e684cc8f2cd28117cb3303f6120</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.07.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.07.005%26sid%3Dliteratum%253Aachs%26aulast%3DMcDonald%26aufirst%3DE.%2BR.%26aulast%3Dde%2BWeck%26aufirst%3DA.%26aulast%3DSchlabach%26aufirst%3DM.%2BR.%26aulast%3DBilly%26aufirst%3DE.%26aulast%3DMavrakis%26aufirst%3DK.%2BJ.%26aulast%3DHoffman%26aufirst%3DG.%2BR.%26aulast%3DBelur%26aufirst%3DD.%26aulast%3DCastelletti%26aufirst%3DD.%26aulast%3DFrias%26aufirst%3DE.%26aulast%3DGampa%26aufirst%3DK.%26aulast%3DGolji%26aufirst%3DJ.%26aulast%3DKao%26aufirst%3DI.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DMegel%26aufirst%3DP.%26aulast%3DPerkins%26aufirst%3DT.%2BA.%26aulast%3DRamadan%26aufirst%3DN.%26aulast%3DRuddy%26aufirst%3DD.%2BA.%26aulast%3DSilver%26aufirst%3DS.%2BJ.%26aulast%3DSovath%26aufirst%3DS.%26aulast%3DStump%26aufirst%3DM.%26aulast%3DWeber%26aufirst%3DO.%26aulast%3DWidmer%26aufirst%3DR.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DYue%26aufirst%3DY.%26aulast%3DAbramowski%26aufirst%3DD.%26aulast%3DAckley%26aufirst%3DE.%26aulast%3DBarrett%26aufirst%3DR.%26aulast%3DBerger%26aufirst%3DJ.%26aulast%3DBernard%26aufirst%3DJ.%2BL.%26aulast%3DBillig%26aufirst%3DR.%26aulast%3DBrachmann%26aufirst%3DS.%2BM.%26aulast%3DBuxton%26aufirst%3DF.%26aulast%3DCaothien%26aufirst%3DR.%26aulast%3DCaushi%26aufirst%3DJ.%2BX.%26aulast%3DChung%26aufirst%3DF.%2BS.%26aulast%3DCortes-Cros%26aufirst%3DM.%26aulast%3DdeBeaumont%26aufirst%3DR.%2BS.%26aulast%3DDelaunay%26aufirst%3DC.%26aulast%3DDesplat%26aufirst%3DA.%26aulast%3DDuong%26aufirst%3DW.%26aulast%3DDwoske%26aufirst%3DD.%2BA.%26aulast%3DEldridge%26aufirst%3DR.%2BS.%26aulast%3DFarsidjani%26aufirst%3DA.%26aulast%3DFeng%26aufirst%3DF.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DFlemming%26aufirst%3DD.%26aulast%3DForrester%26aufirst%3DW.%26aulast%3DGalli%26aufirst%3DG.%2BG.%26aulast%3DGao%26aufirst%3DZ.%26aulast%3DGauter%26aufirst%3DF.%26aulast%3DGibaja%26aufirst%3DV.%26aulast%3DHaas%26aufirst%3DK.%26aulast%3DHattenberger%26aufirst%3DM.%26aulast%3DHood%26aufirst%3DT.%26aulast%3DHurov%26aufirst%3DK.%2BE.%26aulast%3DJagani%26aufirst%3DZ.%26aulast%3DJenal%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DJ.%2BA.%26aulast%3DJones%26aufirst%3DM.%2BD.%26aulast%3DKapoor%26aufirst%3DA.%26aulast%3DKorn%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLoo%26aufirst%3DA.%2BT.%26aulast%3DMacchi%26aufirst%3DK.%2BJ.%26aulast%3DMartin%26aufirst%3DT.%26aulast%3DMcAllister%26aufirst%3DG.%26aulast%3DMeyer%26aufirst%3DA.%26aulast%3DMolle%26aufirst%3DS.%26aulast%3DPagliarini%26aufirst%3DR.%2BA.%26aulast%3DPhadke%26aufirst%3DT.%26aulast%3DRepko%26aufirst%3DB.%26aulast%3DSchouwey%26aufirst%3DT.%26aulast%3DShanahan%26aufirst%3DF.%26aulast%3DShen%26aufirst%3DQ.%26aulast%3DStamm%26aufirst%3DC.%26aulast%3DStephan%26aufirst%3DC.%26aulast%3DStucke%26aufirst%3DV.%2BM.%26aulast%3DTiedt%26aufirst%3DR.%26aulast%3DVaradarajan%26aufirst%3DM.%26aulast%3DVenkatesan%26aufirst%3DK.%26aulast%3DVitari%26aufirst%3DA.%2BC.%26aulast%3DWallroth%26aufirst%3DM.%26aulast%3DWeiler%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DMickanin%26aufirst%3DC.%26aulast%3DMyer%26aufirst%3DV.%2BE.%26aulast%3DPorter%26aufirst%3DJ.%2BA.%26aulast%3DLai%26aufirst%3DA.%26aulast%3DBitter%26aufirst%3DH.%26aulast%3DLees%26aufirst%3DE.%26aulast%3DKeen%26aufirst%3DN.%26aulast%3DKauffmann%26aufirst%3DA.%26aulast%3DStegmeier%26aufirst%3DF.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DSchmelzle%26aufirst%3DT.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26atitle%3DProject%2520DRIVE%253A%2520A%2520compendium%2520of%2520cancer%2520dependencies%2520and%2520synthetic%2520lethal%2520relationships%2520uncovered%2520by%2520large-scale%252C%2520deep%2520RNAi%2520screening%26jtitle%3DCell%26date%3D2017%26volume%3D170%26issue%3D3%26spage%3D577%26epage%3D592%26doi%3D10.1016%2Fj.cell.2017.07.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beetham, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telford, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Single, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarman, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackovic, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luxenburger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guilford, P.</span></span> <span> </span><span class="NLM_article-title">A high-throughput screen to identify novel synthetic lethal compounds for the treatment of E-cadherin-deficient cells</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">12511</span>, <span class="refDoi">Â DOI: 10.1038/s41598-019-48929-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1038%2Fs41598-019-48929-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=31467357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A280%3ADC%252BB3MrjsVWmtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=12511&issue=1&author=H.+Beethamauthor=A.+Chenauthor=B.+J.+Telfordauthor=A.+Singleauthor=K.+E.+Jarmanauthor=K.+Lackovicauthor=A.+Luxenburgerauthor=P.+Guilford&title=A+high-throughput+screen+to+identify+novel+synthetic+lethal+compounds+for+the+treatment+of+E-cadherin-deficient+cells&doi=10.1038%2Fs41598-019-48929-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">A high-throughput screen to identify novel synthetic lethal compounds for the treatment of E-cadherin-deficient cells</span></div><div class="casAuthors">Beetham Henry; Chen Augustine; Telford Bryony J; Single Andrew; Guilford Parry; Jarman Kate E; Lackovic Kurt; Jarman Kate E; Lackovic Kurt; Luxenburger Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12511</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The cell-cell adhesion protein E-cadherin (CDH1) is a tumor suppressor that is required to maintain cell adhesion, cell polarity and cell survival signalling.  Somatic mutations in CDH1 are common in diffuse gastric cancer (DGC) and lobular breast cancer (LBC).  In addition, germline mutations in CDH1 predispose to the autosomal dominant cancer syndrome Hereditary Diffuse Gastric Cancer (HDGC).  One approach to target cells with mutations in specific tumor suppressor genes is synthetic lethality.  To identify novel synthetic lethal compounds for the treatment of cancers associated with E-cadherin loss, we have undertaken a high-throughput screening campaign of ~114,000 lead-like compounds on an isogenic pair of human mammary epithelial cell lines - with and without CDH1 expression.  This unbiased approach identified 12 novel compounds that preferentially harmed E-cadherin-deficient cells.  Validation of these compounds using both real-time and end-point viability assays identified two novel compounds with significant synthetic lethal activity, thereby demonstrating that E-cadherin loss creates druggable vulnerabilities within tumor cells.  In summary, we have identified novel synthetic lethal compounds that may provide a new strategy for the prevention and treatment of both sporadic and hereditary LBC and DGC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRhgHigE2q0VMjl5L8hwNX0fW6udTcc2eZY4HxyrYE5F7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MrjsVWmtA%253D%253D&md5=c29bb1bc6eb8c9124b310f2ab4d67930</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-48929-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-48929-0%26sid%3Dliteratum%253Aachs%26aulast%3DBeetham%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DTelford%26aufirst%3DB.%2BJ.%26aulast%3DSingle%26aufirst%3DA.%26aulast%3DJarman%26aufirst%3DK.%2BE.%26aulast%3DLackovic%26aufirst%3DK.%26aulast%3DLuxenburger%26aufirst%3DA.%26aulast%3DGuilford%26aufirst%3DP.%26atitle%3DA%2520high-throughput%2520screen%2520to%2520identify%2520novel%2520synthetic%2520lethal%2520compounds%2520for%2520the%2520treatment%2520of%2520E-cadherin-deficient%2520cells%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26issue%3D1%26spage%3D12511%26doi%3D10.1038%2Fs41598-019-48929-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hofree, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ideker, T.</span></span> <span> </span><span class="NLM_article-title">Network-based stratification of tumor mutations</span>. <i>Nat. Methods</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1108</span>â <span class="NLM_lpage">1115</span>, <span class="refDoi">Â DOI: 10.1038/nmeth.2651</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1038%2Fnmeth.2651" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=24037242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVeqsrvM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=1108-1115&issue=11&author=M.+Hofreeauthor=J.+P.+Shenauthor=H.+Carterauthor=A.+Grossauthor=T.+Ideker&title=Network-based+stratification+of+tumor+mutations&doi=10.1038%2Fnmeth.2651"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Network-based stratification of tumor mutations</span></div><div class="casAuthors">Hofree, Matan; Shen, John P.; Carter, Hannah; Gross, Andrew; Ideker, Trey</div><div class="citationInfo"><span class="NLM_cas:title">Nature Methods</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1108-1115</span>CODEN:
                <span class="NLM_cas:coden">NMAEA3</span>;
        ISSN:<span class="NLM_cas:issn">1548-7091</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Many forms of cancer have multiple subtypes with different causes and clin. outcomes.  Somatic tumor genome sequences provide a rich new source of data for uncovering these subtypes but have proven difficult to compare, as two tumors rarely share the same mutations.  Here we introduce network-based stratification (NBS), a method to integrate somatic tumor genomes with gene networks.  This approach allows for stratification of cancer into informative subtypes by clustering together patients with mutations in similar network regions.  We demonstrate NBS in ovarian, uterine and lung cancer cohorts from The Cancer Genome Atlas.  For each tissue, NBS identifies subtypes that are predictive of clin. outcomes such as patient survival, response to therapy or tumor histol.  We identify network regions characteristic of each subtype and show how mutation-derived subtypes can be used to train an mRNA expression signature, which provides similar information in the absence of DNA sequence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpD4Es1VR8In7Vg90H21EOLACvtfcHk0li3HCZWVeHlNA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVeqsrvM&md5=4a305ef2d3b1521e344d8895e77efa49</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1038%2Fnmeth.2651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnmeth.2651%26sid%3Dliteratum%253Aachs%26aulast%3DHofree%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DJ.%2BP.%26aulast%3DCarter%26aufirst%3DH.%26aulast%3DGross%26aufirst%3DA.%26aulast%3DIdeker%26aufirst%3DT.%26atitle%3DNetwork-based%2520stratification%2520of%2520tumor%2520mutations%26jtitle%3DNat.%2520Methods%26date%3D2013%26volume%3D10%26issue%3D11%26spage%3D1108%26epage%3D1115%26doi%3D10.1038%2Fnmeth.2651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Y. D.</span></span> <span> </span><span class="NLM_article-title">Identification of synthetic lethality based on a functional network by using machine learning algorithms</span>. <i>J. Cell. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>120</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">405</span>â <span class="NLM_lpage">416</span>, <span class="refDoi">Â DOI: 10.1002/jcb.27395</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1002%2Fjcb.27395" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=30125975" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFequ73E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2019&pages=405-416&issue=1&author=J.+Liauthor=L.+Luauthor=Y.+H.+Zhangauthor=M.+Liuauthor=L.+Chenauthor=T.+Huangauthor=Y.+D.+Cai&title=Identification+of+synthetic+lethality+based+on+a+functional+network+by+using+machine+learning+algorithms&doi=10.1002%2Fjcb.27395"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of synthetic lethality based on a functional network by using machine learning algorithms</span></div><div class="casAuthors">Li, JiaRui; Lu, Lin; Zhang, Yu-Hang; Liu, Min; Chen, Lei; Huang, Tao; Cai, Yu-Dong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Biochemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">405-416</span>CODEN:
                <span class="NLM_cas:coden">JCEBD5</span>;
        ISSN:<span class="NLM_cas:issn">0730-2312</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Synthetic lethality is the synthesis of mutations leading to cell death.  Tumor-specific synthetic lethality has been targeted in research to improve cancer therapy.  With the advances of techniques in mol. biol., such as RNAi and CRISPR/Cas9 gene editing, efforts have been made to systematically identify synthetic lethal interactions, esp. for frequently mutated genes in cancers.  However, elucidating the mechanism of synthetic lethality remains a challenge because of the complexity of its influencing conditions.  In this study, we proposed a new computational method to identify crit. functional features that can accurately predict synthetic lethal interactions.  This method incorporates several machine learning algorithms and encodes protein-coding genes by an enrichment system derived from gene ontol. terms and Kyoto Encyclopedia of Genes and Genomes pathways to represent their functional features.  We built a random forest-based prediction engine by using 2120 selected features and obtained a Matthews correlation coeff. of 0.532.  We examd. the top 15 features and found that most of them have potential roles in synthetic lethality according to previous studies.  These results demonstrate the ability of our proposed method to predict synthetic lethal interactions and provide a basis for further characterization of these particular genetic combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIqf6Yn5s8yrVg90H21EOLACvtfcHk0li3HCZWVeHlNA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFequ73E&md5=264fc3080910418aa96659b623b300d4</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1002%2Fjcb.27395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcb.27395%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%2BH.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DCai%26aufirst%3DY.%2BD.%26atitle%3DIdentification%2520of%2520synthetic%2520lethality%2520based%2520on%2520a%2520functional%2520network%2520by%2520using%2520machine%2520learning%2520algorithms%26jtitle%3DJ.%2520Cell.%2520Biochem.%26date%3D2019%26volume%3D120%26issue%3D1%26spage%3D405%26epage%3D416%26doi%3D10.1002%2Fjcb.27395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benstead-Hume, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wooller, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearl, F. M. G.</span></span> <span> </span><span class="NLM_article-title">âBig dataâ approaches for novel anti-cancer drug discovery</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">599</span>â <span class="NLM_lpage">609</span>, <span class="refDoi">Â DOI: 10.1080/17460441.2017.1319356</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1080%2F17460441.2017.1319356" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=28462602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntVaksbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=599-609&issue=6&author=G.+Benstead-Humeauthor=S.+K.+Woollerauthor=F.+M.+G.+Pearl&title=%E2%80%98Big+data%E2%80%99+approaches+for+novel+anti-cancer+drug+discovery&doi=10.1080%2F17460441.2017.1319356"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">'Big data' approaches for novel anti-cancer drug discovery</span></div><div class="casAuthors">Benstead-Hume, Graeme; Wooller, Sarah K.; Pearl, Frances M. G.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">599-609</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  The development of improved cancer therapies is frequently cited as an urgent unmet medical need.  Recent advances in platform technologies and the increasing availability of biol. 'big data' are providing an unparalleled opportunity to systematically identify the key genes and pathways involved in tumorigenesis.  The discoveries made using these new technologies may lead to novel therapeutic interventions.: The authors discuss the current approaches that use 'big data' to identify cancer drivers.  These approaches include the anal. of genomic sequencing data, pathway data, multi-platform data, identifying genetic interactions such as synthetic lethality and using cell line data.  They review how big data is being used to identify novel drug targets.  The authors then provide an overview of the available data repositories and tools being used at the forefront of cancer drug discovery.: Targeted therapies based on the genomic events driving the tumor will eventually inform treatment protocols.  However, using a tailored approach to treat all tumor patients may require developing a large repertoire of targeted drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9PmQgXTfJvrVg90H21EOLACvtfcHk0li3HCZWVeHlNA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntVaksbc%253D&md5=cf1b0f7e3b9eb520a51efd2d81803b12</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1080%2F17460441.2017.1319356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17460441.2017.1319356%26sid%3Dliteratum%253Aachs%26aulast%3DBenstead-Hume%26aufirst%3DG.%26aulast%3DWooller%26aufirst%3DS.%2BK.%26aulast%3DPearl%26aufirst%3DF.%2BM.%2BG.%26atitle%3D%25E2%2580%2598Big%2520data%25E2%2580%2599%2520approaches%2520for%2520novel%2520anti-cancer%2520drug%2520discovery%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2017%26volume%3D12%26issue%3D6%26spage%3D599%26epage%3D609%26doi%3D10.1080%2F17460441.2017.1319356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oughtred, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breitkreutz, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rust, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucher, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolas, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâDonnell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAdam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willems, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulombe-Huntington, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatr-Aryamontri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolinski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyers, M.</span></span> <span> </span><span class="NLM_article-title">The BioGRID interaction database: 2019 update</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>47</i></span> (<span class="NLM_issue">D1</span>),  <span class="NLM_fpage">D529</span>â <span class="NLM_lpage">D541</span>, <span class="refDoi">Â DOI: 10.1093/nar/gky1079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1093%2Fnar%2Fgky1079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=30476227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1GqsbfP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2019&pages=D529-D541&issue=D1&author=R.+Oughtredauthor=C.+Starkauthor=B.+J.+Breitkreutzauthor=J.+Rustauthor=L.+Boucherauthor=C.+Changauthor=N.+Kolasauthor=L.+O%E2%80%99Donnellauthor=G.+Leungauthor=R.+McAdamauthor=F.+Zhangauthor=S.+Dolmaauthor=A.+Willemsauthor=J.+Coulombe-Huntingtonauthor=A.+Chatr-Aryamontriauthor=K.+Dolinskiauthor=M.+Tyers&title=The+BioGRID+interaction+database%3A+2019+update&doi=10.1093%2Fnar%2Fgky1079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">The BioGRID interaction database: 2019 update</span></div><div class="casAuthors">Oughtred, Rose; Stark, Chris; Breitkreutz, Bobby-Joe; Rust, Jennifer; Boucher, Lorrie; Chang, Christie; Kolas, Nadine; O'Donnell, Lara; Leung, Genie; McAdam, Rochelle; Zhang, Frederick; Dolma, Sonam; Willems, Andrew; Coulombe-Huntington, Jasmin; Chatr-aryamontri, Andrew; Dolinski, Kara; Tyers, Mike</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">D1</span>),
    <span class="NLM_cas:pages">D529-D541</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">1362-4962</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The Biol. General Repository for Interaction Datasets is an open access database dedicated to the curation and archival storage of protein, genetic and chem. interactions for all major model organism species and humans.  As of Sept. 2018 (build 3.4.164), BioGRID contains records for 1,598 688 biol. interactions manually annotated from 55,809 publications for 71 species, as classified by an updated set of controlled vocabularies for exptl. detection methods.  BioGRID also houses records for >700, 000 post-translational modification sites.  BioGRID now captures chem. interaction data, including chem.-protein interactions for human drug targets drawn from the DrugBank database and manually curated bioactive compds. reported in the literature.  A new dedicated aspect of BioGRID annotates genome-wide CRISPR/Cas9-based screens that report gene-phenotype and gene-gene relationships.  An extension of the BioGRID resource called the Open Repository for CRISPR Screens (ORCS) database currently contains over 500 genome-wide screens carried out in human or mouse cell lines.  All data in BioGRID is made freely available without restriction, is directly downloadable in std. formats and can be readily incorporated into existing applications via our web service platforms.  BioGRID data are also freely distributed through partner model organism databases and meta-databases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeOLWfYFTAqrVg90H21EOLACvtfcHk0liT_SI8RIutSQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1GqsbfP&md5=c113318699cae700308688e95853c56c</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgky1079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgky1079%26sid%3Dliteratum%253Aachs%26aulast%3DOughtred%26aufirst%3DR.%26aulast%3DStark%26aufirst%3DC.%26aulast%3DBreitkreutz%26aufirst%3DB.%2BJ.%26aulast%3DRust%26aufirst%3DJ.%26aulast%3DBoucher%26aufirst%3DL.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DKolas%26aufirst%3DN.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DL.%26aulast%3DLeung%26aufirst%3DG.%26aulast%3DMcAdam%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DDolma%26aufirst%3DS.%26aulast%3DWillems%26aufirst%3DA.%26aulast%3DCoulombe-Huntington%26aufirst%3DJ.%26aulast%3DChatr-Aryamontri%26aufirst%3DA.%26aulast%3DDolinski%26aufirst%3DK.%26aulast%3DTyers%26aufirst%3DM.%26atitle%3DThe%2520BioGRID%2520interaction%2520database%253A%25202019%2520update%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2019%26volume%3D47%26issue%3DD1%26spage%3DD529%26epage%3DD541%26doi%3D10.1093%2Fnar%2Fgky1079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehebauer, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pukala, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blundell, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkitaraman, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyvonen, M.</span></span> <span> </span><span class="NLM_article-title">Using a fragment-based approach to target protein-protein interactions</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">332</span>â <span class="NLM_lpage">342</span>, <span class="refDoi">Â DOI: 10.1002/cbic.201200521</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1002%2Fcbic.201200521" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=23344974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Gks7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=332-342&issue=3&author=D.+E.+Scottauthor=M.+T.+Ehebauerauthor=T.+Pukalaauthor=M.+Marshauthor=T.+L.+Blundellauthor=A.+R.+Venkitaramanauthor=C.+Abellauthor=M.+Hyvonen&title=Using+a+fragment-based+approach+to+target+protein-protein+interactions&doi=10.1002%2Fcbic.201200521"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Using a Fragment-Based Approach To Target Protein-Protein Interactions</span></div><div class="casAuthors">Scott, Duncan E.; Ehebauer, Matthias T.; Pukala, Tara; Marsh, May; Blundell, Tom L.; Venkitaraman, Ashok R.; Abell, Chris; Hyvoenen, Marko</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">332-342</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The ability to identify inhibitors of protein-protein interactions represents a major challenge in modern drug discovery and in the development of tools for chem. biol.  In recent years, fragment-based approaches have emerged as a new methodol. in drug discovery; however, few examples of small mols. that are active against chemotherapeutic targets have been published.  Herein, we describe the fragment-based approach of targeting the interaction between the tumor suppressor BRCA2 and the recombination enzyme RAD51; it makes use of a screening pipeline of biophys. techniques that we expect to be more generally applicable to similar targets.  Disruption of this interaction in vivo is hypothesised to give rise to cellular hypersensitivity to radiation and genotoxic drugs.  We have used protein engineering to create a monomeric form of RAD51 by humanising a thermostable archaeal orthologue, RadA, and used this protein for fragment screening.  The initial fragment hits were thoroughly validated biophys. by isothermal titrn. calorimetry (ITC) and NMR techniques and obsd. by X-ray crystallog. to bind in a shallow surface pocket that is occupied in the native complex by the side chain of a phenylalanine from the conserved FxxA interaction motif found in BRCA2.  This represents the first report of fragments or any small mol. binding at this protein-protein interaction site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1wXYv8oa-xLVg90H21EOLACvtfcHk0liT_SI8RIutSQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Gks7Y%253D&md5=deca5d3416f3f07e4614007cc76880c9</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201200521&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201200521%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DD.%2BE.%26aulast%3DEhebauer%26aufirst%3DM.%2BT.%26aulast%3DPukala%26aufirst%3DT.%26aulast%3DMarsh%26aufirst%3DM.%26aulast%3DBlundell%26aufirst%3DT.%2BL.%26aulast%3DVenkitaraman%26aufirst%3DA.%2BR.%26aulast%3DAbell%26aufirst%3DC.%26aulast%3DHyvonen%26aufirst%3DM.%26atitle%3DUsing%2520a%2520fragment-based%2520approach%2520to%2520target%2520protein-protein%2520interactions%26jtitle%3DChemBioChem%26date%3D2013%26volume%3D14%26issue%3D3%26spage%3D332%26epage%3D342%26doi%3D10.1002%2Fcbic.201200521" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coyne, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkitaraman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blundell, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyvonen, M.</span></span> <span> </span><span class="NLM_article-title">Small-molecule inhibitors that target protein-protein interactions in the RAD51 family of recombinases</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">296</span>â <span class="NLM_lpage">303</span>, <span class="refDoi">Â DOI: 10.1002/cmdc.201402428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1002%2Fcmdc.201402428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=25470112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVShtr%252FE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=296-303&issue=2&author=D.+E.+Scottauthor=A.+G.+Coyneauthor=A.+Venkitaramanauthor=T.+L.+Blundellauthor=C.+Abellauthor=M.+Hyvonen&title=Small-molecule+inhibitors+that+target+protein-protein+interactions+in+the+RAD51+family+of+recombinases&doi=10.1002%2Fcmdc.201402428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Inhibitors That Target Protein-Protein Interactions in the RAD51 Family of Recombinases</span></div><div class="casAuthors">Scott, Duncan E.; Coyne, Anthony G.; Venkitaraman, Ashok; Blundell, Tom L.; Abell, Chris; Hyvoenen, Marko</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">296-303</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The development of small mols. that inhibit protein-protein interactions continues to be a challenge in chem. biol. and drug discovery.  Herein we report the development of indole-based fragments that bind in a shallow surface pocket of a humanized surrogate of RAD51.  RAD51 is an ATP-dependent recombinase that plays a key role in the repair of double-strand DNA breaks.  It both self-assocs., forming filament structures with DNA, and interacts with the BRCA2 protein through a common "FxxA" tetrapeptide motif.  We elaborated previously identified fragment hits that target the FxxA motif site and developed small-mol. inhibitors that are approx. 500-fold more potent than the initial fragments.  The lead compds. were shown to compete with the BRCA2-derived Ac-FHTA-NH2 peptide and the self-assocn. peptide of RAD51, but they had no effect on ATP binding.  This study is the first reported elaboration of small-mol.-wt. fragments against this challenging target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppzNQlrMDCabVg90H21EOLACvtfcHk0liT_SI8RIutSQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVShtr%252FE&md5=6e08d0758ee37533018de5e1c28ce596</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201402428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201402428%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DD.%2BE.%26aulast%3DCoyne%26aufirst%3DA.%2BG.%26aulast%3DVenkitaraman%26aufirst%3DA.%26aulast%3DBlundell%26aufirst%3DT.%2BL.%26aulast%3DAbell%26aufirst%3DC.%26aulast%3DHyvonen%26aufirst%3DM.%26atitle%3DSmall-molecule%2520inhibitors%2520that%2520target%2520protein-protein%2520interactions%2520in%2520the%2520RAD51%2520family%2520of%2520recombinases%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26issue%3D2%26spage%3D296%26epage%3D303%26doi%3D10.1002%2Fcmdc.201402428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, L.</span></span> <span> </span><span class="NLM_article-title">Synthetic lethality in drug development: the dawn is coming</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">2129</span>â <span class="NLM_lpage">2132</span>, <span class="refDoi">Â DOI: 10.4155/fmc-2018-0227</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.4155%2Ffmc-2018-0227" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=30043635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1entr%252FI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=2129-2132&issue=18&author=S.+Gaoauthor=L.+Lai&title=Synthetic+lethality+in+drug+development%3A+the+dawn+is+coming&doi=10.4155%2Ffmc-2018-0227"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic lethality in drug development: the dawn is coming</span></div><div class="casAuthors">Gao, Shuaishi; Lai, Luhua</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2129-2132</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  This article discuss about the role of synthetic lethality screening for clin. development and discovery of therapeutic drugs and therapeutic solns. for treatment of complex diseases including prostate cancer in human and Drosophila melanogaster model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwWpGIiqNzAbVg90H21EOLACvtfcHk0ljTk7wgzNR4Og"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1entr%252FI&md5=c6ae84ac8f197590f7aec362da2bca98</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.4155%2Ffmc-2018-0227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc-2018-0227%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DS.%26aulast%3DLai%26aufirst%3DL.%26atitle%3DSynthetic%2520lethality%2520in%2520drug%2520development%253A%2520the%2520dawn%2520is%2520coming%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2018%26volume%3D10%26issue%3D18%26spage%3D2129%26epage%3D2132%26doi%3D10.4155%2Ffmc-2018-0227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, W.</span></span> <span> </span><span class="NLM_article-title">Genome-wide CRISPR/Cas9 screening for high-throughput functional genomics in human cells</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>1656</i></span>,  <span class="NLM_fpage">175</span>â <span class="NLM_lpage">181</span>, <span class="refDoi">Â DOI: 10.1007/978-1-4939-7237-1_11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1007%2F978-1-4939-7237-1_11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=28808970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVygtLbL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1656&publication_year=2017&pages=175-181&author=S.+Zhuauthor=Y.+Zhouauthor=W.+Wei&title=Genome-wide+CRISPR%2FCas9+screening+for+high-throughput+functional+genomics+in+human+cells&doi=10.1007%2F978-1-4939-7237-1_11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Genome-wide CRISPR/Cas9 screening for high-throughput functional genomics in human cells</span></div><div class="casAuthors">Zhu, Shiyou; Zhou, Yuexin; Wei, Wensheng</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">1656</span>
        (<span class="NLM_cas:issue">Innate Antiviral Immunity</span>),
    <span class="NLM_cas:pages">175-181</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1940-6029</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">It is highly desirable to identify gene's function in a high-throughput fashion, and the CRISPR/Cas9 system has been harnessed to meet such a need.  Here, we describe a general method to generate genome-scale lentiviral single-guide RNA (sgRNA) library and conduct a pooled function-based screening in human cells.  This protocol would be of interest to researchers to rapidly identify genes in a variety of biol. processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrE_GA6Br0tRrVg90H21EOLACvtfcHk0ljTk7wgzNR4Og"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVygtLbL&md5=789bbde3f991fc30c9ed5f48e9240de1</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-7237-1_11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4939-7237-1_11%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DWei%26aufirst%3DW.%26atitle%3DGenome-wide%2520CRISPR%252FCas9%2520screening%2520for%2520high-throughput%2520functional%2520genomics%2520in%2520human%2520cells%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2017%26volume%3D1656%26spage%3D175%26epage%3D181%26doi%3D10.1007%2F978-1-4939-7237-1_11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref187"><div class="reference"><strong class="refLabel"><a href="#ref187" class="rightTabRefNumLink">187</a></strong><div class="NLM_citation" id="rightTab-cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navone, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">2451</span>â <span class="NLM_lpage">2463</span>, <span class="refDoi">Â DOI: 10.1038/s41388-018-0606-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1038%2Fs41388-018-0606-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=30532030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVKqtbzK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2019&pages=2451-2463&issue=14&author=C.+Wangauthor=G.+Wangauthor=X.+Fengauthor=P.+Shepherdauthor=J.+Zhangauthor=M.+Tangauthor=Z.+Chenauthor=M.+Srivastavaauthor=M.+E.+McLaughlinauthor=N.+M.+Navoneauthor=G.+T.+Hartauthor=J.+Chen&title=Genome-wide+CRISPR+screens+reveal+synthetic+lethality+of+RNASEH2+deficiency+and+ATR+inhibition&doi=10.1038%2Fs41388-018-0606-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition</span></div><div class="casAuthors">Wang, Chao; Wang, Gang; Feng, Xu; Shepherd, Peter; Zhang, Jie; Tang, Mengfan; Chen, Zhen; Srivastava, Mrinal; McLaughlin, Megan E.; Navone, Nora M.; Hart, Glen Traver; Chen, Junjie</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2451-2463</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Ataxia telangiectasia mutated and RAD3 related (ATR) protein kinase plays crit. roles in ensuring DNA replication, DNA repair, and cell cycle control in response to replication stress, making ATR inhibition a promising therapeutic strategy for cancer treatment.  To identify genes whose loss makes tumor cells hypersensitive to ATR inhibition, we performed CRISPR/Cas9-based whole-genome screens in 3 independent cell lines treated with a highly selective ATR inhibitor, AZD6738.  These screens uncovered a comprehensive genome-wide profile of ATR inhibitor sensitivity.  From the candidate genes, we demonstrated that RNASEH2 deficiency is synthetic lethal with ATR inhibition both in vitro and in vivo.  RNASEH2-deficient cells exhibited elevated levels of DNA damage and, when treated with AZD6738, underwent apoptosis (short-time treated) or senescence (long-time treated).  Notably, RNASEH2 deficiency is frequently found in prostate adenocarcinoma; we found decreased RNASEH2B protein levels in prostate adenocarcinoma patient-derived xenograft (PDX) samples.  Our findings suggest that ATR inhibition may be beneficial for cancer patients with reduced levels of RNASEH2 and that RNASEH2 merits further exploration as a potential biomarker for ATR inhibitor-based therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7pP6ZnD1nMrVg90H21EOLACvtfcHk0ljTk7wgzNR4Og"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVKqtbzK&md5=3007fcb24e0eef9c0155d4ec8f68558a</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1038%2Fs41388-018-0606-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41388-018-0606-4%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DFeng%26aufirst%3DX.%26aulast%3DShepherd%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DSrivastava%26aufirst%3DM.%26aulast%3DMcLaughlin%26aufirst%3DM.%2BE.%26aulast%3DNavone%26aufirst%3DN.%2BM.%26aulast%3DHart%26aufirst%3DG.%2BT.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DGenome-wide%2520CRISPR%2520screens%2520reveal%2520synthetic%2520lethality%2520of%2520RNASEH2%2520deficiency%2520and%2520ATR%2520inhibition%26jtitle%3DOncogene%26date%3D2019%26volume%3D38%26issue%3D14%26spage%3D2451%26epage%3D2463%26doi%3D10.1038%2Fs41388-018-0606-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref188"><div class="reference"><strong class="refLabel"><a href="#ref188" class="rightTabRefNumLink">188</a></strong><div class="NLM_citation" id="rightTab-cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stadtmauer, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraietta, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lancaster, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangan, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulikovskaya, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, I.-y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melenhorst, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plesa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shea, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matlawski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaymon, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desjardins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamontagne, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salas-Mckee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fesnak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jadlowsky, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chew, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, W.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hexner, E. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreno, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nobles, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bushman, F. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satpathy, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacey, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">June, C. H.</span></span> <span> </span><span class="NLM_article-title">CRISPR-engineered T cells in patients with refractory cancer</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>367</i></span> (<span class="NLM_issue">6481</span>), <span class="NLM_elocation-id">eaba7365</span> <span class="refDoi">Â DOI: 10.1126/science.aba7365</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1126%2Fscience.aba7365" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=32029687" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2020&issue=6481&author=E.+A.+Stadtmauerauthor=J.+A.+Fraiettaauthor=M.+M.+Davisauthor=A.+D.+Cohenauthor=K.+L.+Weberauthor=E.+Lancasterauthor=P.+A.+Manganauthor=I.+Kulikovskayaauthor=M.+Guptaauthor=F.+Chenauthor=L.+Tianauthor=V.+E.+Gonzalezauthor=J.+Xuauthor=I.-y.+Jungauthor=J.+J.+Melenhorstauthor=G.+Plesaauthor=J.+Sheaauthor=T.+Matlawskiauthor=A.+Cerviniauthor=A.+L.+Gaymonauthor=S.+Desjardinsauthor=A.+Lamontagneauthor=J.+Salas-Mckeeauthor=A.+Fesnakauthor=D.+L.+Siegelauthor=B.+L.+Levineauthor=J.+K.+Jadlowskyauthor=R.+M.+Youngauthor=A.+Chewauthor=W.-T.+Hwangauthor=E.+O.+Hexnerauthor=B.+M.+Carrenoauthor=C.+L.+Noblesauthor=F.+D.+Bushmanauthor=K.+R.+Parkerauthor=Y.+Qiauthor=A.+T.+Satpathyauthor=H.+Y.+Changauthor=Y.+Zhaoauthor=S.+F.+Laceyauthor=C.+H.+June&title=CRISPR-engineered+T+cells+in+patients+with+refractory+cancer&doi=10.1126%2Fscience.aba7365"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1126%2Fscience.aba7365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aba7365%26sid%3Dliteratum%253Aachs%26aulast%3DStadtmauer%26aufirst%3DE.%2BA.%26aulast%3DFraietta%26aufirst%3DJ.%2BA.%26aulast%3DDavis%26aufirst%3DM.%2BM.%26aulast%3DCohen%26aufirst%3DA.%2BD.%26aulast%3DWeber%26aufirst%3DK.%2BL.%26aulast%3DLancaster%26aufirst%3DE.%26aulast%3DMangan%26aufirst%3DP.%2BA.%26aulast%3DKulikovskaya%26aufirst%3DI.%26aulast%3DGupta%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DTian%26aufirst%3DL.%26aulast%3DGonzalez%26aufirst%3DV.%2BE.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DJung%26aufirst%3DI.-y.%26aulast%3DMelenhorst%26aufirst%3DJ.%2BJ.%26aulast%3DPlesa%26aufirst%3DG.%26aulast%3DShea%26aufirst%3DJ.%26aulast%3DMatlawski%26aufirst%3DT.%26aulast%3DCervini%26aufirst%3DA.%26aulast%3DGaymon%26aufirst%3DA.%2BL.%26aulast%3DDesjardins%26aufirst%3DS.%26aulast%3DLamontagne%26aufirst%3DA.%26aulast%3DSalas-Mckee%26aufirst%3DJ.%26aulast%3DFesnak%26aufirst%3DA.%26aulast%3DSiegel%26aufirst%3DD.%2BL.%26aulast%3DLevine%26aufirst%3DB.%2BL.%26aulast%3DJadlowsky%26aufirst%3DJ.%2BK.%26aulast%3DYoung%26aufirst%3DR.%2BM.%26aulast%3DChew%26aufirst%3DA.%26aulast%3DHwang%26aufirst%3DW.-T.%26aulast%3DHexner%26aufirst%3DE.%2BO.%26aulast%3DCarreno%26aufirst%3DB.%2BM.%26aulast%3DNobles%26aufirst%3DC.%2BL.%26aulast%3DBushman%26aufirst%3DF.%2BD.%26aulast%3DParker%26aufirst%3DK.%2BR.%26aulast%3DQi%26aufirst%3DY.%26aulast%3DSatpathy%26aufirst%3DA.%2BT.%26aulast%3DChang%26aufirst%3DH.%2BY.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DLacey%26aufirst%3DS.%2BF.%26aulast%3DJune%26aufirst%3DC.%2BH.%26atitle%3DCRISPR-engineered%2520T%2520cells%2520in%2520patients%2520with%2520refractory%2520cancer%26jtitle%3DScience%26date%3D2020%26volume%3D367%26issue%3D6481%26doi%3D10.1126%2Fscience.aba7365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref189"><div class="reference"><strong class="refLabel"><a href="#ref189" class="rightTabRefNumLink">189</a></strong><div class="NLM_citation" id="rightTab-cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LiÃ¨vre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachet, J.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Corre, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boige, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emile, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">CÃ´tÃ©, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomasic, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penna, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ducreux, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rougier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penault-Llorca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurent-Puig, P.</span></span> <span> </span><span class="NLM_article-title">KRAS mutation status is predictive of response to Cetuximab therapy in colorectal cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">3992</span>â <span class="NLM_lpage">3995</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-06-0191</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F0008-5472.CAN-06-0191" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=16618717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD28XjsFSlsb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=3992-3995&issue=8&author=A.+Li%C3%A8vreauthor=J.-B.+Bachetauthor=D.+Le+Correauthor=V.+Boigeauthor=B.+Landiauthor=J.-F.+Emileauthor=J.-F.+C%C3%B4t%C3%A9author=G.+Tomasicauthor=C.+Pennaauthor=M.+Ducreuxauthor=P.+Rougierauthor=F.+Penault-Llorcaauthor=P.+Laurent-Puig&title=KRAS+mutation+status+is+predictive+of+response+to+Cetuximab+therapy+in+colorectal+cancer&doi=10.1158%2F0008-5472.CAN-06-0191"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer</span></div><div class="casAuthors">Lievre, Astrid; Bachet, Jean-Baptiste; Le Corre, Delphine; Boige, Valerie; Landi, Bruno; Emile, Jean-Francois; Cote, Jean-Francois; Tomasic, Gorana; Penna, Christophe; Ducreux, Michel; Rougier, Philippe; Penault-Llorca, Frederique; Laurent-Puig, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3992-3995</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The anti-epidermal growth factor receptor (anti-EGFR) cetuximab has been proven to be efficient in metastatic colorectal cancer.  The mol. mechanisms underlying the clin. response to this drug remain unknown.  Genetic alterations of the intracellular effectors involved in EGFR-related signaling pathways may have an effect on response to this targeted therapy.  In this study, tumors from 30 metastatic colorectal cancer patients treated by cetuximab were screened for KRAS, BRAF, and PIK3CA mutation by direct sequencing and for EGFR copy no. by chromogenic in situ hybridization.  Eleven of the 30 patients (37%) responded to cetuximab.  A KRAS mutation was found in 13 tumors (43%) and was significantly assocd. with the absence of response to cetuximab (KRAS mutation in 0% of the 11 responder patients vs. 68.4% of the 19 nonresponder patients; P = 0.0003).  The overall survival of patients without KRAS mutation in their tumor was significantly higher compared with those patients with a mutated tumor (P = 0.016; median, 16.3 vs. 6.9 mo).  An increased EGFR copy no. was found in 3 patients (10%) and was significantly assocd. with an objective tumor response to cetuximab (P = 0.04).  In conclusion, in this study, KRAS mutations are a predictor of resistance to cetuximab therapy and are assocd. with a worse prognosis.  The EGFR amplification, which is not as frequent as initially reported, is also assocd. with response to this treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpS9KZkED-vf7Vg90H21EOLACvtfcHk0lirPJiIHh6icw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjsFSlsb0%253D&md5=f34ea7f50a0be481474624bc494aa9dd</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-0191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-0191%26sid%3Dliteratum%253Aachs%26aulast%3DLi%25C3%25A8vre%26aufirst%3DA.%26aulast%3DBachet%26aufirst%3DJ.-B.%26aulast%3DLe%2BCorre%26aufirst%3DD.%26aulast%3DBoige%26aufirst%3DV.%26aulast%3DLandi%26aufirst%3DB.%26aulast%3DEmile%26aufirst%3DJ.-F.%26aulast%3DC%25C3%25B4t%25C3%25A9%26aufirst%3DJ.-F.%26aulast%3DTomasic%26aufirst%3DG.%26aulast%3DPenna%26aufirst%3DC.%26aulast%3DDucreux%26aufirst%3DM.%26aulast%3DRougier%26aufirst%3DP.%26aulast%3DPenault-Llorca%26aufirst%3DF.%26aulast%3DLaurent-Puig%26aufirst%3DP.%26atitle%3DKRAS%2520mutation%2520status%2520is%2520predictive%2520of%2520response%2520to%2520Cetuximab%2520therapy%2520in%2520colorectal%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26issue%3D8%26spage%3D3992%26epage%3D3995%26doi%3D10.1158%2F0008-5472.CAN-06-0191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref190"><div class="reference"><strong class="refLabel"><a href="#ref190" class="rightTabRefNumLink">190</a></strong><div class="NLM_citation" id="rightTab-cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shiomi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuji, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tateishi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaizumi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiomi, T.</span></span> <span> </span><span class="NLM_article-title">Human RAD18 is involved in S phase-specific single-strand break repair without PCNA monoubiquitination</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">2</span>), <span class="NLM_elocation-id">e9</span> <span class="refDoi">Â DOI: 10.1093/nar/gkl979</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1093%2Fnar%2Fgkl979" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=17158148" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2006&issue=2&author=N.+Shiomiauthor=M.+Moriauthor=H.+Tsujiauthor=T.+Imaiauthor=H.+Inoueauthor=S.+Tateishiauthor=M.+Yamaizumiauthor=T.+Shiomi&title=Human+RAD18+is+involved+in+S+phase-specific+single-strand+break+repair+without+PCNA+monoubiquitination&doi=10.1093%2Fnar%2Fgkl979"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkl979&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkl979%26sid%3Dliteratum%253Aachs%26aulast%3DShiomi%26aufirst%3DN.%26aulast%3DMori%26aufirst%3DM.%26aulast%3DTsuji%26aufirst%3DH.%26aulast%3DImai%26aufirst%3DT.%26aulast%3DInoue%26aufirst%3DH.%26aulast%3DTateishi%26aufirst%3DS.%26aulast%3DYamaizumi%26aufirst%3DM.%26aulast%3DShiomi%26aufirst%3DT.%26atitle%3DHuman%2520RAD18%2520is%2520involved%2520in%2520S%2520phase-specific%2520single-strand%2520break%2520repair%2520without%2520PCNA%2520monoubiquitination%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2006%26volume%3D35%26issue%3D2%26doi%3D10.1093%2Fnar%2Fgkl979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref191"><div class="reference"><strong class="refLabel"><a href="#ref191" class="rightTabRefNumLink">191</a></strong><div class="NLM_citation" id="rightTab-cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawauchi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchida, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasukawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conaway, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conaway, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aso, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitajima, S.</span></span> <span> </span><span class="NLM_article-title">Transcriptional properties of mammalian elongin A and its role in stress response</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>288</i></span> (<span class="NLM_issue">34</span>),  <span class="NLM_fpage">24302</span>â <span class="NLM_lpage">24315</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M113.496703</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1074%2Fjbc.M113.496703" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=23828199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlarsr%252FM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=24302-24315&issue=34&author=J.+Kawauchiauthor=M.+Inoueauthor=M.+Fukudaauthor=Y.+Uchidaauthor=T.+Yasukawaauthor=R.+C.+Conawayauthor=J.+W.+Conawayauthor=T.+Asoauthor=S.+Kitajima&title=Transcriptional+properties+of+mammalian+elongin+A+and+its+role+in+stress+response&doi=10.1074%2Fjbc.M113.496703"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Transcriptional Properties of Mammalian Elongin A and Its Role in Stress Response</span></div><div class="casAuthors">Kawauchi, Junya; Inoue, Makoto; Fukuda, Mizue; Uchida, Yohei; Yasukawa, Takashi; Conaway, Ronald C.; Conaway, Joan W.; Aso, Teijiro; Kitajima, Shigetaka</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">24302-24315</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Elongin A was shown previously to be capable of potently activating the rate of RNA polymerase II (RNAPII) transcription elongation in vitro by suppressing transient pausing by the enzyme at many sites along DNA templates.  The role of Elongin A in RNAPII transcription in mammalian cells, however, has not been clearly established.  In this report, we investigate the function of Elongin A in RNAPII transcription.  We present evidence that Elongin A assocs. with the IIO form of RNAPII at sites of newly transcribed RNA and is relocated to dotlike domains distinct from those contg. RNAPII when cells are treated with the kinase inhibitor 5,6-dichloro-1-Î²-Î´-ribofuranosylbenzimidazole.  Significantly, Elongin A is required for maximal induction of transcription of the stress response genes ATF3 and p21 in response to several stimuli.  Evidence from structure-function studies argues that Elongin A transcription elongation activity, but not its ubiquitination activity, is most important for its function in induction of transcription of ATF3 and p21.  Taken together, our data provide new insights into the function of Elongin A in RNAPII transcription and bring to light a previously unrecognized role for Elongin A in the regulation of stress response genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolU6NWPn2xb7Vg90H21EOLACvtfcHk0lhsRMAj05n2dQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlarsr%252FM&md5=847e65efaf35307e86dd7cb0eca12358</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M113.496703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M113.496703%26sid%3Dliteratum%253Aachs%26aulast%3DKawauchi%26aufirst%3DJ.%26aulast%3DInoue%26aufirst%3DM.%26aulast%3DFukuda%26aufirst%3DM.%26aulast%3DUchida%26aufirst%3DY.%26aulast%3DYasukawa%26aufirst%3DT.%26aulast%3DConaway%26aufirst%3DR.%2BC.%26aulast%3DConaway%26aufirst%3DJ.%2BW.%26aulast%3DAso%26aufirst%3DT.%26aulast%3DKitajima%26aufirst%3DS.%26atitle%3DTranscriptional%2520properties%2520of%2520mammalian%2520elongin%2520A%2520and%2520its%2520role%2520in%2520stress%2520response%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26issue%3D34%26spage%3D24302%26epage%3D24315%26doi%3D10.1074%2Fjbc.M113.496703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref192"><div class="reference"><strong class="refLabel"><a href="#ref192" class="rightTabRefNumLink">192</a></strong><div class="NLM_citation" id="rightTab-cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zofall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grewal, S. I.</span></span> <span> </span><span class="NLM_article-title">HULC, a histone H2B ubiquitinating complex, modulates heterochromatin independent of histone methylation in fission yeast</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>282</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">14065</span>â <span class="NLM_lpage">14072</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M700292200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1074%2Fjbc.M700292200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=17363370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkvVygu7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=14065-14072&issue=19&author=M.+Zofallauthor=S.+I.+Grewal&title=HULC%2C+a+histone+H2B+ubiquitinating+complex%2C+modulates+heterochromatin+independent+of+histone+methylation+in+fission+yeast&doi=10.1074%2Fjbc.M700292200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">HULC, a Histone H2B Ubiquitinating Complex, Modulates Heterochromatin Independent of Histone Methylation in Fission Yeast</span></div><div class="casAuthors">Zofall, Martin; Grewal, Shiv I. S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">282</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">14065-14072</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Heterochromatin in fission yeast is targeted dynamically by opposing chromatin-modifying activities capable of alleviating or promoting transcriptional gene silencing.  In this study, we report the biochem. and genetic characterization of a ubiquitin-conjugating enzyme Rhp6 (a homolog of budding yeast Rad6), which has been shown to neg. affect stability of heterochromatic structures.  We show that Rhp6 is a component of the multisubunit protein complex (termed HULC) that also contains two RING finger proteins Rfp1 and Rfp2, sharing homol. with budding yeast Bre1 protein and a unique serine-rich protein Shf1.  HULC is required for ubiquitination of histone H2B at lysine 119 (H2B-K119), and it localizes to heterochromatic sequences.  Moreover, our analyses suggest that Rhp6-induced changes in heterochromatic silencing are mediated predominantly through H2B ubiquitination (ubH2B), and they correlate with increased RNA polymerase II levels at repeat elements embedded within heterochromatin domains.  Interestingly, heterochromatic derepression caused by Rhp6 occurs independently of the involvement of HULC subunits and ubH2B in methylation of histone H3 at lysine 4 (H3K4me).  These analyses implicate ubH2B in modulation of heterochromatin, which has important implications for dynamics and many functions assocd. with heterochromatic structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqraOlKCKZKjLVg90H21EOLACvtfcHk0lhsRMAj05n2dQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkvVygu7c%253D&md5=64a81c877ab14b353dfab64d26f318a3</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M700292200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M700292200%26sid%3Dliteratum%253Aachs%26aulast%3DZofall%26aufirst%3DM.%26aulast%3DGrewal%26aufirst%3DS.%2BI.%26atitle%3DHULC%252C%2520a%2520histone%2520H2B%2520ubiquitinating%2520complex%252C%2520modulates%2520heterochromatin%2520independent%2520of%2520histone%2520methylation%2520in%2520fission%2520yeast%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26issue%3D19%26spage%3D14065%26epage%3D14072%26doi%3D10.1074%2Fjbc.M700292200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref193"><div class="reference"><strong class="refLabel"><a href="#ref193" class="rightTabRefNumLink">193</a></strong><div class="NLM_citation" id="rightTab-cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cencic, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ertel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roulston, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvius, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shore, G. C.</span></span> <span> </span><span class="NLM_article-title">Obatoclax is a direct and potent antagonist of membrane-restricted Mcl-1 and is synthetic lethal with treatment that induces Bim</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">568</span>, <span class="refDoi">Â DOI: 10.1186/s12885-015-1582-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1186%2Fs12885-015-1582-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=26231047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FpsFKhsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=568&author=M.+Nguyenauthor=R.+Cencicauthor=F.+Ertelauthor=C.+Bernierauthor=J.+Pelletierauthor=A.+Roulstonauthor=J.+R.+Silviusauthor=G.+C.+Shore&title=Obatoclax+is+a+direct+and+potent+antagonist+of+membrane-restricted+Mcl-1+and+is+synthetic+lethal+with+treatment+that+induces+Bim&doi=10.1186%2Fs12885-015-1582-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Obatoclax is a direct and potent antagonist of membrane-restricted Mcl-1 and is synthetic lethal with treatment that induces Bim</span></div><div class="casAuthors">Nguyen Mai; Cencic Regina; Ertel Franziska; Pelletier Jerry; Silvius John R; Shore Gordon C; Bernier Cynthia; Pelletier Jerry; Roulston Anne; Shore Gordon C</div><div class="citationInfo"><span class="NLM_cas:title">BMC cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">568</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Obatoclax is a clinical stage drug candidate that has been proposed to target and inhibit prosurvival members of the Bcl-2 family, and thereby contribute to cancer cell lethality.  The insolubility of this compound, however, has precluded the use of many classical drug-target interaction assays for its study.  Thus, a direct demonstration of the proposed mechanism of action, and preferences for individual Bcl-2 family members, remain to be established.  METHODS:  Employing modified proteins and lipids, we recapitulated the constitutive association and topology of mitochondrial outer membrane Mcl-1 and Bak in synthetic large unilamellar liposomes, and measured bakdependent bilayer permeability.  Additionally, cellular and tumor models, dependent on Mcl-1 for survival, were employed.  RESULTS:  We show that regulation of bilayer permeabilization by the tBid - Mcl-1 - Bak axis closely resemblesthe tBid - Bcl-XL - Bax model.  Obatoclax rapidly and completely partitioned into liposomal lipid but also rapidly exchanged between liposome particles.  In this system, obatoclax was found to be a direct and potent antagonist of liposome-bound Mcl-1 but not of liposome-bound Bcl-XL, and did not directly influence Bak.  A 2.5 molar excess of obatoclax relative to Mcl-1 overcame Mcl-1-mediated inhibition of tBid-Bak activation.  Similar results were found for induction of Bak oligomers by Bim.  Obatoclax exhibited potent lethality in a cellmodel dependent on Mcl-1 for viability but not in cells dependent on Bcl-XL.  Molecular modeling predicts that the 3-methoxy moiety of obatoclax penetrates into the P2 pocket of the BH3 binding site of Mcl-1.  A desmethoxy derivative of obatoclax failed to inhibit Mcl-1 in proteoliposomes and did not kill cells whose survival depends on Mcl-1.  Systemic treatment of mice bearing Tsc2(+) (/) (-) Em-myc lymphomas (whose cells depend on Mcl-1 for survival) with obatoclax conferred a survival advantage compared to vehicle alone (median 31 days vs 22 days, respectively; p=0.003).  In an Akt-lymphoma mouse model, the anti-tumor effects of obatoclax synergized with doxorubicin.  Finally, treatment of the multiple myeloma KMS11 cell model (dependent on Mcl-1 for survival) with dexamethasone induced Bim and Bim-dependent lethality.  As predicted for an Mcl-1 antagonist, obatoclax and dexamethasone were synergistic in this model.  CONCLUSIONS:  Taken together, these findings indicate that obatoclax is a potent antagonist of membranerestricted Mcl-1.  Obatoclax represents an attractive chemical series to generate second generation Mcl-1 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRDceLtzp7_yGlSCSgBhwJFfW6udTcc2eYNhRWDKWNaV7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FpsFKhsg%253D%253D&md5=9e8ac00d7bcf310fed6489fcf841e245</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1186%2Fs12885-015-1582-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12885-015-1582-5%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DM.%26aulast%3DCencic%26aufirst%3DR.%26aulast%3DErtel%26aufirst%3DF.%26aulast%3DBernier%26aufirst%3DC.%26aulast%3DPelletier%26aufirst%3DJ.%26aulast%3DRoulston%26aufirst%3DA.%26aulast%3DSilvius%26aufirst%3DJ.%2BR.%26aulast%3DShore%26aufirst%3DG.%2BC.%26atitle%3DObatoclax%2520is%2520a%2520direct%2520and%2520potent%2520antagonist%2520of%2520membrane-restricted%2520Mcl-1%2520and%2520is%2520synthetic%2520lethal%2520with%2520treatment%2520that%2520induces%2520Bim%26jtitle%3DBMC%2520Cancer%26date%3D2015%26volume%3D15%26spage%3D568%26doi%3D10.1186%2Fs12885-015-1582-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref194"><div class="reference"><strong class="refLabel"><a href="#ref194" class="rightTabRefNumLink">194</a></strong><div class="NLM_citation" id="rightTab-cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Freije, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraile, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Otin, C.</span></span> <span> </span><span class="NLM_article-title">Protease addiction and synthetic lethality in cancer</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">25</span>, <span class="refDoi">Â DOI: 10.3389/fonc.2011.00025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.3389%2Ffonc.2011.00025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=22655236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A280%3ADC%252BC38notFWgsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2011&pages=25&author=J.+M.+Freijeauthor=J.+M.+Fraileauthor=C.+Lopez-Otin&title=Protease+addiction+and+synthetic+lethality+in+cancer&doi=10.3389%2Ffonc.2011.00025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Protease addiction and synthetic lethality in cancer</span></div><div class="casAuthors">Freije Jose M P; Fraile Julia M; Lopez-Otin Carlos</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">25</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The "oncogene addiction" concept refers to the dependence of cancer cells on the function of the oncogenes responsible for their transformed phenotype, while the term "non-oncogene addiction" has been introduced to define the exacerbated necessity of the normal function of non-mutated genes.  In this Perspective, we focus on the importance of proteolytic enzymes to maintain the viability of cancer cells and hypothesize that most, if not all, tumors present "addiction" to a number of proteolytic activities, which in turn may represent valuable targets of anti-cancer therapies, even without being mutated or over-expressed by the malignant cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQGOjJJch7csyCEBeYuoi7AfW6udTcc2eYNhRWDKWNaV7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38notFWgsQ%253D%253D&md5=c7638722f1588919cde3972f6ae4b48f</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2011.00025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2011.00025%26sid%3Dliteratum%253Aachs%26aulast%3DFreije%26aufirst%3DJ.%2BM.%26aulast%3DFraile%26aufirst%3DJ.%2BM.%26aulast%3DLopez-Otin%26aufirst%3DC.%26atitle%3DProtease%2520addiction%2520and%2520synthetic%2520lethality%2520in%2520cancer%26jtitle%3DFront.%2520Oncol.%26date%3D2011%26volume%3D1%26spage%3D25%26doi%3D10.3389%2Ffonc.2011.00025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref195"><div class="reference"><strong class="refLabel"><a href="#ref195" class="rightTabRefNumLink">195</a></strong><div class="NLM_citation" id="rightTab-cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buono, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paez-Valencia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spalding, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otegui, M. S.</span></span> <span> </span><span class="NLM_article-title">Role of SKD1 regulators LIP5 and IST1-LIKE1 in endosomal sorting and plant development</span>. <i>Plant Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>171</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">251</span>â <span class="NLM_lpage">264</span>, <span class="refDoi">Â DOI: 10.1104/pp.16.00240</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1104%2Fpp.16.00240" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=26983994" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslChsrjI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2016&pages=251-264&issue=1&author=R.+A.+Buonoauthor=J.+Paez-Valenciaauthor=N.+D.+Millerauthor=K.+Goodmanauthor=C.+Spitzerauthor=E.+P.+Spaldingauthor=M.+S.+Otegui&title=Role+of+SKD1+regulators+LIP5+and+IST1-LIKE1+in+endosomal+sorting+and+plant+development&doi=10.1104%2Fpp.16.00240"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Role of SKD1 regulators LIP5 and IST1-LIKE1 in endosomal sorting and plant development1[OPEN]</span></div><div class="casAuthors">Buono, Rafael Andrade; Paez-Valencia, Julio; Miller, Nathan D.; Goodman, Kaija; Spitzer, Christoph; Spalding, Edgar P.; Otegui, Marisa S.</div><div class="citationInfo"><span class="NLM_cas:title">Plant Physiology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">251-264</span>CODEN:
                <span class="NLM_cas:coden">PLPHAY</span>;
        ISSN:<span class="NLM_cas:issn">1532-2548</span>.
    
            (<span class="NLM_cas:orgname">American Society of Plant Biologists</span>)
        </div><div class="casAbstract">SKD1 is a core component of the mechanism that degrades plasma membrane proteins via the Endosomal Sorting Complex Required for Transport (ESCRT) pathway.  Its ATPase activity and endosomal recruitment are regulated by the ESCRT components LIP5 and IST1.  How LIP5 and IST1 affect ESCRT-mediated endosomal trafficking and development in plants is not known.  Here we use Arabidopsis mutants to demonstrate that LIP5 controls the constitutive degrdn. of plasma membrane proteins and the formation of endosomal intraluminal vesicles.  Although lip5 mutants were able to polarize the auxin efflux facilitators PIN2 and PIN3, both proteins were mis-sorted to the tonoplast in lip5 root cells.  In addn., lip5 root cells over-accumulated PIN2 at the plasma membrane.  Consistently with the trafficking defects of PIN proteins, the lip5 roots showed abnormal gravitropism with an enhanced response within the first 4 h after gravistimulation.  LIP5 phys. interacts with IST1-LIKE1 (ISTL1), a protein predicted to be the Arabidopsis homolog of yeast IST1.  However, we found that Arabidopsis contains 12 genes coding for predicted IST1-domain contg. proteins (ISTL1-12).  Within the ISTL1-6 group, ISTL1 showed the strongest interaction with LIP5, SKD1, and the ESCRT-III-related proteins CHMP1A in yeast two hybrid assays.  Through the anal. of single and double mutants, we found that the synthetic interaction of LIP5 with ISTL1, but not with ISTL2, 3, or 6, is essential for normal plant growth, repression of spontaneous cell death, and post-embryonic lethality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJn7O_VlyAO7Vg90H21EOLACvtfcHk0lh6U9ecwToyjQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslChsrjI&md5=3dcd874baf8c0a9cf054cd8e9f214158</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1104%2Fpp.16.00240&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1104%252Fpp.16.00240%26sid%3Dliteratum%253Aachs%26aulast%3DBuono%26aufirst%3DR.%2BA.%26aulast%3DPaez-Valencia%26aufirst%3DJ.%26aulast%3DMiller%26aufirst%3DN.%2BD.%26aulast%3DGoodman%26aufirst%3DK.%26aulast%3DSpitzer%26aufirst%3DC.%26aulast%3DSpalding%26aufirst%3DE.%2BP.%26aulast%3DOtegui%26aufirst%3DM.%2BS.%26atitle%3DRole%2520of%2520SKD1%2520regulators%2520LIP5%2520and%2520IST1-LIKE1%2520in%2520endosomal%2520sorting%2520and%2520plant%2520development%26jtitle%3DPlant%2520Physiol.%26date%3D2016%26volume%3D171%26issue%3D1%26spage%3D251%26epage%3D264%26doi%3D10.1104%2Fpp.16.00240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref196"><div class="reference"><strong class="refLabel"><a href="#ref196" class="rightTabRefNumLink">196</a></strong><div class="NLM_citation" id="rightTab-cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hardin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, R. S.</span></span> <span> </span><span class="NLM_article-title">The long and the short of Wnt signaling in C. elegans</span>. <i>Curr. Opin. Genet. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">362</span>â <span class="NLM_lpage">367</span>, <span class="refDoi">Â DOI: 10.1016/j.gde.2008.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.gde.2008.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=18625312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1KmtbfF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=362-367&issue=4&author=J.+Hardinauthor=R.+S.+King&title=The+long+and+the+short+of+Wnt+signaling+in+C.+elegans&doi=10.1016%2Fj.gde.2008.06.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">The long and the short of Wnt signaling in C. elegans</span></div><div class="casAuthors">Hardin, Jeff; King, Ryan S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Genetics & Development</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">362-367</span>CODEN:
                <span class="NLM_cas:coden">COGDET</span>;
        ISSN:<span class="NLM_cas:issn">0959-437X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The simplicity of Caenorhabditis elegans makes it an outstanding system to study the role of Wnt signaling in development.  Many asym. cell divisions in C. elegans require the Wnt/Î²-catenin asymmetry pathway.  Recent studies confirm that SYS-1 is a structurally and functionally divergent Î²-catenin, and implicate lipids and retrograde trafficking in maintenance of WRM-1/Î²-catenin asymmetry.  Wnts also regulate short-range events such as spindle rotation and gastrulation, and a PCP-like pathway regulates asym. divisions.  Long-range, cell non-autonomous Wnt signals regulate vulval induction.  Both short-range and long-range Wnt signals are regulated by recycling of MIG-14/Wntless via the retromer complex.  These studies indicate that C. elegans continues to be useful for identifying new, conserved mechanisms underlying Wnt signaling in metazoans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB2CTQvx3SI7Vg90H21EOLACvtfcHk0lh6U9ecwToyjQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1KmtbfF&md5=886af4022ffd5aeee035959e8fb2f25a</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1016%2Fj.gde.2008.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gde.2008.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DHardin%26aufirst%3DJ.%26aulast%3DKing%26aufirst%3DR.%2BS.%26atitle%3DThe%2520long%2520and%2520the%2520short%2520of%2520Wnt%2520signaling%2520in%2520C.%2520elegans%26jtitle%3DCurr.%2520Opin.%2520Genet.%2520Dev.%26date%3D2008%26volume%3D18%26issue%3D4%26spage%3D362%26epage%3D367%26doi%3D10.1016%2Fj.gde.2008.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref197"><div class="reference"><strong class="refLabel"><a href="#ref197" class="rightTabRefNumLink">197</a></strong><div class="NLM_citation" id="rightTab-cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zinovyev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuperstein, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barillot, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyer, W. D.</span></span> <span> </span><span class="NLM_article-title">Synthetic lethality between gene defects affecting a single non-essential molecular pathway with reversible steps</span>. <i>PLoS Comput. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">4</span>), <span class="NLM_elocation-id">e1003016</span> <span class="refDoi">Â DOI: 10.1371/journal.pcbi.1003016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1371%2Fjournal.pcbi.1003016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=23592964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnt1ejtLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&issue=4&author=A.+Zinovyevauthor=I.+Kupersteinauthor=E.+Barillotauthor=W.+D.+Heyer&title=Synthetic+lethality+between+gene+defects+affecting+a+single+non-essential+molecular+pathway+with+reversible+steps&doi=10.1371%2Fjournal.pcbi.1003016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic lethality between gene defects affecting a single non-essential molecular pathway with reversible steps</span></div><div class="casAuthors">Zinovyev, Andrei; Kuperstein, Inna; Barillot, Emmanuel; Heyer, Wolf-Dietrich</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Computational Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e1003016</span>CODEN:
                <span class="NLM_cas:coden">PCBLBG</span>;
        ISSN:<span class="NLM_cas:issn">1553-7358</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Systematic anal. of synthetic lethality (SL) constitutes a crit. tool for systems biol. to decipher mol. pathways.  The most accepted mechanistic explanation of SL is that the two genes function in parallel, mutually compensatory pathways, known as between-pathway SL.  However, recent genome-wide analyses in yeast identified a significant no. of within-pathway neg. genetic interactions.  The mol. mechanisms leading to within-pathway SL are not fully understood.  Here, we propose a novel mechanism leading to within-pathway SL involving two genes functioning in a single non-essential pathway.  This type of SL termed within-reversible-pathway SL involves reversible pathway steps, catalyzed by different enzymes in the forward and backward directions, and kinetic trapping of a potentially toxic intermediate.  Exptl. data with recombinational DNA repair genes validate the concept.  Math. modeling recapitulates the possibility of kinetic trapping and revealed the potential contributions of synthetic, dosage-lethal interactions in such a genetic system as well as the possibility of within-pathway pos. masking interactions.  Anal. of yeast gene interaction and pathway data suggests broad applicability of this novel concept.  These observations extend the canonical interpretation of synthetic-lethal or synthetic-sick interactions with direct implications to reconstruct mol. pathways and improve therapeutic approaches to diseases such as cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-mNvqfaiz5rVg90H21EOLACvtfcHk0lh6U9ecwToyjQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnt1ejtLc%253D&md5=f405707774525d3c1d635df77940b1cc</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pcbi.1003016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pcbi.1003016%26sid%3Dliteratum%253Aachs%26aulast%3DZinovyev%26aufirst%3DA.%26aulast%3DKuperstein%26aufirst%3DI.%26aulast%3DBarillot%26aufirst%3DE.%26aulast%3DHeyer%26aufirst%3DW.%2BD.%26atitle%3DSynthetic%2520lethality%2520between%2520gene%2520defects%2520affecting%2520a%2520single%2520non-essential%2520molecular%2520pathway%2520with%2520reversible%2520steps%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2013%26volume%3D9%26issue%3D4%26doi%3D10.1371%2Fjournal.pcbi.1003016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref198"><div class="reference"><strong class="refLabel"><a href="#ref198" class="rightTabRefNumLink">198</a></strong><div class="NLM_citation" id="rightTab-cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dasgupta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malhotra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meeker, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amedei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashraf, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aquilano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azmi, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhakta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilsland, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boosani, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciriolo, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guha, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halicka, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helferich, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keith, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammed, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niccolai, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honoki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parslow, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prakash, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rezazadeh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shackelford, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidransky, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maxwell, C. A.</span></span> <span> </span><span class="NLM_article-title">Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition</span>. <i>Semin. Cancer Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">Suppl</span>),  <span class="NLM_fpage">S5</span>â <span class="NLM_lpage">S24</span>, <span class="refDoi">Â DOI: 10.1016/j.semcancer.2015.03.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.semcancer.2015.03.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=25869442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmt1Skt7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2015&pages=S5-S24&issue=Suppl&author=L.+R.+Fergusonauthor=H.+Chenauthor=A.+R.+Collinsauthor=M.+Connellauthor=G.+Damiaauthor=S.+Dasguptaauthor=M.+Malhotraauthor=A.+K.+Meekerauthor=A.+Amedeiauthor=A.+Aminauthor=S.+S.+Ashrafauthor=K.+Aquilanoauthor=A.+S.+Azmiauthor=D.+Bhaktaauthor=A.+Bilslandauthor=C.+S.+Boosaniauthor=S.+Chenauthor=M.+R.+Cirioloauthor=H.+Fujiiauthor=G.+Guhaauthor=D.+Halickaauthor=W.+G.+Helferichauthor=W.+N.+Keithauthor=S.+I.+Mohammedauthor=E.+Niccolaiauthor=X.+Yangauthor=K.+Honokiauthor=V.+R.+Parslowauthor=S.+Prakashauthor=S.+Rezazadehauthor=R.+E.+Shackelfordauthor=D.+Sidranskyauthor=P.+T.+Tranauthor=E.+S.+Yangauthor=C.+A.+Maxwell&title=Genomic+instability+in+human+cancer%3A+Molecular+insights+and+opportunities+for+therapeutic+attack+and+prevention+through+diet+and+nutrition&doi=10.1016%2Fj.semcancer.2015.03.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition</span></div><div class="casAuthors">Ferguson, Lynnette R.; Chen, Helen; Collins, Andrew R.; Connell, Marisa; Damia, Giovanna; Dasgupta, Santanu; Malhotra, Meenakshi; Meeker, Alan K.; Amedei, Amedeo; Amin, Amr; Ashraf, S. Salman; Aquilano, Katia; Azmi, Asfar S.; Bhakta, Dipita; Bilsland, Alan; Boosani, Chandra S.; Chen, Sophie; Ciriolo, Maria Rosa; Fujii, Hiromasa; Guha, Gunjan; Halicka, Dorota; Helferich, William G.; Keith, W. Nicol; Mohammed, Sulma I.; Niccolai, Elena; Yang, Xujuan; Honoki, Kanya; Parslow, Virginia R.; Prakash, Satya; Rezazadeh, Sarallah; Shackelford, Rodney E.; Sidransky, David; Tran, Phuoc T.; Yang, Eddy S.; Maxwell, Christopher A.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Cancer Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">35_Suppl.</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">S5-S24</span>CODEN:
                <span class="NLM_cas:coden">SECBE7</span>;
        ISSN:<span class="NLM_cas:issn">1044-579X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Genomic instability can initiate cancer, augment progression, and influence the overall prognosis of the affected patient.  Genomic instability arises from many different pathways, such as telomere damage, centrosome amplification, epigenetic modifications, and DNA damage from endogenous and exogenous sources, and can be perpetuating, or limiting, through the induction of mutations or aneuploidy, both enabling and catastrophic.  Many cancer treatments induce DNA damage to impair cell division on a global scale but it is accepted that personalized treatments, those that are tailored to the particular patient and type of cancer, must also be developed.  In this review, we detail the mechanisms from which genomic instability arises and can lead to cancer, as well as treatments and measures that prevent genomic instability or take advantage of the cellular defects caused by genomic instability.  In particular, we identify and discuss five priority targets against genomic instability: (1) prevention of DNA damage; (2) enhancement of DNA repair; (3) targeting deficient DNA repair; (4) impairing centrosome clustering; and, (5) inhibition of telomerase activity.  Moreover, we highlight vitamin D and B, selenium, carotenoids, PARP inhibitors, resveratrol, and isothiocyanates as priority approaches against genomic instability.  The prioritized target sites and approaches were cross validated to identify potential synergistic effects on a no. of important areas of cancer biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqluPZhUX3PLrVg90H21EOLACvtfcHk0liCgBcS0C60gA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmt1Skt7w%253D&md5=e030d940320e97bb5498badc7fd7fb28</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1016%2Fj.semcancer.2015.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semcancer.2015.03.005%26sid%3Dliteratum%253Aachs%26aulast%3DFerguson%26aufirst%3DL.%2BR.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DCollins%26aufirst%3DA.%2BR.%26aulast%3DConnell%26aufirst%3DM.%26aulast%3DDamia%26aufirst%3DG.%26aulast%3DDasgupta%26aufirst%3DS.%26aulast%3DMalhotra%26aufirst%3DM.%26aulast%3DMeeker%26aufirst%3DA.%2BK.%26aulast%3DAmedei%26aufirst%3DA.%26aulast%3DAmin%26aufirst%3DA.%26aulast%3DAshraf%26aufirst%3DS.%2BS.%26aulast%3DAquilano%26aufirst%3DK.%26aulast%3DAzmi%26aufirst%3DA.%2BS.%26aulast%3DBhakta%26aufirst%3DD.%26aulast%3DBilsland%26aufirst%3DA.%26aulast%3DBoosani%26aufirst%3DC.%2BS.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DCiriolo%26aufirst%3DM.%2BR.%26aulast%3DFujii%26aufirst%3DH.%26aulast%3DGuha%26aufirst%3DG.%26aulast%3DHalicka%26aufirst%3DD.%26aulast%3DHelferich%26aufirst%3DW.%2BG.%26aulast%3DKeith%26aufirst%3DW.%2BN.%26aulast%3DMohammed%26aufirst%3DS.%2BI.%26aulast%3DNiccolai%26aufirst%3DE.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DHonoki%26aufirst%3DK.%26aulast%3DParslow%26aufirst%3DV.%2BR.%26aulast%3DPrakash%26aufirst%3DS.%26aulast%3DRezazadeh%26aufirst%3DS.%26aulast%3DShackelford%26aufirst%3DR.%2BE.%26aulast%3DSidransky%26aufirst%3DD.%26aulast%3DTran%26aufirst%3DP.%2BT.%26aulast%3DYang%26aufirst%3DE.%2BS.%26aulast%3DMaxwell%26aufirst%3DC.%2BA.%26atitle%3DGenomic%2520instability%2520in%2520human%2520cancer%253A%2520Molecular%2520insights%2520and%2520opportunities%2520for%2520therapeutic%2520attack%2520and%2520prevention%2520through%2520diet%2520and%2520nutrition%26jtitle%3DSemin.%2520Cancer%2520Biol.%26date%3D2015%26volume%3D35%26issue%3DSuppl%26spage%3DS5%26epage%3DS24%26doi%3D10.1016%2Fj.semcancer.2015.03.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref199"><div class="reference"><strong class="refLabel"><a href="#ref199" class="rightTabRefNumLink">199</a></strong><div class="NLM_citation" id="rightTab-cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schott, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coustham, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palladino, F.</span></span> <span> </span><span class="NLM_article-title">Unique and redundant functions of C. elegans HP1 proteins in post-embryonic development</span>. <i>Dev. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>298</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">176</span>â <span class="NLM_lpage">187</span>, <span class="refDoi">Â DOI: 10.1016/j.ydbio.2006.06.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.ydbio.2006.06.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=16905130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD28XpvFeksLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=298&publication_year=2006&pages=176-187&issue=1&author=S.+Schottauthor=V.+Cousthamauthor=T.+Simonetauthor=C.+Bedetauthor=F.+Palladino&title=Unique+and+redundant+functions+of+C.+elegans+HP1+proteins+in+post-embryonic+development&doi=10.1016%2Fj.ydbio.2006.06.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">Unique and redundant functions of C. elegans HP1 proteins in post-embryonic development</span></div><div class="casAuthors">Schott, Sonia; Coustham, Vincent; Simonet, Thomas; Bedet, Cecile; Palladino, Francesca</div><div class="citationInfo"><span class="NLM_cas:title">Developmental Biology (San Diego, CA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">298</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">176-187</span>CODEN:
                <span class="NLM_cas:coden">DEBIAO</span>;
        ISSN:<span class="NLM_cas:issn">0012-1606</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">HP1 proteins are essential components of heterochromatin and contribute to the transcriptional repression of euchromatic genes.  Although most species contain more than one HP1 family member which differ in their chromosomal distribution, it is not known to what extent the activity of these different family members is redundant or specific in a developmental context.  C. elegans has two HP1 homologs, HPL-1 and HPL-2.  While HPL-2 functions in vulval and germline development, no function has so far been attributed to HPL-1.  Here the authors report the characterization of an hpl-1 null allele.  The authors show that while the absence of hpl-1 alone results in no obvious phenotype, hpl-1;hpl-2 double mutants show synthetic, temp. sensitive phenotypes including larval lethality and severe defects in the development of the somatic gonad.  Furthermore, the authors find that hpl-1 has an unexpected role in vulval development by acting redundantly with hpl-2, but not other genes previously implicated in vulval development.  Localization studies show that like HPL-2, HPL-1 is a ubiquitously expressed nuclear protein.  However, HPL-1 and HPL-2 localization does not completely overlap.  The authors' results show that HPL-1 and HPL-2 play both unique and redundant functions in post-embryonic development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoBFG-QUbyZ7Vg90H21EOLACvtfcHk0liCgBcS0C60gA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpvFeksLo%253D&md5=c43b54e246d793cbcfba1989ee91cb24</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1016%2Fj.ydbio.2006.06.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ydbio.2006.06.039%26sid%3Dliteratum%253Aachs%26aulast%3DSchott%26aufirst%3DS.%26aulast%3DCoustham%26aufirst%3DV.%26aulast%3DSimonet%26aufirst%3DT.%26aulast%3DBedet%26aufirst%3DC.%26aulast%3DPalladino%26aufirst%3DF.%26atitle%3DUnique%2520and%2520redundant%2520functions%2520of%2520C.%2520elegans%2520HP1%2520proteins%2520in%2520post-embryonic%2520development%26jtitle%3DDev.%2520Biol.%26date%3D2006%26volume%3D298%26issue%3D1%26spage%3D176%26epage%3D187%26doi%3D10.1016%2Fj.ydbio.2006.06.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref200"><div class="reference"><strong class="refLabel"><a href="#ref200" class="rightTabRefNumLink">200</a></strong><div class="NLM_citation" id="rightTab-cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadgeel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFall, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shields, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matherly, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bepler, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratnam, M.</span></span> <span> </span><span class="NLM_article-title">Glucocorticoid receptor status is a principal determinant of variability in the sensitivity of non-small-cell lung cancer cells to pemetrexed</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">519</span>â <span class="NLM_lpage">526</span>, <span class="refDoi">Â DOI: 10.1097/JTO.0000000000000111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1097%2FJTO.0000000000000111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=24736075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnsFeksr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=519-526&issue=4&author=M.+Patkiauthor=S.+Gadgeelauthor=Y.+Huangauthor=T.+McFallauthor=A.+F.+Shieldsauthor=L.+H.+Matherlyauthor=G.+Beplerauthor=M.+Ratnam&title=Glucocorticoid+receptor+status+is+a+principal+determinant+of+variability+in+the+sensitivity+of+non-small-cell+lung+cancer+cells+to+pemetrexed&doi=10.1097%2FJTO.0000000000000111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Glucocorticoid Receptor Status Is a Principal Determinant of Variability in the Sensitivity of Non-Small-Cell Lung Cancer Cells to Pemetrexed</span></div><div class="casAuthors">Patki, Mugdha; Gadgeel, Shirish; Huang, Yanfang; McFall, Thomas; Shields, Anthony F.; Matherly, Larry H.; Bepler, Gerold; Ratnam, Manohar</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">519-526</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-0864</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Introduction: Pemetrexed is an S-phase targeted drug in front-line or maintenance therapy of advanced nonsquamous non-small-cell lung cancer (NSCLC) but methods are needed for predicting the drug response.  Dexamethasone is typically administered the day before, the day of, and the day after pemetrexed.  As dexamethasone strongly regulates many genes including p53 through the glucocorticoid receptor (GR), we hypothesized that dexamethasone influences tumor response to pemetrexed.  Methods: Eight nonsquamous NSCLC cell line models with varied p53 and GRÎ±/GRÎ² status were used for gene expression and cell-cycle analyses and for loss- or gain-of-function expts.  Results: In three cell lines dexamethasone profoundly, but reversibly, suppressed the fraction of S-phase cells.  Dexamethasone also reversibly repressed expression of thymidylate synthase and dihydrofolate reductase, which are primary targets of pemetrexed but are also quintessential S-phase enzymes as well as the S-phase-dependent expression of thymidine kinase 1.  Dexamethasone also decreased expression of the major pemetrexed transporters, the reduced folate carrier and the proton coupled folate transporter.  Only cells expressing relatively high GRÎ± showed these dexamethasone effects, regardless of p53 status.  In cells expressing low GRÎ±, the dexamethasone response was rescued by ectopic GRÎ±.  Further, depletion of p53 did not attenuate the dexamethasone effects.  The presence of dexamethasone during pemetrexed treatment protected against pemetrexed cytotoxicity in only the dexamethasone responsive cells.  Conclusions: The results predict that in nonsquamous NSCLC tumors, reversible S-phase suppression by dexamethasone, possibly combined with a redn. in the drug transporters, attenuates responsiveness to pemetrexed and that GR status is a principal determinant of tumor variability of this response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonlr2Xw1TFtbVg90H21EOLACvtfcHk0lgPaZOTza_h5g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnsFeksr4%253D&md5=58902ee75fed6685f594546685c195f3</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1097%2FJTO.0000000000000111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0000000000000111%26sid%3Dliteratum%253Aachs%26aulast%3DPatki%26aufirst%3DM.%26aulast%3DGadgeel%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DMcFall%26aufirst%3DT.%26aulast%3DShields%26aufirst%3DA.%2BF.%26aulast%3DMatherly%26aufirst%3DL.%2BH.%26aulast%3DBepler%26aufirst%3DG.%26aulast%3DRatnam%26aufirst%3DM.%26atitle%3DGlucocorticoid%2520receptor%2520status%2520is%2520a%2520principal%2520determinant%2520of%2520variability%2520in%2520the%2520sensitivity%2520of%2520non-small-cell%2520lung%2520cancer%2520cells%2520to%2520pemetrexed%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2014%26volume%3D9%26issue%3D4%26spage%3D519%26epage%3D526%26doi%3D10.1097%2FJTO.0000000000000111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref201"><div class="reference"><strong class="refLabel"><a href="#ref201" class="rightTabRefNumLink">201</a></strong><div class="NLM_citation" id="rightTab-cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mullen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brill, S. J.</span></span> <span> </span><span class="NLM_article-title">Activation of the Slx5-Slx8 ubiquitin ligase by poly-small ubiquitin-like modifier conjugates</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>283</i></span> (<span class="NLM_issue">29</span>),  <span class="NLM_fpage">19912</span>â <span class="NLM_lpage">19921</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M802690200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1074%2Fjbc.M802690200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=18499666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotlOit7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=19912-19921&issue=29&author=J.+R.+Mullenauthor=S.+J.+Brill&title=Activation+of+the+Slx5-Slx8+ubiquitin+ligase+by+poly-small+ubiquitin-like+modifier+conjugates&doi=10.1074%2Fjbc.M802690200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of the Slx5-Slx8 Ubiquitin Ligase by Poly-small Ubiquitin-like Modifier Conjugates</span></div><div class="casAuthors">Mullen, Janet R.; Brill, Steven J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">19912-19921</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Protein sumoylation is a regulated process that is important for the health of human and yeast cells.  In budding yeast, a subset of sumoylated proteins is targeted for ubiquitination by a conserved heterodimeric ubiquitin (Ub) ligase, Slx5-Slx8, which is needed to suppress the accumulation of high mol. wt. small ubiquitin-like modifier (SUMO) conjugates.  Structure-function anal. indicates that the Slx5-Slx8 complex contains multiple SUMO-binding domains that are collectively required for in vivo function.  To det. the specificity of Slx5-Slx8, we assayed its Ub ligase activity using sumoylated Siz2 as an in vitro substrate.  In contrast to unsumoylated or multisumoylated Siz2, substrates contg. poly-SUMO conjugates were efficiently ubiquitinated by Slx5-Slx8.  Although Siz2 itself was ubiquitinated, the bulk of the Ub was conjugated to SUMO residues.  Slx5-Slx8 primarily mono-ubiquitinated the N-terminal SUMO moiety of the chain.  These data indicate that the Slx5-Slx8 Ub ligase is stimulated by poly-SUMO conjugates and that it can ubiquitinate a poly-SUMO chain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNXx0geOY3ZbVg90H21EOLACvtfcHk0lgPaZOTza_h5g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotlOit7w%253D&md5=bfa4e56b59c26cdce11cb56959bddd4f</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M802690200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M802690200%26sid%3Dliteratum%253Aachs%26aulast%3DMullen%26aufirst%3DJ.%2BR.%26aulast%3DBrill%26aufirst%3DS.%2BJ.%26atitle%3DActivation%2520of%2520the%2520Slx5-Slx8%2520ubiquitin%2520ligase%2520by%2520poly-small%2520ubiquitin-like%2520modifier%2520conjugates%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26issue%3D29%26spage%3D19912%26epage%3D19921%26doi%3D10.1074%2Fjbc.M802690200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref202"><div class="reference"><strong class="refLabel"><a href="#ref202" class="rightTabRefNumLink">202</a></strong><div class="NLM_citation" id="rightTab-cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vegetti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrone, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anichini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensi, M.</span></span> <span> </span><span class="NLM_article-title">Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">6503</span>â <span class="NLM_lpage">6511</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-05-4671</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F0008-5472.CAN-05-4671" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=16818621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD28XmsVamtr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=6503-6511&issue=13&author=C.+Pettiauthor=A.+Mollaauthor=C.+Vegettiauthor=S.+Ferroneauthor=A.+Anichiniauthor=M.+Sensi&title=Coexpression+of+NRASQ61R+and+BRAFV600E+in+human+melanoma+cells+activates+senescence+and+increases+susceptibility+to+cell-mediated+cytotoxicity&doi=10.1158%2F0008-5472.CAN-05-4671"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">Coexpression of NRASQ61R and BRAFV600E in Human Melanoma Cells Activates Senescence and Increases Susceptibility to Cell-Mediated Cytotoxicity</span></div><div class="casAuthors">Petti, Carlotta; Molla, Alessandra; Vegetti, Claudia; Ferrone, Soldano; Anichini, Andrea; Sensi, Marialuisa</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6503-6511</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Activating mutations in BRAF and NRAS oncogenes in human melanomas are mutually exclusive.  This finding has suggested an epistatic relationship but is consistent even with synthetic lethality.  To evaluate the latter possibility, a mutated NRASQ61R oncogene was expressed, under a constitutive or a doxycycline-regulated promoter, in a metastatic melanoma clone (clone 21) harboring an activated BRAFV600E oncogene.  After the first 10 to 12 in vitro passages, the constitutive NRASQ61R transfectant displayed progressive accumulation in G0-G1 phase of the cell cycle and stained for the senescence-assocd. Î²-galactosidase activity (SA-Î²-Gal).  Inducible expression of NRASQ61R, by the Tet-Off system, in clone 21 cells (21NRAS61ON) led to overactivation of the RAS/RAF/mitogen-activated protein kinase signaling pathway and, after the 10th in vitro passage, led to promotion of senescence.  This was documented by reduced proliferation, flattened cell morphol., reduced growth in Matrigel, pos. staining for SA-Î²-Gal, and expression of AMP-activated protein kinase and of the cell cycle inhibitor p21waf1/Cip1.  These effects were detected neither in 21 cells with silenced NRASQ61R (21NRAS61OFF) nor in cells transfected with an inducible wild-type NRAS gene (21NRASWTON).  In addn., when compared with parental 21 cells, or with 21NRAS61OFF, 21NRAS61ON and constitutive NRASQ61R transfectants cells showed increased susceptibility to cytotoxicity by both HLA class I antigen-restricted and nonspecific T cells and up-regulation of several MHC class I antigen processing machinery components.  These results suggest a relationship of synthetic lethality between NRAS and BRAF oncogenes, leading to selection against "double-mutant" cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpe5ZV46jNLpbVg90H21EOLACvtfcHk0lgPaZOTza_h5g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmsVamtr0%253D&md5=cb9b674e12d8b306a320fe51c8c0016c</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-4671&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-4671%26sid%3Dliteratum%253Aachs%26aulast%3DPetti%26aufirst%3DC.%26aulast%3DMolla%26aufirst%3DA.%26aulast%3DVegetti%26aufirst%3DC.%26aulast%3DFerrone%26aufirst%3DS.%26aulast%3DAnichini%26aufirst%3DA.%26aulast%3DSensi%26aufirst%3DM.%26atitle%3DCoexpression%2520of%2520NRASQ61R%2520and%2520BRAFV600E%2520in%2520human%2520melanoma%2520cells%2520activates%2520senescence%2520and%2520increases%2520susceptibility%2520to%2520cell-mediated%2520cytotoxicity%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26issue%3D13%26spage%3D6503%26epage%3D6511%26doi%3D10.1158%2F0008-5472.CAN-05-4671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref203"><div class="reference"><strong class="refLabel"><a href="#ref203" class="rightTabRefNumLink">203</a></strong><div class="NLM_citation" id="rightTab-cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Byrum, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vindigni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosammaparast, N.</span></span> <span> </span><span class="NLM_article-title">Defining and modulating âBRCAnessâ</span>. <i>Trends Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">740</span>â <span class="NLM_lpage">751</span>, <span class="refDoi">Â DOI: 10.1016/j.tcb.2019.06.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.tcb.2019.06.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=31362850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlOgsbbO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=740-751&issue=9&author=A.+K.+Byrumauthor=A.+Vindigniauthor=N.+Mosammaparast&title=Defining+and+modulating+%E2%80%98BRCAness%E2%80%99&doi=10.1016%2Fj.tcb.2019.06.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Defining and Modulating 'BRCAness'</span></div><div class="casAuthors">Byrum, Andrea K.; Vindigni, Alessandro; Mosammaparast, Nima</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cell Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">740-751</span>CODEN:
                <span class="NLM_cas:coden">TCBIEK</span>;
        ISSN:<span class="NLM_cas:issn">0962-8924</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The concept of 'BRCAness' defines the pathogenesis and vulnerability of multiple cancers.  The canonical definition of BRCAness is a defect in homologous recombination repair, mimicking BRCA1 or BRCA2 loss.  In turn, BRCA-deficient cells utilize error-prone DNA-repair pathways, causing increased genomic instability, which may be responsible for their sensitivity to DNA damaging agents and poly-(ADP)-ribose polymerase inhibitors (PARPis).  However, recent work has expanded the mechanistic basis of BRCAness, to include defects in replication fork protection (RFP).  Here, we broaden the definition of BRCAness to include RFP and regulatory mechanisms that cause synthetic lethality with PARPis.  We highlight these recent discoveries, which include mechanisms of RFP regulation, DNA damage checkpoint proteins, as well as kinases that regulate BRCA1/2 function.  Importantly, many of these emerging mechanisms may be targeted for inhibition with small mol. inhibitors, thus inducing BRCAness in a much larger subset of BRCA-proficient tumors, with significant translational potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrX_47gRy6gbVg90H21EOLACvtfcHk0lg3ZvC2SXvedw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlOgsbbO&md5=6c96ca15e1ff882a13c00540c1dfccac</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1016%2Fj.tcb.2019.06.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tcb.2019.06.005%26sid%3Dliteratum%253Aachs%26aulast%3DByrum%26aufirst%3DA.%2BK.%26aulast%3DVindigni%26aufirst%3DA.%26aulast%3DMosammaparast%26aufirst%3DN.%26atitle%3DDefining%2520and%2520modulating%2520%25E2%2580%2598BRCAness%25E2%2580%2599%26jtitle%3DTrends%2520Cell%2520Biol.%26date%3D2019%26volume%3D29%26issue%3D9%26spage%3D740%26epage%3D751%26doi%3D10.1016%2Fj.tcb.2019.06.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref204"><div class="reference"><strong class="refLabel"><a href="#ref204" class="rightTabRefNumLink">204</a></strong><div class="NLM_citation" id="rightTab-cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muggia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safra, T.</span></span> <span> </span><span class="NLM_article-title">âBRCAnessâ and its implications for platinum action in gynecologic cancer</span>. <i>Anticancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">551</span>â <span class="NLM_lpage">556</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=24510983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvVCqu70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=551-556&issue=2&author=F.+Muggiaauthor=T.+Safra&title=%E2%80%98BRCAness%E2%80%99+and+its+implications+for+platinum+action+in+gynecologic+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">'BRCAness' and its implications for platinum action in gynecologic cancer</span></div><div class="casAuthors">Muggia, Franco; Safra, Tamar</div><div class="citationInfo"><span class="NLM_cas:title">Anticancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">551-556</span>CODEN:
                <span class="NLM_cas:coden">ANTRD4</span>;
        ISSN:<span class="NLM_cas:issn">0250-7005</span>.
    
            (<span class="NLM_cas:orgname">International Institute of Anticancer Research</span>)
        </div><div class="casAbstract">A review.  Gynecol. carcinomas are major therapeutic targets of platinum-contg. regimens.  They may be particularly susceptible to these agents if their origins are related to hereditary breast cancer (BRCA) mutations; this implicates defective DNA repair secondary to inherited alterations in BRCA function.  The concept of 'BRCAness' was introduced by Ashworth and colleagues in order to identify phenotypic changes in sporadic cancer that would lead to analogous treatment susceptibility.  In fact, recent analyses of genetic alterations in ovarian cancer have led to further extending this concept to all women with high-grade serous cancer, the predominant form of ovarian cancer arising in assocn. with hereditary mutations in BRCA genes.  Presumably, most serous types of cancer of gynecol. origin share BRCA dysfunction to some extent.  This renders these types of cancer susceptible to platinum and to other DNA-damaging agents, justifying the general inclusion of this histol. in trials of new drugs and therapeutic strategies that have shown activity against hereditary cancer.  More recently, however, differences in outcome between BRCA mutation carriers vis-a-vis those with no mutations or those with epigenetic or acquired forms of BRCA genes (somatic mutations) in their resp. tumors have been identified.  These findings raise addnl. questions on modifiers of 'BRCAness' and other pathways that appear to contribute to the effects of platinum and other DNA-damaging agents in ovarian cancer.  The Cancer Genome Atlas analyses delineate the complexity of genomic alterations in ovarian cancer and other malignancies of Mullerian epithelial origin promising further refinements of the 'BRCAness' concept.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3xJ2W88bG67Vg90H21EOLACvtfcHk0lg3ZvC2SXvedw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvVCqu70%253D&md5=509058ca9c85e653d19561025eacfd37</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMuggia%26aufirst%3DF.%26aulast%3DSafra%26aufirst%3DT.%26atitle%3D%25E2%2580%2598BRCAness%25E2%2580%2599%2520and%2520its%2520implications%2520for%2520platinum%2520action%2520in%2520gynecologic%2520cancer%26jtitle%3DAnticancer%2520Res.%26date%3D2014%26volume%3D34%26issue%3D2%26spage%3D551%26epage%3D556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref205"><div class="reference"><strong class="refLabel"><a href="#ref205" class="rightTabRefNumLink">205</a></strong><div class="NLM_citation" id="rightTab-cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Plummer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boddy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHugh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinfeldt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewji, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvert, H.</span></span> <span> </span><span class="NLM_article-title">Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">7917</span>â <span class="NLM_lpage">7923</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-08-1223</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1158%2F1078-0432.CCR-08-1223" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=19047122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVegt7%252FM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=7917-7923&issue=23&author=R.+Plummerauthor=C.+Jonesauthor=M.+Middletonauthor=R.+Wilsonauthor=J.+Evansauthor=A.+Olsenauthor=N.+Curtinauthor=A.+Boddyauthor=P.+McHughauthor=D.+Newellauthor=A.+Harrisauthor=P.+Johnsonauthor=H.+Steinfeldtauthor=R.+Dewjiauthor=D.+Wangauthor=L.+Robsonauthor=H.+Calvert&title=Phase+I+study+of+the+poly%28ADP-ribose%29+polymerase+inhibitor%2C+AG014699%2C+in+combination+with+temozolomide+in+patients+with+advanced+solid+tumors&doi=10.1158%2F1078-0432.CCR-08-1223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Plummer, Ruth; Jones, Christopher; Middleton, Mark; Wilson, Richard; Evans, Jeffrey; Olsen, Anna; Curtin, Nicola; Boddy, Alan; McHugh, Peter; Newell, David; Harris, Adrian; Johnson, Patrick; Steinfeldt, Heidi; Dewji, Raz; Wang, Diane; Robson, Lesley; Calvert, Hilary</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7917-7923</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: One mechanism of tumor resistance to cytotoxic therapy is repair of damaged DNA.  Poly(ADP-ribose) polymerase (PARP)-1 is a nuclear enzyme involved in base excision repair, one of the five major repair pathways.  PARP inhibitors are emerging as a new class of agents that can potentiate chemotherapy and radiotherapy.  The article reports safety, efficacy, pharmacokinetic, and pharmacodynamic results of the first-in-class trial of a PARP inhibitor, AG014699, combined with temozolomide in adults with advanced malignancy.  Exptl. Design: Initially, patients with solid tumors received escalating doses of AG014699 with 100 mg/m2/d temozolomide x 5 every 28 days to establish the PARP ID (PID).  Subsequently, AG014699 dose was fixed at PID and temozolomide escalated to max. tolerated dose or 200 mg/m2 in metastatic melanoma patients whose tumors were biopsied.  AG014699 and temozolomide pharmacokinetics, PARP activity, DNA strand single-strand breaks, response, and toxicity were evaluated.  RESULTS: Thirty-three patients were enrolled.  PARP inhibition was seen at all doses; PID was 12 mg/m2 based on 74% to 97% inhibition of peripheral blood lymphocyte PARP activity.  Recommended doses were 12 mg/m2 AG014699 and 200 mg/m2 temozolomide.  Mean tumor PARP inhibition at 5 h was 92% (range, 46-97%).  No toxicity attributable to AG014699 alone was obsd.  AG014699 showed linear pharmacokinetics with no interaction with temozolomide.  All patients treated at PID showed increases in DNA single-strand breaks and encouraging evidence of activity was seen.  CONCLUSIONS: The combination of AG014699 and temozolomide is well tolerated, pharmacodynamic assessments showing proof of principle of the mode of action of this new class of agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoh3DGcSbf45bVg90H21EOLACvtfcHk0lg3ZvC2SXvedw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVegt7%252FM&md5=76b77d0a31dcb652c31e049a7f6163c2</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-1223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-1223%26sid%3Dliteratum%253Aachs%26aulast%3DPlummer%26aufirst%3DR.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DMiddleton%26aufirst%3DM.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DEvans%26aufirst%3DJ.%26aulast%3DOlsen%26aufirst%3DA.%26aulast%3DCurtin%26aufirst%3DN.%26aulast%3DBoddy%26aufirst%3DA.%26aulast%3DMcHugh%26aufirst%3DP.%26aulast%3DNewell%26aufirst%3DD.%26aulast%3DHarris%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DP.%26aulast%3DSteinfeldt%26aufirst%3DH.%26aulast%3DDewji%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DRobson%26aufirst%3DL.%26aulast%3DCalvert%26aufirst%3DH.%26atitle%3DPhase%2520I%2520study%2520of%2520the%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitor%252C%2520AG014699%252C%2520in%2520combination%2520with%2520temozolomide%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26issue%3D23%26spage%3D7917%26epage%3D7923%26doi%3D10.1158%2F1078-0432.CCR-08-1223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref206"><div class="reference"><strong class="refLabel"><a href="#ref206" class="rightTabRefNumLink">206</a></strong><div class="NLM_citation" id="rightTab-cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poleksic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span> <span> </span><span class="NLM_article-title">Database of adverse events associated with drugs and drug combinations</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">20025</span>, <span class="refDoi">Â DOI: 10.1038/s41598-019-56525-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1038%2Fs41598-019-56525-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=31882773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmtFWqtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=20025&issue=1&author=A.+Poleksicauthor=L.+Xie&title=Database+of+adverse+events+associated+with+drugs+and+drug+combinations&doi=10.1038%2Fs41598-019-56525-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">Database of adverse events associated with drugs and drug combinations</span></div><div class="casAuthors">Poleksic, Aleksandar; Xie, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20025</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Due to the aging world population and increasing trend in clin. practice to treat patients with multiple drugs, adverse events (AEs) are becoming a major challenge in drug discovery and public health.  In particular, identifying AEs caused by drug combinations remains a challenging task.  Clin. trials typically focus on individual drugs rather than drug combinations and animal models are unreliable.  An added difficulty is the combinatorial explosion in the no. of possible combinations that can be made using the increasingly large set of FDA approved chems.  We present a statistical and computational technique for identifying AEs caused by two-drug combinations.  Taking advantage of the large and increasing data deposited in FDA's postmarketing reports, we demonstrate that the task of predicting AEs for 2-drug combinations is amenable to the Likelihood Ratio Test (LRT).  Our pAERS database constructed with LRT contains almost 77 thousand assocns. between pairs of drugs and corresponding AEs caused solely by drug-drug interactions (DDIs).  The DDIs stored in pAERS complement the existing data sets.  Due to our stringent statistical test, we expect many of the assocns. in pAERS to be unrecorded or poorly documented in the literature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmCw2kId84NbVg90H21EOLACvtfcHk0liONkQ1FxgKpQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmtFWqtw%253D%253D&md5=540dbe70825cb60aab98e58c3abfc496</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-56525-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-56525-5%26sid%3Dliteratum%253Aachs%26aulast%3DPoleksic%26aufirst%3DA.%26aulast%3DXie%26aufirst%3DL.%26atitle%3DDatabase%2520of%2520adverse%2520events%2520associated%2520with%2520drugs%2520and%2520drug%2520combinations%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26issue%3D1%26spage%3D20025%26doi%3D10.1038%2Fs41598-019-56525-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref207"><div class="reference"><strong class="refLabel"><a href="#ref207" class="rightTabRefNumLink">207</a></strong><div class="NLM_citation" id="rightTab-cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heinzel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marhold, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomasich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lukas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krainer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perco, P.</span></span> <span> </span><span class="NLM_article-title">Synthetic lethality guiding selection of drug combinations in ovarian cancer</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">1</span>), <span class="NLM_elocation-id">e0210859</span> <span class="refDoi">Â DOI: 10.1371/journal.pone.0210859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1371%2Fjournal.pone.0210859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=30682083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtFCmsbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&issue=1&author=A.+Heinzelauthor=M.+Marholdauthor=P.+Mayerauthor=M.+Schwarzauthor=E.+Tomasichauthor=A.+Lukasauthor=M.+Krainerauthor=P.+Perco&title=Synthetic+lethality+guiding+selection+of+drug+combinations+in+ovarian+cancer&doi=10.1371%2Fjournal.pone.0210859"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic lethality guiding selection of drug combinations in ovarian cancer</span></div><div class="casAuthors">Heinzel, Andreas; Marhold, Maximilian; Mayer, Paul; Schwarz, Michael; Tomasich, Erwin; Lukas, Arno; Krainer, Michael; Perco, Paul</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e0210859</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background: Synthetic lethality describes a relationship between two genes where single loss of either gene does not trigger significant impact on cell viability, but simultaneous loss of both gene functions results in lethality.  Targeting synthetic lethal interactions with drug combinations promises increased efficacy in tumor therapy.  Materials and methods: We established a set of synthetic lethal interactions using publicly available data from yeast screens which were mapped to their resp. human orthologs using information from orthol. databases.  This set of exptl. synthetic lethal interactions was complemented by a set of predicted synthetic lethal interactions based on a set of protein meta-data like e.g. mol. pathway assignment.  Based on the combined set, we evaluated drug combinations used in late stage clin. development (clin. phase III and IV trials) or already in clin. use for ovarian cancer with respect to their effect on synthetic lethal interactions.  We furthermore identified a set of drug combinations currently not being tested in late stage ovarian cancer clin. trials that however have impact on synthetic lethal interactions thus being worth of further investigations regarding their therapeutic potential in ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraSOZUkEy3M7Vg90H21EOLACvtfcHk0liONkQ1FxgKpQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtFCmsbw%253D&md5=1f7a4b658923fc7c46128bb51e4913b3</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0210859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0210859%26sid%3Dliteratum%253Aachs%26aulast%3DHeinzel%26aufirst%3DA.%26aulast%3DMarhold%26aufirst%3DM.%26aulast%3DMayer%26aufirst%3DP.%26aulast%3DSchwarz%26aufirst%3DM.%26aulast%3DTomasich%26aufirst%3DE.%26aulast%3DLukas%26aufirst%3DA.%26aulast%3DKrainer%26aufirst%3DM.%26aulast%3DPerco%26aufirst%3DP.%26atitle%3DSynthetic%2520lethality%2520guiding%2520selection%2520of%2520drug%2520combinations%2520in%2520ovarian%2520cancer%26jtitle%3DPLoS%2520One%26date%3D2019%26volume%3D14%26issue%3D1%26doi%3D10.1371%2Fjournal.pone.0210859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref208"><div class="reference"><strong class="refLabel"><a href="#ref208" class="rightTabRefNumLink">208</a></strong><div class="NLM_citation" id="rightTab-cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sassmannshausen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deurenberg, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kock, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrix, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossen, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedrich, A. W.</span></span> <span> </span><span class="NLM_article-title">MRSA prevalence and associated risk factors among health-care workers in non-outbreak situations in the dutch-german EUREGIO</span>. <i>Front. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1273</span>, <span class="refDoi">Â DOI: 10.3389/fmicb.2016.01273</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.3389%2Ffmicb.2016.01273" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=27597843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A280%3ADC%252BC2sznvFKnuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=1273&author=R.+Sassmannshausenauthor=R.+H.+Deurenbergauthor=R.+Kockauthor=R.+Hendrixauthor=A.+Jurkeauthor=J.+W.+Rossenauthor=A.+W.+Friedrich&title=MRSA+prevalence+and+associated+risk+factors+among+health-care+workers+in+non-outbreak+situations+in+the+dutch-german+EUREGIO&doi=10.3389%2Ffmicb.2016.01273"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">MRSA Prevalence and Associated Risk Factors among Health-Care Workers in Non-outbreak Situations in the Dutch-German EUREGIO</span></div><div class="casAuthors">Sassmannshausen Ricarda; Deurenberg Ruud H; Rossen John W A; Friedrich Alexander W; Kock Robin; Hendrix Ron; Jurke Annette</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in microbiology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1273</span>
        ISSN:<span class="NLM_cas:issn">1664-302X</span>.
    </div><div class="casAbstract">Preventing the spread of methicillin-resistant Staphylococcus aureus (MRSA) in healthcare facilities is a major infection control target.  However, only a few studies have assessed the potential role of healthcare workers (HCWs) for MRSA dissemination.  To investigate the MRSA prevalence and the risk factors for MRSA colonization among HCWs, nasopharyngeal swabs were taken between June 2010 and January 2011 from 726 employees from nine acute care hospitals with different care levels within the German part of a Dutch-German border region (EUREGIO).  The isolated MRSA strains were investigated using spa typing.  The overall MRSA prevalence among HCWs in a non-outbreak situation was 4.6% (33 of 726), and was higher in nurses (5.6%, 29 of 514) than in physicians (1.2%, 1 of 83).  Possible risk factors associated with MRSA colonization were a known history of MRSA carriage and the presence of acne.  Intensive contact with patients may facilitate MRSA transmission between patients and HCWs.  Furthermore, an accumulation of risk factors was accompanied by an increased MRSA prevalence in HCW.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQjOr1PdgGetLmQt-ICR3qNfW6udTcc2eaALTwPnytls7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sznvFKnuw%253D%253D&md5=dae7426d591e50c4963fd080465a5d62</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.3389%2Ffmicb.2016.01273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffmicb.2016.01273%26sid%3Dliteratum%253Aachs%26aulast%3DSassmannshausen%26aufirst%3DR.%26aulast%3DDeurenberg%26aufirst%3DR.%2BH.%26aulast%3DKock%26aufirst%3DR.%26aulast%3DHendrix%26aufirst%3DR.%26aulast%3DJurke%26aufirst%3DA.%26aulast%3DRossen%26aufirst%3DJ.%2BW.%26aulast%3DFriedrich%26aufirst%3DA.%2BW.%26atitle%3DMRSA%2520prevalence%2520and%2520associated%2520risk%2520factors%2520among%2520health-care%2520workers%2520in%2520non-outbreak%2520situations%2520in%2520the%2520dutch-german%2520EUREGIO%26jtitle%3DFront.%2520Microbiol.%26date%3D2016%26volume%3D7%26spage%3D1273%26doi%3D10.3389%2Ffmicb.2016.01273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref209"><div class="reference"><strong class="refLabel"><a href="#ref209" class="rightTabRefNumLink">209</a></strong><div class="NLM_citation" id="rightTab-cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vos, M.</span></span> <span> </span><span class="NLM_article-title">Why do bacteria engage in homologous recombination?</span>. <i>Trends Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">226</span>â <span class="NLM_lpage">232</span>, <span class="refDoi">Â DOI: 10.1016/j.tim.2009.03.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.tim.2009.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=19464181" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntVGmu7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=226-232&issue=6&author=M.+Vos&title=Why+do+bacteria+engage+in+homologous+recombination%3F&doi=10.1016%2Fj.tim.2009.03.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Why do bacteria engage in homologous recombination?</span></div><div class="casAuthors">Vos, Michiel</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Microbiology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">226-232</span>CODEN:
                <span class="NLM_cas:coden">TRMIEA</span>;
        ISSN:<span class="NLM_cas:issn">0966-842X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Microbiologists have long recognized that the uptake and incorporation of homologous DNA from outside the cell is a common feature of bacteria, with important implications for their evolution.  However, the exact reasons why bacteria engage in homologous recombination remain elusive.  This Opinion article aims to reinvigorate the debate by examg. the costs and benefits that homologous recombination could engender in natural populations of bacteria.  It specifically focuses on the hypothesis that homologous recombination is selectively maintained because the genetic variation it generates improves the response of bacterial populations to natural selection, analogous to sex in eukaryotes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9KpYfEk7CerVg90H21EOLACvtfcHk0liONkQ1FxgKpQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntVGmu7c%253D&md5=76ef5f4b44ec31d7b216ffe292c7983b</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1016%2Fj.tim.2009.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tim.2009.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DVos%26aufirst%3DM.%26atitle%3DWhy%2520do%2520bacteria%2520engage%2520in%2520homologous%2520recombination%253F%26jtitle%3DTrends%2520Microbiol.%26date%3D2009%26volume%3D17%26issue%3D6%26spage%3D226%26epage%3D232%26doi%3D10.1016%2Fj.tim.2009.03.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref210"><div class="reference"><strong class="refLabel"><a href="#ref210" class="rightTabRefNumLink">210</a></strong><div class="NLM_citation" id="rightTab-cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aziz, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monk, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">In Loh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abhay Nagle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satyanarayana, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhakshinamoorthy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luche, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitchen, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palsson, B. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charusanti, P.</span></span> <span> </span><span class="NLM_article-title">Systems biology-guided identification of synthetic lethal gene pairs and its potential use to discover antibiotic combinations</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">16025</span>, <span class="refDoi">Â DOI: 10.1038/srep16025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1038%2Fsrep16025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=26531810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslOnsbjO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=16025&author=R.+K.+Azizauthor=J.+M.+Monkauthor=R.+M.+Lewisauthor=S.+In+Lohauthor=A.+Mishraauthor=A.+Abhay+Nagleauthor=C.+Satyanarayanaauthor=S.+Dhakshinamoorthyauthor=M.+Lucheauthor=D.+B.+Kitchenauthor=K.+A.+Andrewsauthor=N.+L.+Fongauthor=H.+J.+Liauthor=B.+O.+Palssonauthor=P.+Charusanti&title=Systems+biology-guided+identification+of+synthetic+lethal+gene+pairs+and+its+potential+use+to+discover+antibiotic+combinations&doi=10.1038%2Fsrep16025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">Systems biology-guided identification of synthetic lethal gene pairs and its potential use to discover antibiotic combinations</span></div><div class="casAuthors">Aziz, Ramy K.; Monk, Jonathan M.; Lewis, Robert M.; In Loh, Suh; Mishra, Arti; Abhay Nagle, Amrita; Satyanarayana, Chitkala; Dhakshinamoorthy, Saravanakumar; Luche, Michele; Kitchen, Douglas B.; Andrews, Kathleen A.; Fong, Nicole L.; Li, Howard J.; Palsson, Bernhard O.; Charusanti, Pep</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">16025</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Math. models of metab. from bacterial systems biol. have proven their utility across multiple fields, for example metabolic engineering, growth phenotype simulation, and biol. discovery.  The usefulness of the models stems from their ability to compute a link between genotype and phenotype, but their ability to accurately simulate gene-gene interactions has not been investigated extensively.  Here we assess how accurately a metabolic model for Escherichia coli computes one particular type of gene-gene interaction, synthetic lethality, and find that the accuracy rate is between 25% and 43%.  The most common failure modes were incorrect computation of single gene essentiality and biol. information that was missing from the model.  Moreover, we performed virtual and biol. screening against several synthetic lethal pairs to explore whether two-compd. formulations could be found that inhibit the growth of Gram-neg. bacteria.  One set of mols. was identified that, depending on the concns., inhibits E. coli and S. enterica serovar Typhimurium in an additive or antagonistic manner.  These findings pinpoint specific ways in which to improve the predictive ability of metabolic models, and highlight one potential application of systems biol. to drug discovery and translational medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIY7RkarwZ07Vg90H21EOLACvtfcHk0ljTuh3BUCsXkg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslOnsbjO&md5=cf0a1e402e1c5985e6edf46dcca5943d</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1038%2Fsrep16025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep16025%26sid%3Dliteratum%253Aachs%26aulast%3DAziz%26aufirst%3DR.%2BK.%26aulast%3DMonk%26aufirst%3DJ.%2BM.%26aulast%3DLewis%26aufirst%3DR.%2BM.%26aulast%3DIn%2BLoh%26aufirst%3DS.%26aulast%3DMishra%26aufirst%3DA.%26aulast%3DAbhay%2BNagle%26aufirst%3DA.%26aulast%3DSatyanarayana%26aufirst%3DC.%26aulast%3DDhakshinamoorthy%26aufirst%3DS.%26aulast%3DLuche%26aufirst%3DM.%26aulast%3DKitchen%26aufirst%3DD.%2BB.%26aulast%3DAndrews%26aufirst%3DK.%2BA.%26aulast%3DFong%26aufirst%3DN.%2BL.%26aulast%3DLi%26aufirst%3DH.%2BJ.%26aulast%3DPalsson%26aufirst%3DB.%2BO.%26aulast%3DCharusanti%26aufirst%3DP.%26atitle%3DSystems%2520biology-guided%2520identification%2520of%2520synthetic%2520lethal%2520gene%2520pairs%2520and%2520its%2520potential%2520use%2520to%2520discover%2520antibiotic%2520combinations%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D5%26spage%3D16025%26doi%3D10.1038%2Fsrep16025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref211"><div class="reference"><strong class="refLabel"><a href="#ref211" class="rightTabRefNumLink">211</a></strong><div class="NLM_citation" id="rightTab-cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, Y.</span></span> <span> </span><span class="NLM_article-title">Proposal for a new therapy for drug-resistant malaria using plasmodium synthetic lethality inference</span>. <i>Int. J. Parasitol.: Drugs Drug Resist.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">119</span>â <span class="NLM_lpage">128</span>, <span class="refDoi">Â DOI: 10.1016/j.ijpddr.2013.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1016%2Fj.ijpddr.2013.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=24533301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A280%3ADC%252BC2cvls1ensQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=119-128&author=S.+J.+Leeauthor=E.+Seoauthor=Y.+Cho&title=Proposal+for+a+new+therapy+for+drug-resistant+malaria+using+plasmodium+synthetic+lethality+inference&doi=10.1016%2Fj.ijpddr.2013.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">Proposal for a new therapy for drug-resistant malaria using Plasmodium synthetic lethality inference</span></div><div class="casAuthors">Lee Sang Joon; Seo Eunseok; Cho Yonghyun</div><div class="citationInfo"><span class="NLM_cas:title">International journal for parasitology. Drugs and drug resistance</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">119-28</span>
        ISSN:<span class="NLM_cas:issn">2211-3207</span>.
    </div><div class="casAbstract">Many antimalarial drugs kill malaria parasites, but antimalarial drug resistance (ADR) and toxicity to normal cells limit their usefulness.  To solve this problem, we suggest a new therapy for drug-resistant malaria.  The approach consists of data integration and inference through homology analysis of yeast-human-Plasmodium.  If one gene of a Plasmodium synthetic lethal (SL) gene pair has a mutation that causes ADR, a drug targeting the other gene of the SL pair might be used as an effective treatment for drug-resistant strains of malaria.  A simple computational tool to analyze the inferred SL genes of Plasmodium species (malaria parasites Plasmodium falciparum and Plasmodium vivax for human malarial therapy, and rodent parasite Plasmodium berghei for in vivo studies of human malarias) was established to identify SL genes that can be used as drug targets.  Information on SL gene pairs with ADR genes and their first neighbors was inferred from yeast SL genes to search for pertinent antimalarial drug targets.  We not only suggest drug target gene candidates for further experimental validation, but also provide information on new usage for already-described drugs.  The proposed specific antimalarial drug candidates can be inferred by searching drugs that cause a fitness defect in yeast SL genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ0kT6fDiRpcZPlX7E30qdzfW6udTcc2eZJZj9U-mP2R7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cvls1ensQ%253D%253D&md5=99215a9d36aaf4d1d2e5ef71a506f7de</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpddr.2013.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpddr.2013.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DSeo%26aufirst%3DE.%26aulast%3DCho%26aufirst%3DY.%26atitle%3DProposal%2520for%2520a%2520new%2520therapy%2520for%2520drug-resistant%2520malaria%2520using%2520plasmodium%2520synthetic%2520lethality%2520inference%26jtitle%3DInt.%2520J.%2520Parasitol.%253A%2520Drugs%2520Drug%2520Resist.%26date%3D2013%26volume%3D3%26spage%3D119%26epage%3D128%26doi%3D10.1016%2Fj.ijpddr.2013.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref212"><div class="reference"><strong class="refLabel"><a href="#ref212" class="rightTabRefNumLink">212</a></strong><div class="NLM_citation" id="rightTab-cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Symington, L. S.</span></span> <span> </span><span class="NLM_article-title">Role of RAD52 epistasis group genes in homologous recombination and double-strand break repair</span>. <i>Microbiol. Mol. Biol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>66</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">630</span>â <span class="NLM_lpage">670</span>, <span class="refDoi">Â DOI: 10.1128/MMBR.66.4.630-670.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1128%2FMMBR.66.4.630-670.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=12456786" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BD38XpslemtL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2002&pages=630-670&issue=4&author=L.+S.+Symington&title=Role+of+RAD52+epistasis+group+genes+in+homologous+recombination+and+double-strand+break+repair&doi=10.1128%2FMMBR.66.4.630-670.2002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit212R"><div class="casContent"><span class="casTitleNuber">212</span><div class="casTitle"><span class="NLM_cas:atitle">Role of RAD52 epistasis group genes in homologous recombination and double-strand break repair</span></div><div class="casAuthors">Symington, Lorraine S.</div><div class="citationInfo"><span class="NLM_cas:title">Microbiology and Molecular Biology Reviews</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">630-670</span>CODEN:
                <span class="NLM_cas:coden">MMBRF7</span>;
        ISSN:<span class="NLM_cas:issn">1092-2172</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A review.  The goal of this review is to provide an update of the role of the RAD52 group genes in spontaneous and DSB-induced homologous recombination.  Most of the genes in the RAD52 epistasis group (RAD50, RAD51, RAD52, RAD54, RAD55, RAD57, RAD59, RDH54 [TID1], MRE11 [RAD58], and XRS2) were identified by their requirement in the repair of ionizing-radiation-induced DNA damage.  Mutations in these genes lead to defects in meiotic and/or mitotic recombination, providing evidence for a link between DSB repair (DSBR) and homologous recombination.  Homologues of the RAD52 group of genes have been identified in many other eukaryotes, and in some cases in prokaryotes and archaea, indicating high conservation of the recombinational repair pathway.  The recent discovery that several human cancer-prone syndromes, for example, Nijmegen breakage syndrome (NBS) and ataxia-telangiectasia-like disorder (A-TLD), are caused by defects in DSBR has highlighted the importance of this repair pathway in maintaining genome integrity and cancer avoidance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNsMWVxVWj8LVg90H21EOLACvtfcHk0ljTuh3BUCsXkg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpslemtL0%253D&md5=6f3c085982682e6cb06ee70a4c8dff9c</span></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.1128%2FMMBR.66.4.630-670.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMMBR.66.4.630-670.2002%26sid%3Dliteratum%253Aachs%26aulast%3DSymington%26aufirst%3DL.%2BS.%26atitle%3DRole%2520of%2520RAD52%2520epistasis%2520group%2520genes%2520in%2520homologous%2520recombination%2520and%2520double-strand%2520break%2520repair%26jtitle%3DMicrobiol.%2520Mol.%2520Biol.%2520Rev.%26date%3D2002%26volume%3D66%26issue%3D4%26spage%3D630%26epage%3D670%26doi%3D10.1128%2FMMBR.66.4.630-670.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref213"><div class="reference"><strong class="refLabel"><a href="#ref213" class="rightTabRefNumLink">213</a></strong><div class="NLM_citation" id="rightTab-cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kelso, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldvogel, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luthman, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sehorn, M. G.</span></span> <span> </span><span class="NLM_article-title">Homologous recombination in protozoan parasites and recombinase inhibitors</span>. <i>Front. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1716</span>, <span class="refDoi">Â DOI: 10.3389/fmicb.2017.01716</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.3389%2Ffmicb.2017.01716" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=28936205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A280%3ADC%252BC1M%252FhtFemug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1716&author=A.+A.+Kelsoauthor=S.+M.+Waldvogelauthor=A.+J.+Luthmanauthor=M.+G.+Sehorn&title=Homologous+recombination+in+protozoan+parasites+and+recombinase+inhibitors&doi=10.3389%2Ffmicb.2017.01716"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">Homologous Recombination in Protozoan Parasites and Recombinase Inhibitors</span></div><div class="casAuthors">Kelso Andrew A; Waldvogel Sarah M; Luthman Adam J; Sehorn Michael G; Kelso Andrew A; Sehorn Michael G; Sehorn Michael G; Sehorn Michael G</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in microbiology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1716</span>
        ISSN:<span class="NLM_cas:issn">1664-302X</span>.
    </div><div class="casAbstract">Homologous recombination (HR) is a DNA double-strand break (DSB) repair pathway that utilizes a homologous template to fully repair the damaged DNA.  HR is critical to maintain genome stability and to ensure genetic diversity during meiosis.  A specialized class of enzymes known as recombinases facilitate the exchange of genetic information between sister chromatids or homologous chromosomes with the help of numerous protein accessory factors.  The majority of the HR machinery is highly conserved among eukaryotes.  In many protozoan parasites, HR is an essential DSB repair pathway that allows these organisms to adapt to environmental conditions and evade host immune systems through genetic recombination.  Therefore, small molecule inhibitors, capable of disrupting HR in protozoan parasites, represent potential therapeutic options.  A number of small molecule inhibitors were identified that disrupt the activities of the human recombinase RAD51.  Recent studies have examined the effect of two of these molecules on the Entamoeba recombinases.  Here, we discuss the current understandings of HR in the protozoan parasites Trypanosoma, Leishmania, Plasmodium, and Entamoeba, and we review the small molecule inhibitors known to disrupt human RAD51 activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR2cvYA9hPVZ1vAgqb2vdc5fW6udTcc2ebsSk93LyxWp7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M%252FhtFemug%253D%253D&md5=1552e6bc7a85d8d6d5bda8ebc1b5bb69</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.3389%2Ffmicb.2017.01716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffmicb.2017.01716%26sid%3Dliteratum%253Aachs%26aulast%3DKelso%26aufirst%3DA.%2BA.%26aulast%3DWaldvogel%26aufirst%3DS.%2BM.%26aulast%3DLuthman%26aufirst%3DA.%2BJ.%26aulast%3DSehorn%26aufirst%3DM.%2BG.%26atitle%3DHomologous%2520recombination%2520in%2520protozoan%2520parasites%2520and%2520recombinase%2520inhibitors%26jtitle%3DFront.%2520Microbiol.%26date%3D2017%26volume%3D8%26spage%3D1716%26doi%3D10.3389%2Ffmicb.2017.01716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref214"><div class="reference"><strong class="refLabel"><a href="#ref214" class="rightTabRefNumLink">214</a></strong><div class="NLM_citation" id="rightTab-cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">OâNeil, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hieter, P.</span></span> <span> </span><span class="NLM_article-title">Synthetic lethality and cancer</span>. <i>Nat. Rev. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">613</span>â <span class="NLM_lpage">623</span>, <span class="refDoi">Â DOI: 10.1038/nrg.2017.47</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1038%2Fnrg.2017.47" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=28649135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVOjsLvL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=613-623&issue=10&author=N.+J.+O%E2%80%99Neilauthor=M.+L.+Baileyauthor=P.+Hieter&title=Synthetic+lethality+and+cancer&doi=10.1038%2Fnrg.2017.47"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit214R"><div class="casContent"><span class="casTitleNuber">214</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic lethality and cancer</span></div><div class="casAuthors">O'Neil, Nigel J.; Bailey, Melanie L.; Hieter, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Genetics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">613-623</span>CODEN:
                <span class="NLM_cas:coden">NRGAAM</span>;
        ISSN:<span class="NLM_cas:issn">1471-0056</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A synthetic lethal interaction occurs between two genes when the perturbation of either gene alone is viable but the perturbation of both genes simultaneously results in the loss of viability.  Key to exploiting synthetic lethality in cancer treatment are the identification and the mechanistic characterization of robust synthetic lethal genetic interactions.  Advances in next-generation sequencing technologies are enabling the identification of hundreds of tumor-specific mutations and alterations in gene expression that could be targeted by a synthetic lethality approach.  The translation of synthetic lethality to therapy will be assisted by the synthesis of genetic interaction data from model organisms, tumor genomes and human cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopIYVNGqWJ77Vg90H21EOLACvtfcHk0lgJJWBwFZGLgA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVOjsLvL&md5=cdcf1455ecb19ab834c01001d1ee9200</span></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.1038%2Fnrg.2017.47&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrg.2017.47%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Neil%26aufirst%3DN.%2BJ.%26aulast%3DBailey%26aufirst%3DM.%2BL.%26aulast%3DHieter%26aufirst%3DP.%26atitle%3DSynthetic%2520lethality%2520and%2520cancer%26jtitle%3DNat.%2520Rev.%2520Genet.%26date%3D2017%26volume%3D18%26issue%3D10%26spage%3D613%26epage%3D623%26doi%3D10.1038%2Fnrg.2017.47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref215"><div class="reference"><strong class="refLabel"><a href="#ref215" class="rightTabRefNumLink">215</a></strong><div class="NLM_citation" id="rightTab-cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walcott, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubet, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calzone, K. A.</span></span> <span> </span><span class="NLM_article-title">Hereditary cancer syndromes as model systems for chemopreventive agent development</span>. <i>Semin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>43</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">134</span>â <span class="NLM_lpage">145</span>, <span class="refDoi">Â DOI: 10.1053/j.seminoncol.2015.09.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=10.1053%2Fj.seminoncol.2015.09.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=26970132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFKgsb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2016&pages=134-145&issue=1&author=F.+L.+Walcottauthor=J.+Patelauthor=R.+Lubetauthor=L.+Rodriguezauthor=K.+A.+Calzone&title=Hereditary+cancer+syndromes+as+model+systems+for+chemopreventive+agent+development&doi=10.1053%2Fj.seminoncol.2015.09.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit215R"><div class="casContent"><span class="casTitleNuber">215</span><div class="casTitle"><span class="NLM_cas:atitle">Hereditary cancer syndromes as model systems for chemopreventive agent development</span></div><div class="casAuthors">Walcott, Farzana L.; Patel, Jigar; Lubet, Ronald; Rodriguez, Luz; Calzone, Kathleen A.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">134-145</span>CODEN:
                <span class="NLM_cas:coden">SOLGAV</span>;
        ISSN:<span class="NLM_cas:issn">0093-7754</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Research in chemoprevention has undergone a shift in emphasis for pragmatic reasons from large, phase III randomized studies to earlier phase studies focused on safety, mechanisms, and utilization of surrogate endpoints such as biomarkers instead of cancer incidence.  This transition permits trials to be conducted in smaller populations and at substantially reduced costs while still yielding valuable information.  This article will summarize some of the current chemoprevention challenges and the justification for the use of animal models to facilitate identification and testing of chemopreventive agents as illustrated though four inherited cancer syndromes.  Preclin. models of inherited cancer syndromes serve as prototypical systems in which chemopreventive agents can be developed for ultimate application to both the sporadic and inherited cancer settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRCj_VaL3uXbVg90H21EOLACvtfcHk0lgJJWBwFZGLgA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFKgsb4%253D&md5=26e21d29bc336ac5e15821b059ff84b1</span></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.1053%2Fj.seminoncol.2015.09.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.seminoncol.2015.09.015%26sid%3Dliteratum%253Aachs%26aulast%3DWalcott%26aufirst%3DF.%2BL.%26aulast%3DPatel%26aufirst%3DJ.%26aulast%3DLubet%26aufirst%3DR.%26aulast%3DRodriguez%26aufirst%3DL.%26aulast%3DCalzone%26aufirst%3DK.%2BA.%26atitle%3DHereditary%2520cancer%2520syndromes%2520as%2520model%2520systems%2520for%2520chemopreventive%2520agent%2520development%26jtitle%3DSemin.%2520Oncol.%26date%3D2016%26volume%3D43%26issue%3D1%26spage%3D134%26epage%3D145%26doi%3D10.1053%2Fj.seminoncol.2015.09.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i18"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00766">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_78346"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00766?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00766</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula string (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00766/suppl_file/jm0c00766_si_001.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00766/suppl_file/jm0c00766_si_001.csv">jm0c00766_si_001.csv (4.4 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00766&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-23%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00766%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00766" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677ab954dbce3cf4","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
